<SEC-DOCUMENT>0001125345-23-000059.txt : 20230315
<SEC-HEADER>0001125345-23-000059.hdr.sgml : 20230315
<ACCEPTANCE-DATETIME>20230315160753
ACCESSION NUMBER:		0001125345-23-000059
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		94
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230315
DATE AS OF CHANGE:		20230315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		23735221

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mgnx-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:49d3a843-ae73-49e6-9afb-5555c20651f7,g:f863eeaf-37fc-4bf3-b50d-59432dc50ee9,d:9064db26008e44ad995ee3ad48ef6721--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:mgnx="http://macrogenics.com/20221231" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-32">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="f-33">2022</ix:nonNumeric><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntityCentralIndexKey" id="f-35">0001125345</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8eb7d177b724915967268594839281d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i31e765beb79e48d59898de0cccf072fe_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ie9c3771622be4a8cabd1a5821e850e19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i4aa22d39a8624176a6fa8407907a9309_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9cd9cf7c6804d5db20f82023e1a54a3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4f2d1a2d1e94bbdad3b332217f7cdc1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa4a44fb906e46059cf27ad3f371c8f4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80cfdb689d6442978f9b166889e5847e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6f8af80ca2f4b52802a161c595e5052_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db8545d9a764d70adfa1bdc46929964_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e3d5dee46f14e89ab361baca8c84d19_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb12fb8ba4294ec0b24b921f652da5b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4583fefc635419baaecffdc14a3347d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a8c07e35eb0448186c12e229bd209be_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3313b69530a74ec6b2e2460d390f798d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61e770fa73c645568d90bb0126331399_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20f8f2550477493380452b0726f39b25_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id38bfa0cc8324178bc6a9c6bcdcbaa4d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i168b736ecb73412f845967d23572788f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib844aa7657c647948f34d81afd439366_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3204ec3dcb94da6895af490452b85e8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60ca2d1b9b3648e78bc6323a0e727305_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6042637bb9814b299266c07d6f819e1a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e5cc6d01e4e4d18ab3182fee2be3b14_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9caefd6e32774b6fa3be813c566241b1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i583ba990216e462fa437b644733fd007_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8feb38eaa7f4d0284d3e12e8c61f985_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cb9f5c3fbbf4386b0b1c7457c63b569_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if007d64ddb0940ae9820885f23536cbe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibca9a275183b461588ccd2c99d84a7b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d09ee83f16a43899a8e2f0580a10ce5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fbdab93b76148c68de348ba99c602c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28ca167332fb4ffca8f0aeb269e494e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fb4710bb5ad4ea39e2ce055f9920e7a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97989f78335d4f06a53493f09437b7a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4886a2c10d494c22822a89f90bb4c4e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie94494340ac149908fbf8ece8b640537_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25b8b9bc70774790a5df2d37523b9735_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7612f92852c41f58ba57ed9d4a891f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a3e10cae8b7460cb0b3c709f1dd7806_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99fe8fd853b04bf9a915b7facf36738b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fd1adc97945441f91da73361323fa86_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide2999adda92451a8ff2e717b50f9e49_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7177857c4ed5490d949b3547941967c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic40f80873ab547fc9bfb939c4cde42e6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13f15ef91e7144c5b9b9a3240d6df07e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66087c2443374414a3213b8856e0c032_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mgnx:Segment</xbrli:measure></xbrli:unit><xbrli:context id="i0f73f14816ca46229e3f5a04cf8f8524_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecec8ea079224e8494dc049a32f87d5f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica167215fb9048c3b86ad884a91a3ad7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0424cfbed6734206b9a86432dd4a627b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief2cfe25e2144cfb983dd1db2b3cb8f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i564748a61ef54aef8920e9ee95f57d20_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5df1bd36e7134fb283ddef9208f2d1d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2e823de84ae4499891e90615ba17bd2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e6cb699e8f846b9a29724cef42aa3dc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief715af7397b4bbc946fd81d6ef9642c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ea080f686ed4c7985dd2ed9b933233d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75573cbeb0d94490a290b059cc9eb61f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i427d51006aa64de0a7a8d0cd8c18a011_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6501227d18c4697ad97204a2bb6636d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62ba5b88f01a40738c1cbf6ae8e4c17d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc13d1fb533048d9a7687c94b7811d70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d03481f525f4af8b46765578d2c616a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f32cea665ba4844b458f7cca002f6d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95312e9fdb7544afa0e46c69a02b159e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6c03a9650c248c7bc7c0dcc9ee0ef29_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7eed347f0fb4bc6a341449db8f7771b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2f906f81cab4560ae73910713996b25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52c92a0b8bdf4ac491affce8a16e718a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53d9dd52b0a848c7af77775ff7df34b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6e62bf001444be7b3fc5d2bac8294e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fc76d0cb27246d89175301dc8968ddf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7b3c6dbfbcc454e915c319790c99bb2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc945f6be73546b2afbc3f7e91a7829e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ie59d44df2b334c9cb26d2a7a0c7871f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib18dc8cc7b9a48b8903b573ec4c92a4e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b8796d99b14454ea1069baedf468150_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70e62fd23da147a7bbfb414455b3e79d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8682e59ba6945349b855aa4242ac643_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i604d5c2d6f54497d9519656986424b6a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eb0cdf897b34e7299f5aed8a57a554c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4946c226bb1048199aac012daace167d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12dd7404d2a7431e85b17656e3f960c6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4eede0cc1bb4da3aaf51c9487514340_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic100551ff962425281acea19be14d51e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ImabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d1bb961749c4c69a5d4f00e2387e986_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie282942c434e49a58118206bfeb797af_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ASDHealthcareAndOncologySupplyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aa7f28c164743c18f02c60499ebf31f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief36ee226752463cbcd31a9ee80c5cfe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f68116386e241a1b517c6290a020dfd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43aae3612f484fc782f7958caa1ea5f0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d86aae1ee24443584fb111e79fb643d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83f6d05daae94102afa6b769661625fd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d7a17d898bc403992983ad4d53cdb20_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief133d06a929409ea24e246bbecdca4d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2861d07b8b44b3bb7d2dabf91c6d1e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iede6b8c452354940bfab31e913316625_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f73d3bc964445778f3435766499d956_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia479f3cd68cd4df3b2165aefbe470f19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i269e66b57b7b42519a681c1a8cc89766_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62bfa97ca0b441f598ddfc23f1117719_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadceb1c7c1874b8ba0b62e7c4d2ff42d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ecc54ff86bd462dbcf7438abf4ac388_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddda6f6be78f4602886e324038e7f82c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c41356f213a40cd81fe3fb1a47a4c2b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc75a33630b8494aa7a9d885440fb55b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6131b1918c0e4fdb853bcc6ad763b7ca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20d7b43945214a0f9748176a7c4e3c92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd0a8a099634446f9fb626545b035d04_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41a609eef7164eeca03b96057a76706d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ca3bfc3b74349b0824017e2224f2eed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fb1258352cf41e99f6e755e10b66dd5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1420654e5aac46a18c1f6b2e6ca46fe7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied072b573720413181b76aa300c73290_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1f326cd30a042929083a704f1d6c9b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fd4290024fb4044a496f5b0095aec3a_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b9d38ff906a423c980d0021ca83eefd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a3cb7b2a9c84dd89c8cfd99ca5abf7c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a5e971264d548579cbdbbcb85309080_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica4884a38171464fb3771d584bde78ae_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24a49a71f1f04f838393fe224709a584_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcbca4caa7f44c80ab53213c339fb544_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icec55a17872746d2856769218fef60aa_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b2c42e5029948ed9d33d72c422ec15b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i867d5919542f4494a26a231e8b7346e0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32e8c25671ba4f6fb24dee37c0820f11_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66fe51ad0d964f1896d0f96af0e1e372_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife8f008f05574ef1870bdae6c66d666b_I20210615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7335e9f1b9ca42eca438a74f5c67ab3a_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bf402b9dbdd4d87ae5d49d80d3bfbd1_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5669556108fb4b49ab6793e93d991f6f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6f88ee6c6234a019d97d24e5e39ceff_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibea2d6a312194bd6a0ecf5f54c65238a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i988a06040edf4aa0b8a3f3cd042479bd_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9110adb267ef45a6aa425a647075f177_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38eeebe054f049c9bc2b9a0534ffdab3_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01a768287b9d4dba83bffa872d2e72c8_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee9e9e7ce67a49de83726523a441d2ff_D20170101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f61d57a20cd4679bf6ecc932ade4702_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i633fd2fb64ad42c4b92eebba0535d397_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60225cd201b84577ac14ccd93f6b150d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2135354a19f64808a2cc5c96c8be75a2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i287b95f9f02e4ed1a66f479666758d0a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1793ad9c6b4f4244b4ee579221db1b13_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75eb5df4d251413fba2adbdc9e57ccb9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc0cec4a5a73427eb832e2674227c093_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b71d094740b4c1e9c5b2ff8f8b13f29_D20221014-20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-14</xbrli:startDate><xbrli:endDate>2022-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf251b9dfa1d4ed89dfd50e9d5821e5e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b7bc40165fd46a193e3cccf1f049cfa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96872571cd0a4110aadf271b65708d4f_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69bfd0f8331b41bba3c4e5efaa36efc4_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54460e4405804e6d8632d256ca806b3a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideaa024a11c34bdb89c49cd5c437abdb_D20200701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3160099d486f4eb0ac91ae68ee1818a5_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idda174e868e34f569bb5414b16d63aaf_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6508d36a64142029325de20e5324de6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d66046a5ee64f7788d581007532e524_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d938aac5ed04e51bcb036c13e6fa016_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1715d94674d945de83bbfd371f7c13c4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i767daa988e954076be39c9747efd7d0d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e1ac66792744af791f7f6abfa4dcef6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54dc0d7d758841359d25ada6f2a3f6bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e5adc3d5e2442fbbb01084952f712f4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05c59e94ee554f07bf1f21a28ba5d901_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib60793823f51401f91c4fe5a62120d5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b1d84cceaa14d2b82272120f3d141a5_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4cc71ed45f8424fb7ad7a930e7af919_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b4b8204955c40b9a81053a2ea6a7a34_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11525e01950f45fa820c699ad1b87012_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i823ffcf87c174dfd869db3d5bf2f4876_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ce4656c88644281a81473a1a311bcbb_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13845f28c8184f82b5a85649094c84bc_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dfb8c7e4fd04324883491a98fdd5523_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5332bdbc1ac4d42acfb85ff18b8d769_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fdd00452e734cd1a063f90a315bd38e_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42483221131f4b7481cd3ebfbdd95b45_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if91ec42029d64d03b3bab9599a9791b5_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i687253dc3b1a4370bafa13817794d0a3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f896d007a6a40c48c8fb6cc5e26ea95_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c37a5c38e654c99b1697de56b18cac8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58e91935654b49eab232a7ec7b32496c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1ecd07929384da0be9ffd4764df7764_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35eba6ff61e44d84bf6a3d50767ad056_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i641ea39eabec428e8868e07727550f9b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i221ddea90685424e9202290d98e954b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d9b291f44c14b62a56b45b107bce2be_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74eb3a9ad62848108dd74bde2d588232_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d15a5f2354a420f9695a7e6099f117f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if52c5ab82dd044a69f0166c3ff58ca62_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e86a555e3f24015bead72636200ae9a_D20101001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57cad70ea273424dabf7a187420e4724_I20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="productcandidate"><xbrli:measure>mgnx:productCandidate</xbrli:measure></xbrli:unit><xbrli:context id="i15b810928e3242aaa7f2093120fe452e_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if20ab34aae324e0ba9bf43107ec6f001_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa77d46ed2c54978a8e628b9c800991f_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if00f09390f0345d98c06a7e6e9cc8a8b_D20220101-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1445c3a2eddd4bfeb9296be4f2aca5ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8717043cd074e1297a517f4c6e6cc88_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAmendmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i623d0a5a27c445f8a4c07b43115440e9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d1179302351453e86c2c3157b6019e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ProventionBioCMOAgreeemntMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib46875612ebc4591ae7244a0f9125f6e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ProventionBioCMOAgreeemntMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c73c17081c04144891915096cd9ed39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5ee02f7ab344826b0c16f694bb46f66_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i691134ba3b13405da417f0241eb6ca6d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e0c41dd27764d34aa9ab34ec3e0805a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf4d116422ce486bb630e9f82b58aeb1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i169fc1b09cca4f95bc19d111a9403716_I20170518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9360fd694d5e424f8c7bd8fd3eb717bc_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i452d203362b14c6ca8da438846c11955_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i957cb602cb054b3ea23a8226a9ddbb3a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0502d2128aa4313a80c03495c0ed1ea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i544f43f987bd419e8c458062ac60ce6f_I20131031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07711b76935c4009a2ace4be4f684dd6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i255a59bd218f42e2af9732b94035f04c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffd00d99f798466d860442a9d6fe22f2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if50f063c6cd94e9a8db88782218b51c9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6968adfd4fe340119028718b06cfb436_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6322f1cbd714b298d2485ddc0fc3322_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i529ec6ae784044b38dc167bc1dfef832_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26acb212525e4cc19f85aeb7f96576bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e619dc3a61b43d087d92cd2fee49ef4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0e3bcdcfbcf4c97b49dae77737eb857_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03b32c2299d94db490057c88800e534c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id868fe5312d548fda66c272fedcbd81c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic345c52c1f4b4493a8a2205795297694_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4a9eb4001cb48e29e15fb1edeea83c2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i458932626a4e44acacb64a6525da2b9a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mgnx:ExercisePriceRangeFromDollars094To500MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i781cf98fff854dee996c091defcba9ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mgnx:ExercisePriceRangeFromDollars094To500MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4f6bf1229f9423d9d74a89cbee04492_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mgnx:ExercisePriceRangeFromDollars501To1500MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bd6e8fd9d6e41759ae8ce19e1f15dc0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mgnx:ExercisePriceRangeFromDollars501To1500MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb9b7e3cc6654c6ab1c1abd54c49d1b0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mgnx:ExercisePriceRangeFromDollars1501To2500MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65f1a38a652c4027a979e5802d9bf79f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mgnx:ExercisePriceRangeFromDollars1501To2500MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d2cf19a216341f7b8ee2b4013afc61e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mgnx:ExercisePriceRangeFromDollars2501To4021MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i734a212745e14c3da7f13584d8590872_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mgnx:ExercisePriceRangeFromDollars2501To4021MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bd6e5ab104947eb9423512ebd965f85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if31e41373baa4fea9e84a7408c5073dd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2847395a9c0e4cb490b51246d0a78963_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1a3ce377fe84955853c621ebe3898e1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8563ce4345344189c9f265ecff1081e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:TaxYear2025To2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i305df6411bc540c288af86c6048f32a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:IndefiniteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabb762e6d67f44868d3a4659e39f91a1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16521e389da946b0bfcbbb417dd1be5e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic22e2b51dfee4a8e88cd23892f992f68_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6170cef51c304b009b2a8259c24dafdc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia220f44f166a475abc1053b676542ca5_I20230315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ec282a2b1564332bd9e83d00ada0da7_D20230301-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9064db26008e44ad995ee3ad48ef6721_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C.&#160;&#160;20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntityFileNumber" id="f-6">001-36112</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntityRegistrantName" id="f-7">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="f-9">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(State of organization)&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="f-10">9704 Medical Center Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="f-11">Rockville</ix:nonNumeric>, <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Maryland</ix:nonNumeric> <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="f-13">20850</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:CityAreaCode" id="f-14">301</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:LocalPhoneNumber" id="f-15">251-5172</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant's telephone number)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:37.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.01 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:TradingSymbol" id="f-17">MGNX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company", and "emerging growth company"  in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:22.294%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="f-24">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-25">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9745;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="f-27">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the registrant's common stock, par value $0.01 per share, held by non-affiliates of the registrant on June&#160;30, <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="f-28">2022</ix:nonNumeric>, the last business day of the registrant's most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-29">181.3</ix:nonFraction> million based on the closing price of the registrant's common stock on the Nasdaq Global Select Market on that date.&#160;&#160;Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of management or policies of the registrant, or that such person is controlled by or under common control with the registrant.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the registrant's common stock outstanding on March&#160;10, 2023 was <ix:nonFraction unitRef="shares" contextRef="i31e765beb79e48d59898de0cccf072fe_I20230228" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">61,838,565</ix:nonFraction>.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true">Portions of MacroGenics, Inc.'s definitive proxy statement for the 2023 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_13">PART I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_16">Business</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_19">Risk Factors</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_22">Unresolved Staff Comments</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_25">Properties</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_28">Legal Proceedings</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_31">Mine Safety Disclosures</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_34">PART II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_37">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_40">Reserved</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_43">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_64">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_67">Financial Statements and Supplementary Data</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_70">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_73">Controls and Procedures</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_76">Other Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_79">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_85">PART III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_88">Directors, Executive Officers and Corporate Governance</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_91">Executive Compensation</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_94">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_97">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_100">Principal Accountant Fees and Services</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_103">PART IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_106">Exhibits and Financial Statement Schedules</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_109">Form 10-K Summary</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_112">Signatures</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Annual Report on Form 10-K. Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Risk Factors"), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to develop and commercialize our product candidates;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes of our ongoing and planned clinical trials and the timing of those outcomes, including when clinical trials will be initiated or completed, enrollment of trials, and when data will be reported or regulatory filings will be made;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates and the labeling for any approved products;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital through the capital markets or through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding product candidates currently being developed by our collaborators;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits and future operation of our existing collaborations; </span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recover the investment in our manufacturing capabilities;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our products;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition in our industry;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of litigation and the failure to successfully defend lawsuits and other claims against us and our expectations regarding the outcome of any regulatory or legal proceedings;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic, political and other risks associated with our international operations;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to receive research funding and achieve anticipated milestones under our collaborations;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss or retirement of key members of management;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully execute our growth strategy, including any delays in our planned future growth;</span></div><div style="margin-bottom:4pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to maintain effective internal controls; and</span></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity and duration of the impact of a global pandemic on our business, operations, clinical programs, manufacturing, financial results and other aspects of our business.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i9064db26008e44ad995ee3ad48ef6721_16"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Except as otherwise indicated herein or as the context otherwise requires, references in this annual report on Form 10-K to "MacroGenics," the "company," "we," "us" and "our" refer to MacroGenics, Inc. and its consolidated subsidiaries.</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MacroGenics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">, the MacroGenics logo, DART</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">, TRIDENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">, MARGENZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> and the phrases Breakthrough Biologics, Life-Changing Medicines&#174; and Developing Breakthrough Biologics, Life-Changing Medicines</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> are our trademark</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">s. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> The other trademarks, trade names and service marks appearing in this report are the property of their respective owners.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. We have a pipeline of product candidates being evaluated in clinical trials sponsored by us or our collaborators in addition to several molecules in preclinical development. Our clinical product candidates include multiple oncology programs, many of which were created using our proprietary, antibody-based technology platforms. We believe our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents. To date, two products originating from MacroGenics&#8217; pipeline of proprietary or partnered product candidates have received U.S. Food and Drug Administration (FDA) approval.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Our lead pipeline program is vobramitamab duocarmazine (vobra duo) (formerly MGC018), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is widely expressed by several different tumor types. We have historically pursued development of other molecules that target B7-H3, including enoblituzumab, an Fc-optimized monoclonal antibody (mAb). We are also developing molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system&#8217;s response to cancer. Our clinical pipeline includes two  product candidates based on our proprietary, bispecific DART technology that co-engage both PD-1 and other checkpoint molecules. These candidates include lorigerlimab, which targets PD-1 and CTLA-4, or cytotoxic T-lymphocyte-associated protein 4, and tebotelimab, which targets PD-1 and LAG-3, or lymphocyte-activation gene 3. In addition, we are developing MGD024, a next-generation bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia (AML). </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaboration partners are developing or commercializing product candidates for which we retain certain economic rights. These molecules include IMGC936, a clinical-stage ADC that targets ADAM9, a cell surface protein over-expressed in several solid tumor types; retifanlimab, an anti-PD-1 mAb that we out-licensed and TZIELD&#8482; (teplizumab-mzwv), an anti-CD3 monoclonal antibody that we sold to a partner.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we and our commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist mAb we developed that is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have created our product candidates based on the following antibody-based technologies:</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ADC platforms, which we have licensed from collaboration partners to leverage third-party proprietary linker payloads, and which link monoclonal antibodies that specifically target cancer cells with cytotoxins that are designed to trigger cell death in the cancer cell;</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Multi-specific platforms, which enable us to design antibodies that can bind to two (in the case of our bispecific DART product candidates) or more distinct targets, each with antibody-like specificity, with the goal of creating a more significant biological effect than binding any one of the targets as with an antibody or two or more of them separately as a combination. We have specifically utilized our DART platform to generate product candidates for use in the following modalities:</span></div><div style="margin-bottom:6pt;padding-left:94.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Bispecific checkpoints</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We leverage our proprietary DART platform to enable simultaneous targeting of multiple co-inhibitory receptors or checkpoints, such as those involved in inhibiting T-cell responses. Targeting two immunoregulatory pathways, such as two checkpoints in a single molecule, affords the clinical benefit of the combination together with the potential for improved efficacy and/or safety, as well as advantages in manufacturing, simplified clinical development and enhanced patient convenience.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:94.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.46pt">Next-Generation T-Cell Engagers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have extensive experience applying our proprietary multi-specific DART and TRIDENT platforms to develop molecules that redirect T-cell activation and killing which: (1) recognize and bind to structures expressed on a cancer cell, (2) recruit all types of cytotoxic, or cell killing, T cells, irrespective of their ability to recognize cancer cells, and (3) trigger T-cell activation, expansion, and cell killing mechanisms to destroy a cancer cell. <br/><br/>MacroGenics&#8217; next-generation T-cell engagers incorporate a CD3 component that is designed to minimize cytokine-release syndrome (CRS), a potentially life-threatening toxicity, while increasing the magnitude of antitumor activity with a longer half-life to permit intermittent dosing; and</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fc Optimization platform, which introduces certain mutations into the Fc domain of a mAb in order to modulate antibody interaction with immune effector cells to enhance the killing of cancer cells.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to be a fully-integrated biotechnology company leading in the discovery, development, manufacturing and commercialization of breakthrough antibody-based biologics for the treatment of patients with cancer.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline of Oncology Clinical Product Candidates for Which We Retain Commercial Rights</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below depicts the status of our oncology product candidates that are in clinical development and for which we retain all or some commercial rights:</span></div><div><img src="mgnx-20221231_g1.jpg" alt="mgnx-20221231_g1.jpg" style="height:325px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">B7-H3 Programs</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two clinical-stage programs, vobra duo and enoblituzumab, that target B7-H3 (CD276), an immune checkpoint molecule that is overexpressed in cancer tissues while showing limited expression in normal tissues. B7-H3 is a member of the B7 family of immune regulator proteins that is widely expressed by different tumor types and may play a key role in regulating the immune response to various cancers. Of the two programs, currently only vobra duo is in active clinical development. There are no currently approved therapeutic agents directed against B7-H3.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vobramitamab Duocarmazine </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vobra duo is an investigational ADC with a cleavable peptide linker designed to deliver a DNA-alkylating duocarmycin payload to dividing and non-dividing cells on solid tumors that express B7-H3. The underlying ADC technology was licensed from Byondis B.V. (Byondis). After completing a dose escalation study in 2020, we initiated the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1/2 dose expansion study of v</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obra duo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">metastatic castration-resistant prostate cancer (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mCRPC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-small cell lung cancer (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NSCLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, melanoma, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">squamous cell carcinoma of the head and neck (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCCHN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">triple negative breast cancer (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TNBC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The purpose of this fully-enrolled study was to evaluate the safety and tolerability, pharmacokinetics, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmacodynamics and preliminary antitumor activity of the molecule. In addition, in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> early 2022, w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e initiated a Phase 1/2 dose escalation study of v</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obra duo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with lorigerlimab </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(formerly MGD019), a bispecific DART molecule designed to block PD-1 and CTLA-4, in patients with solid tumors. This study is ongoing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2022, we initiated the Phase 2 portion of the TAMARACK Phase 2/3 study of vobra duo in patients with mCRPC who have had prior exposure to a taxane and at least one androgen receptor axis-targeted, or ARAT, agent (including abiraterone, enzalutamide or apalutimide), and a PARP (poly adenosine diphosphate-ribose polymerase) inhibitor, if appropriate. This study is designed to evaluate 100 patients across two experimental arms in which they receive vobra duo at either 2.0 mg/kg or 2.7 mg/kg once every four weeks (Q4W). This study initially included a control arm in which patients received a second ARAT agent. The treatment landscape for patients with mCRPC has evolved with declining acceptability regarding the use of a second ARAT agent in patients who progress on earlier therapies and the approval of a radiopharmaceutical medication. Given our objective to enroll TAMARACK and determine an optimal dose expeditiously, as of the first quarter of 2023, we have modified the trial by removing the ARAT control arm and the Phase 3 portion of the study, with regulatory approval for the modified protocol obtained to date in several countries. We believe that removal of the control arm should allow us to provide a clinical update in 2024 potentially in support of a subsequent Phase 3 study in mCRPC.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dose Escalation Study Results (as of May 2020)<br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, data from the dose escalation study of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vobra duo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was initially presented. At the May 6, 2020 data cut-off, 23 evaluable patients with advanced solid tumors had been enrolled in four dose escalation cohorts of 0.5 mg/kg to 3 mg/kg given intravenously every three weeks. Treatment was ongoing in an expanded fifth cohort of patients at 4 mg/kg every three weeks at the data cut-off date.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the May 6, 2020 data cut off, preliminary evidence of anti-tumor activity by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obra duo was observed in the dose escalation portion of the study, particularly in patients with advanced mCRPC. Reductions in prostate-specific antigen (PSA) levels of &#8805; 50% (PSA50) were observed in five of seven mCRPC patients treated, including one with substantial regression of bone disease. Six mCRPC patients had bone-only disease, and one patient with measurable peripheral disease had a 29% reduction in target lesions that did not qualify as a response per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST). Four PSA responders remained on therapy as of the data cut-off. Patients with mCRPC had received a median of four therapies prior to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vobra duo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including taxane chemotherapy (six patients) and next-generation hormonal agents (six patients were treated with both abiraterone and enzalutamide, and one with abiraterone only).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through dose escalation, the safety profile of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vobra duo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which had included hematologic and skin toxicities, was generally manageable as of the data cut-off. At least one treatment-related adverse event (TRAE) occurred in 22 of 23 patients (96%), including Grade &#8805; 3 reported in 14 of 23 patients (61%). Three treatment-related serious adverse events occurred in one patient each: pneumonitis in a patient with concurrent bacterial pneumonia; non-infectious gastroenteritis; and stasis dermatitis in a patient with chronic venous insufficiency. One dose-limiting toxicity of Grade 4 neutropenia that resolved to baseline was reported. No febrile neutropenia was observed.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1/2 Dose Expansion Study Results (as of August 2021)</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary clinical results from the ongoing Phase 1/2 study of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vobra duo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with solid tumors was presented at the 2021 European Society for Medical Oncology (ESMO) Meeting. As of the August 16, 2021 data cut-off, a total of 86 patients with advanced solid tumors were enrolled in the cohort expansion of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vobra duo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the recommended Phase 2 dose (RP2D) of 3.0 mg/kg, administered intravenously every three weeks. The enrollment included 40 patients with mCRPC, 21 patients with NSCLC, 16 patients with TNBC and nine patients with melanoma. In addition, enrollment of patients with SCCHN had been initiated. The safety analysis included all enrolled patients, whereas the efficacy analysis was limited to mCRPC and NSCLC patients; enrollment was ongoing in the other tumor cohorts. In the cohort expansion, tumor response by investigator per RECIST was evaluated every nine weeks for all patients and PSA was assessed every three weeks in mCRPC.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the August 16, 2021 data cut-off, all 40 patients in the mCRPC cohort expansion had been enrolled. Patients had previously received a median of three prior therapies for advanced disease, with all 40 patients having received both chemotherapy and next-generation hormonal therapy. Based on an immunohistochemistry assessment of patient tumor samples, the median B7-H3 H-score (a combined score of the intensity and the proportion of B7-H3 expression, comprising values between 0 and 300) for all mCRPC patients was 223. A total of 39 mCRPC patients were evaluable for PSA response. Reductions in PSA levels of &#8805; 50% (PSA50) were observed in 21 of 39 patients (54%). Twenty-four of the 39 patients (62%) remained on treatment as of the data cut-off. Of the 40 patients in the mCRPC cohort, 16 of the 23 patients with measurable disease were evaluable for tumor response by RECIST as of the data cut-off. Ten of these 16 patients (63%) had reductions in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their target lesion sums from baseline. Four patients (25%) demonstrated a partial response (PR), consisting of two confirmed and two unconfirmed PRs. Treatment was ongoing in six of 16 patients with evaluable tumor response as of the data cut-off.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the August 16, 2021 data cut-off, the NSCLC cohort expansion had been fully enrolled with 21 patients. Patients had previously received a median of two prior therapies for advanced disease, with 15 (71%) having previously received anti-PD-1/PD-L1 therapy. The median B7-H3 H-score for these patients was 139. A total of 16 NSCLC patients were evaluable for tumor response by RECIST. Thirteen of 16 (81%) patients had reductions in their target lesion sums from baseline. Four of these 16 patients (25%) experienced unconfirmed partial responses. Another one of these 16 patients experienced a 30% reduction in target lesions; however, the patient&#8217;s non-target lesions were not evaluated due to an obstruction of the bronchus and overall response was not evaluable. Treatment was ongoing in seven of 16 patients as of the data cut-off.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety analysis includes all 86 patients enrolled in the cohort expansion as of the August 16, 2021 data cut-off. The median number of doses received by mCRPC patients was 3.5 (range: 1-8); those with NSCLC received 3.0 (range: 1-7). Adverse events for the dose expansion cohorts of 3 mg/kg were generally consistent with those previously reported at ASCO 2021. TRAEs included hematologic and skin toxicities that have been clinically manageable to date. In the cohort expansion study overall, at least one TRAE of any grade was experienced by 78 of 86 patients (91%), with 43 of 86 patients (50%) experiencing a Grade &#8805;3 TRAE.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were two Grade 5 fatal events: one from an unknown cause and one due to SARS-CoV-2.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most common TRAEs were fatigue (37% all grades; 1% Grade &#8805;3), neutropenia (34% all grades; 22% Grade &#8805;3), palmar plantar erythrodysesthesia syndrome (31% all grades; 4% Grade &#8805;3), pleural effusion (23% all grades; 1% Grade &#8805;3), nausea (22% all grades; 1% Grade &#8805;3), asthenia (20% all grades; 5% Grade &#8805;3) and thrombocytopenia (14% all grades; 7% Grade &#8805;3). The overall results demonstrated a manageable safety profile with a low rate of treatment discontinuation due to TRAEs: only six of 86 (7%) patients had discontinued therapy in the cohort expansion as of the data cut-off date due to TRAEs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enoblituzumab</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enoblituzumab is an investigational monoclonal antibody that targets B7-H3 that has been engineered using our Fc Optimization platform. A Phase 2 study evaluating enoblituzumab in combination with either retifanlimab (anti-PD-1 monoclonal antibody) or tebotelimab (PD-1 &#215; LAG-3 bispecific DART molecule) in the first-line treatment of patients with recurrent or metastatic SCCHN was discontinued in July 2022.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had initiated a Phase 2 study of this agent in the first-line treatment of patients with relapsed or metastatic SCCHN not curable by local therapy in the first quarter of 2021. This trial included enoblituzumab in a chemotherapy-free regimen in combination with either retifanlimab in patients who are programmed death-ligand 1 (PD-L1) positive or with tebotelimab in patients who are PD-L1 negative. In July 2022, we announced the closure of this study based on an internal review of safety data, which included the occurrence of seven fatalities potentially associated with hemorrhagic events in both arms of the study (of 62 total patients treated). </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the 2022 ASCO Annual Meeting, investigators presented data from an investigator-sponsored trial of a single-center, single arm, open-label Phase 2 study evaluating the safety, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given prior to radical prostatectomy in men with intermediate and high-risk localized prostate cancer. In this study, investigators reported that six weeks of treatment with enoblituzumab demonstrated favorable safety and encouraging clinical activity in high-risk prostate cancer patients with local disease prior to prostatectomy. These trial results, combined with demonstrated favorable safety profile observed by the investigators, provide the rationale for further development of enoblituzumab and other B7-H3 targeted agents in prostate cancer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we licensed the right to develop and commercialize enoblituzumab in mainland China, Hong Kong, Macau and Taiwan to I-Mab Biopharma (I-Mab). In August 2022, I-Mab notified us of its intention to terminate the I-Mab License Agreement effective February 25, 2023. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immune Checkpoint Inhibitors</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Checkpoint inhibition has become an important staple of oncology. Our clinical pipeline includes three product candidates in clinical development that target checkpoint molecules for the potential treatment of a broad range of solid tumors. These candidates include two bispecific DART product candidates that co-engage PD-1 and other checkpoint molecules and an anti-PD-1 monoclonal antibody that we have out-licensed to a partner.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lorigerlimab (formerly MGD019)</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved monoclonal antibodies that target the immune checkpoints PD-1 and CTLA-4 have shown enhanced clinical antitumor activity when given in combination in various cancers, including renal cell carcinoma and NSCLC with high tumor mutational burden. Lorigerlimab is an investigational, bispecific tetravalent DART molecule designed to enable simultaneous and/or independent blockade of PD-1 and CTLA-4, with potentially enhanced CTLA-4 blockade on T cells co-expressing these immune checkpoint molecules.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Dose Escalation Study Results (as of July 21, 2020)</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted a Phase 1/2 clinical trial of lorigerlimab in patients with advanced solid tumors. The study was designed to enroll patients with histologically proven, unresectable, locally advanced or metastatic solid tumors for whom no approved therapy with demonstrated clinical benefit is available or patients who are intolerant to standard therapy. Forty-three patients were enrolled in the 3+3+3 dose escalation study within a dose range of 0.03 &#8211; 10.0 mg/kg, administered every three weeks initially, in a population of heavily pre-treated patients representing a broad range of different types (23) of solid tumors. A total of 28 patients were treated at doses &#8805; 3.0 mg/kg administered every three weeks initially. Of the 18 evaluable patients who received doses &#8805; 3.0 mg/kg as of the July 21, 2020 cut-off date, four objective responses were reported, including a confirmed complete response in mCRPC, confirmed PRs in microsatellite stable colorectal cancer (MSS CRC) and metastatic type AB thymoma, and an unconfirmed PR in serous fallopian tube carcinoma. Lorigerlimab was well-tolerated in patients who received less than 10 mg/kg. The most common TRAEs observed were pruritus (23.3%), arthralgia (18.6%), fatigue (18.6%), rash (18.6%), nausea (16.3%) and infusion-related reaction (16.3%) as of the data cut-off. Several Grade 3 adverse events were observed at the 10.0 mg/kg level; however, none were considered dose limiting.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this study, full and sustained peripheral PD-1 blockade was evident at doses &#8805; 1.0 mg/kg over a 3-week dosing interval. In addition, dose-dependent upregulation of the inducible costimulator (ICOS) molecule was evident in treated patients, including those who responded to lorigerlimab therapy. This is consistent with an observation previously reported in the literature that anti-CTLA-4 therapy increases the frequency of CD4 T cells expressing the ICOS molecule.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Dose Expansion Study Results (as of December 12, 2022)</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are evaluating lorigerlimab in an ongoing Phase 1/2 dose expansion study in patients with MSS CRC, mCRPC, melanoma and checkpoint-naive NSCLC, and reported on preliminary data at the ASCO Genitourinary Cancers Symposium in February 2023. As of the December 12, 2022 data cut-off, 118 patients were enrolled at the dose of 6.0 mg/kg, administered intravenously every three weeks (Q3W). Confirmed objective responses were observed across the histology-specific cohorts; preliminary efficacy results for mCRPC were presented in the poster.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preliminary Safety Results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The safety analysis is based on 127 patients who received lorigerlimab at a dose of 6 mg/kg Q3W, including 118 enrolled in the four dose expansion cohorts plus nine patients from dose escalation. Median exposure was 14.4 weeks (range: 1.9 - 100.1 weeks) with a median of four infusions administered per patient. Twenty-four patients remained on lorigerlimab as of the December 12, 2022 data cut-off; 103 discontinued for the following reasons: progressive disease (PD) (n=66), adverse events (AE) (n=31), patient/physician decision (n=5), or death due to PD (n=1).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results demonstrated a manageable overall safety profile. TRAEs occurred in 86.6% of patients, with the most common among them (&#8805;15%) being fatigue, rash, pruritus, hypothyroidism, and pyrexia. Rates of grade &#8805;3 TRAEs and immune-related AEs were 35.4% and 7.9%, respectively. AEs resulted in treatment discontinuation in 25.2% of patients. There were no fatal AEs related to lorigerlimab.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preliminary Anti-tumor Activity in mCRPC Cohort</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of the December 12, 2022 data cut-off, 42 patients had been enrolled in the mCRPC expansion cohort. Patients had previously received a median of two prior therapies (range: 1 &#8211; 9) for advanced disease, with 35 patients (83.3%) having received docetaxel and 34 patients (81.0%) having received androgen receptor antagonist therapy. The median exposure to lorigerlimab was 19.2 weeks (range: 3.3 - 55.1 weeks), with a median of five infusions administered per patient.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A total of 35 patients with mCRPC had measurable soft tissue disease per RECIST v1.1 at study entry. Nine of the 35 patients (25.7%) achieved confirmed partial responses (cPR). The median duration of response for these nine patients was 4.6 months (range: 2.8 &#8211; 8.6+ months), with four patients remaining on lorigerlimab as of data cut-off. Among the other five patients who had achieved cPR, four discontinued due to unrelated adverse events, and one patient discontinued due to physician decision.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reductions in PSA levels of &#8805; 50% were observed in 12 of 42 patients (28.6%), and 9 of the 12 maintained PSA50 response &#8805; 3 months. Nine of 42 patients (21.4%), including the nine who achieved cPR, had reductions in their PSA levels of &#8805; 90% as of the data cut-off.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the above data, we plan to initiate a randomized Phase 2 study of lorigerlimab in combination with docetaxel vs. docetaxel in second-line, chemotherapy-na&#239;ve mCRPC patients in the second half of 2023. A total of 150 patients are planned to be randomized 2:1. The current study design includes a primary study endpoint of radiographic progression-free survival (rPFS).</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tebotelimab</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tebotelimab is an investigational, first-in-class bispecific, tetravalent DART molecule targeting PD-1 and LAG-3. We have engineered tebotelimab to concomitantly or independently bind to PD-1 and LAG-3 and disrupt these non-redundant inhibitory pathways to further restore exhausted T-cell function. Tebotelimab was evaluated in a Phase 1/2 dose expansion study in several tumor types and was studied in combination with enoblituzumab in SCCHN. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Dose Expansion Study Results (as of April 25, 2020)</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, initial data was presented from a Phase 1 monotherapy dose expansion study of tebotelimab in patients with advanced solid and hematologic neoplasms. At the April 25, 2020 data cut-off, 205 patients had been treated with tebotelimab, of which 152 were evaluable for response. Anti-tumor activity of tebotelimab, as assessed by RECIST, was observed in evaluable patients across several of the tumor types in the selected dose expansion cohorts. Response to tebotelimab monotherapy was associated with LAG-3 expression and an IFN-&#947; gene signature at baseline. The overall safety profile of tebotelimab in the Phase 1 study, including the incidence of immune-mediated adverse events, appeared generally consistent with anti-PD-1 antibody monotherapy with respect to event type and frequency.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Dose Expansion Results in Diffuse Large B-cell Lymphoma (as of October 23, 2020)</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, data was presented from the tebotelimab Phase 1/2 dose expansion study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In this study, 20 DLBCL patients were enrolled, half of whom were chimeric antigen receptor (CAR) T cell therapy experienced. As of the October 23, 2020 data cut-off, there were 13 response-evaluable patients. A preliminary ORR of 53.8% (7 of 13 patients) was observed, including responses in five of seven CAR T cell-na&#239;ve patients and in two of six CAR T cell experienced patients, the latter of whom both had complete responses. A preliminary duration of response of up to 168 days was observed, with six of seven ongoing responses as of the cut-off date. In the study, baseline LAG-3 expression appeared to associate with clinical response. Tebotelimab was generally well-tolerated among heavily pre-treated R/R DLBCL patients, with manageable infusion-related reactions and no evidence of tumor lysis syndrome. The most common TRAE was pyrexia, which occurred in three (15%) patients. A single Grade 3 TRAE of anemia was observed.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our November 2018 license and collaboration agreement with Zai Lab Limited (Zai Lab), we licensed to them the right to develop and commercialize tebotelimab in mainland China, Hong Kong, Macau and Taiwan. Zai Lab has led regional studies evaluating tebotelimab in various indications in its territory. Zai lab discontinued development of tebotelimab for indications they were enrolling in their territory and is evaluating future development plans in other indications.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">T-cell Redirected Bispecific DART Molecules</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing a bispecific DART molecule that can simultaneously target T-cells and tumor cell surface antigens to engage and promote redirected T-cell killing of cancer cells. CD123, the interleukin-3 receptor alpha chain, is widely overexpressed in various hematologic malignancies, including AML and myelodysplastic syndrome (MDS), making it an attractive therapeutic target. Various drugs have been developed to target CD123, but none have received FDA approval. We have created a bispecific DART molecule that engages CD3 expressed on immune effector cells, such as T cells, to kill CD123-expressing cancer cells for the potential treatment of certain hematologic malignancies, including AML.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">MGD024</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MGD024 is an investigational, next-generation, bispecific CD123 &#215; CD3 DART molecule designed to minimize cytokine-release syndrome, while maintaining anti-tumor cytolytic activity, and permitting intermittent dosing through a longer half-life. In December 2021, we presented preclinical MGD024 data at the American Society of Hematology (ASH) Annual Meeting that showed the potential for anti-tumor activity from the combination of MGD024 with standard of care agents used to treat AML. We initiated a Phase 1 study of MG024 in patients with CD123-positive hematologic malignancies in July 2022, and this dose escalation study is ongoing. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2022, we and Gilead Sciences, Inc. (Gilead) entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and create bispecific cancer antibodies using our DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Gilead Agreement, we </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will continue the ongoing phase 1 trial for MGD024 accordi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng to a development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license to develop and commercialize MGD024 and other bispecific antibodies of ours that bind CD123 and CD3 (CD123 Option).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The agreement also grants Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by us and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option). As part of the Gilead Agreement, Gilead paid us a non-refundable upfront payment of $60.0 million and we will be eligible to receive up to $1.7 billion in target nomination, option fees, and development, regulatory and commercial milestones, assuming Gilead exercises the CD123 Option and Research Program Option, successfully develops and commercializes MGD024 or other CD123 products developed under the agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and products result from the two additional research programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming exercise of the CD123 Option, w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(or other CD123 products developed under the agreement) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assuming exercise of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option, a flat royalty on worldwide net sales of any products resulting from the two research programs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Margetuximab</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our commercial partner, Eversana Life Science Services, LLC (Eversana), are currently marketing MARGENZA (margetuximab-cmkb), in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. Margetuximab is an Fc-engineered, mAb that targets the HER2 oncoprotein. HER2 is expressed by tumor cells in breast, gastroesophageal and other solid tumors. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our November 2018 license and collaboration agreement, Zai Lab has the rights to develop margetuximab in mainland China, Hong Kong, Macau and Taiwan. On January 6, 2022, Zai Lab announced that the China NMPA had accepted the New Drug Application (NDA) for margetuximab for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease, in combination with chemotherapy.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse reactions occurring in greater than twenty percent of patients with MARGENZA in combination with chemotherapy were fatigue/asthenia (57%), nausea (33%), diarrhea (25%), and vomiting (21%). The MARGENZA U.S. Prescribing Information has a BOXED WARNING for left ventricular dysfunction and embryo-fetal toxicity. In addition, MARGENZA can cause infusion-related reactions (IRRs). IRRs occurred in 13% of patients treated with MARGENZA, with the majority reported as Grade 2 or less. Grade 3 IRRs occurred in 1.5% of patients.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Partnered Programs</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retifanlimab</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retifanlimab is an investigational mAb targeting PD-1. Marketed antibodies targeting this checkpoint molecule have shown clinical efficacy in the treatment of various tumors by releasing the "brakes" of the immune system and helping to restore the immune system's ability to detect and kill tumor cells. In 2017, we licensed retifanlimab to Incyte Corporation (Incyte) under a global collaboration and license agreement (Incyte Agreement), although we retain the right to develop the molecule in combination with product candidates from our pipeline. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the Incyte Agreement, we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are eligible to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">receive up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$665 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">million in remaining development, regulatory and commercial milestones from Incyte. In addition, we are eligible to receive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tiered royalties of 15% to 24% on any global net sales of the product.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling indications, including in patients with Merkel cell carcinoma, squamous carcinoma of the anal canal, microsatellite instability-high, or MSI-high, endometrial cancer and non-small cell lung cancer. Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">IMGC936</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMGC936 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an ADC that targets ADAM9, a cell surface protein over-expressed in several solid tumor types. IMGC936 is being advanced under a co-development agreement with ImmunoGen, Inc. (ImmunoGen). Under the 50/50 collaboration, ImmunoGen is leading clinical development and has completed Phase 1 dose escalation and initiated dose expansion in NSCLC and triple negative breast cancer. ImmunoGen has indicated they anticipate sharing initial data in the second quarter of 2023.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teplizumab </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we entered into an asset purchase agreement (Asset Purchase Agreement) with Provention Bio, Inc. (Provention) pursuant to which they acquired our interest in teplizumab, a monoclonal antibody we had been developing for the treatment of type 1 diabetes. Teplizumab has been granted Breakthrough Therapy Designation by the FDA and PRIority MEdicines (PRIME) designation by the European Medicines Agency.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2022, the FDA approved TZIELD&#8482; (teplizumab-mzwv) to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D. Under the Asset Purchase Agreement, Provention is obligated to pay us contingent milestone payments totaling $170 million upon the achievement of certain regulatory approval milestones, including $60 million for the approval of a BLA for a first indication in the United States. In addition, Provention is obligated to make contingent milestone payments to us totaling $225 million upon the achievement of certain sales milestones as well as a single-digit royalty on net sales of the product.  On November 30, 2022, we and Provention entered into Amendment No. 1 (APA Amendment) to the Asset Purchase Agreement. Pursuant to the APA Amendment, the $60.0 million milestone payment related to the achievement of FDA approval was revised to require the amount to be paid in four equal installments rather than within 90 days of approval. Under the Amendment, Provention paid us $15.0 million on each of November 30, 2022 and March 1, 2023, and is required to pay us $15.0 million on each of June 1, 2023 and September 1, 2023.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we sold our royalty interest in TZIELD to a wholly-owned subsidiary of DRI Healthcare Trust (DRI). We retain our other economic interests related to TZIELD, including future potential regulatory and commercial milestones. We received a $100.0 million upfront payment from DRI for the sale of our single-digit royalty on global net sales of TZIELD. We retain the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, we are eligible to receive up to $50.0 million from DRI upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed T1D and may also receive an additional $50.0 million if TZIELD achieves a certain level of net sales.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRV-3279 </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we also entered into a license agreement with Provention pursuant to which we granted them exclusive global rights for the purpose of developing and commercializing PRV-3279 (formerly MGD010), a CD32B &#215; CD79B DART molecule being developed for the treatment of autoimmune indications. Provention is initially developing PRV-3279 for the interception of systemic lupus erythematosus (SLE), a chronic autoimmune disorder characterized by an abnormal overactivation of B cells and subsequent pathologic production of auto-antibodies. Provention has disclosed that it believes PRV-3279 also has the potential to prevent or reduce the immunogenicity of biotherapeutics, including but not limited to gene therapy vectors and transgenes. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provention disclosed in the first quarter of 2022 that they had initiated a Phase 2a trial in SLE of PRV-3279. The PREVAIL-2 study is a Phase 2a proof-of-concept (POC) study in moderate-to-severe SLE patients induced into response with a short course of corticosteroids, and then monitored for relapse, after randomization to either PRV-3279 or placebo treatment. Provention has indicated that it expects to report top-line results of the PREVAIL-2 study in the second half of 2024.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HIV DART Molecules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing MGD014 and MGD020 under a contract awarded to us in September 2015 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. These bispecific DART molecules are designed to target the viral envelope (Env) protein of human immunodeficiency virus (HIV) infected cells and CD3 on T cells to redirect the immune system's T cells to kill HIV-infected cells. These molecules may become a key part of a strategy to reduce or eliminate latent HIV reservoirs in conjunction with latency-reversing agents. MGD014 and MGD020 target the gp120 and gp41 subunits of HIV Env, respectively. A Phase 1 study of MGD014 in persons with HIV maintained on antiretroviral therapy has been completed and a Phase 1 study of MGD020 alone and combined with MGD014 initiated in 2022. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Therapeutic Area Focus: Cancer</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancer is a broad group of diseases in which cells divide and grow in an uncontrolled manner, forming malignancies that can invade other parts of the body. In normal tissues, the rates of new cell growth and cell death are tightly regulated and kept in balance. In cancerous tissues, this balance is disrupted as a result of mutations, causing unregulated cell division or proliferation that leads to tumor formation and growth. While tumors can grow slowly or rapidly, the dividing cells will nevertheless accumulate, and the normal organization of the tissue will become disrupted. Cancers subsequently can spread throughout the body by processes known as invasion and metastasis. Once cancer spreads to sites beyond the primary tumor, it generally becomes more difficult to treat and may be incurable. Cancer cells that arise in the lymphatic system and bone marrow are referred to as hematological malignancies. Cancer cells that arise in other tissues or organs are referred to as solid tumors. Cancer can arise in virtually any part of the body, with the most common types arising in the prostate gland, breast, lung, colon and skin. Cancer is the second leading cause of death in the United States, exceeded only by heart disease. An increasing number of people are also living longer with cancer. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our platforms position us very well strategically to actively develop approaches for the treatment of both solid tumors and hematologic malignancies.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Platforms and Technology Expertise</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply our understanding of disease biology, immune-mediated mechanisms and next generation antibody technologies to design specifically targeted antibody-based product candidates based on our DART, Fc Optimization and licensed ADC platforms. Through these platforms we have designed antibody-based product candidates that have the potential to improve on standard treatments by having one or more of the following attributes: (1) multiple specificities; (2) increased abilities to interact with the body's immune system to fight tumors; (3) capacity to bind more avidly to antigen targets: (4) increased potency; (5) reduced immunogenicity or (6) the ability to target and kill cancer cells that are resistant to standard treatments. Moreover, these technology platforms are complementary in certain cases and can be combined to address the complex biology of cancer.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DART and TRIDENT Platforms: Our Proprietary Approach to Engineer Multi-Specific Antibodies</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our DART platform to create derivatives of antibodies with the ability to bind to two distinct targets instead of a single one found in traditional monoclonal antibodies. DART product candidates are therefore bispecific. An example of a bispecific molecule from our DART platform is illustrated below:</span></div><div style="margin-bottom:9pt;text-align:center"><img src="mgnx-20221231_g2.jpg" alt="mgnx-20221231_g2.jpg" style="height:208px;margin-bottom:5pt;vertical-align:text-bottom;width:466px"/></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because cancer cells have developed ways to escape the immune system, we have created DART molecules, which are alternative antibody-like structures with more potent immune properties than the parent antibody molecules from which they are derived. The two variable regions of an antibody are mono-specific and are able to target only a single type structural component of an antigen. For many years, researchers have sought to create recombinant molecules that are capable of targeting two antigens or epitopes (i.e., specific part of an antigen bound by the antibody) within the same molecule. The challenges in creating such molecules have been the instability of the resulting bispecific molecules and their inherently short half-lives, as well as the inefficiencies in manufacturing these compounds. We believe our DART platform has overcome these engineering challenges by incorporating proprietary covalent di-sulfide linkages and particular amino acid sequences that efficiently pair the chains of the DART molecule. This is designed to provide a structure with enhanced manufacturability, long-term structural stability and the ability to tailor the half-lives of the DART molecules to their clinical needs. This engineered antibody-like protein has a compact and stable structure and enables the targeting of two different antigens with a single recombinant molecule.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DART platform has been specifically engineered to accommodate virtually any variable region sequence with predictable expression, folding and antigen recognition. We believe our multi-specific platforms may provide a significant advantage over current biological interventions in cancer, autoimmune disorders and infectious disease by enabling a range of modalities, including those described below.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our DART platform enables us to design multi-specific molecules that seek to exploit different mechanisms of action, including those set forth below.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:10pt">Redirected T cell activation and killing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In this version of the DART molecule, we are engaging the cancer-fighting properties of the immune effector cells, such as T lymphocytes to: (1)&#160;recognize and bind to proteins expressed on a cancer cell, or tumor associated antigens (e.g., CD123), (2)&#160;enable the recruitment of all types of cytotoxic, or cell killing, T cells, irrespective of their ability to recognize cancer cells (e.g., CD3, a common component of the T cell antigen receptor) and (3)&#160;trigger T cell activation, expansion, and cell killing mechanisms to destroy a cancer cell. The outcome is that any of the body's T cells, in theory, could be recruited to destroy a cancer cell and thus, are not limited to the small numbers of specific T cells that might have been generated in response to cancer to kill tumor cells. Furthermore, given the design of a DART molecule, since any T cell could be recruited for this killing process, relatively small amounts of a DART molecule may be required to trigger this potent immune response. Additionally, the compact structure of the DART protein makes it well suited for maintaining cell-to-cell contact, which we believe contributes to the high level of target cell killing. Our DART molecules that redirect T cells against cancer or other targets, including MGD024, are manufactured using a conventional antibody platform without the complexity of having to genetically modify T cells from individual patients, as would be required by approaches such as CAR T cells. We have continued to evolve our bispecific platform with the introduction of a next-generation CD3-engaging DART technology designed to recruit, engage and activate T cells to kill tumor target cells with reduced release of pro-inflammatory cytokines. This next-generation CD3 DART platform is aimed at addressing cytokine-release syndrome, the most frequent and often dose-limiting adverse event associated with CD3-engaging molecules. We believe the next-generation CD3 DART platform could expand the therapeutic window of CD3-engaing DART molecules and further increase their potential application in oncology.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="mgnx-20221231_g3.jpg" alt="mgnx-20221231_g3.jpg" style="height:286px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"/></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:115%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Targeting of multiple co-inhibitory receptors or checkpoints, such as those involved in inhibiting T cell responses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The immune system generally prevents the development of autoimmune phenomena by regulating activated immune cells that have responded to non-self or foreign antigens. This negative feedback loop is triggered by the interactions of co-inhibitory receptors, or checkpoint molecules, expressed on the immune cells with ligands expressed by other cells, such as antigen-presenting cells. This phenomenon is exploited by cancer, whereby tumor cells express checkpoint ligands that block the development of an immune response against the tumor. Antibodies that block the interaction of checkpoint molecules with their ligands have been shown to significantly improve the clinical outcomes of patients with certain advanced cancers. Because of the diversity of immune checkpoint pathways, blockade of a single axis, while clinically significant, as shown in the case of the blockade of the PD-1/PD-L1 axis with pembrolizumab or nivolumab, will not benefit all patients. In fact, combinations of checkpoint inhibitors, such as nivolumab and ipilimumab, a CTLA-4 blocker, have resulted in significantly enhanced benefit compared to ipilimumab or nivolumab alone. We believe that DART molecules targeting two immunoregulatory pathways, such as two checkpoints in a single molecule, could afford the clinical benefit of the combination together with the potential for synergistic activity, as well as significant advantages in manufacturing, simplified clinical development, and enhanced patient convenience.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="mgnx-20221231_g4.jpg" alt="mgnx-20221231_g4.jpg" style="height:334px;margin-bottom:5pt;vertical-align:text-bottom;width:183px"/></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the ability to tailor a DART molecule's valency, we have the capacity to modify the strength by which the binding sites attach to their targets and the molecule's half-life in the blood circulation after delivery to a patient. Furthermore, when an Fc domain is coupled with a DART molecule, additional changes can be included that can modulate the DART molecule's engagement with different immune cells.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently developing product candidates using this technology, including lorigerlimab, MGD024, tebotelimab, MGD014 and MGD020 in clinical trials, as well as others in preclinical development. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also advanced beyond our DART platform to establish a TRIDENT platform, which reflects the continuing evolution of our multi-specific antibody-based targeting expertise. Built on the DART module, the trivalent TRIDENT platform incorporates in an Ig-like format an additional domain capable of engaging an independent antigen. With the inclusion of a third targeting arm, TRIDENT molecules enable a broader range of mechanisms of action than bispecific targeting, allowing, for instance, the engagement of multiple antigens on a single or on different cells or enabling enhanced target selectivity by modulating the avidity of one of two antigens. Product candidates using this technology are currently in preclinical development.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fc Optimization Platform: Our Proprietary Approach to Enhance Immune-Mediated Cancer Cell Killing</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To enhance the body's immune ability, we developed our Fc Optimization platform which introduces certain mutations into the Fc region of an antibody and is able to modulate antibody interaction with immune effector cells. Such interaction enhances the body's immune ability to mediate the killing of cancer cells through antibody-dependent cellular cytotoxicity (ADCC).</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADCC</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><img src="mgnx-20221231_g5.jpg" alt="mgnx-20221231_g5.jpg" style="height:185px;margin-bottom:5pt;vertical-align:text-bottom;width:216px"/></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Fc region mediates the function of IgG antibodies by binding to different activating and inhibitory receptors, referred to as Fc&#947;Rs, on immune effector cells found within the innate immune system. By engineering Fc regions to bind with an increased affinity to the activating Fc&#947;Rs and with a reduced affinity to the inhibitory Fc&#947;Rs, we have been able to impart a more effective immune response and improve effector functions, such as ADCC. This is another example in which small changes in antibody structure can confer improvements on normal immune processes.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a proprietary platform to engineer, screen, identify and test antibodies' Fc regions with customizable activity. In particular, we have licenses to use transgenic mice that express human Fc&#947;Rs. These mice can be used for in vivo testing of antibodies that incorporate Fc domain variants, including those antibodies intended for cancer therapy.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have successfully incorporated our Fc variants in two of our antibody-based molecules, margetuximab and enoblituzumab. In vitro, the modified Fc region of margetuximab increases binding to the activating Fc receptor FCGR3A (CD16A) and decreases binding to the inhibitor Fc receptor FCGR2B (CD32B). These changes lead to greater in vitro ADCC and NK cell activation. The clinical significance of in vitro data is unknown.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensed ADC Platforms </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed ADC platforms from collaboration partners to leverage their past investment in proprietary linker-toxin technology and know-how. While we don&#8217;t necessarily believe there is a single best linker-toxin technology capable of addressing all targets and indications, we have selected what we believe are best-in-class technologies for construction of each of our ADC product candidates. For example, to date we have utilized linker-toxin payloads developed by Byondis for vobra duo, by ImmunoGen for IMGC936 and by Synaffix B.V. (Synaffix) for multiple, non-disclosed preclinical molecules. Utilizing Synaffix&#8217;s ADC technology, we anticipate submitting an Investigational New Drug (IND) application for an undisclosed ADC product candidate in late 2023.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Collaborations</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout our company's history, we have entered into collaborations with other biopharmaceutical companies and plan to continue to do so. We enter into collaborations when there is a strategic advantage to us and when we believe the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial terms of the collaboration are favorable for meeting our short-term and long-term strategic objectives. We are not dependent upon any one of these collaborations, but in many cases, we have rights to receive sales royalties and other significant financial payments if the partnered product candidates achieve certain development and sales milestones. We endeavor to establish collaborations that preserve our right to participate in future commercialization, for example by securing co-promotion or profit-sharing rights under certain circumstances.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Each of our collaborations has a unique set of terms and conditions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patents intended to protect, for example, the composition of matter of our product candidates, their methods of use, the technology platforms used to generate them, related technologies and/or other aspects of the inventions that are important to our business. We also rely on trade secrets, confidentiality and invention assignment agreements and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business.  In addition, there is cost and risk to our business in defending and enforcing our patents, maintaining our licenses to use intellectual property owned by third parties and preserving the confidentiality of our trade secrets and operating without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary positions. We currently use multiple industry-standard patent monitoring systems to monitor new United States Patent and Trademark Office (USPTO) filings for any applications by third parties that may infringe on our patents.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted by the courts after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, narrowed, circumvented or invalidated by third parties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold patents or other intellectual property rights that are important to or necessary for the development of our product candidates or use of our technology platforms. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are not infringed, invalid, and unenforceable, should a court find that they cover margetuximab or enoblituzumab and we are unable to invalidate them, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications in the United States and certain other jurisdictions can be maintained in secrecy for 18 months or potentially even longer, and because publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention. In the ordinary course of business we participate in post-grant challenge proceedings, such as oppositions, that challenge the patentability of third party patents. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Patent Protection</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we held 87 patents in the United States with 45 patent applications pending and 757 patents in other countries of the world with 487 patent applications pending. In addition to patents and patent applications generally providing protection for various aspects of our Fc Optimization, DART, and TRIDENT platforms, we have patent and patent applications for the composition of matter of each of our clinical pipeline product candidates and, in some cases, we also have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other patents and patent application related to various aspects of the technology underlying these product candidates or their methods of use.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent terms may be adjusted or extended, as described in greater detail below, in certain circumstances. However, assuming no adjustments or extensions, the primary composition of matter patent for each of our clinical pipeline product candidates is expected to expire in the following timeframes:</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product or Product Candidate</span></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">margetuximab</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">enoblituzumab</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">retifanlimab</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">tebotelimab</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lorigerlimab</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">vobramitamab duocarmazine</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039*</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">* pending</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term Extension and Reference Product Exclusivity</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hatch-Waxman Act permits a patent term extension for FDA-approved drugs, including biological products, of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved drug. If and when our pharmaceutical product candidates receive FDA approval, we expect to apply, or have applied, for patent term extensions on patents covering those products. We intend to seek, and are seeking, patent term extensions to our issued patents in any jurisdiction where these are available. For example, we have submitted a request to obtain patent term extension of U.S. Patent No. 8,802,093, the primary composition of matter patent for margetuximab. However, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act (collectively the ACA) created a regulatory scheme authorizing the FDA to approve biosimilars via an abbreviated licensure pathway. In many cases, this allows biosimilars to be brought to market without conducting the full suite of clinical trials typically required of originators. Under the ACA, a manufacturer may submit an application for licensure of a biologic product that is "biosimilar to" or "interchangeable with" a previously approved biological product or "reference product." The "biosimilar" application must include specific information demonstrating biosimilarity based on data derived from: (1) analytical studies, (2) animal studies, and&#160;(3) a clinical study or studies that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed, except that FDA may waive some of these requirements for a given application. Under this new statutory scheme, an application for a biosimilar product may not be submitted to the FDA until four years after the date of first licensure. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was first licensed. The law does not change the duration of patents granted on biological products. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor's own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. There have been persistent proposals to repeal or modify the ACA and it is uncertain how any of those proposals, if in the future approved, would affect these provisions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Secrets</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual's relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our confidentiality and other agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to inventions they invent as a result the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-Licensed Intellectual Property</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into patent and know-how license agreements that grant us the rights to use certain technologies related to biological manufacturing for our commercial and clinical product candidates, such as but not limited to technology related to the conjugation of cytotoxic payloads to our antibody drugs. We anticipate using these technologies for future product candidates. These licensors have businesses dedicated to licensing this type of technology and we anticipate that licenses to use these technologies for our future products will be available. The licenses typically include yearly maintenance payments and sales royalties, and may also include upfront payments or milestone payments.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently manufacture drug substance for most of our clinical trials at our manufacturing facility located in Rockville, Maryland. We also rely on contract manufacturers, including Byondis, Synaffix and Millipore Sigma, for producing components of our ADC candidates. We have supplemented our drug substance manufacturing capacity through an arrangement with AGC Biologics, Inc. (AGC, formerly CMC Biologics, Inc.), a contract manufacturing organization, and commercially produced initial margetuximab commercial supply and inventory at AGC. In October 2021, the FDA approved the BLA supplement to add our commercial manufacturing site at 9704 Medical Center Drive in Rockville, Maryland as a licensed manufacturing site for margetuximab drug substance. We commercially produce material for MARGENZA  as well as intend to commercially produce our and partner&#8217;s product candidates when and if approved by the FDA. In addition, we currently rely on and will continue to rely on contract fill-finish service providers, primarily Ajinomoto Bio-Pharma Services and Baxter Healthcare Corporation, to fulfill our fill-finish needs for our current and future product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we obtain certain raw materials principally from only one source. In the event one of these suppliers was unable to provide the materials or product, we generally seek to maintain sufficient inventory to supply the market until an alternative source of supply can be implemented. However, in the event of an extended failure of a supplier or general national supply chain disruption, it is possible that we could experience an interruption in supply until we established new sources or, in some cases, implemented alternative processes.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Production processes for biological therapeutic products are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity can be a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals. Accordingly, if we were to experience extended plant shutdowns at our own facility, extended failure of a contract supplier or contract manufacturing organization, or extraordinary unplanned increases in demand, we could experience an interruption in supply of certain products or product shortages until production could be resumed or expanded.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MARGENZA is currently our only approved product in the U.S. In November 2020, we partnered with Eversana, a pioneer of next-generation commercial services to the global life sciences industry, to commercialize margetuximab in the U.S. by leveraging their integrated commercial services. Under the terms of the agreement, we maintain ownership of margetuximab, including all manufacturing, regulatory and development responsibilities for the product. Eversana received a co-exclusive right to conduct approved commercialization activities. Eversana utilizes its internal capabilities to support sales and marketing, market access, channel management services, data and analytics, medical affairs, and other patient access related services; we book MARGENZA sales. We and Eversana equally share in funding Eversana&#8217;s commercialization expenses. In exchange for co-funding these expenses, Eversana is eligible to earn future revenue share payments which shall be capped at 125% of Eversana&#8217;s cumulative service fees. The term of the agreement is five years following the date of FDA approval, subject to predefined termination provisions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot market or promote a new product in a country until a marketing application has been approved by the appropriate regulatory authority for that jurisdiction. Subject to receiving marketing authorization in a jurisdiction, we believe we will be able to commercialize in that market through arrangements with third-party commercial partners. Other than through our arrangement with Eversana for MARGENZA, we have not established a sales, marketing or distribution capabilities. If we are unable to enter into third-party commercial arrangements for other product candidates with respect to the United States, we believe that we could potentially put in place an appropriately sized organization to commercialize our approved product or products. Outside the United States, our strategy is to enter into arrangements with third-party commercial partners for any of our product candidates that obtain marketing approval.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In particular, MARGENZA is directed against HER2 and many companies have cancer therapeutics directed against HER2 that are either currently approved and on the market or may be in development, such as F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche), particularly through its affiliate, Genentech, Inc., as well as Puma Biotechnology, Inc., Daiichi Sankyo Company, Limited and AstraZeneca plc. (AstraZeneca), Seagen Inc., Zymeworks, Inc., </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shanghai Hengrui Pharmaceutical, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Byondis, many of which have significantly greater resources than we do. Market competition has limited the utilization of MARGENZA as a therapeutic, and these competitors as well as biosimilar trastuzumab competition may limit such utilization in the future.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the immuno-oncology field is competitive, with treatments currently approved and, on the market, or in development for various tumor types and patient populations from a variety of different companies such as Merck &amp; Co., Inc. (Merck), The Bristol-Myers Squibb Company (BMS), and Roche, all of which have significantly greater resources than we do. Many of our pipeline programs, if successful, will likely face significant competition both by therapeutics that are already being marketed as well as those that will be approved for marketing before our programs. In particular, we are developing PD-1-directed product candidates, including a monoclonal antibody that we have outlicensed and two DART molecules. Merck, BMS, Roche, AstraZeneca, Pfizer Inc., Merck KGaA, and Regeneron Pharmaceuticals, Inc. all have approved products that target either the PD-1 receptor or its ligand, PD-L1, and there are several other companies that have anti-PD-1 or anti-PD-L1 antibodies in clinical development, all of which would compete with our PD-1-directed programs. In addition, these and other companies are developing product candidates directed against other immuno-oncology targets that we are pursuing through our bispecific approaches.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, several companies are also developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. Amgen Inc. has obtained marketing approval for one product that works by targeting antigens both on immune effector cell populations and those expressed on certain cancer cells, and has other product candidates in development that use this mechanism. In addition, other companies are developing new treatments for cancer that utilize multi-specific approaches, including Abbvie Inc., Affimed N.V., Eli Lilly and Company, Genmab A/S, Merus B.V., Regeneron, Roche, AstraZeneca, Xencor, Inc. and Zymeworks, Inc.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, our competition in the contract development and manufacturing organization (CDMO) market includes a number of full-service contract manufacturers and large pharmaceutical companies offering third-party development and manufacturing services to fill their excess capacity. Large pharmaceutical companies have been seeking to divest portions of their manufacturing capacity, and any such divested businesses may compete with us in the future. In addition, most of our competitors have substantially greater financial, marketing, technical or other resources than we do.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining top qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key competitive factors affecting the success of all of our therapeutic product candidates, if approved, are likely to be their efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic or biosimilar competition and the availability of reimbursement from government and other third-party payors. In addition, the standard of medical care provided to cancer patients continues to evolve as more scientific and medical information becomes available. These changes in medical care relate to pharmaceutical products, but are also </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affected by other factors, and such changes can positively or negatively affect the prospects of our product candidates as well as those of our competitors.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop, or the standards of care for cancer patients change while our clinical trials are ongoing. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, trastuzumab biosimilars have been approved in the U.S. by the FDA.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug therapies marketed for cancer. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates may compete with many existing drug and other therapies, to the extent an approved drug is ultimately used in combination with or as an adjunct to these therapies, our product candidates will not be competitive with the approved drug.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation and Product Approval</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, pricing, reimbursement, marketing, import and export of pharmaceutical products such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Regulation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our current product candidates are subject to regulation in the United States by the FDA as biological products (biologics). The FDA subjects biologics to extensive pre- and post-market regulation. The Public Health Service Act, the Federal Food, Drug, and Cosmetic Act (FDCA) and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biologics. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending BLAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, or criminal penalties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Drug development in our industry is complex, challenging and risky; failure rates are high. Product development cycles are long - approximately 10 to 15 years from discovery to market. A potential new biological product must undergo many years of preclinical and clinical testing to establish it is pure, potent and safe.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies include laboratory evaluation of product chemistry, formulation and toxicity, pharmacology, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements including the FDA's good laboratory practice (GLP) regulations and the U.S. Department of Agriculture's regulations implementing the Animal Welfare Act. After laboratory analysis and preclinical testing in animals, we file an IND application with the FDA to begin human testing. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature, and a proposed clinical trial protocol, among other things, to the FDA as part of an IND application. Certain preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue even after the IND application is submitted. An IND application automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold or agrees on an alternate approach with us. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the IND application is cleared and the clinical trial can begin. As a result, submission of an IND application may not result in the FDA allowing clinical trials to commence.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Clinical trials involve the administration of the investigational drug to human subjects (healthy volunteers or patients) under the supervision of a qualified investigator. Clinical trials must be conducted: (i) in compliance with all applicable federal regulations and guidance, including those pertaining to good clinical practice (GCP) standards that are meant to protect the rights, safety, and welfare of human subjects and to define the roles of clinical trial sponsors, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investigators, and monitors; as well as (ii) under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing of a new drug in the United States (whether in patients or healthy volunteers) must be included in the IND application submission, and the FDA must be notified of subsequent protocol amendments. In addition, the protocol must be reviewed and approved by an institutional review board (IRB) and all study subjects must provide informed consent prior to participating in the study. Typically, each institution participating in the clinical trial will require review of the protocol before any clinical trial commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health (NIH) for public dissemination on their ClinicalTrials.gov website. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and there are additional, more frequent reporting requirements for suspected unexpected serious adverse events.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A study sponsor might choose to discontinue a clinical trial or a clinical development program for a variety of reasons. The FDA may impose a temporary or permanent clinical hold, or other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial subjects. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements, or may impose other conditions.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to support BLAs for marketing approval are typically conducted in three pre-approval phases, but the phases may overlap or be combined, particularly in testing for oncology indications. In Phase 1, testing is conducted in a small group of subjects who may be patients with the target disease or condition or healthy volunteers, to evaluate its safety, determine a safe dosage range, and identify side effects. In Phase 2, the drug is given to a larger group of subjects with the target condition to further evaluate its safety and gather preliminary evidence of efficacy. Phase 3 studies typically last multiple years for oncology indications. In Phase 3, the drug is given to a large group of subjects with the target disease or condition (several hundred to several thousand), often at multiple geographical sites, to confirm its effectiveness, monitor side effects, and collect data to support drug approval. In some cases, the FDA may require post-market studies, known as Phase 4 studies, to be conducted as a condition of approval in order to gather additional information on the drug's effect in various populations and any side effects associated with long-term use. Depending on the risks posed by the drugs, other post-market requirements may be imposed. Only a small percentage of investigational drugs complete all three phases and obtain marketing approval.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. After completion of the required clinical testing, a BLA can be prepared and submitted to the FDA. FDA approval of the BLA is required before marketing of the product may begin in the United States. The BLA must include the results of preclinical, clinical and other testing and a compilation of data relating to the product's chemistry, manufacture and controls. The cost of preparing and submitting a BLA is substantial. Under federal law, the submission of most BLAs is additionally subject to a substantial application user fee, and annual program user fees also apply. These fees are typically increased annually.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the FDA's threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins a substantive review, and the review period under the PDUFA begins. The standard for reviewing a BLA is whether the product is safe, pure and potent, which has been interpreted to include that the product is safe and effective and has a favorable benefit-risk profile. The FDA's current performance goals call for the FDA to complete review of 90 percent of standard (non-priority) BLAs within 10 months of filing and within six months for priority BLAs, which is 12 months and eight months, respectively, if the 60-day review of the initial application is included in the timeline. In addition, the FDA has developed approaches intended to make certain qualifying products available to patients rapidly - Priority Review, Breakthrough Therapy, Accelerated Approval, and Fast Track. While the timelines for approval under these pathways may be shorter, there are requirements and conditions associated with each pathway, and there can be no assurance that any of our investigational products will be able to meet the conditions or requirements necessary to receive any such designation or be able to receive the review or approval benefits associated with such designations. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes outside clinicians and other experts, for review, evaluation and a recommendation as to whether sufficient data exist in the application to support product approval. The FDA is not bound by the recommendation of an advisory committee, but it generally gives significant deference to such recommendations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will typically inspect one or more clinical sites and possibly the sponsor itself  to assure compliance with GCP. Additionally, the FDA will typically inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance with current Good Manufacturing Practices (cGMPs) is satisfactory. The FDA also reviews the proposed labeling submitted with the BLA and typically requires changes in the labeling text.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the BLA and the manufacturing and testing facilities, it issues either an approval letter or a complete response letter. Complete response letters generally outline the deficiencies in the submission and delineate the additional testing or information needed in order for the FDA to reconsider the application. If and when deficiencies outlined in a complete response letter have been addressed to the FDA's satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing 90 percent of resubmissions within two or six months from receipt depending on the type of information included.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter authorizes commercial marketing of the drug for the approved indication or indications and the other conditions of use set out in the approved prescribing information. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of BLA approval, the FDA may require substantial post-approval testing and surveillance to monitor the drug's safety or efficacy and may impose other conditions, including labeling restrictions that can materially affect the potential market and profitability of the product. As a condition of approval, or after approval, the FDA also may require submission of a risk evaluation and mitigation strategy (REMS) to mitigate any identified or suspected serious risks. The REMS may include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other U.S. Post-Marketing Regulatory Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Once a BLA is approved, a product will be subject to certain post-approval requirements, including those relating to advertising, promotion, adverse event reporting, recordkeeping, and cGMPs, as well as registration, listing, and inspection. There also are continuing, annual program user fee requirements for marketed products, as well as new application fees for supplemental applications with clinical data.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the content and format of prescription drug labeling, advertising, and promotion, including direct-to-consumer advertising and promotional Internet communications. The FDA also establishes parameters for permissible non-promotional communications between industry and the medical community, including industry-supported scientific and educational activities. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion for uses not consistent with the approved labeling, and a company that is found to have improperly promoted off-label uses or otherwise not to have met applicable promotion rules may be subject to significant liability under both the FDCA and other statutes, including the False Claims Act. See "Other Healthcare Laws and Compliance Requirements" below for more information.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All aspects of pharmaceutical manufacture must conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the FDA inspects manufacturing facilities to assess compliance with cGMPs. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, product formulation or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement, in some cases before the change may be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers are subject to requirements for adverse event reporting and submission of periodic reports following FDA approval of a BLA. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, or failure of Phase 4 studies to meet their specified endpoints, may result in revisions to the approved labeling to add new safety information, the need to conduct additional post-market studies or clinical trials to assess new safety risks, imposition of distribution or other restrictions under a REMS program, or recall of the product and withdrawal of the BLA.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompliance with post-marketing requirements can result in one or more of the following consequences:</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Warning letters;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Holds on post-approval clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license approvals;</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (PDMA) which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approval of Biosimilars</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ACA authorized the FDA to approve biosimilars via a separate, abbreviated pathway. In many cases, this allows biosimilars to be brought to market without conducting the full suite of clinical trials typically required of originators. The law establishes a period of 12 years of exclusivity for reference products in order to preserve incentives for future innovation, and outlines statutory criteria for science-based biosimilar approval standards that take into account patient safety considerations. Under this framework, exclusivity protects innovator products by prohibiting others, for a period of 12 years, from being granted FDA approval based in part on reliance on or reference to the innovator's data in their application to the FDA. The law does not change the duration of patents granted on biological products. There are regular legislative proposals to rescind or reduce the biologics exclusivity provisions of the ACA and it is uncertain whether or if any of those proposals may be approved, and if approved, how exclusivity for biologics would be affected. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Compliance Requirements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback and false claims laws, as well as laws related to health care transparency and data protection.. Anti-kickback laws generally prohibit a prescription drug manufacturer from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase or prescription of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may not be regulations, guidance or court decisions that apply the laws to particular industry practices. There is therefore a possibility that our practices might be challenged under such anti-kickback laws. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented, any claims for payment for reimbursed drugs or services to third party payers (including Medicare and Medicaid) that are false or fraudulent. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including fines and civil monetary penalties, and/or exclusion from federal health care programs (including Medicare and Medicaid).</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers with marketed products generally limit financial interactions between manufacturers and health care providers and/or require disclosure to the government and public of such interactions. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures.  Many of these laws and regulations contain ambiguous requirements or require administrative guidance for implementation. We are subject to federal, state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts.  Given the lack of clarity in laws and their implementation, our activities could be subject to the penalty provisions of the pertinent laws and regulations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Regulation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we and our collaborators, may be subject to a variety of foreign regulations governing clinical trials, drug registration, commercial sales and distribution of our product candidates outside the United States. These regulations can vary between jurisdictions and can be more onerous than regulations in the United States. Whether or not we obtain FDA approval for a product candidate, we must obtain approval from the comparable regulatory authorities of foreign countries or economic areas, such as the European Union (EU) before we may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time to approval may be longer or shorter than that required for FDA approval. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain countries outside of the United States have a process that requires the submission of a clinical trial application (CTA) much like an IND prior to the commencement of human clinical trials. In Europe, for example, a CTA must be submitted to the competent national health authority and to independent ethics committees in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical trial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development may proceed in that country. In all cases, the clinical trials must be conducted in accordance with GCP, and other applicable regulatory requirements. A separate CTA must be submitted for each clinical trial to be conducted.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, for example, to obtain regulatory approval of an investigational medicinal product, we must submit a marketing authorisation application (MAA). The content of the MAA is similar to that of a New Drug Application or BLA filed in the United States, with the exception of, among other things, EU-specific document requirements. Under the EU regulatory system, a company may submit marketing authorisation applications either under a centralised or decentralised procedure. Under the centralised procedure in the EU, a MAA is submitted to the European Medicines Agency (EMA) where it will be evaluated by the Committee for Medicinal Products for Human Use (CHMP). The maximum timeframe for a CHMP evaluation of an MAA that has been validated is 210 days, excluding time taken by an applicant to respond to questions. A favorable opinion on the application by the CHMP will typically result in the granting of the marketing authorisation by the European Commission within 67 days of receipt of the opinion. Generally, the entire review process takes approximately 13-14 months. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. In this circumstance, the EMA ensures that the opinion of the CHMP is given within 150 days, excluding time taken by an applicant to respond to questions.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, we or our collaborators may apply for designation of a product as an orphan drug for the treatment of a specific indication in the EU before the MAA is made. Orphan drugs in Europe enjoy certain benefits, including up to 10 years of exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan designated product. The PRIME initiative was established by the EMA to help promote and foster the development of new medicines in the EU that demonstrate potential for a major therapeutic advantage in areas of unmet medical need. Benefits from the PRIME designation include early confirmation of potential for accelerated assessment, early dialogue and increased interaction with relevant regulatory committees to discuss development options, scientific advice at key development milestones, and proactive regulatory support from the EMA.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, or our collaborators, fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BioPharmaceutical Coverage, Pricing, Reimbursement, and Health Care Reform</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of adequate reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations. Third-party payors are increasingly examining the medical necessity and cost effectiveness of medical products and services in addition to safety and efficacy and, accordingly, significant uncertainty exists as to the reimbursement status of newly approved therapeutics. Third-party reimbursement adequate to enable us to realize an appropriate return on our investment in research and product development may not be available or optimal for our products. Further, coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices have become a subject of increased focus in recent years. Although there are currently no direct government price controls over private sector purchases in the U.S., federal law requires pharmaceutical manufacturers to pay prescribed rebates on certain government or Medicaid-reimbursed drugs to enable them to be eligible for reimbursement under certain public healthcare programs such as Medicaid and Medicare Part B. Various states have adopted further mechanisms that seek to control drug prices, including by disfavoring certain higher priced drugs or by seeking supplemental rebates from manufacturers. Managed care has also become a potent force in the marketplace that increases downward pressure on the prices of pharmaceutical products.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public and private healthcare payers control costs and influence drug pricing through a variety of mechanisms, including through negotiating discounts with the manufacturers and through the use of tiered formularies and other mechanisms that provide preferential access to certain drugs over others within a therapeutic class. Payers also set other criteria to govern the uses of a drug that will be deemed medically appropriate and therefore reimbursed or otherwise covered.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, in the U.S., there have been several presidential executive orders, congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had 357 full-time employees, 292 of whom were primarily engaged in research, development and manufacturing activities, and 67 of whom had an M.D. and/or Ph.D. Our employees are critically important to the achievement of our company&#8217;s mission and goals. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior leadership oversees all human capital management matters and are committed to attracting, developing, engaging and retaining the best people.  We strive to offer our employees an intellectually challenging and diverse work environment, opportunities to expand their knowledge and skills, to  receive feedback on performance, and for career advancement. We believe management&#8217;s relationships with our employees is very positive and they are not subject to a collective bargaining agreement or represented by a trade or labor union.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation programs are designed to align our employees' interests with our business goals and stockholder returns. We provide employee wages that are competitive within our industry, and we engage a outside compensation and benefits consulting firm to independently evaluate the effectiveness of our compensation and benefit programs and to provide benchmarking against our peers within the industry. We link annual changes in compensation to overall Company performance, as well as each individual&#8217;s contribution to the results achieved. The emphasis on overall Company performance is intended to align the employee&#8217;s financial interests with the interests of stockholders. MacroGenics is committed to providing our employees with a benefits program that is both comprehensive and competitive. Our benefits program offers health care, dental and vision coverage, along with benefits designed provide increased financial security to our employees and their families. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an Employee Stock Purchase Plan under which employees may purchase Company common stock through payroll deductions at a price equal to 85% of the fair market value of the stock as of the end of the offering periods.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Our Culture; Diversity Equity and Inclusion</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our Living Values are the backbone of our culture: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Patients First, Do It Right, Innovate, Pitch In, Take Action </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"> Be Inclusive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we kicked off a number of initiatives to reinforce the importance of a diverse workforce and culture of belonging to our Company&#8217;s success. We added the Living Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Be Inclusive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and completed company-wide training on Diversity, Equity and Inclusion.  To further champion our DEI efforts, we formed a DEI Committee with strong advocacy from our senior leadership team and our board of directors. The Committee focused on raising awareness of DEI in 2022 and held a number of focus groups and company wide events.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All employees are required to observe high standards of business and personal ethics and must adhere to our Code of Business Conduct and Ethics, for which they receive training annually.  The Code requires reporting any actual or suspected misconduct, illegal activities or fraud. To that end, we maintain a Speak Up Culture where all employees are encouraged to raise issues, report concerns, and ask questions. We also maintain an anonymous hotline that is available to all of our employees to report any matter of concern. Communications to the hotline (which is facilitated by an independent third party) are routed to our General Counsel (or, if the General Counsel is the subject of the communication, to the Chair of our Audit Committee) for investigation and resolution. We also maintain a policy of no retaliation, where employees who report any misconduct are to be free of any harassment, retaliation or adverse employment consequence. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We periodically conduct employee engagement surveys to understand our employees&#8217; perspectives and endeavor to listen, change and improve on how we work together in response to these perspectives. In 2022, 84% of our workforce participated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Learning and Development</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to invest in our employees to achieve their goals and to lead our company through learning and development. We conduct regular performance reviews.  We encourage all employees to take advantage of our leadership, management and technical skill trainings and resources.  In addition, we provide focused development for managers and emerging leaders who are designated as &#8220;key talent&#8221; based on performance and leadership potential.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Community</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe in giving back and supporting the local communities where we work as well as initiatives consistent with our areas of focus.  Employees are encouraged to participate in charitable causes and receive eight hours of voluntary paid time off to participate in local opportunities to give back to the community.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Wellbeing and Safety</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to the health and safety of our employees by providing a safe work environment.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We empowered a cross-functional team in the early days of the ongoing pandemic to recommend safety protocols, ensure timely communications, and make decisions related to the effect of COVID-19 on our employees and work environment. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website address is www.macrogenics.com. We post links to our website to the following filings as soon as reasonably practicable after they are electronically filed with or furnished to the Securities and Exchange Commission (SEC): annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, and any amendments to those reports filed or furnished pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. All such filings are available through our website free of charge. In addition, the SEC makes available at its website (www.sec.gov), free of charge, reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. &#160;&#160;&#160;&#160;RISK FACTORS </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The discussion below addresses material factors, of which we are currently aware, that could have a material and adverse effect on our business, results of operations and financial condition. These risk factors and other forward-looking statements that relate to future events, expectations, trends and operating periods involve certain factors that are subject to change, and important risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties should not be considered a complete discussion of all the risks and uncertainties we may face and although the risks are organized by headings and each risk is discussed separately, many are interrelated. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors Affecting Our Business </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks. The following summary highlights some of the risks you should consider with respect to our business and prospects. This summary is not complete and the risks summarized below are not the only risks we face. You should review and consider carefully the risks and uncertainties described in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, which includes a more complete discussion of the risks summarized below as well as a discussion of other risks related to our business and an investment in our common stock, as well as our other SEC filings. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend substantially on the success of the clinical development of our products and product candidates, through our own efforts or those of our collaborators, including vobra duo and lorigerlimab. If we are unable to successfully complete clinical development, obtain additional regulatory approvals and commercialize our products and product candidates, or experience significant delays in doing so, our business will be materially harmed and we may not be able to generate sufficient revenues and cash flows to continue our operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical drug development involves a lengthy and expensive process, with a highly uncertain outcome. We expect to incur significant additional costs related to the development of vobra duo, lorigerlimab, and our other product candidates and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our other products and product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates may have undesirable side effects which may delay or prevent further clinical development or marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If clinical trials for our product candidates are prolonged, delayed or stopped for any reason, including for safety reasons or lack of efficacy, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The results of previous clinical trials may not be predictive of future results, and interim or top line data may be subject to change or qualification based the complete analysis of data. In addition, the results of our current or planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities for product approval. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. Our first commercial product, MARGENZA, launched in March 2021 and to date has not resulted in revenues sufficient for us to reach profitability.  Accordingly, we may never achieve or sustain profitability.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use or may use novel technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved or may not approve products that utilize these technologies. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vobra duo, lorigerlimab, MARGENZA, or any other product candidate that we develop may fail to achieve or maintain market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition and if our competitors continue to develop and market products that are more effective, safer or less expensive than our product and our product candidates, our current or future commercial opportunities may be negatively impacted. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacture of vobra duo, lorigerlimab, MARGENZA and our product candidates, for ourselves and our collaborators, is complex, and we may encounter difficulties in production.  There can be no assurance that we will be able to effectively manufacture clinical quantities of our product candidates in the future. Further, we have limited experience in large-scale or commercial manufacturing, and there can be no assurance that we will be able to effectively manufacture commercial quantities of MARGENZA, or other products or product candidates, if and when approved. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COVID-19 (or any variant thereof) may have a negative impact on our clinical trials, nonclinical studies, development, manufacturing and commercialization of our product and product candidates and other aspects of our business, staff, and operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited experience in launching and marketing our internally developed products. If we are unable to further develop marketing and sales capabilities or enter into agreements with third parties to market and sell our products, or our existing arrangements are not successful, we may not be able to generate substantial product sales revenue. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Actual or anticipated changes to the laws and regulations governing the health care system may have a negative impact on cost and access to health insurance coverage and reimbursement of health care items and services. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reimbursement decisions by third-party payors, including government payors, may have an adverse effect on pricing and market acceptance. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We contract with, and may in the future contract with, third parties for the distribution and commercialization of MARGENZA and our other product candidates. Failure of third-party contractors to successfully perform their obligations for commercialization, distribution, or other services could harm out ability to commercialize our product or product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends significantly on our ability to operate without infringing the valid patents and other proprietary rights of third parties. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and enforce patent protection for our products and our product candidates and related technology, our business could be materially harmed.  </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to securities litigation, which is expensive and could divert management attention and adversely impact our business. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to successfully develop and commercialize companion diagnostics with third party contractors for use with our product candidates could harm our ability to commercialize our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and the Development and Commercialization of Our Products and Product Candidates </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend substantially on the success of the clinical development of our products and product candidates, through our own efforts or those of our collaborators, including vobra duo and lorigerlimab. If we are unable to successfully complete clinical development, obtain additional regulatory approvals and commercialize our products and product candidates, or experience significant delays in doing so, our business will be materially harmed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and we may not be able to generate sufficient revenues and cash flows to continue our operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends on the successful development, regulatory approval and commercialization of our products and product candidates, including vobra duo and lorigerlimab. We have invested and will continue to invest a significant portion of our efforts and financial resources in the development of our product candidates, including vobra duo and lorigerlimab. The success of our products and product candidates depends on many factors, including but not limited to: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful enrollment in, and completion of, clinical trials, as well as completion of nonclinical studies; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety and favorable efficacy and acceptable safety data from our clinical trials and other studies;</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of our financial resources and ability to obtain additional funding for the development of our products and product candidates;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of regulatory approvals; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the performance by clinical research organizations (CROs) or other third parties we may retain of their duties to us in a manner that complies with our protocols and applicable laws and that protects the integrity of the resulting data; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensuring we do not infringe, misappropriate or otherwise violate the valid patent, trade secret or other intellectual property rights of third parties; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully launching our product candidates, including vobra duo or lorigerlimab, if and when approved; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining commercial manufacturing capabilities, either by utilizing our current manufacturing facilities or making arrangements with third-party manufacturers; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing or obtaining sufficient supplies of our products and product candidates that may be necessary for use in clinical trials for evaluation of our product candidates and commercialization of our products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining favorable reimbursement from third-party payors for products and product candidates;  </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition with other products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-marketing commitments to regulatory agencies following regulatory approval; and</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued acceptable safety profile following regulatory approval.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development involves a lengthy and expensive process, with a highly uncertain outcome. We expect to incur significant additional costs related to the development of vobra duo, lorigerlimab, and our other product candidates and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our other products and product candidates.  </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the FDA and non-U.S. regulatory authorities, which regulations differ from country to country. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a Biologics License Application (BLA) from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inherent in drug development. For example, in July 2022 we announced the closure of our Phase 2 study evaluating the investigational regimen of enoblituzumab in combination with either retifanlimab  or tebotelimab in the first-line treatment of patients with recurrent or metastatic SCCHN. The decision to discontinue the study was based on an internal review of safety data. The approval of a BLA can be a lengthy, expensive and uncertain process.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after product approval, subject our company or our collaborators to administrative or judicially imposed sanctions, including: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the products, manufacturers, manufacturing facilities or manufacturing process; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">civil and criminal penalties; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of regulatory approvals; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizures, detentions or import bans; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">voluntary or mandatory product recalls and publicity requirements; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total or partial suspension of production; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of restrictions on operations, including costly new manufacturing requirements; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending BLAs or supplements to approved BLAs or analogous marketing approvals outside the United States. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and foreign regulatory authorities also have substantial discretion in the drug approval process. The number of nonclinical studies and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular drug candidate. Regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be deemed safe or effective; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results may not confirm the positive results from earlier nonclinical studies or clinical trials; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies may not find the data from nonclinical studies and clinical trials sufficient or meaningful; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies may change their approval policies or adopt new regulations. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. These limitations may limit the size of the potential market for a product candidate, if approved.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If clinical trials for our product candidates are prolonged, delayed or stopped, for any reason, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, or our collaborators, are either currently enrolling patients in clinical trials or anticipate initiating, continuing, or designing, or supporting clinical trials for molecules that include vobra duo, lorigerlimab, retifanlimab, teplizumab, IMGC936 and MGD024 as monotherapies or in combination with other product candidates. For example, we have decided to modify the trial design for our TAMARACK study and it is unclear what impact this will have on costs.   In addition, Incyte is currently enrolling patients in clinical trials for retifanlimab, and other collaborators outside the United States are developing our product candidates. We anticipate in the future collaborators will initiate or continue clinical trials of one or more our product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates. The continuation, modification, or commencement of existing or new clinical trials could be substantially delayed or prevented by several factors, including: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further discussions with the FDA or other regulatory agencies regarding the scope or design of our clinical trials; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as our product candidates; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay or failure in patient recruitment or enrollment in our or our collaborators&#8217; trials for any reason, including as a result of public health crises; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain sufficient funds required for a clinical trial; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to manufacture sufficient supplies of the product candidate for our clinical trials; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to reach agreement on acceptable clinical trial terms or clinical trial protocols with prospective sites or CROs the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to obtain IRB approval to conduct a clinical trial at a prospective site; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition of product candidates that are expected to be more effective or have a more favorable safety profile; and</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval of potential therapies by competitors.</span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The progress or completion of our, or our collaborators', clinical trials have been and could also be substantially delayed or prevented by many factors, including: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including actual and possible deaths; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in expected site initiation, patient recruitment and enrollment, for any reason; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of patients to complete the clinical trial; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of efficacy during clinical trials; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of our clinical trials by one or more clinical trial sites; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic and political instability in countries where our trial sites are located, including terrorist attacks, civil unrest and actual or threatened armed conflict;</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to monitor patients adequately during or after treatment by us, our collaboration partners and/or our CROs; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulatory requirements and guidance may also occur and we may need to significantly amend clinical trial protocols to reflect these changes with appropriate regulatory authorities. Amendments may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or us, due to a number of factors, including: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for the clinical development of any of our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials of our product candidates are subject to partial or full clinical holds from time to time.  A clinical hold received in the midst of conducting a trial may delay the progress of a clinical trial, or may require us to modify or discontinue such trial. Any failure or significant delay in completing clinical trials for our product candidates would adversely affect our ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of previous clinical trials may not be predictive of future results, and interim or top line data may be subject to change or qualification, based on several factors, including a complete analysis of data, or in the case of interim analysis, the continued or ongoing accrual of data. In addition, the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities for product approval. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or nonclinical testing. Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may publicly disclose top line or interim data from time to time, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial or continued progress of the study or trial. The top line or interim results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top line and interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. In addition, the achievement of one primary endpoint for a trial does not guarantee that additional co-primary endpoints or secondary endpoints will be achieved, which may have an adverse effect on our ability to obtain or retain additional regulatory approval of products or product candidates in the U.S. or in other jurisdictions. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use or may use novel technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved products that utilize these technologies. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products in development are based on our technology platforms, including Fc Optimization, DART and TRIDENT technologies. Given the novelty of these technologies, we intend to work closely with the FDA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates. Even though MARGENZA, which incorporates an Fc variation created using our Fc Optimization platform, was approved by the FDA, there is no assurance that the FDA will approve future product candidates using such technology. The validation process takes time and resources, may require independent third-party analyses, and may not be accepted by the FDA and other regulatory authorities. For some of our product candidates that are based on these technology platforms, the regulatory approval path and requirements may not be clear or evolve as more data becomes available for this product candidates, which could add significant delay and expense. Delays or failure to obtain regulatory approval of any of the product candidates that we develop would adversely affect our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to use and expand our technology platforms to continue to build a pipeline of product candidates and progress several of these product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in a pipeline of product candidates directed at various cancers, as well as autoimmune disorders and infectious diseases, we may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for initial or continued clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our stock price. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vobra duo, lorigerlimab, MARGENZA, or any other product candidate that we develop may fail to achieve or maintain market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vobra duo, lorigerlimab, MARGENZA, or any other product candidate that we develop may fail to achieve or maintain market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. For example, revenues from MARGENZA are not anticipated to enable us to reach profitability.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If product candidates that we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of any product candidates that we develop will depend on a number of factors, including but not limited to: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages compared to alternative treatments; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects; any safety events that may have occurred in connection with the development of the product candidate; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to offer our products for sale at competitive prices; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience and ease of administration compared to alternative treatments; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of physicians to prescribe the product or other new therapies, and of the patient population to try the product or these therapies; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing, sales, and distribution support; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of third-party coverage and adequate reimbursement; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of our products together with other medications. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product&#8217;s market acceptance depends significantly on the medical community&#8217;s determination of clinical benefit and safety compared to alternative therapies available both now and in the future. For example, several new therapies for the treatment of HER2-positive breast cancer were approved and certain of these therapies have or may be perceived to have greater efficacy benefits than MARGENZA in clinical trials. Competition from these and other  approved therapies has and may adversely impact the market acceptance of MARGENZA. In particular, final overall survival (OS) endpoint data from the SOPHIA trial analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumab.  This OS data may have adversely affected, or may continue to adversely affect, the market acceptance of MARGENZA</span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the potential market opportunities for our product candidates are difficult to precisely estimate. Our internal estimates of the potential market opportunities for vobra duo, lorigerlimab, and our other product candidates include several key assumptions based on a variety of factors, which may include our industry knowledge, industry publications, third-party research reports, assessment of competition, and other surveys. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. If any of these assumptions proves to be inaccurate, then the actual market for vobra duo, lorigerlimab, or our other product candidates could be smaller than our estimates of our potential market opportunity.  </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8239;Our product candidates may have undesirable side effects which may delay or prevent further clinical development or marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although all of our product candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of our product candidates could arise either during clinical development or after the approved product has been marketed. Ongoing or future trials of our product candidates may not support the conclusion that one or more of these product candidates have acceptable safety profiles. The results of future clinical or nonclinical trials may show undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities with restrictive label warnings, risk management measures, or potential product liability claims. For example, in July 2022 we announced the discontinuation of our Phase 2 trial of enoblituzumab in combination with either retifanlimab or tebotelimab in the treatment of patients with recurrent or metastatic SCCHN, based on an internal review of safety data.</span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or others later identify undesirable or unacceptable side effects potentially caused by such products: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require us to take our approved product off the market; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered, impose other risk-management measures, conduct additional clinical trials or change the labeling of the product; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to limitations on how we may promote the product; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of the product may decrease significantly; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to litigation or product liability claims; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the prescribing information for MARGENZA include warnings and precautions for infusion-related reactions, as well as a boxed warning related to left ventricular dysfunction and embryo-fetal toxicity. Further, based on the identification of future adverse events, we may be required to further revise the prescribing information, including MARGENZA&#8217;s boxed warning, which could negatively impact sales of MARGENZA or adversely affect MARGENZA&#8217;s acceptance in the market. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a limited operating history conducting commercial activities as a CDMO and our contract manufacturing business materially depends upon the regulatory approval of the product candidates we manufacture. We must comply with the FDA&#8217;s cGMP requirements, as set out in statute, regulations and interpreted through guidance. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. See &#8220;Other U.S. Post-Marketing Regulatory Requirements&#8221; above for additional information. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product or product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product or product candidates, including leading to significant delays in the availability of drug product for sale and our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation or negatively impact a product&#8217;s commercial success. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates and/or may be subject to product recalls, seizures, injunctions, or criminal prosecution. Additionally, if the FDA or a comparable foreign regulatory authority does not approve of our facilities for the manufacture of a customer product or if it withdraws such approval in the future, our customers may choose to identify alternative manufacturing facilities and/or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relationships, which could significantly impact our ability to expand our CDMO capacity and capabilities and achieve profitability.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition and if our competitors continue to develop and market products that are more effective, safer or less expensive than our product and our product candidates, our current or future commercial opportunities may be negatively impacted. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The life sciences industry is highly competitive and subject to rapid and significant technological change. We are currently developing therapeutics that will compete with other drugs and therapies that currently exist or are being developed. Products we may develop in the future are also likely to face competition from other drugs and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed, or may have succeeded, in obtaining patent protection and/or FDA approval or discovering, developing and commercializing products in our field before we do. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, there are a large number of companies developing or marketing potential treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. See &#8220;Competition&#8221; above for additional information. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity for MARGENZA is very limited, and the commercial opportunity for future product candidates including vobra duo or lorigerlimab may be reduced or limited if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of biosimilar products. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies, products or product candidates obsolete, less competitive or not economical. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacture of vobra duo, lorigerlimab, MARGENZA and our other product candidates, for ourselves and our collaborators, is complex, and we may encounter difficulties in production. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will be able to effectively manufacture clinical quantities of our product candidates in the future. Further, we have limited experience in large-scale or commercial manufacturing, and there can be no assurance that we will be able to effectively manufacture commercial quantities of MARGENZA, or other products or product candidates, if and when approved.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently manufacture product and product candidates for ourselves and our collaborators in our in-house manufacturing facility, and we anticipate manufacturing both commercial product as well as product candidates in the future, including for example commercial manufacturing of MARGENZA.  We have limited experience in manufacturing at commercial scale. The process of commercial or clinical biotechnology manufacturing for ourselves and our collaborators is highly susceptible to delays or product loss due to a variety of factors, including but not limited to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics, difficulties in scaling the production process, and vendor supply chain disruptions or fluctuations. Even minor deviations from manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in MARGENZA and our product candidates or in the manufacturing facilities in which MARGENZA and our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any adverse developments affecting </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing operations for MARGENZA and our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. In addition, if we fail to supply required quantities of MARGENZA or a product candidate for one of our collaborators, our collaborator may terminate our agreement.</span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we currently maintain insurance coverage against damage to our property and to cover business interruption and research and development restoration expenses, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. If there were to be a catastrophic event or failure of our manufacturing facilities or processes, we may be unable to meet our requirements for supply of MARGENZA and our product candidates.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 (or any variant thereof) may have a significant negative impact on our clinical trials, nonclinical studies, development, manufacturing and commercialization of our product candidates and other aspects of our business, staff, and operations.</span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health crises such as pandemics or similar outbreaks may have a material impact our business.  For instance, the COVID-19 pandemic impaired our ability to enroll patients in clinical trials, continue ongoing clinical trials or activate clinical trial sites, and MARGENZA commercialization, due to, for example, heightened exposure to COVID-19 if an outbreak occurs in a specific geography, the shifting of healthcare resources toward the pandemic or the closing of or limiting of access to clinical facilities, and reduced or eliminated in-person access to physicians and health care centers. Furthermore, patients may be unable or unwilling to enroll in our clinical trials or be unable to comply with clinical trial protocols if COVID-19 related restrictions impede patient movement or interrupt healthcare services. Public health crises may also negatively affect the operations of third-party CROs that we rely upon to carry out our clinical trials, or the operations of other service providers, which could result in delays or disruptions in the supply of our product candidates or other aspects of our business or that of our collaborators. Any negative impact public health crises could have, on patient enrollment or treatment or the timing and execution of our clinical trials could cause delays to our clinical trial activities, which could adversely affect our ability to seek and obtain regulatory approval for and to commercialize any approved product candidates, increase our operating expenses and have a material adverse effect on our business and financial results. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have seen limited business impact from COVID-19 related absences for our employees, but there can be no assurance that there will not be negative business impact in the future. We expect many employees to continue to work remotely or a hybrid of in-person and remote work, which presents risks, uncertainties and costs that could affect our performance, including operational and workplace culture challenges and uncertainty regarding office space needs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also face increased cybersecurity risks due to the shifting of a majority of our corporate functions operating remotely in regions impacted the virus. Increased levels of remote access may create additional opportunities for cybercriminals to attempt to exploit vulnerabilities, and our employees may be more susceptible to phishing and social engineering attempts. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience in launching and marketing products. If we are unable to further develop marketing and sales capabilities or enter into agreements with third parties to market and sell our products, or our existing arrangements are not successful, we may not be able to generate substantial product sales revenue. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the FDA approved MARGENZA, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. We launched MARGENZA in March 2021. In conjunction with Eversana, we continue to build commercialization support in United States to commercialize MARGENZA in a manner we believe to be appropriate in light of the modest size of the market opportunity. We have limited internal commercialization capabilities, and any additional products or product candidates that we may develop or in-license, will require significant capital expenditures, management resources and time. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience in commercializing our products. For example, we have limited experience in building and managing a commercial team, conducting a comprehensive market analysis, and reimbursement, or managing distributors and a field force for our products. We compete with many companies that currently have extensive and well-funded sales and marketing operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For commercialization of any or all of our product candidates, we will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. If we are unable to, or decide not to, further develop internal sales, marketing, and commercial distribution capabilities for any or all of our products, we will likely pursue additional collaborative arrangements regarding the sales and marketing of our products. However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have effective sales forces. Any revenue we receive will depend upon the efforts of such third parties. We would have little or no control over the marketing and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized our products ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts for our products. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There can be no assurance that we will be able to further develop or successfully maintain internal sales and commercial capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any product, and as a result, we may not be able to generate substantial product sales revenue.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Actual or anticipated changes to the laws and regulations governing the health care system may have a negative impact on cost and access to health insurance coverage and reimbursement of healthcare items and services. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and several foreign jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our future approved products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs through lowering prescription drug prices, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives, including the ACA, which became law in 2010. While it is difficult to assess the impact of the ACA in isolation, either in general or on our business specifically, it is widely thought that the ACA increases the likelihood of downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of, and the price we may charge for, any products we develop that receive regulatory approval. Further, the United State and foreign governments regularly consider additional reform measures that affect healthcare coverage and costs. Such reforms may include changes to the coverage and reimbursement of healthcare services and products. In particular, there have been executive, judicial and Congressional challenges to the ACA, which could have an impact on coverage and reimbursement for healthcare services covered by plans authorized by the ACA. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 (Tax Act) included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and any healthcare reform measures of the Biden administration will impact the ACA and our business. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example ,in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services (HHS) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; for such drugs and biologics under the law, and (ii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant impact on the pharmaceutical industry. Further, the Biden administration released an additional executive order on October 14, 2022, directing HHS to submit a report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. It is unclear whether this executive order or similar policy initiatives will be implemented in the future. However, it is unclear whether these or similar policy initiatives will be implemented in the future. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what healthcare initiatives, if any, will be implemented at the federal or state level, however, government and other regulatory oversight and future regulatory and government interference with the healthcare systems could adversely impact our business and results of operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of various and evolving payor models and additional legislative proposals.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products, it is less likely that our products will be widely used. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance and sales of our products and product candidates, if approved for sale by the appropriate regulatory authorities, may depend on reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will reimburse and establish payment levels and, in some cases, utilization management strategies, such as tiered formularies and prior authorization. We cannot be certain that reimbursement will be available for our products or any products that we develop. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, our products. Our ability to commercialize our products may depend, in part, on the extent to which reimbursement for the products will be available from government authorities and third-party payors. If reimbursement for our products is not available or is available on a limited basis, or if the reimbursement amount for our products is inadequate to support a product&#8217;s price, we may not be able to successfully commercialize any of our approved products. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products are typically made by CMS, an agency within HHS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage and reimbursement determination process is often time-consuming and costly. This process may require us to provide scientific and clinical information to support the coverage or reimbursement of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As federal and state governments implement additional health care cost containment measures, including measures to lower prescription drug pricing, we cannot be sure that MARGENZA and our product candidates, if approved, will be covered, or remain covered, by private or public payors, and if covered, whether the reimbursement will be perceived by product purchasers as adequate. Health reform actions by federal and state governments and health plans may put additional downward pressure on pharmaceutical pricing and health care costs, which could negatively impact coverage and reimbursement for MARGENZA and our product candidates, if approved, our revenue, and our ability to compete with other marketed products and to recoup the costs of our research and development. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, third-party payors are requiring that biopharmaceutical manufacturers provide them with discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical products. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific products and product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our products may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any approved product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Further, coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. Additionally, we or our collaborators may develop companion diagnostic tests for use with our product candidates where appropriate. We or our collaborators will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we may seek for our product candidates. While we have not yet developed any companion diagnostic tests for our product candidates, if </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we do, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our products or product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability lawsuits related to the sale of our products to, use of our products by, and testing of our product candidates in, seriously ill patients. Product liability claims may be brought against us or our collaborators by participants enrolled in our clinical trials, patients, health care providers or others using, administering or selling any of our approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities. Regardless of their merit or eventual outcome, liability claims may result in: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our future approved products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of clinical trial sites or entire trial programs; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased regulatory scrutiny; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant litigation costs; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to or costly settlement with patients or other claimants; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls or a change in the indications for which they may be used; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management and scientific resources from our business operations; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to vobra duo, lorigerlimab, MARGENZA and any of our other product candidates that are approved for commercial sale, we are, and will be, highly dependent upon physician and patient perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perceptions, any adverse publicity associated with illness or other adverse effects resulting from patients&#8217; use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our financial condition or results of operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we hold $20 million in product liability insurance coverage in the aggregate, with a per incident limit of $20 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage when we begin the commercialization of additional product candidates. Insurance coverage is becoming increasingly expensive. As a result, we may be unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. A successful product liability claim or series of claims brought against us, particularly if judgments exceed any insurance coverage we may have, could decrease our cash resources and adversely affect our business, financial condition and results of operation. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we and our collaborators obtain regulatory approvals to market our current and any future approved products, we and our collaborators will remain subject to extensive ongoing regulatory obligations and oversight, including post-approval requirements, that could result in significant additional expense and could negatively impact our and our collaborators' ability to commercialize our current and any future approved products. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators are subject to extensive ongoing obligations and continued regulatory review from applicable regulatory agencies with respect to any product obtaining regulatory approval, including vobra duo, lorigerlimab, and MARGENZA, such as continued adverse event reporting requirements and post-marketing commitments, all of which may result in significant expense and limit our and our collaborators' ability to commercialize our current and any future approved products. For example, the FDA's approval of MARGENZA included a requirement that we provide to the FDA the data from the final overall survival endpoint from our SOPHIA study, which we reported in September 2021.  Moreover, in connection with MARGENZA&#8217;s approval, the labeling and advertising and promotion of MARGENZA are subject to additional regulatory requirements, which could entail significant expense and could negatively impact the potential commercialization of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MARGENZA. To the extent other product candidates or those of our partners are approved by the FDA, we or our collaborators may be subject to similar post-marketing obligations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the manufacturers of our current and any future approved products are also required, or will be required, to comply with cGMP regulations, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation. Further, regulatory agencies must approve these manufacturing facilities before they can be used to manufacture our products and product candidates, and these facilities are subject to ongoing regulatory inspections. In addition, regulatory agencies subject an approved product, its manufacturer and the manufacturer&#8217;s facilities to continual review and inspections, including periodic unannounced inspections. The subsequent discovery of previously unknown problems with our current or any future approved products, including adverse events of unanticipated severity or frequency, or problems with the facilities where our current or any future approved products are manufactured, may result in restrictions on the marketing of our current or any such future approved products, up to and including withdrawal of the affected product from the market. If our manufacturing facilities, our collaborators' manufacturing facilities, or those of our respective suppliers, fail to comply with applicable regulatory requirements, such noncompliance could result in regulatory action and additional costs to us. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable FDA and other regulatory requirements may subject us to administrative or judicially imposed sanctions, including: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuance of Form FDA 483 notices or Warning Letters by the FDA or other regulatory agencies; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of fines and other civil penalties; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecutions; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions, suspensions or revocations of regulatory approvals; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of any ongoing clinical trials; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total or partial suspension of manufacturing; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in commercialization; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications submitted by us; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusals to permit drugs to be imported into or exported from the United States; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on operations, including costly new manufacturing requirements; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls or seizures. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The policies of the FDA and other regulatory agencies may change and additional government regulations may be enacted that could prevent or delay regulatory approval of vobra duo, our other product candidates or of MARGENZA in any additional indications or territories, or further restrict or regulate post-approval activities. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are not able to maintain regulatory compliance, we or our collaborators might not be permitted to market our current or any future approved products and our business would suffer.  </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and/or our collaboration partners may never obtain approval or commercialize our products outside of the United States, which would limit our ability to realize their full market potential. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any products outside of the United States, we and our current and potential collaboration partners must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and may require additional nonclinical studies or clinical trials or additional administrative review periods, which could result in significant delays, difficulties and costs for us. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. Although we obtained FDA approval of MARGENZA in December 2020, we do not have any product candidates approved for sale in any international market. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products will be harmed. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA, and other government employees and pause or stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our contract with the National Institute of Allergy and Infectious Diseases (NIAID)&#8239;makes us a government contractor. Laws and regulations affecting government contracts&#8239;may&#8239;make it more costly and difficult for us to successfully conduct our business.&#8239; </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must comply with numerous laws and regulations relating to the procurement, formation, administration and performance of government contracts. Failure to comply with these laws could result in significant civil and criminal penalties. Among the most significant government contracting regulations that may affect our business are: the Federal Acquisition Regulation (FAR) and NIH-NIAID-specific regulations supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts; business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and incorporate other requirements such as the Anti-Kickback Act, the Procurement Integrity Act, and the False Claims Act; export and import control laws and regulations; and laws, regulations and executive orders restricting the use and dissemination of sensitive information we may receive pursuant to our performance of the government contract.   U.S. government agencies routinely audit and investigate government contractors for compliance with applicable laws and standards. If we are audited, such audit could result in disallowance of expected cost reimbursement, or if such audit were to uncover improper or illegal activities, we could be subject to civil and criminal penalties, administrative sanctions, including suspension or debarment from government contracting and significant reputational harm. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. tax law may have a material adverse effect on our business, financial condition and results of operations, and changes in international trade relations may have a material adverse effect on the commercialization of some or all of our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in laws and policy relating to taxes may have an adverse effect on our business, financial condition and results of operations. Recent tax reforms in the United States have resulted in significant changes to preexisting U.S. tax rules and regulations. These changes may trigger an adverse effect on our business, financial conditions and results of operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the U.S. government may seek to implement more protective trade measures with countries in which we plan to conduct business in, with great deal of uncertainty regarding trade policies, tariffs and government regulations, which if altered could have the potential to create a significant adverse effect on trade between the United States and other countries. Overall, changes in international trade relations, such as the imposition of or increase in tariffs or other trade barriers, could materially and adversely impact our costs, the ability to make sales of our product candidates to any of our significant customers in other countries, and reduce the competitiveness of our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing our product candidates through clinical development and have commercialized MARGENZA in collaboration with Eversana. Developing and commercializing pharmaceutical products, including conducting nonclinical studies and clinical trials, is expensive. In order to obtain such regulatory approval of product candidates, we will be required to conduct clinical trials for each indication for each of our product candidates. We will continue to require additional funding beyond what was raised in our public offerings and through our collaborations and license agreements to complete the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development and commercialization of our product candidates and to continue to advance the development of our other product candidates. Due to worsening global economic conditions, including decades-high inflation and concerns of a recession in the United States or other major markets, and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide, including resulting from the ongoing COVID-19 pandemic, such funding may not be available on acceptable terms or at all. Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our cash, cash equivalents and marketable securities as of December 31, 2022, combined with anticipated and potential collaboration payments and product revenues, will enable us to fund our operations through 2025. Such guidance does not reflect anticipated expenditures related to the potential late-stage development of vobra duo in mCRPC or further expansion of studies currently ongoing. Because development of our product candidates is uncertain, we are unable to estimate accurately the actual funds we will require to complete research, development and clinical testing to commercialize our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will depend on many factors, including but not limited to: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of other product candidates and indications that we pursue; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, timing, cost and results of research, nonclinical development, and clinical trials, in particular, our planned potential registrational path trial for MCG018; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of seeking and obtaining FDA and non-U.S. regulatory approvals; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with manufacturing our product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of establishing sales, marketing, and distribution capabilities; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need and ability to hire additional management, scientific, and medical personnel; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing products that may limit market penetration of our product candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the economic and other terms, timing of and success of our existing collaborations, and any collaboration, licensing, or other arrangements into which we may enter in the future, including the timing of receipt of any milestone or royalty payments under these agreements. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through a combination of public or private equity offerings, debt financings, strategic collaborations, and grant funding. If sufficient funds on acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, scale back or eliminate one or more of our development programs or our business operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. Our first commercial product, MARGENZA, launched in March 2021 and to date has not resulted in revenues sufficient for us to reach profitability. Accordingly, we may never achieve or sustain profitability. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant losses since our inception. As of December&#8239;31, 2022, our accumulated deficit was approximately $1.1&#160;billion. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates, manufacture product and product candidate inventory, prepare for and begin to commercialize any future approved products, and add infrastructure and personnel if needed to support our product development efforts and operations as a public company. The net losses and negative cash flows incurred to date, together with expected future losses, have had, and likely will continue to have, an adverse effect on our stockholders' deficit and working capital. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development and commercialization, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. For example, our expenses could increase if we are required by the FDA to perform trials in addition to those that we currently expect to perform, or if there are any delays in completing our currently planned clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials or in the development of any of our product candidates. Our expenses would significantly increase to the extent we build out a sales force and other commercially relevant functions to support the commercialization of any of our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. For example, revenues from MARGENZA are unlikely to be sufficient to enable us to reach profitability. In order to commercialize any additional product candidates, we will need to be successful in a range of challenging activities for which we are only in the preliminary stages, including developing product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling approved products and product candidates for which we may obtain regulatory approval. We may never succeed in these activities and may never generate revenue from product sales that is significant enough to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, develop other product candidates, or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises, political crises, geopolitical events, such as the ongoing military conflict in Ukraine, or other macroeconomic conditions, which have in the past and may in the future negatively impact our business and financial performance.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates and uncertainty about economic stability. The Federal Reserve recently raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly or more dilutive or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available at all, may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, MARGENZA, product candidates, or future revenue streams, or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, scale back or eliminate one or more of our development programs or grant rights to develop and market MARGENZA or product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and other tax attributes may be limited. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to utilize our federal net operating losses (NOLs) and federal tax credits is currently limited, and may be limited further, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. The limitations apply if an ownership change, as defined by Section&#8239;382, occurs. Generally, an ownership change occurs when certain shareholders increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period, which is typically three years or since the last ownership change. We are already subject to Section&#8239;382 limitations due to acquisitions we made in 2002 and 2008.&#8239;As of December 31, 2022, we had federal and state NOL carryforwards of approximately $777 million and federal research and development tax credits of approximately $94 million available. Future changes in stock ownership may also trigger an ownership change and, consequently, another Section&#8239;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited capabilities for drug development and have little to no internal capability for sales, marketing or distribution. We have entered into collaborations with other companies that we believe can provide such capabilities, including our agreements with, for example, Gilead Sciences, Inc., Incyte Corporation, Zai Lab Limited and Janssen Biotech, Inc. These current collaborations also have provided us with important funding for our development programs and technology platforms and we expect to receive additional funding under these collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks, including the following: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators' strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays in payment, or non-payment, of  royalties, milestones or other monies owed, delays or  termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. For example, each of our collaboration and license agreements may be terminated for convenience upon the completion of a specified notice period. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our therapeutic collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form 10-K also apply to the activities of our program collaborators. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might de-emphasize or terminate the development or commercialization of MARGENZA or any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For vobra duo, lorigerlimab, and our other product candidates, we may in the future determine to collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative products, product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of vobra duo, lorigerlimab,  or our other product candidates, reduce or delay one or more of our other development programs, delay the commercialization of a product candidate or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop vobra duo, lorigerlimab, or our other product candidates or bring them to market or continue to develop our technology platforms and our business may be materially and adversely affected. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be restricted under collaboration agreements from entering into additional agreements on certain terms with potential collaborators. Most of our existing therapeutic collaborations contain a restriction on our engaging in activities that are the subject of the collaboration with third parties for specified periods of time. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We contract with, and may in the future contract with, third parties for components of the manufacturing of MARGENZA and our other product candidates. Failure of third-party contractors to successfully perform their obligations could harm our ability to develop or commercialize our product or product candidates.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have one cGMP manufacturing facility located in Rockville, Maryland in compliance with cGMP to support future clinical and commercial production of our and our collaborators&#8217; product candidates. We manufacture drug substance lots at this facility that we use for clinical trials of our and our collaborators&#8217; product candidates. We also have the capability to manufacture commercial supply of MARGENZA. Although we believe we currently have capacity to produce most of the material required for our and our collaborators&#8217; clinical trials and for the commercial supply of MARGENZA, we may not be able to do so in the future, and may continue to rely on arrangements with third parties. We will continue to rely on third parties for bioconjugation to produce ADCs and for fill finish activities, neither of which our cGMP manufacturing facility can currently accommodate.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with contract manufacturing organizations in the past to supplement our clinical supply and internal capacity as we commercialize MARGENZA and advance vobra duo, lorigerlimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other product candidates in our pipeline. In addition, in the future, we may use third parties for the manufacture of some or all components of our product candidates for clinical testing, including anti-body drug conjugates, as well as for commercial manufacture of some of our product candidates that receive marketing approval and that are not manufactured by us or one of our third party collaborators. We may be unable to reach agreement with any of these contract manufacturers, or to identify and reach arrangements on satisfactory terms with other contract manufacturers, to manufacture any of our product candidates. Additionally, the facilities used by any contract manufacturer to manufacture any of our product candidates must be the subject of a satisfactory inspection before the FDA and other regulatory authorities approve a BLA or marketing authorization for the product candidate manufactured at that facility. We will depend on these third-party manufacturing partners for compliance with the FDA&#8217;s requirements for the manufacture of our finished products. If our manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA and other regulatory authorities&#8217; cGMP requirements, our product candidates will not be approved or, if already approved, may be subject to recalls. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured MARGENZA or the product candidates ourselves, including: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the possibility of a breach of the manufacturing agreements by the third parties because of factors beyond our control; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the possibility that we may not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to meet our manufacturing needs. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could adversely impact the commercialization of MARGENZA and the delay of approval or commercialization of our product candidates, cause us to incur higher costs or prevent us from commercializing our product candidates successfully. Furthermore, if contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for MARGENZA or our product candidates and to have any such new source approved by the FDA or any other relevant regulatory authorities. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to successfully develop and commercialize companion diagnostics with third party contractors for use with our product candidates could harm our ability to commercialize our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to develop, or engage third parties to develop, companion diagnostics for our product candidates where appropriate. At least in some cases, the FDA and similar regulatory authorities outside the United States may request or require the development and regulatory approval of a companion diagnostic as a condition to approving one or more of our product candidates. We do not have experience or capabilities in developing or commercializing diagnostics and are relying, and in the future plan to continue to rely, in large part on third parties to perform these functions. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In most cases, we will likely outsource the development, production and commercialization of companion diagnostics to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third party contractors to successfully develop and commercialize these companion diagnostics. Our contractors: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may not perform their obligations as expected; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may encounter production difficulties that could constrain the supply of the companion diagnostic; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may not commit sufficient resources to the marketing and distribution of such product; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may terminate their relationship with us. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any companion diagnostic for use with one of our product candidates fails to gain market acceptance, our ability to derive revenues from sales of such product candidate could be harmed. If our third party contractors fail to commercialize such companion diagnostic, we may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with such product candidate or do so on commercially reasonable terms, which could adversely affect and delay the development or commercialization of such product candidate.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Independent clinical investigators and CROs that we engage to conduct our clinical trials may not devote sufficient time or attention to our clinical trials or be able to repeat their past success. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to depend on independent clinical investigators and CROs to conduct our clinical trials, including future trials for vobra duo, lorigerlimab and other product candidates. CROs may also assist us in the collection and analysis of data. There is a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. These investigators and CROs will not be our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. Further, the FDA requires that we comply with standards, commonly referred to as current Good Clinical Practice (GCP) for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects are protected. Failure of clinical investigators or CROs to meet their obligations to us or comply with GCP procedures could adversely affect the clinical development of our product candidates and harm our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercialization collaborations will be important to our business. If we are unable to maintain commercialization collaborations, or if commercialization collaborations are not successful, our business could be adversely affected. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited capabilities for drug commercialization, with little to no internal capability for sales, marketing or distribution.  For example, we have entered into a collaboration with Eversana for the commercialization of MARGENZA in the United States that we believe can provide such capabilities, and may enter into commercial collaborations in the future for MARGENZA or our product candidates. Our existing commercialization collaboration, and any future commercialization collaborations we enter into, may pose a number of risks, including the following: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue commercialization of MARGENZA or any product candidates that achieve regulatory approval or may elect not to continue commercialization based on clinical trial results, changes in the collaborators' strategic focus or other factors that divert resources or create competing priorities; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently commercialize products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully commercialized under terms that are more economically attractive than ours; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators with marketing and distribution rights to MARGENZA or our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements on contract interpretation, commercialization strategy or tactics, might cause delays or termination of the commercialization of MARGENZA or product candidates, might lead to additional responsibilities for us with respect to MARGENZA or product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly utilize our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may violate, or be investigated for potentially violating, health care compliance and related laws and regulations, which may expose us to litigation, enforcement actions or inquiries, or other potential liability; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further commercialization of MARGNEZA or applicable product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the risks relating to commercialization, and health care legal compliance described in this Annual Report on Form 10-K also apply to the commercialization activities of our collaborators. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might de-emphasize or terminate the development or commercialization of MARGENZA or any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators. We may also be restricted under commercialization collaboration agreements from entering into future agreements on certain terms with potential collaborators. For example, our collaboration with Eversana contains a restriction on our engaging in activities that are the subject of the collaboration with third parties for specified periods of time among other conditions. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are unable to reach agreements with suitable collaborators on a timely </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">basis, on acceptable terms, or at all, we may have to curtail the commercialization of MARGENZA or a product candidate, reduce the scope of any sales or marketing activities, or increase our expenditures and undertake or commercialization activities at our own expense. If in the future we elect to fund and undertake commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations to commercialize our product candidates and do not have sufficient funds or expertise to undertake the necessary commercialization activities, we may not be able to commercialize our product candidates or bring them to market or continue and our business may be materially and adversely affected. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Cybersecurity</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A disruption in our computer networks, including those related to cybersecurity, could adversely affect our financial performance as well as our research, development and commercialization efforts. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security breaches, including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches continue to increase generally and can create system disruptions or shutdowns or the unauthorized disclosure of confidential information. In addition, due to the COVID-19 pandemic a portion of our employees have been working remotely, either from home or elsewhere. If personal information or protected health information is improperly accessed, tampered with or disclosed as a result of a security breach, we may incur significant costs to notify and mitigate potential harm to the affected individuals, and we may be subject to sanctions and civil or criminal penalties if we are found to be in violation of federal, state, or other laws protecting confidential personal information. In addition, a cybersecurity breach could hurt our reputation, subject us to liability claims or regulatory penalties for compromised personal information and could have a material adverse effect on our business, financial condition and results of operations. In order to reduce such risks, our information security program employs a policy-driven information systems security architecture based on National Institute of Standards and Technology (NIST) Cybersecurity Framework and references the NIST 800-53 guidelines for risk-based assessments and implementation of information security controls, which are assessed annually by independent third party auditors. An information security training program is also in place to educate employees and contractors on information security and data protection measures. The cybersecurity program is managed by dedicated Information Security personnel with the primary mission to implement, maintain, and improve the capabilities and practices to ensure the confidentiality, integrity, and availability of the sensitive information it maintains. &#8239; </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends significantly on our ability to operate without infringing the valid patents and other proprietary rights of third parties. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Third parties may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our future approved products or impair our competitive position. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are not infringed, and/or are invalid and/or unenforceable, if a court should find that they cover our products, such as MARGENZA or enoblituzumab, and we are unable to invalidate such patents, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties could possess patents that we may ultimately be found to infringe, or such third party patents could issue in the future. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from developing product candidates using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial condition and results of operations. Moreover, our failure to maintain a license to any technology that we require may also materially harm our business, financial condition, and results of operations. Furthermore, we would be exposed to a threat of litigation. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the pharmaceutical industry, significant litigation and other proceedings regarding patents, patent applications, trademarks and other intellectual property rights have become commonplace. The types of situations in which we may become a party to such litigation or proceedings include: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not infringe those third parties' patents; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference, opposition or other proceedings to determine the priority </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate their patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits would be costly and could affect our results of operations and divert the attention of our management and scientific personnel. There is a risk that a court would decide that we or our collaborators are infringing the third party&#8217;s patents and would order us or our collaborators to stop the activities covered by the patents. In that event, we or our collaborators may not have a viable alternative to the technology protected by the patent and may need to halt work on the affected product candidate or cease commercialization of an approved product. In addition, there is a risk that a court will order us or our collaborators to pay the other party damages. An adverse outcome in any litigation or other proceeding could subject us to significant liabilities to third parties and require us to cease using the technology that is at issue or to license the technology from third parties. We may not be able to obtain any required licenses on commercially acceptable terms or at all. Any of these outcomes could have a material adverse effect on our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products, methods of use, or processes. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. If we are sued for patent infringement, we would need to demonstrate that our products, methods, or processes either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant management time. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and enforce patent protection for our products and our product candidates and related technology, our business could be materially harmed. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued patents may be challenged, narrowed, invalidated or circumvented. In addition, court decisions may introduce uncertainty in the enforceability or scope of patents owned by biotechnology companies. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not allow us to protect our inventions with patents to the same extent as the laws of the United States. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our patents in the United States and in foreign countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection from our pending patent applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy depends on our ability to identify and seek patent protection for our discoveries. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent does not ensure that a court or agency finds or will find the patent valid or enforceable, so even if we obtain patents, they may not be valid or enforceable against third parties. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology. Third parties may also seek to market biosimilar versions of any approved products. Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and factual considerations. The standards which the United States Patent and Trademark Office (USPTO) and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United States, and many companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries. Outside the United States, patent protection must be sought in individual jurisdictions, further adding to the cost and uncertainty of obtaining adequate patent protection outside of the United States. Accordingly, we cannot predict whether additional patents protecting our technology will issue in the United States or in foreign jurisdictions, or whether any patents that do issue will have claims of adequate scope to provide competitive advantage. Moreover, we cannot predict whether third parties will be able to successfully obtain claims or the breadth of such claims. The allowance of broader claims may increase the incidence and cost of patent interference proceedings, opposition proceedings, and/or reexamination proceedings, the risk of infringement litigation, and the vulnerability of the claims to challenge. On the other hand, the allowance of narrower claims does not eliminate the potential for adversarial proceedings, and may fail to provide a competitive advantage. Our issued patents may not contain claims sufficiently broad to protect us against third parties with similar technologies or products, or provide us with any competitive advantage. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after they have been issued, our patents and any patents which we license may be challenged, narrowed, invalidated or circumvented. If our patents are invalidated or otherwise limited or will expire prior to the commercialization of our approved products and product candidates, other companies may be better able to develop products that compete with ours, which could adversely affect our competitive business position, business prospects and financial condition. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are examples of litigation and other adversarial proceedings or disputes that we could become a party to involving our patents or patents licensed to us: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our collaborators may initiate litigation or other proceedings against third parties to enforce our patent rights; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product or technology does not infringe our patents or patents licensed to us; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may initiate opposition, reexamination or inter partes review proceedings challenging the validity or scope of our patent rights, requiring us or our collaborators and/or licensors to participate in such proceedings to defend the validity and scope of our patents; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there may be a challenge or dispute regarding inventorship or ownership of patents currently identified as being owned by or licensed to us; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the USPTO may initiate an interference between patents or patent applications owned by or licensed to us and those of our competitors, requiring us or our collaborators and/or licensors to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent rights; or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may seek approval to market biosimilar versions of our future approved products prior to expiration of relevant patents owned by or licensed to us, requiring us to defend our patents, including by filing lawsuits alleging patent infringement. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits and proceedings would be costly and could affect our results of operations and divert the attention of our managerial and scientific personnel. There is a risk that a court or administrative body would decide that our patents are invalid or not infringed by a third party&#8217;s activities, or that the scope of certain issued claims must be further limited. An adverse outcome in a litigation or proceeding involving our own patents could limit our ability to assert our patents against these or other competitors, affect our ability to receive royalties or other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to develop a platform that is similar to, or better than, ours in a way that is not covered by the claims of our patents; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might not have been the first to make the inventions covered by patents or pending patent applications; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might not have been the first to file patent applications for these inventions; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently party to various intellectual property license agreements. These license agreements impose, and we expect that future license agreements may impose, various diligence, milestone payment, royalty, insurance and other obligations on us. For example, we have entered into patent and know-how license agreements that grant us the right to use certain technologies related to biological manufacturing to manufacture our clinical product candidates. These licenses typically include an obligation to pay yearly maintenance payments and royalties on sales, and may also include upfront and milestone payments. If we fail to comply with our obligations under the licenses, the licensors may have the right to terminate their respective license agreements, in which event we might not be able to market any product that is covered by the agreements. Termination of the license agreements or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, which could adversely affect our competitive business position and harm our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from that individual, or a third party or from that individual&#8217;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously or concurrently employed at research institutions and/or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel or our agents to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. In addition, we may be responsible for the payment of patent fees for patent rights that we license from other parties. If any licensor of these patents does not itself elect to make these payments, and we fail to do so, we may be liable to the licensor for any costs and consequences of any resulting loss of patent rights. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Legal Compliance Matters </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act, (FCPA) and other anti-corruption laws that apply in countries where we do business. The FCPA and these other laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We and our commercial partners operate in a number of jurisdictions that pose a risk of potential FCPA violations, and we participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or other anti-corruption laws. There is no </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws. If we violate provisions of the FCPA or other anti-corruption laws or are subject to an investigation or audit pursuant to these laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures and legal expenses, which could have an adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development involves, and may in the future involve, the use of potentially hazardous materials and chemicals. Our operations may produce hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations and fire and building codes, including those governing laboratory procedures, exposure to blood-borne pathogens, use and storage of flammable agents and the handling of biohazardous materials. Although we maintain workers&#8217; compensation insurance as prescribed by the States of Maryland and California to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators are subject to various healthcare laws, and our failure, or the failure of our collaborators, to comply with those laws could result in significant penalties and adversely affect our business, operations and financial condition. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our operations, and those of our collaborators, are subject to regulation by various local, state, federal authorities in addition to the FDA, including but not limited to, CMS, other divisions of HHS (such as the Office of Inspector General, Office for Civil Rights and the Health Resources and Service Administration), the U.S. Department of Justice (DOJ) and individual U.S. Attorney offices within the DOJ, and state and local governments. We and our collaborators are or may be subject to broadly applicable &#8220;fraud and abuse&#8221; laws, such as false claims, anti-kickback laws, transparency laws, and privacy and security laws. Federal false claims laws, including the federal civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, or causing to be made, a false statement to get a claim paid. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal anti-kickback statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices, or those of our collaborators, may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the intent standard under the federal anti-kickback statute and the criminal healthcare fraud statutes (discussed below) was amended by the ACA to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the federal civil false claims act. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal anti-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">kickback statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Sunshine Act provisions of the ACA, covered manufacturers of drugs, devices, biological and medical supplies for which payment is available under a federal health care program (with certain exceptions) are subject to annual federal reporting and disclosure requirements with regard to payments or other transfers of value made to physicians defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals as well as information regarding certain ownership and investment interests held by physicians and their immediate family members.  </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws, which may apply to items such as pharmaceutical products and services reimbursed by private insurers. Some state laws also prohibit certain gifts to healthcare providers, require pharmaceutical companies to report payments to healthcare professionals, and/or require companies to adopt compliance programs or codes of conduct. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past few years, a number of pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, improper consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. At such time as we or our collaborators market MARGENZA or any of our future approved products and these products are paid for by governmental programs, it is possible that some of our business activities could also be subject to challenge under one or more of these &#8220;fraud and abuse&#8221; laws. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators may also be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business, as well as foreign jurisdictions. In the United States, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and its implementing regulations, impose requirements on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective &#8220;business associates&#8221; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity as well as their covered subcontractors relating to the privacy, security and transmission of individually identifiable health information. We are subject to other state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For example, the General Data Protection Regulation (EU) 2016/679 (GDPR) which went into effect on May 25, 2018, imposes privacy and security obligations on any entity that collects and/or processes health data from individuals located in the European Union. Under the GDPR, fines of up to 20&#160;million Euros or up to 4% of the annual global turnover of the infringer, whichever is greater, could be imposed for significant non-compliance. In addition, on June 28, 2018, California enacted the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent state privacy legislation in the United States, which could increase our potential liability and adversely affect our business. As well as complicating our compliance efforts, non-compliance with these laws could result in penalties or significant legal liability.</span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in order to distribute products commercially in the United States, we or our collaborators must also comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers, and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, track, and report gifts, compensation and other remuneration made to physicians and other healthcare providers, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations, or those of our collaborators marketing, distributing or commercializing any of our products on our behalf, are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, significant civil, criminal and/or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our operations and those of our collaborators may be subject to analogous foreign health care laws in the jurisdictions in which we operate. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA or other agencies, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Employee Matters and Human Capital Management  </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the research and development, clinical and business development expertise of Scott Koenig, M.D., Ph.D., our President and Chief Executive Officer, as well as the other members of our senior management team. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development, manufacturing and commercialization objectives and seriously harm our ability to successfully implement our business strategy. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing and other personnel will also be critical to our success. For example, we have experienced increased employee turnover, consistent with high numbers of employee resignations across the broader American economy, and we may continue to experience employee turnover in the future that may have an adverse effect on our business strategy. New hires require significant training and, in most cases, take significant time before they achieve full productivity. New employees may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Such competition may increase due to the recent move by companies to offer a remote or hybrid work environment. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, motivate existing employees, or maintain our corporate culture in a hybrid or remote work environment and in the midst of higher turnover, our ability to pursue our growth strategy will be limited. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in January 2023, the U.S. Federal Trade Commission published a proposed rule that would generally prohibit post-employment non-compete clauses (or other clauses with comparable effect) in agreements between employers and their employees. If this rule goes into effect, or if we fail to adequately address any of the issues referred to above, it could adversely impact our ability to recruit and retain our skilled employees which may result in a material adverse effect on our business, operating results and financial condition.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our restructuring and the associated workforce reduction announced in August 2022 may not result in anticipated cost savings, could result in total costs and expenses that are greater than expected and could disrupt our business.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced a reduction in workforce by approximately 15% in connection with the restructuring of our business to prioritize and focus on our lead assets. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our operating structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our results of operation and financial condition would be adversely affected. We expect to incur additional costs as we recognize one-time employee termination-related charges. We also cannot guarantee that we will not have to undertake additional workforce reductions or restructuring activities in the future. Furthermore, our strategic restructuring plan may be disruptive to our operations. For example, our workforce reductions could yield unanticipated consequences, such as attrition beyond planned staff reductions, increased difficulties in our day-to-day operations and reduced employee morale. If employees who were not affected by the reduction in force seek alternate employment, this could result in us seeking contract support which may result in unplanned additional expense or harm our productivity. Our workforce reductions could also harm our ability to attract and retain qualified management, scientific, clinical, and manufacturing personnel who are critical to our business. Any failure to attract or retain qualified personnel could prevent us from successfully developing our product candidates in the future.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to provide meaningful equity incentives to our key employees, it could adversely affect our ability to retain these key employees, which in turn could affect our ability to implement our business strategies. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent upon the members of our senior management team and other key employees. In our industry, it is common to attract and retain executive and other key employees with compensation packages that include a significant equity component. As a result, we may have difficulty retaining key personnel, which would have a material adverse effect on our ability to execute our business strategy. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to grow or contract our organization, and we may experience difficulties in managing this growth or contraction, which could disrupt our operations. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had 357 full-time employees, with the announced intention of a workforce reduction totaling 15% from August 2022.  In addition to the risks associated with a reduction in force, as our finances, development and commercialization plans and strategies evolve, we may choose to expand or contract our employee base for managerial, operational, manufacturing, financial and other resources. Future growth or additional contraction would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing either growth or contraction activities. We may not be able to effectively manage our operations which may result in weaknesses in our infrastructure, give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining employees. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of existing and additional product candidates. If our management is unable to effectively manage such growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize MARGENZA, our product candidates and compete effectively with others in our industry will depend, in part, on our ability to effectively manage any such growth. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Common Stock </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to securities litigation, which is expensive and could divert management attention and adversely impact our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has been and may continue to be volatile. Companies that have experienced volatility in the market price of their common stock are often subject to securities class action litigation. For example, on September 13, 2019, a securities class action complaint was filed against us, and certain of our officers and/or directors in the U.S. District Court for the District of Maryland. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice, and on March 2, 2023 the Fourth Circuit affirmed the District Court&#8217;s dismissal. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This or any future securities litigation brought by private parties or government enforcement agencies could result in substantial costs and diversion of management&#8217;s attention and resources, which could adversely impact our business. Any adverse determination in litigation could also subject us to significant liabilities. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our stock may fluctuate unpredictably in response to factors unrelated to our operating performance. The stock market has recently experienced significant volatility, particularly with respect to pharmaceutical, biotechnology, and other life sciences company stocks. The volatility of pharmaceutical, biotechnology, and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. Some of the factors that may cause the market price of our common stock to fluctuate include: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results and timing of our clinical trials and clinical trials of our competitors&#8217; products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure or discontinuation of any of our development programs; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issues in manufacturing our product candidates or future approved products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments or enforcement in the United States and foreign countries with respect to our product candidates or our competitors&#8217; products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from existing products or new products that may emerge; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patents or other proprietary rights; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of technological innovations or new commercial products by us or our competitors; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in estimates or recommendations by securities analysts, if any cover our common stock; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern over our product candidates or any future approved products; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">threatened or actual litigation; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future or anticipated sales of our common stock; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of health care payment systems in the United States or overseas; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of MARGENZA or our product candidates, if approved, to achieve commercial success; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic and other external factors or other disasters or crises; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial condition and results of operations, including the timing of receipt of any milestone or other payments under commercialization or licensing agreements; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions and market conditions for biopharmaceutical stocks; and</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall fluctuations in U.S. equity markets.</span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the company that issued the stock. For example, one such securities class action lawsuit was brought against us. We could incur substantial costs defending this or similar lawsuits, as well as diversion of the time and attention of our management, any or all of which could seriously harm our business. </span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions of our charter, bylaws, third-party agreements and Delaware law may make an acquisition of us or a change in our management more difficult. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of our restated certificate of incorporation and amended and restated bylaws could discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. Stockholders who wish to participate in these transactions may not have the opportunity to do so. Furthermore, since our board of directors is responsible for appointing the members of our management team, these provisions could prevent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or frustrate attempts by our stockholders to replace or remove our management by making it more difficult for stockholders to replace members of our board of directors. These provisions: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of directors to be changed only by resolution of our board of directors; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors, providing that not all members of the board of directors be elected at one time; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our board of directors to issue without stockholder approval blank check preferred stock that, if issued, could operate as a "poison pill" to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that is not approved by our board of directors; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at stockholder meetings; </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call stockholder meetings; and </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of the holders of 75% of the outstanding shares of our capital stock entitled to vote in order to amend certain provisions of our restated certificate of incorporation and restated bylaws. </span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in the ordinary course of our business, from time to time we discuss and enter into collaborations, licenses and other transactions with various third parties, including other pharmaceutical companies and biotechnology companies. When we deem it appropriate, our agreements with such third parties may include standstill provisions. These standstill provisions, several of which may be in force from time-to-time, typically prohibit such parties from acquiring our securities for a period of time, which may discourage such parties from acquiring MacroGenics even if doing so would be beneficial to our stockholders. </span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#8239;203 of the Delaware General Corporation Law, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a prescribed period of time. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div id="i9064db26008e44ad995ee3ad48ef6721_22"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_25"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease a total of approximately 235,000 square feet of manufacturing, office, laboratory and warehouse space in Maryland and California. Our headquarters building in Rockville, Maryland currently houses laboratory, office and manufacturing operations to support clinical and commercial quantities and scale. This location is occupied under a lease that was modified in December 2022 and now expires in 2035. The California facility and the smaller-scale, non-commercial GMP manufacturing site in Maryland will be closed under our restructuring plan announced in August 2022, therefore the leases for those sites will not be renewed when they expire.  Our continuing leases each have one or more five-year options to renew. We believe that our properties are generally in good condition, well maintained, suitable and adequate to carry on our business. We believe our capital resources are sufficient to lease any additional facilities required to meet our expected growth needs.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_28"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are or may be involved in various legal or regulatory proceedings, claims or class actions related to alleged patent infringements and other intellectual property rights, or alleged violation of commercial, corporate, securities, labor and employment, and other matters incidental to our business. We do not, however, expect such legal proceedings to have a material adverse effect on our business, financial condition or results of operations. However, depending on the nature and timing of a given dispute, an eventual unfavorable resolution could materially affect our current or future results of operations or cash flows.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See note 6, Commitments and Contingencies, to the consolidated financial statements for more information. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_31"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160; MINE SAFETY DISCLOSURES</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i9064db26008e44ad995ee3ad48ef6721_37"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. &#160;&#160;&#160;&#160;MARKET FOR REGISTRANT'S COMMON EQUITY,&#160;RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Select Market under the symbol "MGNX".&#160;As of March&#160;10, 2023, we had 61,838,565 shares of common stock outstanding held by approximately 58 holders of record, which include shares held by a broker, bank or other nominee.&#160;We have never declared or paid any cash dividends.&#160;We do not anticipate declaring or paying cash dividends for the foreseeable future.&#160;Instead, we will retain our earnings, if any, for the future operation and expansion of our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the five-year cumulative total return of our common stock with the  Nasdaq Composite Index (U.S.) and the Nasdaq Biotechnology Index.&#160;The comparison assumes a $100 investment on December 31, 2017 in our common stock, the stocks comprising the Nasdaq Composite Index, and the stocks comprising the Nasdaq Biotechnology Index, and assumes reinvestment of the full amount of all dividends, if any.&#160;Historical stockholder return is not necessarily indicative of the performance to be expected for any future periods.</span></div><div style="margin-bottom:9pt;text-align:center"><img src="mgnx-20221231_g6.jpg" alt="mgnx-20221231_g6.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:650px"/></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth under the heading "Performance Graph" shall not be deemed to be "soliciting material" or to be "filed" with the SEC or subject to liabilities of Section 18 of the Exchange Act, except to the extent that we specifically request that such information be treated as soliciting material or specifically be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_40"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;RESERVED</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_43"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read together with our selected consolidated financial data and the consolidated financial statements and related notes included elsewhere herein. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors including, but not limited to, those set forth under the sections entitled "Risk Factors" and "Forward-Looking Statements", our actual results may differ materially from those anticipated in such forward-looking statements.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the discussion of our financial condition and results of operations for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020, please refer to Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the SEC on February&#160;24, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_46"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer.  We have a pipeline of product candidates being evaluated in clinical trials sponsored by us or our collaborators in addition to several molecules in preclinical development.  Our clinical product candidates include multiple oncology programs, many of which were created using our proprietary, antibody-based technology platforms. We believe our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents. To date, two products originating from our pipeline of proprietary or partnered product candidates have received U,S. Food and Drug Administration (FDA) approval. In March 2021, we and our commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. In November 2022, the FDA approved TZIELD&#8482; (teplizumab-mzwv) to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D. Teplizumab was acquired from us by Provention Bio, Inc. (Provention) in 2018, pursuant to an asset purchase agreement. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations to date have concentrated on staffing our company, developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, business planning and raising capital. We only began generating revenues from the sale of products in 2021. We have financed our operations primarily through the public and private offerings of our securities, collaborations with other biopharmaceutical companies, and government grants and contracts.&#160;Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of December&#160;31, 2022, combined with anticipated and potential collaboration payments and product revenues, and $100 million proceeds received in March 2023 pursuant to the sale of our single-digit royalty on future global net sales of TZIELD, should enable us to fund our operations through 2025. Our expected funding requirements reflect anticipated expenditures related to the Phase 2 TAMARACK clinical trial of vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer  (mCRPC), our planned Phase 2 study of lorigerlimab in mCRPC as well as our other clinical and preclinical studies currently ongoing. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2022, we had an accumulated deficit of $1.1 billion.&#160;We expect that over the next several years this deficit will increase as we increase our expenditures in research and development in connection with our ongoing activities with several clinical trials.&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic Conditions </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economy, credit markets and financial markets have and may continue to experience significant volatility as a result of significant worldwide events, including public health crises, such as the COVID-19 pandemic, and geopolitical upheaval, such as Russia&#8217;s incursion into Ukraine (collectively, the Macroeconomic Conditions). These Macroeconomic Conditions have and may continue to create supply chain disruptions, inventory disruptions, and fluctuations in economic growth, including fluctuations in employment rates, inflation, energy prices and consumer sentiment. In particular, the COVID-19 pandemic (or any variant thereof) may have a negative impact on our clinical trials, preclinical nonclinical studies, development, manufacturing and commercialization of our product and product candidates and other aspects of our business, staff, and operations. It remains difficult to assess or predict the ultimate duration and economic impact of the Macroeconomic Conditions including, the path of the COVID-19 pandemic, the evolution of COVID-19 variants or the emergence of other public health crises. In response to the COVID-19 pandemic, we have taken precautionary measures intended to help protect our employees, including enabling our employees to partially work remotely.  Prolonged uncertainty with respect to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Macroeconomic Conditions could cause further economic slowdown or cause other unpredictable events, each of which could adversely affect our business, results of operations or financial condition.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_49"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Our current collaborations include the following:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Incyte. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Under this agreement, as amended, Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while we retain the right to develop our pipeline assets in combination with retifanlimab. In addition to the upfront payment of $150.0 million and milestone payments totaling $100.0 million received from Incyte through December&#160;31, 2022, we are eligible to receive an additional $335.0 million in development and regulatory milestones and $330.0 million in commercial milestones, assuming successful development and commercialization of retifanlimab by Incyte. If retifanlimab is approved and commercialized, we would be eligible to receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote retifanlimab with Incyte. We retain the right to develop our pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and us commercializing our asset(s), if any such potential combinations are approved. We also have an agreement with Incyte under which we are to perform development and manufacturing services for Incyte's clinical needs of retifanlimab (Incyte Clinical Supply Agreement) and another agreement under which we are entitled to manufacture a portion of Incyte&#8217;s global commercial supply of retifanlimab (Incyte Commercial Supply Agreement).</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Gilead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In October 2022, we and Gilead Sciences, Inc. (Gilead) entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and create bispecific cancer antibodies using our DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Gilead Agreement, we </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will continue the ongoing phase 1 trial for MGD024 accordi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng to a development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license to develop and commercialize MGD024 and other bispecific antibodies of ours that bind CD123 and CD3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CD123 Option). The agreement also grants Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by us and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option). As part of the Gilead Agreement, Gilead paid us a non-refundable upfront payment of $60.0&#160;million and we will be eligible to receive up to $1.7&#160;billion in target nomination, option fees, and development, regulatory and commercial milestones, assuming Gilead exercises the CD123 Option and Research Program Option,successfully develops and commercializes MGD024 or other CD123 products developed under the agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and products result from the two additional research programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming exercise of the CD123 Option, w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(or other CD123 products developed under the agreement) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assuming exercise of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option, a flat royalty on worldwide net sales of any products resulting from the two research programs.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Zai Lab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2018, we entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development in its territory. Zai Lab has informed us that they have decided to discontinue development of tebotelimab for indications they were enrolling in their territory and is evaluating future development plans in other indications.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid us an upfront payment of $25.0 million less foreign withholding tax of $2.5 million. Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, we could receive up to $140.0 million in development and regulatory milestones, of which we have earned $9.0 million through December&#160;31, 2022. In addition, Zai Lab would pay us tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances.</span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into two agreements under which we are to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).  </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates our DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by us. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while we receive commercial rights in all other territories. Zai Lab also obtained exclusive, global licenses from us to develop, manufacture and commercialize two additional molecules (license-only programs). Zai Lab granted us a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to us. In August 2022, we and Zai Lab agreed to discontinue research and development of the Lead Program.  </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program included joint research and development services by both us and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with us to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid us an upfront payment of $25.0 million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, we and Zai Lab entered into a separate stock purchase agreement (Stock Purchase Agreement) whereby Zai Lab paid us approximately $30.0 million to purchase 958,467 newly issued shares of our common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the remaining Programs under the 2021 Zai Lab Agreement, we could receive up to $1.3 billion in development, regulatory and commercial milestones. In addition, Zai Lab would pay us tiered royalties at percentage rates of mid-single digits to low double-digit teens on annual net sales of products in Zai's territory, subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, we may also receive reimbursements from Zai Lab for certain research and development costs incurred by us. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Janssen. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech, Inc. (Janssen). The research collaboration will incorporate our proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the agreement, Janssen paid us an upfront payment of $20.0 million and will be responsible for funding all expenses. We will also be eligible to receive up to $312.0 million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Provention</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In 2018, we entered into an asset purchase agreement (APA) with Provention pursuant to which Provention acquired our interest in teplizumab. Under the APA, if Provention successfully develops, obtains regulatory approval for, and commercializes teplizumab, we will be eligible to receive up to $170.0 million in regulatory milestones, and up to $225.0 million in commercial milestones. In November 2022, the FDA approved TZIELD (teplizumab-mzwv) to delay the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older with Stage 2 T1D, and we recognized $60.0 million in milestone revenue during the year ended December 31, 2022.  In November 2022 we and Provention amended the APA. Under the amended APA, the $60.0 million milestone for a first approval was split into four $15 million payments. The first two payments were received in November 2022 and March 2023 and the two remaining payments are due June 1, 2023 and September 1, 2023. We are also eligible to receive single-digit royalties on net sales of TZIELD. Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to us, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention assumed pursuant to the APA. Further, Provention is required to pay us a low double-digit percentage of certain consideration to the extent it is received in connection with a grant of rights by Provention to a third party. <br/></span></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we sold our royalty interest in TZIELD to a wholly-owned subsidiary of DRI Healthcare Trust (DRI). We retain our other economic interests related to TZIELD, including future potential regulatory and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial milestones. We received a $100.0 million upfront payment from DRI for the sale of our single-digit royalty on global net sales of TZIELD. We retain the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, we are eligible to receive up to $50.0 million from DRI upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed T1D and may also receive an additional $50.0 million if TZIELD achieves a certain level of net sales.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">I-Mab Biopharma.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2019, we entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates our proprietary Fc Optimization technology platform (I-Mab License Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by us. In August 2022, I-Mab notified us of its intention to terminate the I-Mab License Agreement effective February 25, 2023.<br/><br/>Under the terms of the agreement, I-Mab paid us an upfront payment of $15.0 million and $5.0 million in milestone revenue has been earned from the inception of the I-Mab License Agreement through December&#160;31, 2022. </span></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we entered into an agreement under which we are to perform development and manufacturing services for I-Mab&#8217;s clinical needs of enoblituzumab. which agreement will co-terminate with the I-Mab license agreement. </span></div><div style="padding-left:18pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_52"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue consists of the following:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenue from collaborative and other agreements which includes amounts recognized relating to upfront nonrefundable payments for licenses or options to obtain future licenses, amounts earned by performing development and manufacturing services, research and development funding and milestone payments earned under our collaboration and license agreements with our strategic collaborators;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product sales, net which reflects sales of MARGENZA which was launched in 2021.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract manufacturing revenue which is earned from manufacturing third parties&#8217; drug substance; and </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government agreements revenue which reflects amounts earned through  grants and/or contracts with the U.S. government and other research institutions on behalf of the U.S. government, primarily with respect to research and development activities related to infectious disease product candidates. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales relates to sales of MARGENZA.  These costs include materials and manufacturing costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  We expect cost of product sales to continue to be positively impacted as we sell through inventory that was expensed prior to FDA approval of MARGENZA. We are currently unable to estimate how long it will be until we begin selling product manufactured post FDA approval.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including labor, materials overhead and other related costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of expenses incurred in performing research and development activities. These expenses include conducting preclinical experiments and studies, clinical trials, manufacturing efforts and regulatory filings for all product candidates, and other indirect expenses in support of our research and development activities. We capture </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research and development expense on a program-by-program basis for our product candidates and recognize these expenses as they are incurred. The following are items we include in research and development expense:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, such as salaries and benefits;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related overhead expenses, such as facilities and other allocated items;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stock-based compensation expense to employees engaged in research and development activities;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">depreciation of laboratory and manufacturing equipment, computers and leasehold improvements;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees paid to consultants, subcontractors, clinical research organizations (CROs) and other third party vendors for work performed under our preclinical and clinical trials including, but not limited to, investigator grants, laboratory work and analysis, database management, statistical analysis, and other items;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amounts paid to vendors and suppliers for laboratory supplies;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">internal and third party costs related to manufacturing clinical trial materials, including vialing, packaging and testing;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">license fees and other third party vendor payments related to in-licensed product candidates and technology; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to compliance with regulatory requirements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval.  The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of future clinical trials and preclinical studies, uncertainties in clinical trial enrollment rates and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate's commercial potential.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense consists of salaries and related benefit costs for employees in our executive, finance, legal and intellectual property, business development, human resources, information technology and other support functions.  Selling, general and administrative expense also includes costs incurred under the arrangement with our commercialization partner, Eversana Life Science Services, LLC, and other legal and professional fees.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income </span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income consists of realized gains and losses on marketable securities and interest income earned on our cash, cash equivalents and marketable securities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_55"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management's discussion and analysis of financial conditions and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the balance sheets and the reported amount of the revenue and expenses recorded during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. We review and evaluate these estimates on an on-going basis. These assumptions and estimates form the basis for making judgments about the carrying values of assets and liabilities and amounts that have been recorded as revenues and expenses. Actual results and experiences may differ from these estimates. We did not make any material changes to these assumptions during the year ended December&#160;31, 2022, and do not expect any material changes in the near term to the underlying assumptions.  If we were to adjust our assumptions, the results of any material revisions would be reflected in the consolidated financial statements prospectively from the date of the change in estimate. Management considers an accounting estimate to be critical if:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it requires a significant level of estimation uncertainty; and </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the estimate are reasonably likely to have a material effect on our financial condition or results of operations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While a summary of significant accounting policies is described fully in Note 2 in our consolidated financial statements, we believe that the following accounting policies are the most critical to assist you in fully understanding and evaluating our financial results and the effect of the estimates and judgments we used in preparing our consolidated financial statements.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we believe regulatory approval is probable and expect future economic benefit from the sales of a product candidate to be realized, we capitalize manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving our first approval from the FDA in December 2020, we expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for us of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, we began capitalizing our third-party contract manufacturing MARGENZA inventory costs.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue under Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s, (ASC 606) when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative and other agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into licensing agreements that are within the scope of ASC 606, under which we may license rights to research, develop, manufacture and commercialize our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. We may also enter into development and manufacturing service agreements with our collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, we identify all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, management estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. We constrain (reduce) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside our control that could result in a significant reversal of revenue. In making these assessments, management considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. We must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, management&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. We do not include a financing component to its estimated transaction price at contract inception unless we estimate that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we grant a license to our intellectual property, we </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determine whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to our intellectual property.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, we recognize revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, we consider factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, we consider whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, management utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue we record in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under our agreements may include research and development or manufacturing services to be performed by us on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, we recognize the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by us does not create an asset with an alternative use and we have an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, we recognize the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, we evaluate whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. We allocate the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, management evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. We evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, management reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, we have not recognized any royalty revenue resulting from any of our licensing arrangements. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze our collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by management. We account for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. We account for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Sales, Net</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. The delivery of our product represents a single performance obligation for these transactions and we record net product revenue when control is transferred to the customer, generally upon receipt by the customer.  The transaction price for net product revenue represents the amount we expect to receive, which is net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns, and other deductions. Accruals are established for these deductions, and actual amounts incurred are offset against applicable accruals. Customer discounts are recorded as reductions of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets. Sales deductions are based on management's estimates that consider payor mix in target markets and experience to-date. These estimates involve a substantial degree of judgment, in particular, for government-mandated rebates and chargebacks, such as for the Medicaid and 340B programs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract manufacturing revenue</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements with third parties to manufacture their drug substance at our GMP facility. The terms of these arrangements typically include an upfront payment to us to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue over time on a straight-line basis as the manufacturing services are performed, as we believe that our efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of product sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales relates to sales of MARGENZA. These costs include materials and manufacturing costs, as well as royalties payable on net sales of MARGENZA and inventory reserves. All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense. We expect cost of product sales to continue to be positively impacted as we sell through inventory that was expensed prior to FDA approval of MARGENZA. We are currently unable to estimate how long it will be until we begin selling product manufactured post FDA approval.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including labor, materials overhead and other related costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of costs we incur for our own research and development activities and costs incurred by our collaborators under cost sharing arrangements. Research and development costs consist of salaries and benefits, including related stock-based compensation, laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on our behalf, such as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CROs, and the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract manufacturing organizations (CMOs). Research and development costs are expensed as incurred. We receive estimates from our collaborators when we are </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sharing development expenses, and use these estimates to record an increase or decrease in research and development expense, depending on how much we have each spent during the period. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expense, and we outsource a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancelable, and related costs are recorded as research and development expense as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, we analyze progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div><div style="margin-bottom:9pt;text-indent:-0.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements for information under the caption "Recent Accounting Pronouncements."</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_58"></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our revenue for the years ended December&#160;31, 2022 and 2021 (dollars in millions):<br/><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:43.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">151.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $56.0 million in revenue from collaborative and other agreements for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021 was primarily due to:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60.0 million in milestone revenue</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">asset purchase agreement with Provention; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $15.0 million in milestone revenue recognized under the Incyte </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License Agreement.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases were partially offset by:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $7.4 million in revenue recognized under the Incyte Commercial Supply Agreement;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $6.9 million in revenue recognized under the I-Mab License Agreement; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.6 million in revenue under the 2021 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from collaborative and other agreements may vary substantially from period to period depending on the progress made by our collaborators with their product candidates and the timing of milestones achieved under current agreements, and whether we enter into additional collaboration agreements. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in product sales, net is due to an increase in volume.  Revenue from product sales is recorded net of applicable provisions for rebates, chargebacks and discounts, distribution-related fees and other sales-related deductions.  The table below includes a reconciliation of the accounts associated with these deductions (in millions):</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Rebates and chargebacks </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Distribution fees, product returns and other </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to current year sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/credits for current year sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to current year sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/credits for current year sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized under the agreements we entered into during 2022 to provide manufacturing services to produce certain bulk drug substance for Incyte and Provention is recorded as contract manufacturing revenue. No such revenue was recognized during the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales for the year ended December&#160;31, 2022 consisted primarily of reserves for unsaleable inventory, as well as product royalties. Product sold during the year ended December&#160;31, 2022 consisted of drug product that was previously charged to research and development expense prior to FDA approval of MARGENZA, which favorably impacted our gross margin for the year ended December&#160;31, 2022. We expect cost of product sales to continue to be positively impacted as we sell through this drug product.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug substance under the Incyte and Provention Manufacturing and Clinical Supply Agreements. We entered into these agreements in 2022, therefore there are no such costs during the year ended December 31, 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our research and development expense for the years ended December&#160;31, 2022 and 2021 (dollars in millions):<br/><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:43.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vobramitamab duocarmazine (formerly MGC018)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margetuximab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lorigerlimab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADCs (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enoblituzumab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next-generation T-cell engagers (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flotetuzumab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tebotelimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMGC936</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DART molecules under HIV government contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retifanlimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other programs (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">207.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">214.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Includes research and discovery projects, as well as early preclinical molecules and molecules not advanced to clinical development.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense for the year ended December&#160;31, 2022 decreased by $7.6 million compared to the year ended December&#160;31, 2021. This decrease was primarily attributable to:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">decreased development, manufacturing and clinical trial costs related to flotetuzumab (due to discontinuance of our company-sponsored trial);</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">decreased retifanlimab manufacturing costs related to the Incyte Commercial Supply Agreement;</span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">decreased development, manufacturing and clinical trial costs related to tebotelimab; and </span></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">decreased margetuximab manufacturing costs related to the Zai Lab Clinical Supply Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased vobra duo development, manufacturing and clinical trial costs;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development of a non-disclosed ADC Investigational New Drug candidate; and </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased clinical trial enrollment costs related to lorigerlimab.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are uncertainties associated with our research and development expenses for future periods which are impacted by multiple variables, including timing of wind down activities for recently closed studies and current and expected expenditures associated with our vobra duo TAMARACK study.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our general and administrative expenses for the years ended December&#160;31, 2022 and 2021 (dollars in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses decreased for the year ended December&#160;31, 2022 by $4.1 million compared to 2021 primarily due to decreased selling costs for MARGENZA as well as decreased legal, consulting and stock-based compensation expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The increase of $1.0 million in other income for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021 is primarily due to increased investment income. </span></div><div><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_61"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a summary of our cash flows for the years ended December&#160;31, 2022 and 2021 (dollars in millions):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(57.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities reflects, among other things, the amounts used to advance our clinical trials and preclinical activities. The principal use of cash in operating activities for all periods presented was primarily the result of our net loss, adjusted for non-cash items, with the year ended December&#160;31, 2022 benefiting from the $60.0 million upfront payment under the Gilead Agreement, $30.0 million milestone payment received from Incyte, and $15.0 million received from Provention related to the achievement of a milestone. The year ended December&#160;31, 2021 benefited from the $25.0 million </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upfront payment under the 2021 Zai Lab Agreement, $15.0 million milestone payment received from Incyte, and $4.5 million milestone payment from I-Mab. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities during the year ended December&#160;31, 2022 is primarily due to maturities of marketable securities, partially offset by purchases of marketable securities. Net cash used in investing activities during the year ended December&#160;31, 2021 is primarily due to purchases of marketable securities, partially offset by maturities of marketable securities.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the years ended December&#160;31, 2022 and 2021 reflects net cash proceeds from our securities offerings of approximately $1.1 million and $117.8 million, respectively, and cash from stock option exercises and the purchase of shares under our employee stock purchase plan.&#160; </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use. As a biotechnology company, we have primarily funded our operations with proceeds from the sale of our common stock in equity offerings, revenue from our multiple collaboration agreements, and contracts and grants from NIAID.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews our available liquidity relative to our operating budget and forecast to monitor the sufficiency of our working capital, and anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support our product development activities. There can be no assurances that new sources of capital will be available to us on commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require us to give up some or all rights to a product or technology at less than its full potential value. If we are unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of, or eliminate one or more of our product research and development programs or clinical studies, and/or downsize our organization. Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of December&#160;31, 2022, as well as anticipated and potential collaboration payments and product revenues, and $100.0 million proceeds received in March 2023 pursuant to the sale of an interest in a specified portion of royalty payments based on future net sales of TZIELD, should enable us to fund our operations through 2025. Our expected funding requirements reflect anticipated expenditures related to the Phase 2 TAMARACK clinical trial of vobra duo in metastatic castration-resistant prostate cancer  (mCRPC), planned Phase 2 study of lorigerlimab in mCRPC as well as our other clinical and preclinical studies currently ongoing.  </span></div><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our short-term and long-term material cash requirements consist of operational and capital expenditures, some of which contain contractual obligations. Our primary uses of cash relate to paying salaries and benefits, administering clinical trials, marketing our product, and providing the technology and facilities necessary to support our operations. The most significant contractual obligations are the operating leases at our facilities in Maryland and California. Our future minimum lease payments as of December&#160;31, 2022 totaled $5.0&#160;million related to short-term lease liabilities, and $70.3&#160;million related to long-term lease liabilities.  See Note 6, Commitments and Contingencies, in the Notes to the Financial Statements in this Annual Report on Form 10-K for additional information about our lease liabilities. We expect to fund these requirements with current cash, cash equivalents and marketable securities as well as anticipated and potential collaboration payments, and product revenues. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_64"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary objective when considering our investment activities is to preserve capital in order to fund our operations.&#160;We also seek to maximize income from our investments without assuming significant risk.&#160;Our current investment policy is to invest principally in deposits and securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations, corporate debt obligations and money market instruments.&#160;As of December&#160;31, 2022, we had cash, cash equivalents and marketable securities of $154.3 million.&#160;Our primary exposure to market risk is related to changes in interest rates.&#160;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term maturities of our cash equivalents and marketable securities and the low risk profile of our marketable securities, an immediate 100 basis point change in interest rates would not have a material effect on </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair market value of our cash equivalents and marketable securities. We have the ability to hold our marketable securities until maturity, and we therefore do not expect a change in market interest rates to affect our operating results or cash flows to any significant degree.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_67"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is set forth beginning on page F-1 in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_70"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.&#160;&#160;&#160;&#160;CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL DISCLOSURE</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_73"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2022. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in this Annual Report on Form 10-K has been appropriately recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosure.&#160;Based on that evaluation, our principal executive and principal financial officers have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive and principal financial officers, has evaluated any changes in our internal control over financial reporting that occurred during the quarterly period ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and has concluded that there was no change that occurred during the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2022 that have materially affected, or are reasonably likely to materially effect, the Company's internal control over financial reporting.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting.&#160;Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, the Company's principal executive and principal financial officers and effected by the Company's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pertain to the management of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&#160;Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.&#160;All internal control systems, no matter how well designed, have inherent limitations.&#160;Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management assessed the effectiveness of the Company's internal control over financial reporting as of December&#160;31, 2022.&#160;In making this assessment, the Company's management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO) in Internal Control-Integrated Framework.&#160;Based on our assessment, management believes that, as of December&#160;31, 2022, the Company's internal control over financial reporting is effective based on those criteria.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December&#160;31, 2022 has been audited by Ernst &amp; Young, LLP, an independent registered public accounting firm, as stated in their report which is included herein on the following page.</span></div><div id="i9064db26008e44ad995ee3ad48ef6721_76"></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i9064db26008e44ad995ee3ad48ef6721_79"></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C.&#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">To the Shareholders and the Board of Directors of MacroGenics, Inc. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited MacroGenics, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, MacroGenics, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2022, based on the COSO criteria.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2022, and the related notes and our report dated March&#160;15, 2023, expressed an unqualified opinion thereon. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tysons, Virginia</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;15, 2023 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i9064db26008e44ad995ee3ad48ef6721_88"></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning directors, executive officers and corporate governance to be included in our definitive proxy statement for the 2023 annual meeting of stockholders (the 2023 Proxy Statement).</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Conduct and Ethics (the &#8220;Code&#8221;) that applies to all of our employees, officers and directors.  The Code is available under the Corporate Governance section of our website at http://ir.macrogenics.com/governance. We expect that any amendments to the Code, or any waivers of its requirements, will be disclosed on our website.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_91"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning executive compensation to be included in the 2023 Proxy Statement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_94"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning security ownership of certain beneficial owners and management to be included in the 2023 Proxy Statement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_97"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. &#160;&#160;&#160;&#160; CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning certain other relationships and related transactions to be included in the 2023 Proxy Statement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_100"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning principal accountant fees and services to be included in the 2023 Proxy Statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i9064db26008e44ad995ee3ad48ef6721_106"></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. &#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The following documents are filed as part of this Annual Report on Form 10-K:</span></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Consolidated Financial Statements:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.912%"><tr><td style="width:1.0%"></td><td style="width:71.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9064db26008e44ad995ee3ad48ef6721_118">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9064db26008e44ad995ee3ad48ef6721_118">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9064db26008e44ad995ee3ad48ef6721_121">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9064db26008e44ad995ee3ad48ef6721_121">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations and Comprehensive Loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9064db26008e44ad995ee3ad48ef6721_124">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9064db26008e44ad995ee3ad48ef6721_124">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Stockholders' Equity</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9064db26008e44ad995ee3ad48ef6721_127">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9064db26008e44ad995ee3ad48ef6721_127">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9064db26008e44ad995ee3ad48ef6721_130">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9064db26008e44ad995ee3ad48ef6721_130">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9064db26008e44ad995ee3ad48ef6721_133">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9064db26008e44ad995ee3ad48ef6721_133">7</a></span></div></td></tr></table></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Financial Statement Schedules:</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.&#160;</span></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Exhibits</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed as part of this Annual Report on Form 10-K are set forth on the Exhibit Index immediately following our consolidated financial statements. The Exhibit Index is incorporated herein by reference.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_109"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:47.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MacroGenics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Koenig</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and CEO and Director</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1934, as amended, this Report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:38.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.384%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Koenig</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and CEO and Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;15, 2023</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Karrels</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief <br/>Financial Officer and Secretary <br/>(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;15, 2023</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lynn Cilinski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Controller and Treasurer<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;15, 2023</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lynn Cilinski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Karen Ferrante, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;15, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen Ferrante, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ William Heiden</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;15, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William Heiden</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Edward Hurwitz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;15, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edward Hurwitz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Jackson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;15, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Jackson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Meenu Chhabra Karson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;15, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meenu Chhabra Karson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Margaret A. Liu, M.D., D.Sc.hc, M.D.hc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;15, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margaret A. Liu, M.D., D.Sc.hc, M.D.hc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Federica O&#8217;Brien</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;15, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federica O&#8217;Brien</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jay Siegel, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;15, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jay Siegel, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Stump, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;15, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Stump, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_118">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm (PCAOB ID: </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:AuditorFirmId" id="f-36">42</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_118">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_118">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_118">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_121">Consolidated Balance Sheets at December 31, 2022 and December 31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_121">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_121">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_124">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2022, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_124">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_124">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_127">Consolidated Statements of Stockholders' Equity for the years ended December 31, 2022, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_127">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_127">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_130">Consolidated Statements of Cash Flows for the years ended December 31, 2022, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_130">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_130"> and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_130">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_130">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_133">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_133">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9064db26008e44ad995ee3ad48ef6721_133">7</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of MacroGenics, Inc. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of MacroGenics, Inc. (the Company) as of December&#160;31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March&#160;15, 2023 expressed an unqualified opinion thereon. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Accounting for the Option and Collaboration Agreement with Gilead Sciences, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 8 of the consolidated financial statements, in October 2022, the Company entered into an exclusive option and collaboration agreement with Gilead Sciences, Inc. (the &#8220;Gilead Agreement&#8221;). The Gilead Agreement resulted in the recognition of $0.2 million of revenue from collaborative and other agreements for the year ended December 31, 2022 and $59.8 million of deferred revenue as of December 31, 2022. The Company evaluated the Gilead Agreement under Accounting Standards Codification 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;) and identified two performance obligations within the arrangement: 1) a combined development term license and development activities (&#8220;Development Activities&#8221;); and 2) a material right relating to the CD123 option to obtain an exclusive license under the Company&#8217;s intellectual property (&#8220;CD123 Option&#8221;). The transaction price of $60.0 million was allocated to each performance obligation based on their relative standalone selling prices. The standalone selling price of the Development Activities was determined using an expected cost-plus margin approach for the pre-option development timeline. The standalone selling price of the CD123 Option was determined using an income-based approach which included assumptions over the post-option development timeline and costs, forecasted revenues, discount rates and probabilities of technical and regulatory success. The transaction price allocated to the Development Activities was recognized over time using an input method. The Company will defer revenue recognition related to the CD123 Option until the period when the CD123 Option is exercised or expired.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting for the Gilead Agreement required the Company to make significant judgments, including but not limited to the identification of performance obligations and the estimation of the standalone selling price of each identified performance obligation. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price for each performance obligation. The estimates of the standalone selling price for the performance obligations relating to the Development Activities and the CD123 Option reflect management&#8217;s assumptions described above. Changes to these assumptions could have a material effect on the allocation of the transaction price to the performance obligations as well as the amount and timing of revenue recognized. As a result, auditing the identification of performance obligations and estimates of standalone selling price for performance obligations required especially complex auditor judgment.</span></div><div><span><br/></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls addressing the risks of material misstatement relating to the accounting for the Gilead Agreement. For example, we tested controls over management's process over the identification of the performance obligations, the determination of the significant assumptions described above with respect to the estimation of the standalone selling price of each performance obligation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To audit the Company&#8217;s accounting related to the Gilead Agreement, we performed audit procedures that included, among others, inspecting the executed agreement and accounting assessment and evaluating the completeness of the performance obligations identified.  In addition, we evaluated management&#8217;s estimates of the standalone selling price of the identified performance obligations. For example, we tested the significant assumptions and the completeness and accuracy of the underlying data used by the Company in developing the expected cost plus a margin for the Development Activities, the post-option development timeline and costs, forecasted revenues, discount rates and probabilities of technical and regulatory success for the CD123 Option. We compared these significant assumptions to industry, business and market data, and information available from third-party sources.  We involved our internal valuation specialists to assist in the assessment of the discount rate used and certain other valuation assumptions used in the determination of the estimated standalone selling prices. We also performed a sensitivity analysis of the significant assumptions to evaluate the impact that the change in the estimated standalone selling price of certain performance obligations resulting from changes in the significant assumptions would have on the allocation of transaction price to each performance obligation, as well as revenue recognized during the period and deferred as of December 31, 2022. </span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:AuditorName" id="f-37">Ernst &amp; Young LLP</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 2006.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="dei:AuditorLocation" id="f-38">Tysons, Virginia</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 2</span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-39">108,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-40">123,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="f-41">45,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="f-42">120,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">56,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">10,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-45">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-46">4,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">10,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">21,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">222,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">279,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-51">29,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-52">37,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-53">27,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-54">16,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">1,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-57">280,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-58">335,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">4,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">15,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">28,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">33,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">9,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">20,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">4,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">4,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">48,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">74,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">59,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:fixed-zero" scale="3" id="f-70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">30,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">20,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-73">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-74">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-75">138,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-76">95,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, <ix:nonFraction unitRef="usdPerShare" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-77"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-78">0.01</ix:nonFraction></ix:nonFraction> par value -- <ix:nonFraction unitRef="shares" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-79"><ix:nonFraction unitRef="shares" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-80">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-81">61,701,467</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-82">61,307,428</ix:nonFraction> shares outstanding at December&#160;31, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-83">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-84">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-85">1,235,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-86">1,213,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-87">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-88">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-89">1,093,694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-90">973,936</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-91">142,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-92">239,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-93">280,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-94">335,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 3</span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other agreements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa22d39a8624176a6fa8407907a9309_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-95">119,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9cd9cf7c6804d5db20f82023e1a54a3_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-96">63,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f2d1a2d1e94bbdad3b332217f7cdc1_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-97">97,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4a44fb906e46059cf27ad3f371c8f4_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-98">16,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80cfdb689d6442978f9b166889e5847e_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-99">12,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f8af80ca2f4b52802a161c595e5052_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db8545d9a764d70adfa1bdc46929964_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-101">13,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3d5dee46f14e89ab361baca8c84d19_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb12fb8ba4294ec0b24b921f652da5b9_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4583fefc635419baaecffdc14a3347d_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-104">1,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a8c07e35eb0448186c12e229bd209be_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-105">1,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3313b69530a74ec6b2e2460d390f798d_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-106">7,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-107">151,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-108">77,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-109">104,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-110">3,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-111">2,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="f-112">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of manufacturing services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:num-dot-decimal" scale="3" id="f-113">4,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:fixed-zero" scale="3" id="f-114">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:fixed-zero" scale="3" id="f-115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-116">207,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-117">214,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-118">193,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-119">58,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-120">63,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-121">42,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-122">273,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-123">280,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-124">235,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-125">121,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-126">202,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-127">131,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-128">1,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-129">680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-130">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-131">119,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-132">202,115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-133">129,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-134">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-135">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-136">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-137">119,702</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-138">202,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-139">129,762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-140"><ix:nonFraction unitRef="usdPerShare" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-141">1.95</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-142"><ix:nonFraction unitRef="usdPerShare" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-143">3.37</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-144"><ix:nonFraction unitRef="usdPerShare" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-145">2.47</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-146"><ix:nonFraction unitRef="shares" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-147">61,433,124</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-148"><ix:nonFraction unitRef="shares" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-149">59,944,717</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-150"><ix:nonFraction unitRef="shares" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-151">52,442,389</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 4</span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.482%"></td><td style="width:0.1%"></td></tr><tr style="height:25pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paid-In</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders'</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id38bfa0cc8324178bc6a9c6bcdcbaa4d_I20191231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-152">48,958,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38bfa0cc8324178bc6a9c6bcdcbaa4d_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-153">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168b736ecb73412f845967d23572788f_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-154">872,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib844aa7657c647948f34d81afd439366_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-155">642,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3204ec3dcb94da6895af490452b85e8_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-156">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60ca2d1b9b3648e78bc6323a0e727305_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-157">230,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6042637bb9814b299266c07d6f819e1a_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-158">20,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-159">20,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e5cc6d01e4e4d18ab3182fee2be3b14_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-160">6,612,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5cc6d01e4e4d18ab3182fee2be3b14_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-161">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6042637bb9814b299266c07d6f819e1a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-162">170,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-163">170,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e5cc6d01e4e4d18ab3182fee2be3b14_D20200101-20201231" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="f-164">673,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5cc6d01e4e4d18ab3182fee2be3b14_D20200101-20201231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-165">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6042637bb9814b299266c07d6f819e1a_D20200101-20201231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" format="ixt:num-dot-decimal" scale="3" id="f-166">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" format="ixt:num-dot-decimal" scale="3" id="f-167">3,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9caefd6e32774b6fa3be813c566241b1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-168">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-169">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i583ba990216e462fa437b644733fd007_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-170">129,739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-171">129,739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8feb38eaa7f4d0284d3e12e8c61f985_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-172">56,244,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8feb38eaa7f4d0284d3e12e8c61f985_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-173">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb9f5c3fbbf4386b0b1c7457c63b569_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-174">1,067,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if007d64ddb0940ae9820885f23536cbe_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-175">771,821</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibca9a275183b461588ccd2c99d84a7b5_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-176">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d09ee83f16a43899a8e2f0580a10ce5_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-177">295,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fbdab93b76148c68de348ba99c602c7_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-178">23,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-179">23,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28ca167332fb4ffca8f0aeb269e494e4_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-180">4,580,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ca167332fb4ffca8f0aeb269e494e4_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-181">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fbdab93b76148c68de348ba99c602c7_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-182">117,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-183">117,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28ca167332fb4ffca8f0aeb269e494e4_D20210101-20211231" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="f-184">482,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ca167332fb4ffca8f0aeb269e494e4_D20210101-20211231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-185">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fbdab93b76148c68de348ba99c602c7_D20210101-20211231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" format="ixt:num-dot-decimal" scale="3" id="f-186">4,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" format="ixt:num-dot-decimal" scale="3" id="f-187">4,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fb4710bb5ad4ea39e2ce055f9920e7a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-188">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-189">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97989f78335d4f06a53493f09437b7a1_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-190">202,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-191">202,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4886a2c10d494c22822a89f90bb4c4e0_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-192">61,307,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4886a2c10d494c22822a89f90bb4c4e0_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-193">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie94494340ac149908fbf8ece8b640537_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-194">1,213,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25b8b9bc70774790a5df2d37523b9735_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-195">973,936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7612f92852c41f58ba57ed9d4a891f0_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-196">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-197">239,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3e10cae8b7460cb0b3c709f1dd7806_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-198">20,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-199">20,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99fe8fd853b04bf9a915b7facf36738b_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-200">160,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99fe8fd853b04bf9a915b7facf36738b_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-201">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3e10cae8b7460cb0b3c709f1dd7806_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-202">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-203">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99fe8fd853b04bf9a915b7facf36738b_D20220101-20221231" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="f-204">233,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99fe8fd853b04bf9a915b7facf36738b_D20220101-20221231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-205">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3e10cae8b7460cb0b3c709f1dd7806_D20220101-20221231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-206">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-207">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fd1adc97945441f91da73361323fa86_D20220101-20221231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-208">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-209">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide2999adda92451a8ff2e717b50f9e49_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-210">119,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-211">119,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7177857c4ed5490d949b3547941967c1_I20221231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-212">61,701,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7177857c4ed5490d949b3547941967c1_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-213">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic40f80873ab547fc9bfb939c4cde42e6_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-214">1,235,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13f15ef91e7144c5b9b9a3240d6df07e_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-215">1,093,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66087c2443374414a3213b8856e0c032_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-216">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-217">142,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 5</span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-218">119,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-219">202,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-220">129,739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-221">11,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-222">11,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-223">11,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-224">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-225">1,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-226">260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-227">20,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-228">23,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-229">20,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-230">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-231">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-232">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-233">45,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-234">12,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-235">10,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-236">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-237">6,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="f-238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-239">11,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-240">4,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-241">5,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-242">10,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-243">5,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-244">581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-245">10,860</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-246">7,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-247">3,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-248">4,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-249">607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-250">6,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="mgnx:IncreaseDecreaseInLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-251">9,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="mgnx:IncreaseDecreaseInLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-252">3,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" sign="-" name="mgnx:IncreaseDecreaseInLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-253">1,324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-254">48,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-255">9,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-256">8,472</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="mgnx:IncreaseDecreaseInDeferredRent" format="ixt:fixed-zero" scale="3" id="f-257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="mgnx:IncreaseDecreaseInDeferredRent" scale="3" id="f-258">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="mgnx:IncreaseDecreaseInDeferredRent" format="ixt:fixed-zero" scale="3" id="f-259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-260">86,959</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-261">143,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-262">111,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-263">120,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-264">231,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-265">223,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-266">194,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-267">200,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-268">221,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-269">3,623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-270">6,201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-271">5,906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-272">70,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-273">36,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-274">7,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-275">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-276">117,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-277">170,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises and ESPP purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="f-278">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" format="ixt:num-dot-decimal" scale="3" id="f-279">4,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" format="ixt:num-dot-decimal" scale="3" id="f-280">3,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-281">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-282">122,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-283">174,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-284">14,585</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-285">57,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-286">54,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-287">123,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d09ee83f16a43899a8e2f0580a10ce5_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-288">181,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60ca2d1b9b3648e78bc6323a0e727305_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-289">126,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-290">108,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-291">123,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d09ee83f16a43899a8e2f0580a10ce5_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-292">181,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash operating and investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment included in accounts payable or accruals</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-293">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-294">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-295">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 6</span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_136"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-296" continuedAt="i962877889dac4f70bc0447fa06a50b81" escape="true">Organization and Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="i962877889dac4f70bc0447fa06a50b81"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company has a pipeline of product candidates being evaluated in clinical trials sponsored by MacroGenics or its collaborators.  These product candidates include multiple oncology programs, some of which were created primarily using the Company&#8217;s proprietary, antibody-based technology platforms. The Company believes our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.</span></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#8217;s stockholders&#8217; equity and working capital, and accordingly, its ability to execute its future operating plans.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital. The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements, and product sales. The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization. It is considered probable that the Company can successfully implement efforts to manage uncommitted spending and carry out necessary cost saving measures, including from the Company's corporate restructuring plan announced in August 2022. Based on the Company&#8217;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Annual Report on Form 10-K was filed.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic and geopolitical tensions, including the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia, and related global slowdown of economic activity, decades-high inflation, rising interest rates and a potential recession in the United States might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to these uncertainties, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_139"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-297" continuedAt="idefbbf33afbd4371aff14a808968e875" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="idefbbf33afbd4371aff14a808968e875" continuedAt="i2d32fa97fb804daeaf86669bd7957f9e"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-298" continuedAt="i550d00882bd44f748076b8727f5f5218" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in <ix:nonFraction unitRef="segment" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-299">one</ix:nonFraction> operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i2d32fa97fb804daeaf86669bd7957f9e" continuedAt="i60c226a391974ba18b86b8fa227b592d"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i550d00882bd44f748076b8727f5f5218">group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="segment" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-300">one</ix:nonFraction> segment, which is developing and commercializing monoclonal antibody-based therapeutics.</ix:continuation></span></div><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:UseOfEstimates" id="f-301" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="f-302" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of current period financial statements. These reclassifications had no effect on the previously reported net loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-303" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#8217;s ability and intent to hold the investment to maturity. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-304" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable arise from product sales, amounts due from the Company&#8217;s collaborative partners and contract manufacturing work performed by the Company.  The amount from product sales represents amounts due from specialty distributors. Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2022 or 2021, as the Company has a history of collecting on all outstanding accounts.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-305" continuedAt="i38561def111c4cc9aefd2de34f8a5055" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i60c226a391974ba18b86b8fa227b592d" continuedAt="i935acce7f5504571a8e79d9d6e1c2557"><ix:continuation id="i38561def111c4cc9aefd2de34f8a5055" continuedAt="i91eda3da14bb45a09c244d07a36eae6e"><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i91eda3da14bb45a09c244d07a36eae6e" continuedAt="ib462b6b829794b008af00592a491f8a2">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.  </ix:continuation></span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib462b6b829794b008af00592a491f8a2">There were no transfers between levels during the periods presented.</ix:continuation> </span></div><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-306" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:51.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f73f14816ca46229e3f5a04cf8f8524_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-307">41,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecec8ea079224e8494dc049a32f87d5f_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-308">41,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica167215fb9048c3b86ad884a91a3ad7_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0424cfbed6734206b9a86432dd4a627b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-310">32,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2cfe25e2144cfb983dd1db2b3cb8f7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564748a61ef54aef8920e9ee95f57d20_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-312">32,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5df1bd36e7134fb283ddef9208f2d1d6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-313">17,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e823de84ae4499891e90615ba17bd2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6cb699e8f846b9a29724cef42aa3dc_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-315">17,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief715af7397b4bbc946fd81d6ef9642c_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-316">92,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea080f686ed4c7985dd2ed9b933233d_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-317">41,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75573cbeb0d94490a290b059cc9eb61f_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-318">50,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i427d51006aa64de0a7a8d0cd8c18a011_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-319">17,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6501227d18c4697ad97204a2bb6636d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-320">17,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ba5b88f01a40738c1cbf6ae8e4c17d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc13d1fb533048d9a7687c94b7811d70_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-322">81,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d03481f525f4af8b46765578d2c616a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-323">81,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f32cea665ba4844b458f7cca002f6d7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95312e9fdb7544afa0e46c69a02b159e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-325">7,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6c03a9650c248c7bc7c0dcc9ee0ef29_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7eed347f0fb4bc6a341449db8f7771b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-327">7,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2f906f81cab4560ae73910713996b25_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-328">37,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52c92a0b8bdf4ac491affce8a16e718a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d9dd52b0a848c7af77775ff7df34b5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-330">37,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e62bf001444be7b3fc5d2bac8294e7_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-331">143,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fc76d0cb27246d89175301dc8968ddf_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-332">98,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b3c6dbfbcc454e915c319790c99bb2_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-333">45,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at December&#160;31, 2022 includes approximately $<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-334">46.5</ix:nonFraction> million reported as cash and cash equivalents and $<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-5" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-335">45.5</ix:nonFraction>&#160;million reported as marketable securities on the balance sheet.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2021 includes approximately $<ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-336">23.2</ix:nonFraction> million reported as cash and cash equivalents and $<ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-5" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-337">120.1</ix:nonFraction>&#160;million reported as marketable securities on the balance sheet.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="f-338" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenue relates to agreements with various collaborators, MARGENZA net product sales and&#160;contracts and research grants received from U.S. government agencies.&#160;<ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-339" continuedAt="i96fe419289ce4322ae147b6b10ed6e4c" escape="true">The following table includes those counterparties </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i935acce7f5504571a8e79d9d6e1c2557" continuedAt="i104aae99d2ca4fb9ade3e58811059011"><ix:continuation id="i96fe419289ce4322ae147b6b10ed6e4c"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that represent more than 10% of total revenue earned in the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:68.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte Corporation (Incyte)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifc945f6be73546b2afbc3f7e91a7829e_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-340">26</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie59d44df2b334c9cb26d2a7a0c7871f7_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-341">31</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib18dc8cc7b9a48b8903b573ec4c92a4e_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-342">47</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen Biotech, Inc. (Janssen)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b8796d99b14454ea1069baedf468150_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-343">19</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab Limited (Zai Lab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70e62fd23da147a7bbfb414455b3e79d_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-344">15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8682e59ba6945349b855aa4242ac643_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-345">30</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i604d5c2d6f54497d9519656986424b6a_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-346">11</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provention Bio, Inc (Provention)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1eb0cdf897b34e7299f5aed8a57a554c_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-347">43</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I-Mab Biopharma (I-Mab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4946c226bb1048199aac012daace167d_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-348">16</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Amount is less than 10% for the period indicated.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provention</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12dd7404d2a7431e85b17656e3f960c6_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-349">84</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia4eede0cc1bb4da3aaf51c9487514340_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-350">23</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I-Mab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic100551ff962425281acea19be14d51e_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-351">12</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3d1bb961749c4c69a5d4f00e2387e986_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-352">18</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD Healthcare and Oncology Supply</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie282942c434e49a58118206bfeb797af_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-353">18</ix:nonFraction>%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Balance is less than 10% as of the date indicated.</span></div></ix:continuation><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="f-354" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the U.S. Food and Drug Administration (FDA) in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-355" continuedAt="id0ceebcff6704081ad7832608eb9685f" escape="true">Property, Equipment and Software</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id0ceebcff6704081ad7832608eb9685f">Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</ix:continuation> <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" id="f-356" continuedAt="i8f609d55e53b427dba808fda574fab17" escape="true">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="i8f609d55e53b427dba808fda574fab17"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9aa7f28c164743c18f02c60499ebf31f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-357">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief36ee226752463cbcd31a9ee80c5cfe_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-358">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2f68116386e241a1b517c6290a020dfd_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-359">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i43aae3612f484fc782f7958caa1ea5f0_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-360">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i104aae99d2ca4fb9ade3e58811059011" continuedAt="i0b6705ec4c6646cc9bec2511fa7920a9"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-361" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2022, and 2021, the Company determined that there were no impaired assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-362" continuedAt="i94dbf83384754d1db966fcd06fbf0275" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative and other agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company grants a license to its intellectual property, it </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determines whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i0b6705ec4c6646cc9bec2511fa7920a9" continuedAt="ia2255e2e00084d8db4889a6fbc6115a3"><ix:continuation id="i94dbf83384754d1db966fcd06fbf0275" continuedAt="i34d49a97cbc4417d9af2becf3ec4cd55"><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s intellectual property</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability  that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="ia2255e2e00084d8db4889a6fbc6115a3" continuedAt="i0f09f05a4dd94781826bc69657a1bd15"><ix:continuation id="i34d49a97cbc4417d9af2becf3ec4cd55" continuedAt="id20ec076797949289c3df0ab4361d830"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 8, Revenue.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product sales, net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the years ended December 31, 2022 and 2021, the shipping costs incurred were immaterial. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the year ended December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i0f09f05a4dd94781826bc69657a1bd15" continuedAt="i0e21e29c63d743539f0de215dd3039ce"><ix:continuation id="id20ec076797949289c3df0ab4361d830" continuedAt="ie2ac638aa4354aa6b32785cec43909c6"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract manufacturing revenue</span></div></ix:continuation><div style="text-indent:36pt"><ix:continuation id="ie2ac638aa4354aa6b32785cec43909c6"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with third parties to manufacture their drug substance at its GMP facility. The terms of these arrangements typically include an upfront payment to the Company to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue over time on a straight-line basis as the manufacturing services are performed, as the Company believes that its efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-363" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including labor, materials overhead and other related costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-364" continuedAt="ibf6f0b631d5b44578b4b3280a6105d47" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expense, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i0e21e29c63d743539f0de215dd3039ce"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibf6f0b631d5b44578b4b3280a6105d47">determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</ix:continuation></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-365" continuedAt="ic17f2ad02e1645f491dece30ae07c3bd" escape="true">Leases</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:36pt"><ix:continuation id="ic17f2ad02e1645f491dece30ae07c3bd" continuedAt="iff65ceb3c1cb4df4a57bfbe24dd0638a"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iff65ceb3c1cb4df4a57bfbe24dd0638a">. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition.</ix:continuation> </span></div><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-366" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-367" continuedAt="i35afa7b86a8e41ca9eb95f61544c04c6" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i35afa7b86a8e41ca9eb95f61544c04c6">Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented.</ix:continuation> <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-368" continuedAt="i7bd0a7a2aec444df90d530b0b549df3e" escape="true">The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:</ix:nonNumeric></span><ix:continuation id="i7bd0a7a2aec444df90d530b0b549df3e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:44.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d86aae1ee24443584fb111e79fb643d_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-369">10,514,013</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83f6d05daae94102afa6b769661625fd_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-370">8,395,421</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d7a17d898bc403992983ad4d53cdb20_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-371">7,467,603</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-372" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_142"></div><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-373" continuedAt="icd6ffcca97e241e582780093b76b6e1d" escape="true">Marketable Securities</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:31.5pt"><ix:continuation id="icd6ffcca97e241e582780093b76b6e1d" continuedAt="i7290de090d2546e6b34de6abec03e75b"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-374" continuedAt="i880219d9353c4eb08cf2d77b7e8d971e" escape="true"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities as of December&#160;31, 2022 and 2021 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief133d06a929409ea24e246bbecdca4d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-375">32,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief133d06a929409ea24e246bbecdca4d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-376">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief133d06a929409ea24e246bbecdca4d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-377">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief133d06a929409ea24e246bbecdca4d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-378">32,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2861d07b8b44b3bb7d2dabf91c6d1e7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-379">12,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2861d07b8b44b3bb7d2dabf91c6d1e7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-380">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2861d07b8b44b3bb7d2dabf91c6d1e7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-381">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2861d07b8b44b3bb7d2dabf91c6d1e7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-382">12,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-383">45,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-384">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-385">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-386">45,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i7290de090d2546e6b34de6abec03e75b"><div style="margin-bottom:9pt;text-align:center"><ix:continuation id="i880219d9353c4eb08cf2d77b7e8d971e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede6b8c452354940bfab31e913316625_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-387">81,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede6b8c452354940bfab31e913316625_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-388">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iede6b8c452354940bfab31e913316625_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-389">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede6b8c452354940bfab31e913316625_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-390">81,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f73d3bc964445778f3435766499d956_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-391">7,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f73d3bc964445778f3435766499d956_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f73d3bc964445778f3435766499d956_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-393">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f73d3bc964445778f3435766499d956_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-394">7,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia479f3cd68cd4df3b2165aefbe470f19_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-395">31,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia479f3cd68cd4df3b2165aefbe470f19_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia479f3cd68cd4df3b2165aefbe470f19_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-397">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia479f3cd68cd4df3b2165aefbe470f19_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-398">31,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-399">120,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-400">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-401">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-402">120,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's available-for-sale securities held at December&#160;31, 2022 and 2021 had contractual maturities of less than one year.  All of the Company&#8217;s available-for-sale marketable debt securities in an unrealized loss position as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2021 were in a loss position for less than twelve months.&#160; Unrealized losses on available-for-sale debt securities as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, <ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt-sec:numwordsen" scale="0" id="f-403"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt-sec:numwordsen" scale="0" id="f-404">no</ix:nonFraction></ix:nonFraction> allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded interest income of $<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-5" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="6" id="f-405">1.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-5" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="6" id="f-406">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-5" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="6" id="f-407">0.8</ix:nonFraction> million during the years ended December&#160;31, 2022, 2021 and 2020, respectively, which is included in other income on the consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_145"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:InventoryDisclosureTextBlock" id="f-408" continuedAt="idd9aa8766fe74c01afd80ecbac8a767d" escape="true">Inventory, Net</ix:nonNumeric></span></div><ix:continuation id="idd9aa8766fe74c01afd80ecbac8a767d"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-409" continuedAt="i71362e5d0fe64e2fb5ffed650d245754" escape="true">The following table sets forth the Company's inventory, net of reserves (in thousands):</ix:nonNumeric></span></div><div style="margin-top:9pt"><ix:continuation id="i71362e5d0fe64e2fb5ffed650d245754"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.233%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcess" scale="3" id="f-410">409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-411">3,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-412">1,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="f-413">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-414">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-415">4,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of December&#160;31, 2022 and December&#160;31, 2021 is net of a reserve of $<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="f-416">4.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="f-417">2.0</ix:nonFraction>&#160;million, respectively, for unsaleable inventory. These reserves are reflected in cost of product sales during the period they are recorded.   </span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="mgnx:ScheduleOfInventoryReservesTableTextBlock" id="f-418" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory Reserves (in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions Charged to Expenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269e66b57b7b42519a681c1a8cc89766_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-419">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62bfa97ca0b441f598ddfc23f1117719_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-420">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62bfa97ca0b441f598ddfc23f1117719_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="0" id="f-421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadceb1c7c1874b8ba0b62e7c4d2ff42d_I20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-422">4,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:3pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_148"></div><div style="margin-bottom:9pt;margin-top:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-423" continuedAt="idaab176e2d414a91bf84b73d89dd122c" escape="true">Property, Equipment and Software</ix:nonNumeric></span></div><ix:continuation id="idaab176e2d414a91bf84b73d89dd122c"><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-424" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ecc54ff86bd462dbcf7438abf4ac388_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-425">3,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddda6f6be78f4602886e324038e7f82c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-426">2,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c41356f213a40cd81fe3fb1a47a4c2b_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-427">9,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc75a33630b8494aa7a9d885440fb55b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-428">9,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6131b1918c0e4fdb853bcc6ad763b7ca_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-429">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d7b43945214a0f9748176a7c4e3c92_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-430">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motor vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0a8a099634446f9fb626545b035d04_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-431">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a609eef7164eeca03b96057a76706d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-432">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ca3bfc3b74349b0824017e2224f2eed_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-433">46,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fb1258352cf41e99f6e755e10b66dd5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-434">45,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1420654e5aac46a18c1f6b2e6ca46fe7_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-435">52,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied072b573720413181b76aa300c73290_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-436">51,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:ConstructionInProgressGross" scale="3" id="f-437">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:ConstructionInProgressGross" scale="3" id="f-438">630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-439">113,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-440">110,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-441">84,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-442">72,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-443">29,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-444">37,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-445">11.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-446">11.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-447">12.0</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i9064db26008e44ad995ee3ad48ef6721_151"></div><div style="margin-bottom:9pt;margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-448" continuedAt="i131d9a6c1cf54791a2bd3213c4ba8484" escape="true">Commitments and Contingencies</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i131d9a6c1cf54791a2bd3213c4ba8484" continuedAt="i982d613477224d7c899f92155441ec2e">&#160;</ix:continuation></span></div><ix:continuation id="i982d613477224d7c899f92155441ec2e" continuedAt="i3dc6223090944adbafbe2711e447b9df"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has non-cancelable operating leases for manufacturing, laboratory, office and warehouse space in Maryland and a non-cancelable operating lease for laboratory and office space in California. A portion of the space under one of these leases is subleased to a third party. The California facility and the smaller-scale, non-commercial GMP manufacturing site in Maryland will be closed under the Company&#8217;s restructuring plan announced in August 2022, therefore the leases for those sites will not be renewed when they expire.  The Company&#8217;s continuing leases each have one or more <ix:nonNumeric contextRef="ia1f326cd30a042929083a704f1d6c9b3_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-449">five-year</ix:nonNumeric> options to renew</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2022, the Company amended the existing lease on its headquarters space to extend the lease term through 2035 in exchange for certain concessions from the lessor.  This amendment was accounted for as a lease modification, and the right-of-use asset and lease liability were remeasured at the modification date, resulting in an increase to both balances of approximately $<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-5" name="mgnx:RightOfUseAssetAndLeaseLiabilityIncrease" format="ixt:num-dot-decimal" scale="6" id="f-450">14.0</ix:nonFraction> million.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" id="f-451" continuedAt="if834f376b1db44ee832c9aac095a81e5" escape="true">The table below presents supplemental balance sheet information related to operating leases:</ix:nonNumeric></span></div><div><ix:continuation id="if834f376b1db44ee832c9aac095a81e5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia8eb7d177b724915967268594839281d_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-452">11.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-453">5.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-454">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-455">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2021, t</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company made cash payments for operating leases of $<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-456">6.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-457">6.7</ix:nonFraction> million, respectively. As of December&#160;31, 2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2021,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s ROU assets were valued at $<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-458">27.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-459">16.6</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="f-460" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2021 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-461">5,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-462">5,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-463">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-464">960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-465">1,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="f-466">814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-467">5,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-468">5,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i3dc6223090944adbafbe2711e447b9df" continuedAt="iac98047e1493419f822d46493efaaab6"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-469" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-470">4,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-471">4,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-472">5,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-473">4,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-474">4,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-475">52,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-476">75,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-477">40,444</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-478">34,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-licensing arrangement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a non-exclusive license agreement with Synaffix B.V. (Synaffix) to develop, manufacture and commercialize up to three antibody-drug conjugate targets using Synaffix&#8217;s proprietary technology. The Company made an upfront payment to Synaffix upon contract execution. Assuming all three targets are successfully developed and commercialized, the Company would be obligated to pay up to $<ix:nonFraction unitRef="usd" contextRef="i2fd4290024fb4044a496f5b0095aec3a_I20220131" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-479">585.0</ix:nonFraction>&#160;million for development, regulatory and sales milestones. Finally, pursuant to the terms of this license agreement, upon commencement of commercial sales of any products developed from these targets, the Company would be required to pay Synaffix tiered royalties in the low&#8209;single digit percentages on net sales of the respective products. The Company may terminate this agreement at any time with 30 days&#8217; notice to Synaffix. Amounts paid to Synaffix under this agreement are recorded as research and development expense in the consolidated statement of operations.  During the year ended December&#160;31, 2022, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i7b9d38ff906a423c980d0021ca83eefd_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-480">1.0</ix:nonFraction>&#160;million under this agreement. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Litigation</span></div></ix:continuation><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iac98047e1493419f822d46493efaaab6">On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial. On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint. The amended complaint asserted a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal in the Fourth Circuit. The Company did not accrue any liability associated with this action as of December 31, 2022. The 4th Circuit affirmed the District Court&#8217;s dismissal in a decision published on March 2, 2023.</ix:continuation> </span></div><div><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_154"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-481" continuedAt="i6360a1771f6745658d468d6cf2efadb5" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i6360a1771f6745658d468d6cf2efadb5" continuedAt="i7f2cfe6f69424543b2c1ae08bdc709c9"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's amended and restated certificate of incorporation authorizes <ix:nonFraction unitRef="shares" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-482">125,000,000</ix:nonFraction> shares of common stock, and <ix:nonFraction unitRef="shares" contextRef="i6a3cb7b2a9c84dd89c8cfd99ca5abf7c_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-483">5,000,000</ix:nonFraction> shares of undesignated preferred stock, both with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3a5e971264d548579cbdbbcb85309080_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-484"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a3cb7b2a9c84dd89c8cfd99ca5abf7c_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-485">0.01</ix:nonFraction></ix:nonFraction> per share.&#160;There were <ix:nonFraction unitRef="shares" contextRef="i6a3cb7b2a9c84dd89c8cfd99ca5abf7c_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-486"><ix:nonFraction unitRef="shares" contextRef="i3a5e971264d548579cbdbbcb85309080_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-487"><ix:nonFraction unitRef="shares" contextRef="i3a5e971264d548579cbdbbcb85309080_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-488"><ix:nonFraction unitRef="shares" contextRef="i6a3cb7b2a9c84dd89c8cfd99ca5abf7c_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-489">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2022 or 2021. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="ica4884a38171464fb3771d584bde78ae_D20201101-20201130" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="f-490">100.0</ix:nonFraction> million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the year ended December 31, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i24a49a71f1f04f838393fe224709a584_D20210101-20211231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-491">3,622,186</ix:nonFraction> shares of common stock at a weighted average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="idcbca4caa7f44c80ab53213c339fb544_I20211231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-492">27.60</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i24a49a71f1f04f838393fe224709a584_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-493">98.2</ix:nonFraction> million, net of underwriting discounts and commissions and other offering expenses. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#8217;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="ica4884a38171464fb3771d584bde78ae_D20201101-20201130" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="f-494">100.0</ix:nonFraction>&#160;million to an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="icec55a17872746d2856769218fef60aa_D20210401-20210430" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease" format="ixt:num-dot-decimal" scale="6" id="f-495">300.0</ix:nonFraction>&#160;million. During the year ended December 31, 2022, the Company sold <ix:nonFraction unitRef="shares" contextRef="i8b2c42e5029948ed9d33d72c422ec15b_D20220101-20221231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-496">160,480</ix:nonFraction> shares of common stock at a weighted average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i867d5919542f4494a26a231e8b7346e0_I20221231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-497">6.87</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i8b2c42e5029948ed9d33d72c422ec15b_D20220101-20221231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-498">1.1</ix:nonFraction> million, net of underwriting discounts and commissions and other offering expenses. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7f2cfe6f69424543b2c1ae08bdc709c9">As part of the consideration for the rights granted to Zai Lab US LLC under the collaboration and license agreement described more fully in Note 8, Revenue, the Company and Zai Lab US LLC entered into a separate stock purchase agreement (Stock Purchase Agreement).  Under this Stock Purchase Agreement in 2021, Zai Lab US LLC paid the Company approximately $<ix:nonFraction unitRef="usd" contextRef="i32e8c25671ba4f6fb24dee37c0820f11_D20210601-20210630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-499">30.0</ix:nonFraction> million to purchase <ix:nonFraction unitRef="shares" contextRef="i66fe51ad0d964f1896d0f96af0e1e372_D20210601-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-500">958,467</ix:nonFraction> newly issued shares of the Company's common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-501">0.01</ix:nonFraction>, at a fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ife8f008f05574ef1870bdae6c66d666b_I20210615" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-502">31.30</ix:nonFraction> which represented a $<ix:nonFraction unitRef="usd" contextRef="i7335e9f1b9ca42eca438a74f5c67ab3a_D20210601-20210630" decimals="-5" name="mgnx:PremiumReceivedOnStockPurchase" format="ixt:num-dot-decimal" scale="6" id="f-503">10.4</ix:nonFraction> million premium over the share price on the Stock Purchase Agreement date.</ix:continuation></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_163"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock" id="f-504" continuedAt="ic0fd038fed6b439d929c359234bb5008" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="ic0fd038fed6b439d929c359234bb5008" continuedAt="i6dbff6e0eb254f868ccdbeaf3603ff3c"><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Collaborative Agreements </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte License Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte, which was amended in March 2018, April 2022 and July 2022, for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab. Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i3bf402b9dbdd4d87ae5d49d80d3bfbd1_D20190101-20190331" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-505">150.0</ix:nonFraction> million in 2017. MacroGenics will manufacture a portion of Incyte&#8217;s global commercial supply of retifanlimab. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies, including in patients with Merkel cell carcinoma, squamous cell carcinoma of the anal canal, MSI-high endometrial cancer and non-small cell lung cancer.  Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.  In April 2022, the Company and Incyte executed an amendment to the Incyte License Agreement to add a milestone for U.S. approval of retifanlimab in a specific indication and to exclude certain other regulatory and development achievements with retifanlimab in this same indication from the milestone events of the Incyte License Agreement. In July 2022, the Company and Incyte further amended the Incyte License Agreement to reflect changes related to the payment of certain milestones and Incyte paid the Company $<ix:nonFraction unitRef="usd" contextRef="i5669556108fb4b49ab6793e93d991f6f_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-506">30.0</ix:nonFraction> million in milestone payments, which the Company recognized as revenue during the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, as amended, Incyte will lead global development of retifanlimab. Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="ia6f88ee6c6234a019d97d24e5e39ceff_I20171031" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-507">435.0</ix:nonFraction> million in development and regulatory milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="ia6f88ee6c6234a019d97d24e5e39ceff_I20171031" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-508">330.0</ix:nonFraction> million in commercial milestones. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="ibea2d6a312194bd6a0ecf5f54c65238a_D20220101-20221231" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="f-509">100.0</ix:nonFraction> million in development milestones under Incyte License Agreement.   If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="i988a06040edf4aa0b8a3f3cd042479bd_D20171001-20171031" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="f-510">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i9110adb267ef45a6aa425a647075f177_D20171001-20171031" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="f-511">24</ix:nonFraction>% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of ASC 606 at inception and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte License Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="i38eeebe054f049c9bc2b9a0534ffdab3_I20171031" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-512">154.0</ix:nonFraction> million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The standalone selling price for agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2018 through </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i6dbff6e0eb254f868ccdbeaf3603ff3c" continuedAt="i2fe29ec59672480588152ad8fb83d2d7"><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ibea2d6a312194bd6a0ecf5f54c65238a_D20220101-20221231" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="f-513">100.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#8217;s initiation of a Phase 3 clinical trial.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i01a768287b9d4dba83bffa872d2e72c8_D20171001-20171031" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-514">150.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $<ix:nonFraction unitRef="usd" contextRef="iee9e9e7ce67a49de83726523a441d2ff_D20170101-20181231" decimals="-5" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" format="ixt:num-dot-decimal" scale="6" id="f-515">4.0</ix:nonFraction> million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i5669556108fb4b49ab6793e93d991f6f_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-516">30.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7f61d57a20cd4679bf6ecc932ade4702_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-517">15.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i633fd2fb64ad42c4b92eebba0535d397_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-518">40.0</ix:nonFraction> million under the Incyte License Agreement during the years ended December&#160;31, 2022, 2021 and 2020, respectively.  All of the revenue recognized during the years ended December&#160;31, 2022 and 2021 was related to development milestones.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into an agreement with Incyte under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2021 and 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i60225cd201b84577ac14ccd93f6b150d_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-519">0.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2135354a19f64808a2cc5c96c8be75a2_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-520">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i287b95f9f02e4ed1a66f479666758d0a_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-521">8.6</ix:nonFraction> million, respectively, for services performed under this agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Commercial Supply Agreement</span></div><div style="text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services. During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, and 2020 the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i1793ad9c6b4f4244b4ee579221db1b13_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-522">0.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i75eb5df4d251413fba2adbdc9e57ccb9_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-523">7.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icc0cec4a5a73427eb832e2674227c093_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-524">1.4</ix:nonFraction>&#160;million, respectively, for services performed under this agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Gilead Sciences, Inc </span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company and Gilead Sciences, Inc. (Gilead) entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024, an investigational, bispecific antibody that binds CD123 and CD3, and create bispecific cancer antibodies using the Company&#8217;s DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under the agreement, the Company will continue the ongoing phase 1 trial for MGD024 accordi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng to a development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license under the Company&#8217;s intellectual property to develop and commercialize MGD024 and other bispecific antibodies of MacroGenics that bind CD123 and CD3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CD123 Option). The agreement also grants Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by the Company and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Gilead Agreement, in October 2022 Gilead paid the Company an upfront payment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i1b71d094740b4c1e9c5b2ff8f8b13f29_D20221014-20221014" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-525">60.0</ix:nonFraction>&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming Gilead exercises the CD123 Option and Research Program Option and successfully develops and commercializes MGD024, or other CD123 products developed under the agreement, and products result from the two additional research programs, the Company would be eligible to receive up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i1b71d094740b4c1e9c5b2ff8f8b13f29_D20221014-20221014" decimals="-5" name="mgnx:PotentialTargetNominationOptionFeesAndMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="f-526">1.7</ix:nonFraction>&#160;billion </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in target nomination, option fees, and development, regulatory and commercial milestones. Assuming exercise of the CD123 Option, the Company will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 (or other CD123 products developed under the agreement) and assuming exercise of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a flat royalty on worldwide net sales of any products resulting from the two research programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i2fe29ec59672480588152ad8fb83d2d7" continuedAt="i1814bfbf33974e0c9752a965714b863a"><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Gilead Agreement under the provisions of ASC 606 and identified the following material promises under the agreement: (i) a license to perform any activities allocated to Gilead under the MGD024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; (ii) development activities regarding MGD024, including manufacturing, research and early clinical development activities, necessary to deliver an informational package of development and clinical data, information and materials specified in the Gilead Agreement during the period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which Gilead can exercise the CD123 Option; (iii) the CD123 Option and (iv) the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the license under the MGD024 developme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development activities are not distinct from one another, as the license has limited value without the Company&#8217;s performance of the development activities. Therefore, the Company determined that the development term license and development activities should be combined into a single performance obligation (Development Activities). The CD123 Option is considered a material right as the value of the exclusive license exceeds the payment to be made by Gilead if they exercise their option to obtain an exclusive license to develop and commercialize MGD024 or an alternative CD123 product, and is therefore a distinct performance obligation. The Company determined that the Research Program Option does not provide a material right, as there is no discount on its standalone selling price.</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company determined that the initial transaction price under the Gilead Agreement was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i1b71d094740b4c1e9c5b2ff8f8b13f29_D20221014-20221014" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-527">60.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consisting of the upfront, non-refundable payment paid by Gilead. The CD123 Option and Research Program Option payments are excluded from the initial transaction price at contract inception along with any future development, regulatory, and commercial milestone payments (including royalties) following the CD123 Option and Research Program Option exercise.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will reassess the amount of variable consideration included in the transaction price every reporting period.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i1b71d094740b4c1e9c5b2ff8f8b13f29_D20221014-20221014" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-528">60.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upfront payment in the transaction price to the Development Activities and the CD123 Option based on each performance obligation&#8217;s relative standalone selling price. The standalone selling price for the Development Activities was calculated using an expected cost-plus margin approach </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the pre-option development timeline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the standalone selling price of the CD123 Option, the Company utilized an income-based approach which included the following key assumptions:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">post-option development timeline and costs, forecasted revenues, discount rates and probabilities of technical and regulatory success. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is recognizing revenue related to the Development Activities performance obligation over the estimated period to complete the Development Activities using an input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the Development Activities. The Company will defer revenue recognition related to the CD123 Option.  If Gilead exercises the CD123 Option and obtains an exclusive license, the Company will recognize revenue as it fulfills its obligations under the Gilead Agreement. If the CD123 Option is not exercised, the Company will recognize the entirety of the revenue in the period when the CD123 Option expires.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company recorded revenue of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="iaf251b9dfa1d4ed89dfd50e9d5821e5e_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-529">0.2</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to the Gilead Agreement. As of December 31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i8b7bc40165fd46a193e3cccf1f049cfa_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-530">59.8</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i8b7bc40165fd46a193e3cccf1f049cfa_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-531">1.8</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i8b7bc40165fd46a193e3cccf1f049cfa_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-532">58.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab Limited</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Zai Lab Agreement</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. Zai Lab has informed the Company that they have decided to discontinue development of tebotelimab for indications they were enrolling in their territory and is evaluating future development plans in other indications.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i96872571cd0a4110aadf271b65708d4f_D20181101-20181130" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-533">25.0</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="i69bfd0f8331b41bba3c4e5efaa36efc4_D20181101-20181130" decimals="-5" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="f-534">22.5</ix:nonFraction> million after netting value-added tax withholdings of  $<ix:nonFraction unitRef="usd" contextRef="i96872571cd0a4110aadf271b65708d4f_D20181101-20181130" decimals="-5" name="mgnx:NonrefundablePaymentTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="f-535">2.5</ix:nonFraction> million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="i54460e4405804e6d8632d256ca806b3a_I20221231" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-536">140.0</ix:nonFraction> million in development and regulatory milestones, of which the Company has earned $<ix:nonFraction unitRef="usd" contextRef="ideaa024a11c34bdb89c49cd5c437abdb_D20200701-20221231" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="f-537">9.0</ix:nonFraction> million through December&#160;31, 2022.  In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to <ix:nonFraction unitRef="number" contextRef="i3160099d486f4eb0ac91ae68ee1818a5_D20181101-20181130" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="f-538">20</ix:nonFraction>% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and <ix:nonFraction unitRef="number" contextRef="idda174e868e34f569bb5414b16d63aaf_D20181101-20181130" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="f-539">10</ix:nonFraction>% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i1814bfbf33974e0c9752a965714b863a" continuedAt="i9b1f224dfce44fc48fa5c4f6eb4d63fb"><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $<ix:nonFraction unitRef="usd" contextRef="i69bfd0f8331b41bba3c4e5efaa36efc4_D20181101-20181130" decimals="-5" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" format="ixt:num-dot-decimal" scale="6" id="f-540">22.5</ix:nonFraction> million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.  From 2020 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it became probable that a significant reversal of cumulative revenue would not occur for development and regulatory milestones totaling $<ix:nonFraction unitRef="usd" contextRef="ideaa024a11c34bdb89c49cd5c437abdb_D20200701-20221231" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="f-541">9.0</ix:nonFraction> million. Therefore, the associated consideration, $<ix:nonFraction unitRef="usd" contextRef="ideaa024a11c34bdb89c49cd5c437abdb_D20200701-20221231" decimals="-5" name="mgnx:MilestonesValueAddedTax" format="ixt:num-dot-decimal" scale="6" id="f-542">8.1</ix:nonFraction>&#160;million net of value-added tax withholdings, was added to the estimated transaction price and was recognized as revenue</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uring the year ended December&#160;31, 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ia6508d36a64142029325de20e5324de6_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-543">4.9</ix:nonFraction>&#160;million under the 2018 Zai Lab Agreement and <ix:nonFraction unitRef="usd" contextRef="i4d66046a5ee64f7788d581007532e524_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-544">no</ix:nonFraction> revenue was recognized during the year ended December&#160;31, 2021 under this agreement. During the year ended December&#160;31, 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i1d938aac5ed04e51bcb036c13e6fa016_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-545">8.6</ix:nonFraction>&#160;million under the 2018 Zai Lab Agreement, $<ix:nonFraction unitRef="usd" contextRef="i1d938aac5ed04e51bcb036c13e6fa016_D20200101-20201231" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="f-546">3.6</ix:nonFraction>&#160;million of which was net milestone revenue and $<ix:nonFraction unitRef="usd" contextRef="i1d938aac5ed04e51bcb036c13e6fa016_D20200101-20201231" decimals="-5" name="mgnx:RevenueFromVariableConsiderationRecognize" format="ixt:num-dot-decimal" scale="6" id="f-547">5.0</ix:nonFraction>&#160;million of which was recognition of variable consideration related to certain regulatory achievements during 2020.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zai Lab Clinical Supply Agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements). The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within the contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab. The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing service. During the years ended December&#160;31, 2022, 2021, and 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i1715d94674d945de83bbfd371f7c13c4_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-548">0.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i767daa988e954076be39c9747efd7d0d_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-549">2.8</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i5e1ac66792744af791f7f6abfa4dcef6_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-550">2.7</ix:nonFraction>&#160;million, respectively, related to the Zai Lab Clinical Supply Agreements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Zai Lab Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#8217;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company. During 2022, the Company and Zai Lab agreed to discontinue research and development of the Lead Program.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program included joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i9b1f224dfce44fc48fa5c4f6eb4d63fb" continuedAt="i793c5081f5964492b0ac0f126eb9d5ee"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i32e8c25671ba4f6fb24dee37c0820f11_D20210601-20210630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-551">25.0</ix:nonFraction>&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into the Stock Purchase Agreement whereby Zai Lab paid the Company approximately $<ix:nonFraction unitRef="usd" contextRef="i32e8c25671ba4f6fb24dee37c0820f11_D20210601-20210630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-552">30.0</ix:nonFraction> million to purchase shares of the Company&#8217;s common stock at a fixed price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ife8f008f05574ef1870bdae6c66d666b_I20210615" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-553">31.30</ix:nonFraction> which represented a $<ix:nonFraction unitRef="usd" contextRef="i7335e9f1b9ca42eca438a74f5c67ab3a_D20210601-20210630" decimals="-5" name="mgnx:PremiumReceivedOnStockPurchase" format="ixt:num-dot-decimal" scale="6" id="f-554">10.4</ix:nonFraction> million premium over the share price on the Stock Purchase Agreement date. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the remaining Programs, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="ife8f008f05574ef1870bdae6c66d666b_I20210615" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-555">680.0</ix:nonFraction>&#160;million in development and regulatory milestones and $<ix:nonFraction unitRef="usd" contextRef="ife8f008f05574ef1870bdae6c66d666b_I20210615" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-556">600.0</ix:nonFraction>&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-single digits to low double digit teens on annual net sales of products in Zai Lab&#8217;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#8217;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#8217;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the estimated transaction price is $<ix:nonFraction unitRef="usd" contextRef="ife8f008f05574ef1870bdae6c66d666b_I20210615" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-557">40.4</ix:nonFraction> million, consisting of the $<ix:nonFraction unitRef="usd" contextRef="i32e8c25671ba4f6fb24dee37c0820f11_D20210601-20210630" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-558">25.0</ix:nonFraction> million upfront payment, the $<ix:nonFraction unitRef="usd" contextRef="i7335e9f1b9ca42eca438a74f5c67ab3a_D20210601-20210630" decimals="-5" name="mgnx:PremiumReceivedOnStockPurchase" format="ixt:num-dot-decimal" scale="6" id="f-559">10.4</ix:nonFraction> million premium related to the purchase of the Company&#8217;s common stock, and the $<ix:nonFraction unitRef="usd" contextRef="i54dc0d7d758841359d25ada6f2a3f6bd_I20221231" decimals="-5" name="mgnx:EstimatedReimbursementForResearchAndDevelopmentT" format="ixt:num-dot-decimal" scale="6" id="f-560">5.0</ix:nonFraction> million estimated reimbursement by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $<ix:nonFraction unitRef="usd" contextRef="ife8f008f05574ef1870bdae6c66d666b_I20210615" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-561">40.4</ix:nonFraction> million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes a market participant is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each Program. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to the Lead Program license and related research and development services performance obligation was  recognized over time as the research and development activities were performed. The Company utilized a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recognized revenue of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i8e5adc3d5e2442fbbb01084952f712f4_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-562">16.8</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i05c59e94ee554f07bf1f21a28ba5d901_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-563">20.3</ix:nonFraction> million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, under the 2021 Zai Lab Agreement. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022, there was <ix:nonFraction unitRef="usd" contextRef="i54dc0d7d758841359d25ada6f2a3f6bd_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="6" id="f-564">no</ix:nonFraction> revenue deferred under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 Zai Lab Agreement</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="ib60793823f51401f91c4fe5a62120d5b_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-565">16.1</ix:nonFraction> million in revenue was deferred under this agreement, all of which was current. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Biotech, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a research collaboration and license agreement with Janssen to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#8217;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i0b1d84cceaa14d2b82272120f3d141a5_D20201201-20201231" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-566">20.0</ix:nonFraction>&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="if4cc71ed45f8424fb7ad7a930e7af919_I20221231" decimals="-5" name="mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales" format="ixt:num-dot-decimal" scale="6" id="f-567">312.0</ix:nonFraction>&#160;million in potential milestone payments and tiered royalties of up to <ix:nonFraction unitRef="number" contextRef="i0b1d84cceaa14d2b82272120f3d141a5_D20201201-20201231" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="f-568">10</ix:nonFraction>% on worldwide product sales. </span><span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i793c5081f5964492b0ac0f126eb9d5ee" continuedAt="i471e2da8e1204022af2793401ecc714a"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#8217;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="if4cc71ed45f8424fb7ad7a930e7af919_I20221231" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-569">22.2</ix:nonFraction>&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration was fully constrained until the Company began its work under the performance obligation.  The potential milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="i6b4b8204955c40b9a81053a2ea6a7a34_D20201201-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-570">20.0</ix:nonFraction>&#160;million allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Janssen in 2020. The $<ix:nonFraction unitRef="usd" contextRef="i0b1d84cceaa14d2b82272120f3d141a5_D20201201-20201231" decimals="-5" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" format="ixt:num-dot-decimal" scale="6" id="f-571">2.2</ix:nonFraction>&#160;million allocated to the research and development activities is being recognized over the Company&#8217;s involvement in the research term, which is estimated to be less than two years.  During the years ended December&#160;31, 2022, and </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i11525e01950f45fa820c699ad1b87012_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-572">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i823ffcf87c174dfd869db3d5bf2f4876_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-573">1.5</ix:nonFraction>&#160;million, respectively, for research and development activities performed under the Janssen Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention Bio, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a license agreement with Provention pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1ce4656c88644281a81473a1a311bcbb_D20180501-20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="f-574">2.50</ix:nonFraction> per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i13845f28c8184f82b5a85649094c84bc_I20180531" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-575">65.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i13845f28c8184f82b5a85649094c84bc_I20180531" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-576">225.0</ix:nonFraction> million in commercial milestones. As of December&#160;31, 2022, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2018, the Company entered into an asset purchase agreement with Provention pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement). As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7dfb8c7e4fd04324883491a98fdd5523_D20180501-20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="f-577">2.50</ix:nonFraction> per share.  Under the Asset Purchase Agreement, Provention is obligated to pay the Company contingent milestone payments totaling $<ix:nonFraction unitRef="usd" contextRef="id5332bdbc1ac4d42acfb85ff18b8d769_I20180531" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-578">170.0</ix:nonFraction> million upon the achievement of certain regulatory milestones.  In addition, Provention is obligated to make contingent milestone payments to the Company totaling $<ix:nonFraction unitRef="usd" contextRef="id5332bdbc1ac4d42acfb85ff18b8d769_I20180531" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-579">225.0</ix:nonFraction> million upon the achievement of certain commercial milestones as well as single-digit royalties on net sales of the product. The FDA approved the BLA for teplizumab in November 2022, and the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i8fdd00452e734cd1a063f90a315bd38e_D20221101-20221130" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="f-580">60.0</ix:nonFraction> million in revenue related to this regulatory milestone during the year ended December 31, 2022.  In November 2022, the Company and Provention amended the Asset Purchase Agreement.  Under this amendment, the milestone for first approval was split into four equal payments, the first of which was received in November 2022. The remaining payments are due on March 1, 2023, June 1, 2023 and September 1, 2023.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $<ix:nonFraction unitRef="usd" contextRef="id5332bdbc1ac4d42acfb85ff18b8d769_I20180531" decimals="-5" name="mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-581">1.3</ix:nonFraction> million and other consideration, for certain third-party intellectual property under agreements Provention assumed pursuant to the Asset Purchase Agreement. Further, Provention is required to </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i471e2da8e1204022af2793401ecc714a" continuedAt="ie443271bdeb248d8a3552041a4c67328"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $<ix:nonFraction unitRef="usd" contextRef="i42483221131f4b7481cd3ebfbdd95b45_I20180531" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-582">6.1</ix:nonFraction> million, based on the Black-Scholes valuation of the warrants to purchase a total of <ix:nonFraction unitRef="shares" contextRef="i42483221131f4b7481cd3ebfbdd95b45_I20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-583">2,432,688</ix:nonFraction> shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such were excluded from the initial transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="if91ec42029d64d03b3bab9599a9791b5_D20180501-20180531" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-584">6.1</ix:nonFraction> million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018. In 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. During the year ended December&#160;31, 2022, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for a regulatory milestone of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i8fdd00452e734cd1a063f90a315bd38e_D20221101-20221130" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="f-585">60.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i687253dc3b1a4370bafa13817794d0a3_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-586">60.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0f896d007a6a40c48c8fb6cc5e26ea95_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-587">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5c37a5c38e654c99b1697de56b18cac8_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-588">0.6</ix:nonFraction> million, respectively, under these agreements. As of December 31, 2022, Provention owes the Company $<ix:nonFraction unitRef="usd" contextRef="i58e91935654b49eab232a7ec7b32496c_I20221231" decimals="-5" name="mgnx:ReceivableFromCollaborationPartner" format="ixt:num-dot-decimal" scale="6" id="f-589">45.0</ix:nonFraction> million related to the achieved milestone, which is included in accounts receivable on the consolidated balance sheet.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab License Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a collaboration and license agreement with I-Mab to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab License Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. In August 2022, I-Mab notified the Company of its intention to terminate the I-Mab License Agreement effective February 25, 2023.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab License Agreement, I-Mab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ia1ecd07929384da0be9ffd4764df7764_D20190701-20190731" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-590">15.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i35eba6ff61e44d84bf6a3d50767ad056_D20220101-20221231" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="f-591">5.0</ix:nonFraction>&#160;million of milestone revenue has been earned from the inception of the I-Mab License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab License Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i) an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $<ix:nonFraction unitRef="usd" contextRef="ia1ecd07929384da0be9ffd4764df7764_D20190701-20190731" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-592">15.0</ix:nonFraction> million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $<ix:nonFraction unitRef="usd" contextRef="i35eba6ff61e44d84bf6a3d50767ad056_D20220101-20221231" decimals="-5" name="mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-593">1.0</ix:nonFraction> million. I-Mab paid the Company for the cost of this study as the costs were incurred and I-Mab received a one-time credit of <ix:nonFraction unitRef="number" contextRef="i35eba6ff61e44d84bf6a3d50767ad056_D20220101-20221231" decimals="2" name="mgnx:CollaborationArrangementOneTimeCreditPaidPercent" format="ixt-sec:numwordsen" scale="-2" id="f-594">eighty</ix:nonFraction> percent of the total amount of such costs against the milestone achieved during 2021. The Company reassessed the transaction price as it became probable that a significant reversal of cumulative revenue would not occur for a $<ix:nonFraction unitRef="usd" contextRef="i641ea39eabec428e8868e07727550f9b_D20220101-20220331" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="f-595">5.0</ix:nonFraction>&#160;million milestone ($<ix:nonFraction unitRef="usd" contextRef="i221ddea90685424e9202290d98e954b3_I20211231" decimals="-5" name="mgnx:OneTimeMillstoneCredit" format="ixt:num-dot-decimal" scale="6" id="f-596">4.5</ix:nonFraction>&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue during 2021.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue under the I-Mab License Agreement was recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, was the best measure of progress towards satisfying the performance obligations. During the years ended December&#160;31, 2022, 2021 and 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i35eba6ff61e44d84bf6a3d50767ad056_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-597">4.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3d9b291f44c14b62a56b45b107bce2be_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-598">11.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i74eb3a9ad62848108dd74bde2d588232_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-599">2.2</ix:nonFraction> million, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="ie443271bdeb248d8a3552041a4c67328" continuedAt="i08cf1028459043f2a93265aefe4ba626"><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, related to the I-Mab License Agreement. At December&#160;31, 2022, no revenue was deferred under the I-Mab License Agreement. At December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i221ddea90685424e9202290d98e954b3_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-600">4.5</ix:nonFraction> million in revenue was deferred under the I-Mab License Agreement, all of which was current.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into an agreement under which the Company was to perform development and manufacturing services for I-Mab&#8217;s clinical needs of enoblituzumab (I-Mab Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of enoblituzumab. The transaction price was based on the costs incurred to develop and manufacture drug product and drug substance, and was recognized over time as the services were provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price was recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended December&#160;31, 2022, and 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i8d15a5f2354a420f9695a7e6099f117f_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-601">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if52c5ab82dd044a69f0166c3ff58ca62_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-602">1.3</ix:nonFraction> million, respectively, for research and development activities performed under the I-Mab Clinical Supply Agreement.  The Company and I-Mab mutually agreed to terminate this agreement in November 2022. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Boehringer Ingelheim International GmbH</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, the Company entered into a collaboration and license agreement with Boehringer Ingelheim International GmbH (BII) to discover, develop and commercialize multiple DART molecules that were to be evaluated during a <ix:nonNumeric contextRef="i8e86a555e3f24015bead72636200ae9a_D20101001-20151031" name="mgnx:CollaborationAndLicenseAgreementTerm" format="ixt-sec:durwordsen" id="f-603">five-year</ix:nonNumeric> period that ended in 2015 (Boehringer Agreement). Under the terms of the agreement, the Company granted BII an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated under the agreement.  During the evaluation period, BII selected <ix:nonFraction unitRef="productcandidate" contextRef="i57cad70ea273424dabf7a187420e4724_I20151031" decimals="INF" name="mgnx:NumberOfProductCandidates" format="ixt-sec:numwordsen" scale="0" id="f-604">two</ix:nonFraction> product candidates to develop (BII DARTs). Under the terms of the Boehringer Agreement, BII paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i8e86a555e3f24015bead72636200ae9a_D20101001-20151031" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-605">15.0</ix:nonFraction>&#160;million which was fully recognized prior to December 31, 2015. The variable consideration under this agreement included potential future development and sales milestones and royalties on net sales in the event that the BII DARTs are commercialized.   </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, BII agreed to a payment of $<ix:nonFraction unitRef="usd" contextRef="i15b810928e3242aaa7f2093120fe452e_D20200601-20200630" decimals="-5" name="mgnx:DevelopmentMilestonesAmount" format="ixt:num-dot-decimal" scale="6" id="f-606">12.0</ix:nonFraction>&#160;million in order to retain rights to develop the BII DARTs under the Boehringer Agreement.  As a result, the Company received and recognized as revenue $<ix:nonFraction unitRef="usd" contextRef="if20ab34aae324e0ba9bf43107ec6f001_D20220101-20221231" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" format="ixt:num-dot-decimal" scale="6" id="f-607">12.0</ix:nonFraction>&#160;million during the year ended December 31, 2020. The remaining potential development milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur and therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Services Agreements</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a <ix:nonNumeric contextRef="ifa77d46ed2c54978a8e628b9c800991f_I20220131" name="mgnx:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="f-608">three-year</ix:nonNumeric> period at one of the Company&#8217;s manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="if00f09390f0345d98c06a7e6e9cc8a8b_D20220101-20220731" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-609">10.0</ix:nonFraction>&#160;million and is eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $<ix:nonFraction unitRef="usd" contextRef="i1445c3a2eddd4bfeb9296be4f2aca5ee_I20221231" decimals="-5" name="mgnx:TotalAnnualFixedPayments" format="ixt:num-dot-decimal" scale="6" id="f-610">14.4</ix:nonFraction>&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services. In July 2022, the Company and Incyte executed an amendment to the Incyte Manufacturing and Clinical Supply Agreement which extended the term for <ix:nonNumeric contextRef="ifa77d46ed2c54978a8e628b9c800991f_I20220131" name="mgnx:CollaborativeArrangementExtensionTerm" format="ixt-sec:durwordsen" id="f-611">one year</ix:nonNumeric> and provided for an additional annual fixed payment of $<ix:nonFraction unitRef="usd" contextRef="ia8717043cd074e1297a517f4c6e6cc88_I20221231" decimals="-5" name="mgnx:AdditionalAnnualFixedPayments" format="ixt:num-dot-decimal" scale="6" id="f-612">5.1</ix:nonFraction>&#160;million (July 2022 Incyte Amendment). </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement and the July 2022 Incyte Amendment under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price consists of the upfront payment received of $<ix:nonFraction unitRef="usd" contextRef="if00f09390f0345d98c06a7e6e9cc8a8b_D20220101-20220731" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-613">10.0</ix:nonFraction>&#160;million and the annual fixed payments totaling $<ix:nonFraction unitRef="usd" contextRef="ia8717043cd074e1297a517f4c6e6cc88_I20221231" decimals="-5" name="mgnx:TotalAnnualFixedPayments" format="ixt:num-dot-decimal" scale="6" id="f-614">19.5</ix:nonFraction>&#160;million. The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i08cf1028459043f2a93265aefe4ba626"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i623d0a5a27c445f8a4c07b43115440e9_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-615">8.7</ix:nonFraction>&#160;million under the Incyte Manufacturing and Clinical Supply Agreement  during the year ended December&#160;31, 2022. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i1445c3a2eddd4bfeb9296be4f2aca5ee_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-616">9.6</ix:nonFraction>&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i1445c3a2eddd4bfeb9296be4f2aca5ee_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-617">8.1</ix:nonFraction>&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i1445c3a2eddd4bfeb9296be4f2aca5ee_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-618">1.5</ix:nonFraction>&#160;million </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of which was non-current.  </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention Bio, Inc. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Provention (Provention Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Provention bulk drug substance. Under the terms of the Provention Manufacturing and Clinical Supply Agreement, the Company received an upfront payment and payments in accordance with the manufacturing schedule.  The Company was also reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention Manufacturing and Clinical Supply Agreement under the provisions of ASC 606 and identified one performance obligation to provide manufacturing services to Provention. The Company determined that the transaction price consisted of the upfront and other fixed payments totaling $<ix:nonFraction unitRef="usd" contextRef="i6d1179302351453e86c2c3157b6019e8_I20221231" decimals="-5" name="mgnx:UpfrontAndFixedPayments" format="ixt:num-dot-decimal" scale="6" id="f-619">4.6</ix:nonFraction>&#160;million. The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Provention, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Provention will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Provention are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ib46875612ebc4591ae7244a0f9125f6e_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-620">5.3</ix:nonFraction>&#160;million under the Provention Manufacturing and Clinical Supply Agreement during the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with NIAID, effective as of September 15, 2015,&#160;to perform product development and to advance up to <ix:nonFraction unitRef="usd" contextRef="i9c73c17081c04144891915096cd9ed39_I20211231" decimals="INF" name="mgnx:NumberOfProductCandidates" format="ixt-sec:numwordsen" scale="0" id="f-621">two</ix:nonFraction> DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of December&#160;31, 2022 is $<ix:nonFraction unitRef="usd" contextRef="if5ee02f7ab344826b0c16f694bb46f66_D20220101-20221231" decimals="-5" name="mgnx:TotalPotentialValueUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-622">25.1</ix:nonFraction> million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023.  The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i691134ba3b13405da417f0241eb6ca6d_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-623">1.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9e0c41dd27764d34aa9ab34ec3e0805a_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-624">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icf4d116422ce486bb630e9f82b58aeb1_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-625">7.1</ix:nonFraction> million under the NIAID contract during the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div id="i9064db26008e44ad995ee3ad48ef6721_157"></div><div><span><br/></span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-626" continuedAt="id557009f3ea94178b261867f38434a01" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><ix:continuation id="id557009f3ea94178b261867f38434a01" continuedAt="i8983a9cb469d4a7ab5fe3d38785a0f6d"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved <ix:nonFraction unitRef="shares" contextRef="i169fc1b09cca4f95bc19d111a9403716_I20170518" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-627">800,000</ix:nonFraction> shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i9360fd694d5e424f8c7bd8fd3eb717bc_D20170501-20170531" decimals="INF" name="mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="f-628">10</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for <ix:nonNumeric contextRef="i452d203362b14c6ca8da438846c11955_D20170501-20170531" name="mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen" id="f-629">six-month</ix:nonNumeric> offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="i9360fd694d5e424f8c7bd8fd3eb717bc_D20170501-20170531" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-630">85</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the last day of the offering period. During the year ended December&#160;31, 2022, employees purchased <ix:nonFraction unitRef="shares" contextRef="i957cb602cb054b3ea23a8226a9ddbb3a_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-631">105,986</ix:nonFraction> shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="i957cb602cb054b3ea23a8226a9ddbb3a_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-632">0.4</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i8983a9cb469d4a7ab5fe3d38785a0f6d" continuedAt="ia184e5ca32e8406995414810865fa885"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Incentive Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options. In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160;As of December&#160;31, 2022, under the 2003 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia0502d2128aa4313a80c03495c0ed1ea_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-633">65,103</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia0502d2128aa4313a80c03495c0ed1ea_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-634">5.90</ix:nonFraction> per share.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was <ix:nonFraction unitRef="shares" contextRef="i544f43f987bd419e8c458062ac60ce6f_I20131031" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-635">1,960,168</ix:nonFraction> shares.&#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) <ix:nonFraction unitRef="shares" contextRef="i544f43f987bd419e8c458062ac60ce6f_I20131031" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-636">1,960,168</ix:nonFraction> shares, (b) <ix:nonFraction unitRef="number" contextRef="i07711b76935c4009a2ace4be4f684dd6_D20220101-20221231" decimals="3" name="mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" scale="-2" id="f-637">4.0</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended December&#160;31, 2022, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to <ix:nonFraction unitRef="shares" contextRef="i07711b76935c4009a2ace4be4f684dd6_D20220101-20221231" decimals="INF" name="mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" format="ixt:num-dot-decimal" scale="0" id="f-638">15,816,949</ix:nonFraction>.&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2022, under the 2013 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i255a59bd218f42e2af9732b94035f04c_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-639">10,033,826</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i255a59bd218f42e2af9732b94035f04c_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-640">18.66</ix:nonFraction> per share. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-641" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd00d99f798466d860442a9d6fe22f2_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-642">10,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50f063c6cd94e9a8db88782218b51c9_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-643">11,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6968adfd4fe340119028718b06cfb436_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-644">10,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6322f1cbd714b298d2485ddc0fc3322_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-645">10,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529ec6ae784044b38dc167bc1dfef832_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-646">11,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26acb212525e4cc19f85aeb7f96576bb_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-647">9,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-648">20,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-649">23,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-650">20,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Options</span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation to employees and non-employee directors in accordance with ASC Topic 718, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Stock Compensation</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company estimates the fair value of stock option awards using the Black-Scholes option pricing model on the date of grant using the assumptions in the table below. Stock options granted to employees generally vest over four years and have a term of ten years. Stock-based compensation expense for stock options is recognized as expense over the requisite service period, which is the vesting period. As the Company has not paid dividends since inception, nor does it expect to pay any dividends for the foreseeable future, the expected dividend yield assumption is zero. The expected volatility is based on the historical stock volatility of the Company&#8217;s own common stock over a period equal to the expected term of the options. The risk-free rate of the stock options is based on the U.S. Treasury rate in effect at the time of grant for the expected term of the stock options. The Company used the simplified method to calculate expected term during 2020 and 2021.  Beginning in 2022, the computation of expected term was determined based on the historical experience with similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and expectations of future employee behavior.  In addition, the Company  estimates the expected forfeiture rate and only recognizes expense for those shares expected to vest. The Company estimates the forfeiture rate based on historical experience and its expectations regarding future pre-vesting termination behavior of employees. The Company reviews its estimate of the expected forfeiture rate annually, and stock-based compensation expense is adjusted accordingly.</span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div></ix:continuation><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-651" continuedAt="i8ed7da93d1d444798ec9f1d31e4acee1" escape="true"></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="ia184e5ca32e8406995414810865fa885" continuedAt="ifd9f39ae895d4de3ab8d117288d6652c"><div><ix:continuation id="i8ed7da93d1d444798ec9f1d31e4acee1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:56.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-652">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-653">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-654">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9e619dc3a61b43d087d92cd2fee49ef4_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-655">88</ix:nonFraction>% -<ix:nonFraction unitRef="number" contextRef="ic0e3bcdcfbcf4c97b49dae77737eb857_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-656">92</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03b32c2299d94db490057c88800e534c_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-657">86</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="id868fe5312d548fda66c272fedcbd81c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-658">87</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic345c52c1f4b4493a8a2205795297694_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-659">67</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="if4a9eb4001cb48e29e15fb1edeea83c2_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-660">109</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9e619dc3a61b43d087d92cd2fee49ef4_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-661">1.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ic0e3bcdcfbcf4c97b49dae77737eb857_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-662">4.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03b32c2299d94db490057c88800e534c_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-663">0.6</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="id868fe5312d548fda66c272fedcbd81c_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-664">1.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic345c52c1f4b4493a8a2205795297694_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-665">0.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="if4a9eb4001cb48e29e15fb1edeea83c2_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-666">1.8</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-667">5.95</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-668">6.25</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-669">6.25</ix:nonNumeric> years</span></div></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-670" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-671">8,373,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-672">21.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-673">6.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-674">2,794,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-675">9.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-676">120,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-677">1.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-678">509,569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-679">15.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-680">439,520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-681">22.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-682">10,098,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-683">18.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-684">6.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-685">1,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2022:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-686">6,694,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-687">21.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-688">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="f-689">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-690">9,456,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-691">18.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-692">6.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-693">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 2021 and 2020 the Company issued <ix:nonFraction unitRef="shares" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-694">120,900</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-695">332,767</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-696">504,445</ix:nonFraction> net shares of common stock, respectively, in conjunction with stock option exercises.&#160;The Company received cash proceeds from the exercise of stock options of approximately $<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-697">0.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-698">5.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-699">5.3</ix:nonFraction> million during 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-700">6.84</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-701">15.20</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-702">10.68</ix:nonFraction> per share, respectively. The total intrinsic value of options exercised during 2022, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-703">0.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-704">3.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-705">4.3</ix:nonFraction> million, respectively.&#160;The total fair value of stock options which vested during 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="f-706">19.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="f-707">20.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="f-708">16.7</ix:nonFraction> million, respectively.&#160;As of December&#160;31, 2022, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was $<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-709">24.3</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-710">1.3</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="f-711" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock options outstanding and exercisable by exercise price at December&#160;31, 2022 are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.134%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options Outstanding </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life in Years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i458932626a4e44acacb64a6525da2b9a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-712">0.94</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i458932626a4e44acacb64a6525da2b9a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-713">5.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i781cf98fff854dee996c091defcba9ec_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-714">357,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i458932626a4e44acacb64a6525da2b9a_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-715">8.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i781cf98fff854dee996c091defcba9ec_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-716">3.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i781cf98fff854dee996c091defcba9ec_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-717">143,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i781cf98fff854dee996c091defcba9ec_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-718">3.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia4f6bf1229f9423d9d74a89cbee04492_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-719">5.01</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="ia4f6bf1229f9423d9d74a89cbee04492_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-720">15.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3bd6e8fd9d6e41759ae8ce19e1f15dc0_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-721">3,355,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia4f6bf1229f9423d9d74a89cbee04492_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-722">8.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3bd6e8fd9d6e41759ae8ce19e1f15dc0_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-723">10.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3bd6e8fd9d6e41759ae8ce19e1f15dc0_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-724">1,211,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3bd6e8fd9d6e41759ae8ce19e1f15dc0_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-725">10.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibb9b7e3cc6654c6ab1c1abd54c49d1b0_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-726">15.01</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="ibb9b7e3cc6654c6ab1c1abd54c49d1b0_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-727">25.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65f1a38a652c4027a979e5802d9bf79f_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-728">4,041,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibb9b7e3cc6654c6ab1c1abd54c49d1b0_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-729">6.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i65f1a38a652c4027a979e5802d9bf79f_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-730">20.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65f1a38a652c4027a979e5802d9bf79f_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-731">3,152,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i65f1a38a652c4027a979e5802d9bf79f_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-732">20.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i2d2cf19a216341f7b8ee2b4013afc61e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-733">25.01</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i2d2cf19a216341f7b8ee2b4013afc61e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-734">40.21</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i734a212745e14c3da7f13584d8590872_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-735">2,343,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2d2cf19a216341f7b8ee2b4013afc61e_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-736">4.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i734a212745e14c3da7f13584d8590872_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-737">29.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i734a212745e14c3da7f13584d8590872_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-738">2,187,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i734a212745e14c3da7f13584d8590872_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-739">29.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-740">10,098,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-741">6.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-742">18.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-743">6,694,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-744">21.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="ifd9f39ae895d4de3ab8d117288d6652c"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company awards RSUs to employees. RSUs are valued based on the closing price of the Company&#8217;s common stock on the date of the grant. The fair value of RSUs is recognized and amortized on a straight-line basis over the requisite service period of the award</span><span style="color:#252525;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-745" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for 2022:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3bd6e5ab104947eb9423512ebd965f85_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-746">21,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3bd6e5ab104947eb9423512ebd965f85_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-747">25.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if31e41373baa4fea9e84a7408c5073dd_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-748">476,772</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if31e41373baa4fea9e84a7408c5073dd_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-749">8.42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if31e41373baa4fea9e84a7408c5073dd_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" format="ixt:num-dot-decimal" scale="0" id="f-750">10,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if31e41373baa4fea9e84a7408c5073dd_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-751">25.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if31e41373baa4fea9e84a7408c5073dd_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-752">72,743</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if31e41373baa4fea9e84a7408c5073dd_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-753">8.74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2847395a9c0e4cb490b51246d0a78963_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-754">415,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2847395a9c0e4cb490b51246d0a78963_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-755">8.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i2847395a9c0e4cb490b51246d0a78963_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-756">2.0</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of <ix:nonNumeric contextRef="if31e41373baa4fea9e84a7408c5073dd_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="f-757">one year</ix:nonNumeric>.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_160"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;<ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-758" continuedAt="i056582c455e2446298da52fd85364728" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="i056582c455e2446298da52fd85364728" continuedAt="i5292ba6295b34e73bdcf3d65ac40567c"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020 there was <ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-759">no</ix:nonFraction> provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-760" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal U.S. net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="3" id="f-761">163,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="3" id="f-762">175,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="f-763">44,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="f-764">49,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-765">65,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-766">60,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" format="ixt:num-dot-decimal" scale="3" id="f-767">35,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" format="ixt:num-dot-decimal" scale="3" id="f-768">24,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="mgnx:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-769">9,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="mgnx:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-770">7,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:fixed-zero" scale="3" id="f-771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-772">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="mgnx:Section174DeferredTaxAsset" format="ixt:num-dot-decimal" scale="3" id="f-773">43,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="mgnx:Section174DeferredTaxAsset" format="ixt:fixed-zero" scale="3" id="f-774">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="f-775">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-776">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-777">19,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-778">16,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-779">381,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-780">336,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-781">372,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-782">327,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-783">9,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-784">8,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-785">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-786">1,688</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-787">7,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-788">4,576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-789">1,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-790">2,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-791">9,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-792">8,524</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax asset/(liability)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-793">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><ix:continuation id="i5292ba6295b34e73bdcf3d65ac40567c" continuedAt="i4f3d08bbc2fe44f2940c23cc19b8d6a7"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ie1a3ce377fe84955853c621ebe3898e1_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-795">777.0</ix:nonFraction> million. Of these NOLs, $<ix:nonFraction unitRef="usd" contextRef="ic8563ce4345344189c9f265ecff1081e_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-796">172.0</ix:nonFraction> million will expire in various years beginning in 2025 through 2037. $<ix:nonFraction unitRef="usd" contextRef="i305df6411bc540c288af86c6048f32a6_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-797">605.0</ix:nonFraction> million of NOLs were generated post December 31, 2017 and carryforward indefinitely. In addition, the Company has U.S. federal tax credits of $<ix:nonFraction unitRef="usd" contextRef="iabb762e6d67f44868d3a4659e39f91a1_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-798">94.0</ix:nonFraction> million which will expire in various years beginning in 2023 through 2041.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i16521e389da946b0bfcbbb417dd1be5e_D20220101-20221231" decimals="-5" name="mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount" format="ixt:num-dot-decimal" scale="6" id="f-799">13.5</ix:nonFraction> million of the Company's U.S. Federal NOLs are limited for use over the years 2023 &#8211; 2028 in which a range of such amounts could be utilized on an annual basis of $<ix:nonFraction unitRef="usd" contextRef="ic22e2b51dfee4a8e88cd23892f992f68_I20221231" decimals="-5" name="mgnx:OperatingLossCarryforwardsAnnualLimitationAmount" format="ixt:num-dot-decimal" scale="6" id="f-800">0.2</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i6170cef51c304b009b2a8259c24dafdc_I20221231" decimals="-5" name="mgnx:OperatingLossCarryforwardsAnnualLimitationAmount" format="ixt:num-dot-decimal" scale="6" id="f-801">1.4</ix:nonFraction> million. The remaining $<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-5" name="mgnx:OperatingLossCarryforwardsNotSubjectToLimitation" format="ixt:num-dot-decimal" scale="6" id="f-802">763.0</ix:nonFraction> million of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-803" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-804">25,149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-805">42,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-806">27,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-807">7,385</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-808">12,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-809">8,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" scale="3" id="f-810">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" scale="3" id="f-811">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" scale="3" id="f-812">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-813">4,569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-814">10,243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-815">14,691</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" format="ixt:num-dot-decimal" scale="3" id="f-816">10,846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" format="ixt:num-dot-decimal" scale="3" id="f-817">1,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsOther" scale="3" id="f-818">528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="3" id="f-819">1,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="3" id="f-820">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="3" id="f-821">1,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-822">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-823">1,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="f-824">554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-825">44,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-826">64,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-827">48,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense/(benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-828">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-829">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-830">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:36pt"><ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-831" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-832">7,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d09ee83f16a43899a8e2f0580a10ce5_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-833">6,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60ca2d1b9b3648e78bc6323a0e727305_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-834">4,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-835">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-836">965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-837">839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases/(decreases) for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-3" sign="-" name="mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="f-838">369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-3" name="mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="f-839">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-3" name="mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="f-840">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-841">7,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-842">7,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d09ee83f16a43899a8e2f0580a10ce5_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-843">6,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, of the total gross unrecognized tax benefits, approximately $<ix:nonFraction unitRef="usd" contextRef="ia8eb7d177b724915967268594839281d_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-844">7.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-845">7.2</ix:nonFraction> million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the Company has <ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-846"><ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-847"><ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-848">not</ix:nonFraction></ix:nonFraction></ix:nonFraction> recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's U.S. Federal and state income tax returns from 2003 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forward remain open to examination due to the carryover of unused income tax credits, and from 2004 forward due to the carryover of unused net operating losses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Revenue Code (IRC) Section 174</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to currently deduct research and development expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the United States and 15 years for research activities performed outside the United States </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4f3d08bbc2fe44f2940c23cc19b8d6a7">pursuant to IRC Section 174. Although Congress is considering legislation that would repeal or defer this capitalization and amortization requirement, it is not certain that this provision will be repealed or otherwise modified. If the requirement is not repealed or replaced, it could increase our U.S. federal and state cash taxes and reduce cash flows in 2023 and future years.</ix:continuation></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_169"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-849" continuedAt="ibf3f4d8a540747bfa8574bcefdb7a142" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibf3f4d8a540747bfa8574bcefdb7a142" continuedAt="i71f6cd795d4a49acb05c81702b692b05">In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan" format="ixt-sec:duryear" id="f-850">21</ix:nonNumeric> years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to <ix:nonFraction unitRef="number" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="f-851">100</ix:nonFraction>% of their salary, subject to government maximums.</ix:continuation></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i71f6cd795d4a49acb05c81702b692b05">Employees are <ix:nonFraction unitRef="number" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="INF" name="mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage" scale="-2" id="f-852">100</ix:nonFraction>% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. For the years ended December&#160;31, 2022, 2021 and 2020, the Company's contributions to the Plan totaled $<ix:nonFraction unitRef="usd" contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-853">2.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-854">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-855">1.4</ix:nonFraction> million, respectively.</ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i9064db26008e44ad995ee3ad48ef6721_172"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="f-856" continuedAt="ie5a80e866c014dd69dca718090ff7621" escape="true">Subsequent Event</ix:nonNumeric></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie5a80e866c014dd69dca718090ff7621" continuedAt="ibbc5cdeaf0d84734a32f2a60c4061c7c">In March 2023, the Company entered into a Purchase and Sale Agreement (Royalty Purchase Agreement) with DRI Healthcare Acquisitions LP (DRI), a wholly-owned subsidiary of DRI Healthcare Trust.  Under the Royalty Purchase Agreement, the Company sold its single-digit royalty interest on global net sales of TZIELD (teplizumab-mzwv) under the Provention Asset Purchase Agreement to DRI.  The Company retains its other economic interests related to TZIELD, including future potential regulatory and commercial milestones.</ix:continuation></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibbc5cdeaf0d84734a32f2a60c4061c7c">Under the terms of the Royalty Purchase Agreement, at the closing of the transaction, DRI paid the Company $<ix:nonFraction unitRef="usd" contextRef="ia220f44f166a475abc1053b676542ca5_I20230315" decimals="-5" name="mgnx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-857">100.0</ix:nonFraction> million for its single-digit royalty interest on global net sales of TZIELD. The Company will have the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, the Company may also receive up to $<ix:nonFraction unitRef="usd" contextRef="i3ec282a2b1564332bd9e83d00ada0da7_D20230301-20230331" decimals="-5" name="mgnx:FutureRevenue" format="ixt:num-dot-decimal" scale="6" id="f-858">50.0</ix:nonFraction> million from DRI upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed type 1 diabetes and transactions regarding TZIELD and Provention. The Company may also receive an additional $<ix:nonFraction unitRef="usd" contextRef="i3ec282a2b1564332bd9e83d00ada0da7_D20230301-20230331" decimals="-5" name="mgnx:FutureMilestone" format="ixt:num-dot-decimal" scale="6" id="f-859">50.0</ix:nonFraction> million milestone from DRI if TZIELD achieves a certain level of sales.</ix:continuation>   </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 32</span></div></div></div><div id="i9064db26008e44ad995ee3ad48ef6721_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restated Certificate of Incorporation of the Company and Certificate of Correction to the Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibits </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513402831/d613759dex31.htm">3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513402831/d613759dex33.htm">3.3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, respectively, to the Company's Current Report on Form 8-K filed on October 18, 2013)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000052/a8-k_bylawxamendmentxexx3x1.htm">Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36112) filed on April 2, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513394786/d575431dex42.htm">Specimen Stock Certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 9, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534521000035/mgnxexhibit4-2202010xk.htm">Description of Common Stock (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Annual Report on Form 10-K filed on February 25, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex1014.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000022/exhibit10-3201710xkfinal.htm">Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated October 24, 2017 (incorporated by reference to Exhibit 10.3 to the Company's Annual Report on Form 10-K filed on February 27, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513357191/d575431dex103.htm">Company 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513357191/d575431dex104.htm">Form of Incentive Stock Option Agreement under 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex105.htm">Company 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex106.htm">Form of Incentive Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex107.htm">Form of Nonstatutory Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534515000013/exhibit10-2.htm">Form of Restricted Stock Units Grant Notice under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on May 6, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000155278116002035/e00576_ex4-1.htm">2016 Employee Stock Purchase Plan (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-8 (File No. 333-214386) filed by the Company on November 2, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1014.htm">Employment Agreement between the Company and Scott Koenig, M.D., Ph.D. (incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K filed by the Company on February 29, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1015.htm">Employment Agreement between the Company and James Karrels (incorporated by reference to Exhibit 10.15 to the Company's Annual Report on Form 10-K filed by the Company on February 29, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000056/exhibit10-3.htm">Employment Agreement between the Company and Ezio Bonvini, M.D. (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on May 4, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534517000041/exhibit1016.htm">Employment Agreement between the Company and Eric Risser (incorporated by reference to Exhibit 10.16 to the Company's Annual Report on Form 10-K filed on February 28, 2017)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000060/exhibit101stepheneckemploy.htm">Employment Agreement between the Company and Stephen Eck, M.D. (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on April 29, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534522000047/ex101spitznagelemploymenta.htm">Employment Agreement between the Company and Thomas Spitznagel Ph.D. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 3, 2022)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">Amendment No, 1 to the Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated March 15, 2018 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">(incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on May 7, 201</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534522000090/exhibit101-incyte2ndamend.htm">Amendment No. 2 to the Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated April 7, 2022 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on August 8, 2022)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534522000104/exhibit101-incyte3rdamend.htm">Amendment No. 3 to the Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated April 7, 2022 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on November 3, 2022)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000035/exhibit1016incytecommercia.htm">Commercial Supply Agreement by and between Incyte Corporation and the Company, dated October 13, 2020 (incorporated by reference to Exhibit 10.16 to the Company&#8217;s Annual Report on Form 10-K filed on February 25, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000035/exhibit1017eversanaagreeme.htm">Product Commercialization Agreement by and between the Company and Eversana Life Science Services, LLC, dated November 13, 2020 (incorporated by reference to Exhibit 10.17 to the Company&#8217;s Annual Report on Form 10-K filed on February 25, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000099/exhibit102stckprchsagrmntz.htm">Stock Purchase Agreement by and between the Company and Zai Lab Limited, dated June 14, 2021 (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on July 29, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1022_gileadcollab.htm">Collaboration and License Agreement by and between the Company and Gilead Science</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1022_gileadcollab.htm">s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1022_gileadcollab.htm">, Inc., dated October 14, 2022</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1023_proventionapa.htm">Asset Purchase Agreement by and between the Company and Provention Bio, Inc., dated May 7, 2018</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1024_proventionapaamendme.htm">Amendment No. 1 to the Asset Purchase Agreement by and between the Company and Provention Bio, Inc., dated November 30, 2022</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1025_hqlease.htm">Lease by and between BMR-Medical Center Drive LLC and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1025_hqlease.htm">J. Craig Venter Institute, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1025_hqlease.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1025_hqlease.htm"> dated May 3, 2010</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1026_firstamendmenttohqle.htm">First Amendment to Lease by and between BMR-Medical Center Drive LLC and J. Craig Venter Institute, Inc. dated March 26, 2014</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1027_secondamendmenttohql.htm">Second Amendment to Lease by and between the Company and BMR-Medical Center Drive LLC, dated July 31, 2015</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1028_thirdamendmenttohqle.htm">Third Amendment to Lease by and between the Company and BMR-Medical Center Drive LLC, dated November 5, 2015</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1029_fourthamendmenttolea.htm">Fourth Amendment to Lease by and between the Company and BMR-Medical Center Drive LLC, dated July 21, 2017</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1030_fifthamendmenttohqle.htm">Fifth Amendment to Lease by and between the Company and ARE-Maryland No. 45, LLC, dated December 14, 2022</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1* </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit23-1202210xk.htm">Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit31-1202210xk.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit31-2202210xk.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit32-1202210xk.htm">Section 1350 Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit32-2202210xk.htm">Section 1350 Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Labels Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data (formatted as Inline XBRL and contained in Exhibit 101 filed herewith)</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment granted by the SEC.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">#&#160;&#160;&#160;&#160;Portions of this document (indicated by &#8220;[***]&#8221; have been omitted because they are not material and are the type that MacroGenics, Inc. treats as private and confidential.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>2
<FILENAME>a1022_gileadcollab.htm
<DESCRIPTION>EX-10.22
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia8200a142e8f47b98d8ec3ae131a117e_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 10.22</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY &#91;***&#93;) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:57.47pt;padding-right:57.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COLLABORATION AND LICENSE AGREEMENT</font></div><div><font><br></font></div><div style="margin-top:10.25pt;padding-left:231.25pt;padding-right:231.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:336%">between M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:336%">ACRO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:336%">G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:336%">ENICS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:336%">, I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:336%">NC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:336%">.</font></div><div style="padding-left:57.65pt;padding-right:57.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">and</font></div><div><font><br></font></div><div style="margin-top:10.3pt;padding-left:57.62pt;padding-right:57.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Sciences, Inc.</font></div><div><font><br></font></div><div style="margin-top:10.05pt;padding-left:57.6pt;padding-right:57.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">dated October 14, 2022</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_4"></div><hr style="page-break-after:always"><div style="min-height:28.08pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:57.57pt;padding-right:57.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="margin-top:0.1pt;padding-right:29.6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></div><div style="margin-top:0.05pt"><font><br></font></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_7"></div><div style="margin-top:4.5pt;padding-left:97pt;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;DEFINITIONS&#160;&#160;&#160;&#160;1</font></div><div style="margin-top:6.05pt;padding-left:97pt;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_28" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">OVERVIEW&#59; GOVERNANCE</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_28" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_28" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">26</a></font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_28" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Joint Steering Committee</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_28" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_28" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">26</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;Additional Subcommittees and Working Groups&#160;&#160;&#160;&#160;29</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;Alliance Managers&#160;&#160;&#160;&#160;29</font></div><div style="margin-top:6.05pt;padding-left:97pt;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">LICENSES</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">29</a></font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Licenses to Gilead</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">29</a></font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Licenses to MacroGenics</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">30</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Sublicensees</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">31</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.4&#160;&#160;&#160;&#160;Subcontractors&#160;&#160;&#160;&#160;32</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.5&#160;&#160;&#160;&#160;Retained Rights&#160;&#160;&#160;&#160;32</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6&#160;&#160;&#160;&#160;Sublicense under the MacroGenics Manufacturing In-Licenses&#160;&#160;&#160;&#160;32</font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7&#160;&#160;&#160;&#160;Existing Upstream License Agreements Amendments&#160;&#160;&#160;&#160;33</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.8&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">New Upstream License Agreements</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">33</a></font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.9&#160;&#160;&#160;&#160;Materials Transfer&#160;&#160;&#160;&#160;38</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.10&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Exclusivity</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">38</a></font></div><div style="margin-top:5.95pt;padding-left:97pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">CD123 DEVELOPMENT PROGRAM&#59; CD123 OPTION</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">39</a></font></div><div style="margin-top:6.1pt;padding-left:132.85pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1&#160;&#160;&#160;&#160;CD123 Development Plan&#160;&#160;&#160;&#160;39</font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2&#160;&#160;&#160;&#160;&#91;***&#93;&#160;&#160;&#160;&#160;39</font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3&#160;&#160;&#160;&#160;Conduct of the Phase 1 Clinical Trial of MGD024&#160;&#160;&#160;&#160;40</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4&#160;&#160;&#160;&#160;Performance Standards&#160;&#160;&#160;&#160;40</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.5&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Assumed CD123 Development Activities</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">40</a></font></div><div style="margin-top:6.1pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.6&#160;&#160;&#160;&#160;CD123 Development Program Costs&#160;&#160;&#160;&#160;41</font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.7&#160;&#160;&#160;&#160;Records&#59; Updates&#160;&#160;&#160;&#160;42</font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.8&#160;&#160;&#160;&#160;Data Ownership&#160;&#160;&#160;&#160;42</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.9&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">CD123 Option</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">42</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.10&#160;&#160;&#160;&#160;&#91;***&#93;&#160;&#160;&#160;&#160;43</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.11&#160;&#160;&#160;&#160;CD123 Development Term and Transfer of Development Activities&#160;&#160;&#160;&#160;44</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.12&#160;&#160;&#160;&#160;Technology Transfer&#160;&#160;&#160;&#160;44</font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.13&#160;&#160;&#160;&#160;CD123 Development Program Termination&#160;&#160;&#160;&#160;44</font></div><div style="margin-top:5.85pt;padding-left:97pt;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;RESEARCH TARGET NOMINATION&#59; RESEARCH PLANS&#59; LICENSED</font></div><div style="margin-top:0.05pt;padding-left:97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">RESEARCH TARGET COMBINATIONS&#160;&#160;&#160;&#160;45</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Research Target Nomination</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">45</a></font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2&#160;&#160;&#160;&#160;Research Program&#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:1pt;margin-top:12pt;padding-left:57.57pt;padding-right:57.57pt;text-align:center"><font><br></font></div><div style="height:71.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:28.08pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:1pt;margin-top:12pt;padding-left:57.57pt;padding-right:57.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="margin-top:3.95pt;padding-left:57.62pt;padding-right:57.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(continued)</font></div><div style="margin-top:12.1pt;padding-right:29.6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></div><div style="margin-top:11.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3&#160;&#160;&#160;&#160;Performance Standards&#160;&#160;&#160;&#160;47</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4&#160;&#160;&#160;&#160;Research Plan Costs&#160;&#160;&#160;&#160;47</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.5&#160;&#160;&#160;&#160;Research Term&#160;&#160;&#160;&#160;47</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6&#160;&#160;&#160;&#160;Records&#59; Updates&#160;&#160;&#160;&#160;48</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7&#160;&#160;&#160;&#160;Data Ownership&#160;&#160;&#160;&#160;48</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.8&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Research Program Opt-In</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">48</a></font></div><div style="margin-top:6.1pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.9&#160;&#160;&#160;&#160;Technology Transfer&#160;&#160;&#160;&#160;49</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.10&#160;&#160;&#160;&#160;Research Program Termination&#160;&#160;&#160;&#160;50</font></div><div style="margin-top:5.95pt;padding-left:97pt;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">GILEAD DEVELOPMENT</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">50</a></font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Antitrust Filings</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">50</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2&#160;&#160;&#160;&#160;CD123 Molecules and CD123 Products&#160;&#160;&#160;&#160;52</font></div><div style="margin-top:6.1pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.3&#160;&#160;&#160;&#160;Research Molecules and Research Products&#160;&#160;&#160;&#160;52</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4&#160;&#160;&#160;&#160;Performance Standards&#160;&#160;&#160;&#160;52</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.5&#160;&#160;&#160;&#160;Records&#160;&#160;&#160;&#160;52</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6&#160;&#160;&#160;&#160;Development Reporting&#160;&#160;&#160;&#160;53</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7&#160;&#160;&#160;&#160;Data Ownership&#160;&#160;&#160;&#160;53</font></div><div style="margin-top:6.1pt;padding-left:97pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">REGULATORY</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">53</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">CD123 Molecules and CD123 Products</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">53</a></font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2&#160;&#160;&#160;&#160;Research Molecules and Research Products&#160;&#160;&#160;&#160;54</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.3&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Transfer of Regulatory Materials</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">54</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4&#160;&#160;&#160;&#160;Right of Reference&#160;&#160;&#160;&#160;54</font></div><div style="margin-top:6.1pt;padding-left:132.85pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5&#160;&#160;&#160;&#160;Adverse Event Reporting&#59; Global Safety Database&#160;&#160;&#160;&#160;55</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.6&#160;&#160;&#160;&#160;Recalls&#160;&#160;&#160;&#160;55</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.7&#160;&#160;&#160;&#160;Conflict&#160;&#160;&#160;&#160;55</font></div><div style="margin-top:5.95pt;padding-left:97pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">COMMERCIALIZATION</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">55</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1&#160;&#160;&#160;&#160;Responsibility&#47;Diligence&#160;&#160;&#160;&#160;55</font></div><div style="margin-top:6.1pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.2&#160;&#160;&#160;&#160;Trademarks&#160;&#160;&#160;&#160;55</font></div><div style="margin-top:5.95pt;padding-left:97pt;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">MANUFACTURE AND SUPPLY</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">56</a></font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.1&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">MGD024 and MGD024 Products</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">56</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.2&#160;&#160;&#160;&#160;Research Molecules and Research Products&#160;&#160;&#160;&#160;57</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3&#160;&#160;&#160;&#160;Observation by Gilead&#160;&#160;&#160;&#160;57</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.4&#160;&#160;&#160;&#160;Manufacturing Technology Transfer&#160;&#160;&#160;&#160;58</font></div><div style="margin-top:12.05pt;padding-left:57.57pt;padding-right:57.57pt;text-align:center"><font><br></font></div><div style="height:71.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:28.08pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12.05pt;padding-left:57.57pt;padding-right:57.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="margin-bottom:11.55pt;margin-top:0.05pt;padding-left:57.62pt;padding-right:57.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(continued)</font></div><div style="margin-top:3.95pt;padding-left:507.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></div><div style="margin-top:11.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.5&#160;&#160;&#160;&#160;MacroGenics Manufacturing Support&#160;&#160;&#160;&#160;58</font></div><div style="margin-top:6.1pt;padding-left:96.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_34" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">PAYMENTS</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_34" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_34" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">59</a></font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1&#160;&#160;&#160;&#160;Upfront Payment&#160;&#160;&#160;&#160;59</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_34" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Development and Regulatory Milestone Payments</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_34" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_34" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">59</a></font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.3&#160;&#160;&#160;&#160;Commercial Milestone Payments&#160;&#160;&#160;&#160;61</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Royalties on Net Sales</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">61</a></font></div><div style="margin-top:6.05pt;padding-left:96.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">PAYMENTS&#59; REPORTS&#59; RECORDS&#59; AUDITS</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">63</a></font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.1&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Development Costs, Plan Costs and Manufacturing Costs</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">63</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Royalty Payments</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">64</a></font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.3&#160;&#160;&#160;&#160;Payment Exchange Rate&#160;&#160;&#160;&#160;64</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.4&#160;&#160;&#160;&#160;Taxes&#160;&#160;&#160;&#160;64</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.5&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Records</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">65</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.6&#160;&#160;&#160;&#160;Audit Rights&#160;&#160;&#160;&#160;65</font></div><div style="margin-top:6.1pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.7&#160;&#160;&#160;&#160;Confidentiality&#160;&#160;&#160;&#160;66</font></div><div style="margin-top:5.95pt;padding-left:96.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">CONFIDENTIALITY&#59; PUBLICATION</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">66</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Nondisclosure Obligation</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">66</a></font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Publication</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">69</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Publicity&#59; Use of Names</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">70</a></font></div><div style="margin-top:6.1pt;padding-left:96.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">COMPLIANCE</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">70</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.1&#160;&#160;&#160;&#160;General&#160;&#160;&#160;&#160;70</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.2&#160;&#160;&#160;&#160;Covenants, Representations and Warranties For Compliance with Laws&#160;&#160;&#160;&#160;71</font></div><div style="margin-top:6.05pt;padding-left:96.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">REPRESENTATIONS AND WARRANTIES</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">74</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1&#160;&#160;&#160;&#160;Representations and Warranties of MacroGenics&#160;&#160;&#160;&#160;74</font></div><div style="margin-top:6.1pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2&#160;&#160;&#160;&#160;Representations and Warranties of Gilead&#160;&#160;&#160;&#160;77</font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3&#160;&#160;&#160;&#160;Mutual Representations and Warranties&#160;&#160;&#160;&#160;78</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.4&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Covenant</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">78</a></font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.5&#160;&#160;&#160;&#160;No Other Representations or Warranties&#160;&#160;&#160;&#160;79</font></div><div style="margin-top:5.95pt;padding-left:96.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">INDEMNIFICATION</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">79</a></font></div><div style="margin-top:6.1pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1&#160;&#160;&#160;&#160;By Gilead&#160;&#160;&#160;&#160;79</font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2&#160;&#160;&#160;&#160;By MacroGenics&#160;&#160;&#160;&#160;80</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.3&#160;&#160;&#160;&#160;Indemnification Procedure&#160;&#160;&#160;&#160;80</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.4&#160;&#160;&#160;&#160;Settlement&#160;&#160;&#160;&#160;81</font></div><div style="margin-top:11.95pt;padding-left:57.57pt;padding-right:57.57pt;text-align:center"><font><br></font></div><div style="height:71.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:28.08pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11.95pt;padding-left:57.57pt;padding-right:57.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="margin-top:0.1pt;padding-left:57.62pt;padding-right:57.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(continued)</font></div><div style="margin-bottom:11.55pt;margin-top:12.05pt;padding-left:507.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></div><div style="margin-top:3.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.5&#160;&#160;&#160;&#160;Insurance&#160;&#160;&#160;&#160;81</font></div><div style="margin-top:6.1pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.6&#160;&#160;&#160;&#160;Limitation of Liability&#160;&#160;&#160;&#160;81</font></div><div style="margin-top:6pt;padding-left:96.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">INTELLECTUAL PROPERTY</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">81</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.1&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Ownership of Intellectual Property</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">81</a></font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.2&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_40" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Patent and Trademark Filing, Prosecution and Maintenance</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_40" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_40" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">83</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.3&#160;&#160;&#160;&#160;Patent Prosecution Cooperation&#160;&#160;&#160;&#160;85</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.4&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_43" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Enforcement</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_43" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_43" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">85</a></font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.5&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Defense</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">88</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.6&#160;&#160;&#160;&#160;Patent Listing&#160;&#160;&#160;&#160;89</font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.7&#160;&#160;&#160;&#160;Patent Term Extensions&#160;&#160;&#160;&#160;89</font></div><div style="margin-top:5.95pt;padding-left:96.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">DISPUTE RESOLUTION</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">89</a></font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.1&#160;&#160;&#160;&#160;Exclusive Dispute Resolution Mechanism&#160;&#160;&#160;&#160;89</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.2&#160;&#160;&#160;&#160;Resolution by Executive Officers&#160;&#160;&#160;&#160;89</font></div><div style="margin-top:6.1pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.3&#160;&#160;&#160;&#160;Expedited Arbitration for Incidental Payment Disputes&#160;&#160;&#160;&#160;90</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.4&#160;&#160;&#160;&#160;Jurisdiction&#59; Venue&#59; Service of Process&#160;&#160;&#160;&#160;90</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.5&#160;&#160;&#160;&#160;Governing Law&#160;&#160;&#160;&#160;91</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.6&#160;&#160;&#160;&#160;Waiver of Jury Trial&#160;&#160;&#160;&#160;91</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.7&#160;&#160;&#160;&#160;Equitable Relief&#160;&#160;&#160;&#160;91</font></div><div style="margin-top:6.1pt;padding-left:96.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">TERM AND TERMINATION</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">91</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.1&#160;&#160;&#160;&#160;Term&#160;&#160;&#160;&#160;91</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.2&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Termination for Material Breach</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">91</a></font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.3&#160;&#160;&#160;&#160;Termination for Convenience&#160;&#160;&#160;&#160;92</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.4&#160;&#160;&#160;&#160;Termination for Force Majeure&#160;&#160;&#160;&#160;92</font></div><div style="margin-top:6.1pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.5&#160;&#160;&#160;&#160;Termination for Bankruptcy&#160;&#160;&#160;&#160;92</font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.6&#160;&#160;&#160;&#160;Termination for Patent Challenge&#160;&#160;&#160;&#160;92</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.7&#160;&#160;&#160;&#160;Termination by Gilead for Safety Reasons&#160;&#160;&#160;&#160;93</font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.8&#160;&#160;&#160;&#160;Alternative Remedy in Lieu of Termination&#160;&#160;&#160;&#160;93</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.9&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Effects of Termination.</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">94</a></font></div><div style="margin-top:6.1pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.10&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Surviving Provisions</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">96</a></font></div><div style="margin-top:6pt;padding-left:96.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">MISCELLANEOUS</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">97</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.1&#160;&#160;&#160;&#160;Force Majeure&#160;&#160;&#160;&#160;97</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.2&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Standstill</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">97</a></font></div><div style="margin-top:11.95pt;padding-left:57.57pt;padding-right:57.57pt;text-align:center"><font><br></font></div><div style="height:71.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:28.08pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:11.95pt;padding-left:57.57pt;padding-right:57.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="margin-top:0.1pt;padding-left:57.62pt;padding-right:57.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(continued)</font></div><div style="margin-top:12.05pt;padding-right:29.6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></div><div style="margin-bottom:11.55pt;margin-top:11.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.3&#160;&#160;&#160;&#160;Section 365(n) of the Bankruptcy Code&#160;&#160;&#160;&#160;98</font></div><div style="margin-top:3.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.4&#160;&#160;&#160;&#160;<a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">Assignment&#59; Change of Control</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#ia8200a142e8f47b98d8ec3ae131a117e_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none">99</a></font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.5&#160;&#160;&#160;&#160;Severability&#160;&#160;&#160;&#160;100</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.6&#160;&#160;&#160;&#160;Notices&#160;&#160;&#160;&#160;100</font></div><div style="margin-top:6.1pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.7&#160;&#160;&#160;&#160;Applicable Intellectual Property Law&#47;Governing Law&#160;&#160;&#160;&#160;100</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.8&#160;&#160;&#160;&#160;Entire Agreement&#59; Amendments&#160;&#160;&#160;&#160;101</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.9&#160;&#160;&#160;&#160;Headings&#160;&#160;&#160;&#160;101</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.10&#160;&#160;&#160;&#160;Independent Contractors&#160;&#160;&#160;&#160;101</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.11&#160;&#160;&#160;&#160;No Third Party Beneficiary Rights&#160;&#160;&#160;&#160;101</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.12&#160;&#160;&#160;&#160;Performance by Affiliates&#160;&#160;&#160;&#160;101</font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.13&#160;&#160;&#160;&#160;Waiver&#160;&#160;&#160;&#160;101</font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.14&#160;&#160;&#160;&#160;Cumulative Remedies&#160;&#160;&#160;&#160;101</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.15&#160;&#160;&#160;&#160;Waiver of Rule of Construction&#160;&#160;&#160;&#160;101</font></div><div style="margin-top:6.05pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.16&#160;&#160;&#160;&#160;Counterparts&#160;&#160;&#160;&#160;101</font></div><div style="margin-top:6pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.17&#160;&#160;&#160;&#160;Further Assurances&#160;&#160;&#160;&#160;102</font></div><div style="margin-top:5.95pt;padding-left:132.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.18&#160;&#160;&#160;&#160;Construction&#160;&#160;&#160;&#160;102</font></div><div style="height:71.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_10"></div><hr style="page-break-after:always"><div style="min-height:28.08pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedules</font></div><div style="margin-top:0.45pt;padding-left:63pt"><font><br></font></div><div style="padding-left:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 1.72&#160;&#160;&#160;&#160;Knowledge Parties</font></div><div style="margin-top:0.1pt;padding-left:63pt;padding-right:246.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 1.80&#160;&#160;&#160;&#160;MacroGenics Licensed Patents </font></div><div style="padding-left:63pt;padding-right:246.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 1.86&#160;&#160;&#160;&#160;MacroGenics Platform</font></div><div style="padding-left:63pt;padding-right:222.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 1.88&#160;&#160;&#160;&#160;MacroGenics Platform Trademarks </font></div><div style="padding-left:63pt;padding-right:222.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 1.114</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:line-through"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 1.118</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 1.151&#160;&#160;&#160;&#160;Existing Upstream License Agreements</font></div><div style="margin-top:0.1pt;padding-left:63pt;padding-right:142.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 3.7&#160;&#160;&#160;&#160;Existing Upstream License Agreements Amendments </font></div><div style="padding-left:63pt;padding-right:142.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 4.1(a)&#160;&#160;&#160;&#160;CD123 Development Plan</font></div><div style="padding-left:63pt;padding-right:268.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 4.1(b)&#160;&#160;&#160;&#160;Clinical Protocol Synopsis </font></div><div style="padding-left:63pt;padding-right:268.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 5.2&#160;&#160;&#160;&#160;Research Plan</font></div><div style="padding-left:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 9.1(a)(i)&#160;&#160;&#160;&#160;Existing CMO Agreements</font></div><div style="margin-top:0.15pt;padding-left:63pt;padding-right:210pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 9.1(a)(iii)&#160;&#160;&#160;&#160; Clinical Supply Agreement Key Terms </font></div><div style="padding-left:63pt;padding-right:210pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 10.4(c)(iii)&#160;&#160;&#160;&#160;Special Offset and Indemnification Schedule 12.1(f)&#160;&#160;&#160;&#160;Third Party Confidential Information </font></div><div style="padding-left:63pt;padding-right:210pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 12.3(a)&#160;&#160;&#160;&#160;Press Release</font></div><div style="padding-left:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Schedule 14.1&#160;&#160;&#160;&#160;Exceptions to the Representations and Warranties of MacroGenics</font></div><div style="height:74.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_13"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:4pt;padding-left:462.2pt;padding-right:29.6pt;text-align:right;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Confidential Execution Copy</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:57.47pt;padding-right:57.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Collaboration and License Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), effective as of October 14, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), is entered into by and between MacroGenics, Inc., a Delaware corporation with a place of business at 9704 Medical Center Drive, Rockville, MD 20850 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and Gilead Sciences, Inc., a Delaware corporation with a place of business at 333 Lakeside Drive, Foster City, CA 94404 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). MacroGenics and Gilead may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:57.4pt;padding-right:57.4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:30pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Whereas, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics has expertise in, and platforms for, the discovery, development and commercialization of products for the treatment of patients with cancer&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Whereas, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics has discovered and is developing a proprietary program that includes a therapeutic bi-specific DART</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> molecule that is directed to each of CD3 and CD123 and is coded by MacroGenics as MGD024 (as further defined below), for the treatment of multiple hematologic malignancies&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Whereas, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">Gilead has expertise in the research, development and commercialization of pharmaceutical products&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Whereas, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics desires to grant, and Gilead desires to receive, an exclusive option, exercisable during a specified period, to obtain an exclusive license under the MacroGenics CD123 Technology for the development, commercialization and other exploitation of CD123 Molecules and CD123 Products, including MGD024, in the Field in the Territory (with each capitalized term as defined below), pursuant to the terms and conditions set forth in this Agreement&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Whereas, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Parties additionally desire to pursue up to two (2) collaborative research programs pursuant to which the Parties would identify, discover and develop bi-specific antibodies based on MacroGenics&#8217; proprietary DART</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and TRIDENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> platforms and targeting specified Research Target Combinations nominated by Gilead, all in accordance with a Research Plan for the given Research Program (with each capitalized term as defined below)&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Whereas, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics desires to grant to Gilead, and Gilead desires to receive, upon Gilead&#8217;s exercise of its Research Program Opt-In for a given Research Program, an exclusive license under the MacroGenics Research Technology to research, develop, commercialize and otherwise exploit Research Molecules and Research Products in the Field in the Territory (with each capitalized term as defined below), pursuant to the terms and conditions set forth in this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Now, Therefore, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">in consideration of the foregoing premises and the mutual covenants herein contained, the Parties hereby agree as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:57.57pt;padding-right:57.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AGREEMENT</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Unless specifically set forth to the contrary herein, the following capitalized terms, whether used in the singular or plural, shall have the respective meanings set forth below&#58;</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_16"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.1&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Accounting Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means, with respect to a Person, the International Financial Reporting Standards or GAAP, as applicable, as generally and consistently applied throughout such Person&#8217;s organization.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Acquirer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Third Party who acquires a Party through a Change of Control transaction and, as of immediately before such Change of Control transaction, any of such Third Party&#8217;s Affiliates.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:30.1pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.3&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means any claim, action, suit, arbitration, inquiry, audit, proceeding or investigation by or before, or otherwise involving, any governmental authority.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means with respect to any Party, any person or entity controlling, controlled by or under common control with such Party, for as long as such control exists. For purposes of this Section 1.4 (Affiliate), &#8220;control&#8221; means (a) in the case of a corporate entity, direct or indirect ownership of at least fifty percent (50%) or more of the stock or shares having the right to vote for the election of directors of such corporate entity and (b) in the case of an entity that is not a corporate entity, the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such entity, whether through the ownership of voting securities, by contract or otherwise.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the individual appointed by each Party from within their respective organization to coordinate and facilitate the communication, interaction and cooperation of the Parties pursuant to this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Allowable Overruns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, for a given Calendar Year, any FTE Costs or Out-of-Pocket Costs incurred by or on behalf of MacroGenics in the performance of activities under the CD123 Development Plan, a Research Plan or the Manufacturing Transition Plan, in each case, that are</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:60.95pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the U.S. Foreign Corrupt Practices Act, the U.S. Travel Act, the U.S. Anti-Kickback Statute, the UK Bribery Act 2010, and any other laws that prohibit the corrupt payment, offer, promise or authorization of the payment or transfer of anything of value (including gifts or entertainment), directly or indirectly, to any Government Official, commercial entity, or any other Person to obtain an improper business, in each case, as amended.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Antitrust Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Applicable Law and Regulations that are designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization, lessening of competition or restraint of trade, including the HSR Act.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Applicable Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all international, national, federal, state, regional, provincial, municipal and local government laws, rules, treaties (including tax treaties), and regulations that apply to either Party or to the conduct of any Development, Manufacturing or Commercialization activities or Regulatory Activities, in each case, under this Agreement including cGMP, GCP, GBPS, and the laws, rules and regulations of the ICH, the United States and any country in the applicable Territory, each as may be then in effect, as applicable and amended from time to time.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.10&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Biosimilar Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Licensed Product sold in a country, a product that&#58; (a) is marketed by a Third Party that has not obtained the rights to such product as a Sublicensee or distributor of, or through any other contractual relationship with, Gilead or any of its</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:30pt;text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Affiliates or Sublicensees&#59; and (b) has been granted Regulatory Approval as a biosimilar or interchangeable biological product by the applicable Regulatory Authority with such Licensed Product as the reference product, including any product authorized for sale in (i) the U.S. pursuant to an application under Section 351(k) of the US Public Health Service Act (42 U.S.C. &#167; 262(k)), as may be amended, or any subsequent or superseding law, statute or regulation and (ii) in any other country or jurisdiction pursuant to the equivalent of such provision.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.11&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Biologics License Application or New Drug Application (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) filed with the FDA for marketing approval of a Licensed Product or any successor applications or procedures, and all supplements and amendments that may be filed with respect to the foregoing, or similar filings with applicable Regulatory Authorities outside of the U.S., for approval to commercially market, import and sell a Licensed Product. The term BLA shall exclude Pricing and Reimbursement Approvals.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.12&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means a day on which banking institutions in Washington, DC and Foster City, California are open for business, excluding (a) any Saturday or Sunday, (b) December 26 through December 31 and (c) the seven (7) day period that begins on a Sunday and ends on a Saturday during which period July 4th occurs.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.13&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall end on the last day of the Term.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.14&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the respective periods of twelve (12) months commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the last day of the Term.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.15&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Cancer Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means an &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.16&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, individually or collectively, as the context requires, the &#91;***&#93; and the &#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.17&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Molecule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) MGD024 and (b) &#91;***&#93; that (i) is &#91;***&#93; or &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective Date or during the Term and (ii) &#91;***&#93;. For the avoidance of doubt, for purposes of this definition, a &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall include &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics&#8217; proprietary DART</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> platform or TRIDENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> platform.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.18&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Option Exercise Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) &#91;***&#93; with respect to the exercise of the CD123 Option during the &#91;***&#93;&#59; and (b) &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with respect to the exercise of the CD123 Option during the &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:60.95pt;padding-right:30pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.19&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, subject to Section 4.13 (CD123 Development Program Termination), any product that contains or incorporates a CD123 Molecule, alone or in combination with</font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:28.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">one (1) or more therapeutically active ingredients, including all forms, formulations, dosages and delivery modes thereof.</font></div><div><font><br></font></div><div style="padding-left:61pt;padding-right:29.8pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.20&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">cGCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the current standards, practices and procedures promulgated or endorsed by the FDA as set forth in the guidelines adopted by the ICH, titled &#8220;guidance for Industry E6 Good clinical Practice&#58; Consolidated Guidance,&#8221; (or any successor document) including related regulatory requirements imposed by the FDA and the equivalent legal requirements in other applicable jurisdictions, all as the same may be amended from time to time.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.21&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">cGMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means current Good Manufacturing Practices as set forth in the FDCA and the Public Health Service Act (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PHS Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and in applicable regulations, including 21 C.F.R. Parts 210, 211, 314 and 600, as in effect at the time when any Licensed Product is being manufactured for clinical development or commercial use, when any Licensed Product is being sold or when any clinical trial regarding a Licensed Product is being conducted, provided, and to the extent applicable to such clinical trial, as such regulations are interpreted and enforced by the FDA, including as set forth in applicable guidance documents issued by the FDA, and in accordance with applicable, generally accepted industry standards, and the equivalent legal requirements in other applicable jurisdictions, all as the same may be amended from time to time.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.22&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party, that&#58; (a) any Third Party acquires directly or indirectly the beneficial ownership of any voting security of such Party, or if the percentage ownership of such Third Party in the voting securities of such Party is increased through stock redemption, cancellation or other recapitalization, and immediately after such acquisition or increase such Third Party is, directly or indirectly, the beneficial owner of voting securities representing more than fifty percent (50%) of the total voting power of all of the then outstanding voting securities of such Party&#59; (b) a merger, consolidation, recapitalization, or reorganization of such Party is consummated that would result in stockholders or equity holders of such Party immediately prior to such transaction owning more than fifty percent (50%) of the outstanding securities of the surviving entity (or its parent entity) immediately following such transaction&#59; (c) the stockholders or equity holders of such Party approve a plan of complete liquidation of such Party, or an agreement for the sale or disposition by such Party of all or substantially of such Party&#8217;s assets, other than pursuant to the transaction described above or to an Affiliate&#59; or (d) the sale or transfer to a Third Party of (i) all or substantially all of such Party&#8217;s assets taken as a whole or (ii) a majority of such Party&#8217;s assets which relate to this Agreement, is effected. Notwithstanding the foregoing, the following will not constitute a Change of Control&#58; (i) a sale of capital stock to underwriters in an underwritten public offering of a Party&#8217;s capital stock solely for the purpose of financing, or (ii) the acquisition of securities of a Party by any Person or group of Persons that acquires such Party&#8217;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for such Party through the issuance of equity securities.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.23&#160;&#160;&#160;&#160;</font><font style="color:#323232;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#323232;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Study Report</font><font style="color:#323232;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Clinical Trial, a report containing the results of such Clinical Trial that is consistent in content and format with Applicable Laws and Regulations and with the guidelines of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) on Structure and Content of Clinical Study Reports.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.24&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means a Phase 1 Clinical Trial &#91;***&#93;, Phase 2 Clinical Trial, Phase 3 Clinical Trial, Pivotal Clinical Trial or Phase 4 Clinical Trial, as applicable.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.25&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Collaboration Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means, individually or collectively, as the context requires, the CD123 Development Term and each Research Term.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.26&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any single product comprising both (i) a Licensed Molecule and (ii) one or more other therapies or pharmaceutically active compounds or substances that is not a Licensed Molecule and, for &#91;***&#93;&#59; (b) any Licensed Product sold together with one or more other therapies or products that are not Licensed Products for a single invoice price&#59; or (c) any Licensed Product sold as part of a bundle with one or more other therapies, products or services that are not Licensed Products, where the sale of the Licensed Product is only available from the seller with the purchase of such other therapies, products or services, for a single invoice price, to the extent not described in clause (a) or (b). The Licensed Molecule or Licensed Product portion of any Combination Product, as applicable, shall be deemed the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensed Component</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and the other portion of such Combination Product shall be deemed the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Component</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, and each Combination Product shall be deemed a Licensed Product hereunder. For clarity, the co-administration of separate products comprising a Licensed Product containing a Licensed Molecule and no Other Component, on the one hand, with another therapy or pharmaceutically active compound or substance on the other hand shall either be (i) a Combination Product, if sold together as reflected in clause (b) or (c) or (ii) two separate products, one a Licensed Product and the other, a product that does not generate Net Sales under this Agreement.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.27&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means activities taken before or after obtaining Regulatory Approval relating specifically to the pre-launch, launch, promotion, marketing, sales force recruitment, sale and distribution of a pharmaceutical product and post-launch medical activities, including&#58; (a) distribution for commercial sale&#59; (b) strategic marketing, sales force, detailing, advertising, and market and product support&#59; (c) medical education and liaison and any Phase 4 Clinical Trials unless required as a condition for Regulatory Approval, to the extent permitted by this Agreement&#59; (d) all customer support and product distribution, invoicing and sales activities&#59; and (e) all post-approval regulatory activities, including those necessary to maintain Regulatory Approvals. For clarity, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; does not include Development or Manufacturing activities.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.28&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to the efforts to be expended by a Party with respect to any objective or activity under this Agreement, that measure of efforts and resources that is consistent with the efforts and resources used by pharmaceutical or biopharmaceutical companies, as applicable, of comparable size and resources to such Party for a similar biological or pharmaceutical product owned by it or to which it has rights, which product is at a similar stage in its development or product life and is of similar market potential taking into account all relevant factors, including efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product and the likelihood of Regulatory Approval given the regulatory structure involved. Commercially Reasonable Efforts will be determined on a country-by-country and indication-by-indication basis for the applicable Licensed Molecule or Licensed Product, and it is anticipated that the level of effort will change over time, reflecting changes in the status of such Licensed Molecule or Licensed Product (as applicable) and the market or country involved.</font></div><div><font><br></font></div><div style="padding-left:61pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.29&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Competing Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">means the &#91;***&#93; of any compound or product that (a) contains a molecule that &#91;***&#93; or (b) &#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.30&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Completion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means the &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">in either the &#91;***&#93;, as applicable.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:29.8pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.31&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compulsory License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Licensed Product in a country or territory, a license, or rights granted to a Third Party by a governmental agency within such country or territory to sell or offer for sale such Licensed Product in such country or territory under any Patents or Know-How</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:28.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">owned or controlled by either Party or its Affiliates, without direct or indirect authorization from such Party or its Affiliates.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.32&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compulsory Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Third Party granted a Compulsory License.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.33&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party, except as otherwise expressly provided in this Agreement, all information (including chemical or biological materials, chemical structures correspondence, customer lists, data, formulae, improvements, inventions, Know-How, processes, Regulatory Approvals, Regulatory Submissions and other regulatory filings, reports, strategies, techniques or other information) that is disclosed by or on behalf of such Party or any of its Affiliates to the other Party or any of its Affiliates pursuant to this Agreement or the Existing CDA, regardless of whether any of the foregoing are marked &#8220;confidential&#8221; or &#8220;proprietary&#8221; or communicated to the other Party by or on behalf of the Disclosing Party in oral, written, visual, graphic or electronic form. Without limiting the generality of the foregoing, and subject to the terms of Article 12 (Confidentiality&#59; Publication)&#58; (a) the existence and terms of this Agreement will be the Confidential Information of both Parties (and both Parties will be deemed to be the Disclosing Party and the Receiving Party with respect thereto), (b) &#91;***&#93; will be (i) the Confidential Information of &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(and &#91;***&#93; will be deemed to be the Disclosing Party and the Receiving Party with respect thereto), (ii) the Confidential Information of &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(and &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Disclosing Party with respect thereto) and (iii) the Confidential Information of &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(and &#91;***&#93; the Disclosing Party and &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Receiving Party with respect thereto), (c) &#91;***&#93; the Confidential Information &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(and &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Disclosing Party and the Receiving Party with respect thereto), (ii) the Confidential Information &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(and &#91;***&#93; the Disclosing Party with respect thereto) and (iii) the Confidential Information &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(and &#91;***&#93; Disclosing Party and &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Receiving Party with respect thereto) and (d) &#91;***&#93; the Confidential Information &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Disclosing Party with respect thereto). For clarity, if any Confidential Information of either &#91;***&#93; as applicable, is &#91;***&#93;, then such Confidential Information will remain the Confidential Information of such Party (and such Party will be deemed to be the Disclosing Party and the other Party will be the Receiving Party with respect thereto).</font></div><div><font><br></font></div><div style="padding-left:61pt;padding-right:29.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.34&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlled by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, subject to Section 3.8 (New Upstream License Agreements), with </font><font style="color:#323232;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">respect to (a) a product or component (including a molecule) thereof, the legal authority or right to grant a license, sublicense, access, or right to use (as applicable) to the other Party under Patents that Cover or proprietary Know-How that is incorporated in or embodies such product or component on the terms set forth herein </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or (b) any Patent, Know-How or other intellectual property right, the extent of the ability of a Party or its Affiliates, as applicable (whether through ownership or license, other than pursuant to this Agreement) to grant to the other Party or its Affiliates access to, or a license or sublicense of, such item or right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, in each case, a Party or any of its Affiliates shall be deemed not to &#8220;Control&#8221; any Patent, Know-How or other intellectual property right if such Patent, Know- How or other intellectual property right is owned or in-licensed by an Acquirer of a Party that becomes an</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:29.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Affiliate of such Party (or that merges or consolidates with such Party) on or after the Effective Date as a result of a Change of Control of such Party, except to the extent, and only to the extent that, such Patent, Know-How or other intellectual property right is either (a) actually used by such Party or its Affiliates, or the Acquirer, to Develop, Manufacture, Commercialize or otherwise Exploit the Licensed Molecules or Licensed Products following the consummation of such Change of Control or (b) made, conceived or reduced to practice by the Acquirer or its Affiliates through the use of, or reference to, any Patent, Know- How or other intellectual property right of such Party or (c) was Controlled by such Party or its Affiliates prior to the applicable Change of Control.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.35&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Covered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a product, technology, process or method, that, in the absence of possession of the right (by ownership, license or otherwise) under a Valid Claim, the practice or exploitation of such product, technology, process or method, in each case as applicable given the context, would infringe such Valid Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such Valid Claim if it were to issue as currently pending).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.36&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CPI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Consumer Price Index-Urban Wage Earners and Clerical Workers, U.S. City Average, All Items, 1982-1984&#61;100, published by the U.S. Department of Labor, Bureau of Labor Statistics (or its successor equivalent index) in the U.S.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.37&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Data Exclusivity Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the period, if any, during which the applicable Regulatory Authority (including the FDA) prohibits reference, without the consent of the owner of a BLA, to the clinical and other data that is contained in such BLA and that is not published or publicly available outside of such BLA.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.38&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Data Protection Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Applicable Law and Regulations relating to privacy, information security, cybersecurity, or data protection, including (a) the General Data Protection Regulation ((EU) 2016&#47;679) and any national implementing law relating to the Processing of personal data or the privacy or security of electronic communications, including the Privacy and Electronic Communications Directive (2002&#47;58&#47;EC) and the Privacy and Electronic Communications (EC Directive) Regulations 2003 (SI 2003&#47;2426) and (b) the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act adopted as part of the American Recovery and Reinvestment Act of 2009, and any regulations promulgated thereunder, and (c) FDA&#8217;s regulatory guidance pertaining to informed consent or cybersecurity requirements.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.39&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means research, discovery, and preclinical and clinical drug or biological development activities, including toxicology, statistical analysis, preclinical studies and Clinical Trials (but excluding Phase 4 Clinical Trials unless required as a condition for Regulatory Approval) and pre-approval regulatory activities, including those in support of other Development activities. For clarity, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; does not include Manufacturing or Commercialization activities.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.85pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.40&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any dispute, claim or controversy (other than matters that are within the decision-making authority of the JSC or a Party pursuant to Section 2.1(c) (Decision-Making), or are expressly stated herein to require the consent of both Parties or only one Party) arising from or related to this Agreement or to the interpretation, application, breach, termination or validity of this Agreement, including any claim of inducement of this Agreement by fraud or otherwise.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:133pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.41&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effector Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;&#58; (a) &#91;***&#93; (b) &#91;***&#93; or (c) such other &#91;***&#93;, in each case, &#91;***&#93;, as further described in Section 5.1(c) (&#91;***&#93;) (such &#91;***&#93; in subsection (c), an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Effector Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.42&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means, with respect to either Party, a senior executive designated by such Party for purposes of resolving Deadlocks at the JSC pursuant to Section 2.1(c) (Decision-Making) and Disputes pursuant to Section 17.2 (Resolution by Executive Officers).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.43&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Existing CDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means that certain Mutual Confidential Disclosure Agreement between the Parties, &#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.85pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.44&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exploit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exploitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means to research, develop, use, have used, sell, have sold, offer for sale, make, have made, distribute, import or otherwise exploit or have exploited.</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.45&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the United States Food and Drug Administration, or any successor agency</font></div><div style="margin-top:0.05pt;padding-left:60.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">thereto.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.46&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FDCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Federal Food, Drug and Cosmetic Act, as amended.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.47&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all uses.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.48&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Licensed Product, the first sale of a such Licensed Product by Gilead, its Affiliates or its Sublicensees to a Third Party for end use or consumption of such Licensed Product in a country after Regulatory Approval has been granted by the Regulatory Authority for such Licensed Product in such country. First Commercial Sale excludes transfers of Licensed Product to Third Parties as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">bona fide </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">samples, as donations, for the performance of Clinical Trials or for similar purposes in accordance with Applicable Law and Regulations pertaining to any expanded access program, any compassionate sales or use program (including named patient program or single patient program) or any indigent program.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.49&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Flotetuzumab</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means the therapeutic bi-specific molecule which binds to CD3 and CD123 and which is generated from MacroGenics&#8217; proprietary DART</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:117%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%"> platform, as further described in &#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.50&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93; of work devoted to or in direct support of specified Development or Manufacturing activities, conducted by one or more qualified employees or full-time contractors of a Party or its Affiliate. For clarity, any individual contributing less than &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">per Calendar Year (or equivalent pro-rata portion thereof for the period beginning on the Effective Date and ending on the last day of the first Calendar Year) shall be deemed a fraction of an FTE on a pro-rata basis. Overtime and work on weekends, holidays and the like will not be counted with any multiplier (e.g., time-and-a-half or double time) toward the number of hours that are used to calculate the FTE contribution. For the avoidance of doubt, no individual will count as more than one FTE for any year.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.51&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FTE Cost</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any period, activity and a Party or its Affiliate, the FTE Rate multiplied by the number of FTEs expended by such Party or its Affiliate in the conduct of such activity during such period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that the other Party shall not be charged more than once for any FTE Cost if such FTE Cost is already included as a component of other expenses payable under this Agreement.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.52&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a rate of &#91;***&#93; per FTE per Calendar Year, pro-rated &#91;***&#93;. The FTE Rate includes all wages and salaries, employee benefits, bonus, travel</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and entertainment, and other direct expenses expended in connection with an FTE&#8217;s performance of activities under this Agreement and excludes indirect allocations, including all general and administrative expenses, human resources, finance, occupancy and depreciation expended in connection with such FTE&#8217;s performance of activities under this Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.53&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Fully Burdened Manufacturing Cost</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to MGD024 or MGD024 Product, whether as active pharmaceutical ingredient or finished form, supplied by MacroGenics to Gilead pursuant to Section 9.1 (MGD024 and MGD024 Products)&#58; &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of&#58; (a) solely with respect to the MGD024 Drug Product (and, for clarity, neither the MGD024 Drug Substance nor any other component thereof), &#91;***&#93; in connection with the supply of MGD024 Drug Product (and, for clarity, not any component thereof),</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:line-through"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;&#59; (b) &#91;***&#93;, means&#58; (i) the direct cost of raw materials (including reagents and associated warehousing costs), packaging and labeling materials (including vials), labor (as measured by FTE Costs and Out-of-Pocket Costs for consultants, contractors and other personnel performing manufacturing or supply activities), (ii) the direct cost of any quality assurance and control activities (including required stability monitoring) for MGD024 or MGD024 Product, (iii) operating costs of equipment and facilities and (iv) shipping costs (including all duties and import fees, as applicable), in each case (i) through (iv), as reasonably incurred by MacroGenics in connection with and reasonably allocated to the Manufacture of MGD024 or MGD024 Products. In no case shall Fully Burdened Manufacturing Costs include any amounts incurred due to the gross negligence or willful misconduct of MacroGenics, its Affiliates or any Third Party. All components of Fully Burdened Manufacturing Costs shall be allocated on a basis consistent with GAAP and consistent with the cost accounting policy applied by MacroGenics to other similar products that it produces. For clarity, Fully Burdened Manufacturing Costs will not include any cost or expense already paid for by Gilead pursuant to this Agreement or any other agreement between the Parties or their Affiliates.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.54&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means U.S. generally accepted accounting principles.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.55&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GBPS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the General Biological Products Standards as set forth in 21 C.F.R. Part 610, to the extent applicable.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.56&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Good Clinical Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means current Good Clinical Practices as set forth in the Applicable Laws and Regulations, such as FDCA and the PHS Act and regulations set forth at 21</font></div><div style="padding-left:60.95pt;padding-right:29.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.F.R. Part 312, as well as (but not limited to) the requirements set forth in Directive 2001&#47;20&#47;EC of the European Parliament and of the Council of 4 April 2001 and Commission Directive 2005&#47;28&#47;EC of 8 April 2005, to the extent applicable to a clinical trial regarding any Licensed Product, as such obligations are interpreted and enforced by the applicable Regulatory Authority, and as interpreted under prevailing industry standards, including standards of medical ethics, applicable guidance documents issued by the FDA and any other Regulatory Authority, including ICH GCP, the informed consent requirements set forth in 21 C.F.R. Part 50 and the equivalent legal requirements in other applicable jurisdictions, the requirements relating to Institutional Review Boards set forth in 21 C.F.R. Part 56 and the equivalent legal requirements in other applicable jurisdictions, as the same may be amended from time to time.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.57&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Agent Improvement IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Gilead Agent Improvement Know-How and Gilead Agent Improvement Patents.</font></div><div><font><br></font></div><div style="padding-left:61pt;padding-right:29.7pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.58&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Know-How (excluding any Patent or Jointly Owned Know-How) Controlled by Gilead or any of its Affiliates as of the Effective Date or at any time during the Collaboration Term that is necessary for MacroGenics to perform its obligations under the CD123 Development Plan or a Research Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.59&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Patents (excluding any Jointly Owned Patent) Controlled by Gilead or any of its Affiliates as of the Effective Date or at any time during the Collaboration Term that are necessary for MacroGenics to perform its obligations under the CD123 Development Plan or a Research Plan.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.60&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Licensed Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Gilead Licensed Patents and the Gilead Licensed Know-How.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.61&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Good Laboratory Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Good Laboratory Practices, set forth in the Applicable Laws and Regulations that govern the conduct of non-clinical safety studies and which seek to ensure the quality, integrity and reliability of study data, including those set forth in 21 C.F.R. Part 58 and the equivalent legal requirements in other applicable jurisdictions, as the same may be amended from time to time.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.62&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Government Official</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any official, officer, employee, or representative of, or any Person acting in an official capacity for or on behalf of, any regional, federal, state, provincial, county, or municipal government or government department, agency, or other division, or any other Governmental Entity&#59; (b) any officer, employee, or representative of any commercial enterprise that is owned or controlled by a government, including any state-owned or controlled veterinary, laboratory, or medical facility&#59; (c) any officer, employee, or representative of any Governmental Entity&#59; (d) any political party or party official or candidate for political office&#59; (e) a Politically Exposed Person (PEP) as defined by the Financial Action Task Force (FATF), Groupe d&#8217;action Financi&#232;re sur le Blanchiment de Capitaux (GAFI)&#59; or (f) any person acting in an official capacity for any government or Governmental Entity, or other government entity, enterprise, or organization identified above.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.63&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governmental Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any&#58; (a) national, federal, state, county, local, municipal, foreign, or other government&#59; (b) governmental or quasigovernmental authority of any nature (including any agency, board, body, branch, bureau, commission, council, department, entity, governmental division, instrumentality, office, officer, official, organization, representative, subdivision, unit, or political subdivision of any government, entity, or organization described in the foregoing clauses (a) or (b), and any court or other tribunal)&#59; (c) public international or multinational governmental organization or body&#59; (d) entity or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military, or taxing authority or power of any nature (including any arbiter) or administrative functions of or pertaining to government&#59; (e) any company, business, enterprise, or other entity owned, in whole or in part, or controlled by any government, entity, organization, or other Person described in the foregoing clauses (a), (b), (c), or (d) of this definition&#59; or (f) any political party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.64&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">HSR Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (15 U.S.C.</font></div><div style="margin-top:0.05pt;padding-left:60.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#167; 18a).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.65&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the International Conference on Harmonisation.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.66&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an Investigational New Drug application, or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.67&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) with respect to solid tumors, any cancer with a particular organ of origin, &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or (b) with respect to non-solid tumors, &#91;***&#93;. For the sake of clarity, (i) &#91;***&#93;,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and regardless of prophylactic or therapeutic use, pediatric or adult use and irrespective of different formulation(s), dosage forms, dosage strengths or delivery system(s) used&#59; (ii) &#91;***&#93; Indication with respect to any Indication for which a Clinical Trial for such pharmaceutical or biological product had already been initiated or Regulatory Approval obtained and (iii) &#91;***&#93; for purposes of this Agreement &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:30.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.68&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Initiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means, with respect to a Clinical Trial of a Licensed Product &#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.69&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Internal Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an internal development program conducted by MacroGenics or its Affiliates that &#91;***&#93;.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.70&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Jointly Owned IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Jointly Owned Know-How and the Jointly Owned Patents.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.71&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any proprietary scientific or technical information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, including databases, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data (including pharmacological, medicinal chemistry, biological, chemical, biochemical, toxicological and clinical test data), analytical and quality control data, stability data, studies and procedures, and manufacturing process and development information, results and data, and (b) any proprietary biological, chemical or physical materials.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.72&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party, the actual knowledge of those Persons listed for such Party on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.72 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Knowledge Parties) after due inquiry.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.73&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensed Molecule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a CD123 Molecule or Research Molecule, as applicable.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.74&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a CD123 Product or Research Product, as applicable.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.75&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any new drug application or other similar marketing authorization application, in each case, filed with the applicable Regulatory Authority in a country or other regulatory jurisdiction, which application is required to commercially market or sell a pharmaceutical or biologic product in such country or jurisdiction (and any amendments thereto), including all BLAs submitted to the FDA in the United States in accordance with the FDCA with respect to a biologic or pharmaceutical product or any analogous application or submission with any Regulatory Authority outside of the United States.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.76&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics CD123 Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Know-How (excluding any Patents or Jointly Owned Know-How) that is Controlled by MacroGenics or any of its Affiliates as of the Effective Date or at any time during the Term that is necessary or reasonably useful to Exploit CD123 Molecules or CD123 Products in the Field in the Territory, including MacroGenics Platform Improvement Know-How.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.77&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;MacroGenics CD123 Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Patents (excluding any Jointly Owned Patents) that are Controlled by MacroGenics or any of its Affiliates as of the Effective Date or at any time during the Term that are necessary or reasonably useful to Exploit CD123 Molecules or CD123 Products in the Field in the Territory.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.78&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics CD123 Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the MacroGenics CD123 Patents and MacroGenics CD123 Know-How.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.79&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">MacroGenics Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means, individually or collectively, as the context requires, MacroGenics CD123 Know-How and MacroGenics Research Know-How.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.80&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Licensed Patent(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, individually or collectively, as the context requires, MacroGenics CD123 Patents and MacroGenics Research Patents. The MacroGenics Licensed Patents Controlled by MacroGenics or any of its Affiliates as of the Effective Date are listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule</font></div><div style="padding-left:61pt;padding-right:29.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.80 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(MacroGenics Licensed Patents) attached hereto&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that any failure of a Patent to be on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.80 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(MacroGenics Licensed Patents) either as of the Effective Date or during the Term shall not, in itself, indicate that such Patent is not a MacroGenics Licensed Patent hereunder. MacroGenics will update </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.80 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(MacroGenics Licensed Patents) &#91;***&#93;, until the CD123 Option Exercise Date (with respect to MacroGenics CD123 Patents) or the Research Program Opt- In Date (with respect to the applicable MacroGenics Research Patents).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.81&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Licensed Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the MacroGenics Licensed Patents and the MacroGenics Licensed Know-How.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.82&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Manufacturing Facilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.83&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">MacroGenics Manufacturing In-Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.84&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.85&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Multi-Product Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any MacroGenics Licensed Patent that Covers the &#91;***&#93; in the Territory, and</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:line-through"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;. The MacroGenics Multi-Product Patents as of the Effective Date are identified as &#8220;MacroGenics Multi-Product Patents&#8221; in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.80 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(MacroGenics Licensed Patents).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.86&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Platform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means MacroGenics&#8217; proprietary DART</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and TRIDENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> platforms regardless of application, each as further described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.86 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(MacroGenics Platform).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.87&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Platform Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a MacroGenics Licensed Patent that (a) Covers the MacroGenics Platform and (b) is not a MacroGenics Product-Specific Patent or a MacroGenics Multi- Product Patent. The MacroGenics Platform Patents as of the Effective Date are identified as &#8220;MacroGenics Platform Patents&#8221; in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.80 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(MacroGenics Licensed Patents).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.88&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Platform Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all Trademarks Controlled by MacroGenics or any of its Affiliates as of the Effective Date or at any time during the Term, that are registered for or apply solely to the MacroGenics Platform. The MacroGenics Platform Trademarks Controlled by MacroGenics or any of its Affiliates as of the Effective Date are listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.88 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(MacroGenics Platform Trademarks) attached hereto.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.89&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Product-Specific Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any MacroGenics Licensed Patent that &#91;***&#93; Covers the</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; in the Territory. The MacroGenics Product-Specific Patents as of the Effective Date are identified as &#8220;MacroGenics Product-Specific Patents&#8221; in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.80 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(MacroGenics Licensed Patents).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.90&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Research Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a given Research Program, any Know-How (excluding any Patents or Jointly Owned Know-How) that is Controlled by MacroGenics or any of its Affiliates as of the Effective Date or at any time during the Term that is necessary or reasonably useful to Exploit Research Molecules or Research Products in the Field in the Territory, including MacroGenics Platform Improvement Know-How.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.91&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Research Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a given Research Program, any Patents (excluding any Jointly Owned Patents) that are Controlled by MacroGenics or any of its Affiliates as of the Effective Date or at any time during the Term that are necessary or reasonably useful to Exploit Research Molecules or Research Products in the Field in the Territory in accordance with this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.92&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">MacroGenics Research Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means the MacroGenics Research Patents and MacroGenics Research Know-How.</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.93&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Major European Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.94&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Major Market Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.95&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all operations involved in the manufacturing (including process development activities, formulation activities, quality assurance and quality control testing (including test method development and in-process, release and stability testing, if applicable), storage, releasing, packaging and importation) to supply molecules and products for Development and Commercialization. For clarity, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; includes Packaging and Labeling and does not include Development or Commercialization activities.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.96&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the manufacturing process for (including any associated Know-How owned or Controlled by MacroGenics relating to the then-current process, and necessary or useful for) the Manufacture of the Licensed Molecules or the Licensed Products at the time of the Manufacturing Technology Transfer as more fully described in Section 9.4 (Manufacturing Technology Transfer) and as further developed under this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.97&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Related Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means those manufacturing-related activities specifically related to a given batch of MGD024 Product that are not included in the Fully Burdened</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:29.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Manufacturing Costs, including manufacturing process development and validation, process improvements, formulation development, associated analytical development and validation and the manufacture and testing of stability and consistency lots (including process development, qualification, and test batches) and reference standards stability testing (including related costs of reference standards), shipment and such other commercially reasonable activities.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.98&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">MGD024</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means the therapeutic bi-specific molecule which is directed to each of CD3 and CD123 and which is generated from MacroGenics&#8217; proprietary DART</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:117%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%"> platform, as further described &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.99&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MGD024 Drug Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the MGD024 Drug Substance in its final finished form and separated into unlabeled vials (unless the Parties agree that MacroGenics shall provide MGD024 Drug Product in labeled vials).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.100&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">MGD024 Drug Substance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means the bulk drug substance for MGD024 for use as an active pharmaceutical ingredient in the MGD024 Drug Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.101&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">MGD024 Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means, subject to Section 4.13 (CD123 Development Program Termination), any product that contains or incorporates MGD024, alone or in combination with one (1) or more therapeutically active ingredients, including all forms, formulations, dosages, and delivery modes thereof (which, for clarity, shall include MGD024 Drug Product).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.102&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the CD123 Development Milestone Payments, the Research Product Development Milestone Payments and the Commercial Milestone Payments.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.103&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means the gross amount invoiced by Gilead or its Related Parties for the sale of a Licensed Product to a Third Party (other than a Related Party) after deducting, if not previously deducted from the amount invoiced, the following&#58;</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.95pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;normal and customary trade, cash, and quantity discounts, allowances, and credits allowed or paid, in the form of deductions actually allowed with respect to sales of Licensed Product&#59;</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:30.05pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;retroactive price reductions, allowances, or credits actually granted upon rejections or returns of Licensed Product, including for recalls or damaged good and billing errors&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;discounts, chargeback payments, rebates, and reimbursements granted to wholesalers or other distributors, pharmacies and other retailers, managed care organizations, group purchasing organizations, or other buying groups, pharmacy benefit management companies, health maintenance organizations, federal, state, provincial, local, or other governments, and any other providers for health insurance coverage, health care organizations, or other health care institutions (including hospitals), health care administrators, or patient assistance or other similar programs&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;compulsory payments and cash rebates related to the sales of such Licensed Products paid to a governmental authority (or agent thereof) pursuant to governmental regulations by reason of any national or local health insurance program or similar program, including required chargebacks and retroactive price reductions, to the extent allowed and taken, including government levied fees as a result of healthcare reform policies, to the extent such fees are specially allocated to sales of such Licensed Product as a percentage of Gilead&#8217;s entire pharmaceutical or biological product sales&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.95pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;costs and expenses (including labor) related to storage and distribution of Licensed Product, including (i) handling and transportation to fulfill orders, (ii) customer services, including order</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:29.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">entry, billing and adjustments, inquiry and credit, and collection, (iii) cost of facilities and labor utilized for the storage or distribution of the Licensed Product, or (iv) amounts paid to Third Parties in respect of the storage or distribution of Licensed Product&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;tariffs, duties, levies, and other similar governmental charges (including goods and services Tax) actually paid in connection with the transportation, distribution, use, or sale of Licensed Product (other than income taxes, franchise taxes, or similar taxes)&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">(g)&#160;&#160;&#160;&#160;other similar and customary deductions which are in accordance with applicable Accounting Standard&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;amounts invoiced for sales of Licensed Product that are written off as uncollectible after reasonable collection efforts&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that any recovery of such amounts will be included in Net Sales.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Such amounts shall be determined from the books and records of Gilead or its Related Party, maintained in accordance with such Person&#8217;s applicable Accounting Standards. Gilead further agrees, in determining such amounts, it shall use Gilead&#8217;s then-current standard procedures and methodology, including Gilead&#8217;s then-current standard exchange rate methodology for the translation of foreign currency sales into US Dollars or, in the case of Sublicensees, such similar methodology, consistently applied. Without limiting the generality of the foregoing, transfers or dispositions of Licensed Product for charitable, compassionate use, promotional (including samples, in amounts reasonably customary in the industry), non-clinical, clinical, or regulatory purposes shall be excluded from Net Sales, as will sales or transfers of Licensed Product among a Party and its Related Parties, unless such Party or Related Party is the end user of such Licensed Product, but rather the Net Sales shall be deemed to have arisen upon the subsequent sale or transfer of Licensed Product to Third Parties.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:30pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">Net Sales will exclude amounts invoiced for Licensed Products or Combination Products, as applicable, by any Compulsory Licensee pursuant to a Compulsory License or any Settlement Sublicensee pursuant to the applicable settlement agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If Gilead or any of its Related Parties sells a Licensed Product as a Licensed Component of a Combination Product in a country in the Territory in any Calendar Quarter, then Net Sales shall be calculated by multiplying the Net Sales of the Combination Product during such Calendar Quarter by the fraction A&#47;(A+B), where A is the average Net Sales per unit sold of the Licensed Component when sold separately in such country during such Calendar Quarter (calculated by determining the Net Sales of the Licensed Component during such Calendar Quarter in accordance with the definition of Net Sales set forth herein and dividing such Net Sales by the number of units of the Licensed Component during such Calendar Quarter) and B is the average Net Sales per unit sold of the Other Component(s) included in the Combination Product when sold separately in such country during such Calendar Quarter (calculated by determining the Net Sales of such Other Component(s) sold during such Calendar Quarter by applying the definition of Net Sales set forth herein as if it applied to sales of such Other Component(s) and dividing such Net Sales by the number of units of such Other Component(s) sold during such Calendar Quarter).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of calculating the average Net Sales per unit sold of a Licensed Component and Other Component(s) of a Combination Product, any of the deductions described herein that apply to such Combination Product shall be allocated among sales of the Licensed Component and sales of the Other Component(s) included in such Combination Product as follows&#58; (i) deductions that are attributable solely to the Licensed Component or one of the Other Component(s) shall be allocated solely to Net Sales of the Licensed Component or such Other Component, as applicable, and (ii) all other deductions shall be allocated among sales of the Licensed Component and sales of the Other Component(s) in proportion to</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:28.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gilead&#8217;s and MacroGenics&#8217; mutual agreement based on a good faith assessment of the fair market value of the Licensed Component and the Other Component(s).</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:30pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that no separate sales of the Licensed Component or any Other Component(s) included in a Combination Product are made by Gilead or its Related Parties during a Calendar Quarter in which such Combination Product is sold, the average Net Sales per unit sold shall be determined by mutual agreement of the Parties in good faith based on the relative economic value contributions of the Licensed Component and each of the Other Component(s) included in such Combination Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.104&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Option Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:30pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.105&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, individually or collectively, as the context requires, &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.106&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Other MacroGenics Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means any MacroGenics Licensed Patents that &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.107&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Out-of-Pocket Costs&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means, with respect to certain activities hereunder, direct expenses actually paid by a Party or its Affiliates to Third Parties and specifically identifiable and incurred to conduct such activities, but excluding any costs included in the FTE Rate.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.108&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Packaging and Labeling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means primary, secondary or tertiary packaging and labeling of a product (in its commercial or clinical packaging presentation) for sale or use and all testing and release thereof.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.109&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means with respect to a Patent, the responsibility for (a) preparing, filing, prosecuting, and pursuing registration of, applications (of all types) for such Patent, (b) maintaining such Patent, and (c) managing any initiation or defense of interference or opposition proceeding relating to the foregoing, including inter partes review, derivations, re-examinations, post-grant proceedings and other similar proceedings (or other defense proceedings with respect to such Patent, but excluding the defense of challenges to such Patent as a counterclaim in an infringement proceeding).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.110&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) all patents and patent applications in any country, region or supranational jurisdiction and (b) any provisionals, substitutions, divisions, continuations, continuations in part, reissues, renewals, registrations, confirmations, reexaminations, extensions, supplementary protection certificates and the like, of any such patents or patent applications.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.111&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.85pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.112&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phase 1 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a human clinical trial, or the relevant portion of such trial, of a Licensed Product conducted in patients in any country in the Territory in accordance with GCP that generally provides for the first introduction into humans of a Licensed Product and intended to determine safety, metabolism and pharmacokinetic properties and clinical pharmacology of such Licensed Product in healthy patients, or that would otherwise satisfy the requirements of Applicable Laws and Regulations for such country in which such human clinical trial is conducted, such as 21 C.F.R. &#167; 312.21(a), relating to</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">human clinical trials conducted in the United States, or any successor regulation thereto or foreign equivalents.</font></div><div><font><br></font></div><div style="padding-left:61pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.113&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.114&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a written report containing all available clinical data obtained from the performance of the Phase 1 Clinical Trial of MGD024 Product in accordance with the CD123 Development Plan &#91;***&#93;. Without limiting the foregoing, the &#91;***&#93; will include all of the information set forth on &#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.115&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means the period commencing upon the Effective Date and ending upon &#91;***&#93; after the date of delivery of a complete &#91;***&#93; in accordance with Section 4.9(c) (CD123 Data Package).</font></div><div><font><br></font></div><div style="padding-left:61pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.116&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:30pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.117&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.118&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a written report containing all available clinical data obtained from the performance of the Phase 1 Clinical Trial of MGD024 Product in accordance with the CD123 Development Plan &#91;***&#93;. Without limiting the foregoing, the &#91;***&#93; will include all of the information set forth on</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.119&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means the period commencing upon the expiration of the &#91;***&#93; in accordance with Section 4.9(c) (CD123 Data Package).</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:29.8pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.120&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phase 2 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a human clinical trial, or the relevant portion of such trial, of a Licensed Product, conducted in patients in any country in the Territory in accordance with GCP and intended to demonstrate efficacy and a level of safety in the particular Indication tested, as well as to obtain a preliminary Indication of the unit or daily dosage regimen required, or that would otherwise satisfy the requirements of Applicable Laws and Regulations of the country in which such human clinical trial is conducted, such as 21 C.F.R. &#167; 312.21(b), relating to human clinical trials conducted in the United States, or any successor regulation thereto or foreign equivalents. For clarity, a Phase 1 Clinical Trial with an expansion cohort of patients that meets the descriptions or otherwise satisfies the requirements in the foregoing shall be deemed a Phase 2 Clinical Trial.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.121&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phase 3 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a human clinical trial, or the relevant portion of such trial, of a Licensed Product, conducted in patients in any country in the Territory in accordance with GCPs and the results of which are intended to be used as a pivotal study to establish both safety and efficacy of such Licensed Product as a basis for a BLA submitted to the FDA or the appropriate Regulatory Authority of such country, or that would otherwise satisfy the requirements of 21 C.F.R. &#167; 312.21(c), or any successor regulation thereto or foreign equivalents.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.122&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phase 4 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a human clinical trial conducted after the Regulatory Approval of a Licensed Product in a country, which trial is conducted (a) voluntarily to enhance scientific knowledge of such Licensed Product (e.g., for expansion of product labeling or dose optimization)&#59; or (b) due to a request or requirement of a Regulatory Authority of such country.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.123&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pivotal Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) a Phase 3 Clinical Trial or other human Clinical Trial designed to be or that becomes a registration trial sufficient for filing a BLA for a Licensed Product, as evidenced by a formal agreement with or statement from the FDA or applicable Regulatory Authority, or</font></div><div style="padding-left:60.95pt;padding-right:30.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b) a Phase 3 Clinical Trial or other human Clinical Trial which Gilead intends to submit as the basis for Regulatory Approval of the Licensed Product. For clarity, the determination of whether a given Clinical Trial is sufficient for registrational purposes to support the filing of a BLA for a given Licensed Product may be made prior to, or any time after, Initiation of such Pivotal Clinical Trial.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.124&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pricing and Reimbursement Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, in a country in which Regulatory Authorities authorize reimbursement for, or approve or determine pricing for, pharmaceutical or biologic products to be marketed and sold or reimbursed in such country, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization or pricing approval or determination (as the case may be).</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.125&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Processing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Processed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any operation or set of operations performed upon personal data or sets of personal data, whether or not by automated means, such as collection, recording, organization, structuring, storage, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, alignment or combination, restriction, erasure or destruction.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.95pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.126&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the CD123 Development Program or a given Research Program, as applicable.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.127&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a given Licensed Product, all regulatory activities required to obtain or maintain Regulatory Approval of such Licensed Product in the Field in the Territory, including&#58; (a) preparing, obtaining and maintaining all Regulatory Submissions and Regulatory Approvals for such Licensed Product&#59; and (b) conducting communications and interactions with the relevant Regulatory Authorities for such Licensed Product.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.128&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a particular country or other regulatory jurisdiction, any approval of a BLA or other MAA from the applicable Regulatory Authority necessary for the commercial marketing or sale of a pharmaceutical or biologic product in such country or other regulatory jurisdiction, including, in each case, Pricing and Reimbursement Approval in those countries and jurisdictions where required.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.129&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means any applicable government regulatory authority involved in granting approvals for the conduct of clinical trials or the manufacturing, marketing, reimbursement or pricing, as applicable, of a Licensed Product, including the FDA and any successor governmental authority having substantially the same function.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.130&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Submissions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any filing, application, or submission with any Regulatory Authority, including authorizations, approvals or clearances arising from the foregoing, including INDs, BLAs, NDAs, and Regulatory Approvals, and all correspondence or communication with or from the relevant Regulatory Authority, as well as minutes of any material meetings, telephone conferences or discussions with the relevant Regulatory Authority, in each case, with respect to a Licensed Product.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.131&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Related Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party, its Affiliates and their respective Sublicensees.</font></div><div><font><br></font></div><div style="padding-left:61pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.132&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.133&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Molecule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Research Program, &#91;***&#93; and (b) is directed to each of the Cancer Target and Effector Target in the Research Target Combination for such Research Program. For the avoidance of doubt, for purposes of this definition, &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that is generated from MacroGenics&#8217; proprietary DART</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> platform or TRIDENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> platform.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.134&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, subject to Section 5.10 (Research Program Termination), any product that contains or incorporates a Research Molecule, alone or in combination with one (1) or more therapeutically active ingredients, including all forms, formulations, dosages and delivery modes thereof.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.135&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a given Research Program, a written report containing all relevant information and data from the performance of the activities under the Research Plan for such Research Program, &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research Molecules and Research Products that are the subject of such Research Program.</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.136&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Opt-In Exercise Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.137&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Bearing Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) a Jointly Owned Patent or (b) a MacroGenics Licensed Patent&#59; &#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.138&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, on a Licensed Product-by-Licensed Product and country-by- country basis, the time period beginning on the First Commercial Sale of a Licensed Product in a country and expiring on the latest of the following dates&#58; (a) the &#91;***&#93; of the date of First Commercial Sale of such Licensed Product in such country, (b) the expiration of the last-to-expire Royalty Bearing Patent having a Valid Claim Covering the composition of matter or method of use of such Licensed Product in the applicable country, or (c) the expiration of the last-to-expire Data Exclusivity Period for such Licensed Product in such country.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.139&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Settlement Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means a Third Party that is granted a license or sublicense under a settlement agreement between such Third Party and a Party, any of its Affiliates, or any of its or their respective licensees or sublicensees, which agreement was entered into in connection with any settlement or similar agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.140&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means a Third Party to whom a Party or any of its Affiliates grants a sublicense under the licenses granted to such Party under this Agreement, as permitted herein, excluding all Permitted Subcontractors.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.141&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Terminated Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any Licensed Product with respect to which this Agreement is terminated pursuant to Article 18 (Term and Termination), and (b) in the event of termination of this Agreement in its entirety, all Licensed Products.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.142&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Terminated Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any Program with respect to which this Agreement is terminated pursuant to Article 18 (Term and Termination), and (b) in the event of termination of this Agreement in its entirety, all Programs.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.143&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all countries and regions of the world.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.144&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an entity other than (a) Gilead and its Affiliates and (b) MacroGenics and its Affiliates.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.145&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means collectively, any and all Third Party demands, claims, actions, suits, and proceedings (whether criminal or civil or in contract, tort, or otherwise).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.146&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Distributor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Third Party that purchases Licensed Product from Gilead or its Affiliates or Sublicensees, takes title to such Licensed Product, and distributes such Licensed Product directly to customers, but does not Develop, Manufacture or otherwise Commercialize any Licensed Product and does not make any upfront, milestone, royalty, profit-share or other payment to Gilead or its Affiliates or Sublicensees, other than payment for the purchase of Licensed Products for resale.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.147&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all trade names, logos, common law trademarks and service marks, trademark and service mark registrations and applications throughout the world.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.148&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trademark Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Trademark, the responsibility for (a) preparing, filing, and seeking registration of, trademark applications (of all types) for such Trademark, (b) maintaining such Trademark, and (c) managing any interference or opposition proceeding relating to the foregoing.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.149&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unavailable Target Combination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to &#91;***&#93;</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.150&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">US</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the United States of America and its territories and possessions, including the Commonwealth of Puerto Rico and the U.S. Virgin Islands.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div></td></tr></table></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_19"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.151  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Upstream License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any contract or agreement with a Third Party pursuant to which MacroGenics in-licenses or otherwise acquires Control of Patents, Know-How or other intellectual property rights that constitute MacroGenics Licensed Technology for purposes of this Agreement, including such Upstream License Agreements set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.151 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Existing Upstream License Agreements) (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Existing Upstream License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.152&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">US Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means United States Dollars, the lawful currency of the US.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.153&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a claim of&#58; (a) an issued and unexpired Patent in a country which has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and has not been abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise&#59; or (b) a pending patent application that has been filed in good faith and that has not been cancelled, withdrawn, or abandoned and has not been pending for more than &#91;***&#93; from the earliest priority date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, if a claim ceases to be a Valid Claim by reason of the foregoing subclause (b), then such claim shall again be deemed a Valid Claim in the event and at the time such claim subsequently issues.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.154&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Additional Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each of the following terms has the meaning described in the corresponding section of this Agreement indicated below&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:64pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.542%"><tr><td style="width:1.0%"></td><td style="width:41.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#9cc1e4;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Definition</font></td><td colspan="3" style="background-color:#9cc1e4;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13D Group</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 19.2(a)(iii) (Standstill)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Acquired Party</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 3.10(c) (Business Combinations)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Acting Improperly</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 13.2(a)(i) (Anti-Corruption Laws)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Antitrust Filing</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 6.1(a) (Filings)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Assigned Regulatory Materials</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 7.3(a) (Regulatory Transfer)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Assumed CD123 Development Activities</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.5(a) (Conditions for Assumption)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Bankrupt Party</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 18.5 (Termination for Bankruptcy)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Bankruptcy Events</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 18.5 (Termination for Bankruptcy)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Breaching Party</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 18.2(a) (Material Breach)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Clinical Subcommittee</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 2.2 (Additional Subcommittees and Working Groups)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123&#160;&#160;&#160;&#160;Development&#160;&#160;&#160;&#160;Activities&#160;&#160;&#160;&#160;Cure Period</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.5(a) (Conditions for Assumption)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Milestone Event</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 10.2(a) (CD123 Products)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Milestone Payment</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 10.2(a) (CD123 Products)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.1 (CD123 Development Plan)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Program</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.1 (CD123 Development Plan)</font></div></td></tr></table></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div></td></tr></table></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_22"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:64pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.542%"><tr><td style="width:1.0%"></td><td style="width:41.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#9cc1e4;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Definition</font></td><td colspan="3" style="background-color:#9cc1e4;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Term</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.11 (CD123 Development Term and Transfer of Development Activities)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Option</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.9(a) (Option Grant)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Option Effective Date</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:5.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">Section&#160;&#160;&#160;&#160;6.1(b)(i)&#160;&#160;&#160;&#160;(CD123&#160;&#160;&#160;&#160;Development&#160;&#160;&#160;&#160;Program Effectiveness)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Option Exercise Date</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.9(e) (Option Exercise)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Option Exercise Notice</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.9(e) (Option Exercise)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Technology Transfer Period</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.12 (Technology Transfer)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Technology Transfer Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.12 (Technology Transfer)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Quality Agreement</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 9.1(a)(iii) (Clinical Supply Agreement)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Supply Agreement</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 9.1(a)(iii) (Clinical Supply Agreement)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Supply Term</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 9.1(a)(ii) (During the Clinical Supply Term)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CMO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 9.3 (Observation by Gilead)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Milestone Event</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 10.3 (Commercial Milestone Payments)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Milestone Payment</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 10.3 (Commercial Milestone Payments)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Competitive Product</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 3.10(c) (Business Combinations)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confirmed Research Target Combination</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.1(c) (Confirmed Research Target Combinations)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Deadlock</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 2.1(c) (Decision-Making)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Deficiency Notice</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.9(c) (CD123 Data Package)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Disclosing Party</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 12.1(a) (Definition and Restrictions)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Enforcement Effort</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">Section 16.4(b)(i) (MacroGenics Platform Patents and Other MacroGenics Licensed Patents)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exchange Act</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 19.2(a)(i) (Standstill)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excused Delay</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.2(a) (Excused Delays)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Existing CMO Agreements</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 9.1(a)(i) (Prior to the CD123 Option Effective Date)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Existing Upstream License Agreement</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 1.151 (Upstream License Agreement)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Existing Upstream License Agreement Amendments</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 3.7 (Existing Upstream License Agreement Amendments)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Export Control Laws</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 13.2(d) (Export Control Laws)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Extrapolated Net Sales</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 16.4(c)(ii) (Recovery Allocations)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Force Majeure</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 19.1 (Force Majeure)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gatekeeper</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.1(b) (Gatekeeper)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preamble</font></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:64pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.542%"><tr><td style="width:1.0%"></td><td style="width:41.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#9cc1e4;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Definition</font></td><td colspan="3" style="background-color:#9cc1e4;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Agent Improvement Know-How</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 16.1(d) (Gilead Agent Improvement IP)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Agent Improvement Patents</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 16.1(d) (Gilead Agent Improvement IP)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead CD123 Development Activities</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.1 (CD123 Development Plan)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Indemnitee(s)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 15.2 (By MacroGenics)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ICC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 17.3 (Expedited Arbitration for Incidental Payment Disputes)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Identified Patent</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 10.4(c)(iii) (Special Offset and Indemnification)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Identified Patent Rights</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 10.4(c)(iii) (Special Offset and Indemnification)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Identified Patent Upstream License</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 10.4(c)(iii) (Special Offset and Indemnification)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Improvement Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 13.2(a)(iii)(1) (Anti-Corruption Laws)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Incidental Payment Disputes</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 17.2 (Resolution by Executive Officers)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Party</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 15.3 (Indemnification Procedure)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnifying Party</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 15.3 (Indemnification Procedure)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Initial CD123 Development Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.1 (CD123 Development Plan)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Initial Outside Date</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 6.1(c) (Outside Date)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Involved Party</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 19.3 (Section 365(n) of the Bankruptcy Code)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IP Assessment</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.5 (Research Term)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IP Counsels</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 3.8(a)(iii) (Third Party Platform Rights Dispute)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint CD123 Development Activities</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.1 (CD123 Development Plan)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Steering Committee </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JSC</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 2.1(a) (Membership)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Jointly Owned Know-How</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 16.1(e) (Jointly Owned IP)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Jointly Owned Patents</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 16.1(e) (Jointly Owned IP)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JSC Co-Chairperson</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 2.1(a) (Membership)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensed Research Target Combination</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.2 (Research Program)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Losses</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 15.1 (By Gilead)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt;padding-right:29.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics CD123 Development Activities</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.1 (CD123 Development Plan)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Identified Rights</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 3.8(b)(i) (Notice of MacroGenics Identified Rights)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Indemnitee(s)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 15.1 (By Gilead)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Negotiation Period</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 3.8(a)(i) (Notice of Third Party Platform Rights)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.542%"><tr><td style="width:1.0%"></td><td style="width:41.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#9cc1e4;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Definition</font></td><td colspan="3" style="background-color:#9cc1e4;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt;padding-right:29.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Platform Improvement Know-How</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 16.1(c) (MacroGenics Platform Improvement IP)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt;padding-right:29.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Identified Upstream License</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 3.8(b)(i) (Notice of MacroGenics Identified Rights)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Technology Transfer</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 9.4 (Manufacturing Technology Transfer)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Transition Budget</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 9.4 (Manufacturing Technology Transfer)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Transition Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 9.4 (Manufacturing Technology Transfer)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Materials</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 3.9 (Materials Transfer)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MGD024 Transfer Price</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 9.1(a)(iii) (Clinical Supply Agreement)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">New License Agreement</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 3.3(c) (Survival of Gilead Sublicensees)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-Bankrupt Party</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 18.5 (Termination for Bankruptcy)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-Breaching Party</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 18.2(a) (Material Breach)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Noninvolved Party</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 19.3 (Section 365(n) of the Bankruptcy Code)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obligants</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 13.2 (Covenants, Representations and Warranties For Compliance with Laws)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OFAC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 13.2(d) (Export Control Laws)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other Effector Target</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 1.41 (Effector Target)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Outside Date</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 6.1(c) (Outside Date)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Party </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Parties</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Challenge</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 18.6 (Termination for Patent Challenge)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Term Extensions</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 16.7 (Patent Term Extensions)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Permitted Subcontractor</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 3.4 (Subcontractors)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PHS Act</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 1.20 (cGMP)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Proposed Research Target Combination</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.1(c) (Confirmed Research Target Combinations)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Upstream License</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 3.8(c)(i) &#91;***&#93; Upstream Licenses)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Protected Personal Information</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 13.2(b) (Data Protection Laws)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recalls</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 7.6 (Recalls)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Receiving Party</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 12.1(a) (Definition and Restrictions)</font></div></td></tr></table></div><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></div></td></tr></table></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_25"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:64pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.542%"><tr><td style="width:1.0%"></td><td style="width:41.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#9cc1e4;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Definition</font></td><td colspan="3" style="background-color:#9cc1e4;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recovery</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 16.4(c)(i) (Recovery Allocations)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Representatives</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 12.1(c)(iii) (Permitted Disclosures)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Requesting Party</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 11.6 (Audit Rights)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Required Regulatory Activities Budget</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 4.2(b) (Required Regulatory Activities)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Budget</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.2 (Research Program)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.2 (Research Program)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Research Product Development Milestone Event</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 10.2(b) (Research Products)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Research Product Development Milestone Payment</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 10.2(b) (Research Products)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.2 (Research Program)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Opt-In</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.8(a) (Opt-In Grant)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Opt-In Date</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.8(c) (Option Exercise)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Opt-In Effective Date</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 6.1(b)(ii) (Research Programs Effectiveness)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:29.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Research Program Opt-In Exercise Notice</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.8(c) (Option Exercise)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Opt-In Term</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.8(c) (Option Exercise)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Subcommittee</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 2.2 (Additional Subcommittees and Working Groups)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Technology Transfer Period</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.9 (Technology Transfer)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Technology Transfer Plan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.9 (Technology Transfer)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Target Combination</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.1(a) (Research Target Nomination Right)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt;padding-right:11.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Target Combination License Date</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.2 (Research Program)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt;padding-right:11.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Target Combination License Fee</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.2 (Research Program)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Target Nomination Right</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.1(a) (Research Target Nomination Right)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Target Selection Period</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.1(a) (Research Target Nomination Right)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Term</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.5 (Research Term)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reverted CD123 Products</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 18.9(b) (Additional Effects of Certain Terminations)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Safety&#47;AE Matters</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 7.5 (Adverse Event Reporting&#59; Global Safety Database)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Secured Information</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 13.2(c)(i) (Information Security)</font></div></td></tr></table></div><div style="height:82.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></div></td></tr></table></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_28"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:64pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.542%"><tr><td style="width:1.0%"></td><td style="width:41.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#9cc1e4;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Definition</font></td><td colspan="3" style="background-color:#9cc1e4;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Regulator</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 12.1(c)(ii) (Permitted Disclosures)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Security Incident</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 13.2(c)(iv) (Information Security)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Skipped Milestone</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 10.2(c) (Skipped Milestone)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standstill Period</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 19.2(a) (Standstill)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subject Party</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 13.1 (General)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subject Party Audit</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 13.2(a)(iii)(6) (Anti-Corruption Laws)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 5.1(d) &#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Supplemental Platform Upstream License</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 3.8(a)(i) (Notice of Third Party Platform Rights)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 18.1 (Term)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:29.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:10.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Expansion Cohort</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Allegation</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 16.5(a) (Notice of Allegations)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Platform Rights</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 3.8(a)(i) (Notice of Third Party Platform Rights)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Suit</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 16.5(b) (Notice of Suit)</font></div></td></tr></table></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:97pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Overview&#59; Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.7pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Membership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Promptly after the Effective Date, the Parties will establish a joint steering committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), to coordinate, oversee and, as applicable, approve the Parties&#8217; activities related to the Licensed Molecules and Licensed Products in accordance with this Article 2 (Overview&#59; Governance). The JSC shall consist of three (3) representatives from each Party (or such other number as the Parties may agree). Each Party shall designate one (1) of its representatives of the JSC as a co-chairperson of the JSC (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JSC Co-Chairperson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Each Party may replace its appointed JSC representatives at any time upon reasonable written notice to the other Party. The JSC Co- Chairpersons, in consultation with the Alliance Managers, will have the following roles and responsibilities&#58;</font></div><div style="margin-top:0.1pt;padding-left:61pt;padding-right:29.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i) to call meetings, send notice of each such meeting and designate the time, date and place of each such meeting&#59; (ii) to convene or poll the representatives by other permitted means&#59; and (iii) to approve (including via email) the final minutes of any meeting of the JSC. The JSC Co-Chairpersons shall have no other authority or special voting power.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The responsibilities of the JSC shall be&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;to provide a forum by which the Parties may share information regarding the overall strategy for the conduct of the CD123 Development Program and each Research Program and to discuss, monitor and coordinate all activities under the CD123 Development Program and each Research Program&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30.05pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;to facilitate the exchange of information between the Parties with respect to the activities hereunder and to establish procedures for the efficient sharing of information necessary for</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></div></td></tr></table></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_31"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:28.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Parties to fulfill their respective responsibilities with respect to conduct of the CD123 Development Program and each Research Program&#59;</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:30.05pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;review, discuss and determine whether to approve updates or amendments to the CD123 Development Plan, as described in Section 4.1 (CD123 Development Plan)&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.95pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;to share and discuss the progress of activities being conducted under the CD123 Development Program on a quarterly basis, as described in Section 4.1 (CD123 Development Plan)&#59;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.9pt;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(v)&#160;&#160;&#160;&#160;develop, discuss and determine whether to approve any amendments to the CD123 Development Plan to reflect any Required Regulatory Activities that will be conducted by MacroGenics, as described in Section 4.2(b) (Required Regulatory Activities) and Section 4.6 (CD123 Development Program Costs)&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.8pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(vi)&#160;&#160;&#160;&#160;develop, discuss and determine whether to approve any Required Regulatory Activities Budget or updates or amendment thereto, as described in Section 4.2(b) (Required Regulatory Activities)&#59;</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;review, discuss and determine whether to approve each Research Plan and Research Budget and updates or amendments thereto, as described in Section 5.2 (Research Program) and Section 5.4 (Research Plan Costs)&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.95pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;to share and discuss the progress of activities being conducted under each Research Program on a quarterly basis, as described in Section 5.2 (Research Program)&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.8pt;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(ix)&#160;&#160;&#160;&#160;review, discuss and determine whether to approve each Manufacturing Transition Plan (including each Manufacturing Transition Budget) and updates or amendments thereto and coordinate the activities under each such Manufacturing Transition Plan, as described in Section 9.4 (Manufacturing Technology Transfer)&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.95pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(x)&#160;&#160;&#160;&#160;to perform such other functions as expressly set forth in this Agreement or as appropriate to further the purposes of this Agreement, as determined by the Parties.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Decision-Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The JSC shall make </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, with each Party&#8217;s representatives collectively </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event the JSC cannot reach agreement regarding any matter within the JSC&#8217;s authority for a period of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Deadlock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then either Party may elect to submit such issue to the Parties&#8217; Executive Officers, and if a Party makes an election to refer a matter to the Executive Officers, then the Executive Officers shall use good faith efforts to promptly resolve such matter, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">after the submission of such matter to them. If the Executive Officers are unable to reach consensus on any such matter within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, then the Deadlock shall be resolved in accordance with the provisions of this Section 2.1(c) (Decision-Making)&#58;</font></div><div><font><br></font></div><div style="margin-top:3.95pt;padding-left:61pt;padding-right:30.05pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Except for those Deadlocks </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, as set forth in Section 2.1(c)(ii) (Decision-Making) and subject to Section 2.1(c)(iii) (Decision-Making), &#91;***&#93; decision-making authority with respect to the &#91;***&#93; decision-making authority with respect to the &#91;***&#93; decision-making authority with respect to the &#91;***&#93; decision-making authority with respect to the &#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Neither Party will have final decision-making authority over any Deadlock &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">thereto, and all matters in the foregoing clauses &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Parties in order to take any action or adopt any change from the then-current </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">status quo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Notwithstanding Section 2.1(c)(i) (Decision-Making) and Section 2.1(c)(ii) (Decision-Making), &#91;***&#93; decision-making authority on any such matters may, &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Applicable Laws and Regulations or any agreement with any Third Party that exists as of the Effective Date (including the MacroGenics Manufacturing In-Licenses) or is otherwise entered into after the Effective Date in accordance with this Agreement or the infringement of intellectual property rights of any Third Party &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.75pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JSC Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. No later than &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">after the Effective Date, the JSC will hold a meeting to establish the JSC&#8217;s operating procedures, and the JSC shall meet &#91;***&#93; as required under this Agreement or to resolve any matter or dispute referred to the JSC in accordance with this Agreement. In the case of any matter or dispute referred to the JSC, such meeting shall be held within &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">following referral to the JSC. Employees or consultants of either Party that are not representatives of the Parties on the JSC may attend JSC meetings with prior notice and with respect to any consultants, prior consent, of the other Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, &#91;***&#93;.</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A JSC meeting may be held either in person or by audio, video or internet teleconference with the consent of each Party. Meetings of the JSC shall be &#91;***&#93;. Each Party shall be responsible for</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:29.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Duration and Scope of JSC and Subsequent Information Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The JSC shall continue to exist &#91;***&#93;, unless the Parties mutually agree in writing to disband the JSC earlier, or upon termination of this Agreement in accordance with the terms hereof. After the dissolution of the JSC &#91;***&#93;, Gilead shall share information and provide updates &#91;***&#93; in accordance with Sections 6.6 (Development Reporting), 7.6 (Recalls), 10.2 (Development and Regulatory Milestone Payments), 10.3 (Commercial Milestone Payments), 10.4 (Royalties on Net Sales) and 11.2 (Royalty Payments) and the Research Molecules and Research Products in accordance with Sections 6.6 (Development Reporting), 7.6 (Recalls), 10.2 (Development and Regulatory Milestone Payments), 10.3 (Commercial Milestone Payments), 10.4 (Royalties on Net Sales) and 11.2 (Royalty Payments).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The JSC shall have no authority other than that expressly set forth in this Section 2.1 (Joint Steering Committee) and, specifically, shall have no authority (i) to amend or interpret this Agreement, or (ii) to determine whether or not a breach of this Agreement has occurred.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Additional Subcommittees and Working Groups</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The JSC may establish other subcommittees or working groups as needed to further the purposes of this Agreement, including any responsibilities assigned to the JSC under this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the JSC shall not delegate its dispute resolution authority. The purpose, scope and procedures of any such subcommittee or working group shall be mutually agreed in writing by the JSC. The Parties shall, within &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">after the Effective Date, establish&#58; (a) a clinical subcommittee to review and discuss activities or matters related to the CD123 Development Program, including the CD123 Development Plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Clinical Subcommittee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and (b) a research subcommittee to review and discuss activities or matters related to each Research Program, including the applicable Research Plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Subcommittee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Neither the CD123 Clinical Subcommittee, the Research Program Subcommittee nor any other subcommittee or working group shall have any decision-making authority.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Promptly following the Effective Date, each Party shall designate in writing an Alliance Manager to serve as the primary point of contact for the Parties regarding all activities contemplated under this Agreement. Each Alliance Manager shall, among other things&#58; (a) facilitate communication and coordination of the Parties&#8217; activities under this Agreement relating to the Licensed Molecules and the Licensed Products&#59; (b) coordinate meetings between members of each Party&#8217;s CD123 Development Program teams and Research Program teams&#59; and (c) attempt to resolve conflicts with respect to the CD123 Development Program and each Research Program. &#91;***&#93;. From time to time, each Party may substitute its Alliance Manager at any time upon written notice to the other Party.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:96.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licenses to Gilead</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Term License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement, effective upon the Research Target Combination License Date for a given Research Program, MacroGenics hereby grants to Gilead, during the Research Term for such Research Program, a worldwide, royalty-free, non-transferable (except in accordance with Section 19.4 (Assignment&#59; Change of Control)), co-exclusive (with MacroGenics) license under the MacroGenics Research Technology and MacroGenics&#8217; right, title and interest in the Jointly Owned IP, with the right to grant sublicenses &#91;***&#93; (subject to Section 3.3(b) (Sublicensing by Gilead)), solely to the extent necessary or reasonably useful to conduct any Development or Manufacturing activities allocated to Gilead under the Research Plan for the applicable Licensed Research Target Combination that is the subject of such Research Program.</font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:61pt;padding-right:29.6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exploitation Licenses for Research Molecules and Research Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement (including Section 3.5 (Retained Rights)), effective upon the Research Program Opt-In Effective Date for a given Research Program, MacroGenics hereby grants to Gilead an exclusive, royalty-bearing, non-transferable (except in accordance with Section 19.4 (Assignment&#59; Change of Control)) license under the MacroGenics Research Technology and MacroGenics&#8217; right, title and interest in the Jointly Owned IP, with the right to grant sublicenses &#91;***&#93; (each subject to Section 3.3(b) (Sublicensing by Gilead)), to Exploit Research Molecules and Research Products with respect to such Research Program in the Field in the Territory. For clarity, the license granted to Gilead under this Section 3.1(b) (Exploitation Licenses for Research Molecules and Research Products) shall not include the right for Gilead or any of its Affiliates to&#58;</font></div><div style="padding-left:61pt;padding-right:29.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i) conduct any Development or Commercialization activities using the MacroGenics Platform or (ii) use any molecule or compound that is proprietary to MacroGenics, its Affiliates or its (sub)licensees (other than a Research Molecule) in combination with any Research Molecule or Research Product. Notwithstanding anything to the contrary in the foregoing, effective upon the Research Program Opt-In Effective Date for a given Research Program, the license granted under this Section 3.1(b) (Exploitation Licenses for Research Molecules and Research Products) shall supersede and extinguish the license granted under Section 3.1(a) (Research Term License).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Term License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement, MacroGenics hereby grants to Gilead, during the CD123 Development Term, a worldwide, royalty-free, non-transferable (except in accordance with Section 19.4 (Assignment&#59; Change of Control)), co-exclusive (with MacroGenics) license under the MacroGenics CD123 Technology and MacroGenics&#8217; right, title and interest in the Jointly Owned IP, with the right to grant sublicenses &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(subject to Section 3.3(b) (Sublicensing by Gilead)), solely to the extent necessary or reasonably useful to perform any Development activities, Manufacturing activities or Regulatory Activities allocated to Gilead under the CD123 Development Plan for the CD123 Molecules and CD123 Products.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exploitation License for CD123 Molecules and CD123 Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement (including Section 3.5 (Retained Rights)), effective upon the CD123 Option Effective Date, MacroGenics hereby grants to Gilead an exclusive, royalty-bearing, non- transferable (except in accordance with Section 19.4 (Assignment&#59; Change of Control)) license under the MacroGenics CD123 Technology and MacroGenics&#8217; right, title and interest in the Jointly Owned IP, with the right to grant sublicenses &#91;***&#93; (each subject to Section 3.3(b) (Sublicensing by Gilead)), to Exploit CD123 Molecules and CD123 Products in the Field in the Territory. For clarity, the foregoing license shall not include the right for Gilead or any of its Affiliates to&#58; (i) conduct any Development or Commercialization activities using the MacroGenics Platform other than as permitted under the CD123 Development Plan, or (ii) use any molecule or compound that is proprietary to MacroGenics, its Affiliates or its (sub)licensees that is not a CD123 Molecule.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licenses to MacroGenics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Term License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement, effective upon the Research Target Combination License Date for a given Research Program, Gilead hereby grants to MacroGenics, during the Research Term for such Research Program, a worldwide, royalty-free, non-transferable (except in accordance with Section 19.4 (Assignment&#59; Change of Control)), co-exclusive (with Gilead) license under the Gilead Licensed Technology and Gilead&#8217;s right, title and interest in the Jointly Owned IP, with the right to grant sublicenses &#91;***&#93; (subject to Section 3.3(a) (Sublicensing by MacroGenics)), to conduct the Development and Manufacturing activities allocated to MacroGenics under the Research Plan for the Research Molecules and Research Products that are the subject of such Research Program.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development License for CD123 Molecules and CD123 Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement, Gilead hereby grants to MacroGenics, during the CD123 Development Term, a worldwide, royalty-free, non-transferable (except in accordance with Section 19.4 (Assignment&#59; Change of Control)) co-exclusive (with Gilead) license under the Gilead Licensed Technology and Gilead&#8217;s right, title and interest in the Jointly Owned IP, with the right to grant sublicenses &#91;***&#93; (subject to Section 3.3(a) (Sublicensing by MacroGenics)), to conduct any Development activities allocated to MacroGenics under the CD123 Development Plan for the CD123 Molecules and CD123 Products.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sublicensees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sublicensing by MacroGenics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MacroGenics shall have the right to grant sublicenses of the licenses granted to it in Section 3.2 (Licenses to MacroGenics), including sublicenses to a subset of the rights granted thereunder, &#91;***&#93;. Each sublicense granted by MacroGenics under this Agreement shall reference, be consistent with and subject to this Agreement, and MacroGenics shall remain responsible to Gilead for the compliance of each such Sublicensee with the terms and conditions of this Agreement. For clarity, any fee-for-service agreement with a Permitted Subcontractor will not be subject to this Section 3.3(a) (Sublicensing by MacroGenics) and will instead be governed by Section 3.4 (Subcontractors).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.8pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sublicensing by Gilead</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Gilead shall have the right to grant sublicenses &#91;***&#93; of the licenses granted to it in Section 3.1 (Licenses to Gilead), including sublicenses to a subset of the rights granted thereunder, &#91;***&#93;. Each sublicense granted by Gilead to a Third Party under this Agreement shall reference, be consistent with and subject to this Agreement, and Gilead shall remain responsible to MacroGenics for the compliance of each such Sublicensee with the terms and conditions of this Agreement, including with respect to the financial obligations and other obligations due under this Agreement. Gilead shall provide a complete copy of each such sublicense to a Third Party (and all material amendments or restatements thereof) granted by Gilead under this Agreement to MacroGenics within &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">after execution&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that Gilead shall have the right to redact commercially sensitive information or information unrelated to the Licensed Products from such copies (which, for clarity, shall not include information regarding the scope of the license grants, territory or term of each such sublicense). For clarity, any fee-for-service agreement with a Permitted Subcontractor will not be subject to this Section 3.3(b) (Sublicensing by Gilead) and will instead be governed by Section 3.4 (Subcontractors).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Survival of Gilead Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon termination of this Agreement for any reason, upon the written request of any Sublicensee of Gilead who is not then in breach of its sublicense agreement or the terms of this Agreement applicable to such Sublicensee, MacroGenics agrees to discuss in good faith with such Sublicensee the possibility of entering into a direct license from MacroGenics, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, MacroGenics shall have sole discretion and decision-making authority as to whether to enter into such license agreement (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">New License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Under any such New License Agreement between MacroGenics and such former Sublicensee, such Sublicensee will be required to pay to MacroGenics the same amounts in consideration for such direct grant as MacroGenics would have otherwise received from Gilead pursuant to this Agreement on account of such Sublicensee&#8217;s Exploitation of the Licensed Products had this Agreement not been terminated. Under such New License Agreement, MacroGenics will not be bound by any grant of rights broader than, and will not be required to perform any obligation other than those rights and obligations contained in, this Agreement and all applicable rights of MacroGenics set forth in this Agreement will be included in such New License Agreement.</font></div><div style="margin-top:0.05pt;padding-left:132.95pt;padding-right:29.7pt;text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subcontractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall have the right to engage Third Party contractors to perform any portion of its obligations or exercise certain rights of such Party under this Agreement on a fee-for-service basis (including Third Party Distributors, contract research organizations and contract manufacturing organizations) (each such subcontractor, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Permitted Subcontractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), except, &#91;***&#93;.</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any such Permitted Subcontractor to be engaged by a Party hereunder shall meet the qualifications typically required by such Party for the performance of work similar in scope and complexity to the subcontracted activity. Any such Permitted Subcontractor engaged by a Party hereunder shall be required to agree in writing to be bound by terms regarding maintaining the confidentiality of proprietary information that are no less stringent than those contained in this Agreement and regarding ownership of intellectual property that are consistent with those contained in this Agreement. A Party&#8217;s use of Permitted Subcontractors shall not relieve it of any of its obligations pursuant to this Agreement. Any Party engaging a Permitted Subcontractor to perform any of its obligations hereunder shall remain principally responsible and obligated for the performance of such activities.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding&#58; (a) the license grant to Gilead pursuant to Section 3.1(d) (Exploitation Licenses for CD123 Molecules and CD123 Products), MacroGenics reserves for itself and its Affiliates&#58; &#91;***&#93;&#59; (iii) the right to Manufacture or have Manufactured MGD024 and MGD024 Products for Gilead during the Clinical Supply Term in accordance with this Agreement and the Clinical Supply Agreement and (iv) the right to conduct Regulatory Activities requested by Gilead for CD123 </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:60.95pt;padding-right:29.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Products, as further described in Section 7.1(b) (After the CD123 Development Term)&#59; and (b) the license grant to Gilead pursuant to Section 3.1(b) (Exploitation Licenses for Research Molecules and Research Products), MacroGenics reserves for itself and its Affiliates the right to conduct Regulatory Activities requested by Gilead for Research Products, as further described in Section 7.2 (Research Molecules and Research Products). Except as explicitly set forth in this Agreement, no license or other right is or shall be created or granted by either Party under this Agreement by implication, estoppel, or otherwise. Each Party shall retain all rights not otherwise granted to the other Party. For clarity, notwithstanding the licenses granted to (A) Gilead pursuant to Section 3.1 (Licenses to Gilead), no right or license is granted by MacroGenics to Gilead under the MacroGenics Licensed Technology or MacroGenics Platform Trademarks with respect to any molecule or product Covered by such MacroGenics Licensed Technology or MacroGenics Platform Trademarks other than the Licensed Molecules and Licensed Products (including any Other Component of a Combination Product)&#59; and (B) MacroGenics pursuant to Section 3.2 (Licenses to MacroGenics), no right or license is granted by Gilead to MacroGenics under the Gilead Licensed Technology with respect to any molecule or product Covered by such Gilead Licensed Technology other than the Licensed Molecules and Licensed Products (including any Other Component of a Combination Product).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sublicense under the MacroGenics Manufacturing In-Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As of the Effective Date, certain MacroGenics Licensed Technology is in-licensed pursuant to the MacroGenics Manufacturing In-Licenses. &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that (a) with respect to the CD123 Development Program, at any time after the Clinical Supply Term, Gilead may elect, upon written notice to MacroGenics, to no longer include the MacroGenics Licensed Technology sublicensed under one or both MacroGenics Manufacturing In-Licenses as MacroGenics CD123 Technology and (b) on a Research Program-by-Research Program basis, at any time</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:29.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">during the Term, Gilead may elect, upon written notice to MacroGenics, to no longer include the MacroGenics Licensed Technology sublicensed under one or both MacroGenics Manufacturing In- Licenses as MacroGenics Research Technology for a Research Program. On a Program-by-Program basis, from and after the date of receipt of any such notice provided by Gilead, (i) the Know-How and Patents licensed to MacroGenics pursuant to the applicable MacroGenics Manufacturing In-Licenses will no longer be deemed MacroGenics Licensed Technology for the applicable Program, (ii) Gilead shall immediately cease to use any MacroGenics Licensed Technology previously sublicensed under such MacroGenics Manufacturing In-Licenses and (iii) &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Existing Upstream License Agreements Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Promptly after the Effective Date, MacroGenics will use good faith efforts to &#91;***&#93; to the (a) &#91;***&#93; and (b) &#91;***&#93;, &#91;***&#93; in each case, that include the conditions &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 3.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Existing Upstream License Agreement Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). MacroGenics will (i) provide Gilead with an opportunity &#91;***&#93; Existing Upstream License Agreement Amendment and (ii) obtain Gilead&#8217;s prior consent (not to be unreasonably withheld) &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Existing Upstream License Agreement Amendments and, subject to the activities in clauses (i) and (ii) taking place,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; specifically related to the &#91;***&#93; but subject to Gilead&#8217;s right to &#91;***&#93;. If MacroGenics &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Existing Upstream License Agreement Amendment(s) that collectively include all of the &#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 3.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Existing Upstream License Agreements Amendments) &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">written notice from Gilead requesting that MacroGenics &#91;***&#93;, as between the Parties, Gilead will have the sole right to &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(as applicable) with respect to the subject matter described in this Section 3.7 (Existing Upstream License Agreements Amendments) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to reflect Gilead as the contracting party, and, if Gilead does &#91;***&#93;,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gilead will use good faith efforts to &#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 3.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Existing Upstream License Agreements Amendments)</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;. The financial obligations under any such agreements with &#91;***&#93;.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:35.9pt;padding-right:255.8pt;text-align:right;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">New Upstream License Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:35.9pt;padding-right:252.2pt;text-align:right;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Platform Rights.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.6pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Notice of Third Party Platform Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MacroGenics will be responsible for using Commercially Reasonable Efforts to obtain and maintain rights to use any and all Patents or Know-How (whether through acquisition or a license) that Cover the use of the MacroGenics Platform under this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Platform Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#59; any such agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Supplemental Platform Upstream License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). For clarity, MacroGenics&#8217; responsibility under this Section 3.8(a)(i) (Notice of Third Party Platform Rights) shall extend to any improvements of the MacroGenics Platform generated or developed after the Effective Date solely to the extent (1) MacroGenics actually uses such improvements in the performance of its activities under this Agreement or (2) the CD123 Development Plan or any Research Plan permits the use of such improvements. &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Patents or Know-How comprise Third Party Platform Rights, &#91;***&#93; MacroGenics in its reasonable discretion &#91;***&#93; Third Party Platform Rights, or otherwise upon MacroGenics otherwise becoming aware of any such Third Party Platform Rights), or &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">pursuant to Section 3.8(a)(iii) (Third Party Platform Rights Dispute), MacroGenics &#91;***&#93;. If MacroGenics &#91;***&#93; after such determination is made in accordance with the immediately preceding sentence (such period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, if MacroGenics is &#91;***&#93;. For clarity, the Parties understand and agree that any Patent or Know-How Controlled by a Third Party that Covers a Research Molecule or Research Product due &#91;***&#93;,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall not be deemed a &#8220;Third Party Platform Right&#8221;. Notwithstanding anything to the contrary herein, this Section 3.8(a)(i) (Notice of Third Party Platform Rights) shall not apply to the Parties&#8217; rights and obligations with respect to any Identified Patent, the acquisition of such rights and obligations are separately addressed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 10.4(c)(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Special Offset and Indemnification).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.4pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Negotiation of Supplemental Platform Upstream License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MacroGenics will use good faith efforts to negotiate a license under Third Party Platform Rights that&#58; (A) to the extent such license also grants rights for any other molecule or product being Exploited by MacroGenics or a (sub)licensee of MacroGenics, &#91;***&#93; the Third Party Platform Rights such that MacroGenics or its Affiliate Controls such rights as MacroGenics Licensed Technology. If any proposed license under Third Party Platform Rights &#91;***&#93;, then, to the extent MacroGenics &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">under such Third Party Platform Rights, MacroGenics will &#91;***&#93;, unless otherwise agreed by the Parties in writing, MacroGenics will &#91;***&#93; and, as between the Parties, Gilead will &#91;***&#93;. At Gilead&#8217;s request, MacroGenics will reasonably cooperate with Gilead to &#91;***&#93;. Prior to execution of any Supplemental Platform </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:60.95pt;padding-right:29.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Upstream License, MacroGenics will &#91;***&#93;. MacroGenics may request, no sooner than &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Supplemental Platform Upstream License in &#91;***&#93; such Supplemental Platform Upstream License and Gilead will promptly &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, in the event that MacroGenics includes the terms set forth in &#91;***&#93; of this Section 3.8(a)(ii) (Negotiation of Supplemental Platform Upstream License) and the activities described in &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereof take place, Gilead shall not unreasonably</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:29.75pt;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Platform Rights Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If a Party disputes whether certain Patents or Know-How Cover the use of the MacroGenics Platform under this Agreement (it being understood that any Patent that is the subject of a dispute under this subsection (iii) shall be valid and enforceable as of the date either Party submits a dispute for resolution hereunder), then each Party may refer the matter to their respective intellectual property counsel (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IP Counsels</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) for resolution. The IP Counsels will meet promptly to discuss and resolve the matter within &#91;***&#93; after referral of such matter to such IP Counsels. If the IP Counsels cannot agree on a resolution to the matter within such &#91;***&#93;, then either Party may refer such matter for resolution to an independent Third Party expert agreed upon by the Parties within &#91;***&#93; after the IP Counsels have failed to resolve such matter. Such independent Third Party expert will be an attorney &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(or who has such other similar credentials as agreed by the Parties), and unless otherwise agreed in writing by the Parties, must not be a current or former employee, contractor, agent or consultant of either Party or its Affiliates. &#91;***&#93; pursuant to this Section 3.8(a)(iii) (Third Party Platform Rights Dispute)</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;such expert and the Parties &#91;***&#93;.</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Within &#91;***&#93; of the engagement of such expert by the disputing Party, such expert will deliver its written decision to the Parties (including a detailed report as to such expert&#8217;s rationale for such decision), &#91;***&#93;. Notwithstanding any provision to the contrary set forth in this Agreement, at any time during the pendency of any such dispute, Gilead will have the right to (1) obtain rights to such Third Party Platform Rights from the applicable Third Party and (2) if the expert &#91;***&#93; the MacroGenics Platform under this Agreement (as described in Section 3.8(a)(i) (Notice of Third Party Platform Rights)), &#91;***&#93; such Third Parties with respect to such Third Party Platform Rights &#91;***&#93;, in all cases, &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in accordance with this Agreement, &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:29.55pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If Gilead obtains rights to Third Party Platform Rights pursuant to Section 3.8(a)(i) (Notice of Third Party Platform Rights) or Section 3.8(a)(iii) (Third Party Platform Rights Dispute), then Gilead &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Third Parties under any agreement between Gilead and such Third Parties with respect to such Third Party Platform Rights &#91;***&#93;, in all cases, &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">under this Agreement (which, for clarity, will include the use of the MacroGenics Platform under this Agreement), &#91;***&#93; a Licensed Product under this Agreement (including, for clarity, any &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, in no event &#91;***&#93; MacroGenics for a given Calendar Quarter &#91;***&#93; Gilead may &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that are &#91;***&#93; in a Calendar Quarter but are not &#91;***&#93; MacroGenics in such Calendar Quarter as a result &#91;***&#93; MacroGenics in any subsequent Calendar Quarter (subject to the &#91;***&#93;) &#91;***&#93;.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Identified Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Notice of MacroGenics Identified Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If MacroGenics or any of its Affiliates is planning to &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Third Party under which MacroGenics or its Affiliate &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Identified Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#59; such agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Identified Upstream License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then MacroGenics &#91;***&#93;. Following the Option Effective Date for the applicable Licensed Molecule or Licensed Product, Gilead will have &#91;***&#93; such MacroGenics Identified Rights, &#91;***&#93; to the extent such MacroGenics Identified Rights &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licensed Molecule or Licensed Product &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and &#91;***&#93; products or programs of MacroGenics, &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:60.95pt;padding-right:29.7pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Negotiation of MacroGenics Identified Upstream License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MacroGenics will use good faith efforts to negotiate a license under MacroGenics Identified Rights that&#58;(A) to the extent such license also grants right for any other molecule or product being Exploited by MacroGenics or a (sub)licensee of MacroGenics &#91;***&#93; as MacroGenics Licensed Technology. If &#91;***&#93; MacroGenics Identified Rights &#91;***&#93; MacroGenics Identified Rights, then, to the extent MacroGenics &#91;***&#93; MacroGenics Identified Rights, MacroGenics will &#91;***&#93; agreed by the Parties in writing, MacroGenics &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics Identified Rights &#91;***&#93; MacroGenics Identified Rights &#91;***&#93;. At Gilead&#8217;s request, MacroGenics will reasonably cooperate with Gilead &#91;***&#93; MacroGenics Identified Upstream License that &#91;***&#93; Licensed Molecule or Licensed Product, MacroGenics will &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics Identified Upstream License, &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics Identified Upstream License. MacroGenics may request, &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:line-through"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics Identified Upstream License &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics Identified Upstream License and Gilead will</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, in the event that MacroGenics includes the terms </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:4.55pt;padding-left:60.95pt;padding-right:29.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">set forth in &#91;***&#93; of this Section 3.8(b)(ii) (Negotiation of MacroGenics Identified Upstream License) and the activities described in</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; hereof take place, &#91;***&#93;.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Upstream Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.9pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;&#91;***&#93; Supplemental Platform Upstream License, MacroGenics Identified Upstream License or Identified Patent Upstream License (such agreement, a &#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Upstream License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), MacroGenics will</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; MacroGenics may redact commercially sensitive information or other information unrelated to the Licensed Molecules or Licensed Products from such copy (which, for clarity, will not include information regarding the scope of the license grants, territory or term of such &#91;***&#93; Upstream License). &#91;***&#93; of the &#91;***&#93; Upstream License, Gilead &#91;***&#93; Third Party Platform Rights, MacroGenics Identified Rights or Identified Patent Rights</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; Notwithstanding the foregoing, if MacroGenics &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in accordance with Section 3.8(a)(ii) (Negotiation of Supplemental Platform Upstream License), Section 3.8(b)(ii) (Negotiation of MacroGenics Identified Upstream License) or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 10.4(c)(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Special Offset and Indemnification),</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as applicable, and in each case, Gilead</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;, then Gilead will &#91;***&#93; Upstream License as long as &#91;***&#93; pursuant to Section 3.8(a)(ii) (Negotiation of Supplemental Platform Upstream License), Section 3.8(b)(ii) (Negotiation of MacroGenics Identified Upstream License) or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 10.4(c)(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Special Offset and Indemnification), as applicable.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:29.85pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;In the event that Gilead &#91;***&#93; Upstream License in accordance with this Section 3.8(c) (&#91;***&#93; Upstream Licenses), &#91;***&#93; Third Party Platform Rights, MacroGenics Identified Rights or Identified Patent Rights (as applicable) &#91;***&#93; MacroGenics Licensed Technology &#91;***&#93; Gilead pursuant to &#91;***&#93;,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2) such agreement will thereafter be &#91;***&#93; Upstream License Agreements, and (3) Gilead hereby agrees &#91;***&#93; Upstream License Agreement with respect to &#91;***&#93; Upstream License Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.9pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;If Gilead does not &#91;***&#93; Upstream License as an Upstream License Agreement pursuant to this Section 3.8(c) (&#91;***&#93; Upstream Licenses), then Gilead and its Affiliates will have &#91;***&#93; Upstream License. Notwithstanding any other provision of this Agreement, &#91;***&#93; MacroGenics CD123 Know-How, MacroGenics CD123 Patents, MacroGenics Research Know-How and MacroGenics Research Patents shall be &#91;***&#93; Third Party Platform Rights, MacroGenics Identified Rights or Identified Patent Rights licensed to MacroGenics or any of its Affiliates pursuant to a license or other agreement entered into by MacroGenics or its Affiliates after the Effective Date &#91;***&#93; Upstream License Agreement pursuant to this Section 3.8(c) (&#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Upstream Licenses).</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.95pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Responsibility for Payments under Upstream License Agreements. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics &#91;***&#93; Third Party under the Existing Upstream License Agreements (other than, subject to Section 3.6 (Sublicense under the MacroGenics Manufacturing In-Licenses), &#91;***&#93; MacroGenics under the MacroGenics Manufacturing In-Licenses to the extent related to the Manufacture of Licensed Molecules or Licensed Products, &#91;***&#93; and (ii) to any Third Party under any Supplemental Platform Upstream License, as described in Section 3.8(a) (Third Party Platform Rights). With respect to any MacroGenics Identified Upstream License that becomes an Upstream License Agreement pursuant to Section 3.8(c)(i) (&#91;***&#93;Upstream Licenses), Gilead will &#91;***&#93; Section 3.8(c)(i) (&#91;***&#93; Upstream Licenses) and that arise from the Exploitation of any Licensed Molecule or Licensed Product by Gilead, its Affiliates or Sublicensees under this Agreement, subject to Gilead&#8217;s &#91;***&#93;.</font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Materials Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In order to facilitate the activities under, or to confirm any results of, a Program, either Party may provide to the other Party certain biological materials or chemical compounds Controlled by the supplying Party (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Except as otherwise expressly set forth under this Agreement, all such Materials delivered to the other Party will remain the sole property of the supplying Party, will be used only in the performance of activities conducted in accordance with the CD123 Development Plan or applicable Research Plan or to confirm any results of a Program, will not be used or delivered to or for the benefit of any Third Party without the prior written consent of the supplying Party (except for Permitted Subcontractors performing any activities under the CD123 Development Plan or a Research Plan), and will be used in compliance with Applicable Law and Regulations (including GLP, cGMP, and cGCP, as applicable). Each Party will use the Materials supplied under this Agreement with prudence and appropriate caution in any experimental work as not all of their characteristics may be known. The supplying Party will provide the other Party the most current material safety data sheet for the Materials upon transfer of any Materials. Prior to the supply of any Materials by or on behalf of the supplying Party, the Parties will, upon the supplying Party&#8217;s request, enter into a </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">material transfer agreement with respect to such supply. Except as expressly set forth in this Agreement, THE MATERIALS ARE PROVIDED &#8220;AS IS&#8221; AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Program Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Commencing on the Effective Date and continuing until the earlier of (i) the five (5) year anniversary of the Effective Date or (ii) the termination of the CD123 Development Program in accordance with Section 4.13 (CD123 Development Program Termination) or Article 18 (Term and Termination), except as permitted under this Agreement, including in connection with</font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1) any Development or other activities conducted with respect to CD123 Molecules or CD123 Products pursuant to the CD123 Development Plan, or (2) the exercise of MacroGenics&#8217; retained rights set forth in Section 3.5 (Retained Rights), MacroGenics shall not, itself, or with or through any of its Affiliates or any Third Party, Develop, have Developed, Commercialize, or have Commercialized any compound or product containing a multi-specific (which includes, for clarity, a bi-specific) antibody molecule that is directed to each of CD3 and CD123.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Research Program-by-Research Program basis, commencing on the Research Target Combination License Date for a given Licensed Research Target Combination that is the subject of a Research Program and ending upon the earlier of (i) the five (5) year anniversary of the Initiation of a Phase 1 Clinical Trial for the first Research Product for such Research Program or (ii) the termination of such Research Program in accordance with Section 5.10 (Research Program Termination) or Article 18 (Term and Termination), except as permitted under this Agreement, including in connection with the conduct of MacroGenics&#8217; activities with respect to such Research Program during the Research Term pursuant to the applicable Research Plan, MacroGenics shall not, itself, or with or through any of its Affiliates or any Third Party, Develop, have Developed, Commercialize, or have Commercialized any compound or product that is directed to the Licensed Research Target Combination that is the subject of such Research Program.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:29.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Business Combinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MacroGenics will not be in breach of the restrictions set forth in Section 3.10(a) (CD123 Program Exclusivity) or Section 3.10(b) (Research Program Exclusivity) if MacroGenics or any of its Affiliates undergoes a Change of Control with a Third Party (together with such Third Party and its Affiliates following the closing of the applicable Change of Control transaction, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Acquired Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that (either directly or through an Affiliate, or in collaboration with any other Third Party) at the closing of the Change of Control transaction is, or later performs, any Development or Commercialization activities on a compound or product that would be in breach of Section 3.10(a) (CD123 Program Exclusivity) or Section 3.10(b) (Research Program Exclusivity), if performed by MacroGenics (such compound or product, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Competitive Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and such Acquired Party may perform such Development or Commercialization activities on a Competitive Product in the Territory, as long as &#91;***&#93; the Licensed Molecules, Licensed Products or Programs hereunder, Confidential Information of MacroGenics.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:96.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Program&#59; CD123 Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the CD123 Development Term, all Development and Manufacturing activities to be conducted by or on behalf of the Parties for the CD123 Molecules and CD123 Products will be conducted solely pursuant to a written development plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and such activities the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The initial CD123 Development Plan is set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 4.1(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(CD123 Development Plan) and includes the material Development and Manufacturing activities anticipated to be required to complete the Phase 1 Clinical Trial for the MGD024 Product (consistent with the clinical protocol synopsis attached hereto in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 4.1(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Clinical Protocol Synopsis)) and the responsible Party(ies) for the performance of such activities (such plan, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Initial CD123 Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The CD123 Development Plan allocates the performance of specific activities to each of MacroGenics (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics CD123 Development Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Gilead (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead CD123 Development Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and specifies activities, if any, to </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">be performed jointly by the Parties (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint CD123 Development Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The JSC shall (a) review, discuss and determine whether to approve any updates or amendments to the CD123 Development Plan &#91;***&#93;, and (b) oversee and facilitate cooperation and information transfer between the Parties in conducting the activities set forth in the CD123 Development Plan. In addition, each Party shall have the right to propose additional amendments to the CD123 Development Plan in connection with the progress of the CD123 Development Program for the JSC to review, discuss and determine whether to approve. Any proposed amendments to the CD123 Development Plan will become effective only upon approval by the JSC. During the CD123 Development Term, each Party shall not, and shall procure that its Affiliates, Sublicensees and Permitted Subcontractors shall not, perform any pre-clinical or clinical Development activities with respect to any CD123 Molecule or CD123 Product other than (i) the activities expressly set forth in the CD123 Development Plan and (ii) any activities expressly permitted pursuant to Section 3.5 (Retained Rights).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Excused Delays</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If MacroGenics is delayed &#91;***&#93;.</font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:29.5pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Required Regulatory Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If any Regulatory Authority requires &#91;***&#93;  (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Required Regulatory Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), &#91;***&#93;. The Parties, through the JSC, will promptly develop, discuss and determine whether to approve (1) an amendment to the CD123 Development Plan to reflect such Required Regulatory Activities &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Required Regulatory Activities Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Conduct of the Phase 1 Clinical Trial of MGD024</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MacroGenics shall be responsible for, and shall use Commercially Reasonable Efforts to conduct, &#91;***&#93; the Phase 1 Clinical Trial for the MGD024 Product, as further described in, and in accordance with, the CD123 Development Plan. If Gilead does not exercise the CD123 Option during the &#91;***&#93;,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:line-through"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">then MacroGenics shall be responsible for, and shall use Commercially Reasonable Efforts to conduct, &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Phase 1 Clinical Trial for MGD024 Product, as further described in, and in accordance with, the CD123 Development Plan.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Performance Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall use Commercially Reasonable Efforts to conduct the CD123 Development Program activities for which it is responsible pursuant to the CD123 Development Plan and in compliance with all Applicable Laws and Regulations, including applicable national and international (e.g., ICH, GCP, GLP and cGMP) guidelines. Additionally, each Party shall use Commercially Reasonable Efforts to provide any assistance required by the other Party to address or complete activities for which such other Party is responsible pursuant to the CD123 Development Plan, or as otherwise mutually agreed upon by the Parties.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Assumed CD123 Development Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Conditions for Assumption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If, following a Change of Control of MacroGenics or Bankruptcy Event of MacroGenics that occurs any time after the Effective Date, Gilead reasonably believes that MacroGenics has defaulted on its obligations to perform one or more Development activities allocated to it under the CD123 Development Plan &#91;***&#93;, then Gilead may provide MacroGenics</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:29.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with written notice regarding such failure to perform. &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Activities Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and (y) at Gilead&#8217;s request, the Parties will meet and cooperate to agree in good faith on a plan to resolve such material delay. If (A) MacroGenics has not commenced performance of such Development activities during the applicable CD123 Development Activities Cure Period, (B) MacroGenics notifies Gilead in writing that it anticipates that it will be unable to perform such Development activities or (C) MacroGenics does not perform such Development activities in accordance with the CD123 Development Plan or otherwise in accordance with this Article 4 (CD123 Development Program&#59; CD123 Option), &#91;***&#93;, Gilead may, upon written notice to MacroGenics, assume those Development activities that are the subject of such default by MacroGenics (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Assumed CD123 Development Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.7pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effects of Assumption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. With respect to any Assumed CD123 Development Activities&#58; (i) MacroGenics will work collaboratively and in good faith with Gilead, and make its personnel reasonably available to Gilead, in each case, in order to (1) transfer any applicable technology, materials or contracts with Permitted Subcontractors to Gilead that are necessary or reasonably useful for the performance of the applicable Assumed CD123 Development Activities, and (2) provide such other reasonable assistance so as to enable Gilead to assume performance of the applicable Assumed CD123 Development Activities, as mutually agreed upon by the Parties and set forth in an amendment to the CD123 Development Plan&#59; (ii) the JSC will update the CD123 Development Plan to allocate performance of the Assumed CD123 Development Activities to Gilead and such Assumed CD123 Development Activities will thereafter be Gilead CD123 Development Activities&#59; and (iii) Gilead will be solely responsible for all FTE Costs and Out-of-Pocket Costs incurred by or on behalf of Gilead in connection with the performance of the applicable Assumed CD123 Development Activities in accordance with the CD123 Development Plan (as applied to Gilead, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">). For the avoidance of doubt, in the event Gilead performs any Assumed CD123 Development Activities under this Agreement, (A) Gilead&#8217;s performance of such Assumed CD123 Development Activities will not effect the timing of the license grants under Section 3.1 (Licenses to Gilead) or the mechanism for Gilead to exercise the CD123 Option (including all payment obligations therefor), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, any provisions or obligations of MacroGenics relevant to the performance of such activities (including the generation and submission of the CD123 Data Package) shall thereafter apply to Gilead, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59; and (B) the assumption of such activities by Gilead shall not, by itself, be deemed to be a breach by MacroGenics of any of its obligations under this Agreement.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Program Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93; CD123 Development Program. Notwithstanding the foregoing, Gilead shall &#91;***&#93; in performing the Required Regulatory Activities to the extent such costs are incurred in accordance with the CD123 Development Plan &#91;***&#93; in accordance with the immediately preceding sentence, and Gilead shall &#91;***&#93; provide notice to the JSC and the JSC shall promptly discuss in good faith and approve an amendment to the CD123 Development Plan or the Required Regulatory Activities Budget in accordance with Section 2.1 (Joint Steering Committee) &#91;***&#93;. &#91;***&#93; JSC approving an amendment to the CD123 Development Plan or the Required Regulatory Activities Budget, &#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Records&#59; Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93;, each Party shall maintain complete, current and accurate records of all activities conducted under the CD123 Development Program, and all data and other information resulting from the performance of such activities. Such records shall fully and properly reflect all work performed and results achieved in the performance of any CD123 Development Program activities in good scientific manner appropriate for regulatory and patent purposes. Additionally, during each JSC meeting, each Party shall provide the JSC with an update on the results and progress of any CD123 Development Program activities conducted by or on behalf of such Party since the prior JSC meeting.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Data Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93;.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Gilead has an exclusive option to obtain an exclusive (subject to Section 3.5 (Retained Rights)), royalty-bearing, non-transferable (other than in accordance with Section</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:61pt;padding-right:29.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.4 (Assignment&#59; Change of Control)) license, with the &#91;***&#93;, MacroGenics Licensed Technology, to Exploit CD123 Molecules and CD123 Products in the Field in the Territory (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><font><br></font></div><div style="padding-left:133pt;padding-right:29.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If &#91;***&#93;, the Phase 1 Clinical Trial of the MGD024 Product &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MacroGenics shall deliver each CD123 Data Package to Gilead as promptly as possible, and in no event &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CD123 Development Program that are required to generate the applicable CD123 Data Package. &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">following Gilead&#8217;s receipt of a CD123 Data Package, Gilead may provide MacroGenics with written notice if Gilead believes in good faith that the purported CD123 Data Package provided by MacroGenics does not contain all of the information required to be provided in such data package, as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.114 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.118</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, as applicable (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Deficiency Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which Deficiency Notice will reasonably specify the missing item(s). MacroGenics will modify such CD123 Data Package to reflect such comments and will provide an updated CD123 Data Package that includes the missing information &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deficiency Notice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, for clarity, MacroGenics shall not be required to generate any additional data that is not in existence as of the date of delivery of each CD123 Data Package (including re-running previously performed studies) to the extent such data is supplementary and not required to be set forth in such CD123 Data Package or comply with any requests to modify the presentation or formatting of the then-existing data unless required to be set forth in such CD123 Data Package. If Gilead provides a Deficiency Notice, then the applicable Option Period will be extended</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:line-through"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, at any time during the Option Period after Gilead&#8217;s receipt of a CD123 Data Package, Gilead may, itself or through the JSC, provide MacroGenics with written notice requesting assistance and cooperation from MacroGenics in analyzing such CD123 Data Package, including a request for a discussion with MacroGenics representative(s) who have relevant knowledge and information regarding such CD123 Data Package, and MacroGenics will use good faith efforts to promptly provide any such assistance and cooperation reasonably requested by Gilead. Additionally, during the CD123 Development Term, Gilead shall use good faith efforts to assist MacroGenics in its efforts to coordinate and compile the contents of the CD123 Data Package in advance of completion of the activities under the CD123 Development Program and to respond to MacroGenics&#8217; queries regarding the formatting and completeness of such aspects of the CD123 Data Package.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Clinical Study Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MacroGenics shall deliver the Clinical Study Report &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Phase 1 Clinical Trial &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical Study Report. If Gilead does not exercise the CD123 Option &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Clinical Study Report for &#91;***&#93; the Phase 1 Clinical Trial, MacroGenics will &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Phase 1 Clinical Trial &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical Study Report. For clarity, the Clinical Study Report will not be required as part of the CD123 Data Package.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.55pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Gilead may exercise the CD123 Option &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) &#91;***&#93; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Option Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#59;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:29.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.10&#160;&#160;&#160;&#160;&#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics, through completion of such activities, in accordance with the CD123 Development Plan &#91;***&#93;.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:61pt;padding-right:29.65pt"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.45pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Term and Transfer of Development Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The CD123 Development Program shall commence on the Effective Date and, unless earlier terminated pursuant to Section 4.13 (CD123 Development Program Termination) or Article 18 (Term and Termination), expire upon the earlier of the CD123 Option Effective Date or the Outside Date, in each case, in accordance with Section 6.1(b)(i) (CD123 Program Effectiveness) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). If Gilead exercises the CD123 Option, then, at such times after the CD123 Option Effective Date as set forth in Section 4.12 (Technology Transfer), MacroGenics will, and will cause its Affiliates and Permitted Subcontractors to, cooperate with Gilead as Gilead may reasonably request to facilitate an orderly transition of the Development of the MGD024 Product to Gilead or its designee. Without limiting the foregoing, if Gilead exercises the CD123 Option &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CD123 Option Effective Date, MacroGenics will (a) cooperate, and will ensure that its Affiliates and Permitted Subcontractors cooperate, with Gilead&#8217;s reasonable requests to transfer the conduct of the Phase 1 Clinical Trial for the MGD024 Product to Gilead or its designees or (b) continue to conduct the Phase 1 Clinical Trial for the MGD024 Product at Gilead&#8217;s cost and in accordance with the CD123 Development Plan &#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CD123 Option Effective Date, MacroGenics will provide Gilead with copies of all MacroGenics CD123 Know-How (other than MacroGenics CD123 Know-How relating to the Manufacture of CD123 Molecule and CD123 Products, the initial transfer of which will be performed in accordance with Section 9.4 (Manufacturing Technology Transfer)) that is necessary or reasonably useful for the Exploitation of the CD123 Molecules and CD123 Products. To facilitate such transfer, the Parties may mutually agree upon a written technology transfer plan to transfer to Gilead such MacroGenics CD123 Know-How (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Technology Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which will set forth a process for the transfer of such MacroGenics CD123 Know-How, and an overall timeline for its progress and completion. Each Party shall complete the activities allocated to it under the CD123 Technology Transfer Plan (if any such plan is agreed upon) and shall use Commercially Reasonable Efforts to do so within the timelines set forth in such plan. Thereafter, on a periodic basis during the &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics CD123 Know-How (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Technology Transfer Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), as Gilead may reasonably request, MacroGenics will provide to Gilead copies of MacroGenics CD123 Know-How &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gilead to continue to Exploit any CD123 Molecules and CD123 Products and (c) related to any activities conducted in connection with the CD123 Development Plan or the Manufacture of MGD024 Products. In addition to providing copies of the MacroGenics CD123 Know-How in accordance with this Section 4.12 (Technology Transfer), MacroGenics will make its personnel reasonably available to Gilead during the CD123 Technology Transfer Period, &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics Technology in connection with the Exploitation of the CD123 Molecules and CD123 Products. Other than as set forth in the preceding sentence, &#91;***&#93; MacroGenics CD123 Know-How in accordance with this Section 4.12 (Technology Transfer).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Program Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event that&#58; (a) Gilead does not exercise the CD123 Option &#91;***&#93;, the following shall occur&#58; (i) the CD123 Development Program and all rights and licenses granted by one Party to the other in connection therewith (including pursuant to Sections 3.1(c) (Development Term License), 3.1(d) (Exploitation License for CD123 Molecules and CD123 Products) and 3.2(b) (Development License for CD123 Molecules and Products)) shall terminate in their entirety, (ii) this Agreement shall terminate with respect to the CD123 Molecules and CD123 Products and for clarity, (1) CD123 Molecules shall not be deemed Licensed Molecules and CD123 Products shall not be deemed Licensed Products hereunder, (2) no molecule shall be deemed a CD123 Molecule or MGD024 and no product shall be deemed a CD123 Product or MGD024 Product hereunder and (3) no CD123 Development Milestone Payments, Commercial Milestone Payments or royalties, in each case, will be due for CD123 Products, (iii) MacroGenics&#8217; exclusivity obligations pursuant to Section 3.10(a) (CD123 Program Exclusivity) shall terminate immediately and (iv) Gilead shall promptly return to MacroGenics or destroy (at MacroGenics&#8217; election) any and all MacroGenics CD123 Know-How and any other Confidential Information of MacroGenics or its Affiliates solely related to the CD123 Molecules, CD123 Products or the CD123 Development Program, in accordance with Section 12.1(e) (Obligations Upon Termination). For the avoidance of doubt, upon the early termination of the CD123 Development Program in accordance with this Section 4.13 (CD123 Development Plan Termination), MacroGenics shall have no further obligations to Gilead with respect to any CD123 Molecule or CD123 Product and shall have the right to Exploit (or not Exploit) in any manner whatsoever, any CD123 Molecule or CD123 Product, in MacroGenics&#8217; sole discretion, without provision or disclosure of any related information or other Know-How to Gilead in connection therewith.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:61pt;padding-right:34.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research  Target  Nomination&#59;  Research  Plans&#59; Licensed  Research  Target Combinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Target Nomination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.55pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Target Nomination Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Target Selection Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Gilead shall have the right, in its sole discretion (subject to the remainder of this Article 5 (Research Target Nomination&#59; Research Plans&#59; Licensed Research Target Combinations)), &#91;***&#93;,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Target Combination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and such right, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Target Nomination Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) for each of up to two (2) Research Programs for which the Parties would Develop Research Molecules and Research Products in accordance with the remainder of this Article 5 (Research Target Nomination&#59; Research Plans&#59; Licensed Research Target Combinations).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gatekeeper</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Within &#91;***&#93; following Gilead&#8217;s request, the Parties will mutually agree on one (1) individual who is not affiliated with either Party, who is experienced in the biopharmaceutical industry and who is able to take on an obligation of confidentiality to both Parties (such individual, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gatekeeper</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Gilead will pay the Out-of-Pocket Costs for the Gatekeeper. The Gatekeeper will be required to keep the identity of any Proposed Research Target Combinations confidential and not disclose the identity of any Proposed Research Target Combinations to MacroGenics or its Affiliates except as otherwise set forth in Section 5.1(c) (Confirmed Research Target Combinations).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confirmed Research Target Combinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. To exercise a Research Target Nomination Right, Gilead shall, within the Research Target Selection Period, notify the Gatekeeper in writing of the identity of a given Research Target Combination that Gilead wishes to nominate (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Proposed Research Target Combination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Gilead shall &#91;***&#93;. Notwithstanding the foregoing, Gilead shall notify MacroGenics in writing of the</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">identity of the Effector Target that Gilead intends to nominate in a given Research Target Combination &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, in the event that such Effector Target constitutes an Other Effector Target, Gilead shall have the right to include such Other Effector Target in a Proposed Research Target Combination solely with MacroGenics&#8217; prior written approval (which may be withheld in MacroGenics&#8217; sole discretion). &#91;***&#93; Gatekeeper&#8217;s receipt of such notice from Gilead, the Gatekeeper will notify MacroGenics that Gilead nominated a Proposed Research Target Combination. Within &#91;***&#93; Gatekeeper, MacroGenics will submit a schedule of the current Unavailable Target Combinations. The Gatekeeper will verify whether the Proposed Research Target Combination is on the list of Unavailable Target Combinations and notify the Parties in writing if the Proposed Research Target Combination is not an Unavailable Target Combination. If the Gatekeeper confirms that the Proposed Research Target Combination is not an Unavailable Target Combination, then the Proposed Research Target Combination shall be deemed to be a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confirmed Research Target Combination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as of the date of such notification by the Gatekeeper. If the Gatekeeper notifies the Parties that the Proposed Research Target Combination is an Unavailable Target Combination, then Gilead shall &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Proposed Research Target Combinations in accordance with the procedure set forth in this Section 5.1(c) (Confirmed Research Target Combinations), &#91;***&#93; two (2) Confirmed Research Target Combinations. Upon the expiration of the Research Target Selection Period, Gilead shall no longer have the right to nominate any Proposed Research Target Combination, except as set forth in Section 5.1(d) (&#91;***&#93;).</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Within the period of &#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Gilead shall have &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Research Target Combination for either Research Program. To exercise such &#91;***&#93;, Gilead will, &#91;***&#93; notify the Gatekeeper in writing of the &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research Target Combination that Gilead &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Confirmed Research Target Combination and the procedure set forth in Section 5.1(c) (Confirmed Research Target Combinations) for confirming whether a Proposed Research Target Combination is not an Unavailable Target Combination (including the procedure applicable to any Proposed Research Target Combination that contains an Effector Target) will apply, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Research Target Combination-by-Research Target Combination basis, &#91;***&#93; Parties receive notification (in accordance with Section</font></div><div style="margin-top:0.1pt;padding-left:61pt;padding-right:29.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1 (Research Target Nomination)) that a given Research Target Combination is a Confirmed Research Target Combination, the Parties shall, through the JSC, discuss in good faith and mutually agree upon a research and early development plan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which shall be attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 5.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Research Plan), for which the overall objective is to generate and characterize Research Molecules and Research Products that are directed to the applicable Confirmed Research Target Combination, from which Gilead can select a product candidate to progress for further Development (such program with respect to a Confirmed Research Target Combination, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Research Plan shall&#58; (a) establish the criteria for evaluating potential Research Molecule candidates&#59; (b) define the deliverables, timelines and responsibilities of each Party through the progression of selecting Research Molecule candidates &#91;***&#93;  (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). On a Research Program-by-Research Program basis, Gilead shall, within &#91;***&#93; Research Plan for the Confirmed Research Target Combination that is the subject of such Research Program (such date of JSC approval of the initial Research Plan, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Target Combination License Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Target Combination License Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Effective as of the Research Target</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:29.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Combination License Date, the applicable Confirmed Research Target Combination shall be deemed a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensed Research Target Combination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, and the license granted under Section 3.1(a) (Research Term License) shall be deemed to be effective as to such Licensed Research Target Combination. The JSC shall</font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i) review, discuss and determine whether to approve any updates or amendments to each Research Plan no less than once per Calendar Quarter&#59; and (ii) oversee and facilitate cooperation and information transfer between the Parties in conducting the activities set forth in each Research Plan. In addition, each Party shall have the right to propose additional amendments to a Research Plan in connection with the progress of the applicable Research Program for the JSC to review, discuss and determine whether to approve. Any proposed amendments to a Research Plan will become effective only upon approval by the JSC. During the applicable Research Term for each Research Program, each Party shall not, and shall procure that its Affiliates, Sublicensees and Permitted Subcontractors shall not, perform any pre-clinical or clinical Development activities with respect to any Research Molecules or Research Products under such Research Program other than the activities expressly set forth in applicable Research Plan.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Performance Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the Research Term for each Research Program, each Party shall use Commercially Reasonable Efforts to conduct the activities allocated to such Party in the applicable Research Plan and in compliance with all Applicable Laws and Regulations, including applicable national and international (e.g., ICH, GCP, GLP and cGMP) guidelines, and the JSC shall oversee and facilitate the conduct of such activities. Additionally, each Party shall use Commercially Reasonable Efforts to provide any assistance required by the other Party to address or complete activities for which such other Party is responsible pursuant to the Research Plans, or as otherwise mutually agreed upon by the Parties.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Plan Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93; conduct of activities under each Research Program. &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in connection with the conduct of Research Program activities allocated to &#91;***&#93; under the applicable Research Plan, to the extent such costs are &#91;***&#93; Research Budget, &#91;***&#93;. If MacroGenics &#91;***&#93; in performing the Research Program activities allocated to MacroGenics under the applicable Research Plan that &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research Budget, &#91;***&#93; (including in connection with the performance of Regulatory Activities pursuant to Section 7.2 (Research Molecules and Research Products)) &#91;***&#93; Research Program activities that is &#91;***&#93; the JSC and the JSC shall promptly discuss in good faith and approve an amendment to the Research Plan or Research Budget in accordance with Section 2.1 (Joint Steering Committee) that &#91;***&#93; Research Budget or &#91;***&#93; applicable Research Plan). For clarity, in the absence of the JSC approving an amendment to the Research Plan or Research Budget, &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Research Program-by-Research Program basis, the term of a Research Program shall commence on the Research Target Combination License Date for the applicable Research Target Combination to which such Research Program is directed and continue until the earlier of</font></div><div style="margin-top:0.1pt;padding-left:60.95pt;padding-right:29.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) the end of the Research Program Opt-In Term for such Research Program, in the event that Gilead does not exercise its Research Program Opt-In for such Research Program, (b) the Research Program Opt-In Effective Date for such Research Program and (c) &#91;***&#93; of the Research Target Combination License Date for the Licensed Research Target Combination that is the subject of such Research Program (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; for such Research Program). On a Research Program-by-</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research Program basis, if Gilead exercises the Research Program Opt-In for a Research Program, then MacroGenics will, and will cause its Affiliates and Permitted Subcontractors to, cooperate with Gilead as Gilead may reasonably request to facilitate an orderly transition of the Development of the applicable Research Molecules and Research Products to Gilead or its designee. During the Research Term for a given Research Program, Gilead shall have right, upon reasonable request and at such times mutually agreed upon by the Parties, to conduct a periodic assessment of the intellectual property landscape for the Research Molecules under such Research Program (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IP Assessment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). MacroGenics shall reasonably cooperate with Gilead in its conduct of such IP Assessment.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Records&#59; Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the Term and &#91;***&#93;, each Party shall maintain complete, current and accurate records of all activities conducted by or on behalf of such Party pursuant to each Research Plan, and all data and other information resulting from the performance of such activities. Such records shall fully and properly reflect all work performed and results achieved in the performance of any Research Program activities in good scientific manner appropriate for regulatory and patent purposes. Additionally, during each JSC meeting, each Party shall provide the JSC with an update on the results and progress of any Research Program activities conducted by or on behalf of such Party since the prior JSC meeting. In addition, on a Calendar Quarter basis during the Research Term for a given Research Program, each performing Party shall provide the other Party with access to all information and data generated by or on behalf of such Party under such Research Program, with such access being provided through a secure dataroom or such other format mutually agreed upon by the Parties.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Data Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93;.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Opt-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Opt-In Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Research Program-by-Research Program basis, Gilead has an exclusive option to obtain an exclusive, royalty-bearing, non-transferable (except in accordance with Section 19.4 (Assignment&#59; Change of Control)) license under the MacroGenics Research Technology, with the right to grant sublicenses &#91;***&#93;,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to Exploit Research Molecules and Research Products that are directed to the applicable Licensed Research Target Combination that is the subject of such Research Program in the Field in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Opt-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MacroGenics shall deliver each Research Program Data Package to Gilead &#91;***&#93; Research Program that were required to generate the applicable Research Program Data Package (&#91;***&#93;,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">for purposes of the Research Program Data Package, being deemed &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:60.95pt;padding-right:29.85pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Deficiency Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93; Research Program Data Package, Gilead may provide MacroGenics with a Deficiency Notice if Gilead believes in good faith that the purported Research Program Data Package provided by MacroGenics does not contain all of the information required to be provided in such Research Program Data Package, which Deficiency Notice will reasonably specify any missing item(s). MacroGenics will modify such Research Program Data Package to reflect such comments and will provide an updated Research Program Data Package that includes the missing information &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:line-through"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deficiency Notice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, for clarity, MacroGenics shall not be required to generate any additional data that is not in existence as of the date of delivery of such Research Program Data Package (including re-running any previously performed studies) to the extent such data is supplementary and not required to be set forth in such Research Program Data Package or comply with any requests to modify the presentation or formatting of the then- existing data unless required to be set forth in such Research Program Data Package. If Gilead provides a Deficiency Notice, then the applicable Research Program Opt-In Term will be extended &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:60.95pt;padding-right:29.65pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In addition, &#91;***&#93;,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gilead may, itself or through the JSC, provide MacroGenics with written notice requesting assistance and cooperation from MacroGenics in analyzing such Research Program Data Package, including a request for a discussion with MacroGenics representative(s) who have relevant knowledge and information regarding such Research Program Data Package, and MacroGenics will use good faith efforts to provide any such assistance and cooperation reasonably requested by Gilead. Additionally, during the applicable Research Program Opt-In Term, Gilead shall use good faith efforts to assist MacroGenics in its efforts to coordinate and compile the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:4.55pt;padding-left:60.95pt;padding-right:29.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">contents of the Research Program Data Package in advance of completion of the activities under the Research Program and to respond to MacroGenics&#8217; queries regarding the formatting and completeness of such aspects of the Research Program Data Package.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Research Program-by-Research Program basis, Gilead may exercise the Research Program Opt-In for a Research Program by providing written notification to MacroGenics that it is doing so (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Opt-In Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Opt-In Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Upon MacroGenics&#8217; receipt of a Research Program Opt-In Exercise Notice for a Research Program during the Research Program Opt-In Term, the license to Gilead under Section 3.1(b) (Exploitation Licenses for Research Molecules and Research Products) for the Research Molecules and Research Products that are directed to the applicable Licensed Research Target Combination that is the subject of such Research Program &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Opt-In Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research Program Opt-In Effective Date for a Research Program, MacroGenics will provide Gilead with copies of all MacroGenics Research Know-How (other than MacroGenics Research Know-How relating to the Manufacture of the applicable Research Molecules and Research Products, the initial transfer of which will be performed in accordance with Section 9.4 (Manufacturing Technology Transfer)) that &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research Molecules and Research Products. To facilitate each such transfer, the Parties may mutually agree upon a written technology transfer plan to such MacroGenics Research Know-How (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Technology Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which will set forth a process and schedule for the transfer of such MacroGenics Research Know-How, projected levels of support to be provided by each Party, allocation among the Parties of the major activities for such technology transfer and an overall timeline for its progress and completion. Each Party shall complete the activities allocated</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to it under each Research Program Technology Transfer Plan (if any such plan is agreed upon). Thereafter, on a periodic basis &#91;***&#93; MacroGenics Research Know-How (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Technology Transfer Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as Gilead may reasonably request, MacroGenics will provide to Gilead copies of all MacroGenics Research Know-How that is (a) created, developed, invented or otherwise made in the &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics Research Know-How, &#91;***&#93; Research Molecules and Research Products in accordance with the terms of this Agreement &#91;***&#93; Research Plan. In addition to providing copies of the MacroGenics Research Know-How in accordance with this Section 5.9 (Technology Transfer), MacroGenics will make its personnel reasonably available to Gilead during the Research Program Technology Transfer Period, at Gilead&#8217;s expense, so as to enable Gilead to practice under the MacroGenics Technology in connection with the Exploitation of the applicable Research Molecules and Research Products. Other than as set forth in the preceding sentence, &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics Research Know- How in accordance with this Section 5.9 (Technology Transfer).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Research Program-by-Research Program basis, in the event that (a) Gilead does not exercise the Research Program Opt-In during the Research Program Opt-In Term for a Research Program or pay the Research Program Opt-In Exercise Fee in accordance with Section 5.8(c) (Option Exercise) or (b) the Outside Date for such Research Program occurs prior to the Research Program Opt-In Effective Date for such Research Program, the following shall occur&#58; (i) such Research Program and all rights and licenses granted by one Party to the other in connection therewith (including pursuant to Sections 3.1(a) (Research Term License), 3.1(b) (Exploitation Licenses for Research Molecules and Research Products) and 3.2(a) (Research Term License)) shall terminate in their entirety,</font></div><div style="padding-left:61pt;padding-right:29.8pt;text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii) this Agreement shall terminate with respect to such Research Program as well as all Research Products and Research Molecules with respect to such Research Program and for clarity, (1) Research Molecules with respect to such Research Program shall not be deemed Licensed Molecules and Research Products with respect to such Research Program shall not be deemed Licensed Products and (2) no Research Product Development Milestone Payments, Commercial Milestone Payments or royalties, in each case, will be due for Research Products with respect to such Research Program, (iii) MacroGenics&#8217; exclusivity obligations pursuant to Section 3.10(b) (Research Program Exclusivity) with respect to the applicable Research Molecules and Research Products shall terminate immediately and (iv) Gilead shall promptly return to MacroGenics or destroy (at MacroGenics&#8217; election) any and all MacroGenics Research Know-How and any other Confidential Information of MacroGenics or its Affiliates solely related to the applicable Research Molecules, Research Products or such Research Program, in accordance with Section 12.1(e) (Obligations Upon Termination). For the avoidance of doubt, upon the early termination of a given Research Program in accordance with this Section 5.10 (Research Program Termination), MacroGenics shall have no further obligations to Gilead with respect to the applicable Research Target Combination and any Research Molecule or Research Product and shall have the right to Exploit (or to not Exploit) in any manner whatsoever any Research Molecule or Research Product, in MacroGenics&#8217; sole discretion, without provision or disclosure of any related information or other Know-How to Gilead in connection therewith.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Antitrust Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.5pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If Gilead determines, in its sole discretion, that any filings, notices, applications or other submissions under Antitrust Law are necessary or advisable in connection with Gilead&#8217;s exercise of the CD123 Option or a Research Program Opt-In (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Antitrust Filing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then Gilead and MacroGenics will submit such Antitrust Filings (in draft form where applicable) as soon as reasonably practicable. MacroGenics will furnish in a timely manner all information, documents and assistance as</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in connection with the antitrust assessment and, if applicable, with the preparation of any such Antitrust Filings, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that such information may be redacted as necessary to address legal privilege or confidentiality concerns, or to comply with Applicable Laws and Regulations, and that any information that is considered competitively sensitive may be designated as for &#8220;outside antitrust counsel only&#8221;. In connection with any such Antitrust Filing, the Parties will furnish promptly to the United States Federal Trade Commission, the Antitrust Division of the United States Department of Justice and any other applicable Governmental Entity any additional information requested within their authority under the HSR Act or other Antitrust Law, use reasonable efforts to obtain antitrust clearance for the transactions contemplated hereunder as soon as practicable and otherwise cooperate with each other in any such governmental antitrust clearance process. &#91;***&#93;.</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, nothing in this Section 6.1(a) (Filings) or otherwise in this Agreement will require Gilead or its Affiliates to, in connection with obtaining antitrust clearance for any of the transactions contemplated hereunder, (i) propose, negotiate, effect or agree to, the sale, divestiture, license or other disposition of any assets or businesses of Gilead or any of its Affiliates or otherwise take any action that limits its freedom of action with respect to, or its ability to retain, any of the businesses, product lines or assets of Gilead or any of its Affiliates, or (ii) litigate or otherwise formally oppose any determination (whether judicial or administrative in nature) by a Governmental Entity seeking to impose any of the restrictions referenced in clause (ii) above.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.45pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Program Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Following the CD123 Option Exercise Date, the license set forth in Section 3.1(d) (Exploitation License for CD123 Molecules and CD123 Products) &#91;***&#93;,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Option Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221; In addition, &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CD123 Option Exercise Notice, the CD123 Development Term &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.75pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Programs Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Research Program-by-Research Program basis, following the Research Program Opt-In Date for a Research Program, the license set forth in Section 3.1(b) (Exploitation Licenses for Research Molecules and Research Products) for the Research Molecules and Research Products that are directed to the applicable Licensed Research Target Combination &#91;***&#93;,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Opt-In Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221; &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research Program Opt-In Exercise Notice for a Research Program, the Research Term for such Research Program</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:29.4pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Outside Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If (i) Gilead determines any Antitrust Filings are necessary or advisable in connection with Gilead&#8217;s exercise of the CD123 Option or a Research Program Opt-In and (ii) the CD123 Option Effective Date or applicable Research Program Opt-In Effective Date does not occur on or before &#91;***&#93; after the CD123 Option Exercise Date or applicable Research Program Opt-In Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Initial Outside Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then Gilead &#91;***&#93; provide written notice to MacroGenics on or prior to the applicable Initial Outside Date to extend such Initial Outside Date by &#91;***&#93; (the Initial Outside Date, as it may be extended, if applicable, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Outside Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the Parties may mutually agree to extend the Outside Date if such extension is necessary for Gilead to litigate, defend against, or otherwise contest any challenge, claim, lawsuit or other cause of action in connection with the Gilead&#8217;s exercise of the CD123 Option Effective Date or applicable Research Program Opt-In Effective Date pursuant to or under any Antitrust Law.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:169pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Without limiting the foregoing obligations in this Section</font></div><div style="margin-top:0.1pt;padding-left:60.95pt;padding-right:29.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1&#160;&#160;&#160;&#160;(Antitrust Filings), each Party will promptly notify the other of the receipt and content of any inquiries or requests for additional information made by any Governmental Entity in connection with Gilead&#8217;s exercise of the CD123 Option or a Research Program Opt-In and keep the other apprised on a prompt basis of the status of any such inquiry or request. Each Party will promptly inform the other Party of any oral communication with, and provide copies of written communications with, any Governmental Entity regarding Gilead&#8217;s exercise of the CD123 Option or a Research Program Opt-In. Except as prohibited by Applicable Law and Regulations, no Party will independently participate in any meeting or conference call with any Governmental Entity in respect of any such filings, investigation or other such inquiry without giving the other Party prior notice of the meeting and, to the extent permitted by such Governmental Entity, the opportunity to attend and participate.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Molecules and CD123 Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. After the CD123 Option Effective Date, Gilead shall &#91;***&#93;, for the Development of the CD123 Molecules and CD123 Products. Gilead shall use Commercially Reasonable Efforts to Develop &#91;***&#93;. After the CD123 Option Effective Date, Gilead &#91;***&#93; Development or obtaining Regulatory Approval of any CD123 Molecules or CD123 Products other than as set forth in this Section</font></div><div style="margin-top:0.15pt;padding-left:77.5pt;text-indent:-16.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2&#160;&#160;&#160;&#160;(CD123 Molecules and CD123 Products).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Molecules and Research Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Research Program-by-Research Program basis, after the applicable Research Program Opt-In Effective Date, Gilead &#91;***&#93; Development of each Research Molecule and Research Product. Gilead shall use Commercially Reasonable Efforts to Develop &#91;***&#93;.</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">After the Research Program Opt-In Effective Date for a Research Program, Gilead will have no other diligence obligations with respect to the Development or obtaining Regulatory Approval of any Research Molecules or Research Products for such Research Program other than as set forth in this Section 6.3 (Research Molecules and Research Products).</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">6.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Performance Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. Each Party shall conduct all Development activities with respect to the Licensed Molecules and Licensed Products in compliance with all Applicable Laws and Regulations, including applicable national and international (e.g., ICH, GCP, GLP and cGMP) guidelines.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93; shall maintain complete, current and accurate records of all activities conducted by or on behalf of Gilead in furtherance of the Development of the Licensed Molecules and Licensed Products after the CD123 Option Effective Date and each Research Program Opt-In Effective Date, as applicable. Such records shall fully and properly reflect all work performed and results achieved in the performance of such Development activities in good scientific manner appropriate for regulatory and patent purposes.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Program-by-Program basis, &#91;***&#93; Licensed Product for a Program in the Field in the Territory, Gilead shall provide MacroGenics &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Development of Licensed Molecules and Licensed Products under such Program during &#91;***&#93;, describing, among other matters, those&#58;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:line-through"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Data Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div style="margin-top:4.5pt;padding-left:97pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Molecules and CD123 Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the CD123 Development Term, MacroGenics shall be solely responsible, &#91;***&#93;, for all Regulatory Activities related to the CD123 Molecules and CD123 Products in the Field in the Territory, and shall own all Regulatory Submissions (including Regulatory Approvals) generated with respect to CD123 Molecules or CD123 Products during the CD123 Development Term. Gilead shall have the right, but not the obligation, to review and comment on all Regulatory Submissions for CD123 Molecules and CD123 Products and MacroGenics shall reasonably incorporate any such comments in such Regulatory Submissions prior to filing thereof and shall promptly provide copies of any Regulatory Submissions (including all material updates thereof) to Gilead. Gilead (or its designee) shall have a right to participate (and MacroGenics may otherwise request Gilead to participate) in meetings and interactions with the Regulatory Authorities that solely relate to any CD123 Molecule or CD123 Product. Gilead shall assist MacroGenics, as reasonably requested by MacroGenics, in connection with the preparation and filing of Regulatory Submissions related to the combination of the &#91;***&#93; with the CD123 Product, including by providing MacroGenics with all necessary data or other information in Gilead&#8217;s possession related to (i) &#91;***&#93; Gilead or (ii) the Required Regulatory Activities if Gilead elects to conduct such activities pursuant to Section 4.2(b) (Required Regulatory Activities).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">After the CD123 Development Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. After the expiration (but not early termination) of the CD123 Development Term (with Gilead having exercised the CD123 Option during such time), Gilead shall have the sole right and sole control over &#91;***&#93;,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">all Regulatory Activities related to the CD123 Molecules and CD123 Products, except for any Regulatory Activities relating to the MacroGenics Manufacturing Facilities, including any Regulatory Authority inspections with respect thereto (for which matters MacroGenics shall have responsibility for in accordance with the Clinical Supply Agreement). MacroGenics will support Gilead as may be reasonably requested by Gilead from time to time in connection with Gilead&#8217;s preparation, submission to Regulatory Authorities and maintenance of Regulatory Submissions for CD123 Products, including, upon Gilead&#8217;s reasonable request, attending meetings with Regulatory Authorities regarding any CD123 Product. &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Regulatory Activities &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">related to the CD123 Molecules or CD123 Products. Gilead shall &#91;***&#93; Regulatory Activities requested by Gilead after the CD123 Option Effective Date, in accordance with Section 11.1 (Development Costs, Plan Costs and Manufacturing Costs).</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Molecules and Research Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Gilead shall have the sole right and sole control over all Regulatory Activities to be undertaken with respect to Research Molecules and Research Products in connection with any Research Program for which Gilead has exercised the Research Program Opt-In. MacroGenics will support Gilead as may be reasonably requested by Gilead from time to time in connection with Gilead&#8217;s preparation, submission to Regulatory Authorities and maintenance of Regulatory Submissions for Research Products, including, upon Gilead&#8217;s reasonable request, attending meetings with Regulatory Authorities regarding any Research Product. &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">related to the Research Molecules or Research Products&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, with respect to MacroGenics, (a) prior to the Research Program Opt-In Effective Date, subject to Section 5.4 (Research Plan Costs), &#91;***&#93; or (b) after the applicable Research Program Opt-In Effective Date, &#91;***&#93; Gilead. Gilead shall &#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transfer of Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Promptly after the CD123 Option Effective Date, MacroGenics will, or will cause its designee to, transfer and assign (and hereby does assign and transfer) to Gilead all rights, title and interests in and to all INDs and all other Regulatory Submissions that solely relate to MGD024 and the MGD024 Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Assigned Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), including copies of </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:60.95pt;padding-right:29.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">all such Assigned Regulatory Materials in electronic format, to the extent the same have not been previously made available to Gilead, which transfer will &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the CD123 Option Effective Date.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.7pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon a Party&#8217;s written request, the other Party will execute and deliver, or will cause to be executed and delivered, to the requesting Party such endorsements, assignments, commitments, acknowledgements and other documents as may be necessary (a) to assign, convey, transfer and deliver to Gilead all of MacroGenics&#8217; or its applicable Affiliate&#8217;s or designee&#8217;s rights, title and interests in and to the applicable Assigned Regulatory Materials, or (b) as a result of the transfer to Gilead of the Assigned Regulatory Materials, including submitting to each applicable Regulatory Authority or other governmental authority in the Territory a letter or other necessary documentation (with copy to the other Party) notifying such Regulatory Authority or other governmental authority of, or otherwise giving effect to, the transfer of ownership to Gilead of the Assigned Regulatory Materials in the Field in the Territory as provided in Section 7.3(a) (Regulatory Transfer).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Right of Reference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MacroGenics will grant, and hereby does grant, to Gilead, effective upon the CD123 Option Effective Date, a &#8220;Right of Reference,&#8221; as that term is defined in 21 C.F.R. &#167; 314.3(b) (or any successor rule or analogous Applicable Laws and Regulations recognized outside of the United States), to all Regulatory Submissions pertaining to the CD123 Products in the Field submitted by or on behalf of MacroGenics or its Affiliates. Gilead and its Sublicensees may use such right of reference solely for the purpose of seeking, obtaining, supporting and maintaining Regulatory Approval and any Pricing and Reimbursement Approvals, as applicable, for the CD123 Products in the Field in the Territory. MacroGenics will take such actions as may be reasonably requested by Gilead to give effect to the intent of this Section 7.4 (Right of Reference), including, if requested by Gilead, (a) providing a signed statement that Gilead may rely on, and that the applicable Regulatory Authority may access, MacroGenics&#8217; Regulatory Submissions in support of Gilead&#8217;s application for Regulatory Approval for any CD123 Product, and (b) providing Gilead with any underlying raw data or information submitted by MacroGenics</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:28.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to the Regulatory Authority with respect to any Regulatory Submissions Controlled by MacroGenics or any of its Affiliates that solely relates to any CD123 Product.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Adverse Event Reporting&#59; Global Safety Database</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the CD123 Development Term, MacroGenics shall establish and maintain a drug safety database for MGD024 and the MGD024 Product, and shall be responsible for monitoring of all related clinical experiences, safety monitoring, pharmacovigilance surveillance and compliance and filing of all required safety reports to all Regulatory Authorities in connection therewith (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Safety&#47;AE Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). MacroGenics will use reasonable efforts to complete the transfer to Gilead of such drug safety database for MGD024 and the MGD024 Product promptly following the CD123 Option Effective Date and, following such transfer, Gilead will have the sole right and responsibility for holding and maintaining such drug safety database. On a Research Program-by-Research Program basis, Gilead shall have the sole right and sole control over, at its sole cost and expense, all Safety&#47;AE Matters in connection with the Research Molecules or Research Products for a given Research Program from and after the Research Program Opt-In Effective Date for such Research Program.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recalls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Program-by-Program basis, during the Collaboration Term for a Program, MacroGenics will be responsible for any recalls, market suspensions or market withdrawals (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recalls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) for the Licensed Products for such Program. On a Program-by-Program basis, after completion of the Collaboration Term for a Program, Gilead shall have the sole right and sole control over any Recalls for the Licensed Products for such Program and MacroGenics will reasonably cooperate in any such Recall efforts. Gilead shall promptly notify MacroGenics in writing of any decision or obligation to undertake a Recall of any Licensed Product and to the extent such Recall is with respect to the MGD024 Product, Gilead shall include in such notice the reasoning behind such determination and any supporting facts. Subject to Article 15 (Indemnification), (a) if a Recall resulted from a Party&#8217;s or its Affiliate&#8217;s breach of its obligations under this Agreement or the Clinical Supply Agreement, or from such Party&#8217;s or its Affiliate&#8217;s gross negligence or willful misconduct, then such Party shall bear the expense of such Recall and (b) with respect to any Recall not covered by clause (a), Gilead shall be responsible for all costs of such Recall.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.95pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Conflict</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If the Parties rights and obligations in this Article 7 (Regulatory) conflict with the Parties rights and obligations with respect to Development or Commercialization activities under this Agreement, then this Article 7 (Regulatory) will control solely with respect to any such conflict.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:96.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Responsibility&#47;Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Effective upon the CD123 Option Effective Date, Gilead shall have the sole right and sole control over, &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:line-through"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercialization of the CD123 Products in the Territory and shall &#91;***&#93; Gilead has received Regulatory Approval for a CD123 Product. Effective upon the Research Program Opt-In Effective Date for a Research Program, Gilead shall have the sole right and sole control over, &#91;***&#93; Commercialization of the Research Products for such Research Program in the Territory and shall use Commercially Reasonable Efforts to &#91;***&#93;. Gilead will have no other diligence obligations with respect to the Commercialization of any Licensed Products other than as set forth in this Section 8.1 (Responsibility&#47;Diligence).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Gilead shall have the sole right and sole control over, at its own expense, all matters relating to the use of, and shall own, all Trademarks used in the Commercialization of Licensed Products, which may vary by country or within a country, but excluding the MacroGenics Platform Trademarks, including the selection, filing, prosecution, maintenance, defense and enforcement thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.05pt;padding-left:96.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacture and Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MGD024 and MGD024 Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.5pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Prior to the CD123 Option Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Commencing on the Effective Date and continuing until the CD123 Option Effective Date, MacroGenics shall be solely responsible, &#91;***&#93; Manufacture, either by itself or through one or more Third Parties selected by MacroGenics in accordance with Section 3.4 (Subcontractors), of MGD024 Products for use in connection with any Development activities conducted by or on behalf of the Parties under the CD123 Development Plan (including, for clarity, the Phase 1 Clinical Trial of MGD024 Product). &#91;***&#93; CD123 Development Term, subject to the terms of MacroGenics&#8217; agreements with its Third Party CMOs responsible for the Manufacture of MGD024 Product (or any component thereof) as of the Effective Date, which agreements are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 9.1(a)(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Existing CMO Agreements) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Existing CMO Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), MacroGenics will use Commercially Reasonable Efforts to &#91;***&#93; MGD024 Drug Products</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:line-through"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, Gilead &#91;***&#93; Manufacturing and supplying to Gilead any such quantities of MGD024 Product in excess of the quantities &#91;***&#93; for such quantities of MGD024 Drug Product. Notwithstanding the foregoing, upon the expiration (solely in the event that Gilead does not exercise the CD123 Option during such time) or termination of the CD123 Development Term, Gilead shall, upon MacroGenics&#8217; request, transfer to MacroGenics, &#91;***&#93;, any MGD024 Drug Product that has not been used by Gilead as of such date.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.5pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">During the Clinical Supply Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to Section 9.1(a)(v) (Failure to Supply), &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Supply Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), MacroGenics shall use Commercially Reasonable Efforts to Manufacture or have Manufactured, itself or through its Permitted Subcontractors in accordance with Section 3.4 (Subcontractors), all clinical supply of MGD024 Drug Product for Gilead pursuant to the terms of the Clinical Supply Agreement entered into between the Parties&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that &#91;***&#93;, MacroGenics will supply Gilead with all clinical supply of MGD024 Drug Product required for Gilead&#8217;s Development activities on and after the CD123 Option Effective Date and Gilead shall &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in accordance with Section 11.1 (Development Costs, Plan Costs and Manufacturing Costs).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.6pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that will set forth the terms and conditions for MacroGenics&#8217; provision, during the Clinical Supply Term, of clinical supplies of the MGD024 Drug Product to Gilead for use in Clinical Trials to be conducted by Gilead using MGD024 Products. The Clinical Supply Agreement will include &#91;***&#93;. Under the Clinical Supply Agreement, MacroGenics shall provide batches of MGD024 Drug Product &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MGD024 Transfer Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Clinical Supply Agreement will also include &#91;***&#93;. The Parties shall &#91;***&#93; that shall further address and govern issues related to the quality of the MGD024 Drug Product to be supplied by MacroGenics pursuant to the Clinical Supply Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). MacroGenics will supply, or cause to be supplied, to Gilead the MGD024 Drug Product, in accordance with the provisions of this Agreement, and once executed, the Parties shall comply with their respective obligations to supply, or cause to be supplied, the MGD024 Drug Product, in accordance with the provisions of the Clinical Supply Agreement and the Clinical Quality Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. For clarity, during the Clinical Supply Term, Gilead will have the sole right and control over the Packaging and Labeling, either by itself or through one or more Third Parties, of the MGD024 Drug Product for Gilead&#8217;s use in Clinical Trials in the Field in the Territory. Subject to completion of the Manufacturing Technology Transfer of all relevant MacroGenics CD123 Know-How in accordance with Section 9.4 (Manufacturing Technology Transfer), following the expiration of the Clinical Supply Term, Gilead shall have the sole right and control over the Manufacture, either by itself or through one or more Third Parties, of MGD024 Products and any other CD123 Products for Development activities conducted by or on behalf of Gilead in the Field in the Territory.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Failure to Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If, (1) in any given &#91;***&#93; of the &#91;***&#93; of MGD024 Drug Product ordered by Gilead for delivery with respect to such period is not delivered or is delivered more than &#91;***&#93; of MGD024 Drug Product ordered by Gilead for delivery for each &#91;***&#93; Gilead will have the right to terminate the Clinical Supply Term after providing written notice to MacroGenics of such </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:60.95pt;padding-right:29.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">failure to supply. For clarity, non-conforming MGD024 Drug Product will be deemed not to have been delivered unless and until MacroGenics supplies conforming replacement MGD024 Drug Product. Notwithstanding anything to the contrary herein, the existence of a supply failure pursuant to this Section 9.1(a)(v) (Failure to Supply) shall not, in itself, constitute a breach of this Agreement by MacroGenics (although, for clarity, the underlying cause of such supply failure may be a breach of this Agreement).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.75pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Gilead shall have the sole right and control over the Manufacture, either by itself or through one or more Third Parties, of MGD024 Products and any other CD123 Products for Commercialization activities conducted by or on behalf of Gilead in the Field in the Territory.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Molecules and Research Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Gilead shall have the sole right and sole control over the Manufacture of clinical and commercial supply of Research Molecules and Research Products, &#91;***&#93; Gilead shall ensure that all clinical and commercial supplies of Research Molecules and Research Products are Manufactured in accordance with all Applicable Laws and Regulations.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Observation by Gilead</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Program-by-Program basis, after (a) with respect to the CD123 Development Program, the CD123 Option Exercise Date and (b) with respect to a Research Program, the Research Program Opt-In Date for such Research Program, MacroGenics will provide Gilead with the opportunity, upon Gilead&#8217;s reasonable request, &#91;***&#93; the Manufacturing processes and procedures for the Licensed Molecules and Licensed Products related to such Program (e.g., review assays, batch records, and release processes and procedures) for the purpose of enabling Gilead (or a Third Party contract manufacturer (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) designated by Gilead) to Manufacture such Licensed Molecules and Licensed Products pursuant to Section 9.4 (Manufacturing Technology Transfer). If MacroGenics utilizes a CMO for the Manufacture of any Licensed Molecules or Licensed Products, then MacroGenics will use Commercially Reasonable Efforts, including entering into a three- party confidentiality agreement with Gilead and such CMO, to enable Gilead to exercise its observational rights under this Section 9.3 (Observation by Gilead) with respect to any Manufacturing activities for the Licensed Molecules and Licensed Products being conducted by such CMO.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Program-by-Program basis, &#91;***&#93; (a) with respect to the CD123 Development Program, the CD123 Option Effective Date and (b) with respect to a Research Program, the Research Program Opt-In Effective Date for such Research Program, MacroGenics will work with Gilead to transfer to Gilead (or its designee) all MacroGenics Licensed Know-How &#91;***&#93; for the applicable Program, to the extent not previously transferred to Gilead under this Agreement, including by providing copies or samples of relevant documentation, materials, and other embodiments of any such MacroGenics Licensed Know-How, and by making available its qualified technical personnel on a reasonable basis to consult with Gilead with respect to such Know-How (for each Program, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Each Manufacturing Technology Transfer &#91;***&#93; Manufacturing Processes and Manufacture the applicable Licensed Product, and shall be subject to a written plan developed and approved by the Parties through the JSC in good faith with respect to the Manufacturing Technology Transfer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Transition Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Each Manufacturing Transition Plan &#91;***&#93; performance of the activities set forth in the applicable Manufacturing Transition Plan (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Transition Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Parties shall use Commercially Reasonable Efforts to implement each Manufacturing Technology Transfer to Gilead or its designee in accordance with the applicable Manufacturing Transition Plan. &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Manufacturing Technology Transfer for the relevant Program(s). &#91;***&#93; MacroGenics to conduct activities under the Manufacturing Transition Plan for such Program(s) in accordance &#91;***&#93; MacroGenics shall provide notice to the JSC and the JSC shall promptly discuss in good faith and consider whether to implement any amendments to the Manufacturing Transition Plan &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Manufacturing Support</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties understand and agree following the Manufacturing Technology Transfer contemplated by Section 9.4 (Manufacturing Technology Transfer) it may be necessary for Gilead from time to time to seek assistance and cooperation from MacroGenics in connection with the Manufacture of Licensed Products, including with respect to activities performed to increase production quantities of the Licensed Products. MacroGenics will use reasonable efforts to provide any such assistance and cooperation reasonably requested by Gilead &#91;***&#93;. </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</font></div></td></tr></table></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_34"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.05pt;padding-left:96.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Within &#91;***&#93; after the Effective Date, Gilead shall pay to MacroGenics Sixty Million US Dollars (US$60,000,000), which shall be non-creditable and non- refundable against any other payments due under this Agreement.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development and Regulatory Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement, Gilead shall pay to MacroGenics the one-time, non-creditable, non-refundable milestone payments set forth in the table below in this Section 10.2(a) (CD123 Products) after the first achievement of the applicable milestone events by a CD123 Product, whether such achievement is by or on behalf of Gilead, its Affiliate or any Sublicensee of Gilead (each event, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and each payment, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). For clarity, each of the CD123 Development Milestone Payments shall be payable only once, regardless of the number of times the corresponding CD123 Development Milestone Event is achieved. Gilead will promptly notify MacroGenics upon the achievement of each CD123 Development Milestone Event and will pay the corresponding CD123 Development Milestone Payment within &#91;***&#93; following receipt of an invoice from MacroGenics for such CD123 Development Milestone Payment. If Gilead or its Affiliates or Sublicensees achieve all of the CD123 Development Milestone Events (regardless of the number of times such events occur or the number of CD123 Products that trigger such event), then the CD123 Development Milestone Payments payable by Gilead under this Section 10.2(a) (CD123 Products) will not exceed &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:59.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.727%"><tr><td style="width:1.0%"></td><td style="width:9.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.887%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#bcd6ed;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:161.05pt;padding-right:161.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:113%">CD123 Development Milestones</font></div></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#bcd6ed;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" rowspan="2" style="background-color:#bcd6ed;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.92pt;padding-right:6.92pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:132%">&#91;***&#93;</font></div></td><td colspan="9" style="background-color:#bcd6ed;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 72.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 27.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 22.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 24.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:5.6pt;padding-right:9.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.6pt;padding-right:9.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.6pt;padding-right:41.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:30pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement, on a Research Program-by-Research Program basis, Gilead shall pay to MacroGenics the one-time, non- creditable, non-refundable milestone payments set forth in the table below in this Section 10.2(b) (Research</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</font></div></td></tr></table></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_37"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Products) within &#91;***&#93; after the first achievement of the applicable milestone events by an Research Product for a Research Program, whether by or on behalf of Gilead, its Affiliate or any Sublicensee of Gilead (each event, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Product Development Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and each payment, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Product Development Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). For clarity, each of the Research Product Development Milestone Payments shall be payable only once for each Research Program, regardless of the number of times the corresponding Research Product Development Milestone Event is achieved for such Research Program. If Gilead or its Affiliates or Sublicensees achieve all of the Research Product Development Milestone Events for a Research Program (regardless of the number of times such events occur or the number of Research Products that trigger such event for such Research Program), then the Research Product Development Milestone Payments payable by Gilead under this Section 10.2(b) (Research Products) for a Research Program will not exceed &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:61.95pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.861%"><tr><td style="width:1.0%"></td><td style="width:9.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#bcd6ed;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:161pt;padding-right:161pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:113%">Research Milestones</font></div></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#bcd6ed;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" rowspan="2" style="background-color:#bcd6ed;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:46.05pt;padding-right:46.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div></td><td colspan="9" style="background-color:#bcd6ed;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 30.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 21.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 21.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.7pt;padding-right:8.3pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.25pt;padding-left:5.7pt;padding-right:8.3pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:5.7pt;padding-right:8.3pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Skipped Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The milestone events in Section 10.2(a) (CD123 Products) and Section 10.2(b) (Research Products) are intended to be successive with respect to each Licensed Product, such that if a particular milestone event set forth in the table above for a Licensed Product is not achieved prior to the achievement of the next milestone event set forth in the table above for such Licensed Product in such Indication (such non-achieved milestone event, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Skipped Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then such Skipped Milestone shall be deemed to have been achieved upon the achievement of such next milestone event to occur, and the milestone payment for such Skipped Milestone shall be due and payable by Gilead to MacroGenics at the time the milestone payment is due and payable for such next milestone event. &#91;***&#93; shall be due and payable by Gilead to MacroGenics at the time the milestone payment for &#91;***&#93; is due and payable under this Section 10.2 (Development and Regulatory Milestone Payments).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement, Gilead shall pay to MacroGenics the one-time, non-creditable, non-refundable milestone payments set forth in the table below in this Section 10.3 (Commercial Milestone Payments) within &#91;***&#93; after the end of the Calendar Quarter after the first achievement of the applicable sales milestone event (each event, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and each payment, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). For clarity&#58; (a) the Commercial Milestone Payments in this Section 10.3 (Commercial Milestone Payments) shall be additive such that if multiple Commercial Milestone Events are achieved in the same Calendar Year, then the Commercial Milestone Payments for all such Commercial Milestone Events shall be payable with respect to such Calendar Year&#59; (b) each of the Commercial Milestone Payments applicable to the CD123 Products shall be payable only once regardless of the number of times the corresponding Commercial Milestone Event is achieved&#59; and (c) each of the Commercial Milestone Payments applicable to Research Products shall be payable only once for each Research Program (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">i.e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">., upon achievement of the applicable Commercial Milestone Event by Research Products in each such Research Program). If Gilead or its Affiliates or Sublicensees achieve all of the Commercial Milestone Events (regardless of the number of times such events occur), then the Commercial Milestone Payments payable by Gilead under this Section</font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:30.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">10.3 (Commercial Milestone Payments) will not exceed &#91;***&#93;.</font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:30.15pt;text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:67pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.850%"><tr><td style="width:1.0%"></td><td style="width:67.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#9cc1e4;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:91.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:106%">Commercial Milestone Event</font></div></td><td colspan="3" style="background-color:#9cc1e4;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:106%">Milestone Payment</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">The aggregate Net Sales of all CD123 Products in the Territory in a Calendar Year &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">The aggregate Net Sales of all CD123 Products in the Territory in a Calendar Year &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The aggregate Net Sales of all CD123 Products in the Territory in a Calendar Year &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The aggregate Net Sales of all Research Products for a Research Program in the Territory in a Calendar Year &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">The aggregate Net Sales of all Research Products for a Research Program in the Territory in a Calendar Year &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The aggregate Net Sales of all Research Products for a Research Program in the Territory in a Calendar Year &#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalties on Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.95pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Section 10.4 (Royalties on Net Sales), Gilead shall pay to MacroGenics, on a Research Product-by-Research Product and country- by-country basis in the Territory, an &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">royalty on Net Sales for each Research Product in</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Territory during the applicable Royalty Term for such Research Product in a country in the Territory. Additionally, subject to the terms and conditions of this Section 10.4 (Royalties on Net Sales), Gilead shall pay to MacroGenics on a CD123 Product-by-CD123 Product and country-by-country basis in the Territory, royalties at following percentages of Net Sales for all CD123 Product in the Territory during the applicable Royalty Term for a CD123 Product in a country in the Territory&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:67pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.789%"><tr><td style="width:1.0%"></td><td style="width:71.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.940%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#9cc1e4;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:106%">Annual Aggregate Net Sales of CD123 Products in the Territory</font></div></td><td colspan="3" style="background-color:#9cc1e4;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:32.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:106%">Royalty Rate</font></div></td></tr><tr style="height:13pt"><td colspan="6" style="background-color:#cfcdcd;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">For that portion of aggregate annual Net Sales of all CD123 Products less than or equal to &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For that portion of aggregate annual Net Sales of all CD123 Products greater than &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For that portion of aggregate annual Net Sales of all CD123 Products greater than &#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.75pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Expiration of the Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon expiration of the Royalty Term for a given Licensed Product in a given country (i) no further royalties will be payable in respect of sales of such Licensed Product in such country and no further Net Sales in such country will accrue toward the achievement of the Commercial Milestone Events by Gilead, and (ii) the licenses granted to Gilead under Section 3.1(b) (Exploitation Licenses for Research Molecules and Research Programs) and Section 3.1(d) (Exploitation License for CD123 Molecules and CD123 Products) with respect to the Exploitation of such Licensed Product in such country will automatically become fully paid-up, perpetual, irrevocable and royalty free. For clarity, only a single royalty will be payable as a result of one or more Valid Claims claiming a Licensed Product during the Royalty Term.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.8pt;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lack of Valid Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Licensed Product-by-Licensed Product and country-by-country basis, if the composition of matter or method of use of a Licensed Product is no longer Covered by a Valid Claim within the Royalty Bearing Patents in a given country, then the royalties payable with respect to such Licensed Product in such country pursuant to Section 10.4(a) (Royalty Rate) will be &#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:60.95pt;padding-right:29.65pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Biosimilar Product Market Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If one or more Biosimilar Products with respect to a Licensed Product are on the market in a country and the volume of sales of such Biosimilar Products in such country constitute &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or more of the total sales for such Biosimilar Products and Licensed Products in such country in a Calendar Quarter, then Gilead may reduce the royalty payments due for Net Sales for such Licensed Product in such country pursuant to Section 10.4(a) (Royalty Rate) by &#91;***&#93; in such Calendar Quarter and in each Calendar Quarter thereafter during the Royalty Term in which such market reduction exists.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.65pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;&#91;***&#93; the royalties payable by Gilead to MacroGenics with respect to Net Sales of such Licensed Product pursuant to Section 10.4(a) (Royalty Rate) shall be reduced, on a Licensed Product-by-Licensed Product basis, by &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of the amounts paid by Gilead or its Affiliates or Sublicensees &#91;***&#93; respect to such Licensed Product &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that the terms of &#91;***&#93; the Licensed Molecules or Licensed Products. In addition, subject to the terms of &#91;***&#93;, Gilead will have the right to reduce the royalties payable by Gilead to MacroGenics with respect to Net Sales of a Licensed Product pursuant to Section 10.4(a) (Royalty Rate), on a Licensed Product-by-Licensed Product basis, &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.55pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Floor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 10.4(c)(c)(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Special Offset and Indemnification), in no event shall the royalty reductions available to Gilead under Section 10.4(c) (Royalty Reduction), collectively or individually, reduce the royalties payable to MacroGenics for a given Calendar Quarter to less than &#91;***&#93; of the amount otherwise payable under Section 10.4 (Royalties on Net Sales) with respect to an applicable Licensed Product. &#91;***&#93;.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:96.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payments&#59; Reports&#59; Records&#59; Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Costs, Plan Costs and Manufacturing Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Within &#91;***&#93; Calendar Quarter during the Term, MacroGenics shall submit an invoice to Gilead detailing the FTE Costs and Out-of-Pocket Costs incurred by MacroGenics during such Calendar Quarter to conduct the following activities and Gilead shall pay MacroGenics the full undisputed amount of each such invoice within &#91;***&#93; after its receipt&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.95pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Research Program activities to the extent &#91;***&#93;, as further described in and subject to Section 5.4 (Research Plan Costs)&#59;</font></div><div><font><br></font></div><div style="padding-left:61pt;padding-right:29.9pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(ii)&#160;&#160;&#160;&#160;&#91;***&#93; CD123 Molecules and CD123 Products &#91;***&#93;, as further described in Section 7.1(b) (After the CD123 Development Term)&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.85pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(iii)&#160;&#160;&#160;&#160;&#91;***&#93; Research Molecules and Research Products &#91;***&#93;, as further described in Section 7.2 (Research Molecules and Research Products)&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.85pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;&#91;***&#93; the Manufacturing Transition Budget, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">plus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any Allowable Overruns, &#91;***&#93;, as further described in and subject to Section 9.4 (Manufacturing Technology Transfer)&#59; and</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.9pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;&#91;***&#93; CD123 Development Plan and within the amount budgeted in the &#91;***&#93;, as further described in and subject to Section 4.6 (CD123 Development Program Costs).</font></div><div><font><br></font></div><div style="padding-left:61pt;padding-right:29.95pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;&#91;***&#93;, as further described in Section 9.1(a)(ii) (During the Clinical Supply Term), then MacroGenics will invoice Gilead for such MGD024 Drug Product at the MGD024 Transfer Price and Gilead will pay MacroGenics the full undisputed amount of each such invoice within &#91;***&#93;of its receipt.</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:60.95pt;padding-right:29.75pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Subject to Section 3.6 (Sublicense under the MacroGenics Manufacturing In- Licenses), &#91;***&#93; Licensed Molecules or Licensed Products, shall be invoiced by MacroGenics and such undisputed invoices paid by Gilead within &#91;***&#93; after receipt thereof.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;During the Term, for each Calendar Quarter following the First Commercial Sale of a Licensed Product in the Territory, Gilead shall furnish to MacroGenics&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.8pt;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;a quarterly written report for the Calendar Quarter showing, on a country- by-country basis, the gross sales of all Licensed Products subject to royalty payments sold by Gilead and its Related Parties in the Territory during the reporting period, a calculation of Net Sales showing the deductions provided for in the definition of &#8220;Net Sales&#8221; and a calculation of the royalties payable under this Agreement&#59; and</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;a quarterly written report for the Calendar Quarter showing, on a country- by-country basis, Gilead&#8217;s royalties payable to Third Parties on Net Sales made during such Calendar Quarter and any royalty adjustments taken by Gilead pursuant to Section 10.4(c) (Royalty Reduction), with such detail as shall reasonably allow MacroGenics to determine the basis for such quarterly costs.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.75pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">(b)&#160;&#160;&#160;&#160;Reports under this Section 11.2 (Royalty Payments) shall be due within &#91;***&#93; following the close of each Calendar Quarter.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:30.05pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Royalties shown to have accrued by each report shall, unless otherwise specified under this Agreement, be due and payable &#91;***&#93; after the date such report is due.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment Exchange Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All payments to be made by Gilead to MacroGenics under this Agreement shall be made in US Dollars by bank wire transfer in immediately available funds to a bank account in the United States designated in writing by MacroGenics. For invoices that Gilead shall forward </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to MacroGenics, Gilead shall use an exchange rate as published &#91;***&#93; or such other source as the Parties may agree in writing.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.8pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall be solely responsible for the payment of all taxes, fees, duties, levies or similar amounts imposed on its share of income arising directly or indirectly from the activities of the Parties under this Agreement. Gilead will make all payments to MacroGenics under this Agreement without deduction or withholding for taxes, except to the extent that any such deduction or withholding is required by Applicable Laws and Regulations in effect at the time of payment. To the extent that Gilead is required by Applicable Laws and Regulations to deduct and withhold taxes on any payment to MacroGenics, Gilead shall pay the amounts of such taxes to the proper governmental authority in a timely manner and promptly transmit to MacroGenics an official tax certificate or other evidence of such payment sufficient to enable MacroGenics to claim such payment of taxes, and in such case, Gilead&#8217;s remittance of such withheld taxes, together with payment to MacroGenics of the remaining payment, will constitute Gilead&#8217;s full satisfaction of payments due under this Agreement. The Parties agree to cooperate with one another and use reasonable efforts to mitigate tax withholding or similar obligations in respect of the payments made under this Agreement, as permitted by Applicable Laws and Regulations. Notwithstanding the foregoing, if Gilead assigns its rights and obligations hereunder to an Affiliate or Third Party in compliance with Section 19.4 (Assignment&#59; Change of Control) and if such Affiliate or Third Party shall be required by Applicable Laws and Regulations to withhold any additional taxes from or in respect of any amount payable under this Agreement as a result of such assignment, then any such amount payable under this Agreement shall be increased to take into account the additional taxes withheld as may be necessary so that, after making all required withholdings, MacroGenics receives an amount equal to the sum it would have received had no such assignment been made.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.8pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Financial Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93;, Gilead shall keep complete and accurate records in sufficient detail (i) to allow MacroGenics to determine the basis for the reimbursement amounts payable to MacroGenics under this Article 11 (Payments&#59; Reports&#59; Records&#59; Audits) and (ii) to ensure that MacroGenics receives the full amount of payments for Commercial Milestone Events under Section 10.3 (Commercial Milestone Payments) and royalties payable to it under Section 10.4 (Royalties on Net Sales).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Financial Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics shall keep complete and accurate records in sufficient detail to allow Gilead to determine the basis for the amounts payable to MacroGenics under (i) Section 11.1 (Development Costs, Plan Costs and Manufacturing Costs), including for the Manufacture of MGD024 and MGD024 Products during the Clinical Supply Term or (ii) the Clinical Supply Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Audit Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon the written request of a Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Requesting Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with reasonable advance notice</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;, the other Party shall permit an independent certified public accounting firm of internationally recognized standing selected by Requesting Party and reasonably acceptable to the other Party, at its own expense, to have access during normal business hours to such of the records as may be reasonably necessary to verify the relevant records required to be maintained by the other Party pursuant to Section 11.5 (Records) or that the correct amounts were paid by or to the Requesting Party under this Agreement as a result during any Calendar Year &#91;***&#93;. The accounting firm shall disclose to the Requesting Party only whether the reports are correct or incorrect and the specific details concerning any discrepancies. No other information shall be provided to Requesting Party in connection with this audit right. &#91;***&#93;. If such accounting firm identifies a discrepancy, the other Party shall pay Requesting Party the amount of the discrepancy &#91;***&#93; of the date Requesting Party delivers to the other Party such accounting firm&#8217;s written report so concluding, or as otherwise agreed upon by the Parties. &#91;***&#93;. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall treat all information of the other Party subject to review under this Article 11 (Payments&#59; Reports&#59; Records&#59; Audits) in accordance with the confidentiality and non- use provisions of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement with the audited Party and any applicable Related Parties, obligating it or them to retain all such information in confidence pursuant to such confidentiality agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:96.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confidentiality&#59; Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nondisclosure Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.45pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Definition and Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All Confidential Information disclosed by one Party or any of its Affiliates (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to the other Party or any of its Affiliates (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) at any time, including before the Effective Date (to the extent related to the subject matter of this Agreement, including pursuant to the Existing CDA), shall&#58; (1) be maintained in confidence by the Receiving Party, using no less than the efforts that Receiving Party uses to maintain in confidence its own confidential or proprietary information of similar kind and value, but in any case no less than reasonable care, and (2) not be disclosed by the Receiving Party to any Third Party or used by the Receiving Party for any purpose except as set forth herein or in connection with the exercise of such Party&#8217;s rights and performance of its obligations under this Agreement without the prior written consent of the Disclosing Party, in each case ((1) and (2)), &#91;***&#93;. In addition, MacroGenics will keep confidential, and will cause its Affiliates and its and their employees, consultants, licensees, Permitted Subcontractors, professional advisors and Affiliates to keep confidential, the Know- How comprising MacroGenics Licensed Technology and Jointly Owned IP, in each case to the extent specifically related to the Licensed Molecules or Licensed Products on confidentiality terms at least as protective as the confidentiality provisions of this Agreement. The following shall not be deemed Confidential Information for purposes of the restrictions set forth in this Section 12.1(a) (Definition and Restrictions)&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.95pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(i)&#160;&#160;&#160;&#160;information that is known by the Receiving Party at the time of its receipt without any obligation to keep it confidential or restriction on its use, and not through a prior disclosure by the Disclosing Party, as documented by the Receiving Party&#8217;s written records&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;information that is or becomes part of the public domain through no wrongful act or fault on the part of the Receiving Party&#59;</font></div><div><font><br></font></div><div style="padding-left:61pt;padding-right:29.8pt;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(iii)&#160;&#160;&#160;&#160;information that is subsequently disclosed to the Receiving Party by a Third Party who may lawfully do so and is not under an obligation of confidentiality or any restriction on use with respect to such information&#59; and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.95pt;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(iv)&#160;&#160;&#160;&#160;information that is developed by the Receiving Party independently of Confidential Information received from the Disclosing Party, as documented by the Receiving Party&#8217;s written records.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Combinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Any combination of features or disclosures shall not be deemed to fall within the exclusions set forth in Section 12.1(a) (Definition and Restrictions) merely because individual features are published or available to the general public or in the rightful possession of the Receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the Receiving Party.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:29.8pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Permitted Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. Notwithstanding the restrictions set forth in Section 12.1(a) (Definition and Restrictions), the Receiving Party may disclose Confidential Information of the other Party (including the existence and terms of this Agreement)&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;to any Governmental Entity in order to obtain Patents or to gain or maintain approval to conduct Clinical Trials or to market Licensed Products, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that such disclosure is only to the extent reasonably necessary to obtain such Patents or authorizations and reasonable steps are taken to ensure confidential treatment of such Confidential Information to the extent available, and for any such disclosure that may be subject to a public disclosure law or regulation, such as the Freedom of Information Act (FOIA) or EU Clinical Trial Regulation, Gilead shall have the obligations as the publishing Party and MacroGenics shall have the rights as the reviewing Party according to the procedure set forth under Section 12.2 (Publication) for review of such disclosure&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;subject to Section 12.1(d) (Securities Filings&#59; Disclosures under Applicable Law), to the extent required in the reasonable opinion of such Party&#8217;s legal counsel, in connection with complying with Applicable Laws and Regulations (including the rules and regulations promulgated by the United States Securities and Exchange Commission or any other national securities exchange in any jurisdiction in the Territory (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Regulator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;))&#59;</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.5pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;to the extent the Receiving Party deems such disclosure necessary to be disclosed (1) to its Related Parties, or its or their respective employees, agents, representatives, consultants and Permitted Subcontractors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) on a need-to-know basis for the Development, Manufacture or Commercialization of Licensed Molecules and Licensed Products, (2) its attorneys, accountants and advisors, (3) in connection with a prospective or actual licensing transaction or other business agreement or contractual obligation related to Licensed Molecules and Licensed Products, (4) to existing or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">bona fide </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">prospective acquirers, merger partners, lenders or investors of the Receiving Party in connection with transactions or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">bona fide </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">prospective transactions with the foregoing, including loans, financings or investments, acquisitions, mergers, consolidations, sale of assets or similar transactions (or for such entities to determine their interest in performing such activities or to determine their rights and obligations as a result of completing such transactions) or (5) in order to perform its obligations or exercise its rights under this Agreement, in each case on the condition that any Third Parties, other than Regulatory Authorities, to whom such disclosures are made agree to be bound by confidentiality and non-use obligations substantially similar to those contained in this Agreement&#59; &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.7pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;if a Party is required by judicial or administrative process to disclose Confidential Information of the other Party that is subject to the non-disclosure provisions of this Section 12.1 (Nondisclosure Obligation), in which case, such Party shall promptly inform the other Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Section 12.1 (Nondisclosure Obligation), and the Party disclosing Confidential Information pursuant to law or court order shall take all steps reasonably necessary, including obtaining an order of confidentiality, to ensure the continued confidential treatment of such Confidential Information, including, by using not less than the same level of efforts to secure such confidential treatment of such information as it would to protect its own Confidential Information of like nature from disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:29.65pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Securities Filings&#59; Disclosure under Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party acknowledges and agrees that the other Party may submit this Agreement to, or file this Agreement with, the Securities Regulators or to other Persons as may be required by Applicable Law and Regulations, and if a Party submits this Agreement to, or files this Agreement with, any Securities Regulator or other Person as may be required by Applicable Law and Regulations, such Party agrees to consult with the other Party with respect to the preparation and submission of a confidential treatment request for this Agreement. Notwithstanding the foregoing, if a Party is required by any Securities Regulator or other Person as may be required by Applicable Law and Regulations to make a disclosure of the terms of this Agreement in a filing or other submission as required by such Securities Regulator or such other Person, and such Party has&#58; (i) provided copies of the disclosure to the other Party reasonably in advance under the circumstances of such filing or other disclosure&#59; (ii) promptly notified the other Party in writing of such requirement and any respective timing constraints&#59; and (iii) given the other Party reasonable time under the circumstances from the date of provision of copies of such disclosure to comment upon and request confidential treatment for such disclosure, then such Party will have the right to make such disclosure at the time and in the manner reasonably determined by its counsel to be required by the Securities Regulator or the other Person. Notwithstanding the foregoing, if a Party seeks to make a disclosure as required by a Securities Regulator or other Person as may be required by Applicable Law and Regulations as set forth in this Section 12.1(d) (Securities Filings&#59; Disclosure under Applicable Law) and the other Party provides comments in accordance with this Section 12.1(d) (Securities Filings&#59; Disclosure under Applicable Law), the Party seeking to make such disclosure or its counsel, as the case may be, will use good faith efforts to incorporate such comments.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obligations Upon Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon the earlier of termination or expiration of the Agreement (or in the case of Confidential Information received pursuant to an Upstream License Agreement, upon the expiration or earlier termination of such agreement), except to the extent prohibited by Applicable Laws and Regulations, the Receiving Party shall, and shall promptly require all of its Representatives, to securely return to the Disclosing Party or securely dispose of all Confidential Information of the Disclosing Party (at the Disclosing Party&#8217;s election), whether such Confidential Information is in written, electronic or other form of media. If the Receiving Party is not reasonably able to return or securely dispose of the Disclosing Party&#8217;s Confidential Information, including, such Confidential Information stored on backup media, then the Receiving Party will continue to protect such Confidential Information in accordance with the terms of this Agreement until such time that it can reasonably return or securely dispose of such Confidential Information. Notwithstanding the foregoing, the Receiving Party may retain&#58; (i) Confidential Information of the Disclosing Party to exercise rights and licenses which expressly survive such termination or expiration pursuant to this Agreement and (ii) solely for the purpose of determining the scope of its obligations under this Agreement, one (1) copy of Confidential Information received hereunder, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that a Receiving Party shall not be required to destroy electronic files containing such Confidential Information of the Disclosing Party that are made in the ordinary course of its business information back-up procedures pursuant to its electronic record retention and destruction practices that apply to its own general electronic files and information, and any such retained copies shall continue to be subject to the confidentiality and non-use obligations in accordance with this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding any provision to the contrary in this Agreement, with respect to Confidential Information that &#91;***&#93;.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.55pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication of Results During the Collaboration Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except for disclosures permitted pursuant to Section 12.1 (Nondisclosure Obligation), on a Program-by-Program basis, during the Collaboration   Term   for   a   Program,   if   a   Party   and   its   employees wish to publish, publicly present or otherwise publicly disclose any paper, publication, oral presentation, abstract, poster, manuscript or other presentation relating to any activity or other matter under this Agreement, then the publishing Party will provide the other Party with, (i) a copy of any proposed written publication at least &#91;***&#93; for an abstract) prior to submission for publication&#59; and (ii) a copy of the graphics and written outline of material to be presented for the proposed oral disclosure (to the extent not included in the graphics) at least &#91;***&#93; prior to submission.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:4.55pt;padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Review of Publications and Presentations During the Collaboration Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.9pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;The reviewing Party shall have the right (1) to propose modifications to the publication or presentation presented for review under Section 12.2(a) (Publication of Results During the Collaboration Period) for patent reasons, trade secret reasons, or for purposes of removing the Confidential Information of the reviewing Party, or (2) to request a reasonable delay in publication or submission for presentation in order to protect trade secret or patentable information.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.9pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;If the reviewing Party requests the removal of the reviewing Party&#8217;s Confidential Information or a delay, the publishing Party shall remove such Confidential Information and if requested by the reviewing Party delay submission for publication or submission for presentation for a period of &#91;***&#93; to enable patent applications protecting each Party&#8217;s rights in such Confidential Information to be filed in accordance with Article 16 (Intellectual Property) below.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:30pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Upon expiration of such &#91;***&#93; and satisfaction of any other conditions requested by the reviewing Party, the publishing Party shall be free to proceed with the publication or submission for presentation.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;Upon request of the Party seeking publication, the reviewing Party shall consider expediting the time frames set forth in this Section 12.2 (Publication).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;If the reviewing Party requests modifications to the publication or submission for presentation, the publishing Party shall edit such publication to prevent disclosure of the Confidential Information of the reviewing Party.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication of Results After the Collaboration Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a Program-by- Program basis, following the expiration of the Collaboration Term for a Program, (i) any proposed public disclosure (whether written, electronic, oral or otherwise) by MacroGenics or any of its Affiliates related to activities under this Agreement or the Licensed Molecules or the Licensed Products, in each case, for such Program will require the prior written consent of Gilead and (ii) Gilead or any of its Affiliates will have the right, without any required consents from MacroGenics, to publish, publicly present or otherwise publicly disclose any paper, publication, oral presentation, abstract, poster, manuscript or other presentation relating to any activity or other matter under this Agreement related to such Program, including the results of any Clinical Trial for such Program, or other activities under this Agreement for such Program. Gilead will provide MacroGenics with, (i) a copy of any proposed written publication at least &#91;***&#93; days for an abstract) prior to submission for publication&#59; and (ii) a copy of the graphics and</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">written outline of material to be presented for the proposed oral disclosure (to the extent not included in the graphics) at least &#91;***&#93; prior to submission. At MacroGenics&#8217; request, Gilead will remove any Confidential Information of MacroGenics from the proposed publication and reasonably delay submission for publication for a period of &#91;***&#93; in order to enable MacroGenics to seek patent protection of MacroGenics&#8217; patentable information disclosed therein.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publicity&#59; Use of Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.55pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Press Releases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On such date and time as may be agreed by the Parties after the Effective Date, the Parties shall issue a joint press release announcing the execution of this Agreement in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 12.3(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Press Release). A Party may issue any subsequent press release relating to this Agreement or activities conducted hereunder &#91;***&#93; of the preceding sentence, the Disclosing Party shall provide the other Party a copy of such proposed disclosures at least &#91;***&#93; prior to the proposed release and consider in good faith any comments the other Party may make, where practicable, and in light of any reporting obligations of such Disclosing Party under Applicable Laws and Regulations, including the rules and regulations promulgated by the United States Securities and Exchange Commission or any other governmental agency.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">No Other Use of Company Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. Neither Party shall use the name, Trademark, trade name or logo of the other Party, its Affiliates or its or their employees in any publicity or news release relating to this Agreement or its subject matter without the prior express written permission of the other Party.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.8pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Approved Press Releases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In addition and notwithstanding anything to the contrary herein, (i) if the relevant text of a proposed press release has already previously been reviewed and approved for disclosure by the other Party then such text may be disclosed or republished in such proposed press release, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that the information in such press release remains true, correct and the most current information with respect to the subject matters set forth therein and, where practicable, the Party issuing such press release provides notice to the other Party of such press release &#91;***&#93; prior to the issuance of such press release, and (ii) if the relevant text of a proposed public announcement such as a corporate presentation or comments to analysts or investors has already previously been reviewed and approved for disclosure by the other Party (whether in the form of an approved press release or prior approved presentation materials, Q&#38;A script or the like) then such text may be included in such proposed public announcement (but not a press release) without resubmission and review by the other Party so long as the information in such materials remains true, correct and the most current information with respect to the subject matters set forth therein.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:30.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall comply with the terms of this Agreement and all Applicable Laws and Regulations relating to activities performed or to be performed by such Party (or its Affiliates, Permitted Subcontractor(s) or Sublicensee(s)) under or in relation to the Development, Manufacturing,</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercialization, or other Exploitation of Licensed Molecules and Licensed Products pursuant to this Agreement (each such Party, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subject Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Covenants, Representations and Warranties For Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Without limiting the generality of Section 13.1 (General), each Subject Party agrees, on behalf of itself, its Affiliates, and its and their officers, directors, employees, agents, representatives, consultants, and Permitted Subcontractors (together with such Party, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obligants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that for the performance of its obligations hereunder&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.65pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Its Obligants shall not directly or indirectly pay, offer or promise to pay, or authorize the payment of any money, or give, offer or promise to give, or authorize the giving of anything else of value, to&#58; (1) any Government Official in order to influence official action&#59; (2) any Person (whether or not a Government Official) (x) to influence such Person to act in breach of a duty of good faith, impartiality or trust (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Acting Improperly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), (y) to reward such Person for Acting Improperly, or (z) where such Person would be Acting Improperly by receiving the money or other thing of value&#59; (3) any other Person while knowing or having reason to know that all or any portion of the money or other thing of value shall be paid, offered, promised or given to, or shall otherwise benefit, a Government Official in order to influence official action for or against either Party in connection with the matters that are the subject of this Agreement&#59; or (4) any Person to reward that Person for Acting Improperly or to induce that Person to Act Improperly.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.95pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Its Obligants shall not, directly or indirectly, solicit, receive or agree to accept any payment of money or anything else of value in violation of the Anti-Corruption Laws.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:30pt;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;The Subject Party and its Obligants shall comply with the Anti-Corruption Laws and shall not take or perform any action that constitutes, or would reasonably be expected to constitute, a violation of any such laws or cause either Party (or its Affiliates) to be in violation of any such laws. In furtherance of the foregoing, each acknowledges and confirms the following&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.85pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Each Subject Party has reviewed its internal programs in relation to the Anti-Corruption Laws and the ability of its Obligants to adhere to such laws in performance of its obligations hereunder in advance of the signing of this Agreement and warrants that it and its Obligants can and shall continue to comply with such Anti-Corruption Laws in performance of its obligations hereunder and further represents and warrants that should either Party identify in writing to the other Party any measures that should be reasonably taken to improve its Obligants&#8217; compliance with such Anti-Corruption Laws for the performance of its obligations hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Improvement Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Subject Party shall use Commercially Reasonable Efforts to implement such Improvement Plan within an agreed reasonable timeframe (which shall in any event not be in &#91;***&#93;) from the &#91;***&#93;. In the absence of such Party using Commercially Reasonable Efforts to achieve the full implementation by such of such Improvement Plan within the aforesaid &#91;***&#93;, the other Party shall be entitled to terminate this Agreement, upon written notice to the Subject Party with immediate effect, to be relieved of any obligations, and to seek compensation from the Subject Party&#59;</font></div><div><font><br></font></div><div style="padding-left:61pt;padding-right:29.8pt;text-indent:143.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;To the best of the Subject Party&#8217;s and its Affiliates&#8217; knowledge after reasonable diligence, none of its Obligants that will participate in or support the Subject Party&#8217;s performance of its obligations hereunder has, directly or indirectly, (x) paid, offered or promised to pay, or authorized the payment of any money&#59; (y) given, offered or promised to give, or authorized the giving of anything else of value&#59; or (z) solicited, received or agreed to accept any payment of money or anything else</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of value, in each case ((x), (y) and (z)), in violation of the Anti-Corruption Laws during the three (3) years preceding the date of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:61pt;padding-right:29.7pt;text-indent:143.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;To the best of the Subject Party&#8217;s and its Affiliates&#8217; knowledge, none of its intellectual property rights, technology, contracts, materials, or licenses or other assets that are the subject of this Agreement, other than those provided by or on behalf of the other Party, were procured in violation of any Anti-Corruption Laws.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.75pt;text-indent:143.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;The Subject Party, on behalf of itself and its Obligants, represents and warrants to the other Party that all information provided by the Subject Party and its Obligants to the other Party in any anti-bribery and corruption due diligence checklist, similar due diligence process performed by the other Party or its Affiliates or inquiry by the other Party related to the Subject Party&#8217;s or its Obligants compliance with Anti-Corruption Laws is true, complete and correct in all material respects at the date it was provided and that any material changes in circumstances relevant to the answers provided in such exercise shall be promptly disclosed to the other Party.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.6pt;text-indent:143.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;The Subject Party shall promptly provide the other Party with written notice of any of the following events&#58; (i) upon becoming aware of any actual, alleged, or potential breach or violation by the Subject Party or any of its Obligant of any representation, warranty or undertaking set forth in this Section 13.2 (Covenants, Representations and Warranties For Compliance with Laws)&#59; (ii) upon receiving a notification that it is the target or subject of an investigation, formal or informal inquiry or enforcement proceedings by a government authority for violation of any Anti-Corruption Laws&#59; (iii) upon receiving any notice, request, subpoena or citation from a government authority for any violation of any Anti-Corruption Law&#59; or (iv) upon receipt of information that any of the Subject Party&#8217;s Obligants is the target or subject of an investigation, formal or inform enquiry or enforcement proceedings by a government authority for a violation of any Anti-Corruption Law.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6)&#160;&#160;&#160;&#160;&#91;***&#93;,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Subject Party shall for the purpose of auditing and monitoring the performance of its compliance with this Agreement and particularly this Section 13.2 (Covenants, Representations and Warranties For Compliance with Laws) permit the other Party, its Affiliates, any auditors of any of them and any government authority to have reasonable access to any premises of the Subject Party or its Obligants used in connection with this Agreement, together with a right to reasonably access personnel and records that relate to this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subject Party Audit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Subject Party shall provide or procure that its Obligants shall provide all co-operation as reasonably requested by the other Party for the purposes of the Subject Party Audit, with the understanding that the other Party shall be responsible for all costs and fees of any Subject Party Audit and the other Party shall procure that any auditor enters into a confidentiality agreement consistent with the confidentiality provisions elsewhere in this Agreement in all material respects.</font></div><div><font><br></font></div><div style="padding-left:61pt;padding-right:29.7pt;text-indent:143.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(7)&#160;&#160;&#160;&#160;If (A) the other Party becomes aware of, whether or not through a Subject Party Audit, that the Subject Party (or any of its Obligants) is in breach or violation of any representation, warranty or undertaking in Section 13.1 (General) or of the Anti-Corruption Laws&#59; or (B) the other Party receives notification that a suspected or actual violation of an Anti-Corruption Law has occurred by the Subject Party or any of its Obligants, in each case of (A)-(B), the other Party shall have the right, in addition to any other rights or remedies under this Agreement or to which the other Party may be entitled in law or equity, to take such steps as are reasonably necessary in order to avoid a potential violation or continuing violation by the other Party or any of its Affiliates of the Anti-Corruption Laws, including by requiring that the Subject Party agrees to and uses Commercially Reasonable Efforts to implement any curative actions requested by the other Party. In the event that the Subject Party refuses to agree to use Commercially Reasonable Efforts to achieve all of the curative actions requested by the other Party (and</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that the other Party has (x) provided the Subject Party with an explanation in reasonable detail as to why the other Party considers such actions necessary, (y) given the Subject Party a reasonable opportunity to review and comment upon the proposed actions and to provide its view as to the necessity or usefulness of these to address the event concerned, and (z) considered such comments in good faith), the other Party shall be entitled to terminate this Agreement in its entirety with immediate effect. Any termination of this Agreement pursuant to this Section 13.2 (Covenants, Representations and Warranties For Compliance with Laws) shall be treated as a termination for breach by the Subject Party of this Agreement and the consequences of termination shall apply and additionally&#58; (1) subject to the accrued rights of the Parties prior to termination, the other Party shall have no liability to the Subject Party for any fees, reimbursements or other compensation or for any loss, cost, claim or damage resulting, directly or indirectly, from such termination&#59; and (2) any amounts that would otherwise be payable to the Subject Party pursuant to this Agreement in its entirety, as applicable, including any then outstanding and unpaid claims for payment shall be null and void to the extent permissible under Applicable Laws and Regulations.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.9pt;text-indent:143.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(8)&#160;&#160;&#160;&#160;The Subject Party shall be responsible for any breach of any representation, warranty or undertaking in this Section 13.2 (Covenants, Representations and Warranties For Compliance with Laws) or of the Anti-Corruption Laws by any of its Obligants.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Data Protection Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. From time to time during the Term, either Party may provide the other Party with personal information that falls under the protection of Data Protection Laws (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Protected Personal Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Each Party agrees to comply with all Data Protection Laws relating to Processing of such Protected Personal Information. The Parties agree to use good-faith efforts to agree upon and implement any security protocols and information handling guidelines that such Party&#8217;s legal advisors recommend in connection with such Party&#8217;s compliance with Data Protection Laws.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Information Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Each Party will comply with Applicable Laws and Regulations in its storage, maintenance, use and dissemination of the other Party&#8217;s Confidential Information which it receives or to which it obtains access (such Confidential Information &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Secured Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Each Party will employ commercially reasonable security measures to protect Secured Information in accordance with accepted applicable industry standards and such Party&#8217;s information security policy as amended from time to time. As necessary, each Party will employ additional security measures to protect Secured Information.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.75pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Each Party agrees and warrants that it will implement administrative, physical and technical safeguards to protect Secured Information that are no less rigorous than accepted industry practices and standards for information security and shall ensure that all such safeguards comply with Applicable Laws and Regulations.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;Each Party will notify the other Party by email immediately, &#91;***&#93; of becoming aware of (1) any act or omission that materially compromises the security, confidentiality, or integrity of the physical, technical, administrative, or organizational safeguards put in place by or on behalf of a Party, that relate to the protection of the security, confidentiality, or integrity of Secured Information or Protected Personal Information, or (2) receipt of a notification in relation to Protected Personal Information or the privacy and data security practices of such Party or any actual or suspected accidental or unlawful destruction, loss, alteration, disclosure of, or access to, Protected Personal Information transmitted, stored or otherwise Processed&#59; (each of (1) and (2) individually and collectively a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Security Incident</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:29.95pt;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;Other than as required by Applicable Laws and Regulations or a contractual obligation to a Third Party, each Party agrees that it will not inform any Third Party of an actual or potential Security Incident related to the other Party&#8217;s Confidential Information (including but not limited to work product under the Agreement and such other Party&#8217;s intellectual property) without first obtaining such other Party&#8217;s prior consent.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.45pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Export Control Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party will comply with all Applicable Laws and Regulations relating to (i) economic and trade sanctions and embargoes imposed by the Office of Foreign Assets Control of the U.S. Department of Treasury or (ii) the export or re-export of commodities, technologies or services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Export Control Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Each Party acknowledges and expressly agrees that certain laws of the United States and other countries, including, without limitation, the Export Control Laws, the United States Anti-Money Laundering laws, the United States Anti-Terrorism laws and the FCPA, and U.S. sanctions programs administered by the Office of Foreign Assets Control (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and the Bureau of Industry and Security, among others, may result in the imposition of sanctions on the other Party or its Affiliates in the event that, directly or indirectly, products are exported to or imported from, or payments are sent to or received from various countries or regions. Each Party warrants that it has searched OFAC&#8217;s Consolidated Sanctions List, available at https&#58;&#47;&#47;sdnsearch.ofac.treas.gov, in order to ensure compliance with all applicable sanctions regulations.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compliance Event Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The other Party may disclose the terms of this Agreement or any action taken under this Section 13.2 (Covenants, Representations and Warranties For Compliance with Laws) to prevent a potential violation or continuing violation of applicable Anti- Corruption Laws, Data Protection Laws or Export Control Laws, including the identity of the Subject Party and the payment terms, to any government authority if the other Party determines, upon advice of counsel, that such disclosure is necessary.</font></div><div><font><br></font></div><div style="padding-left:96.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Representations and Warranties of MacroGenics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 14.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Exceptions to the Representations and Warranties of MacroGenics) (which schedule may be updated by MacroGenics immediately prior to the CD123 Option Effective Date and each Research Program Opt-In Effective Date), MacroGenics represents and warrants to Gilead that, as of the Effective Date the CD123 Option Effective Date and each Research Program Opt-In Effective Date&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30.15pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;it is duly organized, validly existing and in good standing under the Applicable Law and Regulations of the jurisdiction of its formation&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;this Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding obligation, enforceable against it in accordance with its terms, except to the extent that enforcement of the rights and remedies created hereby is subject to&#58; (i) bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors&#59; or (ii) laws governing specific performance, injunctive relief and other equitable remedies&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;it has the full right, power and authority to enter into this Agreement, to grant the licenses contemplated hereunder, and the fulfillment of its obligations and performance of its activities hereunder do not conflict with, violate, or breach or constitute a default under any contractual obligation or court or administrative order by which MacroGenics is bound&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:29.8pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(d)&#160;&#160;&#160;&#160;all necessary consents, approvals and authorizations of all government authorities and other persons required to be obtained by MacroGenics as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;it Controls the right, title and interest in and to the MacroGenics Licensed Patents and MacroGenics Licensed Know-How, and has the right to grant to Gilead the licenses under such MacroGenics Licensed Patents and MacroGenics Licensed Know-How and the sublicenses under the Existing Upstream License Agreements that it purports to grant and may grant hereunder and has not granted any Third Party rights under such MacroGenics Licensed Patents, MacroGenics Licensed Know- How and Existing Upstream License Agreements that would interfere or be inconsistent with Gilead&#8217;s rights hereunder&#59;</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;as of the Effective Date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.80 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(MacroGenics Licensed Patents) sets forth a complete and accurate list of all MacroGenics Licensed Patents issued or pending, and all such Patents have been prosecuted and maintained by or on behalf of MacroGenics in good faith and if issued, are in full force and effect and to its MacroGenics&#8217; Knowledge, are valid and enforceable. All application, registration, maintenance and renewal fees due as of the Effective Date with respect to all MacroGenics Licensed Patents set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.80 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(MacroGenics Licensed Patents) have been paid and all necessary documents and certificates have been filed with the relevant patent registries for the purpose of maintaining such MacroGenics Licensed Patents&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.75pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(g)&#160;&#160;&#160;&#160;Except with respect to any MacroGenics Licensed Technology that is licensed under the Upstream License Agreements, the MacroGenics Licensed Patents and MacroGenics Licensed Know-How are not subject to any other Third Party agreements or existing royalty or other payment obligations to any Third Party&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.95pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;Except with respect to any MacroGenics Licensed Technology that is licensed under the Existing Upstream License Agreements, MacroGenics is the sole and exclusive owner of the MacroGenics Licensed Patents and MacroGenics Licensed Know-How, in each case, free and clear of all liens and encumbrances&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.7pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;MacroGenics and its Affiliates have obtained from all individuals who participated in any respect in the invention or authorship of any MacroGenics Licensed Technology effective assignments of all ownership rights of such individuals in such MacroGenics Licensed Technology, either pursuant to written agreement or by operation of law&#59; and to the Knowledge of MacroGenics, no Person who claims to be an inventor of an invention claimed in a MacroGenics Licensed Patent is not identified as an inventor of such invention in the filed patent documents for such MacroGenics Licensed Patent&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;all of MacroGenics and its Affiliates&#8217; employees, officers and consultants&#58; (1) have executed agreements or have existing obligations under Applicable Law and Regulations requiring assignment to MacroGenics or its Affiliates of all inventions made during the course of and as the result of their association with MacroGenics or its Affiliates, as applicable, and obligating the individual to assign to MacroGenics or its Affiliates, as applicable, all inventions made during the course of performance under this Agreement&#59; (2) are not subject to any agreement with any other Third Party that requires such officer or employee or consultant to assign any interest in any MacroGenics Licensed Technology to such Third Party&#59; and (3) have executed agreements or have existing obligations under Applicable Law and Regulations obligating the individual to maintain as confidential MacroGenics&#8217; Confidential Information as well as confidential information of other parties (including of Gilead and its Affiliates) that such individual may receive in its performance under this Agreement, to the extent required to support MacroGenics&#8217; obligations under this Agreement&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.95pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;there is no action, suit, inquiry, investigation or other proceeding threatened in writing, pending, or ongoing by any Third Party that challenges or threatens the validity or enforceability of any of the MacroGenics Licensed Patents or MacroGenics Licensed Know-How. In the event that MacroGenics receives written notice of any such action or proceeding, it shall notify Gilead in writing&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.85pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;to the Knowledge of MacroGenics, the use of the MacroGenics Licensed Technology in the performance of the activities under the CD123 Development Plan and the Exploitation of any CD123 Molecule or CD123 Product, in each case, as contemplated to be conducted under this Agreement, does not infringe, misappropriate or otherwise violate any intellectual property owned or controlled by any Third Party&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)&#160;&#160;&#160;&#160;there is no action, suit, inquiry, investigation or other proceeding threatened in writing, pending, or ongoing by any Third Party (and it is not aware of any grounds therefor) that alleges the use of the MacroGenics Licensed Patents or the MacroGenics Licensed Know-How or the Exploitation of any Licensed Molecule or Licensed Product would infringe, misappropriate or otherwise violate any intellectual property rights of any Third Party (and it has not received any written notice alleging such an infringement). In the event that MacroGenics receives written notice of any such action or proceeding, it shall notify Gilead in writing&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(n)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.151 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Upstream License Agreements) sets forth a complete and accurate list of the Upstream License Agreements in effect as of the Effective Date, the CD123 Option Effective Date or the Research Program Opt-In Effective Date (as applicable). MacroGenics has provided Gilead true, correct and complete copies of each such Upstream License Agreement (in reasonably redacted form). Each such Upstream License Agreement is in full force and effect, and there has been no default of or under (or notice of default of or under) any such Upstream License Agreement, in each case, that could give the relevant Third Party licensor to such Upstream License Agreement the right to terminate such agreement as a result of any action or omission or alleged act or omission of MacroGenics or its Affiliates or, to the Knowledge of MacroGenics, the actions or omissions of any Third Party. MacroGenics has not waived any of its rights under any such Upstream License Agreement to which it is party. Immediately following the Effective Date, the CD123 Option Effective Date or the Research Program Opt-In Effective Date (as applicable), MacroGenics will continue to be permitted to exercise all of its rights under each such Upstream License Agreement to which it is party pursuant to the terms thereof without the payment of any additional amounts of consideration beyond ongoing fees, royalties or payments that MacroGenics would otherwise be required to pay in accordance with the terms of such Upstream License Agreement had the transactions contemplated by this Agreement not occurred&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.8pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(o)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 9.1(a)(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Existing CMO Agreements) sets forth a complete and accurate list of the Existing CMO Agreements. MacroGenics has provided Gilead true, correct and complete copies of each such Existing CMO Agreement (in reasonably redacted form). Each such Existing CMO Agreement is in full force and effect, and there has been no default of or under (or notice of default of or under) any such Existing CMO Agreement, in each case, that could give the relevant Third Party CMO under such Existing CMO Agreement the right to terminate such agreement as a result of any action or omission or alleged act or omission of MacroGenics or its Affiliates or, to the Knowledge of MacroGenics, the actions or omissions of any Third Party&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(p)&#160;&#160;&#160;&#160;MacroGenics has disclosed to Gilead (i) all safety data and other material information and data related to MGD024, including all safety data from the ongoing clinical trial for MGD024, with the study number CP-MGD024-01&#59; and (ii) all material correspondences sent to or received from any Regulatory Authority related to MGD024, in each case ((i) and (ii)), in the possession or control of MacroGenics or its Affiliates&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.95pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(q)&#160;&#160;&#160;&#160;Other than as permitted under the CD123 Development Plan or Research Plan, (i) the Development or Commercialization of the MacroGenics Platform by Gilead is not necessary (1) for Gilead to conduct the activities contemplated under the CD123 Development Plan or the Research Plans hereunder or (2) to MacroGenics&#8217; Knowledge, for the Exploitation of any Licensed Molecule or Licensed Product by Gilead in accordance with this Agreement to the extent known to MacroGenics and (ii) MacroGenics is not, and has not, Developed or Commercialized the MacroGenics Platform in the Exploitation of any Licensed Molecule or Licensed Product&#59;</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(r)&#160;&#160;&#160;&#160;Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, no government funding, facilities of a university, college, or other educational institution or research center was used in the development of any of the MacroGenics Licensed Patents that are owned or jointly owned by MacroGenics. No individual who was involved in, or who contributed to, the creation or development of any MacroGenics Licensed Patent that is owned or jointly owned by MacroGenics has performed services for the government, a university, a college, or other educational institution or research center in a manner that would affect Gilead&#8217;s rights to such MacroGenics Licensed Patent&#59; and</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.95pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(s)&#160;&#160;&#160;&#160;Solely as of the Effective Date, to the Knowledge of MacroGenics, MacroGenics has not intentionally failed to furnish Gilead with any material information specifically requested by Gilead in writing, or intentionally concealed from Gilead any material information in its possessions, in each case, relating to the MacroGenics Licensed Technology, that MacroGenics reasonably believes would be material to Gilead&#8217;s decision to enter into this Agreement and undertake the commitments and obligations set forth herein as anticipated to be conducted hereunder.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.7pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Representations and Warranties of Gilead</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Gilead represents and warrants to MacroGenics that, as of the Effective Date, the CD123 Option Effective Date and each Research Program Opt-In Effective Date&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;it is duly organized, validly existing and in good standing under the Applicable Law and Regulations of the jurisdiction of its formation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;this Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding obligation, enforceable against it in accordance with its terms, except to the extent that enforcement of the rights and remedies created hereby is subject to&#58; (i) bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors&#59; or (ii) laws governing specific performance, injunctive relief and other equitable remedies&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;it has the full right, power and authority to enter into this Agreement, to grant the licenses granted hereunder, and the fulfillment of its obligations and performance of its activities hereunder do not conflict with, violate, or breach or constitute a default under any contractual obligation or court or administrative order by which Gilead is bound&#59;</font></div><div><font><br></font></div><div style="padding-left:61pt;padding-right:29.85pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;all necessary consents, approvals and authorizations of all government authorities and other persons required to be obtained by Gilead as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained&#59; and</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(e)&#160;&#160;&#160;&#160;solely as of the Effective Date, neither it nor its Affiliates is, directly or indirectly, researching, developing, manufacturing or commercializing any bi-specific molecule that is directed to CD3 and CD123.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party represents and warrants to the other Party as of the Effective Date, such Party is not debarred under the United States Federal Food, Drug and Cosmetic Act or comparable laws in any other country or jurisdiction, and it does not, and will not during the Term, employ or use the services of any person or entity who is debarred, in connection with the Development, Manufacture or Commercialization of the Licensed Products. In the event that either Party becomes aware of the debarment or threatened debarment of any person or entity providing services to such Party, including the Party itself and its Affiliates or (Sub)licensees, which directly or indirectly relate to activities under this Agreement, the other Party shall be immediately notified in writing.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.85pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Mutual Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party hereby covenants to the other Party that it will not, and will not permit its Affiliates, (Sub)licensees or anyone acting on its or their behalf to, grant or otherwise convey to any Third Party any rights that would interfere or be inconsistent with such other Party&#8217;s rights hereunder.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Additional Covenants of MacroGenics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.85pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Neither MacroGenics nor its Affiliates will grant any option, right or license to any Third Party relating to any of the intellectual property rights it Controls (including the MacroGenics Licensed Technology), or otherwise with respect to any Licensed Product, which (1) conflict with any of the options, rights or licenses granted to Gilead hereunder or (2) has an adverse effect on MacroGenics&#8217; ability to grant the options, rights or licenses granted to Gilead hereunder or to perform its obligations under this Agreement.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.8pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Except as otherwise expressly permitted under this Agreement, MacroGenics will not, and will cause its Affiliates not to&#58; (1) assign, transfer, convey, encumber (through a lien, charge, security interest, mortgage or similar encumbrance) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey, encumber (through a lien, charge, security interest, mortgage or similar encumbrance) or dispose of, any assets related to the MacroGenics Licensed Technology or any Licensed Product, except to the extent that such assignment, transfer, conveyance, encumbrance or disposition would not conflict with, be inconsistent with or adversely affect in any respect any of the options, rights or licenses granted to Gilead hereunder&#59; or (2) license or grant to any Third Party, or agree to license or grant to any Third Party, any rights under the MacroGenics Licensed Technology the Exploitation of any Licensed Product.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;MacroGenics will&#58; (1) maintain Control of all MacroGenics Licensed Technology licensed or sublicensed to Gilead under each Upstream License Agreement&#59; and (2) not terminate, intentionally breach or otherwise materially default under any Upstream License Agreement or Existing CMO Agreement in a manner that would permit the counterparty thereto to terminate such Upstream License Agreement or Existing CMO Agreement (as applicable) or otherwise diminish the scope or exclusivity of the licenses granted to Gilead under any MacroGenics Licensed Technology.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;MacroGenics will not (1) modify, amend, or terminate any Upstream License Agreement, or exercise, waive, release, or assign any rights or claims thereunder, in each case in a manner that would adversely affect Gilead&#8217;s rights or MacroGenics&#8217; ability to perform its obligations under this Agreement or (2) modify or amend any Upstream License Agreement in a manner that would impose additional obligations on Gilead as a sublicensee under such Upstream License Agreement, in each case ((1) and (2)), without first obtaining Gilead&#8217;s prior written consent.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.75pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;If MacroGenics receives notice of an alleged default by MacroGenics or its Affiliates under any Upstream License Agreement, where termination of such Upstream License Agreement or any diminishment of the scope or exclusivity of the licenses granted to Gilead under the MacroGenics Licensed Technology is being or could be sought by the counterparty or result from such default, then MacroGenics will provide written notice thereof to Gilead within &#91;***&#93; thereafter, which notice may be redacted to protect commercially sensitive information or information related to products that are not Licensed Products. Within &#91;***&#93; after receipt of such notice (or such other time period as is reasonably necessary to allow Gilead to meaningfully cure the alleged breach) and, solely in the event MacroGenics determines not to contest such alleged default and otherwise fails to cure such alleged default within such period, MacroGenics hereby grants to Gilead the right (but not the obligation) to&#58; (1) cure such alleged breach&#59; and (2) offset any costs or expenses incurred in connection therewith against any payments due or that may become due under this Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Additional Covenants of Gilead</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.95pt;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Gilead and its Affiliates shall comply with, and will contractually require its Sublicensees and Permitted Subcontractors to comply with, all applicable terms of any Upstream License Agreement with respect to a sublicensee that are disclosed to Gilead&#59; and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.95pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;If MacroGenics receives notice of an alleged breach by Gilead or any of its Affiliates, Sublicensees or Permitted Subcontractors of an Upstream License Agreement, then MacroGenics may notify Gilead of such breach and Gilead will use Commercially Reasonable Efforts to cooperate with and assist MacroGenics in curing such breach (which may include, at Gilead&#8217;s election, terminating Gilead&#8217;s sublicense under the applicable Upstream License Agreement).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">No Other Representations or Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD- PARTY INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. WITHOUT LIMITING THE FOREGOING, THE PARTIES AGREE THAT THE CD123 DEVELOPMENT MILESTONE EVENTS, RESEARCH PRODUCT DEVELOPMENT MILESTONE EVENTS, COMMERCIAL MILESTONE EVENTS AND NET SALES LEVELS SET FORTH IN THIS AGREEMENT OR THAT HAVE OTHERWISE BEEN DISCUSSED BY THE PARTIES ARE MERELY INTENDED TO DEFINE THE MILESTONE PAYMENTS AND ROYALTY OBLIGATIONS IF SUCH CD123 DEVELOPMENT MILESTONE EVENTS, RESEARCH PRODUCT DEVELOPMENT MILESTONE EVENTS, COMMERCIAL MILESTONE EVENTS OR NET SALES LEVELS ARE ACHIEVED. NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY DEVELOP, MANUFACTURE OR COMMERCIALIZE ANY LICENSED PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR SALES LEVEL OR PROFIT (LOSS) OF SUCH LICENSED PRODUCT WILL BE ACHIEVED.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:96.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">By Gilead</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Gilead agrees to indemnify and hold harmless MacroGenics, its Affiliates, and its and their directors, officers, employees and agents (individually and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Indemnitee(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) from and against all losses, liabilities, damages and expenses (including reasonable attorneys&#8217; fees and costs) (individually and collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) incurred in connection with any Third</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Party Claims to the extent arising from&#58; (a) activities by Gilead or any of its Related Parties or their respective Representatives with respect to the Programs and any other Development, use, Manufacture, Commercialization, import, distribution, sale or other Exploitation of Licensed Molecules or Licensed Products or the exercise of their rights or performance of their obligations related thereto except those actions for which MacroGenics has an indemnification obligation to a Gilead Indemnitee under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 10.4(c)(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Special Offset and Indemnification), (b) the gross negligence, illegal conduct or willful misconduct of Gilead or any of its Related Parties or their respective Representatives in connection with this Agreement, or (c) Gilead&#8217;s breach of this Agreement or the Clinical Supply Agreement, except, in each case of (a)-(c), to the extent such Third Party Claims arise from any action for which MacroGenics has an indemnification obligation to a Gilead Indemnitee under Section 15.2 (By MacroGenics) or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 10.4(c)(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Special Offset and Indemnification).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">By MacroGenics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In addition to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 10.4(c)(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Special Offset and Indemnification), MacroGenics agrees to indemnify and hold harmless Gilead, its Affiliates, and its and their directors, officers, employees and agents (individually and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Indemnitee(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) from and against all Losses incurred in connection with any Third Party Claims to the extent arising from&#58;</font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) activities by MacroGenics or any of its Related Parties or their respective Representatives with respect to (i) the Programs and any other Development, use, or Manufacture of Licensed Molecules or Licensed Products or the exercise of their rights or performance of their obligations related thereto, (ii) any Exploitation of any CD123 Molecule or CD123 Product prior to the Effective Date or after the effective date of termination of this Agreement and (iii) any Exploitation of any Research Molecule or Research Product after the effective date of termination of this Agreement, (b) the gross negligence, illegal conduct or willful misconduct of or any of MacroGenics or its Related Parties or their respective Representatives in connection with this Agreement, or (c) MacroGenics&#8217; breach of this Agreement or the Clinical Supply Agreement, except, in each case of (a)-(c), to the extent such Third Party Claims arise from any action for which Gilead has an indemnification obligation to a MacroGenics Indemnitee under Section 15.1 (By Gilead).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnification Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Party that is seeking indemnification under Section 15.1 (By Gilead) or Section 15.2 (By MacroGenics) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) will inform the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of the Third Party Claim giving rise to such indemnification obligations promptly after receiving written notice of the Third Party Claim (it being understood and agreed, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the failure or delay by an Indemnified Party to give such notice of a Third Party Claim will not affect the Indemnifying Party&#8217;s indemnification obligations hereunder except to the extent the Indemnifying Party will have been actually and materially prejudiced as a result of such failure or delay to give notice). The Indemnifying Party will have the right, at its option, to assume the defense of any such Third Party Claim for which it is obligated to indemnify the Indemnified Party by giving written notice to the Indemnified Party within &#91;***&#93; after receipt of the notice of the Third Party Claim. The assumption of defense of a Third Party Claim will not be construed as an acknowledgement that the Indemnifying Party is liable to indemnify any Indemnified Party in respect of the Third Party Claim, nor will it constitute a waiver by the Indemnifying Party of any defenses it may assert against the Indemnified Party&#8217;s claim for indemnification. The Indemnified Party will cooperate with the Indemnifying Party and the Indemnifying Party&#8217;s agents and representatives (including insurers) as the Indemnifying Party may reasonably request, and at the Indemnifying Party&#8217;s cost and expense. The Indemnified Party will have the right to participate, at its own expense and with counsel of its choice, in the defense of any Third Party Claim that has been assumed by the Indemnifying Party. If the Indemnifying Party does not assume and conduct the defense of a Third Party Claim as provided above, then (a) the Indemnified Party may defend against such Third Party Claim (and the Indemnified Party need not consult with the Indemnifying Party in connection therewith) and (b) the Indemnified Party reserves any rights it may have under this Article 15 (Indemnification) to obtain indemnification from the Indemnifying Party with respect to such Third Party Claim. If the Parties cannot agree as to the application of Section 15.1 (By Gilead) or Section 15.2 (By</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics) as to any Third Party Claim, pending resolution of the Dispute pursuant to Article 17 (Dispute Resolution), then the Parties may conduct separate defenses of such Third Party Claims, with each Party retaining the right to claim indemnification from the other Party in accordance with Section 15.1 (By Gilead) or Section 15.2 (By MacroGenics), as applicable, upon resolution of the underlying Third Party Claim&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that the Parties will engage in good faith discussions regarding such Dispute before conducting separate defenses.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.8pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Indemnifying Party will not settle any Third Party Claim without first obtaining the prior written consent of the Indemnified Party, such consent not to be unreasonably withheld, conditioned or delayed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the Indemnifying Party will not be required to obtain such consent if the settlement&#58; (a) involves only the payment of money and will not result in the Indemnified Party (or other MacroGenics Indemnitee(s) or Gilead Indemnitee(s), as applicable) becoming subject to injunctive or other similar type of relief&#59; (b) does not require an admission by the Indemnified Party (or other MacroGenics Indemnitee(s) or Gilead Indemnitee(s), as applicable)&#59; and (c) does not adversely affect the rights or licenses granted to the Indemnified Party (or its Affiliates) under this Agreement. The Indemnified Party will not settle or compromise any such claim without first obtaining the prior written consent of the Indemnifying Party.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party will, &#91;***&#93; insurance policies, including product liability insurance when applicable, adequate to cover its obligations hereunder and that are consistent with normal business practices of prudent companies similarly situated. Such insurance will not be construed to create a limit of a Party&#8217;s liability with respect to its indemnification obligations under this Article 15 (Indemnification). Each Party will provide the other Party with written evidence of such insurance upon request from the other Party. Notwithstanding any provision to the contrary set forth in this Agreement, Gilead may self-insure, in whole or in part, the insurance requirements described above.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES OR FOR LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 15.6 (LIMITATION OF LIABILITY) IS INTENDED TO OR SHALL LIMIT OR RESTRICT (A) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER THIS ARTICLE 15 (INDEMNIFICATION),</font></div><div style="margin-top:0.1pt;padding-left:60.95pt;padding-right:30.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(B) DAMAGES AVAILABLE FOR MACROGENICS BREACH OF ITS OBLIGATIONS UNDER SECTION 3.10 (EXCLUSIVITY) OR (C) DAMAGES AVAILABLE FOR A PARTY&#8217;S GROSS NEGLIGENCE, INTENTIONAL MISCONDUCT OR FRAUD OR FOR A PARTY&#8217;S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 12 (CONFIDENTIALITY&#59; PUBLICATION).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:97pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ownership of Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ownership of Current MacroGenics IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As between MacroGenics and Gilead, MacroGenics shall remain the sole and exclusive owner of all MacroGenics Licensed Patents, MacroGenics Platform Trademarks and MacroGenics Licensed Know-How that exist as of the Effective Date, and shall be the sole and exclusive owner of all Patents and Trademarks filed after the Effective Date that claim priority to such MacroGenics Licensed Patents and MacroGenics Platform Trademarks.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:30.05pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ownership of Current Gilead IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As between Gilead and MacroGenics, Gilead shall remain the sole and exclusive owner of all Gilead Licensed Patents and Gilead Licensed Know-How</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:29.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">that exist as of the Effective Date and shall be the sole and exclusive owner of all Patents filed after the Effective Date that claim priority to such Gilead Licensed Patents or any Trademarks that are registered by or on behalf of Gilead for a Licensed Molecule or Licensed Product.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.55pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Platform Improvement IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MacroGenics shall own all Know- How, whether patentable or not, conceived or reduced to practice by MacroGenics or Gilead in the course of conducting activities under this Agreement, in each case, that constitutes an improvement, modification or enhancement of the MacroGenics Platform, which Know-How arises from and only relates to the use of such MacroGenics Platform under this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Platform Improvement Know- How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Gilead shall, and hereby does (and shall cause its Related Parties and its and their respective Representatives to), assign to MacroGenics all of its and their right, title and interest in and to MacroGenics Platform Improvement Know-How. Upon MacroGenics&#8217; written request, Gilead shall, and shall cause its Related Parties and its and their respective Representatives to, execute and deliver such instruments and do such acts and things as may be necessary under Applicable Laws and Regulations, or as MacroGenics may reasonably request, to effectuate and confirm the vesting of all right, title and interest in and to the MacroGenics Platform Improvement Know-How in MacroGenics.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.4pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Agent Improvement IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Gilead shall own all Know-How, whether patentable or not, conceived or reduced to practice by MacroGenics or Gilead in the course of conducting activities under this Agreement, &#91;***&#93;, which Know-How arises from &#91;***&#93; under this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Agent Improvement Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), together with all Patents that Cover such Gilead Agent Improvement Know-How (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Agent Improvement Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). MacroGenics shall, and hereby does (and shall cause its Related Parties and its and their respective Representatives to), assign to Gilead all of its and their right, title and interest in and to Gilead Agent Improvement IP. Upon Gilead&#8217;s written request, MacroGenics shall, and shall cause its Related Parties and its and their respective Representatives to, execute and deliver such instruments and do such acts and things as may be necessary under Applicable Laws and Regulations, or as Gilead may reasonably request, to effectuate and confirm the vesting of all right, title and interest in and to the Gilead Agent Improvement IP in Gilead.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.75pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Jointly Owned IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Other than MacroGenics Platform Improvement Know-How and Gilead Agent Improvement Know-How, MacroGenics and Gilead shall jointly own all Know-How, whether patentable or not, jointly conceived or reduced to practice in the course of conducting activities under this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Jointly Owned Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), together with all Patents that Cover such Jointly Owned Know-How (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Jointly Owned Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), with each Party owning an undivided half interest, subject to any rights or licenses expressly granted by one Party to the other Party under this Agreement, and the right to exploit without the duty of accounting or seeking consent from the other Party to the extent permitted under Applicable Laws and Regulations. Each Party shall, and hereby does (and shall cause its Related Parties and its and their respective Representatives to), assign to the other Party an undivided half interest of its and their right, title and interest in and to Jointly Owned IP. Upon either Party&#8217;s written request, the other Party shall, and shall cause its Related Parties and its and their respective Representatives to, execute and deliver such instruments and do such acts and things as may be necessary under Applicable Laws and Regulations, or as the requesting Party may reasonably request to effectuate and confirm the vesting of such right, title and interest in and to the Jointly Owned IP.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ownership of All Other IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Other than MacroGenics Platform Improvement Know-How, Gilead Agent Improvement Know-How and Jointly Owned Know-How, ownership of all Know-How, whether patentable or not, conceived or reduced to practice in the course of conducting activities under this Agreement shall be based upon inventorship, as determined in accordance with U.S. patent law.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</font></div></td></tr></table></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_40"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.05pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent and Trademark Filing, Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.55pt;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MacroGenics shall have the sole right to conduct any and all Trademark Prosecution for the MacroGenics Platform Trademarks listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.87 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(MacroGenics Platform Trademarks) and Gilead shall have the sole right to conduct any and all Trademark Prosecution for all Trademarks that are registered by or on behalf of Gilead for a Licensed Molecule or Licensed Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.95pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Gilead Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. As between the Parties, the responsibility for Patent Prosecution related to a Patent that is within the Gilead Licensed Patents shall be the responsibility of Gilead.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Platform Patents or Other MacroGenics Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As between the Parties, the responsibility for Patent Prosecution related to a Patent that is within the MacroGenics Platform Patents or Other MacroGenics Licensed Patents shall be the responsibility of MacroGenics. MacroGenics will provide Gilead with a copy of all material communications from any patent authority regarding the MacroGenics Platform Patents or the Other MacroGenics Licensed Patents and copies of any material filings or responses made to such patent authorities (excluding for clarity, any draft responses) promptly after submission thereof.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.6pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Multi-Product Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As between the Parties, the responsibility for Patent Prosecution related to a Patent that is within the MacroGenics Multi-Product Patents shall be the responsibility of MacroGenics. MacroGenics shall provide Gilead with a reasonable opportunity, &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in advance of any relevant deadline, to review and comment on its efforts to prepare, file, prosecute and maintain the MacroGenics Multi-Product Patents, including by providing Gilead with a copy of all material communications from any patent authority regarding any MacroGenics Multi-Product Patent, and by providing drafts of any material filings or responses to be made to such patent authorities in advance of submitting such filings or responses. MacroGenics shall consider Gilead&#8217;s comments regarding such communications and drafts in good faith. In the event that MacroGenics elects not to undertake the Patent Prosecution for any MacroGenics Multi-Product Patents, MacroGenics shall notify Gilead at least &#91;***&#93; before any such patent rights would become abandoned or otherwise forfeited, and the Parties will discuss in good faith whether to continue the prosecution and maintenance of such MacroGenics Multi-Product Patent. If the Parties are unable to agree in good faith whether to continue the prosecution and maintenance of such MacroGenics Multi-Product Patent, then MacroGenics shall, at Gilead&#8217;s reasonable request, continue prosecution or maintenance of such MacroGenics Multi-Product Patent.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:204.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Product-Specific Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.5pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Prior to Option Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Prior to the applicable Option Effective Date for a Licensed Product, MacroGenics shall have the first right (but not the obligation), at its election and cost and expense, to file, prosecute and maintain the MacroGenics Product-Specific Patents for such Licensed Product. MacroGenics shall provide Gilead with a reasonable opportunity, &#91;***&#93; in advance of any relevant deadline, to review and comment on its efforts to prepare, file, prosecute and maintain such MacroGenics Product-Specific Patents, including by providing Gilead with a copy of all material communications from any patent authority regarding any such MacroGenics Product- Specific Patent, and by providing drafts of any material filings or responses to be made to such patent authorities in advance of submitting such filings or responses. MacroGenics shall consider Gilead&#8217;s comments regarding such communications and drafts in good faith. In the event that MacroGenics elects</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</font></div></td></tr></table></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_43"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:29.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">not to undertake the Patent Prosecution for any such MacroGenics Product-Specific Patents, MacroGenics shall notify Gilead &#91;***&#93; before any such patent rights would become abandoned or otherwise forfeited, and Gilead shall have the right (but not the obligation), at its sole cost and expense, to undertake the Patent Prosecution of such MacroGenics Product-Specific Patent.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.6pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">After Option Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. From and after the applicable Option Effective Date for a Licensed Product, Gilead shall have the first right (but not the obligation), at its election and cost and expense, to file, prosecute and maintain the MacroGenics Product-Specific Patents for such Licensed Product and Gilead shall do so using a patent prosecution firm that is (x) reasonably acceptable to both Parties or (y) at Gilead&#8217;s election, selected by MacroGenics from a list of firms proposed by Gilead. Gilead shall provide MacroGenics with a reasonable opportunity to review and comment on its efforts to prepare, file, prosecute and maintain such MacroGenics Product-Specific Patents, including by providing MacroGenics with a copy of all material communications from any patent authority regarding any such MacroGenics Product-Specific Patent, and by providing drafts of any material filings or responses to be made to such patent authorities in advance of submitting such filings or responses. Gilead shall consider MacroGenics&#8217; comments regarding such communications and drafts in good faith. In the event that Gilead elects not to undertake the Patent Prosecution for any such MacroGenics Product-Specific Patent, Gilead shall notify MacroGenics &#91;***&#93; before any such patent rights would become abandoned or otherwise forfeited, and MacroGenics shall have the right (but not the obligation), at its sole cost and expense, to undertake the Patent Prosecution of such MacroGenics Product-Specific Patent. Notwithstanding the foregoing, MacroGenics&#8217; &#91;***&#93; Patent Prosecution of a MacroGenics Licensed Patent under this Section 16.2(a)(v)(2) (After Option Exercise) shall &#91;***&#93; MacroGenics Licensed Patent or Jointly Owned Patent. For clarity,</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:60.95pt;padding-right:29.6pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Jointly Owned Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Gilead shall have the first right (but not the obligation), at its election, to file, prosecute and maintain the Jointly Owned Patents. Gilead shall provide MacroGenics with a reasonable opportunity to review and comment on its efforts to prepare, file, prosecute and maintain the Jointly Owned Patents, including by providing MacroGenics with a copy of all material communications from any patent authority regarding any Jointly Owned Patent, and by providing drafts of any material filings or responses to be made to such patent authorities in advance of submitting such filings or responses. Gilead shall consider MacroGenics&#8217; comments regarding such communications and drafts in good faith. In the event that Gilead elects not to undertake the Patent Prosecution for a Jointly Owned Patent, Gilead shall notify MacroGenics &#91;***&#93; before any such patent rights would become abandoned or otherwise forfeited, and MacroGenics shall have the right (but not the obligation), to undertake the Patent Prosecution of such Jointly Owned Patent and become the prosecuting Party therefor. Notwithstanding the foregoing, MacroGenics&#8217; right to assume Patent Prosecution of a Jointly Owned Patent shall not apply in the event such patent application was abandoned or otherwise forfeited by Gilead for strategic reasons.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.45pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent and Trademark Invalidations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If either Party desires to undertake activities intended to invalidate a pending or issued Patent or Trademark owned or controlled by a Third Party and having one or more claims that Cover a Licensed Product (except insofar as such action is a counterclaim to or defense of, or accompanies a defense of, a Third Party&#8217;s claim or assertion of infringement under Section 16.5 (Defense), in which case the provisions of Section 16.5 (Defense) will govern), such Party will so notify the other Party, and the Parties will promptly confer to determine whether</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:29.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to bring such action, the strategy to be employed in connection with any such action, or the manner in which to settle such action. &#91;***&#93; Third Party Patents in the Territory that Cover the Licensed Product. &#91;***&#93; MacroGenics and MacroGenics will have &#91;***&#93;. The Party not bringing an action under this Section 16.2(b) (Patent and Trademark Invalidations) will be entitled to separate representation in such proceeding by counsel of its own choice and at its own expense and will cooperate fully with the Party bringing such action.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.8pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Costs of Patent and Trademark Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All Out-of-Pocket Costs for Patent Prosecution and Trademark Prosecution of any Patent (other than the Jointly Owned Patents) or Trademark shall be solely incurred by and the sole responsibility of the prosecuting Party. The Parties shall equally share the Out-of-Pocket Costs to prosecute Jointly Owned Patents.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.75pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding MacroGenics&#8217; right to file, prosecute and maintain the MacroGenics Multi-Product Patents&#58; (1) the Parties will, and will cause their Affiliates to, cooperate and implement reasonable patent filing and prosecution strategies (including filing divisionals, continuations or otherwise) so that, to the extent reasonably feasible, the MacroGenics Product-Specific Patents, MacroGenics Platform Patents and MacroGenics Multi-Product Patents are pursued in mutually exclusive patent applications&#59; (2) at Gilead&#8217;s request and expense, MacroGenics will file any new MacroGenics Product-Specific Patents in a separate patent application from the existing MacroGenics Platform Patents and MacroGenics Multi-Product Patents, in each case to the extent reasonably feasible and in a manner that does not materially prejudice the prosecution of other MacroGenics Licensed Patents&#59; and (3) for any MacroGenics Licensed Patents for which MacroGenics is responsible for filing, to the extent legally permitted by the applicable patent authority, MacroGenics will segregate claims to CD123 Products from products directed to other targets into separate Patents.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Prosecution Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. With respect to all Patent Prosecution related to pending or issued Patents that are Jointly Owned Patents, MacroGenics Licensed Patents or Gilead Licensed Patents, each Party shall&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:30pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">(a)&#160;&#160;&#160;&#160;execute all further instruments to document their respective ownership consistent with this Agreement as reasonably requested by the other Party&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;make its employees, agents and consultants reasonably available to the other Party (or to the other Party&#8217;s authorized attorneys, agents or representatives), to the extent reasonably necessary to enable the appropriate Party hereunder to undertake its Patent Prosecution responsibilities&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;cooperate, if necessary and appropriate, with the other Party in gaining Patent term</font></div><div style="margin-top:0.2pt;padding-left:60.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">extensions&#59; and</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:30.05pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">(d)&#160;&#160;&#160;&#160;endeavor in good faith to coordinate its efforts under this Agreement with the other Party to minimize or avoid interference with the Patent Prosecution of the other Party&#8217;s Patents.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall promptly provide, but in no event &#91;***&#93;, the other Party with written notice reasonably detailing any known or alleged infringement, misappropriation or other violation of any MacroGenics Licensed Technology, Jointly Owned IP or Gilead</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licensed Technology. The notifying Party will provide the other Party with all evidence available to it supporting its belief of such infringement.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Enforcement of Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.6pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Platform Patents and Other MacroGenics Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MacroGenics shall have the sole right to initiate and direct any infringement, misappropriation or other appropriate suit with respect to any Competing Activity (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Enforcement Effort</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) under the MacroGenics Platform Patents, the Other MacroGenics Licensed Patents or the MacroGenics Platform Trademarks&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that at Gilead&#8217;s request from and after the applicable Option Effective Date for a Licensed Product, &#91;***&#93;. With respect to any Enforcement Effort requested by Gilead after MacroGenics&#8217; decision not to so initiate or prosecute, MacroGenics will consult with Gilead regarding such Enforcement Effort and will consider, reasonably and in good faith, all input received from Gilead regarding such Enforcement Efforts. For purposes of this Section 16.4(b) (Enforcement of Intellectual Property Rights), a &#91;***&#93; Enforcement Effort, shall mean the following&#58; &#91;***&#93;. </font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.7pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Multi-Product Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MacroGenics shall have the first right (but not the obligation) to institute and direct Enforcement Efforts under the MacroGenics Multi- Product Patents. If MacroGenics (1) does not initiate any Enforcement Effort against a Third Party alleged to be conducting a Competing Activity, including by commencement of a legal action under the applicable MacroGenics Multi-Product Patents or obtaining a settlement thereof (in accordance with this Agreement), within &#91;***&#93; after receiving notice of such Competing Activity, (2) initiates such Enforcement Efforts within such period, and subsequently ceases to pursue or withdraws from such Enforcement Effort, or (3) provides written notice to Gilead that it does not intend to initiate such Enforcement Effort, then in each case ((1) through (3)) Gilead shall have the right (but shall not be obligated) to take all actions reasonably necessary to abate and seek damages resulting from such Competing Activity, including commencement of a lawsuit against the accused Third Party if necessary.</font></div><div><font><br></font></div><div style="padding-left:204.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Product-Specific Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.6pt;text-indent:143.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Prior to Option Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Prior to the applicable Option Effective Date for a Licensed Product, MacroGenics shall have the first right (but not the obligation) to institute and direct Enforcement Efforts under the MacroGenics Product-Specific Patents. If MacroGenics</font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(x) does not initiate any Enforcement Effort against a Third Party alleged to be conducting a Competing Activity, including by commencement of a legal action under the applicable MacroGenics Product-Specific Patents or obtaining a settlement thereof (in accordance with this Agreement), within &#91;***&#93; after receiving notice of such Competing Activity, (y) initiates such Enforcement Efforts within such period, and subsequently ceases to pursue or withdraws from such Enforcement Effort, or (z) provides written notice to Gilead that it does not intend to initiate such Enforcement Effort, then in each case ((x) through (z)) Gilead shall have the right (but shall not be obligated) to take all actions reasonably necessary to abate and seek damages resulting from such Competing Activity, including commencement of a lawsuit against the accused Third Party if necessary&#59; &#91;***&#93;. </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79</font></div></td></tr></table></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_46"></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.75pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">After Option Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. From and after the applicable Option Effective Date for a Licensed Product, Gilead shall have the first right (but not the obligation) to institute and direct Enforcement Efforts under the MacroGenics Product-Specific Patents. If Gilead (x) does not initiate any Enforcement Effort against a Third Party alleged to be conducting a Competing Activity, including by commencement of a legal action under the applicable MacroGenics Product-Specific Patents or obtaining a settlement thereof (in accordance with this Agreement), within &#91;***&#93; after receiving notice of such Competing Activity, (y) initiates such Enforcement Efforts within such period, and subsequently ceases to pursue or withdraws from such Enforcement Effort, or (z) provides written notice to MacroGenics that it does not intend to initiate such Enforcement Effort, then in each case ((x) through (z)) MacroGenics shall have the right (but shall not be obligated) to take all actions reasonably necessary to abate and seek damages resulting from such Competing Activity, including commencement of a lawsuit against the accused Third Party if necessary&#59; &#91;***&#93;.</font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.8pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Jointly Owned IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Gilead shall have the first right (but not the obligation) to institute and direct Enforcement Efforts under the Jointly Owned Patents. If Gilead (x) does not initiate any Enforcement Effort against a Third Party alleged to be conducting a Competing Activity, including by commencement of a legal action under the applicable Jointly Owned Patents or obtaining a settlement thereof (in accordance with this Agreement), within &#91;***&#93; after receiving notice of such Competing Activity, (y) initiates such Enforcement Effort within such period, and subsequently ceases to pursue or withdraws from such Enforcement Effort, or (z) provides written notice to MacroGenics that it does not intend to initiate such Enforcement Effort, then in each case ((x) through (z)) MacroGenics shall have the right (but shall not be obligated) to take all actions reasonably necessary to abate and seek damages resulting from such Competing Activity, including commencement of a lawsuit against the accused Third Party if necessary&#59; &#91;***&#93;.</font></div><div style="margin-top:4.5pt;padding-left:61pt;padding-right:29.75pt;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(v)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. Each Party shall discuss in good faith with the other Party, and shall keep the other Party updated with respect to, the progress of each Enforcement Effort being undertaken by such Party pursuant to this Section 16.4 (Enforcement).</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recovery Allocations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;All amounts recovered by either Party in the Territory relating to an Enforcement Effort (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall be first used to reimburse each Party&#8217;s Out-of-Pocket Costs incurred in connection with such Enforcement Effort.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;After reimbursement of all amounts under Section 16.4(c)(i) (Recovery Allocations), any remainder of a Recovery that is obtained by Gilead from an Enforcement Effort or by MacroGenics from an Enforcement Effort shall be &#91;***&#93;.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80</font></div></td></tr></table></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_49"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cooperation in Enforcement Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. For any action by a Party pursuant to Section 16.4(b) (Enforcement of Intellectual Property Rights), in the event that such Party is unable to initiate or prosecute such action solely in its own name, the other Party shall join such action voluntarily and shall execute all documents necessary for such Party to initiate, prosecute and maintain such action. If either Gilead or MacroGenics initiates an enforcement action pursuant to Section 16.4(b) (Enforcement of Intellectual Property Rights), then the other Party shall cooperate to the extent reasonably necessary and at the first Party&#8217;s sole expense (except for the expenses of the non-controlling Party&#8217;s counsel, if any). Upon the reasonable request of the Party instituting any such action, such other Party shall join the suit and can be represented in any such legal proceedings using counsel of its own choice. Each Party shall assert and not waive the joint defense privilege with respect to all communications between the Parties reasonably the subject thereof.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.8pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Status&#59; Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties shall keep each other reasonably informed of the status of and of their respective activities regarding any enforcement action pursuant to Section 16.4(b) (Enforcement of Intellectual Property Rights). In no event may the Party who has the right to initiate an Enforcement Effort pursuant to Section 16.4(b) (Enforcement of Intellectual Property Rights) settle such Enforcement Effort in a manner that would limit the rights of the other Party or impose any obligation on the other Party, in each case, without the other Party&#8217;s prior written consent, which consent will not be unreasonably withheld, delayed or conditioned.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Notice of Allegations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall notify the other in writing of any allegations it receives from a Third Party that the manufacture, production, use, development, sale, offer for sale, import or distribution of a Licensed Molecule or Licensed Product or practice of any MacroGenics Licensed Technology or Jointly Owned IP infringes, misappropriates or otherwise violates the intellectual property rights of such Third Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Allegation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Such notice shall be provided promptly, but in no event after more than &#91;***&#93;, following receipt of such allegations.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.5pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Notice of Suit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event that a Party receives notice that it or any of its Affiliates have been individually or collectively named as a defendant (or defendants) in a legal proceeding by a Third Party alleging infringement, misappropriation or any other violation of a Third Party&#8217;s intellectual property right as a result of the Development, Manufacture, or Commercialization of a Licensed Molecule or Licensed Product or any of MacroGenics Licensed Technology or Jointly Owned IP (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Suit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), such Party shall promptly notify the other Party in writing and in no event notify such other Party later than &#91;***&#93; after the receipt of such notice. Such written notice shall include a copy of any summons or complaint (or the equivalent thereof) received regarding the foregoing. Each Party shall assert and not waive the joint defense privilege with respect to all communications between the Parties reasonably the subject thereof.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Right to Defend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Prior to Option Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Prior to the Option Effective Date for a Licensed Product, the Parties will meet and discuss any Third Party Allegation or Third Party Suit and determine in good faith how to defend such claim.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.7pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">After Option Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. From and after the applicable Option Effective Date for a Licensed Product, Gilead will have the first right, but not the obligation, to defend any Third Party Allegation or Third Party Suit related to such Licensed Product or the applicable Licensed Molecule at its cost and expense. MacroGenics may participate in any such claim, suit or proceeding with counsel of its choice at its own cost and expense. Without limitation of the foregoing, if Gilead finds it necessary for</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:30.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics to join Gilead as a party to any such action, then the Parties shall cooperate to execute all papers and perform such acts as shall be reasonably required for MacroGenics to join such action. If Gilead</font></div><div style="margin-top:0.1pt;padding-left:60.95pt;padding-right:29.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(x) does not initiate any defense of any Third Party Allegation or Third Party Suit related to such Licensed Product or the applicable Licensed Molecule within &#91;***&#93; after receiving notice of such Third Party Allegation or Third Party Suit, (y) if such defense is initiated within such period, and Gilead ceases to pursue or withdraws from such defense, or (z) provides written notice to MacroGenics that it does not intend to defend against such Third Party Allegation or Third Party Suit, then in each case ((x) through (z)) MacroGenics shall have the right (but shall not be obligated) to take all actions reasonably necessary to defend such Third Party Allegation or Third Party Suit, including commencement of a lawsuit against the accused Third Party if necessary.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Status&#59; Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties shall keep each other informed of the status of and of their respective activities regarding any litigation or settlement thereof initiated by a Third Party as contemplated under Section 16.5(c) (Right to Defend)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that no settlement or consent judgment or other voluntary final disposition of a suit under this Section 16.5(d) (Status&#59; Settlement) that affects the other Party&#8217;s rights or interests may be undertaken by a Party without the consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Listing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. From and after the applicable Option Effective Date for a Licensed Product, &#91;***&#93; in the then-current edition of the FDA&#8217;s Purple Book in connection with the Regulatory Approval of such Licensed Product, or in equivalent patent listings in any other country within the Territory.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Term Extensions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. From and after the applicable Option Effective Date for a Licensed Product, &#91;***&#93; for patent term extensions, supplementary protection certificates, or equivalents thereto in any country in the Territory, in each case, where applicable to such Licensed Product (hereinafter &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Term Extensions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), including for any MacroGenics Licensed Patents or Jointly Owned Patents (but excluding any MacroGenics Platform Patent). &#91;***&#93; will provide support, assistance, and all necessary documents, in full, executed form if needed, to Gilead for the purpose of supporting, filing, obtaining and maintaining Patent Term Extensions.</font></div><div><font><br></font></div><div style="padding-left:97pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exclusive Dispute Resolution Mechanism</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties agree that the procedures set forth in this Article 17 (Dispute Resolution) shall be the exclusive mechanism for resolving any Dispute between the Parties that may arise from time to time pursuant to this Agreement relating to either Party&#8217;s rights or obligations hereunder that is not resolved through good faith negotiation between the Parties. For the avoidance of doubt, this Article 17 (Dispute Resolution) shall not apply to any decision with respect to which a Party has final decision-making authority hereunder. Any Dispute, including Disputes that may involve the parent company, subsidiaries, or Affiliates under common control of any Party, shall be resolved in accordance with this Article 17 (Dispute Resolution).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Resolution by Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as otherwise provided in this Article 17 (Dispute Resolution), in the event of any Dispute, the Parties will refer the Dispute to the Executive Officer of each Party for attempted resolution by good faith negotiation within &#91;***&#93; after such notice is received. Each Party may, in its discretion, seek resolution of &#91;***&#93; hereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Incidental</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:61pt;padding-right:30.1pt;text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payment Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that remains unresolved after escalation to Executive Officers in accordance with this Section 17.2 (Resolution by Execution Officers) through expedited arbitration in accordance with Section</font></div><div style="margin-top:0.1pt;padding-left:61pt;padding-right:29.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">17.3&#160;&#160;&#160;&#160;(Expedited Arbitration for Incidental Payment Disputes) and (b) any other Disputes (other than Incidental Payment Disputes) that are not resolved within such &#91;***&#93; through litigation in accordance with the remainder of this Article 17 (Dispute Resolution).</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Expedited Arbitration for Incidental Payment Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding Section 17.4 (Jurisdiction&#59; Venue&#59; Service of Process), any unresolved Incidental Payment Disputes will be submitted to the International Court of Arbitration of the International Chamber of Commerce (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ICC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and will be finally settled under the Rules of the Arbitration of the ICC as then in effect, except as modified herein. The seat, or legal place, of arbitration will be San Francisco, California and the Parties agree not to contest such seat of arbitration. The arbitration will be conducted by a &#91;***&#93; arbitrators, which will be constituted as follows&#58; each Party will nominate an arbitrator within &#91;***&#93;. Each arbitrator will have expertise and significant experience with respect to licensing and partnering agreements in the pharmaceutical and biotechnology industries, including expertise in the applicable subject matter of the Incidental Payment Dispute. An arbitrator will be deemed to meet these qualifications unless a Party objects &#91;***&#93; after the arbitrator is nominated. If any of the arbitrators are not nominated within the time prescribed above, then the arbitrator(s) will be appointed by the ICC in accordance with ICC rules. The Parties agree not to contest the jurisdiction of the arbitral tribunal. The arbitral tribunal will submit its award to the International Court of Arbitration of the ICC within &#91;***&#93; of the final arbitration hearing or the final post-hearing submission, whichever is later, subject to extension by the Parties&#8217; mutual agreement. The Parties will in good faith facilitate an expedited arbitration process such that the arbitration will conclude within &#91;***&#93;. No arbitrator (nor the arbitral tribunal) will have the power to award punitive damages or to award costs and expenses of the proceeding or reasonable attorney&#8217;s fees to any Party under this Agreement and such award is expressly prohibited. The award will be final and binding on the Parties and the Parties undertake to carry out any award without delay. Judgment on the award so rendered may be entered in any court of competent jurisdiction. No award or procedural order made in the arbitration will be published. The Parties acknowledge that this Agreement evidences a transaction involving interstate and international commerce. Notwithstanding the provision in Section 17.5 (Governing Law) with respect to applicable substantive law, any arbitration conducted pursuant to the terms of this Agreement will be governed by the U.S. Federal Arbitration Act.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Jurisdiction&#59; Venue&#59; Service of Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except with respect to Incidental Payment Disputes, each Party irrevocably submits to the exclusive jurisdiction of &#91;***&#93;. Each Party agrees to commence any Action either in the &#91;***&#93; or if such Action may not be brought in such court for jurisdictional reasons, in the courts of the &#91;***&#93; Each Party further agrees that service of any process, summons, notice or document by the U.S. registered mail to such Party&#8217;s respective address set forth in Section 19.6 (Notices) will be effective service of process for any Action in New York with respect to any matters to which it has submitted to jurisdiction in this Section 17.3. (Jurisdiction&#59; Venue&#59; Service of Process). Each Party irrevocably and unconditionally waives any objection to the laying of venue of any Action arising out of this Agreement in &#91;***&#93;, and hereby and thereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such Action brought in any such court has been brought in an inconvenient forum.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement, and all claims or causes of action (whether in contract, tort, statute, or otherwise) that may be based upon, arise out of, or relate to this Agreement, or the negotiation, execution, or performance of this Agreement, or the breach thereof (including any claim or cause of action based upon, arising out of, or related to any representation or warranty made in or in connection with this Agreement or as an inducement to enter into this Agreement), will be governed by, and enforced in accordance with, &#91;***&#93;, including its statutes of limitations, without giving effect to any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The provisions of the United Nations Convention on Contracts for the International Sale of Goods are expressly excluded.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30.15pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. THE PARTIES HEREBY WAIVE, AND COVENANT THAT THEY WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY ACTION ARISING IN WHOLE OR IN PART UNDER OR IN CONNECTION WITH THIS AGREEMENT, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. THE PARTIES AGREE THAT ANY OF THEM MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND BARGAINED-FOR AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE ITS RIGHT TO TRIAL BY JURY IN ANY PROCEEDING WHATSOEVER BETWEEN THEM RELATING TO THIS AGREEMENT, AND THE PARTIES WILL INSTEAD BE TRIED IN A COURT OF COMPETENT JURISDICTION BY A JUDGE SITTING WITHOUT A JURY.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Equitable Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding anything to the contrary, either Party may at any time seek to obtain preliminary injunctive relief or other applicable provisional relief from a court of competent jurisdiction with respect to an issue arising under this Agreement if the rights of such Party would be prejudiced absent such relief.</font></div><div><font><br></font></div><div style="padding-left:96.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.95pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement shall become effective as of the Effective Date and, unless earlier terminated pursuant to this Article 18 (Term and Termination), shall continue in full force and effect until, on a Licensed Product-by-Licensed Product and country-by-country basis, the expiration of the last Royalty Term for a Licensed Product in a country (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination for Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement may be terminated in its entirety or with respect to a Program at any time during the Term upon written notice by a Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) if the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is in material breach of this Agreement (or in connection with the applicable Program, as applicable) and, in each case, has not cured such breach within the applicable cure period after written notice requesting cure of the breach, which notice will describe such material breach in reasonable detail and will state the Non-Breaching Party&#8217;s intention to terminate this Agreement, in its entirety or in part. For any breach arising from a failure to make a payment set forth in this Agreement, the Breaching Party will have &#91;***&#93; notification to cure such breach. For all breaches other than a failure to make a payment as set forth in this Agreement, the Breaching Party will have &#91;***&#93; to cure such breach&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, if &#91;***&#93;, then such &#91;***&#93;. For clarity, if a material breach is limited to one or more (but not all) Programs, then the Non-Breaching Party will have the right to terminate solely with respect to such Program(s).</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:30pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Disagreement as to Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding Section 18.2(a) (Material Breach), if the Parties in good faith disagree as to whether there has been a material breach of this Agreement, then&#58; (i) the Breaching Party may contest the allegation by referring such matter, within &#91;***&#93;. following its receipt of notice of the alleged material breach, for resolution in accordance with Article 17 (Dispute Resolution)&#59; (ii) the relevant cure period with respect to such alleged material breach will be tolled from the date on which the Breaching Party notifies the Non-Breaching Party of the Dispute and through the resolution of such Dispute in accordance with the applicable provisions of this Agreement&#59; (iii) during the pendency of such Dispute, all of the terms and conditions of this Agreement will remain in effect and the Parties will continue to perform all of their respective obligations hereunder&#59; and (iv) if it is ultimately determined that the Breaching Party committed such material breach, then the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:60.95pt;padding-right:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Breaching Party will have the right to cure such material breach, after such determination, within the applicable cure period set forth in Section 18.2(a) (Material Breach), which cure period will commence as of the date of such determination.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination for Convenience</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. At any time after the &#91;***&#93; of the Effective Date, Gilead may, in its sole discretion, terminate this Agreement in its entirety upon (a) &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">notice to MacroGenics prior to the CD123 Option Effective Date or (b) &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">notice to MacroGenics after the CD123 Option Effective Date. In addition, at any time after the &#91;***&#93; of the Effective Date, Gilead may, at its sole discretion, terminate this Agreement on a Program-by-Program basis upon (i) &#91;***&#93;</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">notice to MacroGenics if such notice is provided &#91;***&#93;, or (ii) &#91;***&#93; notice to MacroGenics &#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.75pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">18.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Termination for Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. This Agreement may be terminated in its entirety or in part on a Program-by-Program basis at any time during the Term upon written notice by either Party in accordance with Section 19.1 (Force Majeure).</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination for Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement may be terminated in its entirety, to the extent permitted by the Applicable Laws and Regulations, by a Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-Bankrupt Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors, in each case, of the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Bankrupt Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that in the case of any involuntary bankruptcy, reorganization, liquidation or receivership proceeding, such right to terminate will only become effective if the Bankrupt Party consents to the involuntary bankruptcy or such proceeding is not dismissed within &#91;***&#93; after the filing thereof (such bankruptcy and related events described in this Section 18.5 (Termination for Bankruptcy), collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Bankruptcy Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination for Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except to the extent the following is unenforceable under the Applicable Laws and Regulations of a particular jurisdiction in the Territory, on a MacroGenics Licensed Patent-by-MacroGenics Licensed Patent basis, MacroGenics may terminate the licenses granted to Gilead under Section 3.1 (Licenses to Gilead) for a MacroGenics Licensed Patent (and such Patent will cease to be a MacroGenics Licensed Patent for all purposes under this Agreement) upon written notice to Gilead if Gilead, its Affiliates, or Sublicensees, individually or in association with any other person or entity, commences a legal action challenging the validity, enforceability or scope of such MacroGenics Licensed Patent in a court or other governmental agency of competent jurisdiction, including a reexamination or opposition proceeding (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and does not withdraw such Patent Challenge within &#91;***&#93; after receipt of notice from MacroGenics requesting</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a withdrawal&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that with respect to any Patent Challenge by any Sublicensee, MacroGenics will not have the right to terminate this Agreement under this Section 18.6 (Termination for Patent Challenge) if, within &#91;***&#93; of MacroGenics&#8217; notice to Gilead under this Section 18.6 (Termination for Patent Challenge), Gilead (a) causes such Patent Challenge to be terminated or dismissed or (b) terminates the sublicense granted to such Sublicensee under this Agreement. Notwithstanding the foregoing, MacroGenics will not have the right to terminate under this Section 18.6 (Termination for Patent Challenge) as a result of (i) any claim or proceeding that would otherwise be a Patent Challenge hereunder to the extent commenced by a Third Party that after the Effective Date acquires or is acquired by Gilead or its Affiliates or its other business assets, whether by stock purchase, merger, asset purchase or otherwise, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that such proceeding was commenced prior to the closing of such acquisition&#59; (ii) any claim or proceeding by a licensor of a product licensed by Gilead for which the licensor has an existing challenge, whether in a court or administrative proceeding against a MacroGenics Licensed Patent&#59; (iii) any Patent Challenge required to be commenced pursuant to an order of a governmental authority or Applicable Laws and Regulations&#59; (iv) any proceeding not initiated, directed or controlled by or on behalf of Gilead or one of its Affiliates (or any of their respective Sublicensees), for which Gilead or the Affiliate, as the case may be, opposes, or assists any Third Party to oppose, the grant of a MacroGenics Licensed Patent pursuant to any application in relation thereto in an administrative proceeding, such as a patent reexamination, inter partes review, or other post grant proceeding or opposition&#59; (v) challenges by an open forum entity or other industry group in which Gilead or its Affiliates or Sublicensees do not direct or control the action of such entity&#59; (vi) general activities not specifically directed to a particular Patent, such as amicus briefs on cases not involving a MacroGenics Licensed Patent&#59; (vii) lobbying or other efforts directed to patent issues generally and not to any specific MacroGenics Licensed Patent&#59; or (viii) providing documents or testimony in response to any discovery requests or court order in a valid legal process not directed to a Patent Challenge of a MacroGenics Licensed Patent.</font></div><div><font><br></font></div><div style="padding-left:61pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Gilead shall have the right, on a Program- by-Program basis, to terminate this Agreement at any time upon providing &#91;***&#93; prior written notice to MacroGenics&#58; &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:60.95pt;padding-right:29.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Alternative Remedy in Lieu of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. MacroGenics agrees that Gilead&#8217;s decision to enter into this Agreement and invest in the Development of the Programs is premised upon the assumption that MacroGenics will perform its obligations under this Agreement, and that a material breach of the Agreement by MacroGenics could undermine the economic fundamentals of the transaction for Gilead, and that in such event Gilead&#8217;s damages arising from MacroGenics&#8217; breach would be of an uncertain amount and difficult to prove. Accordingly, if it has been conclusively determined that Gilead has the right to terminate this Agreement pursuant to Section 18.2 (Termination for Material Breach) or Section 18.5 (Termination for Bankruptcy) (for clarity, (i) based upon MacroGenics&#8217;s acknowledgment of or failure to dispute, as applicable, under Section 18.2(b) (Disagreement as to Material Breach) such material breach or bankruptcy or (ii) pursuant to the procedures set forth in Section 18.2(b) (Disagreement as to Material Breach)), then in lieu of terminating this Agreement due to such material breach or suing MacroGenics for damages arising from such material breach, Gilead may, in its sole discretion, exercise the following remedy (which MacroGenics stipulates and agrees would be a reasonable remedy in such circumstance and not a penalty)&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30.1pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Gilead may retain all of its licenses and other rights granted under this Agreement, subject to all of its payment and other obligations&#59; except that, &#91;***&#93; (which for clarity, shall remain payable in its full amount in accordance with the terms of &#91;***&#93;&#59; and</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:60.95pt;padding-right:30.05pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;any Gilead Confidential Information provided to MacroGenics pursuant to this Agreement will be promptly returned to Gilead or destroyed (at MacroGenics&#8217; election), and Gilead will be released from its ongoing disclosure and information exchange obligations with respect to activities after the date of such election.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For the avoidance of doubt, except as set forth in this Section 18.8 (Alternative Remedy in Lieu of Termination), if Gilead exercises the alternative remedy set forth above in this Section 18.8 (Alternative Remedy in Lieu of Termination), then all rights and obligations of both Parties under this Agreement will continue unaffected, unless and until this Agreement is subsequently terminated by either Party pursuant to this Article 18 (Term and Termination)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that in the event that Gilead exercises the alternative </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">remedy set forth in this Section 18.8 (Alternative Remedy in Lieu of Termination) in the event of a material breach by MacroGenics (as described in Section 18.2 (Termination for Material Breach)) or upon the occurrence of a bankruptcy event of MacroGenics (as described in Section 18.4 (Termination for Bankruptcy)), Gilead will not have the right to terminate this Agreement or to seek monetary damages from MacroGenics for such material breach or, as it relates to this Agreement, bankruptcy, in each case for which the alternative remedy was exercised.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effects of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">In General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon any termination of this Agreement in its entirety or with respect</font></div><div style="margin-top:0.05pt;padding-left:60.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to a Program&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.8pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Gilead shall pay any amounts accrued pursuant to Section 11.1 (Development Costs, Plan Costs and Manufacturing Costs) and Article 10 (Payments) for this Agreement or the Terminated Programs, as applicable, as of the effective date of termination to the extent not previously paid prior to the date of termination&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;The licenses and sublicenses granted to each Party under this Agreement (or with respect to the Terminated Programs, as applicable) including pursuant to Sections 3.1 (Licenses to Gilead) and 3.2 (Licenses to MacroGenics), shall terminate and Gilead will cease any and all Exploitation of the Terminated Products as soon as is reasonably practicable under Applicable Laws and Regulations&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that such licenses will continue as necessary for the Parties to complete the orderly wind-down of their activities under this Agreement in accordance with Applicable Laws and Regulations and as otherwise required in accordance with Section 18.9(a)(iii) (In General) &#91;***&#93;&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Gilead shall cease all Development and Commercialization under each Terminated Program, including, to the extent permitted by any applicable Regulatory Authority or Applicable Laws and Regulations, halting enrollment of subjects (unless otherwise directed in writing by MacroGenics) into any Clinical Trial being conducted by the Gilead for the Terminated Programs and at MacroGenics&#8217; sole election shall either (1) wind-down (including to cease administering the Terminated Products to Clinical Trial subjects and conducting Clinical Trial procedures on such Clinical Trial subjects, to the extent medically advisable and permitted by any applicable Regulatory Authority or Applicable Laws and Regulations) or (2) if a &#91;***&#93; any such Clinical Trial then being conducted by Gilead &#91;***&#93;  but in all cases in a timely manner and in accordance with all Applicable Laws and Regulations&#59;</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:30pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;All sublicenses under the rights granted pursuant to Sections 3.1 (Licenses to Gilead) and 3.2 (Licenses to MacroGenics) shall terminate with respect to the Terminated Products, unless converted to a direct license under Section 3.3(c) (Survival of Gilead Sublicenses) subject to terms and conditions to be agreed between MacroGenics and such Sublicensee&#59; and</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.85pt;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;MacroGenics shall revoke (and Gilead shall allow revocation of) any powers of attorney for any MacroGenics Licensed Patents that Gilead holds as of the time of such termination.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;MacroGenics shall have the right to assume all preparation, filing, prosecution, maintenance and enforcement activities under Article 16 (Intellectual Property) with respect to MacroGenics Licensed Patents as to which Gilead has assumed the right and authority to prepare, file, prosecute, maintain or enforce. Gilead will cooperate with MacroGenics and provide MacroGenics with reasonable assistance with the preparation, filing, prosecution, maintenance, and enforcement activities with respect to such MacroGenics Licensed Patents. The step-in rights granted to MacroGenics with respect to Jointly Owned Patents under Section 16.2(a)(vi) (Jointly Owned Patents) and Section 16.4(b)(iv) (Jointly Owned IP) shall remain in effect.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Additional Effects of Certain Terminations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If (A) MacroGenics terminates this Agreement in its entirety or with respect to the CD123 Development Program pursuant to (1) Section 18.2 (Termination for Material Breach), (2) Section 18.5 (Termination for Bankruptcy) or (3) Section 18.6 ((Termination for Patent Challenge), solely to the extent the relevant Patent that is the subject of such Patent Challenge is the last MacroGenics Licensed Patent for which there exists a Valid Claim that Covers the composition of matter or method of use of a Licensed Product) or (B) if Gilead terminates this </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:60.95pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agreement in its entirety or with respect to the CD123 Development Program pursuant to Section 18.3 (Termination for Convenience), then, in addition to those general effects set forth in Section 18.9(a) (In General), upon such termination the following terms of this Section 18.9(b) (Additional Effects of Certain Terminations) will apply solely with respect to any CD123 Products that are not Combination Products (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reverted CD123 Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Gilead shall &#91;***&#93; MacroGenics, at &#91;***&#93; MacroGenics, &#91;***&#93; and to (1) &#91;***&#93; for the Reverted CD123 Products, to the extent that MacroGenics &#91;***&#93; CD123 Development Program&#59; and (2) &#91;***&#93; of the CD123 Molecules and Reverted CD123 Products), in &#91;***&#93; Related Parties or its or their respective agents solely related to such Reverted CD123 Products&#59; and</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:204.95pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Upon written request from MacroGenics to Gilead provided within &#91;***&#93;</font></div><div style="margin-top:0.15pt;padding-left:60.95pt;padding-right:29.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">following MacroGenics&#8217; receipt or delivery, as applicable, of the notice of termination, the Parties &#91;***&#93; regarding the transition by Gilead to MacroGenics of assets and rights and the provision of assistance by each Party to the other Party as reasonably necessary, subject to agreement of the Parties, to enable the continued Development, Manufacture and Commercialization of the Reverted CD123 Products &#91;***&#93;, among other things, the following matters&#58; (i) &#91;***&#93; for the Reverted CD123 Products&#59; (ii) &#91;***&#93; of the Reverted CD123 Products &#91;***&#93;&#59; (iii) &#91;***&#93; applicable Reverted CD123 Products&#59; (iv) &#91;***&#93; of CD123 Molecules and Reverted CD123 Products &#91;***&#93;&#59; (v) &#91;***&#93; Gilead at the time of termination to &#91;***&#93; the Reverted CD123 Products&#59; (vi) the &#91;***&#93; the Reverted CD123 Products&#59; (vii) the &#91;***&#93; the Reverted CD123 Products&#59; (viii) any &#91;***&#93; Reverted CD123 Products &#91;***&#93;&#59; and (ix) &#91;***&#93; transition and assistance to MacroGenics&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that &#91;***&#93; to MacroGenics under subsection &#91;***&#93; if such termination is &#91;***&#93; for a CD123 Product.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Surviving Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Accrued Rights&#59; Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The expiration or termination of this Agreement for any reason will be without prejudice to any rights that will have accrued to the benefit of any Party prior to such expiration or termination, and any and all damages or remedies (whether at law or in equity) arising from any breach hereunder, each of which will survive expiration or termination of this Agreement. Such expiration or termination will not relieve any Party from obligations which are expressly indicated to survive expiration or termination of this Agreement. Except as otherwise expressly set forth in this Agreement, the termination provisions of this Article 18 (Term and Termination) are in addition to any other relief and remedies available to either Party under this Agreement, at law or in equity.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.75pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Without limiting the provisions of Section 18.10(a) (Accrued Rights&#59; Remedies), the following provisions, as well as any other provisions which by their nature are intended to survive termination or expiration, shall survive the termination or expiration of this Agreement for any reason&#58; Articles 1 (Definitions) (as applicable), 12 (Confidentiality&#59; Publication), 15 (Indemnification) (except that with respect to Section 15.5 (Insurance)), &#91;***&#93; following termination or expiration), 17 (Dispute Resolution), and Sections 3.3(c) (Survival of Gilead Sublicenses), 3.5 (Retained Rights) (solely with respect to the second and third sentences), 3.8(c)(ii) &#91;***&#93; Upstream Licenses) (solely with respect to any surviving provisions of sublicensed Upstream License Agreements), 3.9 (Materials Transfer) (solely with respect to the ownership of Materials and the last sentence), 4.7 (Records&#59; Updates) (solely with respect to the obligation to maintain records for &#91;***&#93; following termination or expiration), 4.8 (Data Ownership), 4.13 (CD123 Development Program Termination), 5.4 (Research Plan Costs) (solely with respect to activities conducted prior to the effective date of termination or expiration of this Agreement), 5.6 (Records&#59; Updates) (solely with respect to the obligation to maintain records for &#91;***&#93; following termination or expiration), 5.7 (Data Ownership), 5.10 (Research Program Termination), 6.5 (Records) (solely with respect to the obligation to maintain records for &#91;***&#93; following termination or expiration), 6.7 (Data Ownership), 9.1(a)(i) (Prior to the CD123 Option Effective Date) (solely with respect to the last sentence), 10.2 (Development and Regulatory Milestone Payments) through 10.4 (Royalties on Net Sales) (solely with respect to obligations accrued, but not yet paid, as of the effective date of expiration or termination of this Agreement), 11.1 (Development Costs, Plan Costs and Manufacturing Costs) and 11.2 (Royalty Payments) (solely with respect to obligations accrued, but not yet paid, as of the effective date of expiration or termination of this Agreement), 11.3 (Payment Exchange Rate), 11.4 (Taxes), 11.5 (Records) and 11.6 (Audit Rights) (solely for &#91;***&#93; following termination or expiration), 11.7 (Confidentiality), 13.2(a)(iii)(6) (Anti- Corruption Laws) (solely for &#91;***&#93; following expiration of termination), 13.2(a)(iii)(7) (solely with respect to the last sentence), 14.5 (No Other Representations or Warranties), 16.1 (Ownership of Intellectual Property), 16.2(a)(vi) (Jointly Owned Patents), 16.3 (Patent </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:61pt;padding-right:29.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prosecution Cooperation) (solely with respect to Jointly Owned Patents), 16.4(a) (Notice) (solely with respect to Jointly Owned IP), 16.4(b)(iv) (Jointly Owned IP), 16.4(b)(v) (Cooperation) (solely with respect to Jointly Owned Patents), 16.4(c) (Recovery Allocations) (solely with respect to Jointly Owned Patents), 16.4(d) (Cooperation in Enforcement Proceedings) (solely with respect to Jointly Owned Patents), 18.9 (Effects of Termination), 18.10 (Surviving Provisions), 19.2 (Standstill) (solely for twelve (12) months after the Effective Date if the Agreement is terminated prior to such time), 19.3 (Section 365(n) of the Bankruptcy Code), 19.4(a) (Assignment), 19.5 (Severability) through 19.18 (Construction), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 10.4(c)(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Special Offset and Indemnification).</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:96.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, including embargoes, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any governmental authority or the other Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that the affected Party (a) notify the other Party of such Force Majeure circumstances as soon as reasonably practical and (b) promptly undertakes all reasonable efforts necessary to cure such Force Majeure circumstances, and will continue performance in accordance with the terms of this Agreement whenever such causes are removed. For the avoidance of doubt, the inability to expend or access financial resources in itself shall not be a Force Majeure. In the event a Party is unable to perform its obligations under this Agreement due to Force Majeure for a period of &#91;***&#93;, the other Party shall have the option of unilaterally terminating this Agreement upon providing &#91;***&#93; written notice.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standstill.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Gilead agrees that neither it nor any of its subsidiaries (but excluding any Acquirer of Gilead or any Affiliates of such Acquirer following a Change of Control of Gilead), officers or directors acting at Gilead&#8217;s direction and on its behalf, alone or as part of any 13D Group (as defined below), shall, directly or indirectly, for &#91;***&#93;(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Standstill Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), &#91;***&#93;&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:4.55pt;padding-left:61pt;padding-right:29.7pt;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;acquire, offer or publicly propose to acquire or agree to acquire or cause to be acquired, ownership (including, but not limited to, beneficial ownership as defined in Rule 13d-3 under the Securities Exchange Act of 1934 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)) of more than &#91;***&#93; of the voting equity securities of MacroGenics, or any rights or options to acquire more than &#91;***&#93; of the voting equity securities of MacroGenics&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:30pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;make or participate in any &#8220;solicitation&#8221; of &#8220;proxies&#8221; (as such terms are used in Regulation 14A of the Exchange Act) to vote, or seek to advise or influence any Person with respect to the voting of, any voting securities of MacroGenics&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.95pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;form or join a &#8220;group&#8221; (within the meaning of Section 13(d)(3) of the Exchange Act) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13D Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with respect to any voting securities of MacroGenics&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;otherwise act to seek to publicly propose to MacroGenics any merger, business combination, restructuring, recapitalization or similar transaction with respect to or with MacroGenics or otherwise act to seek the removal of any member of the Board of Directors of MacroGenics, or nominate any person as a director of MacroGenics who is not nominated by a then incumbent director&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.9pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;publicly announce its intentions to enter into any discussion, negotiations, arrangements or understandings with any Third Party with respect to, any of the foregoing.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The restrictions set forth in this Section 19.2 (Standstill) shall be inoperative and of no force in effect and shall automatically terminate immediately if&#58; (i) a Person or 13D Group (not including Gilead or its Affiliates) (1) commences or publicly announces its intent to commence a tender or exchange offer to acquire voting securities of MacroGenics representing more than twenty percent (20%) of the then-outstanding voting power of the voting securities of MacroGenics or (2) publicly announces a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">bona fide </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">proposal to enter into a transaction described in, or of a similar nature to those described in, clause (ii)(1) or (ii)(2) below and either (x) MacroGenics publicly announces a willingness to consider such proposal or alternative proposals for a transaction described in, or of a similar nature as those described in, clause (ii)(1) or (ii)(2) below, (y) the Board of Directors of MacroGenics determines to engage in negotiations with such Person or 13D Group or any other Party (other than Gilead or its Affiliates) with respect to a transaction described in, or of a similar nature as those described in, clause (ii)(1) or (ii)(2) below, or (z) such offer or proposal is not publicly rejected or recommended against by the MacroGenics&#8217; Board of Directors within &#91;***&#93; after such offer or proposal becomes public or the MacroGenics&#8217; Board of Directors withdraws such recommendation of rejection or recommends acceptance of such tender or exchange offer, (ii) MacroGenics or its Affiliates publicly initiates a process to consider, or enters into a transaction described in clause (1) or (2) below, or enters into a letter of intent or definitive agreement with any Third Party regarding (1) any merger, consolidation, sale, reorganization, recapitalization, tender or exchange offer, restructuring, sale, equity issuance, dual listing structure, joint venture, liquidation, dissolution or other business combination or extraordinary transaction pursuant to which the stockholders or equity holders of MacroGenics immediately prior to such transaction would own, immediately after consummation of such a transaction, less than &#91;***&#93; of the total voting power of MacroGenics, any successor entity, parent entity or other entity surviving such transaction&#59; or (2) any transaction or series of transactions that would result, directly or indirectly, in the sale or transfer to a Third Party of (A) all or a majority of MacroGenics&#8217; consolidated assets&#59; or (B) a majority of MacroGenics&#8217; consolidated assets which relate to this Agreement, whether, in the case of clause (1) or (2), by way of a merger, consolidation, sale, reorganization, recapitalization, tender or exchange offer, restructuring, sale, equity issuance, dual listing structure, joint venture, liquidation, dissolution or other business combination or extraordinary transaction, (iii) any person (other than any person that is eligible to file a Schedule 13G under the Exchange Act with respect to such ownership) or 13D group becomes the beneficial owner of twenty percent (20%) or more of the outstanding voting power of MacroGenics or (iv) MacroGenics enters into a voluntary or involuntary bankruptcy or insolvency proceeding under Applicable Laws and Regulations.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:169pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Nothing in this Agreement, including this Section 19.2 (Standstill), shall prohibit&#58;</font></div><div style="margin-top:0.1pt;padding-left:60.95pt;padding-right:29.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i) Gilead or its Affiliates or its or their Representatives from acquiring or offering to acquire any securities of MacroGenics in connection with any mutual fund, pension plan or employee benefit plan managed on behalf of employees or former employees of Gilead or its Affiliates&#59; or (ii) Gilead or any of its Affiliates or its or their Representatives from making a private proposal to, or engaging in discussions or confidentially communicating with the Board of Directors of MacroGenics or any officer or member of senior management of MacroGenics, on a confidential, non-public basis regarding, any of the transactions contemplated under this Section 19.2 (Standstill) in such a manner that would not reasonably be expected to require Gilead or MacroGenics to make any public disclosure with respect thereto under Applicable Laws and Regulations.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 365(n) of the Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All rights and licenses granted under or pursuant to any section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to &#8220;intellectual property&#8221; as defined under Section 101(35A) of the U.S. Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and elections under the U.S. Bankruptcy Code. The Parties agree that a Party that is a licensee of such rights under this Agreement shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code, and that upon commencement of a bankruptcy proceeding by or against the licensing Party (such Party, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Involved Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) under the U.S. Bankruptcy Code, the other Party (such Party, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Noninvolved Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall be entitled to a complete duplicate of or complete access to (as such Noninvolved Party deems appropriate), any such intellectual property and all embodiments of such intellectual property, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Noninvolved Party continues to fulfill its payment or royalty obligations as specified herein in full. Such intellectual property and all embodiments thereof shall be promptly delivered to the Noninvolved Party (a) upon any such commencement of a bankruptcy proceeding upon written request therefor by the Noninvolved Party, unless the Involved Party elects to continue to perform all of its obligations under this Agreement or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of the Involved Party upon written request therefor by Noninvolved Party. The foregoing is without prejudice to any rights the Noninvolved Party may have arising under the U.S. Bankruptcy Code or other Applicable Laws and Regulations.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:132.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Assignment&#59; Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.6pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Neither Party may assign its rights and obligations under this Agreement without the prior written consent of the other Party, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that each Party may assign its rights and obligations under this Agreement, without such consent from the other Party, to its Affiliate or any successor in interest in connection with the sale of all or substantially all of its assets or a sale of all or substantially of the business related to a Program, or a merger, acquisition or other similar transactions. For the avoidance of doubt, the terms and conditions of this Agreement shall be binding on the permitted successors and assignees of each Party.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:168.9pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;If MacroGenics undergoes a Change of Control, then</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(i)&#160;&#160;&#160;&#160;MacroGenics will notify Gilead thereof within &#91;***&#93; upon the closing of the Change of Control&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:117%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">that a public announcement within such period by or through a nationally recognized news organization recognized pharma&#47;biotech industry news organization or forum of such closing shall be sufficient to provide such notification&#59;</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;If the MacroGenics Acquirer is Exploiting any Competitive Product, then MacroGenics will comply with the terms of Section 3.10(c) (Business Combinations)&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Agreement, Gilead will have the right, at its sole discretion, by written notice delivered to MacroGenics (or its successor) at any time within &#91;***&#93; following the written notice contemplated by the foregoing Section 19.4(b)(i) (Assignment&#59; Change of Control), to (1) terminate any or all provisions of this Agreement providing for any delivery by Gilead to MacroGenics of Confidential Information of Gilead relating to activities contemplated by this Agreement, save only for the provisions of Article 10 (Payments), and (2) require MacroGenics and its Acquirer to adopt reasonable procedures, to be agreed upon by the Parties in writing, to prevent disclosure of Confidential Information of Gilead to MacroGenics&#8217; Acquirer. For clarity this clause 19.4(b)(iii) (Assignment&#59; Change of Control) does not limit any reporting obligations of Gilead that are financial in nature&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.9pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;MacroGenics covenants that there will be no material change in the level or nature of efforts or resources expended by MacroGenics and its Affiliates, which material change would reasonably be expected to adversely impact MacroGenics&#8217; ability to perform its obligations under this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All notices which are required or permitted hereunder shall be in a medium that has the capability to confirm the exact content, the times of transmission and receipt, and the identities or each sender and recipient of each communication sent through such medium. A communication to an intended recipient Party shall be deemed to be received by the intended recipient Party by the existence of documentation that clearly evidences such communication was sent through a medium permitted under this Agreement to an individual who was specifically designated by the recipient Party to receive such communication or, if no such designation was made, an individual who has routinely received communications with similar content under this Agreement on behalf of the recipient Party.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;padding-right:29.6pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#323232;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For notices to be communicated in writing, such notices shall be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:138.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">if to MacroGenics, to&#58;&#160;&#160;&#160;&#160;9704 Medical Center Drive</font></div><div style="padding-left:268.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Rockville, MD 20850</font></div><div style="margin-top:0.1pt;padding-left:268.75pt;padding-right:96.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">Attention&#58; Chief Executive Officer Facsimile&#58; (301) 251-5321</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:138.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">with copy to&#58;</font></div><div style="padding-left:138.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(which shall not constitute notice)</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92</font></div></td></tr></table></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_52"></div><hr style="page-break-after:always"><div style="min-height:31.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.821%"><div style="margin-top:4.65pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">if to Gilead, to&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-right:1.35pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with a copy to&#58;</font></div><div style="margin-top:4.5pt;padding-left:60.9pt;padding-right:181.8pt"><font><br></font></div></div><div style="display:inline-block;max-width:0.357%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.822%"><div style="padding-left:9pt;padding-right:181.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 United States</font></div><div style="margin-top:0.2pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Alliance Manager</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:9pt;padding-right:181.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 United States</font></div><div style="margin-top:0.15pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; General Counsel</font></div></div></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:30pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given upon receipt.</font></div><div><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Applicable Intellectual Property Law&#47;Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All questions of inventorship shall be determined in accordance with U.S. patent laws. In respect to all other Patent issues related to the enforceability or validity of a Patent, the laws of the jurisdiction in which the applicable Patent is filed or granted shall govern.</font></div><div style="height:56.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93</font></div></td></tr></table></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_55"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Entire Agreement&#59; Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Agreement contains the entire understanding of the Parties with respect to the subject matter hereof, including the Programs and licenses granted hereunder. All express or implied prior or contemporaneous agreements and understandings, either oral or written, with regard to the subject matter hereof, including with respect to the Programs and the licenses granted hereunder, are superseded by the terms of this Agreement, including the Existing CDA. The Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both Parties hereto. Any confidential information disclosed by the Parties pursuant to the Existing CDA shall be deemed to constitute Confidential Information under this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.9pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The captions to the several Sections hereof are not a part of the Agreement, but are merely for convenience to assist in locating and reading the several Sections and Sections of this Agreement.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Independent Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. It is expressly agreed that MacroGenics and Gilead shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither MacroGenics nor Gilead shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.85pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">No Third Party Beneficiary Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as expressly set forth in this Agreement, this Agreement is not intended to and will not be construed to give any Third Party any interest or rights (including any Third Party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Performance by Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party will have the right to perform any or all of its obligations and exercise any or all of its rights under this Agreement through any Affiliate. Each Party hereby guarantees the performance by its Affiliates of such Party&#8217;s obligations under this Agreement and will cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party&#8217;s Affiliate of any of such Party&#8217;s obligations under this Agreement will be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party&#8217;s Affiliate.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">19.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. The waiver by either Party of any right hereunder, or the failure of the other Party to perform, or a breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:60.95pt;padding-right:29.85pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cumulative Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.9pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">19.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Waiver of Rule of Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail, including Adobe&#8482; Portable Document Format (PDF) or any electronic signature complying with the U.S. Federal ESIGN Act of 2000, and any counterpart so delivered will be deemed to be original signatures, will be valid and binding upon the Parties, and, upon delivery, will constitute due execution of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:3.85pt;padding-left:60.95pt;padding-right:29.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes, or to better assure and confirm unto such other Party its rights and remedies under this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word &#8220;or&#8221; is used in the inclusive sense (and&#47;or). Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The words &#8220;include&#8221;, &#8220;includes,&#8221; &#8220;including&#8221; and &#8220;such as&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;. The word &#8220;will&#8221; will be construed to have the same meaning and effect as the word &#8220;shall&#8221;. Any reference to any person or entity will be construed to include the person&#8217;s or entity&#8217;s successor and assigns. The words &#8220;herein,&#8221; &#8220;hereof,&#8221; and &#8220;hereunder&#8221;, and words of similar import, will be construed to refer to this Agreement in its entirety and not any particular provision. The word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and will include notices, consents, approvals, and other written communications contemplated under this Agreement. Provisions that require that a Party, the Parties, or any committee hereunder &#8220;agree,&#8221; &#8220;consent,&#8221; &#8220;approve,&#8221; or the like will require that such agreement, consent, or approval be specific and in writing, whether by written agreement, letter, approved minutes, or otherwise (but excluding e-mail and instant messaging). References to &#8220;Section&#8221; or &#8220;Sections&#8221; are references to the numbered sections of this Agreement, unless expressly stated otherwise. All dollars are United States Dollars. Unless the context otherwise requires, countries shall include territories. References to any specific law or article, section or other division thereof, shall be deemed to include the then-current amendments or any replacement law thereto. Except as otherwise expressly set forth in this Agreement, when applied to Gilead, the phrases &#8220;at its own cost and expense,&#8221; &#8220;at its sole cost and expense,&#8221; &#8220;at its cost and expense,&#8221; and similar phrases used in this Agreement do not preclude the possibility that Gilead may share such costs or expenses with a Third Party.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.6pt;padding-left:198.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">(Remainder of page intentionally left blank)</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.887%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.6pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95</font></div></td></tr></table></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_58"></div><hr style="page-break-after:always"><div style="min-height:5.76pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:60.95pt;padding-right:28.85pt;text-indent:35.9pt"><font><br></font></div><div style="padding-right:28.85pt"><font><br></font></div><div style="padding-right:28.85pt"><font><br></font></div><div style="padding-left:72pt;padding-right:28.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Parties have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.</font></div><div style="margin-top:3.9pt;padding-left:60.95pt;padding-right:28.85pt;text-indent:35.9pt"><font><br></font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.571%"><tr><td style="width:1.0%"></td><td style="width:45.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Sciences, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics, Inc.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3.9pt;padding-left:60.95pt;padding-right:28.85pt;text-indent:35.9pt"><font><br></font></div><div><font><br></font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:26.410%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.65pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to Collaboration Agreement&#93;</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:5.76pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.9pt;padding-left:5.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DocuSign Envelope ID&#58; 1F54EEC9-CC02-4CC7-B458-268EC436A598</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:28.85pt;text-indent:35.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Parties have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.</font></div><div style="padding-left:60.95pt;padding-right:28.85pt;text-indent:35.9pt"><font><br></font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.437%"><tr><td style="width:1.0%"></td><td style="width:45.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Sciences, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics, Inc.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="padding-left:60.95pt;padding-right:28.85pt;text-indent:35.9pt"><font><br></font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:26.410%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.65pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to Collaboration Agreement&#93;</font></div></td></tr></table></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_61"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.05pt;padding-left:57.6pt;padding-right:57.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 1.72</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:57.57pt;padding-right:57.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Knowledge Parties</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:9.05pt;padding-left:56.27pt;padding-right:56.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-top:0.05pt;padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:57.47pt;padding-right:57.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-top:4.55pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-top:0.4pt;padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_64"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.05pt;padding-left:57.6pt;padding-right:57.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 1.80</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:57.6pt;padding-right:57.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Licensed Patents</font></div><div><font><br></font></div><div style="margin-bottom:0.05pt;margin-top:0.2pt"><font><br></font></div><div style="padding-left:62.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.604%"><tr><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="15" style="background-color:#d8d8d8;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_67"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:62.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.604%"><tr><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:8.3pt;text-indent:-2.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:195%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.3pt;text-indent:-2.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:200%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.3pt;text-indent:-2.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:200%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt;padding-right:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.3pt;text-indent:-2.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:200%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.5pt;padding-left:8.3pt;text-indent:-2.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:195%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.3pt;text-indent:-2.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:200%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:8.3pt;text-indent:-2.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:195%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.3pt;text-indent:-2.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:200%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:5.5pt;padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:195%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_70"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:62.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.604%"><tr><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="15" style="background-color:#d8d8d8;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.5pt;padding-left:5.5pt;padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:195%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 9.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 9.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt;padding-left:5.5pt;padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:195%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:5.5pt;padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:195%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.5pt;padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:200%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:5.5pt;padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:195%">&#91;***&#93;</font></div></td></tr></table></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_73"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:62.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.604%"><tr><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:5.5pt;padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:195%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.5pt;padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:200%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.5pt;padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:200%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:5.55pt;padding-right:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.5pt;padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:200%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.5pt;padding-left:5.5pt;padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:195%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.5pt;padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:200%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:5.5pt;padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:195%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.5pt;padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:200%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:5.5pt;padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:195%">&#91;***&#93;</font></div></td></tr></table></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_76"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:62.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.604%"><tr><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.45pt;padding-left:5.5pt;padding-right:7.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:195%">&#91;***&#93;</font></div></td></tr><tr><td colspan="15" style="background-color:#d8d8d8;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="12" style="background-color:#d8d8d8;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#d8d8d8;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.35pt;padding-left:5.6pt;padding-right:4.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:173%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_79"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:62.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.604%"><tr><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.2pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_82"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:62.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.604%"><tr><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="15" style="background-color:#d8d8d8;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_85"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:62.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.604%"><tr><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="15" style="background-color:#d8d8d8;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.3pt;padding-left:5.6pt;padding-right:14.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_88"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:62.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.604%"><tr><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.2pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.2pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_91"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:62.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.604%"><tr><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="15" style="background-color:#d8d8d8;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_94"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:62.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.604%"><tr><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.2pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.2pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.2pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_97"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.05pt;padding-left:57.6pt;padding-right:57.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 1.86</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:57.6pt;padding-right:57.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Platform</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_100"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.05pt;padding-left:57.6pt;padding-right:57.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 1.88</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:210.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MacroGenics Platform Trademarks</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_103"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.05pt;padding-left:18.5pt;padding-right:18.5pt;text-align:center;text-indent:19.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Schedule 1.114</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%"> </font></div><div style="margin-top:3.05pt;padding-left:18.5pt;padding-right:18.5pt;text-align:center;text-indent:19.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.2pt;padding-left:97pt;padding-right:30pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_106"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.05pt;padding-left:18.5pt;padding-right:18.5pt;text-align:center;text-indent:19.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Schedule 1.118</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%"> </font></div><div style="margin-top:3.05pt;padding-left:18.5pt;padding-right:18.5pt;text-align:center;text-indent:19.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.2pt;padding-left:97pt;padding-right:30pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_109"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.05pt;padding-left:57.57pt;padding-right:57.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 1.151</font></div><div style="margin-top:6.25pt;padding-left:57.6pt;padding-right:57.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Existing Upstream License Agreements</font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_112"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.05pt;padding-left:57.65pt;padding-right:57.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 3.7</font></div><div style="margin-top:6.25pt;padding-left:57.42pt;padding-right:57.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Existing Upstream License Agreements Amendments</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:115pt;padding-right:30.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.55pt;padding-right:29.9pt"><font><br></font></div><div style="margin-top:4.55pt;padding-right:29.9pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_115"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:57.57pt;padding-right:57.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 4.1(a)</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:57.62pt;padding-right:57.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CD123 Development Plan</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt;padding-left:36.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12.5pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_118"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:57.52pt;padding-right:57.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 4.1(b)</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:57.52pt;padding-right:57.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Protocol Synopsis</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:62.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.811%"><tr><td style="width:1.0%"></td><td style="width:50.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.8pt;padding-left:5.55pt;padding-right:8.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.9pt;padding-left:13.7pt;padding-right:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.9pt;padding-left:5.55pt;padding-right:43.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.85pt;padding-left:5.55pt;padding-right:0.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_121"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.811%"><tr><td style="width:1.0%"></td><td style="width:50.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.9pt;padding-left:5.55pt;padding-right:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.95pt;padding-left:5.55pt;padding-right:8.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:8.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr></table></div><div style="padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_124"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:62.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.811%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.95pt;padding-left:5.55pt;padding-right:8.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:8.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.05pt;padding-left:5.55pt;padding-right:6.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_127"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:62.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.811%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_130"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:57.65pt;padding-right:57.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 5.2</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:57.6pt;padding-right:57.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Plan</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_133"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:57.45pt;padding-right:57.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 9.1(a)(i)</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:57.5pt;padding-right:57.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Existing CMO Agreements</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:97pt;padding-right:48.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127837668_29</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_136"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:57.52pt;padding-right:57.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 9.1(a)(iii)</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:203.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Supply Agreement Key Terms</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:70pt;padding-right:29.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">This term sheet outlines certain key terms that will be included in the Clinical Supply Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Clinical Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">to be entered into pursuant to Section 9.1(a)(iii) of the Collaboration and License Agreement between the Parties (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#8221;). Capitalized terms used but not defined in this term sheet will have the meaning attributed to them in the Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.046%"><tr><td style="width:1.0%"></td><td style="width:21.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:23.55pt;padding-right:10.25pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Purpose and Scope</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pursuant to the Clinical Supply Agreement, MacroGenics will Manufacture and supply exclusively to Gilead MGD024 Drug Products for use in Clinical Trials to be conducted by Gilead under the Agreement.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">2.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:113%">Products</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics will supply the MGD024 Drug Product &#91;***&#93;, in accordance with the applicable specifications for such MGD024 Drug Product set forth in an exhibit to the Clinical Supply Agreement, as the same may be updated from time to time by agreement of the Parties (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Specifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Unless otherwise agreed by the Parties, Gilead will be responsible for &#91;***&#93; MGD024 Drug Products.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">3.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:113%">Term</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;, unless otherwise mutually agreed by the Parties in writing or terminated earlier in accordance with its terms (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Supply Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Purchase</font></div><div style="padding-left:23.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Orders</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; MGD024 Drug Products for use in Clinical Trials as well as to &#91;***&#93;  (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Purchase Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Each Purchase Order will specify the quantities of the applicable MGD024 Drug Products being ordered &#91;***&#93; after MacroGenics&#8217; receipt of a Purchase Order, MacroGenics will confirm the &#91;***&#93; MGD024 Drug Product ordered under such Purchase Order &#91;***&#93; Purchase Order provided by Gilead&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that the</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font><font style="color:#b5072d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">From time to time, Gilead will discuss at the JSC its requirements of MGD024 Drug Products for Clinical Trials under the Agreement.</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:23.55pt;padding-right:15.15pt;text-align:justify;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Supply Price&#59; Invoicing and Delivery</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics will supply MGD024 Drug Products to Gilead at a supply price equal to &#91;***&#93; (as defined in the Agreement) incurred by MacroGenics to Manufacture a batch of MGD024 Drug Product for clinical supply purposes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MGD024 Transfer Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div></td></tr></table></div><div style="padding-left:45pt"><font><br></font></div><div style="padding-left:45pt"><font><br></font></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_139"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:71pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.046%"><tr><td style="width:1.0%"></td><td style="width:21.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.55pt;text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; to have an independent public accounting firm audit MacroGenics&#8217; books and records to verify the accuracy of the &#91;***&#93;. Any overcharges shall be reimbursed to Gilead.</font></div><div style="margin-top:7.15pt;padding-left:5.55pt;padding-right:4.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics will invoice Gilead for &#91;***&#93; MGD024 Transfer Price of MGD024 Drug Products ordered pursuant to a Purchase Order &#91;***&#93; for such MGD024 Drug Products (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Gilead will pay all undisputed invoiced amounts within &#91;***&#93; after the date of the invoice.</font></div><div style="margin-top:7.2pt;padding-left:5.55pt;padding-right:4.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All MGD024 Drug Products will be delivered to Gilead &#91;***&#93; to be defined in the Clinical Supply Agreement.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:23.55pt;padding-right:10.25pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Applicable Laws and Regulations</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The national, federal, regional, state and provincial laws of the United States, EU and any other jurisdictions the Parties may agree on, including cGMP, GCP and GBPS of such jurisdictions.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">7.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:113%">Product</font></div><div style="padding-left:23.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Warranty</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:3.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics shall use Commercially Reasonable Efforts to Manufacture and deliver to Gilead MGD024 Drug Products. The MGD024 Drug Product (a) shall be in conformity with the applicable Specifications&#59; (b) shall have been Manufactured in conformance with applicable cGMP and Applicable Laws and Regulations, the Agreement, the Clinical Supply Agreement and the Clinical Quality Agreement&#59; (c) shall have been Manufactured in facilities that are in compliance with Applicable Laws and Regulations at the time of such Manufacture (including applicable inspection requirements of the FDA, its EU counterparts and other Regulatory Authorities agreed to by the Parties)&#59; (d) shall not be adulterated under the FFDCA, its EU counterparts, and similar provisions of the laws of other jurisdictions agreed to by the Parties&#59; and (e) shall have a minimum shelf life as agreed upon by the Parties and incorporated into the Clinical Supply Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Warranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). MacroGenics shall be responsible for maintaining all regulatory approvals and compliance of the Manufacturing Facility with cGMP requirements and applicable law.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.55pt;padding-right:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Prior to shipment of any MGD024 Drug Product to Gilead, MacroGenics will conduct all QC and QA activities necessary to ensure that such MGD024 Drug Product meets the Product Warranty, including all activities set forth under the Clinical Quality Agreement, and will release such MGD024 Drug Product in compliance with the Product Warranty and Clinical Quality Agreement.</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">8.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:113%">Product</font></div><div style="margin-top:0.1pt;padding-left:23.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Inspection &#47; Replacement of Failed Batches</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gilead will have &#91;***&#93; after delivery to inspect any MGD024 Drug Products and during such &#91;***&#93;, Gilead may reject those lots that do not meet the Specifications. If Gilead identifies any MGD024 Drug Product during such &#91;***&#93; that do not meet Specification or subsequently identifies a latent defect of the MGD024 Drug Product that causes such MGD024 Drug Product to not meet Specifications, MacroGenics will use Commercially Reasonable Efforts to replace such</font></div><div style="padding-left:5.55pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MGD024 Drug Product as soon as reasonably practicable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">at MacroGenics&#8217; sole cost and expense, or if MacroGenics is unable to replace such MGD024</font></div></td></tr></table></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_142"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:71pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.046%"><tr><td style="width:1.0%"></td><td style="width:21.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt;padding-right:4.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">Drug Product, then refund Gilead for the amounts paid for such rejected MGD024 Product.</font></div><div style="margin-top:6.45pt;padding-left:5.55pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Parties disagree as to whether there is a latent defect, then such dispute will be resolved by a root cause analysis conducted by an independent laboratory (with such process to be further specified in the Clinical Supply Agreement).</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">9.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:113%">Subcontracting</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics may only subcontract fill and finishing of the MGD024 Drug Product &#91;***&#93; other fill and finishing subcontractors agreed to by the Parties. Additionally, MacroGenics may subcontract with testing labs and storage facilities.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:23.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ownership of Intellectual Property</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ownership of all Intellectual Property developed by the Parties in the course of the performance of the Clinical Supply Agreement will be governed by the Agreement.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">11. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:113%">Indemnification</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The indemnification obligations and limitations on liability set forth in Article 15 of the Agreement will apply, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">12. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:113%">Quality</font></div><div style="padding-left:23.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Agreement</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In conjunction with the Clinical Supply Agreement, the Parties will enter into a customary clinical quality agreement governing issues related to the quality of the MGD024 Drug Products to be supplied by MacroGenics under the Clinical Supply Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:7.15pt;padding-left:5.55pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MacroGenics will be responsible for the manufacturer release of a cGMP batch of the MGD024 Drug Product to Gilead according to the Specifications and cGMP requirements, including providing a certificate of analysis and a certificate of compliance.</font></div><div style="margin-top:7.1pt;padding-left:5.55pt;padding-right:4.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Either the Clinical Supply Agreement or the Clinical Quality Agreement will provide that &#91;***&#93; MGD024 Drug Products &#91;***&#93;.</font></div><div style="margin-top:7.25pt;padding-left:5.55pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gilead will have the right to audit MacroGenics&#8217; Facility with up to &#91;***&#93; participating in any on-site visits and to the extent permitted by the applicable agreement, to the facilities of MacroGenics&#8217; vendors and subcontractors no more than &#91;***&#93; for quality and regulatory purposes unless for cause, as set forth in the Clinical Quality Agreement.</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:23.55pt;padding-right:10.25pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination&#59; Supply Failure</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">The Clinical Supply Agreement may be terminated by either Party for the other Party&#8217;s uncured material breach, insolvency or by Gilead due to a Supply Failure which is not cured by MacroGenics.</font></div><div style="margin-top:6.6pt;padding-left:5.55pt;padding-right:4.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If, (a) in any given &#91;***&#93; of the &#91;***&#93; of MGD024 Drug Product ordered by Gilead for delivery with respect to such period is &#91;***&#93;, then in either such case,</font></div><div style="padding-left:5.55pt;padding-right:4.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Gilead will have the right to terminate the Clinical Supply Agreement after providing written notice to MacroGenics of such failure to supply.</font></div></td></tr></table></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_145"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:71pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.046%"><tr><td style="width:1.0%"></td><td style="width:21.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.6pt;text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">14. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:113%">Assignment</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">The Clinical Supply Agreement may be assigned by either Party in connection with a permitted assignment of the Agreement by such Party in accordance with Section 19.4 of the Agreement.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">15. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:113%">Applicable</font></div><div style="padding-left:23.55pt;padding-right:10.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Law, Dispute Resolution</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">Article 17 of the Agreement will apply to the Clinical Supply Agreement,</font></div><div style="margin-top:0.35pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:23.55pt;padding-right:31.05pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Additional Terms</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.55pt;padding-right:4.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">The Clinical Supply Agreement will include additional terms and conditions relating to clinical supply that are customary in clinical supply agreements for biologic products.</font></div></td></tr></table></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_148"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:57.6pt;padding-right:57.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 10.4(c)(iii)</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:213.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Special Offset and Indemnification</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:97pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;Acquisition of Rights to the Identified Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.1pt;padding-left:114.95pt;padding-right:29.4pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">During the CD123 Development Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During the CD123 Development Term, MacroGenics will have the &#91;***&#93; Exploit the Licensed Molecules or Licensed Products in the Territory (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Identified Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and such agreement, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Identified Patent Upstream License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and notwithstanding Section 3.8(d) (Responsibility for Payments under Upstream License Agreements), MacroGenics will be &#91;***&#93; Identified Patent Upstream License. MacroGenics will ensure that the terms of any Identified Patent Upstream License that also grants right for any other molecule or product being Exploited by MacroGenics or a sublicensee of MacroGenics &#91;***&#93; the Licensed Molecules or Licensed Products. Prior &#91;***&#93; Identified Patent Upstream License, MacroGenics will &#91;***&#93; with respect to such agreement, and &#91;***&#93; the Identified Patent such that MacroGenics or its Affiliate &#91;***&#93;. MacroGenics may request, &#91;***&#93; Identified Patent Upstream License &#91;***&#93; Identified Patent Upstream License, and Gilead &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, in the event that MacroGenics &#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:114.95pt;padding-right:29.55pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">After the CD123 Option Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. From and after the CD123 Option Effective Date, Gilead will have the &#91;***&#93; Exploitation of Licensed Molecules or Licensed Products under this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, prior to the &#91;***&#93;. Notwithstanding Section 10.4(c)(iii) &#91;***&#93; if Gilead or its Affiliates &#91;***&#93; Gilead or its Affiliate is subject to a &#91;***&#93; Exploitation of any Licensed Molecule or Licensed Product in one or more countries in the Territory under this Agreement, then, in each case ((a) and (b)), Gilead will &#91;***&#93; MacroGenics upon or after Initiation of a Pivotal Clinical Trial for a Licensed Product under this Agreement (including, for clarity, &#91;***&#93;</font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:99pt;padding-right:29.6pt;text-align:justify;text-indent:-25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In no event will &#91;***&#93;, collectively with the other &#91;***&#93; MacroGenics for a given Calendar Quarter &#91;***&#93; of the amount otherwise payable under Section 10.2 (Development and Regulatory Milestone Payments), 10.3 (Commercial Milestone Payments) or 10.4 (Royalties on Net Sales), as applicable, with respect to an applicable Licensed Product. Gilead may &#91;***&#93; and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 10.4(c)(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Special Offset and Indemnification) that are &#91;***&#93; Calendar Quarter but are not &#91;***&#93; MacroGenics in such Calendar Quarter as a result of the &#91;***&#93; MacroGenics in any subsequent Calendar Quarter &#91;***&#93;. </font></div><div style="margin-top:0.05pt;padding-left:99pt;text-indent:-25pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:99pt;padding-right:29.85pt;text-align:justify;text-indent:-25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;Indemnification Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In addition to Section 15.2 (By MacroGenics), MacroGenics agrees to indemnify and hold harmless the Gilead Indemnitee(s) from and against all Losses incurred in connection with any Third Party Claims &#91;***&#93; (a) to the extent &#91;***&#93; Identified Patent Upstream License (by either MacroGenics with Gilead as a sublicensee thereunder or Gilead) or (b) &#91;***&#93; Identified Patent Upstream License, and except in all cases, to the extent such Third Party Claims arise from any action for which Gilead has an indemnification obligation to a MacroGenics Indemnitee under Section 15.1 (By Gilead), subject to the procedures set forth in Section 15.3 (Indemnification Procedures), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_151"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:57.55pt;padding-right:57.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 12.1(f)</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:205.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Confidential Information</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding any provision to the contrary in Section 12.1 (Nondisclosure Obligation), the following obligations will apply, and to the extent there is any conflict with the obligations in Section 12.1 (Nondisclosure Obligation) will supersede, solely with respect to any &#91;***&#93; that is clearly marked as &#91;***&#93;&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:97pt;padding-right:29.75pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The confidentiality and non-use obligations will remain in place until the later of (a) &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:97pt;padding-right:29.7pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="padding-left:60.95pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:97pt;padding-right:29.7pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93; (a) its directors, officers, consultants and employees (i) with a need to know such &#91;***&#93; and (ii) who are bound by written confidentiality obligations at least as stringent as those set forth in this Agreement (including this Schedule) and (b) regulatory or governmental agencies for the purpose of regulatory compliance and for review for registration and use of the Licensed Molecules and Licensed Products.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:96.95pt;padding-right:29.95pt;text-indent:-18.05pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Receiving Party may provide &#91;***&#93; to its Affiliates and its Representatives who have a need to know or are directly concerned with the Receiving Party&#8217;s obligations or exercise of rights &#91;***&#93;. The Receiving Party will advise its Representatives receiving &#91;***&#93; of its proprietary nature and have in place a written agreement covering these confidentiality obligations, and use reasonable safeguards to prevent its Representatives unauthorized use or disclosure of &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:60.95pt;padding-right:29.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of this Schedule, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any officers, representatives, agents, subcontractors, employees, service providers, sublicensee or other Third Party under control or direction of the Receiving Party.</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_154"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:57.62pt;padding-right:57.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 12.3(a)</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:57.57pt;padding-right:57.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Press Release</font></div><div><img alt="image_56a.jpg" src="image_56a.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:164px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_57a.jpg" src="image_57a.jpg" style="height:74px;margin-bottom:5pt;vertical-align:text-bottom;width:133px"></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gilead Contacts&#58;&#160;&#160;&#160;&#160;MacroGenics Contact&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Jacquie Ross, Investors&#160;&#160;&#160;&#160;Jim Karrels, Senior Vice President, CFO</font></div><div style="padding-left:61pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">investor_relations&#64;gilead.com&#160;&#160;&#160;&#160;info&#64;macrogenics.com</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:282.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Marian Cutler, Media Marian.Cutler1&#64;gilead.com</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Confidential Draft &#8211;Not for Distribution</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:57.4pt;padding-right:57.4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GILEAD AND MACROGENICS ANNOUNCE ONCOLOGY COLLABORATION TO DEVELOP BISPECIFIC ANTIBODIES</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:57.65pt;padding-right:57.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Gilead Granted Exclusive Option to License MGD024, a Phase 1 CD123&#215;CD3 DART</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%"> Molecule with Potential to Treat Various Hematologic Malignancies </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8211;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:90.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Potential for Companies to Collaborate on Two Additional Future Research Programs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8211;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:29.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Foster City, Calif., and Rockville, Md. October 17, 2022 &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Gilead Sciences, Inc. (Nasdaq&#58; GILD) and MacroGenics (NASDAQ&#58; MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics&#8217; DART</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> platform, and two additional bispecific research programs. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">A leader in the bispecific antibody space, MacroGenics has extensive experience applying its proprietary DART platform to develop novel therapeutics. MGD024 is a next-generation, bispecific that incorporates a CD3 component that is designed to minimize cytokine-release syndrome (CRS), a potentially life- threatening toxicity, while increasing the magnitude of antitumor activity with a longer half-life to permit intermittent dosing.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:61pt;padding-right:29.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8220;MacroGenics&#8217; bispecific expertise naturally complements Gilead&#8217;s portfolio strengths in immuno- oncology and our growing hematology franchise,&#8221; said Bill Grossman, MD, PhD, Senior Vice President, Oncology Clinical Development, Gilead Sciences. &#8220;We believe MGD024, with its potential to reduce CRS and permit intermittent dosing through a longer half-life, could translate to more patient-friendly dosing and enhanced clinical outcomes for people living with AML and MDS. This partnership is the latest in our efforts to develop and advance transformative new cancer therapies as we deepen our portfolio across oncology indications.&#8221;</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_157"></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.5pt;padding-left:61pt;padding-right:29.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Scott Koenig, MD, PhD, President, and CEO, MacroGenics said, &#8220;Rapid advances over the last decade have made CD123 a very promising target in oncology research. Advancing our bispecific DART molecule, MGD024, through a strategic collaboration with the team at Gilead will accelerate our ability to drive further development of MGD024 to the potential benefit of people living with blood cancers.&#8221;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:60.95pt;padding-right:30pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">MacroGenics will be responsible for the ongoing Phase 1 study for MGD024 during which Gilead may elect to exercise its option to license the program at predefined decision points. The Phase 1 study will include a dose escalation segment and an expansion segment that is intended to evaluate MGD024 as monotherapy and in combination with other therapies across multiple indications.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:61pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Considerations</font></div><div style="margin-top:1.9pt;padding-left:61pt;padding-right:29.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">As part of the agreement, Gilead will pay MacroGenics an upfront payment of $60 million and MacroGenics will be eligible to receive up to $1.7 billion in target nomination, option fees, and development, regulatory and commercial milestones. MacroGenics will also be eligible to receive tiered, double-digit royalties on worldwide net sales of MGD024 and a flat royalty on worldwide net sales of products under the two research programs.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:61pt;padding-right:30.05pt;text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission (SEC), Gilead no longer excludes acquired IPR&#38;D expenses from its non-GAAP financial measures and expects the transaction with MacroGenics to reduce Gilead&#8217;s GAAP and non-GAAP 2022 EPS by approximately $0.04.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:61pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">About MacroGenics, Inc.</font></div><div style="margin-top:1.95pt;padding-left:61pt;padding-right:29.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms,  which  have  applicability  across  broad  therapeutic  domains.  The  combination of MacroGenics' technology platforms and protein engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo, and DART are trademarks or registered trademarks of MacroGenics, Inc.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:61pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">About Gilead Sciences</font></div><div style="margin-top:2pt;padding-left:60.95pt;padding-right:30pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:61pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Gilead Forward-Looking Statements</font></div><div style="margin-top:1.95pt;padding-left:60.95pt;padding-right:32.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties, and other factors, including the ability</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_160"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.05pt;padding-left:61pt;padding-right:29.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">of the parties to complete the transaction in a timely manner or at all&#59; the possibility that various closing conditions for the transaction may not be satisfied or waived, including the possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction&#59; the risk that Gilead may not realize the potential benefits of this collaboration with MacroGenics or its other investments in oncology&#59; difficulties or unanticipated expenses in connection with the collaboration and the potential effects on Gilead&#8217;s revenues and earnings&#59; Gilead&#8217;s ability to achieve its anticipated full year 2022 financial results&#59; the ability of the parties to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional trials, including those involving MGD024 or future research programs&#59; the ability of the parties to file applications for regulatory approval or receive regulatory approvals in a timely manner or at all, including those involving MGD024 or future research programs, and the risk that any such approvals may be subject to significant limitations on use&#59; the possibility that the parties may make a strategic decision to terminate the collaborations, including the development of MGD024 or future research programs, at any time&#59; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:61pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">MacroGenics Forward-Looking Statements</font></div><div style="margin-top:1.85pt;padding-left:60.95pt;padding-right:29.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Any statements in this press release about future expectations, plans and prospects for MacroGenics, including statements about the MacroGenics&#8217; strategy, future operations, clinical development of MGD024, including initiation and enrollment in clinical trials for MGD024, the consummation of the transactions discussed in this press release, milestone or option payments from Gilead and other statements containing the words &#8220;subject to&#8221;, &#34;believe&#34;, &#8220;anticipate&#8221;, &#8220;plan&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;potential,&#8221; &#8220;project&#8221;, &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;would&#8221;, &#8220;could&#8221;, &#8220;can&#8221;, the negatives thereof, variations thereon and similar expressions constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward- looking statements as a result of various important factors, including&#58; risks that MGD024 may not provide a significant clinical benefit to patients with certain blood cancers&#59; the uncertainties inherent in the initiation and enrollment of clinical trials&#59; the availability of financing to fund the development of MGD024 and MacroGenics&#8217; other product candidates&#59; availability and timing of data from ongoing clinical trials&#59; expectations for developing further programs under the collaboration agreement with Gilead&#59; the possibility that the parties may make a strategic decision to terminate the collaborations, including the development of MGD024 or future research programs, at any time&#59; expectations for the timing and steps required in the regulatory review process for MGD024&#59; expectations for regulatory approvals&#59; expectations of milestone payments&#59; the impact of competitive products&#59; economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict&#59; public health crises such as the COVID-19 pandemic&#59; and other risks described in the MacroGenics&#8217; filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_163"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.05pt;padding-left:60.95pt;padding-right:30.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">press release represent MacroGenics&#8217; views only as of the date hereof. MacroGenics anticipates that subsequent events and developments will cause MacroGenics&#8217; views to change. However, while MacroGenics may elect to update these forward-looking statements at some point in the future, MacroGenics specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing MacroGenics&#8217; views as of any date subsequent to the date hereof.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:57.57pt;padding-right:57.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">###</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:57.5pt;padding-right:57.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:47.25pt;padding-right:47.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:134%">For more information about Gilead, please visit the company&#8217;s website at www.gilead.com, follow Gilead on Twitter (&#64;GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia8200a142e8f47b98d8ec3ae131a117e_166"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:57.6pt;padding-right:57.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Schedule 14.1</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:137.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exceptions to the Representations and Warranties of MacroGenics</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10.2pt;padding-left:61pt;padding-right:28.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 14.1(r) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Representations and Warranties of MacroGenics)&#58; &#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.95pt;padding-left:61pt;padding-right:30.2pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:5pt;padding-left:61pt;padding-right:45.55pt"><font style="font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>3
<FILENAME>a1023_proventionapa.htm
<DESCRIPTION>EX-10.23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id08e5795f5b143e09c7b50ccfc37bdd0_1"></div><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">CONFIDENTIAL TREATMENT REQUESTED&#58; Certain portions of this document have been omitted pursuant to a request for confidential treatment and, where applicable, have been marked with an asterisk (&#8220;&#91;*****&#93;&#8221;) to denote where omissions have been made. The confidential material has been filed separately with the Securities and Exchange Commission.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSET PURCHASE AGREEMENT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This Asset Purchase Agreement (this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">) is made and entered into as of the 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.75pt;font-weight:400;line-height:100%;position:relative;top:-5.25pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> day of May 2018 (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Closing Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">), by and between</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PROVENTION BIO, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, a Delaware corporation, the principal place of business of which is at United States of America (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Buyer&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">),</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%">MACROGENICS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">, a Delaware corporation, the principal place of business of which is at 9704 Medical Centre Drive, Rockville, MD 20850, United</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">States of America (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%">&#8220;Seller&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">)&#59;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RECITALS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">Buyer is a clinical stage biopharmaceutical company that possesses expertise in the research and development of pharmaceutical products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">which prevent and intercept immune-mediated diseases&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">Seller is a biopharmaceutical company that discovers and develops novel biologics for the treatment of cancer, autoimmune disorders and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">infectious diseases, and Seller has developed a novel cluster of differentiation 3 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%">CD3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">&#8221;) partial agonist known as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:138%">Teplizumab</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">&#8221;&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">Seller wishes to sell and transfer to Buyer all right, title and interest in and to certain assets related to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:138%">Teplizumab</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">&#8221; pursuant to and in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">accordance with the terms and conditions of this Agreement&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buyer wishes to purchase from Seller such assets related to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Teplizumab</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%">NOW, THEREFORE, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">in consideration of the premises and the mutual covenants and promises contained in this Agreement, and for other good and valuable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:25.85pt">DEFINITIONS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">As used in this Agreement, the following defined terms shall have the meanings provided below&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Accounting</font></td><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means the United States Generally Accepted Accounting Principles (U.S. GAAP) as consistently applied.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Standards&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Accounts Receivable&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means all trade accounts and notes receivable and other miscellaneous receivables, including those that are not</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">evidenced by instruments or invoices, existing as of the Closing Date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Action or Proceeding&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any claim, action, suit, litigation, proceeding, arbitration, order, inquiry, hearing, assessment, audit, contest,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">prosecution, enforcement action, examination or investigation (whether civil, criminal, administrative, investigative,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">appellate or informal) threatened, commenced, brought, conducted, pending or heard by or before, or otherwise</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">involving, any Governmental Authority or any arbitrator or arbitration panel&#59; provided that the foregoing shall</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">exclude patent or trademark prosecution and examination before any relevant patent and&#47;or trademark office in any</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">applicable country or jurisdiction.</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Affiliate&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any corporation or other legal entity controlled by, controlling, or under common control with Buyer or Seller.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the purpose of this definition, the term &#8220;control&#8221; means direct or indirect beneficial ownership of at least fifty</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">percent (50%) of the voting stock of a corporation or other legal entity, or to hold the effective power to appoint or</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">dismiss members of the management.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means this Asset Purchase Agreement, including the Exhibits.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;API&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means an active pharmaceutical ingredient, whether produced from a living organism or through synthetic process,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">i.e., any substance intended to be used in the manufacture of a drug product and that is intended to furnish</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">to affect the structure or any function of the body of man or other animals, including peptides, antibodies, hybrid</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">molecules, fusion proteins, cytokines or other cellular elements.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Applicable Laws&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any and all of the applicable federal, provincial, regional, state or local law, statute or ordinance, rules and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">regulations, including any rules, regulations, guidelines, administrative guidance, or other requirements of any</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Governmental Authorities that may be in effect from time to time in any country or jurisdiction, including, without</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">limitation, the FFDCA, current Good Manufacturing Practices (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">cGMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;) and current Good Clinical Practices</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">cGCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;).</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Assumed Contracts&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means the agreements listed in Exhibit 3 under the heading &#8220;Assumed Contracts.&#8221; For the avoidance of doubt,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8220;Assumed Contracts&#8221; shall not include any agreements or contracts of Seller that are not explicitly scheduled in</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 3 hereto under the heading &#8220;Assumed Contracts.&#8221;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Assumed Liabilities&#8221;&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means, collectively, all of the following liabilities, in each case to the extent related to and solely accruing during the</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">period beginning immediately after the Closing Date in connection with the ownership of the Purchased Assets or the</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">manufacturing, Development or Commercialization of a Product by Buyer, its Affiliates or its Licensees, but in all</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">cases excluding the Retained Liabilities and the other obligations retained by Seller pursuant to Section 2.8 or any</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">other Transaction Documents&#58; (i) subject to Section 3.11, all liabilities to the extent arising out of or relating to the</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assumed Contracts&#59; (ii) all liabilities in respect of any lawsuits, claims, actions or proceedings to the extent arising</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">out of or relating to the manufacture, Development or Commercialization of Products or the ownership, sale, lease or</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">use of any of the Purchased Assets&#59; (iii) all liabilities for warranty claims and product liability or similar claims,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">including all suits, actions or proceedings relating to any such liabilities, to the extent arising out of or relating to any</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">and all Products&#59; (iv) all liabilities for taxes to the extent arising out of or relating to or in respect of any Product or</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">any Purchased Asset after the Closing Date&#59; and (v) all other liabilities and obligations of whatever kind and nature,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">primary, secondary, direct or indirect, absolute or contingent, known or unknown, whether or not accrued, to the</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">extent arising out of or relating to the Product or Purchased Assets. For the avoidance of doubt, Assumed Liabilities</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 14pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">shall not include Excluded Taxes.</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Bill  of  Sale  and</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">General</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assignment</font></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 4.2(i).</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;BLA Approval</font></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 3.2.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Milestone&#8221;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Business Day&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any day other than (i) a Saturday, a Sunday, or (ii) a day on which commercial banks located in Lebanon, New</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jersey, and&#47;or Rockville, Maryland, are authorized or required under Applicable Laws to remain closed.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Buyer&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth at the beginning of this Agreement.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Closing&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 4.1.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Closing Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means the effective date of this Agreement shown at the beginning of this Agreement.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Commercial</font></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 3.4.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Milestone&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Commercialization&#8221;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">or</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Commercialize&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means the commercial manufacture, marketing, promotion, sale, offering for sale, distribution, and&#47;or commercial</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">importation or exportation of a Product.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Combination</font></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means a Product combining Teplizumab together with another API.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Completion&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means, for a clinical trial, the date upon which all patients have completed protocol-defined drug administration and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;.</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Confidential</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any information of a confidential or proprietary nature disclosed by a Party or its Affiliates (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Disclosing</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Information&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">) to the other Party or its Affiliates (the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> &#8220;Receiving Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">), including each Party&#8217;s or its Affiliates&#8217; invention</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">disclosures, proprietary materials, data, including any Data, know-how, including any Know-How, technologies,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">trade secrets, and&#47;or manufacturing, marketing, personnel and other business information and plans, whether in oral,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">written, graphic or electronic form. Confidential Information (as defined in the Prior Confidentiality Agreement)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">disclosed  under  the  Prior  Confidentiality  Agreement  shall  be  deemed  Confidential  Information  hereunder.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Information shall not be deemed &#8220;Confidential Information&#8221; hereunder, and the Receiving Party shall have no</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">obligation with respect to any information if it is&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(i)  known by the Receiving Party prior to disclosure by the Disclosing Party, as evidenced by internal records or</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">documentation of the Receiving Party&#59; or</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ii) information which is in the public domain or subsequently enters the public domain through no fault of the</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receiving Party&#59; or</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iii) information that is received by the Receiving Party from an independent Third Party with the lawful right to</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">disclose it&#59; or</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iv) information that was independently developed by the Receiving Party (or its Affiliates&#8217;) employees or</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">contractors without the use of or reference to Confidential Information of the Disclosing Party as evidenced by</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">internal records or documentation of the Receiving Party.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, any combination of features or disclosures shall not be deemed to fall within the</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">foregoing exclusions merely because individual features are published or available to the general public or in the</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">rightful possession of the Receiving Party unless the combination itself and principle of operation are published or</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">available to the general public or in the rightful possession of the Receiving Party. Confidential Information to the</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">extent solely and specifically related to the Purchased Assets and&#47;or the Product shall be deemed to be the</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Confidential Information of the Buyer, notwithstanding the fact that it was initially disclosed to the Buyer by the</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Seller.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Consents</font></td><td colspan="3" style="padding:2px 1pt 2px 8pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means the &#91;****&#93; Consent, &#91;****&#93; Waiver, &#91;****&#93; Novation and Consent and &#91;****&#93; Comfort Letter.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">and</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Waivers&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Control&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">or</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means, the possession by a Party of the ability to assign, transfer or license rights or assets as contemplated by this Agreement</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Controlled&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">with respect to (i) the Purchased Assets&#59; and (ii) other intellectual property and assets of any kind, unless, with respect to</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">intellectual property and&#47;or assets other than the Purchased Assets, such assignment transfer or license of rights or assets would violate the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be first required to assign, transfer or license such rights or assets&#59; provided however that if such agreement or other arrangement with any Third Party later terminates, or would no longer be violated, then such intellectual property or other assets shall be deemed Controlled by such Party</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Core</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Representation&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:278.5pt"><font><br></font></div><div style="padding-right:278.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">has the meaning set forth in Section 9.1(ii)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Damages&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any loss, damage, injury, liability, settlement, judgment, obligation, award, fine, penalty, tax, fee (including any reasonable legal fee, accounting fee, expert fee or advisory fee), charge, cost (including any reasonable cost of investigation) or expense</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Data&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any and all research data, technical data, test and development data, pre-clinical and clinical data, formulations, processes, protocols, regulatory files and the like which are developed by Seller, its Affiliates, licensees and&#47;or Third Party providers of services, in each case including their respective predecessors in interest, and Controlled by Seller, prior to the Closing Date or generated in the performance of the Technology Transition Plan.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Data Room&#8221;&#58;</font></div><div style="padding-left:36pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means that certain electronic data room populated by the Seller on ShareVault.com relating to the Product and the Purchased Assets</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:153%">&#8220;Development&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:153%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:153%">&#8220;Develop&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:153%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means to discover, research or otherwise develop a product, including conducting any pre-clinical, non-clinical or clinical research and any drug development activity, including discovery, research, toxicology, pharmacology and other similar activities, test method development and stability testing, manufacturing process development, formulation development, delivery system development, quality assurance and quality control development, statistical analysis, clinical studies (including pre- and post-approval studies), diagnostic assays in connection with clinical studies, and all activities directed to obtaining any Regulatory Approval, including any marketing, pricing or reimbursement approval. For the sake of clarity, Development shall not include any activities related to Commercialization.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Development and</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Regulatory Milestone&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 3.2.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Development Plan&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means plans for the Development of the Product as outlined in Exhibit 4 and as may be modified by the Buyer from time to time during the Term.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Device&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:4.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any medical device, instrument, apparatus, implant, or similar or related device that is used to diagnose, prevent and&#47;or treat a disease or other condition, such as a drug delivery system (including a single use disposable injection device), that is distributed, marketed and&#47;or sold by Buyer, its Affiliates and&#47;or Licensees to Third Parties, including hospitals, clinics, medical practitioners, pharmacists, and patients, either in the secondary packaging of the Product or separately, the use of which is related to the use of the Product.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Diagnostic Tool&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any companion and&#47;or diagnostic assay developed and used to (i) identify patients who are most likely to benefit from a Product, (ii) identify patients likely to be at increased risk for serious adverse reactions as a result of treatment with a Product, and&#47;or (iii) monitor a patient&#8217;s response to a Product for the purpose of adjusting treatment (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, schedule, dose, discontinuation) to achieve improved safety or effectiveness.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Disclosing Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:8.35pt"><font><br></font></div><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">shall have the meaning provided in the definition of &#8220;Confidential Information.&#8221;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Disclosure Schedules&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means the Disclosure Schedules set forth in Exhibit 5.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Earn-Out Term&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means, on a Product-by-Product, and country-by-country basis, the period commencing upon the First Commercial Sale of such Product in such country and expiring upon the later of&#58; (i) the last-to-expire Valid Claim in a Product Patent in a given country, or (ii) &#91;****&#93; years after the date of First Commercial Sale of such Product in such country.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:8.35pt"><font><br></font></div><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means the &#8220;&#91;****&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221; entered into by and between Seller and &#91;****&#93;, as subsequently amended on &#91;****&#93; and &#91;****&#93;, which has &#91;****&#93;.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Consent&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:8.35pt"><font><br></font></div><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">means that certain &#91;****&#93; and Seller, dated as of &#91;****&#93;.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Encumbrance&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any lien, pledge, charge, mortgage, security interest, lease, license, option, right of first refusal, preemptive right, put, call or other restriction on transfer (other than express provisions of Assumed Contracts), defect or imperfection of title, assessment, deed of trust, levy, or other encumbrance of any kind, or any conditional sale or title retention agreement or other agreement to give any of the foregoing in the future.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Excluded Taxes&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:8.35pt"><font><br></font></div><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means (i) all Taxes of or relating to Seller, or for which Seller is liable, for any taxable period, including (A) all Taxes of any member of an affiliated group of which Seller (or any predecessor) is or was a member on a prior to the Closing Date, including pursuant to Treasury Regulation Section 1.1502-6 or any analogous or similar state, local or foreign law&#59; (B) any and all Taxes of any person imposed on Buyer as a transferee or successor, by contract or pursuant to any Applicable Law, which Taxes relate to an event or transaction occurring before the Closing Date, and (C) payments under any Tax allocation, sharing or similar agreement (whether oral or written)&#59; (ii) all Taxes relating to the &#8220;Retained Rights&#8221; described in Section 2.3 or Retained Liabilities for any taxable period&#59; (iii) all Taxes attributable to ownership or use of any Purchased Assets or the Assumed Liabilities for any taxable period ending on or prior to the Closing Date and, with respect to any taxable period beginning before and ending after the Closing Date, for the portion of such taxable period ending on the Closing Date&#59; and (iv) Seller&#8217;s portion of transfer taxes (as provided in Section 3.9).</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">&#8220;Exhibit&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any or all of the exhibits attached to this Agreement.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">&#8220;FFDCA&#8221;&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means the Federal Food, Drug, and Cosmetic Act.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">&#8220;First</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Commercial</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Sale&#8221;&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means, with respect to a Product in a given country, the first commercial sale or disposition for value of such Product to a Third Party (other than a Related Party) for end use or consumption of such Product in such country, excluding, however, transfers or dispositions of without consideration&#58; (i) in connection with patient assistance programs&#59; (ii) for charitable or promotional purposes&#59; (iii) for preclinical, clinical, regulatory or governmental purposes or under so-called &#8220;named patient&#8221;, &#8220;compassionate use&#8221; or other limited access programs&#59; or (iv) for use in any tests or studies reasonably necessary to comply with Applicable Laws, regulation or request by a Governmental Authority. For clarity, First Commercial Sale shall be determined on a country-by-country basis.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">&#8220;First</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Indication&#8221;&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means a first indication for which a Product receives approval.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">&#8220;FTE&#8221;&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means a full time equivalent person by year consisting of &#91;****&#93; days per year of work, corresponding to &#91;****&#93; hours per year of work.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">&#8220;FTE Rate&#8221;&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means &#91;****&#93; United States Dollars (US$&#91;****&#93;) per FTE.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">&#8220;Fundamental</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Representation&#8221;&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 9.1(i).</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Generic Competition&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means, with respect to a Product in any country in a given calendar quarter, that, during such calendar quarter, (i) one or more Generic Products are commercially available in such country, and (ii) aggregate Net Sales of such Product in such country in such calendar quarter equal less than &#91;****&#93; percent (&#91;****&#93;%) of the average aggregate Net Sales of the Product over the four (4) calendar quarters immediately prior to the calendar quarter in which one or more Generic Products first became commercially available in such country.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Generic Product&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">for a given country means a pharmaceutical product that (i) is sold by a Person that is not a Related Party under a Regulatory Approval granted by a Government Authority to a Third Party, (ii) contains the same active ingredient(s) as are contained in a Product, and (iii) is approved by the Government Authority pursuant to an abbreviated approval process that relies in part on such Government Authority&#8217;s previous grant of marketing authorization to a Product.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Governmental Authority&#8221;&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any court, tribunal, arbitrator, authority, agency, commission, official or other instrumentality of the United States of America or other country, including without limitation any regulatory authority involved in granting approval to initiate or conduct clinical testing in humans, for regulatory approval to market a pharmaceutical&#47;biologic product and&#47;or, to the extent required in such country or jurisdiction, for pricing or reimbursement approval for a pharmaceutical product in such country or jurisdiction, including (i) the Food and Drug Administration of the United States of America (&#8220;FDA&#8221;), (ii) the European Medicines Agency of the European Union (&#8220;EMA&#8221;), and (iii) the European Commission.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Inbound Licenses&#8221;&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 5.7(v).</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Indemnitee&#8221;&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 9.4.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Indemnitor&#8221;&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 9.4.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;INDs and CTAs&#8221;&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any and all investigational new drug applications and clinical trial applications with respect to the Product as listed in Exhibit 8.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;&#91;****&#93; Agreement&#8221;&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means that certain &#91;****&#93; Agreement between Seller, &#91;****&#93; and &#91;****&#93;, dated &#91;****&#93;.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;&#91;****&#93; Payment&#8221;&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any payment due pursuant to Section 7.1.1(b) of the &#91;****&#93; Agreement.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;&#91;****&#93; Supply&#8221;&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means supply of &#91;****&#93;.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;&#91;****&#93; Waiver&#8221;&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means that certain &#91;****&#93; Agreement, between &#91;****&#93;,&#91;****&#93; and Seller, dated as of &#91;****&#93;.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;&#91;****&#93;&#8221;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means &#91;****&#93;.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;&#91;****&#93; Agreement&#8221;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means that certain &#91;****&#93; Agreement, effective as of &#91;****&#93; between the &#91;****&#93; and Seller.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Know-How&#8221;&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means technical and other information, including trade secrets and information comprising or relating to concepts, discoveries, designs, formulae, ideas, inventions, methods, models, assays, research plans, procedures, designs for experiments and tests and results of experimentation and testing (including results of Development), formulations, processes (including manufacturing processes, specifications and techniques), and any such information contained in the Data, including documents containing any of the above.</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.699%"><tr><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Knowledge&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8pt;padding-right:7.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">with respect to Seller, means the actual knowledge of the vice-president level or higher executive officers (or persons performing similar functions) of Seller after reasonable inquiry.</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Licensee&#8221;&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means a Third Party licensee that has entered into a license agreement with Buyer for the Product.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Listed</font></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 5.7(ii).</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patents&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Lock-Up</font></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means that certain Lock-Up Agreement, substantially in the form attached hereto as Exhibit 12.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Agreement&#8221;</font></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:9.2pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Novation and</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consent&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means that certain Novation Agreement, between &#91;****&#93;, Buyer and Seller, dated as of &#91;****&#93;.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Major</font></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means France, Germany, Italy, Spain or the United Kingdom.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">European</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Country&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8pt;padding-right:7.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any payments due to be &#91;****&#93; under the &#91;****&#93; or any other agreement entered into by Seller or any of its predecessors in interest prior the Closing Date.</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Net Sales&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8pt;padding-right:7.15pt"><font><br></font></div><div style="padding-left:8pt;padding-right:7.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means the gross amount billed or invoiced for a Product by (a) by Buyer&#59; (b) by any Buyer&#8217;s assignee (including such assignee&#8217;s affiliates or licensees), (c) by Buyer&#8217;s Affiliates, or (d) by Licensees (each of the Persons referred to in (b), (c) and (d), a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Related Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;), in each case, for the sale of a Product to Third Parties (excluding a sale of a Product to Affiliates or licensees for resale), subject to the following deductions, as allocable to such Product (if not previously deducted in calculating the amount invoiced and to the extent included in the gross invoice price)&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="padding-left:117pt;padding-right:7.05pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;padding-left:14.02pt">reasonable trade, quantity, prompt settlement and other cash discounts and rebates (including wholesale inventory management fees and fees or allowances to other distributors, buying groups, health care insurance carriers or other pharmacy benefit managers (or equivalents thereof), federal, state&#47;provincial, local or other Governmental Authority or other institution, or their agencies or purchasers, reimbursers, or trade customers), chargebacks, and price reductions or allowances actually allowed or granted from the billed amount, and discounts to customers, including cash coupons, vouchers and loyalty cards (and their redemption) and co-pay assistance&#59;</font></div><div style="padding-left:117pt;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:117pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:11.52pt">credits or allowances actually granted upon claims, rejections or returns of such sales of Products, including recalls&#59;</font></div><div style="padding-left:117pt;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:117pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;padding-left:9.02pt">taxes imposed on the production, sale, delivery, import, export, distribution or use of the Product (including sales, use, excise or value added taxes, but excluding income taxes), duties or other governmental charges levied on or measured by the billing amount when included in billing, as adjusted for tax refunds and tax rebates&#59;</font></div><div style="padding-left:117pt;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:117pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;padding-left:9.52pt">any discounts, rebates or similar payments in respect of sales paid for by any Governmental Authority, including Federal or state Medicaid, Medicare or similar state program, or any other similar program, or any other government imposed rebates or discounts from invoiced prices (to the extent not covered under clause (i) above)&#59; and</font></div><div style="padding-left:117pt;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:117pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:12.02pt">transport, freight, postage and insurance costs relating to the transportation or delivery of Products.</font></div><div style="padding-left:117pt;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">Such amounts shall be determined from the books and records of Buyer or its Related Party, maintained in accordance with Accounting Standards with regard to Buyer, and, with respect to a related Party, in accordance with the accounting standards applicable to such a Related Party.</font></div><div style="padding-left:117pt"><font><br></font></div><div style="padding-left:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">Net Sales shall exclude transfers or dispositions of Product, without consideration&#58; (1) in connection with patient assistance programs&#59; (2) for charitable or promotional purposes&#59; (3) for preclinical, clinical, regulatory or governmental purposes or under so-called &#8220;named patient&#8221;, &#8220;compassionate use&#8221; or other limited access programs&#59; or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">(4) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">for use in any tests or studies reasonably necessary to comply with applicable Law, regulation or request by a Governmental Authority.</font></div><div style="padding-left:117pt"><font><br></font></div><div style="padding-left:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">In the event that a Product is sold as a Combination Product, the Net Sales of the Product shall be determined by multiplying the Net Sales of the Combination Product by the fraction A&#47;(A+B), where A is the weighted (by sales volume) average unit sale price of the Product in the applicable country, where net sales is calculated in the same manner as Net Sales, when sold separately in finished form and B is the weighted average unit sale price in that country (net sales being calculated in the same manner as Net Sales) of the other API which is included in the Combination Product when such API is sold separately in finished form at the same dosage levels, in each case during the applicable royalty reporting period, or, if sales of both the Product and the other API did not occur in the same country in such period, then in the most recent royalty reporting period in which sales of both occurred, provided that such &#8220;recent royalty reporting period&#8221; shall not have been more than twenty-four (24) months earlier.</font></div><div style="padding-left:117pt"><font><br></font></div><div style="padding-left:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In the event that such weighted average sale price of the Product cannot be determined, but the weighted average sale price of the other API can be determined, Net Sales shall be calculated by multiplying the Net Sales of the Combination Product by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-left:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">the following formula&#58; one (1) minus B &#47; C where B is the weighted average sale price of the other API when sold separately in finished form and C is the weighted average selling price of the Combination Product.</font></div><div style="padding-left:117pt"><font><br></font></div><div style="padding-left:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In the event that the weighted average sale price of both the Product and the other API in the Combination Product cannot be determined, the Net Sales of the Product shall be calculated by multiplying the Net Sales of the Combination Product (determined as provided above for Products) by the fraction A &#47; C where A is the predicted fair market value of the Product if such Product were sold as a stand-alone Product as determined in good faith by the Parties and C is the weighted average selling price of the Combination Product.</font></div><div style="padding-left:117pt"><font><br></font></div><div style="padding-left:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">The weighted average sale price for a Product, any other API(s) used in a Combination Product, or any Combination Product shall be calculated once each calendar year, at the beginning of such calendar year, and such price shall be used during all applicable royalty reporting periods for such entire calendar year. When determining the weighted average sale price of a Product, other API(s), or Combination Product, the weighted average sale price shall be calculated by dividing the sales dollar (translated into U.S. dollars) by the units of active ingredient sold during the preceding calendar year (or the number of months sold in a partial calendar year) for the respective Product, other API(s), or Combination Product. In the initial calendar year, a forecasted weighted average sale price will be used for the Product, other API(s) or Combination Product.</font></div><div><font><br></font></div><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Outbound Licenses&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 5.7(iv).</font></div><div><font><br></font></div><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">means either Buyer or Seller, as the context requires, and, when used in plural, shall mean Buyer and Seller.</font></div><div><font><br></font></div><div style="padding-left:113pt;text-indent:-104pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:123%">&#8220;Patents&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">means (i) all issued patents (extensions, restorations by existing or future extension or registration mechanism, including patent term adjustments, patent term extension, supplemental protection certificates or the equivalent thereof, substitutions, confirmations, re-registrations, re-examinations, reissues and patents of addition), (ii) patent applications (including all provisional and non-provisional applications, substitutions, requests for continuation, continuations, continuations-in-part, divisionals and renewals), (iii) inventor&#8217;s certificates, (iv) design registrations, design registration applications, industrial designs, industrial design applications and industrial design registrations,</font></div><div><font><br></font></div><div style="padding-left:113pt;text-indent:0.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;padding-left:20.27pt">any and all divisions, continuations, continuations in part, extensions, substitutions, renewals, registrations, revalidations, reversions, reexaminations, reissues or additions, of or to any of the foregoing items, (vi) all equivalents of the foregoing in any country of the world, and (vii) all rights and priorities afforded under any Applicable Law with respect to each of the foregoing items.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.946%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Patent</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assignment</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Patent Assignment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221; between Seller and Buyer to be executed on or prior to the Closing, in the form</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">attached as Exhibit 7.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Permitted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means all (i) mechanics&#8217;, carriers&#8217;, workmen&#8217;s, repairmen&#8217;s or warehousemen&#8217;s Encumbrances arising under Applicable Law</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Encumbrance&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">and incurred in the ordinary course of Seller&#8217;s business and Encumbrances for taxes and other governmental charges which are</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">not yet due and payable&#59; and (ii) other imperfections of title or encumbrances, if any, which have no more than de minimis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">impact on the continued use and operation or value of the assets to which they relate.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Person&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any natural person, corporation, general partnership, limited partnership, limited liability company, proprietorship, other</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">business organization, trust, union, association or Governmental Authority.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Phase III</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means with regard to the United States of America a clinical trial consistent with the United States Code of Federal</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Clinical Trial&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Regulations, Title 21, Section 312.21 (c) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Phase 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;, and means with regard to other countries a pivotal multi-center human</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">clinical trial in a large number of patients to establish safety and efficacy in the particular claim and indication tested and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">required to obtain a Regulatory Approval.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Prior</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Confidentiality</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means that certain Mutual Confidentiality Agreement entered into by and between Buyer and Seller, effective as of August 8,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2017.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Product&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means a product which contains Teplizumab, whether or not as the sole API (i.e., including any Combination Product), in any</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">dosage form, formulation (including lyophilizate or solution) and mode of administration and for all indications. For the sake of</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">clarity, the term &#8220;Product&#8221; shall not be deemed to include any Device or Diagnostic Tool for purposes of determining if a First</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Sale has been made or for calculating Net Sales.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_4"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.223%"><tr><td style="width:1.0%"></td><td style="width:17.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Product Intellectual</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Property&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="12" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means, any and all of (i) the Product Patents&#59; and (ii) Product Know-How&#59; and (iii) any copyrights, trademarks,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">domain names or any other intellectual property rights that are (a) &#91;****&#93; the Product and (b) Controlled by Seller as</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">of the Closing Date.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Product Know-How&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="12" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means Know-How which (i) is Controlled by Seller as of the Closing Date&#59; (ii) was used for or created as a result of</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">the Development or Commercialization of the Product prior to the Closing Date&#59; and (iii) &#91;****&#93; relates to the</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">manufacture, use, Development or Commercialization of the Product, whether patentable or not. A listing of certain</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product Know-How is set forth on Exhibit 8.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Product Patents&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="9" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means those patents and patent applications set forth in Exhibit 2.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Program Contracts&#8221;</font></td><td colspan="12" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means the Assumed Contracts, the Inbound Licenses, the Outbound Licenses and the Service Contracts.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Program IP&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="6" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 5.7(i)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Purchased Assets&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="6" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means all right, title and interest of Seller in&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(i)</font></td><td colspan="3" style="padding:2px 1pt 2px 3pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">the Product&#59;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ii)</font></td><td colspan="3" style="padding:2px 1pt 2px 3pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">the Assumed Contracts&#59;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iii)</font></td><td colspan="3" style="padding:2px 1pt 2px 3pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">the Product Intellectual Property&#59;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iv)</font></td><td colspan="3" style="padding:2px 1pt 2px 3pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">the Transferred Materials&#59;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(v)</font></td><td colspan="3" style="padding:2px 1pt 2px 3pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">the INDs and CTAs&#59;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(vi)</font></td><td colspan="3" style="padding:2px 1pt 2px 3pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">the Transferable Books and Records&#59;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(vii) any prepaid amounts under the Assumed Contracts&#59;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(viii)all compensation, interests and other rights and benefits due under the Assumed Contracts that accrue after the</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt 2px 3pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Closing Date, including under any Outbound Licenses, but excluding the &#91;****&#93; Payment&#59; and</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ix) all goodwill related to the foregoing.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Qualified</font></td><td colspan="12" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any consideration that Buyer or any of its Affiliates receive in connection with the (and, in a transaction in</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consideration&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="12" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">which rights to multiple products are transferred, to the extent allocable to a) grant of rights under the Product</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intellectual Property and&#47;or rights with respect Products in an agreement or arrangement with a Third Party</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Qualified Consideration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;). In furtherance and not in limitation of the foregoing, Qualified</font></div></td></tr></table></div><div style="padding-left:113pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:121%">Consideration shall not include (i) royalties based on Net Sales, (ii) amounts received to cover future reasonable, fully-burdened costs incurred or to be incurred by Buyer or its Affiliates in the performance of research, development or manufacturing activities to be performed by Buyer or its Affiliates after the Effective Date, (iii) amounts received as reimbursement for out-of-pocket costs incurred by Buyer in the preparation, filing, prosecution and maintenance of the Product Patents, or (iv) consideration for the issuance of equity interests in Buyer or its Affiliates to the extent there is no premium included in such issuance for rights granted with respect to the Product. If Buyer or its Affiliate receives non-cash consideration that otherwise qualifies as Qualified Consideration, the Qualified Consideration will be calculated based on the fair market value of such consideration, at the time of the transaction, assuming an arm&#8217;s length transaction made in the ordinary course of business.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> &#8220;Reasonable</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commercial</font></div><div><font><br></font></div><div style="padding-left:113pt;text-align:justify;text-indent:-113.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:122%">Efforts&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">means those efforts and resources to Develop a Product and Commercialize a Product that are consistent with the usual practice of Buyer in pursuing the development or commercialization of other compounds and pharmaceutical products in its portfolio that are at a similar development stage as the Product or are of a similar market potential as the Product, taking into account all relevant factors, including present and future market potential, and Buyer&#8217;s own pharmaceutical products that are of similar market potential, financial return, medical and clinical considerations, present and future regulatory environment and competitive market conditions, all as measured by the facts and circumstances at the time such efforts are due.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Receiving Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning provided in the definition of &#8220;Confidential Information.&#8221;</font></div><div><font><br></font></div><div style="padding-left:113pt;text-align:justify;text-indent:-113.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:124%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">means approval by a Governmental Authority of (i) a New Drug Approval Application or Biologics License Application (each, as defined in the FFDCA) in the U.S., or (ii) any corresponding application for regulatory approval in any country or jurisdiction outside the U.S., including, with respect to the European Union, a Marketing Authorization Application filed with the EMA pursuant to the Centralised Approval Procedure or with the applicable Regulatory Authority of a country in Europe with respect to the decentralised procedure, mutual recognition or any national approval procedure.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Related Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">has the meaning provided in the definition of &#8220;Net Sales&#8221; in this Section 1.1.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-left:113pt;text-align:justify;text-indent:-113.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:126%">&#8220;Related Technology&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:126%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">means all Know-How Controlled by Seller as of the Closing Date that is not Product Know-How and is necessary or useful for the Development, manufacture or Commercialization of Products&#59; and (ii) all other Patents Controlled by Seller as of the Closing Date that (A) are not Product Patents&#59; and (B) are necessary or useful for the Development, manufacture or Commercialization of Products.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#8220;Required Consents&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 7.1(i).</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means liabilities or obligations of any nature, whether known or unknown, fixed or contingent, accrued or unaccrued,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">to the extent arising in connection with the manufacture, Development or Commercialization of the Product, or the</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">acts or omissions of Seller or its Affiliates prior to the Closing Date or in connection with the &#91;****&#93; Supply. For</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">clarity, Retained Liabilities include but are not limited to (i) the obligations retained pursuant to Section 2.8, (ii)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Excluded Taxes, (iii) any and all obligations in connection with the Related Technology and (iv) the JDRF</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Second Indication&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means a new indication (i.e., a generally recognized distinct medical condition) and not an extension of the First</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indication or a labeling change covering the First Indication.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Seller&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth at the beginning of this Agreement.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Service Contracts&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 5.7(vi).</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Survival Period&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 9.1(iii).</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Taxes&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means all taxes of any kind including all U.S. federal, state, local or non-U.S. net income, capital gains, gross</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">income, gross receipt, license, property, franchise, sales, use, excise, withholding, payroll, employment, social</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">security, worker&#8217;s compensation, disability, severance, unemployment, health-care, stamp, occupation, capital stock,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">transfer, registration, value added, alternative, estimated, gains, windfall profits, net worth, asset, transaction and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">other taxes, whether computed on a separate or consolidated, unitary or combined basis or in any other manner, and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">any interest, penalties or additions to tax with respect thereto, imposed upon any Person by any taxing authority or</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">other Governmental Authority under Applicable Law, whether disputed or not.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Technology Transition</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plan&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means a plan developed and jointly agreed upon by the Parties in good faith after Closing as set forth in Section 2.7</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">for Seller to transfer the Product Intellectual Property to Buyer.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Teplizumab&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means the compound &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Teplizumab</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;, designated by Seller as MGA031, a novel cluster of differentiation 3 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CD3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;)</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">partial agonist, as described in Exhibit 1.</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Third Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means any Person other than (i) Buyer or Seller, or (ii) an Affiliate of Buyer or Seller.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Third   Party</font></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 9.2.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Claims&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third Party</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means (i) the &#91;****&#93; Consideration&#59; (ii) the &#91;****&#93; Royalty&#59; and (iii) all royalties, milestones other consideration due to Third</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Parties in connection with sales of a Product or the assignment or other transfer of rights in connection with a Product or the</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchased Assets under agreements entered into by Seller or its predecessors in interest prior to the Closing Date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means the &#91;****&#93; entered into by and between &#91;****&#93; effective as of &#91;****&#93; and &#91;****&#93;.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consideration&#8221;&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means obligations to provide consideration to Tolerance under the &#91;****&#93;, including such obligations under 2.5(c) of the</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;&#59; provided that this definition shall not include any &#91;****&#93;.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means that certain letter agreement between Buyer, Seller and &#91;****&#93;.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Comfort</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Letter&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Transaction</font></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means the Warrant, Bill of Sale and General Assignment Agreement, Patent Assignment Agreement and Lock-Up Agreement.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Documents&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Transfer</font></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means the transfer letter to be submitted to each relevant Governmental Authority by Seller, in the form attached as Exhibit 9.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Letter&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Transferable</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Books</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">and Records&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">means all of the original (or if unavailable a copy) documents, Data, lists, files, records, research, studies, information and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">correspondence with Governmental Authorities, in whatever form kept, including electronic form, Controlled by Seller as of</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">the Closing Date and relating solely and exclusively to the Assumed Contracts, the Product Intellectual Property or the</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product, including all INDs and CTAs (including all amendments) and any other regulatory documentation to the extent solely</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">and exclusively related to the Product, all clinical study reports, all data sets (SAS, ADaM, SDTM, etc.), copies of all Trial</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Master Files, all Financial Disclosure forms, the pharmacovigilance database and other similar books and records. Drafts,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">internal update reports, summaries of Data compiled for internal reporting, non-official communications and documents</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">incidental to the Development and Commercialization of the Product conducted by Seller and which do not contain material</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Data or Product Know-How not otherwise subject to transfer to Buyer hereunder or under any Transaction Document are not</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">deemed to be Transferrable Books and Records.</font></td></tr></table></div><div style="padding-left:146pt;text-indent:-113.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:126%">&#8220;Transferred Materials&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:126%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">means any and all of the biological and chemical materials and components used for or created as a result of the Development, manufacturing or Commercialization of the Product Controlled by Seller and relating solely and exclusively to the Product, including any work in progress, API, work product, inventory (including clinical supplies), master cell banks and working cell banks, as set forth in Exhibit 8 or in the Technology Transition Plan.</font></div><div><font><br></font></div><div style="padding-left:146pt;text-indent:-113.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:123%">&#8220;Valid Claim&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">means&#58; (i) a claim of an issued and unexpired patent in the Product Patents that has not been (A) held permanently revoked, unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, (B) rendered unenforceable through disclaimer or otherwise, (C) abandoned or (D) permanently lost through an interference or opposition proceeding without any right of appeal or review&#59; or (ii) a claim of a pending patent application in the Product Patents that (A) has been asserted and continues to be prosecuted in good faith and (B) has not been abandoned or finally rejected without the possibility of appeal or refiling, and (C) has not been pending longer than &#91;****&#93; years from the date of issuance of the first substantive patent office action considering patentability of such claim by the relevant patent office in the country or territory in which such claim is pending.</font></div><div><font><br></font></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8220;Warrant&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">has the meaning set forth in Section 3.1.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">For purposes of this Agreement (i) words in the singular shall be held to include the plural and vice versa as the context requires, (ii) the words &#8220;including&#8221; and &#8220;include&#8221; shall mean &#8220;including, without limitation&#8221;, unless otherwise specified&#59; (iii) the terms &#8220;hereof&#8221;, &#8220;herein&#8221;, &#8220;herewith&#8221;, and &#8220;hereunder&#8221;, and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement&#59; (iv) all references to &#8220;Article&#8221; or &#8220;Section&#8221;, unless otherwise specified, are intended to refer to an Article or a Section of this Agreement&#59; and (v) all references to &#8220;Exhibit&#8221; or &#8220;Schedule&#8221;, unless otherwise specified, are intended to refer to an Exhibit or Schedule of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:25.85pt">PURCHASE AND SALE OF ASSETS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:126%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline">Purchase and Sale of the Purchased Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">. Subject to the terms and conditions of this Agreement, on the Closing Date, Seller shall, or shall cause its</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">relevant Affiliates to, sell, transfer, convey, assign and deliver to Buyer, free and clear from all Encumbrances (other than Permitted Encumbrances), and Buyer shall purchase, acquire and accept from Seller, and such Affiliates of Seller, all right, title and interest of Seller and such Affiliates in and to the Purchased Assets.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Assumption of Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">. On the Closing Date, Buyer shall assume and thereafter pay, perform and discharge when due, all Assumed Liabilities.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:136%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline">Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">. Notwithstanding anything to the contrary contained in this Agreement, from and after the Closing Date, other than the Purchased</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">Assets and the license to Related Technology provided hereby, Seller shall retain all of its right, title and interest in and to all of its assets, including&#58;</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:23.72pt">all cash and cash equivalents of Seller and its Affiliates&#59;</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:21.22pt">all Accounts Receivable of Seller and its Affiliates&#59;</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:18.72pt">all Related Technology&#59;</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:19.22pt">all the trademarks and service marks, the corporate logos and trade names of Seller and its Affiliates, together with any variations and derivatives thereof and any other logos, symbols or trademarks, trade names or service marks of Seller and its Affiliates&#59;</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:21.72pt">any refund or credit of taxes attributable to any tax period prior to the Closing Date&#59;</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:19.22pt">all books and records other than the Transferrable Books and Records&#59;</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:16.72pt">all tangible property owned by Seller and its Affiliates, other than such tangible property included in the Purchased Assets&#59; and</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:14.22pt">except as expressly included in the Purchased Assets, all other properties, assets, goodwill and rights of Seller and its Affiliates of whatever kind and nature, real, personal, mixed, tangible or intangible.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Retained Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. Notwithstanding anything to the contrary contained in this Agreement, from and after the Closing Date, Buyer shall not assume</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">any Retained Liability, each of which, as between the Parties, shall remain the sole and exclusive responsibility of Seller, irrespective of whether claims for such liabilities are brought on, before or after the Closing Date, and which Seller shall pay, perform and discharge when due.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline">Retention of Copies of Certain Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">. Notwithstanding anything to the contrary contained in this Agreement, Seller may retain, at its expense, and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">be able to use the information in, copies of any or all of the documentation that Seller or any of Seller&#8217;s Affiliates deliver to Buyer hereunder or that otherwise constitute Purchased Assets solely (i) for archival purposes, (ii) to fulfill or otherwise dispose of any of Seller&#8217;s rights or obligations under this Agreement, (iii) to comply with or fulfill its obligations under Applicable Law, including as necessary for any regulatory, tax or securities filing,</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-0.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;padding-left:26.22pt">for use in any pending or threatened legal or administrative claim, suit, demand or action, (v) subject to its confidentiality obligations under this Agreement, in connection with a financing, acquisition or similar transaction, or (vi) for such other purposes as Seller may reasonably request, subject to Buyer&#8217;s prior written consent, which shall be in Buyer&#8217;s sole discretion.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline">Related Technology License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">. Seller grants to Buyer, and Buyer accepts, a perpetual, worldwide, royalty-free, non-exclusive license, with right to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">grant sublicenses (including through multiple tiers), under the Related Technology solely in connection with the Development, manufacture and Commercialization of the Products. Buyer shall have the right to sublicense its rights under this Section 2.6 to (i) an Affiliate of Buyer or (ii) any Third Party in connection with a license, agreement or transaction under which Buyer grants such Third Party a right to Develop or Commercialize the Product&#59; provided that in each case such sublicensee agrees in writing to be bound by Buyer&#8217;s obligations under this Section 2.6. Buyer shall provide Seller a copy of each executed sublicense entered into by Buyer under this agreement. Buyer shall (a) comply in all material respects with all Applicable Law relating to the Development, manufacture and Commercialization of Products&#59; (b) not claim or represent through the use of the Related Technology that it has acquired any title in or ownership of the Related Technology&#59; and (c) not register or permit any Related Party to register any industrial or intellectual property right embodying the Related Technology in any country without Seller&#8217;s prior written consent, which consent shall not be unreasonably withheld or delayed.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline">Technology Transfer Transition Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">. As soon as practicable after the Closing Date, but in no case later than fifteen (15) Business Days after Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">the Parties shall meet in person at Seller&#8217;s offices to discuss and agree upon a written Technology Transition Plan that will, at a minimum, include the items set forth on Exhibit 8. Beginning on the Closing Date and for a period of one hundred and five (105) days after the Closing Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:122%">Transition Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">&#8221;), Seller shall use commercially reasonable efforts to transfer to Buyer, the Product Know-How, Transferred Materials and Transferable Books and Records in accordance with the Technology Transition Plan. As part of such technology transfer, for the first eighteen (18) months following the Closing Date, Seller shall provide to Buyer or its designee, such Product Know-How and Related Technology as reasonably requested by Seller to enable Seller to Develop, manufacture and Commercialize Products&#59; provided that such Product Know-How and&#47;or Related Technology is in Seller&#8217;s possession and reasonably capable of being transferred. Seller shall provide information and necessary support in accordance with the Technology Transition Plan. During the Transition Period, Seller shall bear its own expenses related to the Technology Transition Plan and the Technology Transfer. Buyer shall fund (a) all of the reasonable FTE costs incurred by Seller in the performance of the Technology Transition Plan after the Transfer Period and any subsequent transfer by Seller of Product Know-How, Transferred Materials or Transferable Books and Records on the basis of the FTE Rate per FTE and (b) all third party out-of-pocket expenses incurred by Seller in the performance of the Technology Transition Plan, to the extent such third party out-of-pocket costs are approved in writing in advance by Buyer. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">Buyer shall pay such FTE costs and such approved third party out-of-pocket expenses within thirty (30) days following receipt of an invoice therefor. Without limiting the foregoing, the Seller shall continue to support the technology transition efforts during the first eighteen (18) months following the Closing Date until all Transferred Materials and Transferable Books and Records have been effectively transferred to Buyer.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">&#91;****&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline">and Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">. The Parties acknowledge that (a) pursuant to the &#91;****&#93;, Seller agreed to &#91;****&#93; with &#91;****&#93; in the performance of a &#91;****&#93; relating to the Product, including by &#91;****&#93; of Product to &#91;****&#93;&#59; and (b) the &#91;****&#93; Payment is a portion of the compensation to be paid by &#91;****&#93; for the rights granted to &#91;****&#93; pursuant to the &#91;****&#93; Agreement. In consideration of the foregoing, and notwithstanding anything to the contrary herein, the Parties agree that (i) Seller (or its designated vendor) shall retain &#91;****&#93; (as defined in the &#91;****&#93; Agreement) of the inventory of Product as required to &#91;****&#93; the &#91;****&#93; under the &#91;****&#93; Agreement&#59; (ii) Seller shall, directly or through its vendor, &#91;****&#93; such quantities of Product as required to &#91;****&#93;&#59; (iii) Seller shall have the right to directly request and receive the &#91;****&#93; Payment&#59; and (iv) Buyer shall not supply Product to &#91;****&#93; until after the &#91;****&#93; has been &#91;****&#93; unless (A) Seller has breached the &#91;****&#93; obligation and (B) the failure of Buyer to &#91;****&#93; would result in a breach of the &#91;****&#93; Agreement. All obligations to Third Parties related to the safety, efficacy or non-conformance of the &#91;****&#93;, including any obligation to replace Product or to engage independent laboratories for testing, shall be deemed Retained Liabilities and shall remain with the Seller and Seller shall discharge all such obligations as required under each applicable agreement or understanding related to the &#91;****&#93;. As reasonably requested by Seller, Buyer shall cooperate with Seller to support Seller&#8217;s efforts to fulfill the &#91;****&#93;.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:136%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline">Grant Back</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">. Buyer grants to Seller, and Seller accepts, a worldwide, royalty-free, non-exclusive license, with right to grant sublicenses, under the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">Purchased Assets solely to perform its obligations under this Agreement.</font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font><br></font></div><div style="padding-left:33pt;text-indent:-32.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:25.85pt">CONSIDERATION AND PAYMENT</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline">Equity Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">. As partial consideration for the Purchased Assets, on the Closing Date the Buyer will issue to Seller a warrant to purchase 2,162,389</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">common shares, which is the number of common shares representing eight percent (8%) of Buyer&#8217;s fully diluted outstanding shares on the issue date. The warrant will be exercisable for the period beginning on the Closing Date and ending on the date that is seven (7) years from the Closing Date at a per share exercise price equal to two dollars and fifty cents ($2.50), the per share price at which the Series A Preferred Shares were issued pursuant to a separate warrant purchase agreement substantially in the form attached hereto as Exhibit 10 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Warrant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8221;).</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;text-decoration:underline">Development and Regulatory Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:124%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">Buyer shall pay (which payments shall not be creditable against any other obligations of Buyer hereunder)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">a non-refundable payment for each of the milestone events set forth in this Section 3.2 (each a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:124%">&#8220;Development and Regulatory Milestone&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">), whether the Development and Regulatory Milestone is achieved by Buyer, its Affiliates or Licensees, or any Third Party acting on behalf of Buyer, its Affiliates or Licensees. Payment for each of the Development and Regulatory Milestones shall be made only once regardless of how many times a Product achieves the corresponding Development and Regulatory Milestone, and no payment shall be due for any Development and Regulatory Milestone which is not achieved. The Development and Regulatory Milestones shall be as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:57pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.623%"><tr><td style="width:0.1%"></td><td style="width:0.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.676%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development and Regulatory Milestone</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:196.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#91;****&#93;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93; United States dollars ($&#91;****&#93;)</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:196.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93; United States dollars ($&#91;****&#93;)</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:196.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93; United States dollars ($&#91;****&#93;)</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:196.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93; United States dollars ($&#91;****&#93;)</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:196.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93; United States dollars ($&#91;****&#93;)</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:196.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93; United States dollars ($&#91;****&#93;)</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">Buyer shall provide Seller with written notice within thirty (30) days after the achievement of the corresponding Development and Regulatory Milestone and the payment pertaining to such Development and Regulatory Milestone shall be made by Buyer to Seller within ninety (90) days after the achievement of the corresponding Development and Regulatory Milestone.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Earn-Out</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;padding-left:22.23pt">Subject to Sections 3.3(b), (c) and (d), Buyer shall pay to Seller &#91;****&#93; percent (&#91;****&#93;%) of aggregate worldwide annual Net Sales of Product by Buyer, its Affiliates or Licensees, or any Third Party acting on behalf of Buyer, its Affiliates or Licensees of all Products in a given calendar year during the Earn-Out Term.</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;padding-left:21.72pt">If, during a given calendar quarter when a Product is being Commercialized by or on behalf of Buyer, its Affiliates or Licensees in a particular country, there is Generic Competition in such country with respect to a Product, then the earn-out payment payable pursuant to Section 3.3(a) on the Net Sales of Product in such country shall thereafter be reduced to &#91;****&#93; percent (&#91;****&#93;%) of the amounts otherwise payable pursuant to Section 3.3(a) with respect to such Product in such country for such calendar quarter for so long as such Generic Competition remains.</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;padding-left:22.23pt">Beginning on the date of the First Commercial Sale of a Product, and thereafter until all payment obligations due in connection with the sale of Product under the &#91;****&#93; Agreement (as such obligations exist as of the Closing Date) are satisfied, the earn-out due to Seller set forth in Section 3.3(a) shall be reduced dollar-for-dollar by the amount payable by Buyer to &#91;****&#93; (or its successor in interest) under the &#91;****&#93; Agreement for the corresponding calendar quarter.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;padding-left:21.72pt">In the event that Buyer enters into a license with &#91;****&#93; in respect of the issue disclosed and further described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Schedule 5.7(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">, Buyer shall be entitled to credit &#91;****&#93; percent (&#91;****&#93;%) of the amount payable to &#91;****&#93; under such license in a given period in connection with such license against the amount payable to Seller under Section 3.3(a) for the corresponding period.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline">Commercial Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:125%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Buyer shall pay a non-creditable, non-refundable milestone payment for each of the milestone events set forth in this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Section 3.4 (each a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#8220;Commercial Milestone&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">), whether the Commercial Milestone is achieved by Buyer, its Affiliates or Licensees, or any Third Party acting on behalf of Buyer, its Affiliates or Licensees. Payment for each of the Commercial Milestones shall be made only once regardless of how many times a Product achieves the corresponding Commercial Milestone, and no payment shall be due for any Commercial Milestone which is not achieved. The Commercial Milestones shall be as follows&#58;</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.298%"><div><font><br></font></div><div style="padding-left:57pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial Milestone</font></div><div><font><br></font></div><div style="padding-left:57pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:121%">Aggregate worldwide Net Sales of Product that exceed &#91;****&#93; United States dollars ($&#91;****&#93;) based on the aggregate of all Net Sales of Product since the first commercial sale of Product</font></div><div><font><br></font></div><div style="padding-left:57pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:121%">Aggregate worldwide Net Sales of Product that exceed &#91;****&#93; United States dollars ($&#91;****&#93;) based on the aggregate of all Net Sales of Product since the first commercial sale of Product</font></div><div><font><br></font></div><div style="padding-left:57pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Aggregate worldwide Net Sales of Product that exceed &#91;****&#93; United States dollars ($&#91;****&#93;) based on the aggregate of all Net Sales of Product since the first commercial sale of Product</font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:1.402%;min-width:0.402%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.300%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#91;****&#93; United States dollars ($&#91;****&#93;)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#91;****&#93; United States dollars ($&#91;****&#93;)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#91;****&#93; United States dollars ($&#91;****&#93;)</font></div><div><font><br></font></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_7"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">Buyer shall provide Seller with written notice within sixty (60) days of Buyer becoming aware of the occurrence of any of the Commercial Milestones (which awareness shall not be deemed to occur prior to twenty (20) days following the end of the fiscal quarter in which such milestone was achieved) and the payment pertaining to such Commercial Milestone shall be made by Buyer to Seller within ninety (90) days after the end of the calendar year in which such Commercial Milestone is achieved.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:126%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline">Qualified Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">. Buyer shall pay Seller an amount equal to &#91;****&#93; percent (&#91;****&#93;%) of all Qualified Consideration received pursuant to any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">Qualified Consideration Agreement&#59; provided that if Buyer or its Affiliates enter into the Qualified Consideration Agreement after the Completion of the first Phase III Clinical Trial for a Product, then all such amounts paid to Seller shall be creditable against future milestones related to the applicable Product which are due to Seller in accordance with Section 3.2 or Section 3.4.</font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline">Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">. Within forty-five (45) days (sixty (60) days in the event that a Licensee has generated Net Sales) after the conclusion of each calendar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">quarter in which Net Sales are generated or Qualified Consideration is received, Buyer shall deliver to Seller a report containing the following information (in each instance, with a Product-by-Product and country-by-country breakdown)&#58; (i) the gross amount billed or invoiced for Products sold, leased or otherwise transferred by Buyer, its Affiliates and Licensees during the applicable calendar quarter&#59; (ii) a calculation of Net Sales for the applicable calendar quarter, including an itemized listing of deductions&#59; (iii) a detailed accounting of all Qualified Consideration received during the applicable calendar quarter, if any&#59; and (iv) the total amount payable to Seller in U.S. Dollars on Net Sales and Qualified Consideration for the applicable calendar quarter, together with the exchange rates used for conversion.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">. Within forty-five (45) days (sixty (60) days in the event that a Licensee has generated Net Sales) after the end of each calendar quarter,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Buyer shall pay Seller all amounts due with respect to Net Sales and Qualified Consideration for the applicable calendar quarter. All payments due under this Agreement will be paid in U.S. Dollars. Conversion of foreign currency to U.S. Dollars will be made at the conversion rate existing in the United States (as reported in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:125%">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">, Eastern Edition) on the last working day of the applicable Calendar Quarter. Such payments will be without deduction of exchange, collection or other charges.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. MacroGenics shall be entitled to charge interest on any payment under this Agreement that is overdue, to the extent permitted by Applicable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">Laws, at the thirty-day United States Dollar London Interbank Offered Rate (LIBOR) effective for the date that payment was due (as published in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:129%">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">, Eastern Edition) plus &#91;****&#93; percent (&#91;****&#93;%), on a per year basis.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">. Buyer and Seller do not anticipate there being any sales taxes, value added tax, use taxes, transfer taxes, or similar taxes or withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">requirements that will become payable in connection with the transactions under this Agreement. In the event any such taxes are payable or withholding is required by Applicable Laws, the Parties shall discuss in good faith and agree on a fair allocation of such taxes or withholding requirements&#59; provided that in the absence of such agreement, the Parties shall equally bear any such taxes or withholding requirements. Seller shall bear any such taxes payable in connection with the manufacture or Development of the Product prior to the Closing Date, Buyer shall bear any such taxes payable in connection with the manufacture, Development or Commercialization of the Product on or after the Closing Date, and the Parties will cooperate in the filing of all necessary tax returns and other documentation with respect to all such taxes. For clarity, Buyer shall be responsible for all fees charged by Governmental Authorities, including recording or filing fees or similar charges, for effecting or recording the transfer to Buyer of any Purchased Assets. For further clarity, Seller shall remain exclusively liable for all corporate income tax, capital tax, and other corporate taxes imposed on the Seller.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">3.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline">Books and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">. With respect to each quarter in which a payment was due hereunder, Buyer will maintain complete and accurate books and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">records in sufficient detail to enable verification of the correctness of the payments due hereunder for a period of five (5) years after such quarter. Seller may audit Buyer&#8217;s and its Affiliates&#8217; and Licensees&#8217; relevant books and records in order to verify the aforesaid matters within the subject five year period. Upon reasonable prior notice and during normal business hours, Seller&#8217;s independent public accountants, subject to confidentiality obligations consistent with Article 7, shall have access to such books and records in order to conduct such a review or audit. The Parties shall reconcile any underpayment within sixty (60) days after the accountant delivers the results of the audit. If any audit performed under this Section 3.10 reveals an underpayment in excess of &#91;****&#93; percent (&#91;****&#93;%) in any calendar year, Buyer shall reimburse Seller for all amounts incurred in connection with such audit. Seller may exercise its rights under this Section 3.10 only once every year per audited entity, each period shall only be subject to audit with reasonable prior notice to the audited entity.</font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">MGNX Stock Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. Notwithstanding anything to the contrary in this Agreement or any other agreement related to the transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">contemplated herein, Seller shall be solely responsible for, and shall perform when required under the Assumed Contracts, all obligations related to the issuance of MGNX Stock Milestones.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:25.85pt">CLOSING DELIVERIES</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Time and Place</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. The closing of the transactions contemplated by this Agreement, including the purchase and sale of the Purchased Assets (the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:129%">&#8220;Closing&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">), shall take place simultaneously with the signing of this Agreement, by electronic exchange of documents or otherwise at the offices of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:129%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">Seller, on the Closing Date, unless another place shall be agreed to by the Parties.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Seller Closing Deliveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. At Closing, Seller shall deliver or cause to be delivered to Buyer&#58;</font></div><div><font><br></font></div><div style="padding-left:49pt;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%;padding-left:7.72pt">the Bill of Sale and General Assignment Agreement (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%">&#8220;Bill of Sale and General Assignment Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">) attached hereto as Exhibit 6, duly executed by Seller&#59;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-left:49pt;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:5.22pt">the Patent Assignment Agreement, duly executed by Seller&#59;</font></div><div><font><br></font></div><div style="padding-left:49pt;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:2.72pt">copies in electronic form of the documents placed in the Data Room prior to the Closing Date&#59;</font></div><div><font><br></font></div><div style="padding-left:49pt;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:3.22pt">a duly executed copy of the Transfer Letter for each IND and CTA&#59;</font></div><div><font><br></font></div><div style="padding-left:49pt;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:5.72pt">the Lock-Up Agreement, duly executed by Seller&#59; and</font></div><div><font><br></font></div><div style="padding-left:49pt;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:3.22pt">a copy of all Consents and Waivers, duly executed by Seller and each consenting Third Party.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer Closing Deliveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. At Closing, Buyer shall deliver or cause to be delivered to Seller&#58;</font></div><div><font><br></font></div><div style="padding-left:32pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(i)the Warrant, duly executed by the Buyer&#59;</font></div><div><font><br></font></div><div style="padding-left:32pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ii)the Lock-Up Agreement, duly executed by MDB Capital&#59;</font></div><div><font><br></font></div><div style="padding-left:32pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iii)the Bill of Sale and General Assignment Agreement, duly executed by Buyer&#59;</font></div><div><font><br></font></div><div style="padding-left:32pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iv)the Patent Assignment Agreement, duly executed by Buyer&#59; and</font></div><div><font><br></font></div><div style="padding-left:32pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(v)a copy of all Consents and Waivers to which Buyer is a party, duly executed by Buyer.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:25.85pt">REPRESENTATIONS AND WARRANTIES OF SELLER</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Seller hereby makes to Buyer the following representations and warranties set forth in Section 5.2 through 5.21, as of the Closing Date.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:136%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline">Corporate Organization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">. Seller is a corporation duly organized, validly existing and in good standing under the Applicable Laws of the State of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">Delaware.</font></div><div style="padding-left:33pt;text-align:justify;text-indent:-32.35pt"><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline">Authority of Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">. Seller has all necessary power and authority and has taken all actions necessary to enter into this Agreement and the other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Transaction Documents and to carry out the transactions contemplated hereby and thereby. This Agreement and the other Transaction Documents have been duly and validly executed and delivered by Seller and, when executed and delivered by Buyer, will constitute legal, valid and binding obligations of Seller enforceable against it in accordance with their respective terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other Applicable Laws of general application affecting enforcement of creditors&#8217; rights generally, and (ii) as limited by Applicable Laws relating to the availability of specific performance, injunctive relief or other equitable remedies. The execution, delivery and performance of this Agreement and all agreements, documents and instruments executed and delivered by Seller pursuant hereto, have been duly authorized by all necessary corporate or other action of Seller.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Non-Contravention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. The execution and delivery by Seller of this Agreement and the other Transaction Documents to which it is a party, does not,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">and the performance by it or its relevant Affiliates of its or their obligations under this Agreement and the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby will not&#58;</font></div><div><font><br></font></div><div style="padding-left:49pt;padding-right:1pt;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:7.72pt">conflict with or result in a material violation or breach of any of the terms, conditions or provisions of the Certificate of Incorporation or Bylaws or other organizational documents of Seller or its relevant Affiliates or of any Program Contract&#59;</font></div><div><font><br></font></div><div style="padding-left:49pt;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:5.22pt">assuming the receipt of the Required Consents, conflict with or result in a material violation or breach of any term or provision of any Applicable Law that applies to Seller, the Product or the Purchased Assets&#59;</font></div><div><font><br></font></div><div style="padding-left:49pt;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;padding-left:2.72pt">other than the Required Consents, the Transfer Letter and the transfer of any other regulatory documentation, require from Seller any notice to, declaration or filing with, or consent or approval of, any Governmental Authority in any country or other Third Party (other than any filing of Product Patents required to be made in accordance with the terms of this Agreement)&#59; or</font></div><div><font><br></font></div><div style="padding-left:49pt;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:3.22pt">assuming the receipt of the Required Consents, accelerate any obligation under, or give rise to a right of termination of, any Program Contract.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Title&#59; Encumbrances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. Seller has exclusive, good, valid and marketable title to all of the Purchased Assets and full right and power to sell, convey,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">assign, transfer and deliver such title to Buyer, in each case free and clear from any and all Encumbrances, except with respect to any Permitted Encumbrance.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline">Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">. Seller has made available to Buyer true, correct and complete copies of the Program Contracts. Except as set forth on Schedule 5.6 of the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Disclosure Schedules, no cancellation of any Program Contract has occurred, Seller has not received any written notice of cancellation of any Program Contract by the other party thereto and, each Program Contract is legal, valid, binding and enforceable in all material respects in accordance with its terms with respect to Seller and, to the Knowledge of Seller, with respect to each other party to such Program Contract, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar Applicable Laws affecting the enforcement of creditors&#8217; rights in general and general principles of equity and the discretion of courts in granting equitable remedies. There does not exist under any Program Contract any material breach or material event of default, or event or condition that, after notice or lapse of time or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">both, would constitute a material breach or material event of default thereunder on the part of Seller or any of its Affiliates or, to Seller&#8217;s Knowledge, on the part of any other party thereto. The JDRF Agreement has been terminated and all obligations thereunder have been satisfied.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;padding-left:23.72pt">As of the Closing Date each item of Product Intellectual Property is Controlled by Seller free and clear of any Encumbrances, other than the Permitted Encumbrances. The Product Intellectual Property, together with the Related Technology (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:124%">Program IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">&#8221;), constitutes all of the intellectual property Controlled by Seller and&#47;or any of its Affiliates as of the Closing Date that is used or held for use in connection with, or otherwise necessary or useful for the manufacture, Development or Commercialization of the Product. Except as set forth on Schedule 5.7(i) of the Disclosure Schedules, neither Seller, nor any of its Affiliates, transferred ownership of, or granted any license of, or right to use, or authorized the retention of any rights to use or joint ownership of any Product Intellectual Property to any other Person.</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;padding-left:21.22pt">Exhibit 2 sets forth a true, correct and complete list of all Patents Controlled by Seller that are solely and exclusively related to the Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:123%">Listed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">&#8221;) including, in each case, the title, jurisdiction(s) in which each Patent was or is filed, and the respective application number, patent number (if any), filing date and issuance date (if any). Seller has taken all actions required to duly file and maintain the Listed Patents in a timely manner, including the timely submission of all necessary filings in accordance with the legal and administrative requirements of the appropriate Government Authority. Neither Seller nor any of its Affiliates has received any written notice of any inventorship challenge, ownership dispute, Third Party right, interference, patentability, validity or enforceability with respect to any Listed Patent. Seller has made timely payment of any filing, registration, examination, maintenance, annuity and renewal fees due with respect to the Listed Patents, and the Listed Patents are not subject to any unpaid fees or taxes for filings falling due within sixty (60) days after the Closing Date.</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;padding-left:18.72pt">Seller has not received any written communication from any Person (A) challenging, or threatening to challenge, the right of Seller or any of its Affiliates to use, exercise, sell, license, transfer or dispose of any Program IP or the Product, or (B) challenging the ownership, validity or enforceability of any Program IP. To Seller&#8217;s Knowledge, (A) all issued Patents included in the Listed Patents are valid, subsisting, and enforceable&#59; and (B) all Patent applications included in the Listed Patents are subsisting and, to Seller&#8217;s Knowledge, valid and enforceable. Seller and its Affiliates have complied (and to Seller&#8217;s Knowledge, any other Person involved in filing, maintaining and prosecution of the Listed Patents, have complied) in all material respects with Applicable Law regarding the duty to disclose and duties of candor in the filing, maintaining and prosecution of the Listed Patents.</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;padding-left:19.22pt;text-decoration:underline">Schedule 5.7(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%"> lists all licenses, sublicenses and other agreements in effect as of the Closing Date to which Seller or any of its Affiliates is a party and pursuant to which any Third Party is granted (A) any license or other right to make, have made, use, sell, have sold, offer for sale, import or otherwise distribute or exploit any Product, including any materials transfer agreements and research agreements related to the Product, and any other material instrument by which the Product has been provided to any Third Party for research or any other purpose,</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:0.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;padding-left:30.77pt">any covenant not to assert&#47;sue or other immunity from suit under or any other rights to, any Product Intellectual Property, (C) any ownership right or title, whether actual or contingent, to any Product Intellectual Property, or (D) an option or right of first refusal relating to any Product Intellectual Property (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:122%">Outbound Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">&#8221;). Seller has delivered or otherwise made available to Buyer accurate and complete copies of all Outbound Licenses, and Seller or its applicable Affiliate is in compliance with (and, to Seller&#8217;s Knowledge, each other party to such Outbound Licenses are in compliance with) all material terms and conditions of all Outbound Licenses. Except as set forth on Schedule 5.7(iv), neither Seller nor any of its Affiliates is party to any contract that provides for earn-outs, milestone payments, royalties or other contingent payments to be paid to Seller or its Affiliates related to the development, approval, manufacture, use, sale, offer for sale, or import or other exploitation of any Product.</font></div><div><font><br></font></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_10"></div><div style="padding-left:32.2pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;padding-left:21.72pt;text-decoration:underline">Schedule 5.7(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%"> lists all licenses, sublicenses and other agreements in effect as of the Closing Date to which Seller or any of its Affiliates is a party and pursuant to which any Third Party grants to Seller or any of its Affiliates (A) any license or other right to make, have made, use, sell, have sold, offer for sale, import or otherwise distribute or exploit any Product, (B) any covenant not to assert&#47;sue or other immunity from suit under or any other rights to, any intellectual property rights claiming or covering the development, approval, manufacture, use, sale, offer for sale, or import or other exploitation of any Product and&#47;or otherwise related to the Product Intellectual Property, (C) any ownership right or title, whether actual or contingent, to any intellectual property rights claiming or covering the development, approval manufacture, use, sale, offer for sale, or import or other exploitation of any Product and&#47;or otherwise related to the Product Intellectual Property, or (D) an option or right of first refusal relating to any intellectual property rights claiming or covering the development, approval, manufacture, use, sale, offer for sale, or import or other exploitation of any Product and&#47;or otherwise related to the Product Intellectual Property (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:122%">Inbound Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">&#8221;). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline">Schedule 5.7(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%"> also identifies all Inbound Licenses requiring Seller or any of its Affiliates to license, assign or otherwise grant rights to any Third Party for any additions, modifications or improvements to any Product Intellectual Property made by or for Seller or its Affiliates. Seller has delivered or otherwise made available to Buyer copies of all Inbound Licenses, and Seller or its Affiliate, as applicable, is in compliance with (and, to Seller&#8217;s Knowledge, each other party to such Inbound Licenses are in compliance with) all material terms and conditions of all Inbound Licenses.</font></div><div><font><br></font></div><div style="padding-left:32.2pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;padding-left:19.22pt;text-decoration:underline">Schedule 5.7(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"> lists agreements for Development (including pre-clinical and clinical) or other services currently being provided by any Third Party or under which Seller has outstanding obligations related to the Product and&#47;or the Product Intellectual Property (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8221;). Seller has delivered or otherwise made available to Buyer copies of all Service Contracts, and Seller or its Affiliate, as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">applicable, is in compliance with (and, to Seller&#8217;s Knowledge, each other party to such Service Contracts are in compliance with) all material terms and conditions of all Service Contracts.</font></div><div><font><br></font></div><div style="padding-left:32.2pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;padding-left:16.72pt">Except as set forth in Schedule 5.7(vii) of the Disclosure Schedules, neither Seller, nor any of its Affiliates, has received any written communication, claim or demand from any Third Party concerning Third Party intellectual property rights in connection with the Product, or alleging that any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-left:32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">material infringement, violation or misappropriation of any Third Party&#8217;s intellectual property rights has occurred with respect to the Program IP or as a result of the manufacture, Development or Commercialization of the Product. During the last three (3) years, neither Seller nor any of its Affiliates has received any written communication alleging that the conduct of the practice of any Program IP violates any right to privacy or publicity of any Person, violates any Applicable Laws or constitutes unfair competition or trade practices under Applicable Law. To the Knowledge of Seller as of the Closing Date, neither the past or current Development, manufacture (including use of certain cells to produce Teplizumab for the Product), Commercialization, use, sale or import of Teplizumab or the Product has or would infringe, misappropriate or otherwise violate the intellectual property rights of any Third Party as of the Closing Date.</font></div><div><font><br></font></div><div style="padding-left:32.2pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;padding-left:14.22pt">Seller has taken customary measures and precautions necessary to protect and maintain the confidentiality of the Product Know-How. During the last three (3) years, neither Seller nor any Seller Affiliate has received any written communication alleging any violation of Applicable Laws pertaining to the privacy and security of protected health information within any clinical data or regulatory materials related to the Product.</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;padding-left:19.22pt">Each current or former employee, consultant and independent contractor employed or engaged by Seller or any of its Affiliates in the manufacture, Development or Commercialization of Product has executed a valid and binding written agreement (A) expressly assigning to Seller all right, title and interest in any intellectual property rights which relate the Product and were invented, created, developed, conceived or reduced to practice during the term of such employee&#8217;s, consultant&#8217;s or and independent contractor&#8217;s employment or engagement&#59; and (B) requiring each such employee, consultant or independent contractor to protect and preserve all applicable Program IP. Such assignments have been directly assigned to Seller or its Affiliates.</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;padding-left:21.72pt">Except as set forth in Schedule 5.7(x) of the Disclosure Schedules, neither Seller nor any of its Affiliates has (A) sought, applied for or received any support, funding, resources, materials or assistance from any Government Authority, university, college or other educational or non-profit institution or research center in connection with the creation or development of the Product Intellectual Property or the Product, or (B) used any facilities of a university, college, or other educational institution or research center in the development of any Product or the creation or development of the Product Intellectual Property. To Seller&#8217;s Knowledge, no current or former employee, consultant or independent contractor who was in any way involved in (or has in any way contributed to) the creation or development of the Product Intellectual Property or the Product has performed services for any Government Authority, university, college or other educational or non-profit institution or research center during a period of time during which such employee, consultant or independent contractor was also performing services for Seller or Seller Affiliates that would result in any adverse claim or right relating to the Product Intellectual Property. Except as set forth in Schedule 5.7(x) of the Disclosure Schedules, no Government Authority, university, college or other educational or non-profit institution or research center has any claim of right to ownership of or other liens, claims or interests with respect to the Product Intellectual Property.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:126%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">. Seller has complied in all material respects with and is not in material breach, violation or noncompliance of any Applicable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">Laws with respect to the ownership, use, manufacture or Commercialization of the Product, except for such non-compliance as would not reasonably be expected to materially adversely affect Buyer&#8217;s interest in the Purchased Assets or Buyer&#8217;s ability to Develop, manufacture or Commercialize any Product.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">5.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">. During the past five (5) years there have been no, and as of the Closing Date there are no Third Party Claims pending or, to the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Knowledge of Seller, threatened against Seller, relating to, affecting or arising in connection with (i) a Product, (ii) the Purchased Assets, (iii) this Agreement, (iv) the Related Technology or (v) the transactions contemplated by this Agreement. To the Knowledge of Seller, no event has occurred, and no condition or circumstance exists, that can be reasonably expected to serve as a basis for the commencement of any such Third Party Claims against Seller with respect to the manufacture or Development of a Product until the Closing Date. Neither the Related Technology, nor the Purchased Assets are subject to any judgment, order, writ, injunction, decree or award of any court, arbitrator or governmental department, commission, board, bureau, agency or instrumentality against Seller that can reasonably be expected to materially and adversely affect, prevent, impair or delay the consummation of this Agreement.</font></div><div style="padding-left:32pt;padding-right:3pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">5.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline">Regulatory Compliance&#59; Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">. As of the Closing Date&#58; (i) there is no pending or, to the Knowledge of Seller, threatened Action or Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">by a Governmental Authority against Seller relating to the Product, the Related Technology or the Purchased Assets, (ii) there is no pending or, to the Knowledge of Seller, threatened Action or Proceeding by a Governmental Authority against a Product Developed, manufactured or Commercialized by or on behalf of Seller or against any Purchased Assets, (iii) there is no act or omission by, or event or circumstance known to the Seller that, to the Knowledge of the Seller, would or reasonably would be expected to result in an Action or Proceeding by a Governmental Authority against Seller relating to the Product, the Related Technology or the Purchased Assets, (iv) all required submissions to the FDA related to Seller&#8217;s manufacture or Development of the Product have been made, (v) all submissions made by or on behalf of Seller to the FDA or any other Governmental Authority, if any, are accurate and complete in all material respects&#59; (vi) there is no arrangement to which Seller is a party or authorized by Seller providing for any rebates, kickbacks or other forms of compensation that are unlawful to be paid to any Person in return for the referral of business or for the arrangement for recommendation of such referrals, (vii) neither Seller, nor any individual who is an officer or director of Seller as of the Closing Date, nor, to the Knowledge of Seller, any other employee, consultant, agent of Seller or any of Seller&#8217;s predecessors in interest or its collaborators, directly involved in the Development or manufacture of a Product (A) has been convicted of, charged with or, to the Knowledge of Seller, investigated for any offense related to healthcare, or (B) has been convicted of, charged with or, to the Knowledge of Seller, investigated for a violation of Applicable Laws related to fraud, theft, embezzlement, breach of fiduciary responsibility, financial misconduct, obstruction of an investigation or distribution of controlled substances, (C) has engaged in any conduct that has resulted, or would reasonably be expected to result, in debarments under 21 U.S.C. &#167; 335a(a) or any similar Applicable Laws, or (D) committed an act, made a statement or failed to make a statement that would provide the basis for the FDA to invoke its policy respecting &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,&#8221; as set forth in 56 Fed. Reg. 46191 (September 10, 1991), (viii) there have been no recalls, field notifications or seizures or adverse regulatory actions taken (or, to the Knowledge of Seller after reasonable investigation, threatened) by any Governmental Authority with respect to the Product or, to the Knowledge of Seller, an ingredient of a Product, including any such actions materially and adversely affecting </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-left:32pt;padding-right:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">facilities where the Product or Product ingredients are manufactured, produced, processed, packaged or stored for Seller, and Seller has not, either voluntarily or at the request of any Governmental Authority, initiated or participated in a recall of a Product.</font></div><div><font><br></font></div><div style="padding-left:32pt;padding-right:3pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">5.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline">Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">. Seller has made available to Buyer true, correct and complete copies of (i) all Program Contracts&#59; (ii) the INDs and CTAs and all</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">material Product related information that Seller is required to maintain pursuant to the requirements of the FDA, including Product complaint files and labeling change files, (iii) all Patents Controlled by Seller, to the extent not publicly available, relating to the Product or its manufacture or Commercialization and to the extent included in the Product Patents, (iv) the Transferrable Books and Records, including the complete regulatory file for the Product. Neither Seller nor any Affiliate is a party to any unwritten agreement directly relating to the Development, manufacture or Commercialization of Product that would materially adversely affect the sale, use, manufacture or Commercialization of a Product. Except as set forth on Schedule 5.11 of the Disclosure Schedules, Seller has not granted to a Third Party any right, and no Third Party has any right under the INDs and CTAs or the Product Intellectual Property, to manufacture, Develop or Commercialize the Product. To the Knowledge of Seller, all information provided by Seller to Buyer relating to the manufacture, Development and Commercialization of the Product has not contained any untrue statement of a material fact or intentionally omitted to state a material fact necessary in order to make the statements therein not misleading in light of the circumstances under which they were made.</font></div><div><font><br></font></div><div style="padding-left:32pt;padding-right:3pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">5.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. Seller has not retained any broker in connection with the transactions contemplated under this Agreement. Buyer will have no obligation to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">pay fees of any brokers, finders, investment bankers, or financial advisors engaged by Seller in connection with this Agreement or the transactions contemplated hereby.</font></div><div><font><br></font></div><div style="padding-left:32pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">5.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;text-decoration:underline">Solvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">. Seller has entered into this Agreement in good faith as a result of arms-length negotiations with Buyer. Seller is not entering into this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">Agreement or any transaction contemplated hereunder with the intent to hinder, delay or defraud any Person to which it is, or may become, indebted. As of the Closing Date, Seller has the capacity and financial capability to comply with and perform all of the covenants and obligations under this Agreement. Further, as of the Closing, giving effect to the consummation of all of the transactions contemplated by this Agreement, including, without limitation, the transfer and delivery of the Purchased Assets, will not cause Seller to be insolvent under any Applicable Law relating to fraudulent transfers or fraudulent conveyance.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">5.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#91;****&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline">Agreement&#59; Third Party Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">. The &#91;****&#93; Agreement has been terminated and the &#91;****&#93; described in Amendment No. 2 to the &#91;****&#93; Agreement, dated as of &#91;****&#93;, has been completed. There are no outstanding obligations or liabilities related to the Product or the Purchased Assets under the &#91;****&#93; Agreement. The total amount due under the &#91;****&#93;Agreement, as agreed between &#91;****&#93;Buyer and Seller in the &#91;****&#93; Consent is &#91;****&#93; U.S. dollars ($&#91;****&#93;) and is exclusively due as a royalty on sales of Product. Schedule 5.14(ii) sets forth a true, complete and correct list of the Third Party Obligations that would be payable on sales of Product.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">5.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline">Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">. Schedule 5.15 contains a complete listing of all clinical trials conducted using Product, including any investigator-Sponsored studies.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">The preclinical studies and clinical trials of the Product conducted by or on behalf of Seller were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Applicable Laws (including, to the extent applicable, cGLPs and cGCPs). All required IRB approvals have been obtained and are currently in place for any ongoing clinical trials of Product. Valid informed consents have been obtained and are in the Seller&#8217;s possession or control for all patients who have been in Seller&#8217;s clinical trials of Product. All adverse experiences occurring in clinical trials have been reported to FDA as required. All Product used in such clinical trials materially complied with all Applicable Laws (including, to the extent applicable, cGMPs), and there have not been any material deficiencies or defects in such Product. Neither Seller, nor any of its agents, or to its Knowledge and of its collaborators, have received any written notices or correspondence from the FDA or any other Government Authority requiring the termination, suspension, hold or material modification of any preclinical study or clinical trial of a Product conducted by or on behalf of Seller. Neither Seller nor any of its agents, or to its Knowledge any of its collaborators, have received any written communication from any Person threatening any claim or lawsuit against Seller, any of its agents or its collaborators, arising from the administration of a Product to any Person in the course of any clinical trial conducted by or on behalf of Seller. FDA has not issued any 483 or finding of deficiency or non-compliance in respect of the Product, any clinical trial of the Product, or any Third Party involved in the conduct of a clinical trial of the Product.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">5.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Undisclosed Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. To Seller&#8217;s Knowledge, except for liabilities to Seller and any liabilities which are disclosed on Schedule 5.14(ii), there is no</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">financial or economic liability that would be due in connection with the Development, manufacturing or Commercialization of the Product under agreements that were entered into by Seller, or to its Knowledge, its predecessors in interest prior to the Closing Date.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">5.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:126%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline">Transferred Materials&#59; Suppliers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">. The Transferred Materials have been manufactured in compliance with all Applicable Laws including cGMP and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">have met all applicable specifications, except as would not materially adversely affect Buyer&#8217;s ability to manufacture, Develop or Commercialize the Product. Neither Seller nor any Third Party has received any written notices or correspondence from the FDA or any other Government Authority regarding the Transferred Materials.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">5.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;text-decoration:underline">Sufficiency&#59; Development and Manufacturing Pre-Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">. The Transferable Notes and Books accurately describe and document the Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">and manufacturing of the Product in the manner done by Seller prior to the Closing Date. The Purchased Assets, together with the Related Technology, constitute the intellectual property rights necessary for the Development or manufacturing of the Product in the manner done by Seller prior to the Closing Date. Except for intellectual property rights that constitute Related Technology or that are included in the Purchased Assets, there are no intellectual property rights that Seller has an interest in prior to the Closing Date that are necessary for the Commercialization of the Product.</font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">5.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;text-decoration:underline">Data Room</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">. All information and documentation contained in the Data Room, to which Buyer has been provided access, is true and accurate in all</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">material respects and reflects the subject matter to which it relates. The Data Room (i) contains all material information in order to give a true and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">documentation fair view of the Purchased Assets, the Assumed Liabilities and the Product, (ii) does not include any matter of material importance which is incorrect or misleading, and (iii) does not omit any information which is of material importance, which by omission would make the contents of the Data Room materially incorrect or misleading, except as would not materially adversely affect Buyer&#8217;s interest in the Purchased Buyer&#8217;s interest in the Purchased Assets or Buyer&#8217;s ability to Develop, manufacture or Commercialize any Product.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">5.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. All of the Purchased Assets which are of an insurable nature have at all material times been insured against all such risks as persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">carrying on a similar business to the Seller would be expected to cover by insurance. Seller has at all relevant times maintained adequate product liability insurance and insurance covering clinical trials related to the Product performed by it or on its behalf.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">5.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline">Accredited Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">. Seller is an &#8220;accredited investor&#8221; within the meaning of Rule 501 of Regulation D under the Securities Act of 1933 (the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">&#8221;), as amended. The Seller has substantial experience in evaluating and investing in securities in companies similar to the Buyer so that Seller is capable of evaluating the merits and risks of Seller&#8217;s investment in Buyer (pursuant to the Warrant) and has the capacity to protect Seller&#8217;s own interests. The Seller is acquiring the Warrant (and the shares issuable upon exercise of this Warrant) for investment for Seller&#8217;s own account, not as a nominee or agent, and not with the view to, or for resale in connection with, any distribution thereof. Seller understands that the Warrant (and the shares issuable upon exercise of the Warrant) have not been, and will not be, registered under the Securities Act by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of Seller&#8217;s representations as expressed herein and in the Warrant.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">5.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;text-decoration:underline">No Other Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">. EXCEPT FOR THE REPRESENTATIONS OR WARRANTIES EXPRESSLY SET FORTH IN THIS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">ARTICLE 5 OR IN ANY OTHER TRANSACTION DOCUMENTS, SELLER DISCLAIMS ANY AND ALL OTHER REPRESENTATIONS OR WARRANTIES, WHETHER EXPRESS OR IMPLIED, ORAL OR WRITTEN, INCLUDING ANY INFORMATION FURNISHED BY SELLER WITH REGARD TO THE PRODUCT OR THE PURCHASED ASSETS, INCLUDING THE FUTURE PROFITABILITY OF ANY PRODUCT, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6. REPRESENTATIONS AND WARRANTIES OF BUYER</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:136%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">. Buyer hereby makes to Seller the representations and warranties set forth in Sections 6.2 through 6.8, as of the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">Closing Date.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Corporate Organization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">. Buyer is a corporation duly organized, validly existing and in good standing under the Applicable Laws of Delaware.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Authority of Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. Buyer has all necessary power and authority and has taken all actions necessary to enter into this Agreement and the Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Documents and to carry out the transactions contemplated hereby and thereby. This Agreement and all Transaction Documents have been duly and validly executed and delivered by Buyer and, when executed and delivered by Seller, will constitute legal, valid and binding obligations of Buyer enforceable against it in accordance with their terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other Applicable Laws of general application affecting enforcement of creditors&#8217; rights generally, and (ii) as limited by Applicable Laws relating to the availability of specific performance, injunctive relief or other equitable remedies. The execution, delivery and performance of this Agreement and all agreements, documents and instruments executed and delivered by Buyer pursuant hereto, have been duly authorized by all necessary corporate or other action of Buyer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Contravention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. The execution and delivery by Buyer of this Agreement does not, and the performance by it of its obligations under this</font></div><div><font><br></font></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement and the consummation of the transactions contemplated hereby will not&#58;</font></div><div><font><br></font></div><div style="padding-left:65pt;padding-right:1pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:23.72pt">conflict with or result in a material violation or breach of any of the terms, conditions or provisions of the Articles of Incorporation, Bylaws or other organizational documents of Buyer&#59;</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;padding-left:21.22pt">assuming the receipt of the Required Consents, violate, conflict with or result in a violation of, or constitute a default (whether after the giving of notice, lapse of time or both) under, any provision of any Applicable Law, regulation or rule, or any order of, or any restriction imposed by, any court or governmental agency applicable to Buyer&#59;</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:18.72pt">other than the Required Consents, require from Buyer any notice to, declaration or filing with, or consent or approval of any Governmental Authority in any country or other Third Party&#59; or</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;padding-left:19.22pt">assuming the receipt of the Required Consents, violate or result in a violation of, or conflict with or constitute or result in a violation of or default (whether after the giving of notice, lapse of time or both) under, accelerate any obligation under, or give rise to a right of termination of, any contract, agreement, permit, license, authorization or other obligation to which Buyer is a party or by which Buyer or any of its assets are bound.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:126%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline">Financial Capability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">. Buyer has entered into this Agreement in good faith as a result of arms-length negotiations with Seller. Buyer is not entering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">into this Agreement or any transaction contemplated hereunder with the intent to hinder, delay or defraud any Person to which it is, or may become, indebted. Buyer believes in good faith that it has or will have at the time required to perform the capacity and financial capability to comply with and perform all of the covenants and obligations under this Agreement.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. Buyer has not retained any broker in connection with the transactions contemplated hereunder. Seller will have no obligation to pay fees of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">any brokers, finders, investment bankers, or financial advisors engaged by Buyer in connection with this Agreement or the transactions contemplated hereby.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:126%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline">Diligence Investigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">. Buyer has conducted its own independent investigation, review and analysis in connection with this Agreement and the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">transactions contemplated hereby, including regarding the Purchased Assets, the Assumed Contracts and the Product and the manufacture and Development thereof. Such investigation shall in no way limit any claims by Buyer resulting from any breach by Seller of any of its representations, warranties and covenants contained herein, including, without limitation, claims arising from or fraud or intentional misconduct.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">6.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline">Buyer Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">. The authorized capital stock of Buyer consists of (i) 50,000,000 shares of common stock, par value $0.0001 per share (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:122%">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:122%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">&#8221;), 10,000,000 of which are issued and outstanding and (ii) 25,000,000 shares of preferred stock, $0.0001 par value, of which</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:122%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">13,000,000 shares have been designated as Series A Preferred Stock (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:122%">Buyer Series A Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">&#8221;), of which 11,381,999 shares of Buyer Series A Preferred Stock are issued and outstanding. Buyer has reserved 3,869,424 shares of Buyer Common Stock for issuance to officers, directors, employees and consultants of Buyer pursuant to its 2017 Equity Incentive Plan duly adopted by the board of directors of Buyer and approved by the stockholders of Buyer, of which 2,656,435 have been issued to employees and consultants of the Buyer. Buyer has reserved 558,740 shares of Buyer Series A Preferred Stock for issuance pursuant to that certain Warrant, dated as of April 25, 2017, in favor of MDB Capital Group, LLC. There are no bonds, debentures, notes or other indebtedness having general voting rights (or convertible into securities having such rights) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:122%">Voting Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">&#8221;) of Buyer issued and outstanding. Except as set forth above, there are no options, warrants, calls, subscriptions or other rights, agreements, arrangements or commitments of any kind relating to the issued or unissued capital stock of Buyer, obligating Buyer to issue, transfer or sell or cause to be issued, transferred or sold any shares of capital stock or Voting Debt of, or other equity interest in, Buyer or securities convertible into or exchangeable for such shares or equity interests, or obligating Buyer to grant, extend or enter into any such option, warrant, call, subscription or other right, agreement, arrangement or commitment.</font></div><div><font><br></font></div><div style="padding-left:33pt;padding-right:1pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">6.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">No Other Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. EXCEPT FOR THE REPRESENTATIONS OR WARRANTIES EXPRESSLY SET FORTH IN THIS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">ARTICLE 6 OF THIS AGREEMENT OR IN ANY OTHER TRANSACTION DOCUMENTS, BUYER DISCLAIMS ALL OTHER REPRESENTATIONS OR WARRANTIES, WHETHER EXPRESS OR IMPLIED, ORAL OR WRITTEN, RELATED TO THIS AGREEMENT.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7. COVENANTS OF THE PARTIES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;padding-left:23.72pt">Each Party shall cooperate fully with the other, as promptly as is reasonably practicable, in preparing and filing all notices, applications, submissions, reports and other instruments and documents that are necessary, proper or advisable under Applicable Law or required under Program Contracts or by Third Parties to consummate and make effective the transactions contemplated by this Agreement and obtaining any consent or approval of any Governmental Authority or other Third Party whose consent may be required to consummate and make effective the transactions contemplated by this Agreement, including the Consents and Waivers (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#8220;Required Consents&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">).</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;padding-left:21.22pt">Seller shall have no obligation to make any payments or provide other consideration to Buyer or any Third Party other than any amounts that are due and payable by Seller as of the Closing, if any, or are otherwise required by the terms of this Agreement or the other Transaction Documents. Seller&#8217;s obligation to transfer or assign any Assumed Contract shall be contingent upon Seller&#8217;s receipt of such Required Consent. Pending receipt of any Required Consent with respect to an Assumed Contract, the Parties shall use their commercially reasonable efforts to implement an alternative arrangement to permit Buyer to receive substantially similar rights and for Buyer to assume substantially similar obligations under such Assumed Contract as if such impediment to assignment or transfer did not exist&#59; provided, however, that commercially reasonable efforts shall not include payment to Seller or Buyer, as applicable, or any Third Party other than payment of amounts due and payable by Seller and or Buyer, as applicable, as of the Closing.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_13"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">. Seller shall from time to time, at the reasonable request of Buyer and at Buyer&#8217;s expense, (i) provide such further information in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Seller&#8217;s possession, (ii) execute and deliver, or cause to be executed and delivered, such other instruments of conveyance and transfer, certificates, deeds or other documents, and (iii) take, or cause to be taken, all other actions and do, or cause to be done, such other acts and things, all as promptly as practicable as Buyer may reasonably request in order to more effectively consummate the transactions contemplated by this Agreement and to vest in Buyer good and marketable title to the Purchased Assets.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">. Each Receiving Party shall maintain the confidentiality of any Confidential Information received from a Disclosing Party, and shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">not disclose such information to any Third Party without the prior written consent of such Disclosing Party, except as otherwise provided in this Agreement (it being understood that any Confidential Information included in the Purchased Assets shall become Confidential Information of Buyer following Closing). As used herein, Confidential Information shall be deemed to include (i) all information that either Party provides in connection with this Agreement or the transactions contemplated hereby (including, without limitation, any claim or dispute arising out of or related to this Agreement or the transactions contemplated hereby, or the interpretation, making, performance, breach or termination thereof) identified to the other in writing as confidential or the nature of which or the circumstances of the disclosure of which would reasonably indicate that such information is confidential, this Agreement and all information concerning this Agreement (which shall be deemed the Confidential Information of both Parties)&#59; and (ii) the Purchased Assets that are not generally available to the public and including, without limitation, any information provided or made available following the Closing pursuant to this Agreement (including, without limitation, any information related to Net Sales any and all books and records, work papers, documents, schedules or other materials or information).</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline">Legally Compelled Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">. In the event that a Receiving Party is required by Applicable Laws to disclose any Confidential Information of its</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Disclosing Party to any Governmental Authority in order to obtain regulatory approval for the Product, in connection with a bona fide legal process (including in connection with any bona fide disputes hereunder) or under the rules of the securities exchange upon which its securities are traded, the confidentiality requirements under Section 7.3 shall not apply, solely with respect to the Confidential Information required to be disclosed by Applicable Law, and so long as such Receiving Party (i) limits disclosure to such information required by Applicable Law while maintaining the confidentiality of all other Confidential Information of its Disclosing Party, and (ii) promptly gives such Disclosing Party advance notice of such disclosure and an opportunity to seek a protective order or confidential treatment. In the event of disclosure required by Applicable Laws under this Section 7.4, the Receiving Party shall cooperate in any such limitation on disclosure efforts at the Disclosing Party&#8217;s reasonable request and expense.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Press Releases and Other Permitted Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;padding-left:23.72pt">Attached as Exhibit 11, is a copy of the press release to be issued by the Buyer on the Closing Date. Except as set forth in the previous sentence or otherwise in this Section 7.5, no press release, public statement or disclosure concerning the existence or terms of this Agreement shall be made, either directly or indirectly, by either Party, without first obtaining the written approval of the other Party, which such approval shall not be unreasonably withheld or delayed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%"> that Seller may disclose the receipt of any milestone payment amount under this Agreement. Once any public statement or disclosure has been approved in accordance with this Section 7.5, then either Party may appropriately communicate information contained in such permitted statement or disclosure.</font></div><div style="padding-left:65pt"><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;padding-left:21.22pt">Each Party may disclose the existence and terms of this Agreement in confidence&#58; (a) (1) to its attorneys, professional accountants, and auditors, and (2) bankers or other financial advisors in connection with an initial public offering, private financing or other strategic transaction, or corporate valuation for internal purposes&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%"> that any such disclosure to such professional accountants, auditors, bankers or other financial advisors is under an agreement to keep the terms of confidentiality and non-use no less rigorous than the terms contained in this Agreement and to use such information solely for the applicable purpose permitted pursuant to this Section 7.4(ii)(a)&#59; (b) to potential acquirers (and their respective attorneys and professional advisors), in connection with a potential merger, acquisition or reorganization&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%"> such disclosure is under an agreement according to terms of confidentiality and non-use that are no less rigorous than the terms contained in this Agreement and require the use of such information solely for the purpose permitted pursuant to this Section 7.5(ii)(b)&#59; (c) to existing or potential investors, lenders or permitted assignees of such Party (and their respective attorneys and professional advisors)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%"> such disclosure is under an agreement according to terms of confidentiality and non-use that are no less rigorous than the terms contained in this Agreement&#59; and (d) to current and potential licensees or sublicensees or potential acquirors of such Party or of the Product (and their respective attorneys and professional advisors).</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;padding-left:18.72pt">Notwithstanding the foregoing provisions of this Article 7, a Party may disclose the existence and terms of this Agreement or a Party&#8217;s or the Parties&#8217; activities under this Agreement where required, as reasonably determined by the legal counsel of the disclosing Party, by Applicable Law, by applicable stock exchange regulation, as required in connection with filings under applicable securities laws or by order or other ruling of a competent court, although, to the extent practicable, the other Party shall be given prompt notice of any such legally required disclosure to comment and reasonably consider such comments provided by such Party on the proposed disclosure.</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;padding-left:19.22pt">Nothing in this Section 7.5 shall be deemed to restrict Buyer from providing public updates on the Product or its Development, manufacturing or Commercialization as deemed necessary or advisable by the Buyer in its sole discretion&#59; provided that Buyer does not use the name of Seller or its Affiliates (except to the extent referred to as the manufacturer of Product or licensor of certain Product-related rights, as may be necessary under applicable law or the Assumed Contracts) in any such public updates and does not otherwise disclose any Confidential Information of Seller.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Commercialization of Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. As of the Closing Date, Buyer shall be solely and exclusively responsible for the manufacture, Development and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">Commercialization of the Products, including all decisions pertaining to such manufacture, Development or Commercialization, including any recall of Products.</font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">7.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline">Regulatory Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">. A copy of each Transfer Letter authorizing the transfer of ownership of the INDs and CTAs as well as the orphan drug</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">designation owned by Seller to Buyer shall be delivered on the Closing Date and within ten (10) Business Days after the Closing Date, (a) Seller shall submit the Transfer Letters to the relevant Governmental Authorities and shall notify Buyer of such submission on the date submitted (providing Buyer an electronic copy of the submission with such notification) and (b) shall provide to Buyer the full regulatory file for the INDs and CTAs held by the Seller, including all available electronic meta data. Upon notification of the Seller&#8217;s submission of the Transfer Letter to the relevant Governmental Authorities, Buyer shall execute and submit to the relevant Governmental Authorities letters acknowledging Buyer&#8217;s commitment to assume ownership of the INDs and CTAs and the orphan drug designation owned by Seller. As of the Closing Date, except as otherwise set forth in this Section 7.7, Buyer shall be solely responsible for taking any actions necessary to (i) obtain any documentation required to maintain the INDs and CTAs or the orphaned drug designation owned by Seller or obtain any further authorizations under any Applicable Law, and otherwise comply with any Applicable Law with respect to regulatory authorizations. During the period between the Closing Date and the date that is that is eighteen (18) months from the Closing Date, Seller shall provide reasonable assistance as requested by Buyer in connection with Buyer&#8217;s fulfilment of its obligations under this Section 7.7. Except as set forth in any further written agreement between the Parties, as of the Closing Date, Buyer shall be solely responsible for investigating and reporting adverse experiences for the Product to any Governmental Authorities and addressing any such Governmental Authorities&#8217; inquiries related to the safety of the Product&#59; provided, however, that Seller shall provide reasonable assistance and cooperation to Buyer to the extent any such investigations or inquiries related to the manufacture or development of the Product prior to the Closing Date by or on behalf of Seller. Except as set forth in any further written agreement between the Parties, as of the Closing Date, Buyer shall be solely responsible for addressing any Person&#8217;s medical inquiries or complaints relating to the Product&#59; provided, however, that Seller shall provide reasonable assistance and cooperation to Buyer to the extent any such inquiries or complaints related to the manufacture or Development of the Product prior to the Closing Date by or on behalf of Seller.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;text-decoration:underline">Development and Commercialization of Products after Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">. Following the Closing Date Buyer agrees to (i) use Reasonable Commercial Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">to commence a &#91;****&#93; in accordance with the Development Plan&#59; and (ii) use Reasonable Commercial Efforts to manufacture, Develop and Commercialize at least one Product in the United States and Europe. Buyer shall provide to Seller, semi-annually, written reports on its completed and planned Development and Commercialization activities with respect to each Product. Each such report shall include an update regarding Development activities conducted by or on behalf of Buyer (including activities conducted under the Development Plan) and progress towards achieving the Development and Regulatory Milestones.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8. MANUFACTURING</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline">Manufacturing and Quality Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">. As part of the Technology Transition Plan described in Section 2.7, during the Transition Period, Buyer and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Seller shall negotiate in good faith manufacturing transfer and quality agreements for the Product that will include provisions regarding the transfer of&#58; (i) existing clinical material&#59; (ii) all cGMP and non-cGMP bulk drug substance or partially finished drug Product, including API, along with the corresponding cell lines and any specialized and dedicated equipment (e.g., proprietary media, dedicated purification columns&#47;filters, etc.) required for the production of Teplizumab&#59; and (iii) the CMC and quality support and documentation necessary to label, package, release and ship the existing inventory of cGMP finished drug product vials to clinical trial sites and&#47;or a corresponding storage and distribution subcontractor. After the Transition Period, Seller shall continue to provide support on the manufacturing transfer described in this Section 8.1 in accordance with the Technology Transition Plan and in accordance with the terms of Section 2.7 for a period of eighteen (18) months from the Effective Date. Costs incurred by Seller in connection with this Section 8.1 shall be subject to the cost allocation and reimbursement provisions of Section 2.7.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9 INDEMNIFICATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Survival of Representations, and Warranties.</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;padding-left:23.72pt">The Fundamental Representations shall survive the Closing Date indefinitely and shall bind the successors and assigns of the relevant Party, whether so expressed or not, and all such representations and warranties shall inure to the benefit of the successors and assigns of the Parties hereto, whether expressed or not. The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Fundamental Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8221; are Sections 5.1 (Corporate Organization), 5.3 (Authority of Seller)&#59; 5.4 (Non-Contravention)&#59; 5.5 (Title&#59; Encumbrances)&#59; 5.14 (Eli Lilly Agreement&#59; Third Party Obligations)&#59; 6.2 (Corporate Organization)&#59; 6.3 (Authority of Buyer)&#59; 6.4 (Non-Contravention) and 6.8 (Buyer Stock).</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;padding-left:21.22pt">The Core Representations shall survive the Closing Date for a period of five (5) years, and during such period shall bind the successors and assigns of the relevant Party, whether so expressed or not, and all such representations and warranties shall inure to the benefit of the successors and assigns of the Parties hereto, whether expressed or not. The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:126%">Core Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">&#8221; are Sections 5.7 (Intellectual Property)&#59; 5.10 (Regulatory Compliance)&#59; and 5.15 (Clinical Trials).</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;padding-left:18.72pt">Except as set forth in subsections (i) and (ii) of this Section 9.1, the representations and warranties of Seller or Buyer contained in Articles 5 and 6 or documents executed in connection herewith shall survive the Closing Date for a period of eighteen (18) months (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:126%">&#8220;Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:126%">Period&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">) and during the Survival Period shall bind the successors and assigns of the relevant Party, whether so expressed or not, and all</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:126%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">such representations and warranties shall inure to the benefit of the successors and assigns of the Parties hereto, whether expressed or not.</font></div><div><font><br></font></div><div style="padding-left:65pt;padding-right:1pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:19.22pt">Any claim whether for indemnification or otherwise based upon a breach of any such representation or warranty and asserted prior to the termination of the Survival Period by written notice in accordance with Section 9.2 shall survive until final resolution of such claim.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline">Indemnification by Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">. From and after the Closing Date, Seller shall indemnify, defend and hold harmless Buyer, its Affiliates and their</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">respective officers, directors, employees, agents, successors and assigns from and against any and all Damages incurred in connection with any claim, action, suit, litigation, proceeding, arbitration or investigation (whether civil, criminal, administrative, investigative, appellate or informal) by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">a Third Party, including a Governmental Authority (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">&#8220;Third Party Claims&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">) arising out of or relating to (i) any breach of any covenant, representation or warranty of Seller in this Agreement, (ii) any Retained Liability or (iii) Seller&#8217;s fraud, gross negligence or willful misconduct.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:126%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline">Indemnification by Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">. From and after the Closing Date, Buyer shall indemnify, defend and hold harmless Seller, its Affiliates, and their</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">respective officers, directors, employees, agents, successors and assigns from and against any and all Damages incurred in connection with any Third Party Claims arising out of or relating to&#58; (i) any breach of any covenant, representation or warranty of Buyer in this Agreement, (ii) any Assumed Liability or (iii) Buyer&#8217;s fraud, gross negligence or willful misconduct.</font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">. A Person intending to claim indemnification under this Article 9 (the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:122%">&#8220;Indemnitee&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">) shall promptly provide written notice to the Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">providing indemnification (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:122%">&#8220;Indemnitor&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">) of any Third Party Claim with respect to which the Indemnitee intends to claim such indemnification, which notice shall include a description of the Third Party Claim, the amount thereof (if known and quantifiable) and the basis for the Third Party Claim&#59; provided that failure of the Indemnitee to give the Indemnitor notice as set forth herein shall not relieve the Indemnitor of its obligations hereunder, except to the extent that the Indemnitor is prejudiced thereby. The Indemnitor shall have the right, in its sole discretion and at its election by written notice to the Indemnitee within fifteen (15) days after delivering notice of the Third Party Claim to the Indemnitee, to conduct the defense against such Third Party Claim in its own name, provided that the Indemnitor (i) shall keep the Indemnitee reasonably informed regarding the status of such Third Party Claim, (ii) shall provide the Indemnitee the reasonable opportunity to consult with the Indemnitor regarding the defense of such claim, and (iii) may not settle or compromise any such Third Party Claim without the prior written consent of the Indemnitee (which consent shall not be unreasonably withheld, conditioned or delayed) unless (A) such settlement or compromise involves no finding or admission of any breach by any Indemnitee of any obligation to any other Person or any violation by any Indemnitee of any Applicable Law, and (B) the sole relief provided in connection with such settlement or compromise is monetary damages that are paid in full by the Indemnitor. If the Indemnitee fails to timely give notice of such election to conduct the defense, it will be deemed to have elected not to conduct the defense of the subject Third Party Claim, and in such event the Indemnitor shall have the right, at its own cost and expense, to conduct the defense in good faith with counsel reasonably satisfactory to the Indemnitee&#59; provided that the Indemnitor (x) shall keep the Indemnitee reasonably informed regarding the status of such Third Party Claim,</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-0.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;padding-left:28.72pt">shall provide the Indemnitee the reasonable opportunity to consult with the Indemnitor regarding the defense of such claim and (z) may not settle or compromise any such Third Party Claim without the prior written consent of the Indemnitee (which consent shall not be unreasonably withheld, conditioned or delayed). The Indemnitee, its employees and agents, shall cooperate fully with the Indemnitor and its legal representative(s) in the investigation and defense of any Third Party Claim covered by this Section 9.4.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Limitation of Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. The indemnification obligations of a Party under Section 9.2 or Section 9.3 and the liability of a Party for all damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">whatsoever arising out of or related to this Agreement and the instruments and agreements contemplated hereby and the transactions contemplated hereby and thereby shall be limited as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:129%;padding-left:23.72pt">Insurance. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">A Party shall not be liable to the extent an Indemnitee or the other Party receives payment from any insurer or other Third Party,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:129%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">but only with respect to amounts actually received from such insurer or other Third Party. The Indemnitor shall remain liable for the balance of any Damages unpaid to the Indemnitee or the other Party.</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:129%;padding-left:21.22pt">Negligence, Illegal Act or Willful Misconduct. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">A Party shall not be liable to the extent that the other Party, its Affiliates or any of their</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:129%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">respective officers, directors, employees, agents, successors and assigns caused, by the illegal conduct, gross negligence or willful misconduct, the Damages.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:126%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">. Buyer and Seller shall each maintain a commercial general liability insurance policy or policies to protect against potential liabilities and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">risk arising out of this Agreement and are as are appropriate to cover the Parties&#8217; respective indemnification obligations hereunder. Upon request, each Party shall provide certificates of insurance to the other evidencing the coverage specifies herein. Neither Party&#8217;s liability to the other is in any way limited to the extent of its insurance coverage.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">9.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline">Limitations on Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">. Notwithstanding anything to the contrary herein, (i) Seller shall not have any liability under Section 9.2 for any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">individual item (or series of related items) where the Damages relating thereto until the aggregate damages related thereto meet or exceed &#91;****&#93; United States dollars ($&#91;****&#93;) provided that once the Damages equal or exceed &#91;****&#93; United States dollars ($&#91;****&#93;), the Seller shall be liable for all Damages from the first dollar and (ii) Seller&#8217;s aggregate liability under Section 9.2(i) (other than for breaches of Fundamental Representations or Core Representations, or for claims related to fraud, gross negligence or willful misconduct) shall in no event exceed, on a cumulative basis, &#91;****&#93; percent (&#91;****&#93;%) of the Aggregate Consideration (as determined from time to time). Notwithstanding anything to the contrary herein, (a) Buyer shall not have any liability under Section 9.3 for any individual item (or series of related items) where the Damages relating thereto until the aggregate damages related thereto meet or exceed &#91;****&#93; United States dollars ($&#91;****&#93;) provided that once the Damages equal or exceed &#91;****&#93; United States dollars ($&#91;****&#93;), the Buyer shall be liable for all Damages from the first dollar and (b) Buyer&#8217;s aggregate liability under Section 9.3(i) (other than for breaches of Fundamental Representations or Core Representations, or for claims related to fraud, gross negligence or willful misconduct) shall in no event exceed, on a cumulative basis, &#91;****&#93; percent (&#91;****&#93;%) of the Aggregate Consideration (as determined from time to time). For purposes of this Section 9.7, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:122%">Aggregate Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">&#8221; means, as determined from time to time, the sum of each of the following amounts&#58; (A) the &#91;****&#93;, (B) the &#91;****&#93;&#59; (C) &#91;****&#93; paid to Seller in accordance with Section &#91;****&#93;&#59; (D) the &#91;****&#93;&#59; (E) &#91;****&#93; paid to Seller in accordance with Section &#91;****&#93;&#59; (F) the aggregate amount of &#91;****&#93;, including consideration due to &#91;****&#93; in connection with the consummation of the transactions contemplated under this Agreement. Nothing in this Section 9.7 is intended to, nor shall it, limit Seller&#8217;s liability under Sections 9.2(ii) or 9.2(iii) or Buyer&#8217;s liability under Section 9.3(ii) or 9.3(iii).</font></div><div style="padding-left:33pt;text-align:justify;text-indent:-32.35pt"><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">9.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:126%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline">Cap on Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">. Except for claims involving fraud, gross negligence or willful misconduct and for Seller&#8217;s indemnification obligations pursuant to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">Section 9.2 or Buyer&#8217;s indemnification obligations pursuant to Section 9.3, each Party&#8217;s aggregate liability under this Agreement (including </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">negligence) shall not exceed the aggregate amounts actually paid (and, with respect to Buyer&#8217;s liability hereunder, payable) by Buyer to Seller pursuant to Sections 3.1 through 3.5.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">9.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Set-Off</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. To the extent that any amount would have been payable to Buyer under Section 9.2 but for the &#8220;Aggregate Consideration&#8221; limitations set</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">forth in Section 9.7, Buyer shall be entitled to set off such unpaid amount against the BLA Approval Milestone payment subject to the following conditions&#58;</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:22.23pt">the amount set off shall have been (i) agreed to by Seller or (ii) determined by an arbitrator, a court of competent jurisdiction or a Third Party mediator appointed by the Parties to make such determination&#59; and</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:21.72pt">the amount set-off shall not exceed the cap on damages under Section 9.7 after calculating the &#8220;Aggregate Consideration&#8221; under Section 9.7 with the inclusion of the payment of the BLA Approval Milestone payment.</font></div><div><font><br></font></div><div style="padding-left:14pt;text-indent:-13.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;padding-left:2.35pt">NOTICES</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:131%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:131%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:131%">Save as otherwise provided in this Agreement, any notice, demand or other communication (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:131%">&#8220;Notice&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:131%">) to be given by either Party under, or in connection with, this Agreement shall be in writing and signed by, on behalf of, the Party giving it. Any Notice shall be served by sending it by email to the address set out in Section 10.2, and&#47;or delivering it by registered mail or courier to the address set out in Section 10.2 and in each case marked for the attention of the relevant Party set out in Section 10.2 (or as otherwise notified from time to time in accordance with the provisions of Section</font></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3). Any Notice so served by email and&#47;or registered mail or courier shall be deemed to have been duly given or made as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:23.72pt">if sent by email, upon acknowledgment of receipt&#59; or</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:21.22pt">in the case of delivery by registered mail, within five (5) Business Days from the date of dispatch&#59; or</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;padding-left:18.72pt">in the case of delivery by nationally recognized overnight courier service, within one (1) Business Day from date of dispatch, provided that in each case where delivery by registered mail or courier occurs after 6pm on a Business Day or on a day which is not a Business Day, service shall be deemed to occur at 9am on the next following Business Day.</font></div><div><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">The addressees of the Parties for the purpose of Section 10.1 are as follows&#58;</font></div><div style="padding-left:33pt"><font><br></font></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buyer</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.843%"><div><font><br></font></div><div style="padding-left:65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Address&#58;</font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:6.313%;min-width:5.313%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.844%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provention Bio, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Email&#58; apalmer&#64;provention.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attention&#58; Ashleigh Palmer</font></div><div><font><br></font></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_16"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><font><br></font></div><div style="padding-left:59pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">With a copy to counsel, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> such copy shall not constitute notice to Buyer&#58;</font></div><div><font><br></font></div><div style="padding-left:33pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.164%"><tr><td style="width:1.0%"></td><td style="width:7.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.649%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lowenstein Sandler LLP</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1251 Avenue of the Americas</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:108%">17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.42pt;font-weight:400;line-height:108%;position:relative;top:-5.07pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:108%"> Floor</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New York, NY 10020</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Email&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">mlerner&#64;lowenstein.com&#59;</font></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">hweinstein&#64;lowenstein.com</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attention&#58; Michael Lerner&#59;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt 2px 46pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Herschel Weinstein</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ii)</font></td><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Seller</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Address&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MacroGenics, Inc.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9704 Medical Centre Drive</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rockville, MD 20850,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Email&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attention&#58; CEO</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">with copies to&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MacroGenics, Inc.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9704 Medical Center Drive</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rockville, MD 20850</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attention&#58; General Counsel</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:33pt;padding-right:1pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:136%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">A Party may notify the other Party of a change to its name, relevant addressee, address or email address for the purposes of this Article 10, provided that such notice shall only be effective on&#58;</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:23.72pt">the date specified in the notification as the date on which the change is to take place&#59; or</font></div><div><font><br></font></div><div style="padding-left:65pt;text-indent:-32.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:21.22pt">if no date is specified or the date is less than five (5) Business Days after the date on which notice is given, the date following five (5) Business Days after notice of any change has been given.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:136%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">In providing service it shall be sufficient to prove that the envelope containing such Notice was properly addressed and delivered to the address shown thereon or that the facsimile transmission was made and a facsimile confirmation report was received, as the case may be.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11. MISCELLANEOUS</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">. This Agreement, including all the Exhibits, sets forth the entire understanding of the Parties with respect to the subject matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">hereof and cancels and supersedes all previous communications, representations or understandings, and agreements, whether oral or written, between the Parties relating to the subject matter hereof including the Prior Confidentiality Agreement. Information disclosed under the Prior Confidentiality Agreement shall be deemed to be Confidential Information disclosed under this Agreement and subject to the same obligations of confidentiality and use as other Confidential Information disclosed hereunder.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:136%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">. No modification or amendment of any provision of this Agreement shall be valid or effective unless made in writing and signed by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">duly authorized officers of each Party.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">. Neither Party may assign, transfer, charge or otherwise encumber this Agreement or any right, benefit or interest under it, nor transfer it</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">without the prior written consent of the other Party provided that a Party may assign this Agreement to any Affiliate or to any successor in interest by way of merger, acquisition or sale of all or substantially all of its assets to which this Agreement relates, provided that such successor agrees in writing to be bound by the terms of this Agreement as if it were the assigning Party. Each Party agrees that, notwithstanding any provisions of this Agreement to the contrary, if this Agreement is assigned by a Party in connection with a merger, acquisition or sale of all or substantially all of its assets, such assignment shall not provide the non-assigning Party with rights or access to any intellectual property or technology of the acquirer of the assigning Party beyond that which is specifically contemplated in this Agreement. This Agreement shall be binding upon the successors and permitted assigns of the Parties. Any assignment not in accordance with this Section 11.3 shall be void.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:126%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">. This Agreement shall be governed by and construed under the laws of the State of Delaware, without regard to conflict of law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">principles. The provisions of the United Nations Convention on Contracts for the International Sale of Goods the 1974 Convention on the Limitation Period in the International Sale of Goods, as amended by that certain Protocol, done at Vienna on April 11, 1980 shall not apply to the Transaction Agreements or any subject matter hereof or thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:126%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">. If any of the provisions of this Agreement are held to be void or unenforceable by a court of competent jurisdiction, then such void or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">unenforceable provisions shall be replaced by valid and enforceable provisions which will achieve as far as possible the economic business intentions of the Parties. However, the remainder of this Agreement will remain in full force and effect, provided that the material interests of the Parties are not affected i.e., the Parties would presumably have concluded this Agreement without the unenforceable provisions.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">11.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:126%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">. A waiver of any default, breach or non-compliance under this Agreement is not effective unless signed by the Party granting such waiver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">No waiver will be inferred from or implied by any failure to act or delay in acting by a Party in respect of any default, breach, non-observance or by anything done or omitted to be done by the other Party. The waiver by a Party of any default, breach or non-compliance under this Agreement will not operate as a waiver of that Party&#8217;s rights under this Agreement in respect of any continuing or subsequent default, breach or non-compliance.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">11.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline">Damages Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">. EXCEPT WITH RESPECT TO THEIR RESPECTIVE INDEMNIFICATION OBLIGATIONS UNDER SECTIONS 9.2 AND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">9.3 OF THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY UNDER OR WITH RESPECT TO THIS AGREEMENT, OR ANY OTHER AGREEMENT OR INSTRUMENT CONTEMPLATED HEREBY, FOR ANY INDIRECT, INCIDENTAL, EXEMPLARY, SPECIAL, OR CONSEQUENTIAL DAMAGES, INCLUDING BUT NOT LIMITED TO LOSS OF PROFITS OR BUSINESS INTERRUPTION, OR PUNITIVE DAMAGES.</font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font><br></font></div><div style="padding-left:33pt;padding-right:1pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">11.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:136%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">. Except as otherwise provided in this Agreement, each Party hereto shall pay its own expenses and costs incidental to the preparation of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">this Agreement and to the consummation of the transactions contemplated hereby, including the fees for any business, legal or regulatory counsel.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">11.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;text-decoration:underline">Relationship of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">. Neither Party shall be deemed an agent or representative of the other Party for any purpose, and this Agreement shall not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">create or establish an agency. Except as may be specifically provided herein, neither Party shall have any right, power, or authority, nor shall they represent themselves as having authority to assume, create or incur any expense, liability or obligation, express or implied, on behalf of the other Party, or otherwise act as an agent for the other Party for any purpose. This Agreement does not, is not intended to, and shall not be construed to, establish or create an employment, agency, partnership, joint venture or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party.</font></div><div><font><br></font></div><div style="padding-left:33pt;padding-right:1pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">11.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:136%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline">No Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">. This Agreement is neither expressly nor impliedly made for the benefit of any entity other than the Parties, and neither</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">any Third Party nor any Affiliate shall have any claim against either Party on the basis of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">11.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:136%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">. This Agreement has been drafted in the English language, and the English language shall control its interpretation. Any translation shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">be for convenience purposes only and shall not be legally binding.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">11.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. The Parties agree that the terms and conditions of this Agreement are the result of negotiations between the Parties and that this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">Agreement shall not be construed in favour of or against either Party by reason of the extent to which such a Party participated in the drafting of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">11.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:136%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline">Descriptive Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">. The descriptive headings of this Agreement are for convenience only and shall be of no force or effect in construing or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">interpreting any of the provisions of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:33pt;text-indent:-32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">11.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. The Parties shall execute this Agreement in two (2) counterparts, either of which the Parties shall deem an original, but which together</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">shall constitute one and the same instrument. Counterparts may be signed and delivered by facsimile or PDF file, each of which shall be binding when received by the applicable Party.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_19"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">the Parties have caused this Agreement to be executed by their duly authorized representatives as of the Closing Date.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PROVENTION BIO, INC.&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MACROGENICS, INC.&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; Ashleigh Palmer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; Scott Koenig</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ashleigh Palmer</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scott Koenig, M.D. Ph.D.</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title&#58;  President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title&#58;  President and Chief Executive Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:0 1pt"><div style="padding-right:19.5pt;text-align:right"><font><br></font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_22"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.027%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibits&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:1pt"><td colspan="3" style="background-color:#000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 1&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Teplizumab</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 2&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product Patents&#59; Program IP</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 3&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assumed Contracts</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 4&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development Plan</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 5&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disclosure Schedules</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 6&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bill of Sale and General Assignment Agreement</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 7&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patent Assignment Agreement</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 8&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transferred Materials. Transferrable Books and Records and INDs and CTAs</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 9&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Transfer Letter</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 10&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Warrant</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 11&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Press Release</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit 12&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Lock-Up Agreement</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 237pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_25"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Teplizumab</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">Teplizumab (MGA031), a recombinant, humanized, FcR non-binding, anti-CD3 monoclonal antibody described in IND# &#91;****&#93;. Secretion Signal Sequence </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline">double underlined</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%"> in lowercase letters.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amino Acid Sequence&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Light Chain</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Heavy Chain</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_28"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.824%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.745%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:66.5pt;padding-right:66.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 2</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:66.5pt;padding-right:66.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product Patents</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Country</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent &#47; Publication No.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Serial No.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="9" style="padding:2px 1pt 2px 86pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="9" style="padding:2px 1pt 2px 86pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="9" style="padding:2px 1pt 2px 86pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="9" style="padding:2px 1pt 2px 86pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="9" style="padding:2px 1pt 2px 86pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="9" style="padding:2px 1pt 2px 86pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="9" style="padding:2px 1pt 2px 86pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_31"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-right:-30pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 3</font></div><div><font><br></font></div><div style="padding-right:187.95pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assumed Contracts</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div><div><font><br></font></div><div style="padding-left:281pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_34"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-right:-30pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 4</font></div><div><font><br></font></div><div style="padding-right:-30pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Development Plan</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Treatment for patients with recent-onset T1D to preserve beta-cell function and insulin secretion</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div><div><font><br></font></div><div style="padding-left:281pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_37"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-right:-30.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 5</font></div><div><font><br></font></div><div style="padding-right:184.95pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Disclosure Schedules</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div><div><font><br></font></div><div style="padding-left:281pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_40"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-right:-0.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 6</font></div><div><font><br></font></div><div style="padding-right:-0.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bill of Sale and General Assignment Agreement</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">BILL OF SALE AND GENERAL ASSIGNMENT AGREEMENT</font></div><div><font><br></font></div><div style="text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">This Bill of Sale and General Assignment Agreement (this &#8220;Agreement&#8221;) is made and entered into effective as of the ___ day of May, 2018 (the &#8220;Effective Date&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:126%">PROVENTION BIO, INC.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%"> a Delaware corporation, having its principal place of business at (hereinafter &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:126%">Provention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:126%">MACROGENICS, INC.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%"> a Delaware corporation having its principal place of business at 9704 Medical Center Drive, Rockville, MD 20850 (hereinafter </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:126%">&#8220;MacroGenics&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">).</font></div><div><font><br></font></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MacroGenics and Provention are parties to that certain Asset Purchase Agreement, dated as of May ____, 2018 (the &#8220;Asset Purchase</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement&#8221;).</font></div><div><font><br></font></div><div style="text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">in connection with the consummation of the transactions contemplated by the Asset Purchase Agreement, (i) MacroGenics shall sell,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">transfer, convey and assign to Provention all of MacroGenics&#8217; right, title, and interest in and to the Purchased Assets, and Provention shall purchase from MacroGenics all of MacroGenics&#8217; right, title, and interest in and to the Purchased Assets, and (ii) MacroGenics shall assign to Provention and Provention has agreed to assume all of the Assumed Liabilities, each to be effective as of the Closing Date, subject to the terms and conditions of the Asset Purchase Agreement.</font></div><div><font><br></font></div><div style="padding-right:1pt;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">legally bound, MacroGenics and Provention (each a &#8220;Party&#8221; and collectively, the &#8220;Parties&#8221;) agree as follows&#58;</font></div><div><font><br></font></div><div style="text-indent:32.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;padding-left:32.45pt;text-decoration:underline">Sale, Assignment, and Assumption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">. To be effective as of the Closing Date, and pursuant to the terms and subject to the conditions of the Asset Purchase Agreement, MacroGenics (i) sells, transfers, conveys and assigns to Provention all of MacroGenics&#8217; right, title, and interest in and to the Purchased Assets and (ii) assigns the Assumed Liabilities to Provention. Provention (x) accepts such sale, transfer, conveyance and assignment of MacroGenics&#8217; right, title, and interest in and to the Purchased Assets, and (y) assumes and agrees to pay, perform and discharge as and when due, as applicable, all of the Assumed Liabilities.</font></div><div><font><br></font></div><div style="text-indent:32.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;padding-left:32.45pt;text-decoration:underline">Terms of the Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">. Nothing contained in this Agreement shall be deemed to modify, limit, expand, supersede, or amend any rights or obligations of MacroGenics or Provention under the Asset Purchase Agreement. This Agreement is intended only to effect the sale, assignment, transfer and conveyance of the Purchased Assets to Provention by MacroGenics and assumption of the Assumed Liabilities by Provention, all in accordance with the terms and conditions of the Asset Purchase Agreement. To the extent any conflict arises between any of the terms and provisions of this Agreement and any of the terms and provisions of the Asset Purchase Agreement, the terms and provisions of the Asset Purchase Agreement shall govern and control.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_43"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-indent:32.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:32.45pt;text-decoration:underline">No Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">. Nothing herein expressed or implied is intended to confer upon any person, other than the Parties and their respective successors and assigns, any rights, remedies, obligations, or liabilities.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:32.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;padding-left:32.45pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">. This Agreement, together with the Asset Purchase Agreement (and the schedules and exhibits thereto) and the other documents executed in connection therewith, sets forth the entire agreement between the Parties with respect to the subject matter hereof, and cancels or supersedes all previous communications, representations, understandings, agreements, and arrangements between the Parties, written or oral, to the extent they relate in any way to the subject matter hereof.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:32.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;padding-left:32.45pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">. Any term or provision of this Agreement that is invalid or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Agreement or affecting the validity or enforceability of any of the terms or provisions of this Agreement in any other jurisdiction. If any provision of this Agreement is so broad as to be unenforceable, such provision shall be interpreted to be only so broad as is enforceable.</font></div><div><font><br></font></div><div style="text-indent:32.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:32.45pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">. This Agreement shall be governed by and construed in accordance with the substantive law of the State of Delaware without regard to conflict of law principles.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:32.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;padding-left:32.45pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">. This Agreement may be executed in multiple counterparts, each of which shall be an original, but all of which together shall constitute one and the same agreement. This Agreement, any and all agreements and instruments executed and delivered in accordance herewith, along with any amendments hereto or thereto, to the extent signed and delivered by means of a facsimile machine or email delivery of a &#8220;.pdf&#8221; or similar format data file, shall be treated in all manner and respects and for all purposes as an original signature, agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. No Party hereto shall raise the use of a facsimile machine or e-mail delivery of a &#8220;.pdf&#8221; or similar format data file to deliver a signature to this Agreement or any amendment hereto or the fact that such signature was transmitted or communicated through the use of a facsimile machine or e-mail delivery of a &#8220;.pdf&#8221; or similar format data file as a defense to the formation or enforceability of a contract and each Party hereto forever waives any such defense.</font></div><div><font><br></font></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment and Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. This Agreement may be amended by the Parties at any time only by a written instrument signed by each of the</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Parties.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_46"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, each of the Parties is signing this Agreement as of the Effective Date.</font></div><div><font><br></font></div><div style="padding-left:253pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">MACROGENICS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#58;</font></div><div><font><br></font></div><div style="padding-left:253pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MacroGenics, Inc.</font></div><div><font><br></font></div><div style="padding-left:253pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></div><div><font><br></font></div><div style="padding-left:253pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:253pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title&#58;</font></div><div><font><br></font></div><div style="padding-left:253pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">PROVENTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#58;</font></div><div><font><br></font></div><div style="padding-left:253pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provention Bio, Inc.</font></div><div><font><br></font></div><div style="padding-left:253pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></div><div><font><br></font></div><div style="padding-left:253pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:253pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title&#58;</font></div><div><font><br></font></div><div style="padding-left:248pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_49"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 7</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Assignment Agreement</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">PATENT ASSIGNMENT AGREEMENT</font></div><div><font><br></font></div><div style="padding-left:65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This Patent Assignment Agreement (this &#8220;Agreement&#8221;) is made and entered into effective as of the ____ day of May, 2018 (the &#8220;Effective</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Date&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:123%">PROVENTION BIO, INC.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%"> a Delaware Corporation, having its principal place of business at (hereinafter &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:123%">Provention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:123%">MACROGENICS, INC., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">a Delaware corporation having its principal place of business at 9704 Medical Center Drive, Rockville, MD 20850 (hereinafter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:123%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:123%">MacroGenics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">&#8221;).</font></div><div><font><br></font></div><div style="padding-left:65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MacroGenics and Provention are parties to that certain Asset Purchase Agreement, dated as of May ____, 2018 pursuant to</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">which MacroGenics shall transfer, convey, assign and deliver to Provention all of MacroGenics&#8217; rights, title and interests in all patent applications and issued patents that are identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%"> attached hereto, or claim priority to any patent application listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%"> (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:123%">Assigned</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:123%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">&#8221;).</font></div><div><font><br></font></div><div style="text-indent:64.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:138%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:138%">to be legally bound, MacroGenics and Provention (each a &#8220;Party&#8221; and collectively, the &#8220;Parties&#8221;) agree as follows&#58;</font></div><div><font><br></font></div><div style="text-indent:65.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;text-decoration:underline">Patent Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">. MacroGenics hereby conveys, transfers, and assigns to Provention, its successors and assigns, MacroGenics&#8217; entire right, title and interest for the United States, its territories and possession, and all foreign countries in and to the Assigned Patents and all rights, claims and privileges pertaining thereto, including without limitation, all inventions and discoveries disclosed therein, certificates of invention and applications for certificates of invention, and any substitutions, reissues, reexaminations, divisions, renewals, extensions, provisionals, continuations, continuations-in-part, continued prosecution applications, and corresponding foreign patents and patent applications and foreign counterparts thereof, and any and all rights to sue and recover for claims and remedies against and collect damages and other recoveries for past, present and future infringements of any or all of the foregoing, and rights for priority and protection of interests therein under the laws of any jurisdiction and hereby grants to Provention the right to apply, obtain and hold in its own name for patents or inventor&#8217;s certificates and related rights heretofore or hereafter filed in any and all countries, including, without limitation, the right to prosecute and maintain the same and all rights to claim priority based thereon, all patents granted thereon and all reissues, extensions and renewals thereof.</font></div><div><font><br></font></div><div style="text-indent:65.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. MacroGenics authorizes and requests the Commissioner of Patents and Trademarks of the United States, and any other official throughout the world whose duty is to register and record ownership in patent registrations and applications for registration of patents, to record Provention as the assignee and owner of any and all right in the Assigned Patents.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_52"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-indent:65.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">. This Assignment will be binding upon and inure to the benefit of the Parties hereto and their respective successors and permitted assigns, each of which such successors and permitted assigns will be deemed to be a Party hereto for all purposes hereof. This Assignment and any of the terms contained herein may be amended or modified by MacroGenics and Provention only in writing. This Assignment is executed by, and shall be binding upon, MacroGenics and Provention and their respective successors and assigns, for the uses and purposes set forth and referred to above, effective immediately upon its delivery to Provention. This Assignment shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to conflict of law principles. This Agreement may be executed in multiple counterparts, each of which shall be an original, but all of which together shall constitute one and the same agreement. This Agreement, any and all agreements and instruments executed and delivered in accordance herewith, along with any amendments hereto or thereto, to the extent signed and delivered by means of a facsimile machine or email delivery of a &#8220;.pdf&#8221; or similar format data file, shall be treated in all manner and respects and for all purposes as an original signature, agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. No Party hereto shall raise the use of a facsimile machine or email delivery of a &#8220;.pdf&#8221; or similar format data file to deliver a signature to this Agreement or any amendment hereto or the fact that such signature was transmitted or communicated through the use of a facsimile machine or e-mail delivery of a &#8220;.pdf&#8221; or similar format date file as a defense to the formation or enforceability of a contract and each Party hereto forever waives any such defense.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_55"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, each of the Parties is signing this Agreement as of the Effective Date.</font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">MACROGENICS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#58;</font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MacroGenics, Inc.</font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:10.5pt;padding-right:10.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:10.5pt;padding-right:10.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">STATE OF ______________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#125;</font></div><div><font><br></font></div><div style="padding-left:258pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#125;ss&#58;</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.843%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">COUNTY OF __________</font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:6.313%;min-width:5.313%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.844%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#125;</font></div><div><font><br></font></div></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On&#160;&#160;&#160;&#160;the&#160;&#160;&#160;&#160;________&#160;&#160;&#160;&#160;day&#160;&#160;&#160;&#160;of&#160;&#160;&#160;&#160;_____________&#160;&#160;&#160;&#160;in&#160;&#160;&#160;&#160;the&#160;&#160;&#160;&#160;year&#160;&#160;&#160;&#160;20____,&#160;&#160;&#160;&#160;before&#160;&#160;&#160;&#160;me,&#160;&#160;&#160;&#160;the&#160;&#160;&#160;&#160;undersigned,&#160;&#160;&#160;&#160;personally&#160;&#160;&#160;&#160;appeared</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_58"></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">______________________________________, personally known to me or proved to me on the basis of satisfactory evidence to be the individual(s) whose</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">name(s) is (are) subscribed to the within instrument and acknowledged to me that he&#47;she&#47;they executed the same in his&#47;her&#47;their capacity(ies), and that by his&#47;her&#47;their signature(s) on the instrument, the individual(s), or the person upon behalf of which the individual(s) acted, executed the instrument.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notary Public, State of _________________</font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Printed Name&#58;</font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commission #&#58;</font></div><div><font><br></font></div><div style="padding-right:-0.47pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_61"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">PROVENTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#58;</font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Provention Bio, Inc.</font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:10.5pt;padding-right:10.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">STATE OF ______________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#125;</font></div><div><font><br></font></div><div style="padding-left:258pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#125;ss&#58;</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.843%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">COUNTY OF __________</font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:6.313%;min-width:5.313%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.844%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#125;</font></div><div><font><br></font></div></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On&#160;&#160;&#160;&#160;the&#160;&#160;&#160;&#160;________&#160;&#160;&#160;&#160;day&#160;&#160;&#160;&#160;of&#160;&#160;&#160;&#160;_____________&#160;&#160;&#160;&#160;in&#160;&#160;&#160;&#160;the&#160;&#160;&#160;&#160;year&#160;&#160;&#160;&#160;20____,&#160;&#160;&#160;&#160;before&#160;&#160;&#160;&#160;me,&#160;&#160;&#160;&#160;the&#160;&#160;&#160;&#160;undersigned,&#160;&#160;&#160;&#160;personally&#160;&#160;&#160;&#160;appeared</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_64"></div><hr style="page-break-after:always"><div style="min-height:33.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">______________________________________, personally known to me or proved to me on the basis of satisfactory evidence to be the individual(s) whose</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">name(s) is (are) subscribed to the within instrument and acknowledged to me that he&#47;she&#47;they executed the same in his&#47;her&#47;their capacity(ies), and that by his&#47;her&#47;their signature(s) on the instrument, the individual(s), or the person upon behalf of which the individual(s) acted, executed the instrument.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notary Public, State of _________________</font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Printed Name&#58;</font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commission #&#58;</font></div><div><font><br></font></div><div style="padding-right:-0.47pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_67"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.910%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:52pt;padding-right:52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Schedule A</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Country</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent &#47; Publication No.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Serial No.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:0 1pt"><div style="padding-right:8pt;text-align:right"><font><br></font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_70"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-right:-0.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 8</font></div><div><font><br></font></div><div style="padding-right:-0.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Transferred Documentation and Biological and Chemical Materials and Reagents</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">The items on this list are anticipated to be transferred by the Seller as soon as practicable using Commercially Reasonable Efforts during the Transition Period. Items that are not transferred during the Transition Period shall be transferred by the Seller during the remainder of the eighteen (18) months after the Effective Date using Commercially Reasonable Efforts to the extent available and feasible. Electronic documentation shall be transferred in formats to be mutually agreed upon by both Parties.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Documentation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div><div><font><br></font></div><div style="padding-right:-0.47pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_73"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 9</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Form of Transfer Letter</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div><div><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.632%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">ATTN&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div></div><div style="display:inline-block;max-width:4.734%;min-width:3.734%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.634%"></div></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:109%">RE&#58;&#160;&#160;&#160;&#160;Transfer of IND Ownership and Notification of New Regulatory </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:109%">Contact </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:109%">IND No. &#91;****&#93; SEQ No.&#58; XXXX</font></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Teplizumab (MGA031), Humanized Anti-Human CD3 Monoclonal Antibody</font></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_76"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.509%"><div><font><br></font></div></div><div style="display:inline-block;max-width:2.981%;min-width:1.981%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.510%"></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dear Dr. &#91;****&#93; &#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">Reference is made to IND &#91;****&#93; and IND &#91;****&#93; for teplizumab, Humanized Anti-Human CD3 Monoclonal Antibody. IND &#91;****&#93; is active to evaluate teplizumab in the treatment of people with recent-onset Type 1 Diabetes Mellitus (T1DM). IND &#91;****&#93; is active to evaluate teplizumab in the prevention&#47;delay of diagnosis of T1DM in people at risk for developing T1DM. A similar letter is being submitted to IND &#91;****&#93;.</font></div><div><font><br></font></div><div style="padding-right:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">As of &#60;insert date&#62; , Provention Bio, &#60;insert address&#62; has acquired the worldwide development and commercialization rights to teplizumab from MacroGenics, Inc., 9640 Medical Center Drive, Rockville, MD 20850 USA.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">On behalf of MacroGenics, I am authorizing the Food and Drug Administration to transfer ownership and responsibility for IND &#91;****&#93; effective as of &#60;insert date&#62; to&#58;</font></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provention Bio</font></div><div><font><br></font></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#60;insert date&#62;</font></div><div><font><br></font></div><div style="padding-right:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">A complete copy of the IND, including all correspondence from the Agency, has been provided to Provention Bio and upon their acceptance of this IND, all future correspondence regarding this IND should be addressed to Provention Bio. The Regulatory contact for Provention Bio is&#58;</font></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#60;insert Provention Bio&#8217;s Regulatory Authorized Sponsor&#62;</font></div><div><font><br></font></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#60;insert address, phone number and email address&#62;</font></div><div><font><br></font></div><div style="padding-right:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">Provention Bio will submit a letter of acknowledgement and acceptance of the IND transfer and regulatory responsibilities under a separate correspondence to the Division.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">If you have any questions regarding this submission, please do not hesitate to contact me at &#91;****&#93;, or you may contact &#91;****&#93;. Please contact &#91;****&#93; for electronic submission-related questions. Thank you.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sincerely,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">&#91;See appended electronic signature page.&#93;</font></div><div><font><br></font></div><div style="padding-right:-0.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;****&#93;</font></div><div><font><br></font></div><div style="padding-right:-0.47pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_79"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form of Warrant</font></div><div><font><br></font></div><div style="padding-left:483pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Warrant Number ____</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:123%">THE WARRANT REPRESENTED BY THIS CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;) OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) SUCH TRANSACTION IS MADE PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER THE SECURITIES ACT AND THE APPLICABLE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OR (2) THE COMPANY IS PROVIDED WITH AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY, STATING THAT SUCH TRANSACTION IS IN COMPLIANCE WITH EXEMPTIONS FROM REGISTRATION UNDER THE SECURITIES ACT AND SUCH OTHER APPLICABLE LAWS. NO TRANSFER OF ANY INTEREST IN THIS WARRANT OR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY BE EFFECTED WITHOUT FIRST SURRENDERING THIS WARRANT OR SUCH SECURITIES, AS THE CASE MAY BE, TO THE COMPANY OR ITS TRANSFER AGENT, IF ANY.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant to Purchase</font></div><div><font><br></font></div><div style="padding-right:-0.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares of</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As Herein Described</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May __, 2018</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WARRANT TO PURCHASE COMMON STOCK OF</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PROVENTION BIO, INC.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:30.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">This is to certify that, for value received, MacroGenics, Inc., or a proper assignee (the &#8220;Holder&#8221;), is entitled to purchase up to 2,162,389 shares (&#8220;Warrant Shares&#8221;) of common stock, $0.0001 par value per share (the &#8220;Common Stock&#8221;), of Provention Bio, Inc., a Delaware corporation (the &#8220;Company&#8221;), subject to the provisions of this Warrant. This Warrant shall be exercisable at Two Dollars and Fifty Cents ($2.50) per share (the &#8220;Exercise Price&#8221;). This Warrant also is subject to the following terms and conditions&#58;</font></div><div><font><br></font></div><div style="padding-left:42pt;text-indent:-8.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:2pt;text-decoration:underline">Exercise and Payment&#59; Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:93.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;padding-left:4.08pt">This Warrant may be exercised in whole or in part at any time from and after the date hereof (the &#8220;Commencement Date&#8221;) through the close of business on May __, 2025 (the &#8220;Expiration Date&#8221;), at which time this Warrant shall expire and become void, but if such date is a day on which federal or state chartered banking institutions located in the State of New York are authorized to close, then on the next succeeding day which shall not be such a day. Exercise (&#8220;Exercise&#8221;) shall be by presentation and surrender to the Company, or at the office of any transfer agent designated by the Company (the &#8220;Transfer Agent&#8221;), of (i) this Warrant, (ii) the attached exercise form properly executed, and (iii) a certified or official bank check for the Exercise Price for the number of Warrant Shares specified in the exercise form. If this Warrant is exercised in part only, the Company or the Transfer Agent shall, upon surrender of the Warrant, execute and deliver a new Warrant evidencing the rights of the Holder to purchase the remaining number of Warrant Shares purchasable hereunder. Upon receipt by the Company of this Warrant, the properly executed exercise form, and payment as aforesaid, the Holder shall be deemed to be the holder of record of the Common Stock issuable upon such exercise, notwithstanding that the stock transfer books of the Company shall then be closed or that certificates representing such Warrant Shares shall not then be actually delivered to the Holder. Under no circumstance shall the Company be required to make any cash payments or net cash settlement to the Holder in lieu of delivery of the Warrant Shares.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_82"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-align:justify;text-indent:65.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;padding-left:32.27pt">In lieu of exercising this Warrant for cash pursuant to Section 2(a), if the fair market value of one Warrant Share is greater than the Exercise Price (at the date of calculation as set forth below), the Holder may elect to receive a number of Warrant Shares equal to the value of this Warrant (or of any portion of this Warrant being canceled) by Exercise of this Warrant, in which event the Company shall issue to the Holder that number of Warrant Shares computed using the following formula&#58;</font></div><div><font><br></font></div><div style="padding-left:223pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:26.173%"><tr><td style="width:1.0%"></td><td style="width:15.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:10.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#61;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Y (A &#8211; B)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Where&#58;</font></div><div><font><br></font></div><div style="padding-left:65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X &#61; The number of Warrant Shares to be issued to the Holder</font></div><div><font><br></font></div><div style="padding-left:98pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">Y &#61; The number of Shares purchasable under this Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being canceled (at the date of such calculation)</font></div><div><font><br></font></div><div style="padding-left:98pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A &#61; The fair market value of one Warrant Share (at the date of such calculation)</font></div><div><font><br></font></div><div style="padding-left:98pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B &#61; The Exercise Price (as adjusted to the date of such calculation)</font></div><div><font><br></font></div><div style="padding-right:-0.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For purposes of the calculation above, the fair market value of one Warrant Share shall be determined as set forth in Section 3(a) &#8211; (c) below.</font></div><div><font><br></font></div><div style="text-indent:95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:2.52pt;text-decoration:underline">Conditions to Exercise or Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">. The restrictions in Section 7 shall apply, to the extent applicable by their terms, to any exercise or exchange of this Warrant permitted by this Section 1.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;padding-left:32.9pt;text-decoration:underline">Reservation of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. The Company shall, at all times until the expiration of this Warrant, reserve for issuance and delivery upon exercise of this Warrant the number of Warrant Shares which shall be required for issuance and delivery upon exercise of this Warrant. Upon issuance, all Warrant Shares will be validly issued and outstanding, fully paid and non-assessable, and free from all taxes, liens and charges with respect to the issuance thereof.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_85"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-align:justify;text-indent:32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;padding-left:32.9pt;text-decoration:underline">Fractional Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. The Company shall not issue any fractional shares or scrip representing fractional shares upon the exercise or exchange of this Warrant. With respect to any fraction of a share resulting from the exercise or exchange hereof, the Company shall pay to the Holder an amount in cash equal to such fraction multiplied by the current fair market value per share of Common Stock, determined as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;padding-left:3.03pt">If the Common Stock is listed on a national securities exchange or admitted to unlisted trading privileges on such an exchange, the current fair market value shall be the last reported sale price of the Common Stock on such exchange on the last business day prior to the date of exercise of this Warrant or if no such sale is made on such day, the mean of the closing bid and asked prices for such day on such exchange&#59;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;padding-left:2.52pt">If the Common Stock is not so listed or admitted to unlisted trading privileges on a national securities exchange, the current fair market value shall be the mean of the last bid and asked prices reported on the last business day prior to the date of the exercise of this Warrant by the OTC Markets Group, Inc.&#59; or</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;padding-left:3.03pt">If the Common Stock is not so listed or admitted to unlisted trading privileges on a national securities exchange and bid and asked prices are not so reported, the current fair market value shall be an amount, not less than book value, determined in such reasonable manner as may be prescribed by the Company in good faith.</font></div><div><font><br></font></div><div style="text-indent:32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:32.9pt;text-decoration:underline">No Rights as Shareholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">. This Warrant shall not entitle the Holder to any rights as a shareholder of the Company, either at law or in equity. The rights of the Holder are limited to those expressed in this Warrant and are not enforceable against the Company except to the extent set forth herein.</font></div><div><font><br></font></div><div style="padding-left:41pt;text-indent:-8.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:1.9pt;text-decoration:underline">Adjustments in Number and Exercise Price of Warrant Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="text-indent:63.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">5.1 The number of shares of Common Stock for which this Warrant may be exercised and the Exercise Price therefor shall be subject to adjustment as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;padding-left:3.03pt">If the Company is recapitalized through the subdivision or combination of its outstanding shares of Common Stock into a larger or smaller number of shares, the number of Warrant Shares shall be increased or reduced, as of the record date for such recapitalization, in the same proportion as the increase or decrease in the outstanding shares of Common Stock, and the Exercise Price shall be adjusted so that the aggregate amount payable for the purchase of all of the Warrant Shares issuable hereunder immediately after the record date for such recapitalization shall equal the aggregate amount so payable immediately before such record date.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;padding-left:2.52pt">If the Company declares a dividend on Common Stock payable in Common Stock or securities convertible into Common Stock, the number of shares of Common Stock for which this Warrant may be exercised shall be increased as of the record date for determining which holders of Common Stock shall be entitled to receive such dividend, in proportion to the increase in the number of outstanding shares (and shares of Common Stock issuable upon conversion of all such securities convertible into Common Stock) of Common Stock as a result of such dividend, and the Exercise Price shall be adjusted so that the aggregate amount payable for the purchase of all the Warrant Shares issuable hereunder immediately after the record date for such dividend shall equal the aggregate amount so payable immediately before such record date.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_88"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-align:justify;text-indent:95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%;padding-left:3.03pt">If the Company distributes to holders of its Common Stock, other than as part of its dissolution or liquidation or the winding up of its affairs, any evidence of indebtedness or any of its assets (other than cash, Common Stock or securities convertible into Common Stock), the Company shall give written notice to the Holder of any such distribution at least fifteen (15) days prior to the proposed record date in order to permit the Holder to exercise this Warrant on or before the record date. There shall be no adjustment in the number of shares of Common Stock for which this Warrant may be exercised, or in the Exercise Price, by virtue of any such distribution.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;padding-left:2.52pt">If the Company offers rights or warrants to the holders of Common Stock which entitle them to subscribe to or purchase additional Common Stock or securities convertible into Common Stock, the Company shall give written notice of any such proposed offering to the Holder at least fifteen (15) days prior to the proposed record date in order to permit the Holder to exercise this Warrant on or before such record date. There shall be no adjustment in the number of shares of Common Stock for which this Warrant may be exercised, or in the Exercise Price, by virtue of any such distribution.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;padding-left:3.03pt">If the event, as a result of which an adjustment is made under paragraph (a) or (b) above, does not occur, then any adjustments in the Exercise Price or number of shares issuable that were made in accordance with such paragraph (a) or (b) shall be adjusted to the Exercise Price and number of shares as were in effect immediately prior to the record date for such event.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:63.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">5.2 In the event of any reorganization or reclassification of the outstanding shares of Common Stock (other than a change in par value or from no par value to par value, or from par value to no par value, or as a result of a subdivision or combination) or in the event of any consolidation or merger of the Company with another entity after which the Company is not the surviving entity, at any time prior to the expiration of this Warrant, upon subsequent exercise of this Warrant the Holder shall have the right to receive the same kind and number of shares of common stock and other securities, cash or other property as would have been distributed to the Holder upon such reorganization, reclassification, consolidation or merger had the Holder exercised this Warrant immediately prior to such reorganization, reclassification, consolidation or merger, appropriately adjusted for any subsequent event described in this Section 5. The Holder shall pay upon such exercise the Exercise Price that otherwise would have been payable pursuant to the terms of this Warrant. If any such reorganization, reclassification, consolidation or merger results in a cash distribution in excess of the then applicable Exercise Price, the Holder may, at the Holder&#8217;s option, exercise this Warrant without making payment of the Exercise Price, and in such case the Company shall, upon distribution to the Holder, consider the Exercise Price to have been paid in full, and in making settlement to the Holder, shall deduct an amount equal to the Exercise Price from the amount payable to the Holder.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_91"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-align:justify;text-indent:63.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">5.3 If the Company shall, at any time before the expiration of this Warrant, dissolve, liquidate or wind up its affairs, the Holder shall have the right to receive upon exercise of this Warrant, in lieu of the shares of Common Stock of the Company that the Holder otherwise would have been entitled to receive, the same kind and amount of assets as would have been issued, distributed or paid to the Holder upon any such dissolution, liquidation or winding up with respect to such Common Stock receivable upon exercise of this Warrant on the date for determining those entitled to receive any such distribution. If any such dissolution, liquidation or winding up results in any cash distribution in excess of the Exercise Price provided by this Warrant, the Holder may, at the Holder&#8217;s option, exercise this Warrant without making payment of the Exercise Price and, in such case, the Company shall, upon distribution to the Holder, consider the Exercise Price to have been paid in full and, in making settlement to the Holder, shall deduct an amount equal to the Exercise Price from the amount payable to the Holder.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;padding-left:32.9pt;text-decoration:underline">Notices to Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">. So long as this Warrant shall be outstanding (a) if the Company shall pay any dividends or make any distribution upon the Common Stock otherwise than in cash or (b) if the Company shall offer generally to the holders of Common Stock the right to subscribe to or purchase any shares of any class of Common Stock or securities convertible into Common Stock or any similar rights or (c) if there shall be any capital reorganization of the Company in which the Company is not the surviving entity, recapitalization of the capital stock of the Company, consolidation or merger of the Company with or into another corporation, sale, lease or other transfer of all or substantially all of the property and assets of the Company, or voluntary or involuntary dissolution, liquidation or winding up of the Company, then in such event, the Company shall cause to be mailed to the Holder, at least thirty (30) days prior to the relevant date described below (or such shorter period as is reasonably possible if thirty (30) days is not reasonably possible), a notice containing a description of the proposed action and stating the date or expected date on which a record of the Company&#8217;s shareholders is to be taken for the purpose of any such dividend, distribution of rights, or such reclassification, reorganization, consolidation, merger, conveyance, lease or transfer, dissolution, liquidation or winding up is to take place and the date or expected date, if any is to be fixed, as of which the holders of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities or other property deliverable upon such event.</font></div><div><font><br></font></div><div style="padding-left:41pt;text-indent:-8.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:1.9pt;text-decoration:underline">Transfer, Exercise, Exchange, Assignment or Loss of Warrant, Warrant Shares or Other Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:63.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">7.1 This Warrant may be transferred, exercised, exchanged or assigned (&#8220;transferred&#8221;), in whole or in part, subject to the following restrictions. This Warrant and the Warrant Shares or any other securities (&#8220;Other Securities&#8221;) received upon exercise of this Warrant shall be subject to restrictions on transferability until registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), unless an exemption from registration is available. Until this Warrant and the Warrant Shares or Other Securities are so registered or exempt from registration, this Warrant and any certificate for Warrant Shares or Other Securities issued or issuable upon exercise of this Warrant shall contain a legend on the face thereof, in form and substance satisfactory to counsel for the Company, stating that this Warrant, the Warrant Shares or Other Securities may not be sold, transferred or otherwise disposed of unless, in the opinion of counsel satisfactory to the Company, which may be counsel to the Company, that this Warrant, the Warrant Shares or Other Securities may be transferred without such registration. This Warrant and the Warrant Shares or Other Securities may also be subject to restrictions on transferability under applicable state securities or blue sky laws.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_94"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-align:justify;text-indent:63.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">7.2 Any transfer permitted hereunder shall be made by surrender of this Warrant to the Company or to the Transfer Agent at its offices with a duly executed request to transfer the Warrant, which shall provide adequate information to effect such transfer and shall be accompanied by funds sufficient to pay any transfer taxes applicable. The Company or Transfer Agent shall, without charge, execute and deliver a new Warrant in the name of the transferee named in such transfer request, and this Warrant promptly shall be cancelled.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:63.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">7.3 Upon receipt by the Company of evidence satisfactory to it of loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, of reasonable satisfactory indemnification, or, in the case of mutilation, upon surrender of this Warrant, the Company will execute and deliver, or instruct the Transfer Agent to execute and deliver, a new Warrant of like tenor and date, any such lost, stolen or destroyed Warrant thereupon shall become void.</font></div><div><font><br></font></div><div style="text-indent:32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:32.9pt;text-decoration:underline">Representations and Warranties of the Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">. The Holder hereby represents and warrants to the Company with respect to the issuance of the Warrant as follows&#58;</font></div><div><font><br></font></div><div style="padding-right:1pt;text-align:justify;text-indent:63.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">8.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline">Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">. The Holder understands and acknowledges that the certificate(s) evidencing the securities issued by the Company will be imprinted with a restrictive legend as referenced in Section 7.1 above.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:63.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">8.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Access to Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. The Holder has had an opportunity to discuss the Company&#8217;s business, management, and financial affairs with the Company&#8217;s management and the opportunity to review the Company&#8217;s facilities and business plans. The Holder has also had an opportunity to ask questions of officers of the Company, which questions were answered to its satisfaction.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:63.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">8.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;text-decoration:underline">Authorization.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%"> This Warrant and the agreements contemplated hereby, when executed and delivered by the Holder, will constitute a valid and legally binding obligation of the Holder, enforceable in accordance with their respective terms.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:63.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">8.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;text-decoration:underline">Brokers or Finders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">. The Company has not incurred, and will not incur, directly or indirectly, as a result of any action taken by such Holder, any liability for brokerage or finders&#8217; fees or agents&#8217; commissions or any similar charges in connection with this Warrant or any transaction contemplated hereby.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%;padding-left:32.9pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">. All notices, requests, demands or other communications hereunder shall be in writing and shall be deemed to have been duly given, if delivered in person or mailed, certified, return-receipt requested, postage prepaid to the address previously provided to the other party, or sent by fax or email (to the extent stated below). Either party hereto may from time to time, by written notice to the other party, designate a different address. If any notice or other document is sent by certified or registered mail, return receipt requested, postage prepaid, properly addressed as aforementioned, the same shall be deemed delivered seventy-two (72) hours after mailing thereof. If any notice is sent by fax or email, it will be deemed to have been delivered on the date the fax or email thereof is actually received, provided the original thereof is sent by certified mail, in the manner set forth above, within twenty-four (24) hours after the fax or email is sent.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_97"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-indent:32.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:29.4pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">. Any provision of this Warrant may be amended or the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the mutual written consent of the Company and the Holder.</font></div><div><font><br></font></div><div style="padding-left:45pt;text-indent:-13.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:2.4pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. This Warrant shall be governed by and construed in accordance with the laws of the State of New York.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature page follows.&#93;</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_100"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PROVENTION BIO, INC.</font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:286pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title&#58;</font></div><div><font><br></font></div><div style="padding-right:-0.47pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_103"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">FORM OF EXERCISE</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">To be executed upon exercise of Warrant</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(please print)</font></div><div><font><br></font></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Number _____certificate, to __________ shares of</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:121%">common stock, $0.0001 par value per share (&#8220;Common Stock&#8221;) of Provention Bio, Inc. (the &#8220;Company&#8221;) and herewith &#91;tenders payment for such shares of Common Stock to the order of the Company the amount of $&#91;&#9679;&#93; per share in accordance with the terms hereof&#47;elects to exercise this Warrant pursuant to Section 2(b) of the attached Warrant&#93;. The undersigned requests that a certificate for such shares of Common Stock be registered in the name of</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">___________________________ whose address is __________________________________________. If said number of shares of Common Stock is less</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:121%">than all of the shares of Common Stock purchasable hereunder, the undersigned requests that a new Warrant Certificate representing the remaining balance of the shares of Common Stock be registered in the name of _______________________________, whose address is</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">________________________________________,&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;that&#160;&#160;&#160;&#160;such&#160;&#160;&#160;&#160;Warrant&#160;&#160;&#160;&#160;Certificate&#160;&#160;&#160;&#160;be&#160;&#160;&#160;&#160;delivered&#160;&#160;&#160;&#160;to_______________,&#160;&#160;&#160;&#160;whose&#160;&#160;&#160;&#160;address</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">is</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">__________________________________.</font></div><div><font><br></font></div><div style="padding-left:33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Representations of the undersigned</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div style="padding-left:49pt;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:9.22pt">The undersigned acknowledges that the undersigned has received, read and understood the Warrant and agrees to abide by and be bound by its terms and conditions.</font></div><div><font><br></font></div><div style="padding-left:49pt;padding-right:1pt;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:8.71pt">(i) The undersigned has such knowledge and experience in business and financial matters that the undersigned is capable of evaluating the Company and the proposed activities thereof, and the risks and merits of this prospective investment.</font></div><div><font><br></font></div><div style="padding-left:264pt;text-indent:-7.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:4.16pt">&#93; YES &#91; &#93; NO</font></div><div><font><br></font></div><div style="padding-left:49pt;padding-right:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:9.52pt">If &#8220;No&#8221;, the undersigned is represented by a &#8220;purchaser representative,&#8221; as that term is defined in the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Regulation D thereunder.</font></div><div><font><br></font></div><div style="padding-left:264pt;text-indent:-7.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:4.16pt">&#93; YES &#91; &#93; NO</font></div><div><font><br></font></div><div style="padding-left:49pt;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:9.22pt">(i) The undersigned is an &#8220;accredited investor,&#8221; as that term is defined in the Securities Act and Rule 501 of Regulation D thereunder.</font></div><div><font><br></font></div><div style="padding-left:265pt;text-indent:-8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:5.01pt">&#93; YES &#91; &#93; NO</font></div><div><font><br></font></div><div style="padding-left:62pt;text-indent:-13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:4.52pt">If &#8220;Yes,&#8221; the undersigned comes within the following category of that definition (check one and complete the blanks as applicable)&#58;</font></div><div><font><br></font></div><div style="padding-left:81pt;text-indent:-15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%;padding-left:12.76pt">&#93; 1. The undersigned is a natural person whose present net worth (or whose joint net worth with his or her spouse), excluding the value of the undersigned&#8217;s primary residence, exceeds $1,000,000. For purposes of calculating the undersigned&#8217;s present net worth, the undersigned has included the following as liabilities&#58; (i) any indebtedness that is secured by the undersigned&#8217;s primary residence in excess of the estimated fair market value of the undersigned&#8217;s primary residence at the time of the sale of the shares, and (ii) any incremental debt secured by the undersigned&#8217;s primary residence that was incurred in the 60 days before the sale of the shares, other than as a result of the acquisition of the undersigned&#8217;s primary residence.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_106"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="padding-left:81pt;text-indent:-15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;padding-left:12.76pt">&#93; 2. The undersigned is a natural person who had individual income in excess of $200,000 in each of the last two years or joint income with the undersigned&#8217;s spouse in excess of $300,000 during such two years, and the undersigned reasonably expects to have the same income level in the current year.</font></div><div><font><br></font></div><div style="padding-left:65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91; &#93; 3. The undersigned is an officer or director of the Company.</font></div><div><font><br></font></div><div style="padding-left:81pt;text-indent:-15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:12.76pt">&#93; 4. The undersigned is a corporation or partnership not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000.</font></div><div><font><br></font></div><div style="padding-left:81pt;text-indent:-15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:129%;padding-left:12.76pt">&#93; 5. The undersigned is a trust with total assets in excess of $5,000,000 whose purchase is directed by a person with such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of the prospective investment.</font></div><div><font><br></font></div><div style="padding-left:73pt;text-indent:-7.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:4.76pt">&#93; 6. The undersigned is an entity, all of whose equity owners are accredited investors under paragraphs 1, 2, 3, 4 or 5, above.</font></div><div><font><br></font></div><div style="padding-left:49pt;text-align:justify;text-indent:-16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:126%;padding-left:8.71pt">The undersigned understands that the shares purchased hereunder have not been registered under the Securities Act, in reliance upon the exemption from the registration requirements under the Securities Act pursuant to Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D thereunder&#59; and, therefore, that the undersigned must bear the economic risk of the investment for an indefinite period of time since the securities cannot be sold, transferred or assigned to any person or entity without compliance with the provisions of the Securities Act.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Submitted by&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accepted by Provention Bio, Inc.&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SS&#47;Tax ID&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax ID&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Telephone&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Email&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Signature must conform in all respects to name of holder as specified on the face of the Warrant Certificate.)</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_109"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 11</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Press Release</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_112"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 12</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form of Lock-Up Agreement</font></div><div><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PROVENTION BIO, INC.</font></div><div><font><br></font></div><div style="padding-left:235pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LOCK-UP AGREEMENT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May __, 2018</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MDB Capital Group, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2425 Cedar Springs Road</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dallas, Texas 75201</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Re&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Provention Bio, Inc. - Lock-Up Agreement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ladies and Gentlemen&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">This Lock-Up Agreement is being delivered to you in connection with the Warrants (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8221;), each dated as of May __, 2018 between Provention Bio, Inc., a Delaware Corporation, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8221;) and MacroGenics, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Subscriber</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8221;), in which Subscriber desires to acquire warrants exercisable into an aggregate of 2,432,688 shares of Common Stock, par value $0.0001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8221;), of the Company in consideration of the Company&#8217;s and Subscriber&#8217;s entry into an Asset Purchase Agreement and License Agreement, each dated as of May __, 2018.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">In order to induce MDB Capital Group, LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:123%">MDB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">&#8221;) to locate investors to participate in an initial public offering by the Company, the undersigned agrees that, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:123%">commencing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%"> on the earlier of (a) the date of the final prospectus relating to the Company&#8217;s initial public offering of its Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:123%">IPO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">&#8221;) and (b) the listing of the Company&#8217;s Common Stock on an exchange or any tier of The NASDAQ Stock Market or New York Stock Exchange and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:123%">ending</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%"> on the date that is 12 months thereafter (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:123%">Lock-Up Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">&#8221;), the undersigned will not, and will cause all affiliates (as defined in Rule 144 promulgated under the Securities Act of 1933 Act, as amended) of the undersigned not to, (i) lend&#59; offer&#59; pledge&#59; sell&#59; contract to sell&#59; sell any option or contract to purchase&#59; purchase any option or contract to sell&#59; grant any option, right, or warrant to purchase&#59; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock, or securities exercisable or convertible into shares of Common Stock, held as of the date hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:123%">Subscriber&#8217;s Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">&#8221;) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Subscriber&#8217;s Shares, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The foregoing restriction is expressly agreed to preclude the undersigned, and any affiliate of the undersigned from engaging in any hedging or other transaction which is designed to or which reasonably could be expected to lead to or result in a sale or disposition of the Subscriber&#8217;s Shares even if the Subscriber&#8217;s Shares would be disposed of by someone other than the undersigned. Such prohibited hedging or other transactions would include, without limitation, any short sale or any purchase, sale or grant of any right (including, without limitation, any put or call option) with respect to any of the Subscriber&#8217;s Shares or with respect to any security that includes, relates to, or derives any significant part of its value from the Subscriber&#8217;s Shares.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_115"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">Notwithstanding the foregoing, the undersigned may transfer the Subscriber&#8217;s Shares, provided that in case of items (i) through (v) below, any such transfer shall not involve a disposition for value, and provided further that any transferee shall agree to be bound by the terms of this Lock-up Agreement&#58;</font></div><div><font><br></font></div><div style="padding-left:11pt;text-indent:-10.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:2.12pt">bona fide gift or gifts or by will or intestate succession upon the death of the undersigned&#59; or</font></div><div><font><br></font></div><div style="padding-left:14pt;text-indent:-13.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:2.62pt">to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned&#59; or</font></div><div><font><br></font></div><div style="padding-left:16pt;text-indent:-15.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:2.12pt">if the undersigned is a trust, any distribution to a beneficiary of the trust or to the estate of a beneficiary of such trust and such transfer is not for value&#59; or</font></div><div><font><br></font></div><div style="padding-right:1pt;text-indent:0.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:22.62pt">as a distribution or transfer to stockholders, members, limited partners, or other securityholders of the undersigned or to regular employees of the undersigned whether or not for value&#59; or</font></div><div><font><br></font></div><div style="padding-right:1pt;text-indent:0.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%;padding-left:25.12pt">to any corporation, partnership, limited liability company or other entity all of the beneficial ownership interests of which are held by the undersigned or to the undersigned&#8217;s affiliates or to any investment fund or other entity controlled or managed by or under common control with the undersigned.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">For purposes of this Lock-Up Agreement, &#8220;immediate family&#8221; shall mean any relationship by blood, marriage or adoption, not more remote than first cousin.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Notwithstanding anything contrary in this Lock-Up Agreement, (i) the undersigned may exercise warrants to purchase shares of Common Stock, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:123%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%"> that the underlying shares of Common Stock shall continue to be subject to the restrictions on transfer set forth in this letter agreement, (ii) the undersigned can enter into a sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:123%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">&#8221;), provided that no sales, dispositions or other transfers of the Subscriber&#8217;s Shares may be made under such plan during the Lock-Up Period and no public announcement or filing under the Exchange Act regarding the establishment of such plan shall be required of or voluntarily made by or on behalf of the undersigned or the Company&#59;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:0.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%;padding-left:22.12pt">nothing in this Lock-Up Agreement shall prevent the transfer of securities of the Company pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Common Stock, provided that in the event that the tender offer, merger, consolidation or other such transaction is not completed, the Subscriber&#8217;s Shares shall remain subject to the restrictions contained in this Lock-Up Agreement, and (iv) nothing in this Lock-Up Agreement shall prevent the transfer of the Subscriber&#8217;s Shares with the written consent of MDB and the agreement of the transferee that it will be subject to the restrictions contained herein.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:127%">In order to enforce this covenant, the Company shall impose stop-transfer instructions preventing the Company&#8217;s transfer agent (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:127%">Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:127%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:127%">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:127%">&#8221;) from effecting any actions in violation of this Lock-Up Agreement. The undersigned agrees and consents to the entry of stop transfer instructions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:127%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:127%">with the Company&#8217;s Transfer Agent and registrar against the transfer of the Undersigned&#8217;s Shares except in compliance with the foregoing restrictions. The Company is a third party beneficiary of this provision.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_118"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The undersigned acknowledges that the execution, delivery and performance of this Lock-Up Agreement is a material inducement to MDB and the Company to complete the transactions contemplated by the Subscription Agreement and the Private Placement, and that MDB and the Company shall each be entitled to specific performance of the undersigned&#8217;s obligations hereunder. The undersigned hereby represents that the undersigned has the power and authority to execute, deliver and perform this Lock-Up Agreement, that the undersigned has received adequate consideration therefor and that the undersigned will indirectly benefit from the closing of the transactions contemplated by the Subscription Agreement entered into in connection with the Private Placement.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">The undersigned understands and agrees that this Lock-Up Agreement is irrevocable and shall be binding upon the undersigned&#8217;s heirs, legal representatives, successors, and assigns.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">At the discretion of MDB some or all of the Subscriber&#8217;s Shares may be released from the restrictions of this Lock-Up Agreement, and the Company will take the required action to permit the securities so released to be free of the restrictions of this Lock-Up Agreement.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:136%">This Lock-Up Agreement may be executed in two counterparts, each of which shall be deemed an original but both of which shall be considered one and the same instrument.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">This Lock-Up Agreement will be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice of law or conflicting provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the laws of any jurisdiction other than the State of Delaware to be applied. In furtherance of the foregoing, the internal laws of the State of Delaware will control the interpretation and construction of this Lock-Up Agreement, even if under such jurisdiction&#8217;s choice of law or conflict of law analysis, the substantive law of some other jurisdiction would ordinarily apply.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#91;Remainder of page intentionally left blank. Signature Page to Follow.&#93;</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_121"></div><hr style="page-break-after:always"><div style="min-height:51.12pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.473%"><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreed to and Acknowledged&#58;</font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:7.052%;min-width:6.052%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.475%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exact Name of Shareholder</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Authorized Signature</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title</font></div><div><font><br></font></div></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MDB CAPITAL GROUP, LLC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id08e5795f5b143e09c7b50ccfc37bdd0_124"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:432pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.23           </font></div></div><div><font><br></font></div><div style="height:43.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>4
<FILENAME>a1024_proventionapaamendme.htm
<DESCRIPTION>EX-10.24
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9980140261064bd6b504c28b252207ad_1"></div><div style="min-height:69.84pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Exhibit.10.24</font></div></div><div style="margin-top:7.25pt;padding-left:1.25pt;padding-right:1.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY &#91;***&#93;) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL.</font></div><div style="margin-top:7.25pt;padding-left:74.67pt;padding-right:74.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:13.95pt;padding-right:5.65pt;text-align:justify;text-indent:36.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Amendment No. 1 to the Asset Purchase Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and between MacroGenics, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a Delaware corporation, having its principal place of business at 9704 Medical Center Drive, Rockville, MD 20850 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and Provention Bio, Inc., a Delaware corporation, having its principal place of business at 55 Broad Street, 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Floor, Red Bank, NJ 07701 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), together with Seller, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and each separately, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and is meant to amend that certain Asset Purchase Agreement, dated as of May 7, 2018, between Seller and Buyer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:13.1pt;padding-right:5.75pt;text-align:justify;text-indent:36.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">WHEREAS, the FDA granted a first Regulatory Approval for the Product on November 17, 2022&#59; and</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:13.1pt;padding-right:5pt;text-align:justify;text-indent:36.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">WHEREAS, the Parties have agreed to revise the payment terms for achievement of the BLA Approval Milestone&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:12.9pt;padding-right:5.75pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained herein, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div><font><br></font></div><div style="margin-top:8.15pt;padding-left:23.55pt;padding-right:5.65pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:8.01pt">This Amendment No. 1 shall be effective on November 30, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:23.55pt;padding-right:5.9pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:8.01pt">The Parties agree that the Agreement shall be amended from and after the Amendment Effective Date as follows&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:41.75pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:8.69pt">The defined term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221; and its following definition are hereby added to Section 1.1 of the Agreement&#58;</font></div><div style="margin-top:7.95pt;padding-left:41.55pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221; means that (a) (i) any Third Party acquires the beneficial ownership of any voting security of Buyer, or (ii) if the percentage ownership of a Third Party in the voting securities of Buyer is increased through stock redemption, cancellation or other recapitalization, and, in the case of (i) and (ii),after such acquisition or increase such Third Party is the beneficial owner of voting securities representing more than fifty percent (50%) of the total voting power of all of the then outstanding voting securities of Buyer&#59; (b) a merger, consolidation, recapitalization, or reorganization of Buyer is consummated that would result in stockholders or equity holders of Buyer immediately prior to such transaction ceasing to own more than fifty percent (50%) of the outstanding securities of the surviving entity (or its parent entity) immediately following such transaction&#59; or (c) the sale or transfer to a Third Party of all or substantially all of Buyer&#8217;s assets taken as a</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9980140261064bd6b504c28b252207ad_4"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:4pt;padding-left:41.55pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">whole or which relate to this Agreement is effected. Notwithstanding the foregoing, the following will not constitute a Change of Control&#58; (i) a sale of capital stock to underwriters in an underwritten public offering of Buyer&#8217;s capital stock solely for the purpose of financing, or (ii) the acquisition of securities of Buyer by any Person or group of Persons that acquires Buyer&#8217;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for Buyer through the issuance of equity securities.</font></div><div><font><br></font></div><div style="margin-top:7.8pt;padding-left:41.55pt;padding-right:5.7pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:126%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:126%;padding-left:8.01pt">The defined term &#8220;Payment Acceleration Event&#8221; and its following definition are hereby added to Section 1.1 of the Agreement&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Payment Acceleration Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Change of Control.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41.55pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.74pt">Section 3.2 is hereby deleted and replaced with the following text&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41.55pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Development and Regulatory Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:125%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Buyer shall pay (which payments shall not be creditable against any other obligations of Buyer hereunder) a non-refundable payment for each of the milestone events set forth in this Section 3.2 (each a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#8220;Development and Regulatory Milestone&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">), whether the Development and Regulatory Milestone is achieved by Buyer, its Affiliates or Licensees, or any Third Party acting on behalf of Buyer, its Affiliates or Licensees. Payment for each of the Development and Regulatory Milestones shall be made only once regardless of how many times a Product achieves the corresponding Development and Regulatory Milestone, and no payment shall be due for any Development and Regulatory Milestone which is not achieved. The Development and Regulatory Milestones shall be as follows&#58;</font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:55.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.143%"><tr><td style="width:1.0%"></td><td style="width:50.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Development and Regulatory Milestone</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Payment</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%">&#91;***&#93; </font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:55.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.143%"><tr><td style="width:1.0%"></td><td style="width:50.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:41.55pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Buyer shall provide Seller with written notice within thirty (30) days after the achievement of the corresponding Development and Regulatory Milestone. The payment pertaining to each Development and Regulatory Milestone, other than the BLA Approval Milestone Payment which shall be governed in accordance with Section 3.2(a), shall be made by Buyer to Seller within ninety (90) days after the achievement of the corresponding Development and Regulatory Milestone.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41.55pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.06pt">The following text is hereby added to the Agreement as new Section 3.2(a)&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41.55pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Payment of BLA Approval Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. The Parties acknowledge and agree that the BLA Approval Milestone was achieved. Buyer shall pay Seller the BLA Approval Milestone payment in four (4) installments as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:77.55pt;padding-right:5.75pt;text-indent:-24.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:18.27pt">an initial payment of Fifteen Million United States dollars ($15,000,000) by November 30, 2022&#59;</font></div><div style="padding-left:77.55pt;padding-right:19.3pt;text-indent:-28.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:18.54pt">a further Fifteen Million United States dollars ($15,000,000) by March 1, 2023&#59;</font></div><div style="padding-left:77.55pt;padding-right:5.8pt;text-indent:-31.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:18.71pt">a further Fifteen Million United States dollars ($15,000,000) by June 1, 2023&#59; and</font></div><div style="padding-left:77.55pt;padding-right:5.65pt;text-indent:-31pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:18.67pt">a further Fifteen Million United States dollars ($15,000,000) by September 1, 2023</font></div><div style="padding-left:77.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">BLA Approval Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41.55pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.74pt">The following text is hereby added to the Agreement as new Section 3.2(b)&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41.55pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Acceleration of BLA Approval Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. On or at any time after the occurrence of a Payment Acceleration Event, Seller may by notice to Buyer declare that all or part of the outstanding BLA Approval Payments, together with accrued interest, and all other amounts accrued or outstanding under this Agreement be due and payable, at which time they shall become due and payable &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41.55pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.07pt">The following text is hereby added to the Agreement in Section 3.5&#58;</font></div><div><font><br></font></div><div style="padding-left:41.55pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Notwithstanding anything contained in the Agreement to the contrary, the &#91;***&#93; with respect to the Product, Teplizumab&#59; provided, that no &#91;***&#93;&#59; provided, further, that &#91;***&#93; may be &#91;***&#93; that may become due pursuant to &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:23.55pt;padding-right:5.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:8.01pt;text-decoration:underline">Entire Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> The Agreement (including Amendment No. 1), as supplemented and modified by this Amendment No. 1, together with the exhibits thereto, contains the entire understanding of the Parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters, which the Parties acknowledge have been merged into the Agreement.</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:23.55pt;padding-right:5.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:8.01pt;text-decoration:underline">Governing Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> This Amendment No. 1 shall be governed by and construed under the laws of the State of Delaware, without giving effect to any choice of law principles that would require the application of the laws of a different state.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:23.55pt;padding-right:5.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:8.01pt;text-decoration:underline">Execution in Counterparts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> This Amendment No. 1 may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Amendment No. 1 may be executed by .pdf or other electronically transmitted signatures and such signatures shall be deemed to bind each Party as if they were the original signatures.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:23.55pt;padding-right:5.95pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:8.01pt;text-decoration:underline">Remaining Provisions of the Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Except as expressly provided herein, each of the other provisions of the Agreement shall remain in full force and effect.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:23.55pt;padding-right:5.65pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:8.01pt;text-decoration:underline">References.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Upon the effectiveness of this Amendment No. 1, on and after the date hereof, each reference in the Agreement to &#8220;this Agreement,&#8221; &#8220;hereunder,&#8221; &#8220;hereof,&#8221; &#8220;herein&#8221; or words of like import shall mean and be a reference to the Agreement, as amended hereby</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:176.97pt;padding-right:176.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;signature page follows&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:4pt;padding-left:5.55pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">IN WITNESS WHEREOF, the Parties hereto have caused this Amendment No. 1 to the Asset Purchase Agreement to be duly executed by their respective authorized signatories effective as of the Amendment Effective Date.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:10.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MACROGENICS, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.75pt;padding-left:25.85pt;padding-right:188.9pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">&#47;s&#47; Scott Koenig, M.D., Ph.D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:25.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Title&#58; President and Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PROVENTION BIO, INC.</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:25.85pt;padding-right:188.9pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">&#47;s&#47; Ashleigh Palmer&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Name&#58; Ashleigh Palmer</font></div><div style="padding-left:25.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Title&#58; President and Chief Executive Officer</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>5
<FILENAME>a1025_hqlease.htm
<DESCRIPTION>EX-10.25
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9d92fac7ad40421488635b1c18634cfa_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit.10.25</font></div></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY &#91;***&#93;) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LEASE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THIS LEASE </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entered </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">into </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Execution </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Date</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and between BMR-MEDICAL CENTER DRIVE LLC, a </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Delaware limited </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">liability company </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and J. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CRAIG VENTER </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">INSTITUTE, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">INC., successor </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interest </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Institute for Genomic </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Research, Inc., </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Maryland non-stock corporation </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8216;&#8216;Tenant&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">WHEREAS, Landlord owns certain real property (&#8220;</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Property</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">improvements on </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Property located </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at 9704 </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Medical </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Center Drive, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rockville, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Maryland, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including the building located thereon (the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Building</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt">WHEREAS, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord wishes </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lease </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Tenant, and Tenant desires </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to lease from Landlord, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">certain premises (the &#8220;</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Premises</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">comprising </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building, pursuant to the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conditions of this </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">detailed below</font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THEREFORE, Landlord and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in consideration </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mutual </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">promises contained herein and for other good and valuable consideration, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the receipt and </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sufficiency </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of which are </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereby </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acknowledged, and intending </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to be legally bound, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Lease of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Premises</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Effective on </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term Commencement </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defined </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">below), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereby </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leases </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereby </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leases </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord, the Premises, as </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shown </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereto, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">patio&#47;deck </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shown </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and all shafts, cable </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">runs, risers, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mechanical spaces and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rooftop </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">areas, for </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accordance </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Permitted Use (as </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defined below) and no </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uses. The Property </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and all </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">landscaping, parking facilities, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">private </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">drives </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">improvements and appurtenances related </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereto, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">buildings located </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at 9708, 9710, 9712 and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9714 Medical </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Center </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Drive (such other buildings, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lower Campus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Rockville, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MD, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereinafter collectively </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">referred to as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Project.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; All driveways, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">loading </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">docks, sidewalks, parking areas </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">landscaped </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">areas for </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">buildings </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project are </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereinafter referred </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Areas</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Basic Lease Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">convenience of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the parties, certain basic </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provisions of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th</font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s Lease are </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">herein. The </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provisions </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set forth </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">herein are </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remaining terms </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conditions </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interpreted in </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">light </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of such remaining </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and conditions.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">This Lease </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">take effect </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Execution </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and, except </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specifically </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">otherwise </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, each of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the provisions hereof </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be binding upon </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and inure </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">benefit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Landlord and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of execution and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delivery hereof by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">parties hereto.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">In </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the definitions below, each </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">current </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rentable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Area (as defined </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">below) is expressed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rentable square </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">footage. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rentable </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Area </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pro </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rata Shares </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(as defined below) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are all subject </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">adjustment as provided </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:6.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Definition or Provision</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Means the Following (As of the Term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rentable Area of Premises</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">square feet</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rentable Area of Building</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">square feet</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rentable Area of Project</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">square feet</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s Pro Rata Share of Building</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s Pro Rata Share of Common Areas</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Initial monthly and </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">annual </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">installments of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Base </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Commencement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">adjustment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Dates</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Square Feet of Rentable Area</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Base Rent per Square Foot of Rentable Area</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Monthly Base Rent</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Annual Base Rent</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;text-decoration:underline">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;text-decoration:underline">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;text-decoration:underline">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;text-decoration:underline">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;text-decoration:underline">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Estimated </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">erm Commencement </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Estimated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term Expiration </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Security Deposit&#58; $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Permitted </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Use&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall have </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">right </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any use in conformity with </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all federal, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">state, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">municipal and local laws, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">codes, ordinances, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rules and regulations of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Governmental Authorities </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(as defined below), </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">committees, associations, or other regulatory </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">committees, agencies </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">governing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bodies having </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">jurisdiction </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">over the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises, the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Property, the Project, Landlord </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or Tenant, including both statutory </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and common law and hazard </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">waste </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rules and regulations (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Laws</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Address for Rent </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Payment&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.9</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.012%"><tr><td style="width:1.0%"></td><td style="width:45.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address for Notices to Landlord&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BMR-Medical Center Drive LLC</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17190 Bernardo Center Drive </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">San Diego, California 92128 </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attn&#58; Cynthia Crossmon</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address for Notices to Tenant&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">J. Craig Venter Institute, Inc. </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">at the Premises</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attn&#58; Vice President, General Counsel</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">With a copy to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Arnold &#38; Porter LLP </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">555 12th Street, NW </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Washington, DC 20004</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Kenneth Schwartz</font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10</font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">The </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibits are attached </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereto </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and incorporated herein by reference&#58;</font></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.019%"><tr><td style="width:1.0%"></td><td style="width:17.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.484%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit A</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Premises</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit B</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Depiction of Tenant&#8217;s Exclusive Parking Area</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit C</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Acknowledgement of Term Commencement Date and Term Expiration Date</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit D</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Intentionally Omitted</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit E</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Form of Letter of Credit</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit F</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Rules and Regulations</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit G</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Intentionally Omitted</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit H</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tenant&#8217;s Personal Property</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit I</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Form of Estoppel Certificate</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit J</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Maintenance and Service Obligations of Landlord and Tenant</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">actual term of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease (as the </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may be </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof and as the </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may be </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">earlier </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminated in accordance with this </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Term&#8221;) shall commence </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on the </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Commencement Date </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) and end </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on the date </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">months after the Term Commencement Date (such </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date, the &#8220;Term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expiration Date&#8221;), </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to earlier termination of this Lease as provided herein.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Possession and </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commencement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">The </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term Commencement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be the date of </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the consummation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the closing of </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acquisition of fee title to the Premises pursuant </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that certain Agreement of Purchase and </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sale </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">dated as of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by and between Landlord and </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall execute </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and deliver to Landlord written acknowledgment of the actual Term </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Commencement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date and the Term Expiration Date within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days after Landlord </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requests </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">form </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto. </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Failure </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to execute and deliver </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such acknowledgment, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">however, </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">affect </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Term </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Commencement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date or </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or Tenant&#8217;s liability hereunder.  Failure by </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#2d2d2d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obtain required </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">governmental licensing for the Permitted Use by Tenant at the Premises shall not serve to extend the Term Commencement Date.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Prior to the Term Commencement Date, Tenant shall furnish to Landlord evidence satisfactory to Landlord that insurance coverages required of Tenant under the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are in effect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Condition of Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty with respect to the condition of the Premises, the Building or the Project, or with respect to the suitability of the Premises, the Building or the Project for the conduct of Tenant&#8217;s business. Tenant acknowledges that (a) Tenant is the prior owner and primary occupant of the Project&#59; (b) Tenant is in possession of the Premises and is fully familiar with the condition of the Premises and agrees to take the same in its condition &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">as is</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as of the Term Commencement Date&#59; and (c) except as otherwise expressly set forth in this Lease, Landlord shall have no obligation to alter, repair or otherwise prepare the Premises for Tenant&#8217;s occupancy or to pay for or construct any improvements to the Premises to prepare the Premises for Tenant&#8217;s continued occupancy.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Rentable Area</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Landlord and Tenant irrevocably stipulate that the Rentable Area of the Premises shall be as set forth in Section 2.2. Subject to the foregoing, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rentable Area</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, to the extent it relates exclusively to the Lower Campus shall reflect such areas as are reasonably calculated by Landlord&#8217;s architect, as the same may be reasonably adjusted from time to time by Landlord in consultation with Landlord&#8217;s architect to reflect changes to the Lower Campus.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">The Rentable Area of the Lower Campus is generally determined by making separate calculations of Rentable Area applicable to each floor within the Lower Campus and totaling the Rentable Area of all floors within the applicable improvements. The Rentable Area of a floor is computed by measuring to the outside finished surface of the permanent outer applicable building walls. The full area calculated as previously set forth is included as Rentable Area, without deduction for columns and projections or vertical penetrations, including stairs, elevator shafts, flues, pipe shafts, vertical ducts and the like, as well as such items&#8217; enclosing walls.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">The Rentable Area of the Project is the total Rentable Area of all buildings within the Project (with the understanding that the Building Rentable Area is stipulated as set forth herein and not subject to further adjustment).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant shall pay to Landlord as Base Rent for the Premises, commencing on the Term Commencement Date, the sums set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, subject to the rental adjustments provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof. Base Rent shall be paid in equal monthly installments as </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set forth </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.3</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the rental adjustments </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereof,</font><font style="color:#bfbfbf;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">each in advance on </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the first day </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of each </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">every calendar </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">month </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">during </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">In addition to Base </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as additional </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) at </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">times hereinafter </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specified </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in this Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s pro rata </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">share, as set </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Pro </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rata </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) the Property </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Management Fee </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defined </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">below) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and (c) any other amounts that Tenant assumes or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agrees to pay </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under the provisions of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease that are </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">owed </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord, including any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other sums </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that may become due </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reason of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any default </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or failure on </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s part to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">comply </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the agreements, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms, covenants </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and conditions </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease to be </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">performed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Tenant, after notice </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lapse </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of any </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cure periods.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Base </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Additional </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">together be denominated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be paid </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Landlord, without abatement, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deduction </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or offset </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">except </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as expressly </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16.2</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">24.5</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">31.14</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lawful money of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the United States of America at </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">office of Landlord as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.8</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to such other </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">person </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or at such </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">place </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from time </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">designate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in writing. </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commences </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ends on a </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">day other than </font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">first </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">day of a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">calendar </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">month, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for such fraction of a month shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prorated for </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on the basis </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of a thirty </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(30) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">day month </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be paid </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the then-current rate for </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fractional month.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Rent Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Base </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject to an annual upward </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost-of-living </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">adjustment of the then-current Base Rent </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">based upon </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">comparing </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the increase </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Consumer Price Index </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">numbers </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">published </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">United States </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Department </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Labor, entitled United States </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Department of Labor, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bureau </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Labor </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Statistics, Consumer Price Index for All Urban Consumers, Washington-Baltimore, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DC-MD-VA-WV </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CPI </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Index</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the month immediately preceding the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">anniversary of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Commencement Date over the CPI </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Index </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">published for the </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">calendar month for the prior year, with </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the understanding that this </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">escalation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is intended </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to be a &#8220;prior </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year&#8217;&#8217; CPI </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Index </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">escalation, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not a</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;base year&#8221; CPI </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Index escalation. </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the event </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the CPI </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Index </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not published for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">one of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">months </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specified </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">immediately </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">preceding </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sentence, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CPI </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Index to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">used </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">last monthly </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CPI </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Index published prior to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the month </font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specified. </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the event that </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">index </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">discontinued, then </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">another comparable </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">index </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or source of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">information generally </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">recognized </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as authoritative </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">substituted </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord with </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consent, such consent </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not to be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unreasonably withheld, conditioned or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delayed. The </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">first such adjustment </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">become </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effective </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commencing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">monthly </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rental installment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">due on or after </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the first (1</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) annual anniversary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term Commencement </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and subsequent adjustments shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">become </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effective on every successive annual </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">anniversary for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">long </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease continues </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in effect&#59; provided, in no </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event shall </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Base Rent </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">increased </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by less than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> percent (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%) of Base Rent in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect for the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">preceding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year, or increased </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">more </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> percent (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%) of the Base Rent in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">preceding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Operating Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">As used herein, subject to the exclusions listed below and the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Operating Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall include the following costs and expenses with respect to the Building and the Common Areas consistent with the standards applicable to comparable first-class combined laboratory&#47;office facilities in the Rockville, Maryland area (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Comparable Buildings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), with the understanding that if the cost or expense relates to the Common Areas then the Tenant&#8217;s Pro Rata Share of Common Areas shall apply, not the Tenant&#8217;s Pro Rata Share of the Building&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Government impositions including property tax costs consisting of real and personal property taxes and assessments, including amounts due under any improvement bond upon the Building or the Common Areas, including the parcel or parcels of real property upon which the Building and areas serving the Building are located or assessments in lieu thereof imposed by any federal, state, regional, local or municipal governmental authority, agency or subdivision (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) are levied&#59; taxes on or measured by gross rentals received from the rental of space in the Building or the Common Areas&#59; taxes based on the square footage of the Premises, the Building or the Common Areas, as well as any parking charges, utilities surcharges or any other costs levied, assessed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or imposed by, or at the direction of, or resulting from Applicable Laws or interpretations thereof, promulgated by any Governmental Authority in connection with the use or occupancy of the Building or the Common Areas&#59; any fee for a business license to operate an office building&#59; and any expenses, including the reasonable cost of attorneys or experts, reasonably incurred by Landlord in seeking reduction by the taxing authority of the applicable taxes, with a credit against Operating Expenses for any tax refunds obtained as a result of an application for review thereof (or a payment of such refunds if the Term has expired). Operating Expenses shall not include any net income, franchise, capital stock, gift, estate or inheritance taxes, or taxes that are the personal obligation of Landlord or of another tenant of the Project&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">All other costs of any kind paid or incurred by Landlord in connection with the operation or maintenance of the Building (including, without limitation, the service corridors, stairways, elevators, public restrooms and public lobbies contained therein) and the Common Areas, including costs of repairs and replacements to improvements within the Building and the Common Areas as appropriate to maintain the Building and the Common Areas as required hereunder, excluding costs of funding such reserves for future repairs and replacements&#59; costs of utilities furnished to the Building and the Common Areas&#59; sewer fees&#59; trash collection&#59; cleaning, including windows&#59; heating&#59; ventilation&#59; air-conditioning&#59; maintenance of landscaping and grounds&#59; maintenance of drives and parking areas&#59; maintenance of the roof&#59; security services and devices&#59; building supplies&#59; maintenance or replacement of equipment utilized for operation and maintenance of the Building and the Common Areas&#59; license, permit and inspection fees&#59; sales, use and excise taxes on goods and services purchased by Landlord in connection with the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operation, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">maintenance </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or repair of the Building or Common Areas systems and equipment&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">telephone, postage, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">stationery supplies </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and other </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">similar </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expenses </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incurred </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in connection with </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operation, maintenance or repair of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Common Areas&#59; accounting, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">legal </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and other </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">professional </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fees </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expenses </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incurred in </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">connection </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building and </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the</font><font style="color:#bfbfbf;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Common Areas&#59; costs of carpeting, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">landscaping </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and other customary </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ordinary items of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">personal property </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Landlord </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use in </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Common Areas&#59; Capital Expenditures, as </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereinafter </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defined (provided </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Capital </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenditures </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amortized over their useful life with an interest rate </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exceed </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the prime rate </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">listed </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the Wall Street </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Journal plus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">percent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%) </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">per annum) determined pursuant to generally accepted </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accounting </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">principles </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applied </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on a consistent basis&#59; costs of complying with Applicable </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laws </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(except to the extent such costs are incurred </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remedy </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">non</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">compliance </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the Execution Date </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with Applicable </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laws)&#59; </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">long </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">owns solely the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the costs </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expenses </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incurred </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Landlord associated with </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the operation </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of business of the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">legal </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entity or entities which constitute </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord, not to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exceed $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; costs </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">keep </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building and the Common Areas </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">compliance with, or </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fees </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">otherwise </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under, any CC&#38;Rs (as </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defined </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">below)&#59; insurance premiums, including premiums for </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">public liability, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">property</font><font style="color:#7e7e7e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">casualty, terrorism and environmental coverages </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(but not </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">earthquake coverage)&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">portions </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insured </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">losses paid </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Landlord </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">part of the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deductible </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">portion of a </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">loss pursuant </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of insurance policies&#59; service contracts&#59; costs of services of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">independent </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contractors retained to do work of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nature </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">referenced </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">above&#59; and costs </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">compensation (including </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employment </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taxes and fringe benefits) of all </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">persons </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">who perform regular </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and recurring </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">duties connected with </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the day-today </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operation and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">maintenance </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Common Areas, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its equipment, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">adjacent walks, landscaped areas, drives and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">parking </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">areas, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including janitors, floor </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">waxers, window washers, watchmen, gardeners, sweepers and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">handymen, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pro-rated </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">their services </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are part-time </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building and the Common Areas as applicable. For purposes of this </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">term &#8220;</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Capital </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Expenditures</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall include </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1) </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">capital </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">replacements </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">improvements, fixtures, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equipment, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">systems and </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">similar </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">property at the end of such </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">property&#8217;s </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">useful </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">life&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font><font style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2) </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any capital expenditures </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Landlord </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, but shall </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specifically </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exclude any enhancements or additions </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Common Areas.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Notwithstanding </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foregoing, Operating Expenses </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">include </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any</font><font style="color:#7e7e7e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leasing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commissions&#59; expenses </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that relate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">preparation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rental </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">space </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a tenant&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expenses of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">initial development </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and construction, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">grading, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">paving, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">landscaping </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">decorating </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(as distinguished from </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">maintenance, repair </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and replacement of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foregoing)&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">legal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expenses </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relating to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenants&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">costs </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of repairs to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extent </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reimbursed by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payment of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proceeds received by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interest </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon loans </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">secured </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mortgage </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deed of trust </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">covering </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project or a portion </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof (</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that interest </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon a government </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assessment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">improvement bond payable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in installments </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">constitute </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an Operating Expense </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subsection 9.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)&#59; any ground rent&#59; </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">salaries </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of executive officers of Landlord </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any employee of Landlord at or above </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">level </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of director (or </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">above </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the level </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the property </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">manager </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or building </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">engineer)&#59; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">depreciation claimed by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord for </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tax purposes (</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this exclusion of depreciation is not intended to delete from Operating Expenses actual costs of repairs and replacements that are </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subsection 9.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)&#59; taxes that are excluded from Operating Expenses by the last sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subsection 9.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; property management fees and expenses (except for the Property Management Fee)&#59; general overhead and administrative and accounting expenses, except to the extent reasonably and properly directly allocable to the operation of the Building and the Common Areas&#59; advertising, legal and space planning expenses and leasing commissions and other costs and expenses incurred in procuring and leasing space to tenants for the Project, including any free rent and construction allowances for tenants&#59; legal and other expenses incurred in (i) the negotiation, interpretation, preparation, termination or enforcement of leases or other occupancy agreements affecting the Project or (ii) the review, approval or other actions in connection with the sublease or assignment of tenant leases&#59; costs to be reimbursed by other tenants of the Project or taxes to be paid directly by Tenant or other tenants of the Project, whether or not actually paid&#59; the salaries, wages, benefits and other compensation paid to any employee of Landlord or Landlord&#8217;s managing agent who does not devote substantially all of his or her time to the Project, except to the extent such wages and benefits are reasonably, properly and equitably allocable to time spent by such employee in directly servicing the Project&#59; at such time as Landlord owns real property and assets unrelated to the Project, the costs and expenses incurred by Landlord associated with the operation of the business of the legal entity or entities which constitute Landlord&#59; bad debt losses, rent losses and costs (including attorneys&#8217; fees and costs of settlement, judgments and payments in lieu thereof) incurred in connection with disputes with tenants, other occupants, or prospective tenants, and costs and expenses, including legal fees, incurred in connection with negotiations or disputes with employees, consultants, management agents, leasing agents, purchasers or mortgagees of the Project&#59; costs incurred by Landlord due to the violation by Landlord, its employees, agents or contractors or any tenant of the terms and conditions of any lease of space in the Project (except Tenant)&#59; penalties, fines or interest incurred as a result of Landlord&#8217;s inability or failure to make payment of Taxes and&#47;or to file any tax or informational returns when due, or from Landlord&#8217;s failure to make any payment of taxes required to be made by Landlord hereunder before delinquency, unless such failure is due to Tenant&#8217;s failure to pay </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any Rent due hereunder&#59; the costs of any item paid to Landlord or to any entity or person related to or affiliated with Landlord to the extent such cost exceeds the amount payable for such services at then-existing market rates to unrelated persons or entities&#59; costs of Landlord&#8217;s charitable or political contributions, or of fine art maintained at the Project&#59; costs in connection with services (including electricity), items or other benefits which are not available to Tenant without specific charges therefor, but which are provided to another tenant or occupant of the Project, whether or not such other tenant or occupant is specifically charged therefor by Landlord&#59; costs incurred in the sale or refinancing of the Project&#59; rent for any commercially reasonable sized office at market rates for Landlord or its managing agent located in the Project or offsite&#59; costs associated maintaining, managing, operating, repairing or replacing any of the buildings comprising the Lower Campus&#59; costs associated with any property or building other than the Building and the Common Areas&#59; costs of repairs and replacements caused by the exercise of any right of condemnation or eminent domain by any public or quasi-public authority&#59; and any other costs or expenses for which Landlord actually receives reimbursement from any source (except from tenants as part of their operating expense obligations), including condemnation awards and costs for which Landlord has been reimbursed by its insurance carrier, any tenant&#8217;s insurance carrier, any tenant, any warrantor or </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any other third party. To the extent </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant uses more than Tenant&#8217;s Pro Rata Share </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any item of Operating Expenses, Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay Landlord </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for such excess </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in addition to Tenant&#8217;s </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligation to </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay Tenant&#8217;s Pro Rata </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Share </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Operating Expenses. In </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant be required to pay any </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expense, </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost or tax twice under the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms of this </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.2</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay to Landlord on the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">first </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">day of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">each calendar </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">month of the Term, as Additional Rent, </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Property Management Fee and (b). Landlord&#8217;s reasonable estimate of Tenant&#8217;s </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pro </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rata </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Share </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating Expenses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with respect </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the Building </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the Project, as </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">month</font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x)&#160;&#160;&#160;&#160;The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Property Management Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> percent (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%) of Base Rent due from Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(y)&#160;&#160;&#160;&#160;Within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after the conclusion </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of each calendar </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(or </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">longer period as </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be reasonably required by Landlord, but no later than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the end of the applicable year)</font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">furnish to Tenant a </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">statement showing in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonable detail the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">actual </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and Tenant&#8217;s </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pro </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rata Share of Operating Expenses </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the previous calendar year. Any </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">additional sum </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">due from Tenant to Landlord </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be immediately due and payable</font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the amounts paid by </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant to this </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exceed Tenant&#8217;s Pro Rata </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Share of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating Expenses for the previous </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">calendar </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year, then Landlord </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">credit </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">difference against the Rent next due and owing </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">erm has expired, Landlord </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accompany </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">said statement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with payment for </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the amount </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of such difference.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(z)&#160;&#160;&#160;&#160;Any amount due under this </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section for any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period that is less than </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">full month </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be prorated (based on </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thirty (30)-day month) for </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such fractional month.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Landlord&#8217;s annual </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">statement shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">final and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">binding upon Tenant unless Tenant</font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days after Tenant&#8217;s receipt thereof, </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">request </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the right </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">review </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">audit the same. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event, Landlord </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provide Tenant with reasonable access</font><font style="color:#bfbfbf;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">books and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">records </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the extent relevant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determination of Operating </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">information as Landlord reasonably determines to be responsive to Tenant&#8217;s </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written inquiries. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the event that, after </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s review o</font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such information, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord and Tenant cannot agree upon the amount </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s Pro Rata Share of Opera</font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ing Expenses or </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">enant desires </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a third </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">party review and audit the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same, then </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">right to have an independent public accountant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other person </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">firm </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with expertise </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in commercial real estate accounting and auditing (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) hired </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contingent </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fee </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">basis (at Tenant&#8217;s </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sole </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost and </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expense) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">approved by Landlord (which approval Landlord </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not unreasonably </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">withhold, condition </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or delay) audit and review such of Landlord&#8217;s books and </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">records for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">question </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">directly relate to the determination of Operating </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such year </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Independent Review</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make such books </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and records </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">available </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Auditor </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">review and copying at the location where Landlord maintains </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">them in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the ordinary course of its </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">business. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord need not provide copies of any book</font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or records. Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commence </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Independent Review </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within fifteen </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(15) days after the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord has given Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">access </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Landlord&#8217;s books </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">records for </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Independent </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Review. Tenant shall complete the Independent Review and notify Landlord </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in writing </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Tenant&#8217;s </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specific </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">objections to Landlord&#8217;s calculation of Operating Expenses (including Tenant&#8217;s </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Auditor&#8217;s </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written statement of the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">basis, </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nature and amount of each </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proposed </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">adjustment) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no later than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after Landlord </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">first </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">given Tenant access </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">books </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">records for the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Independent Review. Landlord shall review the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">results of </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any such Independent </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Review. </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">parties </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">endeavor to agree </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">promptly and </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably upon Operating </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taking </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">into </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">account the results of such Independent Review. If, as of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days after Tenant </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">submitted </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Independent </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Review </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Landlord, the parties have </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agreed on the appropriate adjustments to Operating Expenses, then the parties </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">engage a </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mutually </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agreeable independent third </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">party </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accountant with at </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">years&#8217; experience </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commercial real estate </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accounting </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and auditing </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Washington, DC region </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Accountant&#8217;&#8217;). If </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the parties </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cannot </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agree </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accountant, each shall within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">impasse appoint an </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accountant </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(different </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the accountant and accounting firm </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conducted </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Independent </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Review) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and, within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days after the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">appointment </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of both </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accountants, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">those </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">two Accountants </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall select a third </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(which </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cannot be </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accountant and accounting firm </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conducted </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Independent </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Review). </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">either party </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fails to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">timely appoint </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accountant, then </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accountant the other party appoints shall be </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sole </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accountant. Within </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ten </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after appointment of the Accountant(s), Landlord and Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">each </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">simultaneously </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">give </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accountants (with </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">copy to the other party) its determination of Operating </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses, </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with such </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">supporting </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">data </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">information </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">each </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">submitting </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">party </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determines appropriate. Within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days after </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">submissions, the Accountants </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by majority </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vote select </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">either </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or Tenant&#8217;s </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determination </font><font style="color:#a8a8a8;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accountants </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not select or designate any other</font><font style="color:#7e7e7e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determination </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Operating Expenses. The </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determination </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accountant(s) shall </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bind </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the parties. If the parties agree or the Accountant(s) determine that </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pro </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rata </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Share </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Operating Expenses actually </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">paid </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for the calendar </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">question exceeded Tenant&#8217;s obligations for </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">calendar year, then </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall, </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at Tenant&#8217;s option, either (a) credit the excess to the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">next succeeding </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">installments of estimated Additional Rent or (b) pay the excess to Tenant within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delivery of such </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">results. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the parties agree or the Accountant(s) determine </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payments </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Tenant&#8217;s Pro Rata </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Share </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Operating Expenses for </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">calendar year were </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">less </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than Tenant&#8217;s obligation for the calendar </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year, </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the deficiency to Landlord within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days after delivery of such results. If the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Independent </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Review reveals or </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accountant(s) determine </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Operating </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">billed </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Tenant by </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">paid by Tenant </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for the applicable </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">calendar </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year in question exceeded by more than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> percent </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">what </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">should </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have been billed </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">during </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">calendar year, </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay the reasonable cost </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Independent Review and </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">review by the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accountant(s). </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other cases, Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Independent Review.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">responsible </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">costs of any </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">services </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or utilities incurred by </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and attributable to </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time period prior to </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term Commencement </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s responsibility </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pro </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rata </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Share </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Operating Expenses </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">continue until </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expiration of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease Term or the earlier </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termination </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.5</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Operating </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses for </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">calendar year </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">share </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">therein </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commences </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">calendar year </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suc</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligation ceases shall be </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prorated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on a </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">basis rea</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">onably </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determined by </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lord. </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ex</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">penses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such as taxes, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assessment</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and insurance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">premiums </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">inc</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">urred </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extended </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ime </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall b</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prorated </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">based upon the time periods </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to which </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">they </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">apply so that </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the amounts </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">att</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ributed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the Premises </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in a </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rea</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">manner </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the time period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">wherein </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has an obligation </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">share </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in Operat</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ng </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">In the event </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">easonably belie</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ves </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">it </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entitled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reimbursements </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from Landlord</font><font style="color:#a8a8a8;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days after </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">end of each calendar month, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">submit </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an invoice, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event an invoice </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not available, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">itemized </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">list</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of all costs and expenses </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant has </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incurred </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ther internally </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employing third </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">partie</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s) </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">during the prior month </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for which </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">believ</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">es </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">it i</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entitled to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reimbur</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">semen</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ts </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from Landlord </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant to the term</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#91;intentionally </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deleted&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">So </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">long </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant has not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assigned </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall have </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exclusive right </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contest applicable taxes </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ncluded </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operat</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ing Ex</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">penses</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sole </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">co</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">st </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and expense, and Landlord shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cooperate </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">wi</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with respect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such contest, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pro</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vided </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incur </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any costs or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">liabilit</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">y </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in connection with </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">In </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant delivers a Turnover Notice </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(as defined below)</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for each year following </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Turnover </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date (a</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defined </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">below)</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord shall deliver </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonab</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ly </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">item</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ized </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">budget </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building and for th</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Common Areas (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Operating Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">setting </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth Landlord&#8217;s good </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fa</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ith reasonable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">estimate of the Operating </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">xpenses for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the following partial or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">full </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">calendar year, respectively, it </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">being </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agreed that </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Land</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lo</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall pro</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vide </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such estimate </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">la</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">te</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">han </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days prior </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">calendar year. Upon </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reque</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">st </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from time </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time within </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">final </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">day</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">each </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">calendar </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year, Landlord shall provide Tenant with Landlord&#8217;s </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hen-current </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">good faith estimate </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i.e., then-current working draft) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Budget </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">next following calendar year. Tenant acknowledges that </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating Budget </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">simply </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">good </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">faith </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">estimate of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event operate </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to restrict </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or prohibit Landlord from </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ncluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Opera</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ting </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses amounts or categories of expenses </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are not </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reflected </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suc</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Budget. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Tenant </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any comments </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">egar</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ing the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Budget, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall notify Landlord </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fter </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delivery </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suc</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h Operating </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Budget (which </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall also set </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth Tenant&#8217;s comments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with reasonable particularity), with </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failure of Tenant </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">do the </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ame </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">day </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period being </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deemed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an approval by Tenant </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">discuss </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the line </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">item</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating Budget </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(or items de</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sired </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">added to or deleted </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such budget) with respect </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which Tenant has commented and the amounts allocated </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to each </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ine item. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord shall consider </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in good </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">faith the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">budget </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">changes proposed </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant. In the event </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that the Operating </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses which are within </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">control and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">di</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">scre</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tion </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord (the &#8220;</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Controllable </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Operating </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Expenses</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exceed the Controllable Operating </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses for </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year of the Term by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> percent </font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">more, </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">portion of </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating Budget relating </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controllable Operating </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be subject </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Tenant&#8217;s </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">approval </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(not to be unreasonably withheld, conditioned </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delayed)&#59; provided, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">however, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">neither Landlord nor Tenant </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be required to consent to </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">change </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">resulting variation in </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">types </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">levels </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of services provided </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord) that (a) </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">inconsistent </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with the </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operation and </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">management </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">practices </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">landlords </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Comparable </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buildings or </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord reasonably determines </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have an adverse </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect on the </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">structure </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or cause </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building to fail to comply with Applicable </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laws. In the </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event that </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is entitled to </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">approve </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Controllable Operating </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth in </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating Budget pursuant to the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foregoing sentence, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant fails to </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respond </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="background-color:#000000;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Landlord&#8217;s </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delivery to Tenant </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Operating </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Budget, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be deemed </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to have approved </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Operating Budget and </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Controllable Operating </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses. </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Landlord </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determines </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that an </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Budget was incorrect </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">material </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amount, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">endeavor </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to provide Tenant </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with a </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">revised Operating Budget&#59; provided </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">revised </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating Budget </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accompanied by a good </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">faith explanation </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">increased amounts </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth thereon.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Taxes on Tenant&#8217;s Property.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior to delinquency any and </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taxes </font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ev</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ied </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">against any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">personal </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pr</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">op</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rty</font><font style="color:#7e7e7e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">trade fixtures placed by Tenant in or </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">about </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">If any </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such taxes </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on Tenant&#8217;s personal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">property or trade fixtures </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are levied against </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">property </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assessed valuation of </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Property or </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Project </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">increased </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">inclusion </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">therein of </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">value </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">attributable to Tenant&#8217;s personal </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">property </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">trade </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fixtures, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after written notice to </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pays </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taxes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">based upon </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">increase in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assessed value of </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Property or the Project, then </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall, upon </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">demand, repay to Landlord </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the taxes so </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">paid by Landlord.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.3</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">If </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any improvements in </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or alterations </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">space </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lower </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Campus </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leased </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by other tenants </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Project, </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whether owned </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Landlord </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other tenant and </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whether or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">affixed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the real property </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as to </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">become </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a part thereof, </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are assessed for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">real </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">property </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tax </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purposes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a valuation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">higher than </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">valuation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">improvements </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conforming </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Landlord&#8217;s building </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">standards </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Building </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Standard</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then the real property </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taxes </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and assessments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">levied </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">against </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building, the </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Property or the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project by reason </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">excess </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assessed </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">valuation shall not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be included </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses. </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the records </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">County Assessor</font><font style="color:#bfbfbf;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">available </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sufficiently </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">detailed </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to serve as </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">basis </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determining </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whether </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">said </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">improvements </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">alterations </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assessed at a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">higher </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">valuation than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">records shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be binding </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">both Landlord </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Security </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Deposit.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deposit with Landlord, on </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">before </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Execution Date, the sum </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth in </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.6</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Security Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which sum </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">held by Landlord </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for the faithful </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">performance by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant of all of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">covenants and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conditions of </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease to be kept </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and performed by </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">during the Term. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant defaults </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(after applicable notice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cure periods) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with respect </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provision </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including any </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provision </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relating to the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payment of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent, </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may (but </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be required </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to) use, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">apply </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">retain </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all or any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">part </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Security Deposit for </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the payment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of any Rent </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sum </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in default (after applicable </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice and cure periods), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or to compensate </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord for any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other loss </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that Landlord may suffer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by reason of </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">default. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at any time prior to the date that is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days prior to </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expiration of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">portion </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security Deposit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">used or applied, </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall, within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">business days </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">demand </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">therefor, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deposit </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cash </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amount </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sufficient </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to restore </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposit to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">original </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amount, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and Tenant&#8217;s </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failure </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to do </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be a material breach </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The provisions of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Article </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">survive </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expiration </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">earlier </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termination </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">In the event of bankruptcy </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other debtor-creditor proceedings </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">against </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security Deposit </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deemed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to be </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applied first to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payment of Rent and </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">charges due </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord for all periods </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior to the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">filing of </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proceedings.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may deliver </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to any </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purchaser </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Landlord&#8217;s entire interest </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises the Security Deposit delivered hereunder </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant, and, upon </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such purchaser&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agreement in </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">writing to assume </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s obligations under this Lease </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with respect </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the Security Deposit, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be discharged </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">further liability</font><font style="color:#bfbfbf;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respect to </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security Deposit. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This provision </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">also </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">apply to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subsequent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transfers.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">The </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposit, or </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remaining </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">balance </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof following </font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use, application </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">retention </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposit pursuant to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">returned </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(or, at Landlord&#8217;s </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">option, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the last </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assignee of </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interest he</font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eunder) within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thirty (30) </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days after </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expiration </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">earlier termination </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Intentionally Deleted.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">If the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposit </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in cash, Landlord </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hold </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposit </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interest-bearing account at a </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">federally-insured </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">banking </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">organization selected </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Landlord&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, however, that </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">maintain a </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">separate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">account for the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposit, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and shall not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">intermingle </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">it with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">funds </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord. </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entitled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to all interest </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and&#47;or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">dividends, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accruing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Security Deposit. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord shall not </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be required to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">credit Tenant with </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any interest for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period during </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which Landlord does not </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">receive </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interest </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security Deposit.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">The </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposit may </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the form of cash, a </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">letter </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of credit or, to the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acceptable to Landlord in its </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sole </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">discretion, any other </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">instrument. Tenant may </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any time, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">except when Tenant is in </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Default </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(as </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defined below), deliver a letter of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">credit </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;L&#47;C Security&#8217;&#8217;) </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as the </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e</font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ntire Security Deposit, as </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.7.1.</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">If Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">elects </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deliver </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C Security, then </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prov</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">de Landlo</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and maintain in full force and effect </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">throughout the Term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and until the date </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is two (2) </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">months after </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the then-current </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expiration </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">letter </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cred</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t in the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">form </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit E</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ued by an issuer reasonably </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">satisfactory </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amount of the Security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposit, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ini</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ial term </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of at least one year. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the foregoing, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">right </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time and from </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">during </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deliver </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cash </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">security deposit </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lieu </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon not less than </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days&#8217; advance </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon delivery of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a cash security deposit by Tenant </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in lieu of the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C Security, </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">dlord </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">promptly return the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">original </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C Security to Tenant. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">require the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C Security </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">re-issued </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">different issuer </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at any time during </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">believes </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that the issuing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bank </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the L&#47;C Security </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or may soon </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">become </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insolvent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">return the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">existing L&#47;C Security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exist</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">issuer </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">immediately upon </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ece</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ipt </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">substitute </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any issuer </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the L&#47;C Security shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">become </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insolvent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or placed </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">into </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FD</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C receivership, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then Tenant </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">day</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereafter </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deliver to Landlord (without the requi</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of notice from </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord) substitute L&#47;C Security issued </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tisfactory to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and otherwise </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conforming </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requirements set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article. As used </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">herein </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with respect </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the issuer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C Security, &#8220;insolvent&#8221; </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mean </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the determination of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insolvency as made by such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">issuer&#8217;s primary bank </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regulator </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">(i.e., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">state </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bank </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">supervisor for state chartered </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">banks&#59; </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OCC </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OTS, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respectively, for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">federally </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">chartered banks or thrifts&#59; or the Federal Reserve for its member banks).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.7.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">If </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant delivers </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord L&#47;C Security conforming </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the requirements set </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in place </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entire Security </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposi</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord shall </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remit </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant any cash Security </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ep</font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">osit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">previously </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">held </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within ten </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(10) business days after such delivery.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.7.3.</font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Landlord may draw upon the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C Security, and hold and apply </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proceeds in </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ame </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">manner </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purposes</font><font style="color:#bfbfbf;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Depo</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sit, if</font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) an </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uncu</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r</font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ed De</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fault </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exists&#59; </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the date </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days b</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e</font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fore </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any L&#47;C Security expires </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">even </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sc</font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">heduled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expiry </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is after the Term Expiration </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date but the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">must be before the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">outside </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expiry </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required hereunder) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delivered to Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an amendment or </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">replacement for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such L&#47;C Security, reasonably satisfactory </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Landlord, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extending the expiry date to the </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">earlier </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of (1) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">months </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the then-current </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term Expiration </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Da</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">te </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or (2) </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the date </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the then-current </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expiry date </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security&#59; </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the L&#47;C Security </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provides </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for automatic renewals, </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lan</font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lor</font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">asks </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the issuer </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">confirm </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">current L&#47;C Security </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expiry </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date, and the issuer </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fails </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">business days&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv) Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fails to </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(when </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and as </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord reasonably requires) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bank charges </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transfer </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the L&#47;C Security&#59; </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or (v) the issuer o</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C Security ceases, or announces that </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">it </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">will cease, </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to maintain an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">office </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the United States </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">America </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">where Landlord may present drafts under the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security (and fails to permit drawing upon </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the L&#47;C </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security by overnight courier or facsimile). This Section does not </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">limit any </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provisions </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this Lease allowing Landlord to draw </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C Security under </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specified </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">circumstances.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.7.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">seek </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">enjoin, prevent, or otherwise interfere with Landlord&#8217;s draw </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C Security, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">even </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if it violates </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lea</font><font style="color:#4f4f4f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e. Tenant acknowledges </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the only effect of a wrongful draw would be to substitute </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cash </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposit for L&#47;C Security, causing Tenant </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no legally </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">recognizable damage. Landlord </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hold </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the proceeds of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">draw </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">manner and for </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same purposes as a cash</font><font style="color:#a8a8a8;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security Deposit. In </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">wrongful draw, the parties </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cooperate </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">allow Tenant to </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">post </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">replacement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C Security </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">simultaneously </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with the return to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">wrongfully </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">drawn </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sums, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon request </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">confirm </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">writing to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">issuer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C Security </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s draw was erroneous.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.7.5.</font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">If </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transfers </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interest </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises, then Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at Tenant&#8217;s expense, within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">business </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after receiving a request from Landlord</font><font style="color:#4f4f4f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deliver (and, if </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">issuer requires, Landlord shall consent to) an amendment </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L&#47;C Security </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">naming </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s grantee as </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">substitute </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">beneficiary. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security Deposit changes while L&#47;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">force, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then Tenant shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deliver </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(and, if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">issuer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requires, Landlord shall consent </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to) </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">corresponding amendment to the L&#47;C Security.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.1</font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the purpose </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not use </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises, or permit or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suffer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">used, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for any other purpose without Landlord&#8217;s </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written consent, which consent Landlord may withhold </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in its </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sole </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and absolute discretion.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant shall </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not use </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or occupy the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">violation of Applicable </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laws&#59; </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">zoning </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ordinances&#59; or </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">certificate of occupancy issued for </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall, </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days&#8217; written notice from Landlord, discontinue any </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Premises </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is declared or claimed </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any Governmental </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Authority </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">having jurisdiction to be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a violation of any </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">above. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall comply with any direction of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any Governmental </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Authority having jurisdiction </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by</font><font style="color:#4f4f4f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reason of the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nature </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Tenant&#8217;s use or occupancy of the Premises, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">impose </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any duty upon Tenant or Landlord with respect </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the use or </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">occupation thereof.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.3</font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">do </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">permit </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">done anything that will (a) invalidate or (b) increase </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost of (unless </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant agrees </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay for </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any fire, </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">environmental, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extended coverage or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other insurance policy covering </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and shall comply with all rules, orders, </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regulations </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requirements </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurers </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Project, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">promptly, upon </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">demand, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reimburse Landlord </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any additional premium charged for such </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">policy </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by reason of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failure </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">comply with </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provisions </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant shall, upon termination of this Lease, return to Landlord all keys to offices and restrooms either furnished to or otherwise procured by Tenant. In the event any key so furnished to Tenant is lost, Tenant shall pay to Landlord the cost of replacing the same or of changing the lock or locks opened by such lost key if Landlord shall deem it necessary to make such change.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">No awnings or other projections shall be attached to any outside wall of the Building other than those existing as of the date hereof. Neither the interior nor exterior of any windows shall be coated or otherwise sunscreened without Landlord&#8217;s prior written consent. No equipment, furniture or other items of personal property other than those in existence as of the date hereof shall be placed on any exterior balcony without Landlord&#8217;s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant shall be entitled to building signage for the Premises, inside and outside the Building and on the Property (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Signage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), at Tenant&#8217;s sole discretion and expense, subject to all Applicable Laws. AJ&#93; existing Signage is hereby approved by Landlord. For any Signage, Tenant shall, at Tenant&#8217;s own cost and expense, (a) acquire all permits for such Signage in compliance with Applicable Laws and (b) design, fabricate, install and maintain such Signage in a first-class condition. The existing directory tablet shall be provided exclusively for the display of the name and location of tenants only.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant shall only place equipment within the Premises with floor loading consistent with the Building&#8217;s structural design without Landlord&#8217;s prior written approval, and such equipment shall be placed in a location designed to carry the weight of such equipment.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Subject to Section 22, Tenant shall cause any equipment or machinery to be installed in the Premises so as to reasonably prevent sounds or vibrations therefrom from extending into the Common Areas or other buildings in the Project.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant shall not (a) do or permit anything to be done in or about the Premises that shall in any way unreasonably interfere with the rights of other tenants or occupants of the Project, (b) use or allow the Premises to be used for unlawful purposes, (c) cause, maintain or permit any nuisance or waste in, on or about the Project or (d) take any other action that would in Landlord&#8217;s reasonable determination in any manner adversely affect other tenants&#8217; quiet use and enjoyment of their space or adversely impact their ability to conduct business in a professional and suitable work environment. Landlord shall use commercially reasonable efforts to apply similar standards on other tenants in the Project for the benefit of the Tenant.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Notwithstanding any other provision herein to the contrary, Tenant shall be responsible for all liabilities, costs and expenses arising out of or in connection with the compliance of the Premises with the Americans with Disabilities Act, 42 U.S.C. &#167; 12101, et seq., and any state and local accessibility laws, codes, ordinances and rules (collectively, and together with regulations promulgated pursuant thereto, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided that&#58; (a) if </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADA </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">compliance requires alteration of the Premises from </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its condition </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as</font><font style="color:#bfbfbf;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Commencement </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date due </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to a change </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADA </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">enforcement </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">takes effect after the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Commencement Date&#59; (b) </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such</font><font style="color:#5e5e5e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADA compliance </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not required as the result of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Alterations made by Tenant after the Term Commencement Date&#59; and </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) </font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">alteration of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">considered capital </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nature in </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accordance </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with generally accepted accounting principles, then Landlord shall be </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">responsible </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for performing such </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">alterations, </font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost for which shall be considered an Operating </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expense </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be amortized in accordance with </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9</font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The provisions of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Section shall survive </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the expiration or earlier </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termination </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this Lease.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Rules and Regulations, CC&#38;Rs, Parking Facilities and Common Areas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have the non-exclusive right, </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">common </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with other </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenants </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Project, to use the Common Areas, </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the rules and regulations </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">adopted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord and attached </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereto as </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, together with </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other reasonable and </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nondiscriminatory </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rules and regulations as </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereafter promulgated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord in its reasonable discretion </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rules </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">faithfully observe and comply with the Rules and </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Regulations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent the Rules and Regulations </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conflict with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the terms of this Lease, </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the terms of this Lease </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prevail. Landlord </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be responsible to Tenant for the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">violation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or non-performance by any other </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenant or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any agent, employee or </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">invitee </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof of any of </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rules </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Regulations.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">This Lease is subject </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">recorded </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">covenants, conditions </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restrictions on </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project or Property (the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CC&#38;Rs</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may be amended, amended and </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">es</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tated,</font><font style="color:#7e7e7e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">supplemented </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or otherwise modified </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time to time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that any </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amendments, </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restatements, </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">supplements </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or modifications do not materially modify </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rights </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligations </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereunder. Tenant shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">comply </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the CC&#38;Rs.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exclusive license </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">up </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">parking </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">spaces </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">serving the Premises (equal </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> parking </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">spaces per </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rentable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">square feet of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises), at no cost </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant during the Term, </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the area </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shown on </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reserves </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the right to modify </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Common </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Areas, </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">right </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to add or remove exterior and interior </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">landscaping </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and to </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subdivide </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">real property, provided </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the same </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">does not </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unreasonably </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interfere with Tenant&#8217;s use of the Premises. Tenant acknowledges </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specifically </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reserves the right </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">allow the exclusive </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">corridors </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and restroom facilities located on </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specific </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">floors </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to one or more tenants occupying </font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">floors </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lower </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Campus&#59; </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">however, that Tenant or </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subtenants </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or assigns </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have exclusive use of the corridors, restrooms, </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lobbies, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entryways, and patios that </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">serve the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Project Control by Landlord.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord reserves full control over the Building and the Project to the extent not inconsistent with Tenant&#8217;s rights under this Lease. This reservation includes Landlord&#8217;s right to subdivide the Project&#59; convert the Lower Campus to condominium units&#59; grant easements and licenses to third parties </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that no such easement or license materially and adversely affects Tenant&#8217;s use or occupancy of the Premises for the Permitted Use&#59; maintain or establish ownership of the Building separate from fee title to the Property&#59; make additions to or reconstruct portions of the Lower Campus provided the same does not unreasonably interfere with Tenant&#8217;s use of the Premises&#59; install, use, maintain, repair, replace and relocate for service to the Premises and other parts of the Building or the Project pipes, ducts, conduits, wires and appurtenant fixtures, wherever located in the Premises, the Building or elsewhere at the Project, provided the same does not materially and adversely interfere with Tenant&#8217;s use of the Premises&#59; and alter or relocate any other Common Area or facility, including private drives, lobbies and entrances located on the Lower Campus provided the same does not unreasonably interfere with Tenant&#8217;s use of the Premises.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 31.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, possession of areas of the Premises necessary for utilities, services, safety and operation of the Building is reserved to Landlord.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant shall, at Landlord&#8217;s request, promptly execute such further documents as may be reasonably appropriate to assist Landlord in the performance of its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligations hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Tenant need not execute any document that creates additional liability for Tenant, that imposes additional obligations on Tenant or that deprives Tenant of the quiet enjoyment and use of the Premises as provided for in this Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord may, at any and all reasonable times during non-business hours (or during business hours if Tenant so requests), and upon twenty-four (24) hours&#8217; prior notice (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that no time restrictions shall apply or advance notice be required if an emergency necessitates immediate entry), enter the Premises to (a) inspect the same and to determine whether Tenant is in compliance with its obligations hereunder, (b) supply any service Landlord is required to provide hereunder, (c) show the Premises to prospective purchasers or tenants during the final year of the Term, (d) post notices of non-responsibility, (e) access the telephone equipment, electrical substation and fire risers and (f) alter, improve or repair any portion of the Building other than the Premises and other than areas for which access to the Premises is reasonably necessary. In connection with any such alteration, improvement or repair as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subsection 14.4(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Landlord may erect in the Premises or elsewhere in the Project scaffolding and other structures reasonably required for the alteration, improvement or repair work to be performed, provided the same does not materially and adversely impair Tenant&#8217;s use of the Premises. In no event shall Tenant&#8217;s Rent abate as a result of Landlord&#8217;s activities pursuant to this Section&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, however, that all such activities shall be conducted in such a manner so as to cause as little interference to Tenant as is reasonably possible. Landlord shall at all times retain a key with which to unlock all of the doors in the Premises. If an emergency necessitates immediate access to the Premises, Landlord may use whatever force is necessary to enter the Premises, and any such entry to the Premises shall not constitute a forcible or unlawful entry to the Premises, a detainer of the Premises, or an eviction of Tenant from the Premises or any portion thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Quiet Enjoyment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. So long as Tenant is not in default under this Lease after applicable notice and cure periods, Landlord or anyone acting through or under Landlord shall not disturb Tenant&#8217;s occupancy of the Premises, except as permitted by this Lease.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Utilities and Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The parties acknowledge that Tenant shall initially be responsible for the utilities and services to the Premises including, without limitation, the utilities and services listed as Tenant&#8217;s responsibility on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto and incorporated herein by reference, and that Landlord&#8217;s responsibilities under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> do not arise until after the Turnover Date (or unless otherwise specifically set forth herein).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord shall provide the following services and utilities to the Premises to a standard consistent with those provided to Comparable Buildings&#58; the following services shall be provided 24 hours per day, 7 days per week, 365 days per year unless Tenant elects to reduce such hours&#58; hot and cold water&#59; gas&#59; heat, ventilation and air conditioning&#59; light&#59; telephone&#59; fire and life safety&#59; electricity&#59; sewer&#59; other utilities&#59; security system services existing as of the Term Commencement Date. In addition, Landlord shall provide cleaning (internal and external) and trash removal at reasonable times or as otherwise mutually agreed to by Landlord and Tenant (provided Landlord shall use commercially reasonable efforts to provide internal cleaning and trash removal after 5&#58;00 p.m. on weekdays)&#59; extermination and pest control at appropriate intervals&#59; snow removal from sidewalks, drives, and entrances at reasonable times or as otherwise mutually agreed to by Landlord and Tenant (provided Landlord shall use commercially reasonable efforts to provide such snow removal prior to 7&#58;00 a.m. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on any weekday or weekend day)&#59; elevator service with at least one (1) elevator in service and operational at all times&#59; and access to the Premises (including, without limitation, the Building and the parking facilities) twenty-four (24) hours per day, three hundred sixty-five (365) days per year. Tenant shall pay for the foregoing along with any fees, surcharges and taxes thereon. If any such utility is not separately metered to Tenant, Tenant shall pay a reasonable proportion (to be determined by Landlord based on Tenant&#8217;s usage) of all charges of such utility jointly metered with other premises in the Building as part of Tenant&#8217;s Pro Rata Share of Operating Expenses or, in the alternative, Landlord may, at its option, monitor the usage of such utilities by Tenant and pay the cost of purchasing, installing and monitoring such metering equipment, which cost shall be paid by Landlord. Notwithstanding the foregoing, during the Lease Term, Landlord and Tenant shall discuss, on an annual basis, the scope of services and utilities to be provided to Tenant under this Lease and Tenant shall have the right to request and Landlord shall consider in good faith any request for adjustment in the amount and&#47;or quality of services and utilities provided Tenant confirms that it shall pay the costs of the same as Operating Expenses.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Except with respect to the gross negligence or intentional misconduct of Landlord, its contractors, employees or agents, Landlord shall not be liable for, nor shall any </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eviction of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">result from, the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failure to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">furnish any utility or service Landlord is </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to provide pursuant to this Lease, whether or not such failure </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">caused by accident&#59; breakage&#59; repair&#59; strike, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lockout </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other labor </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">disturbance or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">labor dispute </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of any character&#59; act of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terrorism&#59; </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shortage of materials, which shortage </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unique </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Landlord or Tenant, as </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">case may </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be&#59; </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">governmental </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regu</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">la</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tion, moratorium </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or other governmental action, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">inaction </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or delay&#59; or other causes beyond Landlord&#8217;s control </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">collectively, &#8220;</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Force Majeure</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). In the event of such failure, Tenant shall not be entitled to termination of </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease or any abatement or </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">red</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uct</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ion </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Rent, nor </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant be relieved from </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operation of any covenant or agreement of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease. Landlord shall exercise </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonable di</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">igence and </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">good faith efforts </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remedy any </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interruption</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">curtailment, stoppage or suspension of services, utilities or systems, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and if </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interruption </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">services, utilities or systems is caused </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s gross negligence or willful misconduct </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall continue </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for more </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> busines</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">render </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any material portion of the Premises unusable for </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the purpose of </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conducting Tenant&#8217;s </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bus</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iness </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">permitted </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under this Lease, then all Base Rent </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payable </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereunder with respect </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the affected portion of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises shall be abated for the period beginning on the </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sixth </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) business day of such failure and </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">continue </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">until </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ubstant</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ia</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use of the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entire Premises is </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restored </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Tenant. In </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">addition, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any such interruption </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">caused </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the gross negligence </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">willful misconduct of Landlord and such interruption renders a </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mate</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rial </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">portion of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises untenan</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tab</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">le </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unusable</font><font style="color:#7e7e7e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Tenant for </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">it</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">business purposes, and Tenant, by reason thereof, cannot occupy all or such </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">material </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">portion of </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consecutive </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or a total </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, then </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have the right </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminate this Lease by giving notice to Landlord within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days after such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expires, and the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">partie</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no further obligations </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to each </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other except for such obligations as are expressly </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">stated </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thi</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease to </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">surv</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ive </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the termination of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thi</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.3</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">T</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">enan</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay for, prior to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delinqu</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ency </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of payment therefor, any </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uti</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ities </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and services that may </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">furnished to </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">during </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant occupies </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises after </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the exp</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iration </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">earlier </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termination </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Term, after </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Term, beyond those </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">utilities </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be provided </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuan</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">telephone, </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nternet </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">service, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cable television and other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">te</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lecommunica</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tions, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">together with </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fees, surcharges and taxes thereon. </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">demand</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">util</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ies </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and services provided </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are separately </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">metered </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be paid </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant directly </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the supplier of such utilities or services.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Regardless of whether a Turnover has occurred, Tenant </font><font style="color:#bfbfbf;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not, without </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior written consent, use any </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">device </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises (including data processing machines) that will in any way (a) increase the amount of ventilation, air exchange, gas, steam, electricity or water beyond </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the existing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">capacity of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building or </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he Project </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proportionately </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">allocated </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">based </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon Tenant&#8217;s Pro </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rata </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Share of the Common Areas&#59; or (b) exceed Tenant&#8217;s Pro Rata Share of the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bui</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lding&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(as </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ppl</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">icab</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">le) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">capacity </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to pro</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vide </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such utilities </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">services, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unless </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant makes </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">alterations </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">permit such device and agrees </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay any </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">increased </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">costs in connection therewith, provided Tenant shall obtain Landlord&#8217;s prior approval with respect to any such alterations (unless such alterations constitute Cosmetic Alterations), such approval not to be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord shall ensure that the Project will be managed and operated in accordance with comparable standards of quality followed in Comparable Buildings and Landlord shall take reasonable efforts to advise Tenant of all status changes relating to the management personnel for the Building.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord shall provide hot and cold water in the Premises for drinking, lavatory, kitchen, toilet and ordinary cleaning purposes only&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, however, that if Landlord determines that Tenant requires, uses or consumes water for any purpose other than such purposes, Landlord may install a water meter. Landlord shall keep said meter and installation equipment in good working order and repair at Landlord&#8217;s sole cost and expense. Tenant agrees to pay for water consumed, as shown on said meter, as and when bills are rendered. If Tenant fails to timely make such payments, Landlord may pay such charges and collect the same from Tenant. Any such costs or expenses incurred, or payments made by Landlord for any of the reasons or purposes hereinabove stated, shall be deemed to be Additional Rent payment by Tenant and collectible by Landlord as such.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Regardless of whether or not a Turnover has occurred, provided Landlord does not unreasonably interfere with Tenant&#8217;s use of the Premises and provided Landlord uses commercially reasonable efforts to provide such service again as soon as is reasonably possible after the cessation thereof, Landlord reserves the right to stop service of the elevator, plumbing, ventilation, air conditioning and electric systems due to accident, emergency or the need to make repairs, alterations or improvements, until such repairs, alterations or improvements shall have been completed, and Landlord shall further have no responsibility or liability for failure to supply elevator facilities, plumbing, ventilation, air conditioning or electric service when prevented from doing so by Force Majeure&#59; a failure by a third party to deliver gas, oil or another suitable fuel supply&#59; or Landlord&#8217;s inability by exercise of reasonable diligence to obtain gas, oil or another suitable fuel. Without limiting the foregoing, it is expressly understood and agreed that any covenants on Landlord&#8217;s part to furnish any service pursuant to any of the terms, covenants, conditions, provisions or agreements of this Lease, or to perform any act or thing for the benefit of Tenant, shall not be deemed breached if Landlord is unable to furnish or perform the same by virtue of Force Majeure.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">For the Premises, Landlord shall (a) maintain and operate the heating, ventilating and air conditioning systems used for the standard office and R&#38;D only, including HVAC related to laboratory fixtures and equipment (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">HVAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and (b) subject to clause (a) above, furnish HVAC as reasonably required (except as this Lease otherwise provides) for reasonably comfortable occupancy of the Premises twenty-four (24) hours a day, every day during the Term, subject to casualty, eminent domain or as otherwise specified in this Article. Notwithstanding anything to the contrary in this Section, Landlord shall have no liability, and Tenant shall have no right or remedy, on account of any interruption or impairment in HVAC services except as set forth to the contrary in this Lease&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Landlord diligently endeavors to cure any such interruption or </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">impairment as soon as the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">occurs. Any existing supplemental HVAC systems are hereby approved. Tenant shall have the right to install additional </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">supp</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lemental </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HVAC units in the Premises and </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">connect </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building&#8217;s chiller&#47;condenser system, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">su</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bje</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ct to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the prior </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">wri</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tten </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consent of Landlord, which consent </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be unreasonably withheld or delayed.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Throughout the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall be permitted to provide </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upplemental </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">services for the Building, subject to Landlord&#8217;s prior written consent, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consent not to </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unreasonably withheld, conditioned or delayed, including without limitation the right </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) mount, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operate and modify from </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ime </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to time </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">security </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">systems serving t</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building and in particular </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cameras </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">located </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on the exterior of the Building, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operate, modify from </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to time, remove and&#47;or </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">replace </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the deionized water </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">system serving </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building and </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operate, modify from time to </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">me</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remove and&#47;or </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">replace </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the fire&#47;life&#47;safety systems serving the Building. Landlord and Tenant each agree </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cooperate with the other to coordinate the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">secu</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ri</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ty </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">it provides with any security provided </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the other.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">For any utilities </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">serving </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises for which Tenant is billed directly by </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">utility provider, Tenant agrees </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">furnish </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord (a) any invoices or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tatements </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for such utilities within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days after Tenant&#8217;s </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">receipt </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof, </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days after Landlord&#8217;s </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">request, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any other </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">utility </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">usage information reasonably </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requ</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ested by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord, and (</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days after each calendar year during the </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ENERGY </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">STAR&#174; Statement of </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Performance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">similar </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">comprehensive utility usage report (e.g</font><font style="color:#565656;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, related </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Labs 21), if requested by Landlord) to the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">available </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant at </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">minim</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any other </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">inform</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ation reasonably </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requested </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord for </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he i</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mmedia</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ely </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">preceding </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">retain records of utility usage at the </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises, i</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nclud</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nvo</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ces </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and statements </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fro</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m the utili</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ty </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pro</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vider, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for at </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lea</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">st </font><font style="color:#7e7e7e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">months</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shorte</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of time as may be requested by Landlord. Tenant acknowledges </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any utility information for the </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premi</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ses, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building and the Project may be </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shared </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with third </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">parties, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including Landlord&#8217;s consultants </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Governmental Authorities. In </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that Tenan</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fails to comply with this Section, Tenant hereby authorizes Landlord to collect </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ut</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ility </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">u</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sage </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">information directly from </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">utility </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">providers.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Alterations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make no </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">alterat</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ion</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">additions or improvements </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises or engage in any construction, demolition, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">recons</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">truct</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ion, renovation, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or other </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">work (w</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ether </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">major or minor) of any kind in, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">serving </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premi</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Alterations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) without Landlord&#8217;s prior written approval, which approval Landlord </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not unreasonably withheld, conditioned or </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delayed</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">however</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that in </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event any proposed Alteration affects (a) any </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tructural </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">portions of the Building, including exterior walls, roof, foundation, foundation </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">systems </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(including barriers and </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subs</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lab </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">systems), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or core </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building, (b) the exterior of </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building or (c) </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">syste</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s, i</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ncluding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">elevator, </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">plumbing, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">air </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conditioning, heating, electrical, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">security, </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fe </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">safety </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and power, then Landlord </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">withhold its approval with </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respect </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereto in </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ts </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sole and </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">absolute </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">discretion. </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in making any </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such Alterations, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">only </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">those </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">architects, contractors, suppliers and mechanics </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord has </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">given </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior written approval, which </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">approval shall </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unreasonably </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">withheld, </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conditioned or delayed. </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">seeking </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">approval, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provide Landlord, </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">least </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fourteen </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(14) </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days in </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">advance </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of any proposed </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">construction, with plans, specifications, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bid proposals, </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">certified </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">stamped </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">engineering </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">drawings </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">calculations </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">engineer </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">record </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">architect or </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">record, (including connections to the Building&#8217;s </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">structural </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">system, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">modifications to the </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building&#8217;s envelope, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">non-structural penetrations </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">slabs </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or walls, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and modifications </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-ins </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ife </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">safety systems), </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">work contracts, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requests </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">laydown </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">areas </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other information concerning the nature </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and cost of </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Alterations as Landlord </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">request. </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">twith</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tand</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ng the </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foregoing, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">strictly </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cosmetic </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">changes to </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;Cosmetic </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Alterations&#8221;) </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s consent&#59; </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that (y) the </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost of any Cosmetic </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Alterations </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">does </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exceed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">one instance </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in any twelve-month </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period, (z) </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cosmetic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Alterations </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">do </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not (i) </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">require any </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">structural </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">modifications to the Premises, (ii) require any </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">changes </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to, </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or adversely </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">affect, the Building </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">systems, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">affect </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exterior </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Buildings </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or (iv) </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">trigger </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requirement under </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Applicable Laws </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">would </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">require Landlord </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make any alteration </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or improvement </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises, the Building or the Project. </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall give Landlord </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days&#8217; prior written notice o</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cosmetic </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Alterations.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.2</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant shall not </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">construct </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or permit </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">constructed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">partitions or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obstructions </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">might interfere with free </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">access </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to mechanical installation </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or service </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">facilities </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Building or </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other tenants&#8217; components </font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">located </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building, or interfere </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the moving </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equipment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to or from the enclosures containing </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such installations </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">facilities.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accomplish any work </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">performed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on the Premises or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">u</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">manner as </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">permit any life safety </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">systems </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to remain fully operable </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">times.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.4</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Any work </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">performed </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises, the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Project by </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or Tenant&#8217;s contractors </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">done at </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">times </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and in </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">manner </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time to time reasonably </font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">designate. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">covenants and agrees </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that all work done </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contractors </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">performed </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">full </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">compliance with Applicable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laws. Within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after completion </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of any Alterations, </font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Te</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provide Landlord </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with complete </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;as-built&#8221; drawing print </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sets </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and electronic </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CADD </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">files </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">disc </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or files </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">current </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">format </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">common </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably approves </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requires) showing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">changes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the Premises.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Before commencing any </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">work, Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">give Landlord </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">business </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days&#8217; prior </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the proposed commencement of </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such work&#59; provided, however, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deadline for Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to post </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notices of non</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">responsibility </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">similar </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notices requires more </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">advance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice, Tenant </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provide Landlord </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with prior written </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice at least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> business</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days&#8217; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior to </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deadline. </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the work is anticipated to </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">more than $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if required </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Landlord, Tenant shall secure, at Tenant&#8217;s own cost and expense, a completion and lien indemnity bond satisfactory to Landlord for said work (unless said work relates to Cosmetic Alterations).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">All Alterations, fixtures, equipment, additions, improvements and Signage, permanently attached to or built into the Premises and not listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto shall become the property of Landlord upon the expiration or earlier termination of the Term, and shall remain upon and be surrendered with the Premises as a part thereof&#59; provided, Landlord shall have the right to notify&#59; Tenant, at the time Landlord provides its consent to any Alteration, that Tenant shall be required to remove such Alteration upon the expiration or earlier termination of the Term. Tenant shall have the right to deliver an updated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> from time to time, which </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be deemed to replace the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto, provided such updates shall be subject to the prior written approval of Landlord, such approval not to be unreasonably withheld, conditioned or delayed. The Premises shall at all times remain the property of Landlord and shall be surrendered to Landlord upon the expiration or earlier termination of this Lease. All such Alterations, fixtures, equipment, additions, improvements and Signage installed by or under Tenant shall be the property of Landlord.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant shall repair any damage to the Premises caused by Tenant&#8217;s removal of any property from the Premises. During any such restoration period, Tenant shall pay Rent to Landlord as provided herein as if said space were otherwise occupied by Tenant. The provisions of this Section shall survive the expiration or earlier termination of this Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Except as to those items listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto, all business and trade fixtures, machinery and equipment, built-in furniture and cabinets, together with all additions and accessories thereto, installed in and upon the Premises and owned by Tenant as of the date of this Lease shall be and remain the property of Tenant and shall not be moved by Tenant at any time during the Term (unless the same is replaced with items of reasonably equivalent value). If Tenant shall fail to remove any of its effects from the Premises which are not required to stay in the Premises under the terms of this Lease prior to or upon the termination of this Lease, then upon prior written notice to Tenant Landlord may, at its option, remove the same in any manner that Landlord shall choose and store said effects without liability to Tenant for loss thereof or damage thereto, and Tenant shall pay Landlord, upon demand, any costs and expenses incurred due to such removal and storage or Landlord may, at its sole option and without notice to Tenant, sell such property or any portion thereof at private sale and without legal process for such price as Landlord may obtain and apply the proceeds of such sale against any (a) amounts due by Tenant to Landlord under this Lease and (b) any expenses incident to the removal, storage and sale of said personal property, with the balance thereafter being paid to Tenant.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Notwithstanding any other provision of this Article to the contrary, in no event shall Tenant remove any improvement from the Premises as to which Landlord contributed payment without Landlord&#8217;s prior written consent, which consent Landlord </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may withhold </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n it</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s sole </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and absolute discretion, </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unle</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ss the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same is replaced with </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equivalent value improvement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sh</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord an amount equal to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">percent (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the actual costs to Tenant of all changes </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">stalled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Tenant or </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ts </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contractors or agents which </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">require </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s approval, which costs will include </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">actual </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">third party out-of-pocket costs incurred by Landlord in connection </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">therewith </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(but not in excess of </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.00 per </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rentable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">square foot of </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises), </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cover </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">overhead and expenses </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">plan </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rev</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iew</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">coordination, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sched</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uling </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and supervision thereof. For purposes of payment of such sum, Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">submit to Landlord copies of all </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bills, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">invoices and </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">statements </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">covering the costs of </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such charges, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accompanied by payment to Landlord of </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the fee se</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in thi</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section. Tenant shall reimburse Landlord </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for any extra </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expenses incurred by Landlord </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reason of faulty work </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">done by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contractors or by reason of </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">inadequate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">clean-up.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> da</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ys </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after final completion of any Alterations performed by </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">wi</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respect </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the Premises, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Te</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">submi</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord documentation </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">howing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the amounts expended by Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respect to </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suc</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Al</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">teratio</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ns </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">performed </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant with respect to the </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premi</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ses, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">together with </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">support</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">documentation reasonably acceptable </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.12</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Tenan</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requ</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ire its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contractors and </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">su</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bcontractors </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">performing work on </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o name Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ts </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">affiliates and Lenders as additional insureds on </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">their </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respec</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tive </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">policie</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Repairs and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">As further detailed on </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhi</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">bit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nd </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incorporated herein by </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">refe</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rence</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord shall </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">repair, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">replace and maintain </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accordance </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with s</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tandard</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for comparable first-class buildings in the Rockville, Maryland area and in accordance with all </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">App</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">licable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laws (a) the Common Areas, (b) the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">struc</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tural </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and exterior </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">po</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rtion</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Building and </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pro</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">jec</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including without </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">limitation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">roofing and covering materials, foundations and exterior walls (collectively, the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">S</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">tructura</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">l </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Building improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and (c) upon Tenant&#8217;s request for a </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Turnover </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">43</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Turnover </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Da</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">te, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the elevators </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">base Building </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">plumb</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ing, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fire </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and life </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">safe</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ty</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hea</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ting, ventilating, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">air conditioning, electrical, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">security and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mechanical systems </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">collectively, </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buildin</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">g </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">System </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">As </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">further </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">detailed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto</font><font style="color:#aaaaaa;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incorporated herein by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reference, Tenant shall at Tenant&#8217;s sole cost and </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ex</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">maintain and </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">keep </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises and every part thereof in good condition and repair, damage thereto from ordinary wear </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tear excepted, it being </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">understood </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and agreed by Landlord </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hat o</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rdi</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">wear and </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ear </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purpo</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ses of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease shall mean operation of the Building and the Building </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sys</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tem</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24 </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hours </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">per </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">day, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days per week, 365 days per year. Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sh</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">al</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon the expiration or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sooner </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termination of the Term, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">urrender </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premi</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Landlord </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as good a condition as </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">when </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">received</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ordinary wear </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tear excepted&#59; </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall remove all </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Tenant&#8217;s personal </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">property listed on </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">H</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">attached </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereto </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nd incorporated herein </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by reference </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(which list may be updated from time </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to time </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant</font><font style="color:#5b5b5b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject to Landlord&#8217;s prior written approval, such approval </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not to b</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unreasonably withheld, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conditioned </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delayed), </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">repair </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Pre</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mises </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">caused </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">her</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eby. Upon </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such surrender, Landlord shall have </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligation to alter</font><font style="color:#5b5b5b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remodel, improve, repair, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">decorate </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">paint the Premises </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or any </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">part </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reof.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Except as otherwise set forth herein, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#5b5b5b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be liable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for any failure </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make any </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">repairs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">perform any </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">maintenance that is an obligation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">except as set </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 31.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">If any excavation shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">made </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon land </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">adjacent </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bu</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lding</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">authorized </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">made, Tenant </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">afford to the person causing or authorized </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cause such excavation, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">license </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">enter the Premises </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purpo</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">se </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">performing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such work as said </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">person </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall deem </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">necessary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">desirable to preserve </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pro</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tec</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building from injury </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to support the same </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proper foundations, without any claim for damages or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">liability </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">against Landlord and without reducing or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">otherwise </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">affecting </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pro</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">v</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ided Tenant</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">will </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">materially and adversely interfered with </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">connection </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">therewith.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.5</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">T</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">his Article relates to repa</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">irs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">maintenance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">arising </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ordinary course of operation of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event of a casualty described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">24</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">apply </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in l</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ieu </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Article</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event of eminent </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">domain</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall apply in </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ieu </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Costs </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incurred by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Article </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">constitute Operating Expenses, unless such costs are incurred </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">due </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whole or </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n part to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any act, neglect, fault or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">omissions </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ts </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employees, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agent</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contractors or </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nvitees</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which case Tenant shall pay </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Land</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lo</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost of such </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">repairs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and maintenance.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.1</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Te</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nant </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall keep the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">P</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ojec</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">free </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from any liens arising </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">out </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of work performed </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by, material</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">furnished </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligations </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incurred by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant. </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ten</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ant further </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">covenants and agrees </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mechanic&#8217;</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lien </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">filed against </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises, the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bu</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lding or the Project </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for work </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">claimed to have been </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">done for, or materials </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">claimed to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have been furnished to, Tenant shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">discharged or bonded </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days after the filing </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sole cost </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expense.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Should </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant fail to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">discharge or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bond </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">against any </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lien </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nature described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">19</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.1</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Lan</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may, at </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lan</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">dlord&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">election, pay such claim or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">post a bond </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or otherwise </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provide </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">security </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to elim</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ina</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">te the lien </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as a </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">claim </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">against </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">title, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and Tenant shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">immediate</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ly </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reimburse Landlord </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for the costs thereof </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Additional Rent. Tenant </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall indemnify, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">save, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defend </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(at </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lan</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lo</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd&#8217;</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">option and with counsel </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acceptable </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Landlo</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ho</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ld </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Landlord Indemnitees </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">harmless from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and against any Claims </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">arising </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any such </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">liens, including </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">administrative, </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">court </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or other leg</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proceedings </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">related </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such liens.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.3</font><font style="color:#010101;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">In </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the event </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leases </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">finance</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s t</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acquisition </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">trade fixtures, office </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equipment, furni</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sh</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ings or </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">personal property of </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a removable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nature utilized by </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Tenant&#8217;s business, Tenant </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">warrants that any Uniform Commercial </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Code financing </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">statement shall, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">face </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or by exhibit </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereto, indicate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such financing statement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable only </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">re</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mova</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ble per</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">onal property of </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant located within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises. In no event </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">address of the Premises, the Building </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project be furnished </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">financing statement without qualifying </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">guage </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicabilit</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">y </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the lien only to </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">removable personal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">property </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">located </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in an </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">identified </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sui</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leased by </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant. Should </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">holder </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a financing statement record </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">place of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">record </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a financing statement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that appears to </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">constitute </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a lien </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">against any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interest o</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or against </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equipment that may be </font><font style="color:#010101;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">located </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other than </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">identified </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suite </font><font style="color:#010101;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leased </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant, Tenant shall, within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#010101;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after filing such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">financing </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">statement, cause (a) a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">copy </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Lender </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">security agreement or other </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">document</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">financi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ng </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">statement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pertains </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be furnished </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Landlord to facilitate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Land</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd&#8217;s </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ability </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to demonstrate that the lien </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">financing statement is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Land</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd&#8217;s interest and </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lender </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to amend such financing statement and any other documents of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">record </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">clarify </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">liens </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">imposed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereby </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable to </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">intere</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Landlord in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises, the Building or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Pro</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">jec</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Estoppel Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenan</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall, within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#010101;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days after </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">receipt </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of written </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from Landlord, execute, acknowledge </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and deli</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">v</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">er </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sta</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tement in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Writing </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ubstantially in </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he form attached to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">I</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any other form </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably requested by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a proposed </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lender or purchaser</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) certifying </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unmodified and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">full force and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">modified, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">stating </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nature </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">modification </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and certifying </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that this Lea</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">se </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o modified is in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">full </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">force </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and effect) and the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rental </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and other charges </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">paid </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">advance, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acknowledging </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">there are </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">knowledge, any uncured defaults on the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">part </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Landlord </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereunder, or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specifying </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defaults </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">claimed, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">se</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tting </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth such further factual information with respect to this </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease or </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he Pr</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">emises </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be reasonably </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requested </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereon. </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such statement may be </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relied </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prospective </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purchaser or encumbrancer of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any portion of the real property </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which the Premises are a part. </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fa</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lure </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delive</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such statement within such </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prescribed time shall, at </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">option, constitute a </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Default (a</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defined below) under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, and, in </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event, shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">binding upon Tenant </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in full force </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and effect </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and without modification except as may be represented </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Landlord </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any certificate </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prepared by Land</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lo</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd and delivered to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant for </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">execution. Landlo</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after receipt of written </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">execute, acknowledge and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">del</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ive</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">comparable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">certificate to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as set forth above, provided </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Land</font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lo</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failure to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deliver </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tatement within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prescribed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be deemed to be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an acknowledgment </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that the Lease </font><font style="color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in full force </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect and without </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">modification.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant shall not cause or permit any Hazardous Materials (as defined below) to be brought upon, kept or used in or about the Premises, the Building or the Project in violation of Applicable Laws by Tenant or its employees, agents, contractors or invitees. In the event that&#58; (a) any Hazardous Materials are brought upon, kept or used in or about the Premises, the Building or the Project in violation of Applicable Laws by Tenant or its employees, agents, contractors or invitees at any time during the Term or any extension or renewal hereof or holding over hereunder, (b) the presence of Hazardous Materials is the result of Tenant&#8217;s breach of the covenants set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 21.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and results in contamination of the Project, any portion thereof, or any adjacent property, or (c) contamination of the Project, any portion thereof, or any adjacent property by Hazardous Materials otherwise occurs at any time during the Term or any extension or renewal hereof or holding over hereunder, then Tenant shall indemnify, save, defend (at Landlord&#8217;s option and with counsel reasonably acceptable to Landlord) and hold the Landlord Indemnitees harmless from and against any and all Claims, including (a) diminution in value of the Project or any portion thereof, (b) damages for the loss or restriction on use of rentable or usable space or of any amenity of the Project, (c) damages arising from any adverse impact on marketing of space in the Project or any portion thereof and (d) sums paid in settlement of Claims that arise prior to, during or after the Term as a result of such breach or contamination. This indemnification by Tenant includes costs incurred in connection with any investigation of site conditions or any clean-up, remedial, removal or restoration work required by any Governmental Authority because of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Hazardous Materials present in the air, soil or groundwater above, on or under or about the Project. Without limiting the foregoing, if the presence of any Hazardous Materials in, on, under or about the Project, any portion thereof or any adjacent property caused or permitted by Tenant results in any contamination of the Project, any portion thereof or any adjacent property, then Tenant shall promptly take all actions at its sole cost and expense as are necessary to return the Project, any portion thereof or any adjacent property to its respective condition existing prior to the time of such contamination&#59; provided that Landlord&#8217;s written approval of such action shall first be obtained, which approval Landlord shall not unreasonably withhold&#59; and provided, further, that it shall be reasonable for Landlord to withhold its consent if such actions could have a material adverse long-term or short-term effect on the Project, any portion thereof or any adjacent property. Nothing in the foregoing shall obligate Tenant to provide any indemnity with respect to periods prior to the Commencement Date.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord acknowledges that it is not the intent of this Article to prohibit Tenant from operating its business for the Permitted Use. Tenant may operate its business according to the custom of Tenant&#8217;s industry so long as the use or presence of Hazardous Materials is strictly and properly monitored in accordance with Applicable Laws. As a material inducement to Landlord to allow Tenant to use Hazardous Materials in connection with its business, Tenant agrees to deliver to Landlord upon the request of Landlord prior to the Term Commencement Date a list identifying each type of Hazardous Material to be present at the Project arid setting forth any and all governmental approvals or permits required in connection with the presence of such Hazardous Material at the Project (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Hazardous Materials List</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Upon Landlord&#8217;s request, Tenant shall deliver to Landlord an updated Hazardous Materials List on or prior to each annual anniversary of the Term Commencement Date and shall also deliver an updated Hazardous Materials List before any new Hazardous Materials are brought to the Project. Tenant shall deliver to Landlord true and correct copies of the following documents (hereinafter referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) relating to the handling, storage, disposal and emission of Hazardous Materials prior to the Term Commencement Date or, if unavailable at that time, concurrently with the receipt from or submission to any Governmental Authority&#58; permits&#59; approvals&#59; reports and correspondence&#59; storage and management plans&#59; notices of violations of Applicable Laws&#59; plans relating to the installation of any storage tanks to be installed in, on, under or about the Project (provided that installation of storage tanks shall only be permitted after Landlord has given Tenant its written consent to do so, which consent Landlord may withhold in its sole and absolute discretion)&#59; and all closure plans or any other documents required by any and all Governmental Authorities for any storage tanks installed in, on, under or about the Project for the closure of any such storage tanks. Tenant shall not be required, however, to provide Landlord with any portion of the Documents containing information of a proprietary nature, which Documents, in and of themselves, do not contain a reference to any Hazardous Materials or activities related to Hazardous Materials. Upon Landlord&#8217;s written request, Tenant agrees that it shall enter into a written agreement with other tenants of the Project concerning the equitable allocation of fire control areas (as defined in the Uniform Building Code as adopted by the city or municipality(ies) in which the Project is located (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">UBC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)) within the Project for the storage of Hazardous Materials. In the event that Tenant&#8217;s use of Hazardous Materials is such that it utilizes fire control areas in the Project in excess of Tenant&#8217;s Pro Rata Share of the Building or Common Areas, as applicable, as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Tenant agrees that it shall, at its sole cost and expense and upon Landlord&#8217;s written request, establish and maintain </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a separate area of the Premises classified by the UBC as an &#8220;H&#8221; occupancy area for the use and storage of Hazardous Materials or take such other action as is necessary to ensure that its share of the fire control areas of the Building and the Project is not greater than Tenant&#8217;s Pro Rata Share of the Building or Common Areas, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">At any time, and from time to time, prior to the expiration of the Term, Landlord shall have the right to conduct appropriate tests of the Project or any portion thereof to demonstrate that Hazardous Materials are present or that contamination has occurred due to Tenant or Tenant&#8217;s employees, agents, contractors or invitees. Tenant shall pay all reasonable costs of such tests if such tests reveal that Hazardous Materials exist at the Project in violation of this Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">If underground or other storage tanks storing Hazardous Materials are located on the Premises or are hereafter placed on the Premises by any party, Tenant shall monitor the storage tanks, maintain appropriate records, implement reporting procedures, properly close any underground storage tanks, and take or cause to be taken all other steps necessary or required under the Applicable Laws.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant&#8217;s obligations under this Article shall survive the expiration or earlier termination of the Lease. During any period of time needed by Tenant or Landlord after the termination of this Lease to complete the removal from the Premises of any such Hazardous Materials, Tenant shall be deemed a holdover tenant and subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">As used herein, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Hazardous Material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any hazardous or toxic substance, material or waste that is or becomes regulated by any Governmental Authority.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord shall require other tenants in the Project to comply with obligations comparable to those set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Odors and Exhaust</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant will restrict odors or fumes (whether or not noxious), from emanating from the Premises, provided, however, that Landlord acknowledges and agrees that Tenant shall have the right to operate one or more (currently three) supplemental generators during the Term generally consistent with the demand response requirements currently set forth in Tenant&#8217;s utility contract with Enernoc, a copy of which has been provided to Landlord. In addition, Tenant shall have the right to operate such generators on a regular basis for maintenance purposes and at any other times in Tenant&#8217;s reasonable discretion.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant shall vent all fumes and odors from the Premises (and remove odors from Tenant&#8217;s exhaust stream) in compliance with Applicable Laws, and as Landlord reasonably requires. The placement and configuration of all material changes to the ventilation exhaust pipes, louvers and other equipment shall be subject to Landlord&#8217;s approval, such approval not to be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant shall, at Tenant&#8217;s sole cost and expense, provide odor eliminators and other devices (such as filters, air cleaners, scrubbers and whatever other equipment may in Landlord&#8217;s reasonable judgment be necessary or appropriate from time to time) to remove, eliminate and abate to the extent practicable any odors, fumes or other substances in Tenant&#8217;s exhaust stream that, in Landlord&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonable judgment, emanate from Tenant&#8217;s Premises. Any work Tenant performs under this Section shall constitute Alterations.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall continue throughout the Term. In connection with any request by Tenant to make Alterations associated with the ventilation system of the Building, Landlord&#8217;s approval of such Alterations shall not preclude Landlord from requiring additional measures to eliminate odors, fumes and other adverse impacts of Tenant&#8217;s exhaust stream (as Landlord may designate in Landlord s discretion).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord shall use commercially reasonable efforts to require other tenants in the Project to comply with obligations comparable to those set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Insurance&#59; </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subrogation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.1</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">maintain </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Project </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in amounts equal to </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">full </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">replacement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost (exclusive of the costs of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">excavation, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foundations and footings, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without reference </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">depreciation taken by </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon its books or </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tax returns) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or such </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lesser </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">coverage as </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">elect. provided </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">coverage </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">less </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> percent (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">full </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">replacement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost or </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amount </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s Lender, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requires Landlord to maintain, providing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">protection against any peril generally included within </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the classification </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Fire </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Extended Coverage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">together </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with insurance against sprinkler </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(if </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vandalism and malicious </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mischief. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord, subject </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">availability </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall further </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insure, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deems </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">it </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">appropriate, coverage against </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">flood, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">environmental hazard, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">loss </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or failure of building equipment, rental loss during </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">repairs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rebuilding, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">workmen&#8217;s compensation </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and fidelity bonds for employees employed to </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">perform </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">services. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foregoing, Landlord may, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">but </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be deemed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to, provide </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for any </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">improvements </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">installed </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">addition</font><font style="color:#aaaaaa;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">standard </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">improvements </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">customarily furnished </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Landlord, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regard </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to whether or not </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are made a </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">part </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of or are affixed </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">In addition, Landlord shall carry comprehensive public </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">liability </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance with limits of not </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">less </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Dollars </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">($</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) per </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">occurrence for death or bodily </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">injury </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or property </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with respect </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Project.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">own cost </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and expense, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">procure </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">maintain </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in effect, beginning on the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term Commencement Date and continuing </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">throughout </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term (and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">occupancy by </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any, after </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termination </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">comprehensive </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">public liability insurance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">limits </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of not </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">less </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#c3c3c3;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dollars ($ </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) per occurrence for </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">death </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bodily </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">injury </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for property </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respect to </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(including $ </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fire </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">legal liability </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(each </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">loss)).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.4</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">The </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required to be purchased </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">maintained by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant pursuant to this Lease </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">name </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BioMed Realty, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L.P., BioMed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Realty </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Trust, Inc. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and their respective officers, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">directors, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employees, agents, general </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">partners, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">members, subsidiaries, affiliates </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lenders (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as additional </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insureds. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Said insurance shall be with </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">companies </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">having a rating of not less </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">policyholder rating </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of A minus and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">financial </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">category rating of at least </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Class </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VIII X in &#8220;Best&#8217;s </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Insurance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Guide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; Tenant</font><font style="color:#aaaaaa;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obtain for </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">companies or cause </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance companies </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">furnish certificates of coverage </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord. </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">policy </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cancelable or </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cancellation except after </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days&#8217; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior written </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord from </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurer </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">except </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of non-payment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">premium, in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which case </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days&#8217; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">given). All </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">policies shall be written as primary policies, not contributing with and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in excess of the coverage </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may carry.</font><font style="color:#c3c3c3;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">policy </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may be </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;blanket </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">policy&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specifically </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provides that </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amount of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be prejudiced </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by other losses covered </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">policy. </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall, at </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expiration </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such policies, furnish Landlord with renewals or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">binders</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant agrees that </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">does </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">take </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">out </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and maintain such </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance, Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may (but </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll not be required </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to) </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">procure </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">said </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on Tenant&#8217;s behalf and at </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ts </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">paid by Tenant as Additional Rent.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant assumes </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">risk of damage to any fixtures, goods, inventory, merchandise, equipment and </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leasehold </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">improvements owned by Tenant, and Landlord </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">injury </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bu</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">siness </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any loss </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of income therefrom, relative </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch damage</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all as more particularly set forth </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Te</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nant&#8217;s so</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">le </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost and expense, carry such </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nsurance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Tenant desires for </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Te</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nant&#8217;s pro</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tection </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">res</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pect to pe</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rsonal </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">property </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Tenant or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bus</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iness </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interruption.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">In each instance where insurance is to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">name </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Parties </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as additional insureds, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon Landlo</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written request, also designate and furnish certificates evidencing </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Parties as additional </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ins</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ureds </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to (a) any Lender of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">holding </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">security </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interest  the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building, the Property or the Project, (b) the </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">land</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lo</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under any </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whereunder Landlord </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s a tenan</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Property </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if the interest of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is or </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">become that of a </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenant under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a ground </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rather than that </font><font style="color:#4b4b4b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fee owner and </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c) </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">management company retained by Landlord to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">manage the Pro</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">jec</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.7</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Te</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">each </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereby </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">waive any </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all rights of recovery against the other or </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">aga</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">inst </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">officers, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">directors</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employees, agents, general partners, members, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ub</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">idiaries, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">affiliates and </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lenders of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the other on account of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">loss </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or damage occasioned by </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">waiving </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">p</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">arty </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its property </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">property </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of others </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">waiving party&#8217;s </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contro</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">each case </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extent </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">loss </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or damage is insured against </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any fire and extended coverage insurance policy </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tha</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">either </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ten</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may have </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">force at </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he time </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of such </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">loss </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or damage or is </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">req</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uired to be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">carried under </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease. Such waivers shall continue so </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">long </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as their respective </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurers </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so permit. Any </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termi</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a waiver </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written notice </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">party</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">containing a </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">de</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">scri</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ption </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the circumstances </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereinafter </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set forth in. </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section. Landlord and Tenant, upon obtaining the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">policie</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of insurance </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">permitted under </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">give notice to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the insurance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">carrier or carriers that the foregoing </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mutual </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">waiver of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">su</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">brogat</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ion is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contained </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the extent </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required by </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance policy. If </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">p</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">olicies shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obtainable with </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">waiver or </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obtainable only at a premium over that chargeable without such waiver, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then the party </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">seeking such policy </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tify </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the other of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conditions, and the party </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notified shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ave </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days thereafter to either (a) procure </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance with companies </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">satisfactory </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other party or (b) agree to pay such additional premium (in Tenant&#8217;s case, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he proportion tha</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">area of the Premises bears </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insured area). </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the parties do </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accomplish either (a) or (b), then this </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ha</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ve </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">during such time as </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suc</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h policies </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obtainable or the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">party in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whose </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">favo</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">waiver of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ubrog</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ion is </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">de</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sired </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">refuses to pay the additional premium. If </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">policies </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at any </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ime </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be unobtainable, but </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll be </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ub</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">seq</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uently </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obtainable, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hen </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">neither </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">party </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subsequently </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">liable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for a failure to obtain such insurance until a reasonable </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after notification </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereo</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other party. If the release of either </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenan</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth in </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">first sentence of this </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section, shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contravene Applicable </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">aws, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then the </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">liability of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">party in question </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deemed </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not released but </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">secondary </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the other party&#8217;s insurer.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord may require insurance </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">policy </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">limits </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required under</font><font style="color:#bfbfbf;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease to be </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">raised </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to time, provided, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">increases </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not exceed </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">coverage amounts required by landlords in other Comparable Buildings.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Any costs </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incurred </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Landlord pursuant to this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">constitute a portion </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Operating Expenses.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Damage </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Destruction.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">In the event of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">partial destruction </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) the Premises or (b) Common </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Areas </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">((a) and </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">together, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affected </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Areas</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fire </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or other perils </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">covered </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extended coverage </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exceeding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> percent (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%)</font><font style="color:#010101;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the full insurable </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">value </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and provided </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x) the damage thereto is </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that the Affected </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Areas </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may be </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">repaired, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reconstructed </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restored within a </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of twelve (12) </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">months from the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">happening </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">casualty, (y) Landlord </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">receive insurance proceeds </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sufficient </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cover </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">repairs (</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">except for any deductible </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amount provided by Landlord&#8217;s policy, which deductible amount, if paid by Landlord, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">constitute </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating Expense), and (z) </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">casualty was not intentionally caused by Tenant or its </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employees, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commence </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proceed diligently with the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">work </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">repair, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reconstruction </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restoration of the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Affected </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Areas </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">continue </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in full </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">force and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">In </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event of any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage to or destruction </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises or the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Common </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Areas </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as described </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">24.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Landlord </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may elect </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to repair, reconstruct and restore the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Common Areas, as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable, in which case </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease shall </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">continue in full </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">force and </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Landlord </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">elects </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not to repair the Building or the Project, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as applicable, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then this Lease </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminate </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the date of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">destruction.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord shall </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">give </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written notice </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days following the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date of damage </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or destruction </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of its </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">election </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not to repair, reconstruct </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or restore </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building or the Project, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable, subject </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.4</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">anything </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the contrary </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contained </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in this Article, </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of any damage to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">destruction of (a) the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that materially and </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">adversely </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">affects </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operations </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises&#59; (b) the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Common </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Areas </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">materially </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and adversely </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">impairs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s access to </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises&#59; or (c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> percent (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%) </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s lab </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">space </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> percent </font><font style="color:#010101;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#010101;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%) </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">office space </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determined by Landlord&#8217;s architect (each, a </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Material </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and the Premises cannot be made reasonably tenantable for Tenant&#8217;s </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operations </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">access </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cannot </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be reasonably </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restored </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within one </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year after </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage or </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">destruction, as reasonably estimated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#010101;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">destruction occurred, </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then Tenant shall have the right to </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminate the Lease </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the date of </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">destruction.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.5</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Upon </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any termination </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease under any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provi</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ions of </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Article, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the part</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">es shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be re</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eased </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereby </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without further </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligation to </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other from the date </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">possession of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">surrendered to Landlord</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">except </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with rega</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd to </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) items </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">occurring prior to the damage or </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">destruction </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and (b) </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provisions of this Lease that,</font><font style="color:#bcbcbc;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by their </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">express </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms, </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">survive </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expiration </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">earlier </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termination </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereof.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.6</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">In </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event of repair, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reconstruction </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and restoration as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article, all Rent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be paid </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">abated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proportionately based </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the extent to </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises is impaired during </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of such repair, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reconstruction </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or restoration, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unless </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord provides Tenant with other space </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">during the period </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of repair that, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s reasonable opinion, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suitable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for the temporary </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conduct of Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">business&#59; provided, </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the amount of such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">abatement </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be reduced by the </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proceeds </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">business </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interruption or loss </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of rental income </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insur</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nce </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">actually received by Tenant with </font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">espect </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises</font><font style="color:#5e5e5e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Notwithstanding anything </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the contrary contained </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in</font><font style="color:#7e7e7e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article, should Landlord </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be delayed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prevented from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">completing the </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">repair, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reconstruction </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or restoration </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or destruction </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises after </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the occurrence </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of such </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">destruction </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Force Majeure, then </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the time </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">comm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ence </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">complete repairs shall </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extended on a day-for-day basis&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, however, after </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of such </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delay</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s election, </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be relieved </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligation </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make such </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">repair, reconstruction </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restoration. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Land</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ord </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">elects </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to make </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">repair, reconstruction </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restoration </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or destruction constitutes a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Material Loss, </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">right </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminate this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease as of </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such damage </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or destruction.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.8</font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">If Landlord is obligated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">elects to repair, </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reconstruct or restore as herein provided, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then Landlord </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be obligated to </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make such repair, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reconstruction </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restoration </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">only with regard to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) those portions of the Premises that </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">were </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">originally </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided at Landlord&#8217;s expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or in </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">existence at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Commencement Date and (b) the Common Area </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">portion of </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Affected </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Areas. </font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">repair, reconstruction </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restoration </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">improvements </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">originally </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided by Landlord </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at Landlord&#8217;s expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in existence</font><font style="color:#bcbcbc;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Commencement Date shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the obligation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant. In the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">elected </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to upgrade </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">certain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">improvements </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">need for </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">replacement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">due to </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insured loss, provide only </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standard, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unless </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">again </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">elects to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upgrade </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such improvements and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any incremental </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">costs related </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereto, except </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the extent tha</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">excess </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proceeds, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">received, are adequate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to provide </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upgrades, in </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">addition </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to providing </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">basic repair, </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reconstruction </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and restoration </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2a2a2a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the Project.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Notwithstanding anything to the contrary contained </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article, Landlord shall </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not have any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligation whatsoever to repair, </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reconstruct or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restore the </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if the </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">resulting </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any casualty covered </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under this Article </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">occurs during </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the last </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">months of the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or any extension hereof or to the extent that insurance</font><font style="color:#bfbfbf;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proceeds are not </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">available&#59; </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided, however, if Landlord elects not ot make such repair, reconstruction or restoration and </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage or destruction constitutes a Material </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Loss, then </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shal</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have the right to terminate this Lease </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage or destruction. </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">anything </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the contrary contained in </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article, in the event that any </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Material </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Loss occurs during the last </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">months </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term and </font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th</font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises cannot be reasonably </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restored within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> months after the date of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage or destruction, as reasonably estimated by Landlord </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days after </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage or destruction occurred, then Tenant shall have the right to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminate the Lease </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the date of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such damage or </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">destruction.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Landlord&#8217;s obligation, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shou</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ld </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">it elect or be obligated to repair or rebuild, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be limited </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Affected Areas. Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at its expense, replace or fully repair </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Tenant&#8217;s personal property and any Alterations installed by Tenant existing at the </font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage or destruction. If Affected Areas are to be repaired in accordance with the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foregoing, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall make </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">available to Tenant any portion of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proceeds </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">it </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">receives that </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are allocab</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">le </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the Alterations constructed by Tenant pursuant to this Lease&#59; provided Tenant is not then </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">default under this Lease, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the requirements of any Lender of Landlord.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Eminent Domain</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25.1</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">In </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the event (a) the whole of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or either of the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Affected </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Areas or (b) such </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">part </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as shall substantially </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interfere with Tenant&#8217;s use and occupancy of the Premises for the Permitted </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Use shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taken </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for any public or quasi-public purpose by any lawful power or authority by exercise of the right of appropriation, condemnation or eminent domain, or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sold </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to prevent </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taking, Tenant or Landlord </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminate this Lease effective </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date possession </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is required </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to be </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">surrendered </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">said authority, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">except with regard to (y) </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">items </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">occurring prior to the damage or destruction and (z) provisions of this </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, by their express terms, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">survive </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expiration </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">earlier termination </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereof.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">In the event of a partial taking of (a) the Building or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Common Areas or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">drives, walkways or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">parking </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">areas </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">serving </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building or the Project for any </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">public </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or quasi-public </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purpose </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lawful power or authority by exercise </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">right of appropriation, condemnation, or eminent domain, or sold to prevent </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such taking, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then, without regard to whether any portion of the Premises occupied by Tenant was </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taken, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord may </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">elect to terminate this </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(except with regard to (a) items occurring prior to the damage or destruction and (b) provisions of this Lease that, by </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">their </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">express </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms, survive </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the expiration or earlier termination hereof) as of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taking if </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such taking </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is, in Landlord&#8217;s reasonable opinion, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">material nature </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">it uneconomical </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">continue use of the unappropriated portion for purposes of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">renting </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">office or </font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">laboratory </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">space and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminates </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all of the other </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leases </font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Project </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">im</font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#050505;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">larly </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">affected.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be entitled </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">award that </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specifically </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">awarded </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">compensation for </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the taking </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">personal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">property </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">was installed </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expense </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and (b) the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">costs </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">moving to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">new </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">location. Except </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as set forth in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the previous </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sentence, any </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">award </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for such </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taking </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the property </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">If, upon </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taking of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nature described </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease continues </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect, then </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">promptly </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proceed to </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restore </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Affected </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Areas to </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">substantially </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">their </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">condition prior to </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such partial </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taking. </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extent such </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restoration </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">infeasible, </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determ</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Landlord in </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">scre</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ti</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">decreased </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proportionately to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reflect </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">loss </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">portion </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">longer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">available </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Surrender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.1</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">At </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s surrender of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">possession of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">part of the Premises, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Permitted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Use </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for other than office use</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall provide </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a facility decomm</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ssio</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ning </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Hazardous </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Materials closure plan </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exit </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survey</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prepared by </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">independent </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">third party </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acceptable </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord, and </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written evidence of all </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">appropriate governmental releases obtained </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accordance with Applicable </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laws, including </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">laws </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pertaining </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">surrender </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises. </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">addition, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agrees </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to remain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">responsible after </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">surrender </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remediation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">recognized </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">environmental </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conditions </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set forth </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exit Survey </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">compliance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">recommendations </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth in </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exit Survey. Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligations under this </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">survive </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expiration or </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">earlier </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termination of the Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">No surrender of </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">possession of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">part of the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">release Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 26.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unless </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such surrender </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accepted </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">writing by Landlord </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in its reasonable discretion.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">The </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">voluntary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">surrender </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease by </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">merger with Landlord&#8217;s </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fee title </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">easehold </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interest </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the Premises</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Property </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or the Project, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unless </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consents in writing</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at Landlord&#8217;s </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">op</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ti</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on,</font><font style="color:#7e7e7e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operate as an </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assignment </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord of any or </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all subleases.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.4</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">The </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">voluntary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other surrender </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of any ground or other </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">underlying lease </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that now </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exists or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereafter </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">executed affecting the Building </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project, or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a mutual cancellation thereof or of Landlord&#8217;s </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interest </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">therein </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and its le</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect a merger with </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fee title </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leasehold </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interest </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the P</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remi</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">es, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building or the Property </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and shall, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">option </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">successor </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Landlord&#8217;s </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interest in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building or </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Project, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable, operate </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as an assignment of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease</font><font style="color:#484848;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Holding Over</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">If, with Landlord&#8217;s prior </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consent, Tenant </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">holds </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">possession of all or any part of the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Term, Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">become</font><font style="color:#9e9e9e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from month to month </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expiration or earlier termination of the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term, and in such case </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall continue to pay (a) Base </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent in accordance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">adjusted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and (b) any </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amounts </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for which </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">would otherwise be liable </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease were </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">still </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in</font><font style="color:#545454;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect, including </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for Tenant&#8217;s Pro </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rata </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Share of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses. </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">month-to-month </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenancy </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to every other term, covenant and agreement contained herein.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27.2</font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foregoing, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remains </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in possession of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises after the expiration or earlier termination of the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without Landlord&#8217;s prior written consent, (a) Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">become </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a tenant at sufferance subject </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms and conditions of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, except </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">monthly </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rent </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equal </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">percent (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%) of the Base Rent and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> percent (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%) of Additional Rent </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect during </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the last </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93; </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be liable to Landlord for any and </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damages </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suffered </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord as a </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">result </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of such </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">holdover</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including any lost </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rent </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consequential, special and indirect damages.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27.3</font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Acceptance </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord of Rent after the expiration or earlier termination of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">result in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an extension, renewal or reinstatement of this Lease.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">The foregoing provisions of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article are </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">addition </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">do not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">affect Landlord&#8217;s right of reentry or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other rights of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Land</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereunder </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or as otherwise provided </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Applicable Laws. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Indemnification </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">and Exculpation</font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28.1</font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agrees to </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">indemnify, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">save, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defend (at </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">option and with counsel </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acceptable to Landlord) and hold the Landlord </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Indemnitees harmless </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from and </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">against </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any and all Claims arising from injury or death to any </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">person </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or damage </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">property </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">occurring within or about the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">arising directly or </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">indirectly </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">out of Tenant&#8217;s or Tenant&#8217;s employees&#8217;, agents&#8217;, contractors&#8217; or </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">invitees&#8217; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use or occupancy of the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or a breach or default </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the performance of any of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligations </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereunder, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">except </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all cases </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the extent caused </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s or Landlord&#8217;s employees&#8217;, agents&#8217; or contractors&#8217; </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">negligence </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or willful </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">misconduct. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord agrees </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">indemnify, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">save, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defend </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">option and with counsel </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acceptable </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant) and hold the Tenant and Tenant&#8217;s affiliates, employees, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agents, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and contractors </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">harmless </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from and against any </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all Claims arising from </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">injury </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or death </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any person or damage to any property occurring within or about the </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">arising directly </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">out </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Landlord&#8217;s or Landlord&#8217;s employees&#8217;, agents&#8217; or contractors&#8217; gross </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">negligence </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or willful misconduct, except </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all cases to the extent caused </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s or Tenant&#8217;s employees&#8217;, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agents&#8217; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or contractors&#8217; negligence or willful misconduct.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Notwithstanding any provision of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 28.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the contrary, Landlord shall </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">liable to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant for, and Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assumes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all risk of, damage </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">personal </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">property </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">scientific </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">research, including </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">loss </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">records </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">kept </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant within </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises and </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">losses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">caused by </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fire, electrical </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">malfunction, gas explosion or water damage of </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">type </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">broken water </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lines, malfunctioning </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fire </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sprinkler </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">systems, roof </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leaks </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">stoppages </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of lines), unless </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any such </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">loss is due to Landlord&#8217;s failure </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to respond to </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written notice </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant of need </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for a </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">repair that Landlord is responsible </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for ten </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(10) </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">business </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">further </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">waives any claim </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">injury to Tenant&#8217;s business or loss of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">income </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relating to any </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage or </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">destruction of </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">personal property </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">described in this </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">liable for any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damages arising </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">act, omission or neglect of any other tenant in the Building or the Project, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for any other third </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acknowledges </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">devices </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and services, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if any, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">while </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">intended </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deter crime, may not </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">given </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">instances prevent </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">theft </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or other criminal </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acts. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">liable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for injuries or losses </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">caused </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">criminal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acts of third parties, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant assumes the risk that any </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">device or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">serv</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ce </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">malfunction or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">otherwise be circumvented </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">criminal. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">desires </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">protection against such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">criminal acts, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall, at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sole </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expense, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obtain </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">appropriate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance coverage.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">The provisions </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#4b4b4b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Article </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall survive </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expiration </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or earlier </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termination </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Assignment or </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subletting</font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Except </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereinafter expressly permitted, Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">either voluntarily </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or by </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Applicable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laws, directly </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">indirectly </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sell, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hypothecate, assign, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pledge, encumber or otherwise </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transfer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease, or </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sublet </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(each, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s prior </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written consent, which consent </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unreasonably </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">withheld, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conditioned </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delayed. </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foregoing, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transfer </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">include and </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">right </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to transfer, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sublease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assign </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s prior written </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises or </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any part </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to any person that </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date of determination and </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">times </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereafter directly, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">indirectly </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">one or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">more </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">intermediaries, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">controls, is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">controlled by, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is under common </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">control </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dr. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">J. Craig Venter </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;Tenant&#8217;s </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Affiliate&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notify Landlord </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">writing at </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effectiveness of such transfer, </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sublease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assignment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s Affiliate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exempt </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">otherwise </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">comply </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requirements of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other than this </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29) </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regarding </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such Exempt </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transfer. </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purposes of </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exempt Transfers, &#8220;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">control</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; requires </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">either&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) owning (directly or </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">indirectly) </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">more </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> percent (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%) of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">stock </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equity interests </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of another person or (b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">possessing, </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">directly or indirectly, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">power </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">direct </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cause the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">direction of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the management </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">policies </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">person.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Commencing </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">promptly </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Commencement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and continuing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">until the earlier </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">second </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">anniversary of the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Commencement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and (ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date on which </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord has </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entered </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">into </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leases </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for all of </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">available </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">office space </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lower </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Campus, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A) </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and Tenant </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">will </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">jointly market </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lower Campus and </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(to the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extent Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">desires </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to sublease </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building) to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prospective tenants and </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subtenants, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable, on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms acceptable to </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(with </font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Lower </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Campus </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(with respect </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building 1) </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B) Tenant </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Transfer to or with an entity that is a </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then-current </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenant </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lower </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Campus without Landlord&#8217;s </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consent, </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consent </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may be withheld by Landlord </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sole </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">absolute </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">discretion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Thereafter, Tenant </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the right to</font><font style="color:#a3a3a3;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">market, advertise </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and sublease </font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">space </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or assign </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Lease in </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accordance with the </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provisions of </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.1. </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s reasonable request from time to </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time, </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall provide </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">documentation </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the leasing </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">status </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lower Campus. In connection with </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the joint </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">marketing </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Lower </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Campus </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building, Landlord </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">solely </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">responsible for </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">costs </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and fees </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">associated with </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leasing </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Lower </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Campus </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">solely </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">responsible </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">costs </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and fees </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">associated with </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leasing </font><font style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Building.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">In </font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant desires to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transfer, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> but not </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">more </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day prior </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date when Tenant </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">desires </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assignment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sublease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to be </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effective </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer Date</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provide </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Landlord </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8216;&#8216;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer Notice</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) containing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">information </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">references) </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">concerning </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">character </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proposed </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transferee, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assignee or </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sublessee&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transfer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#59; </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ownership or commercial relationship </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">between Tenant and the </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proposed </font><font style="color:#a3a3a3;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transferee, assignee </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sublessee&#59; </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the consideration </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other material terms </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conditions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the proposed </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transfer, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">detail </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">require.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord, </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determining </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whether </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consent should </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">given </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a proposed Transfer, may </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">give consideration to (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the financ</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">al </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">strength </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such transferee, assignee </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sublessee </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(notwithstanding Tenant rem</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ining </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">liable </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">performance), provided </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">however </font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hat </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">right </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">review </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and approve </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">financial </font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">strength </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subtenant </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subleasing </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">space </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which comprises less </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises and for </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">term of less </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all or </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">substantially </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all o</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the balance of the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and (b) any change in use </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transferee, </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assignee </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or sublessee </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">propo</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">es </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the use </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises. Except as </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">herein to the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contrary, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in no event </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord be deemed </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be unreasonable for declining to consent to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transfer to a transferee, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assignee</font><font style="color:#bfbfbf;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or sublessee </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of poor </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reputation, </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lacking </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">financial qualifications </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or seeking a change </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from the Permitted </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Use, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or jeopardizing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">directly </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">indirectly </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the status </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Landlord or </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Landlord&#8217;s </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">affiliates </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Real Estate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Investment Trust under </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Internal Revenue </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Code of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1986 (as the </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from time to </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Revenue </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">anything </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contained </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in this Lease to the </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contrary, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(w) </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no Transfer shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be consummated </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">basis </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rental </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other amounts </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to be paid by the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">occupant, assignee, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">manager or </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transferee </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereunder </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">would </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be based, in </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whole </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in part</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the income o</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">profits </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">derived </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by the business activities </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of such occupant, </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assignee, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">manager or </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transferee&#59; (x) Tenant </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">furnish or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">render </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">services beyond what is typical in </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">market to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">occupant, </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assignee, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">manager </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or other transferee with </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respect </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to whom </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consideration </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be paid </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord pursuant to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 29.5.2, or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">manage </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operate </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises or any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">capital </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">additions so </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tr</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ansferr</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ed</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with respect to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which consideration </font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required to be paid </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.5.2, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s consent, not to be</font><font style="color:#bfbfbf;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unrea</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nably withheld, to ensure </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord Parties&#8217; </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">compliance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">REIT </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tax </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rules </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regulations&#59; (y) Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consummate a Transfer with any </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">person in which </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord owns </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interest, directly or indirectly (by applying constructive ownership </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rules </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set forth in </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">856(d)(5) of the Revenue Code)&#59; and </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(z) </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not consummate a Transfer </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any person or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">manner </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">could cause any portion of </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amounts received </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease or any </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sublease, </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">license or other arrangement </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the right </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use, occupy or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">possess </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any portion of the Premises to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fail to </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">qualify </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as &#8220;rents from real property&#8221; within the meaning of Section 856(</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d) </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Revenue </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Code, or any similar or successor provision </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereto </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or which could cause any</font><font style="color:#c8c8c8;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">income </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to fail to qualify as income described in </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">856(c)(2) of the Revenue Code.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">As conditions precedent to Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subleasing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises or </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord considering a request by </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transfer of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rights </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sharing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises, Landlord may </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">require any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or all of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.5.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall remain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fully liable under this Lease </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">during </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the unexpired </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.5.2.</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">If Tenant&#8217;s </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transfer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rights </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or sharing of the </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provides for </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">receipt </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on behalf of or on account of Tenant of any consideration of any kind whatsoever (including a premium </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rental </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for a </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sublease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or lump </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sum </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payment for an assignment, but excluding </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonable costs in marketing and </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subleasing </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises) in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">excess of the rental and other </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">charges </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">due to Landlord under </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, Tenant shall </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">percent</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of all of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">excess to Landlord, after making deductions </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">marketing </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expenses, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenant </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">improvement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">funds expended by Tenant, alterations, cash concessions, brokerage commissions, attorneys&#8217; fees and </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">free </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rent actually paid </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Tenant. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If said consideration consists of cash paid to Tenant, payment </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be made upon receipt by Tenant of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cash payment&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.5.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reimburse </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for Landlord&#8217;s actual and </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonable costs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and expenses, </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including reasonable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">attorneys&#8217; fees, charges </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">disbursements incurred in </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">connection </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with the </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">review, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">processing </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">documentation of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">request, not in </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">excess of</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dollars ($</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">per </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">occurrence&#47;request.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">The proposed transferee, assignee or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sublessee </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agree that, </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event Landlord gives </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proposed transferee, assignee or sublessee notice </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">long </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant is in Default under this </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, such proposed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transferee, assignee or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sublessee shall thereafter </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all payments otherwise </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">due Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">directly </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord, which payments shall be </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">received by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord without any liability being </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incurred </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">except to credit such </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">against those </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">due </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, and any </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proposed transferee, assignee or sublessee shall </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agree </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">attorn to Landlord or </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">successors and assigns should </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminated </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any reason&#59; provided, however, that </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no event </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord or its Lenders, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">successors </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assigns </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be obligated </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accept </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such attornment, except Landlord shall provide a </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commercially </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">non-disturbance agreement </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any entity that subleases for greater </font><font style="color:#0c0c0c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">one-half (1</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;2) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Premises or takes an </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assignment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Lease&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord&#8217;s consent to any such Transfer shall be effected on commercially reasonable forms&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant shall not be in default of any its monetary obligations or in Default of any of its non-monetary obligations hereunder.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Such proposed transferee, assignee or sublessee shall not use the Premises for any use that is not a Permitted Use&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Landlord shall not be bound by any provision of any agreement pertaining to the Transfer, except for Landlord&#8217;s written consent to the same and except for the nondisturbance described above&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Tenant shall pay all transfer and other taxes (including interest and penalties) assessed or payable for any Transfer&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Landlord&#8217;s consent (or waiver of its rights) for any Transfer shall not waive Landlord&#8217;s right to consent to any later Transfer&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Tenant shall deliver to Landlord one executed copy of any and all written instruments evidencing the Transfer&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Any Transfer that is not in compliance with the provisions of this Article shall be void and a default.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The consent by Landlord to a Transfer shall not relieve Tenant or proposed transferee, assignee or sublessee from obtaining Landlord&#8217;s consent to any further Transfer in accordance with the terms hereof, nor shall it release Tenant or any proposed transferee, assignee or sublessee of Tenant from full and primary liability under this Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Notwithstanding any Transfer, Tenant shall remain fully and primarily liable for the payment of all Rent and other sums due or to become due hereunder, and for the full performance of all other terms, conditions and covenants to be kept and performed by Tenant. The acceptance of Rent or any other sum due hereunder, or the acceptance of performance of any other term, covenant or condition thereof, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from any person or entity other than Tenant shall not be deemed a waiver of any of the provisions of this Lease or a consent to any Transfer.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">If Tenant sublets the Premises or any portion thereof, Tenant hereby immediately and irrevocably assigns to Landlord, as security for Tenant&#8217;s obligations under this Lease, all rent from any such subletting, and appoints Landlord as assignee and attorneyin-fact for Tenant, and Landlord (or a receiver for Tenant appointed on Landlord&#8217;s application) may collect such rent and apply it toward Tenant&#8217;s obligations under this Lease&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Tenant shall have the right to collect such rent so long as no Default exists or is continuing.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Subordination </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">and </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Attornment</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30.1</font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provisions set </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b</font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">el</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ow</font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease shall be </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and subordinate to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the lien </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any mortgage, deed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">trust, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lease in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">now or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereafter </font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">force against the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Common Areas (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mortgage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">advances </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">made or hereafter </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">made </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the security thereof </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">necessity </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the execution </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delivery </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">further </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">instruments on </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">part </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effectuate such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subordination.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30.2</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foregoing, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">execute </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deliver </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">demand </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">further instrument or instruments </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">evidencing </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such subordination </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the lien of any </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mortgage </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mortgages </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deeds </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of trust or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord is </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenant as may </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be required </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord. If </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mortgagee, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">beneficiary </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">landlord under </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lease </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">wherein </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord is </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">each, a &#8220;</font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mortgagee</font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) so </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">elects, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">however, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be deemed </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in lien to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lease, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mortgage, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or deed of </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">trust upon </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regardless </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of date </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">execute </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">statement </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">writing </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s request. If </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant fails to execute </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any document required </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under this </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after written </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">request </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">therefor, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereby constitutes and appoints </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">special attorney-in-fact </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">execute </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deliver </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">document </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">documents </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the name </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Tenant. </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Such </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">power </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">coupled </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an interest and is irrevocable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30.3</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">represents and warrants </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the Execution </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date, there </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">current </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mortgagee </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respect to the Property. </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligation to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subordinate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and attorn to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">future </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mortgagees </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conditioned </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delivering to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commercially </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonable </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subordination, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">non-disturbance and attornment </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SNDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). If </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at any time after </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">should </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">desire to place </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Mortgage on </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building, Land or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project, Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agrees that it will </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commercially </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonable </font><font style="color:#bfbfbf;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ef</font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forts </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cause </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the holder of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mortgage to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">enter </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">into </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a SNDA </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in connection </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease whereby such </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mortgagee </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agrees </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">long </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no Default </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have occurred </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">continuing </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leasehold </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">estate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">granted </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rights </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">quiet and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">peaceful </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">possession </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminated, modified, affected or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">disturbed by any action </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Mortgagee </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may take to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foreclose or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminate </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mo</font><font style="color:#494949;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tgage, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">successor </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">recognize this Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as being in full </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">force </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">In </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proceedings </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are brought </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foreclosure, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exercise </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">power </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sale </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mortgage or deed </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">trust made by Landlord covering the Premises, Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the election </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purchaser </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foreclosure </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or sale </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">attorn </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the purchaser upon </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foreclosure </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or sale </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and recognize </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purchaser </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Landlord under this </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Defaults and Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.1</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Late payment by </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant to Landlord </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and other </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sums </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">due </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cause </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incur costs </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contemplated </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by this </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exact </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amount </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be ex</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remely difficult and impracticable to </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ascertain. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Such costs include processing and accounting charges and </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">la</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">te </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">charges </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may be imposed on Landlord by </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms of any </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mortgage </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or trust deed covering </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises. </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">T</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">herefore</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any installment of Rent </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">due </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant is </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">received by Landlord within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the date </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payment is due, Tenant </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Land</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) an </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">additional sum </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">percen</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the overdue Rent </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">late </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">charge plus (b) interest </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ann</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ua</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rate </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) equal </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">le</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sser </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">percent (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%)</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and (b) the highest </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">permitted by Applicable Laws. Tenant </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll r</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eceive</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> notice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of any </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">every </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> month period </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he foregoing applies</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he parties agree that this late charge represents a </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fair </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">re</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">asonable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">estimate of </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">costs that </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Land</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lo</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incur by reason of </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">late </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payment </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">y Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be payable as Additional Rent to Landlord due within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">business days after Landlord&#8217;s demand. </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlo</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acceptance of any Additional Rent (including a </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">la</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">te </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">charge or any other amount hereunder) </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be deemed an extension of the date that Rent is due or prevent Landlord from </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pur</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">su</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any other </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rights </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or remedies under this </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">law </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equity.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.2</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">No </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payment by </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">enant or receipt by Landlord of </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">le</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sser </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amount </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Rent payment </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">herein </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">st</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ipul</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ate</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be deemed to be other than on account of the Rent, nor </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any endorsement or </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">statement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on any check or any letter accompanying any check or payment as Rent be deemed an </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">satisfactio</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and Landlord may accept such check or payment without prejudice to Landlord&#8217;s right to recover </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the balance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch Rent or pursue any</font><font style="color:#7e7e7e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other remedy provided </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease or in equity or at </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">law</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If a dispute shall </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">arise </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as to </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amount or </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sum </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mone</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">y </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to be paid by </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Landlord hereunder, Tenant shall </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ha</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ve </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the right </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make payment </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8216;&#8216;unde</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r prote</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t,&#8221; </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payment </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be regarded </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as a vo</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">luntary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payment, and </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">there </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">survive the right on </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">part o</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">institute </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for recovery of the </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">paym</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ent </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">paid </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under protest.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">If Tenant fails </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any sum </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of money </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">paid </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by it hereunder, or </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fai</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">perform </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any other act on </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">part </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be performed hereunder</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord may, without waiving or </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relea</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant from any obligations o</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant, but </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be obligated to, make </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payment or perform such </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">act&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failure </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant continues for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days after Landlord delivers notice </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant demanding performance </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#59; or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">prov</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ided</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> t</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hat </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suc</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failure by </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">enant unreasonably interfered </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">u</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">se </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Building or the Project </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other tenant or with the efficient operation of the Building or the Project, or resulted or could have </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">resulted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a v</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iolation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Applicable Laws or the cancellation of an </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uranc</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">policy maintained by Landlord. </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwiths</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tanding </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foregoing, in the event of an emergency, Landlord </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the righ</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to enter </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises and act </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accordance with </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rights as provided elsewhere </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease. In addition to </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the late </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">charge described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 31.</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant s</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay to Landlord as Additional Rent </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sums so </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">paid or incurred </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">y Landlord, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">together </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interest at the Default Rate, computed from </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sums were paid or </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incurr</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ed.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">The occurrence of any one or </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">more </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the following events </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reunder </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">y </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.4.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Tenant abandons or vacates </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and fails </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provide for </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on-going maintenance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">repair </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Premises </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accordance with Tenant&#8217;s </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligations pursuant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to this </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.4.2.</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">The </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failure </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Tenant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make any </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Rent, as and when </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">due, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or to satisfy its obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">19</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">where such failure shall continue for a </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">five </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5) days after written notice </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from Landlord </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.4.3.</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">The </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failure by Tenant to observe </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or perform </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any obligation </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">covenant contained herein </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than described </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subsections 3</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">1.4(a)</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">31.4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be performed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Tenant, where such </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failure </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall continue for a </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">often </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(10) business days </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after written notice </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from Landlord to Tenant&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that, if the nature </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">default is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that it </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably requires more than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> business </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cure, Tenant </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be deemed </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to be in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Default </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commence such cure within </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">said </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">business day period and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereafter diligently prosecute </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the same </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to completion&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided, </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">further, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that such cure </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">completed </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">later than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days from the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s receipt</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of written </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice from Landlord&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.4.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Tenant makes an </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assignment for </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">benefit of creditors&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.4.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">A </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">receiver, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">trustee or custodian </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">appointed </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or does </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">take </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">title, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">possession </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or control </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">substantially </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s assets&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.4.6.</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Tenant files </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a voluntary petition </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">United </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">States </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bankruptcy </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Code or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">successor </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">statute </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same may </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amended </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to time, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or an order for </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relief is entered </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">against Tenant pursuant </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to a </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">voluntary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">involuntary proceeding commenced </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any chapter of the Bankruptcy </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Code&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.4.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Any </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">involuntary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">petition is filed against </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">chapter of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bankruptcy Code and is not dismissed within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.4.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Tenant fails to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deliver </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an estoppel certificate </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">20</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.4.9.</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interest in </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">attached, executed </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or otherwise </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">judicially </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">seized </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and such action </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">released </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">action.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notices given under this Section </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specify the alleged default and </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">demand </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">perform the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provisions </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or pay the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in arrears, as the case may be, </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the applicable period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of time, or quit </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises. No such notice </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deemed a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forfeiture or </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termination </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unless </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">elects otherwise in </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.5</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">In the </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Default </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Tenant, and at </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time thereafter, with or without notice or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">demand </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and without </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">limiting Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exercise </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of any right or remedy that </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord may have, Landlord </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entitled </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminate </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">right </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">possession of the Premises by written notice to Tenant or by any lawful means, in which case this Lease shall terminate and Tenant shall immediately surrender possession of the Premises to Landlord. In such event, Landlord shall have the immediate right to re-enter and remove all persons and property, and such property may be removed and stored in a public warehouse or elsewhere at the cost and for the account of Tenant, all without service of notice or resort to legal process and without being deemed guilty of trespass or becoming liable for any loss or damage that may be occasioned thereby. In the event that Landlord shall elect to so terminate this Lease, then Landlord shall be entitled to recover from Tenant all damages incurred by Landlord by reason of Tenant&#8217;s default, including&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.5.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">The worth at the time of award of any unpaid Rent that had accrued at the time of such termination&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.5.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">The worth at the time of award of the amount by which the unpaid Rent that would have accrued during the period commencing with termination of the Lease and ending at the time of award exceeds that portion of the loss of Landlord&#8217;s rental income from the Premises that Tenant proves to Landlord&#8217;s reasonable satisfaction could have been reasonably avoided&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.5.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">The worth at the time of award of the amount by which the unpaid Rent for the balance of the Term after the time of award exceeds that portion of the loss of Landlord&#8217;s rental income from the Premises that Tenant proves to Landlord&#8217;s reasonable satisfaction could have been reasonably avoided&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.5.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Any other amount necessary to compensate Landlord for all the detriment caused by Tenant&#8217;s failure to perform its obligations under this Lease or that in the ordinary course of things would be likely to result therefrom, including the cost of restoring the Premises to the condition required under the terms of this Lease&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.5.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">At Landlord&#8217;s election, such other amounts in addition to or in lieu of the foregoing as may be permitted from time to time by Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As used in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subsections 3l .5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">31.5(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">worth at the time of award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be computed by allowing interest at the Default Rate. As used in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subsection 31.5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the &#8220;worth at the time of the award&#8221; shall be computed by taking the present value of such amount, using the discount rate of the Federal Reserve Bank of San Francisco at the time of the award plus one (1) percentage point.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">In addition to any other remedies available to Landlord at law or in equity and under this Lease, Landlord may continue this Lease in effect after Tenant&#8217;s Default and abandonment and recover Rent as it becomes due. Landlord shall use reasonable efforts to relet the Premises, but shall not be liable in any way whatsoever for its failure to relet the Premises notwithstanding the exercise of such reasonable efforts. For purposes of this Section, the following acts by Landlord will not constitute the termination of Tenant&#8217;s right to possession of the Premises&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Acts of maintenance or preservation or efforts to relet the Premises, including alterations, remodeling, redecorating, repairs, replacements or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">painting as Landlord shall consider advisable for the purpose of reletting the Premises or any part thereof&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.6.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">The appointment of a receiver upon the initiative of Landlord to protect Landlord&#8217;s interest under this Lease or in the Premises.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, in the event of a Default by Tenant, Landlord may elect at any time to terminate this Lease and to recover damages to which Landlord is entitled.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">If Landlord does not elect to terminate this Lease as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 31.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, then Landlord may, from time to time, recover all Rent as it becomes due under this Lease. At any time thereafter, Landlord may elect to terminate this Lease and to recover damages to which Landlord is entitled.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">In the event Landlord elects to terminate this Lease and relet the Premises, Landlord may execute any new lease in its own name. Tenant hereunder shall have no right or authority whatsoever to collect any Rent from such tenant. The proceeds of any such reletting shall be applied as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.8.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">First, to the payment of any indebtedness other than Rent due hereunder from Tenant to Landlord, including storage charges or brokerage commissions owing from Tenant to Landlord as the result of such reletting&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.8.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Second, to the payment of the costs and expenses of reletting the Premises, including (i) alterations and repairs that Landlord deems reasonably necessary and advisable and (ii) reasonable attorneys&#8217; fees, charges and disbursements incurred by Landlord in connection with the retaking of the Premises and such reletting&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.8.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Third, to the payment of Rent and other charges due and unpaid hereunder&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.8.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Fourth, to the payment of future Rent and other damages payable by Tenant under this Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">All of Landlord&#8217;s rights, options and remedies hereunder shall be construed and held to be nonexclusive and cumulative. Landlord shall have the right to pursue any one or all of such remedies, or any other remedy or relief that may be provided by Applicable Laws, whether or not stated in this Lease. No waiver of any default of Tenant hereunder shall be implied from any acceptance by Landlord of any Rent or other payments due hereunder or any omission by Landlord to take any action on account of such default if such default persists or is repeated, and no express waiver shall affect defaults other than as specified in said waiver.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Landlord&#8217;s termination of (a) this Lease or (b) Tenant&#8217;s right to possession of the Premises shall not relieve Tenant of any liability to Landlord that has previously accrued </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall arise </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ba</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sed </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">events </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">occurred </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">la</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ter to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">occur of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) the date </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Lease termination or (ii) </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the date Tenant </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">surrenders possession of the Premises.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">To the extent permitted </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Applicable Laws, Tenant waives any and all rights of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">edemp</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tion </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">granted </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or under any present </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">future Applicable Laws </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is evicted or dispossessed for any cause, or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord obtains possession of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">due </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s default hereunder or otherwise.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.12</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Landlo</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be in defaul</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under this Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">un</font><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ess Landlord fails to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">perform </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligations </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Landlord within a reasonable </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">but in </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event shall </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suc</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failure continue </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">more than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written notice from </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">specifying </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nature </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Landlord&#8217;s failure&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">howe</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ver, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">na</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ur</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Landlord&#8217;s obligation </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">more </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days are </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">performanc</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then Landlord </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">default </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord commences </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">performan</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ce </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereafter </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">diligently prosecutes </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same to completion. In no event shall Tenant have </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ight </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminate or cancel </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease or to withhold or abate rent or to </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">se</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">off any Claims against </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as a </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">resu</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of any defau</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">breach by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord of any of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">covenants, obligations, representations, warranties or promises herem1der, </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exce</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pt </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">otherwise be expressly </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">et </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">In </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event of any default </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">give notice </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by r</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eg</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iste</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">red </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or certified mail </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any (a) beneficiary of a </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of trust or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mortgagee under a </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mortgage </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">covering </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises, the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of land upon </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within which </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises, the Building or the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Proj</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ec</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t i</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s loca</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ted, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and shall offer such </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">beneficiary, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mortgagee or </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">land</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">opportunity to cure </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">default, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time to obtain </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pos</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">session </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Building or the Project by </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">power </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sa</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">le </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or a judicial </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ac</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ion </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if such </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shou</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ld prov</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nec</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">essary to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effect a cure&#59; provided that Landlord shall furnish to </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Te</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nant in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">writing, upon written </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reques</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t by T</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nan</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">names </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and addresses of all </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">persons who are to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">receive </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">So </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">long </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenan</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lea</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ses t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entire Building, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenan</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remedi</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">es </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 31.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fails to meet </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">material obligation of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease, and (a) </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failure </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rela</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tes to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">repair of the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bu</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or causes Tenant to be unable to use </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Pr</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">emises </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or a substantial </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">part </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof, and </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord fails to commence a cure within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days after </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">receipt </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">secon</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ice (such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">second notice </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">given at </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after receipt of Tenant&#8217;s first </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failure), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then Tenant shall have the right to fulfill </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligation on behalf of Landlord, the cost of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">paid </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pro</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mptly </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following demand </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">re</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s cure </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be extended where </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failure </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably curable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after the </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">seco</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nd </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and Landlord uses good faith efforts and works diligently and </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">continuou</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ly to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fulfill its obligations. Notwithstanding anything </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contrary </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">previous sentence, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an emergency, Tenant </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">right </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to fulfill Landlord&#8217;s obligation on </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">half </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Landlord, after </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(in </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">circumstances) oral notice to Landlord, </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s cost </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including interest thereo</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Default </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reimbursed by Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after written </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">demand therefor </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenan</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event of </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an emergency </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requiring Tenant to exercise </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its self-help after oral notice, </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provide </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord with a </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">follow-up </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written notice within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days after </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">emergency. </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As used </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in this </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 31.14</font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, an &#8220;emergency&#8221; </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means an imminent threat </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of injury to person, </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage to property or </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">material </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interruption of Tenant&#8217;s business </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operations. </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event Tenant exercises </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">right, then Tenant </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set-off </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">abate the </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payment of Rent </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with any costs </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incurred by </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in connection </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exercise of this right, to the </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extent such </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">costs </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">do </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">constitute </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expenses.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event a debtor, trustee </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or debtor </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in possession </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under the Bankruptcy </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Code, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">another person with similar </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rights, duties and powers under any other </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Applicable Laws, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proposes to </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cure any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">default under this </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or to </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assume or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assign this </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease and is obliged </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to provide adequate </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assurance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that (a) a default </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cured, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) Landlord shall be compensated </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for its damages arising </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">breach of </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease and </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c) future </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">performance of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligations wider </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">occur, </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">adequate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assurances </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall include </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any or </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the following, </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">designated by </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in its </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sole </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and absolute </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">discretion&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32.1</font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Those </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acts specified in </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Bankruptcy </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Code </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or other </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Applicable Laws as </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">included within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">meaning of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">adequate assurance,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; even </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if this Lease does not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">concern </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shopping </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">center </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">facility </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such Applicable </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laws&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">A </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prompt cash payment to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">compensate Landlord for any </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">monetary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defaults </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or actual damages </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">arising directly </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a breach </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32.3</font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">A cash </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deposit </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an amount at least equal to the </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then-current amount </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Security </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposit&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32.4</font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">The assumption or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assignment </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s interest and obligations </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease</font><font style="color:#575757;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33.1</font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant represents and warrants</font><font style="color:#a1a1a1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that it </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has had no dealings with </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any real </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">estate broker or </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">connection </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">negotiation of </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other than Holliday Fenoglio </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fowler, </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LP. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and that it knows </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no other real </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">estate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">broker or agent that is or might be </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entitled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to a </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commission </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">connection with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease. </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">compensate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Broker in </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to this </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant to a </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">separate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agreement between </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Broker.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant represents and</font><font style="color:#b8b8b8;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">warrants </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">broker </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or agent has made </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">representation </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or warranty relied </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Tenant in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s decision </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to enter </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">into </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other than as </font><font style="color:#2b2b2b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contained </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in this Lease.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33.3</font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acknowledges and </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agrees </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employment of brokers </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purpose </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of solicitation of offers of </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leases </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prospective tenants </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that no authority is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">granted </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to any broker </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">furnish any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">representation </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(written </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or oral) </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">warranty </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from Landlord unless </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expressly contained within </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease.  Landlord </font><font style="color:#181818;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">executing this Lease in reliance upon Tenant&#8217;s representations, warranties and agreements contained within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 33.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">33.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant agrees to indemnify, save, defend (at Landlord&#8217;s option and with counsel reasonably acceptable to Landlord) and hold the Landlord Indemnitees harmless from any and all cost or liability for compensation claimed by any broker or agent, other than Broker, employed or engaged by it or claiming to have been employed or engaged by it.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Definition of Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  With regard to obligations imposed upon Landlord pursuant to this Lease, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as used in this Lease, shall refer only to Landlord or Landlord&#8217;s then-current successor-in-interest. In the event of any transfer, assignment or conveyance of Landlord&#8217;s interest in this Lease or in Landlord&#8217;s fee title to or leasehold interest in the Property, as applicable, which Landlord may do without Tenant&#8217;s consent, Landlord herein named (and in case of any subsequent transfers or conveyances, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subsequent Landlord) shall be automatically freed and relieved, from and after the date of such transfer, assignment or conveyance, from all liability for the performance of any covenants or obligations contained in this Lease thereafter to be performed by Landlord and, without further agreement, the transferee, assignee or conveyee of Landlord&#8217;s in this Lease or in Landlord&#8217;s fee title to or leasehold interest in the Property, as applicable, shall be deemed to have assumed and agreed to observe and perform any and all covenants and obligations of Landlord hereunder during the tenure of its interest in the Lease or the Property. Landlord or any subsequent Landlord may transfer its interest in the Premises or this Lease without Tenant&#8217;s consent but upon notice to Tenant.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Limitation of Landlord&#8217;s Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">If Landlord is in default under this Lease and, as a consequence, Tenant recovers a monetary judgment against Landlord, the judgment shall be satisfied only out of (a) the proceeds of sale received on execution of the judgment and levy against the right, title and interest of Landlord in the Building and the Project, (b) rent, casualty proceeds, condemnation awards or other income from such real property receivable by Landlord or (c) the consideration received by Landlord from the sale, financing, refinancing or other disposition of all or any part of Landlord&#8217;s right, title or interest in the Building or the Project.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord shall not be personally liable for any deficiency under this Lease. If Landlord is a partnership or joint venture, then the partners of such partnership shall not be personally liable for Landlord&#8217;s obligations under this Lease, and no partner of Landlord shall be sued or named as a party in any suit or action, and service of process shall not be made against any partner of Landlord except as may be necessary to secure jurisdiction of the partnership or joint venture. If Landlord is a corporation, then the shareholders, directors, officers, employees and agents of such corporation shall not be personally liable for Landlord&#8217;s obligations under this Lease, and no shareholder, director, officer, employee or agent of Landlord shall be sued or named as a party in any suit or action, and service of process shall not be made against any shareholder, director, officer, employee or agent of Landlord. If Landlord is a limited liability company, then the members of such limited liability company shall not be personally liable for Landlord&#8217;s obligations under this Lease, and no member of Landlord shall be sued or named as a party in any suit or action, and service of process shall not be made against any member of Landlord except as may be necessary to secure jurisdiction of the limited liability company. No partner, shareholder, director, employee, member or agent of Landlord shall be required to answer or otherwise plead to any service of process, and no judgment shall be taken or writ of execution levied against any partner, shareholder, director, employee, member or agent of Landlord.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Each of the covenants and agreements of this Article shall be applicable to any covenant or agreement either expressly contained in this Lease or imposed by Applicable Laws and shall survive the expiration or earlier termination of this Lease.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Joint and Several Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If more than one person or entity executes this Lease as Tenant, then&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Each of them is jointly and severally liable for the keeping, observing and performing of all of the terms, covenants, conditions, provisions and agreements of this Lease to be kept, observed or performed by Tenant&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as used in this Lease shall mean and include each of them, jointly and severally. The act of, notice from, notice to, refund to, or signature of any one or more of them with respect to the tenancy under this Lease, including any renewal, extension, expiration, termination or modification of this Lease, shall be binding upon each and all of the persons executing this Lease as Tenant with the same force and effect as if each and all of the parties had so acted, so given or received such notice or refund, or so signed.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant guarantees, warrants and represents that (a) Tenant is duly incorporated or otherwise established or formed and validly existing under the laws of its state of incorporation, establishment or formation, (b) Tenant has and is duly qualified to do business in the state in which the Property is located, (c) Tenant has full corporate, partnership, trust, association or other appropriate power and authority to enter into this Lease and to perform all Tenant&#8217;s obligations hereunder and (d) each person (and all of the persons if more than one signs) signing this Lease on behalf of Tenant is duly and validly authorized to do so. Landlord guarantees, warrants and represents that (w) Landlord is duly incorporated or otherwise established or formed and validly existing under the laws of its state of incorporation, establishment or formation, (x) Landlord has and is duly qualified to do business in the state in which the Property is located, (y) Landlord has full corporate, partnership, trust, association or other appropriate power and authority to enter into this Lease and to perform all Landlord&#8217;s obligations hereunder and (z) each person (and all of the persons if more than one signs) signing this Lease on behalf of Landlord is duly and validly authorized to do so.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant shall keep the terms and conditions of this Lease and any non-public financial information or non-public information about Landlord&#8217;s ownership structure </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant or its employees, agents or contractors pursuant to </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9</font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> confidential and </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) disclose to </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">third party </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms or </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conditions </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this Lease </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any other Lease-related </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">document </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(including </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subleases, </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assignments</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">work </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">letters, </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">construction contracts, </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">letters </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">credit, </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subordination agreements, </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">non-disturbance agreements, </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">brokerage </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agreements or </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">estoppels) </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or (b) provide to any third </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">party an </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">original or copy of this Lease (or any </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease-related </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">document). Landlord </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not release </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to any </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">third party any non-public financial information or non-public information about Tenant&#8217;s ownership structure that</font><font style="color:#bfbfbf;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">T</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">enant </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">gives Landlord. Notwithstanding the foregoing, confidential </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">information </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under this </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may be </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">released </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or Tenant </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the following circumstances&#58; </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x) </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if required by Applicable Laws or </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any judicial </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proceeding&#59; </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided that the releasing party has given </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other party reasonable </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such requirement, </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if feasible</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(y) to </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a party&#8217;s attorneys, accountants, brokers and other </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bona </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fide consultants or advisers </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(with </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respect to </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">only)&#59; provided </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">third parties </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agree </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bound by this Section or (z) to bona fide prospective assignees or </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subtenants </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this Lease&#59; </font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#1c1c1c;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> they agree in writing to be bound by this Section.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice, consent, demand, bill, </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">statement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or other communication required or permitted to be given hereunder shall </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in writing and shall be given by personal delivery</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">overnight </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delivery with </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reputable </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nationwide </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">overnight delivery service, or certified </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mail </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(return receipt requested), and </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">given by personal delivery, shall be deemed delivered </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">receipt&#59; if given by overnight delivery, shall </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be deemed delivered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deposit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with a reputable nationwide overnight </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delivery </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">service&#59; and, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if given </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">certified mail (return receipt </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requested), </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be deemed </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delivered </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after the time </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he</font><font style="color:#7e7e7e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notifying party deposits the notice with </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the United States </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Postal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Service. Any notices </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">given </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pursuant </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be addressed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Landlord or </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at the addresses </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shown </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, respectively. </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Either </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">party </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may, by notice </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">given pursuant </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section, specify </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">additional or different addresses for notice purposes.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Rooftop Installation Area</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord hereby approves any existing equipment on the rooftop of the Building which </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">serves </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises. In addition, Tenant may use those portions </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Building </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">identified </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a &#8220;Rooftop Installation </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Area&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereto (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rooftop </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Installation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Area</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">solely </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to operate, maintain, repair and replace rooftop antennae, </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mechanical </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equipment</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">communications antennas and other equipment </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">installed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Tenant in the Rooftop Installation Area in accordance with this Article (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant&#8217;s Rooftop </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Equipment</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s Rooftop </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Equipment shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be only for Tenant&#8217;s (or its subtenant&#8217;s or assignee&#8217;s) use of </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises for the Permitted Use.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">install </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rooftop </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Equipment at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sole </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost and </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expense, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">times and in </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">manner </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord may reasonably </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">designate, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and in accordance with this </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the applicable provisions of this Lease regarding </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Alterations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s Rooftop </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Equipment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">installation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof shall </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject to Landlord&#8217;s prior written approval</font><font style="color:#4d4d4d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which approval </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not be unreasonably </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">withheld, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">conditioned or </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delayed. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Among other reasons, Landlord may withhold approval if the installation or operation of </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rooftop </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Equipment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">could reasonably be expected </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">structural integrity of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transmit vibrations or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">noise </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or cause other adverse effects beyond the Premises </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an extent not customary in Comparable. Buildings, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unless </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant implements </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">measures </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acceptable to Landlord in </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ts </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonable </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cretion to </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">avoid </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suc</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transm</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ission.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Tenant shall comply with any </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">roof </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or roof-related warranties. Tenant shall obtain a </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">letter from Landlord&#8217;s roofing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contractor within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after completion of any Tenant work on the rooftop stating that such work </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">id </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not affect any such warranties. Tenant, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at its </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">le </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cost </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expense, shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insp</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ect </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rooftop </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Installat</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ion </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Area at </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lea</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">st </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">annually, and correct any </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">loose </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bolts, fittings or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ther </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">appurtenances and </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">re</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pair </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the roof caused by the </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ins</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tallation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or operation of </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Te</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rooftop Equipment. </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">permit </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the installat</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">io</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">maintenance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or operation of</font><font style="color:#7e7e7e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s Rooftop </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">quipment to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">violate any Applicable Laws or constitute a nuisance. Tenant </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay Landlord within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after demand </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all applicable </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taxes</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">charges, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fee</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">impo</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ition</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">imposed on Landlord by Governmental Authorities as </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">result of Tenant&#8217;s </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Rooftop Installation Areas in excess of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">those </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for which </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlo</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">would </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">otherwise be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">responsible for </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ins</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ta</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">llat</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ion </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Tenant&#8217;s </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rooftop </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">quipment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and (b) the amount of any increase </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in Landlord</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8217;s </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">surance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">premiums as a </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">result </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the installation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Tenant&#8217;s Rooftop </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Equipmen</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon Tenant&#8217;s written request </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord, Landlord shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">u</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">se </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commercially </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">efforts </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cause other tenants to </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remedy </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any interference </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operation of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rooftop </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">quipment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">caused by </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenants&#8217; equipment </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">installed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after the applicable piece of </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rooftop </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">quipment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that Landlord shall not </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reque</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">st t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hat </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suc</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenants </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">wai</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ve </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">their </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rights </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under their respe</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ctive </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eases.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">If Tenant&#8217;s Equipment </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">causes physical damage to the </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">structura</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">integrity of </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Bu</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ilding, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) interferes with </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any telecommunication</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mechanical or other systems </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">loca</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at or near or </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">serv</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">icing </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building or the Project that were installed prior </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">installation of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rooftop Equipment, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nterferes </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other service provided </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other tenants in the Building or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project by rooftop or penthouse installations that were </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ins</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ta</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior to the installation of Tenant&#8217;s Rooftop </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">qu</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pmen</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interferes with any other </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenant</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s&#8217; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">business, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">each case in excess of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">permissible under Federal Communications Commission regulations, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then Tenant </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cooperate with Landlord </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determine the source of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">inter</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ference </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and promptly repair such </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damag</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">liminate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interfe</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rence, in </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eac</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">case at Tenant&#8217;s sole cost and expense, within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days after receipt of notice of </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage or </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nterference (which </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice may be oral&#58; </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Land</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lo</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">also delivers to Tenant written notice of such damage or interference within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hour</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after providing oral notice).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord reserves the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">righ</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to cause Tenant </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to reloca</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">te Tenan</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t&#8217;</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rooftop Equipment </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">comparably functional space on the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">roof </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or in </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">penthouse of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Bui</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ld</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by giving Tenant </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof. Landlord agrees </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay the reasonable costs </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof. Tenant </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">arrange for </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relocation of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s Rooftop </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Equipment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days after </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ece</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ipt </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notificatio</font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">su</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relocation. In the </font><font style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant fails </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">arrange for relocation within such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period, Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall have the right </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">arrange for the relocation of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rooftop </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Equipment </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a manner that does </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unnecessarily </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interrupt </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interfere with Tenant&#8217;s use of the Premises for </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Permitted </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Use</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">So long as Tenant </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eases the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entire Building, Landlord </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not have the right </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">change </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">name of the Building without </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior written consent of Tenant, which consent may </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">withheld by Tenant </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in it</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s so</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">le </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and absolute discretion.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.2</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereby approves the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">location</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">design, and operation of any and all generators, storage tanks and other </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">spec</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iali</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">zed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equipment or </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">systems </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">located </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">land, on </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exterior of the Building, on the roof or in adjacent parking structures. </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall maintain, operate as currently operated and replace </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the two generators currently </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lo</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on the Lower Campus. In addition, Tenant </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sh</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">right </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to move </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">generators from the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lower </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Campus </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Land and Tenant </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll have th</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e r</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ight </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to place </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">new </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">generators on </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Land during the Term, subject </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prio</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">written consent, which consent </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unreasonable withheld, conditioned or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delay</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ed.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">To induce </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to enter into </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, Tenant agrees that it shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">promptly </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fu</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rni</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ime </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ime, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon Landlord&#8217;s written </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">re</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">quest, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the most </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">recent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">audited </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">yea</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-e</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nd financial </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">state</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ments </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">re</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">flect</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ing </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ten</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">current financial condition. Tenant </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days after the </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">en</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">financial </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">furnish </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord with a draft of Tenant&#8217;s audited year-end financial statements </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">previous </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year and </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">end of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8217;s </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">financial </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year, furnish Landlord with a </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">certified </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">copy of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">audited year-end financial statements for </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">previous year. Tenant </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">represent</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and warrants that all financial statements, records </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and information </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">furnished by Tenant to Landlord in connection with </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Le</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ase are </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tru</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">correct and </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">comp</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lete in all mat</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eria</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respects. If audited financials are not otherwise prepared, unaudited financials certified </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">chief </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">financial </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">officer of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as true, correct and </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">comp</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ete in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all material respects </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suffice </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purpo</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">th</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Where applicable </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease, the </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">si</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ngular </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">includes the </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">plural </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">masculine or </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">neu</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">te</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">includes </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the mascul</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ine, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">feminine </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">neuter. The words &#8220;include</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">includes,&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;included&#8221; and &#8220;including&#8221; shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mean </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#8216;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">include,&#8217; etc., without </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">limitation</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221; </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">section headings of </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a part of </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hi</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no effect upon </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">construction or interpretation of any </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">part hereof. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.5</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">If </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">either </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">party </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commences an action against the other </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">p</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">arty </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">arising out </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">connection with </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, then the substantially prevailing </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">party </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reimbursed </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other party for </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all rea</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">costs and </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">xpense</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cl</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uding r</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eason</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">abl</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">attorneys&#8217; </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fee</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and expenses, </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incurred </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by the </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ub</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tanti</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lly prevailing party </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">action or proceeding and </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any appeal </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">connection </font><font style="color:#0f0f0f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">therewith.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for a lease, and shall not be effective as a lease or otherwise until execution by and delivery to both Landlord and Tenant.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Time is of the essence with respect to the performance of every provision of this Lease in which time of performance is a factor.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Each provision of this Lease performable by Tenant shall be deemed both a covenant and a condition.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Whenever consent or approval of either party is required, that party shall not unreasonably withhold, condition or delay such consent or approval, except as may be expressly set forth to the contrary.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The terms of this Lease are intended by the parties as a final expression of their agreement with respect to the terms as are included herein, and may not be contradicted by evidence of any prior or contemporaneous agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Any provision of this Lease that shall prove to be invalid, void or illegal shall in no way affect, impair or invalidate any other provision hereof, and all other provisions of this Lease shall remain in full force and effect and shall be interpreted as if the invalid, void or illegal provision did not exist.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Landlord or Tenant may, but shall not be obligated to, record a short form or memorandum hereof without the other party&#8217;s consent but such other party shall execute such short form or memorandum if requested to do so. Upon either party&#8217;s request, Landlord and Tenant shall execute, deliver and record such short form or memorandum in such form as mutually agreed to by the parties, along with an instrument signed by Tenant acknowledging the termination of this Lease to be held by Landlord until such termination actually occurs. Landlord shall not record the instrument acknowledging the termination of this Lease until the expiration or earlier termination of this Lease. Neither party shall record this Lease. The party asking to record such short form or memorandum shall be responsible for the cost of recording the same, including any transfer or other taxes incurred in connection with said recordation.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The language in all parts of this Lease shall be in all cases construed as a whole according to its fair meaning and not strictly for or against either Landlord or Tenant.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Each of the covenants, conditions and agreements herein contained shall inure to the benefit of and shall apply to and be binding upon the parties hereto and their respective heirs&#59; legatees&#59; devisees&#59; executors&#59; administrators&#59; and permitted successors, assigns, sublessees. Nothing in this Section shall in any way alter the provisions of this Lease restricting assignment or subletting.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">This Lease shall be governed by, construed and enforced in accordance with the laws of the state in which the Premises are located, without regard to such state&#8217;s conflict of law principles.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.16</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">guarantees, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">warrants and represents that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">individual </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or individuals </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">signing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease on its behalf </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have the power, authority </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">legal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">capacity </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sign this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on behalf </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bind </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all entities, corporations, partnerships, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">limited liability </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">companies, joint venturers or other organizations and entities </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whose </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">behalf </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">said </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">individual or individuals have </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">signed. Landlord </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">guarantees, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">warrants and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">represents that the individual </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">individuals </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">signing this </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on its </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">behalf have </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">power, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">authority </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">legal </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">capacity </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to sign </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease on </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">behalf </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to bind </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all entities, corporations, partnerships, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">limited </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">liability companies, joint </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">venturers or other </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">organizations </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entities </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whose behalf </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">said individual </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or individuals </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">signed.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">This Lease </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be executed in one </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">more </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">counterparts, each </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">when taken together, </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">constitute one </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">document.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.18</font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">No provision </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may be </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">modified, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amended or supplemented except by an </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in writing signed </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and Tenant. The </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">waiver </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or Tenant </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of any breach by </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant or Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of any term, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">covenant or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">condition </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">herein contained </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be deemed </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a waiver of any </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subsequent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">breach of the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">same </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">term, covenant or condition </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">herein </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contained.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.19</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">To </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extent permitted </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Applicable Laws, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the parties </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">waive </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t1ial </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by jury </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">action, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proceeding or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">counterclaim brought by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other party </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereto </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">related </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">matters </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">arising </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">out </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of or in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any way connected with </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease&#59; </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relationship between </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#59; Tenant&#8217;s use or occupancy </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises&#59; or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">claim </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of injury </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage related to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41.20</font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">As </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">between </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and Tenant, Tenant </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have the exclusive right to its name&#58; </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">J. </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Craig </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Venter </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Institute, Inc.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Options </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">to Extend Term</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have two </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">options </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(each, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extend </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term, </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">each case </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an additional </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> year </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i.e., </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">total, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if both </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">options </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are exercised as </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">herein, of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> successive years </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">beyond the original </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term) as </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">entire Premises and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no less than the entire Premises (each </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> year </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">being referred </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to herein as </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an &#8220;</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Extension </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon the following </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and conditions. All </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provisions </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">during </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">each </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such Extension </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term except </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have no option to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extend </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of this Lease </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">beyond the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">second </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Extension Term&#59; </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Base Rent </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">each Extension Term </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be determined in accordance with </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42</font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as otherwise </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">On </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the first </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">day </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of each </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Extension </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term, Base Rent </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equal to</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%) of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Fair </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Market Rent </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defined below) of </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises, </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accordance </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42.7</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> through </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42.10</font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, inclusive, below, provided in </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Base Rent be less than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Base </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent in effect </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">immediately prior to </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and shall </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereafter be adjusted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on each annual </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">anniversary date thereof in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accordance </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8</font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">No </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Option is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assignable </font><font style="color:#343434;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">separate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and apart from this </font><font style="color:#131313;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Bach Option is conditional upon Tenant giving Landlord written notice of its election to exercise such Option at least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">months prior </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the end </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the expiration of the then-current Term. Time </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be of the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">essence </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as to Tenant&#8217;s exercise of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Option. Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assumes</font><font style="color:#7e7e7e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">full responsibility for </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">maintaining </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a record of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deadlines to </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exercise </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an Option. Tenant acknowledges that </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">it </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">would be inequitable to require Landlord to </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accept </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exercise of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an Option </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the date provided for in this </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Notwithstanding anything </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contained </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Article to the contrary, Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not have </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">right </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exercise an Option or to </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commence an Extension </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term unless Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Default. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">The period of</font><font style="color:#a3a3a3;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time within </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant may exercise an Option </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be extended or </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">enlarged </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reason </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Tenant&#8217;s inability to exercise </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Option </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">because </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the provisions </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Landlord </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reject </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">either or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">both of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Options hereunder if&#59; </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the twenty </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">four (24) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">months immediately preceding the date </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Option </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">due, </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has Defaulted under this </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">three (3) </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">more times, </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whether </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or not Tenant has </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">cured such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Defaults.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42.7</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 42.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below, in </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">order </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determine </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fair </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Market Rent </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purposes </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of calculating </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Base </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Extension </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term, Tenant and Landlord </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall eac</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deliver to </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other their respective determinations of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Fai</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Market Rent (hereinafter respectively referred to </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord&#8217;s Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no later </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than the date that is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days prior </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">scheduled commencement date </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable Extension Term. If Tenant&#8217;s Determination is lower than Landlord&#8217;s Determination, then Landlord </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">attempt </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">good faith </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agree upon </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fair Market Rent for </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a period </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after the date </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which both </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s Determination and </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Determination have been duly delivered </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Determination Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s Determination is higher </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s Determination, then the </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fair </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Market Rent for the Premises </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Determination. </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and Tenant do not agree </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fair </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Market </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent for the Premises within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Determination Delivery Date, then Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sha</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ll </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">have the tight </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rescind the exercise of the Option by written notice to </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landl</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rd </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or before the date </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Business Days </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the expiration </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">day period. In the event Tenant does not deliver </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rescission </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Landlord, Landlord and Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">jointly select </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">independent </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">re</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">al </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">estate appraiser that (a) neither </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nor Tenant, nor any of their respective affiliates, has </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">engaged </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">during </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">immediately </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">preceding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">years&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) has </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at </font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ten (10) years of experience </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leasing first-class office properties </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">located </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the Rockville, Maryland </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">area </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(such appraiser being referred to herein </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as the &#8220;</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appraiser</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord and Tenant </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall each </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> percent (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%) of the Appraiser&#8217;s fee. If </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">do not agree on the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">App</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rai</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">er </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days after the </font><font style="color:#030303;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">la</font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">st </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">day of </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">period of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days, then the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">parties shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">request tha</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#bfbfbf;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the American Arbitration </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Association select </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Appraiser.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">The parties </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">instruct the </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Appraiser </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) conduct the </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hearings and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">investigations </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he or </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">she </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deems </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">appropriate, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b) </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">choose either </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;s Determination or </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Determination </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">better </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">estimate of </font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fair </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Market </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent for </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises, </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within </font><font style="background-color:#000000;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date that the </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Appraiser is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">de</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">signat</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ed</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Appraiser&#8217;s </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">aforesaid choice </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be conclusive </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and binding </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon Landlord </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant. </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">party </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pay </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">own </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">counsel </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fees </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expenses, if </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any, in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">connect</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the procedure </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">described </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42.8</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Appraiser </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not have the power to </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">supplement </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">modify any </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the provisions of thi</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease</font><font style="color:#575757;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42.9</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">For </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purposes </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of calculating </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Fair </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Market </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent, the following presumptions </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">apply&#58; </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises is free </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">clear </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">leases and </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenancies </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(including thi</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">eas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e)</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Premises is </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">available for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purposes </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">permitted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease in the then rental mar</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ke</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that Landlord has had </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonable </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">time to locate </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenant, </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hat </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">neither </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord nor </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pro</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pec</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tive </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under any compulsion </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rent, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taking </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">into </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">account all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relevant </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">factors.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42.10</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">For </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purposes </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease, </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Fair </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Market </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent&#8217;&#8217; for the Premises </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">based on a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">year extension </font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall be </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the monthly base rental rate (on </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">per </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">square </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">foot of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rentable </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">area </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">basis) </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agreed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by willing sophisticated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenants </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and willing </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sophisticated landlords </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in leasing </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transactions (the </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Comparable Transactions</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of a particular </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">me</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">arms-length transactions for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">non</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-sub</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lea</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">non-encumbered, non </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">equity, non-expansion, non-renewal </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">space </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">comparable in </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">size, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">location, height and quality </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Premises, </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with a commencement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">more </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">months </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prior to the </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commencement date of the extension </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">term, </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">there </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Comparable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transactions, in </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other first-class combined office&#47;laboratory facilities containing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">located </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rockville</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Maryland area, </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with appropriate adjustments to </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">account </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">differences in </font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Adjustment Factors </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(as </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defined </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">below) and </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">factors reasonably relevant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fair market </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determination. </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any determination of </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fair Market </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rent</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">appropriate </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">consideration </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">should </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">given </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relevant </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">factor </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or difference </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the subject </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transaction or </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Comparable </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transactions used </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for purposes </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of comparison), </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without limitation, the following factors </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Adjustment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58; (a) </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">monthly </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">base </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rental </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rates </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">per rentable </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">square foot&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">abatement provisions</font><font style="color:#9e9e9e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reflectin</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g free </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rent </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or early </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">occupancy during </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lease </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">term&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) the </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">size, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">location </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">floor </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">height </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the premises being leased&#59; (d) the </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">condition and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">market </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">value </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the existing </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenant </font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mp</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">emen</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ts, </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any (from </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a general marketing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">perspective </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and without </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regard to their </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">value, usability or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">function to Tenant </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or to any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenant in </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any Comparable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transaction)</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">existence </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amount of any tenant </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">improvement or comparable allowance&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e) </font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">existence </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amount </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any other cash </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">paymen</font><font style="color:#424242;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or other equivalent concession, </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including, </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without limitation, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">moving </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">allowances, </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lease takeover allowances (or where a lease assumption is applicable, </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">value </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereof), </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and any comparable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenant </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">inducement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f) the </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">existence </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">favorable expansion and&#47;or extension options, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">value thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g) </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">special </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">parking rights, rates or concessions&#59; </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h) whether the lease transaction </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">question </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">grants </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the tenant any protection </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">increases in </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">real </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">property </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taxes </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and&#47;or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">operating </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expenses, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and if </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">so, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the am</font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">unt</font><font style="color:#575757;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,. </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">value or cost associated </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">therewith&#59; </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) the </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">credit standing </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenant in question </font><font style="color:#313131;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and&#47;or </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the amount of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">letters of credit, cash security deposits, and&#47;or other credit enhancements required to be made available by the tenant in question.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Tenant&#8217;s Maintenance of Building&#59; Turnover Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Tenant shall have the right, no more than once during the Term of this Lease, to elect to turnover Tenant&#8217;s obligations pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 43.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> through (c), inclusive, to Landlord (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Turnover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by delivery of written notice to Landlord, together with copies of all Service Contracts, warranties and any other documentation related to the maintenance of the Building then in effect and in the possession or control of Tenant (the &#8216;&#8216;Turnover Notice&#8221;), subject to and in accordance with the following provisions&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Notwithstanding any provision to the contrary in this Lease, as of the Term Commencement Date and continuing until the earlier to occur of (a) the expiration of the Term or (b) the Turnover Date, the following provisions shall apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43.1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Tenant shall repair, replace and maintain in accordance with standards for comparable first-class buildings in the Rockville, Maryland area and in accordance with all Applicable Laws the Building, including the Building System Improvements (except for the Structural Building Improvements capital repairs or replacements of the Building System Improvements, which both shall remain the responsibility of Landlord throughout the Term).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43.1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Tenant shall make all arrangements for and pay for all utilities, including water, electricity, air, sewer, refuse, gas, heat, light, power, telephone service and any other service or utility Tenant required at the Premises.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43.1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Tenant shall, at Tenant&#8217;s sole cost and expense, procure and maintain (i) contracts, with copies furnished promptly to Landlord after execution thereof, in customary form and substance for, and with contractors specializing and experienced in, the maintenance and repair of the Building System Improvements including, without limitation, the (a) HVAC equipment, (b) boilers and pressure vessels, (c) fire and life safety systems, including fire alarm and smoke detection devices, (d) roof coverings and drains, (e) clarifiers, and (f) basic utility feeds to the perimeter of the Building (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Service Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and (ii) warranties for any Building improvements.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43.1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Landlord shall not be required to provide the following services to the Building&#58; cleaning and trash removal&#59; hot and cold water&#59; gas&#59; heat, ventilation and air conditioning&#59; light&#59; telephone&#59; fire and life safety&#59; electricity&#59; sewer&#59; other utilities&#59; security system services or elevator service.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43.1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Landlord shall, at all times regardless of whether or not the Turnover has occurred, have the right to inspect the Premises in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43.1.6.</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">In </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">addition </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord&#8217;</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remedies under </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease, if (a) Tenant does </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">maintain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Building </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease or (b) repairs or replacement of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any portion </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Build</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Proj</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ec</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">made necessary </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any act, omission or negligence of Tenant or its agents, employees </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or invitees, then </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lan</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">dlord may </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch repair</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or provide such maintenance without </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">liabili</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ty </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Tenant for any </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lo</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ss </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or damage to Tenant or </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">merchandise, fixtures or other property, or to Tenant&#8217;s </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">busine</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ss </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reason of such repairs or maintenance (except to </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extent such </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lo</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ss </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">damage </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">caused by the gross negligence or willful </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">misconduct </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Landlord, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agents, employees or contractors) provided that </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failure by </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">T</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">enant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">continues for three (3) </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">busine</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ss </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">days after Landlord </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deli</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ver</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice to </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Te</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">demanding performance </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#59; or that such failure </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant unreasonably </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interfered </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">use of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buildings </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tenant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or with </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">efficient operation of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Project, or resulted or could have resulted </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in a violation of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Applicable </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Law</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or the cancellation of an </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">insurance policy maintained by Land</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lor</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or cancellation of any warranty on the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bu</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ld</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ng. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Further, upon completion of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">uch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">repairs or maintenance and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">advance written </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">been </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">given to Tenant by Landlord, Tenant shall pay </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon demand, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as Additional Rent, Landlord&#8217;s costs for making such repairs or providing such maintenance, together with </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">intere</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t thereon</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the date </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">tha</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such sums were </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">paid </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incurred</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Default </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rate or </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">highest </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rate permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Applicable </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Law</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">whichever is </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">less.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">Subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">43.</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">1</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on the date </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following Landlord&#8217;s receipt of Tenant&#8217;s Turnover Notice (the </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Turn</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">over </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Landlord shall </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligated </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to maintain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and repair the Building System </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Improvements </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and to </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provide the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">utilities and </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">serv</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ices </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">1</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">.7</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16.9</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and in accordance with </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he provi</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sions </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of such Sections. </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within thirty (30) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">calendar </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">day</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following Landlord&#8217;s receipt </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Te</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nt</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Turnover </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord shall </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prov</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ide </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant with written </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of those Service Contracts </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that Landlord </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has agreed </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assume as of </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Turnover </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Da</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">te </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(colle</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ti</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ve</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ly</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ass</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">umed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Service Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Te</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nant s</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hall be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligated </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminate all of </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Service Contracts other </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Assumed Service Contracts and shall </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">solely </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respon</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sible </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for all </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termi</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nation fee</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">penalties </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">associated with such termination(s). Within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> days </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Turnover </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date, Landlord and </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Te</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall execute an amendment </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">this Lease acknowledge </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms of the Turnover Prior to the </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Turno</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ver </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date</font><font style="color:#545454;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant shall deliver </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assignment of </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Service Contracts, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">du</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ly </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">executed </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant&#59; assigning </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Tenant&#8217;s right, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">title </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nterest </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Assumed Service Contracts, and Landlord </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">accept </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assignment and assume all obligations under such Assumed Service Contracts for the period commencing on </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Turnover Date.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">For </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purpo</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of clarification, Landlord and Tenant&#8217;s maintenance </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">service obligations, prior to and following a Turnover, are further detailed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and inco</font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rporated here</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by reference.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;REMAINDER </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OF </font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IS PAGE INTENTIO</font><font style="color:#3b3b3b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LLY </font><font style="color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LEFT BLANK&#93;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WITNESS WHEREOF, the parties hereto have executed </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thi</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Lease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">date </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">first above </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">wr</font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">itte</font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">LANDLORD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BMR-MEDICAL CENTER DRIVE LLC,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">limit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ed l</font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iabil</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ity company</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TENANT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">J. CRA</font><font style="color:#525252;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">G </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VENTER INSTITUTE, INC.,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">successor </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in interest </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Institute </font></div><div><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for Genomic Research, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Inc.,</font></div><div><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Maryland </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">stock </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">corporation</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; J. Craig Venter</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160; J. Craig Venter&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;President&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have executed this Lease as of the date first above written.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">LANDLORD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BMR-MEDICAL CENTER DRIVE LLC,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">limit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ed l</font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iabil</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ity company</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> Kevin M. Simonsen</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;Kevin M. Simonsen&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;VP, Real Estate Counsel&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TENANT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">J. CRA</font><font style="color:#525252;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">G </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">VENTER INSTITUTE, INC.,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">successor </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in interest </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Institute </font></div><div><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for Genomic Research, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Inc.,</font></div><div><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Maryland </font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o</font><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">stock </font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">corporation</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#0e0e0e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>6
<FILENAME>a1026_firstamendmenttohqle.htm
<DESCRIPTION>EX-10.26
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i369f95cee3414689b3d7728afcd28fd4_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit.10.26</font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY &#91;***&#93;) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FIRST AMENDMENT TO LEASE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THIS FIRST AMENDMENT TO LEASE (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of this &#91;***&#93;day of &#91;***&#93; March, 2014, by and between BMR-MEDICAL CENTER DRIVE LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and J. CRAIG VENTER INSTITUTE, INC., successor in interest to The Institute for Genomic Research, Inc., a Maryland non-stock corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;WHEREAS, Landlord and Tenant entered into that certain Lease dated as of May 3, 2010 (as the same may have been amended, supplemented or modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Existing Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), whereby Tenant leases certain premises (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from Landlord at 9704 Medical Center Drive in Rockville, Maryland (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;WHEREAS, Landlord and Tenant desire to revise Base Rent for the Premises&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;WHEREAS, Landlord and Tenant desire to modify and amend the Existing Lease only in the respects and on the conditions hereinafter stated.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Amendment, capitalized terms shall have the meanings ascribed to them in the Existing Lease unless otherwise defined herein. The Existing Lease, as amended by this Amendment, is referred to collectively herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lease.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Effective as of &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rent Adjustment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), initial monthly and annual installments of Base Rent for the Premises shall be as set forth in the chart below, subject to adjustment under the Lease&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Dates</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Square Feet of Rentable Area</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Base Rent Per Square Foot of Rentable Area</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Monthly Base Rent</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Annual Base Rent</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Rent Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Effective as of the Rent Adjustment Date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing Lease is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BioMed Realty form dated 1&#47;28&#47;14</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Rent Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Base Rent shall be subject to an annual upward adjustment of &#91;***&#93; percent (&#91;***&#93;%) of the then-current Base Rent. The first such adjustment shall become effective commencing on the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) annual anniversary of the Rent Adjustment Date, and subsequent adjustments shall become effective on every successive annual anniversary for so long as this Lease continues in effect.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant represents and warrants that it has not dealt with any broker or agent in the negotiation for or the obtaining of this Amendment and agrees to reimburse, indemnify, save, defend (at Landlord&#8217;s option and with counsel reasonably acceptable to Landlord, as Broker&#8217;s sole cost and expense) and hold harmless the Landlord Indemnitees for, from and against any and all cost or liability for compensation claimed by any such broker or agent employed or engaged by it or claiming to have been employed or engaged by it.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord Indemnitees,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as used in the Lease, means, collectively, Landlord and its affiliates, employees, agents, contractors and Lenders. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lender,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as used in the Lease, means any lender, mortgagee or beneficiary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">No Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant represents, warrants and covenants that, to the best of Tenant&#8217;s knowledge, Landlord and Tenant are not in default of any of their respective obligations under the Lease and no event has occurred that, with the passage of time or the giving of notice (or both) would constitute a default by either Landlord or Tenant thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant confirms that, notwithstanding anything in the Lease to the contrary, notices delivered to Tenant pursuant to the Lease should be sent to&#58;</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">J. Craig Center Institute, Inc.</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9704 Medical Center Drive</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rockville, Maryland 20859</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; Vice President, General Counsel&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with a copy to&#58;</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Arnold &#38; Porter LLP</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">555 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Street, NW</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Washington, DC 20004</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; Kenneth Schwartz.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Effect of Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as modified by this Amendment, the Existing Lease and all the covenants, agreements, terms, provisions and conditions thereof shall remain in full force and effect and are hereby ratified and affirmed. In the event of any conflict between the terms contained in this Amendment and the Existing Lease, the terms herein contained shall supersede and control the obligations and liabilities of the parties. From and after the dat hereof, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as used in the Lease shall mean the Existing Lease, as modified by this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each of the covenants, conditions and agreements contained in this Amendment shall inure to the benefit of and shall apply to and be binding upon the parties hereto and their respective heirs, legatees, devisees, executors, administrators and permitted successors and assigns and sublessees. Nothing in this section shall in any way alter the provisions of the Lease restricting assignment or subletting.</font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Amendment becomes effective only upon execution and delivery hereof by Landlord and Tenant. The captions of the paragraphs and subparagraphs in this Amendment are inserted and included solely for convenience and shall not be considered or given any effect in construing the provisions hereof. All exhibits hereto are incorporated herein by reference. Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for a lease, and shall not be effective as a lease, lease amendment or otherwise until execution by and delivery to both Landlord and Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant guarantees, warrants and represents that the individual or individuals signing this Amendment have the power, authority and legal capacity to sign this Amendment on behalf of and to bind all entities, corporations, partnerships, limited liability companies, joint venturers or other organizations and entities on whose behalf such individual or individuals have signed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Counterparts&#59; Facsimile and PDF Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Amendment may be executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document. A facsimile or portable document format (PDF) signature on this Amendment shall be equivalent to, and have the same force and effect as, an original signature.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><div id="i369f95cee3414689b3d7728afcd28fd4_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Landlord and Tenant have executed this Amendment as of the date and year first above written.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LANDLORD&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BMR-MEDICAL CENTER DRIVE LLC,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47; Jonathan P., Klassen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   Jonathan P. Klassen&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   Senior Vice President &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TENANT&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">J. CRAIG VENTER INSTITUTE, INC.,</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">successor in interest to The Institute for Genomic Research, Inc.,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Maryland non-stock corporation</font></div><div style="margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47; Robert J. Walden</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   Robert J. Walden&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   Vice President Finance&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>7
<FILENAME>a1027_secondamendmenttohql.htm
<DESCRIPTION>EX-10.27
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i57978fd50a15435389ce860713342635_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit.10.27</font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY &#91;***&#93;) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL.</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECOND AMENDMENT TO LEASE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THIS SECOND AMENDMENT TO LEASE (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Second Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of this &#91;***&#93; day of &#91;***&#93;, &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Execution Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and between BMR-MEDICAL CENTER DRIVE LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and MACROGENICS, INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;WHEREAS, pursuant to that certain Assignment and Assumption Agreement dated as of &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) between J. Craig Venter Institute, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">JCVI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as assignor, and Tenant, as assignee, and that certain Landlord Consent attached to the Assignment Agreement and executed by Landlord (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as of the Effective Date (as defined below), Landlord and Tenant are parties to that certain Lease dated as of &#91;***&#93; (as amended by that certain First Amendment to Lease dated as of &#91;***&#93;, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Existing Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), whereby Tenant leases certain premises (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; from Landlord at 9704 Medical Center Drive in Rockville, Maryland (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;WHEREAS, effective as of the Effective Date, Landlord and Tenant desire to revise the Base Rent for the Premises, extend the Term of the Existing Lease and modify certain other provisions of the existing Lease on the terms and conditions set forth in this Second Amendment&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;WHEREAS, effective as of the Effective Date, Landlord and Tenant desire to modify and amend the Existing Lease only in the respects and on the conditions hereinafter stated.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Second Amendment shall be effective concurrently with the effectiveness of the assignment of JCVI&#8217;s interest in, to and under the Existing Lease to Tenant pursuant to the Assignment Agreement. The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; for purposes of this Second Amendment shall mean the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as such term is defined in the Assignment Agreement &#91;***&#93; Landlord and Tenant shall execute and deliver the Acknowledgment of Second Amendment Effective Date in substantially the form attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to this Second Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Second Amendment, capitalized terms shall have the meanings ascribed to them in the Existing Lease unless otherwise defined herein. The Existing Lease, as amended by this Second Amendment, is referred to collectively herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lease.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; From and after the date hereof, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lease,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as used in the Existing Lease, shall mean the Existing Lease, as amended by this Second Amendment. To the extent terms are defined in both the Existing Lease and the Second Amendment, the defined terms in this Second Amendment shall control for the entire Lease, as amended.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BioMed Realty form dated 3&#47;27&#47;15</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Revised Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Landlord and Tenant have agreed to extend the Term of the Existing Lease and to modify certain terms and provisions of the Existing Lease in connection therewith on the terms and conditions set forth in this Second Amendment. Notwithstanding any provision in the Existing Lease to the contrary, the Term shall be extended &#91;***&#93; and shall be subject to further extension pursuant to Section 14 of this Second Amendment. The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Revised Term Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be the later of (a) &#91;***&#93; and (b) the day Landlord tenders possession of the Premises to Tenant. The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; in the Lease and the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Revised Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; in this Second Amendment shall mean and refer to the period of time commencing on the Revised Term Commencement Date and continuing through the Term Expiration Date, as extended by this Second Amendment, and as the same may be extended pursuant to Section 14 of this Second Amendment, and subject to the earlier termination of the Lease as therein provided. Landlord and Tenant shall execute and deliver to the other written acknowledgment of the actual Revised Term Commencement Date and the Term Expiration Date &#91;***&#93; in the form provided by Landlord, which form shall be consistent with the form attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to this Second Amendment. Notwithstanding anything to the contrary contained in this Second Amendment, in the event that (i) the Effective Date does not occur or (ii) Landlord fails to deliver the Premises to Tenant &#91;***&#93; for any reason, except for any delay caused by Tenant or an event of Force Majeure (however, Force Majeure shall not include holdover in the Premises by JCVI), then Tenant shall receive either (y) a day-for-day abatement &#91;***&#93; of the initial Monthly Base Rent &#91;***&#93; if such failure to deliver is due to holdover in the Premises by JCVI or (z) a day-for-day abatement of one hundred percent 100% of the amount of the initial Monthly Base Rent &#91;***&#93; if such failure to deliver the Premises is not due to holdover in the Premises by JCVI, in each case for each day after &#91;***&#93; that the Effective Date does not occur or Landlord fails to deliver possession of the Premises to Tenant, which abatement shall be applied against the first and subsequent accruing Monthly Base Rent due for the Premises following the Revised Term Commencement Date until exhausted. To the extent not delivered by JCVI directly to Tenant pursuant to the Assignment Agreement, Landlord shall deliver all keys, security codes and electronic access cards to the Premises and all offices and restrooms therein received by Landlord from JCVI.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Revised Term&#58; Amended Lease Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Effective as of the Effective Date, the Existing Lease shall be amended as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Deleted Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Effective as of the Effective Date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Articles 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 9.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (except that Landlord shall remain responsible for the external cleaning of the Building and snow removal obligations set forth in Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing Lease), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">18.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">29.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">41&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">41.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibits C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing Lease are hereby deleted in their entirety and replaced with the following&#58; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Intentionally Omitted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;. In addition to the foregoing, all references to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Turnover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; in the Existing Lease, the words &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">So long as Tenant has not assigned the Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the first sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the second sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are hereby deleted in their entirety. The following is hereby added to the end of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">the first sentence of Section 12.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; &#8220;without Landlord&#8217;s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.&#8221; The following is hereby added to the end of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">t</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">he second sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">which consent shall not be unreasonably withheld, conditioned or delayed.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is hereby replaced with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto. Notwithstanding the foregoing, Tenant may submit an updated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the Lease pursuant to the terms and conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Existing Lease, and, for clarity, bioreactors, centrifuges, media and buffer preparation tanks, manufacturing skids (such as for depth filtration, ultrafiltration and clean-in-place processes) and similar types of equipment used for biologics manufacturing in the Premises that are purchased by Tenant will be deemed to be &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; owned by Tenant and not &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">fixtures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; regardless of whether such equipment is physically anchored to the Building.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Revised Term Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. From and after the Revised Term Commencement Date, the monthly and annual installments of Base Rent for the Premises during the Revised Term shall be as set forth in the chart below, subject to adjustment under the Lease&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Dates</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Square Feet of Rentable Area</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Base Rent per Square Foot of Rentable Area</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Monthly Base Rent</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Annual Base Rent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Security Deposit.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Security Deposit &#91;***&#93; shall be deposited by Tenant with Landlord on or before the Revised Term Commencement Date and otherwise in accordance with the Existing Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADA Compliance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding any other provision herein or in the Lease to the contrary, Tenant shall be responsible for all liabilities, costs and expenses arising out of or in connection with the compliance of the Premises with the Americans with Disabilities Act, 42 U.S.C. &#167; 12101, et seq., and any state and local accessibility laws, codes, ordinances and rules (collectively, and together with regulations promulgated pursuant thereto, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), provided that&#58; (i) if ADA compliance requires alteration of the Premises from its condition as of the Revised Term Commencement Date due to a change in the ADA or the enforcement thereof which takes effect after the Revised Term Commencement Date&#59; (ii) such ADA compliance is not required as the result of any Alterations (including any Tenant Improvements) made by Tenant&#59; and (iii) such alteration of the Premises is considered capital in nature in accordance with generally accepted accounting principles, then Landlord shall be responsible for performing such alterations, the cost of which shall be considered an Operating Expense and shall be amortized in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; further, provided, that if ADA compliance requires alteration of the Premises from its condition as of the Revised Term Commencement Date due to a violation in the ADA which exists as of the Revised Term Commencement Date or the enforcement thereof (provided such enforcement is not the result of any Alterations (including any Tenant Improvements) made by Tenant), then Landlord shall be responsible for performing such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">alterations, the cost of which shall not be considered an Operating Expense. The provisions of this Section shall survive the expiration or earlier termination of the Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Signage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The first two sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing Lease are hereby deleted in their entirety and replaced with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No sign, advertisement or notice (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Signage&#8221;) shall be exhibited, painted or affixed by Tenant on any part of the Premises or the Building without Landlord&#8217;s prior written consent, not to be unreasonably withheld, conditioned or delayed, provided that Tenant shall have the right, without obligation, to install and maintain a Building top signage and a monument sign at the entry to the driveway of the parking lot serving the Building, in each case, with Tenant&#8217;s logo at a location and in a manner to be reasonably approved by Landlord, subject to all Applicable Laws. Upon the expiration or earlier termination of the Term, Tenant shall be responsible for removing all of Tenant&#8217;s Signage, including any monument sign installed by Tenant pursuant to this Section, and restoring the Premises, Building or other portions of the Project damaged by the installation or removal of such Tenant&#8217;s Signage to their condition prior to such damage at Tenant&#8217;s sole cost and expense.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment or Subletting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 29.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing Lease is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">29.1 Except as hereinafter expressly permitted, none of the following (each, a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Transfer&#8221;), either voluntarily or by operation of Applicable Laws, shall be directly or indirectly performed without Landlord&#8217;s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed&#58; (a) Tenant selling, hypothecating, assigning, pledging, encumbering or otherwise transferring this Lease or subletting the Premises or (b) a controlling interest in Tenant being sold, assigned or otherwise transferred (other than as a result of shares in Tenant being sold on a public stock exchange). For purposes of the preceding sentence, &#8220;control&#8221; means (i) owning (directly or indirectly) more than &#91;***&#93; of the stock or other equity interests of another person or (ii) possessing, directly or indirectly, the power to direct or cause the direction of the management and policies of such person. Notwithstanding the foregoing, Tenant shall have the right to Transfer, without Landlord&#8217;s prior written consent, Tenant&#8217;s interest in this Lease or the Premises or any part thereof to (x) any person that as of the date of determination and at all times thereafter directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with Tenant, (y) the surviving corporation or other entity in a merger or consolidation in accordance with applicable statutory provisions, provided that the liabilities of the corporations or other business entities participating in such merger or consolidation are assumed by the corporation or other business entity surviving such merger or consolidation, or (z) a bona fide purchaser of all or substantially all of the stock, membership interests or partnership interests (as applicable) or assets of Tenant ((x), (y) and (z), each, a &#8220;Tenant&#8217;s Affiliate&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Tenant shall notify Landlord in writing at least ten (10) days before such Transfer (in which case, Landlord shall comply (during the period of time prior to the effective date of the Exempt Transfer) with any reasonable and appropriate confidentiality requirements with respect to such notification as may be requested in writing by Tenant) (each an &#8220;Exempt Transfer&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> and the assignee or transferee being an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Exempt Transferee&#8221;) and otherwise comply with the requirements of this Lease regarding such Transfer&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, further, that the Exempt Transferee has a net worth (as of both the day immediately prior to and the day </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">immediately after the Exempt Transfer) that is equal to or greater than the net worth (as of both the Revised Term Commencement Date and the date of the Exempt Transfer) of the transferring Tenant. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 29.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not apply to any Exempt Transfer to an Exempt Transferee, nor are such provisions intended to, nor shall they be interpreted to extend or apply to, the consideration given or the purchase price paid by a bona fide purchaser for all of the stock, membership interests or partnership interests (as applicable) or assets of Tenant, regardless of whether such a Transfer to Tenant&#8217;s Affiliate constitutes an Exempt Transfer pursuant to this Section. In no event shall Tenant perform a Transfer to or with an entity that is a tenant at the Project or that is or has been in discussions or negotiations with Landlord or an affiliate of Landlord within the last six (6) months to lease premises at the Project or a property owned by Landlord or an affiliate of Landlord in Rockville or Gaithersburg, Maryland. Notwithstanding anything in this Lease to the contrary, if (a) Tenant or any proposed transferee, assignee or sublessee of Tenant has been required by any prior landlord, Lender or Governmental Authority to take material remedial action in connection with Hazardous Materials contaminating a property if the contamination resulted from such party&#8217;s action or omission or use of the property in question or (b) Tenant or any proposed transferee, assignee or sublessee is subject to a material enforcement order issued by any Governmental Authority in connection with the use, disposal or storage of Hazardous Materials, then Landlord shall have the right to terminate this Lease in Landlord&#8217;s sole and absolute discretion (with respect to any such matter involving Tenant), and it shall not be unreasonable for Landlord to withhold its consent to any proposed transfer, assignment or subletting (with respect to any such matter involving a proposed transferee, assignee or sublessee).&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 29.5.3 of the Existing Lease is hereby amended to replace &#91;***&#93; per occurrence&#47;request&#8221; with &#91;***&#93;&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Loading Dock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the Revised Term, and notwithstanding Section 13 of the Lease, Tenant shall have the exclusive right to use the warehouse&#47;receiving and loading dock adjacent to the Building as depicted on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Loading Dock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Tenant, Landlord and the tenants of 9708 Medical Center Drive shall have non-exclusive access to use the area adjacent to the Loading Dock, provided such access and use of the area adjacent to the Loading Dock by Landlord and tenants of 9708 Medical Center Drive shall be limited to maneuvering vehicles to gain access to the loading dock adjacent to 9708 Medical Center Drive. Landlord shall not unreasonably interfere with Tenant&#8217;s use of or access to the Loading Dock, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, however, that the foregoing restriction shall not apply in the event of any emergency. Landlord acknowledges that Tenant desires to construct a utility space in the area adjacent to the Loading Dock and that Landlord is amenable to such a request, provided that the construction of any such utility space shall be subject to all of the requirements in the Lease relating to Alterations, including Landlord&#8217;s prior consent to such proposed Alteration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Holding Over</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The holdover rent payable by Tenant pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 27.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the Lease shall be prorated on a daily basis for each day that Tenant remains in <br>possession of the Premises after the expiration or earlier termination of the Term without Landlord&#8217;s prior written consent. In addition, notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 27.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing <br>Lease, Tenant shall not be liable to Landlord for any damages suffered by Landlord as a result of such holdover (including lost rent or consequential, special or indirect damages) &#91;***&#93; and thereafter, Tenant shall be liable to Landlord for any and all damages suffered by Landlord as a result of such holdover, including any lost rent or consequential, special and indirect damages.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subordination and Attornment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Landlord represents and warrants to Tenant that as of the Effective Date there is no current mortgagee with respect to the Property. To the extent that a short form or memorandum of this Lease has not been recorded, Landlord shall provide any future Mortgagee with written notice of the existence of the Lease prior to the recordation of any Mortgage. Notwithstanding anything to the contrary contained in the Lease, the Assignment or the Landlord Consent, Tenant&#8217;s obligation to subordinate and attorn to a future Mortgagee shall be conditioned upon Landlord delivering to Tenant a SNDA whereby such Mortgagee agrees, in the event of sale or transfer of the Building or any interest therein (including by foreclosure), to recognize the Lease and abide by the provisions in at least Sections 14, 15 and 16 of this Second Amendment, provided Tenant is not in uncured default of the Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">j.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Operating Expenses.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Any references to the Execution Date in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall hereafter be a reference to the Revised Term Commencement Date. Notwithstanding any other provision herein or in the Lease to the contrary, Landlord shall not include in Operating Expenses (i) any costs incurred to remove any Hazardous Materials from the Project, the Building or the Premises which were the result of a another tenant&#8217;s default under its lease&#59; or (ii) any costs incurred to remedy any enforceable violation of Applicable Law existing at the Premises, the Building or the Project as of the Revised Commencement Date&#59; In addition, to the extent that the Property Management Fee, any Operating Expenses or other costs under the Lease are computed based upon the Base Rent payable by Tenant under the Lease such computations shall be determined as though the Base Rent paid by Tenant is as follows&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Dates</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Square Feet of Rentable Area</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Base Rent per Square Foot of Rentable Area</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Monthly Base Rent</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Annual Base Rent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">k.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Taxes on Tenant&#8217;s Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Upon Tenant&#8217;s written request, Landlord shall provide Tenant with reasonable supporting documentation for any determination of value attributable to Tenant&#8217;s personal property or trade fixtures under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Lease.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">l.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Intentionally Omitted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">m.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord Maintenance and Repair.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In addition to the repairs and maintenance obligations of Landlord set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 18.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Landlord shall provide window washing services for the Building in accordance with standards for comparable first-class buildings in the Rockville, Maryland area, the cost of which shall be included as an Operating Expense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">n.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Alterations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing Lease is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Tenant shall make no alterations, additions or improvements in or to the Premises or engage in any construction, demolition, reconstruction, renovation, or other work (whether major or minor) of any kind in, at, or serving the Premises (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Alterations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) without Landlord&#8217;s prior written approval, which approval Landlord shall not unreasonably withhold, condition or delay&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, however, that in the event any proposed Alteration (a) any structural portions of the Building, including exterior walls, roof, foundation, foundation systems (including barriers and subslab systems), or core of the Building, (b) the exterior of the Building or (c) any Building systems, including elevator, plumbing, air conditioning, heating, electrical, security, life safety and power (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Material Alteration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then Landlord may withhold its approval with respect thereto in its sole and absolute discretion. Notwithstanding the foregoing, with respect to any Material Alterations that are critical or essential for biologics manufacturing as intended by Tenant, Landlord shall not unreasonably withhold, condition or delay its consent with respect to any such Material Alterations. Tenant shall, in making any such Alterations, use only those architects, general contractors and material suppliers and mechanics of which Landlord has given prior written approval, which approval shall not be unreasonably withheld, conditioned or delayed. In seeking Landlord&#8217;s approval, Tenant shall provide Landlord, at least fourteen (14) days in advance of any proposed construction, with plans, specifications, bid proposals, certified stamped engineering drawings and calculations by Tenant&#8217;s engineer of record or architect of record, (including connections to the Building&#8217;s structural system, modifications to the Building&#8217;s envelope, non-structural penetrations in slabs or walls, and modifications or tie-ins to life safety systems), work contracts, requests for laydown areas and such other information concerning the nature and cost of the Alterations as Landlord may reasonably request (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Alterations Submittals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). With respect to any Alterations that require Landlord&#8217;s prior consent relating to the maintenance, repair, replacement or upgrade of any systems or equipment or the Building structure (including the floor load) involved in Tenant&#8217;s manufacturing operations which are required to comply with Applicable Laws, Landlord shall use commercially reasonable efforts to respond to a notice for approval of such Alterations within ten (10) days of Landlord&#8217;s receipt of Tenant&#8217;s request therefor and the applicable Alterations Submittals and Landlord shall not unreasonably withhold, condition or delay its consent with respect to any such Alterations. Notwithstanding the foregoing, Tenant may make strictly cosmetic changes to the Premises &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cosmetic Alterations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; without Landlord&#8217;s consent&#59; provided that &#91;***&#93; such Cosmetic Alterations do not (i) require any structural modifications to the Premises, (ii) require any changes to, or adversely affect, the Building systems, (iii) affect the exterior of the Buildings or (iv) trigger any requirement under Applicable Laws that would require Landlord to make any alteration or improvement to the Premises, the Building or the Project. Tenant shall give Landlord &#91;***&#93; prior written notice of any Cosmetic Alterations involving a third party contractor or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">supplier which could give rise to a mechanic&#8217;s lien. Promptly after the end of each calendar quarter of the Revised Term, Tenant shall give Landlord a written summary of any other Cosmetic Alterations made by Tenant at the Premises during such calendar quarter. To the extent that Tenant fails to give the required prior notice for Cosmetic Alterations that could give rise to a mechanic&#8217;s lien, Tenant may cure such default by providing Landlord with notice of such Cosmetic Alterations at the end of the applicable calendar quarter. Any notice of Cosmetic Alterations required to be delivered by Tenant to Landlord may be delivered by electronic mail to Landlord&#8217;s authorized recipients, which recipients shall initially be Kevin Reap and Erin Travis, subject to change by written notice from Landlord to Tenant.&#8221; Tenant shall &#91;***&#93; pay Landlord for additional premiums charged under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Surrender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding any other provision herein or in the Lease to the contrary, Tenant shall have no obligation to remove any Alterations, fixtures, equipment, additions, improvements, signage or Tenant&#8217;s Rooftop Equipment installed by or on behalf of JCVI at the Premises or the Building prior to the Revised Term Commencement Date. In addition, Landlord shall not be permitted to require that Tenant remove any Alterations at the end of the Revised Term other than Alterations which, at the time that Landlord granted its consent to such Alterations, Landlord advised Tenant, in writing with reasonable specificity, that such Alterations would be required to be removed at the end of the Revised Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">p.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 41.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing Lease to the contrary, so long as (i) Tenant (or, if Tenant&#8217;s financial statement is consolidated with its parent, Tenant&#8217;s parent) is a publicly traded company on an &#8220;over-the-counter&#8221; market or any recognized national or international securities exchange, and (ii) Tenant&#8217;s (or, if Tenant&#8217;s financial statement is consolidated with its parent, Tenant&#8217;s parent&#8217;s) current public annual report (in compliance with applicable securities laws) for such applicable year is available to Landlord in the public domain, then, Tenant shall have no obligation to provide financial statements to Landlord.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">q.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord&#8217;s Access</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding anything in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or any other provision of the Existing Lease to the contrary, neither Landlord nor its agents or employees may enter the portions of the Premises, unless accompanied by a representative of Tenant, provided that Tenant makes such a representative reasonably available to Landlord and further, provided that if a bona-fide health or safety emergency or an imminent risk of damage to the Premises or the Project or to persons or property necessitates immediate entry to the Premises, Landlord or any emergency response or service provider contacted by Landlord (e.g., the fire department or utility providers) may use whatever force is necessary to enter the Premises, and any such entry to the Premises in accordance with the preceding clauses shall not constitute a forcible or unlawful entry to the Premises, a detainer of the Premises or an eviction of Tenant from the Premises or any portion thereof or result in any liability to Landlord. In the event of an emergency, Landlord will use reasonable efforts to notify Tenant of the emergency situation as soon as reasonably practicable after Landlord becomes aware of such emergency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">r.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Without limitation of Section 2.7 of the Existing Lease, Tenant may use the Premises for biologics manufacturing, laboratory and vivarium uses, provided such uses are conducted in accordance with all Applicable Laws and the terms and provisions of the Lease. Landlord hereby acknowledges and agrees that Landlord and its affiliates and their respective employees will not assert that the biologics manufacturing, laboratory and vivarium uses constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">waste</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">nuisance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; under the Lease, provided such uses are conducted in accordance with all Applicable Laws and the terms and provisions of the Lease.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 38(z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing Lease shall include all bona fide prospective purchasers of Tenant or its assets. Notwithstanding anything in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing Lease or otherwise herein to the contrary, Tenant shall be entitled to make any disclosure of the Lease that Tenant, in its good faith judgment, believes is required by Applicable Law or by any stock exchange on which its securities or those of its affiliates are listed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The second sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 21.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing Lease is hereby amended and restated as follows&#58; &#8220;If during any period of time needed by Tenant or Landlord after the expiration or earlier termination of this Lease to complete the removal from the Premises of any such Hazardous Materials, Landlord is prevented from or delayed in (a) performing work in the Premises or the Building necessary or desirable in order to prepare the Premises to be marketed or to be delivered to a subsequent tenant or occupant, and&#47;or (b) delivering the Premises to a subsequent tenant or occupant, then Tenant shall be deemed a holdover tenant and subject to the provisions of Section 27.2&#59; provided, however, that, in such event, the monthly holdover rent under Section 27.2(a) shall be calculated to exclude any portion of the monthly holdover rent that is allocable to any floor or floors of the Building (if any) that do not contain Hazardous Material in violation of this Lease.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Early Access to Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to JCVI&#8217;s compliance with its obligation to allow Tenant early access to the Premises under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Assignment Agreement, &#91;***&#93; Landlord shall use commercially reasonable efforts to grant Tenant access to the Premises and Common Areas prior to the Revised Term Commencement Date for the purpose of constructing improvements, installing furniture, fixtures and equipment or the placement of personal property, but not for the purpose of conducting Tenant&#8217;s business, provided Tenant shall furnish to Landlord evidence satisfactory to Landlord in advance that insurance coverages required of Tenant under the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing Lease are in effect, and such entry shall be subject to all the terms and conditions of the Lease other than the payment of Base Rent or Tenant&#8217;s Share of Operating Expenses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TI Allowance&#59; Construction of Tenant Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TI Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In accordance with the terms and conditions of this Second Amendment, Landlord shall make available to Tenant (i) a tenant improvement allowance &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base TI Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) plus (ii) if properly requested by Tenant pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, an additional tenant allowance &#91;***&#93; the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional TI Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), &#91;***&#93; for use for any purpose elected by Tenant, in Tenant&#8217;s sole discretion, which may include, among others, improvements to the Premises (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) as described in the Work Letter attached to this Amendment as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Work Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and as otherwise provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Base TI Allowance, together with Additional TI Allowance (if properly requested by Tenant pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), shall be referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TI Allowance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; Landlord shall disburse the Base TI Allowance to Tenant &#91;***&#93; by wire transfer of immediately available funds to an account specified by Tenant. If Tenant desires all or any portion of the Additional TI Allowance, then Tenant shall deliver to Landlord a written request for such Additional TI Allowance, in the form attached to this Amendment as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, executed by an authorized officer of Tenant (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional TI Allowance Request</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and, provided that no monetary or material non-monetary Default has occurred and is then continuing, Landlord shall disburse the requested amount of the Additional TI Allowance b wire transfer of immediate) available funds &#91;***&#93;. Tenant may make multiple draws against the Additional TI Allowance until such time as the entire Additional TI Allowance has been disbursed or the occurrence of the TI Deadline (as defined below), whichever occurs first. Tenant may use the Base TI Allowance (and Additional TI Allowance, if properly requested by Tenant pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) in Tenant&#8217;s sole discretion for, among other things, financing hard and soft costs of the Tenant Improvements, purchasing furniture, fixtures and equipment for Tenant&#8217;s use at the Premises or defraying the cost of moving expenses and costs incurred by Tenant for any other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">lease obligations, or for any other purpose desired by Tenant. Landlord shall not be obligated to disburse any portion of the Additional TI Allowance unless and until Landlord shall have received from Tenant an Additional TI Allowance Request. In no event shall any portion of the TI Allowance not properly requested by Tenant pursuant to this Section 6.a entitle Tenant to a credit against Rent payable under this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TI Deadline&#59; TI True-Up Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Tenant shall &#91;***&#93; request disbursement of any portion of the Additional TI Allowance not previously disbursed, after which date Landlord&#8217;s obligation to fund such costs shall expire. Upon disbursement of any portion of the Additional TI Allowance, Base Rent shall be increased to include such amount of the Additional TI Allowance then disbursed by Landlord in accordance with this Lease amortized over the Revised Term &#91;***&#93;. The amount by which Base Rent shall be increased with respect to any disbursement of the Additional IT Allowance shall be determined (and Base Rent shall be increased accordingly) as of the date of such disbursement, with Tenant paying (on the next succeeding day that Base Rent is due under this Lease (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TI True-Up Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)) any underpayment of the further adjusted Base Rent for the period beginning on the Revised Term Commencement Date and ending on the TI True-Up Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Completion Evidence.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Tenant shall deliver to Landlord the following (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Completion Evidence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on or before the TI Deadline (time being of the essence)&#58; (i) a statement setting forth the total cost of the Tenant Improvements, including supporting invoices (paid or presently due and payable) for Tenant&#8217;s costs&#59; (ii) all of the TI Submittals (as defined in the Work Letter)&#59; and (iii) such other deliveries as Landlord or one of its lenders reasonably requests. Notwithstanding the TI Deadline, Tenant shall cooperate with Landlord&#8217;s reasonable requests for portions of the Completion Evidence from time to time as the same become available. Tenant&#8217;s failure to deliver the Completion Evidence on or before the TI Deadline shall constitute a Default under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 31.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing Lease, and in addition to all other remedies available to Landlord under the Lease, at law and in equity, shall permit Landlord to obtain such Completion Evidence on Tenant&#8217;s behalf and Tenant shall immediately reimburse Landlord for the reasonable costs thereof as Additional Rent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insurance Coverage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Prior to entering upon the Premises, Tenant shall furnish to Landlord evidence satisfactory to Landlord that insurance coverages required of Tenant under the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing Lease are in effect, and such entry shall be subject to all the terms and conditions of this Lease other than the payment of Base Rent or Tenant&#8217;s Share of Operating Expenses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Construction of Tenant Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant shall select the architect, engineer, and general contractor for the construction of the Tenant Improvements, subject to Landlord&#8217;s approval, such approval not to be unreasonably withheld, conditioned or delayed. Notwithstanding anything to the contrary set forth in the Lease, Tenant shall not be obligated to pay Landlord a construction management fee or any similar construction oversight fee with respect to the Tenant Improvements. Upon Substantial Completion (as hereinafter defined) of the Tenant Improvements, Tenant shall deliver to Landlord (i) a certificate of occupancy for the Premises suitable for the Permitted Use and (ii) a Certificate of Substantial Completion in the form of the American Institute of Architects document G704, executed by the project architect and the general contractor. The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Substantially Complete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Substantial Completion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that the Tenant Improvements are substantially complete in accordance with the Approved Plans (as defined in the Work Letter), except for punch list items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Controllable Operating Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding anything to the contrary set forth in the Lease, during the Revised Term, Tenant shall not be obligated to pay any increase in Controllable Operating Expenses (as hereinafter defined) on a non-cumulative basis by more than &#91;***&#93; in any calendar year over the amount of Controllable Operating Expenses chargeable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to Tenant for the immediately preceding calendar year, beginning with Controllable Operating Expenses from the calendar year immediately succeeding the calendar year in which the Revised Term Commencement Date occurs. The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Controllable Operating Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all Operating Expenses except for taxes, assessments or impositions, Capital Expenditures, costs for repairs and maintenance (excluding preventative maintenance), utility charges, sewer fees, license, permit or inspection fees imposed by a Governmental Authority, insurance premiums, mandatory payments under CC&#38;R&#8217;s or to an owners&#8217; association, costs for snow removal, costs associated with repairs due to casualty, vandalism, costs for snow removal or other costs outside of Landlord&#8217;s reasonable control or costs that Landlord reasonably determines are necessary to prevent an adverse effect on the Building structure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Project Amenities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#91;***&#93; Tenant shall be entitled to use the large conference areas and exercise&#47;fitness areas located at 9714 Medical Center Drive in the Lower Campus and the parking spaces serving such areas (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amenities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) at no additional charge (except as provided in this Section), provided such use shall be subject to the use of such Amenities by other tenants of the Project on a first come, first served basis, as well as any temporary closures of the Amenities (or any portion thereof) by Landlord in connection with any maintenance, repair, alterations or improvements to be performed. During the Revised Term, Tenant shall be required to pay its proportionate share of the operating costs paid or incurred by Landlord in connection with the operation or maintenance of such Amenities, to the extent considered Operating Expenses under Section 9 of the Lease. During the Revised Term, Landlord shall continue to operate and maintain the Amenities in a manner substantially consistent with its current practices, subject to temporary closures for maintenance and repairs, alterations or additions necessitated by Applicable Laws and events of Force Majeure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Condition of Premises.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Landlord shall deliver to Tenant a copy of each final Exit Survey submitted by JCVI pursuant to the Assignment Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">JCVI Exit Survey</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) upon Landlord&#8217;s receipt, without any representation or warranty, express or implied, including but not limited to any representation or warranty regarding the accuracy or completeness of the JCVI Exit Survey. The delivery of such JCVI Exit Survey shall not be deemed to be a representation or warranty regarding the physical or environmental condition of the Premises. On the Revised Term Commencement Date, Landlord shall deliver possession of the Premises to Tenant in broom clean condition. Tenant acknowledges that (a) except as expressly provided in this Second Amendment or the Lease, Tenant agrees to take the Premises in its condition &#8220;as is&#8221; as of the first day of the Revised Term, and (b) Landlord shall have no obligation to alter, repair or otherwise prepare the Premises for Tenant&#8217;s continued occupancy for the Revised Term or to pay for any improvements to the Premises, except as expressly provided in this Second Amendment or the Lease. Tenant&#8217;s taking of possession of the Premises on the Revised Term Commencement Date shall, except as otherwise agreed to in writing by Landlord and Tenant, conclusively establish that the Premises, the Building, the Building systems and the Project were at such time in good, sanitary and satisfactory condition and repair. Notwithstanding the foregoing, at any time during the first twenty-four (24) months of the Revised Term (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Warranty Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), if any standard HVAC units (but specifically excluding any specialized HVAC units added by Tenant, such as those units that may be required for manufacturing) serving the Premises shall fail to be in good working order, then Tenant may deliver written notice to Landlord describing in reasonable detail such failure, and Landlord will perform the work necessary to put the HVAC unit in good working order with reasonable promptness and at Landlord&#8217;s sole cost as Tenant&#8217;s sole remedy for any such failure (and Tenant shall not be entitled to damages or any other remedy as a result of such failure, except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 16.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Lease)&#59; provided, however, that Landlord&#8217;s obligations pursuant to the foregoing shall be limited to necessary repairs and&#47;or replacements, as determined by Landlord in its reasonable discretion, and Tenant shall remain responsible for the standard preventative maintenance and upkeep of such HVAC units in the ordinary course. During the Warranty Period, all costs which are the obligation of Landlord pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be borne </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">solely by Landlord and not included as Operating Expenses, provided Tenant (and not Landlord) shall be responsible for all costs, in whole or in part, that are incurred to the extent attributable to the negligence or willful misconduct of Tenant or any of its employees, contractors or subcontractors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Utilities and Services.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> During the Revised Term, Tenant shall, at its sole cost and expense, promptly and properly observe and comply with (including in the making by Tenant of any Alterations to the Premises) all orders, regulations, directions, rules, laws, ordinances, and requirements of all Governmental Authorities from the use or occupancy of, or applicable to, the Premises or any portion thereof, except as otherwise provided under this Second Amendment or the Lease, and subject to the terms and conditions of the Landlord Consent. During the Revised Term, Tenant shall, at Tenant&#8217;s sole cost and expense, procure and maintain standard preventative maintenance contracts, with copies of the same, in customary form and substance for, and with contractors specializing and experienced in, the maintenance of the following equipment and improvements, if any, if and when installed on the Premises&#58; (i) heating, ventilating and air conditioning (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">HVAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) equipment, (ii) boilers and pressure vessels, (iii) fire extinguishing systems, including fire alarm and smoke detection devices, (iv) roof coverings and drains, (v) clarifiers, (vi) basic utility feeds to the perimeter of the Building, (vii) hoods, and (viii) any other equipment located in the Premises reasonably required by Landlord. Tenant shall make all arrangements for and pay for all water, electricity, air, sewer, refuse, gas, heat, light, power, telephone service and any other service or utility Tenant required at the Premises. Tenant shall not be liable for the cost of utilities supplied to the Premises attributable to the time period prior to the Revised Term Commencement Date&#59; provided, however, that, if Landlord shall permit Tenant possession of the Premises prior to the Revised Term Commencement Date and Tenant uses the Premises for any purpose other than the installation of furniture, fixtures and equipment and the placement of personal property as set forth in Section 5 above, then Tenant shall be responsible for the actual out-of-pocket cost of utilities supplied to the Premises from such earlier date of possession.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Repairs and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except to the extent required to be performed by Landlord pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 18.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing Lease, and subject to Landlord&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above, Tenant shall repair, replace and maintain in accordance with standards for comparable first-class buildings in the Rockville, Maryland area and in accordance with all Applicable Laws the Premises, including the elevators and the base Building plumbing, fire and life safety, HVAC, electrical, security and mechanical systems (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Building System Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Notwithstanding anything to the contrary in the Lease, in the event that Tenant&#8217;s performance of any of its repair, replacement or maintenance obligations under the Lease requires prior notice to Landlord, in an emergency, Tenant shall have the right to perform such repair, replacement or maintenance obligations after reasonable (in the circumstances) oral notice to Landlord, followed by written notice to Landlord within three (3) days after such emergency. As used in this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#8220;emergency&#8221; shall have the meaning ascribed thereto in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 31.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Generator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Landlord acknowledges that JCVI has conveyed ownership of the existing 1000 kw generator serving the Premises (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Generator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to Tenant pursuant to a separate agreement between JCVI and Tenant and Tenant has accepted the Generator in its existing condition &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">as is</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as of the Revised Term Commencement Date. Tenant shall be entitled to use the Generator and, if so desired by Tenant, to replace such Generator. Tenant shall maintain, repair and (if necessary) replace the Generator at its sole cost and expense. Landlord expressly disclaims any warranties, whether express or implied, with regard to the Generator or the installation thereof, including any warranty of merchantability, suitability or fitness for a particular purpose. Tenant expressly assumes all risks arising from Tenant&#8217;s failure to perform (or properly perform) the maintenance, repair and&#47;or or replacement of the Generator, the Generator&#8217;s malfunction, any failure or interruption of power to the Premises attributable to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Generator or any election by Tenant to remove the Generator, and Landlord expressly disclaims any liability or responsibility therefor, except as expressly provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 16.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Existing Lease. In the event of any malfunction or failure of the Generator, Tenant shall not be entitled to any termination of the Lease or any abatement or reduction of Rent, and Tenant shall not be relieved from the operation of any covenant, obligation or agreement of this Lease. Tenant may remove the Generator from the Premises at any time at Tenant&#8217;s sole cost and expense. In addition, Tenant shall have the right to place new generators on the Land during the Term, subject to Landlord&#8217;s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Environmental Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding anything in the Existing Lease to the contrary, (i) Tenant shall not be responsible for (A) any recognized environmental conditions set forth in any JCVI Exit Survey or (B) the presence of Hazardous Materials at the Premises or the Building as of the Revised Term Commencement Date, unless placed at the Premises or the Building by a Tenant Party, or the presence of Hazardous Materials at the Premises or the Building placed at the Premises or the Building by Landlord or Landlord&#8217;s affiliates, employees, agents, contractors or invitees and (ii) Landlord shall indemnify, save, defend (at Tenant&#8217;s option and with counsel reasonably acceptable to Tenant) and hold the Tenant and Tenant&#8217;s affiliates, employees, agents, contractors or invitees (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) harmless from and against any and all Claims resulting from (y) the presence of Hazardous Materials at the Premises or the Building as of the Revised Term Commencement Date, unless such Hazardous Materials were placed at the Premises or the Building by a Tenant Party or Tenant agreed to permit such Hazardous Materials to remain at the Premises for use and operation of the Premises following JCVI&#8217;s surrender of the Premises in accordance with the Assignment Agreement, and (z) the presence of Hazardous Materials at the Premises or the Building placed at the Premises or the Building by Landlord or Landlord&#8217;s affiliates, employees, agents, contractors or invitees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option to Extend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant shall have two (2) options (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to extend the Revised Term by seven (7) years each as to the entire Premises (and no less than the entire Premises) upon the following terms and conditions (each seven (7) year period being referred to herein as an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Extension Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Any extension of the Revised Term pursuant to an Option shall be on all the same terms and conditions as this Lease, except as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Base Rent at the commencement of each Extension Term shall equal (i) if there are no brokerage commissions payable by Landlord to Tenant&#8217;s broker in connection with the Option, ninety-five percent (95%) of the then-current FMV (as defined below), or (ii) if there are brokerage commissions payable by Landlord to Tenant&#8217;s broker in connection with the Option, one hundred percent (100%) of the then-current FMV, and in each case shall be further increased on each annual anniversary of the Extension Term commencement date by two and one-half percent (2.5%). Tenant may, no more than fifteen (15) months prior to the date the then-current Term is then scheduled to expire, request Landlord&#8217;s estimate of the FMV for the next Extension Term. Landlord shall, within fifteen (15) days after receipt of such request, give Tenant a written proposal of such FMV. If Tenant gives written notice to exercise an Option (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Extension Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), such Extension Notice shall specify whether Tenant accepts Landlord&#8217;s proposed estimate of FMV. If Tenant does not accept the FMV, then the parties shall endeavor to agree upon the FMV, taking into account all relevant factors. In the event that the parties are unable to agree upon the FMV within thirty (30) days after Landlord&#8217;s receipt of the Extension Notice, then same shall be determined as follows&#58; (i) Landlord and Tenant shall each appoint one broker who shall, by profession, be a licensed real estate broker, of good reputation, and who shall have been active over the ten (10) year period ending on the date of Landlord&#8217;s receipt of the Extension Notice in the leasing of similar properties within the Rockville, Maryland laboratory&#47;research and development leasing market. Each such broker shall be appointed within thirty (30) days after the date of Landlord&#8217;s receipt of the applicable Extension Notice. (ii) The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">two brokers so appointed shall, within ten (10) days of the date of the appointment of the last appointed broker, agree upon and appoint a third broker who shall be qualified based upon the same criteria set forth hereinabove for the qualification of the initial two brokers and shall not have been employed or retained by either Landlord or Tenant or any affiliate of either for a period of at least ten (10) years prior to appointment pursuant hereto. The third broker shall be paid for jointly by Landlord and Tenant. If Landlord and Tenant are unable to agree upon the third broker, then the same shall be designated by the Washington, D.C. local chapter of the Judicial Arbitration and Mediation Services or any successor organization thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). (iii) The three brokers shall within ten (10) business days of the appointment of the third broker reach a decision regarding the determination of the FMV, and shall notify Landlord and Tenant thereof. (iv) The decision of the majority of the three brokers shall be binding upon Landlord and Tenant and shall serve as the basis for determination of Base Rent payable for the applicable Extension Term. Failure of a majority of such brokers to reach agreement shall result in the FMV being designated by averaging the appraisals of the three brokers, ignoring for the purposes of such averaging the high and&#47;or low appraisal which is more than ten percent (10%) in excess of or less than the middle appraisal, if applicable. (v) If either Landlord or Tenant fails to appoint a broker within the time period specified in subparagraph (i) hereinabove, the broker appointed by one of them shall reach a decision and notify Landlord and Tenant thereof, and such broker&#8217;s decision shall be binding upon Landlord and Tenant. (vi) The cost of the three-broker determination shall be paid by Landlord and Tenant equally. (vii) If, as of the commencement date of an Extension Term, the amount of Base Rent payable during the Extension Term shall not have been determined, then, pending such determination, Tenant shall pay Base Rent equal to the Base Rent payable with respect to the last year of the then-current Term. After the final determination of Base Rent payable for the Extension Term, the parties shall promptly execute a written amendment to this Lease specifying the amount of Base Rent to be paid during the applicable Extension Term. Any failure of the parties to execute such amendment shall not affect the validity of the FMV determined pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14.a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or the extension of the Revised Term for such Extension Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;No Option is assignable separate and apart from this Lease. Tenant&#8217;s rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be transferable in connection with an assignment of this Lease to an Exempt Transferee, but shall not be transferable to any other assignee without the prior written consent of Landlord, which consent Landlord may withhold in its sole and absolute discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;Each Option is conditional upon Tenant giving Landlord written notice of its election to exercise such Option at least twelve (12) months prior to the expiration of the then-current Term. Time shall be of the essence as to Tenant&#8217;s exercise of an Option. Tenant assumes full responsibility for maintaining a record of the deadlines to exercise an Option. Tenant acknowledges that it would be inequitable to require Landlord to accept any exercise of an Option after the date provided for in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;Notwithstanding anything contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the contrary, Tenant shall not have the right to exercise an Option or to commence an Extension Term unless Tenant is not then in Default.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;For purposes of this Lease, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FMV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; for the Premises shall be based on a seven (7) year extension term and shall be equal to the monthly base rental rate (on a per square foot of rentable area basis) agreed to by willing sophisticated tenants and willing sophisticated landlords in leasing transactions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Comparable Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as of a particular time, in arms-length transactions for non-sublease, non-encumbered, non-equity, non-expansion, non-renewal space comparable in size, location, height and quality to the Premises, with a commencement date not more than eighteen (18) months prior to the commencement date of the extension term, or if there are no Comparable Transactions, in other first-class combined office&#47;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">laboratory facilities containing located in the Rockville, Maryland area, with appropriate adjustments to account for differences in the Adjustment Factors (as defined below) and all other factors reasonably relevant to a fair market rent determination. In any determination of FMV, appropriate consideration should be given to any reasonably relevant factor (or difference in the subject transaction or Comparable Transactions used for purposes of comparison), including without limitation, the following factors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Adjustment Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58; (a) monthly base rental rates per rentable square foot&#59; (b) abatement provisions reflecting free rent or early occupancy during the lease term&#59; (c) the size, location and floor height of the premises being leased&#59; (d) the condition and market value of the existing tenant improvements, if any (from a general marketing perspective and without regard to their value, usability or function to Tenant or to any tenant in any Comparable Transaction), and the existence and amount of any tenant improvement or comparable allowance&#59; (e) the existence and amount of any other cash payment or other equivalent concession, including, without limitation, moving allowances, lease takeover allowances (or where a lease assumption is applicable, the value thereof), and any comparable tenant inducement&#59; (f) the existence of favorable expansion and&#47;or extension options, and the value thereof&#59; (g) any special parking rights, rates or concessions&#59; (h) whether the lease transaction in question grants to the tenant any protection from increases in real property taxes and&#47;or operating expenses, and if so, the amount, value or cost associated therewith&#59; and (i) the credit standing of the tenant in question and&#47;or the amount of letters of credit, cash security deposits, and&#47;or other credit enhancements required to be made available by the tenant in question.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;For purposes of calculating the FMV, the following presumptions shall apply&#58; the Premises is free and clear of all leases and tenancies (including this Lease), the Premises is available for the purposes permitted by this Lease in the then rental market, that Landlord has had a reasonable time to locate a tenant, and that neither Landlord nor the prospective tenant is under any compulsion to rent, and taking into account all relevant factors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Right of First Offer to Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For so long as MacroGenics, Inc. and&#47;or an Exempt Transferee of MacroGenics, Inc. pursuant to an Exempt Transfer (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">MacroGenics Exempt Transferee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) leases the entire Premises and personally occupies at least ninety percent (90%) of the entire Premises and subject to any other parties&#8217; pre-existing rights with respect to Available ROFO Premises (as defined below), Tenant shall have a right of first offer to lease (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lease ROFO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) as to any rentable premises in the buildings located at 9708, 9712 and 9714 Medical Center Drive which Landlord is marketing and for which Landlord is seeking a tenant (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Available ROFO Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; provided, however, that in no event shall Landlord be required to lease any Available ROFO Premises to Tenant for any period past the date on which this Lease expires or is terminated pursuant to its terms (including available Options). To the extent that Landlord renews or extends a then-existing lease with such then existing tenant for the same premises pursuant to a contractual extension option existing as of the date hereof, the affected space shall not be deemed to be Available ROFO Premises. In the event Landlord intends to market Available ROFO Premises, Landlord shall provide written notice thereof to Tenant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Marketing to Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Within fifteen (15) days following its receipt of a Notice of Marketing to Lease (time being strictly of the essence), Tenant shall advise Landlord in writing whether Tenant elects to lease all (not just a portion) of the Available ROFO Premises and on what terms and conditions. If Tenant fails to notify Landlord of Tenant&#8217;s election within such fifteen (15) day period (time being strictly of the essence), then Tenant shall be deemed to have elected not to lease the Available ROFO Premises.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;If Tenant notifies Landlord that Tenant elects to lease all of the Available ROFO Premises and of the terms and conditions therefore (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant&#8217;s Leasing Offer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) within the &#91;***&#93; period described above (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Tenant shall be required to lease the Available </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ROFO Premises for at least the remainder of the then-current Revised Term), then Landlord shall have &#91;***&#93; days after receipt of Tenant&#8217;s Leasing Offer to respond to Tenant in writing whether Landlord elects to lease the Available ROFO Premises to Tenant on the terms and conditions set forth in Tenant&#8217;s Leasing Offer. If Tenant delivers Tenant&#8217;s Leasing Offer within the &#91;***&#93; period described above and Landlord elects to lease the Available ROFO Premises to Tenant on the terms and conditions set forth in Tenant&#8217;s Leasing Offer, then Landlord shall lease the Available ROFO Premises to Tenant upon the terms and conditions set forth in Tenant&#8217;s Leasing Offer. If Landlord fails to deliver notice of Landlord&#8217;s election to lease the Available ROFO Premises to Tenant within such &#91;***&#93; period, then Landlord shall be deemed to have elected not to lease the Available ROFO Premises to Tenant upon the terms and conditions set forth in Tenant&#8217;s Leasing Offer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;If (i) Tenant notifies Landlord that Tenant elects not to lease the Available ROFO Premises, (ii) Tenant fails to notify Landlord of Tenant&#8217;s election within the &#91;***&#93; period described above (time being strictly of the essence), (iii) Landlord declines (or is deemed to have declined) to lease the Available ROFO Premises to Tenant on the terms and conditions set forth in Tenant&#8217;s Leasing Offer or (iv) Landlord fails to notify Tenant of Landlord&#8217;s election to lease the Available ROFO Premises to Tenant on the terms and conditions set forth in Tenant&#8217;s Leasing Offer within the &#91;***&#93; period described above (time being strictly of the essence), then Landlord shall have the right to consummate a lease of the Available ROFO Premises &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;Notwithstanding anything in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the contrary, Tenant shall not have the right to exercise the Lease ROFO during such period of time that there exists a monetary default or material non-monetary default by Tenant under any provision of this Lease for which notice has been given to Tenant by Landlord (to the extent notice is required under this Lease). Any attempted exercise of the Lease ROFO during a period of time in which Tenant is so in default shall be void and of no effect. Notwithstanding anything in this Lease to the contrary, Tenant shall not assign or transfer the Lease ROFO, except in conjunction with an assignment or transfer of Tenant&#8217;s interest in the Lease to an Exempt Transferee pursuant to an Exempt Transfer, without Landlord&#8217;s prior written consent, which consent Landlord shall not unreasonably withhold, condition or delay.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;If Tenant exercises the Lease ROFO, Landlord does not guarantee that the Available ROFO Premises will be available on the anticipated commencement date for the Lease as to such Premises due to a holdover by the then-existing occupants of the Available ROFO Premises or for any other reason beyond Landlord&#8217;s reasonable control, so long as Landlord acts in good faith to promptly and diligently pursue all reasonable means to obtain possession of such space, including the commencement of eviction proceedings when appropriate, as soon as reasonably practicable, but Tenant shall not be liable for any rent until the time when Landlord can deliver possession of the ROFO Premises to Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;Tenant&#8217;s rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be transferable in connection with an assignment of this Lease to an Exempt Transferee, but shall not be transferable to any other assignee without the prior written consent of Landlord, which consent Landlord may withhold in its sole and absolute discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Right of First Offer to Purchase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For so long as MacroGenics and&#47;or a MacroGenics Exempt Transferee leases all, and personally occupies at least ninety percent (90%), of the entire Premises, Tenant shall have a right of first offer to purchase the fee interest (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase ROFO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in the Building and underlying parcel of land (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ROFO Real Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Landlord shall not sell the entire Building in fee simple unless Landlord shall first offer the Building to Tenant as follows&#58; (i) Landlord shall give to Tenant an irrevocable written notice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord&#8217;s Purchase ROFO Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) specifying the Basic Sale Terms (as hereinafter defined) upon which Landlord desires to sell the Building&#59; and (ii) Tenant shall then have the one-time </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">right to purchase the Building (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase ROFO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by notifying Landlord in writing of the exercise of such Purchase ROFO &#91;***&#93; and delivering one-half of the deposit required pursuant to the Additional Sale Terms (as hereinafter defined), time being of the essence.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;If Tenant exercises the Purchase ROFO &#91;***&#93; (time being strictly of the essence), then Tenant shall have the one-time right and obligation (subject to Landlord and Tenant entering into a Purchase Agreement pursuant to the Additional Sale Terms) to purchase the Building upon the Basic Sale Terms and the Additional Sale Terms to the extent such Additional Sale Terms are not inconsistent with the Basic Sale Terms.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary herein, Tenant&#8217;s rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not apply to&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;any sale&#47;leaseback transaction made in connection with a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">bona fide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> financing&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;any sale or transfer of less than eighty percent (80%) of all of the direct and indirect interests in Landlord (but, whether or not in excess of eighty percent (80%), in no event shall Tenant&#8217;s rights apply to a sale or transfer among then-existing direct or indirect interest holders in Landlord, sales or transfers of beneficial interests in direct or indirect interest holders in Landlord that are part of a portfolio transaction that includes properties other than the Building, and mergers, acquisitions, sales or transfers of or in entities with a direct or indirect interest in Landlord that own direct or indirect interests in properties other than the Building, in each case unless such transfers are made with the intention of allowing a transfer of the Building in avoidance of Tenant&#8217;s rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;any sale or transfer of the Building to a partnership, corporation, limited liability company, trust or other entity that is under control by, common control with, or controls Landlord or any direct or indirect owner of Landlord, but any such transferee shall hold title subject to Tenant&#8217;s rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;any transfer in the nature of a financing transaction with a financial institution that is made for a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">bona fide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> business purpose (i.e., other than in order to allow a transfer of the Building in avoidance of Tenant&#8217;s rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), including without limitation the granting of, or foreclosure or deed-in-lieu of foreclosure, under a mortgage&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;any portfolio transaction that includes at least one other real estate asset consisting of a building with at least 40,000 square feet in gross floor area or land capable of accommodating a new building of at least 40,000 rentable square feet in area. In connection with any portfolio transaction that includes only the Building and a related asset, and, therefore, is subject to the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Tenant must exercise its election to purchase, if at all, with respect to the entire portfolio transaction offered in Landlord&#8217;s Purchase ROFO Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;If Tenant either rejects the Landlord&#8217;s Purchase ROFO Notice or does not exercise the Purchase ROFO within the &#91;***&#93; period described above (time being strictly of the essence), then Landlord shall be free to sell the Building to a third-party person or entity upon terms and conditions no less favorable to Landlord in any material respect than the Basic Sale Terms without further obligation to Tenant, except that the purchase price may be as much as ten percent (10%) less than that reflected in the Basic Sale Terms. If after Tenant either rejects the Landlord&#8217;s Purchase ROFO Notice or does not exercise the Purchase ROFO within the &#91;***&#93; period described above, and Landlord desires to offer the Building for sale upon terms that are materially less favorable to Landlord than the Basic Sale Terms and&#47;or at a purchase price that is more than ten percent (10%) less than the purchase price stated in the Basic Sale Terms, then Landlord must resubmit a Landlord&#8217;s Purchase ROFO Notice in accordance with the procedures </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set forth above. However, if the new notice to Tenant is given not more than &#91;***&#93; after the previous notice to Tenant, then Tenant&#8217;s time to exercise its Right of First Offer pursuant to such new notice shall be reduced to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;Upon (i) any sale of the Building, (ii) any portfolio transaction sale that includes the Building and is not subject to the rights of Tenant under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or (iii) any foreclosure of a mortgage on the Building or conveyance by deed-in-lieu of foreclosure, in each case to a third-party person or entity in accordance with the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Tenant&#8217;s Purchase ROFO shall forever terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;As used herein&#58; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Basic Sale Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the purchase price and terms of any seller financing offered by Landlord&#59; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Sale Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean those terms set forth on Exhibit E attached to this Amendment. The Lease shall terminate upon transfer of title to Tenant pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;Notwithstanding any provision of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the contrary, Tenant&#8217;s rights under this Article shall be void (i) at Landlord&#8217;s election, if a Default is then continuing at the time Tenant makes any election with under this Article or at the time the closing under the purchase contemplated by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is scheduled to occur, and (ii) &#91;***&#93; prior to the then-scheduled expiration of the term of this Lease unless Tenant has properly exercised its right to extend the term of this Lease pursuant to an Option (if any such right remains). If Tenant asserts any rights in the Building by means of lis pendens or similar notice, or any method claiming any rights or interest in any space in the applicable building (as opposed to a claim strictly for monetary damages, for which the indemnity set forth in this sentence will not apply), and fails to prevail in such proceeding, then Tenant shall indemnify, defend and hold harmless Landlord for any loss, cost, damage or injury that Landlord suffers or incurs on account of the delay caused by such proceeding, including without limitation any lost sale transaction or tenant leases for space in the Building or change in market conditions directly affecting a sale or lease for tenant space in the Building. Furthermore, the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are personal to MacroGenics, Inc. and may not be assigned except to a MacroGenics Exempt Transferee in connection with an Exempt Transfer of this Lease to such MacroGenics Exempt Transferee without Landlord&#8217;s prior written consent, which consent may be withheld in Landlord&#8217;s sole and absolute discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;Any Landlord&#8217;s Purchase ROFO Notice and information in connection therewith, and any information regarding a sale of the Building, provided to Tenant by Landlord pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be held confidential by Tenant and not disclosed to any third party except as required by Applicable Laws or in connection with any dispute between Landlord and Tenant regarding this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and for disclosures to Tenant&#8217;s attorneys and third-party consultants to the extent such attorneys and consultants are reasonably required for Tenant to evaluate such information and, in each case, provided that such attorneys and consultants are made subject to the provisions of this paragraph. Any such information shall be returned by Tenant to Landlord in the event that Tenant&#8217;s rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> terminate in accordance with the terms hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.&#160;&#160;&#160;&#160;Any disputes regarding the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be resolved by arbitration as follows&#58; the parties shall promptly meet and confer to attempt in good faith to resolve such dispute, and if such dispute is not resolved within thirty (30) days after Landlord or Tenant delivers written notice of such dispute to the other, the parties shall direct the Washington, DC office of the JAMS to appoint an arbitrator who shall have a minimum of ten (10) years&#8217; experience in commercial real estate disputes and who shall not be affiliated with either Landlord or Tenant and has not worked for either party or its affiliates at any time during the prior five (5) years. Both Landlord and Tenant shall have the opportunity to present evidence and outside consultants to the arbitrator. The arbitration shall be conducted in accordance with the expedited commercial arbitration rules of the JAMS insofar as such rules are not inconsistent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with the provisions of this Lease (in which case the provisions of this Lease shall govern). The cost of the arbitration (exclusive of each party&#8217;s witness and attorneys&#8217; fees, which shall be paid by such party) shall be borne equally by the parties. The arbitrator&#8217;s decision shall be final and binding on the parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i.&#160;&#160;&#160;&#160;Upon Tenant&#8217;s request, Landlord agrees to execute and deliver to Tenant a memorandum of Tenant&#8217;s Purchase ROFO, in form and substance reasonably acceptable to Landlord and Tenant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase ROFO Memorandum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), provided that Tenant executes and delivers to Landlord or a third party escrow agent reasonably acceptable to Landlord and Tenant an instrument acknowledging the termination of Tenant&#8217;s Purchase ROFO, in form and substance reasonably acceptable to Landlord and Tenant, to be held in escrow and recorded upon the earlier to occur of the termination of this Lease or the termination of Tenant&#8217;s Purchase ROFO in accordance with the terms of this Second Amendment. Tenant may, but shall not be obligated to, record the Purchase ROFO Memorandum, provided Tenant shall be obligated to pay all costs and expenses relating thereto, including any taxes assessed as a result of such recording.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant and Landlord each represents and warrants that it has not dealt with any broker or agent in the negotiation for or the obtaining of this Second Amendment, other than CBRE, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and agrees to reimburse, indemnify, save, defend (at the indemnified party&#8217;s option and with counsel reasonably acceptable to the indemnified party, at the indemnifying party&#8217;s sole cost and expense) and hold harmless the indemnified party for, from and against any and all cost or liability for compensation claimed by any such broker or agent, other than Broker, employed or engaged by it or claiming to have been employed or engaged by it. Broker is entitled to a leasing commission in connection with the making of the Assignment Agreement, the Landlord Consent and this Second Amendment, and Landlord shall pay such commission to Broker pursuant to a separate agreement between Landlord and Broker and Tenant shall have no obligation to pay Broker a leasing commission in connection with the making of the Assignment Agreement, the Landlord Consent and this Second Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant confirms that, notwithstanding anything in the Lease to the contrary, notices delivered to Tenant pursuant to the Lease should be sent to&#58;</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MacroGenics, Inc.</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9704 Medical Center Drive</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rockville, Maryland 20850</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; General Counsel</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with a copy to (which copy shall not constitute notice)&#58;</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Covington &#38; Burling LLP</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">One CityCenter</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">850 Tenth Street, NW</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Washington, DC 20001</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; Heather G. Haberl</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effect of Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as modified by this Second Amendment and the Assignment Agreement and Landlord Consent, the Existing Lease and all the covenants, agreements, terms, provisions and conditions thereof shall remain in full force and effect and are hereby ratified and affirmed. In the event of any conflict between the terms contained in this Second Amendment and the Existing Lease, the terms herein contained shall supersede and control the obligations and liabilities of the parties.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each of the covenants, conditions and agreements contained in this Second Amendment shall inure to the benefit of and shall apply to and be binding upon the parties hereto and their respective heirs, legatees, devisees, executors, administrators and permitted successors and assigns and sublessees. Nothing in this section shall in any way alter the provisions of the Lease restricting assignment or subletting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Second Amendment becomes effective only upon execution and delivery hereof by Landlord and Tenant. The captions of the paragraphs and subparagraphs in this Second Amendment are inserted and included solely for convenience and shall not be considered or given any effect in construing the provisions hereof. All exhibits hereto are incorporated herein by reference. Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for a lease, and shall not be effective as a lease, lease amendment or otherwise until execution by and delivery to both Landlord and Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord Representations, Warranties and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Landlord hereby represents and warrants to Tenant that, as of date hereof and as of the Revised Term Commencement Date&#58; (i) the Existing Lease attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is the true, complete and correct copy of the Existing Lease and the Existing Lease has not been amended or modified except as otherwise set forth in this Second Amendment and as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto&#59; (ii) the Existing Lease is valid, binding and in full force and effect, and enforceable in accordance with its terms by Landlord and Tenant&#59; (iv) to Landlord&#8217;s knowledge, no party is in breach or default under the Existing Lease (whether monetary or otherwise) or has given or received any notice of breach or default or termination under the Existing Lease&#59; (v) to Landlord&#8217;s knowledge, JCVI did not made any assignment, sublease, transfer, conveyance or other disposition of the Existing Lease or any interest therein, or grant any sublease, license, occupancy agreement or other use or occupancy right to any other person or entity, except for JCVI&#8217;s grant of the Early Access Rights (as defined in the Assignment Agreement) pursuant to the Assignment Agreement&#59; and (vi) to Landlord&#8217;s knowledge, there are no parties in possession of the Premises other than Tenant. Each Party guarantees, warrants and represent to the other and to Landlord that the execution and consummation of this Assignment have been duly authorized by all appropriate company action, and the individual or individuals signing this Assignment have the power, authority and legal capacity to sign this Assignment on behalf of and to bind all entities, corporations, partnerships, limited liability companies, joint ventures or other organizations and entities on whose behalf such individual or individuals have signed. Notwithstanding anything to the contrary contained in the Lease, the Assignment or the Landlord Consent, Landlord hereby covenants that Landlord shall not exercise Landlord&#8217;s remedy to terminate the Lease or Tenant&#8217;s possession of the Premises, nor shall Tenant be prohibited from exercising an Option, the Lease ROFO or the Purchase ROFO, nor shall Landlord (a) refuse to fund the Base TI Allowance or Additional TI Allowance, (b) fail to deliver any SNDA required by the Lease, (c) fail to make casualty insurance proceeds available under Section 24.10 of the Lease, (d) refuse to permit a Transfer or allow Tenant to collect rents directly from a transferee under Section 29 of the Lease, (e) charge Additional Rent under Section 7.2 of the Lease, (f) draw against the Security Deposit or (g) fail to recognize Tenant&#8217;s quiet enjoyment rights under Section 15 of the Lease, solely by reason of any breach or default of JCVI under the Existing Lease existing as of the Revised Term Commencement Date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the foregoing shall in no way be deemed to limit Landlord&#8217;s ability to exercise any remedies under the Lease, including without limitation the termination of the Lease or Tenant&#8217;s possession of the Premises, due to any Default caused by Macrogenics, Inc. as the Tenant during its early access to the Premises pursuant to Section 5 of this Second Amendment or any Default resulting from its exacerbation of a breach or default of JCVI under the Existing Lease existing as of the Revised Term Commencement Date. In no event shall Tenant be required to make any certification in an estoppel certificate about the existence of tenant defaults under the Lease as of the Revised Term Commencement Date. In addition, notwithstanding any provision to the contrary contained in the Existing Lease, Landlord agrees </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to look solely to JCVI for satisfaction of any default of the tenant&#8217;s obligations under the Lease occurring prior to or existing as of the Revised Commencement Date and for satisfaction of all obligations of the tenant under the Lease to the extent accruing prior to or existing as of the Revised Commencement Date, including, without limitation, the obligation to pay any amount payable by the tenant under the Lease to the extent accruing prior to or existing as of the Revised Commencement Date, and the recovery of any losses accruing to Landlord and recoverable under the Lease, at law or in equity, to the extent arising under the Lease prior to or existing as of the Revised Commencement Date, provided that the foregoing shall in no way be deemed to limit Landlord&#8217;s ability to exercise any remedies under the Lease due to any Default caused by Macrogenics, Inc. as the Tenant during its early access to the Premises pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Second Amendment or any Default resulting from Tenant&#8217;s exacerbation of a breach or default of JCVI under the Existing Lease existing as of the Revised Term Commencement Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant guarantees, warrants and represents that the individual or individuals signing this Second Amendment have the power, authority and legal capacity to sign this Second Amendment on behalf of and to bind all entities, corporations, partnerships, limited liability companies, joint venturers or other organizations and entities on whose behalf such individual or individuals have signed. Landlord guarantees, warrants and represents that the individual or individuals signing this Second Amendment have the power, authority and legal capacity to sign this Second Amendment on behalf of and to bind all entities, corporations, partnerships, limited liability companies, joint venturers or other organizations and entities on whose behalf such individual or individuals have signed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts&#59; Facsimile and PDF Signatures.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> This Second Amendment may be executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document. A facsimile or portable document format (PDF) signature on this Second Amendment shall be equivalent to, and have the same force and effect as, an original signature.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Landlord and Tenant have executed this Second Amendment as of the date and year first above written.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LANDLORD&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BMR-MEDICAL CENTER DRIVE LLC,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47; Jonathan P. Klassen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   Jonathan P. Klassen&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   Executive Vice President &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TENANT&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MACROGENICS, INC.,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47; Scott Koenig</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   Scott Koenig&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   CEO&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4813-5202-3331.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;22</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>8
<FILENAME>a1028_thirdamendmenttohqle.htm
<DESCRIPTION>EX-10.28
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i33fa928350364f03ba2ae50cb649067c_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit.10.28</font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY &#91;***&#93;) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL.</font></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THIRD AMENDMENT TO LEASE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THIS THIRD AMENDMENT TO LEASE (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of this &#91;***&#93; day of &#91;***&#93;, &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Amendment Execution Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and between BMR-MEDICAL CENTER DRIVE LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and MACROGENICS, INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;WHEREAS, pursuant to that certain Assignment and Assumption Agreement dated as of &#91;***&#93;  (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Original Assignment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, as amended by that certain First Amendment to Assignment and Assumption Agreement dated as of &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">First Amendment to Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and collectively with the Original Assignment Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) between J. Craig Venter Institute, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">JCVI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as assignor, and Tenant, as assignee, and that certain Landlord Consent dated as of &#91;***&#93; attached to the Original Assignment Agreement and executed by Landlord (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Original Landlord Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as amended by that certain First Amendment to Landlord Consent dated as of &#91;***&#93; attached to the First Amendment to Assignment and executed by Landlord (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">First Amendment to Landlord Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and collectively with the Original Landlord Consent, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Landlord and Tenant are parties to that certain Lease dated as of &#91;***&#93;, as amended by that certain First Amendment to Lease dated as of &#91;***&#93; and that certain Second Amendment to Lease dated as of &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Second Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Existing Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), whereby Tenant leases certain premises (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from Landlord at 9704 Medical Center Drive in Rockville, Maryland (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;WHEREAS, Landlord and Tenant desire to modify certain provisions of the existing Lease on the terms and conditions set forth in this Third Amendment&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;WHEREAS, Landlord and Tenant desire to modify and amend the Existing Lease only in the respects and on the conditions hereinafter stated.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Third Amendment, capitalized terms shall have the meanings ascribed to them in the Existing Lease unless otherwise defined herein. The Existing Lease, as amended by this Third Amendment, is referred to collectively herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lease.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; From and after the date hereof, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lease,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as used in the Existing Lease, shall mean the Existing Lease, as amended by this Third Amendment. To the extent terms are defined in both the Existing Lease and the Third Amendment, the defined terms in this Third Amendment shall control for the entire Lease, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Early Access to Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Section 5 of the Second Amendment is hereby deleted. Subject to JCVI&#8217;s compliance with its obligation to allow Tenant early access to the Premises under Section 2 of the Assignment Agreement, from and after the Third Amendment Execution Date, with respect to the Premises (excluding the Second Floor Premises (as defined in the First </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amendment to Assignment)), Landlord shall use commercially reasonable efforts to grant Tenant access to the Premises and Common Areas prior to the Revised Term Commencement Date for the purposes of conducting design phase inspections, constructing improvements, installing furniture, fixtures and equipment or the placement of personal property, but not for the purpose of conducting Tenant&#8217;s business, provided Tenant shall furnish to Landlord evidence satisfactory to Landlord in advance that insurance coverages required of Tenant under the provisions of Article 23 of the Existing Lease are in effect, and such entry shall be subject to all the terms and conditions of the Lease other than the payment of Base Rent or Tenant&#8217;s Share of Operating Expenses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Loading Dock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Exhibit K attached hereto shall replace </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached to the Second Amendment, and shall hereafter be the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> referenced in Section 4(g) of the Second Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant and Landlord each represents and warrants that it has not dealt with any broker or agent in the negotiation for or the obtaining of this Third Amendment, and agrees to reimburse, indemnify, save, defend (at the indemnified party&#8217;s option and with counsel reasonably acceptable to the inclemnified party, at the indemnifying party&#8217;s sole cost and expense) and hold harmless the indemnified party for, from and against any and all cost or liability for compensation claimed by any such broker or agent employed or engaged by it or claiming to have been employed or engaged by it.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Effect of Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as modified by this Third Amendment and the Assignment Agreement and Landlord Consent, each as amended through the date hereof, the Existing Lease and all the covenants, agreements, terms, provisions and conditions thereof shall remain in full force and effect and are hereby ratified and affirmed. In the event of any conflict between the terms contained in this Third Amendment and the Existing Lease, the terms herein contained shall supersede and control the obligations and liabilities of the parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each of the covenants, conditions and agreements contained in this Third Amendment shall inure to the benefit of and shall apply to and be binding upon the parties hereto and their respective heirs, legatees, devisees, executors, administrators and permitted successors and assigns and sublessees. Nothing in this section shall in any way alter the provisions of the Lease restricting assignment or subletting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Third Amendment becomes effective only upon execution and delivery hereof by Landlord and Tenant. The captions of the paragraphs and subparagraphs in this Third Amendment are inserted and included solely for convenience and shall not be considered or given any effect in construing the provisions hereof. All exhibits hereto are incorporated herein by reference. Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for a lease, and shall not be effective as a lease, lease amendment or otherwise until execution by and delivery to both Landlord and Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant guarantees, warrants and represents that the individual or individuals signing this Third Amendment have the power, authority and legal capacity to sign this Third Amendment on behalf of and to bind all entities, corporations, partnerships, limited liability companies, joint venturers or other organizations and entities on whose behalf such individual or individuals have signed. Landlord guarantees, warrants and represents that the individual or individuals signing this Third Amendment have the power, authority and legal capacity to sign this Third Amendment on behalf of and to bind all entities, corporations, partnerships, limited liability companies, joint venturers or other organizations and entities on whose behalf such individual or individuals have signed.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Counterparts&#59; Facsimile and PDF Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Third Amendment may be executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document. A facsimile or portable document format (PDF) signature on this Third Amendment shall be equivalent to, and have the same force and effect as, an original signature.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><div id="i33fa928350364f03ba2ae50cb649067c_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Landlord and Tenant have executed this Third Amendment as of the date and year first above written.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LANDLORD&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BMR-MEDICAL CENTER DRIVE LLC,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47; Jonathan P. Klassen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   Jonathan P. Klassen&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   Executive Vice President &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TENANT&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MACROGENICS, INC.,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="margin-top:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47; Atul Saran</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   Atul Saran&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   SVP &#38; GC&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>9
<FILENAME>a1029_fourthamendmenttolea.htm
<DESCRIPTION>EX-10.29
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1035913c16ff4756b0fcca9568f5aab0_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit.10.29</font></div></div><div style="margin-bottom:24pt;padding-right:-18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY &#91;***&#93;) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL.</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FOURTH AMENDMENT TO LEASE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THIS FOURTH AMENDMENT TO LEASE (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of this  &#91;***&#93; day of &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Execution Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and between BMR-MEDICAL CENTER DRIVE LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and MACROGENICS, INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;WHEREAS, pursuant to that certain Assignment and Assumption Agreement dated as of &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Original Assignment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, as amended by that certain First Amendment to Assignment and Assumption Agreement dated as of &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">First Amendment to Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and collectively with the Original Assignment Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) between J. Craig Venter Institute, Inc. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">JCVI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as assignor, and Tenant, as assignee, and that certain Landlord Consent dated as of &#91;***&#93; attached to the Original Assignment Agreement and executed by Landlord (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Original Landlord Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as amended by that certain First Amendment to Landlord Consent dated as of &#91;***&#93; attached to the First Amendment to Assignment and executed by Landlord (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">First Amendment to Landlord Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and collectively with the Original Landlord Consent the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Landlord and Tenant are parties to that certain Lease dated as of &#91;***&#93;, as amended by that certain First Amendment to Lease dated as of &#91;***&#93; that certain Second Amendment to Lease dated as of &#91;***&#93;  (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Second Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and that certain Third Amendment to Lease dated as of &#91;***&#93; (collectively, and as the same may have been further amended, amended and restated, supplemented or modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Existing Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), whereby Tenant leases certain premises (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from Landlord at 9704 Medical Center Drive in Rockville, Maryland (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;WHEREAS, Landlord and Tenant desire to extend the Term of the Existing Lease and modify certain other provisions of the existing Lease on the terms and conditions set forth in this Amendment&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;WHEREAS, Landlord and Tenant desire to modify and amend the Existing Lease only in the respects and on the conditions hereinafter stated.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Amendment, capitalized terms shall have the meanings ascribed to them in the Existing Lease unless otherwise defined herein. The Existing Lease, as amended by this Amendment, is referred to collectively herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lease.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; From and after the date hereof, the term &#8220;Lease,&#8221; as used in the Existing Lease, shall mean the Existing Lease, as amended by this Amendment.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DC&#58; 6471715-2&#160;&#160;&#160;&#160;BioMed Realty form dated 3&#47;27&#47;15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Further Revised Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Revised Term of the Lease is hereby extended through the end of the ten (10)-year period commencing on &#91;***&#93; and expiring on &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Further Revised Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and the Term Expiration Date is hereby extended from &#91;***&#93; to &#91;***&#93;. From and after the Execution Date, any references in the Lease to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93; and any references in the Lease to &#8220;Term&#8221; shall mean the Revised Term, as extended by this Amendment, and as the same may be further extended pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Second Amendment, and subject to the earlier termination of the Lease as therein provided.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Condition of Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant acknowledges that (a) as of the Execution Date it is in possession of and is fully familiar with the condition of the Premises and, notwithstanding anything contained in the Lease to the contrary, except as otherwise expressly provided in the Existing Lease, the Assignment Agreement or the Landlord Consent, agrees to take the same in its condition &#8220;as is&#8221; as of the first day of the Further Revised Term, subject to Landlord&#8217;s delivery of the Fourth Amendment TI Allowance, and (b) Landlord shall have no obligation to alter, repair or otherwise prepare the Premises for Tenant&#8217;s continued occupancy for the Further Revised Term or to pay for any improvements to the Premises, except, in each case, as may be expressly provided in the Lease, the Assignment Agreement, the Landlord Consent or this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Effective as of &#91;***&#93; the chart in Section 4(b) of the Second Amendment is hereby amended for the period commencing on &#91;***&#93; and ending on &#91;***&#93; to be as set forth below and monthly and annual installments of Base Rent for the Premises during the Further Revised Term (as extended by this Amendment) shall be as set forth in the chart below, subject to adjustment under the Lease.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Dates</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Square Feet of Rentable Area</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Base Rent per Square Foot of Rentable Area</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Monthly Base Rent</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Annual Base Rent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Operating Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Effective as of &#91;***&#93;  the last clause of Section 4(j) of the Second Amendment, commencing with the words &#8220;In addition, to the extent...&#8221; and including the chart set forth at the end of Section 4(j), shall be deleted and shall be of no further force or effect.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">TI Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Effective as of the Execution Date, (a) Landlord shall have no further obligation to fund, and Tenant shall have no further right receive, the Additional TI Allowance and (b) any rights and&#47;or obligations with respect to such Additional TI Allowance shall be null and void and of no force or effect. As of the Execution Date, Landlord confirms that&#58; (x) it has not disbursed any of the Additional TI Allowance to Tenant and (y) therefore, Landlord has not increased, and shall have no further right from and after the Execution Date to increase, Base Rent upon any disbursement of any Additional TI Allowance pursuant to Section 6(b) of the Second Amendment. From and after the Execution Date, Section 6(b) shall have no further force and effect, with the exception of the definition of &#8220;TI Deadline,&#8221; which shall be amended and restated to mean &#91;***&#93;  for all purposes under the Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">In accordance with the terms and conditions of this Amendment, Landlord shall make available to Tenant an additional tenant improvement allowance in the amount of &#91;***&#93;  Dollars ($&#91;***&#93;) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Fourth Amendment TI Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to be applied to the cost of the Tenant </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Improvements (as defined below) performed by Tenant in the Premises within the &#91;***&#93; period immediately prior to the Execution Date or to be performed by Tenant after the Execution Date, pursuant to Section 6 of the Second Amendment and the Work Letter attached to the Second Amendment as Exhibit C (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Work Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as the same may be amended by this Amendment. Landlord shall disburse the Fourth Amendment TI Allowance to Tenant on the Execution Date (provided that Tenant delivers its duly executed counterpart of this Amendment no later than 12&#58;00 pm Pacific time on the Execution Date, otherwise Landlord shall disburse the Fourth Amendment TI Allowance to Tenant no later than one (1) business day after the Execution Date) by wire transfer of immediately available funds to an account specified by Tenant. Tenant shall apply the Fourth Amendment TI Allowance to finance hard and soft costs of the Tenant Improvements, including costs of commissioning of any mechanical, electrical and plumbing systems and preparation and review of any related commissioning report, building permits and other taxes, fees, charges and levies charged by Governmental Authorities for permits for or inspections of the Tenant Improvements, and costs and expenses for labor, material, equipment and fixtures. For purposes of this Amendment, &#8220;Tenant Improvements&#8221; shall mean the first floor, second floor and fifth floor renovations to be performed by Tenant in the Premises, as substantially described in the documents entitled &#8220;MacroGenics 9704 MCD Level 1 &#38; 2 Renovation Construction Set&#8221; dated May 18, 2016 prepared by CRB Architects-Engineers P.C. and consisting of 76 pages and approved by Landlord by a letter from Landlord to Tenant dated &#91;***&#93; with certain conditions stated therein, and &#8220;MacroGenics 9704 MCD Level 1 &#38; 2 Renovation Construction Set, Bulletin #1&#8221; dated &#91;***&#93; prepared by CRB Architects-Engineers P.C. and consisting of 130 pages, and approved by a letter from Landlord to Tenant dated &#91;***&#93;, with certain conditions stated therein, and as each of the same may be modified or narrowed by Tenant from time to time, in its sole discretion, but subject to Landlord&#8217;s approval or consent, to the extent that Landlord&#8217;s approval or consent is required under the Work Letter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant shall perform the Tenant Improvements in accordance with Section 6 of the Second Amendment and the Work Letter, as the same may be modified by this Amendment. Without limiting the generality of the foregoing&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Tenant shall deliver to Landlord the Completion Evidence for the Tenant Improvements on or before the TI Deadline (time being of the essence), and any failure to do so shall constitute a Default under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 31.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Lease. Landlord and Tenant hereby agree that Completion Evidence&#8221; shall consist of the following for purposes of this Amendment&#58; (i) a statement setting forth the total cost of the Tenant Improvements, including supporting invoices (paid or presently due and payable) for Tenant&#8217;s costs of the Tenant Improvements, and certifying that the Fourth Amendment TI Allowance was applied to the Tenant Improvements in accordance with this Amendment&#59; and (ii) all of the TI Submittals. Landlord and Tenant hereby agree that &#8220;TI Submittals&#8221; shall consist of the following for purposes of this Amendment&#58; (t) commercially reasonable evidence satisfactory to Landlord that (i) all Tenant Improvements have been completed and paid for in full (an architect&#8217;s certificate of completion and the general contractor&#8217;s and each subcontractor&#8217;s and material supplier&#8217;s final unconditional waivers and releases of liens, each in a form acceptable to Landlord and complying with Applicable Laws, and a Certificate of Substantial Completion in the form of the American Institute of Architects document G704, executed by the project architect and the general contractor, together with a statutory notice of substantial completion from the general contractor shall be deemed evidence of completion of all Tenant Improvements and the same are paid in full), and (ii) any and all liens related to the Tenant Improvements have either been discharged of record (by payment, bond, order of a court of competent jurisdiction or otherwise) or waived by the party filing such lien&#59; (u) certificates of insurance required by the Lease to be purchased and maintained by Tenant&#59; (v) an affidavit from Tenant&#8217;s architect certifying that all work performed in, on or about the Premises is in accordance with the Approved Plans&#59; (w) complete &#8220;as built&#8221; drawing print sets, project specifications and shop drawings and electronic CADD files on disc (showing the Tenant Improvements as an overlay on the Building &#8220;as built&#8221; plans (provided that Landlord </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provides the Building &#8220;as-built&#8221; plans provided to Tenant) of all contract documents for work performed by their architect and engineers in relation to the Tenant Improvements, together with a consent by Tenant&#8217;s architects and engineers to Landlord&#8217;s use of such plans and specifications, as revised (if and to the extent such consent is granted following Tenant&#8217;s request therefor from Tenant&#8217;s architects and engineers, provided, that Tenant have no liability to Landlord, nor be in breach or default under the Lease or this Amendment, if Tenant&#8217;s architects or engineers fail to consent to Landlord&#8217;s use of such plans and specifications, as revised), upon the expiration or earlier termination of the Lease, in such form as Landlord shall reasonably require&#59; and (x) a commissioning report prepared by a licensed, qualified commissioning agent hired by Tenant and approved by Landlord for all new or affected mechanical, electrical and plumbing systems (which report Landlord may hire a licensed, qualified commissioning agent to peer review, and whose reasonable recommendations Tenant&#8217;s commissioning agent shall perform and incorporate into a revised report).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">If not previously selected by Tenant and approved by Landlord, Tenant shall select the architect, engineer, and general contractor for the construction of the Tenant Improvements, subject to Landlord&#8217;s approval, such approval not to be unreasonably withheld, conditioned or delayed. Landlord hereby approves the following architect and for design of the Tenant Improvements&#58; CRB Architects-Engineers P.C. Landlord hereby approves the following general contractor for construction of the Tenant Improvements&#58; CRB Builders, LLC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Tenant&#8217;s Authorized Representatives shall continue to be Thomas Spitznagel and Chris Holmes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Tenant shall perform the Tenant Improvements in accordance with the Schedule and Approved Plans, and any changes to the Approved Plans required for the Tenant Improvements shall be requested and instituted in accordance with Article 2 of the Work Letter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Upon Substantial Completion of any Tenant Improvements in any portion of the Premises in which Tenant is not currently in occupancy and conducting business, prior to occupying and commencing to conduct business in such portion of the Premises (but without limitation of Tenant&#8217;s right to conduct installation, qualification and validation of equipment in such portion of the Premises at any time and without the Required Occupancy Approvals), Tenant shall deliver to Landlord any certifications and approvals with respect to the Tenant Improvements from any Governmental Authority and any board of fire underwriters or similar body for the use and occupancy of the Premises, to the extent required by Applicable Laws (including a certificate of occupancy for the Permitted Use, if such certificate of occupancy is required by Applicable Law) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Required Occupancy Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; provided, that, the Required Occupancy Approvals shall be not be considered Completion Evidence&#59; further, provided, that, Tenant shall not be obligated to refund or repay any of the Fourth Amendment TI Allowance by reason of Tenant&#8217;s failure to deliver such Required Occupancy Approvals to Landlord (but Tenant may not occupy or commence to conduct business in the applicable portion of the Premises until Tenant delivers the Required Occupancy Approvals, and the failure to deliver to Required Occupancy Approvals shall not excuse, waive, postpone or constitute any defense to Tenant&#8217;s obligations under the Lease, including the obligation to pay Rent).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">Landlord confirms that Tenant shall not be obligated to pay Landlord a construction management fee or any similar construction oversight fee with respect to the Tenant Improvements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">SNDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Landlord agrees to request a subordination and non-disturbance agreement (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SNDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from its current Mortgagees in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (which is consistent with the form of SNDA attached to that certain Loan Agreement dated as of &#91;***&#93;, as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amended by that certain First Amendment to Loan Agreement and Other Loan Documents dated as of &#91;***&#93; (collectively, as the same may be amended, restated and&#47;or replaced from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Loan Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and among Landlord, as mortgagor, the current Mortgagees and certain other parties thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Required Form of SNDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)) with such changes requested by Tenant, within thirty (30) days after the Execution Date. Landlord agrees to use reasonable efforts, at no cost to Landlord, to obtain the SNDA substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> from such Mortgagees. Landlord will not obstruct Tenant&#8217;s negotiations with the Mortgagees regarding Tenant&#8217;s requested changes to such SNDA. Tenant acknowledges that, while Tenant may request changes to the Required Form of SNDA from the current Mortgagees, the current Mortgagees have no contractual or other obligation to deliver any SNDA other than the Required Form of SNDA, and there is no definite time period during which such Mortgagees are required to respond to any request for or to deliver a Required Form of SNDA under the Loan Agreement, and therefore, any refusal or failure to deliver or delay in delivering any SNDA to Tenant shall not constitute a default of Landlord under the Lease. For purposes of clarity, using &#8220;reasonable efforts&#8221; to obtain the Required Form of SNDA from the Mortgagees shall not require Landlord to assert any default of Mortgagees or otherwise take any enforcement actions under the Loan Agreement or any other loan documents affecting the Premises. Within &#91;***&#93; days after Landlord&#8217;s written demand therefor, together with reasonable supporting documentation, Tenant shall reimburse any fees charged by the Mortgagees or their legal counsel pursuant to the Loan Agreement and any other third party out-of-pocket costs incurred by Landlord in connection with the request for, drafting or negotiation of and&#47;or delivery of any SNDA requested by Tenant under this Amendment, regardless of whether the current Mortgagees agree to or actually execute and deliver such SNDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Security Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Landlord acknowledges that pursuant to Section 4(c) of the Second Amendment, as of the Execution Date, it is currently holding a Security Deposit in the amount of &#91;***&#93; Dollars ($&#91;***&#93;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">ROFO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Upon Tenant&#8217;s request, Landlord agrees to execute and deliver to Tenant an amended and restated Purchase ROFO Memorandum, with the sole change to being to reflect the execution of this Amendment and the Further Revised Term, as the same may be further extended pursuant to Section 14 of the Second Amendment. Tenant may, but shall not be obligated to, record the amended and restated Purchase ROFO Memorandum, provided that Tenant shall be obligated to pay all costs and expenses relating thereto, including any taxes assessed as a result of such recording.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant and Landlord each represents and warrants that it has not dealt with any broker or agent in the negotiation for or the obtaining of this Amendment, other than CBRE, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and agrees to reimburse, indemnify, save, defend (at the indemnified party&#8217;s option and with counsel reasonably acceptable to the indemnified party, at the indemnifying party&#8217;s sole cost and expense) and hold harmless the indemnified party for, from and against any and all cost or liability for compensation claimed by any such broker or agent, other than Broker, employed or engaged by it or claiming to have been employed or engaged by it. Landlord shall pay any commission to the extent required to be paid to Broker in connection with making of this Amendment pursuant to a separate agreement between Landlord and Broker. Tenant shall have no obligation to pay Broker a leasing commission in connection with the making of this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">No Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant represents, warrants and covenants that, to the best of Tenant&#8217;s knowledge, Landlord and Tenant are not in default of any of their respective obligations under the Existing Lease beyond applicable notice and cure periods. Landlord represents, warrants and covenants that, to the best of Landlord&#8217;s knowledge, Landlord and Tenant are not in default of any of their respective obligations under the Existing Lease beyond applicable notice and cure periods.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant confirms that, notwithstanding anything in the Lease to the contrary, notices delivered to Tenant pursuant to the Lease should be sent to&#58;</font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MacroGenics, Inc.</font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9704 Medical Center Drive </font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rockville, Maryland 20850 </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; General Counsel&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with a copy to&#58;</font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Covington &#38; Burling LLP </font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">One CityCenter</font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">850 Tenth Street, NW </font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Washington, DC 20001</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; Heather G. Haberl</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Effect of Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as modified by this Amendment, the Existing Lease and all the covenants, agreements, terms, provisions and conditions thereof shall remain in full force and effect and are hereby ratified and affirmed. In the event of any conflict between the terms contained in this Amendment and the Existing Lease, the terms herein contained shall supersede and control the obligations and liabilities of the parties.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each of the covenants, conditions and agreements contained in this Amendment shall inure to the benefit of and shall apply to and be binding upon the parties hereto and their respective heirs, legatees, devisees, executors, administrators and permitted successors and assigns and sublessees. Nothing in this section shall in any way alter the provisions of the Lease restricting assignment or subletting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Amendment becomes effective only upon execution and delivery hereof by Landlord and Tenant and Tenant&#8217;s receipt of the Fourth Amendment TI Allowance from Landlord. The captions of the paragraphs and subparagraphs in this Amendment are inserted and included solely for convenience and shall not be considered or given any effect in construing the provisions hereof. All exhibits hereto are incorporated herein by reference. Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for a lease, and shall not be effective as a lease, lease amendment or otherwise until execution by and delivery to both Landlord and Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant guarantees, warrants and represents that the individual or individuals signing this Amendment have the power, authority and legal capacity to sign this Amendment on behalf of and to bind all entities, corporations, partnerships, limited liability companies, joint venturers or other organizations and entities on whose behalf such individual or individuals have signed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Counterparts&#59; Facsimile and PDF Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Amendment may be executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document. A facsimile or portable document format (PDF) signature on this Amendment shall be equivalent to, and have the same force and effect as, an original signature.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><div id="i1035913c16ff4756b0fcca9568f5aab0_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Landlord and Tenant have executed this Amendment as of the date and year first above written.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LANDLORD&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BMR-MEDICAL CENTER DRIVE LLC, </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Marie Lewis&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Marie Lewis&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vice President, Legal&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">TENANT&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MACROGENICS, INC., </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Scott Koenig&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Scott Koenig&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CEO&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>10
<FILENAME>a1030_fifthamendmenttohqle.htm
<DESCRIPTION>EX-10.30
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie686fa2e31fb4e42b060909157569035_1"></div><div style="min-height:82.8pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit.10.30</font></div></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY &#91;***&#93;) HAVE BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE THEY ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FIFTH AMENDMENT TO LEASE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THIS FIFTH AMENDMENT TO LEASE (this &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is entered into as of this &#91;***&#93;, &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Execution Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), by and between ARE-MARYLAND NO. 45, LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Landlord</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and MACROGENICS, INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tenant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Pursuant to that certain Assignment and Assumption Agreement dated as of &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Assignment Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), as amended by that certain First Amendment to Assignment and Assumption Agreement dated as of &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First Amendment to Assignment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and collectively with the Original Assignment Agreement, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assignment Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; between J. Craig Venter&#160;Institute, Inc., (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">JCVI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), as assignor, and Tenant, as assignee, and that certain Landlord Consent dated as of &#91;***&#93; attached to the Original Assignment Agreement and executed by BMR-Medical Center Drive LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BMR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Landlord Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), as amended&#160;by that certain First Amendment to Landlord Consent dated as of &#91;***&#93; attached to the First Amendment to Assignment and executed by BMR First Amendment to Landlord Consent and&#160;collectively with the Original Landlord Consent, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Landlord Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), BMR and Tenant are parties to that certain Lease dated as of &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Lease</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), as amended by that certain First Amendment to Lease dated as of &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), that certain Second Amendment to Lease dated as of &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), that certain Third Amendment to Lease dated as of &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and that certain Fourth Amendment to Lease dated as of &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fourth Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)&#59; together with the Original Lease, the First Amendment, the Second Amendment, and the Third Amendment, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Existing Lease</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), whereby Tenant leases certain premises (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) from Landlord at 9704 Medical Center Drive in Rockville, Maryland (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Building</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Landlord and Tenant desire to extend the Term of the Existing Lease, provide an abatement of certain of the Base Rent for the Premises, modify the existing options to extend the Term, and modify certain other provisions of the Existing Lease on the terms and conditions set forth in this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;Landlord and Tenant desire to modify and amend the Existing Lease only in the respects and on the conditions stated in this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br><br><br><br><br><br><br><br><br><br><br><br>1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Definitions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  For purposes of this Amendment, capitalized terms shall have the meanings ascribed to them in the Existing Lease unless otherwise defined herein.  The Existing Lease, as amended by this Amendment, is referred to collectively herein as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; From and after the Execution Date, this term &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; as used in the Existing Lease, shall mean the Existing Lease, as amended by this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br><br><br><br><br><br><br><br><br><br><br><br>2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Second Revised Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Further Revised Term of the Lease for the Premises (which was added to the Existing Lease pursuant to the Fourth Amendment) expires on &#91;***&#93;.  The Further Revised Term for the Premises is hereby extended for the period beginning on &#91;***&#93; and, unless earlier terminated or extended as provided in the Lease, expiring on &#91;***&#93; Second Revised Term, and the Term Expiration Date for the Premises is hereby extended from &#91;***&#93; to &#91;***&#93;.  From and after the Execution Date, any references in the Lease to&#160;the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term Expiration Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93; (and, if the Term is extended for the First Extension Term, &#91;***&#93;, and if the Term is extended for the Second Extension Term, &#91;***&#93;), and any references in the Lease to &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the Revised Term, the Further Revised Term, all as extended by the Second Revised Term, and as the same may be further extended pursuant to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Section 6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of this Amendment.</font></div><div style="height:94.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:179.75pt"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fifth Amendment to Lease &#8212; MacroGenics, Inc.&#160;&#160;&#160;&#160;Page - 2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9704 Medical Center Drive, Rockville, Maryland</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br><br><br><br><br><br><br><br><br><br><br><br>3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Condition of Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Tenant acknowledges that (a) as of the Execution Date it is in possession of and is fully familiar with the condition of the Premises and, except as otherwise expressly provided in the Existing Lease, the Assignment Agreement, the Landlord Consent, or this Amendment, agrees to take the Premises in its condition &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">as is</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34; as of the first day of the Second Revised Term, and (b) Landlord shall have no obligation to alter, repair, or otherwise prepare the Premises for Tenant's continued occupancy for the Second Revised Term or to pay for any improvements to the Premises, except, in each case under clauses (a) and (b), as may be expressly provided in the Existing Lease or this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br><br><br><br><br><br><br><br><br><br><br><br>4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Base Rent for Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Effective as of the Execution Date, the table in Section 4 of the Fourth Amendment setting forth the Base Rent for the Premises is hereby amended for the period commencing on &#91;***&#93; and ending on &#91;***&#93; as set forth in the table below&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dates</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Square Feet of Rentable Area For Premises</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Annual Base Rent per Square Foot of Rentable Area&#8224;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Monthly Base Rent</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Annual Base Rent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8224;The calculation of the Annual Base Rent and Monthly Base Rent in this table is based on escalating the Annual Base Rent per square foot of rentable area amount each year by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">% and multiplying that amount by the rentable square footage of the Premises (i.e., </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> rentable square feet).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br><br><br><br><br><br><br><br><br><br><br><br>5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Abatement of Base Rent for Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary contained in the Lease or this Amendment, Landlord hereby grants Ten ant an abatement of &#91;***&#93; of the Base Rent payable for the Premises during the period beginning on the Execution Date and ending &#91;***&#93; months after the Execution Date (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Base Rent Abatement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that during any period in which Tenant is in Default, Landlord may, upon prior written notice to Tenant accompanied by a rent invoice, suspend the Base Rent Abatement day for day, effective as of the first day of such Default until the day Tenant cures such Default, at which time the Base Rent Abatement shall be reinstituted for the full number of days that remained in the Base Rent Abatement period on the first day of such Default.  For the avoidance of doubt, if the Execution Date occurs on the first day of a month, the Base Rent Abatement will be measured from that date.  If the Execution Date occurs on a day other than the first day of a month, the Base Rent Abatement will be measured from the first day of the following month.  Except as provided in the preceding sentences, Tenant shall pay the full amount of Base Rent for the Premises due in accordance with the provisions of the Lease.  The Property Management Fee shall not be abated </font></div><div style="height:94.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:179.75pt"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fifth Amendment to Lease &#8212; MacroGenics, Inc.&#160;&#160;&#160;&#160;Page - 3</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9704 Medical Center Drive, Rockville, Maryland</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and shall be based on the amount of Base Rent for the Premises that would have been payable but for the Base Rent Abatement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br><br><br><br><br><br><br><br><br><br><br><br>6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Option to Extend</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Section 14 of the Second Amendment is hereby deleted in its entirely and replaced with the words &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intentionally Deleted.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34; Tenant shall have the right to extend the Term of the Lease for the Premises upon the following terms and conditions&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Extension Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Tenant shall have 2 consecutive rights (each an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Extension Right</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) to extend the Term of the Lease for the Premises for 5 years each (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First Extension Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and&#160;the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second Extension Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; as applicable&#59; collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Extension Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) on the same terms and&#160;conditions as the Lease (other than Base Rent) by giving Landlord written notice of its election to exercise the Extension Right at least 12 months prior, and no earlier than 18 months prior, to the expiration of the Second Revised Term (with respect to the First Extension Term) or the First Extension Term (with respect to the Second Extension Term).  The First Extension Term shall commence on &#91;***&#93; and, unless earlier terminated or extended in accordance with the terms and conditions of the Lease, expire on &#91;***&#93;, and the Second Extension Term shall commence on &#91;***&#93; and, unless earlier terminated in accordance with the terms and conditions of the Lease, expire on &#91;***&#93;.  For ease of reference, set forth in the table below are the dates for the Further Revised Term, Second Revised Term, First Extension Term, and Second Extension Term&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:0.36pt;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.13pt">Base Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Base Rent at the commencement of the applicable Extension Term shall equal the greater of (i) the Market Rate (as defined below), and (ii) the Base Rent payable immediately before the commencement of the applicable Extension Term multiplied by &#91;***&#93;%.  Base Rent shall thereafter be adjusted on each anniversary of the commencement of the applicable Extension Term by a percentage as determined by Landlord and agreed to by Tenant at the time the Market Rate is determined.  As used herein, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Rate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall mean the then market base rental rate and annual escalations thereof for comparable space for a comparable term in buildings in the Rockville, Maryland submarket comparable in age, location, and quality to the Building, taking into account the existence and amount of any tenant improvement allowance or any other cash payment or other equivalent concession, including, without limitation, lease allowances, and any other comparable tenant inducement and market concession, leasehold improvements, and brokerage fees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant may, &#91;***&#93;, request Landlord&#8217;s proposed Market Rate for the next Extension Term.  Landlord shall, &#91;***&#93;, give Tenant a written and binding proposal for the Market Rate.  If, &#91;***&#93; Landlord and Tenant have not agreed on the determination of the Market Rate and the rent escalations during such subsequent Extension Term after negotiating in good faith, Tenant may by written notice to Landlord &#91;***&#93; elect arbitration as described in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.c</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> below.  If Tenant does not elect such arbitration, Tenant shall be deemed to have waived any right to extend the Term of the Lease and the Extension Right shall terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Arbitration</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:31.01pt">&#91;***&#93; each party shall deliver to the other a proposal containing the Market Rate and&#160;escalations that the submitting party believes to be correct (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Extension Proposal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  If either party fails to timely submit an Extension Proposal, the other party&#8217;s submitted proposal shall determine the Base Rent and escalations for the applicable Extension Term.  If both parties submit Extension Proposals, then&#160;Landlord and Tenant shall meet &#91;***&#93; and make a good faith attempt to mutually appoint a single Arbitrator (as defined below) to determine the Market Rate and escalations.  If Landlord and Tenant are unable to agree upon a single Arbitrator, then each shall, by written notice delivered to the other &#91;***&#93;, select an Arbitrator.  If either party fails to timely give notice of its selection for an Arbitrator, the other party&#8217;s submitted proposal shall be used to determine the Base Rent for the applicable Extension Term.  </font></div><div style="height:94.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:179.75pt"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fifth Amendment to Lease &#8212; MacroGenics, Inc.&#160;&#160;&#160;&#160;Page - 4</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9704 Medical Center Drive, Rockville, Maryland</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The 2 Arbitrators so appointed shall &#91;***&#93; appoint a third Arbitrator.  If the 2 Arbitrators so selected cannot agree on the selection of the third Arbitrator within the time above specified, then either party, on behalf of both parties, may request such appointment of such third Arbitrator by application to any state court of general jurisdiction in the jurisdiction in which the Premises are located &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.79pt">The decision of the Arbitrator(s) shall be made &#91;***&#93;.  The decision of the single Arbitrator shall be final and binding upon the parties.  The average of the two closest Arbitrators in a three Arbitrator panel shall be final and binding upon the parties.  Each party shall pay the fees and expenses of the Arbitrator appointed by or on behalf of such party and the fees and expenses of the third Arbitrator shall be borne equally by both parties.  If the Market Rate and escalations are not determined by the first day of the applicable Extension Term, then Tenant shall pay Landlord Base Rent in an amount equal to the Base Rent in effect immediately prior to the applicable Extension Term and increased by &#91;***&#93;% until such determination is made.  After the determination of the Base Rent and escalations, the parties shall make any necessary adjustments to such payments made by Tenant.  Landlord and Tenant shall then execute and deliver an amendment recognizing the Base Rent (as determined in the first sentence of Section 6.b.  above) and escalations for the applicable Extension Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">An &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Arbitrator</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; shall be any person appointed by or on behalf of either party&#160;or appointed pursuant to the provisions hereof and&#58; (1) shall be (A) a member of the American Institute of Real Estate Appraisers with not less than 10 years of experience in the appraisal of improved office and high tech industrial real estate in the greater Rockville, Maryland metropolitan area, or (B) a licensed commercial real estate broker with not less than 15 years&#8217; experience representing landlords and&#47;or tenants in the leasing of high tech or life sciences space in the greater Rockville, Maryland metropolitan area, (2) devoting substantially all of their time to professional appraisal or brokerage work, as applicable, at the time of appointment and (3) be in all respects impartial and disinterested.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.13pt">Assignment of Extension Right</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Extension Right is not assignable separate and apart from the Lease.  Tenant&#8217;s rights under this Section 6 shall be transferable in connection with an assignment of the Lease to an Exempt Transferee, but shall not be transferable to any other assignee without the prior written consent of Landlord, which consent Landlord may withhold in its sole and absolute discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Exceptions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding anything set forth above to the contrary, the Extension Right shall not be in effect and Tenant may not exercise the Extension Right&#58; (i) during any period&#160;of time that Tenant is in Default under any provision of the Lease&#59; or (ii) if Tenant has been in Default under any provision of the Lease 3 or more times, regardless of whether the Defaults are cured, during the &#91;***&#93; period immediately prior to the date that Tenant intends to exercise the Extension Right, regardless of whether the Defaults are cured.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:29.9pt">No Extension</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The period of time within which the Extension Right may be exercised shall not be extended or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.13pt">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Extension Right shall terminate and be of no further force or effect even after Tenant's due and timely exercise of the Extension Right, if, after such exercise, but before the commencement date of the applicable Extension Term, Tenant has Defaulted 3 or more times during the period from the date of the exercise of the Extension Right to the date of the commencement of the Extension Term, regardless of whether such Defaults are cured.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br><br><br><br><br><br><br><br><br><br><br><br>7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Miscellaneous</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Entire Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Lease, as amended by this Amendment, is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions.  The Lease, as so amended by this Amendment, may be amended only by an agreement in writing, signed by the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.13pt">Binding Effect</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  This Amendment is binding upon and shall inure to the benefit of the parties hereto, their respective agents, employees, members, representatives, officers, directors, divisions, subsidiaries, affiliates, assigns, heirs, successors in interest and shareholders.</font></div><div style="height:94.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:179.75pt"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fifth Amendment to Lease &#8212; MacroGenics, Inc.&#160;&#160;&#160;&#160;Page - 5</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9704 Medical Center Drive, Rockville, Maryland</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Counterparts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  This Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S.  federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.  Electronic signatures shall be deemed original signatures for purposes of this Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.13pt">Broker</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent, or other person (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Broker</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) in connection with this Amendment and that no Broker brought about this transaction, other than Tenant&#8217;s broker, Jones Lang LaSalle Brokerage, Inc.  (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">JLL</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  JLL shall be paid by Landlord pursuant to a separate agreement between Landlord and JLL.  Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker, other than JLL, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Ratification&#59; Conflicts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Except as amended and&#47;or modified by this Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Amendment.  In the event of any conflict between the provisions of this Amendment and the provisions of the Lease, the provisions of this Amendment shall prevail.  Regardless of whether specifically amended by this Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Amendment.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;END OF PAGE&#59; SIGNATURES APPEAR ON FOLLOWING PAGE&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:94.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:179.75pt"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fifth Amendment to Lease &#8212; MacroGenics, Inc.&#160;&#160;&#160;&#160;Page - 6</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9704 Medical Center Drive, Rockville, Maryland</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have executed this Amendment as a document under seal as of the day and year first above written.</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">LANDLORD</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARE-MARYLAND NO. 45, LLC,<br>a Delaware limited liability company</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;Alexandria Real Estate Equities, LP.,<br>a Delaware limited partnership,<br>managing member</font></div><div style="margin-bottom:24pt;padding-left:252pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;ARE-ORS CORP.,<br>a Maryland corporation,<br>general partner</font></div><div style="padding-left:288pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;Gregory Kay&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(SEAL)</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;Gregory Kay&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;Senior Vice President&#160;&#160;&#160;&#160;</font></div><div style="padding-left:126pt;padding-right:126pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Legal Affairs</font></div><div style="margin-bottom:12pt;margin-top:24pt;padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">TENANT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:36pt;padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MACROGENICS, INC.,<br>a Delaware corporation</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;Scott Koenig&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(SEAL)</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;Scott Koenig&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;CEO&#160;&#160;&#160;&#160;</font></div><div style="height:94.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:179.75pt"><font><br></font></div><div><font><br></font></div></div></div><div id="ie686fa2e31fb4e42b060909157569035_4"></div><hr style="page-break-after:always"><div style="min-height:82.8pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fifth Amendment to Lease &#8212; MacroGenics, Inc.&#160;&#160;&#160;&#160;Page - 6</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9704 Medical Center Drive, Rockville, Maryland</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have executed this Amendment as a document under seal as of the day and year first above written.</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">LANDLORD</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARE-MARYLAND NO. 45, LLC,<br>a Delaware limited liability company</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;Alexandria Real Estate Equities, LP.,<br>a Delaware limited partnership,<br>managing member</font></div><div style="margin-bottom:24pt;padding-left:252pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;ARE-ORS CORP.,<br>a Maryland corporation,<br>general partner</font></div><div style="padding-left:288pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;Gregory Kay&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(SEAL)</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;Gregory Kay&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;Senior Vice President&#160;&#160;&#160;&#160;</font></div><div style="padding-left:126pt;padding-right:126pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Legal Affairs</font></div><div style="margin-bottom:12pt;margin-top:24pt;padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">TENANT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:36pt;padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MACROGENICS, INC.,<br>a Delaware corporation</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;Scott Koenig&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(SEAL)</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;Scott Koenig&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;CEO&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:94.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:179.75pt"><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>11
<FILENAME>mgnxexhibit23-1202210xk.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i900cadc2c0114983b6be46248fe8aad9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 23.1</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-192277) pertaining to the 2000 Stock Option and Incentive Plan, the 2003 Equity Incentive Plan, and 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-202470) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-209812) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-217620) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-223682) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-230292) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-237127) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-253502) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-262967) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-214386) pertaining to the 2016 Employee Stock Purchase Plan of MacroGenics, Inc., and</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Registration Statement (Form S-3 No. 333-249851) of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated March&#160;15, 2023, with respect to the consolidated financial statements of MacroGenics, Inc. and the effectiveness of internal control over financial reporting of MacroGenics, Inc.&#160;included in this Annual Report (Form 10-K) of MacroGenics, Inc. for the year ended December&#160;31, 2022.</font></div><div style="margin-bottom:3pt;margin-top:18pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst&#160;&#38; Young LLP</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tysons, Virginia</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;15, 2023</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>12
<FILENAME>mgnxexhibit31-1202210xk.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i38c53a5280cc449aad452c672d4172ba_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K for the period ended December&#160;31, 2022 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:126pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.538%"><tr><td style="width:1.0%"></td><td style="width:40.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Scott&#160;Koenig</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;March&#160;15, 2023&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>13
<FILENAME>mgnxexhibit31-2202210xk.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5c9e018b859d4fd29966336ef55001cb_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K for the period ended December&#160;31, 2022 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.339%"><tr><td style="width:1.0%"></td><td style="width:22.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.179%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James Karrels</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;March&#160;15, 2023&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>14
<FILENAME>mgnxexhibit32-1202210xk.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8b56ad413a644e349ecae9af0e64da69_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the &#8220;Registrant&#8221;), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended December&#160;31, 2022 of the Registrant (the &#8220;Report&#8221;), that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d)&#160;of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig </font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  March&#160;15, 2023 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>15
<FILENAME>mgnxexhibit32-2202210xk.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i71a5f67b29564753b6bf6663ed15de76_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.2</font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the &#8220;Registrant&#8221;), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended December&#160;31, 2022 of the Registrant (the &#8220;Report&#8221;), that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d)&#160;of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels&#160;&#160;&#160;&#160;</font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; James Karrels</font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;15, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>mgnx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:49d3a843-ae73-49e6-9afb-5555c20651f7,g:f863eeaf-37fc-4bf3-b50d-59432dc50ee9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://macrogenics.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://macrogenics.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandNatureofOperations" roleURI="http://macrogenics.com/role/OrganizationandNatureofOperations">
        <link:definition>0000008 - Disclosure - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://macrogenics.com/role/MarketableSecurities">
        <link:definition>0000010 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://macrogenics.com/role/Inventory">
        <link:definition>0000011 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftware" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftware">
        <link:definition>0000012 - Disclosure - Property, Equipment and Software</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://macrogenics.com/role/CommitmentsandContingencies">
        <link:definition>0000013 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://macrogenics.com/role/StockholdersEquity">
        <link:definition>0000014 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://macrogenics.com/role/Revenue">
        <link:definition>0000015 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://macrogenics.com/role/StockbasedCompensation">
        <link:definition>0000016 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://macrogenics.com/role/IncomeTaxes">
        <link:definition>0000017 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://macrogenics.com/role/EmployeeBenefitPlan">
        <link:definition>0000018 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://macrogenics.com/role/SubsequentEvents">
        <link:definition>0000019 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000021 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://macrogenics.com/role/MarketableSecuritiesTables">
        <link:definition>0000022 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetTables" roleURI="http://macrogenics.com/role/InventoryNetTables">
        <link:definition>0000023 - Disclosure - Inventory, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftwareTables" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables">
        <link:definition>0000024 - Disclosure - Property, Equipment and Software (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://macrogenics.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000025 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://macrogenics.com/role/StockbasedCompensationTables">
        <link:definition>0000026 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://macrogenics.com/role/IncomeTaxesTables">
        <link:definition>0000027 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsTables" roleURI="http://macrogenics.com/role/SubsequentEventsTables">
        <link:definition>0000028 - Disclosure - Subsequent Events (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>0000029 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails">
        <link:definition>0000030 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails">
        <link:definition>0000031 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails">
        <link:definition>0000032 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails">
        <link:definition>0000033 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails">
        <link:definition>0000034 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAvailableForSaleSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails">
        <link:definition>0000035 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetScheduleofInventoryDetails" roleURI="http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails">
        <link:definition>0000036 - Disclosure - Inventory, Net - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetDetails" roleURI="http://macrogenics.com/role/InventoryNetDetails">
        <link:definition>0000037 - Disclosure - Inventory, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftwareDetails" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails">
        <link:definition>0000038 - Disclosure - Property, Equipment and Software (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://macrogenics.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000039 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://macrogenics.com/role/StockholdersEquityDetails">
        <link:definition>0000040 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueIncyteCorporationDetails" roleURI="http://macrogenics.com/role/RevenueIncyteCorporationDetails">
        <link:definition>0000041 - Disclosure - Revenue - Incyte Corporation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueGileadSciencesIncDetails" roleURI="http://macrogenics.com/role/RevenueGileadSciencesIncDetails">
        <link:definition>0000042 - Disclosure - Revenue - Gilead Sciences Inc (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueZaiLabDetails" roleURI="http://macrogenics.com/role/RevenueZaiLabDetails">
        <link:definition>0000043 - Disclosure - Revenue - Zai Lab (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueJanssenDetails" roleURI="http://macrogenics.com/role/RevenueJanssenDetails">
        <link:definition>0000044 - Disclosure - Revenue - Janssen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueIMabBiopharmaDetails" roleURI="http://macrogenics.com/role/RevenueIMabBiopharmaDetails">
        <link:definition>0000045 - Disclosure - Revenue - I-Mab Biopharma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueProventionDetails" roleURI="http://macrogenics.com/role/RevenueProventionDetails">
        <link:definition>0000046 - Disclosure - Revenue - Provention (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueBoehringerIngelheimInternationalGmbHDetails" roleURI="http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails">
        <link:definition>0000047 - Disclosure - Revenue - Boehringer Ingelheim International GmbH (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNIAIDContractDetails" roleURI="http://macrogenics.com/role/RevenueNIAIDContractDetails">
        <link:definition>0000048 - Disclosure - Revenue - NIAID Contract (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationEmployeeStockPurchasePlanDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails">
        <link:definition>0000049 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>0000050 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationOptionPricingAssumptionsDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails">
        <link:definition>0000051 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationOptionExercisePriceRangeTableDetails" roleURI="http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails">
        <link:definition>0000052 - Disclosure - Share-based Compensation - Option, Exercise Price Range Table (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails">
        <link:definition>0000053 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>0000054 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>0000055 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails">
        <link:definition>0000056 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>0000057 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails">
        <link:definition>0000058 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://macrogenics.com/role/SubsequentEventsDetails">
        <link:definition>0000059 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" abstract="false" name="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mgnx_OneTimeMillstoneCredit" abstract="false" name="OneTimeMillstoneCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_UpfrontPayment" abstract="false" name="UpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuance" abstract="false" name="CommonStockMaximumAmountAvailableForIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProventionPRV3279Member" abstract="true" name="ProventionPRV3279Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ZaiLabMember" abstract="true" name="ZaiLabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueFromGovernmentAgreementsMember" abstract="true" name="RevenueFromGovernmentAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ScheduleOfInventoryReservesTableTextBlock" abstract="false" name="ScheduleOfInventoryReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mgnx_AssetPurchaseAgreementMember" abstract="true" name="AssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenuesFromCMOAgreementsMemberMember" abstract="true" name="RevenuesFromCMOAgreementsMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementTransactionPrice" abstract="false" name="CollaborativeAgreementTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_MilestonesValueAddedTax" abstract="false" name="MilestonesValueAddedTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_A2021ZaiLabAgreementsMember" abstract="true" name="A2021ZaiLabAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_Section174DeferredTaxAsset" abstract="false" name="Section174DeferredTaxAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_UndesignatedPreferredStockMember" abstract="true" name="UndesignatedPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" abstract="false" name="PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_SynaffixBVMember" abstract="true" name="SynaffixBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" abstract="false" name="CollaborationAndLicenseAgreementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" abstract="true" name="McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" abstract="true" name="RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" abstract="false" name="PotentialTargetNominationOptionFeesAndMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_JanssenBiotechIncMember" abstract="true" name="JanssenBiotechIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" abstract="true" name="BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_LaboratoryAndOfficeEquipmentMember" abstract="true" name="LaboratoryAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ZaiLabCollaborationAndLicenseAgreementMember" abstract="true" name="ZaiLabCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_NonRefundableUpfrontFees" abstract="false" name="NonRefundableUpfrontFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_TaxYear2025To2037Member" abstract="true" name="TaxYear2025To2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueFromCollaborativeAgreementsMember" abstract="true" name="RevenueFromCollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementTerm" abstract="false" name="CollaborationAndLicenseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" abstract="false" name="PotentialMilestonePaymentsAndRoyaltiesOnProductSales" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" abstract="false" name="CommonStockMaximumAmountAvailableForIssuanceIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NumberOfProductCandidates" abstract="false" name="NumberOfProductCandidates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_ZaiLabClinicalSupplyAgreementsMember" abstract="true" name="ZaiLabClinicalSupplyAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ProventionBioCMOAgreeemntMember" abstract="true" name="ProventionBioCMOAgreeemntMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ZaiLabsMember" abstract="true" name="ZaiLabsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_DevelopmentMilestonesAmount" abstract="false" name="DevelopmentMilestonesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProventionPRV031Member" abstract="true" name="ProventionPRV031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IndefiniteMember" abstract="true" name="IndefiniteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborativeArrangementExtensionTerm" abstract="false" name="CollaborativeArrangementExtensionTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_EquityIncentivePlan2003Member" abstract="true" name="EquityIncentivePlan2003Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_FutureMilestone" abstract="false" name="FutureMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" abstract="true" name="LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" abstract="false" name="RevenueInformationUsedToAssessVariableConsiderationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncreaseDecreaseInLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ExercisePriceRangeFromDollars501To1500MemberMember" abstract="true" name="ExercisePriceRangeFromDollars501To1500MemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IncyteClinicalSupplyAgreementMember" abstract="true" name="IncyteClinicalSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenuesFromGrantsMember" abstract="true" name="RevenuesFromGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ProventionBioMember" abstract="true" name="ProventionBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" abstract="false" name="RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementMember" abstract="true" name="IncyteMGA012AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" abstract="false" name="NonrefundableUpfrontFeesNetOfTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DRIHealthcareAcquisitionsLPDRIMember" abstract="true" name="DRIHealthcareAcquisitionsLPDRIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" abstract="false" name="PotentialCommercialMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" abstract="false" name="DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AdditionalAnnualFixedPayments" abstract="false" name="AdditionalAnnualFixedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember" abstract="true" name="ExercisePriceRangeFromDollars1501To2500MemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CostOfManufacturingServices" abstract="false" name="CostOfManufacturingServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ExercisePriceRangeFromDollars094To500MemberMember" abstract="true" name="ExercisePriceRangeFromDollars094To500MemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IncyteCommercialSupplyAgreementMember" abstract="true" name="IncyteCommercialSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenuesFromCMOAmendmentAgreementMember" abstract="true" name="RevenuesFromCMOAmendmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" abstract="true" name="IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IncreaseDecreaseInDeferredRent" abstract="false" name="IncreaseDecreaseInDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ReceivableFromCollaborationPartner" abstract="false" name="ReceivableFromCollaborationPartner" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" abstract="true" name="DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" abstract="false" name="OperatingLossCarryforwardsNotSubjectToLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" abstract="true" name="IMabBiopharmaCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" abstract="false" name="EmployeesEligibleAgeToParticipateInBenefitPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" abstract="false" name="ProceedsfromStockOptionsExercisedAndESPPPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabLimitedMember" abstract="true" name="ZaiLabLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodValueStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodValueStockPlanActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" abstract="false" name="DefinedContributionPlanEmployeesContributionVestedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_TotalAnnualFixedPayments" abstract="false" name="TotalAnnualFixedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_FurnitureAndOfficeEquipmentMember" abstract="true" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborationArrangementOneTimeCreditPaidPercent" abstract="false" name="CollaborationArrangementOneTimeCreditPaidPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" abstract="false" name="PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NonrefundablePaymentTaxWithholding" abstract="false" name="NonrefundablePaymentTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_A2022GileadCollaborationAndLicenseAgreementMember" abstract="true" name="A2022GileadCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_BoehringerIngelheimInternationalGmbHMember" abstract="true" name="BoehringerIngelheimInternationalGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_ContractManufacturingMember" abstract="true" name="ContractManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ProceedsfromRoyaltiesPercent" abstract="false" name="ProceedsfromRoyaltiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_ProventionLicenseAgreementMember" abstract="true" name="ProventionLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" abstract="true" name="A2018ZaiLabCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mgnx_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ImabMember" abstract="true" name="ImabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" abstract="true" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_JanssenCollaborationAndLicenseAgreementMember" abstract="true" name="JanssenCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_TotalPotentialValueUnderAgreement" abstract="false" name="TotalPotentialValueUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_StockIncentivePlan2013Member" abstract="true" name="StockIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IncyteCorporationMember" abstract="true" name="IncyteCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_UpfrontAndFixedPayments" abstract="false" name="UpfrontAndFixedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_GileadMember" abstract="true" name="GileadMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RevenueFromVariableConsiderationRecognize" abstract="false" name="RevenueFromVariableConsiderationRecognize" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_IMabBiopharmaMember" abstract="true" name="IMabBiopharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" abstract="false" name="OperatingLossCarryforwardsAnnualLimitationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesFromLicenseAgreementsMember" abstract="true" name="RevenuesFromLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PremiumReceivedOnStockPurchase" abstract="false" name="PremiumReceivedOnStockPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" abstract="false" name="PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ASDHealthcareAndOncologySupplyMember" abstract="true" name="ASDHealthcareAndOncologySupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" abstract="false" name="OperatingLossCarryforwardsLimitationsOnUseAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_EstimatedReimbursementForResearchAndDevelopmentT" abstract="false" name="EstimatedReimbursementForResearchAndDevelopmentT" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" abstract="false" name="RightOfUseAssetAndLeaseLiabilityIncrease" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodSharesStockPlanActivity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_FutureRevenue" abstract="false" name="FutureRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember" abstract="true" name="ExercisePriceRangeFromDollars2501To4021MemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>mgnx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:49d3a843-ae73-49e6-9afb-5555c20651f7,g:f863eeaf-37fc-4bf3-b50d-59432dc50ee9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2b9f03ae-18f1-4de7-a3ac-11b263578cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4dc9540f-d303-4cdc-aa97-7c42527e6bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b9f03ae-18f1-4de7-a3ac-11b263578cb2" xlink:to="loc_us-gaap_AccountsPayableCurrent_4dc9540f-d303-4cdc-aa97-7c42527e6bf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_efbfafc7-ce3c-4874-a191-8228f9cd929d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b9f03ae-18f1-4de7-a3ac-11b263578cb2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_efbfafc7-ce3c-4874-a191-8228f9cd929d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_7fa78828-581f-4578-bdc3-981d7ee77dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b9f03ae-18f1-4de7-a3ac-11b263578cb2" xlink:to="loc_us-gaap_DeferredRevenueCurrent_7fa78828-581f-4578-bdc3-981d7ee77dcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_054af7a1-8166-4ce5-8113-733ee75069c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b9f03ae-18f1-4de7-a3ac-11b263578cb2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_054af7a1-8166-4ce5-8113-733ee75069c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1206681e-6ddf-4b3a-93d4-73e241159dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2b5ab28b-3036-4fed-8329-5e3218afee35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1206681e-6ddf-4b3a-93d4-73e241159dfc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2b5ab28b-3036-4fed-8329-5e3218afee35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b855c673-300e-4e21-b83d-0e6d23547674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1206681e-6ddf-4b3a-93d4-73e241159dfc" xlink:to="loc_us-gaap_AssetsCurrent_b855c673-300e-4e21-b83d-0e6d23547674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3a3717e9-713f-4a1f-95be-9239c0dbcca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1206681e-6ddf-4b3a-93d4-73e241159dfc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3a3717e9-713f-4a1f-95be-9239c0dbcca8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1968a4ae-60ef-42d4-bb6d-012f5a5992d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1206681e-6ddf-4b3a-93d4-73e241159dfc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1968a4ae-60ef-42d4-bb6d-012f5a5992d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2637c5aa-687e-4da7-abad-49dd32608fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_8ce44b1b-f1d8-4913-84b4-53bc1f14f0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2637c5aa-687e-4da7-abad-49dd32608fb4" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_8ce44b1b-f1d8-4913-84b4-53bc1f14f0a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9a305ab3-fb06-45c3-83d7-0ed978a9ffc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2637c5aa-687e-4da7-abad-49dd32608fb4" xlink:to="loc_us-gaap_InventoryNet_9a305ab3-fb06-45c3-83d7-0ed978a9ffc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_784689a7-6413-4a19-ac5d-00b37f0c063b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2637c5aa-687e-4da7-abad-49dd32608fb4" xlink:to="loc_us-gaap_Investments_784689a7-6413-4a19-ac5d-00b37f0c063b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1d934b32-5603-47b8-b180-34b6cb666452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2637c5aa-687e-4da7-abad-49dd32608fb4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1d934b32-5603-47b8-b180-34b6cb666452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_da2f0f14-380e-43a8-86c1-38d7a38d38e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2637c5aa-687e-4da7-abad-49dd32608fb4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_da2f0f14-380e-43a8-86c1-38d7a38d38e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_529b8c7a-9345-4e9d-afde-4816556d49a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_63d61076-927b-412f-a629-13860f98691e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_529b8c7a-9345-4e9d-afde-4816556d49a1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_63d61076-927b-412f-a629-13860f98691e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ad79d09d-ccdc-4c1b-b46d-57ac81777459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_529b8c7a-9345-4e9d-afde-4816556d49a1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ad79d09d-ccdc-4c1b-b46d-57ac81777459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5057f7cf-587f-4794-bcca-3a0d3c5820d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_529b8c7a-9345-4e9d-afde-4816556d49a1" xlink:to="loc_us-gaap_LiabilitiesCurrent_5057f7cf-587f-4794-bcca-3a0d3c5820d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_880ae0ae-0f5f-48ba-9bf3-1e387626aa87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_529b8c7a-9345-4e9d-afde-4816556d49a1" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_880ae0ae-0f5f-48ba-9bf3-1e387626aa87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fec31faa-613d-41e0-b365-78e49324a960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9af5624c-4855-4e35-a807-fd1ba4ad75e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fec31faa-613d-41e0-b365-78e49324a960" xlink:to="loc_us-gaap_CommonStockValue_9af5624c-4855-4e35-a807-fd1ba4ad75e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_67274f85-cc50-47bd-9637-21dc4143cb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fec31faa-613d-41e0-b365-78e49324a960" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_67274f85-cc50-47bd-9637-21dc4143cb59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5c102c83-edc9-4bc9-aa88-4596191d8a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fec31faa-613d-41e0-b365-78e49324a960" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5c102c83-edc9-4bc9-aa88-4596191d8a98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d6297869-229c-4e6c-9799-14ba6396f894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fec31faa-613d-41e0-b365-78e49324a960" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d6297869-229c-4e6c-9799-14ba6396f894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fec0b7ec-49be-42ef-a39f-f3f4fc625ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c14b7cd5-e504-4c56-b86c-b80d54f4ae51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fec0b7ec-49be-42ef-a39f-f3f4fc625ebe" xlink:to="loc_us-gaap_Liabilities_c14b7cd5-e504-4c56-b86c-b80d54f4ae51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_aad46587-176f-4b26-a376-9c3ae0e3801c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fec0b7ec-49be-42ef-a39f-f3f4fc625ebe" xlink:to="loc_us-gaap_StockholdersEquity_aad46587-176f-4b26-a376-9c3ae0e3801c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3334ac77-12a4-4405-affd-bcf922832e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d40e5f50-67dd-460e-8040-e3eb6e96c0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3334ac77-12a4-4405-affd-bcf922832e23" xlink:to="loc_us-gaap_OperatingIncomeLoss_d40e5f50-67dd-460e-8040-e3eb6e96c0ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1e377498-3bc6-4e12-87fa-9abe403cdf92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3334ac77-12a4-4405-affd-bcf922832e23" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1e377498-3bc6-4e12-87fa-9abe403cdf92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1ca896a7-c8a8-41bc-a24c-8b22d68d3d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_cc1aa767-ef2b-42cb-b024-0b9611688dde" xlink:href="mgnx-20221231.xsd#mgnx_CostOfManufacturingServices"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1ca896a7-c8a8-41bc-a24c-8b22d68d3d81" xlink:to="loc_mgnx_CostOfManufacturingServices_cc1aa767-ef2b-42cb-b024-0b9611688dde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3fde3ed4-75b1-4e9b-b83e-94e4870ae674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1ca896a7-c8a8-41bc-a24c-8b22d68d3d81" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3fde3ed4-75b1-4e9b-b83e-94e4870ae674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_75bd508f-3092-4932-9010-c55504c24a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1ca896a7-c8a8-41bc-a24c-8b22d68d3d81" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_75bd508f-3092-4932-9010-c55504c24a9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c6ba3b4a-551c-43f3-b23b-deb65200dcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1ca896a7-c8a8-41bc-a24c-8b22d68d3d81" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c6ba3b4a-551c-43f3-b23b-deb65200dcb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_63d0ef93-9e91-4af6-b3f4-61908a556d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_55a4477c-ff5a-408f-9af5-68eda045f7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_63d0ef93-9e91-4af6-b3f4-61908a556d99" xlink:to="loc_us-gaap_NetIncomeLoss_55a4477c-ff5a-408f-9af5-68eda045f7a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3ffe8751-0917-463a-862c-c18b5b077f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_63d0ef93-9e91-4af6-b3f4-61908a556d99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3ffe8751-0917-463a-862c-c18b5b077f9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0531febc-08d1-438f-8068-1d2d2a59b7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c1021783-3fb8-48de-bc90-d5102034324d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0531febc-08d1-438f-8068-1d2d2a59b7e9" xlink:to="loc_us-gaap_Revenues_c1021783-3fb8-48de-bc90-d5102034324d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_072ebe1a-ee9f-4d82-97a2-6e7a0140fe42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0531febc-08d1-438f-8068-1d2d2a59b7e9" xlink:to="loc_us-gaap_CostsAndExpenses_072ebe1a-ee9f-4d82-97a2-6e7a0140fe42" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd7123d0-0129-4db7-b3ed-fa35d2b6c680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b275e0ec-27bd-40d1-8ee3-451ea8e5aa49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd7123d0-0129-4db7-b3ed-fa35d2b6c680" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b275e0ec-27bd-40d1-8ee3-451ea8e5aa49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_bdb73187-c9f7-49c5-8a7a-32a4c5b7dee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd7123d0-0129-4db7-b3ed-fa35d2b6c680" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_bdb73187-c9f7-49c5-8a7a-32a4c5b7dee5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dc677a28-3d1d-4518-95e8-eb51b5609d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd7123d0-0129-4db7-b3ed-fa35d2b6c680" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dc677a28-3d1d-4518-95e8-eb51b5609d12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14c1d621-eacc-417b-930a-210e378e56ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_6ed3b992-9a95-4495-9eda-ff84241f16c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14c1d621-eacc-417b-930a-210e378e56ef" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_6ed3b992-9a95-4495-9eda-ff84241f16c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_400b4b39-c6da-48ea-82ef-9d3ed524b9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14c1d621-eacc-417b-930a-210e378e56ef" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_400b4b39-c6da-48ea-82ef-9d3ed524b9fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f8023deb-c868-4583-9a51-f2b1bff7fda1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14c1d621-eacc-417b-930a-210e378e56ef" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f8023deb-c868-4583-9a51-f2b1bff7fda1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5bb794e7-e8f6-40c0-b35a-9ad7ad5e2db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14c1d621-eacc-417b-930a-210e378e56ef" xlink:to="loc_us-gaap_ShareBasedCompensation_5bb794e7-e8f6-40c0-b35a-9ad7ad5e2db8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1e401a2e-45f0-4509-850d-e1b15bc696bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14c1d621-eacc-417b-930a-210e378e56ef" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1e401a2e-45f0-4509-850d-e1b15bc696bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4f7b24b9-4a82-47bf-9fa8-0310f566ccf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14c1d621-eacc-417b-930a-210e378e56ef" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4f7b24b9-4a82-47bf-9fa8-0310f566ccf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c8769d66-c75c-4bb7-ad45-e8626c18dde6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14c1d621-eacc-417b-930a-210e378e56ef" xlink:to="loc_us-gaap_NetIncomeLoss_c8769d66-c75c-4bb7-ad45-e8626c18dde6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_e91e710a-61c7-4d8e-b961-9c1c2b40785c" xlink:href="mgnx-20221231.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14c1d621-eacc-417b-930a-210e378e56ef" xlink:to="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_e91e710a-61c7-4d8e-b961-9c1c2b40785c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_f0fb0214-cb21-4b47-8428-2daa1c1bcf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14c1d621-eacc-417b-930a-210e378e56ef" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_f0fb0214-cb21-4b47-8428-2daa1c1bcf6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_efefdd20-fff7-425a-ae88-ec0b03e67e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14c1d621-eacc-417b-930a-210e378e56ef" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_efefdd20-fff7-425a-ae88-ec0b03e67e00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6c5cf440-0cd0-453c-aed4-a6e1da957ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14c1d621-eacc-417b-930a-210e378e56ef" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6c5cf440-0cd0-453c-aed4-a6e1da957ae9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e541d6b4-0d01-4bf8-b0c8-c0c9ab74edf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14c1d621-eacc-417b-930a-210e378e56ef" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e541d6b4-0d01-4bf8-b0c8-c0c9ab74edf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_e6a317e5-92cc-48b6-a87c-dd3ada5e72d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14c1d621-eacc-417b-930a-210e378e56ef" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_e6a317e5-92cc-48b6-a87c-dd3ada5e72d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_128c2cf1-8007-484f-b8fb-1445453bf894" xlink:href="mgnx-20221231.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14c1d621-eacc-417b-930a-210e378e56ef" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_128c2cf1-8007-484f-b8fb-1445453bf894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f20893cd-1e2e-4811-a37a-d15bc894af3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb1ff146-fdc2-4032-9288-fcc3124ee86c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f20893cd-1e2e-4811-a37a-d15bc894af3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb1ff146-fdc2-4032-9288-fcc3124ee86c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c91a3be9-ffa2-4516-bc7d-69ec4477fd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f20893cd-1e2e-4811-a37a-d15bc894af3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c91a3be9-ffa2-4516-bc7d-69ec4477fd0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6e1609ba-2306-4a63-ba2a-d7b29a3e1543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f20893cd-1e2e-4811-a37a-d15bc894af3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6e1609ba-2306-4a63-ba2a-d7b29a3e1543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d8cc171-2147-417d-a018-39e784d4dee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9967f538-59eb-4c03-918d-300e7927e2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d8cc171-2147-417d-a018-39e784d4dee7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9967f538-59eb-4c03-918d-300e7927e2b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_04b9ad42-f074-4b87-bc6c-e0a02cc0a214" xlink:href="mgnx-20221231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d8cc171-2147-417d-a018-39e784d4dee7" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_04b9ad42-f074-4b87-bc6c-e0a02cc0a214" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_736b6f08-23a8-4ac0-bb29-3893ab2dd449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_dc208c66-04c8-4d12-85d2-5de0d04dd328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_736b6f08-23a8-4ac0-bb29-3893ab2dd449" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_dc208c66-04c8-4d12-85d2-5de0d04dd328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f4dd7e6-a8c1-4ae9-8c8b-393c55ca8047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_736b6f08-23a8-4ac0-bb29-3893ab2dd449" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f4dd7e6-a8c1-4ae9-8c8b-393c55ca8047" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_365583ca-82b2-4ab3-9f92-c74ab3f35dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_58734509-2e14-4f54-a405-109bd1618bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_365583ca-82b2-4ab3-9f92-c74ab3f35dd6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_58734509-2e14-4f54-a405-109bd1618bdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1b5492be-eb0b-451c-86a7-947845dbc0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_365583ca-82b2-4ab3-9f92-c74ab3f35dd6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1b5492be-eb0b-451c-86a7-947845dbc0c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e8ebdfbe-8677-4de8-846c-fef27dff2f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_365583ca-82b2-4ab3-9f92-c74ab3f35dd6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e8ebdfbe-8677-4de8-846c-fef27dff2f0c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a63b0016-a6b7-4d81-9eaf-c306890e62c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e1bac534-820a-45d8-b561-8c5f9a980dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a63b0016-a6b7-4d81-9eaf-c306890e62c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e1bac534-820a-45d8-b561-8c5f9a980dd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c71ccf80-bade-4a61-a903-5bd94c8ee64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a63b0016-a6b7-4d81-9eaf-c306890e62c5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c71ccf80-bade-4a61-a903-5bd94c8ee64e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_3b8c35dc-5f1e-4e75-a450-b73e64c7a2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4b97c47c-06f0-4dae-b6d1-4c361a741c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_3b8c35dc-5f1e-4e75-a450-b73e64c7a2fd" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4b97c47c-06f0-4dae-b6d1-4c361a741c99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ed23d348-2dc2-44fe-a01a-625b277162ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_3b8c35dc-5f1e-4e75-a450-b73e64c7a2fd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ed23d348-2dc2-44fe-a01a-625b277162ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b8b0a1c5-ee0c-4142-a976-e3171c88e12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_a908264e-918b-4a08-92d5-da66e56c05c5" xlink:href="mgnx-20221231.xsd#mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b8b0a1c5-ee0c-4142-a976-e3171c88e12e" xlink:to="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_a908264e-918b-4a08-92d5-da66e56c05c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_1643aea8-004a-4c19-a7c9-a9f854d482e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b8b0a1c5-ee0c-4142-a976-e3171c88e12e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_1643aea8-004a-4c19-a7c9-a9f854d482e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a36250ec-a8ea-4a7a-8b87-60ad5e7d3091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_b8b0a1c5-ee0c-4142-a976-e3171c88e12e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a36250ec-a8ea-4a7a-8b87-60ad5e7d3091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8d525dc7-6712-4249-9ea7-5269644815a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_23185907-729f-4be5-8dc9-5b77c50051a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d525dc7-6712-4249-9ea7-5269644815a9" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_23185907-729f-4be5-8dc9-5b77c50051a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_3b1ccd62-d3f7-43b3-85a3-6c327c640308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d525dc7-6712-4249-9ea7-5269644815a9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_3b1ccd62-d3f7-43b3-85a3-6c327c640308" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_9b29e238-b297-4018-b6da-9dff54499711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d525dc7-6712-4249-9ea7-5269644815a9" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_9b29e238-b297-4018-b6da-9dff54499711" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_Section174DeferredTaxAsset_0d5e2d2d-15d6-40e8-a92f-9cca5de31683" xlink:href="mgnx-20221231.xsd#mgnx_Section174DeferredTaxAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d525dc7-6712-4249-9ea7-5269644815a9" xlink:to="loc_mgnx_Section174DeferredTaxAsset_0d5e2d2d-15d6-40e8-a92f-9cca5de31683" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_63d17a42-043d-4812-aa0b-acd724c17f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d525dc7-6712-4249-9ea7-5269644815a9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_63d17a42-043d-4812-aa0b-acd724c17f48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_34e04eae-fba1-491e-ae49-f3fc09588aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d525dc7-6712-4249-9ea7-5269644815a9" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_34e04eae-fba1-491e-ae49-f3fc09588aad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_66e2581a-7816-450f-b305-03e614f4ff09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d525dc7-6712-4249-9ea7-5269644815a9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_66e2581a-7816-450f-b305-03e614f4ff09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_d1c4d1bc-7a4a-4d22-a099-99c9b7a50238" xlink:href="mgnx-20221231.xsd#mgnx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d525dc7-6712-4249-9ea7-5269644815a9" xlink:to="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_d1c4d1bc-7a4a-4d22-a099-99c9b7a50238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c349ab2d-7c31-4aa3-84c2-480c7eb1e100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d525dc7-6712-4249-9ea7-5269644815a9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c349ab2d-7c31-4aa3-84c2-480c7eb1e100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b3ee1f30-2d20-4462-836f-c614cd38a7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_edc9b817-320c-46b8-9c30-28a55999a4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b3ee1f30-2d20-4462-836f-c614cd38a7d3" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_edc9b817-320c-46b8-9c30-28a55999a4d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b0d09ece-feea-46d5-855d-ce18f195a9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b3ee1f30-2d20-4462-836f-c614cd38a7d3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b0d09ece-feea-46d5-855d-ce18f195a9ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a5c6c52f-13c0-48ab-bf4d-f2aa0b0b88a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ccb4df25-300a-4420-860f-833bcb0871ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a5c6c52f-13c0-48ab-bf4d-f2aa0b0b88a1" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ccb4df25-300a-4420-860f-833bcb0871ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_15e4dc49-5078-47b0-bd4f-f3126b70aec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a5c6c52f-13c0-48ab-bf4d-f2aa0b0b88a1" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_15e4dc49-5078-47b0-bd4f-f3126b70aec4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_a3353fcd-67c6-47df-a27f-15aa450ea268" xlink:href="mgnx-20221231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a5c6c52f-13c0-48ab-bf4d-f2aa0b0b88a1" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_a3353fcd-67c6-47df-a27f-15aa450ea268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_e1f870c3-25ed-47ad-ad7f-013ae1da95e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a5c6c52f-13c0-48ab-bf4d-f2aa0b0b88a1" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_e1f870c3-25ed-47ad-ad7f-013ae1da95e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_f611baa3-7adb-48ed-95cc-460de389f1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a5c6c52f-13c0-48ab-bf4d-f2aa0b0b88a1" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_f611baa3-7adb-48ed-95cc-460de389f1f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_009cc141-4a39-46fc-9670-6ebe733b099c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a5c6c52f-13c0-48ab-bf4d-f2aa0b0b88a1" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_009cc141-4a39-46fc-9670-6ebe733b099c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_75e3e059-6c3c-47a1-ba7f-20e90b96ee26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a5c6c52f-13c0-48ab-bf4d-f2aa0b0b88a1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_75e3e059-6c3c-47a1-ba7f-20e90b96ee26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c663fa07-cd49-48ab-95ae-bffe7c5804a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a5c6c52f-13c0-48ab-bf4d-f2aa0b0b88a1" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c663fa07-cd49-48ab-95ae-bffe7c5804a5" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>mgnx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:49d3a843-ae73-49e6-9afb-5555c20651f7,g:f863eeaf-37fc-4bf3-b50d-59432dc50ee9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="ic26a3d143837423db94bd288a8aec5ac_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_14b14402-22ef-411f-a189-89047e591cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_RevenuesAbstract_14b14402-22ef-411f-a189-89047e591cbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_54c27c0e-4679-4452-a314-730ad83e4a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_14b14402-22ef-411f-a189-89047e591cbc" xlink:to="loc_us-gaap_Revenues_54c27c0e-4679-4452-a314-730ad83e4a05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_4d52d2d5-b5e9-44c0-bf8e-91bf60ec8e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_4d52d2d5-b5e9-44c0-bf8e-91bf60ec8e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_163c9245-73d4-46e1-8b7b-2d79c1ce1670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4d52d2d5-b5e9-44c0-bf8e-91bf60ec8e4e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_163c9245-73d4-46e1-8b7b-2d79c1ce1670" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_071fd1be-2110-4252-9f39-6f0889d9016f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4d52d2d5-b5e9-44c0-bf8e-91bf60ec8e4e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_071fd1be-2110-4252-9f39-6f0889d9016f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_36588033-0721-4526-b186-aba99eb51ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4d52d2d5-b5e9-44c0-bf8e-91bf60ec8e4e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_36588033-0721-4526-b186-aba99eb51ca2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cb78539c-b5d0-4a93-9644-c0f64235541c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4d52d2d5-b5e9-44c0-bf8e-91bf60ec8e4e" xlink:to="loc_us-gaap_CostsAndExpenses_cb78539c-b5d0-4a93-9644-c0f64235541c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_28dba03d-ec22-4ce1-b2f7-86edf218b63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_OperatingIncomeLoss_28dba03d-ec22-4ce1-b2f7-86edf218b63d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e59ee97d-2636-4c5b-a347-0f669ca489fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e59ee97d-2636-4c5b-a347-0f669ca489fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a41b78b3-f3b5-464b-bb5d-9abaa7fb3f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_NetIncomeLoss_a41b78b3-f3b5-464b-bb5d-9abaa7fb3f91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_00330f80-95c3-4353-b725-56651cb43cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_00330f80-95c3-4353-b725-56651cb43cd0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_97c0a941-85f5-456c-abd1-c64f70b8c419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_97c0a941-85f5-456c-abd1-c64f70b8c419" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5aed8bf0-fc5b-4c1e-8168-78092002d297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5aed8bf0-fc5b-4c1e-8168-78092002d297" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1cf4af28-a9c6-40df-8cbf-d595b0f8f90b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1cf4af28-a9c6-40df-8cbf-d595b0f8f90b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eb9109c3-19ce-440f-af66-241375355536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eb9109c3-19ce-440f-af66-241375355536" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_0ad1be1c-57e1-4ee1-93a3-083f8ea0dde9" xlink:href="mgnx-20221231.xsd#mgnx_CostOfManufacturingServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_mgnx_CostOfManufacturingServices_0ad1be1c-57e1-4ee1-93a3-083f8ea0dde9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4238255a-f9bb-4a3a-8ad7-6b6192c26119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_EarningsPerShareBasic_4238255a-f9bb-4a3a-8ad7-6b6192c26119" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_917b914e-3e5a-4a9f-9a15-d50187b6a01b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_EarningsPerShareDiluted_917b914e-3e5a-4a9f-9a15-d50187b6a01b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_843ce05a-6142-4502-b229-c5ffd0f4d6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_StatementTable_843ce05a-6142-4502-b229-c5ffd0f4d6b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_05c9b244-6196-4f71-8f86-255920503062" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_843ce05a-6142-4502-b229-c5ffd0f4d6b4" xlink:to="loc_srt_ProductOrServiceAxis_05c9b244-6196-4f71-8f86-255920503062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_05c9b244-6196-4f71-8f86-255920503062_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_05c9b244-6196-4f71-8f86-255920503062" xlink:to="loc_srt_ProductsAndServicesDomain_05c9b244-6196-4f71-8f86-255920503062_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_995ed69a-442d-445d-b41f-1c72297283e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_05c9b244-6196-4f71-8f86-255920503062" xlink:to="loc_srt_ProductsAndServicesDomain_995ed69a-442d-445d-b41f-1c72297283e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_aa8aaaeb-c8b8-4652-8450-2992586a0988" xlink:href="mgnx-20221231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_995ed69a-442d-445d-b41f-1c72297283e8" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_aa8aaaeb-c8b8-4652-8450-2992586a0988" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_c832bbaf-1755-4c72-af61-aed4e2bed32e" xlink:href="mgnx-20221231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_995ed69a-442d-445d-b41f-1c72297283e8" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_c832bbaf-1755-4c72-af61-aed4e2bed32e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_268b61be-08d8-490b-aef7-3c718e27fc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_995ed69a-442d-445d-b41f-1c72297283e8" xlink:to="loc_us-gaap_ProductMember_268b61be-08d8-490b-aef7-3c718e27fc0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractManufacturingMember_fe0106b0-359e-4d46-9075-ca7571aa5d7d" xlink:href="mgnx-20221231.xsd#mgnx_ContractManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_995ed69a-442d-445d-b41f-1c72297283e8" xlink:to="loc_mgnx_ContractManufacturingMember_fe0106b0-359e-4d46-9075-ca7571aa5d7d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i5e40e34507ef45cf810f7cbb82175434_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_4f613c9e-a877-42d6-a5c6-b7c7d2a14088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_SharesIssued_4f613c9e-a877-42d6-a5c6-b7c7d2a14088" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_de962672-1c27-44e7-8d34-07f3680b69b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_StockholdersEquity_de962672-1c27-44e7-8d34-07f3680b69b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_14aeb61e-f822-4bf3-b0be-1565274aa1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_14aeb61e-f822-4bf3-b0be-1565274aa1e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35358dc6-9c54-478b-a25e-9f2a038b4e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35358dc6-9c54-478b-a25e-9f2a038b4e11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_025be7a0-08c5-4ce9-b5d5-fa3f2786c26a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_025be7a0-08c5-4ce9-b5d5-fa3f2786c26a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_121e9d78-285c-4231-99ea-60faef2afaa3" xlink:href="mgnx-20221231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_121e9d78-285c-4231-99ea-60faef2afaa3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_e806c33a-f6fa-4786-9ede-35ea7054d177" xlink:href="mgnx-20221231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_e806c33a-f6fa-4786-9ede-35ea7054d177" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_8d3f5057-07ba-4e6c-b2a2-9a2b5d5d8a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_8d3f5057-07ba-4e6c-b2a2-9a2b5d5d8a6b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_18e38c34-1cb8-4486-b684-f15cbd916569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_NetIncomeLoss_18e38c34-1cb8-4486-b684-f15cbd916569" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ea9e13db-77d4-445b-8d4b-53bb0520a451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d09a5598-1c5b-4918-be40-76b75fd00539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8e0a4281-5574-4d15-a007-999a998ce21b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_StatementTable_8e0a4281-5574-4d15-a007-999a998ce21b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_22d3600b-d2fc-4baf-a14a-2864fb1e487b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8e0a4281-5574-4d15-a007-999a998ce21b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_22d3600b-d2fc-4baf-a14a-2864fb1e487b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_22d3600b-d2fc-4baf-a14a-2864fb1e487b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_22d3600b-d2fc-4baf-a14a-2864fb1e487b" xlink:to="loc_us-gaap_EquityComponentDomain_22d3600b-d2fc-4baf-a14a-2864fb1e487b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3b069c43-b7ad-4bbc-a600-5bde2b36692d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_22d3600b-d2fc-4baf-a14a-2864fb1e487b" xlink:to="loc_us-gaap_EquityComponentDomain_3b069c43-b7ad-4bbc-a600-5bde2b36692d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1c27c607-a466-4dd3-9cd2-6b4d2ffc4714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b069c43-b7ad-4bbc-a600-5bde2b36692d" xlink:to="loc_us-gaap_CommonStockMember_1c27c607-a466-4dd3-9cd2-6b4d2ffc4714" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f4312f68-6a24-4c6e-aa9c-a11ed8b4a72a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b069c43-b7ad-4bbc-a600-5bde2b36692d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f4312f68-6a24-4c6e-aa9c-a11ed8b4a72a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_59bb35c2-970a-43d8-8248-6267b59da87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b069c43-b7ad-4bbc-a600-5bde2b36692d" xlink:to="loc_us-gaap_RetainedEarningsMember_59bb35c2-970a-43d8-8248-6267b59da87c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a6cd2ef3-61f5-42b9-af2f-e1d437131581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b069c43-b7ad-4bbc-a600-5bde2b36692d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a6cd2ef3-61f5-42b9-af2f-e1d437131581" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended" id="i953549e0da1d4b78abde37f0583b73e8_SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c275092-2c23-48eb-a9ea-8b6e0938c8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_451a5b5e-7b79-4cd6-a099-85fc5111d152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c275092-2c23-48eb-a9ea-8b6e0938c8d9" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_451a5b5e-7b79-4cd6-a099-85fc5111d152" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a8ed4f62-a89f-4ff4-903f-5cde2c45e772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_451a5b5e-7b79-4cd6-a099-85fc5111d152" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a8ed4f62-a89f-4ff4-903f-5cde2c45e772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4625fd84-087d-443b-9e70-f9eb5e389b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_451a5b5e-7b79-4cd6-a099-85fc5111d152" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4625fd84-087d-443b-9e70-f9eb5e389b5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9123b6b8-214a-4411-9f3d-43f809b09654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_451a5b5e-7b79-4cd6-a099-85fc5111d152" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9123b6b8-214a-4411-9f3d-43f809b09654" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_cf1ad3c3-2808-49a7-b2c2-726244cea5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c275092-2c23-48eb-a9ea-8b6e0938c8d9" xlink:to="loc_us-gaap_Investments_cf1ad3c3-2808-49a7-b2c2-726244cea5ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f06f26b-dd53-402d-8383-17daa9a27cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c275092-2c23-48eb-a9ea-8b6e0938c8d9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f06f26b-dd53-402d-8383-17daa9a27cb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4b979b4e-634c-4929-aa90-06060128fc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f06f26b-dd53-402d-8383-17daa9a27cb0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4b979b4e-634c-4929-aa90-06060128fc9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4b979b4e-634c-4929-aa90-06060128fc9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4b979b4e-634c-4929-aa90-06060128fc9d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4b979b4e-634c-4929-aa90-06060128fc9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bdccdbdd-ed4f-4a1c-a067-b145a51024c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4b979b4e-634c-4929-aa90-06060128fc9d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bdccdbdd-ed4f-4a1c-a067-b145a51024c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_763ed819-1955-4559-a830-3b29e38222ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bdccdbdd-ed4f-4a1c-a067-b145a51024c9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_763ed819-1955-4559-a830-3b29e38222ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_df9201e4-5d46-459c-85df-9a1a514386e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bdccdbdd-ed4f-4a1c-a067-b145a51024c9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_df9201e4-5d46-459c-85df-9a1a514386e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1ea3b1cb-4ae6-4373-aff7-bc78bf87b790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f06f26b-dd53-402d-8383-17daa9a27cb0" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1ea3b1cb-4ae6-4373-aff7-bc78bf87b790" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ea3b1cb-4ae6-4373-aff7-bc78bf87b790_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1ea3b1cb-4ae6-4373-aff7-bc78bf87b790" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1ea3b1cb-4ae6-4373-aff7-bc78bf87b790_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a405a092-6b45-4198-9e70-f4ffaf44725c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1ea3b1cb-4ae6-4373-aff7-bc78bf87b790" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a405a092-6b45-4198-9e70-f4ffaf44725c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_f0cd2d5e-6845-4ab6-bc9a-affcf9af6262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a405a092-6b45-4198-9e70-f4ffaf44725c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_f0cd2d5e-6845-4ab6-bc9a-affcf9af6262" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0b831f01-58ff-4380-a2d5-407a7e4eab40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a405a092-6b45-4198-9e70-f4ffaf44725c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0b831f01-58ff-4380-a2d5-407a7e4eab40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_a67203d2-067a-4535-8617-04ee82c4773f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a405a092-6b45-4198-9e70-f4ffaf44725c" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_a67203d2-067a-4535-8617-04ee82c4773f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ecc292cf-20d7-4c6b-a53a-7eef66abcf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a405a092-6b45-4198-9e70-f4ffaf44725c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ecc292cf-20d7-4c6b-a53a-7eef66abcf7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e69aecff-54f8-4b9e-a426-b921219c5eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f06f26b-dd53-402d-8383-17daa9a27cb0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e69aecff-54f8-4b9e-a426-b921219c5eea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e69aecff-54f8-4b9e-a426-b921219c5eea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e69aecff-54f8-4b9e-a426-b921219c5eea" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e69aecff-54f8-4b9e-a426-b921219c5eea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_849780a1-e60e-4cba-a9cf-e0bd8b952754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e69aecff-54f8-4b9e-a426-b921219c5eea" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_849780a1-e60e-4cba-a9cf-e0bd8b952754" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8763a91e-7ffc-4510-b853-2e552dfcfed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_849780a1-e60e-4cba-a9cf-e0bd8b952754" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8763a91e-7ffc-4510-b853-2e552dfcfed3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="extended" id="i944224d1f1dc4b5dacf66387312528aa_SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_cce55c49-5df5-4e06-b926-9a6472e775c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7c416020-743e-4189-ab32-99b347419aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_cce55c49-5df5-4e06-b926-9a6472e775c0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7c416020-743e-4189-ab32-99b347419aa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_e928b8e0-9a9b-4d0b-8391-550b6679e97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_cce55c49-5df5-4e06-b926-9a6472e775c0" xlink:to="loc_us-gaap_ConcentrationRiskTable_e928b8e0-9a9b-4d0b-8391-550b6679e97e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c37a21c4-5685-467d-9b52-13d41c5a7129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e928b8e0-9a9b-4d0b-8391-550b6679e97e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c37a21c4-5685-467d-9b52-13d41c5a7129" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c37a21c4-5685-467d-9b52-13d41c5a7129_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c37a21c4-5685-467d-9b52-13d41c5a7129" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c37a21c4-5685-467d-9b52-13d41c5a7129_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4b480a2f-4e31-4665-9c44-ca1457743fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c37a21c4-5685-467d-9b52-13d41c5a7129" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4b480a2f-4e31-4665-9c44-ca1457743fdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_22898f82-0c4f-410b-a1ba-d2c4154ebc17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4b480a2f-4e31-4665-9c44-ca1457743fdd" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_22898f82-0c4f-410b-a1ba-d2c4154ebc17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f899ba13-0f12-49b9-97f4-068c5dfe1ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e928b8e0-9a9b-4d0b-8391-550b6679e97e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f899ba13-0f12-49b9-97f4-068c5dfe1ba1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f899ba13-0f12-49b9-97f4-068c5dfe1ba1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f899ba13-0f12-49b9-97f4-068c5dfe1ba1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f899ba13-0f12-49b9-97f4-068c5dfe1ba1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5a499531-4cc4-4644-b895-4bea898b933a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f899ba13-0f12-49b9-97f4-068c5dfe1ba1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5a499531-4cc4-4644-b895-4bea898b933a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_0d7f4e79-3f92-4502-8011-c40be7d24864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5a499531-4cc4-4644-b895-4bea898b933a" xlink:to="loc_us-gaap_SalesRevenueNetMember_0d7f4e79-3f92-4502-8011-c40be7d24864" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_df558d06-4493-482c-9c19-3beabbb2a29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5a499531-4cc4-4644-b895-4bea898b933a" xlink:to="loc_us-gaap_AccountsReceivableMember_df558d06-4493-482c-9c19-3beabbb2a29f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6d228b34-4456-4067-a40a-2ce548a7c5b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e928b8e0-9a9b-4d0b-8391-550b6679e97e" xlink:to="loc_srt_MajorCustomersAxis_6d228b34-4456-4067-a40a-2ce548a7c5b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6d228b34-4456-4067-a40a-2ce548a7c5b8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6d228b34-4456-4067-a40a-2ce548a7c5b8" xlink:to="loc_srt_NameOfMajorCustomerDomain_6d228b34-4456-4067-a40a-2ce548a7c5b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6d228b34-4456-4067-a40a-2ce548a7c5b8" xlink:to="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_d6f41b24-e4d0-4b1c-a3d3-a560df75908f" xlink:href="mgnx-20221231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_IncyteCorporationMember_d6f41b24-e4d0-4b1c-a3d3-a560df75908f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_d2dd3c34-3908-46ed-9218-3fe2d6fc0016" xlink:href="mgnx-20221231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_JanssenBiotechIncMember_d2dd3c34-3908-46ed-9218-3fe2d6fc0016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember_caa21e70-150b-45df-a47c-e3aa78e49fa0" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_ZaiLabLimitedMember_caa21e70-150b-45df-a47c-e3aa78e49fa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_1dce2900-9453-4ef1-8253-ed7aa4c3fd05" xlink:href="mgnx-20221231.xsd#mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_1dce2900-9453-4ef1-8253-ed7aa4c3fd05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_24b6e249-51e7-455c-8a78-c3f97785a092" xlink:href="mgnx-20221231.xsd#mgnx_IMabBiopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_IMabBiopharmaMember_24b6e249-51e7-455c-8a78-c3f97785a092" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_471b54b8-ddfc-48f7-88bd-9f1c840f3e48" xlink:href="mgnx-20221231.xsd#mgnx_ProventionBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_ProventionBioMember_471b54b8-ddfc-48f7-88bd-9f1c840f3e48" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_5bd48e18-19ed-45ef-b10b-a642f3bfef0d" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_ZaiLabMember_5bd48e18-19ed-45ef-b10b-a642f3bfef0d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ImabMember_23dd2e84-f458-4642-b736-087284c430e5" xlink:href="mgnx-20221231.xsd#mgnx_ImabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_ImabMember_23dd2e84-f458-4642-b736-087284c430e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_c851b8a2-31fa-4b88-bce6-ec7b2ada3d2f" xlink:href="mgnx-20221231.xsd#mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_c851b8a2-31fa-4b88-bce6-ec7b2ada3d2f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ASDHealthcareAndOncologySupplyMember_34c2e23d-4693-4998-9203-4917ecbb163f" xlink:href="mgnx-20221231.xsd#mgnx_ASDHealthcareAndOncologySupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_ASDHealthcareAndOncologySupplyMember_34c2e23d-4693-4998-9203-4917ecbb163f" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended" id="ie2a904e5db3e475e8eb25693a4f8224e_SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81f2975e-23e4-480a-b9d5-fd7afa8ba86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_85ba2a03-5e57-45d6-851d-f575b0893583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81f2975e-23e4-480a-b9d5-fd7afa8ba86e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_85ba2a03-5e57-45d6-851d-f575b0893583" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_458f4434-0753-4856-974e-dbc962b41ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81f2975e-23e4-480a-b9d5-fd7afa8ba86e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_458f4434-0753-4856-974e-dbc962b41ff6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d14c853-cc79-4203-ade9-0a0123050ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_458f4434-0753-4856-974e-dbc962b41ff6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d14c853-cc79-4203-ade9-0a0123050ebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d14c853-cc79-4203-ade9-0a0123050ebc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d14c853-cc79-4203-ade9-0a0123050ebc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d14c853-cc79-4203-ade9-0a0123050ebc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b7e37d2-4e5c-477e-b7ec-d3b9ee8fc631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d14c853-cc79-4203-ade9-0a0123050ebc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b7e37d2-4e5c-477e-b7ec-d3b9ee8fc631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_8ee2802f-4f6e-4176-96e8-47da22d263ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b7e37d2-4e5c-477e-b7ec-d3b9ee8fc631" xlink:to="loc_us-gaap_ComputerEquipmentMember_8ee2802f-4f6e-4176-96e8-47da22d263ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e6d91eef-db4e-4949-89cd-24b8ccc3f2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b7e37d2-4e5c-477e-b7ec-d3b9ee8fc631" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e6d91eef-db4e-4949-89cd-24b8ccc3f2d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1700812b-e2db-4171-a691-2d01a84301ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b7e37d2-4e5c-477e-b7ec-d3b9ee8fc631" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1700812b-e2db-4171-a691-2d01a84301ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_51f71bab-84cc-4721-8e4b-78fc5599fdcf" xlink:href="mgnx-20221231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b7e37d2-4e5c-477e-b7ec-d3b9ee8fc631" xlink:to="loc_mgnx_LaboratoryAndOfficeEquipmentMember_51f71bab-84cc-4721-8e4b-78fc5599fdcf" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="extended" id="i996e62776c3941b696dba61cb320f5ea_SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a051df5d-da37-480d-b646-083f78367883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e93bfa69-5594-4755-aad0-bbb6e49bebee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a051df5d-da37-480d-b646-083f78367883" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e93bfa69-5594-4755-aad0-bbb6e49bebee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6b9b77b4-ab9c-4f6b-a742-51283d8321d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a051df5d-da37-480d-b646-083f78367883" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6b9b77b4-ab9c-4f6b-a742-51283d8321d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7afb000e-f101-456e-922a-1883f44d2ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6b9b77b4-ab9c-4f6b-a742-51283d8321d2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7afb000e-f101-456e-922a-1883f44d2ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7afb000e-f101-456e-922a-1883f44d2ef6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7afb000e-f101-456e-922a-1883f44d2ef6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7afb000e-f101-456e-922a-1883f44d2ef6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e06bc4a-db7c-4986-b280-d472b63132a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7afb000e-f101-456e-922a-1883f44d2ef6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e06bc4a-db7c-4986-b280-d472b63132a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_6216b00f-8501-4e35-9942-31cf33ef20b7" xlink:href="mgnx-20221231.xsd#mgnx_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e06bc4a-db7c-4986-b280-d472b63132a7" xlink:to="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_6216b00f-8501-4e35-9942-31cf33ef20b7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="ic8b8bc8ccd734ac19b5eb58982ee651f_MarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bc63600-05c6-494f-8229-4ed18c11489b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f3a666bf-500d-4e72-a2cc-b38dce3290e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bc63600-05c6-494f-8229-4ed18c11489b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f3a666bf-500d-4e72-a2cc-b38dce3290e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cd3fe975-f9f3-4056-89b9-c91f6441c016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bc63600-05c6-494f-8229-4ed18c11489b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cd3fe975-f9f3-4056-89b9-c91f6441c016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_770fd335-6d21-4d07-a1b7-205355f33287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bc63600-05c6-494f-8229-4ed18c11489b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_770fd335-6d21-4d07-a1b7-205355f33287" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cbaf2727-a3f4-4bb5-9f14-7978aecd0359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bc63600-05c6-494f-8229-4ed18c11489b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cbaf2727-a3f4-4bb5-9f14-7978aecd0359" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_43f3baf1-ad01-4348-ab46-507dbed0a95d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bc63600-05c6-494f-8229-4ed18c11489b" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_43f3baf1-ad01-4348-ab46-507dbed0a95d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_187a9996-13c8-46d4-9206-817fc97a12b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_43f3baf1-ad01-4348-ab46-507dbed0a95d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_187a9996-13c8-46d4-9206-817fc97a12b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_187a9996-13c8-46d4-9206-817fc97a12b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_187a9996-13c8-46d4-9206-817fc97a12b7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_187a9996-13c8-46d4-9206-817fc97a12b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ddc96fce-be88-48b9-8e57-0d2d8d216287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_187a9996-13c8-46d4-9206-817fc97a12b7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ddc96fce-be88-48b9-8e57-0d2d8d216287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b74bf86a-058b-447d-aae7-a90082979c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ddc96fce-be88-48b9-8e57-0d2d8d216287" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b74bf86a-058b-447d-aae7-a90082979c05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2d73be51-87df-49da-aabc-0b97d71f290d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ddc96fce-be88-48b9-8e57-0d2d8d216287" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2d73be51-87df-49da-aabc-0b97d71f290d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_df8d8d50-c702-4373-96bf-c77658a57946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ddc96fce-be88-48b9-8e57-0d2d8d216287" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_df8d8d50-c702-4373-96bf-c77658a57946" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#InventoryNetDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/InventoryNetDetails" xlink:type="extended" id="i2ea46630f01e41fd8516ad966787ff1b_InventoryNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_01cf81a2-0e6d-41c6-a849-96b2400ee0ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c4647354-8433-4ab7-84a3-1ef1bb359247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_01cf81a2-0e6d-41c6-a849-96b2400ee0ce" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_c4647354-8433-4ab7-84a3-1ef1bb359247" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_768da552-0578-4690-9dc9-66dff191f04b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_01cf81a2-0e6d-41c6-a849-96b2400ee0ce" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_768da552-0578-4690-9dc9-66dff191f04b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_6e4c20a8-4248-4c43-ba06-8d56382426a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_01cf81a2-0e6d-41c6-a849-96b2400ee0ce" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_6e4c20a8-4248-4c43-ba06-8d56382426a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c48815b0-2add-4eb3-a7fb-2be516de2f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_3a0a4dc3-ed93-487b-8e6d-70ee87e6090b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_01cf81a2-0e6d-41c6-a849-96b2400ee0ce" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_3a0a4dc3-ed93-487b-8e6d-70ee87e6090b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c5ad22e1-11b1-4f40-aaf6-4b35cee67534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_3a0a4dc3-ed93-487b-8e6d-70ee87e6090b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c5ad22e1-11b1-4f40-aaf6-4b35cee67534" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_c5ad22e1-11b1-4f40-aaf6-4b35cee67534_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c5ad22e1-11b1-4f40-aaf6-4b35cee67534" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_c5ad22e1-11b1-4f40-aaf6-4b35cee67534_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_d87bef20-04dd-4e1b-924e-3c470424202b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c5ad22e1-11b1-4f40-aaf6-4b35cee67534" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_d87bef20-04dd-4e1b-924e-3c470424202b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserveMember_7aecb412-fa58-4a6f-8a3f-cc1908a0b81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d87bef20-04dd-4e1b-924e-3c470424202b" xlink:to="loc_us-gaap_InventoryValuationReserveMember_7aecb412-fa58-4a6f-8a3f-cc1908a0b81e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended" id="icf4e1cf37fdb4e468f56142defb965aa_PropertyEquipmentandSoftwareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_57e20558-01c9-41d8-81d5-b4574306f0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0e7df9d5-be9e-44be-b9fd-28a54342fc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_57e20558-01c9-41d8-81d5-b4574306f0c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0e7df9d5-be9e-44be-b9fd-28a54342fc83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_6d35008d-9a5e-41d8-beb1-78b9bb0f5149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_57e20558-01c9-41d8-81d5-b4574306f0c4" xlink:to="loc_us-gaap_ConstructionInProgressGross_6d35008d-9a5e-41d8-beb1-78b9bb0f5149" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b3550af8-45b3-4e7d-8744-eaec8fdba010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_57e20558-01c9-41d8-81d5-b4574306f0c4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b3550af8-45b3-4e7d-8744-eaec8fdba010" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d786b38a-466b-4918-b1d3-70a8f491c24f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_57e20558-01c9-41d8-81d5-b4574306f0c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d786b38a-466b-4918-b1d3-70a8f491c24f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_96857baa-6969-4c23-8b39-2feb4d0f98f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_57e20558-01c9-41d8-81d5-b4574306f0c4" xlink:to="loc_us-gaap_Depreciation_96857baa-6969-4c23-8b39-2feb4d0f98f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_890f4234-8c01-4bb1-b91f-cec7929a743b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_57e20558-01c9-41d8-81d5-b4574306f0c4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_890f4234-8c01-4bb1-b91f-cec7929a743b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce68b2a5-d2f7-44e1-8fb3-89b3039975fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_890f4234-8c01-4bb1-b91f-cec7929a743b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce68b2a5-d2f7-44e1-8fb3-89b3039975fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce68b2a5-d2f7-44e1-8fb3-89b3039975fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce68b2a5-d2f7-44e1-8fb3-89b3039975fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce68b2a5-d2f7-44e1-8fb3-89b3039975fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ebbd7ac-1d83-4009-a163-76e13e749d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce68b2a5-d2f7-44e1-8fb3-89b3039975fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ebbd7ac-1d83-4009-a163-76e13e749d51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_fb9981e1-6e84-4187-85b3-4ce7561c76a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ebbd7ac-1d83-4009-a163-76e13e749d51" xlink:to="loc_us-gaap_ComputerEquipmentMember_fb9981e1-6e84-4187-85b3-4ce7561c76a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_4e77aaf0-0c71-4e1b-b028-f2eae84d9953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ebbd7ac-1d83-4009-a163-76e13e749d51" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_4e77aaf0-0c71-4e1b-b028-f2eae84d9953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_d3636d31-5be6-40b7-896b-962f07058148" xlink:href="mgnx-20221231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ebbd7ac-1d83-4009-a163-76e13e749d51" xlink:to="loc_mgnx_FurnitureAndOfficeEquipmentMember_d3636d31-5be6-40b7-896b-962f07058148" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_9130979e-3336-4634-adec-321a57c82350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ebbd7ac-1d83-4009-a163-76e13e749d51" xlink:to="loc_us-gaap_VehiclesMember_9130979e-3336-4634-adec-321a57c82350" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_8a0a0ce6-7919-4e81-ac95-15c1c0414514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ebbd7ac-1d83-4009-a163-76e13e749d51" xlink:to="loc_us-gaap_EquipmentMember_8a0a0ce6-7919-4e81-ac95-15c1c0414514" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_74bf80d9-462f-409e-ba75-48761d438d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ebbd7ac-1d83-4009-a163-76e13e749d51" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_74bf80d9-462f-409e-ba75-48761d438d4d" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i40ba9f87f3484a6b9c00e796d67fffc0_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_13df9dda-aaf4-4084-bde0-b0aff86074ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_13df9dda-aaf4-4084-bde0-b0aff86074ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_4c9a48d0-7595-493d-90e7-2a23c5132ed8" xlink:href="mgnx-20221231.xsd#mgnx_RightOfUseAssetAndLeaseLiabilityIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_4c9a48d0-7595-493d-90e7-2a23c5132ed8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_65eef1ac-87d7-4301-aeb8-ded330e3e386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_OperatingLeasePayments_65eef1ac-87d7-4301-aeb8-ded330e3e386" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fb4a9b55-0dc8-4c86-b783-49e6073462d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fb4a9b55-0dc8-4c86-b783-49e6073462d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ac6144f5-9354-4ebf-90cc-e68e04bae1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_OperatingLeaseCost_ac6144f5-9354-4ebf-90cc-e68e04bae1f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_9ac5cd95-619e-4e3f-af40-862c159ffe12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_VariableLeaseCost_9ac5cd95-619e-4e3f-af40-862c159ffe12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_00bdecbe-3384-4532-a403-a29ce1acc09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_SubleaseIncome_00bdecbe-3384-4532-a403-a29ce1acc09a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_45278c9c-35f8-4444-b71a-64dc0a457b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LeaseCost_45278c9c-35f8-4444-b71a-64dc0a457b33" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_63e78a98-73f5-4fb0-bb8d-3aebc06da1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_63e78a98-73f5-4fb0-bb8d-3aebc06da1db" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_889a1ac6-796d-49fb-b5f4-de113be55fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_889a1ac6-796d-49fb-b5f4-de113be55fb3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1caf635b-7542-46ca-98d9-aabce3714282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1caf635b-7542-46ca-98d9-aabce3714282" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b18715ab-e3bf-49a2-860f-54705b0e3e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b18715ab-e3bf-49a2-860f-54705b0e3e9a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_123d6031-8539-4f93-90e5-6e095c3fe09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_123d6031-8539-4f93-90e5-6e095c3fe09b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0a86e1f4-86c9-4090-852c-3e31bc3dc205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0a86e1f4-86c9-4090-852c-3e31bc3dc205" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f4cc3cf0-b45b-4d3c-bdec-f146c79808c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f4cc3cf0-b45b-4d3c-bdec-f146c79808c9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2335ee45-b059-422f-845f-a589a6e33c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2335ee45-b059-422f-845f-a589a6e33c44" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f70892ee-d403-4526-9025-f2850ea77c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_OperatingLeaseLiability_f70892ee-d403-4526-9025-f2850ea77c33" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_fa792e7a-9f2f-4bfb-81e5-1f3b6ccf1192" xlink:href="mgnx-20221231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_fa792e7a-9f2f-4bfb-81e5-1f3b6ccf1192" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_50dfde26-504a-4b26-b15f-fc8d4ab6333c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_50dfde26-504a-4b26-b15f-fc8d4ab6333c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_a82dfee6-ccb6-44b6-bf8a-a2546caf0e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_a82dfee6-ccb6-44b6-bf8a-a2546caf0e31" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d02fe9a2-8595-4314-ad18-52b7b3f2fa90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d02fe9a2-8595-4314-ad18-52b7b3f2fa90" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a15defe5-c205-4337-a725-ac0e698705d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a15defe5-c205-4337-a725-ac0e698705d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_22b1dec2-3768-4abe-a507-22573ba406f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a15defe5-c205-4337-a725-ac0e698705d2" xlink:to="loc_srt_CounterpartyNameAxis_22b1dec2-3768-4abe-a507-22573ba406f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22b1dec2-3768-4abe-a507-22573ba406f3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_22b1dec2-3768-4abe-a507-22573ba406f3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22b1dec2-3768-4abe-a507-22573ba406f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcfdb92f-6027-4ded-8c1d-30f7e462b6f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_22b1dec2-3768-4abe-a507-22573ba406f3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcfdb92f-6027-4ded-8c1d-30f7e462b6f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_SynaffixBVMember_9c1b8f12-9a63-47e6-9a48-9d373459f937" xlink:href="mgnx-20221231.xsd#mgnx_SynaffixBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcfdb92f-6027-4ded-8c1d-30f7e462b6f5" xlink:to="loc_mgnx_SynaffixBVMember_9c1b8f12-9a63-47e6-9a48-9d373459f937" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f2ac3fa5-c8c7-4020-a51e-0650ba46e441" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a15defe5-c205-4337-a725-ac0e698705d2" xlink:to="loc_srt_RangeAxis_f2ac3fa5-c8c7-4020-a51e-0650ba46e441" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f2ac3fa5-c8c7-4020-a51e-0650ba46e441_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f2ac3fa5-c8c7-4020-a51e-0650ba46e441" xlink:to="loc_srt_RangeMember_f2ac3fa5-c8c7-4020-a51e-0650ba46e441_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2a14c818-cf41-494f-abc4-f16a8f2e9994" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f2ac3fa5-c8c7-4020-a51e-0650ba46e441" xlink:to="loc_srt_RangeMember_2a14c818-cf41-494f-abc4-f16a8f2e9994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_14bd6a47-8e9b-4d4b-844a-e8a2d82d3d39" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2a14c818-cf41-494f-abc4-f16a8f2e9994" xlink:to="loc_srt_MinimumMember_14bd6a47-8e9b-4d4b-844a-e8a2d82d3d39" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended" id="ia70790af592e4d34914e6fed61d37ee2_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_05aacdda-f26d-412a-9e21-ced8cf0637f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_05aacdda-f26d-412a-9e21-ced8cf0637f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_11100eab-0c1c-450c-b253-67f7ee3f204c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_11100eab-0c1c-450c-b253-67f7ee3f204c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7d6ea728-70d1-4b15-8386-9c519a908135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7d6ea728-70d1-4b15-8386-9c519a908135" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f436e2d2-f08d-419e-aa69-d6ab4842ae80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f436e2d2-f08d-419e-aa69-d6ab4842ae80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_615264db-a88a-4317-af6c-efa1e6c02321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_615264db-a88a-4317-af6c-efa1e6c02321" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_23684cd8-a95c-476d-9979-f7df250af22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_23684cd8-a95c-476d-9979-f7df250af22a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c53626ec-1623-40ac-955f-208be72dd8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c53626ec-1623-40ac-955f-208be72dd8e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_996994c5-a95c-4e3c-beb4-2321a0ddc4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4843c38f-f3bb-4055-9613-95bed2280290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4843c38f-f3bb-4055-9613-95bed2280290" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_97eb7896-3f11-4f0b-ac04-0490c2c7a024" xlink:href="mgnx-20221231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_97eb7896-3f11-4f0b-ac04-0490c2c7a024" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_338e2d4e-799f-46aa-9ac2-c097ef467dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_338e2d4e-799f-46aa-9ac2-c097ef467dbe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_24cbad53-cd5f-42eb-8803-0d2cd2f12e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_24cbad53-cd5f-42eb-8803-0d2cd2f12e3b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0ea82060-e10e-4c70-9ada-d3bff2ce5bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0ea82060-e10e-4c70-9ada-d3bff2ce5bdb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_21066b22-ae4b-4129-8f5d-1a0fc8860367" xlink:href="mgnx-20221231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_21066b22-ae4b-4129-8f5d-1a0fc8860367" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_77c4a472-3648-4266-b57b-32b7cb5a1728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_77c4a472-3648-4266-b57b-32b7cb5a1728" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_217587f7-8b85-4d9f-80e9-b37f45d96e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c4a472-3648-4266-b57b-32b7cb5a1728" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_217587f7-8b85-4d9f-80e9-b37f45d96e80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_217587f7-8b85-4d9f-80e9-b37f45d96e80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_217587f7-8b85-4d9f-80e9-b37f45d96e80" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_217587f7-8b85-4d9f-80e9-b37f45d96e80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64a29245-99e8-4483-97bf-66e1864d47a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_217587f7-8b85-4d9f-80e9-b37f45d96e80" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64a29245-99e8-4483-97bf-66e1864d47a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_42239c9d-effa-43d8-b5a7-782263c819b8" xlink:href="mgnx-20221231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64a29245-99e8-4483-97bf-66e1864d47a1" xlink:to="loc_mgnx_AtTheMarketOfferingMember_42239c9d-effa-43d8-b5a7-782263c819b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_47fb8219-c16d-4715-b339-d7eeafa4b643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c4a472-3648-4266-b57b-32b7cb5a1728" xlink:to="loc_us-gaap_StatementClassOfStockAxis_47fb8219-c16d-4715-b339-d7eeafa4b643" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_47fb8219-c16d-4715-b339-d7eeafa4b643_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_47fb8219-c16d-4715-b339-d7eeafa4b643" xlink:to="loc_us-gaap_ClassOfStockDomain_47fb8219-c16d-4715-b339-d7eeafa4b643_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d76f9110-bef5-4b78-b953-088241c22ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_47fb8219-c16d-4715-b339-d7eeafa4b643" xlink:to="loc_us-gaap_ClassOfStockDomain_d76f9110-bef5-4b78-b953-088241c22ebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_d9095ad4-544a-465c-aede-7d84e1de6362" xlink:href="mgnx-20221231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d76f9110-bef5-4b78-b953-088241c22ebc" xlink:to="loc_mgnx_UndesignatedPreferredStockMember_d9095ad4-544a-465c-aede-7d84e1de6362" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6414497d-ef3e-444a-baf2-760004437abe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c4a472-3648-4266-b57b-32b7cb5a1728" xlink:to="loc_srt_CounterpartyNameAxis_6414497d-ef3e-444a-baf2-760004437abe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6414497d-ef3e-444a-baf2-760004437abe_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6414497d-ef3e-444a-baf2-760004437abe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6414497d-ef3e-444a-baf2-760004437abe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1038347c-e225-48d8-877f-24642f4251e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6414497d-ef3e-444a-baf2-760004437abe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1038347c-e225-48d8-877f-24642f4251e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_db2b0c7e-972e-4336-b106-4de071823da1" xlink:href="mgnx-20221231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1038347c-e225-48d8-877f-24642f4251e8" xlink:to="loc_mgnx_IncyteCorporationMember_db2b0c7e-972e-4336-b106-4de071823da1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_39462cf3-4dd2-44fc-9a4c-82cbb9b93236" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1038347c-e225-48d8-877f-24642f4251e8" xlink:to="loc_mgnx_ZaiLabMember_39462cf3-4dd2-44fc-9a4c-82cbb9b93236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba766a4f-52d0-4927-8a41-64e2f23de36a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c4a472-3648-4266-b57b-32b7cb5a1728" xlink:to="loc_srt_RangeAxis_ba766a4f-52d0-4927-8a41-64e2f23de36a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba766a4f-52d0-4927-8a41-64e2f23de36a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ba766a4f-52d0-4927-8a41-64e2f23de36a" xlink:to="loc_srt_RangeMember_ba766a4f-52d0-4927-8a41-64e2f23de36a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_42421b52-ed10-46af-8ce6-a9013b5bb68d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ba766a4f-52d0-4927-8a41-64e2f23de36a" xlink:to="loc_srt_RangeMember_42421b52-ed10-46af-8ce6-a9013b5bb68d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_99f34257-8ed4-43c9-8fe7-74022823031e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_42421b52-ed10-46af-8ce6-a9013b5bb68d" xlink:to="loc_srt_MaximumMember_99f34257-8ed4-43c9-8fe7-74022823031e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_db2ecf75-3ccb-408a-ab8b-5256f321fe1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c4a472-3648-4266-b57b-32b7cb5a1728" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_db2ecf75-3ccb-408a-ab8b-5256f321fe1c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_db2ecf75-3ccb-408a-ab8b-5256f321fe1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_db2ecf75-3ccb-408a-ab8b-5256f321fe1c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_db2ecf75-3ccb-408a-ab8b-5256f321fe1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b888a4df-f149-4607-a709-43d5c717f5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_db2ecf75-3ccb-408a-ab8b-5256f321fe1c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b888a4df-f149-4607-a709-43d5c717f5cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_19db769a-d9ce-42de-86be-4a0c34e650c8" xlink:href="mgnx-20221231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b888a4df-f149-4607-a709-43d5c717f5cf" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_19db769a-d9ce-42de-86be-4a0c34e650c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_7444babf-2c38-4d4f-92b5-4dc937520e17" xlink:href="mgnx-20221231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b888a4df-f149-4607-a709-43d5c717f5cf" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_7444babf-2c38-4d4f-92b5-4dc937520e17" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#RevenueIncyteCorporationDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueIncyteCorporationDetails" xlink:type="extended" id="i9a03d0380b0748d696bb73980de06ba7_RevenueIncyteCorporationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementTerm_5e2504fc-dc0f-430e-aa91-b6f7d0d7609f" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_CollaborativeArrangementTerm_5e2504fc-dc0f-430e-aa91-b6f7d0d7609f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_459225ab-0720-4017-9b31-75eea78624d2" xlink:href="mgnx-20221231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_NonRefundableUpfrontFees_459225ab-0720-4017-9b31-75eea78624d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementExtensionTerm_047f84d4-b10f-465b-82ae-33a67c640eac" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeArrangementExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_CollaborativeArrangementExtensionTerm_047f84d4-b10f-465b-82ae-33a67c640eac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_9a66f7f0-0d3a-42a9-9608-870f4215fb3b" xlink:href="mgnx-20221231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_9a66f7f0-0d3a-42a9-9608-870f4215fb3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_471597ac-e593-448c-8155-ae3a4fa09e9b" xlink:href="mgnx-20221231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_471597ac-e593-448c-8155-ae3a4fa09e9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_65701265-ec0e-4b5c-8d6a-e420a6251b38" xlink:href="mgnx-20221231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_65701265-ec0e-4b5c-8d6a-e420a6251b38" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_34d35b54-bcef-47fd-a0cd-e38776b2fbb4" xlink:href="mgnx-20221231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_34d35b54-bcef-47fd-a0cd-e38776b2fbb4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_c4f877a2-cfb4-4074-a154-b4e8f0d41406" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_c4f877a2-cfb4-4074-a154-b4e8f0d41406" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_ce07acac-d2a1-4cfe-86d0-15267c73ebe9" xlink:href="mgnx-20221231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_ce07acac-d2a1-4cfe-86d0-15267c73ebe9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f9c5e302-b8f6-4e1b-a5bd-6f748bd138fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_us-gaap_Revenues_f9c5e302-b8f6-4e1b-a5bd-6f748bd138fa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cd2969db-b5d5-46ed-b36a-23bb52e668bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cd2969db-b5d5-46ed-b36a-23bb52e668bc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7c6ee4e6-f46e-4d2d-a936-03825e871a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7c6ee4e6-f46e-4d2d-a936-03825e871a7a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalAnnualFixedPayments_94a4a356-b3c5-4afd-aa05-8420a67a6606" xlink:href="mgnx-20221231.xsd#mgnx_TotalAnnualFixedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_TotalAnnualFixedPayments_94a4a356-b3c5-4afd-aa05-8420a67a6606" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalAnnualFixedPayments_371deede-c587-4b39-b28e-dbf964796f32" xlink:href="mgnx-20221231.xsd#mgnx_AdditionalAnnualFixedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_AdditionalAnnualFixedPayments_371deede-c587-4b39-b28e-dbf964796f32" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d6fc0fd3-0a20-4070-b4be-f73c0426f5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d6fc0fd3-0a20-4070-b4be-f73c0426f5f2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_07a6a0fb-4959-4278-9d95-2633e03c645f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_07a6a0fb-4959-4278-9d95-2633e03c645f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_75d92b29-eb1b-42e8-bb3e-bbedf8bdd13e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_07a6a0fb-4959-4278-9d95-2633e03c645f" xlink:to="loc_srt_ProductOrServiceAxis_75d92b29-eb1b-42e8-bb3e-bbedf8bdd13e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_75d92b29-eb1b-42e8-bb3e-bbedf8bdd13e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_75d92b29-eb1b-42e8-bb3e-bbedf8bdd13e" xlink:to="loc_srt_ProductsAndServicesDomain_75d92b29-eb1b-42e8-bb3e-bbedf8bdd13e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e671b208-9e5a-4e89-bc0a-45a375c944bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_75d92b29-eb1b-42e8-bb3e-bbedf8bdd13e" xlink:to="loc_srt_ProductsAndServicesDomain_e671b208-9e5a-4e89-bc0a-45a375c944bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_a18cca3b-ad07-40c7-97b1-5511be8ce0d0" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e671b208-9e5a-4e89-bc0a-45a375c944bb" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_a18cca3b-ad07-40c7-97b1-5511be8ce0d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_51edfa13-a838-4710-a1a4-5b880e826e86" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e671b208-9e5a-4e89-bc0a-45a375c944bb" xlink:to="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_51edfa13-a838-4710-a1a4-5b880e826e86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember_e5d53109-ce96-471c-a844-5be5f564b27a" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromCMOAmendmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e671b208-9e5a-4e89-bc0a-45a375c944bb" xlink:to="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember_e5d53109-ce96-471c-a844-5be5f564b27a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f9e2c883-d42e-4841-9f74-bf9828dbc1fc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_07a6a0fb-4959-4278-9d95-2633e03c645f" xlink:to="loc_srt_RangeAxis_f9e2c883-d42e-4841-9f74-bf9828dbc1fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f9e2c883-d42e-4841-9f74-bf9828dbc1fc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f9e2c883-d42e-4841-9f74-bf9828dbc1fc" xlink:to="loc_srt_RangeMember_f9e2c883-d42e-4841-9f74-bf9828dbc1fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d8a75ed-3cef-40e8-8be1-b685cbc497cd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f9e2c883-d42e-4841-9f74-bf9828dbc1fc" xlink:to="loc_srt_RangeMember_6d8a75ed-3cef-40e8-8be1-b685cbc497cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3431b4ea-c510-4f67-9d3d-24429b1bc213" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6d8a75ed-3cef-40e8-8be1-b685cbc497cd" xlink:to="loc_srt_MinimumMember_3431b4ea-c510-4f67-9d3d-24429b1bc213" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0344aea3-c58a-4ad9-bfff-7317313385ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6d8a75ed-3cef-40e8-8be1-b685cbc497cd" xlink:to="loc_srt_MaximumMember_0344aea3-c58a-4ad9-bfff-7317313385ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6843a407-a79d-462c-aa14-0641a4718ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_07a6a0fb-4959-4278-9d95-2633e03c645f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6843a407-a79d-462c-aa14-0641a4718ee7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6843a407-a79d-462c-aa14-0641a4718ee7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6843a407-a79d-462c-aa14-0641a4718ee7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6843a407-a79d-462c-aa14-0641a4718ee7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be74af17-4435-4134-a15c-bb79d5b540d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6843a407-a79d-462c-aa14-0641a4718ee7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be74af17-4435-4134-a15c-bb79d5b540d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_70918949-257c-4301-bdbb-e937bcfbcf5c" xlink:href="mgnx-20221231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be74af17-4435-4134-a15c-bb79d5b540d8" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_70918949-257c-4301-bdbb-e937bcfbcf5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCommercialSupplyAgreementMember_994b4f71-90dc-4775-94c8-191d697b87cb" xlink:href="mgnx-20221231.xsd#mgnx_IncyteCommercialSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be74af17-4435-4134-a15c-bb79d5b540d8" xlink:to="loc_mgnx_IncyteCommercialSupplyAgreementMember_994b4f71-90dc-4775-94c8-191d697b87cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteClinicalSupplyAgreementMember_286996e8-fd5b-4710-81ed-0b204c1713fa" xlink:href="mgnx-20221231.xsd#mgnx_IncyteClinicalSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be74af17-4435-4134-a15c-bb79d5b540d8" xlink:to="loc_mgnx_IncyteClinicalSupplyAgreementMember_286996e8-fd5b-4710-81ed-0b204c1713fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4d13b615-0317-4a25-83eb-08084c6ae30b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_07a6a0fb-4959-4278-9d95-2633e03c645f" xlink:to="loc_srt_CounterpartyNameAxis_4d13b615-0317-4a25-83eb-08084c6ae30b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d13b615-0317-4a25-83eb-08084c6ae30b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4d13b615-0317-4a25-83eb-08084c6ae30b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d13b615-0317-4a25-83eb-08084c6ae30b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f229aa22-985e-44eb-8e35-7d3dfbb7fd11" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4d13b615-0317-4a25-83eb-08084c6ae30b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f229aa22-985e-44eb-8e35-7d3dfbb7fd11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_ea400fbb-62c8-4493-87a2-1ee8a1e421e8" xlink:href="mgnx-20221231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f229aa22-985e-44eb-8e35-7d3dfbb7fd11" xlink:to="loc_mgnx_IncyteCorporationMember_ea400fbb-62c8-4493-87a2-1ee8a1e421e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8c96112c-f96d-40e0-96ad-837d5a91edce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_07a6a0fb-4959-4278-9d95-2633e03c645f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8c96112c-f96d-40e0-96ad-837d5a91edce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8c96112c-f96d-40e0-96ad-837d5a91edce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8c96112c-f96d-40e0-96ad-837d5a91edce" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8c96112c-f96d-40e0-96ad-837d5a91edce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e2cf805-da6c-4b34-afdf-7c198fa77c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8c96112c-f96d-40e0-96ad-837d5a91edce" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e2cf805-da6c-4b34-afdf-7c198fa77c2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_190e63ea-c129-47ec-acd3-8da4ed04ad41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e2cf805-da6c-4b34-afdf-7c198fa77c2c" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_190e63ea-c129-47ec-acd3-8da4ed04ad41" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueGileadSciencesIncDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#RevenueGileadSciencesIncDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueGileadSciencesIncDetails" xlink:type="extended" id="ie24ae6a451364566b9e0d8e2100cdfa1_RevenueGileadSciencesIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408d04c6-e3ac-4af8-827b-a411b269dfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_160c1938-674c-4fd9-9af4-347514a24ba8" xlink:href="mgnx-20221231.xsd#mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408d04c6-e3ac-4af8-827b-a411b269dfc0" xlink:to="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_160c1938-674c-4fd9-9af4-347514a24ba8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_4ec3a36e-3bc7-45a9-a932-326cebd3c183" xlink:href="mgnx-20221231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408d04c6-e3ac-4af8-827b-a411b269dfc0" xlink:to="loc_mgnx_NonRefundableUpfrontFees_4ec3a36e-3bc7-45a9-a932-326cebd3c183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_489c846c-060e-4f65-b54a-ede24c70b922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408d04c6-e3ac-4af8-827b-a411b269dfc0" xlink:to="loc_us-gaap_Revenues_489c846c-060e-4f65-b54a-ede24c70b922" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_551f54d7-1cdb-4880-ae19-5edc32768e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408d04c6-e3ac-4af8-827b-a411b269dfc0" xlink:to="loc_us-gaap_ContractWithCustomerLiability_551f54d7-1cdb-4880-ae19-5edc32768e06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b6bd0be8-8fb3-4428-ac71-ca2bc47ebd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408d04c6-e3ac-4af8-827b-a411b269dfc0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b6bd0be8-8fb3-4428-ac71-ca2bc47ebd5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_84890869-0dda-4861-af38-356ff44cd77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408d04c6-e3ac-4af8-827b-a411b269dfc0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_84890869-0dda-4861-af38-356ff44cd77b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ed53868c-2d00-4a65-85de-9360f843aece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408d04c6-e3ac-4af8-827b-a411b269dfc0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ed53868c-2d00-4a65-85de-9360f843aece" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_786fcb0b-ad43-4c23-8cb6-ddad71e1550f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ed53868c-2d00-4a65-85de-9360f843aece" xlink:to="loc_srt_CounterpartyNameAxis_786fcb0b-ad43-4c23-8cb6-ddad71e1550f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_786fcb0b-ad43-4c23-8cb6-ddad71e1550f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_786fcb0b-ad43-4c23-8cb6-ddad71e1550f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_786fcb0b-ad43-4c23-8cb6-ddad71e1550f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf2c6c12-0c1d-4a25-9131-04078b91a06b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_786fcb0b-ad43-4c23-8cb6-ddad71e1550f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf2c6c12-0c1d-4a25-9131-04078b91a06b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadMember_62ff865e-a1f0-4095-ae88-3126b00b87d9" xlink:href="mgnx-20221231.xsd#mgnx_GileadMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf2c6c12-0c1d-4a25-9131-04078b91a06b" xlink:to="loc_mgnx_GileadMember_62ff865e-a1f0-4095-ae88-3126b00b87d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c73443fd-ec32-41ce-afc1-5cb705b54ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ed53868c-2d00-4a65-85de-9360f843aece" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c73443fd-ec32-41ce-afc1-5cb705b54ab0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c73443fd-ec32-41ce-afc1-5cb705b54ab0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c73443fd-ec32-41ce-afc1-5cb705b54ab0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c73443fd-ec32-41ce-afc1-5cb705b54ab0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_47915cc1-4657-49d9-bf3e-6a1c5d8a1944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c73443fd-ec32-41ce-afc1-5cb705b54ab0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_47915cc1-4657-49d9-bf3e-6a1c5d8a1944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_89621673-e005-4a07-ae86-4b329882fb41" xlink:href="mgnx-20221231.xsd#mgnx_A2022GileadCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_47915cc1-4657-49d9-bf3e-6a1c5d8a1944" xlink:to="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_89621673-e005-4a07-ae86-4b329882fb41" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#RevenueZaiLabDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueZaiLabDetails" xlink:type="extended" id="ief81a2dec7aa43758676a4f509007310_RevenueZaiLabDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_739ddb0a-e654-4e94-8304-00b39461dacf" xlink:href="mgnx-20221231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_NonRefundableUpfrontFees_739ddb0a-e654-4e94-8304-00b39461dacf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_d1c59ddc-e8f2-4897-86fc-75a2b5cd5fd6" xlink:href="mgnx-20221231.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_d1c59ddc-e8f2-4897-86fc-75a2b5cd5fd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_c4049ae1-c80f-4256-b2f0-f656c1dd029b" xlink:href="mgnx-20221231.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_c4049ae1-c80f-4256-b2f0-f656c1dd029b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_28b4980a-4ddc-4700-9810-aabfee493f55" xlink:href="mgnx-20221231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_28b4980a-4ddc-4700-9810-aabfee493f55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1bb225e3-4c47-48eb-a38d-f1037ae8fe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_us-gaap_Revenues_1bb225e3-4c47-48eb-a38d-f1037ae8fe7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_18da73a6-066f-4a56-97d0-81b0a052c690" xlink:href="mgnx-20221231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_18da73a6-066f-4a56-97d0-81b0a052c690" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cfe78bec-bcf0-4aea-94d1-f63bb8fceec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cfe78bec-bcf0-4aea-94d1-f63bb8fceec4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_852e0eff-eee1-42b5-bd6d-38015ac5117d" xlink:href="mgnx-20221231.xsd#mgnx_EstimatedReimbursementForResearchAndDevelopmentT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_852e0eff-eee1-42b5-bd6d-38015ac5117d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_4e50e679-ccbe-4283-80f3-3c1f798ac5f3" xlink:href="mgnx-20221231.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_4e50e679-ccbe-4283-80f3-3c1f798ac5f3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_66a0c412-222c-43e9-844b-39cd772c3107" xlink:href="mgnx-20221231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_66a0c412-222c-43e9-844b-39cd772c3107" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_78b0d2f0-8087-4149-9528-9f25aeb4e807" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_78b0d2f0-8087-4149-9528-9f25aeb4e807" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonesValueAddedTax_1cff99c2-be2e-46a7-8c13-5b0ec614bdd9" xlink:href="mgnx-20221231.xsd#mgnx_MilestonesValueAddedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_MilestonesValueAddedTax_1cff99c2-be2e-46a7-8c13-5b0ec614bdd9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_e031af97-a8c6-473f-84ec-12d2354f2000" xlink:href="mgnx-20221231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_e031af97-a8c6-473f-84ec-12d2354f2000" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromVariableConsiderationRecognize_4dee572b-eece-4533-85b3-f9f5d5854734" xlink:href="mgnx-20221231.xsd#mgnx_RevenueFromVariableConsiderationRecognize"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_RevenueFromVariableConsiderationRecognize_4dee572b-eece-4533-85b3-f9f5d5854734" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa8301d3-fb2b-49ea-bca6-402821e4c8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa8301d3-fb2b-49ea-bca6-402821e4c8f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_22439f0a-d7c1-4042-a114-d3fc805b8e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa8301d3-fb2b-49ea-bca6-402821e4c8f0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_22439f0a-d7c1-4042-a114-d3fc805b8e5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_22439f0a-d7c1-4042-a114-d3fc805b8e5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_22439f0a-d7c1-4042-a114-d3fc805b8e5a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_22439f0a-d7c1-4042-a114-d3fc805b8e5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_22439f0a-d7c1-4042-a114-d3fc805b8e5a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_625d0efc-4679-44a9-aed7-ed7b0031af24" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_625d0efc-4679-44a9-aed7-ed7b0031af24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_d76db26b-9b05-4484-8c9f-b6694a42f596" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_d76db26b-9b05-4484-8c9f-b6694a42f596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_49742858-31bb-4e15-a195-daccfd47ae72" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_49742858-31bb-4e15-a195-daccfd47ae72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_d2557c74-19bf-42da-8050-d190cf59fd81" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_d2557c74-19bf-42da-8050-d190cf59fd81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_e98da7ba-8845-41f6-806c-bdc9e457412c" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:to="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_e98da7ba-8845-41f6-806c-bdc9e457412c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_5277ddd5-6c9f-44a2-9bde-6295c52e4513" xlink:href="mgnx-20221231.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:to="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_5277ddd5-6c9f-44a2-9bde-6295c52e4513" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_9e341896-cc6d-49e2-9e78-56457adb896b" xlink:href="mgnx-20221231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_9e341896-cc6d-49e2-9e78-56457adb896b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_84507b85-a0a1-49b0-bc13-c4ca4d8c2760" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa8301d3-fb2b-49ea-bca6-402821e4c8f0" xlink:to="loc_srt_CounterpartyNameAxis_84507b85-a0a1-49b0-bc13-c4ca4d8c2760" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84507b85-a0a1-49b0-bc13-c4ca4d8c2760_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_84507b85-a0a1-49b0-bc13-c4ca4d8c2760" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84507b85-a0a1-49b0-bc13-c4ca4d8c2760_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c52cbb27-a5c9-4aad-8981-40f8ad7d7a01" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_84507b85-a0a1-49b0-bc13-c4ca4d8c2760" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c52cbb27-a5c9-4aad-8981-40f8ad7d7a01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsMember_b2a0a126-c675-4115-9396-77da1716a854" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c52cbb27-a5c9-4aad-8981-40f8ad7d7a01" xlink:to="loc_mgnx_ZaiLabsMember_b2a0a126-c675-4115-9396-77da1716a854" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_045f39aa-d4b4-4441-aed3-4307bcd23332" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c52cbb27-a5c9-4aad-8981-40f8ad7d7a01" xlink:to="loc_mgnx_ZaiLabMember_045f39aa-d4b4-4441-aed3-4307bcd23332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_11cd2264-036c-410b-a377-34961154a163" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa8301d3-fb2b-49ea-bca6-402821e4c8f0" xlink:to="loc_srt_RangeAxis_11cd2264-036c-410b-a377-34961154a163" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11cd2264-036c-410b-a377-34961154a163_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_11cd2264-036c-410b-a377-34961154a163" xlink:to="loc_srt_RangeMember_11cd2264-036c-410b-a377-34961154a163_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_453e420e-f81e-47fe-8f4e-498dd22b9e2e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_11cd2264-036c-410b-a377-34961154a163" xlink:to="loc_srt_RangeMember_453e420e-f81e-47fe-8f4e-498dd22b9e2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c9c11666-ef3c-4cd0-806c-815cd2188c33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_453e420e-f81e-47fe-8f4e-498dd22b9e2e" xlink:to="loc_srt_MaximumMember_c9c11666-ef3c-4cd0-806c-815cd2188c33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9bffa1cb-e7f5-44c7-b0e3-9897cb2e2962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa8301d3-fb2b-49ea-bca6-402821e4c8f0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9bffa1cb-e7f5-44c7-b0e3-9897cb2e2962" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9bffa1cb-e7f5-44c7-b0e3-9897cb2e2962_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9bffa1cb-e7f5-44c7-b0e3-9897cb2e2962" xlink:to="loc_us-gaap_EquityComponentDomain_9bffa1cb-e7f5-44c7-b0e3-9897cb2e2962_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_af093e73-496f-4694-85a2-3333b04ec16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9bffa1cb-e7f5-44c7-b0e3-9897cb2e2962" xlink:to="loc_us-gaap_EquityComponentDomain_af093e73-496f-4694-85a2-3333b04ec16b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f0f44d59-92b0-4877-80b8-46a3e8aaf916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_af093e73-496f-4694-85a2-3333b04ec16b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f0f44d59-92b0-4877-80b8-46a3e8aaf916" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueJanssenDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#RevenueJanssenDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueJanssenDetails" xlink:type="extended" id="i1aee139ca739428ea8682b5066d5df61_RevenueJanssenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d53fab4-8d00-42ac-a948-15eacded67e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_ae8dbdae-6311-4733-8526-ec0a8e6378a4" xlink:href="mgnx-20221231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d53fab4-8d00-42ac-a948-15eacded67e7" xlink:to="loc_mgnx_NonRefundableUpfrontFees_ae8dbdae-6311-4733-8526-ec0a8e6378a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_9d793c15-89ae-4a6b-bab8-9ab630d1fc3d" xlink:href="mgnx-20221231.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d53fab4-8d00-42ac-a948-15eacded67e7" xlink:to="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_9d793c15-89ae-4a6b-bab8-9ab630d1fc3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_ecef203a-71dd-4883-a492-5d0c796b9d8a" xlink:href="mgnx-20221231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d53fab4-8d00-42ac-a948-15eacded67e7" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_ecef203a-71dd-4883-a492-5d0c796b9d8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_730a45e0-338e-4a43-ba6d-12725d139d5f" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d53fab4-8d00-42ac-a948-15eacded67e7" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_730a45e0-338e-4a43-ba6d-12725d139d5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_712b1e4e-d2b2-4551-a5d6-9c3915f5e342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d53fab4-8d00-42ac-a948-15eacded67e7" xlink:to="loc_us-gaap_Revenues_712b1e4e-d2b2-4551-a5d6-9c3915f5e342" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_426c85af-e079-4e7c-8566-9d8fe51b6e6e" xlink:href="mgnx-20221231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d53fab4-8d00-42ac-a948-15eacded67e7" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_426c85af-e079-4e7c-8566-9d8fe51b6e6e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f43285d-c20c-4849-8815-2d21bc69a058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d53fab4-8d00-42ac-a948-15eacded67e7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f43285d-c20c-4849-8815-2d21bc69a058" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_33833303-da70-40da-891b-5bda453c2155" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f43285d-c20c-4849-8815-2d21bc69a058" xlink:to="loc_srt_CounterpartyNameAxis_33833303-da70-40da-891b-5bda453c2155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33833303-da70-40da-891b-5bda453c2155_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_33833303-da70-40da-891b-5bda453c2155" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33833303-da70-40da-891b-5bda453c2155_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_252ae359-7579-4f00-a6b3-5198e61b21a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_33833303-da70-40da-891b-5bda453c2155" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_252ae359-7579-4f00-a6b3-5198e61b21a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_dfd6b0d3-a027-4be3-a258-4b1fdd349390" xlink:href="mgnx-20221231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_252ae359-7579-4f00-a6b3-5198e61b21a4" xlink:to="loc_mgnx_JanssenBiotechIncMember_dfd6b0d3-a027-4be3-a258-4b1fdd349390" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ce2c445e-9ebb-482c-b0db-bb7928a2b029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f43285d-c20c-4849-8815-2d21bc69a058" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ce2c445e-9ebb-482c-b0db-bb7928a2b029" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ce2c445e-9ebb-482c-b0db-bb7928a2b029_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ce2c445e-9ebb-482c-b0db-bb7928a2b029" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ce2c445e-9ebb-482c-b0db-bb7928a2b029_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e295dd98-f51f-4a7f-a259-ce52dbde3841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ce2c445e-9ebb-482c-b0db-bb7928a2b029" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e295dd98-f51f-4a7f-a259-ce52dbde3841" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_d374a93b-bb3f-4880-836e-256b6d2e7dc9" xlink:href="mgnx-20221231.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e295dd98-f51f-4a7f-a259-ce52dbde3841" xlink:to="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_d374a93b-bb3f-4880-836e-256b6d2e7dc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8da45df1-56e2-4a6e-b8a8-1f0a17449648" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f43285d-c20c-4849-8815-2d21bc69a058" xlink:to="loc_srt_ProductOrServiceAxis_8da45df1-56e2-4a6e-b8a8-1f0a17449648" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8da45df1-56e2-4a6e-b8a8-1f0a17449648_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8da45df1-56e2-4a6e-b8a8-1f0a17449648" xlink:to="loc_srt_ProductsAndServicesDomain_8da45df1-56e2-4a6e-b8a8-1f0a17449648_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_548b4bfa-afde-4c18-8ac9-fed0935f2def" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8da45df1-56e2-4a6e-b8a8-1f0a17449648" xlink:to="loc_srt_ProductsAndServicesDomain_548b4bfa-afde-4c18-8ac9-fed0935f2def" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_c1c8aa28-8f73-4fd9-bb92-8aeace1f0cee" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_548b4bfa-afde-4c18-8ac9-fed0935f2def" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_c1c8aa28-8f73-4fd9-bb92-8aeace1f0cee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_415d1e41-5aa8-4448-bf27-0ba432eca3a4" xlink:href="mgnx-20221231.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_548b4bfa-afde-4c18-8ac9-fed0935f2def" xlink:to="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_415d1e41-5aa8-4448-bf27-0ba432eca3a4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#RevenueIMabBiopharmaDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueIMabBiopharmaDetails" xlink:type="extended" id="i86b4cb2084d241f787d962a3f437d29d_RevenueIMabBiopharmaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_65e689a6-b688-454d-a0a1-75a3aaaea582" xlink:href="mgnx-20221231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_mgnx_NonRefundableUpfrontFees_65e689a6-b688-454d-a0a1-75a3aaaea582" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_a76fb41b-1733-40dd-9a01-3a6d2bab2474" xlink:href="mgnx-20221231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_a76fb41b-1733-40dd-9a01-3a6d2bab2474" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_2e4c0d76-78a2-4dda-8452-c8cca9439aa4" xlink:href="mgnx-20221231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_2e4c0d76-78a2-4dda-8452-c8cca9439aa4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_676ed3be-a6e3-4b77-ba1d-0ba9cbc9fb75" xlink:href="mgnx-20221231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_676ed3be-a6e3-4b77-ba1d-0ba9cbc9fb75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_8ca0e551-7b04-499c-bd1b-608b32fa13bf" xlink:href="mgnx-20221231.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_8ca0e551-7b04-499c-bd1b-608b32fa13bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOneTimeCreditPaidPercent_a70c5881-58e7-4f6a-b621-d4b2eb5376ff" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationArrangementOneTimeCreditPaidPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_mgnx_CollaborationArrangementOneTimeCreditPaidPercent_a70c5881-58e7-4f6a-b621-d4b2eb5376ff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OneTimeMillstoneCredit_39e1f3f5-102d-498c-8a84-6c1fb5a7198c" xlink:href="mgnx-20221231.xsd#mgnx_OneTimeMillstoneCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_mgnx_OneTimeMillstoneCredit_39e1f3f5-102d-498c-8a84-6c1fb5a7198c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6157c9a6-1e38-44a5-98ed-f0944067feda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_us-gaap_Revenues_6157c9a6-1e38-44a5-98ed-f0944067feda" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_799413e0-de46-44c7-93be-8eeb3ad50602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_us-gaap_ContractWithCustomerLiability_799413e0-de46-44c7-93be-8eeb3ad50602" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_00f988e3-b3d3-4120-a816-ebafd92f6c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_00f988e3-b3d3-4120-a816-ebafd92f6c7f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1b2860ae-23fa-45b9-88fe-809745f1808f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1b2860ae-23fa-45b9-88fe-809745f1808f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_983a9870-3ad9-41a9-bb01-65235980a0be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_983a9870-3ad9-41a9-bb01-65235980a0be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2d1aa177-eafb-46eb-b631-9e40aff7cc35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_983a9870-3ad9-41a9-bb01-65235980a0be" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2d1aa177-eafb-46eb-b631-9e40aff7cc35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2d1aa177-eafb-46eb-b631-9e40aff7cc35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2d1aa177-eafb-46eb-b631-9e40aff7cc35" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2d1aa177-eafb-46eb-b631-9e40aff7cc35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6b9e4553-3e14-4548-b6dc-4732c029acd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2d1aa177-eafb-46eb-b631-9e40aff7cc35" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6b9e4553-3e14-4548-b6dc-4732c029acd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_41e30c10-10a6-444e-bd20-0d73ca6710a4" xlink:href="mgnx-20221231.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6b9e4553-3e14-4548-b6dc-4732c029acd1" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_41e30c10-10a6-444e-bd20-0d73ca6710a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_39b6a64b-ba99-47f1-80b5-72445709b6e4" xlink:href="mgnx-20221231.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6b9e4553-3e14-4548-b6dc-4732c029acd1" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_39b6a64b-ba99-47f1-80b5-72445709b6e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_18eaf495-f76b-4f9f-bc77-50b5644e3694" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_983a9870-3ad9-41a9-bb01-65235980a0be" xlink:to="loc_srt_CounterpartyNameAxis_18eaf495-f76b-4f9f-bc77-50b5644e3694" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18eaf495-f76b-4f9f-bc77-50b5644e3694_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_18eaf495-f76b-4f9f-bc77-50b5644e3694" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18eaf495-f76b-4f9f-bc77-50b5644e3694_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59c4925c-3772-44e2-ac1e-e93a28810406" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_18eaf495-f76b-4f9f-bc77-50b5644e3694" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59c4925c-3772-44e2-ac1e-e93a28810406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_3188daf6-7a0e-4cdd-bf99-a9034f9d2d6d" xlink:href="mgnx-20221231.xsd#mgnx_IMabBiopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59c4925c-3772-44e2-ac1e-e93a28810406" xlink:to="loc_mgnx_IMabBiopharmaMember_3188daf6-7a0e-4cdd-bf99-a9034f9d2d6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dcd7eb3d-b2d3-4db1-9681-3733f26ce1e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_983a9870-3ad9-41a9-bb01-65235980a0be" xlink:to="loc_srt_RangeAxis_dcd7eb3d-b2d3-4db1-9681-3733f26ce1e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dcd7eb3d-b2d3-4db1-9681-3733f26ce1e8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dcd7eb3d-b2d3-4db1-9681-3733f26ce1e8" xlink:to="loc_srt_RangeMember_dcd7eb3d-b2d3-4db1-9681-3733f26ce1e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bf116f32-684c-4628-ad80-d85fab2210cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dcd7eb3d-b2d3-4db1-9681-3733f26ce1e8" xlink:to="loc_srt_RangeMember_bf116f32-684c-4628-ad80-d85fab2210cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9fda8fe7-fbed-4e17-a8e2-d4dfdc9583c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bf116f32-684c-4628-ad80-d85fab2210cf" xlink:to="loc_srt_MaximumMember_9fda8fe7-fbed-4e17-a8e2-d4dfdc9583c6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueProventionDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#RevenueProventionDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueProventionDetails" xlink:type="extended" id="i95036d02aa5a48d090a6ed90731a5daa_RevenueProventionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_0827cd02-e4b7-4c4a-901a-9384375ab51a" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_0827cd02-e4b7-4c4a-901a-9384375ab51a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_49c5a783-72a0-4b04-956e-628fbc190575" xlink:href="mgnx-20221231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_49c5a783-72a0-4b04-956e-628fbc190575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_286c1ac9-f606-413a-b94a-7cd239c4af4b" xlink:href="mgnx-20221231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_286c1ac9-f606-413a-b94a-7cd239c4af4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_408d320a-d54a-4adc-9b73-c8bceb814259" xlink:href="mgnx-20221231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_408d320a-d54a-4adc-9b73-c8bceb814259" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_6738703b-6762-4a8a-b57b-c84df301d645" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_6738703b-6762-4a8a-b57b-c84df301d645" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_91c6126e-9d89-4cdd-9bc5-579db48a5a88" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_91c6126e-9d89-4cdd-9bc5-579db48a5a88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cb980e88-d9eb-42cd-a909-0bee635ab8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_us-gaap_Revenues_cb980e88-d9eb-42cd-a909-0bee635ab8c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ReceivableFromCollaborationPartner_fc8b7ff5-a972-4371-81b6-e3ed8fb1ec45" xlink:href="mgnx-20221231.xsd#mgnx_ReceivableFromCollaborationPartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_ReceivableFromCollaborationPartner_fc8b7ff5-a972-4371-81b6-e3ed8fb1ec45" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontAndFixedPayments_98ab5999-59b0-42be-8c8f-11ea0306e300" xlink:href="mgnx-20221231.xsd#mgnx_UpfrontAndFixedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_UpfrontAndFixedPayments_98ab5999-59b0-42be-8c8f-11ea0306e300" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_38097c32-6cd4-4ec9-a169-e9d342027c5b" xlink:href="mgnx-20221231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_38097c32-6cd4-4ec9-a169-e9d342027c5b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e413ad47-14bf-4732-9bdd-a32c15e9711c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e413ad47-14bf-4732-9bdd-a32c15e9711c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_abcd5475-e566-440c-9213-9a99503cfc70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e413ad47-14bf-4732-9bdd-a32c15e9711c" xlink:to="loc_srt_ProductOrServiceAxis_abcd5475-e566-440c-9213-9a99503cfc70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_abcd5475-e566-440c-9213-9a99503cfc70_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_abcd5475-e566-440c-9213-9a99503cfc70" xlink:to="loc_srt_ProductsAndServicesDomain_abcd5475-e566-440c-9213-9a99503cfc70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_be286a66-b1fe-4307-96f7-87142db40402" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_abcd5475-e566-440c-9213-9a99503cfc70" xlink:to="loc_srt_ProductsAndServicesDomain_be286a66-b1fe-4307-96f7-87142db40402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_b2948c3b-bedc-45ba-86fb-e687a1dada00" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_be286a66-b1fe-4307-96f7-87142db40402" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_b2948c3b-bedc-45ba-86fb-e687a1dada00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioCMOAgreeemntMember_f0109582-f4ad-4da5-b09c-eb7823705aab" xlink:href="mgnx-20221231.xsd#mgnx_ProventionBioCMOAgreeemntMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_be286a66-b1fe-4307-96f7-87142db40402" xlink:to="loc_mgnx_ProventionBioCMOAgreeemntMember_f0109582-f4ad-4da5-b09c-eb7823705aab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0ba91336-8f5c-4a0e-b28c-01cbbfdf3c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e413ad47-14bf-4732-9bdd-a32c15e9711c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0ba91336-8f5c-4a0e-b28c-01cbbfdf3c04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ba91336-8f5c-4a0e-b28c-01cbbfdf3c04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0ba91336-8f5c-4a0e-b28c-01cbbfdf3c04" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ba91336-8f5c-4a0e-b28c-01cbbfdf3c04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b7fd238-4763-4042-a6b2-2a46df958a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0ba91336-8f5c-4a0e-b28c-01cbbfdf3c04" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b7fd238-4763-4042-a6b2-2a46df958a81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_2275c352-c950-407a-9313-08b0457d22fd" xlink:href="mgnx-20221231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b7fd238-4763-4042-a6b2-2a46df958a81" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_2275c352-c950-407a-9313-08b0457d22fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_32bbca8a-896a-44e4-9db4-4b9c35823a27" xlink:href="mgnx-20221231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b7fd238-4763-4042-a6b2-2a46df958a81" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_32bbca8a-896a-44e4-9db4-4b9c35823a27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5832053a-b451-4ca0-977d-d4974eab5d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e413ad47-14bf-4732-9bdd-a32c15e9711c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5832053a-b451-4ca0-977d-d4974eab5d6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5832053a-b451-4ca0-977d-d4974eab5d6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5832053a-b451-4ca0-977d-d4974eab5d6d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5832053a-b451-4ca0-977d-d4974eab5d6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8cf2d032-ffad-4def-ac3a-f144a9e86bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5832053a-b451-4ca0-977d-d4974eab5d6d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8cf2d032-ffad-4def-ac3a-f144a9e86bb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_efdce806-144a-45d9-9e92-c6f7e7c109ce" xlink:href="mgnx-20221231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8cf2d032-ffad-4def-ac3a-f144a9e86bb1" xlink:to="loc_mgnx_ProventionPRV3279Member_efdce806-144a-45d9-9e92-c6f7e7c109ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_40c9e742-db49-4cdf-b54a-a2b12d429e2c" xlink:href="mgnx-20221231.xsd#mgnx_ProventionPRV031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8cf2d032-ffad-4def-ac3a-f144a9e86bb1" xlink:to="loc_mgnx_ProventionPRV031Member_40c9e742-db49-4cdf-b54a-a2b12d429e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bb7cb8d3-3a39-4dfb-8e87-d75a11ee2ac2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bb7cb8d3-3a39-4dfb-8e87-d75a11ee2ac2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4c6f3341-505d-4928-a103-196901e60a95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_a6b70e7c-8334-4a4d-9c67-8dd1ab026c1c" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b073698b-21ed-4fd6-b648-db7f5f9a4cef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e413ad47-14bf-4732-9bdd-a32c15e9711c" xlink:to="loc_srt_CounterpartyNameAxis_b073698b-21ed-4fd6-b648-db7f5f9a4cef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b073698b-21ed-4fd6-b648-db7f5f9a4cef_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b073698b-21ed-4fd6-b648-db7f5f9a4cef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b073698b-21ed-4fd6-b648-db7f5f9a4cef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7d45dca-90dd-4f70-ac31-3de0d799fca6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b073698b-21ed-4fd6-b648-db7f5f9a4cef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7d45dca-90dd-4f70-ac31-3de0d799fca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_e89de650-e6bb-402a-8d54-78c79bfdf683" xlink:href="mgnx-20221231.xsd#mgnx_ProventionBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7d45dca-90dd-4f70-ac31-3de0d799fca6" xlink:to="loc_mgnx_ProventionBioMember_e89de650-e6bb-402a-8d54-78c79bfdf683" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#RevenueBoehringerIngelheimInternationalGmbHDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails" xlink:type="extended" id="i961446ccb0fa43c7926519a8d2e529ce_RevenueBoehringerIngelheimInternationalGmbHDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d075eca2-dcd7-4b3b-9b91-25dfadf5a729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementTerm_fdee1b9f-b540-418a-a5cb-46ccda2b959b" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationAndLicenseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d075eca2-dcd7-4b3b-9b91-25dfadf5a729" xlink:to="loc_mgnx_CollaborationAndLicenseAgreementTerm_fdee1b9f-b540-418a-a5cb-46ccda2b959b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates_bf00f897-c522-4bfe-b23f-84dfcc219d9e" xlink:href="mgnx-20221231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d075eca2-dcd7-4b3b-9b91-25dfadf5a729" xlink:to="loc_mgnx_NumberOfProductCandidates_bf00f897-c522-4bfe-b23f-84dfcc219d9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_a98a6ff9-14e5-44ae-9af6-6279e5ebb29c" xlink:href="mgnx-20221231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d075eca2-dcd7-4b3b-9b91-25dfadf5a729" xlink:to="loc_mgnx_NonRefundableUpfrontFees_a98a6ff9-14e5-44ae-9af6-6279e5ebb29c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentMilestonesAmount_a8b02ad2-2bf8-490c-98b0-1eaceb54f7d4" xlink:href="mgnx-20221231.xsd#mgnx_DevelopmentMilestonesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d075eca2-dcd7-4b3b-9b91-25dfadf5a729" xlink:to="loc_mgnx_DevelopmentMilestonesAmount_a8b02ad2-2bf8-490c-98b0-1eaceb54f7d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_2698ed92-053d-42f2-ad8c-a33bf3d99e34" xlink:href="mgnx-20221231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d075eca2-dcd7-4b3b-9b91-25dfadf5a729" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_2698ed92-053d-42f2-ad8c-a33bf3d99e34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7d1deb3-d9c0-430b-bde5-1fd3fe041b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d075eca2-dcd7-4b3b-9b91-25dfadf5a729" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7d1deb3-d9c0-430b-bde5-1fd3fe041b56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c1291ac5-4f10-42bd-a70d-dd91881f5c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7d1deb3-d9c0-430b-bde5-1fd3fe041b56" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c1291ac5-4f10-42bd-a70d-dd91881f5c8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c1291ac5-4f10-42bd-a70d-dd91881f5c8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c1291ac5-4f10-42bd-a70d-dd91881f5c8d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c1291ac5-4f10-42bd-a70d-dd91881f5c8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3a5f9945-eef2-48ac-b0c6-d444ad4af4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c1291ac5-4f10-42bd-a70d-dd91881f5c8d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3a5f9945-eef2-48ac-b0c6-d444ad4af4bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_9625d7b6-05f8-4022-8f14-813ec1a3d6c7" xlink:href="mgnx-20221231.xsd#mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3a5f9945-eef2-48ac-b0c6-d444ad4af4bc" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_9625d7b6-05f8-4022-8f14-813ec1a3d6c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_502407ca-ffb1-4cbc-a622-3dee56d2e223" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7d1deb3-d9c0-430b-bde5-1fd3fe041b56" xlink:to="loc_srt_CounterpartyNameAxis_502407ca-ffb1-4cbc-a622-3dee56d2e223" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_502407ca-ffb1-4cbc-a622-3dee56d2e223_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_502407ca-ffb1-4cbc-a622-3dee56d2e223" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_502407ca-ffb1-4cbc-a622-3dee56d2e223_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f0c9a06-272c-4780-8868-e49ddb713d7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_502407ca-ffb1-4cbc-a622-3dee56d2e223" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f0c9a06-272c-4780-8868-e49ddb713d7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_b4b69349-3a03-431e-b08f-e3a7d1f5d437" xlink:href="mgnx-20221231.xsd#mgnx_BoehringerIngelheimInternationalGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f0c9a06-272c-4780-8868-e49ddb713d7c" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_b4b69349-3a03-431e-b08f-e3a7d1f5d437" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#RevenueNIAIDContractDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueNIAIDContractDetails" xlink:type="extended" id="ie15554beb46b4c439002207bd52c5777_RevenueNIAIDContractDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02c4289a-dfeb-4bea-8e92-84b5436fbcb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates_956789f2-c821-4023-9db8-18ed5bbd015f" xlink:href="mgnx-20221231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02c4289a-dfeb-4bea-8e92-84b5436fbcb6" xlink:to="loc_mgnx_NumberOfProductCandidates_956789f2-c821-4023-9db8-18ed5bbd015f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_5ce51303-ac52-46f9-a66a-7d1e5b26624e" xlink:href="mgnx-20221231.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02c4289a-dfeb-4bea-8e92-84b5436fbcb6" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_5ce51303-ac52-46f9-a66a-7d1e5b26624e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_91c41ff8-7b23-4d93-9b4f-5e4663806f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02c4289a-dfeb-4bea-8e92-84b5436fbcb6" xlink:to="loc_us-gaap_Revenues_91c41ff8-7b23-4d93-9b4f-5e4663806f23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5344283d-eb66-4e57-9936-dcce0e6313ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02c4289a-dfeb-4bea-8e92-84b5436fbcb6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5344283d-eb66-4e57-9936-dcce0e6313ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_22e5d234-d9f6-4717-a15d-f9e5762312a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5344283d-eb66-4e57-9936-dcce0e6313ec" xlink:to="loc_srt_ProductOrServiceAxis_22e5d234-d9f6-4717-a15d-f9e5762312a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_22e5d234-d9f6-4717-a15d-f9e5762312a9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_22e5d234-d9f6-4717-a15d-f9e5762312a9" xlink:to="loc_srt_ProductsAndServicesDomain_22e5d234-d9f6-4717-a15d-f9e5762312a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7ce7d94e-a2b1-45cf-9d43-cc1a2d9b97f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_22e5d234-d9f6-4717-a15d-f9e5762312a9" xlink:to="loc_srt_ProductsAndServicesDomain_7ce7d94e-a2b1-45cf-9d43-cc1a2d9b97f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_ef696581-8509-48e4-8470-dfd8655d50db" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7ce7d94e-a2b1-45cf-9d43-cc1a2d9b97f1" xlink:to="loc_mgnx_RevenuesFromGrantsMember_ef696581-8509-48e4-8470-dfd8655d50db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7615eef4-933e-404b-acd8-4e448cf2b5df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5344283d-eb66-4e57-9936-dcce0e6313ec" xlink:to="loc_srt_CounterpartyNameAxis_7615eef4-933e-404b-acd8-4e448cf2b5df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7615eef4-933e-404b-acd8-4e448cf2b5df_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7615eef4-933e-404b-acd8-4e448cf2b5df" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7615eef4-933e-404b-acd8-4e448cf2b5df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf47f051-52a2-4cd4-80ba-2110cc9ebe85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7615eef4-933e-404b-acd8-4e448cf2b5df" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf47f051-52a2-4cd4-80ba-2110cc9ebe85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_5d1d5b13-8c8b-4609-82a7-885894993b11" xlink:href="mgnx-20221231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf47f051-52a2-4cd4-80ba-2110cc9ebe85" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_5d1d5b13-8c8b-4609-82a7-885894993b11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_ceefed5d-1bf7-4ee5-b7f3-db46af667b20" xlink:href="mgnx-20221231.xsd#mgnx_BoehringerIngelheimInternationalGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf47f051-52a2-4cd4-80ba-2110cc9ebe85" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_ceefed5d-1bf7-4ee5-b7f3-db46af667b20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9b2449f3-57fc-449d-980c-22354215c8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5344283d-eb66-4e57-9936-dcce0e6313ec" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9b2449f3-57fc-449d-980c-22354215c8bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9b2449f3-57fc-449d-980c-22354215c8bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9b2449f3-57fc-449d-980c-22354215c8bc" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9b2449f3-57fc-449d-980c-22354215c8bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_939876bc-9ce2-4d4e-a593-65049412db3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9b2449f3-57fc-449d-980c-22354215c8bc" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_939876bc-9ce2-4d4e-a593-65049412db3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_a0159d00-943b-4674-a8b5-477d12a058ab" xlink:href="mgnx-20221231.xsd#mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_939876bc-9ce2-4d4e-a593-65049412db3d" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_a0159d00-943b-4674-a8b5-477d12a058ab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#StockbasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended" id="i21e94c2fb9a348048ce634bd90916648_StockbasedCompensationEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8602438-df77-4b2c-ac1c-b55dad029b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2fbdc7e1-53e2-493c-9275-71753bfc43aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8602438-df77-4b2c-ac1c-b55dad029b7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2fbdc7e1-53e2-493c-9275-71753bfc43aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_381be6e1-cb71-46f0-8c34-66dbb2a065af" xlink:href="mgnx-20221231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8602438-df77-4b2c-ac1c-b55dad029b7d" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_381be6e1-cb71-46f0-8c34-66dbb2a065af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_56eef5c8-a5f3-4efa-8426-d5424002d2dd" xlink:href="mgnx-20221231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8602438-df77-4b2c-ac1c-b55dad029b7d" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_56eef5c8-a5f3-4efa-8426-d5424002d2dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_84d46c61-e89c-45e8-8f8c-a7e806485c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8602438-df77-4b2c-ac1c-b55dad029b7d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_84d46c61-e89c-45e8-8f8c-a7e806485c1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6f5cfb25-ec46-4593-9653-2d4f2cde92ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8602438-df77-4b2c-ac1c-b55dad029b7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6f5cfb25-ec46-4593-9653-2d4f2cde92ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8bc9b7d6-5255-418f-b6bd-b715a9f103ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8602438-df77-4b2c-ac1c-b55dad029b7d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8bc9b7d6-5255-418f-b6bd-b715a9f103ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1d464e7-3fbe-4942-bc79-da372afd4d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8602438-df77-4b2c-ac1c-b55dad029b7d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1d464e7-3fbe-4942-bc79-da372afd4d2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5a218167-ffd0-4fca-b8eb-3105184c2355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1d464e7-3fbe-4942-bc79-da372afd4d2c" xlink:to="loc_us-gaap_PlanNameAxis_5a218167-ffd0-4fca-b8eb-3105184c2355" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5a218167-ffd0-4fca-b8eb-3105184c2355_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5a218167-ffd0-4fca-b8eb-3105184c2355" xlink:to="loc_us-gaap_PlanNameDomain_5a218167-ffd0-4fca-b8eb-3105184c2355_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1e406201-c499-4469-b919-c467a4e895c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5a218167-ffd0-4fca-b8eb-3105184c2355" xlink:to="loc_us-gaap_PlanNameDomain_1e406201-c499-4469-b919-c467a4e895c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_75af1ea9-0641-4313-ac30-a4d6cbed6c0b" xlink:href="mgnx-20221231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1e406201-c499-4469-b919-c467a4e895c9" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_75af1ea9-0641-4313-ac30-a4d6cbed6c0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e3ed48fd-cba0-479c-a354-c1e42b5b7bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1d464e7-3fbe-4942-bc79-da372afd4d2c" xlink:to="loc_us-gaap_AwardTypeAxis_e3ed48fd-cba0-479c-a354-c1e42b5b7bd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3ed48fd-cba0-479c-a354-c1e42b5b7bd6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e3ed48fd-cba0-479c-a354-c1e42b5b7bd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3ed48fd-cba0-479c-a354-c1e42b5b7bd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f8a07d9-1083-4deb-a2c4-334642bd9d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e3ed48fd-cba0-479c-a354-c1e42b5b7bd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f8a07d9-1083-4deb-a2c4-334642bd9d39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b5ec1893-9e33-4f7e-89d7-db2c5555f3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f8a07d9-1083-4deb-a2c4-334642bd9d39" xlink:to="loc_us-gaap_EmployeeStockMember_b5ec1893-9e33-4f7e-89d7-db2c5555f3ed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#StockbasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="if04df575f838449cb8aa01c22c16081c_StockbasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f5d515-6b79-48a0-9c44-11501e2fddee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9f5f38a8-0a80-427e-b2ef-eeec9e4236bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f5d515-6b79-48a0-9c44-11501e2fddee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9f5f38a8-0a80-427e-b2ef-eeec9e4236bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_09ec06d1-80cc-4359-9cc4-87f2594fd7dc" xlink:href="mgnx-20221231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f5d515-6b79-48a0-9c44-11501e2fddee" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_09ec06d1-80cc-4359-9cc4-87f2594fd7dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ae4a716f-d12c-4908-8a97-4c73f3eb2cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f5d515-6b79-48a0-9c44-11501e2fddee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ae4a716f-d12c-4908-8a97-4c73f3eb2cf5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0d45716a-c5b4-40f6-a6f1-1fa04356c069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f5d515-6b79-48a0-9c44-11501e2fddee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0d45716a-c5b4-40f6-a6f1-1fa04356c069" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_69891739-defe-40f2-b3f4-e3c3c3fe3ce9" xlink:href="mgnx-20221231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f5d515-6b79-48a0-9c44-11501e2fddee" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_69891739-defe-40f2-b3f4-e3c3c3fe3ce9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b603c0a-05ce-43af-82df-6a71664b2f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f5d515-6b79-48a0-9c44-11501e2fddee" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b603c0a-05ce-43af-82df-6a71664b2f06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9b66fc91-1bb7-40fd-a9dd-d7f07a46ff73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b603c0a-05ce-43af-82df-6a71664b2f06" xlink:to="loc_us-gaap_PlanNameAxis_9b66fc91-1bb7-40fd-a9dd-d7f07a46ff73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9b66fc91-1bb7-40fd-a9dd-d7f07a46ff73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9b66fc91-1bb7-40fd-a9dd-d7f07a46ff73" xlink:to="loc_us-gaap_PlanNameDomain_9b66fc91-1bb7-40fd-a9dd-d7f07a46ff73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9adadd21-0b93-468e-abd2-f7bf42577d09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9b66fc91-1bb7-40fd-a9dd-d7f07a46ff73" xlink:to="loc_us-gaap_PlanNameDomain_9adadd21-0b93-468e-abd2-f7bf42577d09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EquityIncentivePlan2003Member_2f0c8768-3ded-481a-a0af-912f1c7c1ebc" xlink:href="mgnx-20221231.xsd#mgnx_EquityIncentivePlan2003Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9adadd21-0b93-468e-abd2-f7bf42577d09" xlink:to="loc_mgnx_EquityIncentivePlan2003Member_2f0c8768-3ded-481a-a0af-912f1c7c1ebc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_24db6701-81ec-424f-92a9-15038ecbfe61" xlink:href="mgnx-20221231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9adadd21-0b93-468e-abd2-f7bf42577d09" xlink:to="loc_mgnx_StockIncentivePlan2013Member_24db6701-81ec-424f-92a9-15038ecbfe61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9af20b96-09b2-451f-8ee4-09b316940705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f4a4d967-0efb-48a1-a12c-69d732413819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9af20b96-09b2-451f-8ee4-09b316940705" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f4a4d967-0efb-48a1-a12c-69d732413819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_92757ce7-f709-4958-89ba-292d608d5c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9af20b96-09b2-451f-8ee4-09b316940705" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_92757ce7-f709-4958-89ba-292d608d5c9c" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9100b2e3-1bbf-4f3a-857f-c1d6e2e2e527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_92757ce7-f709-4958-89ba-292d608d5c9c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9100b2e3-1bbf-4f3a-857f-c1d6e2e2e527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9100b2e3-1bbf-4f3a-857f-c1d6e2e2e527_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9100b2e3-1bbf-4f3a-857f-c1d6e2e2e527" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9100b2e3-1bbf-4f3a-857f-c1d6e2e2e527_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5c6289ee-9b72-4cd9-b9de-f2e14d365f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9100b2e3-1bbf-4f3a-857f-c1d6e2e2e527" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5c6289ee-9b72-4cd9-b9de-f2e14d365f7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e31a0aa9-2a3c-48b3-824e-546adbfc38cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c6289ee-9b72-4cd9-b9de-f2e14d365f7d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e31a0aa9-2a3c-48b3-824e-546adbfc38cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e611d7a1-8778-48d1-91ed-9bf63b57e856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c6289ee-9b72-4cd9-b9de-f2e14d365f7d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e611d7a1-8778-48d1-91ed-9bf63b57e856" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#StockbasedCompensationOptionPricingAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended" id="i268afbb1fae54726a3b6da0621405369_StockbasedCompensationOptionPricingAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03922e89-b3ec-44e4-9147-2fcfe8b1326e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_625ed54e-9e6e-495a-9f11-8c066c8ec247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03922e89-b3ec-44e4-9147-2fcfe8b1326e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_625ed54e-9e6e-495a-9f11-8c066c8ec247" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8afaa9c9-226c-4470-9dec-12fd6a89c36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03922e89-b3ec-44e4-9147-2fcfe8b1326e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8afaa9c9-226c-4470-9dec-12fd6a89c36b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1f6fcac0-083e-40c4-b8a0-8b5aed59c78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03922e89-b3ec-44e4-9147-2fcfe8b1326e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1f6fcac0-083e-40c4-b8a0-8b5aed59c78d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7cdb8774-8b56-42ad-ba2d-1003df99324c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03922e89-b3ec-44e4-9147-2fcfe8b1326e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7cdb8774-8b56-42ad-ba2d-1003df99324c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4278bdb-2887-4c3f-83f6-357e1dc66de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03922e89-b3ec-44e4-9147-2fcfe8b1326e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4278bdb-2887-4c3f-83f6-357e1dc66de4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_414b230a-4f84-4bbe-8267-ee33376647b2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4278bdb-2887-4c3f-83f6-357e1dc66de4" xlink:to="loc_srt_RangeAxis_414b230a-4f84-4bbe-8267-ee33376647b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_414b230a-4f84-4bbe-8267-ee33376647b2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_414b230a-4f84-4bbe-8267-ee33376647b2" xlink:to="loc_srt_RangeMember_414b230a-4f84-4bbe-8267-ee33376647b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f2020e4a-f9d3-4647-aa31-9014adc0b982" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_414b230a-4f84-4bbe-8267-ee33376647b2" xlink:to="loc_srt_RangeMember_f2020e4a-f9d3-4647-aa31-9014adc0b982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_faec4b52-b924-4d27-b432-cd0d7ea90c20" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f2020e4a-f9d3-4647-aa31-9014adc0b982" xlink:to="loc_srt_MinimumMember_faec4b52-b924-4d27-b432-cd0d7ea90c20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_66d67034-91fe-464a-8d9c-869ce3be5a1a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f2020e4a-f9d3-4647-aa31-9014adc0b982" xlink:to="loc_srt_MaximumMember_66d67034-91fe-464a-8d9c-869ce3be5a1a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SharebasedCompensationOptionExercisePriceRangeTableDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails" xlink:type="extended" id="i5ebe31278b91486488da3fb1f28067bb_SharebasedCompensationOptionExercisePriceRangeTableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_598cc3c8-5546-4a33-b3d3-5a143e1f911f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_2b08e939-e21a-40b5-8df7-5108a6cbe1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_598cc3c8-5546-4a33-b3d3-5a143e1f911f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_2b08e939-e21a-40b5-8df7-5108a6cbe1ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_5c5c2260-c28c-42c9-a936-a5795203b6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_598cc3c8-5546-4a33-b3d3-5a143e1f911f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_5c5c2260-c28c-42c9-a936-a5795203b6c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_728177d2-6461-41f8-92eb-c80ab04542ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_598cc3c8-5546-4a33-b3d3-5a143e1f911f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_728177d2-6461-41f8-92eb-c80ab04542ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_d1a28c5f-3f19-46b6-83cd-9cf785d0cd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_728177d2-6461-41f8-92eb-c80ab04542ed" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_d1a28c5f-3f19-46b6-83cd-9cf785d0cd8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_58fb3957-6f86-4323-b4da-0d05bfa04ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_728177d2-6461-41f8-92eb-c80ab04542ed" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_58fb3957-6f86-4323-b4da-0d05bfa04ba2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_57c18a4f-3d15-4eb7-8dce-27492f0cda17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_728177d2-6461-41f8-92eb-c80ab04542ed" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_57c18a4f-3d15-4eb7-8dce-27492f0cda17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_6b2a3a97-2cac-4d78-a594-c15f9c4c730d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_598cc3c8-5546-4a33-b3d3-5a143e1f911f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_6b2a3a97-2cac-4d78-a594-c15f9c4c730d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_ccc420bf-0915-4063-95cc-d598c6ac1f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_6b2a3a97-2cac-4d78-a594-c15f9c4c730d" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_ccc420bf-0915-4063-95cc-d598c6ac1f0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c2156f14-7d6c-47b8-b7aa-d7b6eaf71f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_6b2a3a97-2cac-4d78-a594-c15f9c4c730d" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c2156f14-7d6c-47b8-b7aa-d7b6eaf71f87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_8d24ed58-cbe8-44be-aed5-9b8fea0b337a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_598cc3c8-5546-4a33-b3d3-5a143e1f911f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_8d24ed58-cbe8-44be-aed5-9b8fea0b337a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a87229ba-5577-4bff-89bb-68eb7e2e5008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_8d24ed58-cbe8-44be-aed5-9b8fea0b337a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a87229ba-5577-4bff-89bb-68eb7e2e5008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a87229ba-5577-4bff-89bb-68eb7e2e5008_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a87229ba-5577-4bff-89bb-68eb7e2e5008" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a87229ba-5577-4bff-89bb-68eb7e2e5008_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f434ece0-12cc-4b14-b14e-10abcb582288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a87229ba-5577-4bff-89bb-68eb7e2e5008" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f434ece0-12cc-4b14-b14e-10abcb582288" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisePriceRangeFromDollars094To500MemberMember_43de983c-514e-46c8-a47a-034e9528bcf6" xlink:href="mgnx-20221231.xsd#mgnx_ExercisePriceRangeFromDollars094To500MemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f434ece0-12cc-4b14-b14e-10abcb582288" xlink:to="loc_mgnx_ExercisePriceRangeFromDollars094To500MemberMember_43de983c-514e-46c8-a47a-034e9528bcf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisePriceRangeFromDollars501To1500MemberMember_ce853eb2-6232-42d5-a505-b3c80f93c8dd" xlink:href="mgnx-20221231.xsd#mgnx_ExercisePriceRangeFromDollars501To1500MemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f434ece0-12cc-4b14-b14e-10abcb582288" xlink:to="loc_mgnx_ExercisePriceRangeFromDollars501To1500MemberMember_ce853eb2-6232-42d5-a505-b3c80f93c8dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember_0ef63e5d-f795-492a-843c-c1507afd838e" xlink:href="mgnx-20221231.xsd#mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f434ece0-12cc-4b14-b14e-10abcb582288" xlink:to="loc_mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember_0ef63e5d-f795-492a-843c-c1507afd838e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember_5f5766bd-f80b-454a-a3c2-2677f77f8b21" xlink:href="mgnx-20221231.xsd#mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f434ece0-12cc-4b14-b14e-10abcb582288" xlink:to="loc_mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember_5f5766bd-f80b-454a-a3c2-2677f77f8b21" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="extended" id="i79a0e10b28e945f7a0ce57d00407947d_StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f03eb1ab-bfa5-4734-8b8c-07caf6b03736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f03eb1ab-bfa5-4734-8b8c-07caf6b03736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_beae0fa0-0b40-438e-b2d3-ad81086e2a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_beae0fa0-0b40-438e-b2d3-ad81086e2a34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3921a1d0-5771-4eac-9d1e-aa13c57e50ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3921a1d0-5771-4eac-9d1e-aa13c57e50ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_032921c4-abd4-4a31-9b3b-9bf4c4849de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_032921c4-abd4-4a31-9b3b-9bf4c4849de9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e6b18c61-3eb4-400f-9c0a-9f124b39a7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e6b18c61-3eb4-400f-9c0a-9f124b39a7cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3d82cffc-6d2e-41c3-8123-8d9eff31999d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3d82cffc-6d2e-41c3-8123-8d9eff31999d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e5732882-5fc4-47d5-a01a-cf279d76a682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_45112385-01a5-47f8-b690-d056d414353f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_45112385-01a5-47f8-b690-d056d414353f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ba1d6320-1145-4650-b51a-24998c8ed195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ba1d6320-1145-4650-b51a-24998c8ed195" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eb9e6bd2-be5d-4680-9871-a711288c28df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eb9e6bd2-be5d-4680-9871-a711288c28df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43f42e34-2678-4f8e-8387-5f4b039a1a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43f42e34-2678-4f8e-8387-5f4b039a1a96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_20fd41bc-1bb7-40af-a8c6-e77bb107fc18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_20fd41bc-1bb7-40af-a8c6-e77bb107fc18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_da18064a-14b0-4d66-be01-eb3b63d8b13a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_da18064a-14b0-4d66-be01-eb3b63d8b13a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_82ce7c38-0bb5-4466-a09a-acc449bd5e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8ccea48f-76da-4522-9dc8-b246ffa8ea64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8ccea48f-76da-4522-9dc8-b246ffa8ea64" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b9d338e1-7bc0-4aa8-a323-6c9bdeb6da7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b9d338e1-7bc0-4aa8-a323-6c9bdeb6da7f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_89eaa7c6-77be-4ac0-8a80-d8ee73e4b8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_89eaa7c6-77be-4ac0-8a80-d8ee73e4b8e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e6d938d6-a8fe-4858-a43d-bce05abcc32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_89eaa7c6-77be-4ac0-8a80-d8ee73e4b8e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e6d938d6-a8fe-4858-a43d-bce05abcc32e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c471645f-b476-44d3-b8d6-779aeafb5f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_89eaa7c6-77be-4ac0-8a80-d8ee73e4b8e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c471645f-b476-44d3-b8d6-779aeafb5f01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_21fd5029-661f-4be3-92d2-f362075da952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_89eaa7c6-77be-4ac0-8a80-d8ee73e4b8e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_21fd5029-661f-4be3-92d2-f362075da952" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_86bcec6e-97aa-4c50-ac06-313f6ecda626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_89eaa7c6-77be-4ac0-8a80-d8ee73e4b8e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_86bcec6e-97aa-4c50-ac06-313f6ecda626" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3a2b8d1a-e08e-48cf-ab63-69685551371d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_89eaa7c6-77be-4ac0-8a80-d8ee73e4b8e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3a2b8d1a-e08e-48cf-ab63-69685551371d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c64377d9-cf0d-42aa-b40f-481e5a5759a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_89eaa7c6-77be-4ac0-8a80-d8ee73e4b8e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c64377d9-cf0d-42aa-b40f-481e5a5759a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b5c4439d-0d92-4cd9-965c-7ed23ed301b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b5c4439d-0d92-4cd9-965c-7ed23ed301b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b01c4813-b601-47e8-8b88-90e9a4649ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b5c4439d-0d92-4cd9-965c-7ed23ed301b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b01c4813-b601-47e8-8b88-90e9a4649ecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_69f5e27f-4c08-4388-9eae-9a8eccf62487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b5c4439d-0d92-4cd9-965c-7ed23ed301b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_69f5e27f-4c08-4388-9eae-9a8eccf62487" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_3aaef029-15f9-48ce-9c2c-41b65eb92aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b5c4439d-0d92-4cd9-965c-7ed23ed301b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_3aaef029-15f9-48ce-9c2c-41b65eb92aa5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e1c3460f-091b-4dd9-9d17-e97feb55a84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b5c4439d-0d92-4cd9-965c-7ed23ed301b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e1c3460f-091b-4dd9-9d17-e97feb55a84a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9a4f9144-08c0-4178-8d7e-af7d749a5b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e062169f-e1b9-4116-bf09-5fd8764392af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e062169f-e1b9-4116-bf09-5fd8764392af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b41b08f-9706-4298-b135-6d6e9f6e1338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e062169f-e1b9-4116-bf09-5fd8764392af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b41b08f-9706-4298-b135-6d6e9f6e1338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3331399d-bdde-461f-bdbf-c4c4828e1a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e062169f-e1b9-4116-bf09-5fd8764392af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3331399d-bdde-461f-bdbf-c4c4828e1a55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a4bda963-280b-4357-8dc4-6e8a24d8dd26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e062169f-e1b9-4116-bf09-5fd8764392af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a4bda963-280b-4357-8dc4-6e8a24d8dd26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_19932e94-3fef-45ec-86a6-159856b5a6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e062169f-e1b9-4116-bf09-5fd8764392af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_19932e94-3fef-45ec-86a6-159856b5a6cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_05db9e40-a54f-467c-8cc1-cd2f86d91dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5a96ca04-51c3-4209-b905-15c4a610836c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5a96ca04-51c3-4209-b905-15c4a610836c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4210fe38-9c26-4b5f-be35-d1fca4e2e142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4210fe38-9c26-4b5f-be35-d1fca4e2e142" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc2f9de3-1101-4cdf-becc-d7cec0e6052d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc2f9de3-1101-4cdf-becc-d7cec0e6052d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2dda31bb-763f-4430-9ec1-61fdec5d02e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2dda31bb-763f-4430-9ec1-61fdec5d02e5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_161b3ac3-9dbf-4d82-b39b-e9dd16313c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_161b3ac3-9dbf-4d82-b39b-e9dd16313c9f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_871b9cb6-7220-4cc8-9951-6494c29d3243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_871b9cb6-7220-4cc8-9951-6494c29d3243" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3eab483e-4414-4aea-a1af-b958f55569e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3eab483e-4414-4aea-a1af-b958f55569e6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3dfebda1-637e-4689-8724-188f9259bd23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4ecf3186-5e69-4488-9da2-13ff868bf053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4ecf3186-5e69-4488-9da2-13ff868bf053" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a1658589-0ad1-4a67-b257-3dbe6f25532d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638cebc0-8d47-4b93-999d-855c2f506711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638cebc0-8d47-4b93-999d-855c2f506711" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_509408d9-7ccf-4a33-9490-33be771a13b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638cebc0-8d47-4b93-999d-855c2f506711" xlink:to="loc_us-gaap_AwardTypeAxis_509408d9-7ccf-4a33-9490-33be771a13b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_509408d9-7ccf-4a33-9490-33be771a13b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_509408d9-7ccf-4a33-9490-33be771a13b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_509408d9-7ccf-4a33-9490-33be771a13b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1de773c9-f3d1-431d-b3e9-6ca3d586562b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_509408d9-7ccf-4a33-9490-33be771a13b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1de773c9-f3d1-431d-b3e9-6ca3d586562b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_32bc92f1-f6d9-40b7-afcc-ce8d5a5153fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1de773c9-f3d1-431d-b3e9-6ca3d586562b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_32bc92f1-f6d9-40b7-afcc-ce8d5a5153fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9c169c1a-86a3-4508-b935-c13caaedb403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638cebc0-8d47-4b93-999d-855c2f506711" xlink:to="loc_us-gaap_PlanNameAxis_9c169c1a-86a3-4508-b935-c13caaedb403" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9c169c1a-86a3-4508-b935-c13caaedb403_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9c169c1a-86a3-4508-b935-c13caaedb403" xlink:to="loc_us-gaap_PlanNameDomain_9c169c1a-86a3-4508-b935-c13caaedb403_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_be9ea29b-1a4b-4f8b-b4c0-da19b017db6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9c169c1a-86a3-4508-b935-c13caaedb403" xlink:to="loc_us-gaap_PlanNameDomain_be9ea29b-1a4b-4f8b-b4c0-da19b017db6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_85dfd8b8-e32e-4ae4-9d1b-3fce5126afcc" xlink:href="mgnx-20221231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_be9ea29b-1a4b-4f8b-b4c0-da19b017db6e" xlink:to="loc_mgnx_StockIncentivePlan2013Member_85dfd8b8-e32e-4ae4-9d1b-3fce5126afcc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="ib2aa49a7ebbe4af89318eeea0b9857fc_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c77b737a-aaea-45c6-b2a6-fc64a8153bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c77b737a-aaea-45c6-b2a6-fc64a8153bb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_e4829b24-c7a3-405a-85a0-bd915404dd22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_e4829b24-c7a3-405a-85a0-bd915404dd22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_c84ace39-e5da-4c7a-a2c3-8d1ac60b770d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_c84ace39-e5da-4c7a-a2c3-8d1ac60b770d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_fac0d874-005e-4c43-88db-9bb09510f11e" xlink:href="mgnx-20221231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_fac0d874-005e-4c43-88db-9bb09510f11e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_fe503281-9fb7-422b-9d4d-b75a3dad5379" xlink:href="mgnx-20221231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_fe503281-9fb7-422b-9d4d-b75a3dad5379" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_4ee68e34-52d7-46f0-b17a-50fda875c4a1" xlink:href="mgnx-20221231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_4ee68e34-52d7-46f0-b17a-50fda875c4a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_74e857e3-a0a1-42aa-ac9a-d70b1f46a8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_74e857e3-a0a1-42aa-ac9a-d70b1f46a8ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_308a985f-f541-45c7-ba32-183f51ecf0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_308a985f-f541-45c7-ba32-183f51ecf0e3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_c7229aa6-d776-44fd-8b50-3b29cd068a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_c7229aa6-d776-44fd-8b50-3b29cd068a39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6e77d83f-7025-4607-844d-162d76e763fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c7229aa6-d776-44fd-8b50-3b29cd068a39" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6e77d83f-7025-4607-844d-162d76e763fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6e77d83f-7025-4607-844d-162d76e763fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6e77d83f-7025-4607-844d-162d76e763fc" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6e77d83f-7025-4607-844d-162d76e763fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a9e9b88a-36d0-4c17-b7e0-847a4a77f704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6e77d83f-7025-4607-844d-162d76e763fc" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a9e9b88a-36d0-4c17-b7e0-847a4a77f704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_b4e912f1-9677-43d7-9f9f-c755f0cc5632" xlink:href="mgnx-20221231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a9e9b88a-36d0-4c17-b7e0-847a4a77f704" xlink:to="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_b4e912f1-9677-43d7-9f9f-c755f0cc5632" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_a465e5d9-d130-4f2c-81bf-d2aba2ce202a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a9e9b88a-36d0-4c17-b7e0-847a4a77f704" xlink:to="loc_us-gaap_DomesticCountryMember_a465e5d9-d130-4f2c-81bf-d2aba2ce202a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_725fea8d-1583-426b-b3c6-086a4f84b653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c7229aa6-d776-44fd-8b50-3b29cd068a39" xlink:to="loc_us-gaap_TaxPeriodAxis_725fea8d-1583-426b-b3c6-086a4f84b653" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_725fea8d-1583-426b-b3c6-086a4f84b653_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_725fea8d-1583-426b-b3c6-086a4f84b653" xlink:to="loc_us-gaap_TaxPeriodDomain_725fea8d-1583-426b-b3c6-086a4f84b653_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_6aa838f4-b838-4078-945d-28e1e1b9213c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_725fea8d-1583-426b-b3c6-086a4f84b653" xlink:to="loc_us-gaap_TaxPeriodDomain_6aa838f4-b838-4078-945d-28e1e1b9213c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2025To2037Member_193f07cd-40f7-41db-9b80-2a39a880ab63" xlink:href="mgnx-20221231.xsd#mgnx_TaxYear2025To2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_6aa838f4-b838-4078-945d-28e1e1b9213c" xlink:to="loc_mgnx_TaxYear2025To2037Member_193f07cd-40f7-41db-9b80-2a39a880ab63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember_fe5b9e96-18e6-461f-afc9-1f8d08d9eb10" xlink:href="mgnx-20221231.xsd#mgnx_IndefiniteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_6aa838f4-b838-4078-945d-28e1e1b9213c" xlink:to="loc_mgnx_IndefiniteMember_fe5b9e96-18e6-461f-afc9-1f8d08d9eb10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6d2e88f2-548a-4176-baee-05e3ba58312a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c7229aa6-d776-44fd-8b50-3b29cd068a39" xlink:to="loc_srt_RangeAxis_6d2e88f2-548a-4176-baee-05e3ba58312a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d2e88f2-548a-4176-baee-05e3ba58312a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6d2e88f2-548a-4176-baee-05e3ba58312a" xlink:to="loc_srt_RangeMember_6d2e88f2-548a-4176-baee-05e3ba58312a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a53fc1c3-64b1-48cf-8ca7-ec02151dd53b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6d2e88f2-548a-4176-baee-05e3ba58312a" xlink:to="loc_srt_RangeMember_a53fc1c3-64b1-48cf-8ca7-ec02151dd53b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7f6f81fe-82d1-4eb5-a7c9-8b0bb388b6f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a53fc1c3-64b1-48cf-8ca7-ec02151dd53b" xlink:to="loc_srt_MinimumMember_7f6f81fe-82d1-4eb5-a7c9-8b0bb388b6f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_98d424ce-522e-4e7a-a770-aa8282492740" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a53fc1c3-64b1-48cf-8ca7-ec02151dd53b" xlink:to="loc_srt_MaximumMember_98d424ce-522e-4e7a-a770-aa8282492740" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SubsequentEventsDetails" xlink:type="extended" id="ie77cf052f7394397b4a7d05ce0e97645_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_2e5647cf-e07f-42b2-80da-9882ad21f69e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_c8e37642-fd76-499d-94ac-e361cb706162" xlink:href="mgnx-20221231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2e5647cf-e07f-42b2-80da-9882ad21f69e" xlink:to="loc_mgnx_NonRefundableUpfrontFees_c8e37642-fd76-499d-94ac-e361cb706162" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPayment_245c9ac4-547a-419b-8e94-adc460eb90ec" xlink:href="mgnx-20221231.xsd#mgnx_UpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2e5647cf-e07f-42b2-80da-9882ad21f69e" xlink:to="loc_mgnx_UpfrontPayment_245c9ac4-547a-419b-8e94-adc460eb90ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureMilestone_52426b4b-d7c2-4319-99db-ab7d91d9a43c" xlink:href="mgnx-20221231.xsd#mgnx_FutureMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2e5647cf-e07f-42b2-80da-9882ad21f69e" xlink:to="loc_mgnx_FutureMilestone_52426b4b-d7c2-4319-99db-ab7d91d9a43c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureRevenue_c5ece0a1-e3bb-45e9-b38d-8154269f9e2e" xlink:href="mgnx-20221231.xsd#mgnx_FutureRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2e5647cf-e07f-42b2-80da-9882ad21f69e" xlink:to="loc_mgnx_FutureRevenue_c5ece0a1-e3bb-45e9-b38d-8154269f9e2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_b3366b2f-fa55-446f-8ef0-ca6d0e3fd97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_2e5647cf-e07f-42b2-80da-9882ad21f69e" xlink:to="loc_us-gaap_SubsequentEventTable_b3366b2f-fa55-446f-8ef0-ca6d0e3fd97c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_15d9c498-f8cc-4a09-89fc-5a3b3609077b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b3366b2f-fa55-446f-8ef0-ca6d0e3fd97c" xlink:to="loc_srt_CounterpartyNameAxis_15d9c498-f8cc-4a09-89fc-5a3b3609077b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_15d9c498-f8cc-4a09-89fc-5a3b3609077b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_15d9c498-f8cc-4a09-89fc-5a3b3609077b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_15d9c498-f8cc-4a09-89fc-5a3b3609077b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51d6246c-5de4-437a-a6b7-fa46a076a699" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_15d9c498-f8cc-4a09-89fc-5a3b3609077b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51d6246c-5de4-437a-a6b7-fa46a076a699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_63d0ec5c-611e-4e61-8b58-770baeaea2a4" xlink:href="mgnx-20221231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51d6246c-5de4-437a-a6b7-fa46a076a699" xlink:to="loc_mgnx_IncyteCorporationMember_63d0ec5c-611e-4e61-8b58-770baeaea2a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_d145d358-db98-442c-b53a-82d42afb5a47" xlink:href="mgnx-20221231.xsd#mgnx_DRIHealthcareAcquisitionsLPDRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51d6246c-5de4-437a-a6b7-fa46a076a699" xlink:to="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_d145d358-db98-442c-b53a-82d42afb5a47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c24a55f2-66a4-4d91-b7e3-de26ce993329" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b3366b2f-fa55-446f-8ef0-ca6d0e3fd97c" xlink:to="loc_srt_ProductOrServiceAxis_c24a55f2-66a4-4d91-b7e3-de26ce993329" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c24a55f2-66a4-4d91-b7e3-de26ce993329_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c24a55f2-66a4-4d91-b7e3-de26ce993329" xlink:to="loc_srt_ProductsAndServicesDomain_c24a55f2-66a4-4d91-b7e3-de26ce993329_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a685654-1e7f-4d12-9685-7b97de181e1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c24a55f2-66a4-4d91-b7e3-de26ce993329" xlink:to="loc_srt_ProductsAndServicesDomain_5a685654-1e7f-4d12-9685-7b97de181e1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_ca20d527-1019-4ee5-b5e9-f30a8ab104b3" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5a685654-1e7f-4d12-9685-7b97de181e1f" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_ca20d527-1019-4ee5-b5e9-f30a8ab104b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b17b83e6-2eae-43f8-ae6b-96df19d63650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b3366b2f-fa55-446f-8ef0-ca6d0e3fd97c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b17b83e6-2eae-43f8-ae6b-96df19d63650" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b17b83e6-2eae-43f8-ae6b-96df19d63650_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b17b83e6-2eae-43f8-ae6b-96df19d63650" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b17b83e6-2eae-43f8-ae6b-96df19d63650_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c8cf074d-c755-4de1-b2f5-7224c69b348d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b17b83e6-2eae-43f8-ae6b-96df19d63650" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c8cf074d-c755-4de1-b2f5-7224c69b348d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_05936526-d417-40e3-8c19-482dd184c728" xlink:href="mgnx-20221231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c8cf074d-c755-4de1-b2f5-7224c69b348d" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_05936526-d417-40e3-8c19-482dd184c728" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f991028a-7e21-410b-9e09-db39a45f8c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b3366b2f-fa55-446f-8ef0-ca6d0e3fd97c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f991028a-7e21-410b-9e09-db39a45f8c83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f991028a-7e21-410b-9e09-db39a45f8c83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f991028a-7e21-410b-9e09-db39a45f8c83" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f991028a-7e21-410b-9e09-db39a45f8c83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e065989e-e938-4122-800b-a5230b0da5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f991028a-7e21-410b-9e09-db39a45f8c83" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e065989e-e938-4122-800b-a5230b0da5ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9fbaccca-a085-4a01-bca4-78079e833ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e065989e-e938-4122-800b-a5230b0da5ce" xlink:to="loc_us-gaap_SubsequentEventMember_9fbaccca-a085-4a01-bca4-78079e833ea2" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>mgnx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:49d3a843-ae73-49e6-9afb-5555c20651f7,g:f863eeaf-37fc-4bf3-b50d-59432dc50ee9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_mgnx_FutureRevenue_391ba5b0-c55c-465b-a12f-4d8f4c5b7ae8_terseLabel_en-US" xlink:label="lab_mgnx_FutureRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Revenue from DRI</link:label>
    <link:label id="lab_mgnx_FutureRevenue_label_en-US" xlink:label="lab_mgnx_FutureRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Revenue</link:label>
    <link:label id="lab_mgnx_FutureRevenue_documentation_en-US" xlink:label="lab_mgnx_FutureRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureRevenue" xlink:href="mgnx-20221231.xsd#mgnx_FutureRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FutureRevenue" xlink:to="lab_mgnx_FutureRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6c2233da-8548-4a15-9aa5-7ee482390162_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_63cb4966-b6cd-4d13-9d9e-d56fe1308e54_terseLabel_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of employee vested contribution</link:label>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_label_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employees Contribution, Vested Percentage</link:label>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_documentation_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage vested of employee's contributions to defined contribution plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:href="mgnx-20221231.xsd#mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:to="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember_ae2f836a-208d-4265-b961-18a9f9b5f579_terseLabel_en-US" xlink:label="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DRI Healthcare Acquisitions LP (DRI)</link:label>
    <link:label id="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember_label_en-US" xlink:label="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DRI Healthcare Acquisitions LP (DRI) [Member]</link:label>
    <link:label id="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember_documentation_en-US" xlink:label="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DRI Healthcare Acquisitions LP (DRI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:href="mgnx-20221231.xsd#mgnx_DRIHealthcareAcquisitionsLPDRIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:to="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a297543d-9d76-4e50-96d5-22ead7382096_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_84b5108a-9981-4cac-9b5a-d823f6e0a461_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_df6fde32-57a7-43ea-aecd-e256b6a7c630_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_b1a6df81-9098-4ef2-b41a-2744b312aa8c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_80e426e6-aad2-4caf-9981-54eb723eb553_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:href="mgnx-20221231.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserveMember_80d95102-1b05-4114-af69-fb35b90b357b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Reserve, Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserveMember_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Reserve, Inventory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserveMember" xlink:to="lab_us-gaap_InventoryValuationReserveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7bc77bf9-7e80-4545-90c0-d1d9e82e5a1c_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_018222fc-6a26-4d03-8349-51eb0e8445af_terseLabel_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Collaboration and License Agreement</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20221231.xsd#mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_20c3c6c3-f7e6-4a8b-869d-1cb16b4028df_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_02f71d6e-7aa3-42c1-aaf6-ef48f4114827_terseLabel_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="mgnx-20221231.xsd#mgnx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_0d2f6bed-03ae-4458-9fe3-17e159073053_terseLabel_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIAID</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_label_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="mgnx-20221231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_92eb421b-ee8f-4453-896a-bafb42890794_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3e37c46f-1ab4-4999-91af-81b5a1661fae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5a223506-6f88-4afe-b46a-947aea8fe375_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_c772c615-826c-4600-8146-6d1e8bcc2c5e_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment, net of tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:href="mgnx-20221231.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:to="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6e58eca4-6a39-447e-a7e9-95ad9c9f683f_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_6d9f1b63-fe6e-49b7-a5c4-44a332c2449d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_7c2b192d-4fc7-457c-89d9-0f2f40c808ea_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_8caae5bd-7b36-4599-be57-a178bb9c416f_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4b351160-b69c-48b6-a0ef-f74e0a3abdcb_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_4c8584db-4f69-4aef-a7d2-2ad73eed8ae5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax asset/(liability)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_c5632016-0092-4734-bbe5-08e3bfcedee7_terseLabel_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_label_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment Estimated Useful Life Table [Table Text Block]</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property plant and equipment estimated useful life.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:href="mgnx-20221231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:to="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_577abf05-2057-4e46-87a3-f2087a1f16a0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_22158bc2-52d0-4396-81d6-0c723e1ba433_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_5b1dd026-87ad-4148-a89d-f3dd0b82abea_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal Government</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_1c28ac7e-25d7-4554-b81d-d4827e5e503e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_b079916e-88aa-4f88-af3b-411a0be1e54f_terseLabel_en-US" xlink:label="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</link:label>
    <link:label id="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_label_en-US" xlink:label="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC [Member]</link:label>
    <link:label id="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_documentation_en-US" xlink:label="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:href="mgnx-20221231.xsd#mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:to="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_2d6d7ff7-3ca4-40cd-95aa-f981adf9413b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b7e55ea5-f2f8-4798-b578-a8cd57b7bbb2_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_170914c1-67ca-4853-8d3b-d1f15766a32a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_63b7ec49-07e1-4666-a9e3-a9636654fb3a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_233086ff-dd8d-4948-87a9-88e1f3fbc75e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive stock options</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_32d8e58b-4cfb-4db4-bcaa-c57f5e1981b7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_41bbf62a-df4c-42b1-890c-fc94dd27bbe9_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4477cd0d-15a4-4138-8c8d-e85623d4840e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeArrangementTerm_b45d1937-f081-4168-8aeb-f2ad6ea929aa_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, term</link:label>
    <link:label id="lab_mgnx_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_mgnx_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_mgnx_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_mgnx_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementTerm" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeArrangementTerm" xlink:to="lab_mgnx_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_2959a1de-bdb8-49a0-9c04-322ecc8cc889_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d8785fdb-b90d-4d8c-9f54-cd0fd66d6865_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_cb04031d-b862-4130-a752-29538c16eaee_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_cee0e25a-4fa9-4126-985f-825535907c4d_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements Disclosure [Text Block]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c306e84c-f54b-4a3a-96f8-8a2e51102aaf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9efa296c-ad70-4277-8d98-456ba117a149_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_eb8e3e08-05d2-4f15-abc0-96297b236964_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_f2859b17-dbe4-4c4f-8ae2-50d2cb42b502_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_9e9db553-1e42-4259-b866-47a405ca0894_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases for current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_f267b5f4-15f4-4d03-9827-18e686a6cd6b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_4ca6908d-5808-4f08-be54-1970d28eb7f8_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAgreementsMember</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAgreementsMember [Member]</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_documentation_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:to="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_b9c0edee-0c8c-4cb3-a9ce-dc1bb502eb53_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_d540d86f-5cae-48cc-a143-17ac6d42196a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_27bc1e10-018a-4aef-9625-4f97dc7a1e3d_terseLabel_en-US" xlink:label="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Use asset and Lease Liability Increase</link:label>
    <link:label id="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_label_en-US" xlink:label="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Use asset and Lease Liability Increase</link:label>
    <link:label id="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_documentation_en-US" xlink:label="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Use asset and Lease Liability Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:href="mgnx-20221231.xsd#mgnx_RightOfUseAssetAndLeaseLiabilityIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:to="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8e97bc95-8e7c-425d-9b49-5f12d8aaa9bf_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_afcc38dc-222a-4432-b4c2-5b7c78b2fb4a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeArrangementExtensionTerm_0f1fdb5b-f5f8-4a4e-a08c-42024075f719_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeArrangementExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, extension term</link:label>
    <link:label id="lab_mgnx_CollaborativeArrangementExtensionTerm_label_en-US" xlink:label="lab_mgnx_CollaborativeArrangementExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Extension Term</link:label>
    <link:label id="lab_mgnx_CollaborativeArrangementExtensionTerm_documentation_en-US" xlink:label="lab_mgnx_CollaborativeArrangementExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementExtensionTerm" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeArrangementExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeArrangementExtensionTerm" xlink:to="lab_mgnx_CollaborativeArrangementExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_3dfc124d-7c21-404f-844f-21f8d020b539_terseLabel_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_label_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_documentation_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial fee received from collaboration or license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees" xlink:href="mgnx-20221231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonRefundableUpfrontFees" xlink:to="lab_mgnx_NonRefundableUpfrontFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_25c955ad-c5fa-414a-acaf-5373777c1ddd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_0e1727d0-dee2-4800-85c4-d46f0dd7534d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2b1d0639-f838-47f3-8020-1ff2d8bb6595_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_e61b21f7-0484-435f-9402-885c4aa0a6ec_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_52e3b4e9-88cf-47db-a3e7-0fdab652b1dd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_32e43148-fded-43f0-a348-6c712e957af3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_149b5367-6950-4981-83a6-d01e6f83c001_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_05f0fafc-8619-4235-ab82-236c5c2d3537_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e309e9d1-4135-41c9-b14f-983924c3d757_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_df95429e-584d-4f28-8689-1492b2b9b901_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FutureMilestone_97d05bbe-86af-4216-a54f-db5955da7893_terseLabel_en-US" xlink:label="lab_mgnx_FutureMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone from DRI</link:label>
    <link:label id="lab_mgnx_FutureMilestone_label_en-US" xlink:label="lab_mgnx_FutureMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Milestone</link:label>
    <link:label id="lab_mgnx_FutureMilestone_documentation_en-US" xlink:label="lab_mgnx_FutureMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureMilestone" xlink:href="mgnx-20221231.xsd#mgnx_FutureMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FutureMilestone" xlink:to="lab_mgnx_FutureMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementTerm_819182fa-6740-4998-9ee0-ddd8460650c3_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement (in years)</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementTerm_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement, Term</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementTerm_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementTerm" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationAndLicenseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementTerm" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_b39200c3-c6bf-4eb3-b60c-3f8126a8d43a_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises and ESPP purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_label_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised And ESPP Purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_documentation_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised And ESPP Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:href="mgnx-20221231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:to="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_eedfd26a-ba41-46a4-a56b-c8e4179b3326_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Total</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UpfrontAndFixedPayments_fa3dfc84-202d-4357-b112-857f793e6cb5_terseLabel_en-US" xlink:label="lab_mgnx_UpfrontAndFixedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">upfront and fixed payments</link:label>
    <link:label id="lab_mgnx_UpfrontAndFixedPayments_label_en-US" xlink:label="lab_mgnx_UpfrontAndFixedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">upfront and fixed payments</link:label>
    <link:label id="lab_mgnx_UpfrontAndFixedPayments_documentation_en-US" xlink:label="lab_mgnx_UpfrontAndFixedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">upfront and fixed payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontAndFixedPayments" xlink:href="mgnx-20221231.xsd#mgnx_UpfrontAndFixedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UpfrontAndFixedPayments" xlink:to="lab_mgnx_UpfrontAndFixedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_93bae250-fb5a-4d79-9643-18d1ab84452d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d648696b-b732-44cf-aaf5-f52253821449_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_548ab747-72b7-4e11-a52c-9fffad4d4b18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_4ca11e59-476b-480c-96e4-20c5ed7086eb_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock maximum amount available for issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:href="mgnx-20221231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_ff3fe3c8-6ff1-4f18-ad48-4c7898472e73_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_8b7ab7e8-5a2e-48ee-8d83-68c001021440_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_3576220c-bce1-4c03-8192-186091b48b4b_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_8597e806-b807-4045-a3fd-2b6f0e13d52a_terseLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax adjustments</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:href="mgnx-20221231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:to="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_77919f49-7520-4e36-9513-202dd4e5f987_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other permanent items</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5b91ac7b-5695-4d68-9112-97182bb0d76f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_fd4ad115-bb04-4625-a1ac-4afe3dcd641e_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IndefiniteMember_d6bebf10-6983-47e9-afad-a6b7782793fa_terseLabel_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_mgnx_IndefiniteMember_label_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite [Member]</link:label>
    <link:label id="lab_mgnx_IndefiniteMember_documentation_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember" xlink:href="mgnx-20221231.xsd#mgnx_IndefiniteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IndefiniteMember" xlink:to="lab_mgnx_IndefiniteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_3a001fb6-ad47-40b8-9842-4567407ca791_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of employee contribution to salary</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionBioCMOAgreeemntMember_e48ee512-e109-443f-8e46-ab9f83e61e07_terseLabel_en-US" xlink:label="lab_mgnx_ProventionBioCMOAgreeemntMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio CMO Agreeemnt</link:label>
    <link:label id="lab_mgnx_ProventionBioCMOAgreeemntMember_label_en-US" xlink:label="lab_mgnx_ProventionBioCMOAgreeemntMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio CMO Agreeemnt [Member]</link:label>
    <link:label id="lab_mgnx_ProventionBioCMOAgreeemntMember_documentation_en-US" xlink:label="lab_mgnx_ProventionBioCMOAgreeemntMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio CMO Agreeemnt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioCMOAgreeemntMember" xlink:href="mgnx-20221231.xsd#mgnx_ProventionBioCMOAgreeemntMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionBioCMOAgreeemntMember" xlink:to="lab_mgnx_ProventionBioCMOAgreeemntMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ea0fe154-b9f6-4232-b213-c1eab66ccc37_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_4ee663d8-ff02-476b-8b55-43a499b6fc9c_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_fd9f9ce1-c843-4b8c-b675-ec47316de66b_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5e4ed023-81f2-4a31-9b13-479e4f9c9340_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b63e94b2-9834-4383-8685-d916ab49cf22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfProductCandidates_c673229f-41ed-45f5-8241-f95345db6046_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product candidates to develop</link:label>
    <link:label id="lab_mgnx_NumberOfProductCandidates_label_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:label id="lab_mgnx_NumberOfProductCandidates_documentation_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates" xlink:href="mgnx-20221231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfProductCandidates" xlink:to="lab_mgnx_NumberOfProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_695c88ee-20a0-42f4-90ab-d9824a889899_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_fd067008-adbf-4699-b67b-4955a3fe6ca3_terseLabel_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development and Regulatory Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development and Regulatory Milestone Payments Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:href="mgnx-20221231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b7b7fa84-72f6-4133-a889-d6d8a8eb0a20_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_6eaabd42-d6d8-46e4-96aa-95a29c271a63_terseLabel_en-US" xlink:label="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases/(decreases) for prior year tax positions</link:label>
    <link:label id="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions</link:label>
    <link:label id="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_documentation_en-US" xlink:label="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:href="mgnx-20221231.xsd#mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d5907287-31f5-4a18-8b6a-274107711745_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ContractManufacturingMember_8913f46f-9f8a-4512-9a8a-4cfc3f2506e7_terseLabel_en-US" xlink:label="lab_mgnx_ContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing</link:label>
    <link:label id="lab_mgnx_ContractManufacturingMember_label_en-US" xlink:label="lab_mgnx_ContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing [Member]</link:label>
    <link:label id="lab_mgnx_ContractManufacturingMember_documentation_en-US" xlink:label="lab_mgnx_ContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractManufacturingMember" xlink:href="mgnx-20221231.xsd#mgnx_ContractManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ContractManufacturingMember" xlink:to="lab_mgnx_ContractManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_f9a10980-02d9-4cf5-a09b-2cec344b884f_terseLabel_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember" xlink:href="mgnx-20221231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AtTheMarketOfferingMember" xlink:to="lab_mgnx_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_a4994064-5da1-446a-8bd4-8ce6c3d3ae57_terseLabel_en-US" xlink:label="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Gilead Collaboration And License Agreement</link:label>
    <link:label id="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Gilead Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Gilead Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20221231.xsd#mgnx_A2022GileadCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_ee06eee4-d128-4c36-bb94-9776730b4aca_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ac845ce0-9992-4a27-8409-7fff46494258_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e2835ded-e051-4de7-b2ce-16c25e7ac7ab_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e04c135d-c70a-462b-abe8-c366f2e37e79_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1e6cb0df-38f8-487a-89ec-1f206b0b67ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ImabMember_a42ccf49-4eec-40d9-ac07-a071930d7fda_terseLabel_en-US" xlink:label="lab_mgnx_ImabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imab</link:label>
    <link:label id="lab_mgnx_ImabMember_label_en-US" xlink:label="lab_mgnx_ImabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imab [Member]</link:label>
    <link:label id="lab_mgnx_ImabMember_documentation_en-US" xlink:label="lab_mgnx_ImabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ImabMember" xlink:href="mgnx-20221231.xsd#mgnx_ImabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ImabMember" xlink:to="lab_mgnx_ImabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_2ede0bad-d717-4032-ac05-d94db1451e92_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dcc0653d-0c16-404f-8598-3a58df4d01de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_9b3067c9-4526-4ad6-9eaf-75fef212cae2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_2c53c9bb-b934-4297-8d03-d0fc7b6a14b0_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable Payment, Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable Payment, Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:href="mgnx-20221231.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:to="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_83e49963-027f-4914-9b2d-424a0bb1a8c5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_da41a162-00ff-4585-9c01-0c5265f72f19_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_661d8715-5d3a-4274-a5f9-66660d7290a7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_43545e6f-4736-4f00-943f-cbc937326601_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_d2bf6635-c962-4440-b875-dbcbfdc136af_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_659a9390-5d6f-4ca8-a3c8-a8c25ca6321c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_fb2eb8b2-3ff9-4db4-a343-420643f2569e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_3fad502a-90fc-42c1-aa4d-ca3f87a50141_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_6b875662-f821-4764-94ce-352e4762fc77_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="mgnx-20221231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_0b1634ab-14eb-4d8b-8862-4af508cc8879_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_696afcbd-e50c-429a-9b33-c005dc366934_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_da080bc4-d9c9-4f8a-8982-f7dcac1b5456_terseLabel_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated variable consideration</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_label_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:href="mgnx-20221231.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:to="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_1155d108-8971-4678-a754-9e93b12f7636_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_9d221018-7378-48a5-8bd2-535ede107e43_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_53cadd7d-f2d8-4778-9fb6-594c51a26f51_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Motor vehicles</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_29f46229-090b-4564-8347-f4fe35eda3a8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_c75aa2f4-60f9-4e18-b8b3-81731a289be7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_90cd5e09-885a-45f9-aae7-0f55ee582670_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales revenue, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_405f5c6e-ee89-432d-8b89-be36884801a2_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from collaborative agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:href="mgnx-20221231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:to="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_62dbc05c-9856-4fab-a3b6-66be6f8355c9_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_label_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:to="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_dc016a5f-0dbe-44da-a2a9-1a5e6f49b9ed_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_79f7889d-83a1-460b-a2a2-9a3fb10f15e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_e3644895-c0e9-436a-acc3-62e32dbd9171_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment to third parties for intellectual property under agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:href="mgnx-20221231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:to="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_a54ce1b1-0f73-4913-a920-c7a10c8dc07e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_48f2469b-58b8-4e55-938b-067e81e1098d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CostOfManufacturingServices_854b7ccf-682c-46c7-b34a-2c827fee60cc_terseLabel_en-US" xlink:label="lab_mgnx_CostOfManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of manufacturing services</link:label>
    <link:label id="lab_mgnx_CostOfManufacturingServices_label_en-US" xlink:label="lab_mgnx_CostOfManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of manufacturing services</link:label>
    <link:label id="lab_mgnx_CostOfManufacturingServices_documentation_en-US" xlink:label="lab_mgnx_CostOfManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of manufacturing services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices" xlink:href="mgnx-20221231.xsd#mgnx_CostOfManufacturingServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CostOfManufacturingServices" xlink:to="lab_mgnx_CostOfManufacturingServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_682a905c-1eda-4553-b051-897b8b0f2e52_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_92abdcab-61ec-4d9b-99e7-61aa57989fa4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_a4a1a336-b540-4b5f-98d7-0c84e619617c_negatedLabel_en-US" xlink:label="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease ROU assets</link:label>
    <link:label id="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right Of Use Assets</link:label>
    <link:label id="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:href="mgnx-20221231.xsd#mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TaxYear2025To2037Member_057db605-ef9b-422a-b73c-b174fa52c4bd_terseLabel_en-US" xlink:label="lab_mgnx_TaxYear2025To2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2025 To 2037</link:label>
    <link:label id="lab_mgnx_TaxYear2025To2037Member_label_en-US" xlink:label="lab_mgnx_TaxYear2025To2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2025 To 2037 [Member]</link:label>
    <link:label id="lab_mgnx_TaxYear2025To2037Member_documentation_en-US" xlink:label="lab_mgnx_TaxYear2025To2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2025 To 2037</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2025To2037Member" xlink:href="mgnx-20221231.xsd#mgnx_TaxYear2025To2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TaxYear2025To2037Member" xlink:to="lab_mgnx_TaxYear2025To2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_75d6e574-ed70-4d24-808d-51a6746d551d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value Measurement Financial Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCommercialSupplyAgreementMember_415ce7c4-67b0-42ce-8d19-76ded76309aa_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCommercialSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:label id="lab_mgnx_IncyteCommercialSupplyAgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteCommercialSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Commercial Supply Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteCommercialSupplyAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteCommercialSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Commercial Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCommercialSupplyAgreementMember" xlink:href="mgnx-20221231.xsd#mgnx_IncyteCommercialSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCommercialSupplyAgreementMember" xlink:to="lab_mgnx_IncyteCommercialSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_56bf2a77-d222-485d-a258-3502dcefac40_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_5d4efbaf-4495-4c47-ae42-2c52cad845f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_3ac4a90e-de5d-4cf5-915f-77ee73e79f0c_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_7b997758-bee4-4e29-9b04-9c4a924e233c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a79fb6b8-bd0a-4982-b011-cf9579081d68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c0cd0998-6386-493d-92b4-44efcd42ef3a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6465f7ba-fcda-4154-9989-17dca1d1bb47_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Total</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_a7a61f87-607a-4a7e-a112-d3b10fd8c2a6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan drug credit, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_3ab2020f-841d-4500-bc2e-1c3def83e8e2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentMilestonesAmount_094fa3c6-a858-41e3-b554-8abc3f5bbb0b_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestones</link:label>
    <link:label id="lab_mgnx_DevelopmentMilestonesAmount_label_en-US" xlink:label="lab_mgnx_DevelopmentMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones, Amount</link:label>
    <link:label id="lab_mgnx_DevelopmentMilestonesAmount_documentation_en-US" xlink:label="lab_mgnx_DevelopmentMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentMilestonesAmount" xlink:href="mgnx-20221231.xsd#mgnx_DevelopmentMilestonesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentMilestonesAmount" xlink:to="lab_mgnx_DevelopmentMilestonesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_f9e4888f-1f54-4a8f-88a7-49fd06bc951f_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement Clinical Supply</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement Clinical Supply [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement Clinical Supply</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:href="mgnx-20221231.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:to="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ASDHealthcareAndOncologySupplyMember_2d128d91-10a4-425e-933d-2d6f7c0facb9_terseLabel_en-US" xlink:label="lab_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASD Healthcare and Oncology Supply</link:label>
    <link:label id="lab_mgnx_ASDHealthcareAndOncologySupplyMember_label_en-US" xlink:label="lab_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASD Healthcare and Oncology Supply [Member]</link:label>
    <link:label id="lab_mgnx_ASDHealthcareAndOncologySupplyMember_documentation_en-US" xlink:label="lab_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASD Healthcare and Oncology Supply</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:href="mgnx-20221231.xsd#mgnx_ASDHealthcareAndOncologySupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:to="lab_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AuditorInformationAbstract_label_en-US" xlink:label="lab_mgnx_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_mgnx_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_mgnx_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AuditorInformationAbstract" xlink:href="mgnx-20221231.xsd#mgnx_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AuditorInformationAbstract" xlink:to="lab_mgnx_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_fbfb7ade-488e-443a-9847-be2280982ba9_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_4e0d47ec-ad30-4d99-b683-70e74f234028_verboseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestones recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_label_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_documentation_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:href="mgnx-20221231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:to="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_5f98b975-9143-4898-859c-83714a443448_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_ae5e57c3-e52e-4c60-88c0-59b2537ae089_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments and royalties on product sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties On Product Sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments and Royalties On Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:href="mgnx-20221231.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:to="lab_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_cfc3c5e7-0415-45b6-9694-0b87dd841730_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteClinicalSupplyAgreementMember_f0f22ec6-ca3c-4d11-9d9a-4a2ac210ccf0_terseLabel_en-US" xlink:label="lab_mgnx_IncyteClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Supply Agreement</link:label>
    <link:label id="lab_mgnx_IncyteClinicalSupplyAgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Clinical Supply Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteClinicalSupplyAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Clinical Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteClinicalSupplyAgreementMember" xlink:href="mgnx-20221231.xsd#mgnx_IncyteClinicalSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteClinicalSupplyAgreementMember" xlink:to="lab_mgnx_IncyteClinicalSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_019c9845-70ee-4112-b8d1-a58d16a3a915_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b3a17ded-269c-4f3c-a547-a14e8d3d1e54_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Stock Options Award Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_SynaffixBVMember_fb4a3068-a9c9-4f0a-bdcc-54476f6e8b94_terseLabel_en-US" xlink:label="lab_mgnx_SynaffixBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synaffix B.V.</link:label>
    <link:label id="lab_mgnx_SynaffixBVMember_label_en-US" xlink:label="lab_mgnx_SynaffixBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synaffix B.V. [Member]</link:label>
    <link:label id="lab_mgnx_SynaffixBVMember_documentation_en-US" xlink:label="lab_mgnx_SynaffixBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synaffix B.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_SynaffixBVMember" xlink:href="mgnx-20221231.xsd#mgnx_SynaffixBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_SynaffixBVMember" xlink:to="lab_mgnx_SynaffixBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_dd93826a-c9be-43b0-a0df-d2aae3b132d2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d201f478-5ff6-40ec-a813-4cf0bc6cd356_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05cdfbbc-6f85-45fc-a9cf-2df2e1fa07e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_7eeda382-4802-4729-8b75-709375c9073d_terseLabel_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Collaboration And License Agreement</link:label>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Zai Lab Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20221231.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_adc811ac-103b-4324-a87f-aa7ba03cac45_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_9c76c946-2f8f-4b15-bf90-a462ef43eed5_terseLabel_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:href="mgnx-20221231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_745f4cb2-e592-4f38-9d99-c0b042544050_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_62c572e2-40dc-4e6c-8b52-f312383324cb_terseLabel_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated Preferred Stock</link:label>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_label_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_documentation_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember" xlink:href="mgnx-20221231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UndesignatedPreferredStockMember" xlink:to="lab_mgnx_UndesignatedPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_d0a24735-914b-49ee-98b4-952c9936dcbc_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_bb49e2df-6461-4419-98b1-20d7247c4b2b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_672135ae-26b1-43c0-b582-413bb89941fe_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_42b5367a-2d83-483b-8b55-6b2d56d9e2cf_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb873df2-2a1b-422a-bfaf-fa62e16fb083_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e2bf2aa6-4910-43e7-a302-410d6184ecc5_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued or sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OneTimeMillstoneCredit_877b3f21-6e49-4301-8bae-6ea2c5ccc822_terseLabel_en-US" xlink:label="lab_mgnx_OneTimeMillstoneCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Millstone Credit</link:label>
    <link:label id="lab_mgnx_OneTimeMillstoneCredit_label_en-US" xlink:label="lab_mgnx_OneTimeMillstoneCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Millstone Credit</link:label>
    <link:label id="lab_mgnx_OneTimeMillstoneCredit_documentation_en-US" xlink:label="lab_mgnx_OneTimeMillstoneCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Millstone Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OneTimeMillstoneCredit" xlink:href="mgnx-20221231.xsd#mgnx_OneTimeMillstoneCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OneTimeMillstoneCredit" xlink:to="lab_mgnx_OneTimeMillstoneCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_8ff0a4ba-af59-4286-8f93-ddfc4d52c420_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_b7ad1693-627a-4e80-81bc-970e5b4b27c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b9449552-1d21-47c7-85fa-afedbb18331a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1fbcadd9-2572-4329-8bea-6d3ee7dc6a5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Price, upper limit</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCorporationMember_e3d13e0f-c38a-4970-98cb-558b72ff4a77_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation (Incyte)</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_label_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation [Member]</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_documentation_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember" xlink:href="mgnx-20221231.xsd#mgnx_IncyteCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCorporationMember" xlink:to="lab_mgnx_IncyteCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1b1ad5c6-f615-4151-bcd0-126fa734887f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6122d4d1-23f4-4d78-ae1a-b958ecaf5f05_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7f1726db-7b30-4a22-8601-8760481eb41a_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_79ef01b1-0156-4bf2-b272-9175afde2642_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromGrantsMember</link:label>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromGrantsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromGrantsMember" xlink:to="lab_mgnx_RevenuesFromGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember_3675209a-1138-47c8-8e66-4ff413540e1f_terseLabel_en-US" xlink:label="lab_mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range From Dollars 15.01 to 25.00 Member</link:label>
    <link:label id="lab_mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember_label_en-US" xlink:label="lab_mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range From Dollars 15.01 to 25.00 Member [Member]</link:label>
    <link:label id="lab_mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember_documentation_en-US" xlink:label="lab_mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range From Dollars 15.01 to 25.00 Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember" xlink:href="mgnx-20221231.xsd#mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember" xlink:to="lab_mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fa85a1ef-73d7-4f8b-9aed-cc820bb66fdf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_b1ccca0b-ce8a-4ece-8b99-7da5e702dac3_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_15791721-c81a-4ada-8748-7fec03bb2219_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_19b9c29d-6784-436d-b6f8-5763444f505e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0ba4e4d1-1b03-4d85-afb7-8002a6f07fe0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_a50e0621-be0a-46fe-ad0c-ec75f0a7b4dc_terseLabel_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible age to participate in plan</link:label>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_label_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees Eligible Age To Participate In Benefit Plan</link:label>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_documentation_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to minimum eligible age of employee to participate in benefit plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:href="mgnx-20221231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:to="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_bd32a0f2-7d3a-455f-ac3a-f793a991263a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_fcf3d751-347d-4c9d-b692-1d8a6fcb30fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_f968c9da-951c-46ab-99ce-d5acd767611a_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_ac106fa6-b2ae-43a1-acd5-08d1c9511f8a_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e152e67d-ee81-4a1b-a48a-f758e77884ef_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2631dc9c-8993-4cef-93de-d45229ad960a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_fca4281e-88e8-4299-a28d-b3855bd5d8dd_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increased number of shares authorized (in shares)</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award number of shares authorized after increase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:href="mgnx-20221231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_d6f40734-8010-4abb-878e-9d3421bb8a05_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_af1c95f1-ac33-4c9b-95c9-8da57357e56a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Life in Years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_2b179c0f-f632-451e-ae3b-2082fbcf4a62_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_4b897895-5f9c-4664-a16c-b4d253db3ed7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_6e8e9a1b-d740-404d-84d5-f356da4bc74c_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalAnnualFixedPayments_a7c3b9c9-56c9-47b7-a75a-5bb48deab1ca_terseLabel_en-US" xlink:label="lab_mgnx_TotalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Annual Fixed Payments</link:label>
    <link:label id="lab_mgnx_TotalAnnualFixedPayments_label_en-US" xlink:label="lab_mgnx_TotalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Annual Fixed Payments</link:label>
    <link:label id="lab_mgnx_TotalAnnualFixedPayments_documentation_en-US" xlink:label="lab_mgnx_TotalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Annual Fixed Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalAnnualFixedPayments" xlink:href="mgnx-20221231.xsd#mgnx_TotalAnnualFixedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalAnnualFixedPayments" xlink:to="lab_mgnx_TotalAnnualFixedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5648eaf7-1dfa-49ce-9bf4-95f7125af2e4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a373862c-466b-4933-b725-bfa28e50ab7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_7f5571e8-34c7-4bee-880d-a0cd38362c5c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_da9d84a0-fbd7-4ede-bd65-b0aad5a25a9f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_a1a4888a-7fdd-43cf-af2f-b847c4dd0fce_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3874da68-e6d0-41ca-a545-2f478f75daa6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credit, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3b354ad6-2f01-4cd8-bc02-be66dc34f534_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_ecf67af4-403a-4534-b97b-bfd2be0fa3da_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_aaacdec8-d19c-4305-9808-30e2393bf24e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8689805b-db01-49ba-aa97-c79432e0e213_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaMember_a83120b5-94fc-4234-a9f5-ba2f054fdd3c_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember" xlink:href="mgnx-20221231.xsd#mgnx_IMabBiopharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaMember" xlink:to="lab_mgnx_IMabBiopharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_dc9191c6-7612-44f0-8089-ea074cc894ea_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_c594a3f8-f92c-42a2-929a-80116655a824_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Limited (Zai Lab)</link:label>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_label_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Limited [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabLimitedMember" xlink:to="lab_mgnx_ZaiLabLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_76f22fca-aedb-4fb5-bb75-a6654878ab43_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of significant accounts receivable</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_6651f24b-4d60-4f31-a15b-84e9805ceda0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_4e96b404-5908-4001-a679-d96eb864b630_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AdditionalAnnualFixedPayments_ba78ef00-b51a-4e28-96f8-a987f277613a_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Annual Fixed Payments</link:label>
    <link:label id="lab_mgnx_AdditionalAnnualFixedPayments_label_en-US" xlink:label="lab_mgnx_AdditionalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Annual Fixed Payments</link:label>
    <link:label id="lab_mgnx_AdditionalAnnualFixedPayments_documentation_en-US" xlink:label="lab_mgnx_AdditionalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Annual Fixed Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalAnnualFixedPayments" xlink:href="mgnx-20221231.xsd#mgnx_AdditionalAnnualFixedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalAnnualFixedPayments" xlink:to="lab_mgnx_AdditionalAnnualFixedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_674d2278-f386-44fb-bbce-3c42059e9cc9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_33ee4b73-87b2-49e7-8d5b-52c0810a9aab_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_3f1f1270-5516-4eb8-a6b0-fcb4e3e60f89_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d4547c1c-1f22-423f-b862-5f3006390caa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_37dc2b58-ec9b-4ee3-a898-937129d20a11_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_1384039e-42f2-4f51-920c-eb17f0d983bd_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_71350f0d-fed4-41cc-bcf1-1da858c05638_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_4fd40e71-d918-419a-941e-bfe65a43d6f5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_792da95e-ecf1-446d-8f26-8b7753ae7447_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_9436603d-e570-4018-bc72-7435a3cec29b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b74def1c-9ee9-4d6d-84b4-c75556863b01_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e769e4b4-0730-4141-b2d2-8b7c0289241c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_3a9e0879-6b39-41da-b29e-72126c320eef_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_8d93cdb3-85d7-4ecc-9939-157a35be0e37_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Federal tax credits carry forward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_cba23ea6-f973-4a1a-abd6-80144d87187f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_d1e398e1-63f7-40a3-a4f0-04d62eaa3bf4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_3f4d3899-1936-4631-b569-c1b90fab3361_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f22a1879-5e1f-454f-84e4-50751e46fc28_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3511fc79-9586-4e9b-a2e5-c54e0812f60d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_b47014b0-75c2-4d13-b3fd-ecf06724b2d0_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining portion of net operating losses</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Not Subject To Limitation</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards not subject to limitation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:href="mgnx-20221231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:to="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_6cecb9b2-26fa-44ba-9498-1b6934e8c6bb_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock warrants (in shares)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_504f3582-b775-4d77-87fd-30f6a3bed419_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_dfadbf21-61f7-4d0d-a1d9-ebd838a516b4_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_42fc774e-d819-4d42-887a-f9104e37b9a0_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b7606ca-8698-4705-8e66-6ad458a49aeb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_1c7deed5-a92a-415b-af49-58f331d8c0b6_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_bae2117d-f2e3-446a-bbff-08a34fd2bc15_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_ee32f877-cb79-4f83-ada3-2b4c45d5d8e6_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Transaction Price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:to="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_330bd0b4-3bdb-4d5c-a85c-bc204332cade_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e3cb1fd0-a54a-40c0-9e3d-d53522bdf625_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9044c663-850d-49c3-a72f-b0f098282a66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_e0e6faf0-ac6d-4435-965f-41fc375e8925_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_9084d428-f74a-48aa-bde9-f36f0b775b94_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_654a6673-9c5c-4851-b7f0-9733b73857b7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_cd42b49a-63aa-4106-82d1-3a140debfad9_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:href="mgnx-20221231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5b02f9e9-54fd-4669-8953-f56affbfa988_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e1e59953-34bc-41bb-a4d4-c3fe01b22e19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_cbbe5a8c-822f-44bd-ab25-215176b80774_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_fcc15b54-b759-4633-b907-742a973eab9c_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_13b0f089-4e11-4647-b519-8af1503588f1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3ba40f41-d5cc-45e1-a012-1860189351c2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized interest or penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_adc6c62a-8acf-4063-b6b0-bfe7bf1ebc16_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c33cfac7-28c1-48e6-9503-d59d8d1fcb8f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c2cb8d3d-5988-42db-9ae8-08726a652a9f_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_b1daf56d-7a8e-4023-aaa2-de0574ed3478_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from government agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Government Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Government Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:href="mgnx-20221231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:to="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember_175ce73a-7882-4939-b80a-e3ae5e50f505_terseLabel_en-US" xlink:label="lab_mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range From Dollars 25.01 to 40.21 Member</link:label>
    <link:label id="lab_mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember_label_en-US" xlink:label="lab_mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range From Dollars 25.01 to 40.21 Member [Member]</link:label>
    <link:label id="lab_mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember_documentation_en-US" xlink:label="lab_mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range From Dollars 25.01 to 40.21 Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember" xlink:href="mgnx-20221231.xsd#mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember" xlink:to="lab_mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ExercisePriceRangeFromDollars094To500MemberMember_4ff1919a-2800-44f1-8d31-6de8ede0758f_terseLabel_en-US" xlink:label="lab_mgnx_ExercisePriceRangeFromDollars094To500MemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range From Dollars 0.94 to 5.00 Member</link:label>
    <link:label id="lab_mgnx_ExercisePriceRangeFromDollars094To500MemberMember_label_en-US" xlink:label="lab_mgnx_ExercisePriceRangeFromDollars094To500MemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range From Dollars 0.94 to 5.00 Member [Member]</link:label>
    <link:label id="lab_mgnx_ExercisePriceRangeFromDollars094To500MemberMember_documentation_en-US" xlink:label="lab_mgnx_ExercisePriceRangeFromDollars094To500MemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range From Dollars 0.94 to 5.00 Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisePriceRangeFromDollars094To500MemberMember" xlink:href="mgnx-20221231.xsd#mgnx_ExercisePriceRangeFromDollars094To500MemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ExercisePriceRangeFromDollars094To500MemberMember" xlink:to="lab_mgnx_ExercisePriceRangeFromDollars094To500MemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_aeb165cb-16c4-4f98-b4d1-3fdd3252f177_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received common stock warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_a6de0e1b-af2d-4e78-9d0a-49d65815e99e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_083594c4-8a59-4e59-bd9e-8191b3b35032_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b1a96f4e-b7da-45d6-a107-6e9eaf03fbf6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8ccd07e8-28fa-45b5-932d-cf819b7a1ef5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_49e46de7-d9cb-4f66-b92a-c8442a2ea753_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0a8af1e9-e24c-4cf7-85ea-cab986ce6656_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_7382a7f1-1266-4d39-b95e-5dd78a2937d4_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0d8726b3-02d8-41f5-97cf-78a9bbb2f9ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_11a8428d-88c9-461a-81bc-4ec073277b31_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_19b62098-b586-4b0c-bd1a-2365732dde8c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8db2763a-49ac-4e7c-bca7-1e74c1af9428_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_182e4fd0-491e-41c1-88cd-f0ad3aa93380_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_53292bd4-738f-4d38-9e60-c108d1bfda68_terseLabel_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential value</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_label_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential value of agreement</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to total potential value under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:href="mgnx-20221231.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:to="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_9c92cc9a-f107-4301-8514-3d095d5a4148_terseLabel_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_label_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements [Member]</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:href="mgnx-20221231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:to="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_55eeefd0-9d50-4137-8693-c530dbf0af7b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_fec544a8-bb59-4ef9-a50f-8f6929ac51d9_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for federal or state income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_88394886-739a-497e-8840-d04bff4dd056_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_ea01d14d-0fac-4d3d-bbee-04df0ea2ba08_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_50897585-0560-4940-a0b4-ccaabdd97ab6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, ROU Assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e509650b-0364-4658-b2a9-9746ca4f7458_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_31ae9df7-82aa-4e70-b69f-39fb24646c01_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_25542db3-c101-4df6-9d05-668f77b3233e_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2bca979d-6578-41e3-927e-24280f7047c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_260e68f7-2378-45e9-81e0-76087d07921a_terseLabel_en-US" xlink:label="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information, Operating Leases</link:label>
    <link:label id="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information, Operating Leases [Table Text Block]</link:label>
    <link:label id="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information, Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:href="mgnx-20221231.xsd#mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:to="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_dc291cf0-35a7-411d-8182-9c0e13e2ae11_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_336ff9bb-d209-4215-b81d-4b3871ad4f1e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0a2fc490-d0f8-4eff-81d0-fa41813f84f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3a9aaa0c-e9c9-4b16-8f1c-27857b34cd64_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4d6487c0-11a2-49a3-baa0-5001813c79d1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_b259428e-baf7-4815-aea7-a9f35c0b952c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal U.S. net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c5ce987b-e8bb-4fa8-bd8f-877fda38070a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_87211b4e-f7e1-4e1f-a26a-d00afebb7dc0_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_bab142b2-9bcf-4011-8589-07c69b782b72_terseLabel_en-US" xlink:label="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Reimbursement for Research and Development t</link:label>
    <link:label id="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_label_en-US" xlink:label="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Reimbursement for Research and Development t</link:label>
    <link:label id="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_documentation_en-US" xlink:label="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Reimbursement for Research and Development t</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:href="mgnx-20221231.xsd#mgnx_EstimatedReimbursementForResearchAndDevelopmentT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:to="lab_mgnx_EstimatedReimbursementForResearchAndDevelopmentT" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_c054b801-20b5-483b-9c3b-d4587e8689fb_terseLabel_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal and State</link:label>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_label_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]</link:label>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_documentation_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:href="mgnx-20221231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:to="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b291153e-a952-4c0d-b984-fc93d428b483_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_50f671e5-3030-44a4-a3d4-2802ea1e8933_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5e140bf0-ec8a-40d0-8734-3ab210cea685_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_fbdc3413-bf72-4085-9790-1bc661307004_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense/(benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1cfa8686-ea28-4d78-b328-280c8d1cff3f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b6ed71e2-9879-495e-ab39-9e97b2a49af5_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_42299072-aac3-425d-aa3b-cf25aa6dea68_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c8c20614-6987-4c37-b985-951bccf5ba7c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Equipment and Software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_21a884f0-7440-4008-9d19-f90b20c1b14b_terseLabel_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercial milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Commercial Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Commercial Milestone Payments Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:href="mgnx-20221231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_c57c0b88-79df-4928-92bd-d1c922ebda9b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_853df6d6-0d57-4b02-97a9-14204d5f16ad_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_5af8de34-52f1-4b03-a295-44d43d4e6bb6_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_5b6ca8eb-3ac6-423c-9b34-c21a021f892f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_376650fc-6ca9-430f-8f3d-41a06053c96c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3e167504-44a2-481b-aba5-a634317c3db8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_5db5609e-8fa7-4dd0-bfa4-368de5afd1c5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_a4b7ef12-8fa2-44da-bed2-7772abf456a9_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenditures</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fd39fac9-f5dd-4d22-9e19-ec04845c9e31_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average number of common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_76c86764-202d-41cb-bb70-aab329d19cb7_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_30977470-e759-4e18-b559-4cb918008231_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_22b913f1-6a0e-4a2b-a3b2-c235f30b1877_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_f654d044-3e93-44d4-891c-4ab5818d1c85_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential proceeds from royalties percent</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_label_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties, Percent</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_documentation_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:href="mgnx-20221231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:to="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c6e4fcd9-6b79-4b44-b6cc-80729a27e162_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ea1f5c6-c15d-4f12-94ab-387e6f7dfc1c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_7dc16f61-b420-456a-891e-768974c65ef6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_1b1848ad-0cc3-4f37-84f0-2d48470de1a6_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_869d8f75-541a-4702-aeba-33faeb4550ea_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses limited for use utilized on an annual basis</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Annual Limitation Amount</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net operating loss which are limited for use, utilized on a annual basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:href="mgnx-20221231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:to="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_933d231c-2fc9-4152-b444-2b4eea3cd52d_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_Investments_9d8434b1-cdab-4cf7-9dd3-4a4d31e63e50_verboseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_48391949-7f4e-4c72-8733-348c91fef6dc_terseLabel_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2003</link:label>
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_label_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2003 [Member]</link:label>
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_documentation_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2003</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EquityIncentivePlan2003Member" xlink:href="mgnx-20221231.xsd#mgnx_EquityIncentivePlan2003Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EquityIncentivePlan2003Member" xlink:to="lab_mgnx_EquityIncentivePlan2003Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_da473e90-4d0b-4ec2-af72-13b5ada22689_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, 0.01 par value -- 125,000,000 shares authorized, 61,701,467 and 61,307,428 shares outstanding at December&#160;31, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8ad24837-cf22-4d76-81d5-701bc59c3ea5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3dfd2390-5330-450b-b0e9-cd7a29ca94e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bff1ea75-9dbc-45de-9bfc-09b030d1e507_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_d4c139a1-c3af-417a-ae30-81b7fa337f04_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cd54a8ae-42f7-44a5-be75-6ae078f621d4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2d30c060-77fd-461e-ae61-b6a47f888fbb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_c896b857-c7ee-4337-b342-d3ff6b89859f_terseLabel_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_1dfeb0f8-82ad-4306-a026-76b33bce7f2c_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember" xlink:href="mgnx-20221231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementMember" xlink:to="lab_mgnx_IncyteMGA012AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f2221200-9ce2-429f-9a4d-10a02d366245_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b5fdae9d-88bf-4b53-94d7-34b2c190f412_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_e5def2b6-ba70-4b92-89ca-868ff10abaa0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9f99f1ca-912a-4e1e-bbc3-b2f99a9bc523_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_6265184f-c24f-4099-ac82-f854b7b9e17c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_f9cbb674-1856-4014-a4cd-248e2f8c372f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_59af4403-d4a7-4f0f-8dba-939788a30fae_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_5f30c301-31a3-4fcc-88a4-f6eb6bf674a2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan drug credit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3c80aaaf-2627-4150-9d11-d68f98ea4a2b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_615cea28-328d-442d-97f2-38a4aaa53f8a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_37715821-8a3d-4dc5-aa84-98c9753df3f2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6f14f28b-adcd-4f22-9d04-9e514dd9b980_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Total</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_7bb23a5e-3016-4f8c-bc33-bc5b27228441_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2bea9257-4ea9-42b3-a288-fefe17f8c1b2_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_49c633c9-cd75-484e-aec8-ce8a3022b885_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1386bf83-a9fe-4648-bcfe-cbf51f65df15_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_16dea75f-a263-46cc-86d7-c44e2cf58ecc_terseLabel_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and office equipment</link:label>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_label_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and Office Equipment [Member]</link:label>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:href="mgnx-20221231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:to="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1c002023-a819-496b-8370-4b3857c962e0_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f87f9f1a-0814-46a2-8979-5e3a99672cb4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d0a75ab-1f30-4344-a931-b54072ab7888_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_879e084e-a21c-4956-a88d-67fabe78f923_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_6d274d2b-be21-4b07-9770-a2020dbdf3f3_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_ad2a8098-4b67-4b34-b65e-4ee24c7f1740_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of fair market value to purchase shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_MilestonesValueAddedTax_a16fcdb5-8841-4dbc-a70d-32c5f5a49846_terseLabel_en-US" xlink:label="lab_mgnx_MilestonesValueAddedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones Value Added Tax</link:label>
    <link:label id="lab_mgnx_MilestonesValueAddedTax_label_en-US" xlink:label="lab_mgnx_MilestonesValueAddedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones Value Added Tax</link:label>
    <link:label id="lab_mgnx_MilestonesValueAddedTax_documentation_en-US" xlink:label="lab_mgnx_MilestonesValueAddedTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones Value Added Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonesValueAddedTax" xlink:href="mgnx-20221231.xsd#mgnx_MilestonesValueAddedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_MilestonesValueAddedTax" xlink:to="lab_mgnx_MilestonesValueAddedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_e1730f7d-2403-40ae-bd6e-7281c64b2271_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions Charged to Expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d4c40364-6db4-409a-8004-982bfdc38e48_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ExercisePriceRangeFromDollars501To1500MemberMember_05d49081-6661-4b1b-a5dd-2e3e2d45eb2b_terseLabel_en-US" xlink:label="lab_mgnx_ExercisePriceRangeFromDollars501To1500MemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range From Dollars 5.01 to 15.00 Member</link:label>
    <link:label id="lab_mgnx_ExercisePriceRangeFromDollars501To1500MemberMember_label_en-US" xlink:label="lab_mgnx_ExercisePriceRangeFromDollars501To1500MemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range From Dollars 5.01 to 15.00 Member [Member]</link:label>
    <link:label id="lab_mgnx_ExercisePriceRangeFromDollars501To1500MemberMember_documentation_en-US" xlink:label="lab_mgnx_ExercisePriceRangeFromDollars501To1500MemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range From Dollars 5.01 to 15.00 Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisePriceRangeFromDollars501To1500MemberMember" xlink:href="mgnx-20221231.xsd#mgnx_ExercisePriceRangeFromDollars501To1500MemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ExercisePriceRangeFromDollars501To1500MemberMember" xlink:to="lab_mgnx_ExercisePriceRangeFromDollars501To1500MemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f74bc3c0-445f-430c-a366-c2ffa5164831_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7f2c8390-2f86-4d53-87ac-f37e32473f0a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e6669fc0-fd83-4a4e-a36c-1e9ebe226da1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV3279Member_437fed05-1f92-4b48-8d86-88a6f25cfb86_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV3279</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV3279 [Member]</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_documentation_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV3279</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member" xlink:href="mgnx-20221231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV3279Member" xlink:to="lab_mgnx_ProventionPRV3279Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_ce72bb98-3535-4710-ac16-d21530c455b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember_254b44e5-e58b-4a12-a5e2-bf2e344e5c58_terseLabel_en-US" xlink:label="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and RSUs</link:label>
    <link:label id="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:href="mgnx-20221231.xsd#mgnx_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_e1a18d91-d0d5-4136-aa62-d68395daa487_terseLabel_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc.</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_label_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Biotech Inc [Member]</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_documentation_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty in collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember" xlink:href="mgnx-20221231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenBiotechIncMember" xlink:to="lab_mgnx_JanssenBiotechIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_910c0eca-5e88-4f67-8476-e8cedb5e4f2a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ade3166-a6d8-4eed-8fa1-16ef4b53681b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Agreements [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ff7d7854-d1a6-45d0-bfab-9bc92bd5e9ef_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_19c97755-7273-4eac-8f30-da4dff086605_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2ca35af7-1cb2-4218-b2a6-442df1b4da32_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_ec5427a5-5866-472d-b0b3-1dda19d251fc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d8f8e026-a278-49a9-a8e1-f1602cbefe8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f2f91818-7ad1-422a-87d5-42850b6f55e7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b1647735-3d4b-4b13-8792-0520041448b7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_57a15abb-4ec2-4fe8-aec4-bf6dac8bfd82_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_4e1578be-22b0-4c0c-9dc1-c610dd57b7df_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_2572681d-dc95-47d8-b057-cea68f26ec81_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity (in shares)</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:href="mgnx-20221231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_58be0a54-bed4-43f7-b8c3-0c605b7cea72_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_50111f28-6daa-4eff-98be-6e59903fae40_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b1ebf9c8-67d6-415c-bee9-beec81235d6d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_987f8018-f4bc-44c5-ac47-a9bacaef775c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4da4a4e6-a854-4861-9b7a-8b75708f94ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a3ea197b-8f1e-46f6-a709-ee7d04fd7c61_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_d3a17fae-afb2-4c27-991f-54518f8a0607_terseLabel_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_label_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember" xlink:href="mgnx-20221231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AssetPurchaseAgreementMember" xlink:to="lab_mgnx_AssetPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2ac9b6f6-ae48-443b-a0ce-c801f8399245_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_69c21a2c-14c8-4749-967e-61bc4b7400f9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_f39236b6-8e7f-420c-88ac-54d2a200338c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5c2e43f2-da68-4f82-b78b-53f029d34a2c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_99a84864-8f90-455a-8f1b-b4f7bd13617a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchased by employees (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ReceivableFromCollaborationPartner_b5af8274-2d30-4419-9a41-bdabb0bd32f5_terseLabel_en-US" xlink:label="lab_mgnx_ReceivableFromCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio Milestone Revenue in A/R</link:label>
    <link:label id="lab_mgnx_ReceivableFromCollaborationPartner_label_en-US" xlink:label="lab_mgnx_ReceivableFromCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from collaboration partner</link:label>
    <link:label id="lab_mgnx_ReceivableFromCollaborationPartner_documentation_en-US" xlink:label="lab_mgnx_ReceivableFromCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from collaboration partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ReceivableFromCollaborationPartner" xlink:href="mgnx-20221231.xsd#mgnx_ReceivableFromCollaborationPartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ReceivableFromCollaborationPartner" xlink:to="lab_mgnx_ReceivableFromCollaborationPartner" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_b2a11ade-2c2a-4b76-bbf4-542ff2aea7b3_terseLabel_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium received on stock purchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_label_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium received on stock purchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_documentation_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount by which purchase price exceeds fair value for common stock purchased by collaborator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase" xlink:href="mgnx-20221231.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PremiumReceivedOnStockPurchase" xlink:to="lab_mgnx_PremiumReceivedOnStockPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_69e4ddc5-fb7f-4a6f-ad26-4cd149c654cb_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_a1ffb852-fedf-4ad4-bebe-fbedeaae2074_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_906c98a0-6081-4269-bf67-6c2b39c2f5bb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_48b07624-50c0-40b5-ad37-426d31c40be3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_b358cb5a-b6cf-4d7d-a8c4-df4433aaea8b_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Product Sales and Cost of Manufacturing Services</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_271c9477-8c9a-4c39-9b65-43bd40065485_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_Section174DeferredTaxAsset_020fb321-5cb4-4537-97c8-c959ffd49391_terseLabel_en-US" xlink:label="lab_mgnx_Section174DeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 174 deferred tax asset</link:label>
    <link:label id="lab_mgnx_Section174DeferredTaxAsset_label_en-US" xlink:label="lab_mgnx_Section174DeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 174 deferred tax asset</link:label>
    <link:label id="lab_mgnx_Section174DeferredTaxAsset_documentation_en-US" xlink:label="lab_mgnx_Section174DeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 174 deferred tax asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_Section174DeferredTaxAsset" xlink:href="mgnx-20221231.xsd#mgnx_Section174DeferredTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_Section174DeferredTaxAsset" xlink:to="lab_mgnx_Section174DeferredTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f5884b1f-c961-4737-aabf-9fd9e15220fd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_GileadMember_5e7af3a3-d870-4fa3-8580-b06927c5d92e_terseLabel_en-US" xlink:label="lab_mgnx_GileadMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead</link:label>
    <link:label id="lab_mgnx_GileadMember_label_en-US" xlink:label="lab_mgnx_GileadMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead [Member]</link:label>
    <link:label id="lab_mgnx_GileadMember_documentation_en-US" xlink:label="lab_mgnx_GileadMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadMember" xlink:href="mgnx-20221231.xsd#mgnx_GileadMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_GileadMember" xlink:to="lab_mgnx_GileadMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_268b525f-d680-4359-825f-8f470bef231b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember_b27d3360-8ad9-439a-acb0-6532d9cc07c3_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAmendmentAgreement</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAmendmentAgreement [Member]</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember_documentation_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromCMOAmendmentAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromCMOAmendmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:to="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_818227d8-721f-41ba-8d24-fe4257417e3a_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Percentage of Customer Concentration</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6c2147fc-37d0-44c8-b670-8305d53a118e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Equipment and Software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_3ef336e0-24a5-40e0-842f-59fbeff9ece9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e349acab-b072-4e08-82dc-daf1bd00dcb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_365cc9e4-aae0-4356-ac24-edca91fcb1ae_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_78dd0f7a-6245-4809-925d-13feb26c7206_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9c843ec5-ec3e-4072-aab1-1df1ceea9f51_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7f8a8b10-bbd2-4f20-b6fe-f07c02653e5f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Nature of Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_0632bfec-4272-4d44-bb1b-ef1819cee3c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_9e1b0e3a-b207-45bb-bd7e-2486adea0ad2_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_68fc537c-0b93-4d5c-aa97-005e59d59a6f_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, TRIDENT molecule</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_62986f72-245f-4205-a47a-1423d14a39c7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8f308406-614e-4564-84f2-6d757b8bee0b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ba42334d-6730-44fc-a84a-4b502b91f36d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_d138731d-5bee-4a89-baa5-08619be50bba_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d2051646-50ac-4905-ac3f-e8eb34140436_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_a213f2f9-e584-4795-9252-913bda7bbee0_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at Beginning of Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_9697e238-d5aa-4465-8bc4-1888e89aeee0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at End of Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_aecebeb5-9ee3-44a8-9eba-51616a526f66_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums and discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c9bcf694-5eee-436d-bc1b-fd436346ca72_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_0e5cf033-b55a-4de4-a94a-38d05be1e913_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_4e5353a3-4326-46cc-8c7a-da2ac0711278_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5f5c3654-be11-4b87-9750-1b764d809d3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc0b7b35-3fb0-4332-b1a9-5f33f04d3cd9_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca97f22f-c9bc-4117-82a6-f930fbc50f65_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_25e0c1c6-eefb-4f38-9e32-2c4d33ba99cb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_22fcea17-5a95-4f0f-bb43-c4d3df11ebe0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromVariableConsiderationRecognize_4d651331-a102-4a58-a606-50a2cbd9fe5b_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromVariableConsiderationRecognize" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from variable consideration recognize</link:label>
    <link:label id="lab_mgnx_RevenueFromVariableConsiderationRecognize_label_en-US" xlink:label="lab_mgnx_RevenueFromVariableConsiderationRecognize" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from variable consideration recognize</link:label>
    <link:label id="lab_mgnx_RevenueFromVariableConsiderationRecognize_documentation_en-US" xlink:label="lab_mgnx_RevenueFromVariableConsiderationRecognize" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from variable consideration recognize</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromVariableConsiderationRecognize" xlink:href="mgnx-20221231.xsd#mgnx_RevenueFromVariableConsiderationRecognize"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromVariableConsiderationRecognize" xlink:to="lab_mgnx_RevenueFromVariableConsiderationRecognize" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_bff89854-12e2-4b8f-84f4-aa4093c613c1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_724678f8-2716-4382-b11c-38396798d57a_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss for limited use</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Limitations On Use Amount</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net operating loss carryforward, which are limited for use over the range of years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:href="mgnx-20221231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:to="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_6604e91f-7276-46f5-b0b4-a7d9769e789d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cd94dbb4-9e75-441c-9fb2-aa2483cd9bce_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b32aa9f1-c9f4-42a2-86e6-f751ee0d9c0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_3bfbda2d-7d08-47e2-bdd8-9373c8b9ca0b_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, Margetuximab</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_490979c0-2a6b-44f2-92b3-5b27e0c0d16d_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_96b02b21-e22d-468a-951d-dd141f667075_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1c5cdef1-602d-4a8b-a6ab-860d3caf55fc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0496ed6e-affe-4b6e-96b6-d6dec55a6941_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average number of common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_38038c3e-6bfd-44d6-835f-fdda2211438f_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6f1e14d9-52f0-4ceb-9c61-22449cf2477c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating and investing activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c328577f-6588-4414-944f-6b6fec957ad8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eb62f269-10e1-49b9-bfd2-492b35fd08aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d0a2c8d5-2183-4661-a2c2-cdadf0ab859e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2bcc5e3f-fbd9-4541-a99b-35066bbf4ee0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UpfrontPayment_ee6727ab-7f81-41dc-b33f-a5e8d789dc83_terseLabel_en-US" xlink:label="lab_mgnx_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment from DRI Health Trust</link:label>
    <link:label id="lab_mgnx_UpfrontPayment_label_en-US" xlink:label="lab_mgnx_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_mgnx_UpfrontPayment_documentation_en-US" xlink:label="lab_mgnx_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPayment" xlink:href="mgnx-20221231.xsd#mgnx_UpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UpfrontPayment" xlink:to="lab_mgnx_UpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e96f51ea-7382-47bb-96c0-258da6c11195_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_5b046dcd-deae-484c-ac4e-e6993cd2f4d7_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_de8ffff4-329c-4b57-8e1e-e651885ac118_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_07adfd23-f401-4564-89cd-0446b98073d9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_95fb98dc-e0b2-40be-8060-575c38ef9f7d_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_7a1c44a7-0133-463b-8626-800943b72c93_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0e37bd54-310b-424a-8c71-3c498f524ef5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_b2b615ee-119d-4ea0-bd71-10ef05ed96e1_terseLabel_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of common stock share outstanding</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_label_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Shares Of Companys Common Stock Outstanding For Increase In Shares Reserved For Issuance Under Stock Plan</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_documentation_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:href="mgnx-20221231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:to="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_87bb48b0-7643-4998-9ddc-ab4679baa622_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_81f58bdf-9449-4a1c-b62f-2d78644aee1d_terseLabel_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee contribution percent</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_documentation_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="mgnx-20221231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_32432890-393e-4474-a23f-c3426de0bbb4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_b041fdfc-6699-4c1e-aaf6-87a059bf8778_terseLabel_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement</link:label>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20221231.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_JanssenCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_2933c944-ffc3-4c53-83c0-6195c10c4265_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_af7b2761-7797-41cb-92b1-d52ec3c0019c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_368aeeb0-612b-49e7-97e5-144f6e80f0d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of the Company's Deferred Income Tax Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3b7f278b-9ea8-42e8-9dd6-65013befb871_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_88e7e21b-bd59-48e0-b680-a05a2f91d0d6_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_ad80c38e-93ec-47e1-b17b-e3b3017e9328_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_39551cb6-a099-4b0f-9f7d-dc786a9adaca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_195c6a64-7cd6-4b9a-9f97-340455d6797b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_af2ac7fe-ee9a-4b4d-b6b1-012a35c5ad93_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_c51b11eb-21c3-48ea-b900-b12ff54523fc_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsMember_ac62862f-30b8-429e-bac7-a12851747c18_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:label id="lab_mgnx_ZaiLabsMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsMember" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsMember" xlink:to="lab_mgnx_ZaiLabsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7ab7deb5-4f83-4f0b-9b44-fddf74c2334e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c53ecdbe-4168-4bd0-8b25-16bf3c3e853a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_e31ccf95-2c22-485a-8b35-0e245f0f405a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_017f5b03-55ad-4ca2-9516-7245bbf139a9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_d7c7523f-8577-42ea-93c6-19693ba78208_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_c161a947-fc8f-4319-b3db-3b231b936b9e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_44eb8c80-43cf-45e5-8614-584c86f0e364_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationArrangementOneTimeCreditPaidPercent_d1565cde-8ff4-4813-ba66-df3fcbea271d_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationArrangementOneTimeCreditPaidPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, One-time Credit Paid, Percent</link:label>
    <link:label id="lab_mgnx_CollaborationArrangementOneTimeCreditPaidPercent_label_en-US" xlink:label="lab_mgnx_CollaborationArrangementOneTimeCreditPaidPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, One-time Credit Paid, Percent</link:label>
    <link:label id="lab_mgnx_CollaborationArrangementOneTimeCreditPaidPercent_documentation_en-US" xlink:label="lab_mgnx_CollaborationArrangementOneTimeCreditPaidPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, One-time Credit Paid, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOneTimeCreditPaidPercent" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationArrangementOneTimeCreditPaidPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationArrangementOneTimeCreditPaidPercent" xlink:to="lab_mgnx_CollaborationArrangementOneTimeCreditPaidPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d9d9f7ef-6e0f-4977-a9bc-d81d903e2707_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_1da33aa2-4d13-49b0-bb9b-11ca2559cccc_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_c30980e5-acb8-4766-949b-8ebecd18a0ad_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_bee0a119-7bd7-457e-9c3c-bc4a31e4b4b0_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_6dd20066-faf4-4552-aae2-d7588fef2100_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHMember_fc3cdf9f-3173-42f7-be65-84bad37d47fa_terseLabel_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHMember_label_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH [Member]</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHMember_documentation_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:href="mgnx-20221231.xsd#mgnx_BoehringerIngelheimInternationalGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:to="lab_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_8ba450bd-bf0d-48a7-91a7-0ba925e493fa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV031Member_1c48bd72-6aca-4f8e-baf8-2ce528760866_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV031</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV031 [Member]</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_documentation_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member" xlink:href="mgnx-20221231.xsd#mgnx_ProventionPRV031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV031Member" xlink:to="lab_mgnx_ProventionPRV031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_f941a2a8-0891-4732-8e8e-88829edee05a_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Collaboration And License Agreement</link:label>
    <link:label id="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_52018647-9503-4dd9-ac3c-3f73b29aaeda_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_55c77d4f-43d9-466d-951f-0c1343bb5647_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_30089eab-916f-4c70-8f32-16a3a5b22ca2_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e9022cae-7e7d-472d-b142-f63bce7bd78c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_4e10ca9f-d6dc-4fcc-8a0b-a7f45e5f08bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Price, lower limit</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3600ea54-4d6b-4249-bea8-0a9f9f56ae42_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_51de53b6-8404-401f-b73c-2a15450fc350_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_2aed4ada-edf9-46ee-9073-a0ca19f7308f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_42c4a2d1-6333-4225-ac95-42eda0b6292b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_7ac1c081-1ee7-48e7-89eb-51390e44b2df_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20221231.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_c2e4cf32-aa8d-41f9-ad43-53526ac47045_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_d67fd7ca-daa7-46ab-a404-8679b2d24b4f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_27ee128c-c289-4503-bc7a-3f5d5cc75ccc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_99a06ff1-08b3-497c-9b24-cd6c08f38dd0_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_71697149-c2fc-46e8-aa17-1d98566ca7db_terseLabel_en-US" xlink:label="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Les Laboratoires Servier And Institut De Recherches Servier (Servier)</link:label>
    <link:label id="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_label_en-US" xlink:label="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Les Laboratoires Servier And Institut De Recherches Servier (Servier) [Member]</link:label>
    <link:label id="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_documentation_en-US" xlink:label="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Les Laboratoires Servier And Institut De Recherches Servier (Servier)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:href="mgnx-20221231.xsd#mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:to="lab_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_20d7b48f-38d2-4359-b0d3-77bdf76cc9c4_terseLabel_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and office equipment</link:label>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_label_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember" xlink:href="mgnx-20221231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FurnitureAndOfficeEquipmentMember" xlink:to="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_44927094-13cd-4325-8263-e2b32850da85_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_ae4d9e19-b09f-4fd2-b534-2d021c50c3a6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory valuation reserves</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_59563513-789d-47e5-8e23-473cc5260825_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_78deb140-628f-41c9-8166-25d77b7bc81d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer discretionary contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_7512881c-9b53-453c-a112-36729b461a2c_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance Of The Research And Development Activities</link:label>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_label_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance Of The Research And Development Activities [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Performance Of The Research And Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:href="mgnx-20221231.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:to="lab_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_5c9491f4-d69b-4c71-9657-6b6e1fcbf369_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_97049695-c1de-4650-b7da-f4517f519c59_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1b3ea73a-bd96-4074-b9ea-c9d34c7dbec7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_2e667a07-80a4-4d62-8f24-929ceed8ae83_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabMember_5c60c6ca-352e-4476-bc5c-97fa5d3a4940_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabMember" xlink:to="lab_mgnx_ZaiLabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_80fb8cdc-b9e4-4791-a1c2-68e2e5dbcfb8_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_4894db7b-7130-47cb-b0ad-73cb5a2cb9fb_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:to="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ae2caf35-05da-4f00-919a-df8012ffdfcf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Reported Estimated Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_68bd5717-fbe3-46a7-83de-051a6bde273f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_7267c8c7-bd34-49ce-a274-371cb1a2edbd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes (net of federal benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_d84f252a-ed43-4e97-b478-75d917c58321_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Rent</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_documentation_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in deferred rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent" xlink:href="mgnx-20221231.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInDeferredRent" xlink:to="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_0a1fca94-2009-4416-9098-e9c9153290b8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3e6f2358-8c24-427b-8de0-c504cfd38335_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_be8b511a-0faf-4c39-9581-04c0a1a9450c_terseLabel_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention License Agreement</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember" xlink:href="mgnx-20221231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionLicenseAgreementMember" xlink:to="lab_mgnx_ProventionLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8cce9ab0-44c4-497e-ac4b-8aea62df6c40_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_abd3b463-a12d-4ce9-9af1-2ba0918016e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_db3ca424-0660-4b6a-8fde-7557e76c03d6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses, Including Clinical Trial Accruals/Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ad022f64-15bf-44e0-8785-c7d6871224ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a9e650a-9c41-4ec2-a119-b8fb127747d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_c93c4fcc-bd9b-45d0-834d-63a14df8a926_terseLabel_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial activities selling price amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_label_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:href="mgnx-20221231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:to="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_4080cb4a-852a-4fd0-b76f-6e4f7fca1f78_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_d0b75908-be34-49cc-81dd-f05d8897aa5f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6a747ae7-1004-4225-97e7-108dd3caf0c6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_082ebdf9-2bfd-407b-9d53-dff82763a83e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_642ede5c-653d-4c3d-829b-f83eddd86fe5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7ccba07b-32f2-4332-bf8d-74bad30a749e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock_9f5f5390-b6c5-4af5-a819-e0066ddae050_terseLabel_en-US" xlink:label="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory Reserves</link:label>
    <link:label id="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock_label_en-US" xlink:label="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory Reserves [Table Text Block]</link:label>
    <link:label id="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:href="mgnx-20221231.xsd#mgnx_ScheduleOfInventoryReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:to="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_c5836ac3-cb78-4bf5-a7bb-1446408e2019_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ee63a068-acb7-4402-bbc4-05cb9469ddee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States federal tax at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_84ef80d5-5fb2-4381-93a8-2bfe8dc2a227_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:href="mgnx-20221231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_02f72d9c-e54b-4033-9dcc-ef5585910461_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_09543ea8-341e-4d69-adf4-2facf0648b05_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_f74f02fc-ef0d-4c56-87a6-c8275360abfc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f4b88cb6-26c8-4593-9ee4-48fa68c74816_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionBioMember_fb926a6e-0e66-48c8-814c-d784d2dcf388_terseLabel_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio, Inc. (Provention)</link:label>
    <link:label id="lab_mgnx_ProventionBioMember_label_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio [Member]</link:label>
    <link:label id="lab_mgnx_ProventionBioMember_documentation_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember" xlink:href="mgnx-20221231.xsd#mgnx_ProventionBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionBioMember" xlink:to="lab_mgnx_ProventionBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9be12ae3-a24e-4a8c-9983-b71cb5251854_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_987a815f-4694-4522-ba1a-5d1f7fdf35da_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013 [Member]</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_documentation_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member" xlink:href="mgnx-20221231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2013Member" xlink:to="lab_mgnx_StockIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1dfc3007-a8e6-4ce1-9bb8-d12eee0ac1ac_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8c81aed4-ab92-44f4-9e7a-0922c2163114_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_6e418e94-9148-40bb-98f2-be40e0f389d7_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_919ec496-8b21-4431-a461-8950956f083d_terseLabel_en-US" xlink:label="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target nomination, option fees and milestone</link:label>
    <link:label id="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_label_en-US" xlink:label="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential target nomination, option fees and milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_documentation_en-US" xlink:label="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential target, nomination, option fees and milestone payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:href="mgnx-20221231.xsd#mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:to="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>mgnx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:49d3a843-ae73-49e6-9afb-5555c20651f7,g:f863eeaf-37fc-4bf3-b50d-59432dc50ee9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c343075b-5f1c-49cd-ab30-f1dd6e97c8ba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_DocumentType_c343075b-5f1c-49cd-ab30-f1dd6e97c8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_9f601a05-356f-471a-94b7-3c10cb94c8cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_DocumentAnnualReport_9f601a05-356f-471a-94b7-3c10cb94c8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e93cc098-ded9-408b-959d-10aa8bc7ef3f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_DocumentPeriodEndDate_e93cc098-ded9-408b-959d-10aa8bc7ef3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_aaedcfe1-31d6-4b4a-baea-14087d0dde5a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_CurrentFiscalYearEndDate_aaedcfe1-31d6-4b4a-baea-14087d0dde5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_eb0a30db-d0c4-46dd-88dd-f482e50ac992" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_DocumentTransitionReport_eb0a30db-d0c4-46dd-88dd-f482e50ac992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8edbb0d1-a45b-46a1-a9e8-b5affcd12cc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityFileNumber_8edbb0d1-a45b-46a1-a9e8-b5affcd12cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f237485d-dd14-4f00-b5a8-240bca51e77b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityRegistrantName_f237485d-dd14-4f00-b5a8-240bca51e77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_51233634-446b-43c1-bb97-be609183ffe7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_51233634-446b-43c1-bb97-be609183ffe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_581763a1-abe0-491f-8013-5b0bf8633154" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityTaxIdentificationNumber_581763a1-abe0-491f-8013-5b0bf8633154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_46ab69d6-e357-460b-99b4-f5b76dbe7271" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityAddressAddressLine1_46ab69d6-e357-460b-99b4-f5b76dbe7271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_dffa9735-de49-4031-955e-00f560787a24" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityAddressCityOrTown_dffa9735-de49-4031-955e-00f560787a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_03b7be32-c767-4ade-aad5-18c327fb59e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityAddressStateOrProvince_03b7be32-c767-4ade-aad5-18c327fb59e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e9666ffb-b547-483d-ab6b-78d4a1b96fab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityAddressPostalZipCode_e9666ffb-b547-483d-ab6b-78d4a1b96fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f2c65862-85cf-45f2-b877-279b09a941c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_CityAreaCode_f2c65862-85cf-45f2-b877-279b09a941c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fb92c024-0af5-4a8f-aaef-b749b88812ba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_LocalPhoneNumber_fb92c024-0af5-4a8f-aaef-b749b88812ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b8993f6f-234f-49fb-833e-b4ec8cd6a556" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_Security12bTitle_b8993f6f-234f-49fb-833e-b4ec8cd6a556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6d1bb317-c688-4d44-a7ab-983a95d90853" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_TradingSymbol_6d1bb317-c688-4d44-a7ab-983a95d90853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f8a70cdd-bf76-4e35-ab46-8010fb76ade5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_SecurityExchangeName_f8a70cdd-bf76-4e35-ab46-8010fb76ade5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_575220e9-ddb4-410c-8663-e1d89d87b6d8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_575220e9-ddb4-410c-8663-e1d89d87b6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_72c68652-b756-4b75-8f6b-e0c13b33fc97" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityVoluntaryFilers_72c68652-b756-4b75-8f6b-e0c13b33fc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_99994a86-f885-437c-b503-97b087c693cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityCurrentReportingStatus_99994a86-f885-437c-b503-97b087c693cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_30a39874-1e1e-4b51-be78-f19d0d2c6af2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityInteractiveDataCurrent_30a39874-1e1e-4b51-be78-f19d0d2c6af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_eaee16f3-a6c5-4cdf-831c-26db435d3497" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityFilerCategory_eaee16f3-a6c5-4cdf-831c-26db435d3497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_10b891ae-b398-4b35-bda1-fe016b987137" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntitySmallBusiness_10b891ae-b398-4b35-bda1-fe016b987137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c78e7d10-c453-4200-abcd-66c44495394a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityEmergingGrowthCompany_c78e7d10-c453-4200-abcd-66c44495394a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_8355411b-386e-4c34-b895-cee4acf86625" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_IcfrAuditorAttestationFlag_8355411b-386e-4c34-b895-cee4acf86625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_0c4644c2-c5a2-4402-bd19-d978668cfe4c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityShellCompany_0c4644c2-c5a2-4402-bd19-d978668cfe4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_dc2a4b05-a014-41d6-bc53-9e8fd7d74584" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityPublicFloat_dc2a4b05-a014-41d6-bc53-9e8fd7d74584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0c1e4e4b-a205-457f-a08b-4aa85f9af5e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0c1e4e4b-a205-457f-a08b-4aa85f9af5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_af9ad395-f1fa-4954-affb-e3c1192f92c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_af9ad395-f1fa-4954-affb-e3c1192f92c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_87811b8f-e820-47d7-a13e-80459e9bcd7e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_AmendmentFlag_87811b8f-e820-47d7-a13e-80459e9bcd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1c514dc4-84dc-4984-965a-67bc97ef8c8c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_DocumentFiscalYearFocus_1c514dc4-84dc-4984-965a-67bc97ef8c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c2fd0379-876e-418c-91c9-5f9cb2856803" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c2fd0379-876e-418c-91c9-5f9cb2856803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c536aa79-73db-4a70-a1bf-8e57573347a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5aae8e4-0a91-4bc6-9ec0-7447de9b801c" xlink:to="loc_dei_EntityCentralIndexKey_c536aa79-73db-4a70-a1bf-8e57573347a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/AuditInformation" xlink:type="simple" xlink:href="mgnx-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AuditorInformationAbstract_df4347e9-8380-45d7-be01-76d3057c108f" xlink:href="mgnx-20221231.xsd#mgnx_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_ef671978-0528-4f75-a3bf-501a4e5944b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_AuditorInformationAbstract_df4347e9-8380-45d7-be01-76d3057c108f" xlink:to="loc_dei_AuditorFirmId_ef671978-0528-4f75-a3bf-501a4e5944b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_db1bad2e-ee7d-4156-90c3-9805c5fc7e33" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_AuditorInformationAbstract_df4347e9-8380-45d7-be01-76d3057c108f" xlink:to="loc_dei_AuditorName_db1bad2e-ee7d-4156-90c3-9805c5fc7e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_6b168d9c-a815-462a-b7b0-28848c80a3df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_AuditorInformationAbstract_df4347e9-8380-45d7-be01-76d3057c108f" xlink:to="loc_dei_AuditorLocation_6b168d9c-a815-462a-b7b0-28848c80a3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4a3d7c49-8721-4d18-aa5f-f0a0383d41b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f318358c-2fa8-4679-9489-dd1d73cf0422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4a3d7c49-8721-4d18-aa5f-f0a0383d41b6" xlink:to="loc_us-gaap_AssetsAbstract_f318358c-2fa8-4679-9489-dd1d73cf0422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6b776373-1e83-41b4-8153-68283dcd8064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f318358c-2fa8-4679-9489-dd1d73cf0422" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6b776373-1e83-41b4-8153-68283dcd8064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_730cf098-0ee5-4094-9abb-0c471cef5dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6b776373-1e83-41b4-8153-68283dcd8064" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_730cf098-0ee5-4094-9abb-0c471cef5dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_522425a8-b7f6-4c71-a0c3-41858fd75dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6b776373-1e83-41b4-8153-68283dcd8064" xlink:to="loc_us-gaap_Investments_522425a8-b7f6-4c71-a0c3-41858fd75dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4806e148-dae5-473e-900e-c9bbd3927b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6b776373-1e83-41b4-8153-68283dcd8064" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4806e148-dae5-473e-900e-c9bbd3927b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_32198abd-85e8-4a94-81c2-67eb42f0eae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6b776373-1e83-41b4-8153-68283dcd8064" xlink:to="loc_us-gaap_InventoryNet_32198abd-85e8-4a94-81c2-67eb42f0eae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_42d3ec0b-73f8-45dd-af14-e75744ec6b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6b776373-1e83-41b4-8153-68283dcd8064" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_42d3ec0b-73f8-45dd-af14-e75744ec6b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dea2066d-964f-459e-b44f-8d9326b8a9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6b776373-1e83-41b4-8153-68283dcd8064" xlink:to="loc_us-gaap_AssetsCurrent_dea2066d-964f-459e-b44f-8d9326b8a9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2ebda7b1-84be-4c59-973e-005b71190b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f318358c-2fa8-4679-9489-dd1d73cf0422" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2ebda7b1-84be-4c59-973e-005b71190b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3ef02980-0767-4f04-9297-a0f6dc8ea81d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f318358c-2fa8-4679-9489-dd1d73cf0422" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3ef02980-0767-4f04-9297-a0f6dc8ea81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9f7756ca-fa34-45e8-933a-0ac2c6e2b6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f318358c-2fa8-4679-9489-dd1d73cf0422" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9f7756ca-fa34-45e8-933a-0ac2c6e2b6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6ede2234-e56f-42dc-bf42-83c0a7dd2da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f318358c-2fa8-4679-9489-dd1d73cf0422" xlink:to="loc_us-gaap_Assets_6ede2234-e56f-42dc-bf42-83c0a7dd2da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a9c58998-a1fa-40b5-a071-7f86d8bf5021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4a3d7c49-8721-4d18-aa5f-f0a0383d41b6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a9c58998-a1fa-40b5-a071-7f86d8bf5021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_44d3cea3-dcd2-46ad-8791-275442b6d717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a9c58998-a1fa-40b5-a071-7f86d8bf5021" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_44d3cea3-dcd2-46ad-8791-275442b6d717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9a49bd87-798a-40a1-ad72-b8375b030563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_44d3cea3-dcd2-46ad-8791-275442b6d717" xlink:to="loc_us-gaap_AccountsPayableCurrent_9a49bd87-798a-40a1-ad72-b8375b030563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d2759a2f-8289-4354-a8ec-681b438116fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_44d3cea3-dcd2-46ad-8791-275442b6d717" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d2759a2f-8289-4354-a8ec-681b438116fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_82af19a1-3363-43fe-bd5d-155351f976ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_44d3cea3-dcd2-46ad-8791-275442b6d717" xlink:to="loc_us-gaap_DeferredRevenueCurrent_82af19a1-3363-43fe-bd5d-155351f976ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_06a3df72-7610-48c8-bae4-1ac791969ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_44d3cea3-dcd2-46ad-8791-275442b6d717" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_06a3df72-7610-48c8-bae4-1ac791969ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c8ec3c17-65bc-442a-88ce-d2c1007d7fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_44d3cea3-dcd2-46ad-8791-275442b6d717" xlink:to="loc_us-gaap_LiabilitiesCurrent_c8ec3c17-65bc-442a-88ce-d2c1007d7fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_49b86297-307c-4ce0-8908-70a5b1822c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a9c58998-a1fa-40b5-a071-7f86d8bf5021" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_49b86297-307c-4ce0-8908-70a5b1822c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7bcd15f6-049e-4fad-806f-1e83c908e8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a9c58998-a1fa-40b5-a071-7f86d8bf5021" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7bcd15f6-049e-4fad-806f-1e83c908e8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7d282faa-1552-4505-ac53-f303882ace68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a9c58998-a1fa-40b5-a071-7f86d8bf5021" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7d282faa-1552-4505-ac53-f303882ace68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b8d96055-09fe-4686-89eb-2d0f83c86290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a9c58998-a1fa-40b5-a071-7f86d8bf5021" xlink:to="loc_us-gaap_Liabilities_b8d96055-09fe-4686-89eb-2d0f83c86290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_164a2d54-2fa6-4e65-afc4-ced8b8975913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a9c58998-a1fa-40b5-a071-7f86d8bf5021" xlink:to="loc_us-gaap_StockholdersEquityAbstract_164a2d54-2fa6-4e65-afc4-ced8b8975913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9ca9e18c-dceb-47f5-930c-9205532b2fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_164a2d54-2fa6-4e65-afc4-ced8b8975913" xlink:to="loc_us-gaap_CommonStockValue_9ca9e18c-dceb-47f5-930c-9205532b2fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1429e67e-b69b-4d23-a07c-12ba27065a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_164a2d54-2fa6-4e65-afc4-ced8b8975913" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1429e67e-b69b-4d23-a07c-12ba27065a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_36d815b6-1422-4cf3-bc52-c21fe736ce85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_164a2d54-2fa6-4e65-afc4-ced8b8975913" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_36d815b6-1422-4cf3-bc52-c21fe736ce85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b87ba486-643b-4b18-9095-151f152f7a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_164a2d54-2fa6-4e65-afc4-ced8b8975913" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b87ba486-643b-4b18-9095-151f152f7a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_57359e27-9859-4032-b77f-11a95bfb93fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_164a2d54-2fa6-4e65-afc4-ced8b8975913" xlink:to="loc_us-gaap_StockholdersEquity_57359e27-9859-4032-b77f-11a95bfb93fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_91a48100-49a9-41bd-a606-21ac563a7a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a9c58998-a1fa-40b5-a071-7f86d8bf5021" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_91a48100-49a9-41bd-a606-21ac563a7a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cfe75663-a70c-48c1-837d-11474c1be371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_921d8f64-92ed-47eb-8381-31673af1d8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cfe75663-a70c-48c1-837d-11474c1be371" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_921d8f64-92ed-47eb-8381-31673af1d8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6c9853f5-54a6-4bac-b071-04a16a63dd25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cfe75663-a70c-48c1-837d-11474c1be371" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6c9853f5-54a6-4bac-b071-04a16a63dd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dac8ea0b-176f-4529-a680-94f7e5172f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cfe75663-a70c-48c1-837d-11474c1be371" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dac8ea0b-176f-4529-a680-94f7e5172f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e8fc07df-e7ed-474c-af6d-bb138d6ea3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_843ce05a-6142-4502-b229-c5ffd0f4d6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e8fc07df-e7ed-474c-af6d-bb138d6ea3cb" xlink:to="loc_us-gaap_StatementTable_843ce05a-6142-4502-b229-c5ffd0f4d6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_05c9b244-6196-4f71-8f86-255920503062" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_843ce05a-6142-4502-b229-c5ffd0f4d6b4" xlink:to="loc_srt_ProductOrServiceAxis_05c9b244-6196-4f71-8f86-255920503062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_995ed69a-442d-445d-b41f-1c72297283e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_05c9b244-6196-4f71-8f86-255920503062" xlink:to="loc_srt_ProductsAndServicesDomain_995ed69a-442d-445d-b41f-1c72297283e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_aa8aaaeb-c8b8-4652-8450-2992586a0988" xlink:href="mgnx-20221231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_995ed69a-442d-445d-b41f-1c72297283e8" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_aa8aaaeb-c8b8-4652-8450-2992586a0988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_c832bbaf-1755-4c72-af61-aed4e2bed32e" xlink:href="mgnx-20221231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_995ed69a-442d-445d-b41f-1c72297283e8" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_c832bbaf-1755-4c72-af61-aed4e2bed32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_268b61be-08d8-490b-aef7-3c718e27fc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_995ed69a-442d-445d-b41f-1c72297283e8" xlink:to="loc_us-gaap_ProductMember_268b61be-08d8-490b-aef7-3c718e27fc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractManufacturingMember_fe0106b0-359e-4d46-9075-ca7571aa5d7d" xlink:href="mgnx-20221231.xsd#mgnx_ContractManufacturingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_995ed69a-442d-445d-b41f-1c72297283e8" xlink:to="loc_mgnx_ContractManufacturingMember_fe0106b0-359e-4d46-9075-ca7571aa5d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_843ce05a-6142-4502-b229-c5ffd0f4d6b4" xlink:to="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_14b14402-22ef-411f-a189-89047e591cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_RevenuesAbstract_14b14402-22ef-411f-a189-89047e591cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_54c27c0e-4679-4452-a314-730ad83e4a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_14b14402-22ef-411f-a189-89047e591cbc" xlink:to="loc_us-gaap_Revenues_54c27c0e-4679-4452-a314-730ad83e4a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_4d52d2d5-b5e9-44c0-bf8e-91bf60ec8e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_4d52d2d5-b5e9-44c0-bf8e-91bf60ec8e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_163c9245-73d4-46e1-8b7b-2d79c1ce1670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4d52d2d5-b5e9-44c0-bf8e-91bf60ec8e4e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_163c9245-73d4-46e1-8b7b-2d79c1ce1670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_071fd1be-2110-4252-9f39-6f0889d9016f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4d52d2d5-b5e9-44c0-bf8e-91bf60ec8e4e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_071fd1be-2110-4252-9f39-6f0889d9016f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_36588033-0721-4526-b186-aba99eb51ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4d52d2d5-b5e9-44c0-bf8e-91bf60ec8e4e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_36588033-0721-4526-b186-aba99eb51ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cb78539c-b5d0-4a93-9644-c0f64235541c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_4d52d2d5-b5e9-44c0-bf8e-91bf60ec8e4e" xlink:to="loc_us-gaap_CostsAndExpenses_cb78539c-b5d0-4a93-9644-c0f64235541c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_28dba03d-ec22-4ce1-b2f7-86edf218b63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_OperatingIncomeLoss_28dba03d-ec22-4ce1-b2f7-86edf218b63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e59ee97d-2636-4c5b-a347-0f669ca489fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e59ee97d-2636-4c5b-a347-0f669ca489fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a41b78b3-f3b5-464b-bb5d-9abaa7fb3f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_NetIncomeLoss_a41b78b3-f3b5-464b-bb5d-9abaa7fb3f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_00330f80-95c3-4353-b725-56651cb43cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_00330f80-95c3-4353-b725-56651cb43cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_97c0a941-85f5-456c-abd1-c64f70b8c419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_97c0a941-85f5-456c-abd1-c64f70b8c419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5aed8bf0-fc5b-4c1e-8168-78092002d297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5aed8bf0-fc5b-4c1e-8168-78092002d297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1cf4af28-a9c6-40df-8cbf-d595b0f8f90b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1cf4af28-a9c6-40df-8cbf-d595b0f8f90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eb9109c3-19ce-440f-af66-241375355536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eb9109c3-19ce-440f-af66-241375355536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_0ad1be1c-57e1-4ee1-93a3-083f8ea0dde9" xlink:href="mgnx-20221231.xsd#mgnx_CostOfManufacturingServices"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_mgnx_CostOfManufacturingServices_0ad1be1c-57e1-4ee1-93a3-083f8ea0dde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4238255a-f9bb-4a3a-8ad7-6b6192c26119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_EarningsPerShareBasic_4238255a-f9bb-4a3a-8ad7-6b6192c26119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_917b914e-3e5a-4a9f-9a15-d50187b6a01b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de49d2d0-fcd9-4fbf-b24b-0e2cb0001f40" xlink:to="loc_us-gaap_EarningsPerShareDiluted_917b914e-3e5a-4a9f-9a15-d50187b6a01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_952e85e9-8441-4b9f-87f7-b737c8196abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8e0a4281-5574-4d15-a007-999a998ce21b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_952e85e9-8441-4b9f-87f7-b737c8196abd" xlink:to="loc_us-gaap_StatementTable_8e0a4281-5574-4d15-a007-999a998ce21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_22d3600b-d2fc-4baf-a14a-2864fb1e487b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8e0a4281-5574-4d15-a007-999a998ce21b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_22d3600b-d2fc-4baf-a14a-2864fb1e487b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3b069c43-b7ad-4bbc-a600-5bde2b36692d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_22d3600b-d2fc-4baf-a14a-2864fb1e487b" xlink:to="loc_us-gaap_EquityComponentDomain_3b069c43-b7ad-4bbc-a600-5bde2b36692d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1c27c607-a466-4dd3-9cd2-6b4d2ffc4714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b069c43-b7ad-4bbc-a600-5bde2b36692d" xlink:to="loc_us-gaap_CommonStockMember_1c27c607-a466-4dd3-9cd2-6b4d2ffc4714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f4312f68-6a24-4c6e-aa9c-a11ed8b4a72a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b069c43-b7ad-4bbc-a600-5bde2b36692d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f4312f68-6a24-4c6e-aa9c-a11ed8b4a72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_59bb35c2-970a-43d8-8248-6267b59da87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b069c43-b7ad-4bbc-a600-5bde2b36692d" xlink:to="loc_us-gaap_RetainedEarningsMember_59bb35c2-970a-43d8-8248-6267b59da87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a6cd2ef3-61f5-42b9-af2f-e1d437131581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b069c43-b7ad-4bbc-a600-5bde2b36692d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a6cd2ef3-61f5-42b9-af2f-e1d437131581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8e0a4281-5574-4d15-a007-999a998ce21b" xlink:to="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_4f613c9e-a877-42d6-a5c6-b7c7d2a14088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_SharesIssued_4f613c9e-a877-42d6-a5c6-b7c7d2a14088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_de962672-1c27-44e7-8d34-07f3680b69b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_StockholdersEquity_de962672-1c27-44e7-8d34-07f3680b69b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_14aeb61e-f822-4bf3-b0be-1565274aa1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_14aeb61e-f822-4bf3-b0be-1565274aa1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35358dc6-9c54-478b-a25e-9f2a038b4e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35358dc6-9c54-478b-a25e-9f2a038b4e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_025be7a0-08c5-4ce9-b5d5-fa3f2786c26a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_025be7a0-08c5-4ce9-b5d5-fa3f2786c26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_121e9d78-285c-4231-99ea-60faef2afaa3" xlink:href="mgnx-20221231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_121e9d78-285c-4231-99ea-60faef2afaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_e806c33a-f6fa-4786-9ede-35ea7054d177" xlink:href="mgnx-20221231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_e806c33a-f6fa-4786-9ede-35ea7054d177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_8d3f5057-07ba-4e6c-b2a2-9a2b5d5d8a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_8d3f5057-07ba-4e6c-b2a2-9a2b5d5d8a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_18e38c34-1cb8-4486-b684-f15cbd916569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_NetIncomeLoss_18e38c34-1cb8-4486-b684-f15cbd916569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ea9e13db-77d4-445b-8d4b-53bb0520a451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_SharesIssued_ea9e13db-77d4-445b-8d4b-53bb0520a451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d09a5598-1c5b-4918-be40-76b75fd00539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3033baed-a499-4e76-becb-c1764a198623" xlink:to="loc_us-gaap_StockholdersEquity_d09a5598-1c5b-4918-be40-76b75fd00539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_70d60ad3-5c08-49ea-a10f-719b8c32d2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_52883db3-d17e-4643-a099-a831a6a6ccfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_70d60ad3-5c08-49ea-a10f-719b8c32d2de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_52883db3-d17e-4643-a099-a831a6a6ccfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4bb78d46-e702-4072-909d-ac3819e10f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_52883db3-d17e-4643-a099-a831a6a6ccfb" xlink:to="loc_us-gaap_NetIncomeLoss_4bb78d46-e702-4072-909d-ac3819e10f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a254b7d7-0dd0-4321-8fb9-80860ec009e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_52883db3-d17e-4643-a099-a831a6a6ccfb" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a254b7d7-0dd0-4321-8fb9-80860ec009e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6aeadc5f-c5f6-4bdf-9977-52e6af537ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a254b7d7-0dd0-4321-8fb9-80860ec009e3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6aeadc5f-c5f6-4bdf-9977-52e6af537ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fbed4ec4-2e36-46a4-ad82-997d0ce42205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a254b7d7-0dd0-4321-8fb9-80860ec009e3" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fbed4ec4-2e36-46a4-ad82-997d0ce42205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d332c6b3-2b8b-4dd2-a6be-0d294cb3e500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a254b7d7-0dd0-4321-8fb9-80860ec009e3" xlink:to="loc_us-gaap_ShareBasedCompensation_d332c6b3-2b8b-4dd2-a6be-0d294cb3e500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c1461f6d-c6c6-466a-8f47-d901ccbd1dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a254b7d7-0dd0-4321-8fb9-80860ec009e3" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c1461f6d-c6c6-466a-8f47-d901ccbd1dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0ba6cc5-ad1e-403b-badb-782bf5631f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a254b7d7-0dd0-4321-8fb9-80860ec009e3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0ba6cc5-ad1e-403b-badb-782bf5631f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c54bc172-d536-4d18-8a80-14d4da0bdb86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0ba6cc5-ad1e-403b-badb-782bf5631f9e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c54bc172-d536-4d18-8a80-14d4da0bdb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d4da645d-e85f-41bb-96b9-21e8c2ec5839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0ba6cc5-ad1e-403b-badb-782bf5631f9e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d4da645d-e85f-41bb-96b9-21e8c2ec5839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_acad7af6-27dd-4c93-8bca-8bb32f73704b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0ba6cc5-ad1e-403b-badb-782bf5631f9e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_acad7af6-27dd-4c93-8bca-8bb32f73704b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_36afb9c3-db34-4905-ae08-229de9d5ce9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0ba6cc5-ad1e-403b-badb-782bf5631f9e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_36afb9c3-db34-4905-ae08-229de9d5ce9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_666e62e2-de7e-4b5c-8f46-61cec7593b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0ba6cc5-ad1e-403b-badb-782bf5631f9e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_666e62e2-de7e-4b5c-8f46-61cec7593b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a091a8e9-9855-4a09-ace5-26c64da8a53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0ba6cc5-ad1e-403b-badb-782bf5631f9e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a091a8e9-9855-4a09-ace5-26c64da8a53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_0270ff8d-d1a9-4073-bcde-14244d130ad7" xlink:href="mgnx-20221231.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0ba6cc5-ad1e-403b-badb-782bf5631f9e" xlink:to="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_0270ff8d-d1a9-4073-bcde-14244d130ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_02d50d48-fba4-4a7b-bb72-0575d69f0041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0ba6cc5-ad1e-403b-badb-782bf5631f9e" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_02d50d48-fba4-4a7b-bb72-0575d69f0041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_86669668-8552-43df-8c7a-6086456da07f" xlink:href="mgnx-20221231.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0ba6cc5-ad1e-403b-badb-782bf5631f9e" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_86669668-8552-43df-8c7a-6086456da07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d5f2d90-898b-4efa-89ea-8d83ce9f2f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_52883db3-d17e-4643-a099-a831a6a6ccfb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d5f2d90-898b-4efa-89ea-8d83ce9f2f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_52d226ff-e429-435b-9d36-b47b4d885025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_70d60ad3-5c08-49ea-a10f-719b8c32d2de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_52d226ff-e429-435b-9d36-b47b4d885025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7055ad93-f802-418b-b64f-eb8dca0559b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_52d226ff-e429-435b-9d36-b47b4d885025" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7055ad93-f802-418b-b64f-eb8dca0559b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9e7a1f68-fe8e-404c-964a-18447862e096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_52d226ff-e429-435b-9d36-b47b4d885025" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9e7a1f68-fe8e-404c-964a-18447862e096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4f19dd19-1d30-47d0-ab97-62c393f22b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_52d226ff-e429-435b-9d36-b47b4d885025" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4f19dd19-1d30-47d0-ab97-62c393f22b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_80896f70-b6a4-45f4-a046-3f697f8ba6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_52d226ff-e429-435b-9d36-b47b4d885025" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_80896f70-b6a4-45f4-a046-3f697f8ba6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_50ab69bc-f170-429f-b430-ba7eb76123d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_70d60ad3-5c08-49ea-a10f-719b8c32d2de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_50ab69bc-f170-429f-b430-ba7eb76123d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7f69fa44-97f4-41b7-a479-dbf39a19b3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_50ab69bc-f170-429f-b430-ba7eb76123d4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7f69fa44-97f4-41b7-a479-dbf39a19b3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_6f95e9e2-d549-485d-b123-df513bc79d26" xlink:href="mgnx-20221231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_50ab69bc-f170-429f-b430-ba7eb76123d4" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_6f95e9e2-d549-485d-b123-df513bc79d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dac4c8ba-2b22-41eb-928d-59b6ba308296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_50ab69bc-f170-429f-b430-ba7eb76123d4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dac4c8ba-2b22-41eb-928d-59b6ba308296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2e261d84-b243-44ce-ad89-5d6886157ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_70d60ad3-5c08-49ea-a10f-719b8c32d2de" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2e261d84-b243-44ce-ad89-5d6886157ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e774840c-804a-4096-a5e2-97fad448a18a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_70d60ad3-5c08-49ea-a10f-719b8c32d2de" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e774840c-804a-4096-a5e2-97fad448a18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5d299491-8b47-4079-8397-0543bf06d1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_70d60ad3-5c08-49ea-a10f-719b8c32d2de" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5d299491-8b47-4079-8397-0543bf06d1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_fb4287cd-020d-4e3c-aa99-bfca7c256e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_70d60ad3-5c08-49ea-a10f-719b8c32d2de" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_fb4287cd-020d-4e3c-aa99-bfca7c256e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_33306519-6c29-487b-845f-47c729b7f683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_fb4287cd-020d-4e3c-aa99-bfca7c256e16" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_33306519-6c29-487b-845f-47c729b7f683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="simple" xlink:href="mgnx-20221231.xsd#OrganizationandNatureofOperations"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2fb54085-a736-4010-9e4e-770726b47f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8de61571-5419-45a3-8588-e641550270e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2fb54085-a736-4010-9e4e-770726b47f9d" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8de61571-5419-45a3-8588-e641550270e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8a4bf00a-f76e-4ca9-a267-25a878882535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c4bba2a5-c703-461e-9e99-21d346f5675b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8a4bf00a-f76e-4ca9-a267-25a878882535" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c4bba2a5-c703-461e-9e99-21d346f5675b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20221231.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1f51781c-b10f-4fc8-b82b-7df27eb0ae8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_9e7344f5-84c2-4b64-b12a-7173ba5cbd44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1f51781c-b10f-4fc8-b82b-7df27eb0ae8e" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_9e7344f5-84c2-4b64-b12a-7173ba5cbd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Inventory" xlink:type="simple" xlink:href="mgnx-20221231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1402e00e-8b15-4b55-8cf6-425bc52e767d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_733f2feb-6f0b-414b-a75c-7e753296011f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1402e00e-8b15-4b55-8cf6-425bc52e767d" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_733f2feb-6f0b-414b-a75c-7e753296011f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="simple" xlink:href="mgnx-20221231.xsd#PropertyEquipmentandSoftware"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7c5a117d-aaa2-470e-924c-5ff4f68964ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d43cd736-2f0d-4ac7-b9ff-e1aa5398b63e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7c5a117d-aaa2-470e-924c-5ff4f68964ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d43cd736-2f0d-4ac7-b9ff-e1aa5398b63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_115006ff-2f68-4176-85ef-cdeec71cddc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_73ead8d1-9d80-4a0a-b679-fc931f2a050f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_115006ff-2f68-4176-85ef-cdeec71cddc3" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_73ead8d1-9d80-4a0a-b679-fc931f2a050f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6c276c13-fad3-43af-a528-a3f545fa6dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_527a4197-1d58-4952-adf6-c1f3a0449290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6c276c13-fad3-43af-a528-a3f545fa6dcf" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_527a4197-1d58-4952-adf6-c1f3a0449290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Revenue" xlink:type="simple" xlink:href="mgnx-20221231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_4436884b-0659-41d7-aadc-513971d5dbd5" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_9b316b81-cbc1-420c-ad94-bc8f6a5f86c8" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_4436884b-0659-41d7-aadc-513971d5dbd5" xlink:to="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_9b316b81-cbc1-420c-ad94-bc8f6a5f86c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="mgnx-20221231.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b940cc8e-752d-4710-a1f8-c6e5d06ed35a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8f6b5a83-8dd6-4b70-b78f-1791ab4392e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b940cc8e-752d-4710-a1f8-c6e5d06ed35a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8f6b5a83-8dd6-4b70-b78f-1791ab4392e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mgnx-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3ba6ea1f-6bed-4d71-88b3-90d83c811083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_52dd5312-8621-4833-94b1-4fd7e08bbe8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ba6ea1f-6bed-4d71-88b3-90d83c811083" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_52dd5312-8621-4833-94b1-4fd7e08bbe8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="mgnx-20221231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_84796235-69ef-4dce-a035-dbccdbd2b725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_9bd75b73-5ca7-4993-bbe4-406e540fac36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_84796235-69ef-4dce-a035-dbccdbd2b725" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_9bd75b73-5ca7-4993-bbe4-406e540fac36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_86dea17b-97e5-4b45-863b-42105dba48dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_12718304-88ff-403e-acec-647583bf76ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_86dea17b-97e5-4b45-863b-42105dba48dd" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_12718304-88ff-403e-acec-647583bf76ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_95c18815-1f5f-4ae8-9da7-eec7d4148ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_95c18815-1f5f-4ae8-9da7-eec7d4148ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_feb7b4ef-d6c4-4b31-a8dd-8f4f92b58794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_UseOfEstimates_feb7b4ef-d6c4-4b31-a8dd-8f4f92b58794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3a65da7b-6352-42eb-8895-b4642503e698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_3a65da7b-6352-42eb-8895-b4642503e698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4c23af60-b379-4a51-8eeb-5bfd516f24b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4c23af60-b379-4a51-8eeb-5bfd516f24b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_912457ab-633e-455c-bbaf-df2ba8c8021a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_912457ab-633e-455c-bbaf-df2ba8c8021a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_ecd7dd22-79a2-48f6-a122-7fb55aec6b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_ecd7dd22-79a2-48f6-a122-7fb55aec6b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_2e8163b6-9966-40e4-a4e8-4c334d702f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_2e8163b6-9966-40e4-a4e8-4c334d702f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_a46d92e3-ecd8-42c2-ae05-6c86df2a6e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_a46d92e3-ecd8-42c2-ae05-6c86df2a6e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3ae157a3-10fe-4c11-9689-4ad100470113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3ae157a3-10fe-4c11-9689-4ad100470113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_6d5c2c13-74e6-4ae1-a67a-1e5668077186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_6d5c2c13-74e6-4ae1-a67a-1e5668077186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_ddf2580c-055a-4262-85bf-6497c886f626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_ddf2580c-055a-4262-85bf-6497c886f626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_963403e1-edd0-4b1a-9327-7c89bf80ad18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_963403e1-edd0-4b1a-9327-7c89bf80ad18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_bf3a0d62-1f07-4382-87e6-7ab97309c560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_bf3a0d62-1f07-4382-87e6-7ab97309c560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_e716d870-7a79-417c-8060-de299678b886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_e716d870-7a79-417c-8060-de299678b886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0e37a217-239c-48c5-a0ba-bdce8170b9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0e37a217-239c-48c5-a0ba-bdce8170b9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7307bf56-045b-4771-885c-e2530f13684f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_7307bf56-045b-4771-885c-e2530f13684f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b837545d-4f16-470f-b805-467dd6a307af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b72dfe4-726e-42cf-8a73-2a49de21448e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b837545d-4f16-470f-b805-467dd6a307af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_84efa402-8143-4c00-9e2c-941e59f8f228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_a3f0ed81-e7cb-4eab-904f-5743f56ed550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_84efa402-8143-4c00-9e2c-941e59f8f228" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_a3f0ed81-e7cb-4eab-904f-5743f56ed550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_6ceaf999-68a1-4805-90d2-1bcb73c1e0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_84efa402-8143-4c00-9e2c-941e59f8f228" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_6ceaf999-68a1-4805-90d2-1bcb73c1e0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_f86cc7a1-b6ec-4351-941c-c424dd965bd6" xlink:href="mgnx-20221231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_84efa402-8143-4c00-9e2c-941e59f8f228" xlink:to="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_f86cc7a1-b6ec-4351-941c-c424dd965bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_313bf4e0-7eff-4b04-b085-46563522ff61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_84efa402-8143-4c00-9e2c-941e59f8f228" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_313bf4e0-7eff-4b04-b085-46563522ff61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20221231.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c040e6e6-cddc-47c1-8f61-4f327aa9f698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_8a48772a-df3e-443f-83b6-dc8a2b16e4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c040e6e6-cddc-47c1-8f61-4f327aa9f698" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_8a48772a-df3e-443f-83b6-dc8a2b16e4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetTables" xlink:type="simple" xlink:href="mgnx-20221231.xsd#InventoryNetTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6a89dc32-0d06-4ec7-872c-90f87689e580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5c12ad07-e7e3-43e8-88f1-4af7a15b0ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6a89dc32-0d06-4ec7-872c-90f87689e580" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5c12ad07-e7e3-43e8-88f1-4af7a15b0ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfInventoryReservesTableTextBlock_dec74a02-d2e8-4d8b-ba3a-fc4885617d0c" xlink:href="mgnx-20221231.xsd#mgnx_ScheduleOfInventoryReservesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6a89dc32-0d06-4ec7-872c-90f87689e580" xlink:to="loc_mgnx_ScheduleOfInventoryReservesTableTextBlock_dec74a02-d2e8-4d8b-ba3a-fc4885617d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="simple" xlink:href="mgnx-20221231.xsd#PropertyEquipmentandSoftwareTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fec14558-2be9-4b66-8abd-4beeb220e5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2c5fa46b-6567-42c4-9414-a726f8d3934e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fec14558-2be9-4b66-8abd-4beeb220e5ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2c5fa46b-6567-42c4-9414-a726f8d3934e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="mgnx-20221231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51f6f6d5-9e28-4dec-a418-23025c078119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_719bcd70-1703-49ea-869c-c83049378c05" xlink:href="mgnx-20221231.xsd#mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51f6f6d5-9e28-4dec-a418-23025c078119" xlink:to="loc_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_719bcd70-1703-49ea-869c-c83049378c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_d6522183-9c6d-4d2b-b185-7986c799b88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51f6f6d5-9e28-4dec-a418-23025c078119" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_d6522183-9c6d-4d2b-b185-7986c799b88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_33fef2c5-7aea-46d0-b5aa-91eabac6bc51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51f6f6d5-9e28-4dec-a418-23025c078119" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_33fef2c5-7aea-46d0-b5aa-91eabac6bc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20221231.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca7185f3-d687-4c6d-a89c-bfa776d5ce24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6f2b18f0-b070-43fd-9c16-b46d0ea3f72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca7185f3-d687-4c6d-a89c-bfa776d5ce24" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6f2b18f0-b070-43fd-9c16-b46d0ea3f72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_887b449a-3064-4d30-a5c7-34a4caa5d672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca7185f3-d687-4c6d-a89c-bfa776d5ce24" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_887b449a-3064-4d30-a5c7-34a4caa5d672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2bd4a5a3-2746-4ae6-bc22-5fa7950c9b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca7185f3-d687-4c6d-a89c-bfa776d5ce24" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2bd4a5a3-2746-4ae6-bc22-5fa7950c9b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_dc877082-f7e6-4a69-89ea-1da17d357f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca7185f3-d687-4c6d-a89c-bfa776d5ce24" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_dc877082-f7e6-4a69-89ea-1da17d357f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_9a7f39f7-39d2-4f9a-9775-04d4c42069a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca7185f3-d687-4c6d-a89c-bfa776d5ce24" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_9a7f39f7-39d2-4f9a-9775-04d4c42069a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mgnx-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_83729ca1-971f-4197-b166-6fd2518164d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_482ee4d7-f6d8-4cdb-b717-1589c358595f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83729ca1-971f-4197-b166-6fd2518164d7" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_482ee4d7-f6d8-4cdb-b717-1589c358595f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_cb909550-4dab-4d2c-bd3b-b7cab99e8592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83729ca1-971f-4197-b166-6fd2518164d7" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_cb909550-4dab-4d2c-bd3b-b7cab99e8592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_0a47f490-ce24-4475-9b6f-1f185fb10dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83729ca1-971f-4197-b166-6fd2518164d7" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_0a47f490-ce24-4475-9b6f-1f185fb10dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SubsequentEventsTables" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SubsequentEventsTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SubsequentEventsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_2c84d6c7-6680-4664-bc26-4967ba85d89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b9cc26d0-4747-4ab7-8884-6d033ffa6a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_80a537a1-8463-483a-86c5-821405fa7fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b9cc26d0-4747-4ab7-8884-6d033ffa6a10" xlink:to="loc_us-gaap_NumberOfOperatingSegments_80a537a1-8463-483a-86c5-821405fa7fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bd1e25b0-69d3-428d-bcd9-1385a80fcc84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f06f26b-dd53-402d-8383-17daa9a27cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd1e25b0-69d3-428d-bcd9-1385a80fcc84" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f06f26b-dd53-402d-8383-17daa9a27cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4b979b4e-634c-4929-aa90-06060128fc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f06f26b-dd53-402d-8383-17daa9a27cb0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4b979b4e-634c-4929-aa90-06060128fc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bdccdbdd-ed4f-4a1c-a067-b145a51024c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4b979b4e-634c-4929-aa90-06060128fc9d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bdccdbdd-ed4f-4a1c-a067-b145a51024c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_763ed819-1955-4559-a830-3b29e38222ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bdccdbdd-ed4f-4a1c-a067-b145a51024c9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_763ed819-1955-4559-a830-3b29e38222ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_df9201e4-5d46-459c-85df-9a1a514386e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bdccdbdd-ed4f-4a1c-a067-b145a51024c9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_df9201e4-5d46-459c-85df-9a1a514386e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1ea3b1cb-4ae6-4373-aff7-bc78bf87b790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f06f26b-dd53-402d-8383-17daa9a27cb0" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1ea3b1cb-4ae6-4373-aff7-bc78bf87b790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a405a092-6b45-4198-9e70-f4ffaf44725c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1ea3b1cb-4ae6-4373-aff7-bc78bf87b790" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a405a092-6b45-4198-9e70-f4ffaf44725c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_f0cd2d5e-6845-4ab6-bc9a-affcf9af6262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a405a092-6b45-4198-9e70-f4ffaf44725c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_f0cd2d5e-6845-4ab6-bc9a-affcf9af6262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0b831f01-58ff-4380-a2d5-407a7e4eab40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a405a092-6b45-4198-9e70-f4ffaf44725c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0b831f01-58ff-4380-a2d5-407a7e4eab40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_a67203d2-067a-4535-8617-04ee82c4773f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a405a092-6b45-4198-9e70-f4ffaf44725c" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_a67203d2-067a-4535-8617-04ee82c4773f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ecc292cf-20d7-4c6b-a53a-7eef66abcf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a405a092-6b45-4198-9e70-f4ffaf44725c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ecc292cf-20d7-4c6b-a53a-7eef66abcf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e69aecff-54f8-4b9e-a426-b921219c5eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f06f26b-dd53-402d-8383-17daa9a27cb0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e69aecff-54f8-4b9e-a426-b921219c5eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_849780a1-e60e-4cba-a9cf-e0bd8b952754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e69aecff-54f8-4b9e-a426-b921219c5eea" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_849780a1-e60e-4cba-a9cf-e0bd8b952754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8763a91e-7ffc-4510-b853-2e552dfcfed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_849780a1-e60e-4cba-a9cf-e0bd8b952754" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8763a91e-7ffc-4510-b853-2e552dfcfed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c275092-2c23-48eb-a9ea-8b6e0938c8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3f06f26b-dd53-402d-8383-17daa9a27cb0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c275092-2c23-48eb-a9ea-8b6e0938c8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_451a5b5e-7b79-4cd6-a099-85fc5111d152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c275092-2c23-48eb-a9ea-8b6e0938c8d9" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_451a5b5e-7b79-4cd6-a099-85fc5111d152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a8ed4f62-a89f-4ff4-903f-5cde2c45e772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_451a5b5e-7b79-4cd6-a099-85fc5111d152" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a8ed4f62-a89f-4ff4-903f-5cde2c45e772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4625fd84-087d-443b-9e70-f9eb5e389b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_451a5b5e-7b79-4cd6-a099-85fc5111d152" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4625fd84-087d-443b-9e70-f9eb5e389b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9123b6b8-214a-4411-9f3d-43f809b09654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_451a5b5e-7b79-4cd6-a099-85fc5111d152" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9123b6b8-214a-4411-9f3d-43f809b09654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_cf1ad3c3-2808-49a7-b2c2-726244cea5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0c275092-2c23-48eb-a9ea-8b6e0938c8d9" xlink:to="loc_us-gaap_Investments_cf1ad3c3-2808-49a7-b2c2-726244cea5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_04520668-e18b-47a8-9bb0-9104eb710350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_e928b8e0-9a9b-4d0b-8391-550b6679e97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04520668-e18b-47a8-9bb0-9104eb710350" xlink:to="loc_us-gaap_ConcentrationRiskTable_e928b8e0-9a9b-4d0b-8391-550b6679e97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c37a21c4-5685-467d-9b52-13d41c5a7129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e928b8e0-9a9b-4d0b-8391-550b6679e97e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c37a21c4-5685-467d-9b52-13d41c5a7129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4b480a2f-4e31-4665-9c44-ca1457743fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c37a21c4-5685-467d-9b52-13d41c5a7129" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4b480a2f-4e31-4665-9c44-ca1457743fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_22898f82-0c4f-410b-a1ba-d2c4154ebc17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4b480a2f-4e31-4665-9c44-ca1457743fdd" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_22898f82-0c4f-410b-a1ba-d2c4154ebc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f899ba13-0f12-49b9-97f4-068c5dfe1ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e928b8e0-9a9b-4d0b-8391-550b6679e97e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f899ba13-0f12-49b9-97f4-068c5dfe1ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5a499531-4cc4-4644-b895-4bea898b933a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f899ba13-0f12-49b9-97f4-068c5dfe1ba1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5a499531-4cc4-4644-b895-4bea898b933a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_0d7f4e79-3f92-4502-8011-c40be7d24864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5a499531-4cc4-4644-b895-4bea898b933a" xlink:to="loc_us-gaap_SalesRevenueNetMember_0d7f4e79-3f92-4502-8011-c40be7d24864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_df558d06-4493-482c-9c19-3beabbb2a29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5a499531-4cc4-4644-b895-4bea898b933a" xlink:to="loc_us-gaap_AccountsReceivableMember_df558d06-4493-482c-9c19-3beabbb2a29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6d228b34-4456-4067-a40a-2ce548a7c5b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e928b8e0-9a9b-4d0b-8391-550b6679e97e" xlink:to="loc_srt_MajorCustomersAxis_6d228b34-4456-4067-a40a-2ce548a7c5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_6d228b34-4456-4067-a40a-2ce548a7c5b8" xlink:to="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_d6f41b24-e4d0-4b1c-a3d3-a560df75908f" xlink:href="mgnx-20221231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_IncyteCorporationMember_d6f41b24-e4d0-4b1c-a3d3-a560df75908f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_d2dd3c34-3908-46ed-9218-3fe2d6fc0016" xlink:href="mgnx-20221231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_JanssenBiotechIncMember_d2dd3c34-3908-46ed-9218-3fe2d6fc0016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember_caa21e70-150b-45df-a47c-e3aa78e49fa0" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_ZaiLabLimitedMember_caa21e70-150b-45df-a47c-e3aa78e49fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_1dce2900-9453-4ef1-8253-ed7aa4c3fd05" xlink:href="mgnx-20221231.xsd#mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember_1dce2900-9453-4ef1-8253-ed7aa4c3fd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_24b6e249-51e7-455c-8a78-c3f97785a092" xlink:href="mgnx-20221231.xsd#mgnx_IMabBiopharmaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_IMabBiopharmaMember_24b6e249-51e7-455c-8a78-c3f97785a092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_471b54b8-ddfc-48f7-88bd-9f1c840f3e48" xlink:href="mgnx-20221231.xsd#mgnx_ProventionBioMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_ProventionBioMember_471b54b8-ddfc-48f7-88bd-9f1c840f3e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_5bd48e18-19ed-45ef-b10b-a642f3bfef0d" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_ZaiLabMember_5bd48e18-19ed-45ef-b10b-a642f3bfef0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ImabMember_23dd2e84-f458-4642-b736-087284c430e5" xlink:href="mgnx-20221231.xsd#mgnx_ImabMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_ImabMember_23dd2e84-f458-4642-b736-087284c430e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_c851b8a2-31fa-4b88-bce6-ec7b2ada3d2f" xlink:href="mgnx-20221231.xsd#mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_c851b8a2-31fa-4b88-bce6-ec7b2ada3d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ASDHealthcareAndOncologySupplyMember_34c2e23d-4693-4998-9203-4917ecbb163f" xlink:href="mgnx-20221231.xsd#mgnx_ASDHealthcareAndOncologySupplyMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_bde3b003-d1d3-45ec-8460-bb7863d2f8d7" xlink:to="loc_mgnx_ASDHealthcareAndOncologySupplyMember_34c2e23d-4693-4998-9203-4917ecbb163f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_cce55c49-5df5-4e06-b926-9a6472e775c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e928b8e0-9a9b-4d0b-8391-550b6679e97e" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_cce55c49-5df5-4e06-b926-9a6472e775c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7c416020-743e-4189-ab32-99b347419aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_cce55c49-5df5-4e06-b926-9a6472e775c0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7c416020-743e-4189-ab32-99b347419aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_656f828e-00b6-4d81-9682-a9cfb87f5125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_458f4434-0753-4856-974e-dbc962b41ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_656f828e-00b6-4d81-9682-a9cfb87f5125" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_458f4434-0753-4856-974e-dbc962b41ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d14c853-cc79-4203-ade9-0a0123050ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_458f4434-0753-4856-974e-dbc962b41ff6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d14c853-cc79-4203-ade9-0a0123050ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b7e37d2-4e5c-477e-b7ec-d3b9ee8fc631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1d14c853-cc79-4203-ade9-0a0123050ebc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b7e37d2-4e5c-477e-b7ec-d3b9ee8fc631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_8ee2802f-4f6e-4176-96e8-47da22d263ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b7e37d2-4e5c-477e-b7ec-d3b9ee8fc631" xlink:to="loc_us-gaap_ComputerEquipmentMember_8ee2802f-4f6e-4176-96e8-47da22d263ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e6d91eef-db4e-4949-89cd-24b8ccc3f2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b7e37d2-4e5c-477e-b7ec-d3b9ee8fc631" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e6d91eef-db4e-4949-89cd-24b8ccc3f2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1700812b-e2db-4171-a691-2d01a84301ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b7e37d2-4e5c-477e-b7ec-d3b9ee8fc631" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1700812b-e2db-4171-a691-2d01a84301ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_51f71bab-84cc-4721-8e4b-78fc5599fdcf" xlink:href="mgnx-20221231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b7e37d2-4e5c-477e-b7ec-d3b9ee8fc631" xlink:to="loc_mgnx_LaboratoryAndOfficeEquipmentMember_51f71bab-84cc-4721-8e4b-78fc5599fdcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81f2975e-23e4-480a-b9d5-fd7afa8ba86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_458f4434-0753-4856-974e-dbc962b41ff6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81f2975e-23e4-480a-b9d5-fd7afa8ba86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_85ba2a03-5e57-45d6-851d-f575b0893583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81f2975e-23e4-480a-b9d5-fd7afa8ba86e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_85ba2a03-5e57-45d6-851d-f575b0893583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8c8583be-1b85-45f8-8d3b-50bf228c9702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6b9b77b4-ab9c-4f6b-a742-51283d8321d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8c8583be-1b85-45f8-8d3b-50bf228c9702" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6b9b77b4-ab9c-4f6b-a742-51283d8321d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7afb000e-f101-456e-922a-1883f44d2ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6b9b77b4-ab9c-4f6b-a742-51283d8321d2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7afb000e-f101-456e-922a-1883f44d2ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e06bc4a-db7c-4986-b280-d472b63132a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7afb000e-f101-456e-922a-1883f44d2ef6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e06bc4a-db7c-4986-b280-d472b63132a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_6216b00f-8501-4e35-9942-31cf33ef20b7" xlink:href="mgnx-20221231.xsd#mgnx_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5e06bc4a-db7c-4986-b280-d472b63132a7" xlink:to="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_6216b00f-8501-4e35-9942-31cf33ef20b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a051df5d-da37-480d-b646-083f78367883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6b9b77b4-ab9c-4f6b-a742-51283d8321d2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a051df5d-da37-480d-b646-083f78367883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e93bfa69-5594-4755-aad0-bbb6e49bebee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a051df5d-da37-480d-b646-083f78367883" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e93bfa69-5594-4755-aad0-bbb6e49bebee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c57e3bbb-1cea-43d5-9bb1-2a4e242d3007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_43f3baf1-ad01-4348-ab46-507dbed0a95d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c57e3bbb-1cea-43d5-9bb1-2a4e242d3007" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_43f3baf1-ad01-4348-ab46-507dbed0a95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_187a9996-13c8-46d4-9206-817fc97a12b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_43f3baf1-ad01-4348-ab46-507dbed0a95d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_187a9996-13c8-46d4-9206-817fc97a12b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ddc96fce-be88-48b9-8e57-0d2d8d216287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_187a9996-13c8-46d4-9206-817fc97a12b7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ddc96fce-be88-48b9-8e57-0d2d8d216287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b74bf86a-058b-447d-aae7-a90082979c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ddc96fce-be88-48b9-8e57-0d2d8d216287" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b74bf86a-058b-447d-aae7-a90082979c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2d73be51-87df-49da-aabc-0b97d71f290d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ddc96fce-be88-48b9-8e57-0d2d8d216287" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2d73be51-87df-49da-aabc-0b97d71f290d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_df8d8d50-c702-4373-96bf-c77658a57946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ddc96fce-be88-48b9-8e57-0d2d8d216287" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_df8d8d50-c702-4373-96bf-c77658a57946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bc63600-05c6-494f-8229-4ed18c11489b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_43f3baf1-ad01-4348-ab46-507dbed0a95d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bc63600-05c6-494f-8229-4ed18c11489b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f3a666bf-500d-4e72-a2cc-b38dce3290e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bc63600-05c6-494f-8229-4ed18c11489b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f3a666bf-500d-4e72-a2cc-b38dce3290e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cd3fe975-f9f3-4056-89b9-c91f6441c016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bc63600-05c6-494f-8229-4ed18c11489b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cd3fe975-f9f3-4056-89b9-c91f6441c016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_770fd335-6d21-4d07-a1b7-205355f33287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bc63600-05c6-494f-8229-4ed18c11489b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_770fd335-6d21-4d07-a1b7-205355f33287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cbaf2727-a3f4-4bb5-9f14-7978aecd0359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7bc63600-05c6-494f-8229-4ed18c11489b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cbaf2727-a3f4-4bb5-9f14-7978aecd0359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#MarketableSecuritiesAvailableForSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_63a0d732-be82-4388-93cb-612d965df2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_6af0823e-87b2-4e35-a816-80f8123e047a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_63a0d732-be82-4388-93cb-612d965df2b9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_6af0823e-87b2-4e35-a816-80f8123e047a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_469483e4-3294-4a20-b82c-16edfa59e287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_63a0d732-be82-4388-93cb-612d965df2b9" xlink:to="loc_us-gaap_InterestIncomeOther_469483e4-3294-4a20-b82c-16edfa59e287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#InventoryNetScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d6439386-9714-4187-a7cc-a5a76cc20db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_3fb8a3ec-8bbf-4318-8ed2-3e1904e2ee4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d6439386-9714-4187-a7cc-a5a76cc20db8" xlink:to="loc_us-gaap_InventoryWorkInProcess_3fb8a3ec-8bbf-4318-8ed2-3e1904e2ee4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_b315fda8-3db0-4f62-9808-2b0a8d23c5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d6439386-9714-4187-a7cc-a5a76cc20db8" xlink:to="loc_us-gaap_InventoryFinishedGoods_b315fda8-3db0-4f62-9808-2b0a8d23c5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e25ac97b-e55e-46e8-8c60-bfe253ce30cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d6439386-9714-4187-a7cc-a5a76cc20db8" xlink:to="loc_us-gaap_InventoryNet_e25ac97b-e55e-46e8-8c60-bfe253ce30cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_17b9a0f0-79fc-4727-a8c6-92b2be03b043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d6439386-9714-4187-a7cc-a5a76cc20db8" xlink:to="loc_us-gaap_InventoryValuationReserves_17b9a0f0-79fc-4727-a8c6-92b2be03b043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#InventoryNetDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7fc29074-685e-4c0c-a056-3733269e83ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_3a0a4dc3-ed93-487b-8e6d-70ee87e6090b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7fc29074-685e-4c0c-a056-3733269e83ed" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_3a0a4dc3-ed93-487b-8e6d-70ee87e6090b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c5ad22e1-11b1-4f40-aaf6-4b35cee67534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_3a0a4dc3-ed93-487b-8e6d-70ee87e6090b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c5ad22e1-11b1-4f40-aaf6-4b35cee67534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_d87bef20-04dd-4e1b-924e-3c470424202b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c5ad22e1-11b1-4f40-aaf6-4b35cee67534" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_d87bef20-04dd-4e1b-924e-3c470424202b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserveMember_7aecb412-fa58-4a6f-8a3f-cc1908a0b81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d87bef20-04dd-4e1b-924e-3c470424202b" xlink:to="loc_us-gaap_InventoryValuationReserveMember_7aecb412-fa58-4a6f-8a3f-cc1908a0b81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_01cf81a2-0e6d-41c6-a849-96b2400ee0ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_3a0a4dc3-ed93-487b-8e6d-70ee87e6090b" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_01cf81a2-0e6d-41c6-a849-96b2400ee0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c4647354-8433-4ab7-84a3-1ef1bb359247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_01cf81a2-0e6d-41c6-a849-96b2400ee0ce" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_c4647354-8433-4ab7-84a3-1ef1bb359247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_768da552-0578-4690-9dc9-66dff191f04b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_01cf81a2-0e6d-41c6-a849-96b2400ee0ce" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_768da552-0578-4690-9dc9-66dff191f04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_6e4c20a8-4248-4c43-ba06-8d56382426a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_01cf81a2-0e6d-41c6-a849-96b2400ee0ce" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_6e4c20a8-4248-4c43-ba06-8d56382426a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c48815b0-2add-4eb3-a7fb-2be516de2f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_01cf81a2-0e6d-41c6-a849-96b2400ee0ce" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_c48815b0-2add-4eb3-a7fb-2be516de2f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_04c2c950-93c6-4daf-ba97-387b3190f627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_890f4234-8c01-4bb1-b91f-cec7929a743b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_04c2c950-93c6-4daf-ba97-387b3190f627" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_890f4234-8c01-4bb1-b91f-cec7929a743b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce68b2a5-d2f7-44e1-8fb3-89b3039975fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_890f4234-8c01-4bb1-b91f-cec7929a743b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce68b2a5-d2f7-44e1-8fb3-89b3039975fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ebbd7ac-1d83-4009-a163-76e13e749d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce68b2a5-d2f7-44e1-8fb3-89b3039975fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ebbd7ac-1d83-4009-a163-76e13e749d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_fb9981e1-6e84-4187-85b3-4ce7561c76a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ebbd7ac-1d83-4009-a163-76e13e749d51" xlink:to="loc_us-gaap_ComputerEquipmentMember_fb9981e1-6e84-4187-85b3-4ce7561c76a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_4e77aaf0-0c71-4e1b-b028-f2eae84d9953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ebbd7ac-1d83-4009-a163-76e13e749d51" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_4e77aaf0-0c71-4e1b-b028-f2eae84d9953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_d3636d31-5be6-40b7-896b-962f07058148" xlink:href="mgnx-20221231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ebbd7ac-1d83-4009-a163-76e13e749d51" xlink:to="loc_mgnx_FurnitureAndOfficeEquipmentMember_d3636d31-5be6-40b7-896b-962f07058148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_9130979e-3336-4634-adec-321a57c82350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ebbd7ac-1d83-4009-a163-76e13e749d51" xlink:to="loc_us-gaap_VehiclesMember_9130979e-3336-4634-adec-321a57c82350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_8a0a0ce6-7919-4e81-ac95-15c1c0414514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ebbd7ac-1d83-4009-a163-76e13e749d51" xlink:to="loc_us-gaap_EquipmentMember_8a0a0ce6-7919-4e81-ac95-15c1c0414514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_74bf80d9-462f-409e-ba75-48761d438d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1ebbd7ac-1d83-4009-a163-76e13e749d51" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_74bf80d9-462f-409e-ba75-48761d438d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_57e20558-01c9-41d8-81d5-b4574306f0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_890f4234-8c01-4bb1-b91f-cec7929a743b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_57e20558-01c9-41d8-81d5-b4574306f0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0e7df9d5-be9e-44be-b9fd-28a54342fc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_57e20558-01c9-41d8-81d5-b4574306f0c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0e7df9d5-be9e-44be-b9fd-28a54342fc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_6d35008d-9a5e-41d8-beb1-78b9bb0f5149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_57e20558-01c9-41d8-81d5-b4574306f0c4" xlink:to="loc_us-gaap_ConstructionInProgressGross_6d35008d-9a5e-41d8-beb1-78b9bb0f5149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b3550af8-45b3-4e7d-8744-eaec8fdba010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_57e20558-01c9-41d8-81d5-b4574306f0c4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b3550af8-45b3-4e7d-8744-eaec8fdba010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d786b38a-466b-4918-b1d3-70a8f491c24f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_57e20558-01c9-41d8-81d5-b4574306f0c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d786b38a-466b-4918-b1d3-70a8f491c24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_96857baa-6969-4c23-8b39-2feb4d0f98f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_57e20558-01c9-41d8-81d5-b4574306f0c4" xlink:to="loc_us-gaap_Depreciation_96857baa-6969-4c23-8b39-2feb4d0f98f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ee6f4bf5-8d52-4323-97d0-ad6d4aaf54c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a15defe5-c205-4337-a725-ac0e698705d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ee6f4bf5-8d52-4323-97d0-ad6d4aaf54c5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a15defe5-c205-4337-a725-ac0e698705d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_22b1dec2-3768-4abe-a507-22573ba406f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a15defe5-c205-4337-a725-ac0e698705d2" xlink:to="loc_srt_CounterpartyNameAxis_22b1dec2-3768-4abe-a507-22573ba406f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcfdb92f-6027-4ded-8c1d-30f7e462b6f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_22b1dec2-3768-4abe-a507-22573ba406f3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcfdb92f-6027-4ded-8c1d-30f7e462b6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_SynaffixBVMember_9c1b8f12-9a63-47e6-9a48-9d373459f937" xlink:href="mgnx-20221231.xsd#mgnx_SynaffixBVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcfdb92f-6027-4ded-8c1d-30f7e462b6f5" xlink:to="loc_mgnx_SynaffixBVMember_9c1b8f12-9a63-47e6-9a48-9d373459f937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f2ac3fa5-c8c7-4020-a51e-0650ba46e441" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a15defe5-c205-4337-a725-ac0e698705d2" xlink:to="loc_srt_RangeAxis_f2ac3fa5-c8c7-4020-a51e-0650ba46e441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2a14c818-cf41-494f-abc4-f16a8f2e9994" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f2ac3fa5-c8c7-4020-a51e-0650ba46e441" xlink:to="loc_srt_RangeMember_2a14c818-cf41-494f-abc4-f16a8f2e9994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_14bd6a47-8e9b-4d4b-844a-e8a2d82d3d39" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2a14c818-cf41-494f-abc4-f16a8f2e9994" xlink:to="loc_srt_MinimumMember_14bd6a47-8e9b-4d4b-844a-e8a2d82d3d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a15defe5-c205-4337-a725-ac0e698705d2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_13df9dda-aaf4-4084-bde0-b0aff86074ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_13df9dda-aaf4-4084-bde0-b0aff86074ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_4c9a48d0-7595-493d-90e7-2a23c5132ed8" xlink:href="mgnx-20221231.xsd#mgnx_RightOfUseAssetAndLeaseLiabilityIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_4c9a48d0-7595-493d-90e7-2a23c5132ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_65eef1ac-87d7-4301-aeb8-ded330e3e386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_OperatingLeasePayments_65eef1ac-87d7-4301-aeb8-ded330e3e386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fb4a9b55-0dc8-4c86-b783-49e6073462d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fb4a9b55-0dc8-4c86-b783-49e6073462d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ac6144f5-9354-4ebf-90cc-e68e04bae1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_OperatingLeaseCost_ac6144f5-9354-4ebf-90cc-e68e04bae1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_9ac5cd95-619e-4e3f-af40-862c159ffe12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_VariableLeaseCost_9ac5cd95-619e-4e3f-af40-862c159ffe12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_00bdecbe-3384-4532-a403-a29ce1acc09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_SubleaseIncome_00bdecbe-3384-4532-a403-a29ce1acc09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_45278c9c-35f8-4444-b71a-64dc0a457b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LeaseCost_45278c9c-35f8-4444-b71a-64dc0a457b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_63e78a98-73f5-4fb0-bb8d-3aebc06da1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_63e78a98-73f5-4fb0-bb8d-3aebc06da1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_889a1ac6-796d-49fb-b5f4-de113be55fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_889a1ac6-796d-49fb-b5f4-de113be55fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1caf635b-7542-46ca-98d9-aabce3714282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1caf635b-7542-46ca-98d9-aabce3714282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b18715ab-e3bf-49a2-860f-54705b0e3e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b18715ab-e3bf-49a2-860f-54705b0e3e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_123d6031-8539-4f93-90e5-6e095c3fe09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_123d6031-8539-4f93-90e5-6e095c3fe09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0a86e1f4-86c9-4090-852c-3e31bc3dc205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0a86e1f4-86c9-4090-852c-3e31bc3dc205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f4cc3cf0-b45b-4d3c-bdec-f146c79808c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f4cc3cf0-b45b-4d3c-bdec-f146c79808c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2335ee45-b059-422f-845f-a589a6e33c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2335ee45-b059-422f-845f-a589a6e33c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f70892ee-d403-4526-9025-f2850ea77c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_OperatingLeaseLiability_f70892ee-d403-4526-9025-f2850ea77c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_fa792e7a-9f2f-4bfb-81e5-1f3b6ccf1192" xlink:href="mgnx-20221231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_fa792e7a-9f2f-4bfb-81e5-1f3b6ccf1192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_50dfde26-504a-4b26-b15f-fc8d4ab6333c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_50dfde26-504a-4b26-b15f-fc8d4ab6333c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_a82dfee6-ccb6-44b6-bf8a-a2546caf0e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_a82dfee6-ccb6-44b6-bf8a-a2546caf0e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d02fe9a2-8595-4314-ad18-52b7b3f2fa90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9be0271a-da65-4fb0-9a89-67f407a51d9e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d02fe9a2-8595-4314-ad18-52b7b3f2fa90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a7790e5f-3a7f-4bb9-ab1b-247969149ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_77c4a472-3648-4266-b57b-32b7cb5a1728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a7790e5f-3a7f-4bb9-ab1b-247969149ac5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_77c4a472-3648-4266-b57b-32b7cb5a1728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_217587f7-8b85-4d9f-80e9-b37f45d96e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c4a472-3648-4266-b57b-32b7cb5a1728" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_217587f7-8b85-4d9f-80e9-b37f45d96e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64a29245-99e8-4483-97bf-66e1864d47a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_217587f7-8b85-4d9f-80e9-b37f45d96e80" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64a29245-99e8-4483-97bf-66e1864d47a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_42239c9d-effa-43d8-b5a7-782263c819b8" xlink:href="mgnx-20221231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64a29245-99e8-4483-97bf-66e1864d47a1" xlink:to="loc_mgnx_AtTheMarketOfferingMember_42239c9d-effa-43d8-b5a7-782263c819b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_47fb8219-c16d-4715-b339-d7eeafa4b643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c4a472-3648-4266-b57b-32b7cb5a1728" xlink:to="loc_us-gaap_StatementClassOfStockAxis_47fb8219-c16d-4715-b339-d7eeafa4b643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d76f9110-bef5-4b78-b953-088241c22ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_47fb8219-c16d-4715-b339-d7eeafa4b643" xlink:to="loc_us-gaap_ClassOfStockDomain_d76f9110-bef5-4b78-b953-088241c22ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_d9095ad4-544a-465c-aede-7d84e1de6362" xlink:href="mgnx-20221231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d76f9110-bef5-4b78-b953-088241c22ebc" xlink:to="loc_mgnx_UndesignatedPreferredStockMember_d9095ad4-544a-465c-aede-7d84e1de6362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6414497d-ef3e-444a-baf2-760004437abe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c4a472-3648-4266-b57b-32b7cb5a1728" xlink:to="loc_srt_CounterpartyNameAxis_6414497d-ef3e-444a-baf2-760004437abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1038347c-e225-48d8-877f-24642f4251e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6414497d-ef3e-444a-baf2-760004437abe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1038347c-e225-48d8-877f-24642f4251e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_db2b0c7e-972e-4336-b106-4de071823da1" xlink:href="mgnx-20221231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1038347c-e225-48d8-877f-24642f4251e8" xlink:to="loc_mgnx_IncyteCorporationMember_db2b0c7e-972e-4336-b106-4de071823da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_39462cf3-4dd2-44fc-9a4c-82cbb9b93236" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1038347c-e225-48d8-877f-24642f4251e8" xlink:to="loc_mgnx_ZaiLabMember_39462cf3-4dd2-44fc-9a4c-82cbb9b93236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba766a4f-52d0-4927-8a41-64e2f23de36a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c4a472-3648-4266-b57b-32b7cb5a1728" xlink:to="loc_srt_RangeAxis_ba766a4f-52d0-4927-8a41-64e2f23de36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_42421b52-ed10-46af-8ce6-a9013b5bb68d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ba766a4f-52d0-4927-8a41-64e2f23de36a" xlink:to="loc_srt_RangeMember_42421b52-ed10-46af-8ce6-a9013b5bb68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_99f34257-8ed4-43c9-8fe7-74022823031e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_42421b52-ed10-46af-8ce6-a9013b5bb68d" xlink:to="loc_srt_MaximumMember_99f34257-8ed4-43c9-8fe7-74022823031e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_db2ecf75-3ccb-408a-ab8b-5256f321fe1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c4a472-3648-4266-b57b-32b7cb5a1728" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_db2ecf75-3ccb-408a-ab8b-5256f321fe1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b888a4df-f149-4607-a709-43d5c717f5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_db2ecf75-3ccb-408a-ab8b-5256f321fe1c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b888a4df-f149-4607-a709-43d5c717f5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_19db769a-d9ce-42de-86be-4a0c34e650c8" xlink:href="mgnx-20221231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b888a4df-f149-4607-a709-43d5c717f5cf" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_19db769a-d9ce-42de-86be-4a0c34e650c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_7444babf-2c38-4d4f-92b5-4dc937520e17" xlink:href="mgnx-20221231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b888a4df-f149-4607-a709-43d5c717f5cf" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_7444babf-2c38-4d4f-92b5-4dc937520e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c4a472-3648-4266-b57b-32b7cb5a1728" xlink:to="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_05aacdda-f26d-412a-9e21-ced8cf0637f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_05aacdda-f26d-412a-9e21-ced8cf0637f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_11100eab-0c1c-450c-b253-67f7ee3f204c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_11100eab-0c1c-450c-b253-67f7ee3f204c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7d6ea728-70d1-4b15-8386-9c519a908135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7d6ea728-70d1-4b15-8386-9c519a908135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f436e2d2-f08d-419e-aa69-d6ab4842ae80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f436e2d2-f08d-419e-aa69-d6ab4842ae80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_615264db-a88a-4317-af6c-efa1e6c02321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_615264db-a88a-4317-af6c-efa1e6c02321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_23684cd8-a95c-476d-9979-f7df250af22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_23684cd8-a95c-476d-9979-f7df250af22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c53626ec-1623-40ac-955f-208be72dd8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c53626ec-1623-40ac-955f-208be72dd8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_996994c5-a95c-4e3c-beb4-2321a0ddc4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_996994c5-a95c-4e3c-beb4-2321a0ddc4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4843c38f-f3bb-4055-9613-95bed2280290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4843c38f-f3bb-4055-9613-95bed2280290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_97eb7896-3f11-4f0b-ac04-0490c2c7a024" xlink:href="mgnx-20221231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_97eb7896-3f11-4f0b-ac04-0490c2c7a024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_338e2d4e-799f-46aa-9ac2-c097ef467dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_338e2d4e-799f-46aa-9ac2-c097ef467dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_24cbad53-cd5f-42eb-8803-0d2cd2f12e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_24cbad53-cd5f-42eb-8803-0d2cd2f12e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0ea82060-e10e-4c70-9ada-d3bff2ce5bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0ea82060-e10e-4c70-9ada-d3bff2ce5bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_21066b22-ae4b-4129-8f5d-1a0fc8860367" xlink:href="mgnx-20221231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d3e1fec5-14cc-4721-9e6b-e19c0811990c" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease_21066b22-ae4b-4129-8f5d-1a0fc8860367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#RevenueIncyteCorporationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueIncyteCorporationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_71a0fac9-fe11-4585-82c6-876e3c96a46e" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_07a6a0fb-4959-4278-9d95-2633e03c645f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_71a0fac9-fe11-4585-82c6-876e3c96a46e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_07a6a0fb-4959-4278-9d95-2633e03c645f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_75d92b29-eb1b-42e8-bb3e-bbedf8bdd13e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_07a6a0fb-4959-4278-9d95-2633e03c645f" xlink:to="loc_srt_ProductOrServiceAxis_75d92b29-eb1b-42e8-bb3e-bbedf8bdd13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e671b208-9e5a-4e89-bc0a-45a375c944bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_75d92b29-eb1b-42e8-bb3e-bbedf8bdd13e" xlink:to="loc_srt_ProductsAndServicesDomain_e671b208-9e5a-4e89-bc0a-45a375c944bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_a18cca3b-ad07-40c7-97b1-5511be8ce0d0" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e671b208-9e5a-4e89-bc0a-45a375c944bb" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_a18cca3b-ad07-40c7-97b1-5511be8ce0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_51edfa13-a838-4710-a1a4-5b880e826e86" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e671b208-9e5a-4e89-bc0a-45a375c944bb" xlink:to="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_51edfa13-a838-4710-a1a4-5b880e826e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember_e5d53109-ce96-471c-a844-5be5f564b27a" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromCMOAmendmentAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e671b208-9e5a-4e89-bc0a-45a375c944bb" xlink:to="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember_e5d53109-ce96-471c-a844-5be5f564b27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f9e2c883-d42e-4841-9f74-bf9828dbc1fc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_07a6a0fb-4959-4278-9d95-2633e03c645f" xlink:to="loc_srt_RangeAxis_f9e2c883-d42e-4841-9f74-bf9828dbc1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d8a75ed-3cef-40e8-8be1-b685cbc497cd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f9e2c883-d42e-4841-9f74-bf9828dbc1fc" xlink:to="loc_srt_RangeMember_6d8a75ed-3cef-40e8-8be1-b685cbc497cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3431b4ea-c510-4f67-9d3d-24429b1bc213" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6d8a75ed-3cef-40e8-8be1-b685cbc497cd" xlink:to="loc_srt_MinimumMember_3431b4ea-c510-4f67-9d3d-24429b1bc213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0344aea3-c58a-4ad9-bfff-7317313385ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6d8a75ed-3cef-40e8-8be1-b685cbc497cd" xlink:to="loc_srt_MaximumMember_0344aea3-c58a-4ad9-bfff-7317313385ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6843a407-a79d-462c-aa14-0641a4718ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_07a6a0fb-4959-4278-9d95-2633e03c645f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6843a407-a79d-462c-aa14-0641a4718ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be74af17-4435-4134-a15c-bb79d5b540d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6843a407-a79d-462c-aa14-0641a4718ee7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be74af17-4435-4134-a15c-bb79d5b540d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_70918949-257c-4301-bdbb-e937bcfbcf5c" xlink:href="mgnx-20221231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be74af17-4435-4134-a15c-bb79d5b540d8" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_70918949-257c-4301-bdbb-e937bcfbcf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCommercialSupplyAgreementMember_994b4f71-90dc-4775-94c8-191d697b87cb" xlink:href="mgnx-20221231.xsd#mgnx_IncyteCommercialSupplyAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be74af17-4435-4134-a15c-bb79d5b540d8" xlink:to="loc_mgnx_IncyteCommercialSupplyAgreementMember_994b4f71-90dc-4775-94c8-191d697b87cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteClinicalSupplyAgreementMember_286996e8-fd5b-4710-81ed-0b204c1713fa" xlink:href="mgnx-20221231.xsd#mgnx_IncyteClinicalSupplyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be74af17-4435-4134-a15c-bb79d5b540d8" xlink:to="loc_mgnx_IncyteClinicalSupplyAgreementMember_286996e8-fd5b-4710-81ed-0b204c1713fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4d13b615-0317-4a25-83eb-08084c6ae30b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_07a6a0fb-4959-4278-9d95-2633e03c645f" xlink:to="loc_srt_CounterpartyNameAxis_4d13b615-0317-4a25-83eb-08084c6ae30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f229aa22-985e-44eb-8e35-7d3dfbb7fd11" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4d13b615-0317-4a25-83eb-08084c6ae30b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f229aa22-985e-44eb-8e35-7d3dfbb7fd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_ea400fbb-62c8-4493-87a2-1ee8a1e421e8" xlink:href="mgnx-20221231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f229aa22-985e-44eb-8e35-7d3dfbb7fd11" xlink:to="loc_mgnx_IncyteCorporationMember_ea400fbb-62c8-4493-87a2-1ee8a1e421e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8c96112c-f96d-40e0-96ad-837d5a91edce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_07a6a0fb-4959-4278-9d95-2633e03c645f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8c96112c-f96d-40e0-96ad-837d5a91edce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e2cf805-da6c-4b34-afdf-7c198fa77c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8c96112c-f96d-40e0-96ad-837d5a91edce" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e2cf805-da6c-4b34-afdf-7c198fa77c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_190e63ea-c129-47ec-acd3-8da4ed04ad41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e2cf805-da6c-4b34-afdf-7c198fa77c2c" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_190e63ea-c129-47ec-acd3-8da4ed04ad41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_07a6a0fb-4959-4278-9d95-2633e03c645f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementTerm_5e2504fc-dc0f-430e-aa91-b6f7d0d7609f" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeArrangementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_CollaborativeArrangementTerm_5e2504fc-dc0f-430e-aa91-b6f7d0d7609f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_459225ab-0720-4017-9b31-75eea78624d2" xlink:href="mgnx-20221231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_NonRefundableUpfrontFees_459225ab-0720-4017-9b31-75eea78624d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementExtensionTerm_047f84d4-b10f-465b-82ae-33a67c640eac" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeArrangementExtensionTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_CollaborativeArrangementExtensionTerm_047f84d4-b10f-465b-82ae-33a67c640eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_9a66f7f0-0d3a-42a9-9608-870f4215fb3b" xlink:href="mgnx-20221231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_9a66f7f0-0d3a-42a9-9608-870f4215fb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_471597ac-e593-448c-8155-ae3a4fa09e9b" xlink:href="mgnx-20221231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_471597ac-e593-448c-8155-ae3a4fa09e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_65701265-ec0e-4b5c-8d6a-e420a6251b38" xlink:href="mgnx-20221231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_65701265-ec0e-4b5c-8d6a-e420a6251b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_34d35b54-bcef-47fd-a0cd-e38776b2fbb4" xlink:href="mgnx-20221231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_34d35b54-bcef-47fd-a0cd-e38776b2fbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_c4f877a2-cfb4-4074-a154-b4e8f0d41406" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_c4f877a2-cfb4-4074-a154-b4e8f0d41406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_ce07acac-d2a1-4cfe-86d0-15267c73ebe9" xlink:href="mgnx-20221231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_ce07acac-d2a1-4cfe-86d0-15267c73ebe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f9c5e302-b8f6-4e1b-a5bd-6f748bd138fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_us-gaap_Revenues_f9c5e302-b8f6-4e1b-a5bd-6f748bd138fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cd2969db-b5d5-46ed-b36a-23bb52e668bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cd2969db-b5d5-46ed-b36a-23bb52e668bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7c6ee4e6-f46e-4d2d-a936-03825e871a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7c6ee4e6-f46e-4d2d-a936-03825e871a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalAnnualFixedPayments_94a4a356-b3c5-4afd-aa05-8420a67a6606" xlink:href="mgnx-20221231.xsd#mgnx_TotalAnnualFixedPayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_TotalAnnualFixedPayments_94a4a356-b3c5-4afd-aa05-8420a67a6606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalAnnualFixedPayments_371deede-c587-4b39-b28e-dbf964796f32" xlink:href="mgnx-20221231.xsd#mgnx_AdditionalAnnualFixedPayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_mgnx_AdditionalAnnualFixedPayments_371deede-c587-4b39-b28e-dbf964796f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d6fc0fd3-0a20-4070-b4be-f73c0426f5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06388e79-f8e1-4cc8-8476-dc645484b8c6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d6fc0fd3-0a20-4070-b4be-f73c0426f5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueGileadSciencesIncDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#RevenueGileadSciencesIncDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueGileadSciencesIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_270443e5-d7cd-43a9-97aa-55f3ff8db0e7" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ed53868c-2d00-4a65-85de-9360f843aece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_270443e5-d7cd-43a9-97aa-55f3ff8db0e7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ed53868c-2d00-4a65-85de-9360f843aece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_786fcb0b-ad43-4c23-8cb6-ddad71e1550f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ed53868c-2d00-4a65-85de-9360f843aece" xlink:to="loc_srt_CounterpartyNameAxis_786fcb0b-ad43-4c23-8cb6-ddad71e1550f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf2c6c12-0c1d-4a25-9131-04078b91a06b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_786fcb0b-ad43-4c23-8cb6-ddad71e1550f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf2c6c12-0c1d-4a25-9131-04078b91a06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadMember_62ff865e-a1f0-4095-ae88-3126b00b87d9" xlink:href="mgnx-20221231.xsd#mgnx_GileadMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf2c6c12-0c1d-4a25-9131-04078b91a06b" xlink:to="loc_mgnx_GileadMember_62ff865e-a1f0-4095-ae88-3126b00b87d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c73443fd-ec32-41ce-afc1-5cb705b54ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ed53868c-2d00-4a65-85de-9360f843aece" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c73443fd-ec32-41ce-afc1-5cb705b54ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_47915cc1-4657-49d9-bf3e-6a1c5d8a1944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c73443fd-ec32-41ce-afc1-5cb705b54ab0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_47915cc1-4657-49d9-bf3e-6a1c5d8a1944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_89621673-e005-4a07-ae86-4b329882fb41" xlink:href="mgnx-20221231.xsd#mgnx_A2022GileadCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_47915cc1-4657-49d9-bf3e-6a1c5d8a1944" xlink:to="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_89621673-e005-4a07-ae86-4b329882fb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408d04c6-e3ac-4af8-827b-a411b269dfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ed53868c-2d00-4a65-85de-9360f843aece" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408d04c6-e3ac-4af8-827b-a411b269dfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_160c1938-674c-4fd9-9af4-347514a24ba8" xlink:href="mgnx-20221231.xsd#mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408d04c6-e3ac-4af8-827b-a411b269dfc0" xlink:to="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_160c1938-674c-4fd9-9af4-347514a24ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_4ec3a36e-3bc7-45a9-a932-326cebd3c183" xlink:href="mgnx-20221231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408d04c6-e3ac-4af8-827b-a411b269dfc0" xlink:to="loc_mgnx_NonRefundableUpfrontFees_4ec3a36e-3bc7-45a9-a932-326cebd3c183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_489c846c-060e-4f65-b54a-ede24c70b922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408d04c6-e3ac-4af8-827b-a411b269dfc0" xlink:to="loc_us-gaap_Revenues_489c846c-060e-4f65-b54a-ede24c70b922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_551f54d7-1cdb-4880-ae19-5edc32768e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408d04c6-e3ac-4af8-827b-a411b269dfc0" xlink:to="loc_us-gaap_ContractWithCustomerLiability_551f54d7-1cdb-4880-ae19-5edc32768e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b6bd0be8-8fb3-4428-ac71-ca2bc47ebd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408d04c6-e3ac-4af8-827b-a411b269dfc0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b6bd0be8-8fb3-4428-ac71-ca2bc47ebd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_84890869-0dda-4861-af38-356ff44cd77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408d04c6-e3ac-4af8-827b-a411b269dfc0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_84890869-0dda-4861-af38-356ff44cd77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#RevenueZaiLabDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueZaiLabDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_5e3f4d3b-2f0b-4723-9882-7b597f8411c1" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa8301d3-fb2b-49ea-bca6-402821e4c8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_5e3f4d3b-2f0b-4723-9882-7b597f8411c1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa8301d3-fb2b-49ea-bca6-402821e4c8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_22439f0a-d7c1-4042-a114-d3fc805b8e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa8301d3-fb2b-49ea-bca6-402821e4c8f0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_22439f0a-d7c1-4042-a114-d3fc805b8e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_22439f0a-d7c1-4042-a114-d3fc805b8e5a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_625d0efc-4679-44a9-aed7-ed7b0031af24" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMember_625d0efc-4679-44a9-aed7-ed7b0031af24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_d76db26b-9b05-4484-8c9f-b6694a42f596" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_d76db26b-9b05-4484-8c9f-b6694a42f596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_49742858-31bb-4e15-a195-daccfd47ae72" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_49742858-31bb-4e15-a195-daccfd47ae72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_d2557c74-19bf-42da-8050-d190cf59fd81" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_d2557c74-19bf-42da-8050-d190cf59fd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_e98da7ba-8845-41f6-806c-bdc9e457412c" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:to="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_e98da7ba-8845-41f6-806c-bdc9e457412c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_5277ddd5-6c9f-44a2-9bde-6295c52e4513" xlink:href="mgnx-20221231.xsd#mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:to="loc_mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember_5277ddd5-6c9f-44a2-9bde-6295c52e4513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_9e341896-cc6d-49e2-9e78-56457adb896b" xlink:href="mgnx-20221231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0fd35808-2f22-4746-b005-97b062b7e758" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_9e341896-cc6d-49e2-9e78-56457adb896b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_84507b85-a0a1-49b0-bc13-c4ca4d8c2760" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa8301d3-fb2b-49ea-bca6-402821e4c8f0" xlink:to="loc_srt_CounterpartyNameAxis_84507b85-a0a1-49b0-bc13-c4ca4d8c2760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c52cbb27-a5c9-4aad-8981-40f8ad7d7a01" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_84507b85-a0a1-49b0-bc13-c4ca4d8c2760" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c52cbb27-a5c9-4aad-8981-40f8ad7d7a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsMember_b2a0a126-c675-4115-9396-77da1716a854" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c52cbb27-a5c9-4aad-8981-40f8ad7d7a01" xlink:to="loc_mgnx_ZaiLabsMember_b2a0a126-c675-4115-9396-77da1716a854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_045f39aa-d4b4-4441-aed3-4307bcd23332" xlink:href="mgnx-20221231.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c52cbb27-a5c9-4aad-8981-40f8ad7d7a01" xlink:to="loc_mgnx_ZaiLabMember_045f39aa-d4b4-4441-aed3-4307bcd23332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_11cd2264-036c-410b-a377-34961154a163" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa8301d3-fb2b-49ea-bca6-402821e4c8f0" xlink:to="loc_srt_RangeAxis_11cd2264-036c-410b-a377-34961154a163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_453e420e-f81e-47fe-8f4e-498dd22b9e2e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_11cd2264-036c-410b-a377-34961154a163" xlink:to="loc_srt_RangeMember_453e420e-f81e-47fe-8f4e-498dd22b9e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c9c11666-ef3c-4cd0-806c-815cd2188c33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_453e420e-f81e-47fe-8f4e-498dd22b9e2e" xlink:to="loc_srt_MaximumMember_c9c11666-ef3c-4cd0-806c-815cd2188c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9bffa1cb-e7f5-44c7-b0e3-9897cb2e2962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa8301d3-fb2b-49ea-bca6-402821e4c8f0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9bffa1cb-e7f5-44c7-b0e3-9897cb2e2962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_af093e73-496f-4694-85a2-3333b04ec16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9bffa1cb-e7f5-44c7-b0e3-9897cb2e2962" xlink:to="loc_us-gaap_EquityComponentDomain_af093e73-496f-4694-85a2-3333b04ec16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f0f44d59-92b0-4877-80b8-46a3e8aaf916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_af093e73-496f-4694-85a2-3333b04ec16b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f0f44d59-92b0-4877-80b8-46a3e8aaf916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa8301d3-fb2b-49ea-bca6-402821e4c8f0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_739ddb0a-e654-4e94-8304-00b39461dacf" xlink:href="mgnx-20221231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_NonRefundableUpfrontFees_739ddb0a-e654-4e94-8304-00b39461dacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_d1c59ddc-e8f2-4897-86fc-75a2b5cd5fd6" xlink:href="mgnx-20221231.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_d1c59ddc-e8f2-4897-86fc-75a2b5cd5fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_c4049ae1-c80f-4256-b2f0-f656c1dd029b" xlink:href="mgnx-20221231.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_c4049ae1-c80f-4256-b2f0-f656c1dd029b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_28b4980a-4ddc-4700-9810-aabfee493f55" xlink:href="mgnx-20221231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_28b4980a-4ddc-4700-9810-aabfee493f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1bb225e3-4c47-48eb-a38d-f1037ae8fe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_us-gaap_Revenues_1bb225e3-4c47-48eb-a38d-f1037ae8fe7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_18da73a6-066f-4a56-97d0-81b0a052c690" xlink:href="mgnx-20221231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_18da73a6-066f-4a56-97d0-81b0a052c690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cfe78bec-bcf0-4aea-94d1-f63bb8fceec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cfe78bec-bcf0-4aea-94d1-f63bb8fceec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_852e0eff-eee1-42b5-bd6d-38015ac5117d" xlink:href="mgnx-20221231.xsd#mgnx_EstimatedReimbursementForResearchAndDevelopmentT"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_EstimatedReimbursementForResearchAndDevelopmentT_852e0eff-eee1-42b5-bd6d-38015ac5117d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_4e50e679-ccbe-4283-80f3-3c1f798ac5f3" xlink:href="mgnx-20221231.xsd#mgnx_PremiumReceivedOnStockPurchase"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_4e50e679-ccbe-4283-80f3-3c1f798ac5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_66a0c412-222c-43e9-844b-39cd772c3107" xlink:href="mgnx-20221231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_66a0c412-222c-43e9-844b-39cd772c3107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_78b0d2f0-8087-4149-9528-9f25aeb4e807" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_78b0d2f0-8087-4149-9528-9f25aeb4e807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonesValueAddedTax_1cff99c2-be2e-46a7-8c13-5b0ec614bdd9" xlink:href="mgnx-20221231.xsd#mgnx_MilestonesValueAddedTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_MilestonesValueAddedTax_1cff99c2-be2e-46a7-8c13-5b0ec614bdd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_e031af97-a8c6-473f-84ec-12d2354f2000" xlink:href="mgnx-20221231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_e031af97-a8c6-473f-84ec-12d2354f2000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromVariableConsiderationRecognize_4dee572b-eece-4533-85b3-f9f5d5854734" xlink:href="mgnx-20221231.xsd#mgnx_RevenueFromVariableConsiderationRecognize"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7bbc659-4d32-4c96-9e74-87272147ea29" xlink:to="loc_mgnx_RevenueFromVariableConsiderationRecognize_4dee572b-eece-4533-85b3-f9f5d5854734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueJanssenDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#RevenueJanssenDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueJanssenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_9eee0820-49f9-4b67-ad3a-97248c1f0f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f43285d-c20c-4849-8815-2d21bc69a058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_9eee0820-49f9-4b67-ad3a-97248c1f0f5d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f43285d-c20c-4849-8815-2d21bc69a058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_33833303-da70-40da-891b-5bda453c2155" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f43285d-c20c-4849-8815-2d21bc69a058" xlink:to="loc_srt_CounterpartyNameAxis_33833303-da70-40da-891b-5bda453c2155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_252ae359-7579-4f00-a6b3-5198e61b21a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_33833303-da70-40da-891b-5bda453c2155" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_252ae359-7579-4f00-a6b3-5198e61b21a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenBiotechIncMember_dfd6b0d3-a027-4be3-a258-4b1fdd349390" xlink:href="mgnx-20221231.xsd#mgnx_JanssenBiotechIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_252ae359-7579-4f00-a6b3-5198e61b21a4" xlink:to="loc_mgnx_JanssenBiotechIncMember_dfd6b0d3-a027-4be3-a258-4b1fdd349390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ce2c445e-9ebb-482c-b0db-bb7928a2b029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f43285d-c20c-4849-8815-2d21bc69a058" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ce2c445e-9ebb-482c-b0db-bb7928a2b029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e295dd98-f51f-4a7f-a259-ce52dbde3841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ce2c445e-9ebb-482c-b0db-bb7928a2b029" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e295dd98-f51f-4a7f-a259-ce52dbde3841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_d374a93b-bb3f-4880-836e-256b6d2e7dc9" xlink:href="mgnx-20221231.xsd#mgnx_JanssenCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e295dd98-f51f-4a7f-a259-ce52dbde3841" xlink:to="loc_mgnx_JanssenCollaborationAndLicenseAgreementMember_d374a93b-bb3f-4880-836e-256b6d2e7dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8da45df1-56e2-4a6e-b8a8-1f0a17449648" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f43285d-c20c-4849-8815-2d21bc69a058" xlink:to="loc_srt_ProductOrServiceAxis_8da45df1-56e2-4a6e-b8a8-1f0a17449648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_548b4bfa-afde-4c18-8ac9-fed0935f2def" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8da45df1-56e2-4a6e-b8a8-1f0a17449648" xlink:to="loc_srt_ProductsAndServicesDomain_548b4bfa-afde-4c18-8ac9-fed0935f2def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_c1c8aa28-8f73-4fd9-bb92-8aeace1f0cee" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_548b4bfa-afde-4c18-8ac9-fed0935f2def" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_c1c8aa28-8f73-4fd9-bb92-8aeace1f0cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_415d1e41-5aa8-4448-bf27-0ba432eca3a4" xlink:href="mgnx-20221231.xsd#mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_548b4bfa-afde-4c18-8ac9-fed0935f2def" xlink:to="loc_mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember_415d1e41-5aa8-4448-bf27-0ba432eca3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d53fab4-8d00-42ac-a948-15eacded67e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9f43285d-c20c-4849-8815-2d21bc69a058" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d53fab4-8d00-42ac-a948-15eacded67e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_ae8dbdae-6311-4733-8526-ec0a8e6378a4" xlink:href="mgnx-20221231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d53fab4-8d00-42ac-a948-15eacded67e7" xlink:to="loc_mgnx_NonRefundableUpfrontFees_ae8dbdae-6311-4733-8526-ec0a8e6378a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_9d793c15-89ae-4a6b-bab8-9ab630d1fc3d" xlink:href="mgnx-20221231.xsd#mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d53fab4-8d00-42ac-a948-15eacded67e7" xlink:to="loc_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales_9d793c15-89ae-4a6b-bab8-9ab630d1fc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_ecef203a-71dd-4883-a492-5d0c796b9d8a" xlink:href="mgnx-20221231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d53fab4-8d00-42ac-a948-15eacded67e7" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_ecef203a-71dd-4883-a492-5d0c796b9d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_730a45e0-338e-4a43-ba6d-12725d139d5f" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d53fab4-8d00-42ac-a948-15eacded67e7" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_730a45e0-338e-4a43-ba6d-12725d139d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_712b1e4e-d2b2-4551-a5d6-9c3915f5e342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d53fab4-8d00-42ac-a948-15eacded67e7" xlink:to="loc_us-gaap_Revenues_712b1e4e-d2b2-4551-a5d6-9c3915f5e342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_426c85af-e079-4e7c-8566-9d8fe51b6e6e" xlink:href="mgnx-20221231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d53fab4-8d00-42ac-a948-15eacded67e7" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_426c85af-e079-4e7c-8566-9d8fe51b6e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#RevenueIMabBiopharmaDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueIMabBiopharmaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_b47c1c35-cac1-47bb-90d2-edcdcff72876" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_983a9870-3ad9-41a9-bb01-65235980a0be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_b47c1c35-cac1-47bb-90d2-edcdcff72876" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_983a9870-3ad9-41a9-bb01-65235980a0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2d1aa177-eafb-46eb-b631-9e40aff7cc35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_983a9870-3ad9-41a9-bb01-65235980a0be" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2d1aa177-eafb-46eb-b631-9e40aff7cc35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6b9e4553-3e14-4548-b6dc-4732c029acd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2d1aa177-eafb-46eb-b631-9e40aff7cc35" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6b9e4553-3e14-4548-b6dc-4732c029acd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_41e30c10-10a6-444e-bd20-0d73ca6710a4" xlink:href="mgnx-20221231.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6b9e4553-3e14-4548-b6dc-4732c029acd1" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_41e30c10-10a6-444e-bd20-0d73ca6710a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_39b6a64b-ba99-47f1-80b5-72445709b6e4" xlink:href="mgnx-20221231.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6b9e4553-3e14-4548-b6dc-4732c029acd1" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember_39b6a64b-ba99-47f1-80b5-72445709b6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_18eaf495-f76b-4f9f-bc77-50b5644e3694" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_983a9870-3ad9-41a9-bb01-65235980a0be" xlink:to="loc_srt_CounterpartyNameAxis_18eaf495-f76b-4f9f-bc77-50b5644e3694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59c4925c-3772-44e2-ac1e-e93a28810406" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_18eaf495-f76b-4f9f-bc77-50b5644e3694" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59c4925c-3772-44e2-ac1e-e93a28810406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_3188daf6-7a0e-4cdd-bf99-a9034f9d2d6d" xlink:href="mgnx-20221231.xsd#mgnx_IMabBiopharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59c4925c-3772-44e2-ac1e-e93a28810406" xlink:to="loc_mgnx_IMabBiopharmaMember_3188daf6-7a0e-4cdd-bf99-a9034f9d2d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dcd7eb3d-b2d3-4db1-9681-3733f26ce1e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_983a9870-3ad9-41a9-bb01-65235980a0be" xlink:to="loc_srt_RangeAxis_dcd7eb3d-b2d3-4db1-9681-3733f26ce1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bf116f32-684c-4628-ad80-d85fab2210cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dcd7eb3d-b2d3-4db1-9681-3733f26ce1e8" xlink:to="loc_srt_RangeMember_bf116f32-684c-4628-ad80-d85fab2210cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9fda8fe7-fbed-4e17-a8e2-d4dfdc9583c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bf116f32-684c-4628-ad80-d85fab2210cf" xlink:to="loc_srt_MaximumMember_9fda8fe7-fbed-4e17-a8e2-d4dfdc9583c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_983a9870-3ad9-41a9-bb01-65235980a0be" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_65e689a6-b688-454d-a0a1-75a3aaaea582" xlink:href="mgnx-20221231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_mgnx_NonRefundableUpfrontFees_65e689a6-b688-454d-a0a1-75a3aaaea582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_a76fb41b-1733-40dd-9a01-3a6d2bab2474" xlink:href="mgnx-20221231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_a76fb41b-1733-40dd-9a01-3a6d2bab2474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_2e4c0d76-78a2-4dda-8452-c8cca9439aa4" xlink:href="mgnx-20221231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_2e4c0d76-78a2-4dda-8452-c8cca9439aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_676ed3be-a6e3-4b77-ba1d-0ba9cbc9fb75" xlink:href="mgnx-20221231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_676ed3be-a6e3-4b77-ba1d-0ba9cbc9fb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_8ca0e551-7b04-499c-bd1b-608b32fa13bf" xlink:href="mgnx-20221231.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_8ca0e551-7b04-499c-bd1b-608b32fa13bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOneTimeCreditPaidPercent_a70c5881-58e7-4f6a-b621-d4b2eb5376ff" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationArrangementOneTimeCreditPaidPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_mgnx_CollaborationArrangementOneTimeCreditPaidPercent_a70c5881-58e7-4f6a-b621-d4b2eb5376ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OneTimeMillstoneCredit_39e1f3f5-102d-498c-8a84-6c1fb5a7198c" xlink:href="mgnx-20221231.xsd#mgnx_OneTimeMillstoneCredit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_mgnx_OneTimeMillstoneCredit_39e1f3f5-102d-498c-8a84-6c1fb5a7198c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6157c9a6-1e38-44a5-98ed-f0944067feda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_us-gaap_Revenues_6157c9a6-1e38-44a5-98ed-f0944067feda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_799413e0-de46-44c7-93be-8eeb3ad50602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_us-gaap_ContractWithCustomerLiability_799413e0-de46-44c7-93be-8eeb3ad50602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_00f988e3-b3d3-4120-a816-ebafd92f6c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_00f988e3-b3d3-4120-a816-ebafd92f6c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1b2860ae-23fa-45b9-88fe-809745f1808f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf7a7662-9b41-433d-b38a-fd8c3c3b366c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1b2860ae-23fa-45b9-88fe-809745f1808f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueProventionDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#RevenueProventionDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueProventionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_f4b8ff28-0704-4533-aeb9-b45d6876337b" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e413ad47-14bf-4732-9bdd-a32c15e9711c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_f4b8ff28-0704-4533-aeb9-b45d6876337b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e413ad47-14bf-4732-9bdd-a32c15e9711c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_abcd5475-e566-440c-9213-9a99503cfc70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e413ad47-14bf-4732-9bdd-a32c15e9711c" xlink:to="loc_srt_ProductOrServiceAxis_abcd5475-e566-440c-9213-9a99503cfc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_be286a66-b1fe-4307-96f7-87142db40402" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_abcd5475-e566-440c-9213-9a99503cfc70" xlink:to="loc_srt_ProductsAndServicesDomain_be286a66-b1fe-4307-96f7-87142db40402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_b2948c3b-bedc-45ba-86fb-e687a1dada00" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_be286a66-b1fe-4307-96f7-87142db40402" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_b2948c3b-bedc-45ba-86fb-e687a1dada00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioCMOAgreeemntMember_f0109582-f4ad-4da5-b09c-eb7823705aab" xlink:href="mgnx-20221231.xsd#mgnx_ProventionBioCMOAgreeemntMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_be286a66-b1fe-4307-96f7-87142db40402" xlink:to="loc_mgnx_ProventionBioCMOAgreeemntMember_f0109582-f4ad-4da5-b09c-eb7823705aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0ba91336-8f5c-4a0e-b28c-01cbbfdf3c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e413ad47-14bf-4732-9bdd-a32c15e9711c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0ba91336-8f5c-4a0e-b28c-01cbbfdf3c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b7fd238-4763-4042-a6b2-2a46df958a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0ba91336-8f5c-4a0e-b28c-01cbbfdf3c04" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b7fd238-4763-4042-a6b2-2a46df958a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_2275c352-c950-407a-9313-08b0457d22fd" xlink:href="mgnx-20221231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b7fd238-4763-4042-a6b2-2a46df958a81" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_2275c352-c950-407a-9313-08b0457d22fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_32bbca8a-896a-44e4-9db4-4b9c35823a27" xlink:href="mgnx-20221231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b7fd238-4763-4042-a6b2-2a46df958a81" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_32bbca8a-896a-44e4-9db4-4b9c35823a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5832053a-b451-4ca0-977d-d4974eab5d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e413ad47-14bf-4732-9bdd-a32c15e9711c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5832053a-b451-4ca0-977d-d4974eab5d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8cf2d032-ffad-4def-ac3a-f144a9e86bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5832053a-b451-4ca0-977d-d4974eab5d6d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8cf2d032-ffad-4def-ac3a-f144a9e86bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_efdce806-144a-45d9-9e92-c6f7e7c109ce" xlink:href="mgnx-20221231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8cf2d032-ffad-4def-ac3a-f144a9e86bb1" xlink:to="loc_mgnx_ProventionPRV3279Member_efdce806-144a-45d9-9e92-c6f7e7c109ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_40c9e742-db49-4cdf-b54a-a2b12d429e2c" xlink:href="mgnx-20221231.xsd#mgnx_ProventionPRV031Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8cf2d032-ffad-4def-ac3a-f144a9e86bb1" xlink:to="loc_mgnx_ProventionPRV031Member_40c9e742-db49-4cdf-b54a-a2b12d429e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bb7cb8d3-3a39-4dfb-8e87-d75a11ee2ac2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4c6f3341-505d-4928-a103-196901e60a95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_a6b70e7c-8334-4a4d-9c67-8dd1ab026c1c" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b073698b-21ed-4fd6-b648-db7f5f9a4cef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e413ad47-14bf-4732-9bdd-a32c15e9711c" xlink:to="loc_srt_CounterpartyNameAxis_b073698b-21ed-4fd6-b648-db7f5f9a4cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7d45dca-90dd-4f70-ac31-3de0d799fca6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b073698b-21ed-4fd6-b648-db7f5f9a4cef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7d45dca-90dd-4f70-ac31-3de0d799fca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_e89de650-e6bb-402a-8d54-78c79bfdf683" xlink:href="mgnx-20221231.xsd#mgnx_ProventionBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7d45dca-90dd-4f70-ac31-3de0d799fca6" xlink:to="loc_mgnx_ProventionBioMember_e89de650-e6bb-402a-8d54-78c79bfdf683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e413ad47-14bf-4732-9bdd-a32c15e9711c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_0827cd02-e4b7-4c4a-901a-9384375ab51a" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_0827cd02-e4b7-4c4a-901a-9384375ab51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_49c5a783-72a0-4b04-956e-628fbc190575" xlink:href="mgnx-20221231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_49c5a783-72a0-4b04-956e-628fbc190575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_286c1ac9-f606-413a-b94a-7cd239c4af4b" xlink:href="mgnx-20221231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_286c1ac9-f606-413a-b94a-7cd239c4af4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_408d320a-d54a-4adc-9b73-c8bceb814259" xlink:href="mgnx-20221231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_408d320a-d54a-4adc-9b73-c8bceb814259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_6738703b-6762-4a8a-b57b-c84df301d645" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_6738703b-6762-4a8a-b57b-c84df301d645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_91c6126e-9d89-4cdd-9bc5-579db48a5a88" xlink:href="mgnx-20221231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_91c6126e-9d89-4cdd-9bc5-579db48a5a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cb980e88-d9eb-42cd-a909-0bee635ab8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_us-gaap_Revenues_cb980e88-d9eb-42cd-a909-0bee635ab8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ReceivableFromCollaborationPartner_fc8b7ff5-a972-4371-81b6-e3ed8fb1ec45" xlink:href="mgnx-20221231.xsd#mgnx_ReceivableFromCollaborationPartner"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_ReceivableFromCollaborationPartner_fc8b7ff5-a972-4371-81b6-e3ed8fb1ec45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontAndFixedPayments_98ab5999-59b0-42be-8c8f-11ea0306e300" xlink:href="mgnx-20221231.xsd#mgnx_UpfrontAndFixedPayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_UpfrontAndFixedPayments_98ab5999-59b0-42be-8c8f-11ea0306e300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_38097c32-6cd4-4ec9-a169-e9d342027c5b" xlink:href="mgnx-20221231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_972dcbef-0cbf-4990-a964-8fc88732d4cc" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_38097c32-6cd4-4ec9-a169-e9d342027c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#RevenueBoehringerIngelheimInternationalGmbHDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_195ada0e-7b8c-4345-9699-a5e2b8c1cb45" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7d1deb3-d9c0-430b-bde5-1fd3fe041b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_195ada0e-7b8c-4345-9699-a5e2b8c1cb45" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7d1deb3-d9c0-430b-bde5-1fd3fe041b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c1291ac5-4f10-42bd-a70d-dd91881f5c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7d1deb3-d9c0-430b-bde5-1fd3fe041b56" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c1291ac5-4f10-42bd-a70d-dd91881f5c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3a5f9945-eef2-48ac-b0c6-d444ad4af4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c1291ac5-4f10-42bd-a70d-dd91881f5c8d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3a5f9945-eef2-48ac-b0c6-d444ad4af4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_9625d7b6-05f8-4022-8f14-813ec1a3d6c7" xlink:href="mgnx-20221231.xsd#mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3a5f9945-eef2-48ac-b0c6-d444ad4af4bc" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_9625d7b6-05f8-4022-8f14-813ec1a3d6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_502407ca-ffb1-4cbc-a622-3dee56d2e223" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7d1deb3-d9c0-430b-bde5-1fd3fe041b56" xlink:to="loc_srt_CounterpartyNameAxis_502407ca-ffb1-4cbc-a622-3dee56d2e223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f0c9a06-272c-4780-8868-e49ddb713d7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_502407ca-ffb1-4cbc-a622-3dee56d2e223" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f0c9a06-272c-4780-8868-e49ddb713d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_b4b69349-3a03-431e-b08f-e3a7d1f5d437" xlink:href="mgnx-20221231.xsd#mgnx_BoehringerIngelheimInternationalGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f0c9a06-272c-4780-8868-e49ddb713d7c" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_b4b69349-3a03-431e-b08f-e3a7d1f5d437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d075eca2-dcd7-4b3b-9b91-25dfadf5a729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b7d1deb3-d9c0-430b-bde5-1fd3fe041b56" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d075eca2-dcd7-4b3b-9b91-25dfadf5a729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementTerm_fdee1b9f-b540-418a-a5cb-46ccda2b959b" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationAndLicenseAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d075eca2-dcd7-4b3b-9b91-25dfadf5a729" xlink:to="loc_mgnx_CollaborationAndLicenseAgreementTerm_fdee1b9f-b540-418a-a5cb-46ccda2b959b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates_bf00f897-c522-4bfe-b23f-84dfcc219d9e" xlink:href="mgnx-20221231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d075eca2-dcd7-4b3b-9b91-25dfadf5a729" xlink:to="loc_mgnx_NumberOfProductCandidates_bf00f897-c522-4bfe-b23f-84dfcc219d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_a98a6ff9-14e5-44ae-9af6-6279e5ebb29c" xlink:href="mgnx-20221231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d075eca2-dcd7-4b3b-9b91-25dfadf5a729" xlink:to="loc_mgnx_NonRefundableUpfrontFees_a98a6ff9-14e5-44ae-9af6-6279e5ebb29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentMilestonesAmount_a8b02ad2-2bf8-490c-98b0-1eaceb54f7d4" xlink:href="mgnx-20221231.xsd#mgnx_DevelopmentMilestonesAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d075eca2-dcd7-4b3b-9b91-25dfadf5a729" xlink:to="loc_mgnx_DevelopmentMilestonesAmount_a8b02ad2-2bf8-490c-98b0-1eaceb54f7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_2698ed92-053d-42f2-ad8c-a33bf3d99e34" xlink:href="mgnx-20221231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d075eca2-dcd7-4b3b-9b91-25dfadf5a729" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_2698ed92-053d-42f2-ad8c-a33bf3d99e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#RevenueNIAIDContractDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueNIAIDContractDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_45c7d0c9-f638-4cf9-bee8-c622598cc109" xlink:href="mgnx-20221231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5344283d-eb66-4e57-9936-dcce0e6313ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_45c7d0c9-f638-4cf9-bee8-c622598cc109" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5344283d-eb66-4e57-9936-dcce0e6313ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_22e5d234-d9f6-4717-a15d-f9e5762312a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5344283d-eb66-4e57-9936-dcce0e6313ec" xlink:to="loc_srt_ProductOrServiceAxis_22e5d234-d9f6-4717-a15d-f9e5762312a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7ce7d94e-a2b1-45cf-9d43-cc1a2d9b97f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_22e5d234-d9f6-4717-a15d-f9e5762312a9" xlink:to="loc_srt_ProductsAndServicesDomain_7ce7d94e-a2b1-45cf-9d43-cc1a2d9b97f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_ef696581-8509-48e4-8470-dfd8655d50db" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7ce7d94e-a2b1-45cf-9d43-cc1a2d9b97f1" xlink:to="loc_mgnx_RevenuesFromGrantsMember_ef696581-8509-48e4-8470-dfd8655d50db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7615eef4-933e-404b-acd8-4e448cf2b5df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5344283d-eb66-4e57-9936-dcce0e6313ec" xlink:to="loc_srt_CounterpartyNameAxis_7615eef4-933e-404b-acd8-4e448cf2b5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf47f051-52a2-4cd4-80ba-2110cc9ebe85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7615eef4-933e-404b-acd8-4e448cf2b5df" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf47f051-52a2-4cd4-80ba-2110cc9ebe85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_5d1d5b13-8c8b-4609-82a7-885894993b11" xlink:href="mgnx-20221231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf47f051-52a2-4cd4-80ba-2110cc9ebe85" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_5d1d5b13-8c8b-4609-82a7-885894993b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_ceefed5d-1bf7-4ee5-b7f3-db46af667b20" xlink:href="mgnx-20221231.xsd#mgnx_BoehringerIngelheimInternationalGmbHMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf47f051-52a2-4cd4-80ba-2110cc9ebe85" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_ceefed5d-1bf7-4ee5-b7f3-db46af667b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9b2449f3-57fc-449d-980c-22354215c8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5344283d-eb66-4e57-9936-dcce0e6313ec" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9b2449f3-57fc-449d-980c-22354215c8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_939876bc-9ce2-4d4e-a593-65049412db3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9b2449f3-57fc-449d-980c-22354215c8bc" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_939876bc-9ce2-4d4e-a593-65049412db3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_a0159d00-943b-4674-a8b5-477d12a058ab" xlink:href="mgnx-20221231.xsd#mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_939876bc-9ce2-4d4e-a593-65049412db3d" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_a0159d00-943b-4674-a8b5-477d12a058ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02c4289a-dfeb-4bea-8e92-84b5436fbcb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5344283d-eb66-4e57-9936-dcce0e6313ec" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02c4289a-dfeb-4bea-8e92-84b5436fbcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates_956789f2-c821-4023-9db8-18ed5bbd015f" xlink:href="mgnx-20221231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02c4289a-dfeb-4bea-8e92-84b5436fbcb6" xlink:to="loc_mgnx_NumberOfProductCandidates_956789f2-c821-4023-9db8-18ed5bbd015f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_5ce51303-ac52-46f9-a66a-7d1e5b26624e" xlink:href="mgnx-20221231.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02c4289a-dfeb-4bea-8e92-84b5436fbcb6" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_5ce51303-ac52-46f9-a66a-7d1e5b26624e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_91c41ff8-7b23-4d93-9b4f-5e4663806f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02c4289a-dfeb-4bea-8e92-84b5436fbcb6" xlink:to="loc_us-gaap_Revenues_91c41ff8-7b23-4d93-9b4f-5e4663806f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#StockbasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9fc2aa10-4d2a-4d85-9b97-3c3f26672662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1d464e7-3fbe-4942-bc79-da372afd4d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9fc2aa10-4d2a-4d85-9b97-3c3f26672662" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1d464e7-3fbe-4942-bc79-da372afd4d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5a218167-ffd0-4fca-b8eb-3105184c2355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1d464e7-3fbe-4942-bc79-da372afd4d2c" xlink:to="loc_us-gaap_PlanNameAxis_5a218167-ffd0-4fca-b8eb-3105184c2355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1e406201-c499-4469-b919-c467a4e895c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5a218167-ffd0-4fca-b8eb-3105184c2355" xlink:to="loc_us-gaap_PlanNameDomain_1e406201-c499-4469-b919-c467a4e895c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_75af1ea9-0641-4313-ac30-a4d6cbed6c0b" xlink:href="mgnx-20221231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1e406201-c499-4469-b919-c467a4e895c9" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_75af1ea9-0641-4313-ac30-a4d6cbed6c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e3ed48fd-cba0-479c-a354-c1e42b5b7bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1d464e7-3fbe-4942-bc79-da372afd4d2c" xlink:to="loc_us-gaap_AwardTypeAxis_e3ed48fd-cba0-479c-a354-c1e42b5b7bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f8a07d9-1083-4deb-a2c4-334642bd9d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e3ed48fd-cba0-479c-a354-c1e42b5b7bd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f8a07d9-1083-4deb-a2c4-334642bd9d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b5ec1893-9e33-4f7e-89d7-db2c5555f3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f8a07d9-1083-4deb-a2c4-334642bd9d39" xlink:to="loc_us-gaap_EmployeeStockMember_b5ec1893-9e33-4f7e-89d7-db2c5555f3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8602438-df77-4b2c-ac1c-b55dad029b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1d464e7-3fbe-4942-bc79-da372afd4d2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8602438-df77-4b2c-ac1c-b55dad029b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2fbdc7e1-53e2-493c-9275-71753bfc43aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8602438-df77-4b2c-ac1c-b55dad029b7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2fbdc7e1-53e2-493c-9275-71753bfc43aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_381be6e1-cb71-46f0-8c34-66dbb2a065af" xlink:href="mgnx-20221231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8602438-df77-4b2c-ac1c-b55dad029b7d" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_381be6e1-cb71-46f0-8c34-66dbb2a065af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_56eef5c8-a5f3-4efa-8426-d5424002d2dd" xlink:href="mgnx-20221231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8602438-df77-4b2c-ac1c-b55dad029b7d" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_56eef5c8-a5f3-4efa-8426-d5424002d2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_84d46c61-e89c-45e8-8f8c-a7e806485c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8602438-df77-4b2c-ac1c-b55dad029b7d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_84d46c61-e89c-45e8-8f8c-a7e806485c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6f5cfb25-ec46-4593-9653-2d4f2cde92ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8602438-df77-4b2c-ac1c-b55dad029b7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6f5cfb25-ec46-4593-9653-2d4f2cde92ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8bc9b7d6-5255-418f-b6bd-b715a9f103ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d8602438-df77-4b2c-ac1c-b55dad029b7d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8bc9b7d6-5255-418f-b6bd-b715a9f103ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#StockbasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f6dfcea-192e-417a-b98d-ec1a4ba3532d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b603c0a-05ce-43af-82df-6a71664b2f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f6dfcea-192e-417a-b98d-ec1a4ba3532d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b603c0a-05ce-43af-82df-6a71664b2f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9b66fc91-1bb7-40fd-a9dd-d7f07a46ff73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b603c0a-05ce-43af-82df-6a71664b2f06" xlink:to="loc_us-gaap_PlanNameAxis_9b66fc91-1bb7-40fd-a9dd-d7f07a46ff73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9adadd21-0b93-468e-abd2-f7bf42577d09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9b66fc91-1bb7-40fd-a9dd-d7f07a46ff73" xlink:to="loc_us-gaap_PlanNameDomain_9adadd21-0b93-468e-abd2-f7bf42577d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EquityIncentivePlan2003Member_2f0c8768-3ded-481a-a0af-912f1c7c1ebc" xlink:href="mgnx-20221231.xsd#mgnx_EquityIncentivePlan2003Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9adadd21-0b93-468e-abd2-f7bf42577d09" xlink:to="loc_mgnx_EquityIncentivePlan2003Member_2f0c8768-3ded-481a-a0af-912f1c7c1ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_24db6701-81ec-424f-92a9-15038ecbfe61" xlink:href="mgnx-20221231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9adadd21-0b93-468e-abd2-f7bf42577d09" xlink:to="loc_mgnx_StockIncentivePlan2013Member_24db6701-81ec-424f-92a9-15038ecbfe61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f5d515-6b79-48a0-9c44-11501e2fddee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0b603c0a-05ce-43af-82df-6a71664b2f06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f5d515-6b79-48a0-9c44-11501e2fddee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9f5f38a8-0a80-427e-b2ef-eeec9e4236bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f5d515-6b79-48a0-9c44-11501e2fddee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9f5f38a8-0a80-427e-b2ef-eeec9e4236bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_09ec06d1-80cc-4359-9cc4-87f2594fd7dc" xlink:href="mgnx-20221231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f5d515-6b79-48a0-9c44-11501e2fddee" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_09ec06d1-80cc-4359-9cc4-87f2594fd7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ae4a716f-d12c-4908-8a97-4c73f3eb2cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f5d515-6b79-48a0-9c44-11501e2fddee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ae4a716f-d12c-4908-8a97-4c73f3eb2cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0d45716a-c5b4-40f6-a6f1-1fa04356c069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f5d515-6b79-48a0-9c44-11501e2fddee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0d45716a-c5b4-40f6-a6f1-1fa04356c069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_69891739-defe-40f2-b3f4-e3c3c3fe3ce9" xlink:href="mgnx-20221231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71f5d515-6b79-48a0-9c44-11501e2fddee" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_69891739-defe-40f2-b3f4-e3c3c3fe3ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_92757ce7-f709-4958-89ba-292d608d5c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f6dfcea-192e-417a-b98d-ec1a4ba3532d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_92757ce7-f709-4958-89ba-292d608d5c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9100b2e3-1bbf-4f3a-857f-c1d6e2e2e527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_92757ce7-f709-4958-89ba-292d608d5c9c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9100b2e3-1bbf-4f3a-857f-c1d6e2e2e527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5c6289ee-9b72-4cd9-b9de-f2e14d365f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9100b2e3-1bbf-4f3a-857f-c1d6e2e2e527" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5c6289ee-9b72-4cd9-b9de-f2e14d365f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e31a0aa9-2a3c-48b3-824e-546adbfc38cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c6289ee-9b72-4cd9-b9de-f2e14d365f7d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e31a0aa9-2a3c-48b3-824e-546adbfc38cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e611d7a1-8778-48d1-91ed-9bf63b57e856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c6289ee-9b72-4cd9-b9de-f2e14d365f7d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e611d7a1-8778-48d1-91ed-9bf63b57e856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9af20b96-09b2-451f-8ee4-09b316940705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_92757ce7-f709-4958-89ba-292d608d5c9c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9af20b96-09b2-451f-8ee4-09b316940705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f4a4d967-0efb-48a1-a12c-69d732413819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9af20b96-09b2-451f-8ee4-09b316940705" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f4a4d967-0efb-48a1-a12c-69d732413819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#StockbasedCompensationOptionPricingAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e2ab6e6a-eb9a-4c0e-9c01-8d8ae8ae841a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4278bdb-2887-4c3f-83f6-357e1dc66de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e2ab6e6a-eb9a-4c0e-9c01-8d8ae8ae841a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4278bdb-2887-4c3f-83f6-357e1dc66de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_414b230a-4f84-4bbe-8267-ee33376647b2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4278bdb-2887-4c3f-83f6-357e1dc66de4" xlink:to="loc_srt_RangeAxis_414b230a-4f84-4bbe-8267-ee33376647b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f2020e4a-f9d3-4647-aa31-9014adc0b982" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_414b230a-4f84-4bbe-8267-ee33376647b2" xlink:to="loc_srt_RangeMember_f2020e4a-f9d3-4647-aa31-9014adc0b982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_faec4b52-b924-4d27-b432-cd0d7ea90c20" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f2020e4a-f9d3-4647-aa31-9014adc0b982" xlink:to="loc_srt_MinimumMember_faec4b52-b924-4d27-b432-cd0d7ea90c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_66d67034-91fe-464a-8d9c-869ce3be5a1a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f2020e4a-f9d3-4647-aa31-9014adc0b982" xlink:to="loc_srt_MaximumMember_66d67034-91fe-464a-8d9c-869ce3be5a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03922e89-b3ec-44e4-9147-2fcfe8b1326e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4278bdb-2887-4c3f-83f6-357e1dc66de4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03922e89-b3ec-44e4-9147-2fcfe8b1326e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_625ed54e-9e6e-495a-9f11-8c066c8ec247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03922e89-b3ec-44e4-9147-2fcfe8b1326e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_625ed54e-9e6e-495a-9f11-8c066c8ec247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8afaa9c9-226c-4470-9dec-12fd6a89c36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03922e89-b3ec-44e4-9147-2fcfe8b1326e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8afaa9c9-226c-4470-9dec-12fd6a89c36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1f6fcac0-083e-40c4-b8a0-8b5aed59c78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03922e89-b3ec-44e4-9147-2fcfe8b1326e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1f6fcac0-083e-40c4-b8a0-8b5aed59c78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7cdb8774-8b56-42ad-ba2d-1003df99324c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03922e89-b3ec-44e4-9147-2fcfe8b1326e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7cdb8774-8b56-42ad-ba2d-1003df99324c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SharebasedCompensationOptionExercisePriceRangeTableDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_28976212-5221-45d7-8caa-730ba924f5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_8d24ed58-cbe8-44be-aed5-9b8fea0b337a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_28976212-5221-45d7-8caa-730ba924f5a4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_8d24ed58-cbe8-44be-aed5-9b8fea0b337a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a87229ba-5577-4bff-89bb-68eb7e2e5008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_8d24ed58-cbe8-44be-aed5-9b8fea0b337a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a87229ba-5577-4bff-89bb-68eb7e2e5008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f434ece0-12cc-4b14-b14e-10abcb582288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a87229ba-5577-4bff-89bb-68eb7e2e5008" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f434ece0-12cc-4b14-b14e-10abcb582288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisePriceRangeFromDollars094To500MemberMember_43de983c-514e-46c8-a47a-034e9528bcf6" xlink:href="mgnx-20221231.xsd#mgnx_ExercisePriceRangeFromDollars094To500MemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f434ece0-12cc-4b14-b14e-10abcb582288" xlink:to="loc_mgnx_ExercisePriceRangeFromDollars094To500MemberMember_43de983c-514e-46c8-a47a-034e9528bcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisePriceRangeFromDollars501To1500MemberMember_ce853eb2-6232-42d5-a505-b3c80f93c8dd" xlink:href="mgnx-20221231.xsd#mgnx_ExercisePriceRangeFromDollars501To1500MemberMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f434ece0-12cc-4b14-b14e-10abcb582288" xlink:to="loc_mgnx_ExercisePriceRangeFromDollars501To1500MemberMember_ce853eb2-6232-42d5-a505-b3c80f93c8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember_0ef63e5d-f795-492a-843c-c1507afd838e" xlink:href="mgnx-20221231.xsd#mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f434ece0-12cc-4b14-b14e-10abcb582288" xlink:to="loc_mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember_0ef63e5d-f795-492a-843c-c1507afd838e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember_5f5766bd-f80b-454a-a3c2-2677f77f8b21" xlink:href="mgnx-20221231.xsd#mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f434ece0-12cc-4b14-b14e-10abcb582288" xlink:to="loc_mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember_5f5766bd-f80b-454a-a3c2-2677f77f8b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_598cc3c8-5546-4a33-b3d3-5a143e1f911f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_8d24ed58-cbe8-44be-aed5-9b8fea0b337a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_598cc3c8-5546-4a33-b3d3-5a143e1f911f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_2b08e939-e21a-40b5-8df7-5108a6cbe1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_598cc3c8-5546-4a33-b3d3-5a143e1f911f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_2b08e939-e21a-40b5-8df7-5108a6cbe1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_5c5c2260-c28c-42c9-a936-a5795203b6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_598cc3c8-5546-4a33-b3d3-5a143e1f911f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_5c5c2260-c28c-42c9-a936-a5795203b6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_728177d2-6461-41f8-92eb-c80ab04542ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_598cc3c8-5546-4a33-b3d3-5a143e1f911f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_728177d2-6461-41f8-92eb-c80ab04542ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_d1a28c5f-3f19-46b6-83cd-9cf785d0cd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_728177d2-6461-41f8-92eb-c80ab04542ed" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_d1a28c5f-3f19-46b6-83cd-9cf785d0cd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_58fb3957-6f86-4323-b4da-0d05bfa04ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_728177d2-6461-41f8-92eb-c80ab04542ed" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_58fb3957-6f86-4323-b4da-0d05bfa04ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_57c18a4f-3d15-4eb7-8dce-27492f0cda17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_728177d2-6461-41f8-92eb-c80ab04542ed" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_57c18a4f-3d15-4eb7-8dce-27492f0cda17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_6b2a3a97-2cac-4d78-a594-c15f9c4c730d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_598cc3c8-5546-4a33-b3d3-5a143e1f911f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_6b2a3a97-2cac-4d78-a594-c15f9c4c730d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_ccc420bf-0915-4063-95cc-d598c6ac1f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_6b2a3a97-2cac-4d78-a594-c15f9c4c730d" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_ccc420bf-0915-4063-95cc-d598c6ac1f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c2156f14-7d6c-47b8-b7aa-d7b6eaf71f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_6b2a3a97-2cac-4d78-a594-c15f9c4c730d" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c2156f14-7d6c-47b8-b7aa-d7b6eaf71f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59a2234e-28fe-4ab6-80a3-e566143c6684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638cebc0-8d47-4b93-999d-855c2f506711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59a2234e-28fe-4ab6-80a3-e566143c6684" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638cebc0-8d47-4b93-999d-855c2f506711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_509408d9-7ccf-4a33-9490-33be771a13b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638cebc0-8d47-4b93-999d-855c2f506711" xlink:to="loc_us-gaap_AwardTypeAxis_509408d9-7ccf-4a33-9490-33be771a13b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1de773c9-f3d1-431d-b3e9-6ca3d586562b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_509408d9-7ccf-4a33-9490-33be771a13b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1de773c9-f3d1-431d-b3e9-6ca3d586562b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_32bc92f1-f6d9-40b7-afcc-ce8d5a5153fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1de773c9-f3d1-431d-b3e9-6ca3d586562b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_32bc92f1-f6d9-40b7-afcc-ce8d5a5153fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9c169c1a-86a3-4508-b935-c13caaedb403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638cebc0-8d47-4b93-999d-855c2f506711" xlink:to="loc_us-gaap_PlanNameAxis_9c169c1a-86a3-4508-b935-c13caaedb403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_be9ea29b-1a4b-4f8b-b4c0-da19b017db6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9c169c1a-86a3-4508-b935-c13caaedb403" xlink:to="loc_us-gaap_PlanNameDomain_be9ea29b-1a4b-4f8b-b4c0-da19b017db6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_85dfd8b8-e32e-4ae4-9d1b-3fce5126afcc" xlink:href="mgnx-20221231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_be9ea29b-1a4b-4f8b-b4c0-da19b017db6e" xlink:to="loc_mgnx_StockIncentivePlan2013Member_85dfd8b8-e32e-4ae4-9d1b-3fce5126afcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638cebc0-8d47-4b93-999d-855c2f506711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f03eb1ab-bfa5-4734-8b8c-07caf6b03736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f03eb1ab-bfa5-4734-8b8c-07caf6b03736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_beae0fa0-0b40-438e-b2d3-ad81086e2a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_beae0fa0-0b40-438e-b2d3-ad81086e2a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3921a1d0-5771-4eac-9d1e-aa13c57e50ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3921a1d0-5771-4eac-9d1e-aa13c57e50ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_032921c4-abd4-4a31-9b3b-9bf4c4849de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_032921c4-abd4-4a31-9b3b-9bf4c4849de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e6b18c61-3eb4-400f-9c0a-9f124b39a7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e6b18c61-3eb4-400f-9c0a-9f124b39a7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3d82cffc-6d2e-41c3-8123-8d9eff31999d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3d82cffc-6d2e-41c3-8123-8d9eff31999d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e5732882-5fc4-47d5-a01a-cf279d76a682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e5732882-5fc4-47d5-a01a-cf279d76a682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_45112385-01a5-47f8-b690-d056d414353f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_45112385-01a5-47f8-b690-d056d414353f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ba1d6320-1145-4650-b51a-24998c8ed195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7a7e5898-8b57-4601-8a64-7f4703056d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ba1d6320-1145-4650-b51a-24998c8ed195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eb9e6bd2-be5d-4680-9871-a711288c28df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eb9e6bd2-be5d-4680-9871-a711288c28df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43f42e34-2678-4f8e-8387-5f4b039a1a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_43f42e34-2678-4f8e-8387-5f4b039a1a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_20fd41bc-1bb7-40af-a8c6-e77bb107fc18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_20fd41bc-1bb7-40af-a8c6-e77bb107fc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_da18064a-14b0-4d66-be01-eb3b63d8b13a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_da18064a-14b0-4d66-be01-eb3b63d8b13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_82ce7c38-0bb5-4466-a09a-acc449bd5e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_82ce7c38-0bb5-4466-a09a-acc449bd5e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8ccea48f-76da-4522-9dc8-b246ffa8ea64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8ccea48f-76da-4522-9dc8-b246ffa8ea64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b9d338e1-7bc0-4aa8-a323-6c9bdeb6da7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_7cf31ca6-7d2a-4bb9-a626-7e4de14148f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b9d338e1-7bc0-4aa8-a323-6c9bdeb6da7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_89eaa7c6-77be-4ac0-8a80-d8ee73e4b8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_89eaa7c6-77be-4ac0-8a80-d8ee73e4b8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e6d938d6-a8fe-4858-a43d-bce05abcc32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_89eaa7c6-77be-4ac0-8a80-d8ee73e4b8e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e6d938d6-a8fe-4858-a43d-bce05abcc32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c471645f-b476-44d3-b8d6-779aeafb5f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_89eaa7c6-77be-4ac0-8a80-d8ee73e4b8e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c471645f-b476-44d3-b8d6-779aeafb5f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_21fd5029-661f-4be3-92d2-f362075da952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_89eaa7c6-77be-4ac0-8a80-d8ee73e4b8e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_21fd5029-661f-4be3-92d2-f362075da952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_86bcec6e-97aa-4c50-ac06-313f6ecda626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_89eaa7c6-77be-4ac0-8a80-d8ee73e4b8e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_86bcec6e-97aa-4c50-ac06-313f6ecda626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3a2b8d1a-e08e-48cf-ab63-69685551371d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_89eaa7c6-77be-4ac0-8a80-d8ee73e4b8e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3a2b8d1a-e08e-48cf-ab63-69685551371d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c64377d9-cf0d-42aa-b40f-481e5a5759a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_89eaa7c6-77be-4ac0-8a80-d8ee73e4b8e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c64377d9-cf0d-42aa-b40f-481e5a5759a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b5c4439d-0d92-4cd9-965c-7ed23ed301b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b5c4439d-0d92-4cd9-965c-7ed23ed301b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b01c4813-b601-47e8-8b88-90e9a4649ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b5c4439d-0d92-4cd9-965c-7ed23ed301b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b01c4813-b601-47e8-8b88-90e9a4649ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_69f5e27f-4c08-4388-9eae-9a8eccf62487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b5c4439d-0d92-4cd9-965c-7ed23ed301b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_69f5e27f-4c08-4388-9eae-9a8eccf62487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_3aaef029-15f9-48ce-9c2c-41b65eb92aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b5c4439d-0d92-4cd9-965c-7ed23ed301b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_3aaef029-15f9-48ce-9c2c-41b65eb92aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e1c3460f-091b-4dd9-9d17-e97feb55a84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b5c4439d-0d92-4cd9-965c-7ed23ed301b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e1c3460f-091b-4dd9-9d17-e97feb55a84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9a4f9144-08c0-4178-8d7e-af7d749a5b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b5c4439d-0d92-4cd9-965c-7ed23ed301b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9a4f9144-08c0-4178-8d7e-af7d749a5b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e062169f-e1b9-4116-bf09-5fd8764392af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e062169f-e1b9-4116-bf09-5fd8764392af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b41b08f-9706-4298-b135-6d6e9f6e1338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e062169f-e1b9-4116-bf09-5fd8764392af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b41b08f-9706-4298-b135-6d6e9f6e1338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3331399d-bdde-461f-bdbf-c4c4828e1a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e062169f-e1b9-4116-bf09-5fd8764392af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3331399d-bdde-461f-bdbf-c4c4828e1a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a4bda963-280b-4357-8dc4-6e8a24d8dd26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e062169f-e1b9-4116-bf09-5fd8764392af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a4bda963-280b-4357-8dc4-6e8a24d8dd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_19932e94-3fef-45ec-86a6-159856b5a6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e062169f-e1b9-4116-bf09-5fd8764392af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_19932e94-3fef-45ec-86a6-159856b5a6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_05db9e40-a54f-467c-8cc1-cd2f86d91dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e062169f-e1b9-4116-bf09-5fd8764392af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_05db9e40-a54f-467c-8cc1-cd2f86d91dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5a96ca04-51c3-4209-b905-15c4a610836c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5a96ca04-51c3-4209-b905-15c4a610836c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4210fe38-9c26-4b5f-be35-d1fca4e2e142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4210fe38-9c26-4b5f-be35-d1fca4e2e142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc2f9de3-1101-4cdf-becc-d7cec0e6052d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc2f9de3-1101-4cdf-becc-d7cec0e6052d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2dda31bb-763f-4430-9ec1-61fdec5d02e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2dda31bb-763f-4430-9ec1-61fdec5d02e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_161b3ac3-9dbf-4d82-b39b-e9dd16313c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_161b3ac3-9dbf-4d82-b39b-e9dd16313c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_871b9cb6-7220-4cc8-9951-6494c29d3243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_871b9cb6-7220-4cc8-9951-6494c29d3243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3eab483e-4414-4aea-a1af-b958f55569e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3eab483e-4414-4aea-a1af-b958f55569e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3dfebda1-637e-4689-8724-188f9259bd23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3dfebda1-637e-4689-8724-188f9259bd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4ecf3186-5e69-4488-9da2-13ff868bf053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6a9b400-7fef-4b8a-b890-573762b20c39" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4ecf3186-5e69-4488-9da2-13ff868bf053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a1658589-0ad1-4a67-b257-3dbe6f25532d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7a0b8286-5b7f-45a1-ac8f-36aaf290b4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_c7229aa6-d776-44fd-8b50-3b29cd068a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7a0b8286-5b7f-45a1-ac8f-36aaf290b4c7" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_c7229aa6-d776-44fd-8b50-3b29cd068a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6e77d83f-7025-4607-844d-162d76e763fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c7229aa6-d776-44fd-8b50-3b29cd068a39" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6e77d83f-7025-4607-844d-162d76e763fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a9e9b88a-36d0-4c17-b7e0-847a4a77f704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6e77d83f-7025-4607-844d-162d76e763fc" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a9e9b88a-36d0-4c17-b7e0-847a4a77f704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_b4e912f1-9677-43d7-9f9f-c755f0cc5632" xlink:href="mgnx-20221231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a9e9b88a-36d0-4c17-b7e0-847a4a77f704" xlink:to="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_b4e912f1-9677-43d7-9f9f-c755f0cc5632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_a465e5d9-d130-4f2c-81bf-d2aba2ce202a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a9e9b88a-36d0-4c17-b7e0-847a4a77f704" xlink:to="loc_us-gaap_DomesticCountryMember_a465e5d9-d130-4f2c-81bf-d2aba2ce202a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_725fea8d-1583-426b-b3c6-086a4f84b653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c7229aa6-d776-44fd-8b50-3b29cd068a39" xlink:to="loc_us-gaap_TaxPeriodAxis_725fea8d-1583-426b-b3c6-086a4f84b653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_6aa838f4-b838-4078-945d-28e1e1b9213c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_725fea8d-1583-426b-b3c6-086a4f84b653" xlink:to="loc_us-gaap_TaxPeriodDomain_6aa838f4-b838-4078-945d-28e1e1b9213c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2025To2037Member_193f07cd-40f7-41db-9b80-2a39a880ab63" xlink:href="mgnx-20221231.xsd#mgnx_TaxYear2025To2037Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_6aa838f4-b838-4078-945d-28e1e1b9213c" xlink:to="loc_mgnx_TaxYear2025To2037Member_193f07cd-40f7-41db-9b80-2a39a880ab63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember_fe5b9e96-18e6-461f-afc9-1f8d08d9eb10" xlink:href="mgnx-20221231.xsd#mgnx_IndefiniteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_6aa838f4-b838-4078-945d-28e1e1b9213c" xlink:to="loc_mgnx_IndefiniteMember_fe5b9e96-18e6-461f-afc9-1f8d08d9eb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6d2e88f2-548a-4176-baee-05e3ba58312a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c7229aa6-d776-44fd-8b50-3b29cd068a39" xlink:to="loc_srt_RangeAxis_6d2e88f2-548a-4176-baee-05e3ba58312a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a53fc1c3-64b1-48cf-8ca7-ec02151dd53b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6d2e88f2-548a-4176-baee-05e3ba58312a" xlink:to="loc_srt_RangeMember_a53fc1c3-64b1-48cf-8ca7-ec02151dd53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7f6f81fe-82d1-4eb5-a7c9-8b0bb388b6f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a53fc1c3-64b1-48cf-8ca7-ec02151dd53b" xlink:to="loc_srt_MinimumMember_7f6f81fe-82d1-4eb5-a7c9-8b0bb388b6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_98d424ce-522e-4e7a-a770-aa8282492740" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a53fc1c3-64b1-48cf-8ca7-ec02151dd53b" xlink:to="loc_srt_MaximumMember_98d424ce-522e-4e7a-a770-aa8282492740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c7229aa6-d776-44fd-8b50-3b29cd068a39" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c77b737a-aaea-45c6-b2a6-fc64a8153bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c77b737a-aaea-45c6-b2a6-fc64a8153bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_e4829b24-c7a3-405a-85a0-bd915404dd22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_e4829b24-c7a3-405a-85a0-bd915404dd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_c84ace39-e5da-4c7a-a2c3-8d1ac60b770d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_c84ace39-e5da-4c7a-a2c3-8d1ac60b770d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_fac0d874-005e-4c43-88db-9bb09510f11e" xlink:href="mgnx-20221231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_fac0d874-005e-4c43-88db-9bb09510f11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_fe503281-9fb7-422b-9d4d-b75a3dad5379" xlink:href="mgnx-20221231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_fe503281-9fb7-422b-9d4d-b75a3dad5379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_4ee68e34-52d7-46f0-b17a-50fda875c4a1" xlink:href="mgnx-20221231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_4ee68e34-52d7-46f0-b17a-50fda875c4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_74e857e3-a0a1-42aa-ac9a-d70b1f46a8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_74e857e3-a0a1-42aa-ac9a-d70b1f46a8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_308a985f-f541-45c7-ba32-183f51ecf0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_0bec1cca-e76a-452f-bdc1-182f328b7dc3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_308a985f-f541-45c7-ba32-183f51ecf0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bd7645ae-7dc1-4fb4-a377-1dbc2fd339d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4a60a894-3ad7-472c-8e25-7ffcd16f7d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd7645ae-7dc1-4fb4-a377-1dbc2fd339d6" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4a60a894-3ad7-472c-8e25-7ffcd16f7d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_134dc2a5-1899-41da-8d14-38a00f40ea4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4a60a894-3ad7-472c-8e25-7ffcd16f7d28" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_134dc2a5-1899-41da-8d14-38a00f40ea4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_a18d5fa9-6ca6-4744-88dd-885d14016d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4a60a894-3ad7-472c-8e25-7ffcd16f7d28" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_a18d5fa9-6ca6-4744-88dd-885d14016d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6465e4d9-68a4-4a96-bf0d-525adb7d0947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4a60a894-3ad7-472c-8e25-7ffcd16f7d28" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6465e4d9-68a4-4a96-bf0d-525adb7d0947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_194998e8-afbd-4333-bfd4-fd2ebc2d829f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4a60a894-3ad7-472c-8e25-7ffcd16f7d28" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_194998e8-afbd-4333-bfd4-fd2ebc2d829f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_da53dc7c-c400-4ebf-8b98-dacdddf76c99" xlink:href="mgnx-20221231.xsd#mgnx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4a60a894-3ad7-472c-8e25-7ffcd16f7d28" xlink:to="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_da53dc7c-c400-4ebf-8b98-dacdddf76c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_135f87a3-147b-4b34-8094-ee7f4aec9799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4a60a894-3ad7-472c-8e25-7ffcd16f7d28" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_135f87a3-147b-4b34-8094-ee7f4aec9799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_Section174DeferredTaxAsset_66836304-5f29-4862-a08a-aa802afbf251" xlink:href="mgnx-20221231.xsd#mgnx_Section174DeferredTaxAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4a60a894-3ad7-472c-8e25-7ffcd16f7d28" xlink:to="loc_mgnx_Section174DeferredTaxAsset_66836304-5f29-4862-a08a-aa802afbf251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_b89a0d4c-0e43-4a01-a629-89c0e0081d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4a60a894-3ad7-472c-8e25-7ffcd16f7d28" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_b89a0d4c-0e43-4a01-a629-89c0e0081d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_65f4bc2a-0ee1-4df5-87e3-e1049bd2b60a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4a60a894-3ad7-472c-8e25-7ffcd16f7d28" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_65f4bc2a-0ee1-4df5-87e3-e1049bd2b60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_fac94297-cccb-45ff-b75e-f05bb48373a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4a60a894-3ad7-472c-8e25-7ffcd16f7d28" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_fac94297-cccb-45ff-b75e-f05bb48373a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_94456f8a-e7b2-4b82-8aa8-e6e676a2db79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4a60a894-3ad7-472c-8e25-7ffcd16f7d28" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_94456f8a-e7b2-4b82-8aa8-e6e676a2db79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4945b677-42db-4a58-8db8-c8e1063076c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4a60a894-3ad7-472c-8e25-7ffcd16f7d28" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_4945b677-42db-4a58-8db8-c8e1063076c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e119f002-095d-4231-943b-bb8605e253cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd7645ae-7dc1-4fb4-a377-1dbc2fd339d6" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e119f002-095d-4231-943b-bb8605e253cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2d93cf7c-b9fd-4132-95bc-649eb9432004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e119f002-095d-4231-943b-bb8605e253cc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2d93cf7c-b9fd-4132-95bc-649eb9432004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_853836c3-7d09-4d52-ae85-8a8ea842fc39" xlink:href="mgnx-20221231.xsd#mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e119f002-095d-4231-943b-bb8605e253cc" xlink:to="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_853836c3-7d09-4d52-ae85-8a8ea842fc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_8b3d119f-2616-4665-92ad-8e830853f888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e119f002-095d-4231-943b-bb8605e253cc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_8b3d119f-2616-4665-92ad-8e830853f888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_42eb50b0-cacb-47e6-8e25-fdc0b9531c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e119f002-095d-4231-943b-bb8605e253cc" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_42eb50b0-cacb-47e6-8e25-fdc0b9531c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_148c4a90-c058-49d8-ac5d-2e6d096a846b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_e119f002-095d-4231-943b-bb8605e253cc" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_148c4a90-c058-49d8-ac5d-2e6d096a846b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b137b061-dbbc-48be-90ff-f14a29c82726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b610585f-16f9-4ae9-a644-2dacdefe5e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b137b061-dbbc-48be-90ff-f14a29c82726" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b610585f-16f9-4ae9-a644-2dacdefe5e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_939406f4-0acd-4f0e-8d50-07e18914ccfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b137b061-dbbc-48be-90ff-f14a29c82726" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_939406f4-0acd-4f0e-8d50-07e18914ccfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_0b73bf70-076c-4909-99dd-895f619dc5e4" xlink:href="mgnx-20221231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b137b061-dbbc-48be-90ff-f14a29c82726" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_0b73bf70-076c-4909-99dd-895f619dc5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_6092dfc6-60bf-4277-9425-285e4ba2317f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b137b061-dbbc-48be-90ff-f14a29c82726" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_6092dfc6-60bf-4277-9425-285e4ba2317f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_7be0aa06-0e27-4744-b5c2-ba0b27b65e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b137b061-dbbc-48be-90ff-f14a29c82726" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_7be0aa06-0e27-4744-b5c2-ba0b27b65e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_a818e94f-d194-4fed-8899-ef69a6e2834f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b137b061-dbbc-48be-90ff-f14a29c82726" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_a818e94f-d194-4fed-8899-ef69a6e2834f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1439d1ac-010a-4ad7-892f-dc394b66d853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b137b061-dbbc-48be-90ff-f14a29c82726" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1439d1ac-010a-4ad7-892f-dc394b66d853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_e353dafa-a617-401b-a568-0f6203cafde9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b137b061-dbbc-48be-90ff-f14a29c82726" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_e353dafa-a617-401b-a568-0f6203cafde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8e41763d-7c6e-45a7-a008-d1928f509b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b137b061-dbbc-48be-90ff-f14a29c82726" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8e41763d-7c6e-45a7-a008-d1928f509b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_992a1de4-1cf4-4c86-bfcf-f5f071ef33e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b84cf97c-caba-4c6b-84ef-a779b5d4b78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_992a1de4-1cf4-4c86-bfcf-f5f071ef33e0" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b84cf97c-caba-4c6b-84ef-a779b5d4b78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e3c961ba-218a-40cd-9a47-2b8e1f3e8be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b84cf97c-caba-4c6b-84ef-a779b5d4b78d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e3c961ba-218a-40cd-9a47-2b8e1f3e8be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0d094dd4-9161-4e15-a31d-8007dfc82a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b84cf97c-caba-4c6b-84ef-a779b5d4b78d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0d094dd4-9161-4e15-a31d-8007dfc82a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_a44d81bf-fd0a-4761-8116-fbd3d3610b44" xlink:href="mgnx-20221231.xsd#mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b84cf97c-caba-4c6b-84ef-a779b5d4b78d" xlink:to="loc_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_a44d81bf-fd0a-4761-8116-fbd3d3610b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1aa7b937-ee02-4462-bdb4-e4ea1905cbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b84cf97c-caba-4c6b-84ef-a779b5d4b78d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1aa7b937-ee02-4462-bdb4-e4ea1905cbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_236106b5-9df6-4d45-b9d3-0fe872018633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_ef0eaade-33cb-4952-aa2b-cd2629b6d1a7" xlink:href="mgnx-20221231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_236106b5-9df6-4d45-b9d3-0fe872018633" xlink:to="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_ef0eaade-33cb-4952-aa2b-cd2629b6d1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_14063061-e900-4e3a-a1c7-a39bfe2044da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_236106b5-9df6-4d45-b9d3-0fe872018633" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_14063061-e900-4e3a-a1c7-a39bfe2044da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_5690597b-bebe-4697-bab7-e48df1c3c7a8" xlink:href="mgnx-20221231.xsd#mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_236106b5-9df6-4d45-b9d3-0fe872018633" xlink:to="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_5690597b-bebe-4697-bab7-e48df1c3c7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_4822b104-4a14-4eee-8741-0c221e99c762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_236106b5-9df6-4d45-b9d3-0fe872018633" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_4822b104-4a14-4eee-8741-0c221e99c762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mgnx-20221231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_bb112c3a-59dc-4525-8d78-e9c21babd3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_b3366b2f-fa55-446f-8ef0-ca6d0e3fd97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_bb112c3a-59dc-4525-8d78-e9c21babd3b1" xlink:to="loc_us-gaap_SubsequentEventTable_b3366b2f-fa55-446f-8ef0-ca6d0e3fd97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_15d9c498-f8cc-4a09-89fc-5a3b3609077b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b3366b2f-fa55-446f-8ef0-ca6d0e3fd97c" xlink:to="loc_srt_CounterpartyNameAxis_15d9c498-f8cc-4a09-89fc-5a3b3609077b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51d6246c-5de4-437a-a6b7-fa46a076a699" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_15d9c498-f8cc-4a09-89fc-5a3b3609077b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51d6246c-5de4-437a-a6b7-fa46a076a699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_63d0ec5c-611e-4e61-8b58-770baeaea2a4" xlink:href="mgnx-20221231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51d6246c-5de4-437a-a6b7-fa46a076a699" xlink:to="loc_mgnx_IncyteCorporationMember_63d0ec5c-611e-4e61-8b58-770baeaea2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_d145d358-db98-442c-b53a-82d42afb5a47" xlink:href="mgnx-20221231.xsd#mgnx_DRIHealthcareAcquisitionsLPDRIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51d6246c-5de4-437a-a6b7-fa46a076a699" xlink:to="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_d145d358-db98-442c-b53a-82d42afb5a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c24a55f2-66a4-4d91-b7e3-de26ce993329" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b3366b2f-fa55-446f-8ef0-ca6d0e3fd97c" xlink:to="loc_srt_ProductOrServiceAxis_c24a55f2-66a4-4d91-b7e3-de26ce993329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a685654-1e7f-4d12-9685-7b97de181e1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c24a55f2-66a4-4d91-b7e3-de26ce993329" xlink:to="loc_srt_ProductsAndServicesDomain_5a685654-1e7f-4d12-9685-7b97de181e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_ca20d527-1019-4ee5-b5e9-f30a8ab104b3" xlink:href="mgnx-20221231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5a685654-1e7f-4d12-9685-7b97de181e1f" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_ca20d527-1019-4ee5-b5e9-f30a8ab104b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b17b83e6-2eae-43f8-ae6b-96df19d63650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b3366b2f-fa55-446f-8ef0-ca6d0e3fd97c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b17b83e6-2eae-43f8-ae6b-96df19d63650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c8cf074d-c755-4de1-b2f5-7224c69b348d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b17b83e6-2eae-43f8-ae6b-96df19d63650" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c8cf074d-c755-4de1-b2f5-7224c69b348d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_05936526-d417-40e3-8c19-482dd184c728" xlink:href="mgnx-20221231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c8cf074d-c755-4de1-b2f5-7224c69b348d" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_05936526-d417-40e3-8c19-482dd184c728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f991028a-7e21-410b-9e09-db39a45f8c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b3366b2f-fa55-446f-8ef0-ca6d0e3fd97c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f991028a-7e21-410b-9e09-db39a45f8c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e065989e-e938-4122-800b-a5230b0da5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f991028a-7e21-410b-9e09-db39a45f8c83" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e065989e-e938-4122-800b-a5230b0da5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9fbaccca-a085-4a01-bca4-78079e833ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e065989e-e938-4122-800b-a5230b0da5ce" xlink:to="loc_us-gaap_SubsequentEventMember_9fbaccca-a085-4a01-bca4-78079e833ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_2e5647cf-e07f-42b2-80da-9882ad21f69e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b3366b2f-fa55-446f-8ef0-ca6d0e3fd97c" xlink:to="loc_us-gaap_SubsequentEventLineItems_2e5647cf-e07f-42b2-80da-9882ad21f69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_c8e37642-fd76-499d-94ac-e361cb706162" xlink:href="mgnx-20221231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2e5647cf-e07f-42b2-80da-9882ad21f69e" xlink:to="loc_mgnx_NonRefundableUpfrontFees_c8e37642-fd76-499d-94ac-e361cb706162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPayment_245c9ac4-547a-419b-8e94-adc460eb90ec" xlink:href="mgnx-20221231.xsd#mgnx_UpfrontPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2e5647cf-e07f-42b2-80da-9882ad21f69e" xlink:to="loc_mgnx_UpfrontPayment_245c9ac4-547a-419b-8e94-adc460eb90ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureMilestone_52426b4b-d7c2-4319-99db-ab7d91d9a43c" xlink:href="mgnx-20221231.xsd#mgnx_FutureMilestone"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2e5647cf-e07f-42b2-80da-9882ad21f69e" xlink:to="loc_mgnx_FutureMilestone_52426b4b-d7c2-4319-99db-ab7d91d9a43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureRevenue_c5ece0a1-e3bb-45e9-b38d-8154269f9e2e" xlink:href="mgnx-20221231.xsd#mgnx_FutureRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2e5647cf-e07f-42b2-80da-9882ad21f69e" xlink:to="loc_mgnx_FutureRevenue_c5ece0a1-e3bb-45e9-b38d-8154269f9e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_46eae6bd-1369-4028-8774-fd3746268fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_bb112c3a-59dc-4525-8d78-e9c21babd3b1" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_46eae6bd-1369-4028-8774-fd3746268fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_56a.jpg
<TEXT>
begin 644 image_56a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !P 8@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;$\9)'_U\6EQ'_Z'$*^;?#/_  3A\27EO&^N^*M-TEQUCL;:2[_GY56/$/\
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M';V-NC/-+)PB)WS6E7S+^W5\1_\ A"/@Y)H\#;=1\22_8A_>C@'SRG\OW?\
MVTH ]-M?VCOAG>W4-M;^-M&FN)GV1QK<C+&O2J_$/]Y%Y;_ZG_GG)7ZV?L[_
M !*3XK_"70=>W>9?&/[/>=,K<1_))^>-W_ JIH#U.BBBI \*D_;4^#T4DB/X
ML97BZC^R[S_XU3/^&VO@U_T-DO\ X*[S_P"-5XQ<?\$UOM4TCGXC8\R3S?\
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MC>=972J"T$@[_3VKX<^ ?P&U32_VH=+\-^)K5%?1IO[5F\N7S(Y5C_>1R?\
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M.2^DWE(_*CP,UY__ ,%+HY)?^%<^6N[YM0_]MJE:,#8_X)L_\B5XR_["%O\
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C5].T4 <7\,?AW:_#'PK;Z':W$]YY7SM<7#99VHKM** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_57a.jpg
<TEXT>
begin 644 image_57a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !? *L# 2(  A$! Q$!_\0
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M^>E>ST %%%% !1152:;[+N=_N4 6Z*** "BBB@ HHHH **** "BBB@ HHHH
MXSP3\1+3QE->6OV>33=2LY-D]C=?ZQ:[.O,OB1X#N;B\A\3>'/\ 1_$-@O\
M=_U\?_/.M[X?^.K3QYH_VR#_ $>XC^2>V;_EG)0!U]>.>,[Z?XF^+/\ A#=+
MD>/2[-]^J74?_HNM[XG>-KG1EL]#T7;-XAU/Y+=-W^K7O)6Q\/?!,/@/08[!
M/WUP_P"]N)_^>DE &_ING6^DV-O:6L?DV\";$C_NBKU%% !1110 4SAEI]%
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M*;QKK_FM\_\ H:2?Q?\ V%?0- !1110 4444 %%%% !1110 4444 >6_&/\
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F>UCM88X8XUC1/N)5NBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>mgnx-20221231_g1.jpg
<TEXT>
begin 644 mgnx-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ;K#I # 2(  A$! Q$!_\0
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MXZ_\ +/_ .2Z/^'P'P:_Z%GQU_X 6?\ \ET?5:_\@71]ST5\,?\ #X#X-?\
M0L^.O_ "S_\ DNC_ (? ?!K_ *%GQU_X 6?_ ,ET?5:_\@71]ST5\,?\/@/@
MU_T+/CK_ , +/_Y+H_X? ?!K_H6?'7_@!9__ "71]5K_ ,@71]ST5\,?\/@/
M@U_T+/CK_P  +/\ ^2Z/^'P'P:_Z%GQU_P" %G_\ET?5:_\ (%T?<]%?#'_#
MX#X-?]"SXZ_\ +/_ .2Z/^'P'P:_Z%GQU_X 6?\ \ET?5:_\@71]ST5\,?\
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M "71]5K_ ,@71]ST5\,?\/@/@U_T+/CK_P  +/\ ^2Z/^'P'P:_Z%GQU_P"
M%G_\ET?5:_\ (%T?<]%?#'_#X#X-?]"SXZ_\ +/_ .2Z/^'P'P:_Z%GQU_X
M6?\ \ET?5:_\@71]ST5\,?\ #X#X-?\ 0L^.O_ "S_\ DNC_ (? ?!K_ *%G
MQU_X 6?_ ,ET?5:_\@71]ST5\,?\/@/@U_T+/CK_ , +/_Y+H_X? ?!K_H6?
M'7_@!9__ "71]5K_ ,@71]ST5\,?\/@/@U_T+/CK_P  +/\ ^2Z/^'P'P:_Z
M%GQU_P" %G_\ET?5:_\ (%T?<]%?#'_#X#X-?]"SXZ_\ +/_ .2Z/^'P'P:_
MZ%GQU_X 6?\ \ET?5:_\@71]ST5\,?\ #X#X-?\ 0L^.O_ "S_\ DNC_ (?
M?!K_ *%GQU_X 6?_ ,ET?5:_\@71]ST5\,?\/@/@U_T+/CK_ , +/_Y+H_X?
M ?!K_H6?'7_@!9__ "71]5K_ ,@71]ST5\,?\/@/@U_T+/CK_P  +/\ ^2Z/
M^'P'P:_Z%GQU_P" %G_\ET?5:_\ (%T?<]%?#'_#X#X-?]"SXZ_\ +/_ .2Z
M/^'P'P:_Z%GQU_X 6?\ \ET?5:_\@71]ST5\,?\ #X#X-?\ 0L^.O_ "S_\
MDNOHW]F_]I#PS^U!X&OO%/A:QU;3]/L]1DTR2+6(HHYFE2.*0D".1QMQ,HR3
MG(;C&"<YT:M-<TXV071ZU17DO[2'[2'AG]E_P-8^*?%-CJVH:?>:C'ID<6CQ
M123+*\<L@)$DB#;B%AD'.2O&,D?.7_#X#X-?]"SXZ_\  "S_ /DNB%&K47-"
M-T%T?<]%?#'_  ^ ^#7_ $+/CK_P L__ )+H_P"'P'P:_P"A9\=?^ %G_P#)
M=:?5:_\ (%T?<]%?#'_#X#X-?]"SXZ_\ +/_ .2Z/^'P'P:_Z%GQU_X 6?\
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MH_X? ?!K_H6?'7_@!9__ "71]5K_ ,@71]ST5\,?\/@/@U_T+/CK_P  +/\
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MXZ_\ +/_ .2Z/^'P'P:_Z%GQU_X 6?\ \ET?5:_\@71]ST5\,?\ #X#X-?\
M0L^.O_ "S_\ DNC_ (? ?!K_ *%GQU_X 6?_ ,ET?5:_\@71]ST5\,?\/@/@
MU_T+/CK_ , +/_Y+H_X? ?!K_H6?'7_@!9__ "71]5K_ ,@71]ST5\,?\/@/
M@U_T+/CK_P  +/\ ^2Z/^'P'P:_Z%GQU_P" %G_\ET?5:_\ (%T?<]%?#'_#
MX#X-?]"SXZ_\ +/_ .2Z/^'P'P:_Z%GQU_X 6?\ \ET?5:_\@71]ST5\,?\
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M "71]5K_ ,@71]ST5\,?\/@/@U_T+/CK_P  +/\ ^2Z/^'P'P:_Z%GQU_P"
M%G_\ET?5:_\ (%T?<]%?#'_#X#X-?]"SXZ_\ +/_ .2Z/^'P'P:_Z%GQU_X
M6?\ \ET?5:_\@71]ST5\,?\ #X#X-?\ 0L^.O_ "S_\ DNC_ (? ?!K_ *%G
MQU_X 6?_ ,ET?5:_\@71]ST5\,?\/@/@U_T+/CK_ , +/_Y+H_X? ?!K_H6?
M'7_@!9__ "71]5K_ ,@71]ST5\,?\/@/@U_T+/CK_P  +/\ ^2Z/^'P'P:_Z
M%GQU_P" %G_\ET?5:_\ (%T?<]%?#'_#X#X-?]"SXZ_\ +/_ .2Z/^'P'P:_
MZ%GQU_X 6?\ \ET?5:_\@71]ST5\,?\ #X#X-?\ 0L^.O_ "S_\ DNC_ (?
M?!K_ *%GQU_X 6?_ ,ET?5:_\@71]ST5\,?\/@/@U_T+/CK_ , +/_Y+H_X?
M ?!K_H6?'7_@!9__ "71]5K_ ,@71]ST5\,?\/@/@U_T+/CK_P  +/\ ^2Z/
M^'P'P:_Z%GQU_P" %G_\ET?5:_\ (%T?<]%?#'_#X#X-?]"SXZ_\ +/_ .2Z
M/^'P'P:_Z%GQU_X 6?\ \ET?5:_\@71]ST5\,?\ #X#X-?\ 0L^.O_ "S_\
MDNC_ (? ?!K_ *%GQU_X 6?_ ,ET?5:_\@71]ST5\,?\/@/@U_T+/CK_ , +
M/_Y+H_X? ?!K_H6?'7_@!9__ "71]5K_ ,@71]ST5\,?\/@/@U_T+/CK_P
M+/\ ^2Z/^'P'P:_Z%GQU_P" %G_\ET?5:_\ (%T?<]%?#'_#X#X-?]"SXZ_\
M +/_ .2Z/^'P'P:_Z%GQU_X 6?\ \ET?5:_\@71]ST5\,?\ #X#X-?\ 0L^.
MO_ "S_\ DNC_ (? ?!K_ *%GQU_X 6?_ ,ET?5:_\@71]ST5\,?\/@/@U_T+
M/CK_ , +/_Y+H_X? ?!K_H6?'7_@!9__ "71]5K_ ,@71]ST5\,?\/@/@U_T
M+/CK_P  +/\ ^2Z/^'P'P:_Z%GQU_P" %G_\ET?5:_\ (%T?<]%?#'_#X#X-
M?]"SXZ_\ +/_ .2Z/^'P'P:_Z%GQU_X 6?\ \ET?5:_\@71]ST5\,?\ #X#X
M-?\ 0L^.O_ "S_\ DNC_ (? ?!K_ *%GQU_X 6?_ ,ET?5:_\@71]ST5\,?\
M/@/@U_T+/CK_ , +/_Y+H_X? ?!K_H6?'7_@!9__ "71]5K_ ,@71]ST5\,?
M\/@/@U_T+/CK_P  +/\ ^2Z/^'P'P:_Z%GQU_P" %G_\ET?5:_\ (%T?<]%?
M#'_#X#X-?]"SXZ_\ +/_ .2Z/^'P'P:_Z%GQU_X 6?\ \ET?5:_\@71]ST5\
M,?\ #X#X-?\ 0L^.O_ "S_\ DNC_ (? ?!K_ *%GQU_X 6?_ ,ET?5:_\@71
M]ST5\,?\/@/@U_T+/CK_ , +/_Y+H_X? ?!K_H6?'7_@!9__ "71]5K_ ,@7
M1]ST5\,?\/@/@U_T+/CK_P  +/\ ^2Z/^'P'P:_Z%GQU_P" %G_\ET?5:_\
M(%T?<]%?#'_#X#X-?]"SXZ_\ +/_ .2Z/^'P'P:_Z%GQU_X 6?\ \ET?5:_\
M@71]ST5\,?\ #X#X-?\ 0L^.O_ "S_\ DNC_ (? ?!K_ *%GQU_X 6?_ ,ET
M?5:_\@71]ST5\,?\/@/@U_T+/CK_ , +/_Y+H_X? ?!K_H6?'7_@!9__ "71
M]5K_ ,@71]ST5\,?\/@/@U_T+/CK_P  +/\ ^2Z]Q_9C_; \&_M7?\)+_P (
MEIFN:=_8'V;[5_;4$,6_S_-V;/+EDSCR6SG'5<9SQ$J%6FN:4;(+H]VHK@OC
M=\8-%^ OPOUGQWX@M;Z\T?2C#Y\.FQH\[>;/'"NU7=%.&D4G+#@'&3P?E7_A
M\!\&O^A9\=?^ %G_ /)=*%&I45X1N%S[GHKX8_X? ?!K_H6?'7_@!9__ "71
M_P /@/@U_P!"SXZ_\ +/_P"2ZT^JU_Y NC[GHKX8_P"'P'P:_P"A9\=?^ %G
M_P#)='_#X#X-?]"SXZ_\ +/_ .2Z/JM?^0+H^YZ*^&/^'P'P:_Z%GQU_X 6?
M_P ET?\ #X#X-?\ 0L^.O_ "S_\ DNCZK7_D"Z/N>BOAC_A\!\&O^A9\=?\
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M'P:_Z%GQU_X 6?\ \ET?\/@/@U_T+/CK_P  +/\ ^2Z/JM?^0+H^YZ*^&/\
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M"Z/N>BOAC_A\!\&O^A9\=?\ @!9__)='_#X#X-?]"SXZ_P# "S_^2Z/JM?\
MD"Z/N>BOAC_A\!\&O^A9\=?^ %G_ /)='_#X#X-?]"SXZ_\  "S_ /DNCZK7
M_D"Z/N>BOAC_ (? ?!K_ *%GQU_X 6?_ ,ET?\/@/@U_T+/CK_P L_\ Y+H^
MJU_Y NC[GHKX8_X? ?!K_H6?'7_@!9__ "71_P /@/@U_P!"SXZ_\ +/_P"2
MZ/JM?^0+H^YZ*^&/^'P'P:_Z%GQU_P" %G_\ET?\/@/@U_T+/CK_ , +/_Y+
MH^JU_P"0+H^YZ*^&/^'P'P:_Z%GQU_X 6?\ \ET?\/@/@U_T+/CK_P  +/\
M^2Z/JM?^0+H^YZ*^&/\ A\!\&O\ H6?'7_@!9_\ R71_P^ ^#7_0L^.O_ "S
M_P#DNCZK7_D"Z/N>BOAC_A\!\&O^A9\=?^ %G_\ )='_  ^ ^#7_ $+/CK_P
M L__ )+H^JU_Y NC[GHKX8_X? ?!K_H6?'7_ ( 6?_R71_P^ ^#7_0L^.O\
MP L__DNCZK7_ ) NC[GHKX8_X? ?!K_H6?'7_@!9_P#R71_P^ ^#7_0L^.O_
M   L_P#Y+H^JU_Y NC[GHKX8_P"'P'P:_P"A9\=?^ %G_P#)='_#X#X-?]"S
MXZ_\ +/_ .2Z/JM?^0+H^YZ*^&/^'P'P:_Z%GQU_X 6?_P ET?\ #X#X-?\
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M\/@/@U_T+/CK_P  +/\ ^2Z/JM?^0+H^YZ*^&/\ A\!\&O\ H6?'7_@!9_\
MR71_P^ ^#7_0L^.O_ "S_P#DNCZK7_D"Z/N>BOAC_A\!\&O^A9\=?^ %G_\
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M1]ST5\,?\/@/@U_T+/CK_P  +/\ ^2Z/^'P'P:_Z%GQU_P" %G_\ET?5:_\
M(%T?<]%?#'_#X#X-?]"SXZ_\ +/_ .2Z/^'P'P:_Z%GQU_X 6?\ \ET?5:_\
M@71]ST5\,?\ #X#X-?\ 0L^.O_ "S_\ DNC_ (? ?!K_ *%GQU_X 6?_ ,ET
M?5:_\@71]ST5\,?\/@/@U_T+/CK_ , +/_Y+H_X? ?!K_H6?'7_@!9__ "71
M]5K_ ,@71]ST5\,?\/@/@U_T+/CK_P  +/\ ^2Z/^'P'P:_Z%GQU_P" %G_\
MET?5:_\ (%T?<]%?#'_#X#X-?]"SXZ_\ +/_ .2Z/^'P'P:_Z%GQU_X 6?\
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MH_X? ?!K_H6?'7_@!9__ "71]5K_ ,@71]ST5\,?\/@/@U_T+/CK_P  +/\
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MXZ_\ +/_ .2Z/^'P'P:_Z%GQU_X 6?\ \ET?5:_\@71]ST5\,?\ #X#X-?\
M0L^.O_ "S_\ DNC_ (? ?!K_ *%GQU_X 6?_ ,ET?5:_\@71]ST5\,?\/@/@
MU_T+/CK_ , +/_Y+H_X? ?!K_H6?'7_@!9__ "71]5K_ ,@71]ST5\,?\/@/
M@U_T+/CK_P  +/\ ^2Z]4_9O_;P\ _M0>.;[PKX5TCQ)I^H6>G2:H\FL6UO%
M"8DDBC(!CG=MV9E." , \\8,RP]6"YI1T"Z/I.BN>\>>,++X=^!_$/BG48KB
M?3]#TZYU.YCME!E>*")I'"!F +$*0 2 3C)'6OCG_A\!\&O^A9\=?^ %G_\
M)=13I5*NL%<#[GHKX8_X? ?!K_H6?'7_ ( 6?_R71_P^ ^#7_0L^.O\ P L_
M_DNM?JM?^0+H^YZ*^&/^'P'P:_Z%GQU_X 6?_P ET?\ #X#X-?\ 0L^.O_ "
MS_\ DNCZK7_D"Z/N>BOAC_A\!\&O^A9\=?\ @!9__)='_#X#X-?]"SXZ_P#
M"S_^2Z/JM?\ D"Z/N>BOAC_A\!\&O^A9\=?^ %G_ /)='_#X#X-?]"SXZ_\
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M#7_0L^.O_ "S_P#DNCZK7_D"Z/N>BOAC_A\!\&O^A9\=?^ %G_\ )='_  ^
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MU_X 6?\ \ET?\/@/@U_T+/CK_P  +/\ ^2Z/JM?^0+H^YZ*^&/\ A\!\&O\
MH6?'7_@!9_\ R71_P^ ^#7_0L^.O_ "S_P#DNCZK7_D"Z/N>BOAC_A\!\&O^
MA9\=?^ %G_\ )='_  ^ ^#7_ $+/CK_P L__ )+H^JU_Y NC[GHKX8_X? ?!
MK_H6?'7_ ( 6?_R71_P^ ^#7_0L^.O\ P L__DNCZK7_ ) NC[GHKX8_X? ?
M!K_H6?'7_@!9_P#R71_P^ ^#7_0L^.O_   L_P#Y+H^JU_Y NC[GHKX8_P"'
MP'P:_P"A9\=?^ %G_P#)='_#X#X-?]"SXZ_\ +/_ .2Z/JM?^0+H^YZ*^&/^
M'P'P:_Z%GQU_X 6?_P ET?\ #X#X-?\ 0L^.O_ "S_\ DNCZK7_D"Z/N>BOA
MC_A\!\&O^A9\=?\ @!9__)='_#X#X-?]"SXZ_P# "S_^2Z/JM?\ D"Z/N>BO
MAC_A\!\&O^A9\=?^ %G_ /)='_#X#X-?]"SXZ_\  "S_ /DNCZK7_D"Z/N>B
MOAC_ (? ?!K_ *%GQU_X 6?_ ,ET?\/@/@U_T+/CK_P L_\ Y+H^JU_Y NC[
MGHKX8_X? ?!K_H6?'7_@!9__ "71_P /@/@U_P!"SXZ_\ +/_P"2Z/JM?^0+
MH^YZ*^&/^'P'P:_Z%GQU_P" %G_\ET?\/@/@U_T+/CK_ , +/_Y+H^JU_P"0
M+H^YZ*^&/^'P'P:_Z%GQU_X 6?\ \ET?\/@/@U_T+/CK_P  +/\ ^2Z/JM?^
M0+H^YZ*^&/\ A\!\&O\ H6?'7_@!9_\ R71_P^ ^#7_0L^.O_ "S_P#DNCZK
M7_D"Z/N>BOAC_A\!\&O^A9\=?^ %G_\ )='_  ^ ^#7_ $+/CK_P L__ )+H
M^JU_Y NC[GHKX8_X? ?!K_H6?'7_ ( 6?_R71_P^ ^#7_0L^.O\ P L__DNC
MZK7_ ) NC[GHKX8_X? ?!K_H6?'7_@!9_P#R71_P^ ^#7_0L^.O_   L_P#Y
M+H^JU_Y NC[GHKX8_P"'P'P:_P"A9\=?^ %G_P#)='_#X#X-?]"SXZ_\ +/_
M .2Z/JM?^0+H^YZ*^&/^'P'P:_Z%GQU_X 6?_P ET?\ #X#X-?\ 0L^.O_ "
MS_\ DNCZK7_D"Z/N>BOAC_A\!\&O^A9\=?\ @!9__)='_#X#X-?]"SXZ_P#
M"S_^2Z/JM?\ D"Z/N>BOAC_A\!\&O^A9\=?^ %G_ /)='_#X#X-?]"SXZ_\
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M'</^"P'_ ";3X:_[&ZV_]([VOR!K]?O^"P'_ ";3X:_[&ZV_]([VOR!IX#^
M@EN%%%%>@0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5^F7_!%_P#YK%_W!_\ V^K\S:_3+_@B_P#\
MUB_[@_\ [?5PXW^!+Y?FBH[GTS_P4G_Y,K^(W_<._P#3E:U^&E?N7_P4G_Y,
MK^(W_<._].5K7X:5CEW\)^OZ(<]PHHHKU" HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH _H8_9?\ ^3:?A+_V*.D?^D45?#/_  6@_P":._\
M<8_]L:^YOV7_ /DVGX2_]BCI'_I%%7PS_P %H/\ FCO_ '&/_;&OFL-_O2]7
M^IM+8_,VBBBOI3$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGKBRWX)>HY!1117KD!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_0Q^R_P#\
MFT_"7_L4=(_](HJ].KS']E__ )-I^$O_ &*.D?\ I%%7IU?&U/C?J=!\+_\
M!8#_ )-I\-?]C=;?^D=[7Y U^OW_  6 _P"3:?#7_8W6W_I'>U^0-?18#^ C
M*6X4445Z! 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %?K]_P1__ .3:?$O_ &-US_Z1V5?D#7Z_?\$?
M_P#DVGQ+_P!C=<_^D=E7G8_^#\T7'</^"P'_ ";3X:_[&ZV_]([VOR!K]?O^
M"P'_ ";3X:_[&ZV_]([VOR!IX#^ @EN%%%%>@0%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^F7_!%
M_P#YK%_W!_\ V^K\S:_3+_@B_P#\UB_[@_\ [?5PXW^!+Y?FBH[GTS_P4G_Y
M,K^(W_<._P#3E:U^&E?N7_P4G_Y,K^(W_<._].5K7X:5CEW\)^OZ(<]PHHHK
MU" HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0P8$@@@@G-&J?LZ_%?0]+N]0U'X8^,=/T^SA>>YO+GP_=QPPQ("SN[M&%55
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOASXO?M/^#/"7BW3O[5\/ZA]M^TV?GR0[]EE/*GSQLK##HK<,,XYR"0?<_\
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MM0?\FT_%K_L4=7_](I:_GGKBRWX)>HY!1117KD!1110 4444 %%%% !1110
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MZ]X.2[N+7P5X0U*73[32]HC$MW#F*>YE 9A(WF"18R2 L>,*K/)N^RO^"/\
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M36=<^'_CSP?>S&?1_#UW:7>G^8SN\/VH3^;$N6*K&&MPX55'S2RDDEN/#/\
M@K#\:-2\5?'6/X>VU_?1>'_"]I;O<:;(%2"74)D,IN%VDF3$$T* O@J?-"@!
MV+^G?\$7_P#FL7_<'_\ ;ZOF7_@I-_R>I\1O^X=_Z;;6E3A%XV6FRO\ D'V3
MV#_@CSXDU*U^.'C/P_%<[='OO#AO[BW\M?GFM[F%(6W$;AM6ZG& 0#OR0<+C
M,_X+ ?\ )RWAK_L4;;_TLO:/^"/_ /R<MXE_[%&Y_P#2RRH_X+ ?\G+>&O\
ML4;;_P!++VJLEC?D'V3X:HHHKU3,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K]?O^"/\ _P FT^)?^QNN?_2.RK\@:_7[
M_@C_ /\ )M/B7_L;KG_TCLJ\['_P?FBX[A_P6 _Y-I\-?]C=;?\ I'>U^0-?
MK]_P6 _Y-I\-?]C=;?\ I'>U^0-/ ?P$$MPHHHKT" HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OTR
M_P""+_\ S6+_ +@__M]7YFU^F7_!%_\ YK%_W!__ &^KAQO\"7R_-%1W/IG_
M (*3_P#)E?Q&_P"X=_Z<K6OPTK]R_P#@I/\ \F5_$;_N'?\ IRM:_#2L<N_A
M/U_1#GN%%%%>H0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
M]#'[+_\ R;3\)?\ L4=(_P#2**OAG_@M!_S1W_N,?^V-?<W[+_\ R;3\)?\
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M]G?V_JUII7VSRO,\CSYTBW[-PW;=V[;N&<8R,Y'Z&?\ #E__ *K%_P"6Q_\
M=E?FMIFJ7NB:I::AI]W<:?J%G,D]M>6TICFAE4AD='4@JRD @@@@@$$8KT/_
M (:@^,?_ $5OQU_X4EY_\<KJK0K2:]G*PE;J>Y?M@?\ !/O_ (91^&>F>+?^
M$\_X2K[9JT>E?8_[&^R;-\,TN_?]HDSCR,;=HSNZC&#S/_!-G_D]3X<_]Q'_
M --MU7BWC#XQ^/\ XA:7'I_BGQOXD\2Z?%,)TL]8U>XNX4E 90X21RH8!F4,
M!D!F&>37M/\ P39_Y/4^'/\ W$?_ $VW53*,XT)JH[NS#2ZL?JQ^TY^V!X-_
M91_X1K_A+=,US4?[?^T_9?[%@AEV>1Y6_?YDL>,^<N,9Z-G&.?#O^'P'P:_Z
M%GQU_P" %G_\EUYE_P %H/\ FCO_ '&/_;&OS-KAPV#I5:2G+=_YE.33/VV^
M"/\ P4@^&GQZ^)^C> _#^A>*[36-5\_R)M2M;5(%\J"29MS)<.1E8V PIY(S
MCDCY[_X+0?\ -'?^XQ_[8U\R_P#!-G_D]3X<_P#<1_\ 3;=5]-?\%H/^:._]
MQC_VQI1HQHXN$8=O\PO>)Z9_P1__ .3:?$O_ &-US_Z1V5?#/_!2;_D]3XC?
M]P[_ --MK7V!_P $</&GV[X:_$/PD;/;_96K6^J_;/-SYOVJ$Q;-F/EV_8LY
MR<^9C V\_*7_  4\\-:EH7[8GBJ]O;;R+76K33[^QD\Q6\^%;6.W+84DKB6"
M5<, ?DST()THZ8R:?]; _A.Z_P""/_\ R<MXE_[%&Y_]++*O3?\ @M!_S1W_
M +C'_MC7'?\ !'WP/KTGQ>\6>,ETNX'A>#0IM(?5&4+"UV]Q;2K"I)R[".-F
M; .T%=V-Z[NQ_P""T'_-'?\ N,?^V-*33QRMV_0/LA_P1?\ ^:Q?]P?_ -OJ
M\,_X*E_$/6?%7[56J^'+V?\ XD_A6TM;33[6-I-B^=;Q7$LC*6(\QFF"EE"Y
M6*($'9D^Y_\ !%__ )K%_P!P?_V^KYE_X*3?\GJ?$;_N'?\ IMM:JFD\;._;
M_(7V4>P?\$>?$FI6OQP\9^'XKG;H]]X<-_<6_EK\\UO<PI"VXC<-JW4XP" =
M^2#A<;G_  6+^(][<>.O ?@"/[1!I]GITFN3;;D^5=2SR/!'NAP!NB%O)M<D
MG%PP 7DMR'_!'_\ Y.6\2_\ 8HW/_I994?\ !8#_ ).6\-?]BC;?^EE[1RKZ
M[\A_9///^"9^IWNG_MF>!X;6[N+:&^AU""[CAE*)<1"QGD"2 '#J)(XWP<@,
MBGJ 1](?\%H/^:._]QC_ -L:^9?^";/_ ">I\.?^XC_Z;;JOIK_@M!_S1W_N
M,?\ MC55/]]AZ?YB^R?"'P;^$/Q)^,FJ:AH?P[T/5M::YA6#4?L+>3:^5GSD
M2YF9EC16>V#*)& 9XEV@L *^OO!__!'7Q_>ZI(GBGQYX<T73UA+)<:-#<:A,
MTN5PICD2!0I&XE@Q(( VG)(^M?\ @F'X;TW0_P!COPK>V-OY%UK5WJ%]?R>8
MQ\Z9;J2W#8)PN(K>%<* /DSC))/Y*_&CXX_%3XHZWJ%E\2/$^N:A=6]W_I&B
MZ@S6T%K=1*8CBS4)'%(HW*V$5LEB>2Q+56K6J2A3:BE\V.R2U/VM_9+_ &=[
MW]F'X6R^"KKQA<>,81J,MY:7$UJ;9+6.1(\P1QF60*OF+))P0"TK'&22?Q(_
M:*TNRT/]H/XG:=I]I;Z?I]GXGU2"VL[:(1PPQ)=RJB(B@!54   #   &,5^O
MO_!./X)Z]\$/V;;6S\307&GZUKVHS:W-I=S"(Y;)72**.-QN)W&.!)""%93(
M490R'/Y&?M0?\G*_%O\ [&[5O_2R6L<'_&J:W"6Q^T?[;WQ$UGX5_LK_ !!\
M1>'Y_LNL16D5I#=*SJ\'VBXBMVEC9&5ED19F9&!^5E4D$#!_!"OW+_X*3_\
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M&L6Z 72!/W0C(^49&#SG)^>_^"+_ /S6+_N#_P#M]7S+_P %)O\ D]3XC?\
M<._]-MK7B.FZN+FE)K3IZ(TO:*/T4T_X^?LH?L?^$VL_"&M>&X%N8991:^%)
M/[5O;YHBSK'-<(7.[,K+&;B55 9@K!5.W\LOVG/VG/%?[47Q ;7_ ! WV/2[
M;=%I.AP.7@TZ%B,@' WR-A2\A +D  *JHB^045WT<+"E+GO>7=DN5]#]?O\
M@C__ ,FT^)?^QNN?_2.RKX/_ &_/C9KWQ@_:2\66>HSW$>C>%]1N=$TK2VF#
MPVZP/Y,LB@*HW321F1B06 *H681KC[P_X(__ /)M/B7_ +&ZY_\ 2.RK\S?V
MH/\ DY7XM_\ 8W:M_P"EDM<M"*>*J-]"GL>T_P#!+_X;V7Q _:KTR[O_ +/)
M#X9TZXUT6MQ;"=)Y4*018W$!&22Y697P2&A7&"0R_1__  6(^)FI:7HO@/P-
MINO>18ZK]KOM8T>"50\ZQM +1IE'S>7O\\J#A6:/."T8*_+O_!-KXJ1?"_\
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M]_9'V;_B7_V%]F\WS;F*#_6?:7V[?,W?=.=N.,Y'S/\ \-0?&/\ Z*WXZ_\
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M+_W#5^&E?N7_ ,XT_P#ND7_N&K\-*K _;]12"BBBO4("BBB@ K[E_P""/_\
MR<MXE_[%&Y_]++*OAJON7_@C_P#\G+>)?^Q1N?\ TLLJY<5_!GZ%1W/TS_:@
M_P"3:?BU_P!BCJ__ *12U_//7]#'[4'_ ";3\6O^Q1U?_P!(I:_GGKBRWX)>
MHY!1117KD!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M']0^P_9;SR)(=^RR@B?Y)%5AAT9>5&<<9!!/AM%$:,8U756["^ECZK_X)O\
MQN\%? 7XX:YX@\>:U_8>CW/AR>QBN/LD]QNF:YM9%7;"CL,K&YR1CCU(!/\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_3+_@B_\
M\UB_[@__ +?5^9M?IE_P1?\ ^:Q?]P?_ -OJX<;_  )?+\T5'<^F?^"D_P#R
M97\1O^X=_P"G*UK\-*_<O_@I/_R97\1O^X=_Z<K6OPTK'+OX3]?T0Y[A1117
MJ$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_0Q^R_\ \FT_
M"7_L4=(_](HJ^&?^"T'_ #1W_N,?^V-?<W[+_P#R;3\)?^Q1TC_TBBKX9_X+
M0?\ -'?^XQ_[8U\UAO\ >EZO]3:6Q^9M%%%?2F(4444 %%%% !1110 5]?\
M_!/O]L#P;^RC_P )Y_PENF:YJ/\ ;_\ 9_V7^Q((9-GD?:=^_P R6/&?.7&,
M]&SC'/R!16=2G&K%PEL-.QZ_^UO\8-&^/7[0GBKQYH%M?6FCZK]D\F'4HT2=
M?*M(86W*CN!EHV(PQX()QR!Y!1151BH145T$>O\ [)'Q@T;X"_M">%?'FOVU
M]=Z/I7VOSH=-C1YV\VTFA7:KN@.&D4G+#@$C/ /L'_!03]L#P;^U=_P@?_")
M:9KFG?V!_:'VK^VX(8]_G_9MFSRY9,X\ELYQU7&<\?(%%9RHQE455[H=]+'U
M_P#\$^_VP/!O[*/_  GG_"6Z9KFH_P!O_P!G_9?[$@ADV>1]IW[_ #)8\9\Y
M<8ST;.,<^/\ [6_Q@T;X]?M">*O'F@6U]::/JOV3R8=2C1)U\JTAA;<J.X&6
MC8C#'@@G'('D%%$:,8U'56[_ *_0+Z6.F^%_C3_A6_Q*\)^+?L?]H?V!JUIJ
MOV/S?+\_R)TEV;]IV[MNW=M.,YP<8K]3H_V[_P!DGXV:I/J/CSPQ;VNH6<,<
M%O>>,?"D5]-+$2[;(G@6X*JI))5BHS)QGYL?D7145L/&LTVVFNP)V/U#\3_\
M%0/A'\)?#.KZ+\$_AQY5TUW-Y3?V=!I6E2OL*+>>7"?,ER4A^1DB9DX+(5 K
M\V/''CC7?B5XLU3Q/XGU6XUG7=3F,]W?7+#>[8     55 "JJ@*JJJJ   ,.
MBG2H0HW<=WU!NY]W?L3?\%'-,_9[^&Z^ O'&@ZMJ^BV,UQ/IFH:/Y#S0K(ZO
M]F,+>6&7S&N)/,,I8%U0+@ CL/VVOVPO@!\1OAWXST7P)I7]K^./$UI91R^+
MK70DM=R17D$K03SS".X;"6J8 1EXBYX.W\X:*S^J4_:>T6X^9A111782%?H]
M_P /(/AK_P ,B_\ "K?[#\5_\)#_ ,(-_P (S]J^RVOV3[5]@^S[]WVG=Y>_
MG.W=M_ASQ7YPT5C4HQJVYN@T['7_  <\867P]^+W@CQ3J$5Q/I^AZ[8ZI<QV
MR@S/%!<)*X0,P4L0I !8 G&2.M?7_P"WA^W?X _:@^$.D>%O"VD>)-/U"SUV
M'5'DUBVMXX3$EO<1$ QSNV[,RG! & >00 ?A&BB5&,YJ;W0[] K]'O\ AY!\
M-?\ AD7_ (5;_8?BO_A(?^$&_P"$9^U?9;7[)]J^P?9]^[[3N\O?SG;NV_PY
MXK\X:**E&-6W-T$G8****V$%>O\ [)'Q@T;X"_M">%?'FOVU]=Z/I7VOSH=-
MC1YV\VTFA7:KN@.&D4G+#@$C/ /D%%3**G%Q?49]?_\ !03]L#P;^U=_P@?_
M  B6F:YIW]@?VA]J_MN"&/?Y_P!FV;/+EDSCR6SG'5<9SQ\@445-.G&E%0CL
M#=SU_P#9(^,&C? 7]H3PKX\U^VOKO1]*^U^=#IL:/.WFVDT*[5=T!PTBDY8<
M D9X!]@_X*"?M@>#?VKO^$#_ .$2TS7-._L#^T/M7]MP0Q[_ #_LVS9Y<LF<
M>2V<XZKC.>/D"BIE1C*HJKW07TL>O_LQ_M.>*_V7?B NO^'V^V:7<[8M6T.=
MRD&HPJ3@$X.R1<L4D )0D@AE9T;])]4_X*+?LQ?%GP/=MXSTRXNUL9GGMO#/
MB;PZM[-<2I$=CPA?-@5FWO&K/(A!+9*J=Q_'FBLJN%IUI<ST?D-2:/TZT3_@
MK)X2TKXI16]OX5U;1OA!IFA_8=.TG3;&U^VO=[H-CNGFK'##%&DL:1QN1\VX
MYRJQ>"?\%!/VP/!O[5W_  @?_"):9KFG?V!_:'VK^VX(8]_G_9MFSRY9,X\E
MLYQU7&<\?(%%*&%I4Y*<5J@YFSZ__P""??[8'@W]E'_A//\ A+=,US4?[?\
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MA:<:GM$/F84445V$A1110 5]R_\ !'__ ).6\2_]BC<_^EEE7PU7W+_P1_\
M^3EO$O\ V*-S_P"EEE7+BOX,_0J.Y^F?[4'_ ";3\6O^Q1U?_P!(I:_GGK^A
MC]J#_DVGXM?]BCJ__I%+7\\]<66_!+U'(****]<@**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OU^_P""/_\ R;3XE_[&ZY_]([*OR!K]?O\ @C__ ,FT^)?^QNN?_2.RKSL?
M_!^:+CN'_!8#_DVGPU_V-UM_Z1WM?D#7Z_?\%@/^3:?#7_8W6W_I'>U^0-/
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MT+5;FRLK=< +'%"CA550 ,G+-@LS,Q+']3OV7_B%!^W5^R!J&G>/H/M-]/\
M:?#NMW$5M%&)9E5'CNH%.]5D5)8) VT!9E8J@4+64ZF(P]IU&FGOY#T>Q^,O
M@/P?>_$+QSX?\+:?+;P:AKFHVVEVLERQ6%)9Y%B0N54D*"P)(4D#. >E>^?'
MS_@G[\2OV>O#.C:SK%YH>OC5M6@T2RL/#LUU<W<MU*DCQJL;6Z;MWE%0 2Q9
ME !SQPWP'\-:EX-_:[^'F@:S;?8]8TKQSIUC>V_F*_E317\<<B[D)5L,I&02
M#C()ZU^R'[9'QVTS]G/X,S>-I],L=7\06UVEOX>M]0B9T&H2QR1[PRJ2FV W
M+'!3<H>/>ID%7B*\Z=2$8:W$DNI\(_#?_@CWXWU[3/M7C7QKI/A&:2&&6&QT
M^T;4IHV8$R1S'?$B,AVC,;2JQW8; !;YP_:3_8W^(G[+1TJX\5P6.H:1J>4A
MUC1)9)K19ADFW=G1&23:-P!4!EW;2Q1PNGH/[?WQYT/X@-XM?Q_?:K=2[%N-
M+U!5?39HT*906J@1Q;A& SPK&_S,0X+L3^K'[2W]C?'K]AOQCK*?;K/2-6\(
MCQ-:*VQ)QY4*W\"2#YU&6C17 )X+ ,#AAG*KB*$X^T::8]'L?EC^S?\ L(>/
M_P!J#P/?>*?"VK^&]/T^SU&33'CUBYN(YC*D<4I($<#C;B90"3G(/ P"?UT_
M:X^$&L_'O]GOQ5X$\/W-C9ZQJIM/)FU*1T@7RKN&9MS(C,,K&P&%/)'3K7XM
M_!_]K?XL? 7PS<^'_ ?BK^P]'N;MKZ6W_LVTN-TS(D;-NFB<C*QH, @<9QR2
M?V1_;<^)/B/X0_LP^,_%OA+4/[)\0:?]B^S7GD1S;/,O8(G^2164Y1V'(XSD
M8(R,<6JOMH:K?3\-QQM8_(']IS]C_P 9?LH_\(U_PENIZ'J']O\ VG[-_8D\
M\FSR/*W[_,BCQGSUQC.<-G&!GN?@C_P3A^)?QZ^%^B^//#^N>$[31]5,WDPZ
ME=W23KY4\D#;E2W91EHV(PQX(SSD#R#XT?M)?$?]H;^R/^%@>(_[>_LCSOL7
M^@VUMY7F[/,_U,:;MWEIUSC;QC)S^O\ _P $V/\ DROX<_\ <1_].5U73B*M
M6A13;7-<E6;/PTKZK^$?_!-/XS_%SPU:Z_%!H?AK1[ZTMK[3[C6M2_X_89D\
MQ&1;=)F3"[21($(WJ #A@/E2OH;QI^W3\5?$'@_PAX2T#Q'?>!_#?AS2=/TV
M&WT*Y:">XDMK81-/+<(%D.\[CY88( $!5F0NW95]KHJ5OF2K=3Z.\8?\$;?$
MUGI<;^%?B5I6M:@9@KV^LZ;+I\*Q8;+"2-YR6!V@+M P6.X8 /PU\5/A#XP^
M"7BR3PSXWT.XT'6D@2=;>=DD1XG'RO'(C,DBY!7<K$!E9205('V1^QG\5OVG
M]#^+7@ZXUO3/B1XO^'WB.[M8KV;6K2[NK3[+,&2.Z2YFCD\N-/.$Y:-E618U
M#-C!'JW_  6*^&]E<^!_ ?C]#;P:A9ZD^A3!;8>==13Q/-'NFR#MB-O+M0@C
M-PY!7G=PTZU6G65*HTTR[)JZ,3_@B_\ \UB_[@__ +?5\R_\%)O^3U/B-_W#
MO_3;:U]-?\$7_P#FL7_<'_\ ;ZOF7_@I-_R>I\1O^X=_Z;;6G3_WR?I_D+[*
M/F>BBBO4(/N7_@C_ /\ )RWB7_L4;G_TLLJ/^"P'_)RWAK_L4;;_ -++VC_@
MC_\ \G+>)?\ L4;G_P!++*C_ (+ ?\G+>&O^Q1MO_2R]KR_^8WY&GV3RG]F_
M]A#Q_P#M0>![[Q3X6U?PWI^GV>HR:8\>L7-Q',94CBE) C@<;<3* 2<Y!X&
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M_P!FZ3_:5CKER0MVD<3P0&"4JH\[=YBOYCGS-P?<S[QLYK_@M!_S1W_N,?\
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M6D,EW]A002:OJ$K10&XD9V<IYDK(227,<8"J&"*E.OB)4X14=92!(^-_!_\
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MN>)M'\;Z'X@\/Z'I,^K7K7L$UC=MY*222)'$@F5OD0;6,BY9B"!C<5_X(_\
M_)RWB7_L4;G_ -++*O#-'_;9^,VF>$->\*WOC>^\2Z!KEI=V5[9Z^?MSNEQ;
M- Q6>3,R;00ZJKA0RY*G+!O<_P#@C_\ \G+>)?\ L4;G_P!++*G456-":JNX
M*U] _P""P'_)RWAK_L4;;_TLO:\I_9O_ &$/'_[4'@>^\4^%M7\-Z?I]GJ,F
MF/'K%S<1S&5(XI20(X'&W$R@$G.0>!@$^K?\%@/^3EO#7_8HVW_I9>U],_\
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M-@CF7:SHA.%D4'*CD$#/!/<_\-Q?'G_A-/\ A*O^%GZY_:G_ #[^8O\ 9_\
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M[HMI ID=)&1E:)92%@\S<"K3*1DX!Z(.I2A*59WL+?8W?V>_V$_BK^TCH?\
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MG+>)?^Q1N?\ TLLJ^&J^Y?\ @C__ ,G+>)?^Q1N?_2RRKEQ7\&?H5'<_3/\
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M3@[<$$$@_/5>E_LR>*/^$-_:*^&>LOJ_]AVMMXCL?M>H-<_9TBM6G1)_,DR
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MHHHKT2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OU^_X(_P#_ ";3XE_[&ZY_]([*OR!K]?O^"/\
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MW^RS_P ('HG@[4;[4=8U/[?>ZDVK7T<UVL(^S); QQHBI'N%SM;9EF\P%FV
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M^X:HQ$/9TZ4'T81UN?AI7Z_?\$?_ /DVGQ+_ -C=<_\ I'95^0-?K]_P1_\
M^3:?$O\ V-US_P"D=E73C_X/S0H[GYF_M0?\G*_%O_L;M6_]+):_43_@K3X;
MU'7/V6[2^L;;S[71?$=G?7TF]5\F%HI[<-AB"V9;B)<*"?GSC )'Y=_M0?\
M)ROQ;_[&[5O_ $LEK]5M!D@_;._X)SMI6G7U]K7B"?PXEA.LEY%]LEUFQ".J
MSR.[A?.G@C<F1@S13JQ*%LC+$/D]C4Z+_@#74_%VOK_]F/\ X*4>//@'HB>'
M->L_^%@^%;2T6VTRQN[L6L]AM8E0EP(W9X]I*B-PVT+&$9%0JWR!7ZP_$3_@
MDS\-OB-<6.O_  T\:7'A'1;Z%9UMUC_MBREB:./RGMI#,CA6 9RS22AC(-NT
M  ]6)G1BE&LM&3&_0]H^'_Q=^ '[?>BSZ;+I%CKVIV-I,TFB^)-/5-2L(96\
MMY(7!.W=MC)DMY"4+0[BK%17Y4?MC_LUG]EKXS3^%+?5/[9TB\M$U73+B1<3
MK:O))&J3@ #S%:)UW+\K *P"EBB_I/\ LO\ [%'AG]AW7O$7Q"\2?$NWOH)=
M.72S>:A;1Z596D4D\;,9'DF<,S2)"JG<H!+##%QM_/3]O?\ :(T+]I3X[-KW
MABVN$T'2M-CT:TO+G*/?K'+-*;@1D!HU8SD*K?-M52P4L47APFE9JDVX%2VU
M.0_8_P##6I>*_P!J3X666EVOVFZB\1V=\\?F*F(;>5;B=LL0/EBB=L Y.W !
M) /VG_P6@_YH[_W&/_;&O*/^"3/PKE\8?M#7?C*6*X73_"&FR2B:&9%3[7<J
MT$4<B-EF5H3=L"H&&C7+#(5JW_!6#XB'Q9^TU'X=AGOOLOA72;>TEM9V_<"Z
MFS</)"H8CYHIK=68A6)BP<A%-;R?/C(I?90OLGQ;1117ID!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4T>Y'F(HFB.]48CSX\.KHP+,A;"N,,7!1K1J35X]2H['R_\ \/H#_P!$>_\
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MEXL\:WWB/5](TF_N;!F6/2]/\XVS):H\>YW>3[05*@2J'8QH4/(?S3_@C_\
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M;^-7P@_:?\9^$O"7C/\ LKP_I_V+[+9_V593;/,LH)7^>2%F.7=CRQQG X
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MY=^(_P#P6+\3W.J;/ /@/2=/T^*:9?M'B.:2[ENHLCR6\N%XA"V 2R[I1E@
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MPAILDHFAF14^UW*M!%'(C99E:$W; J!AHURPR%;TZU11HRGY$K<]7_X+0?\
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MVJ:Y;3MY>J31YVPQ!6"R6Z,=Q9@0[HC)A45Y"I-8RI&-+9;L$N579F_\$?\
M_DY;Q+_V*-S_ .EEE1_P6 _Y.6\-?]BC;?\ I9>T?\$?_P#DY;Q+_P!BC<_^
MEEE1_P %@/\ DY;PU_V*-M_Z67M:_P#,;\@^R?#5%%%>H9A7Z_\ [//_ "B5
MU7_L4?%'_HV_K\@*_7_]GG_E$KJO_8H^*/\ T;?UYV-^&/JBX[GYO_LE_&F?
MX!_'[PCXJ&H?V?I"W:6>LLWFO&VGRL$N"\<1#2;%/F*N&&^*-MK8 /Z=?\%
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MXC?]P[_TY6M?AI6.7?PGZ_HASW"BBBO4("BBB@ HHHH **** "BBB@ HHHH
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M*Q+.[NQ)9F)))))))))S5:BBRO< HHHI@%%%% !1110 4444 %%%% !1110
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M*-9\9:W<ZSK^KWVN:Q<;?.U#4KE[F>7:H1=TCDLV%55&2<  #H*S***$K:(
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M$&K>)=0AA$"7FL7TEW,D0+,$#R,6"@LS!0< LQZDUAT44)):( HHHH ****
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MY T\!_ 02W"BBBO0("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *_3+_@B__P UB_[@_P#[?5^9M?IE
M_P $7_\ FL7_ '!__;ZN'&_P)?+\T5'<^F?^"D__ "97\1O^X=_Z<K6OPTK]
MR_\ @I/_ ,F5_$;_ +AW_IRM:_#2L<N_A/U_1#GN%%%%>H0%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% ']#'[+__ ";3\)?^Q1TC_P!(HJ^&
M?^"T'_-'?^XQ_P"V-?<W[+__ ";3\)?^Q1TC_P!(HJ^&?^"T'_-'?^XQ_P"V
M-?-8;_>EZO\ 4VEL?F;1117TIB%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'IG[+_P#R<K\)/^QNTG_TLBK^AJOYY?V7_P#DY7X2?]C=I/\
MZ615_0U7@YC\<?0UCL?SR_M0?\G*_%O_ +&[5O\ TLEKS.O3/VH/^3E?BW_V
M-VK?^EDM>9U[=/X%Z&;"BBBK$%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?<O_!'_P#Y.6\2_P#8HW/_ *665?#5?<O_  1__P"3EO$O_8HW/_I9
M95RXK^#/T*CN?IG^U!_R;3\6O^Q1U?\ ](I:_GGK^AC]J#_DVGXM?]BCJ_\
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M^&7_ (-_]$E\#?\ A-V7_P ;KTZBCVD_YF!YC_PR_P#!O_HDO@;_ ,)NR_\
MC='_  R_\&_^B2^!O_";LO\ XW7IU%'M)_S,#S'_ (9?^#?_ $27P-_X3=E_
M\;H_X9?^#?\ T27P-_X3=E_\;KTZBCVD_P"9@>8_\,O_  ;_ .B2^!O_  F[
M+_XW1_PR_P#!O_HDO@;_ ,)NR_\ C=>G44>TG_,P/,?^&7_@W_T27P-_X3=E
M_P#&Z/\ AE_X-_\ 1)? W_A-V7_QNO3J*/:3_F8'F/\ PR_\&_\ HDO@;_PF
M[+_XW1_PR_\ !O\ Z)+X&_\ ";LO_C=>G44>TG_,P/,?^&7_ (-_]$E\#?\
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M7P-_X3=E_P#&Z/\ AE_X-_\ 1)? W_A-V7_QNO3J*/:3_F8'F/\ PR_\&_\
MHDO@;_PF[+_XW1_PR_\ !O\ Z)+X&_\ ";LO_C=>G44>TG_,P/,?^&7_ (-_
M]$E\#?\ A-V7_P ;H_X9?^#?_1)? W_A-V7_ ,;KTZBCVD_YF!YC_P ,O_!O
M_HDO@;_PF[+_ .-T?\,O_!O_ *)+X&_\)NR_^-UZ=11[2?\ ,P/,?^&7_@W_
M -$E\#?^$W9?_&Z/^&7_ (-_]$E\#?\ A-V7_P ;KTZBCVD_YF!YC_PR_P#!
MO_HDO@;_ ,)NR_\ C='_  R_\&_^B2^!O_";LO\ XW7IU%'M)_S,#S'_ (9?
M^#?_ $27P-_X3=E_\;H_X9?^#?\ T27P-_X3=E_\;KTZBCVD_P"9@>8_\,O_
M  ;_ .B2^!O_  F[+_XW1_PR_P#!O_HDO@;_ ,)NR_\ C=>G44>TG_,P/,?^
M&7_@W_T27P-_X3=E_P#&Z/\ AE_X-_\ 1)? W_A-V7_QNO3J*/:3_F8'F/\
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M>G44>TG_ #,#S'_AE_X-_P#1)? W_A-V7_QNC_AE_P"#?_1)? W_ (3=E_\
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M\,O_  ;_ .B2^!O_  F[+_XW7IU%'M)_S,#S'_AE_P"#?_1)? W_ (3=E_\
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M_P#1)? W_A-V7_QNC_AE_P"#?_1)? W_ (3=E_\ &Z].HH]I/^9@>8_\,O\
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MS \Q_P"&7_@W_P!$E\#?^$W9?_&Z/^&7_@W_ -$E\#?^$W9?_&Z].HH]I/\
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M?_@9'_C1_P )UX<_Z&#2_P#P,C_QH_M"C_S^7_@7_!#ZM6_Y]O[F<=_PR_\
M!O\ Z)+X&_\ ";LO_C='_#+_ ,&_^B2^!O\ PF[+_P"-UV/_  G7AS_H8-+_
M / R/_&C_A.O#G_0P:7_ .!D?^-']H4?^?R_\"_X(?5JW_/M_<SCO^&7_@W_
M -$E\#?^$W9?_&Z/^&7_ (-_]$E\#?\ A-V7_P ;KL?^$Z\.?]#!I?\ X&1_
MXT?\)UX<_P"A@TO_ ,#(_P#&C^T*/_/Y?^!?\$/JU;_GV_N9QW_#+_P;_P"B
M2^!O_";LO_C='_#+_P &_P#HDO@;_P )NR_^-UV/_"=>'/\ H8-+_P# R/\
MQH_X3KPY_P!#!I?_ (&1_P"-']H4?^?R_P# O^"'U:M_S[?W,X[_ (9?^#?_
M $27P-_X3=E_\;H_X9?^#?\ T27P-_X3=E_\;KL?^$Z\.?\ 0P:7_P"!D?\
MC1_PG7AS_H8-+_\  R/_ !H_M"C_ ,_E_P"!?\$/JU;_ )]O[F<=_P ,O_!O
M_HDO@;_PF[+_ .-T?\,O_!O_ *)+X&_\)NR_^-UV/_"=>'/^A@TO_P #(_\
M&C_A.O#G_0P:7_X&1_XT?VA1_P"?R_\  O\ @A]6K?\ /M_<SCO^&7_@W_T2
M7P-_X3=E_P#&Z/\ AE_X-_\ 1)? W_A-V7_QNNQ_X3KPY_T,&E_^!D?^-'_"
M=>'/^A@TO_P,C_QH_M"C_P _E_X%_P $/JU;_GV_N9QW_#+_ ,&_^B2^!O\
MPF[+_P"-T?\ #+_P;_Z)+X&_\)NR_P#C==C_ ,)UX<_Z&#2__ R/_&C_ (3K
MPY_T,&E_^!D?^-']H4?^?R_\"_X(?5JW_/M_<SCO^&7_ (-_]$E\#?\ A-V7
M_P ;H_X9?^#?_1)? W_A-V7_ ,;KL?\ A.O#G_0P:7_X&1_XT?\ "=>'/^A@
MTO\ \#(_\:/[0H_\_E_X%_P0^K5O^?;^YG'?\,O_  ;_ .B2^!O_  F[+_XW
M1_PR_P#!O_HDO@;_ ,)NR_\ C==C_P )UX<_Z&#2_P#P,C_QH_X3KPY_T,&E
M_P#@9'_C1_:%'_G\O_ O^"'U:M_S[?W,X[_AE_X-_P#1)? W_A-V7_QNC_AE
M_P"#?_1)? W_ (3=E_\ &Z['_A.O#G_0P:7_ .!D?^-'_"=>'/\ H8-+_P#
MR/\ QH_M"C_S^7_@7_!#ZM6_Y]O[F<=_PR_\&_\ HDO@;_PF[+_XW1_PR_\
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M?;^YG'?\,O\ P;_Z)+X&_P#";LO_ (W1_P ,O_!O_HDO@;_PF[+_ .-UV/\
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M_@W_ -$E\#?^$W9?_&Z/^&7_ (-_]$E\#?\ A-V7_P ;KL?^$Z\.?]#!I?\
MX&1_XT?\)UX<_P"A@TO_ ,#(_P#&C^T*/_/Y?^!?\$/JU;_GV_N9QW_#+_P;
M_P"B2^!O_";LO_C='_#+_P &_P#HDO@;_P )NR_^-UV/_"=>'/\ H8-+_P#
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M_P #(_\ &C^T*/\ S^7_ (%_P0^K5O\ GV_N9QW_  R_\&_^B2^!O_";LO\
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M^?R_\"_X(?5JW_/M_<SCO^&7_@W_ -$E\#?^$W9?_&Z/^&7_ (-_]$E\#?\
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M)NR_^-UV/_"=>'/^A@TO_P #(_\ &C_A.O#G_0P:7_X&1_XT?VA1_P"?R_\
M O\ @A]6K?\ /M_<SCO^&7_@W_T27P-_X3=E_P#&Z/\ AE_X-_\ 1)? W_A-
MV7_QNNQ_X3KPY_T,&E_^!D?^-'_"=>'/^A@TO_P,C_QH_M"C_P _E_X%_P $
M/JU;_GV_N9QW_#+_ ,&_^B2^!O\ PF[+_P"-T?\ #+_P;_Z)+X&_\)NR_P#C
M==C_ ,)UX<_Z&#2__ R/_&C_ (3KPY_T,&E_^!D?^-']H4?^?R_\"_X(?5JW
M_/M_<SCO^&7_ (-_]$E\#?\ A-V7_P ;H_X9?^#?_1)? W_A-V7_ ,;KL?\
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M ,#(_P#&C_A.O#G_ $,&E_\ @9'_ (T?VA1_Y_+_ ,"_X(?5JW_/M_<SCO\
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MUX<_Z&#2_P#P,C_QH_M"C_S^7_@7_!#ZM6_Y]O[F<=_PR_\ !O\ Z)+X&_\
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M^AE\"_\ @=>?_(E?L!11]?K>7W!RH_'_ /X<_?&3_H9? O\ X'7G_P B4?\
M#G[XR?\ 0R^!?_ Z\_\ D2OV HH^OUO+[@Y4?C__ ,.?OC)_T,O@7_P.O/\
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M1*_8"BCZ_6\ON#E1^/\ _P .?OC)_P!#+X%_\#KS_P"1*/\ AS]\9/\ H9?
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MAE\"_P#@=>?_ ")1_P .?OC)_P!#+X%_\#KS_P"1*_8"BCZ_6\ON#E1^/_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?$E%%%?R.?T0%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 =M\%O^2E:-_VV_P#1#U]2
MU\M?!;_DI6C?]MO_ $0]?4M?N7 O_(MJ?XW_ .DQ/ROBO_?8?X%^<@HHHK]&
M/BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS0!^BM%%% !1110 4451U;5K+0=+O-3U.\M].TRSA>YN;R[E6*&")%+.[NQ
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MXQ21,?O5[%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!\24445_(Y_1 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=)L=!_X*;?'_ $O3+.WT[3;.'Q!;6UG:1+%#!$FM6RHB(H"JJJ  H     H
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MTLF^1N22SL2222?S-_9[^)7B?_@F)^T;/\"/B)/I^J_#?Q1>PZC8Z]$\=O\
M9?/86\>H.68>7&?)$<\4C?N_)+QLP'[_ /6J@#\J_P!OK_E*9^SC_P!RY_Z?
M+BOU&U;5K+0=+O-3U.\M].TRSA>YN;R[E6*&")%+.[NQ 5%4$DD@  D\"OR.
M_P""J'@4?%#]OCX2>#?MW]F?\)%HVD:1]N\KS?L_VC5;N+S-FY=^W?G;N&<8
MR,YKT#PO_P $/=$M=>MI?$?Q;U#5=%7=]HL]+T)+&X?*D+LF>>94PVTG,;9
M(&,A@ >:_MK?$>Q_X*"_M?\ PW^#_P .-1M]0T/29I[$^(((E=&ED*R7]Q$S
M2JL\$,%JK+C:9&CEV%U>-C[I_P %J/B5_P (_P# _P &>"89]0MKKQ)K+WDO
MV:3;;SVMG'\\,V&!;,MS:R*I4KF(L2"BY^J?V;?V0?AK^ROH/V+P9H_FZK)Y
MJW/B34UCFU2X1V5C&\ZHN(QLC C0*F4#%2Y9C\K?\%J/AK_PD'P/\&>-H8-0
MN;KPWK+V<OV:/=;P6MY'\\TV%)7$MM:QJQ8+F4J02ZX /JC]BOPOIG@_]DCX
M16&D6WV.UE\,V.H/'O9]T]S$MS.^6)/S2S2-@' W8    ]MKQ+]BOQ1IGC#]
MDCX17^D7/VRUB\,V.GO)L9-L]M$MM.F& /RRPR+D#!VY!(()]MH **** "OS
M?U/2;WXV?\%EDM]1M-'GTGX9>'X;E8KF)B\L7V598I &#*TZ7FIHZM\@58E(
M^=06_2"OS*_8_P!-\0Z3_P %9/VA(/$[W#ZDVF:G/$US<B=_L<E_8260#!CA
M1;/ %3/R*%3"[=H /TUHHHH _*O_ ((8_P#-;/\ N"?^W]?JI7Y5_P#!#'_F
MMG_<$_\ ;^OU4H _.K_@L-\8M3M/ G@[X,>&8_[1UKQO>B>]T^R99[Q[>&6/
M[- +<(TG[^Y*E'4J2UHR#<&8#Z(TG]C_ $:;]B.S^ 6J?9[1&T!+.YNK22>>
M&+5"1.]VFYT>11>YG$9**0 A"J=H_+KXQ?%#Q_\ &K]O#Q/\4OASX&U#XH6O
M@G688-*M;&*]UK3H4M2T=K.&M&0K'++#)=(BL$9F;/F ON]^_P"&^OVW?^C<
M?_+'US_X_0!U7_!'+XQ7%MH/C?X'^(X]0L?$GAV]EU6TL=2:;?!;LR0W5L(F
M0"W\FX"LR%@6>[<A 5<G]*J_"/X9_&'QS^SW^VYH?QC^)W@+6/AGIOBO4[G^
MVK-K'4=.M+B*X 6\F5)Q+).L<LJ730@L-ZH%"?)M_=R@#\@/V7/AIH?QC_X*
M"?M7>"?$<'GZ+KEEXGLKC:B,\6[6K?;+'O5E62-MLB,5.UT5@,BO0/\ @E7X
MHU/X#_&3XJ_LW^-[G[#K-O>G4-+M7C6*"XGB'EW3PM($FE\Z 6LT8VD&&%Y
M%YW97[ O_*4S]H[_ +F/_P!/EO6K_P %.?"VJ? ']H[X2_M+^'[;_1;>]MM/
MU>WT^1;&2YN(&>54EG4EY/M-KYUNQ,;!8[<*Q8.J  _3'5M6LM!TN\U/4[RW
MT[3+.%[FYO+N58H8(D4L[N[$!450222  "3P*_,[]@^UN/VL?VY/BC^TC>:'
M]D\-Z?NL=#DF2:!UG>)+: X5FC>1+&-A,ID8*]U&RKAE*]__ ,%3/VG+32/V
M2?#EIX/UK_DI_E-;3I%<PRW&C>2L\TB,-GE[_,M(V23EH[B12A^8K]*?L;_
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M?#SX,/<?$7Q7XXAF\/F./3+N%+2*X3R6VQR1I)-.XDV1)&"-V68_*J2>;?\
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MK6EP)8W,F=1-\NQ'\Y4PVU#G=D GC/'YA_\ #%?@C_AY-_PSY_:OB#_A#/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^3V+S_L.:Q_Z!<U]T5\(_#N\M]-_;,U.ZNIX[:V@UC6I99IG"(BK'<EF9C@
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MV4VG@3:G PD9UBF\^<1RP>5(@BDB956..,*)%<,OZZ5R7CKX3^"/B?\ 8?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!\24445_(Y_1 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!VWP6_Y*5HW_;;_ -$/7U+7RU\%
MO^2E:-_VV_\ 1#U]2U^Y<"_\BVI_C?\ Z3$_*^*_]]A_@7YR"BBBOT8^+"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.^(_Q"M?A
M_HZW#J+F^F.VWM=VW?ZD^@'\R!WR.AUK5K70=+N=0O9/*M;=#([?T'J3T [D
MBO'/ >DW7Q8\92^,-8CQI5J_EV5JW0E>5'N%SDGNQ],@- >P>']0GU31;*\N
M;9K*XGB61[=FR4)&<=OU /K6G112 **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>,;Z;[7J>LXMH)9&\QX;2 ^4L8++N7+(05#%=L</3;BG_MS?\DFTC_L-P_\
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M?Z7H$2QM<QIYM[-'@^=<OS(V[:I8 _*I(SL5 >E?$7[2'A,_#/XV7W]CVO\
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M]]WY>G%=910 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?$E%%%?R.?T0%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB"_&1DUNZ'^QCXE\0>*FO_'_ (GCOK5T)FN+&[EGO9G"A4!>:,   #YCN.%
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MUM].CM&6^FD1]ZR2N2 L;#&''?U_'FO^&=_CQ_T4W_ROW_\ \11_PSO\>/\
MHIO_ )7[_P#^(KGPU&&%J>UI8B-_0TJ3E6CRSINQ]<U\G_&[]E7Q9\2/B=K/
MB/3-0T:"RO/)\J.[GE60;((XSD+$1U4D8)XQT[5O^&=_CQ_T4W_ROW__ ,11
M_P ,[_'C_HIO_E?O_P#XBJPM.&#FZE+$1NU;8563K1Y9TV?0'Q<^%NF_%WP=
M-H6HRR6S"07%K=1#)MYE#!7VY 889@5/4,<$'##Y4T;]E_XQ^#]:^P:%K,>F
M6MX@>XU+3=7D@@!7?M60 +(Q';",!Y@Y'S8ZO_AG?X\?]%-_\K]__P#$4?\
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M+HWBS[=X=FF:T6S@U.>"-+=RVZ26%L*$()+HA<DL<!N36S_PSO\ 'C_HIO\
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M =6BT_4+:^FFEA$ZM;1HR[2S+_$X.<J>V.E<_P#\-*>&?^?'5O\ OS%_\<H
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M_M**N=^[&-K'^Z>N.U6_''CBQ\!Z3%J&H17$T,DX@5;95+9*LW\3 8PI[^E
M'245Y+_PTIX9_P"?'5O^_,7_ ,<KT'PIXDM?&&@VVKV<<T5O<;MBS*%?Y6*'
M(!(ZJ>] &S17"^-OBYH_@'5HM/U"VOIII81.K6T:,NTLR_Q.#G*GMCI7/_\
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M&E/#/_/CJW_?F+_XY6KX5^-VA^+]>M=(L[34([FXW;&N(XPGRJ7.2')Z*>U
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MGB2U\8:#;:O9QS16]QNV+,H5_E8H<@$CJI[T?4\-_P ^X_<@^LU_YW][(_\
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MI^H6U]--+")U:VC1EVEF7^)P<Y4]L=*/J>&_Y]Q^Y!]9K_SO[V;O_""^'/\
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M>1S2V]OMWK"H9_F8(, D#JP[T?4\-_S[C]R#ZS7_ )W][(_^$%\.?]"_I?\
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MIX;_ )]Q^Y!]9K_SO[V=1_P@OAS_ *%_2_\ P#C_ ,*/^$%\.?\ 0OZ7_P"
M<?\ A7&:3^T#X>UK5K+3X;/5%FNIT@1I(HP 68*,XD)QD]A7J%'U/#?\^X_<
M@^LU_P"=_>S"_P"$%\.?]"_I?_@''_A1_P (+X<_Z%_2_P#P#C_PK@O^&E/#
M/_/CJW_?F+_XY70>"?BYH_C[5I=/T^VOH9HH3.S7,:*NT,J_PN3G+#MCK1]3
MPW_/N/W(/K-?^=_>S=_X07PY_P!"_I?_ (!Q_P"%'_""^'/^A?TO_P  X_\
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M,NTLR_Q.#G*GMCI1]3PW_/N/W(/K-?\ G?WLW?\ A!?#G_0OZ7_X!Q_X4?\
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M3VQTKG_^&E/#/_/CJW_?F+_XY1]3PW_/N/W(/K-?^=_>SO?^$%\.?]"_I?\
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MW%6_"OQNT/Q?KUKI%G::A'<W&[8UQ'&$^52YR0Y/13VH^IX;_GW'[D'UFO\
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MT+^E_P#@''_A6%XV^+FC^ =6BT_4+:^FFEA$ZM;1HR[2S+_$X.<J>V.E<_\
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M8Z4?4\-_S[C]R#ZS7_G?WLW?^$%\.?\ 0OZ7_P" <?\ A1_P@OAS_H7]+_\
M ./_  K@O^&E/#/_ #XZM_WYB_\ CE>M4?4\-_S[C]R#ZS7_ )W][,+_ (07
MPY_T+^E_^ <?^%'_  @OAS_H7]+_ / ./_"N"_X:4\,_\^.K?]^8O_CE:OA7
MXW:'XOUZUTBSM-0CN;C=L:XCC"?*I<Y(<GHI[4?4\-_S[C]R#ZS7_G?WLZJS
M\*:+I]REQ:Z1I]M/'DI+#;(CKD8."!D9!(_&MNL;Q7XDM?!^@W.KWD<TMO;[
M=ZPJ&?YF"# ) ZL.]>??\-*>&?\ GQU;_OS%_P#'*WITH4ERTXI+R5C*4Y5'
M>;NSUJBN0\!_$G2_B']N_LV"\@^Q[-_VE%7._=C&UC_=/7':CQY\2=+^'GV'
M^TH+R?[9OV?9D5L;-N<[F']X=,]ZU(.OHKR7_AI3PS_SXZM_WYB_^.5Z#X4\
M26OC#0;;5[..:*WN-VQ9E"O\K%#D D=5/>@#9HKSKQ5\;M#\(:]=:1>6FH27
M-OMWM;QQE/F4.,$N#T8=JRO^&E/#/_/CJW_?F+_XY0!ZU117DO\ PTIX9_Y\
M=6_[\Q?_ !R@#UJBO.O"OQNT/Q?KUKI%G::A'<W&[8UQ'&$^52YR0Y/13VKK
M/%?B2U\'Z#<ZO>1S2V]OMWK"H9_F8(, D#JP[T ;-%>2_P##2GAG_GQU;_OS
M%_\ '*ZOP'\2=+^(?V[^S8+R#['LW_:45<[]V,;6/]T]<=J .OHKD/'GQ)TO
MX>?8?[2@O)_MF_9]F16QLVYSN8?WATSWKE/^&E/#/_/CJW_?F+_XY0!ZU16-
MX4\26OC#0;;5[..:*WN-VQ9E"O\ *Q0Y )'53WKD_%7QNT/PAKUUI%Y::A)<
MV^W>UO'&4^90XP2X/1AVH ]%HKR7_AI3PS_SXZM_WYB_^.5ZU0 45Y+_ ,-*
M>&?^?'5O^_,7_P <K5\*_&[0_%^O6ND6=IJ$=S<;MC7$<83Y5+G)#D]%/:@#
MT6BL;Q7XDM?!^@W.KWD<TMO;[=ZPJ&?YF"# ) ZL.]>??\-*>&?^?'5O^_,7
M_P <H ]:HKD/ ?Q)TOXA_;O[-@O(/L>S?]I15SOW8QM8_P!T]<=J/'GQ)TOX
M>?8?[2@O)_MF_9]F16QLVYSN8?WATSWH Z^BO)?^&E/#/_/CJW_?F+_XY7H/
MA3Q):^,-!MM7LXYHK>XW;%F4*_RL4.0"1U4]Z -FBO.O%7QNT/PAKUUI%Y::
MA)<V^W>UO'&4^90XP2X/1AVJII/[0/A[6M6LM/AL]46:ZG2!&DBC !9@HSB0
MG&3V% 'J%%%>2_\ #2GAG_GQU;_OS%_\<H ]:HKA?!/Q<T?Q]JTNGZ?;7T,T
M4)G9KF-%7:&5?X7)SEAVQUKH?%?B2U\'Z#<ZO>1S2V]OMWK"H9_F8(, D#JP
M[T ;-%8WA3Q):^,-!MM7LXYHK>XW;%F4*_RL4.0"1U4]ZV: "BBB@ HHHH B
MDC69&1U#*PP5;H0:\*UC3[_X$^*O[6TY6N?"]\^V:W_YY=\9]1R5)ZC(/<GW
MJJ.JZ7:ZSI\]E>PK/;3H8W1NX_H1USU%,!-'UBSUS3H+^RG6>VG&Y9%_D?0C
MI@]#5^O!=,O;[X#^*O[-OWDNO">H/NBFV_ZH],_[PX#*.HP1V%>WR:E:QZ:U
M^T\8LUB\[S]WR>7C.[/ICG- &+X[\:6O@70)]1N,-)]RWASS+(>@^G<GT!KA
MO@[X,NKJZG\:Z]^\U34,R6ZM_ C?QX[9' ]%^H Q-)MYOCIXY;4KI&7POIC;
M8H6_Y:G.=I]VZMZ# ]#7NRJJ(H"[0.BT; /HHHI %%%% !1110 4444 9VKV
MOVBU+)_K(OF7^H_SW I=(OQJ%FKC_6+\K_7U_'K6A7*VD_\ 9'BJ6T;Y8;C[
MGX\CZ <@4 =51110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !117'_&#_ ))+XU_[ E]_Z3O5PCSS4>Y,I<J;.PHK\P?A3\*M7^+_
M (BN='T>ZL[6Z@M6NV:^D=$VJZ(0"J,<Y<=L8SSZ^H7G[$7CZVLYYXK[0KR1
M$9Q;P7<H>4@9"J6B R>G+ 9/)'6OI*N4X:A/DJXE)^G_  3S88RI47-&E=>O
M_ /NZBO@70_CQ\5/@?XB;2_%'VS4H]YDET_7V9W==X5GAG)+8/ELJD%H^6(5
MJ^T_ 'Q T;XE>&K;7-#N?/M)OE>-L"6"0 ;HI%R=K#(XR00002""?+QF7U<&
ME-^]%]5L=5'$0K72T:Z,Z>BBBO,.H**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ***R?$F@VWBCP[JNC73R1VVHVLM
MI*T) <)(A0E200#@G&1UIJU]=A/;0PO!_P 6/"/C_5M1TO0-<M]2OM/.9XHP
MPX#;2R$@"1,\;D++\R\_,,]G7S+\#?V3[_X:_$5O$6KZS;WD-AYBZ='9!@9=
MZO&6F#+A,(V=JEOF;[V%^;Z:KLQE/#TJO+AI\T;+[_Z_R,:,JDH7JJS"BBBN
M(W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P/^$!\,?]"YI/\
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M!/AZTGBG@T'3(9HF#I)'9QJR,#D$$+D$'G([UNT4 %8'_" ^&/\ H7-)_P#
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M@A<C()!^M;-% %2^L+;5+9K:\MH;NW?!>&>,.C8.1D$$'! /U%9?_" ^&/\
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MP2/Q-9W_  @/AC_H7-)_\ 8O_B:WZ* *.EZ/8:+;M#IUE;V,+-O,=K$L:EB
M,X4 9P /P%5]2\+Z-K5P)]0TJQOI@NP27%NDC!02<989QDDX]S6M10!@?\(#
MX8_Z%S2?_ &+_P")K7M[>*UMXH88E@AB4)''&H544#   X  XP*L44 84_@G
MP]=SRSSZ#IDTTK%WDDLXV9V)R225R23SD]Z(/!/AZTGBG@T'3(9HF#I)'9QJ
MR,#D$$+D$'G([UNT4 5[BWBNK>6&:)9X95*21R*&5U(P00>"".,&LC_A ?#'
M_0N:3_X Q?\ Q-;]% &3IOA?1M%N#/I^E6-C,5V&2WMTC8J2#C*C.,@''L*L
M:IH]AK5NL.HV5O?0JV\1W42R*& (SA@1G!(_$U>HH P/^$!\,?\ 0N:3_P"
M,7_Q-:EC86VEVRVUG;0VENF2D,$81%R<G   &22?J:MT4 9.I>%]&UJX$^H:
M58WTP78)+BW21@H).,L,XR2<>YJM_P (#X8_Z%S2?_ &+_XFM^B@ K"G\$^'
MKN>6>?0=,FFE8N\DEG&S.Q.222N22><GO6[10!C6/A'0]-NDN;/1M/M+A,[)
MH+1$=<C!P0N1D$@_6M&XMXKJWEAFB6>&52DD<BAE=2,$$'@@CC!JQ10!@?\
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M\T;3[NX?&^:>T1W; P,DKDX  'TJ'_A ?#'_ $+FD_\ @#%_\36_10 5@?\
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M7)R<   9))^IJW10!C7WA'0]2NGN;S1M/N[A\;YI[1'=L# R2N3@  ?2H?\
MA ?#'_0N:3_X Q?_ !-;]% !6!_P@/AC_H7-)_\  &+_ .)K?HH QK'PCH>F
MW27-GHVGVEPF=DT%HB.N1@X(7(R"0?K5Z^L+;5+9K:\MH;NW?!>&>,.C8.1D
M$$'! /U%6Z* ,#_A ?#'_0N:3_X Q?\ Q-7M+T#3-#,G]FZ=9Z?YN-_V6!8]
M^,XSM SC)_,^M:-% &=JF@:9KAC_ +2TZSU#RL[/M4"R;,XSC<#C.!^0]*H_
M\(#X8_Z%S2?_  !B_P#B:WZ* *]O;Q6MO%##$L$,2A(XXU"JB@8  '  '&!6
M=?>$=#U*Z>YO-&T^[N'QOFGM$=VP,#)*Y.  !]*V:* ,*#P3X>M)XIX-!TR&
M:)@Z21V<:LC Y!!"Y!!YR.];M%% &!_P@/AC_H7-)_\  &+_ .)JSIOA?1M%
MN#/I^E6-C,5V&2WMTC8J2#C*C.,@''L*UJ* *E]86VJ6S6UY;0W=N^"\,\8=
M&P<C(((." ?J*R_^$!\,?]"YI/\ X Q?_$UOT4 4=+T>PT6W:'3K*WL86;>8
M[6)8U+$ 9PH S@ ?@*9JF@:9KAC_ +2TZSU#RL[/M4"R;,XSC<#C.!^0]*T:
M* ,#_A ?#'_0N:3_ . ,7_Q-:]O;Q6MO%##$L$,2A(XXU"JB@8  '  '&!5B
MB@#&OO".AZE=/<WFC:?=W#XWS3VB.[8&!DE<G   ^E1P>"?#UI/%/!H.F0S1
M,'22.SC5D8'(((7((/.1WK=HH *P/^$!\,?]"YI/_@#%_P#$UOT4 9.F^%]&
MT6X,^GZ58V,Q789+>W2-BI(.,J,XR <>PJW?6%MJELUM>6T-W;O@O#/&'1L'
M(R""#@@'ZBK=% &!_P (#X8_Z%S2?_ &+_XFM'2]'L-%MVATZRM[&%FWF.UB
M6-2Q &<* ,X 'X"KU% &=JF@:9KAC_M+3K/4/*SL^U0+)LSC.-P.,X'Y#TJC
M_P (#X8_Z%S2?_ &+_XFM^B@"O;V\5K;Q0PQ+!#$H2..-0JHH&  !P !Q@5E
M3^"?#UW/+//H.F332L7>22SC9G8G)))7))/.3WK=HH PH/!/AZTGBG@T'3(9
MHF#I)'9QJR,#D$$+D$'G([UJW%O%=6\L,T2SPRJ4DCD4,KJ1@@@\$$<8-6**
M ,#_ (0'PQ_T+FD_^ ,7_P 35G3?"^C:+<&?3]*L;&8KL,EO;I&Q4D'&5&<9
M ./85K44 4=4T>PUJW6'4;*WOH5;>([J)9%# $9PP(S@D?B:SO\ A ?#'_0N
M:3_X Q?_ !-;]% %'2]'L-%MVATZRM[&%FWF.UB6-2Q &<* ,X 'X"J^I>%]
M&UJX$^H:58WTP78)+BW21@H).,L,XR2<>YK6HH P/^$!\,?]"YI/_@#%_P#$
MUKV]O%:V\4,,2P0Q*$CCC4*J*!@  <  <8%6** ,*?P3X>NYY9Y]!TR::5B[
MR26<;,[$Y))*Y))YR>]$'@GP]:3Q3P:#ID,T3!TDCLXU9&!R""%R"#SD=ZW:
M* *]Q;Q75O+#-$L\,JE)(Y%#*ZD8((/!!'&#61_P@/AC_H7-)_\  &+_ .)K
M?HH R=-\+Z-HMP9]/TJQL9BNPR6]ND;%20<949QD X]A5C5-'L-:MUAU&RM[
MZ%6WB.ZB610P!&<,",X)'XFKU% &!_P@/AC_ *%S2?\ P!B_^)K1TO1[#1;=
MH=.LK>QA9MYCM8EC4L0!G"@#. !^ J]10!DZEX7T;6K@3ZAI5C?3!=@DN+=)
M&"@DXRPSC))Q[FJW_" ^&/\ H7-)_P# &+_XFM^B@"O;V\5K;Q0PQ+!#$H2.
M.-0JHH&  !P !Q@5E3^"?#UW/+//H.F332L7>22SC9G8G)))7))/.3WK=HH
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MX0'PQ_T+FD_^ ,7_ ,36I8V%MI=LMM9VT-I;IDI#!&$1<G)P  !DDGZFK=%
M&-?>$=#U*Z>YO-&T^[N'QOFGM$=VP,#)*Y.  !]*A_X0'PQ_T+FD_P#@#%_\
M36_10 5@?\(#X8_Z%S2?_ &+_P")K?HH QK'PCH>FW27-GHVGVEPF=DT%HB.
MN1@X(7(R"0?K5Z^L+;5+9K:\MH;NW?!>&>,.C8.1D$$'! /U%6Z* ,#_ (0'
MPQ_T+FD_^ ,7_P 35[2] TS0S)_9NG6>G^;C?]E@6/?C.,[0,XR?S/K6C10!
MG:IH&F:X8_[2TZSU#RL[/M4"R;,XSC<#C.!^0]*H_P#" ^&/^A<TG_P!B_\
MB:WZ* *EC86VEVRVUG;0VENF2D,$81%R<G   &22?J:HWWA'0]2NGN;S1M/N
M[A\;YI[1'=L# R2N3@  ?2MFB@# _P"$!\,?]"YI/_@#%_\ $UOT44 8'_"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%9PW6&3S\%I&;:ZJ5PTA7!!SLR#S7W/\'_\ DDO@K_L"6/\ Z3I7BOC3X6_
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M^(=FNLQW5M=K#'K=F(-\ 0(-I4M@^6,_-GDX(XQZQ_PN#P)_T.WAW_P:V_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P #9/\ XJC_ (3GQ%_T,&J?^!LG_P 56)11]<Q/_/V7WL/JU#_GVON1M_\
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M $,&J?\ @;)_\56)11]<Q/\ S]E][#ZM0_Y]K[D;?_"<^(O^A@U3_P #9/\
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ME%'US$_\_9?>P^K4/^?:^Y&W_P )SXB_Z&#5/_ V3_XJC_A.?$7_ $,&J?\
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M/^?:^Y&W_P )SXB_Z&#5/_ V3_XJC_A.?$7_ $,&J?\ @;)_\56)11]<Q/\
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M ,_9?>P^K4/^?:^Y&W_PG/B+_H8-4_\  V3_ .*H_P"$Y\1?]#!JG_@;)_\
M%5B44?7,3_S]E][#ZM0_Y]K[D;?_  G/B+_H8-4_\#9/_BJ/^$Y\1?\ 0P:I
M_P"!LG_Q58E%'US$_P#/V7WL/JU#_GVON1M_\)SXB_Z&#5/_  -D_P#BJ/\
MA.?$7_0P:I_X&R?_ !58E%'US$_\_9?>P^K4/^?:^Y&W_P )SXB_Z&#5/_ V
M3_XJC_A.?$7_ $,&J?\ @;)_\56)11]<Q/\ S]E][#ZM0_Y]K[D;?_"<^(O^
MA@U3_P #9/\ XJC_ (3GQ%_T,&J?^!LG_P 56)11]<Q/_/V7WL/JU#_GVON1
M]MT445_5I_/X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJV^N>'=5A$]I?6S'9(N2""" RLK JR, RLK*P!!%']IXW_GZP^JT?Y4>+?\
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M);M?,$JQL6(W1I)RNW[SQJY_:>-_Y^L/JM'^5'%_\,-^ _\ H+^(O_ FW_\
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M[3QO_/UA]5H_RH^<_P#AAOP'_P!!?Q%_X$V__P 8H_X8;\!_]!?Q%_X$V_\
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M<_\ AAOP'_T%_$7_ ($V_P#\8H_X8;\!_P#07\1?^!-O_P#&*^C**/[3QO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'Q)1117\CG]$!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'VW1117]<'\[A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;VN6$*O,6>.3;+'=0J(VVK';Q@ #:S?:U?G_ /LW_P#%"_\ !57]HOP;H?\
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M^<ZW^?\ H6* /N?]LKXTZW^SO^S=XO\ B#X<M=/OM9T?['Y$&J1O);MYMY!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /MNBBBOZX/YW"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(Y1U*L,@@@D5])Z3I-EH.EV>F:99V^G:99PI;6UG:1+%#!$BA41$4 *BJ
M    .!0!Y7^UY\7I?@3^S5\0?&UI)<0:EIVF-%I]Q;11S/#>3LMO;2%)/E94
MFEC9@0?E5OE;[I\@_P""5/PT_P"%>?L<>'+N6#4+._\ %%[=:]<V^H)LV[W$
M$+1*5!$;V]O;R*3NW>86!VLH'TI\4/A?X7^-'@34_!OC+3?[9\-ZEY7VNQ^T
M2P>;Y<J2I\\3*XP\:'AAG&#D$@ZGA3POI?@;PKHWAS1+;[#HNCV4.GV-KYC2
M>5!%&(XTW,2S850,L23C))YH V:*** "OS_^,G_*9+X$_P#8F7/_ *)UFOT
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M(+3P%:V:P-<17^HVUQ9;%98X8+%+@Q-&H6)0?/CP&;"_( P!E?\ !7SXE?\
M"QM=^&?P#\(SZ?KGBB^UJ.]O=-C?%S;W4BB#3XFE9A%'YHNIR5<[@!"YV*P+
M_9'QN\%V/PU_8<\?>$-,EN)]-T#X<ZAI5K+=LK3/%!IDD2%RJA2Q5020H&<X
M Z5Y_P#L@_\ !.7P'^RCJO\ PDYU"X\:>.O):!-:O[=(8;-69PQM8 6,3-&R
MH[L[L0K!2BR.A^BOBQX%_P"%H?"WQCX-%]_9H\1:->:1]N\KSOL_VB!XO,V;
MEW[=^=NX9QC(SF@#XL_X(J_\FL^*?^QSNO\ TAL:\K_;Z_Y2F?LX_P#<N?\
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MK_Z0WU?7OP,^!GA']G3X<Z?X*\%Z?]ATFU^>6:3#W%Y.P >XG< ;Y&P,G
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M.B_<- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'Q)1117\CG]$!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'VW1117]<'\[A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%-"DT;)(JR(W56&1
M^58%Y\._#-\S-+H=CN;JT<(0G\5Q7244 <?_ ,*E\)'_ )@T?_?V3_XJI[7X
M8^%+-U=-!LV93N5I(_,_]"S74T4 06MK#9Q^5;P1P1C^&-0H_(5/110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!SGB+X>^%O&.JZ-JFO^&='UO4=%G^TZ5>:E8Q7$UA+N1M\#NI,3;H
MT.4(.44]ACHZ** "BBB@ HHHH **** "BBB@ HHHH **** "N<\1?#WPMXQU
M71M4U_PSH^MZCHL_VG2KS4K&*XFL)=R-O@=U)B;=&ARA!RBGL,='10 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /MNBBBOZX/YW"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>J44?ZNY3_T#Q#^V<P_Y_,\K_P"&=_#G_/\ :I_W]B_^-T?\,[^'/^?[5/\
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M>J44?ZNY3_T#Q#^V<P_Y_,\K_P"&=_#G_/\ :I_W]B_^-T?\,[^'/^?[5/\
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M>J44?ZNY3_T#Q#^V<P_Y_,\K_P"&=_#G_/\ :I_W]B_^-T?\,[^'/^?[5/\
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M>J44?ZNY3_T#Q#^V<P_Y_,\K_P"&=_#G_/\ :I_W]B_^-T?\,[^'/^?[5/\
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M>J44?ZNY3_T#Q#^V<P_Y_,\K_P"&=_#G_/\ :I_W]B_^-T?\,[^'/^?[5/\
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M>J44?ZNY3_T#Q#^V<P_Y_,\K_P"&=_#G_/\ :I_W]B_^-T?\,[^'/^?[5/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5 'Z 45^?_\ P[C^-_\ T>A\0/\ OW??_+*C_AW'\;_^CT/B!_W[OO\ Y94
M?H!17Y__ /#N/XW_ /1Z'Q _[]WW_P LJ/\ AW'\;_\ H]#X@?\ ?N^_^65
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M_P!'H?$#_OW??_+*C_AW'\;_ /H]#X@?]^[[_P"65 'Z 45^?_\ P[C^-_\
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M5 'Z 45^?_\ P[C^-_\ T>A\0/\ OW??_+*C_AW'\;_^CT/B!_W[OO\ Y94
M?H!17Y__ /#N/XW_ /1Z'Q _[]WW_P LJ/\ AW'\;_\ H]#X@?\ ?N^_^65
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M_P!'H?$#_OW??_+*C_AW'\;_ /H]#X@?]^[[_P"65 'Z 45^?_\ P[C^-_\
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M5 'Z 45^?_\ P[C^-_\ T>A\0/\ OW??_+*C_AW'\;_^CT/B!_W[OO\ Y94
M?H!17Y__ /#N/XW_ /1Z'Q _[]WW_P LJ/\ AW'\;_\ H]#X@?\ ?N^_^65
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M_P!'H?$#_OW??_+*C_AW'\;_ /H]#X@?]^[[_P"65 'Z 45^?_\ P[C^-_\
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M5 'Z 45^?_\ P[C^-_\ T>A\0/\ OW??_+*C_AW'\;_^CT/B!_W[OO\ Y94
M?H!17Y__ /#N/XW_ /1Z'Q _[]WW_P LJ/\ AW'\;_\ H]#X@?\ ?N^_^65
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M_P!'H?$#_OW??_+*C_AW'\;_ /H]#X@?]^[[_P"65 'Z 45^?_\ P[C^-_\
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M5 'Z 45^?_\ P[C^-_\ T>A\0/\ OW??_+*C_AW'\;_^CT/B!_W[OO\ Y94
M?H!17Y__ /#N/XW_ /1Z'Q _[]WW_P LJ/\ AW'\;_\ H]#X@?\ ?N^_^65
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M_P!'H?$#_OW??_+*C_AW'\;_ /H]#X@?]^[[_P"65 'Z 45^?_\ P[C^-_\
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M5 'Z 45^?_\ P[C^-_\ T>A\0/\ OW??_+*C_AW'\;_^CT/B!_W[OO\ Y94
M?H!17Y__ /#N/XW_ /1Z'Q _[]WW_P LJ/\ AW'\;_\ H]#X@?\ ?N^_^65
M'Z 45^?_ /P[C^-__1Z'Q _[]WW_ ,LJ/^'<?QO_ .CT/B!_W[OO_EE0!^@%
M%?G_ /\ #N/XW_\ 1Z'Q _[]WW_RRH_X=Q_&_P#Z/0^('_?N^_\ EE0!^@%%
M?G__ ,.X_C?_ -'H?$#_ +]WW_RRH_X=Q_&__H]#X@?]^[[_ .65 'Z 45^?
M_P#P[C^-_P#T>A\0/^_=]_\ +*C_ (=Q_&__ */0^('_ '[OO_EE0!^@%%?G
M_P#\.X_C?_T>A\0/^_=]_P#+*C_AW'\;_P#H]#X@?]^[[_Y94 ?H!17Y_P#_
M  [C^-__ $>A\0/^_=]_\LJ/^'<?QO\ ^CT/B!_W[OO_ )94 ?H!17Y__P##
MN/XW_P#1Z'Q _P"_=]_\LJ/^'<?QO_Z/0^('_?N^_P#EE0!^@%%?G_\ \.X_
MC?\ ]'H?$#_OW??_ "RH_P"'<?QO_P"CT/B!_P!^[[_Y94 ?H!17Y_\ _#N/
MXW_]'H?$#_OW??\ RRH_X=Q_&_\ Z/0^('_?N^_^65 'Z 45^?\ _P .X_C?
M_P!'H?$#_OW??_+*C_AW'\;_ /H]#X@?]^[[_P"65 'Z 45^?_\ P[C^-_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***X'XH?$K_
M (06UMK>RBCO-:NF'D6[J2,9P68*0>>@ ZG/I0!WU%9VA37\^CV4NIQ1P:@\
M2M<1Q9V(Y'(&2>GU/]:T: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW04445SF@4444 %%%% !16/XEU.XT7P]JNHVME)J=U:6LL\5C#G?<.B%EC7
M)RQ 7@'KT-?,/[./[1GC;XA?%&31-;CCU+3KY)9_]'MQ&--"!F!!49,9)6/Y
MR3ED^;.0W;1P=7$4IUH6M#<PJ5HTYQA+=GUM1117$;A1110 4444 %%%% !1
M110 45\G_LJ?&[QI\2?B'J&F>(]9_M"QATN2Y2'[+!%B02PJ#E$!Z,PP3CGI
MQQW'[5GQ<\2?"WPSI'_".P^1+J4[)+JS1"06NP*P0*RE=S@MRV<*CX'\2^I/
M+JT,4L)=<S^XY(XF$J3K=#WBBO*?V<?B+K/Q/^&EMJ^NVGDWT4SVOVI8RB7H
M0+^_5< #))4[<KN1L8^ZOJU<%:E*C4E3GNM#HA)5(J2V84445D6%%%% !111
M0 4444 %%?)_@/XV>-=:_:AN?"-YK/G^'H]5U*V6S^RPK^[B6<QC>$#?*47G
M=DXYSGGZPKLQ6%GA)1C-K5)Z>9A2K1K)N/1V"BBBN,W"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHJ.218T9W8*JC)9N@% &7XJ\36?A+0[G4[UML,(^5?
MXG;LH]S_ (D]*\N^%7AN]\:>()_'.OKN:1S]AMV^ZN. P!_A7H/<$]@3GWTT
M_P =O'BV<#-'X5TIMSR+_P M3G&?JV"!Z $^H/N-M;16=O%!!&L4,2A$C5<!
M5 P !Z"F!8HHHI %%%% !1153;);/\OS0G^'N#[>WM^5 %NBFJV[D=*=0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR0\[0"$2)U"KD$@'<PW$%C@8\O#1PEG+%-^D;?J==5UKVI6]6;O@?]IOX?\
MCJ\T^PM=6DL=6OG,4=AJ%NT;[LD*I< QY; V@.<[E'WCBO6Z_/\ _:B\"^ _
M!.K:-%X)GMUF;[1!J-C;:A]I^SR1L@7>&9FC8EG!!./W8P!AL_6O[//BB_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110![C^Q+
M_P G.>#/^WS_ -(IZ_56ORJ_8E_Y.<\&?]OG_I%/7ZJU\/G?^\1_P_JSUL)\
M#]?T04445\^=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%-*D$+RNVU$
M!9F]AR:Q/"?C72O&EG+<Z7<>:L3^6\;#:Z'MD>A['Z]P0.@KPWQQX9U#X4^(
MO^$N\-KNTR4[;VQ_@7)Z8'\![?W3C'7 8'N5%8WA;Q-9>+M%@U*PDWQ2CYE[
MHW=6]Q_@1P:V:0!7CWQ@\87FJWT'@C0/WNH7C!;IE;[BGG83VR.6/8>N3CKO
MB=\0(? /A]IP5?4)\QVL+=V[L1_=7K[\#C.:PO@YX!ET6VD\0ZONDU[409&:
M3[T2,<X.?XFZG\!QSE^8'7^!_!]IX'\/P:;:_.R_---WED/5C_(#L *Z&BBD
M 4444 %%%% !36 9<'H:=10!G+-]CN?*D;Y'^XS>_P#G'Y'G)QHU1U6S^UV;
M ?ZQ?F3Z^GX]*BT34?MUK\W^MC^5O?T/X_S!H TZ*** "BBB@ HHHH ****
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MQ.6/0>FL1B,70IRP-1)I6DG;R[IZ'-[.G1J25>-T]F=?_P ,"_\ 4]?^4?\
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M,D.BZ%%%/>+ -P-Q(KR(J1[EV LP+-NVA@DA7XXD_P""I?Q\^+.E6VJ?!_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*R0@13$,S.2K2JY!+9P1TZ#@*JG-5(J:Z@URMH****LD**** "BBB@ HHHH
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M .+KZYHH^O4/^@>/XA]7J?\ /QGR-_PT1\>/^B9?^4"__P#BZ/\ AHCX\?\
M1,O_ "@7_P#\77US11]>H?\ 0/'\0^KU/^?C/D;_ (:(^/'_ $3+_P H%_\
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MM+L]3TR\M]1TR\A2YMKRTE66&>)U#(Z.I(9&4@@@D$$$<&@#\H_^"D?BC2_
MO_!2+X&>(];N?L.C:/9Z%J%]=;&D\J"+6+J21]J@LV%4G"@DXX!KZTU;_@JA
M^S3IVEWEY;^/;C5;B"!YHK&TT*_6:X95)$:&2!$#L1@%V5<D98#)KY+_ ."D
M?A?2_'7_  4B^!GAS6[;[=HVL6>A:??6N]H_-@EUBZCD3<I#+E6(RI!&>"*^
MT_"__!.']F_P?KUKJ]A\+M/GNK?=LCU2\N]0MSN4H=\%Q,\3\,2-RG!PPP0"
M #X-C;Q3_P %6/VOO#FLS^%M8TSX&>'9VMFDG64VHMH2)I8Y9%E6-;NZ+P1L
ML#;XT>(_O! 7;U7_ (+>>-+ZQ\ _"SPC'%;MINJZG>ZM/*RMYRRVD4<484[L
M!2M[*6!!)*I@C!!_1SPOX3T/P/H-MHGAO1=/\/Z+:[OL^FZ7:QVUO%N8NVR-
M %7+,S' Y+$GK7Q9_P %AOAI_P )?^RI%XF@M]/%WX2UJVO9;JX3_2!:SYM7
MBA8*3\TLUJS*2JD0@DDHH(!]*_LG_P#)K/P;_P"Q,T;_ -(8:]6KY=_X)T?'
MCP]\:OV7?!MEIES;Q:YX3TRUT'5M)6<O-;-!'Y4,K JIVSQQ"12 5!+H&9HV
MQ]14 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X<T445^L'S@4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:?._^01:G5E-/2QX#\.?V!?'_C+1)]2UF>U\([[=I+*TU!3)<3R%5:,2HO\
MJ4;<0Q),BE2#'TKR3XR? _Q1\"_$$&D^)((66YB\ZVU"T9GM;H#&X([*#N4D
M*P*@C*GHRD\MXJ\5:MXW\07VN:Y?3:GJU]+YMQ=3_><]  !@*H "@  *
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M@$ ,,X)VL%X?QCXXU_XA:Y+J_B35[K6=2DR/.NW+[%+,^Q%Z1H&9B$4!1D@
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M3EV+*&+5YS3P5+V5*[=W)N6FVO;R%5ES2]- HHHKO,3W']B7_DYSP9_V^?\
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M*VUYF;.U%Z[5 !SCH, =1CZ&O/V:OAW=V7V<:#Y/'RS17,N\>^2Q!_$&O/\
M]BO4[=O#'B#3U9?M4=VEPR]]K)M'X H?S]ZYSXR?#+QGX'T;5_%!\<7DMJ+D
M,MK%/,A"O)@#[V!C/TK7!4\/A\KAC)X?VSES.3=KJS\_T]3OQE2OB,SEA(XC
MV*CRJ*5[.Z7;]?0]O\(^!8O@S\/];MM-O)+U(?M%] URH^3$8VJ<=<;!SQG)
MKP'PC\:OC'X^N+R+P\D.H-:X:55@MTV!B0OW\=<'IGI7H/P(UK4-=_9^\23Z
MC?7%],GVR-9+F0NP7R%.,G)QDD_C7AOP-U#Q_87VN?\ ""6,=Y,RQ_:]PC.
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M!SDKQU(^8?\ A]3\$/\ H5OB!_X+K'_Y,H_X+5?\FL^%O^QSM?\ TAOJ]?\
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M)_\ ANUUSX_)>SO,DNCZ7<WUNL9 #2,4@(?()*[+AS@$'(7T(KYLKW#]F?\
M:8_X9U_X2/\ XIS_ (2#^V/LW_+]]E\KR?-_Z9ONW>;[8V]\\<6-C4J8><*2
MNVK?U\C6DU&:<MCE?VBO&'_">?''QEK*R6L]O)J+VUO-8G=#+!!B&)U;<0VZ
M.-6)!P220 " /.:**Z:<%3@H+9:$2?,VS5\*>';KQAXJT;0+)H8KS5+V"QAD
MG8B-9)7"*6(!(4%AD@$XZ ]*^J?^"BVKVMKXJ\"^$;+3X;&ST?2GN8?(PD8C
MF<1K$L84!%06@Q@\A\8&.?FOX6^,K+X>_$+0?$U]I']O0:5<"[73_M)M]\J
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M"^^]^P[XDN=&_9H^(,NAI#J7B33;R\OK?3%4RR/)]CB, :)"'*N\;* ,%MK
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MR2Z)!1117K'E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6_X(J_\ )TWBG_L3+K_TNL:_:FOQ6_X(J_\ )TWBG_L3+K_TNL: /VIHHHH
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M_P#!+G]AG_DF7[1O_":_]!/_ (IG^RO^ONP_X^?/_P"VG^J_V?\ :H ^B/\
M@K3X*L?%7[%_B'4[N6XCN/#6IZ?JMHL#*%>5IQ9D2 J25\N[D. 0=RJ<X!!Z
MO_@F;JU]K7[#WPPN-1O+B^GC@OK99KF5I&6**_N8HHP6)(5(T1%7HJJH&  *
M\U_X+#?$O_A$/V5(O#,%QIYN_%NM6UE+:W#_ .D&U@S=/+"H8'Y98;568AE
MF (!=2/:OV!? W_"N_V./A/I7VW^T/M&C)J_G>5Y>W[:[7OEXW'.S[1LW9^;
M9NPN=H /H&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#\.:***_6#YP**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH Z/X=>'[#Q5XZT+2-5OH=-TFZO(TOKR>ZBM1#;;@97$DI"*P0,1G.3@
M $D _5_A74O@?^R'G6+3Q!_PM'Q[);LMO)IOEM;VX;S0"C*62'< L;DO)* <
MJH5V!^+:*XJ^&^L.TI-1ZI=?5[FL*G)LM36\5>*M6\;^(+[7-<OIM3U:^E\V
MXNI_O.>@  P%4 !0  %      R:**[$E%61GYL*^J/V#?$G@[P%KGC7Q3XI\
M1VNAW%GIT=M;PW=RB?:(I&:2;9&1OE=3;Q *F3\Y&TDKCY7HKGQ%'ZQ2=)NU
MRZ<^27,7]<UJ]\2ZWJ&KZE/]IU&_N)+NYFVA-\KL7=MJ@*,L2<  #L!5"BBN
MA))61 4444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>U?!G
M]HQ/@S\.?&&@Z=X=FDU[Q#$\7_"00:F]O);#R62$K&(R-T;O(X964DOR1@5X
MK1656E"M'DJ*Z+C)Q=T%%%%:D!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'N/[$O_ "<YX,_[
M?/\ TBGK]5:_*K]B7_DYSP9_V^?^D4]?JK7P^=_[Q'_#^K/6PGP/U_1!1117
MSYVA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7GWQR_Y)_<_]=HO_ $,5
MZ#7GWQR_Y)_<_P#7:+_T,5\_Q!_R*,5_U[E_Z2SU<J_W^A_BC^9T'P^_Y$?0
M?^O*+_T$5T-<]\/O^1'T'_KRB_\ 0170UZ6 _P!TI?X8_DCCQ/\ 'J>K_,**
M**[CF"BBB@ HHHH **** "BBHI95@5G=E6-1DLW  '4DT <U\1O%R>"?"=YJ
M.]?M&/*MU;^*5NGUQRV/0&O(?V<?"\FH:W?>)+H,RP9BB9N=TK?>.?4+P?7?
M6'\1/$UW\7O'-MH^D*TMC$_E6Z] _P#>D/H.,^P'KD5]%>$_#MMX3\/V>E6O
M^KMTVLV,;V/+,?J<G]*K9 ;5%%%2 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!^2W[/UOJG_!,S]M/5?!'C6?^S/A%X\\R#3/
M$E_*IMV2)V:RGEG$(Q)'YA@F3]TB&Y\UOW8C9OTF^-?P%\"_M$>%;7PY\0="
M_M_1K6]74(;7[7<6VV=4DC5]T+HQPLKC!./FZ< C6\=?"?P1\3_L/_"9>#O#
M_BW[#O\ LG]NZ7!>_9]^W?Y?FHVS=L3.,9VKGH*ZV@#&\*>%]+\#>%=&\.:)
M;?8=%T>RAT^QM?,:3RH(HQ'&FYB6;"J!EB2<9)/-;-%% 'GGQK^ O@7]HCPK
M:^'/B#H7]OZ-:WJZA#:_:[BVVSJDD:ONA=&.%E<8)Q\W3@$>+_\ #KC]F+_H
MF?\ Y7M4_P#DFOJNB@#S+X0_LV?"_P" L,4?@+P/H_AVX2&2V.H0V_F7TL3R
M>8T<ET^Z:1=X4X=R %4# 50/3:** "BBB@ KQ+X+?L:_![]G?Q3=>(_A]X0_
MX1[6KJR;3YKK^T[RYW0,\<C)MFF=1EHD.0 ?EX."<^VT4 %%%% !1110 444
M4 %<C\2OA5X1^,GA:X\.>-O#FG^)=%FW-]EOX0_E.R-'YD3?>BD"NX61"KKN
M.UAUKKJ* /E3_AUQ^S%_T3/_ ,KVJ?\ R37J?P5_99^%/[._VE_A_P""M/\
M#]U=;Q-?[I+B\9&\O=%]HF9Y!&3$C>6&V;ESMR23ZQ10 5XE\%OV-?@]^SOX
MINO$?P^\(?\ "/:U=63:?-=?VG>7.Z!GCD9-LTSJ,M$AR #\O!P3GVVB@ KY
M]^*7[!OP)^-'CO4O&7C+P-_;/B34_+^UWW]KWT'F>7$D2?)%.J#"(@X49QD\
MDFOH*B@#Y4_X=<?LQ?\ 1,__ "O:I_\ )-=3XB_8+^!7BSP)X1\&ZIX&^U>&
M_"?VO^Q;'^U[Y/LOVJ42W'SK.'?<X#?.S8Q@8'%?05% &-X4\+Z7X&\*Z-X<
MT2V^PZ+H]E#I]C:^8TGE011B.--S$LV%4#+$DXR2>:V:** /"--_8C^#.B_%
MQOB=I_A.XL?'+ZE+J[:Q;:YJ$;M=2NSRL46X$95R[AH]NQE9E*E217N]%% !
M1110!YY\:_@+X%_:(\*VOASX@Z%_;^C6MZNH0VOVNXMMLZI)&K[H71CA97&"
M<?-TX!&M\+_A?X8^"_@33/!O@W3/['\-Z;YOV2R\^6?RO,E>5_GE9G.7D9N6
M.,X&  !UM% 'Y+?M V^J?\%,_P!M/2O!'@J?^T_A%X#\N#4_$EA*HMU25U:]
MGBG,)S))Y8@A3]ZCFV\U?W9D9?UIKDO WPG\$?# WW_"'>#O#_A+[=L^U_V%
MI<%E]HV;MGF>4B[]N]L9SC<V.IKK: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M  Q+\%O^A,_\JE[_ /'J]SHH^N8G_GY+[V'LX?RH\,_X8E^"W_0F?^52]_\
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M  Q+\%O^A,_\JE[_ /'J]SHH^N8G_GY+[V'LX?RH\,_X8E^"W_0F?^52]_\
MCU'_  Q+\%O^A,_\JE[_ /'J]SHH^N8G_GY+[V'LX?RH\,_X8E^"W_0F?^52
M]_\ CU'_  Q+\%O^A,_\JE[_ /'J]SHH^N8G_GY+[V'LX?RH\,_X8E^"W_0F
M?^52]_\ CU'_  Q+\%O^A,_\JE[_ /'J]SHH^N8G_GY+[V'LX?RH\,_X8E^"
MW_0F?^52]_\ CU'_  Q+\%O^A,_\JE[_ /'J]SHH^N8G_GY+[V'LX?RH\,_X
M8E^"W_0F?^52]_\ CU'_  Q+\%O^A,_\JE[_ /'J]SHH^N8G_GY+[V'LX?RH
M\,_X8E^"W_0F?^52]_\ CU'_  Q+\%O^A,_\JE[_ /'J]SHH^N8G_GY+[V'L
MX?RH\,_X8E^"W_0F?^52]_\ CU'_  Q+\%O^A,_\JE[_ /'J]SHH^N8G_GY+
M[V'LX?RH\,_X8E^"W_0F?^52]_\ CU'_  Q+\%O^A,_\JE[_ /'J]SHH^N8G
M_GY+[V'LX?RH\,_X8E^"W_0F?^52]_\ CU'_  Q+\%O^A,_\JE[_ /'J]SHH
M^N8G_GY+[V'LX?RH\,_X8E^"W_0F?^52]_\ CU'_  Q+\%O^A,_\JE[_ /'J
M]SHH^N8G_GY+[V'LX?RH\,_X8E^"W_0F?^52]_\ CU'_  Q+\%O^A,_\JE[_
M /'J]SHH^N8G_GY+[V'LX?RH\,_X8E^"W_0F?^52]_\ CU'_  Q+\%O^A,_\
MJE[_ /'J]SHH^N8G_GY+[V'LX?RH\,_X8E^"W_0F?^52]_\ CU'_  Q+\%O^
MA,_\JE[_ /'J]SHH^N8G_GY+[V'LX?RH\,_X8E^"W_0F?^52]_\ CU'_  Q+
M\%O^A,_\JE[_ /'J]SHH^N8G_GY+[V'LX?RH\,_X8E^"W_0F?^52]_\ CU'_
M  Q+\%O^A,_\JE[_ /'J]SHH^N8G_GY+[V'LX?RH\,_X8E^"W_0F?^52]_\
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M  Q+\%O^A,_\JE[_ /'J]SHH^N8G_GY+[V'LX?RH\,_X8E^"W_0F?^52]_\
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M  Q+\%O^A,_\JE[_ /'J]SHH^N8G_GY+[V'LX?RH\,_X8E^"W_0F?^52]_\
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M%&*_Z]R_])9ZN5?[_0_Q1_,Z#X??\B/H/_7E%_Z"*Z&N>^'W_(CZ#_UY1?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JE?:?;ZI:M;7<$=S _WHY%W
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MC_A<G_!0S_HA/P__ / Z'_Y;5^@%% 'Y_P#_  N3_@H9_P!$)^'_ /X'0_\
MRVH_X7)_P4,_Z(3\/_\ P.A_^6U?H!10!^?_ /PN3_@H9_T0GX?_ /@=#_\
M+:C_ (7)_P %#/\ HA/P_P#_  .A_P#EM7Z 44 ?G_\ \+D_X*&?]$)^'_\
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M?_EM7Z 44 ?G_P#\+D_X*&?]$)^'_P#X'0__ "VH_P"%R?\ !0S_ *(3\/\
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M /PN3_@H9_T0GX?_ /@=#_\ +:C_ (7)_P %#/\ HA/P_P#_  .A_P#EM7Z
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MA_\ EM7Z 44 ?G__ ,+D_P""AG_1"?A__P"!T/\ \MJ/^%R?\%#/^B$_#_\
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MH9_T0GX?_P#@=#_\MJ/^%R?\%#/^B$_#_P#\#H?_ );5^@%% 'Y__P#"Y/\
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M4 ?G_P#\+D_X*&?]$)^'_P#X'0__ "VH_P"%R?\ !0S_ *(3\/\ _P #H?\
MY;5^@%% 'Y__ /"Y/^"AG_1"?A__ .!T/_RVH_X7)_P4,_Z(3\/_ /P.A_\
MEM7Z 44 ?G__ ,+D_P""AG_1"?A__P"!T/\ \MJ/^%R?\%#/^B$_#_\ \#H?
M_EM7Z 44 ?G_ /\ "Y/^"AG_ $0GX?\ _@=#_P#+:C_A<G_!0S_HA/P__P#
MZ'_Y;5^@%% 'Y_\ _"Y/^"AG_1"?A_\ ^!T/_P MJ/\ A<G_  4,_P"B$_#_
M /\  Z'_ .6U?H!10!^?_P#PN3_@H9_T0GX?_P#@=#_\MJ/^%R?\%#/^B$_#
M_P#\#H?_ );5^@%% 'Y__P#"Y/\ @H9_T0GX?_\ @=#_ /+:C_A<G_!0S_HA
M/P__ / Z'_Y;5^@%% 'Y_P#_  N3_@H9_P!$)^'_ /X'0_\ RVH_X7)_P4,_
MZ(3\/_\ P.A_^6U?H!10!^?_ /PN3_@H9_T0GX?_ /@=#_\ +:C_ (7)_P %
M#/\ HA/P_P#_  .A_P#EM7Z 44 ?G_\ \+D_X*&?]$)^'_\ X'0__+:C_A<G
M_!0S_HA/P_\ _ Z'_P"6U?H!10!^?_\ PN3_ (*&?]$)^'__ ('0_P#RVH_X
M7)_P4,_Z(3\/_P#P.A_^6U?H!10!^?\ _P +D_X*&?\ 1"?A_P#^!T/_ ,MJ
M/^%R?\%#/^B$_#__ ,#H?_EM7Z 44 ?G_P#\+D_X*&?]$)^'_P#X'0__ "VH
M_P"%R?\ !0S_ *(3\/\ _P #H?\ Y;5^@%% 'Y__ /"Y/^"AG_1"?A__ .!T
M/_RVH_X7)_P4,_Z(3\/_ /P.A_\ EM7Z 44 ?G__ ,+D_P""AG_1"?A__P"!
MT/\ \MJ/^%R?\%#/^B$_#_\ \#H?_EM7Z 44 ?G_ /\ "Y/^"AG_ $0GX?\
M_@=#_P#+:C_A<G_!0S_HA/P__P# Z'_Y;5^@%% 'Y_\ _"Y/^"AG_1"?A_\
M^!T/_P MJ/\ A<G_  4,_P"B$_#_ /\  Z'_ .6U?H!10!^?_P#PN3_@H9_T
M0GX?_P#@=#_\MJ/^%R?\%#/^B$_#_P#\#H?_ );5^@%% 'Y__P#"Y/\ @H9_
MT0GX?_\ @=#_ /+:C_A<G_!0S_HA/P__ / Z'_Y;5^@%% 'Y_P#_  N3_@H9
M_P!$)^'_ /X'0_\ RVH_X7)_P4,_Z(3\/_\ P.A_^6U?H!10!^?_ /PN3_@H
M9_T0GX?_ /@=#_\ +:C_ (7)_P %#/\ HA/P_P#_  .A_P#EM7Z 44 ?G_\
M\+D_X*&?]$)^'_\ X'0__+:C_A<G_!0S_HA/P_\ _ Z'_P"6U?H!10!^?_\
MPN3_ (*&?]$)^'__ ('0_P#RVH_X7)_P4,_Z(3\/_P#P.A_^6U?H!10!^?\
M_P +D_X*&?\ 1"?A_P#^!T/_ ,MJ/^%R?\%#/^B$_#__ ,#H?_EM7Z 44 ?G
M_P#\+D_X*&?]$)^'_P#X'0__ "VH_P"%R?\ !0S_ *(3\/\ _P #H?\ Y;5^
M@%% 'Y__ /"Y/^"AG_1"?A__ .!T/_RVH_X7)_P4,_Z(3\/_ /P.A_\ EM7Z
M 44 ?G__ ,+D_P""AG_1"?A__P"!T/\ \MJ/^%R?\%#/^B$_#_\ \#H?_EM7
MZ 44 ?G_ /\ "Y/^"AG_ $0GX?\ _@=#_P#+:C_A<G_!0S_HA/P__P# Z'_Y
M;5^@%% 'Y_\ _"Y/^"AG_1"?A_\ ^!T/_P MJ/\ A<G_  4,_P"B$_#_ /\
M Z'_ .6U?H!10!^?_P#PN3_@H9_T0GX?_P#@=#_\MJ/^%R?\%#/^B$_#_P#\
M#H?_ );5^@%% 'Y__P#"Y/\ @H9_T0GX?_\ @=#_ /+:C_A<G_!0S_HA/P__
M / Z'_Y;5^@%% 'Y_P#_  N3_@H9_P!$)^'_ /X'0_\ RVH_X7)_P4,_Z(3\
M/_\ P.A_^6U?H!10!^?_ /PN3_@H9_T0GX?_ /@=#_\ +:C_ (7)_P %#/\
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MH_X7)_P4,_Z(3\/_ /P.A_\ EM7Z 44 ?G__ ,+D_P""AG_1"?A__P"!T/\
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M+D_X*&?]$)^'_P#X'0__ "VH_P"%R?\ !0S_ *(3\/\ _P #H?\ Y;5^@%%
M'Y__ /"Y/^"AG_1"?A__ .!T/_RVH_X7)_P4,_Z(3\/_ /P.A_\ EM7Z 44
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M'_Y;5^@%% 'Y_P#_  N3_@H9_P!$)^'_ /X'0_\ RVH_X7)_P4,_Z(3\/_\
MP.A_^6U?H!10!^?_ /PN3_@H9_T0GX?_ /@=#_\ +:C_ (7)_P %#/\ HA/P
M_P#_  .A_P#EM7Z 44 ?G_\ \+D_X*&?]$)^'_\ X'0__+:C_A<G_!0S_HA/
MP_\ _ Z'_P"6U?H!10!^?_\ PN3_ (*&?]$)^'__ ('0_P#RVH_X7)_P4,_Z
M(3\/_P#P.A_^6U?H!10!^?\ _P +D_X*&?\ 1"?A_P#^!T/_ ,MJ/^%R?\%#
M/^B$_#__ ,#H?_EM7Z 44 ?G_P#\+D_X*&?]$)^'_P#X'0__ "VH_P"%R?\
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M=#_\MJ/^%R?\%#/^B$_#_P#\#H?_ );5^@%% 'Y__P#"Y/\ @H9_T0GX?_\
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M  .A_P#EM7Z 44 ?G_\ \+D_X*&?]$)^'_\ X'0__+:C_A<G_!0S_HA/P_\
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M<G_!0S_HA/P__P# Z'_Y;5^@%% 'Y_\ _"Y/^"AG_1"?A_\ ^!T/_P MJ/\
MA<G_  4,_P"B$_#_ /\  Z'_ .6U?H!10!^?_P#PN3_@H9_T0GX?_P#@=#_\
MMJ/^%R?\%#/^B$_#_P#\#H?_ );5^@%% 'Y__P#"Y/\ @H9_T0GX?_\ @=#_
M /+:C_A<G_!0S_HA/P__ / Z'_Y;5^@%% 'Y_P#_  N3_@H9_P!$)^'_ /X'
M0_\ RVH_X7)_P4,_Z(3\/_\ P.A_^6U?H!10!^?_ /PN3_@H9_T0GX?_ /@=
M#_\ +:C_ (7)_P %#/\ HA/P_P#_  .A_P#EM7Z 44 ?G_\ \+D_X*&?]$)^
M'_\ X'0__+:C_A<G_!0S_HA/P_\ _ Z'_P"6U?H!10!^?_\ PN3_ (*&?]$)
M^'__ ('0_P#RVH_X7)_P4,_Z(3\/_P#P.A_^6U?H!10!^?\ _P +D_X*&?\
M1"?A_P#^!T/_ ,MJ/^%R?\%#/^B$_#__ ,#H?_EM7Z 44 ?G_P#\+D_X*&?]
M$)^'_P#X'0__ "VH_P"%R?\ !0S_ *(3\/\ _P #H?\ Y;5^@%% 'Y__ /"Y
M/^"AG_1"?A__ .!T/_RVH_X7)_P4,_Z(3\/_ /P.A_\ EM7Z 44 ?G__ ,+D
M_P""AG_1"?A__P"!T/\ \MJ/^%R?\%#/^B$_#_\ \#H?_EM7Z 44 ?G_ /\
M"Y/^"AG_ $0GX?\ _@=#_P#+:C_A<G_!0S_HA/P__P# Z'_Y;5^@%% 'Y_\
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MC_A<G_!0S_HA/P__ / Z'_Y;5^@%% 'Y_P#_  N3_@H9_P!$)^'_ /X'0_\
MRVH_X7)_P4,_Z(3\/_\ P.A_^6U?H!10!^?_ /PN3_@H9_T0GX?_ /@=#_\
M+:C_ (7)_P %#/\ HA/P_P#_  .A_P#EM7Z 44 ?G_\ \+D_X*&?]$)^'_\
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M?_EM7Z 44 ?G_P#\+D_X*&?]$)^'_P#X'0__ "VH_P"%R?\ !0S_ *(3\/\
M_P #H?\ Y;5^@%% 'Y__ /"Y/^"AG_1"?A__ .!T/_RVH_X7)_P4,_Z(3\/_
M /P.A_\ EM7Z 44 ?G__ ,+D_P""AG_1"?A__P"!T/\ \MJ/^%R?\%#/^B$_
M#_\ \#H?_EM7Z 44 ?G_ /\ "Y/^"AG_ $0GX?\ _@=#_P#+:C_A<G_!0S_H
MA/P__P# Z'_Y;5^@%% 'Y_\ _"Y/^"AG_1"?A_\ ^!T/_P MJ/\ A<G_  4,
M_P"B$_#_ /\  Z'_ .6U?H!10!^?_P#PN3_@H9_T0GX?_P#@=#_\MJ/^%R?\
M%#/^B$_#_P#\#H?_ );5^@%% 'Y__P#"Y/\ @H9_T0GX?_\ @=#_ /+:C_A<
MG_!0S_HA/P__ / Z'_Y;5^@%% 'Y_P#_  N3_@H9_P!$)^'_ /X'0_\ RVH_
MX7)_P4,_Z(3\/_\ P.A_^6U?H!10!^?_ /PN3_@H9_T0GX?_ /@=#_\ +:C_
M (7)_P %#/\ HA/P_P#_  .A_P#EM7Z 44 ?G_\ \+D_X*&?]$)^'_\ X'0_
M_+:C_A<G_!0S_HA/P_\ _ Z'_P"6U?H!10!^?_\ PN3_ (*&?]$)^'__ ('0
M_P#RVH_X7)_P4,_Z(3\/_P#P.A_^6U?H!10!^?\ _P +D_X*&?\ 1"?A_P#^
M!T/_ ,MJ/^%R?\%#/^B$_#__ ,#H?_EM7Z 44 ?G_P#\+D_X*&?]$)^'_P#X
M'0__ "VH_P"%R?\ !0S_ *(3\/\ _P #H?\ Y;5^@%% 'Y__ /"Y/^"AG_1"
M?A__ .!T/_RVH_X7)_P4,_Z(3\/_ /P.A_\ EM7Z 44 ?G__ ,+D_P""AG_1
M"?A__P"!T/\ \MJ/^%R?\%#/^B$_#_\ \#H?_EM7Z 44 ?G_ /\ "Y/^"AG_
M $0GX?\ _@=#_P#+:C_A<G_!0S_HA/P__P# Z'_Y;5^@%% 'Y_\ _"Y/^"AG
M_1"?A_\ ^!T/_P MJ/\ A<G_  4,_P"B$_#_ /\  Z'_ .6U?H!10!^?_P#P
MN3_@H9_T0GX?_P#@=#_\MJ/^%R?\%#/^B$_#_P#\#H?_ );5^@%% 'Y__P#"
MY/\ @H9_T0GX?_\ @=#_ /+:C_A<G_!0S_HA/P__ / Z'_Y;5^@%% 'Y_P#_
M  N3_@H9_P!$)^'_ /X'0_\ RVH_X7)_P4,_Z(3\/_\ P.A_^6U?H!10!^?_
M /PN3_@H9_T0GX?_ /@=#_\ +:C_ (7)_P %#/\ HA/P_P#_  .A_P#EM7Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **_''_A>WQ)_P"BB>*O_!W<_P#Q='_"
M]OB3_P!%$\5?^#NY_P#BZ^F_L.I_.OQ.#ZVNQ^QU%?CC_P +V^)/_11/%7_@
M[N?_ (NC_A>WQ)_Z*)XJ_P#!W<__ !=']AU/YU^(?6UV/V.HK\<?^%[?$G_H
MHGBK_P '=S_\71_PO;XD_P#11/%7_@[N?_BZ/[#J?SK\0^MKL?L=17XX_P#"
M]OB3_P!%$\5?^#NY_P#BZ/\ A>WQ)_Z*)XJ_\'=S_P#%T?V'4_G7XA];78_8
MZBOQQ_X7M\2?^BB>*O\ P=W/_P 71_PO;XD_]%$\5?\ @[N?_BZ/[#J?SK\0
M^MKL?L=17XX_\+V^)/\ T43Q5_X.[G_XNC_A>WQ)_P"BB>*O_!W<_P#Q=']A
MU/YU^(?6UV/V.HK\<?\ A>WQ)_Z*)XJ_\'=S_P#%T?\ "]OB3_T43Q5_X.[G
M_P"+H_L.I_.OQ#ZVNQ^QU%?CC_PO;XD_]%$\5?\ @[N?_BZ/^%[?$G_HHGBK
M_P '=S_\71_8=3^=?B'UM=C]CJ*_''_A>WQ)_P"BB>*O_!W<_P#Q='_"]OB3
M_P!%$\5?^#NY_P#BZ/[#J?SK\0^MKL?L=17XX_\ "]OB3_T43Q5_X.[G_P"+
MH_X7M\2?^BB>*O\ P=W/_P 71_8=3^=?B'UM=C]CJ*_''_A>WQ)_Z*)XJ_\
M!W<__%T?\+V^)/\ T43Q5_X.[G_XNC^PZG\Z_$/K:['['45^./\ PO;XD_\
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MZ/\ A>WQ)_Z*)XJ_\'=S_P#%T?V'4_G7XA];78_8ZBOQQ_X7M\2?^BB>*O\
MP=W/_P 71_PO;XD_]%$\5?\ @[N?_BZ/[#J?SK\0^MKL?L=17XX_\+V^)/\
MT43Q5_X.[G_XNC_A>WQ)_P"BB>*O_!W<_P#Q=']AU/YU^(?6UV/V.HK\<?\
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M\2?^BB>*O_!W<_\ Q=']AU/YU^(?6UV/V.HK\<?^%[?$G_HHGBK_ ,'=S_\
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MT?\ "]OB3_T43Q5_X.[G_P"+H_L.I_.OQ#ZVNQ^QU%?CC_PO;XD_]%$\5?\
M@[N?_BZ/^%[?$G_HHGBK_P '=S_\71_8=3^=?B'UM=C]CJ*_''_A>WQ)_P"B
MB>*O_!W<_P#Q='_"]OB3_P!%$\5?^#NY_P#BZ/[#J?SK\0^MKL?L=17XX_\
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MP:U::MJGB'58A++:6PNE(AM[;STM6D+(KYC55?;(YC /0?\ @EQ_R8I\,_\
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M1110 4444 %%%% !1110 4444 %%%% 'D/[6/_) ?%/_ &Z_^E<->1_L"_\
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MN=0=UMK&WFW;))GR1N*CHJJ[D9&=FT$$BOB[]K'_ ). \5?]NO\ Z20UZ_\
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M('C)/V=_@G8,&CU._L+6VTFQ\Y&1+B98PH9@N=H"H\A!89V[0P)!KC_V&?\
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M(^'.A^(VB\B:\A_?1A<*LR,8Y-HW'Y=Z,5R<[<9P>*^2?V&?^2M:M_V!)O\
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M7GGQB^/WP]^ &@Q:O\0/%FG^&K67/D1W+%[FYPR(WDP(&EFVF5"WEJVT,&;
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M5XG^255<8>-EY49QD9!!(!UM%%% !1110 4444 %%%% !1110 4444 %%%%
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MW<1BFB97:.2-UY 9)$="5)4E259E(8]S0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !17R]\-O^"@'@+XD?M0^(/@A;Z9K&EZYILUW8VU]?1(8
M;Z\M))Q=1((V8H@CA\Q)'(WCS%(C94$GU#0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^'-%
M%%?K!\X%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'N/[$O\ R<YX
M,_[?/_2*>OU5K\JOV)?^3G/!G_;Y_P"D4]?JK7P^=_[Q'_#^K/6PGP/U_1!1
M117SYVA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-X5\_P#L7P=J.C>?M\[[!I=I!YF,[=VR49QDXSZG%?14Z.*A@9X3V+O)WO\
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MGP=:>PC\T:5?1ZA<1JK,YA5)(V*A0?N^8&). %5B>F#E?\-R> _^@1XB_P#
M:W_^/T?\-R> _P#H$>(O_ :W_P#C]>;*GF,\6L7*D[I[>78Z5+#1H^Q4]#R+
M]F[]I#0?A#X3U/1-;TS4K@37QO(;C3UC?.Z-$965V7;CRP003G<<@8Y]Q^,W
M@&Z_:&^"^@ZII-M;VVN-!#J]K;S$%F$D.Y[99B!MSN4Y("EHTSM^\OE4WQF_
M9^GUJ#56^'%ZMU!&8UCCL+=(&!W?>@6<1N?F/+*3T]!CNK/]MCX=Z;906MKH
M.O6UK BQ10PV=NB(H&%55$V     .!TKJQ-*O*O'$X:A)3O=W_+?^O(RI2@J
M;I5:B:/(_@3^TE<_!:SN?"GB72+RYTZ&ZD;Y6*W5BV"'B$3D C> 2N4*EI"=
MQ.!ZMJW[=7A.'3Y7TS0-9O+X8\N&[\F"-N1G+J[D8&3PIR0.F<USGBK]HGX(
M^./M1UOP'J5]<76WSKS[!;1W+;<;?WRSB08"@<-T&.F147A[X_? KPK#:+IG
MP]O(I+-_-AN)--M9IXV#;PWG/,7R#R"6R,#&, 5K5P\*\O:U,++G>Z3LG_7I
MYDPJ2IKDC55O34^G_ >N3^)_ WAW6;I8X[K4=.M[N5800@:2)78*"20,DXR3
M]:^./V&?^2M:M_V!)O\ THMZ]=_X;D\!_P#0(\1?^ UO_P#'ZP-"_:J^#WA>
M\:ZT;P1>:/=2(8FFL=(LX'9202I9902,@''3@>E<-##XJC2K4O8OW[6\K7_S
M-ZE2E.<)<Z]TZ#]N;_DDVD?]AN'_ -)[BNM_9._Y(#X6_P"WK_TKFKS[7?VP
M/A;XHLTM=8\+:MJ]K&XE6&]TVUG16 (#!6E(!P2,]>2.]3:3^V9\-=!L(K#2
M_#FM:?8Q9\NVL[&UBC3)+'"K, ,DD\#J3ZU,L-BY8*.%]B[J5[_UZC52BJ[J
M\ZVL>8?$_P#Y/8L_^PYH_P#Z!;5]T5\J77[57P>OM;76;CP1>7&KJZ2C4)-(
MLWG#)C8WF&7=E=HP<Y&!TQ6__P -R> _^@1XB_\  :W_ /C]&,P^+Q,*451:
MY(I!1J4:3FW-:NYY'\3_ /D]BS_[#FC_ /H%M7W17RI=?M5?!Z^UM=9N/!%Y
M<:NKI*-0DTBS><,F-C>89=V5VC!SD8'3%;__  W)X#_Z!'B+_P !K?\ ^/T8
MS#XO$PI15%KDBD%&I1I.;<UJ[GSK_P W9?\ <\?^W]?37[9GAW4O$'PACDTZ
MTDO%TW48[ZY\KEHH%BE5I,=2%+J3CH,L> 2.+_X:<^"W]J_VI_P@%Q_:?G_:
M?MW]C67G^=NW>9O\W=NW<[LYS[UTG_#<G@/_ *!'B+_P&M__ (_797^N5*U&
MM"@_<[]3&G[&,)PE->\>9_ +]J[2/AOX%B\->(-+O)X[%V:SN--1'+H[M(PD
M#NN"&8X()!!&0-N6XO\ :-^*&J_%NXT'76TBXTCPL/M5MI/VEE+7#(Z^=+PH
M(R#"I7+*&1@&)#8[^;XS?L_3ZU!JK?#B]6Z@C,:QQV%ND# [OO0+.(W/S'EE
M)Z>@QT6J?M5?![6[.PMM0\$7E]:V*>5:0W.DV<B6ZX VQJ9<(,*HP./E'H*Z
MHQ]EB%B:>%ES/>_GV_KN9-\U/V<JJL>F_LG?\D!\+?\ ;U_Z5S5\@ZE9ZO=?
MM*>(9="ACN=7L=>U#4;6WDC=UG>VDEN-FU>6+>5M"C!)(&1G(^@])_;,^&N@
MV$5AI?AS6M/L8L^7;6=C:Q1IDECA5F &22>!U)]:S;7]JKX/6.MMK-OX(O+?
M5V=Y3J$>D6:3EGSO;S!+NRVXY.<G)ZYKDP\<70K5ZOL&^>]O*[OJ:U'2G"$.
M=>Z7+;]NSPT^BM+<>'-5BU?RW(M8WB>#<,[!YQ(;!XR?+XR<!L#/C&EZ7XA_
M:S^,\NHS6TEMI0>/[6T<I,>GV:G C1V!'F, Q "X9V9MH7<1Z)KOQ\^!7B2\
M2ZU#X>WD]TMT+UIETVUC>67)),C+,#("22ROE6[@UT>A?M@?"WPO9O:Z/X6U
M;2+61S*T-EIMK C,0 6*K* 3@ 9Z\ =JUA3GA8REA,-)3?5N]O0F4E5:56JG
M%'TI9V=OIMG!:6L$=M;6Z+%%#"@1$51A54#@    "K=>:_"'XY:#\9CJO]B6
M>I6O]F^5YW]H1(F[S-^W;M=LXV'.<=1C/./2J^/J4YT9N%16:/9C*,X\T7H%
M%%%9%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?CM^R5\/(O^
M"F'[4/Q%^)'Q;^T:KX4T6!5MO#K:E)&;=;B2465HKQ(A,$,<<Y8H8F:78[!M
M\H/[$U^-?Q4^"?Q>_P""8?QO\1_%WX9:1I^K?#2Z\RSBFN(FN;:UM;J3<EE=
MQF7[0GE21PA9PX5RL.7W2M#0!^F6E?L>_ S1=+L].M_@]X(DM[6%((VN] M;
MF9E50H+RR(TDC8'+NQ9CDDDDFJG[/?[(GP]_9?U[QC?_  _MM0TVU\4?8_M&
MEW-XUQ;VOV99%7R2X,OS&9V;?(_)&W:!BO-?V5_^"DGPO_:2@L],U"\M_ 'C
MF>9H%\-ZM=[DN"9$2+[-=,B1S,YD0"+"R[@X"%5#M];T %<YXT^(7A;X:Z7%
MJ?B_Q-H_A7399A;1WFMWT5G"\I5F"!Y&"EBJL0H.<*3V-?(/_!1_]L[Q#\"K
M?PU\.?A=-<?\+:\23V\\*P:6+UX;-I'C01*P*O/-,@C5 DGRK+D*QB8^5_"'
M_@CKI/B[P;'X@^-GB_Q0_P 1-7FDO]1AT?4+=TA:0[BDTTL,K3S[BS22!MI9
MB!N"^8X!^D^DZM9:]I=GJ>F7EOJ.F7D*7-M>6DJRPSQ.H9'1U)#(RD$$$@@@
MC@U>K\B_CI^QSXU_X)OZI!\=_@IXQN-4\/:5-';:IIFMJGG1VLK11[+@H46[
M@EF.U@J1O&6A9<E#+'^D_P"S?\;K+]H[X)^%OB+I^FW&C0:U!(S:?<NLC02Q
M2O#*H=>'421/M;"EEVDJI)4 'Y\?L"_\I3/VCO\ N8__ $^6]?ICX^\ ^'OB
MIX.U;PIXKTJWUSP[JL)@N[&Y4[)%R""""&5E8!E=2&5E5E((!K\SOV!?^4IG
M[1W_ ',?_I\MZ^J?^"H__)BGQ,_[AG_ITM* /HCP#X!\/?"OP=I/A3PII5OH
M?AW2H1!:6-LIV1KDDDDDLS,Q+,[$LS,S,22371U\J?\ !+C_ ),4^&?_ '$_
M_3I=U\K?M6?'/XE?MC?M5/\ LW_"K4=0T;P9IEZ^F^(]4T<2*\R#$.H37>XQ
M?Z-!OEB\@L$F<?>D,D*H ?IC9?$+PMJ/C*^\(VGB71[GQ7I\(N;O08;^)[ZW
MB(0AY( QD12)(SN( _>+ZC/YG?M]?\I3/V<?^Y<_]/EQ7I.D_P#!%/X/PZ79
MQZIXQ\<7>I+"BW5Q:7-G!#+*%&]DC:V<QH6R0I=B 0"S8R?D/QU\/?BC\*O^
M"AGP4\+?%/Q9<>.+S3M?T1=$\07<_G37NEOJS21,Y9C(&$K7"E969E*E59HQ
M&Q /W'HHHH ^??BE^P;\"?C1X[U+QEXR\#?VSXDU/R_M=]_:]]!YGEQ)$GR1
M3J@PB(.%&<9/))K\V/\ @JS^R[\,?V:_^%7?\*X\-?\ "._VU_:GV_\ XF%U
M=>=Y/V3RO]?*^W;YLGW<9W<YP,?M37Y5_P#!<[_FB?\ W&__ &PH ^J?^'7'
M[,7_ $3/_P KVJ?_ "37OWPO^%_ACX+^!-,\&^#=,_L?PWIOF_9++SY9_*\R
M5Y7^>5F<Y>1FY8XS@8  '6U^5?\ SG6_S_T+% 'ZJ445^5?_ #G6_P _]"Q0
M!^JE%>4_M8?\FL_&3_L3-9_](9J_+?\ X)O_  :\>_M+?#7Q+X"F\7:QX&^"
MVGZG/>ZQ)X>W6U]KUY=6B0?8_M#*T9@CBB#R1D'/GH&1M\;Q '[#:=XLT/6-
M>UC1;#6=/O=9T?R?[2TVVNDDN++S5+Q>=&"6CWJ"R[@-P!(S6Q7Y%_M@?\$O
M;']G3X8_\+1^#_B?Q1<ZEX5F74+ZWOY5DNTB5TVW5K);0QM&T#?O'+# 0,^]
M/*P^K\!X_BA_P54M[:W^(WBK5_"OPP\*:9'INMQ>'C]F7Q/JC2/*DN#$80R(
MEJ\B-YBQLJ&..,7!,8!^GGAWXA>%O&.JZSI>@>)M'UO4=%G^S:K9Z;?17$UA
M+N==DZ(Q,3;HW&' .48=CCHZ_(']M'_@FGH?[+7PI3XK_##QGX@@NO#-[;SW
ML>L72?:1OGBC@FM)K>*,QR1RNAP>H.X,I0*_Z)?L8_&+4_CY^S%X \<:U'MU
MK4+)X+Z3<I\^>WFDMI)\(B*GFM"9-BJ N_:,XR0#VRN1U[XL>"/"GBK3?#.M
M>,= T;Q)J?E_8='U#4X(+RZ\QS''Y4+N'?<X*KM!RP(&2,5^<G[87[0OQ0_:
MN_:$U#]F[X$7UQ%H<,,VE>*;G[-]G1Y4FVWAFN6!DCM(0%B)14,K/+'B99(E
M;OM)_P""*?P?ATNSCU3QCXXN]26%%NKBTN;."&64*-[)&ULYC0MDA2[$ @%F
MQD@'Z%T5^0&FZG\0_P#@CY\9-+TC5]4_X3_X->+\SO';*()7DC$:3SPP-(WD
MW,6^,$%C'/&44L& ,'Z_T %%?@;^P+;_ !0^(VJ>*?A%\+=>N/!5YXGFT[5=
M;\76=YY$VFZ78M.LH15Q(S/+>6^!$Z,2@1B(WD9?U&_9C_X)Y>"/V3_BE/XQ
M\&^(O$%]]KT:YTB[L==>"?=YD]M*DD;Q1Q;-OV=@5*MN\Q2"NPA@#ZLKG/#O
MQ"\+>,=5UG2] \3:/K>HZ+/]FU6STV^BN)K"7<Z[)T1B8FW1N,. <HP[''Y7
M2:-XA_X*)_MZ_$CX8_$+QMK&D?#[P7-J3VFAZ$XCA9;*[^Q0LJOOC$[&Y,CS
M.CL07C7:I41^O^*O^")_PMO-!N8O#GCGQAI6M-M^SW>J-:WULF&!;?"D,+/E
M=P&)%P2#SC:0#]%:*** ///V@_%.J>!_@'\2_$>B7/V'6M'\,ZGJ%C=>6LGE
M3Q6LDD;[7!5MK*#A@0<<@CBOSX_X)/\ [._@+XR^ ?''Q1^(6@V_C_Q9>>(+
MC2WD\41KJ,(40V]Q)-Y<JL&GDDG):5]S84!2NY]_Z>:MJUEH.EWFIZG>6^G:
M99PO<W-Y=RK%#!$BEG=W8@*BJ"220  2>!7XH>!_BEXD^!7[0'CF\_8MTWQ!
M\1_AQ=?9)]1TV?PM<WULCF.?RH"X470CC:24QNQA=BA5O-">9( >T_\ !63X
M%_#3X*^%?A]X_P# &G:?\//'T>LI:6MOX9\K3?.@1))C=+#$%/F02B "=,%?
M.4,3^ZV_HW\/O&6K:C\%_#7BOQ=I5QI>N3^'[;5-8TNTT^X::WN&MEEGA2V
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MO\_]"Q0!^JE4=6U:RT'2[S4]3O+?3M,LX7N;F\NY5BA@B12SN[L0%15!))(
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M?$#0_$EK^_TS5/MUJ_V.Z7YH9L1V\;G8X5L+(C<<,IP1\K_LN^'_ (A>$_\
M@J]X9T3XJ:E_;/CG3?M5G>ZEYXG^U1QZ%*EM+Y@ +[K<0MN<"0YS)\Y:@#]J
M**\I_:P_Y-9^,G_8F:S_ .D,U?DO^P'X!^(7[3?@F[^#N@^(]0\$?#/3M9N-
M<\;:KI=\([G4H;RVAMH;!(PNX[EM;K.XM"1(6D1FBC20 _9NR^(7A;4?&5]X
M1M/$NCW/BO3X1<W>@PW\3WUO$0A#R0!C(BD21G<0!^\7U&>CK\J_VG_^"1'@
MCX<_!#Q5XP\ ^+/$']L^';*;5YK?Q)/!-;W%K!$\DT:F&W1DDVKN1CN4E=I
MW[T]^_X)7_M.:Y^T'\#]4TKQAK7]M^+O"5['92W$D3_:9K"2,&UEGE/RRR%D
MN4+ [B(59\LV]P#[6KD=>^+'@CPIXJTWPSK7C'0-&\2:GY?V'1]0U.""\NO,
M<QQ^5"[AWW."J[0<L"!DC%>5_MJ? CQO^T9\+=*\'>"?&'_"%?:-9B;6[[[3
M/'Y^E-!/%<0;(O\ 7[O-0^2[*C[,,R\&OG;2?^"*?P?ATNSCU3QCXXN]26%%
MNKBTN;."&64*-[)&ULYC0MDA2[$ @%FQD@'Z%T5^6O[ ?Q$\:?LR?M9^(OV4
MO%VH7&L^'EFO/["9HD)MY5B-XDRD2MY,%Q;!I6A!<K*Z<*6F+>E?\%JO^36?
M"W_8YVO_ *0WU 'Z 5SG@OXA>%OB5I<NI^$/$VC^*M-BF-M)>:)?17D*2A58
MH7C8J&"LI*DYPP/<5^9W[-_[+'B?]O;X6^&_$/Q1\7>(/#GPBTG1M/T/PIX4
MT+4HSYTUA +2:_D#1-&FZ5+H#>C3'S2N\1QH9?-?VSOV,)?^"?=QX'^+OPB\
M<:Q;)#J:Z>&U22-[ZWO&CFD5T9(DCD@>*.2-XW7V/F+*RH ?L]17F7[-OQ>B
M^//P'\#^/8Y;>6?6M,CEO5M(9(H8KQ?W=U&BR98*DZ2H"200H(9@0Q^(OVR_
MVL/B'\9OV@+']F3X":E_8>M->B#5O%%IJ0@=IHX_/EABGC8M#' JL9BO[YGB
M>(*-K+, ?H/XB^(7A;P=JNC:7K_B;1]$U'6I_LVE6>I7T5O-?R[D79 CL#*V
MZ1!A 3EU'<9Z.OSJ\*_\$3_A;9Z#;1>(_'/C#5=:7=]HN]+:UL;9\L2NR%X9
MF3"[0<R-D@GC.T?3W[(/[+%C^R+X"\0>$=,\07'B#3=1\07&LVLMW;+%-;Q2
M10Q) Y5B)&58 3(%0,6.$7&* .T\(? /X>^ /B-XH\>^'O">GZ5XN\38_M75
M(%.^?!W-@$E8][ /)Y87S' =]S &O0Z_*O\ 8%_Y2F?M'?\ <Q_^GRWKZH_X
M*'?M=?\ #*?P;_XDMSY7Q"\2>9:^']]GY\<.PQ_:+E]Q"#RTD&T-NS(\>4=!
M)@ ^B?&GQ"\+?#72XM3\7^)M'\*Z;+,+:.\UN^BLX7E*LP0/(P4L55B%!SA2
M>QKHZ_,#X-_\$FO^%O>%;/QY\>/B#XPU#QIXAL[6]ELX9=EY993 BNIKR.62
M618O(4J5C\ID=,R *PX#XL?#WQ?_ ,$C_C)H'CCX<:KJ'BKX6>)L66HZ3JV?
MWKQ ,UO<RQQB)9"&DDMYE4.N)E*,BR>: ?K]6/XH\6:'X'T&YUOQ)K6G^']%
MM=OVC4M4NH[:WBW,$7?(Y"KN9E49/)8 =:\+_:T_:&O? '[%_B/XM?#F]MY[
MBXTRPN]&U"YMF*>5>3V\:7 B< [A'<;U5UP& W*1E3\6?LH_\$Z?"W[7GP3T
MGXO?%'X@^-]9\5^))KAI)X;^(NL5O*UI&LDEQ%,\K8MR0Q90%94"_)N8 _5'
M2=6LM>TNSU/3+RWU'3+R%+FVO+25989XG4,CHZDAD92"""0001P:O5\D_LP?
M\$[_  K^R?\ &?4/&OA'Q5K&HZ;>>'Y-&ETG6HHI)A*]S%*9Q<1B,;=L"KY9
MB)R6;?T4?6U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'X<T445^L'S@4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >X_L2_\G.>#/^WS_P!(IZ_56ORJ_8E_Y.<\&?\ ;Y_Z13U^JM?#
MYW_O$?\ #^K/6PGP/U_1!1117SYVA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%<7\4/&5SX)\.+>V<4<L\DP
MA'F@E1E6;. 1G[N.O>N/&8NE@<//$UOABKLWP]">)JQHT]Y.R.:^+7P]NFND
M\6^'=T.N6>'ECA',P7^(#NP'!'<<=L&"3X_Z?_P@+:@FU==_U'V'^[+C[^/[
MG?\ 3WJ#X?\ QJOO$'B.VTS5K:WB6X^6*2!67#8XSECD'I]2*Z.;X*Z%-XT3
M7]FU=WFO8[1Y;2_WOIGG&.3[$BN/*LWPN<T'7PLKI.SNK-,Z<=@:^7U%2KJS
M:N4_@SX!FT2SEU_5]TNN:EERTGWXHV.<'/\ $QY/X#USZA7@OB;X]ZE:ZW>0
M:5;6K64+F-99(V8O@XW9# <]1QTKU[PEK3^(?#=AJ,J+')<1;F5>F<X.,]N*
MX\OXAP&:XBIAL+)N4-7IIO;1]3?%Y5BL#2C6KJREY_/4W**SKS7-.TYUCN]0
MM;:0C(6:94./7!-689TN(5EB=9(V&0RG((]0:^@52$I.$9)M'E.,DE)K1EBB
MJ\LR6\+22NL:+R68X ^IK/M/%&CWTXM[75;*>;IY<<ZLWX &IG6ITY*,Y)-[
M:E1ISDFXIM(V**IWFI6E@%^TW4-MNZ>=($S],FH(?$&F7$@CBU&TDD/15G4G
M\@:'6I1ER.2OVN"IS:NHNQIT45GZEK5AI**U]?6]F&Z>=*J;OIDU<YQIQYIN
MR\R8QE)VBKLT*XSQ!<?V+XFL[S[L4^-_;IPQ/T&*Z'3O$&G:QN%AJ%K>%?O"
M"97(_(U@?$:RDO-/L4A7S)FN1$J^NX$X_P#'113J0JQYH.Z\@E&4'RR5F=C1
M7S;\0OVJ#H=^N@^%+*'6M2B @EO)-S1M*, B-5P7Y_BR >P.<UA-\:/C3I,7
MVZ^\*LUF/F99-,E4 >Y&"/J37SE3B+!4ZDJ<>:?+NXIM+Y_Y'T5/A_&U*:J2
MY87V4G9OY'U?17!?"+XE#XH^$/[9:T_L^:*9K>:'=E5955B02!P0P^G/)QFN
M@_X3CP[_ -#!I?\ X&Q__%5[=+%4:U.-:,O=DKKI^9XE7#5J-25&<?>B[/K^
M1NT5G:;KFG:RLAL-0M;X)C?]FF63;GIG:3C-01^*=&FO/LB:OI[W1?8(5N4+
M[O3;G.?:MO:0LG=:F/LYW:L]#8HJG?:A:Z5:M<WMS#:6Z?>FG<(@[#))P*CA
MUBQN-/\ M\5Y;RV6TO\ :5F4QX'4[@<8'KFJYXWLWJ+EE:]M#0HK.TO6]/UN
M%I-.U"UOXT.UGMIED"GT)4G!IVJ:Q8:+:_:-0OK>QMQUFN95C3\R0*/:1Y>>
M^@<DN;EMJ7Z*QM&\7:'XB9ETG6+'4F3[RVERDI7ZA2:FUC7M-\/6XN-3U"UT
MZ$G:)+J98U)] 6(J55@X\ZDK=[Z%.G-2Y'%W[=33HK)T7Q/H_B-&?2M5L]35
M?O&UG23;]=IX_&M:JC*,US1=T3*,H/EDK,****LD**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/U36+'0M/GOM2O;?3[*%=
MTMU=RK'&@]69B !]:I^&_%VA^,=/>]T#6M/UNS5O+:XTZZCN(PV =I9&(S@@
MXSW%?F!^W#\:-3^(OQ>U/0DN;JV\.Z"XLTT_[2WD2W$9?=<&/A0_[QDS@G:H
MYY(KRWX*?%+6?A+\1=&US2[VXMH8[J%;VWAF*)=6^\%X7 X92,]0<'!'05\]
M/-XPK<G+[J>Y^^8+PHQ&*RB.,E7M7E'F4+:;72;ON^^RV/VMHJCI.I1:QI5G
M?P?ZFZA2=,_W64,/T-7J^@6I^"2BXMQ>Z"BBBF(**** "BBB@ HHHH ****
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MSRG;9NV-C.,[6QT-=;1[>K_._O#V<.QQ_P#PI_P)_P!"1X=_\%5O_P#$4?\
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M+D]O5_G?WA[.'8]1_P"%/^!/^A(\._\ @JM__B*/^%/^!/\ H2/#O_@JM_\
MXBNPHH]O5_G?WA[.'8X__A3_ ($_Z$CP[_X*K?\ ^(H_X4_X$_Z$CP[_ ."J
MW_\ B*Z+5M6LM!TN\U/4[RWT[3+.%[FYO+N58H8(D4L[N[$!450222  "3P*
M^=O%'_!1[]F_P?KUUI%_\4=/GNK?;ODTNSN]0MSN4.-D]O"\3\, =K'!RIP0
M0#V]7^=_>'LX=CV?_A3_ ($_Z$CP[_X*K?\ ^(H_X4_X$_Z$CP[_ ."JW_\
MB*=\-?BKX1^,GA:W\1^"?$>G^)=%FVK]JL)@_E.R+)Y<J_>BD"NA:-PKKN&Y
M1THU[XL>"/"GBK3?#.M>,= T;Q)J?E_8='U#4X(+RZ\QS''Y4+N'?<X*KM!R
MP(&2,4>WJ_SO[P]G#L:7A_P?H7A7[1_8FB:;H_VC;YW]GVD<'F;<[=VP#.,G
M&>F3ZUN445BY.3O)W9:22L@HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***_.KX&?\%F/A]XHLM.L/B?H>H>"=9;]W<ZIIL1OM+^6$,92
M%)GCWR!U$0CEV@IF0@L5 .U_:@_X)5_"[XQ:5J6J^ K"W^'/C;R&:U_LU?)T
MBYE"QJBSVRJ1&FV,KNMPA#2M(RRD;3Y__P $I?V@/&I\0>,_V>?B$]Q<ZMX(
MAD.FM+LF>RBM[@6US9R3JY#K'(\(B"A@%\Q0^Q8E'I7Q,_X*W? +PCX5GO\
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M/%&J37E\^C793SK"UET29[.W?:B_,ELT"'<JOE3O ?<  ?J1^UA_R:S\9/\
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MFL_^D,U?*O\ P15_Y-9\4_\ 8YW7_I#8U]5?M8?\FL_&3_L3-9_](9J^5?\
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M.A=2<$HS+D'#$8- 'S#^R[^R[^TY_P -U>&OC)\9/#/_ #]?VKK7]H:7_P!
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M?L.BZ/93:A?77EM)Y4$49DD?:H+-A5)PH)., 'BOSC\-_M:_M3?MM^)M:B^
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MQSM?_2&^H ]T^'OC:]^&O_!//PWXNTN*WGU+0/A;;:K:PW:LT+RP:2LJ!PK
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MHDSV=N^U%^9+9H$.Y5?*G> ^X  _4C]K#_DUGXR?]B9K/_I#-7RK_P $5?\
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MX>TGQ!-H=G>7.4>_6.WMY3<B,J#&K-,0JM\VU59@A8HH!\&_L"_\I3/VCO\
MN8__ $^6]<5_P6TU+Q%-\9_A[I]TEP/"D'A^2?3V:V"PF]>Y=;L++M!=Q'%9
M;DW':"AP-Y+=K^P+_P I3/VCO^YC_P#3Y;U[G_P54_97\0_M#?"/0_$'@ZTN
M-6\3^#9KB==(@<;KRSG1/M BCV$R3JT$#*@92RB4 .Y12 >&?\;./\_\(Q7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML9&BMVD)^;Y4V@GKC<V/8<=JX_P#X)N?BM?:AJNL:A<>3&X4LI&YV/.!G(
M]NA& .W8ZG/:^)O@9.^E6T=I'%&K/;Q](RCAGZ]>/FR?7UJK^SOJ]K_9>HZ8
M956[\X3B-N"5*A3CUQC]17N*C3QF/RW+L;4]I1]ES+5VE+6WK9)6OK]YYOM)
M8?"XS%X>')4Y[><5I_P?(Y?XC> 9?AC/I^K:1J%QY+/M#,P$D<@Y'(P"",]A
MT.<YKMO'7CJ<_ +4/$*,L=Z]IY7F+QLD=Q"S+Z'YB1Z52_:'URU;2[#2EE5K
MSSOM!C7DJH4J,^F=WZ&H-3\-OJ'[/Z^'3D:CJ5L\MI"W6216,Z*/<A0!]17?
M@:"P.<X_!9;I3]E?E6J4[*UNSU?]+3*I5^L8+!XG&ZR]HE=]8WUOY'#_ +&G
M@^TN(=9\37$"R7D4PM+=F7_5?+N<CW(91GJ!D=Z]/OOVFOA_IM]/9SZK,LT$
MC1.JVDIY4X/.VO&/V3_B9IOA"\U;PYK=S'IZW4JRV\TS;$\T?*RL3P"1MP3@
M?*?49[+]I+P/X.TGX:ZGJNGZ=I\&K3W$3)<1,-[EI07V\\Y&<X'3->ME^*JX
M?)HU< X7@I.:E>]_E;7U\BLPPU.OG,J6.4K3<5!K:WSZ>G6YZ3:^*O#_ (P^
M&?B+5/#;Q_8Y+>Z\UHX/*/F^62Q88!+$$'/?BOD[X(_#?0/B1?:TGB'7)-(6
MT6-H&2>./>6+9^^#G&!T]>>U>S?LX_\ )NWBG_?O/_29*\A^ /PCTKXK7VOQ
M:KJ%U9+8K&R?965=V\N#G<IZ;1C%<6.G/,*N G*FIRG&3Y=D_P#+N=N"A#+Z
M6.A&HX*,H^]NU_6Q]/\ P=^%.@?#>UU.?0=7FU>.^,:O-++'(!LW8 * #/SG
MK[5\01Z?J++J&MV;2>7IMQ'YLBMRA<ML;\TQGL2/6OO?X8_#G3?AAX?GTG3+
MNXO8);AKEY+EE9]Q55Q\H QA1VKYQ_9F\,VWC)/B'HMY_J;RTABW?W3N<JWU
M5@"/<5TYME_ME@\'&"@VJEDG=)VOOZG/E68>Q>,Q<IN:3IW;6K5[;>AVWQ0\
M=1_$+]EM]:5E%R[V\=RJ?P3+*H?Z ]1[,*3P3_R9W?\ _7I>?^CGKP#^W+WP
M9X9\9^!-3C:-IIHF6-OX)XIESCCHR@\]]JU[_P""?^3.M0_Z\KS_ -&O7-@\
M8\=B9U)_&J$E+U3U_P _F;XS!K X:%.'PNO%Q]&M/NV^14_8UNDM?"_BFXG?
M9%%-%([-V 5R37FNGQ:U^T]\6)XKJ^DL]/C#S;>6%K;J0 JKD#<<J,]R23TQ
M7?\ [)=B^J?#[QQ9Q?ZRX40K]6CD _G7%_LL^)K/P?\ $^^L]7E73VO+=[56
MN3MVRAU(4D\#.TCGO@=ZYH6JX7+L+6=J4G*_2]I:)_UU.J=Z6)S#$T5>K%1M
MULFM7_78];T?]EBT\'^+-#UO0=>O%^PW22SPW>#OC!^8*R@8)&1@@@@GIW\<
M^(-]:^+OVA;VQ\::G<:;HL%V]MN4_P"JB4'RP."%#$*2<'[Q-?9=_P"(M+TN
M>TAO-0MK>:\D$5O')* TK'@!1G))]J\W^('P>\&_&F:YNX;V.+6+=S!->:?(
MKLKK\I65,\D8QS@\#G %?2YEDM.5%4LO44U)2<&])66V_P#D?-Y=G%15W5Q[
M;3BXJ:6L;O?;_,@^'7P)\.^$O%5EXI\+ZW-<V/DNAA:1)HY0RX!5UQP.N"#D
M@=,5[+7Q)\++W6OA+\=(O"T.IK>V<E\MG=1PL3%*'P V.S+D'U!!&<9S]MUZ
M.05Z-:A.-*E[-QDU*.ZOY'!GM"M1KPE5J^T4HIQ?6WG_ %_D%%%%?3GS0444
M4 %%%% !1110 4444 %%%% !117Y=W?_  4-^*D%U/&LFF[4=E'^B+V/TKBQ
M.+IX6WM.I]EP[PGF'%'M?J'+^[M?F=OBO:VC[,_42BORV_X>*?%;_GKI?_@&
MO^%'_#Q3XK?\]=+_ / -?\*XO[6PWG]Q]I_Q"?B'O3_\"?\ \B?J317Y;?\
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M /V,/BKJFGQ6\T]QIBZ2R7*L4\J\GBLY2 K [Q'.Y4YP&"D@@$$ ^-_V-/\
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MN^Z<[<<9R/@+_A^=_P!43_\ +K_^XJ /U4HKSSP?\9=#U?X'^%_B=XCO-/\
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M'&@W.B>)-%T_Q!HMUM^T:;JEK'<V\NU@Z[XW!5L,JL,C@J".E;%% 'A'AO\
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M HHHH _#FBBBOU@^<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#W
M']B7_DYSP9_V^?\ I%/7ZJU^57[$O_)SG@S_ +?/_2*>OU5KX?._]XC_ (?U
M9ZV$^!^OZ(****^?.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KE/B!X/B\;:&MC+=_85CE$OG;<C@$8/(]?6
MNKK@/C?(T?P_O,,R[I85.W_?%>+G4J4<MQ$J\.>*BVU>U[*]KK5'H9<JDL92
M5*7+)R23WMKV.B\*^'D\,>';72A*;E(%8>8RXW;F+'CGCG%<9X<^"=CX?\51
MZN+UIHH79XK8Q8VGG;EMQSC@].H%=AX"8MX)T-BVYOL4/S-_NBN@K".5X#&T
M<+4J4E^Z2<-7[NBMZVLM[[&KQF*PU2M&%3XVU+;75_=N]CD?B%X%3QYI=O:/
M=M:>3+YP<)OSP1C&1Z^M8^O_  G&N>&]&T?^U6@AT_=EO(W>:3WQN&,<CKT)
MKT:BM,3DF Q<ZE2M3NZB49:M72::6C75+8SHYCBJ$80ISLH.ZT6C?R,S0=(B
MT#1K/3H#F.WB$:LW5L=2?<G)_&N)\8?"&/Q1XD_MF'4FTZXVKG9!O^9> V=P
MYP!V[5Z316^+RK!X[#QPN(IWA&UEJK6T5K-/0BAC<1AJKKTI6D[W>CWWW.)\
M<_#'3?'"QRW#/;7T:[5N8E'(]&'<?CGWKBK']G58[I6O-;:2W4YVPP;'/XEB
M!^1KVNBO.QG#.4X^O]9Q%!.;W=VK^J32?S.O#YQCL+2]C2JM1[:.WI=:?(X'
MQY\+XO&S:9B^:Q2Q0Q@>5OR./]H>E;.M>#X-<\(C0IY3Y8ACC$VWD%<8;'X=
M,]S72T5W_P!DX+GK5/9ZUE:>^J2M;?33M8Y/KV)Y:<.?2F[QVT>YQ7P_^'Y\
M#V%[:-??;[>Y8-Y;0[ IQ@_Q'.1C\JY37OV?;.[O);G2M3;3MYW>3)'Y@7V!
M!!Q]<_6O8**XZW#N5XC#4\)4HWA#X=7=7[.]_E<Z:>;8VE6E7A4M*6^BU^5K
M?@>2>'?@'8:?>)=:K?-JC(=PA6/RT8_[7))'MW[^E<S^T5XFEL_$&@Z?93M!
M-:I]I_='!!9AMQCN-F?Q%>^2RK#&SNRJB@LS-T '4U\P:/GXJ?&W[4 SV:W'
MGD-VACQMR/<!5(]6KORW*<%E,'#!TU%/?=M^K=V_O.;%X[$8Z2GB)\UOZV1V
M/CC]F/1?'JP:F;B31==EB5KJ:",-%+*0-S&/(PQ.3P0,YR">:XNT_8G?[1_I
M7BQ6A_NQV)!_63%?4]%<=?(,MQ%1U:E)7?9M?DST*.>YCAZ:IPJZ+ND_S1PW
M@WX5Z5X'\#W?A>PGN&MKI9/-GE8&1F==A;@ #@# QV[UX^/V*[568KXLF7=_
MTXC_ ..5],T5O7R; 8F,(5:=U!66K5E\F8T,WQV&E.=.IK-W>B=W\TSR_P"#
MOP53X1MJK1ZS-JGV]8QM>+RPFS=SC<<D[O;I47P?^",7PEU'5[J/5FU,Z@J+
MM:#R]@4L?[QR3GVKU6BMJ6682C[+DA;V=^75Z<V_76_F8U,RQ5;VG/._M+<V
MBUMMTZ>1XC\5/V9M,^)7B9M<359-+N9459E2 2"1E& WW@0<  _0=.:ZK2OA
M';:3\)9_ T=_(\,MO+$;QHQNS(Q8G;GH">F>G?O7HE%*.5X.%6I7C3M*::D]
M=4]^O7R*EF>+G2A1E.\8--:+2VW3IYGFOP9^#Z?"'3M1M8]2.IF\D61G,/E;
M=H(Z;CGKZUS?Q1_9@T3X@:M/J]E>2:)JEPVZ9DC\R*5N[%<@ACZ@\]<9R:]N
MHI3RG!5,-'"2IITULM=/GN$<TQD,0\7&I:;W>FORVZ=CY[^'G[*%OX1\266L
MZCX@DU*2QE6>"&&#R5W*<KN)8D@'G'%-\7?LHIJ_B.]U?1/$]QH[7DSSRQ/#
MYF'<EFVLK*<9)P"#BOH:BN7^P<N]E[#V7NWON[WVO>]SJ_MS,/:^V]KK:VRM
M;TM8\9^%'[-^D?#?5EUBZOI-9UA0?+FDC$<<1(P2JY)W8)&2>AZ"O9J**]3"
M8.A@:?LL/'EB>9BL77QM3VN(ES2"BBBNPY HHHH **** "BBB@ HHHH ****
M "OS:N?^"9_Q#GN9Y1XE\,@2.6 \ZX[G/_/&OTEHKCQ&$I8JWM.A]=P_Q3F7
M#/M?[/DE[2U[J_PWM^;/S5_X=D?$3_H9O#/_ ']N?_C-?.GQ<^&<OPA\;7'A
MFZUS2];OK51]HETF1I(X),D&%BRJ=ZXY !QD G(('ZB_M6_'RU^ _P ,Y[N*
M3?XCU426>E0(Z[TD*,3<,I.2D?!) /S,@.-V1^2DTVI>*M>>21KG5=8U&X+,
MS9DFN)I&_$L[,?<DGWKY7,*&'P[5.DO>ZG].\ YSGW$%*>89G-*@M(I12YGU
M=^R_/T.__9W^"U[\=_B9IWAZV#)IJ%;G4[A6V&&U5U$A4[2 Y!VJ"""Q&>,D
M?K7K6IZ'\&?AG<WAB6TT'PWIGR0JP'[J&/"1J6/+':%&3DD@=Z\Y_9)^ MO\
M#_AG:I<6ZGQ+J@6\U&9D'F1%E7$ ;:#M3'W3_$6K@_\ @I!X@FTCX%Z;96]T
M\#ZCK4,,L:L1YL2Q3.P..HW!#@\9Q7KX:C_9^%E5:]YJ_P#DC\GXBS?_ %YX
MGP^5T9?[/&?*K=?YY?-)I>7JS\_OC!\5M9^,GCS4?$>LW,DC2NRVUN[$I:P;
MB4B0$G:HST!Y))[U7^&OPL\4?%KQ!'H_AC2+C4KHD>;(J'RK<'/S2OC"+P>3
MC)&!DD \BJL[*JKN9NBU^N_['_P@M/A'\%]&C:TACUW5H5OM2NE7]Y*6R\2,
M2 <(CA=IX!+8ZDGPL'AI8ZJ^=Z;MG[CQ;Q#1X+RF'U2FN9^Y3CT5EN_)+MNV
MN]SY,L_^"9?CV2T\RZ\3>'8+G_GC&T\B_BWEC] ?QKP;XS?L\^-/@5J44/B7
M3U:SG.V#5+(M):2MC)57*@AAZ$ \' XK]GZY/XD?#S1OBEX+U/PQKL/FZ=J$
M7EL4 WQD<JZ$@@,I (..U>[5R>BX/V5T_4_#LJ\5\WHXN+S%1G1;U2BDTNZM
MO;L]^Z/Q K[T_P""6?WOB?\ ]PS_ -NZ^%]5TRXT75+S3KN/R[RTF>":-NJR
M*2K#\""*^Z/^"6?WOB?_ -PS_P!NZ\++O]\A?S_)G[;XCR4N%,7*+NG[/_TY
M X'_ (*8?\EYT7_L7+?_ -*;JO&OV7?^3B/AY_V&;?\ ]"KV7_@IA_R7G1?^
MQ<M__2FZKQK]EW_DXCX>?]AFW_\ 0JK$?[\_\2_-"R#_ )(FG_UYE^3/MC_@
MIHW_ !9OPT/^H_'_ .D\]?4'P^?S/ ?AI_[VFVS?^0EKY?\ ^"FO_)&?#1_Z
MC\?_ *33U],?#&^@U+X;^%+NU97MY])M)8F7H5:%2/TKZBE_OE3TB?S-F2?^
MJ67/_IY6_P#;3JJ***](_.0HHKPW]LKQ9JO@O]G/Q7J>B7]QINI#[-!'>6C;
M9(@]S&CD,""I*EAD<Y/XUG4J*G"4WT5ST,NP4\RQM'!4W:5248IO9<S2O^)U
MFO?M"_#/PS?-9:EX[T&VNT.UX?MT;NA]&"D[3['FLW_AJOX1_P#10M#_ / G
M_P"M7S;^SA^Q%\-_B%\'_#_BC7+O4-7U/586GF:SO0D$+;V&Q0J9W* %8,3\
MP;&!@#U"/_@GE\(5;=]CU9O]Z_/_ ,37F0JXVI%3C&-GYL_1,3EG!V!KU,+7
MQ-=S@W%VA&UT[.UW?<]"_P"&K/A%_P!% T/_ ,"/_K4VX^*OPV^,&@Z[X?TS
MQ!HOB:233YWET]9%D+H$()V'J!D<CIFO/W_X)X_"!FS]CU9?]V_/_P 36]X1
M_9=^'7P)MM=\1Z';7$%VNF7,;W5_=;Q%$4W.02 %X7J>V:UB\6W:I&/+UW."
MK1X4IPYL!7KNLK<J<8)7OI=IW^[4\$_X)TWDEOH?Q5TCSY&MHO+E2-FX4[94
M9L= 2 H) YVCTKI_^"8W_)-_%G_86'_HF.N9_P""<%F^J6OQ3NHXV:.;R(D8
M\9+"8X^O3Z9%;/\ P3-U6UB\)^,M&>54U2+4%N&M6.)%0QJF=O7&Y2#Z'BO,
MP?\ S#W_ +Q^E<6Q37$"@M5+#-_=N?;M%%%?2G\X!7P+;VD5C_P5(\N&,11L
M&;:HP,G1LDX'J<GZYK[ZKX(CG2Y_X*E;D976/<FY>>1HN"/P.1^=>7C_ /ES
M_CC^I^F<#WMFJ_ZA*W_MI][T5YSKWQFTWP_\1-/\&7.B:_+J.H;C;7$-@7M9
M554:1UDW?=3>H8XX)Q698?M*>!]1\#>)/%D-],-.\/7#6M]"T6)UE#^6BJF>
M2[_*O/)/:NUUJ:;3EM^FY\7')\PG"-2%&3C+ELTKWYGRQV[M-+STW/6:*QO"
MWB"U\6>&=(URP\S[%J5I#>V_F#:_ER('7<,\'##C-;-;)IJZ/*G"5.3A-6:T
M84444R HHHH **** "OFC_@H_P"%]4\8?L3_ !1L=(M?M=U#96^H/'YBIBWM
MKN"YG?+D#Y8H9&P#D[< $D _2]8WBOPOI?CGPKK/AS6[;[=HNL64VGWUKYC1
M^;!+&8Y$W*0RY5B,J01G((XH ^3/^"2WC6Q\5?L7^'M,M(KB.X\-:GJ&E7;3
MJH5Y6G-X#&0Q)7R[N,9(!W*PQ@ GB_\ @M5_R:SX6_['.U_](;ZO*_\ @EW\
M0-<_9W_: \??LR^.$^S74][/=Z;MB=4:_@C_ 'ICW0AVCN+6-)DDD95V6Z[5
MS-S]I_MJ?LI_\-@?"W2O!O\ PE'_  B?V'68=7^W?V?]MW[()XO+V>;'C/GY
MW;C]W&.<@ Y_]F;]F7X/Z]^S?\*=4U/X4^"-0U&\\)Z3<W5Y=^';.6:>5[.)
MG=W:,LS,Q)+$DDDDU]$^%_">A^!]!MM$\-Z+I_A_1;7=]GTW2[6.VMXMS%VV
M1H JY9F8X')8D]:ROA/X%_X5?\+?!W@TWW]I#P[HUGI'V[RO)^T?9X$B\S9N
M;9NV9V[CC.,G&:ZV@#\__P#@M5_R:SX6_P"QSM?_ $AOJ^JOV3_^36?@W_V)
MFC?^D,-<I^VI^RG_ ,-@?"W2O!O_  E'_")_8=9AU?[=_9_VW?L@GB\O9YL>
M,^?G=N/W<8YR/BS_ (<8_P#5;/\ RU/_ +MH ^B?VU/^"B?@+X"^#O$OA[PI
MXCM]>^*;02V5I9Z2R3II5PQDB,]S(4>)6@="3;MF0L$5D57+KY!_P1W_ &8]
M<\ Z%XB^*_BC1?[-D\264%EX=>>5TN7L"YDGE,/W1%,RVQC9LL1$64!'5I._
M^!G_  2'^$/PQO-.U7Q?=ZA\2M9M?F:'4E6VTLR"821N+5,LV%4(4EEDC<,^
M4Y 7[KH \2^-/[&OP>_:(\4VOB/X@^$/^$AUJULET^&Z_M.\MML"O)(J;89D
M4X:5SD@GYN3@#&5\+OV#?@5\%_'>F^,O!W@;^QO$FF>9]DOO[7OI_+\R)XG^
M26=D.4=QRIQG(Y -?05% !7XK?\ !%7_ ).F\4_]B9=?^EUC7[4U\4_L5_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYXJ_\"[;_P"1Z/\ AW+\-O\ H.>*O_ NV_\ D>C^V,+W?W!]5J'YR45^C?\
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MSQ5_X%VW_P CT?VQA>[^X/JM0_.2BOT;_P"'<OPV_P"@YXJ_\"[;_P"1Z/\
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M\CT?VQA>[^X/JM0_.2BOT;_X=R_#;_H.>*O_  +MO_D>C_AW+\-O^@YXJ_\
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MQ_Z*1!_WW%_\;J,_"C]K0?\ -18?^_D/_P 17VS16/U&/\\O_ F>M_KMBO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\
M_#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZG
MX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]
M"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0
M/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=
M8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\
MR91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_
MP^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^
M"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0
MK?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#
M_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %
MUC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\
MF4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?
MH!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17
MY_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\
M_#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZG
MX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]
M"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0
M/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=
M8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\
MR91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_
MP^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^
M"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0
MK?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#
M_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %
MUC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\
MF4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?
MH!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17
MY_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\
M_#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZG
MX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]
M"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0
M/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=
M8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\
MR91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_
MP^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^
M"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0
MK?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#
M_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %
MUC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\
MF4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?
MH!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17
MY_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\
M_#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZG
MX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]
M"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0
M/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=
M8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\
MR91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_
MP^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^
M"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0
MK?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#
M_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %
MUC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\
MF4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?
MH!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17
MY_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\
M_#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZG
MX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]
M"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0
M/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=
M8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\
MR91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_
MP^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^
M"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0
MK?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#
M_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %
MUC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\
MF4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?
MH!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17
MY_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\
M_#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZG
MX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]
M"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0
M/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=
M8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\
MR91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_
MP^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^
M"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0
MK?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#
M_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %
MUC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\
MF4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?
MH!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17
MY_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\
M_#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZG
MX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]
M"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0
M/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=
M8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\
MR91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_
MP^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^
M"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0
MK?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#
M_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %
MUC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\
MF4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?
MH!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17
MY_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\
M_#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZG
MX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]
M"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0
M/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=
M8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\
MR91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_
MP^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^
M"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0
MK?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#
M_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %
MUC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\
MF4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?
MH!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17
MY_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\
M_#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZG
MX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]
M"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0
M/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=
M8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\
MR91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_
MP^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^
M"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0
MK?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#
M_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %
MUC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\
MF4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?
MH!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17
MY_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\
M_#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZG
MX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]
M"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0
M/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=
M8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\
MR91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_
MP^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^
M"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0
MK?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#
M_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %
MUC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\
MF4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?
MH!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17
MY_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\
M_#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZG
MX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]
M"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0
M/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=
M8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\
MR91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_
MP^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^
M"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0
MK?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#
M_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %
MUC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\
MF4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?
MH!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17
MY_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\
M_#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZG
MX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]
M"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0
M/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=
M8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\
MR91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_
MP^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^
M"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0
MK?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#
M_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %
MUC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\
MF4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?
MH!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17
MY_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\
M_#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZG
MX(?]"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]
M"M\0/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0
M/_!=8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=
M8_\ R91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\
MR91_P^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_
MP^I^"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^
M"'_0K?$#_P %UC_\F4 ?H!17Y_\ _#ZGX(?]"M\0/_!=8_\ R91_P^I^"'_0
MK?$#_P %UC_\F4 ?H!6=J&AV6J[6N(-TB_<F5BDB_1E((_.OA#_A]3\$/^A6
M^('_ (+K'_Y,H_X?4_!#_H5OB!_X+K'_ .3* /M63PWKEG\VF>(Y=O7[/J4"
MSCZ;QM;\R:HR77Q"M-P-EH-\/X6@>2,M]0QP/S-?''_#ZGX(?]"M\0/_  76
M/_R91_P^I^"'_0K?$#_P76/_ ,F4 ?7<VM?$D_ZKP]I:_P"TTX/_ +4%9%UI
M_P 6=;^1K[3='C;KY&.GUPY_(BOEO_A]3\$/^A6^('_@NL?_ ),H_P"'U/P0
M_P"A6^('_@NL?_DRF!],V_[/<NJW'VCQ)XCNM1F_Z9YW?3>Y.1_P$5Z%X9^'
MN@>$5!TW3HXYO^?B3YY/^^CR/H,"OB3_ (?4_!#_ *%;X@?^"ZQ_^3*/^'U/
MP0_Z%;X@?^"ZQ_\ DRB[ _0"BOS_ /\ A]3\$/\ H5OB!_X+K'_Y,H_X?4_!
M#_H5OB!_X+K'_P"3*0'Z 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*
MWQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _
M\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _\%UC
M_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _\%UC_P#)
ME 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _\%UC_P#)E 'Z
M 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _\%UC_P#)E 'Z 45^
M?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _\%UC_P#)E 'Z 45^?_\
MP^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _\%UC_P#)E 'Z 45^?_\ P^I^
M"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0
MK?$#_P %UC_\F4?\/J?@A_T*WQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#
M_P %UC_\F4?\/J?@A_T*WQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %
MUC_\F4?\/J?@A_T*WQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\
MF4?\/J?@A_T*WQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\
M/J?@A_T*WQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@
MA_T*WQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*
MWQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _
M\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _\%UC
M_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _\%UC_P#)
ME 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _\%UC_P#)E 'Z
M 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _\%UC_P#)E 'Z 45^
M?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _\%UC_P#)E 'Z 45^?_\
MP^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _\%UC_P#)E 'Z 45^?_\ P^I^
M"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0
MK?$#_P %UC_\F4?\/J?@A_T*WQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#
M_P %UC_\F4?\/J?@A_T*WQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %
MUC_\F4?\/J?@A_T*WQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\
MF4?\/J?@A_T*WQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\
M/J?@A_T*WQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@
MA_T*WQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*
MWQ _\%UC_P#)E 'Z 45^?_\ P^I^"'_0K?$#_P %UC_\F4?\/J?@A_T*WQ _
M\%UC_P#)E 'Z 45SGP^\:6/Q*\ ^&O%^F17$&FZ_IEMJMK#=JJS)%/$LJ!PK
M%0P5@" Q&<X)ZUT= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445D^(/$5AX7TN74=
M1G\BUCP"W4DGH !U- &M15'2-4MM:TNVO[1_-MKA!)&^TKD'V/3Z5>H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **XWQ]\6/"GPO^P_\)-J
MG]F?;O,^S_Z---OV;=W^K1L8WKUQU]C71:/JUIX@TFRU.PE\^RO($N8)MI7?
M&ZAE." 1D$'! -:.G.,5-Q=GL^A*E%MQ3U1H4445F4%%<#JGQN\%:-XV3PC>
M:UY/B%YX;9;/[),?WDH4QC>$*\AUYW8&><8-=G>7EOIMG/=W4\=M;6Z-++-,
MX1$51EF8G@  $DFM)4ZD+.46K[>?H2I1E>SV+=%<EX$^)WA?XF6=U<^&=6CU
M*.U<1S*L;QNA(R,HZAL'G#8P<-@\&NMJ91E3DXS5FAQDI*\7=!1114C"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BL/Q9XLTGP-X?N=:
MUJY^Q:9:[/.N/+:3;N8(ORJ"3EF X'>J?@?X@^'_ (D:3-JGAR__ +2L8IC;
M/+Y4D6) JL1AU!Z,ISC'/UJ_9S</:*+Y=KVT^\GFC?EOJ=11114%!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 1R2+"C.[!449+-P !7A5Y+-\=/'R6L/F)X5TIMSR+QYIS
MU^K=!Z $\<@['QB\7W>JW\'@GP^WFZA>,%NV7^!3SL)[9'+>@Z\$UZ!X'\'V
MG@?P_!IMK\[+\\TW\4LAZL?Y =@!3V V;:VBL[>*""-8H8E")&JX"J!@ #T%
M6***0!1110 4457CN/WGE2#;)V]&'J/\* +%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7'_ !@_Y)+XU_[ E]_Z3O78
M5Q_Q@_Y)+XU_[ E]_P"D[UM1_BP]5^9G4^!GYX_"GX5:O\7_ !%<Z/H]U9VM
MU!:M=LU](Z)M5T0@%48YRX[8QGGU]6_X87\>?]!?P[_X$W'_ ,8K,_8X\2:1
MX7^)VI76L:I9Z1;/H\L2S7UPD"%S- 0H9B 3@$XZX!]*^R_^%P>!/^AV\._^
M#6W_ /BZ^VS+'XS#XAPH+W;=KGB87#T:E/FF]?4H_!+P/?\ PV^&&C>'-3EM
MY[ZS\[S9+1F,;;YY)!@LH/1QU'7/6N^JI9WEOJ5G!=VL\=S;7"++%-"X='5A
ME64C@@@@@BOCV/\ :?\ $7A?X[ZU9^(M<DE\':=J.HPM9PV,)=DC$RPQJRH&
M)WB,9+#G[Q R:^5HX:MF$ZM2/Q*\GY^2\SU9U(8:,8O;8^S:*^,O&FH?M$?$
M*SO-8L]*U;P[H6]KFWTVQECM;J)4#+M(RMPY(!.TC#D@JH&T#<_9F_:8U_QE
MXN3PIXK?^U+C4/,DLM0CBCB:(I&79'50H*%4)! W!N#D$%>B>558T958SC+E
MW2=VOZ_JYG'%P<U!IJ^UUN?6-%<]XX\9:;\/?"NH>(=7>1=/L4#R>3&7=BS!
M551ZLS*.2 ,Y) R1\;M^T)\7/C1XDN='\'+_ &>L\,BKI^FI&&2'+9=[B091
MP&5=X9!NV[0"<'GPF JXM.<;**W;T1K6Q$*+47JWT1]TT5\*WGBC]H#X)6,%
MYK$NI2:3Y_GROJ#1:E'P479),"[1(Q*@#>N<G:<Y-?2OP#^-UK\:/#,LS0?8
MM<T_RTU"V53Y66!VO&QS\K;6X)RI!!R,,UXG+JF'I^VC)3AW3O\ >12Q,:DN
M1II^9XU^WU_S(O\ V_\ _MO7T5\'_P#DDO@K_L"6/_I.E?.O[?7_ #(O_;__
M .V]0:5\8O'?C3PQX:\)_".QDEGT/1[,:KJDD<('FB%4,2^?A  P;D_,Q1MO
MRH2WJO#SQ.74(Q:23E=O1+5[LY545/$U&]=MO1'V#17P+J7Q*^-WP'O+*SU_
M4+Q8[A_M:1ZL8[Y+@ @,GG9<@< %%=2H8$ ;LG['^%7Q(L/BKX)L?$-@GV?S
MLQW%HTJN]O,IPR,5_ @D E64X&<5Y.+R^IA8*KS*4'U1UT<3&LW&UFNC/DKX
MG_\ )[%G_P!AS1__ $"VKZ[^)W@.W^)G@/5_#5S=26,=\BJ+B-0Q1T=9$.#]
MX;D&1D$C(!&<CY$^)_\ R>Q9_P#8<T?_ - MJ^P?B/JUSH/P]\3ZG82^1?6>
MEW5Q;R[0VR1(F96P00<$ X((KT<PYDL(X.SY8V]=#FP]KUN;:[/(OV;OV;K_
M .$.K:EK6MZE;W>IW$)LX;?3V9H%A+([,S.BDL60     '.[=\O=?'+XO?\
M"F?"=GK?]E?VS]HODL_L_P!I\C;N21]V[8V<>7C&.^<\8KSS]D7XK^*OB?\
M\)9_PDVJ_P!I_8?LGV?_ $:*'9O\[=]Q%SG8O7/3BO(_VHO^%J?\3'_A*?\
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M[CHKY"\$_MB:S=>!=234-+M]4\71S6UCI<-IE3>R2JXWR0@Y.UH\MY?WFE1
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M68?\_F']BY=_SY1[S_PV9XU_Z!6@_P#?B?\ ^/4?\-F>-?\ H%:#_P!^)_\
MX]7@U%']M9A_S^8?V+EW_/E'O/\ PV9XU_Z!6@_]^)__ (]1_P -F>-?^@5H
M/_?B?_X]7@U%']M9A_S^8?V+EW_/E'O/_#9GC7_H%:#_ -^)_P#X]1_PV9XU
M_P"@5H/_ 'XG_P#CU>#44?VUF'_/YA_8N7?\^4>\_P##9GC7_H%:#_WXG_\
MCU'_  V9XU_Z!6@_]^)__CU>#44?VUF'_/YA_8N7?\^4>\_\-F>-?^@5H/\
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MXG_^/5X-11_;68?\_F']BY=_SY1[S_PV9XU_Z!6@_P#?B?\ ^/4?\-F>-?\
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M@_\ ?B?_ ./5X-11_;68?\_F']BY=_SY1[S_ ,-F>-?^@5H/_?B?_P"/4?\
M#9GC7_H%:#_WXG_^/5X-11_;68?\_F']BY=_SY1[S_PV9XU_Z!6@_P#?B?\
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M2+YF]P/\.?PR*L6-XM]:I(ORGHR^A]* +=%%% !1110 4444 %%%% !1110
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M><?L+>%K"+PGKWB/RM^J3WW]G^8P4[(4CCDPIQD;FDRPS@[$XXR?1_VL?^2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?ES1117\Z']&A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!ZC^S'_P EP\-?]O/_ *2RU]ZU\%?LQ_\ )</#
M7_;S_P"DLM?>M?JW"?\ N,_\;_*)^3\6?[]#_ OSD%%%%?:GQ04444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5PWCGQ5X+N=.UGPQKOBS2M*DN[62TN89=1@AGB26/&=KGY3M;(
MR".0>17<UXG\0/V5/"7Q*\77_B/5-1UF"^O/+\V.TGB6(;8UC& T1/10>2><
M_2NK#*BZEZTG%+LKZF-7GY?<5SS'_AGGX$?]%,_\K]A_\;H_X9Y^!'_13/\
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MQ1_PPWX#_P"@OXB_\";?_P",5%*6"HW]E6DK[Z%25>I;F@G;S/7/^%P>!/\
MH=O#O_@UM_\ XNO!/&GP5^!?B>\O+W3_ !QI/ARYE1ML=EK-JUJLK%B',3$D
M#) V(RKA0 %ZUO\ _##?@/\ Z"_B+_P)M_\ XQ1_PPWX#_Z"_B+_ ,";?_XQ
M54:F#P[YJ->:^0IQK5%:<$_F<3X=_9[^"NGQVCZQ\3+/5[J*3?,L6KVEO!,
MV0NP%G4%< XDR>2"N0!]":5\1OAKH-A%8:7XH\*:?919\JUL]0MHHTR2QPJL
M ,DD\#J3ZUYC_P ,-^ _^@OXB_\  FW_ /C%'_##?@/_ *"_B+_P)M__ (Q5
M5ZV$Q5O;5Y/Y"IPJTO@II?,U?BYI?PF^-!TK^V_B#IUM_9OG>3_9^M6B;O,V
M;MVX-G&P8QCJ<YXKF_%GPM^!OC"'1EN?'&FV-QIEC%I_VJRUJS22ZCC18XS-
MN!5G"KC( .#@Y 4"_P#\,-^ _P#H+^(O_ FW_P#C%'_##?@/_H+^(O\ P)M_
M_C%.G7PM)1C3Q$TH[:=]PE"K)MRIIW\SE?!/P-^"GAF\T^_U?XA:3XCN[5S(
M\,^J6D=G,V3MW19+8'RY!<AB.002M?0W_"X/ G_0[>'?_!K;_P#Q=>1_\,-^
M _\ H+^(O_ FW_\ C%'_  PWX#_Z"_B+_P ";?\ ^,5%>I@\3+FK5Y-^@Z<:
MU)6A!+YDFO>#_@_XB^*,?CRX^(=FNLQW5M=K#'K=F(-\ 0(-I4M@^6,_-GDX
M(XQZ'XD^(/P[\4>'=4T>Z\<:#';:C:RVDK0ZO;AU21"C%26(!P3C(/-><?\
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MM&,(.W7->5_\,\_ C_HIG_E?L/\ XW77?\,-^ _^@OXB_P# FW_^,4?\,-^
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M2,1J[OD[PQ9RTC$L3R3D\DD^U?\ "X/ G_0[>'?_  :V_P#\77D?_##?@/\
MZ"_B+_P)M_\ XQ1_PPWX#_Z"_B+_ ,";?_XQ6%26"K)1J5Y-+;3N:15>#;C!
M*_F2?"GP?\'O@_XBN=8T;XAV=S=7%JUHRWVMV;IL9T<D!%4YR@[XQGBO6/\
MA<'@3_H=O#O_ (-;?_XNO(_^&&_ ?_07\1?^!-O_ /&*/^&&_ ?_ $%_$7_@
M3;__ !BE5>!KRYZM:3?H.'MZ:Y8P27J2?"GP?\'O@_XBN=8T;XAV=S=7%JUH
MRWVMV;IL9T<D!%4YR@[XQGBO0_$GQ!^'?BCP[JFCW7CC08[;4;66TE:'5[<.
MJ2(48J2Q ."<9!YKSC_AAOP'_P!!?Q%_X$V__P 8H_X8;\!_]!?Q%_X$V_\
M\8IU)8*K/VDZ\G+O8457A'EC!6]23X4^#_@]\'_$5SK&C?$.SN;JXM6M&6^U
MNS=-C.CD@(JG.4'?&,\5H?%?1_@W\8_L,NM>,]&M;ZU^6.^L-9M8YVC.3Y3%
MBP9,G< 1D'.",L#E_P###?@/_H+^(O\ P)M__C%'_##?@/\ Z"_B+_P)M_\
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M3I-EH.EV>F:99V^G:99PI;6UG:1+%#!$BA41$4 *BJ       .!0!^;'A?\
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MNGWVLZ/]C\B#5(WDMV\V\@@;>J.C'"RL1AAR!G/0_#'[ O\ RE,_:._[F/\
M]/EO7U3_ ,%1_P#DQ3XF?]PS_P!.EI0!WW[&OQIUO]HC]F[PA\0?$=KI]CK.
ML?;//@TN-X[=?*O)X%V*[NPRL2DY8\DXQT'E?[9G_!032_V<=>L? /@S0_\
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M?B#XC?$/QO?0?:=:\-V=G9Z=YD:.D/VPS^;*N5++(%MA&&5A\DLJD$/Q^O\
M0!\$_&'_ (*$>/?$'QXU/X-_LY_#JW\=^+-%FECU/4]:9X[1&@WI=1B,O"$5
M)/+3SY)E5GRBHV^-VX&3XR?\%#_AI;^(_$6M_##1_%&FSS++%IJVUK>OIZM(
M0([6&PNA<2K^\4$R><P6,,6&'8^5:UXT\0_\$X?^"@'CWQ[XV\'W&N>%_'DV
MHR:?>Z;<A$>SNM0AN9)(BR8DGA50CV[&/YF4[PC([?I/^S_^UE\+_P!IC2UN
M/ OB>WO-26'SKG0;O]QJ-H L9?? W+*K2HAECW1%B55VQ0![%1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?ES1117\Z']&A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!ZC^S'_R7#PU_P!O/_I++7WK
M7P5^S'_R7#PU_P!O/_I++7WK7ZMPG_N,_P#&_P HGY/Q9_OT/\"_.04445]J
M?%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$IX6M[.E*+]Z2YG96M?\CCP>6QQ,L74Q-%5*L9+W8OE5WO;\SZH^#OQJM?C
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M/_!)WP]IOQ/_ .$Z^+GQ#UCXSZM'-#/'%J]L8X;EHT* 7GF2SR7*@"':F]%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'Y<T445_.A_1H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
MH_LQ_P#)</#7_;S_ .DLM?>M?!7[,?\ R7#PU_V\_P#I++7WK7ZMPG_N,_\
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MD;<^BUR/PS^('_"M[B_TS5[&80O+N;RE&^*0<'(8CJ,=^W?-?0&GZ+8:3O\
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MS@>1$RE5C#6R.(R&4%F4 )M10#]TZ^-/^"JGQXE^#G[+U_HNF7-O'KGC:<Z
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M\(_M ^*/A3IMMID=C)HVB+<F&:5997-P?+NX5W,LBIRI.(UY/  !]0U^?_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?ES1117\Z']
M&A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!ZC^S'_P EP\-?]O/_
M *2RU]ZU\%?LQ_\ )</#7_;S_P"DLM?>M?JW"?\ N,_\;_*)^3\6?[]#_ OS
MD%%%%?:GQ04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXU^$/L=U+9ZAJ%OJW]J6;YU:YE19'\JUF(^:*:[&"NP;N "%Q^G]% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_05T'_O_ #__ !FOLVBC_5G+^S^\/]9\Q[K[CXR_X8S\:_\ 05T'_O\ S_\
MQFC_ (8S\:_]!70?^_\ /_\ &:^S:*/]6<O[/[P_UGS'NON/C+_AC/QK_P!!
M70?^_P#/_P#&:/\ AC/QK_T%=!_[_P __P 9K[-HH_U9R_L_O#_6?,>Z^X^,
MO^&,_&O_ $%=!_[_ ,__ ,9H_P"&,_&O_05T'_O_ #__ !FOLVBC_5G+^S^\
M/]9\Q[K[CXR_X8S\:_\ 05T'_O\ S_\ QFC_ (8S\:_]!70?^_\ /_\ &:^S
M:*/]6<O[/[P_UGS'NON/C+_AC/QK_P!!70?^_P#/_P#&:/\ AC/QK_T%=!_[
M_P __P 9K[-HH_U9R_L_O#_6?,>Z^X^,O^&,_&O_ $%=!_[_ ,__ ,9H_P"&
M,_&O_05T'_O_ #__ !FOLVBC_5G+^S^\/]9\Q[K[CXR_X8S\:_\ 05T'_O\
MS_\ QFC_ (8S\:_]!70?^_\ /_\ &:^S:*/]6<O[/[P_UGS'NON/C+_AC/QK
M_P!!70?^_P#/_P#&:/\ AC/QK_T%=!_[_P __P 9K[-HH_U9R_L_O#_6?,>Z
M^X^,O^&,_&O_ $%=!_[_ ,__ ,9H_P"&,_&O_05T'_O_ #__ !FOLVBC_5G+
M^S^\/]9\Q[K[CXR_X8S\:_\ 05T'_O\ S_\ QFC_ (8S\:_]!70?^_\ /_\
M&:^S:*/]6<O[/[P_UGS'NON/C+_AC/QK_P!!70?^_P#/_P#&:/\ AC/QK_T%
M=!_[_P __P 9K[-HH_U9R_L_O#_6?,>Z^X^,O^&,_&O_ $%=!_[_ ,__ ,9H
M_P"&,_&O_05T'_O_ #__ !FOLVBC_5G+^S^\/]9\Q[K[CXR_X8S\:_\ 05T'
M_O\ S_\ QFC_ (8S\:_]!70?^_\ /_\ &:^S:*/]6<O[/[P_UGS'NON/C+_A
MC/QK_P!!70?^_P#/_P#&:/\ AC/QK_T%=!_[_P __P 9K[-HH_U9R_L_O#_6
M?,>Z^X^,O^&,_&O_ $%=!_[_ ,__ ,9H_P"&,_&O_05T'_O_ #__ !FOLVBC
M_5G+^S^\/]9\Q[K[CXR_X8S\:_\ 05T'_O\ S_\ QFC_ (8S\:_]!70?^_\
M/_\ &:^S:*/]6<O[/[P_UGS'NON/C+_AC/QK_P!!70?^_P#/_P#&:/\ AC/Q
MK_T%=!_[_P __P 9K[-HH_U9R_L_O#_6?,>Z^X^,O^&,_&O_ $%=!_[_ ,__
M ,9H_P"&,_&O_05T'_O_ #__ !FOLVBC_5G+^S^\/]9\Q[K[CXR_X8S\:_\
M05T'_O\ S_\ QFC_ (8S\:_]!70?^_\ /_\ &:^S:*/]6<O[/[P_UGS'NON/
MC+_AC/QK_P!!70?^_P#/_P#&:/\ AC/QK_T%=!_[_P __P 9K[-HH_U9R_L_
MO#_6?,>Z^X^,O^&,_&O_ $%=!_[_ ,__ ,9H_P"&,_&O_05T'_O_ #__ !FO
MLVBC_5G+^S^\/]9\Q[K[CXR_X8S\:_\ 05T'_O\ S_\ QFC_ (8S\:_]!70?
M^_\ /_\ &:^S:*/]6<O[/[P_UGS'NON/C+_AC/QK_P!!70?^_P#/_P#&:/\
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M_05T'_O_ #__ !FOLVBC_5G+^S^\/]9\Q[K[CXR_X8S\:_\ 05T'_O\ S_\
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M,_&O_05T'_O_ #__ !FOLVBC_5G+^S^\/]9\Q[K[CXR_X8S\:_\ 05T'_O\
MS_\ QFC_ (8S\:_]!70?^_\ /_\ &:^S:*/]6<O[/[P_UGS'NON/C+_AC/QK
M_P!!70?^_P#/_P#&:/\ AC/QK_T%=!_[_P __P 9K[-HH_U9R_L_O#_6?,>Z
M^X^,O^&,_&O_ $%=!_[_ ,__ ,9H_P"&,_&O_05T'_O_ #__ !FOLVBC_5G+
M^S^\/]9\Q[K[CXR_X8S\:_\ 05T'_O\ S_\ QFC_ (8S\:_]!70?^_\ /_\
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M_5G+^S^\/]9\Q[K[CXR_X8S\:_\ 05T'_O\ S_\ QFC_ (8S\:_]!70?^_\
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M\#I3J0!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"PO(7Z\GWKOJ**0!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\
MX<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?
M!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H
M:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!
M_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#
M"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^
M0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^
M'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP
M0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&
MGX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?
M^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q
M_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D
M.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#]
M **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_
M/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\
MX<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?
M!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H
M:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!
M_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#
M"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^
M0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^
M'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP
M0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&
MGX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?
M^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q
M_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D
M.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#]
M **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_
M/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\
MX<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?
M!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H
M:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!
M_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#
M"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^
M0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^
M'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP
M0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&
MGX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?
M^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q
M_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D
M.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#]
M **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_
M/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\
MX<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?
M!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H
M:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!
M_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#
M"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^
M0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^
M'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP
M0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&
MGX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?
M^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q
M_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D
M.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#]
M **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_
M/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\
MX<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?
M!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H
M:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!
M_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#
M"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^
M0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^
M'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP
M0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&
MGX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?
M^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q
M_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D
M.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#]
M **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_
M/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\
MX<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?
M!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H
M:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!
M_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#
M"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^
M0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^
M'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP
M0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&
MGX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?
M^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q
M_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D
M.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#]
M **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_
M/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\
MX<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?
M!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H
M:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!
M_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#
M"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^
M0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^
M'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP
M0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&
MGX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?
M^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q
M_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D
M.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#]
M **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_
M/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\
MX<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?
M!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H
M:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!
M_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#
M"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^
M0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^
M'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP
M0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&
MGX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?
M^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q
M_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D
M.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#]
M **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_
M/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\
MX<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?
M!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H
M:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!
M_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#
M"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^
M0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^
M'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP
M0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&
MGX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?
M^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q
M_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D
M.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#]
M **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_
M/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\
MX<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?
M!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H
M:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!
M_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#
M"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^
M0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^
M'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP
M0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&
MGX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?
M^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q
M_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D
M.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#]
M **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_
M/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\
MX<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?
M!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H
M:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!
M_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#
M"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^
M0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^
M'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP
M0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&
MGX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?
M^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q
M_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D
M.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#]
M **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_
M/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\
MX<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?
M!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H
M:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!
M_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#
M"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^
M0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^
M'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP
M0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&
MGX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?
M^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q
M_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D
M.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#]
M **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_
M/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\
MX<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?
M!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H
M:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!
M_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#
M"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^
M0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^
M'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP
M0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&
MGX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?
M^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q
M_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D
M.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#]
M **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_
M/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\
MX<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?
M!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H
M:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!
M_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#
M"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^
M0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^
M'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP
M0_Z&GX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&
MGX@?^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?
M^#"Q_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q
M_P#D.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D
M.@#] **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#]
M **_/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_
M/_\ X<K?!#_H:?B!_P"#"Q_^0Z/^'*WP0_Z&GX@?^#"Q_P#D.@#] **_/_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*_O4Y^89 /A?_@BK_P FL^*?^QSNO_2&QK@/V*_A/IG[?WQ'^(/[0/QCL_\
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MT/[/UI;-['1&7R7D;4IE*6Y2.4A9-C'S67#?NXI&VL%(H ^8/V<=6LOVJ_\
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M7Z/J&NWD6GZ58W'AVP^T7\\DT4*I#$(B\F'GB#%00@<,Q5030!X!_P %JO\
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M*L<[?+W(6 )#2)TR"/._@GX!D\*_LM>.]9N[?R;W7M+O)T9MX<VJ6SK#N5@
M,DR." =RR*<G@#PLM_V3#RQ+^*348_J_Z['?BOWU14NB5W^APW[#/_)6M6_[
M DW_ *46]>J_MK>/]2\+^#](T#3I9+4:\\RW5Q$^TM#&$#0XQG#F5<D,.$*G
M(8BO*OV&?^2M:M_V!)O_ $HMZ/VYO^2M:3_V!(?_ $HN*]6I2C5SF/-LE?\
M Y8S<,$[=SOOV._@MIR^&U\<:M;6>I7-Z_\ Q+(Y8M[6@BD96D^;Y0[.@((&
M5"##?.P'U77#_!6\M[[X0^"I;>>.=!I%K$6B<.%9(E1UR.ZLI4CJ""#TKR/]
MH[QE\6O#WCBQMO <&K2Z0VG1R2M8Z0MVGGF64-ES$^#M"<9'8XYKYVJJN8XR
M:<DGKOLDNAZ,''#4$TK^A]$WEG;ZE9SVEU!'<VUPC12PS('1U8896!X(()!!
MJW7Y]:[^T9\:_"]XMKK.JWFD73H)5AOM&MX'*$D!@KP@D9!&>F0?2OM[X<:M
M<Z]\/?#&IW\OGWUYI=K<7$NT+OD>)69L  #)).  *RQ>7U<'",YR33[/_@(J
MCB85VXQ337<^$?V3O^3@/"O_ &]?^DDU?HK7YU?LG?\ )P'A7_MZ_P#22:OT
M5KT^(/\ >H_X5^;.;+OX3]?\CP?]J#X,:-XP\!ZUXAMK&WM/$FF0M??;4 C:
MXCC4&1)2%)?]VF%ST95P0"P/C_[#OC2XL?&6K^&)KR-=/U"U-W!#.Y!:YC*@
MB)2V,M&S%L#)$2GHE?9&L:M:>'])O=3OY?(LK.![F>;:6V1HI9C@ DX )P 3
M7Y__ +)5G/<_'KP])#!))';I=2S-&A(C4VTB!F(^Z-S*N3@98#J15X&<J^75
MZ53:*NOSM^'XD8B*IXFG..[W-S]M+Q1_;/Q<724DN/)T>QB@>&1OW?G/F5G0
M9(^9'B4G .4P<@"OM+P+X5M_ _@[1M M_+,>G6J0&2*(1"5P/GDV@G!=LL>3
MRQR3G-?!G[6/_)P'BK_MU_\ 22&OT5K/,UR8+"PCLU?YV7^;+POO5ZLGO<^)
M_P!N?PK;Z=XR\/Z_"(T?5+9X)HXX@I9X"N)&8'YR5E5>1D")>2,8^FO@;XH_
MX3+X1^%=5:2XGF>Q2"::[;,DLT68I')R2=SHQR3D@@G!XKP/]OK_ )D7_M__
M /;>O7/V3O\ D@/A;_MZ_P#2N:C%>_E-"<MT[?+7_)!2]W&5(K:W^7^9Z=I6
MCV'A_3XK#2[*WT^RBSY=M:1+%&F26.%48&22>!U)KR/]KS[#_P *+UG[7]G^
MT>?;?8_.V[_.\Y<^7GG=Y?F9QSMW]LUZ+X_^(&C?#7PU<ZYKESY%I#\J1K@R
MSR$';%&N1N8X/&0  22 "1\0^)O$GCG]K;QEI]K9:1'%9V+M'"L,;>19)*2Q
M>XF(/)6, G@-Y>$3)(/)E>%G5JK$S=H0=VWY:_\ #FN*K1A!TDKM]#U7]@S2
M;F'2?&&J21;;&XFM;>*7</FDC61G&,Y&!+&<D8.[C.#CZPKD?AK\/=.^&/@^
MPT#38XU6! UQ/''L-U,0 \S DG+$="3@!5' %>2?M3?M 6_@71;GPMH5[(OB
MN\15EFM) IT^)L$EFP<2,O  PRAM^5^3=%;FS3'2]BOB?X+2[*A;"T%S]#SO
M]H;QEJ7QT^*.G_#'PLT<MK9W3),URGD@WD8D$K%SD[(DWC@9)WX#_(:\E\-Z
M%;^%_P!I+2M&MGDEM=-\60VD;3,"Y6.\"*6( !. .@ SV%?5_P"RW\#S\,?#
M+:UJGS>(M9AC>2-XMC64.-PA^90P<D@R X&Y5&#LW-\P_P#-V7_<\?\ M_7T
MV#K4_P!YA:'P0COW?5GEUJ<O=JU-Y/[ET/T6HHHKX$^A"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.?$G_H!^%?\ P$N?_DBOE6BC^S\+_P ^T'MZG<^JO^'CGQ)_Z ?A7_P$N?\
MY(H_X>.?$G_H!^%?_ 2Y_P#DBOE6BC^S\+_S[0>WJ=SZJ_X>.?$G_H!^%?\
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M!+G_ .2*^5:*/[/PO_/M![>IW/JK_AXY\2?^@'X5_P# 2Y_^2*/^'CGQ)_Z
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MBOE6BC^S\+_S[0>WJ=SZJ_X>.?$G_H!^%?\ P$N?_DBC_AXY\2?^@'X5_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<;Y6?9C(K[?\ ?#_ $;X:^&K;0]#MO(M(?F>1L&6>0@;I9&P-S' YP
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M)7P7\ >+M3BMX-2\0>']/U6YAM%984EGMHY7"!F)"AG( +$XQDGK7YR>./\
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MR8F:],XC<1J&'FO]FDNSL(8!0SX^3<.V_P""<']M_P##$_PM_P"$A_M#[?\
M8KCRO[2W^9]E^US_ &7;OY\O[/Y/EX^7R]FWY<4 >?\ QQ_:@_:-D^.OB/X=
M_ OX-Z?XEM?#.Q=0\0Z[(_V2X>2UM+@1QR-+;112(+H9C,LCNI5PJ@'/@%]^
MTU^W-^RKH,OB_P"+W@W3_%7@S[;:PW<UVMAOM4+,&"/ISCR?,R$\V:.1%?R@
M!EMK_JK7.?$+4O#VB^ ?$NH^+EMY/"EIIES<:PMW;&XA:S6)FG#Q!6,B>6&R
M@4[AD8.<4 <!^RO^TMX>_:N^$EGXV\/VUQI\BSM8ZEI=SDM8WB(CR1"3:!*N
MV1&610-RNN0K;D7V*OR__P""'OA?5+3PK\6O$<MMLT74+W3=/MKKS%/F3VZ7
M$DR;0=PVK=0') !WX!.& _4"@ HHKY4_89_;F_X;0_X3;_BBO^$._P"$;^P_
M\Q;[=]I^T?:/^F$6S;Y'OG=VQR ?5=%%% !7B7[97QIUO]G?]F[Q?\0?#EKI
M]]K.C_8_(@U2-Y+=O-O((&WJCHQPLK$88<@9ST/MM?*G_!4?_DQ3XF?]PS_T
MZ6E '??L:_&G6_VB/V;O"'Q!\1VNGV.LZQ]L\^#2XWCMU\J\G@78KN[#*Q*3
MECR3C'0>VU\J?\$N/^3%/AG_ -Q/_P!.EW7U70!\4_\ !1_]M3QO^Q^?AY_P
MANE>']2_X2'^T?M?]NVT\NSR/LNSR_*FCQGSVSG/1<8YS]K5^5?_  7._P":
M)_\ <;_]L*_52@ HKPC]I;]M#X7_ +*=O;1^-=5N)]<O(?M-IX?TF#S[ZXB\
MQ8S)@LL<:Y+$-*Z!O+D";F4K7RMX<_X+:?#J[U364U_X?>*--TV&?&EW&FS6
MUY-=1;G^:>-WB6!MHC.U'E&68;OE!8 _2"BN<\ ^/O#WQ4\':3XK\*:K;ZYX
M=U6$3VE];,=DBY((((#*RL"K(P#*RLK $$5Y#\7OVU/!'P8^/G@KX1ZWI7B"
MZ\1^+/L7V&ZL+>![2+[5=/:Q^:SS*XPZ$MM1L*1C)XH ^@:*^%/CG_P5X^$/
MPQO-1TKPA::A\2M9M?E6;366VTLR"8QR(;I\LV%4N'BBDC<,F'Y)7U_]G+]O
M/X3_ +3&E^);O0]3N/#MQX>@:\U"Q\4>39S162J"UYE970P*259MWR$#>%#H
M6 /HRBOSU^+G_!9KX7^$;B6T\!>&M8^(-Q'-&IO)F_LJQEB:/<S1NZ/,65RJ
M%7A0'YB&P%W?1'[+G[;WPU_:V_MBW\'S:AIFLZ7B2;1==BB@O&@.T"XC5)'5
MX]S;"58E6V[@H>,L ?05%%?"GQS_ ."O'PA^&-YJ.E>$+34/B5K-K\JS::RV
MVEF03&.1#=/EFPJEP\44D;ADP_)*@'W717QG^SM_P5,^$_Q^\8Z#X.EL]8\&
M>)]5A58EUA8?L,MX0O\ HD-PLA+,S%A&SQQ[]H  =E0_9E !7B7[97QIUO\
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M;2X  /M:BN<^'WC2Q^)7@'PUXOTR*X@TW7],MM5M8;M569(IXEE0.%8J&"L
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M<:;-;7DUU%N?YIXW>)8&VB,[4>499AN^4%OT@H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /PYHHHK]8/G HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#]QJ***_)SZ,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "OW_P#\11_PSO\ 'C_HIO\ Y7[_ /\ B*^N:*/[6K_RQ^Y!]3I]W]Y\C?\
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MK96]P)((UMRVZ:+:C;2'0DA_V>HH ^??V*?C5\(?BW\&[*S^#UM_8.A>'O\
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M^LUPRJ 9'$<Z('8C)"*JY)PH&!7R7_P3;_L/_AY)\=/^$8_L_P#X1O[%KO\
M9G]D[/L?V7^V+7R?(V?)Y>S;MV_+MQCC% &M_P %SO\ FB?_ '&__;"OU4K\
MJ_\ @N=_S1/_ +C?_MA7ZJ4 ?E7_ ,$,?^:V?]P3_P!OZ/\ @JQJ6N?%C]J;
MX*? S^U?[(\-ZK]BG\Z)7DQ=7M])9^=+%Y@27R4BR@PK#S9ANP_!_P $,?\
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M34-3M8[N2YNV1_LD<#RM-(\HC)BG" G9N6;:,ES7[4T ?B%_P2G_ &;=+_:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN4TJY;3K.+YL1RF-$4G@%EY8G]<'@5T&KZ/8:5\"K@:+-)<P3F*=IMN&<F1
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M?V%T("]M"9"JM+!YDDB@,Q6V3YML1R ?J_1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /W&HHHK\G/HPHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQK_Q^W2G:2<<LH8[5'0XR>O'Z#^.-7?0/!>OZI%_KK+3[BY3ZI&S#^5?F?\
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ME7[4W_)O'CS_ +!LG\Q7Q#^Q+X-T/QQ\7+G3O$&D6NJV/]E32K;W<0=%8/&
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M/^"KWB;XC_V)_P )'_8OV7_B6_:_LOG>=H44'^MV/MQYN[[ISMQQG(]*U/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<YXT^'O
MA;XE:7%IGB_PSH_BK38IA<QV>MV,5Y"DH5E#A)%*A@K, P&<,1W-='10!\O:
MM_P3._9IUK5;S4+CX86\=Q=S//(MIJU_;0AF8L0D4=PL<:Y/"(H51@   "O?
MO!?P]\+?#72Y=,\(>&='\*Z;+,;F2ST2QBLX7E*JI<I&H4L5506(SA0.PKHZ
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P
MYHHHK]8/G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#]QJ***_)SZ,**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML\_"SQC_ -@>\_\ 1#U^>O["O_)Q6B_]>-W_ .BZ_0KXM?\ )*O&/_8&O?\
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MJTPOM;U2"%41I0H5+>)BHD:"(;MN\Y+22N GF%%^C:* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_(]'_#N/XD_]!SPK_P"!=S_\CU^CE%']L8KNON#ZM3/SC_X=Q_$G_H.>%?\
MP+N?_D>C_AW'\2?^@YX5_P# NY_^1Z_1RBC^V,5W7W!]6IGYQ_\ #N/XD_\
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MCU^CE%']L8KNON#ZM3/SC_X=Q_$G_H.>%?\ P+N?_D>C_AW'\2?^@YX5_P#
MNY_^1Z_1RBC^V,5W7W!]6IGYQ_\ #N/XD_\ 0<\*_P#@7<__ "/1_P .X_B3
M_P!!SPK_ .!=S_\ (]?HY11_;&*[K[@^K4S\X_\ AW'\2?\ H.>%?_ NY_\
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M7W!]6IGYQ_\ #N/XD_\ 0<\*_P#@7<__ "/1_P .X_B3_P!!SPK_ .!=S_\
M(]?HY11_;&*[K[@^K4S\X_\ AW'\2?\ H.>%?_ NY_\ D>C_ (=Q_$G_ *#G
MA7_P+N?_ )'K]'**/[8Q7=?<'U:F%%%%>(=04444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTX;$2PU55$KKJNZ>Z.=\!^/=(^)'AFQUW0[N.[L;I VY6^9&P-R,.S#."/\
MZU0^'?!?]A^-O%6OM(LCZT;;'JBQ1; #^))_&O&_%OPV\4? OQ/>>-?AA:MJ
MFAW1,NL>#-VQ')QNGM^H#\9*CH. ,<5ZK\+_ (Q>&OB]HKWOA^^622'Y;FSD
MRD]K)_==#@C'KT-3&6T9;G7B,/[.#KX9WI/[X^4NWKL^A\R_\%& N[P+_P!O
M?_M*OC'_ &J^SO\ @HN<_P#""M_U]_-^$5?&<43SRQ1(K2S2,%6.-278GH
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M6+C.[R_N1YZ\\[F_, ]Q7K]%%P*UG9P6%K';VL$=M!&-J1QJ%51[ <59HHI
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M?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\ !0S_ *+M\/\
M_P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^%-_\%#/^B[?#
M_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__ /A3?_!0S_HN
MWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _/_\ X4W_ ,%#
M/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\
M!0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^
M%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__
M /A3?_!0S_HNWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _
M/_\ X4W_ ,%#/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH
M_/\ _P"%-_\ !0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RI
MK] ** /S_P#^%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\
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M?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\ !0S_ *+M\/\
M_P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^%-_\%#/^B[?#
M_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__ /A3?_!0S_HN
MWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _/_\ X4W_ ,%#
M/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\
M!0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^
M%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__
M /A3?_!0S_HNWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _
M/_\ X4W_ ,%#/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH
M_/\ _P"%-_\ !0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RI
MK] ** /S_P#^%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\
M\J:_0"B@#\__ /A3?_!0S_HNWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##
M_P#*FOT HH _/_\ X4W_ ,%#/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@#
M#_\ *FOT HH _/\ _P"%-_\ !0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=
MOA__ . ,/_RIK] ** /S_P#^%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1
M=OA__P" ,/\ \J:_0"B@#\__ /A3?_!0S_HNWP__ / &'_Y4T?\ "F_^"AG_
M $7;X?\ _@##_P#*FOT HH _/_\ X4W_ ,%#/^B[?#__ , 8?_E31_PIO_@H
M9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\ !0S_ *+M\/\ _P  8?\ Y4T?
M\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^%-_\%#/^B[?#_P#\ 8?_ )4T
M?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__ /A3?_!0S_HNWP__ / &'_Y4
MT?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _/_\ X4W_ ,%#/^B[?#__ , 8
M?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\ !0S_ *+M\/\
M_P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^%-_\%#/^B[?#
M_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__ /A3?_!0S_HN
MWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _/_\ X4W_ ,%#
M/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\
M!0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^
M%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__
M /A3?_!0S_HNWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _
M/_\ X4W_ ,%#/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH
M_/\ _P"%-_\ !0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RI
MK] ** /S_P#^%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\
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M?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\ !0S_ *+M\/\
M_P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^%-_\%#/^B[?#
M_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__ /A3?_!0S_HN
MWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _/_\ X4W_ ,%#
M/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\
M!0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^
M%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__
M /A3?_!0S_HNWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _
M/_\ X4W_ ,%#/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH
M_/\ _P"%-_\ !0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RI
MK] ** /S_P#^%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\
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M?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\ !0S_ *+M\/\
M_P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^%-_\%#/^B[?#
M_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__ /A3?_!0S_HN
MWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _/_\ X4W_ ,%#
M/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\
M!0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^
M%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__
M /A3?_!0S_HNWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _
M/_\ X4W_ ,%#/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH
M_/\ _P"%-_\ !0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RI
MK] ** /S_P#^%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\
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M?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\ !0S_ *+M\/\
M_P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^%-_\%#/^B[?#
M_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__ /A3?_!0S_HN
MWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _/_\ X4W_ ,%#
M/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\
M!0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^
M%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__
M /A3?_!0S_HNWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _
M/_\ X4W_ ,%#/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH
M_/\ _P"%-_\ !0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RI
MK] ** /S_P#^%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\
M\J:_0"B@#\__ /A3?_!0S_HNWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##
M_P#*FOT HH _/_\ X4W_ ,%#/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@#
M#_\ *FOT HH _/\ _P"%-_\ !0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=
MOA__ . ,/_RIK] ** /S_P#^%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1
M=OA__P" ,/\ \J:_0"B@#\__ /A3?_!0S_HNWP__ / &'_Y4T?\ "F_^"AG_
M $7;X?\ _@##_P#*FOT HH _/_\ X4W_ ,%#/^B[?#__ , 8?_E31_PIO_@H
M9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\ !0S_ *+M\/\ _P  8?\ Y4T?
M\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^%-_\%#/^B[?#_P#\ 8?_ )4T
M?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__ /A3?_!0S_HNWP__ / &'_Y4
MT?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _/_\ X4W_ ,%#/^B[?#__ , 8
M?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\ !0S_ *+M\/\
M_P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^%-_\%#/^B[?#
M_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__ /A3?_!0S_HN
MWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _/_\ X4W_ ,%#
M/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\
M!0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^
M%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__
M /A3?_!0S_HNWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _
M/_\ X4W_ ,%#/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH
M_/\ _P"%-_\ !0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RI
MK] ** /S_P#^%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\
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M?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\ !0S_ *+M\/\
M_P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^%-_\%#/^B[?#
M_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__ /A3?_!0S_HN
MWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _/_\ X4W_ ,%#
M/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\
M!0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^
M%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__
M /A3?_!0S_HNWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _
M/_\ X4W_ ,%#/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH
M_/\ _P"%-_\ !0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RI
MK] ** /S_P#^%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\
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M?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\ !0S_ *+M\/\
M_P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^%-_\%#/^B[?#
M_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__ /A3?_!0S_HN
MWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _/_\ X4W_ ,%#
M/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\
M!0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^
M%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__
M /A3?_!0S_HNWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _
M/_\ X4W_ ,%#/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH
M_/\ _P"%-_\ !0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RI
MK] ** /S_P#^%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\
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M?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\ !0S_ *+M\/\
M_P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^%-_\%#/^B[?#
M_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__ /A3?_!0S_HN
MWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _/_\ X4W_ ,%#
M/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\
M!0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^
M%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__
M /A3?_!0S_HNWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _
M/_\ X4W_ ,%#/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH
M_/\ _P"%-_\ !0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RI
MK] ** /S_P#^%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\
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M?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\ !0S_ *+M\/\
M_P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^%-_\%#/^B[?#
M_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__ /A3?_!0S_HN
MWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _/_\ X4W_ ,%#
M/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\
M!0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^
M%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#\__
M /A3?_!0S_HNWP__ / &'_Y4T?\ "F_^"AG_ $7;X?\ _@##_P#*FOT HH _
M/_\ X4W_ ,%#/^B[?#__ , 8?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH
M_/\ _P"%-_\ !0S_ *+M\/\ _P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RI
MK] ** /S_P#^%-_\%#/^B[?#_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\
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M?_E31_PIO_@H9_T7;X?_ /@##_\ *FOT HH _/\ _P"%-_\ !0S_ *+M\/\
M_P  8?\ Y4T?\*;_ ."AG_1=OA__ . ,/_RIK] ** /S_P#^%-_\%#/^B[?#
M_P#\ 8?_ )4T?\*;_P""AG_1=OA__P" ,/\ \J:_0"B@#G/A[9>(=.\ ^&;3
MQ=?6^J^*X-,MHM8OK10L-Q>+$HGD0!$ 5I Q "KP1\HZ5T=%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^PZ+H]E-J%]=>6TGE011F21]J@LV%4G"@DXP >*^5]&_;VU2\_8GU[]H>_\
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MBNZGEG5_+0$<[6YR%!7OC'+98AX'V;6MN:^M]MMO3\CG;Q*I^WYO.UNG]?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HKYU_X:(\1_\ /CI?_?J3_P".4?\ #1'B/_GQ
MTO\ []2?_'*^%_USRG^:7_@)]7_JSF'9?>?15%?.O_#1'B/_ )\=+_[]2?\
MQRC_ (:(\1_\^.E_]^I/_CE'^N>4_P TO_ 0_P!6<P[+[SZ*HKYU_P"&B/$?
M_/CI?_?J3_XY1_PT1XC_ .?'2_\ OU)_\<H_USRG^:7_ ("'^K.8=E]Y]%45
M\Z_\-$>(_P#GQTO_ +]2?_'*/^&B/$?_ #XZ7_WZD_\ CE'^N>4_S2_\!#_5
MG,.R^\^BJ*^=?^&B/$?_ #XZ7_WZD_\ CE'_  T1XC_Y\=+_ ._4G_QRC_7/
M*?YI?^ A_JSF'9?>?15%?.O_  T1XC_Y\=+_ ._4G_QRC_AHCQ'_ ,^.E_\
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M&B/$?_/CI?\ WZD_^.4?ZYY3_-+_ ,!#_5G,.R^\^BJ*^=?^&B/$?_/CI?\
MWZD_^.4?\-$>(_\ GQTO_OU)_P#'*/\ 7/*?YI?^ A_JSF'9?>?15%?.O_#1
M'B/_ )\=+_[]2?\ QRC_ (:(\1_\^.E_]^I/_CE'^N>4_P TO_ 0_P!6<P[+
M[SZ*HKYU_P"&B/$?_/CI?_?J3_XY1_PT1XC_ .?'2_\ OU)_\<H_USRG^:7_
M ("'^K.8=E]Y]%45\Z_\-$>(_P#GQTO_ +]2?_'*/^&B/$?_ #XZ7_WZD_\
MCE'^N>4_S2_\!#_5G,.R^\^BJ*^=?^&B/$?_ #XZ7_WZD_\ CE'_  T1XC_Y
M\=+_ ._4G_QRC_7/*?YI?^ A_JSF'9?>?15%?.O_  T1XC_Y\=+_ ._4G_QR
MC_AHCQ'_ ,^.E_\ ?J3_ ..4?ZYY3_-+_P !#_5G,.R^\^BJ*^=?^&B/$?\
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M17SK_P -$>(_^?'2_P#OU)_\<H_X:(\1_P#/CI?_ 'ZD_P#CE'^N>4_S2_\
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M_'*/]<\I_FE_X"'^K.8=E]Y]%45\Z_\ #1'B/_GQTO\ []2?_'*/^&B/$?\
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M9=/\,7EO_:VA:9'I.DW$\JPO=:I<O^\NHXYC*&8223W?D?,NV-E&$&0 >?\
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M:72+;5%N3*GD%IX1;1[HU<QQ/9R%&<D[)50*BQJM=!XT_;N\>:CI<6G?#?\
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M_P 9(_M3M>P_Z5X>LYEN-MS^^C^PVY4 >7)M(29\93;E3.Q(.&SZ_P#MS?\
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M=+%3@HSB[::7V_S-*:EA\2J2;::Z_/\ R/K:BBBOECU@HHHH **** "BBB@
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M1110 45\:?L+?\% +W]L3QEXTT:[\ 7'ANWTJ&*^M+ZTG:[MHXF"1FWN9BJ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/B2BBBOY'/Z("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /MNBBBOZX/YW"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHR!>P21.)E"HR #:0LTPS\]>Q44 %%%% !1110 4444 %%%% !1110 4444
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MVNV_(Q?CI^R-JNGWVH:_X+C_ +4L;B:2XET6&)8Y;12-^(@"!(N=P"* P!0
M/R:X>X^-GQK^'=C:66J:GK6EQ/O^SMK>FJTDN#EL23QEGP6'5C@%1QP*]2_X
M:(^/'_1,O_*!?_\ Q='_  T1\>/^B9?^4"__ /BZ[Z<L3R*GB8PJ)=VK_DSG
MDJ7,Y4G*-_(XF\N/VB/BI9SZ'=6VO+:F-GECGLX]+25"-C(TA6(."'.8RQ!'
M.T[<CZQ^-P\2+\,=:E\(_:/^$BA\BXM?LF#*?+GC=P%/W\HK#9@[AE<'.#X)
M_P -$?'C_HF7_E O_P#XNC_AHCX\?]$R_P#*!?\ _P 77%7P]>M.G)0IQ4'>
MR>CVW^XWIU*<(R3<FV8$O[5_Q;\/7>GZ+J7A>S75Y$C2.*^TJYCNKHL=BL(Q
M(N2S CY% )R !C I^%?@3\1/C]XJ&O\ C^XO-*LXY$@N)-0@-O=/$JD[+>'8
M%4=,L0%!<D!R&%=7_P -$?'C_HF7_E O_P#XNC_AHCX\?]$R_P#*!?\ _P 7
M75RUJ:?U:G"$GUO?[NQC[DG^\E*2[6/JZSL[?3;."TM8([:VMT6**&% B(JC
M"JH'     %?)/BKQ]\;?A'XX\5SQZ7>:SX9FN;N^M_MUL][:V]L9"4<2QMNB
M"HG^K+ *"24&0:L?\-$?'C_HF7_E O\ _P"+H_X:(^/'_1,O_*!?_P#Q=>=A
M<#6P\GSQA-/HV=-6O"HERMIKR.$\2?&[XO\ QJ\-3V6FZ)<?V-)OMKMO#>ES
MNLV0I,;R$N5P,9"LN5<A@00*]@_9?_9QO?AU>2>*/%,<<6NNCP6VGC9+]E4G
M#2%QD>8P&T;#@(Q!)+$+S7_#1'QX_P"B9?\ E O_ /XNC_AHCX\?]$R_\H%_
M_P#%UW5H8B5%T*$80B][2U?S,:<J:FJE1N37D?3GB[PK8>-?#.I:#J<?F6%_
M"T$G"EDR.'7<" RG#*2#@J#VKXGM_#7Q0_9=\;:K<:+IUQJ^D+"7FO([*26P
MNK<!BKS!#^[9.206!4[L$HQ+=Y_PT1\>/^B9?^4"_P#_ (NC_AHCX\?]$R_\
MH%__ /%US8/#XK"QE3?+*$MTV:5JE*JU)7376QY]XBU;XK_M1WF@P2:++!HL
MCD6\EK:30Z:'!8//)*Q8$J R]21@A5W,0WUW\%_AA:_"7P'9:)"=]XV+F_F$
MA=9;EE42%<@84;0JC X49R22?!?^&B/CQ_T3+_R@7_\ \76IX1^.OQHUCQ9H
MECJOP\^PZ9=7T,%W=?V)>Q^5"SJKON9R%VJ2<D$#'/%/&4L36I*E!1A".ME+
M^KBHSIPGS.[D^MCZEHHHKY(]@**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "OQ!_;G\+Z7XT_;J_: TBZM?-U
MH^&8=0T:X>1DBM;BRTNQOKAWVGG=96M]$H*L#)+'D+_K$_;ZORK_ .<ZW^?^
MA8H ^GO^"9/Q_L?C=^R[X>TMFMX/$/@N&'P[J%G%M4^5"@6TG";V;:\*J"[!
M0TL4^T **^MJ_*#X(Z;%^P#_ ,%+]2^'D[W%M\/OB%"MOHBI<R>2BW$VZP+1
M*TK2-%.DUDKRE6Q(\I*JQ#?J_0!\$_\ !6+]H"^\)?"_2/A!X1:XO/&WQ!G6
MVDL]-+/=K8!PIC5(Y!)ON92L*KL994%RG45\V?\ !)GP7??#;]N/XG>$-3EM
MY]2T#0-4TJYFM&9H7E@U.SB<H6525+*2"5!QC('2O0/V>=4E_;L_X*1:]\60
MEO>?#KX<0B#2%N;:.5)5'G1V)"NL<B,\IN;Y79&:)HUC)!",*G[ O_*4S]H[
M_N8__3Y;T ?IYXH\6:'X'T&YUOQ)K6G^']%M=OVC4M4NH[:WBW,$7?(Y"KN9
ME49/)8 =:/"_BS0_'&@VVM^&]:T_Q!HMUN^SZEI=U'<V\NUBC;)$)5MK*RG!
MX*D'I7S9_P %1_\ DQ3XF?\ <,_].EI1_P $N/\ DQ3X9_\ <3_].EW0!])^
M*/%FA^!]!N=;\2:UI_A_1;7;]HU+5+J.VMXMS!%WR.0J[F95&3R6 '6CPOXL
MT/QQH-MK?AO6M/\ $&BW6[[/J6EW4=S;R[6*-LD0E6VLK*<'@J0>E?-G_!4?
M_DQ3XF?]PS_TZ6E'_!+C_DQ3X9_]Q/\ ].EW0!\K?M]?\I3/V<?^Y<_]/EQ7
MZ3^.OBQX(^&'V'_A,O&/A_PE]NW_ &3^W=4@LOM&S;O\OS77?MWIG&<;ESU%
M?FQ^WU_RE,_9Q_[ES_T^7%??OQR_9=^&/[2?]B?\+'\,_P#"1_V+Y_V'_B87
M5KY/G>7YO^HE3=GRH_O9QMXQDY /SM_X)+_M":'H^N?&?6_BK\2M/LM:UC^Q
M=FH^,->2.XO?*6\0XDN) TFQ3&O4[04' Q7ZC>"_B%X6^)6ERZGX0\3:/XJT
MV*8VTEYHE]%>0I*%5BA>-BH8*RDJ3G# ]Q7X\_\ !*;]EWX8_M*?\+1_X6/X
M:_X2+^Q?[+^P?\3"ZM?)\[[7YO\ J)4W;O*C^]G&WC&3G]9O@I\!? O[._A6
MZ\.?#[0O[ T:ZO6U":U^UW%SNG9(XV?=,[L,K$@P#CY>G)) %^$_BSX6>)/[
M>'PRUGP?JOF7IU+6/^$3NK6;==3YS/<>03F63RS\[_,VP\G%:OCKXL>"/AA]
MA_X3+QCX?\)?;M_V3^W=4@LOM&S;O\OS77?MWIG&<;ESU%?FQ_P0Q_YK9_W!
M/_;^C_@N=_S1/_N-_P#MA0!^CGQ0^-/@+X+:7_:/CGQ=H_A6W>&:>%=1NTCF
MN5A4-(((L^9,RAE^2-68EE !) //_"[]JCX0_&C^S(_!OQ%\/ZQ?ZEYOV32?
MMBP:C)Y>_?\ Z'+MG&!&[<H,J-PRI!/SM\+_ -A?3OVA=+_X6C^TW:W'C'X@
M^*(8;J'1?M-YIMIX9LRI>'3XH4DCD5E$A,@DSA\CYF\R67PS]O/_ ()QZ!\'
M? L?Q;^!D6H>%KOPGY=UJ&DV=U=W,NQ)0POK:5F>6*2$D.^6"".,R H8SY@!
M^JE?E7_SG6_S_P!"Q7VE^PQ^T5_PTY^SCX>\4WDOF^)+/.D:]\NW-_"J[Y.(
MT3]ZC13[8P53SM@)*&OBW_G.M_G_ *%B@#]5*\R^+W[2?PO^ L,LGCWQQH_A
MVX2&.Y&GS7'F7TL3R>6LD=JFZ:1=X891" %8G 5B. _;R_:7E_9:_9[U+Q+I
M]M<3^(=4F_L/1IH?*V6EY-#*Z7,GF!@5C6)WV[6WLJH0 Q9?E;]BW_@FAX+^
M)7PQTKXI?&M=8\8>)_&$,FJG3[O4WCA2*=UDAN7E@D\V6>1/WI9I0,7!5H]Z
M%J /O+X9_M _#7XR&!/!'COP_P");J6R74/L&GZA&]Y% =OSRV^?,BP9$5@Z
MJ59@K 'BO0Z_*O\ ;K_8NTO]D?0?#_QW^ #ZAX)O_"U[#'J-K#>M<)$DK&-+
ML-<2,YR\B020_O$D2891563?]^?LM_&K_AHC]G_P5\0'MOL-UK%D?MENL?EH
MMU%(\%QY:[W(C,L4A3+%MA7.#D  ]8K\U?\ @MA\2M<\/_#GX>>"+&?[-HOB
M2]O+W4?+D='F^QB#RHFPP5HRUR9"K*?GBB8$%.?TJKYR_;A_9'LOVO?A(NAQ
M7EOI'BO29C?:)JD\*NBRE2KV\K!3(L$HV[MAR&CB<A_+", =!^S!^SC\-?@;
M\.?"O_"%:5X?OK_^QH8)?&>FVD7VC64D"2O.;@,[M'*X$BIYC(HV!?E1<=5\
M8O@#\/?C_H,6D?$#PGI_B6UBSY$ERI2XMLLCMY,Z%98=QB0-L9=P4*V1Q7Y<
M^ ?VM?C_ /\ !._QEI/PU^,6C7'B/X=6,XT^TFDMR7-G$"2^EWIV+.JK/"?+
MF+;%2.'_ $<YV_I/^S_^UE\+_P!IC2UN/ OB>WO-26'SKG0;O]QJ-H L9??
MW+*K2HAECW1%B55VQ0![%7.>-/B%X6^&NEQ:GXO\3:/X5TV686T=YK=]%9PO
M*59@@>1@I8JK$*#G"D]C1\0?&EC\-? /B7Q?J<5Q/IN@:9<ZK=0VBJTSQ01-
M*X0,P4L54@ L!G&2.M?E)^SO\&/%_P#P4\^,FN?%7XIZSJ"_"31]:G2R\-MJ
M1DP[")QI]N$""&-8OLPFG54>7"XR[-)$ ??N@?M\_L]^)/%6I>'K3XL>'XK^
MP\SSIM0E>RM&V2"-O*NIE2";)(*^6[;ERRY4$CW/2=6LM>TNSU/3+RWU'3+R
M%+FVO+25989XG4,CHZDAD92"""0001P:^3/%'_!*']F_Q!H5U86/A#4/#5U-
MMV:II>MW;W,.'#'8+B26([@"IW1MPQQ@X(^;/V,_BIXO_8Y_:\OOV5?%OB+3
M_$7@R:],6F:A<3&W%A/-;?:K?R0^=OVC>D;6V2!/*#&Y);S@#U3_ (+5?\FL
M^%O^QSM?_2&^KZJ_9/\ ^36?@W_V)FC?^D,-?*O_  6J_P"36?"W_8YVO_I#
M?5]5?LG_ /)K/P;_ .Q,T;_TAAH T_"'BSX6ZG\1O%%GX5UGP?>>/9L?\)!;
MZ/=6KZH_V8^0/M:QDRGR2PC'F?<W;>,XKT.ORK_8%_Y2F?M'?]S'_P"GRWKW
M/_@JI^U1XA_9Y^$>A^'_  ==W&D^)_&4UQ NL0(-UG9P(GV@Q2;P8YV:>!5<
M*Q53*04<(P /?_B]^UW\'/@3<26GC?X@Z/I.I13)!-I<$C7E]"SQ^8ADMH%>
M6-2F#O90OS)S\RY\6_X*'?$+PK\2?V ?BCJGA'Q+H_BK3(IM-MI;S1;^*\A2
M4:E9,4+QL0&"LAVDYPRGN*X#]E__ ()+?#?0_A?IMY\8_#UQXA\=:A"LM_8_
MVS,EIIK;Y"L41MC$6?RVC60LTJ[XSY;;3EO*O^"B'_!/GPG\$?@_J?Q(^$L]
MQX/TFQ@@T_Q'X=:_N9X=2MY+N$1.KR,[%EG,!:-R4(C1UV/%^\ /K3_@EQ_R
M8I\,_P#N)_\ ITNZ^JZ^5/\ @EQ_R8I\,_\ N)_^G2[KZKH YSQI\/?"WQ*T
MN+3/%_AG1_%6FQ3"YCL];L8KR%)0K*'"2*5#!68!@,X8CN:\!_:9_9E^#^@_
MLW_%;5-,^%/@C3]1L_">K7-K>6GAVSBF@E2SE9'1UC#*RL 0P(((!%?4->4_
MM8?\FL_&3_L3-9_](9J /B#_ ()&_!'X=?$K]F_Q)J?B[P!X7\5:E#XLN;:.
M\UK1K:\F2(6=FPC#R(2$#,QV@XRQ]37V]_PB?P0_9L'_  DW]C> /A8;K_B6
M_P!L?9;'1_.W?O/L_G83=N\K=LSSY><?+D?*W_!%7_DUGQ3_ -CG=?\ I#8T
M?\%JO^36?"W_ &.=K_Z0WU 'WEI.K66O:79ZGIEY;ZCIEY"ES;7EI*LL,\3J
M&1T=20R,I!!!((((X-97C3XA>%OAKI<6I^+_ !-H_A7399A;1WFMWT5G"\I5
MF"!Y&"EBJL0H.<*3V-<9^R?_ ,FL_!O_ +$S1O\ TAAKY5_X+5?\FL^%O^QS
MM?\ TAOJ /O+2=6LM>TNSU/3+RWU'3+R%+FVO+25989XG4,CHZDAD92"""00
M01P:P?\ A;'@C_A//^$)_P"$Q\/_ /"9_P#0N_VI!_:/^J\[_CWW^9_JOWGW
M?N_-TYKE?V3_ /DUGX-_]B9HW_I##7Y;_M&>&_&OC#_@KIK.@?#[6;CPYXHU
M2:SL4UFT">=86LNB0I>7";G7YDMFG<;65\J-A#[2 #]1_B1^U1\(?A'KUOHO
MB_XB^']%UF:]@L&TV6]5[BWDF7?&T\:9:",J0QEE"QJ&4E@",]_X7\6:'XXT
M&VUOPWK6G^(-%NMWV?4M+NH[FWEVL4;9(A*MM964X/!4@]*^5O\ AU#^S?\
M\(K_ &3_ ,(AJ'V_[%]E_MS^V[O[9YFS;]IV^9Y'FY^?'E>7N_@V_+7YQ> _
M OQC^'/QX\;_ +'NA>);BVTGQ?J:Z;J$F54)9CR[AM2BC6<!'DL$)DA\P^9$
MYA<,X3: ?KEXX_;1^!WPW\567ASQ!\3_  _::S=7LFGM;07/VG[).CK&Z731
M!EM=K-@F<Q@;6R?D;'JGA?Q9H?CC0;;6_#>M:?X@T6ZW?9]2TNZCN;>7:Q1M
MDB$JVUE93@\%2#TKY6_X=0_LW_\ "*_V3_PB&H?;_L7V7^W/[;N_MGF;-OVG
M;YGD>;GY\>5Y>[^#;\M?,/\ P2S\3WWP5_:N^+OP$N_$%O?:'#-?+:-=,T#W
M5_870@+VT)D*JTL'F22* S%;9/FVQ'(!^K]>3_%#]JCX0?!?^TT\8_$7P_HU
M_IGE?:]*^V+/J,?F;-G^AQ;ISD.C<(<*=QPH)KP'_@J/^U;J?[.OP;L?#WAE
MM0T_Q=XU\^VLM:LI5C_LZ" PFY<,06\QEF6-"H4KO9PZM&H;BOV:?^"4_A(>
M#;K7_P!H&TN/''Q%U^?^T+V&35[E4T]G+,R--!*IN)V9BTLC,R[L!,@&24 ^
ML_A=^U1\(?C1_9D?@WXB^']8O]2\W[)I/VQ8-1D\O?O_ -#EVSC C=N4&5&X
M94@GUBOS5_:^_P""8?@7P+\.=8^)WP;O=0^'WB3P;9'6UM5U*>:WE2U$D\DD
M<KEYX;D *4</LS$J[5+F1??_ /@G3^U9JG[5/P0GO_$[Z?\ \)IX?O?[+U'[
M)*JO=)Y:/%>/  /)\S+K@#8SP2E-H^1 #WW7OBQX(\*>*M-\,ZUXQT#1O$FI
M^7]AT?4-3@@O+KS',<?E0NX=]S@JNT'+ @9(Q57QM\;OAU\-=4CTOQ=X_P#"
M_A74IH1<QV>MZS;6<SQ%F42!)'4E"RL,@8RK#/!K\N?^"J&OZYX5_;X^$NM^
M&=-_MGQ)IFBZ3>Z9IOD//]JNH]5NWAB\N,AWW.%7:I#'. <D5])_#?\ X)-_
M#'_A7,\?Q4;4/''Q,UCS[O5?%D>JW4;PW4PRQ@!<+)L8EA).CM(Y9F4*PC4
M^ZZ\(\2?MS? #PKJFC:?>_%KPO//J\WD6[:=?"^A1MR+F>6#?';KEQ\\S(N
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'Q)1117\CG]$!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'VW1117]<'\[A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^VZ***_K@
M_G<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O+?VA/^1+MO^OU/_1<E
M>I5Y?^T(/^*)@_Z_5_\ 0'KYCB?_ )$V*_PL]K)?^1C0_P 2/-_%&A'_ (5E
MX5UJ)?FB\R"5E]#([+^7S#\17>^+OB"L_P (+>\27=>:C$+5MO\ >'$O\B/^
M!"K'AO0?^$F^",5@J[I)(9&B_P"NBR,R_J,?C7A^AVU]XBU+3=!61_*:X.Q.
MR%MH9L?10?H*_),56Q&31I_5H_[Y0IQ5OY[1C?UL_O9]U0ITLPE+VS_W>I)O
M_#=O\U]R.H\0: =%^$.C3/\ ZZ_OC<M_N^6P7\"/F_X%7M?P\N([/X=Z5-*V
MV*.V+NWH 22:X[]H*W2T\'Z1#$FV..Z5$4=@(F %5O$'B#^P_@=IL,;_ +Z^
MC\A?]W)+?A@;?^!5[N$]EP]FF)[4</'YM<OYO\6>97Y\VP5'O4JOY+7\D<?H
M_A^7XF:IXKU:7<S10O/$O_30G*+]-JLOY5VO[//B#SM/U#196_>0/Y\7^Z<*
MP'L" ?\ @5<UX&\)^/+318KG0[J.SM+S][M9DW-V!.X$X]/KGO63X3DO?AO\
M3+:/4U6)MXBN-N,;7 Y!'&!D-QZ8KYK+:U3*\3@LPJT9PYVU4G)6C+VCNFG?
MHM=EL>OC*<,=1Q&$IU(RY4G"*=VN56?W[?,L^*&E\>?%Q].N96%N+O[(J_W(
MT8@X^N"WU->SW7PN\,75A]E_LB")=N%FB7$@]]_4GZ]?>O&/&<-U\/\ XK-J
MKPLT#7/VR-NSJS98 ^O)'M^(KU&;XY>%TL//CGN)9B/EMEB(?/ID_+^OTS7T
M>1U<LHU\PCG+BJKJ._/;6/E?\ETMY'DYE3QM2EA99?S>SY5;E[^=OU\SBOVA
MHTM[SP[$OW(X9%'T!451\::IX)G\"VD.GP6_]M^5%\UM 8V5@!OW' ![COS]
M*O?M!RK>77AR3;E987;;[$J:A^(?PZL=+\#Z7KNF0-!-''%]IVR,0VY1\W).
M#NXXQ]ZO'S:&(EC\UEAH0E%1AS<RNU'E6L.EUJ]>VFIZ& E2CA<"JTI)MRM;
M9N[TEY,T?"=UJ/@WX*ZM>R^9#))*?LW9E#;(]PSTYR1],]ZJ? SP5INO6^H:
MKJ5O'>LDHB2.9<H#@,3@\'J ,].?:MW3=0N?B=\'KVW+&?4X5\MO[TK(0Z_B
MP&W/KFN6^#/Q T_PC#?:9J[-;)+*)4FVE@&QM(( R. ,<>N:[:;P5',,L>(E
M?#>R]URVYM;WZ)K3T=M3FE]8J87&JDK5N?51WY=+6ZVW_$O_ !T\$Z9HNGV.
MJ:=;1V+-+Y$D<*[4.06!P. >"..N?:G>-O$=S=?LOZA=EF:X^S+:NV[DKYZQ
M')[Y7KZ\U0^,/Q LO&26.D:/YEVB2^8TFPC<Y&U0H(R>I[<Y&*Z/Q%I-II/P
MMTWPAJLL=HVK0R6[S,W$$K?.K'U"R,@/MFO4P-.EB\[S!Y7;V3I<MX_#SNUK
M6T[[>9S5:DL-@<&\=?G51/7?E3U\^WX''_L5Z;;KX7\07ZJOVF2[2!CWVJFX
M?@2Y_*F^)OVJ-?\ #>H7T4_@>1;6VG:+[1+*ZJ0&V@D^7CFO-/A'\2+S]GWQ
M=JNC>(]/N!:3N$N(E^_$ZD[77. P()[@$8(/'/>_'KX]>#O&WPSO-(T?4);F
M^N98F6-K9T "N&.2P Z#MFNS#9A&GE,:='$>RJ4E*\6E>3ULO>_0[<1@)5,U
ME4K4/:TZKC:2;LE97>GZGI'A'XF-\5?@_P"(M8>R&GO'#=6S0K)O'RP[L@X'
M9L?45\Q_ _Q-X'\-W^N-XUTR/4XY1$MLLMHL^P@MN^]TSE?KCVKV?]G+C]G?
MQ/\ [][_ .DR5Y%^S_K7@31[[7F\<0VLT<B1?9?MEH9]I!??C"G'\/IG\*SQ
M5>KB)Y?6J3BI.,KN=N7;KLO3S-,+0IT(8^E3A)Q4HV46^;Y;OU\CZI^$.I>"
M]<T.]U/P;I<.F6K3>1/Y=JL!9U4,,@=0 _'U-?$NF>#9_$.@^*M5M=S3:.\$
MKQ_WHG9U8_\  2%/TW'M7V[\+?%G@?7K.]LO!)MH[>V82S6]K;- H+Y ;!49
MSMQD9Z"O"_V1K"#5=6\=65U$LEK<VT4,L;?Q*QD!'Y&N_,L-#'RP6'<HOF51
M7C\-[+5?,X<MQ,\"L;749+E=-VE\5K[/Y#]<^('_  GG[)]UYTF[4M-FMK.Z
MW=6VR+L;\5QSW(:NB\$_\F=:A_UY7G_HUZ^?O&5CJ7PLUCQ9X/E9FM;MD0_[
M:HZRQ2=.N/3IN85] ^"?^3.[_P#Z\KS_ -&O7G9?B:F(Q515E[\*,H2]8O\
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MNN?#"QMO/VRVFH+K#/)97"G*3*/)&<<@C(!!(/6OEGX9:Q>^'OB7X0U33?\
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M:IK_ (9T?6]1T6?[3I5YJ5C%<36$NY&WP.ZDQ-NC0Y0@Y13V&.CHHH ****
M"BBB@ HHHH *Q_%'A/0_'&@W.B>)-%T_Q!HMUM^T:;JEK'<V\NU@Z[XW!5L,
MJL,C@J".E;%% %'2=)LM!TNSTS3+.WT[3+.%+:VL[2)8H8(D4*B(B@!450
M    !P*O444 %%%% !7.>'?A[X6\':KK.J:!X9T?1-1UJ?[3JMYIMC%;S7\N
MYVWSNB@RMND<Y<DY=CW.>CHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#XDHHHK^1S^B HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#[;HHHK^N#^=PHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI5:49.5D[Q3NEJD[[V:NC.&)KTTE";26UF]/0JVMK%96T5O#&L<,2!(XUZ*
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M-VW=C.!G&<"@I.QS'@#_ )0_^+_]^Z_].*5^=VC?\AC3O^OJ'_T,5^U7A_\
M8K30OV0-7^!7_"9S3K?F5O\ A(/[-563?<B?_4>80<8V_>[Y]J^=K'_@C>EG
M?VUP?C#=2^5*LNW_ (1U!NVD'&?M'&<4#3/T%^(/_(@^)?\ L&7/_HIJ_G(L
M_P#CU@_W%_E7](OB#2?[>T#4M-\SR?MEK);>9MW;-ZE<XXSC.<5^<L?_  1C
M2*-47XR76U5"_P#(MQ]O^WB@29]L?LH_\FQ?";_L5=,_])8Z_#GXZ?\ );OB
M'_V,>I?^E4E?O=\*_ R_#'X9>$_!XO6U-=!TJVTO[8T7EF?R8ECWE 2%W;<X
MR<9QDU\-^._^"1R>-/&_B+Q#_P +9N+'^V-2N=0^RCP^C^5YTK2;-WGC=MW8
MS@9QG H!,XWPG_RAY\2_]?TG_IWCKX,\"?\ (^>%_P#L+6G_ */2OV3TG]B-
M-+_8]U+X$?\ ":S2K>3-+_PD']FJ'3-VMQCR/,P?N[?O=\^U>">'_P#@CVFA
MZ]IFIGXOW5P+&[AN_)_X1U$W['#[<_:#C.,9P<4#N?='QN_Y(SX]_P"P!J'_
M *325_.VG_'BO_7(?RK^CWQMX;'C+P;KV@-<?9%U73[BQ^T*F\Q>;&T>[;D9
MQNSC(SCJ*_.T?\$8X_*\O_A<MUMQM_Y%N/Z?\_% DS[Q^ /_ "0GX<_]BWIO
M_I+'7X$_$+_DHGBS_L-W_P#Z4R5_0GX!\+_\(/X%\.>&Q=-??V/IUMI_VIDV
M&7RHECW[<G;NVYQDXSWKX$\2?\$?8M?\2:OJR_%VYM5U"]GO/)_X1]'V>9(T
MFW=YXSC=C.!GT% D:_P>^$M[\;O^"5D'A72XEDUB:&[NM/C9L;[B#4))40'H
M"^PKD\ MD\5^7FF:E>Z#JUGJ-C+)8ZEI]PD\,R\2031L&4X/1E91P>XP:_??
M]FWX*+^SS\'=#\!+K3^(%TLSG^T)+86YE\R9Y?N!F QOQU.<9XSBO&_VF_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ^)**]1_X9W\1_P#/]I?_ ']D_P#C='_#._B/_G^TO_O[)_\
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M\,[^(_\ G^TO_O[)_P#&Z/\ AG?Q'_S_ &E_]_9/_C='^KN;?] \@_MG+_\
MG\CRZBO4?^&=_$?_ #_:7_W]D_\ C='_  SOXC_Y_M+_ ._LG_QNC_5W-O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,O!WA_Q;]AW_ &3^W=+@O?L^_;O\OS4;9NV)G&,[5ST%=;110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6/XH\)Z'XXT&YT3Q)HNG^(-%NMO
MVC3=4M8[FWEVL'7?&X*MAE5AD<%01TK8HH Q_"_A/0_ ^@VVB>&]%T_P_HMK
MN^SZ;I=K';6\6YB[;(T 5<LS,<#DL2>M;%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"C+_B!_P!_+[_Y6T ?H!17Y_\ _#QSXW_]&7_$#_OY??\ RMH_X>.?&_\
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M5M 'Z 45^?\ _P /'/C?_P!&7_$#_OY??_*VC_AXY\;_ /HR_P"('_?R^_\
ME;0!^@%%?G__ ,/'/C?_ -&7_$#_ +^7W_RMH_X>.?&__HR_X@?]_+[_ .5M
M 'Z 45^?_P#P\<^-_P#T9?\ $#_OY??_ "MH_P"'CGQO_P"C+_B!_P!_+[_Y
M6T ?H!17Y_\ _#QSXW_]&7_$#_OY??\ RMH_X>.?&_\ Z,O^('_?R^_^5M '
MZ 45^?\ _P /'/C?_P!&7_$#_OY??_*VC_AXY\;_ /HR_P"('_?R^_\ E;0!
M^@%%?G__ ,/'/C?_ -&7_$#_ +^7W_RMH_X>.?&__HR_X@?]_+[_ .5M 'Z
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MY_\ _#QSXW_]&7_$#_OY??\ RMH_X>.?&_\ Z,O^('_?R^_^5M 'Z 45^?\
M_P /'/C?_P!&7_$#_OY??_*VC_AXY\;_ /HR_P"('_?R^_\ E;0!^@%%?G__
M ,/'/C?_ -&7_$#_ +^7W_RMH_X>.?&__HR_X@?]_+[_ .5M 'Z 45^?_P#P
M\<^-_P#T9?\ $#_OY??_ "MH_P"'CGQO_P"C+_B!_P!_+[_Y6T ?H!17Y_\
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M_$#_ +^7W_RMH_X>.?&__HR_X@?]_+[_ .5M 'Z 45^?_P#P\<^-_P#T9?\
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M "MH_P"'CGQO_P"C+_B!_P!_+[_Y6T ?H!17Y_\ _#QSXW_]&7_$#_OY??\
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M_P"C+_B!_P!_+[_Y6T ?H!17Y_\ _#QSXW_]&7_$#_OY??\ RMH_X>.?&_\
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M5M 'Z 45^?\ _P /'/C?_P!&7_$#_OY??_*VC_AXY\;_ /HR_P"('_?R^_\
ME;0!^@%%?G__ ,/'/C?_ -&7_$#_ +^7W_RMH_X>.?&__HR_X@?]_+[_ .5M
M 'Z 45^?_P#P\<^-_P#T9?\ $#_OY??_ "MH_P"'CGQO_P"C+_B!_P!_+[_Y
M6T ?H!17Y_\ _#QSXW_]&7_$#_OY??\ RMH_X>.?&_\ Z,O^('_?R^_^5M '
MZ 45^?\ _P /'/C?_P!&7_$#_OY??_*VC_AXY\;_ /HR_P"('_?R^_\ E;0!
M^@%%?G__ ,/'/C?_ -&7_$#_ +^7W_RMH_X>.?&__HR_X@?]_+[_ .5M 'Z
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MY_\ _#QSXW_]&7_$#_OY??\ RMH_X>.?&_\ Z,O^('_?R^_^5M 'Z 45^?\
M_P /'/C?_P!&7_$#_OY??_*VC_AXY\;_ /HR_P"('_?R^_\ E;0!^@%%?G__
M ,/'/C?_ -&7_$#_ +^7W_RMH_X>.?&__HR_X@?]_+[_ .5M 'Z 45^?_P#P
M\<^-_P#T9?\ $#_OY??_ "MH_P"'CGQO_P"C+_B!_P!_+[_Y6T ?H!17Y_\
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M_$#_ +^7W_RMH_X>.?&__HR_X@?]_+[_ .5M 'Z 45^?_P#P\<^-_P#T9?\
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M "MH_P"'CGQO_P"C+_B!_P!_+[_Y6T ?H!17Y_\ _#QSXW_]&7_$#_OY??\
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M_P"C+_B!_P!_+[_Y6T ?H!17Y_\ _#QSXW_]&7_$#_OY??\ RMH_X>.?&_\
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M5M 'Z 45^?\ _P /'/C?_P!&7_$#_OY??_*VC_AXY\;_ /HR_P"('_?R^_\
ME;0!^@%%?G__ ,/'/C?_ -&7_$#_ +^7W_RMH_X>.?&__HR_X@?]_+[_ .5M
M 'Z 45^?_P#P\<^-_P#T9?\ $#_OY??_ "MH_P"'CGQO_P"C+_B!_P!_+[_Y
M6T ?H!17Y_\ _#QSXW_]&7_$#_OY??\ RMH_X>.?&_\ Z,O^('_?R^_^5M '
MZ 45^?\ _P /'/C?_P!&7_$#_OY??_*VC_AXY\;_ /HR_P"('_?R^_\ E;0!
M^@%%?G__ ,/'/C?_ -&7_$#_ +^7W_RMH_X>.?&__HR_X@?]_+[_ .5M 'Z
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MY_\ _#QSXW_]&7_$#_OY??\ RMH_X>.?&_\ Z,O^('_?R^_^5M 'Z 45^?\
M_P /'/C?_P!&7_$#_OY??_*VC_AXY\;_ /HR_P"('_?R^_\ E;0!^@%%?G__
M ,/'/C?_ -&7_$#_ +^7W_RMH_X>.?&__HR_X@?]_+[_ .5M 'Z 45^?_P#P
M\<^-_P#T9?\ $#_OY??_ "MH_P"'CGQO_P"C+_B!_P!_+[_Y6T ?H!17Y_\
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M_$#_ +^7W_RMH_X>.?&__HR_X@?]_+[_ .5M 'Z 45^?_P#P\<^-_P#T9?\
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M "MH_P"'CGQO_P"C+_B!_P!_+[_Y6T ?H!17Y_\ _#QSXW_]&7_$#_OY??\
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M_P"C+_B!_P!_+[_Y6T ?H!17Y_\ _#QSXW_]&7_$#_OY??\ RMH_X>.?&_\
MZ,O^('_?R^_^5M 'Z 45^?\ _P /'/C?_P!&7_$#_OY??_*VC_AXY\;_ /HR
M_P"('_?R^_\ E;0!^@%%?G__ ,/'/C?_ -&7_$#_ +^7W_RMH_X>.?&__HR_
MX@?]_+[_ .5M 'Z 45^?_P#P\<^-_P#T9?\ $#_OY??_ "MH_P"'CGQO_P"C
M+_B!_P!_+[_Y6T ?H!17Y_\ _#QSXW_]&7_$#_OY??\ RMH_X>.?&_\ Z,O^
M('_?R^_^5M 'Z 45^?\ _P /'/C?_P!&7_$#_OY??_*VC_AXY\;_ /HR_P"(
M'_?R^_\ E;0!^@%%?G__ ,/'/C?_ -&7_$#_ +^7W_RMH_X>.?&__HR_X@?]
M_+[_ .5M 'Z 4TC=P:^ ?^'CGQO_ .C+_B!_W\OO_E;1_P /'/C?_P!&7_$#
M_OY??_*V@#[;O_A]H5_(TPLOLETW_+Q92- _URA&?QK+D^&]Y#N^Q>+M<@7L
ML\_G!?ID _F37QQ_P\<^-_\ T9?\0/\ OY??_*VC_AXY\;_^C+_B!_W\OO\
MY6T ?7<WPSUZ;@^.M4Q_LJ5_DXK+D_9_L]0F5]5\0:IJ&T_Q./YMN-?+'_#Q
MSXW_ /1E_P 0/^_E]_\ *VC_ (>.?&__ *,O^('_ '\OO_E;3NP/LG1?@YX2
MT7YH]*CNI/\ GI=L9?T/'Y"NQBA2WB5(D6.-1A508 'L!7P+_P /'/C?_P!&
M7_$#_OY??_*VC_AXY\;_ /HR_P"('_?R^_\ E;2 _0"BOS__ .'CGQO_ .C+
M_B!_W\OO_E;1_P /'/C?_P!&7_$#_OY??_*V@#] **_/_P#X>.?&_P#Z,O\
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M_P#E;1_P\<^-_P#T9?\ $#_OY??_ "MH _0"BOS_ /\ AXY\;_\ HR_X@?\
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M_$#_ +^7W_RMH _0"BOS_P#^'CGQO_Z,O^('_?R^_P#E;1_P\<^-_P#T9?\
M$#_OY??_ "MH _0"BOS_ /\ AXY\;_\ HR_X@?\ ?R^_^5M'_#QSXW_]&7_$
M#_OY??\ RMH _0"BOS__ .'CGQO_ .C+_B!_W\OO_E;1_P /'/C?_P!&7_$#
M_OY??_*V@#] **_/_P#X>.?&_P#Z,O\ B!_W\OO_ )6T?\/'/C?_ -&7_$#_
M +^7W_RMH _0"BOS_P#^'CGQO_Z,O^('_?R^_P#E;1_P\<^-_P#T9?\ $#_O
MY??_ "MH _0"BOS_ /\ AXY\;_\ HR_X@?\ ?R^_^5M'_#QSXW_]&7_$#_OY
M??\ RMH _0"BOS__ .'CGQO_ .C+_B!_W\OO_E;1_P /'/C?_P!&7_$#_OY?
M?_*V@#] **YSX?>(K[QAX!\-:_J>BW'AS4M4TRVOKK1;O<9K"66)7>W?<JMN
M1F*'*J<J<J.E='0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%122+#&SNRJJ\EFX
MH EHIBLLBJRMN4\AA3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% 'B'_#2G_4N_P#D]_\ :Z/^&E/^I=_\GO\ [77B=%?S
MK_K9G7_/_P#\EA_\B?L_^K^6?\^O_)I?YGMG_#2G_4N_^3W_ -KH_P"&E/\
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MYGMG_#2G_4N_^3W_ -KH_P"&E/\ J7?_ ">_^UUXG11_K9G7_/\ _P#)8?\
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M ">_^UUXG11_K9G7_/\ _P#)8?\ R(?ZOY9_SZ_\FE_F>V?\-*?]2[_Y/?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWFMWT5G"\I5F"!Y&"EBJL0H.<*3V-<9_PUA\$/\ HLGP_P#_  J+'_X[5/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7G7Q8^&B^,;)=1T[]QKUF-T,B\&
M4#G83Z]U/8_7(]%HH \X^$_Q*_X2RU;3-4_<>(+/*RQN-IE"\%L>HZ$>OIG
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT:X@1F( +%5A )P ,]< #M6I_P -9?"O_H:?_*==_P#QJC_ADWX5_P#0K?\
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MM\STJBBBO).P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX/-M<:O\/OAG#(NJ6LEPK6TLMJY>X9K:= I5[Q[:SE55<R)$&#;<%*O[ O\
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M5<P_ZORVQG=_K3C'.?BS]OK_ )2F?LX_]RY_Z?+BOU4H _"S_@G!^SCXW_:
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M_P!LSQ?<>.Y/V=?CG8ZA9?%/1_,MM/U*[4R2WZ11F4Q7+KD-*(E,B7 )2>,
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M2<94'L*P/^"*O_)K/BG_ +'.Z_\ 2&QH_P""U7_)K/A;_L<[7_TAOJ /K/\
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MHN+A92#MW,I^="=X_1[]D_\ Y-9^#?\ V)FC?^D,-? /_.=;_/\ T+% '?\
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MK+)!'"R*D2P[E0YA,??_ /!6[]G'PAXB_9^UCXI6NE:?I7C/P_>6D]SJUM:
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MF2W$^FZ!IEMI5K-=LK3/%!$L2%RJA2Q5020H&<X Z4 ?D?\ M4?#?7_VT/\
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M9XL\$>$_"L__  L'6?#^C^'-2W:;-_PDUU!!:77F(VZW;SB$?<@?*'.5#<$
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MN-*46JJS^;>#['$2&8#:)+A"QSD*&(!. ?@/_@G/^QO%^T5\(['4?B%-J_\
MPJ;3]3N[FV\(M=200:UJS*(9-1+QI$P@BA6&!%$DA\Z*X.^-2\3@'Z.?#?\
M:H^$/Q<UZXT7PA\1?#^M:S#>SV"Z;%>JEQ<20KOD:"-\-/&%!82Q!HV"L0Q
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M)+#.7E$20I<*3$T[.0! ',I!#!,'-?F;_P $X?V?O%_[3'PMO?"WB#5?[*^
M&F^)I-3U;3=/E,5WXDU(06NVSE=6W);1+'#(Q 4EI!MW.%>W]*_X*,?L(_!#
MX)_LTWOC#P3I-OX*\0V.IVBPK-J5W=/JBR,8WM(UGN" P5C/E59MMLPP 68
M'ZE5C^*/%FA^!]!N=;\2:UI_A_1;7;]HU+5+J.VMXMS!%WR.0J[F95&3R6 '
M6O-?@CX^BT7]D7P#XW\7:M<26]IX&T_6=8U:[:2YF*K81S3SN0&DD; 9C@%F
M.>I-?!GP%^&^J?\ !5CXC>(?BK\7I]0T[X;^&[U--\.^$](NU2WW92:>!Y/]
M9_JO)$LH5'E,Z[)(Q"L:@'W3X'_;1^!WQ(\57OASP_\ $_P_=ZS:WL>GK;3W
M/V;[7.[M&B6K2A5NMS+@& R [EP?G7/ME?E5_P %'/V/OV;_ -GO]G^35/#F
ME_\ "(^/;J]A70[>/5;NY?4=LBBY1HII)1Y:1.SEP%VNL*E_G"/]?>#_ (^7
M'PD_8#\,?%;QU_IU_I_@VPOI-U]-<OJ4\D$:6HDG,1<27#O"'8JPC>5LLZH7
M8 ]T\:?$+PM\-=+BU/Q?XFT?PKILLPMH[S6[Z*SA>4JS! \C!2Q56(4'.%)[
M&O"]?_X*%? ZW\*^/[_0/B#X?U[6O"=E<SKI,]]]A_M.>-)62"UEE0+<;VBV
MAX!*/G0C(==WR#^RK^RMKG[?OBJ[_:%_:%O/[9\-ZGYUIH7ANRN7@BECC>2+
M \M]]O;0N)%2,,))) TDC8R9];_@H7^QK^SQ^SO^S#K?B/PYX0_X1_Q==7MG
MI^B7/]IZC<[KAIEDE3:\SQC-M%<G+@#Y>#N*T =5_P $5_AK_P (_P# _P 9
M^-IH-0MKKQ)K*6<7VF/;;SVMG'\DT.5!;,MS=1LP8KF(* "C9_16OG[]@7P-
M_P *[_8X^$^E?;?[0^T:,FK^=Y7E[?MKM>^7C<<[/M&S=GYMF["YVCZ!H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XOXH>,KGP3X<6]LXH
MY9Y)A"/-!*C*LV< C/W<=>]=I7EO[0G_ ")=M_U^I_Z+DKY_B#$5<+E>(K49
M6E&+:?8]3*Z4*^-I4ZBNFU<ROA_\:K[Q!XCMM,U:VMXEN/EBD@5EPV.,Y8Y!
MZ?4BNCF^"NA3>-$U_9M7=YKV.T>6TO\ >^F><8Y/L2*\?U[39=)\-^$?$-K\
MKLKHS?W9$F8J?K@_^.U[5XK\;1VGPU;7(&\N2[MU$'JLCC'YKR?^ FOC^&\\
MKT\/B*>9U.:5.,:EWNX2BI?A^MCZ#.,MIRJTIX*%E-N%O[R=OQ_0\_\ $WQ[
MU*UUN\@TJVM6LH7,:RR1LQ?!QNR& YZCCI7KWA+6G\0^&[#4946.2XBW,J],
MYP<9[<5\W7N@_8/A?;:E+'MFOM2^1O\ IFJ./_0BWY"OH/X8_P#(@Z+_ -<?
M_9C7+PIF698O,:D,;4;4J:FH]%S-6M\F;9Y@\'A\)"6&A9J7*WWLM?Q-F\US
M3M.=8[O4+6VD(R%FF5#CUP35F&=+B%98G62-AD,IR"/4&OF7Q!'>?$;Q1XCU
M*U9OL]G$TZ]QY:$* /<K\V/8UZA\!/$']I>%I;"5]UQ8RG:O?RVY'_CV[]*]
MG*N*O[1S)X25/EA+FY)7^+E=ORN_(\[&Y)]4P:Q"G>2Y>9=KH]*EF2WA:25U
MC1>2S' 'U-9]IXHT>^G%O:ZK93S=/+CG5F_  UX?\3]?U#QOXZ7PW8RLMK%.
M+9(U;"M)G#,WT.1[ <=:Z6?]GFT6S4VNK7"Z@HSND4>6Q^@Y'UR:/]8<?C,3
M6AE6%52G2=FW+ENUNHA_96%P]&G/'5W"4U=)*]EYGJ]YJ5I8!?M-U#;;NGG2
M!,_3)J"'Q!IEQ((XM1M))#T59U)_(&O%_P!H*-X;GPY$\C,RPNI;U.5!-9_C
M#X8:?H'@6VUN#4;A+ITB;R9F&'+ 9"X /&<]^ :PQO$V.H8K%4:&&4HT$G)N
M5G9J_;?[S3#Y-AJE"A4JUG&55M*T;JZ=NY]%UGZEK5AI**U]?6]F&Z>=*J;O
MIDUY?\._&EYI_P *-2U._8SM8R-%;M(3\WRIM!/7&YL>PX[5Q_@'P3<_%:^U
M#5=8U"X\F-PI92-SL><#.0 ![=", =NFMQ1*M'"T\OH<]:O'F46[**[M_)V[
MV^1E3R6,'6GBJG+3INS:5[OR_ ]^T[Q!IVL;A8:A:WA7[P@F5R/R-8'Q&LI+
MS3[%(5\R9KD1*OKN!./_ !T5X_\ $;P#+\,9]/U;2-0N/)9]H9F DCD'(Y&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%?JI7E'_  R[\,?^%Z_\+D_X1K_BY'_0:_M"Z_Y]?LO^I\SR?]3\GW/?[W-
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M#WP0OOA)8_#*7P';KX)L]3.LQ:;#?7<3->%'3SI)UE$LK;)&3YW;"A5'"*
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ME^)^@:?\1?A?X(\(^"99RVJ:Q:.EU-%$J,VU$34W.YV58PVU@A<.58*0>_\
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M'XE?\*B_95^)WB9)[^SNHM&FL[*ZTM]ES;W5SBUMY4;<I39+/&Q8'<H4E02
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M  1M\ R^&?V7]4\0W>DV]I/XD\07$]KJ"B,S7=G#'' @9E)8*DZ7@5'Q@L[
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MR[6YD@>)[J%_,C>-5#AF1D(;AB40 [__ (+5?\FL^%O^QSM?_2&^KZJ_9/\
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M)^STWAWPI<VZ^(M)U./7+2SN<(E^T<,T9MA(2%B9EG)5F^7<JJQ4,74 J_\
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M\%>'Y=*U"#3_  #964]S>:>WF9^SPOJ<,TN8R(HS<74%NP.<Y&&5I%"^T_\
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M;6]_XLM+:[BAE9$N(A:W<HCD (#J)(HWVG(W1HW4#':_ ;6/VQ_'7Q8T._\
MBKH/A#X=> M*\_\ M+2]+DCFN-9\V"18MA66Z*>3*L;'$D.0Y_UG1?2OVT/V
M:(OVK?@/JW@M+FWT_7(IH]2T6^NO,\FWO8]P&\(02KQO+$20^T2EPC,BB@#H
M?V3_ /DUGX-_]B9HW_I##7P!_P %?/B5=_$WXC?#/X!^$9_[3UJ2]CO+W38W
MM]CW]R1!I\32LVZ*0*\[%7*+LN87.[(*ZWPK\7_M[>"=!\.?!:R^&WA_3_L&
MC1VEIXNU2!)$T^S#?9XI'N8;AK5Y(%VD1".25DB#M%+DEK6J?\$^?B1??MF?
M!GQUJ$]QK,%K#I^O>./&L]]#<BXUNWGFN)(HH&>*18"([6VB$<2I'%Y9VDHX
M(!^D^DZ39:#I=GIFF6=OIVF6<*6UM9VD2Q0P1(H5$1% "HJ@      #@5>HH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\N_:$&?!-M_U^
MK_Z ]>HUQOQ,\.V?B;PUY%[J"Z7;Q2K*UQ(,CH5 /(Z[O7KBOG\_H5,5E>(H
MTOB<7;5+\79+YGJ975C0QM*I/9->9QD.@_V_\ H(T7=-#')<1\9.4D?./<KN
M'XUY2->O]<T32O#*KN$%TQB7N2Q  _ EO^^J^F_!^APZ#X8L=/AN5O8(T)6?
M PZL2V1@D8Y]3Q7'^'/@G8^'_%4>KB]::*%V>*V,6-IYVY;<<XX/3J!7Y[F?
M#..Q<<']7TO3C3JZK2*Y7WUUOM?9=#ZO!9SAJ$L1[77WI3AH]W?[OGW,;XY:
M7%HO@'0;"'F.WG6)??$;#/X]:T9?$ \._ ZUG#;9IK?[-%Z[F+ D>X7<?PKJ
MOB%X%3QYI=O:/=M:>3+YP<)OSP1C&1Z^M8^O_"<:YX;T;1_[5:"'3]V6\C=Y
MI/?&X8QR.O0FO6QF5YA1QV+Q.!I:2HJ$-4M=%U>EE=Z]C@H8["5,+AZ.)GK&
MHY2T>VOEU/*/AWXNN_".G7HB\/-J:W^ \VY@&49&WA3ZFG?!_6W\/?$".WG6
M2WCO,VSQR?PEL%<YQSNP/Q-?1&@Z1%H&C6>G0',=O$(U9NK8ZD^Y.3^-<3XP
M^$,?BCQ)_;,.I-IUQM7.R#?\R\!L[AS@#MVKR)<+YI@*6#K8:K[25&2:A:,;
M)ZR2E=7N^_1L]".=X+%3KTZT.2-1?%=N[6D=.GR/+KNX7PI\:I;F^S'"FH-*
M6V]$=B0?^^6S7T1-K5A;6'VV6^MTL]N[SC(-A'L>AKF_'/PQTWQPL<MPSVU]
M&NU;F)1R/1AW'XY]ZXJQ_9U6.Z5KS6VDMU.=L,&QS^)8@?D:]+!X3.<AKXBE
M@\.JU.I)RB^=1Y6^Z>K^7;<X\1B,NS2E2G7JNG."LURMWMV_X)1_:*9;B^\/
MLC;E>.3:R^A*\UR_C;X=W/AKP_I&KB\^W6=PB;XV0CRBRA@.IR",\\=/>O8_
M'GPOB\;-IF+YK%+%#&!Y6_(X_P!H>E;.M>#X-<\(C0IY3Y8ACC$VWD%<8;'X
M=,]S7%F'"M;,L9C\16AK)1=-W^TEJK7V;5O>7FCHPN>4\'A\+2IR^%OG5NC>
MFMOGH<+J<]KXF^!D[Z5;1VD<4:L]O'TC*.&?KUX^;)]?6JO[.^KVO]EZCIAE
M5;OSA.(VX)4J%./7&/U%=I\/_A^? ]A>VC7WV^WN6#>6T.P*<8/\1SD8_*N4
MU[]GVSN[R6YTK4VT[>=WDR1^8%]@00<?7/UKIEEV;T:V#S:E14JL(<DZ=XK:
M^J?PZWO9;::;F*QF J4\1@9U&H2ES1E9OMHUOY%?]H?7+5M+L-*656O/.^T&
M->2JA2HSZ9W?H:@U/PV^H?L_KX=.1J.I6SRVD+=9)%8SHH]R% 'U%:GAWX!V
M&GWB76JWS:HR'<(5C\M&/^UR21[=^_I7,_M">)I4\2:'I>FSM%<6?[XK#PRL
MQ&W'N H(Q_>%>KEF4XS&8[$YEF4%3]I#D4$U)J.EVVM+Z?F<F*Q]##8>CA<%
M+GY)<_,U:[Z678X']D_XF:;X0O-6\.:W<QZ>MU*LMO-,VQ/-'RLK$\ D;<$X
M'RGU&>R_:2\#^#M)^&NIZKI^G:?!JT]Q$R7$3#>Y:4%]O/.1G.!TS6WXZ_9A
MT7QX8]2^TR:+KLL:M=S6T8:*64@;F,>1@DY/!&3R<FN*M/V)W^T?Z5XL5H?[
ML=B0?UDQ7-+ YG0PDLN>'C5BDU&=TK7ZV?\ P/5GL+&Y;7Q<<P6(E2EHY1LW
M>W2Z_P"#\C8_9Q_Y-V\4_P"_>?\ I,E>0_ 'X1Z5\5K[7XM5U"ZLEL5C9/LK
M*N[>7!SN4]-HQBOK3P;\*]*\#^![OPO83W#6UTLGFSRL#(S.NPMP !P!@8[=
MZ\?'[%=JK,5\63+N_P"G$?\ QRJQ.3XKDP:=%5%3BU)<R2U\V/#YOA>?%M5G
M3=22<7RM_@OZU/8_AC\.=-^&'A^?2=,N[B]@EN&N7DN65GW%57'R@#&%':OG
M']F;PS;>,D^(>BWG^IO+2&+=_=.YRK?56 (]Q7NGP=^"J?"-M5:/69M4^WK&
M-KQ>6$V;N<;CDG=[=*B^#_P1B^$NHZO=1ZLVIG4%1=K0>7L"EC_>.2<^U>L\
M!5KSP;=#DA#G4HW3LFK+UOY?,\A8ZE0IXM1K<\Y\CC*S5VG=^ECY&_MR]\&>
M&?&?@34XVC:::)EC;^">*9<XXZ,H//?:M>_^"?\ DSK4/^O*\_\ 1KUT/Q4_
M9FTSXE>)FUQ-5DTNYE15F5(!()&48#?>!!P #]!TYKJM*^$=MI/PEG\#1W\C
MPRV\L1O&C&[,C%B=N>@)Z9Z=^]>3@,FQN%Q%935X*G*$'=:W=TM_7<]7'9Q@
ML50HN#M-SC*2L]+*SZ?D>/?LEV+ZI\/O'%G%_K+A1"OU:.0#^=<7^RSXFL_!
M_P 3[ZSU>5=/:\MWM5:Y.W;*'4A23P,[2.>^!WKZ/^#/P?3X0Z=J-K'J1U,W
MDBR,YA\K;M!'3<<]?6N;^*/[,&B?$#5I]7LKR31-4N&W3,D?F12MW8KD$,?4
M'GKC.351RG'4<+A*U**=6C>\;[IN^^W_  Y+S;!5L3BZ-63]E6M:26S22VW_
M .&/6+_Q%I>ESVD-YJ%M;S7D@BMXY)0&E8\ *,Y)/M7F_P 0/@]X-^-,US=P
MWL<6L6[F":\T^17977Y2LJ9Y(QCG!X'. *YGX>?LH6_A'Q)9:SJ/B"34I+&5
M9X(88/)7<IRNXEB2 ><<4WQ=^RBFK^([W5]$\3W&CM>3//+$\/F8=R6;:RLI
MQDG (.*]?$2QV+P]L1@U)-_#S*]K;WVO>^VIY.'C@<+B$Z&,<6E\7*[7[6WM
M;OH>5?"R]UKX2_'2+PM#J:WMG)?+9W4<+$Q2A\ -CLRY!]001G&<_;=>,_"C
M]F_2/AOJRZQ=7TFLZPH/ES21B..(D8)5<D[L$C)/0]!7LU;Y!@L1@</*%?2\
MFU&]^5=KF.>XVACL1&=#6R2<K6YGWL%%%%?3GS84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/W[?7C
MG_A7?[''Q8U7[%_:'VC1GTCR?-\O;]M=;+S,[3G9]HW[<?-LVY7.X?0-?+W_
M  4RTF^UK]A[XGV^G6=Q?3QP6-RT-M$TCK%%?VTLLA"@D*D:.[-T558G !-
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MHHP6(!=Y'1%7JS,H&20" ?!O_!#'_FMG_<$_]OZ\J_:5_P"4R.D?]CGX3_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\24445_(Y_1 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7U%\%_^29Z-])O_1SU\NU]1?!?_DF>C?2;_P!'/7Z+P+_R
M,JG^!_\ I43XSBO_ '&'^-?E([FBBBOW,_*@HHHH **** "BBB@#X4_X*)_L
M.:I\9O[(^)OPCTW[)\8=*O;=I9K'4$T^6_@3B.4.Q5?M,+"(I(7C/EJREF*0
MJOU1\#?%7CKQ=\.=/O/B3X*_X07QG'^XU#38KRWNK>5U _?P/%+)B-\Y".=Z
M$,IW +(_H=% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.7_)/[G_ *[1?^ABOG^(/^11BO\ KW+_ -)9ZN5?[_0_Q1_,Z#X??\B/H/\
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M@+7Z(_&?X1>'OCU\,/$'@+Q3'<2Z'K4*Q3-:2F*:)E=9(Y$;D!DD1' 8%25
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MW_;_ /&&A7.D7_Q[\'P6MSMWR:6[Z?<#:P8;)[?34E3E1G:PR,@Y!(/Z*T4
M>>>$_@[I>D_ /1OA3K<G_"0:+:^&8/#%])M:V^VP+:BVD.$<M'O4$_*Y*[N&
MXS7YV^'_ /@ES\>O@#\9-2\3_ OXH^']&L%\R#3[S69Y5NWM9 "8+J%;26"7
M:<<D%6:-) J-A4_56B@#\MOC)_P2V^-GQTTM?&'C7XLZ/XK^+5Q-!;2QW2O:
MZ196$:S@QPM';EF9F-NX58855FN"?,9PY^W/V-?@MK?[._[-WA#X?>([K3[[
M6='^V>?/I<CR6[>;>3SKL9T1CA95!RHY!QGJ?;:X?XS^"_$/Q%^&'B#PWX6\
M8W'@#7-2A6"'Q%:6HN)K-2ZF0HF]"&:,.@=65D+AU.Y10!^8>DZLO[;7_!6J
MSU/2[VXU7P5X%F2YM;RTEM4$5KII#)(CJ6$\$NHN&# L[17((V ?)^NE>$?L
M@_LG^'OV1_A?_P (WI<MOJ^N74S3ZOXB6S-M-J3!W,(9#)(46.-@BH&VYWN
M&D8GW>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^6O^%+>,O\ H#?^3,'_ ,71
M_P *6\9?] ;_ ,F8/_BZ^I:*_.O]1<M_Y^3^^/\ \B?:?ZUXW^2'W/\ ^2/E
MK_A2WC+_ * W_DS!_P#%T?\ "EO&7_0&_P#)F#_XNOJ6BC_47+?^?D_OC_\
M(A_K7C?Y(?<__DCY:_X4MXR_Z W_ ),P?_%T?\*6\9?] ;_R9@_^+KZEHH_U
M%RW_ )^3^^/_ ,B'^M>-_DA]S_\ DCY:_P"%+>,O^@-_Y,P?_%T?\*6\9?\
M0&_\F8/_ (NOJ6BC_47+?^?D_OC_ /(A_K7C?Y(?<_\ Y(^6O^%+>,O^@-_Y
M,P?_ !='_"EO&7_0&_\ )F#_ .+KZEHH_P!1<M_Y^3^^/_R(?ZUXW^2'W/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]OE?P&*H2>'?&]KG[/XLM[M?X?M.GJA_$KG/Y"@#NJ*\ZFT7XDR\+XATN/\
MW8/\4-9%U\+O&>N<:IXXD6'^*.V1@"/HI0?F#3 [OQ%X\T'PJK'4]2A@D7_E
MBK;Y/^^%RWXXKR+Q!\=-:\577]E^#=-F5I,K]H:/?*1TR ,A1[\_A75:/^SS
MX;L6\R_DNM5DW;OWLFQ/R7!_6O0])T'3] M_(TVQALH>ZPH%S[D]2?<T: >-
M^"_@#/=77]J>,+EKJX9O,^QK)DL?^FC_ -%/X]J]MM;2&PM8K>VB2"WB 5(X
MUPJ@=@!5BB@ HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ@#RK_AZ/^S%_P!%,_\ *#JG_P C4?\ #T?]F+_HIG_E!U3_ .1J]5_X9/\
M@A_T1OX?_P#A+V/_ ,:H_P"&3_@A_P!$;^'_ /X2]C_\:H \J_X>C_LQ?]%,
M_P#*#JG_ ,C4?\/1_P!F+_HIG_E!U3_Y&KU7_AD_X(?]$;^'_P#X2]C_ /&J
M/^&3_@A_T1OX?_\ A+V/_P :H \J_P"'H_[,7_13/_*#JG_R-1_P]'_9B_Z*
M9_Y0=4_^1J]5_P"&3_@A_P!$;^'_ /X2]C_\:H_X9/\ @A_T1OX?_P#A+V/_
M ,:H \J_X>C_ +,7_13/_*#JG_R-1_P]'_9B_P"BF?\ E!U3_P"1J]5_X9/^
M"'_1&_A__P"$O8__ !JC_AD_X(?]$;^'_P#X2]C_ /&J /*O^'H_[,7_ $4S
M_P H.J?_ "-1_P /1_V8O^BF?^4'5/\ Y&KU7_AD_P""'_1&_A__ .$O8_\
MQJC_ (9/^"'_ $1OX?\ _A+V/_QJ@#RK_AZ/^S%_T4S_ ,H.J?\ R-1_P]'_
M &8O^BF?^4'5/_D:O5?^&3_@A_T1OX?_ /A+V/\ \:H_X9/^"'_1&_A__P"$
MO8__ !J@#RK_ (>C_LQ?]%,_\H.J?_(U'_#T?]F+_HIG_E!U3_Y&KU7_ (9/
M^"'_ $1OX?\ _A+V/_QJC_AD_P""'_1&_A__ .$O8_\ QJ@#RK_AZ/\ LQ?]
M%,_\H.J?_(U'_#T?]F+_ **9_P"4'5/_ )&KU7_AD_X(?]$;^'__ (2]C_\
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M8O\ HIG_ )0=4_\ D:O5?^&3_@A_T1OX?_\ A+V/_P :H_X9/^"'_1&_A_\
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M .$O8_\ QJC_ (9/^"'_ $1OX?\ _A+V/_QJ@#RK_AZ/^S%_T4S_ ,H.J?\
MR-1_P]'_ &8O^BF?^4'5/_D:O5?^&3_@A_T1OX?_ /A+V/\ \:H_X9/^"'_1
M&_A__P"$O8__ !J@#RK_ (>C_LQ?]%,_\H.J?_(U'_#T?]F+_HIG_E!U3_Y&
MKU7_ (9/^"'_ $1OX?\ _A+V/_QJC_AD_P""'_1&_A__ .$O8_\ QJ@#RK_A
MZ/\ LQ?]%,_\H.J?_(U'_#T?]F+_ **9_P"4'5/_ )&KU7_AD_X(?]$;^'__
M (2]C_\ &J/^&3_@A_T1OX?_ /A+V/\ \:H \J_X>C_LQ?\ 13/_ "@ZI_\
M(U'_  ]'_9B_Z*9_Y0=4_P#D:O5?^&3_ ((?]$;^'_\ X2]C_P#&J/\ AD_X
M(?\ 1&_A_P#^$O8__&J /*O^'H_[,7_13/\ R@ZI_P#(U'_#T?\ 9B_Z*9_Y
M0=4_^1J]5_X9/^"'_1&_A_\ ^$O8_P#QJC_AD_X(?]$;^'__ (2]C_\ &J /
M*O\ AZ/^S%_T4S_R@ZI_\C4?\/1_V8O^BF?^4'5/_D:O5?\ AD_X(?\ 1&_A
M_P#^$O8__&J/^&3_ ((?]$;^'_\ X2]C_P#&J /*O^'H_P"S%_T4S_R@ZI_\
MC4?\/1_V8O\ HIG_ )0=4_\ D:O5?^&3_@A_T1OX?_\ A+V/_P :H_X9/^"'
M_1&_A_\ ^$O8_P#QJ@#RK_AZ/^S%_P!%,_\ *#JG_P C4?\ #T?]F+_HIG_E
M!U3_ .1J]5_X9/\ @A_T1OX?_P#A+V/_ ,:H_P"&3_@A_P!$;^'_ /X2]C_\
M:H \J_X>C_LQ?]%,_P#*#JG_ ,C4?\/1_P!F+_HIG_E!U3_Y&KU7_AD_X(?]
M$;^'_P#X2]C_ /&J/^&3_@A_T1OX?_\ A+V/_P :H \J_P"'H_[,7_13/_*#
MJG_R-1_P]'_9B_Z*9_Y0=4_^1J]5_P"&3_@A_P!$;^'_ /X2]C_\:H_X9/\
M@A_T1OX?_P#A+V/_ ,:H \J_X>C_ +,7_13/_*#JG_R-1_P]'_9B_P"BF?\
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M_E!U3_Y&KU7_ (9/^"'_ $1OX?\ _A+V/_QJC_AD_P""'_1&_A__ .$O8_\
MQJ@#RK_AZ/\ LQ?]%,_\H.J?_(U'_#T?]F+_ **9_P"4'5/_ )&KU7_AD_X(
M?]$;^'__ (2]C_\ &J/^&3_@A_T1OX?_ /A+V/\ \:H \J_X>C_LQ?\ 13/_
M "@ZI_\ (U'_  ]'_9B_Z*9_Y0=4_P#D:O5?^&3_ ((?]$;^'_\ X2]C_P#&
MJ/\ AD_X(?\ 1&_A_P#^$O8__&J /*O^'H_[,7_13/\ R@ZI_P#(U'_#T?\
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MQ?\ 13/_ "@ZI_\ (U'_  ]'_9B_Z*9_Y0=4_P#D:O5?^&3_ ((?]$;^'_\
MX2]C_P#&J/\ AD_X(?\ 1&_A_P#^$O8__&J /*O^'H_[,7_13/\ R@ZI_P#(
MU'_#T?\ 9B_Z*9_Y0=4_^1J]5_X9/^"'_1&_A_\ ^$O8_P#QJC_AD_X(?]$;
M^'__ (2]C_\ &J /*O\ AZ/^S%_T4S_R@ZI_\C4?\/1_V8O^BF?^4'5/_D:O
M5?\ AD_X(?\ 1&_A_P#^$O8__&J/^&3_ ((?]$;^'_\ X2]C_P#&J /*O^'H
M_P"S%_T4S_R@ZI_\C4?\/1_V8O\ HIG_ )0=4_\ D:O5?^&3_@A_T1OX?_\
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M'5/_ )&KU7_AD_X(?]$;^'__ (2]C_\ &J/^&3_@A_T1OX?_ /A+V/\ \:H
M\J_X>C_LQ?\ 13/_ "@ZI_\ (U'_  ]'_9B_Z*9_Y0=4_P#D:O5?^&3_ ((?
M]$;^'_\ X2]C_P#&J/\ AD_X(?\ 1&_A_P#^$O8__&J /*O^'H_[,7_13/\
MR@ZI_P#(U'_#T?\ 9B_Z*9_Y0=4_^1J]5_X9/^"'_1&_A_\ ^$O8_P#QJC_A
MD_X(?]$;^'__ (2]C_\ &J /*O\ AZ/^S%_T4S_R@ZI_\C4?\/1_V8O^BF?^
M4'5/_D:O5?\ AD_X(?\ 1&_A_P#^$O8__&J/^&3_ ((?]$;^'_\ X2]C_P#&
MJ /*O^'H_P"S%_T4S_R@ZI_\C4?\/1_V8O\ HIG_ )0=4_\ D:O5?^&3_@A_
MT1OX?_\ A+V/_P :H_X9/^"'_1&_A_\ ^$O8_P#QJ@#RK_AZ/^S%_P!%,_\
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MO^BF?^4'5/\ Y&KU7_AD_P""'_1&_A__ .$O8_\ QJC_ (9/^"'_ $1OX?\
M_A+V/_QJ@#RK_AZ/^S%_T4S_ ,H.J?\ R-1_P]'_ &8O^BF?^4'5/_D:O5?^
M&3_@A_T1OX?_ /A+V/\ \:H_X9/^"'_1&_A__P"$O8__ !J@#RK_ (>C_LQ?
M]%,_\H.J?_(U'_#T?]F+_HIG_E!U3_Y&KU7_ (9/^"'_ $1OX?\ _A+V/_QJ
MC_AD_P""'_1&_A__ .$O8_\ QJ@#RK_AZ/\ LQ?]%,_\H.J?_(U'_#T?]F+_
M **9_P"4'5/_ )&KU7_AD_X(?]$;^'__ (2]C_\ &J/^&3_@A_T1OX?_ /A+
MV/\ \:H \J_X>C_LQ?\ 13/_ "@ZI_\ (U'_  ]'_9B_Z*9_Y0=4_P#D:O5?
M^&3_ ((?]$;^'_\ X2]C_P#&J/\ AD_X(?\ 1&_A_P#^$O8__&J /*O^'H_[
M,7_13/\ R@ZI_P#(U'_#T?\ 9B_Z*9_Y0=4_^1J]5_X9/^"'_1&_A_\ ^$O8
M_P#QJC_AD_X(?]$;^'__ (2]C_\ &J /*O\ AZ/^S%_T4S_R@ZI_\C4?\/1_
MV8O^BF?^4'5/_D:O5?\ AD_X(?\ 1&_A_P#^$O8__&J/^&3_ ((?]$;^'_\
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M (>C_LQ?]%,_\H.J?_(U'_#T?]F+_HIG_E!U3_Y&KU7_ (9/^"'_ $1OX?\
M_A+V/_QJC_AD_P""'_1&_A__ .$O8_\ QJ@#RK_AZ/\ LQ?]%,_\H.J?_(U'
M_#T?]F+_ **9_P"4'5/_ )&KU7_AD_X(?]$;^'__ (2]C_\ &J/^&3_@A_T1
MOX?_ /A+V/\ \:H \J_X>C_LQ?\ 13/_ "@ZI_\ (U'_  ]'_9B_Z*9_Y0=4
M_P#D:O5?^&3_ ((?]$;^'_\ X2]C_P#&J/\ AD_X(?\ 1&_A_P#^$O8__&J
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M^&3_ ((?]$;^'_\ X2]C_P#&J /*O^'H_P"S%_T4S_R@ZI_\C4?\/1_V8O\
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M (9/^"'_ $1OX?\ _A+V/_QJC_AD_P""'_1&_A__ .$O8_\ QJ@#RK_AZ/\
MLQ?]%,_\H.J?_(U'_#T?]F+_ **9_P"4'5/_ )&KU7_AD_X(?]$;^'__ (2]
MC_\ &J/^&3_@A_T1OX?_ /A+V/\ \:H \J_X>C_LQ?\ 13/_ "@ZI_\ (U'_
M  ]'_9B_Z*9_Y0=4_P#D:O5?^&3_ ((?]$;^'_\ X2]C_P#&J/\ AD_X(?\
M1&_A_P#^$O8__&J /*O^'H_[,7_13/\ R@ZI_P#(U'_#T?\ 9B_Z*9_Y0=4_
M^1J]5_X9/^"'_1&_A_\ ^$O8_P#QJC_AD_X(?]$;^'__ (2]C_\ &J /*O\
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MI_\ (U'_  ]'_9B_Z*9_Y0=4_P#D:O5?^&3_ ((?]$;^'_\ X2]C_P#&J/\
MAD_X(?\ 1&_A_P#^$O8__&J /*O^'H_[,7_13/\ R@ZI_P#(U'_#T?\ 9B_Z
M*9_Y0=4_^1J]5_X9/^"'_1&_A_\ ^$O8_P#QJC_AD_X(?]$;^'__ (2]C_\
M&J /*O\ AZ/^S%_T4S_R@ZI_\C4?\/1_V8O^BF?^4'5/_D:O5?\ AD_X(?\
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MT4S_ ,H.J?\ R-1_P]'_ &8O^BF?^4'5/_D:O5?^&3_@A_T1OX?_ /A+V/\
M\:H_X9/^"'_1&_A__P"$O8__ !J@#RK_ (>C_LQ?]%,_\H.J?_(U'_#T?]F+
M_HIG_E!U3_Y&KU7_ (9/^"'_ $1OX?\ _A+V/_QJC_AD_P""'_1&_A__ .$O
M8_\ QJ@#RK_AZ/\ LQ?]%,_\H.J?_(U'_#T?]F+_ **9_P"4'5/_ )&KU7_A
MD_X(?]$;^'__ (2]C_\ &J/^&3_@A_T1OX?_ /A+V/\ \:H \J_X>C_LQ?\
M13/_ "@ZI_\ (U'_  ]'_9B_Z*9_Y0=4_P#D:O5?^&3_ ((?]$;^'_\ X2]C
M_P#&J/\ AD_X(?\ 1&_A_P#^$O8__&J /*O^'H_[,7_13/\ R@ZI_P#(U'_#
MT?\ 9B_Z*9_Y0=4_^1J]5_X9/^"'_1&_A_\ ^$O8_P#QJC_AD_X(?]$;^'__
M (2]C_\ &J /*O\ AZ/^S%_T4S_R@ZI_\C4?\/1_V8O^BF?^4'5/_D:O5?\
MAD_X(?\ 1&_A_P#^$O8__&J/^&3_ ((?]$;^'_\ X2]C_P#&J /*O^'H_P"S
M%_T4S_R@ZI_\C4?\/1_V8O\ HIG_ )0=4_\ D:O5?^&3_@A_T1OX?_\ A+V/
M_P :H_X9/^"'_1&_A_\ ^$O8_P#QJ@#RK_AZ/^S%_P!%,_\ *#JG_P C4?\
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M_P#X2]C_ /&J /*O^'H_[,7_ $4S_P H.J?_ "-1_P /1_V8O^BF?^4'5/\
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M_P"4'5/_ )&KU7_AD_X(?]$;^'__ (2]C_\ &J/^&3_@A_T1OX?_ /A+V/\
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M_P!F+_HIG_E!U3_Y&KU7_AD_X(?]$;^'_P#X2]C_ /&J/^&3_@A_T1OX?_\
MA+V/_P :H \J_P"'H_[,7_13/_*#JG_R-1_P]'_9B_Z*9_Y0=4_^1J]5_P"&
M3_@A_P!$;^'_ /X2]C_\:H_X9/\ @A_T1OX?_P#A+V/_ ,:H \J_X>C_ +,7
M_13/_*#JG_R-1_P]'_9B_P"BF?\ E!U3_P"1J]5_X9/^"'_1&_A__P"$O8__
M !JC_AD_X(?]$;^'_P#X2]C_ /&J /*O^'H_[,7_ $4S_P H.J?_ "-1_P /
M1_V8O^BF?^4'5/\ Y&KU7_AD_P""'_1&_A__ .$O8_\ QJC_ (9/^"'_ $1O
MX?\ _A+V/_QJ@#RK_AZ/^S%_T4S_ ,H.J?\ R-1_P]'_ &8O^BF?^4'5/_D:
MO5?^&3_@A_T1OX?_ /A+V/\ \:H_X9/^"'_1&_A__P"$O8__ !J@#RK_ (>C
M_LQ?]%,_\H.J?_(U'_#T?]F+_HIG_E!U3_Y&KU7_ (9/^"'_ $1OX?\ _A+V
M/_QJC_AD_P""'_1&_A__ .$O8_\ QJ@#RK_AZ/\ LQ?]%,_\H.J?_(U'_#T?
M]F+_ **9_P"4'5/_ )&KU7_AD_X(?]$;^'__ (2]C_\ &J/^&3_@A_T1OX?_
M /A+V/\ \:H \J_X>C_LQ?\ 13/_ "@ZI_\ (U'_  ]'_9B_Z*9_Y0=4_P#D
M:O5?^&3_ ((?]$;^'_\ X2]C_P#&J/\ AD_X(?\ 1&_A_P#^$O8__&J /*O^
M'H_[,7_13/\ R@ZI_P#(U'_#T?\ 9B_Z*9_Y0=4_^1J]5_X9/^"'_1&_A_\
M^$O8_P#QJC_AD_X(?]$;^'__ (2]C_\ &J /*O\ AZ/^S%_T4S_R@ZI_\C4?
M\/1_V8O^BF?^4'5/_D:O5?\ AD_X(?\ 1&_A_P#^$O8__&J/^&3_ ((?]$;^
M'_\ X2]C_P#&J /*O^'H_P"S%_T4S_R@ZI_\C4?\/1_V8O\ HIG_ )0=4_\
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MJ@#RK_AZ/^S%_P!%,_\ *#JG_P C4?\ #T?]F+_HIG_E!U3_ .1J]5_X9/\
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M_P H.J?_ "-1_P /1_V8O^BF?^4'5/\ Y&KU7_AD_P""'_1&_A__ .$O8_\
MQJC_ (9/^"'_ $1OX?\ _A+V/_QJ@#RK_AZ/^S%_T4S_ ,H.J?\ R-1_P]'_
M &8O^BF?^4'5/_D:O5?^&3_@A_T1OX?_ /A+V/\ \:H_X9/^"'_1&_A__P"$
MO8__ !J@#RK_ (>C_LQ?]%,_\H.J?_(U'_#T?]F+_HIG_E!U3_Y&KU7_ (9/
M^"'_ $1OX?\ _A+V/_QJC_AD_P""'_1&_A__ .$O8_\ QJ@#RK_AZ/\ LQ?]
M%,_\H.J?_(U'_#T?]F+_ **9_P"4'5/_ )&KU7_AD_X(?]$;^'__ (2]C_\
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M8O\ HIG_ )0=4_\ D:O5?^&3_@A_T1OX?_\ A+V/_P :H_X9/^"'_1&_A_\
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M .$O8_\ QJC_ (9/^"'_ $1OX?\ _A+V/_QJ@#RK_AZ/^S%_T4S_ ,H.J?\
MR-1_P]'_ &8O^BF?^4'5/_D:O5?^&3_@A_T1OX?_ /A+V/\ \:H_X9/^"'_1
M&_A__P"$O8__ !J@#RK_ (>C_LQ?]%,_\H.J?_(U'_#T?]F+_HIG_E!U3_Y&
MKU7_ (9/^"'_ $1OX?\ _A+V/_QJC_AD_P""'_1&_A__ .$O8_\ QJ@#RK_A
MZ/\ LQ?]%,_\H.J?_(U'_#T?]F+_ **9_P"4'5/_ )&KU7_AD_X(?]$;^'__
M (2]C_\ &J/^&3_@A_T1OX?_ /A+V/\ \:H \J_X>C_LQ?\ 13/_ "@ZI_\
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MJG_R-1_P]'_9B_Z*9_Y0=4_^1J]5_P"&3_@A_P!$;^'_ /X2]C_\:H_X9/\
M@A_T1OX?_P#A+V/_ ,:H \J_X>C_ +,7_13/_*#JG_R-1_P]'_9B_P"BF?\
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M_E!U3_Y&KU7_ (9/^"'_ $1OX?\ _A+V/_QJC_AD_P""'_1&_A__ .$O8_\
MQJ@#RK_AZ/\ LQ?]%,_\H.J?_(U'_#T?]F+_ **9_P"4'5/_ )&KU7_AD_X(
M?]$;^'__ (2]C_\ &J/^&3_@A_T1OX?_ /A+V/\ \:H \J_X>C_LQ?\ 13/_
M "@ZI_\ (U'_  ]'_9B_Z*9_Y0=4_P#D:O5?^&3_ ((?]$;^'_\ X2]C_P#&
MJ/\ AD_X(?\ 1&_A_P#^$O8__&J /*O^'H_[,7_13/\ R@ZI_P#(U'_#T?\
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MQ?\ 13/_ "@ZI_\ (U'_  ]'_9B_Z*9_Y0=4_P#D:O5?^&3_ ((?]$;^'_\
MX2]C_P#&J/\ AD_X(?\ 1&_A_P#^$O8__&J /*O^'H_[,7_13/\ R@ZI_P#(
MU'_#T?\ 9B_Z*9_Y0=4_^1J]5_X9/^"'_1&_A_\ ^$O8_P#QJC_AD_X(?]$;
M^'__ (2]C_\ &J /*O\ AZ/^S%_T4S_R@ZI_\C4?\/1_V8O^BF?^4'5/_D:O
M5?\ AD_X(?\ 1&_A_P#^$O8__&J/^&3_ ((?]$;^'_\ X2]C_P#&J /*O^'H
M_P"S%_T4S_R@ZI_\C4?\/1_V8O\ HIG_ )0=4_\ D:O5?^&3_@A_T1OX?_\
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MVMK.TB6*&")%"HB(H 5%4       <"KU !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M3U#4[72[.6ZO)X[:WC^_)(V O;^=7*\*\7ZG<?&#QM%X7TJ=DT.Q;S+NZ3[K
MD<,?0@?=4="23R,$,#VRSNX-0M8KFVE6>WE0.DD9RK \@@U9JGIFFV^D:?;6
M5K&(K>W01QKZ # JY2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%>5_\-$>'/\ GQU3_OU%_P#'*/\ AHCPY_SXZI_WZB_^.5\Y
M_K%E/_01$]G^QLP_Y\L]4HKRO_AHCPY_SXZI_P!^HO\ XY1_PT1X<_Y\=4_[
M]1?_ !RC_6+*?^@B(?V-F'_/EGJE%>5_\-$>'/\ GQU3_OU%_P#'*/\ AHCP
MY_SXZI_WZB_^.4?ZQ93_ -!$0_L;,/\ GRSU2BO*_P#AHCPY_P ^.J?]^HO_
M (Y1_P -$>'/^?'5/^_47_QRC_6+*?\ H(B']C9A_P ^6>J45Y7_ ,-$>'/^
M?'5/^_47_P <H_X:(\.?\^.J?]^HO_CE'^L64_\ 01$/[&S#_GRSU2BO*_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !117->//&=KX&T"?4+D!I/\
M5V\.>9)#T'T[GV!H Y+XS>/)]+@@\-Z-NEUK4OW;>5]^*-N./1FZ#T&>F0:Z
M+X:> X/ /AR.U&V6]EP]U-_>?T!_NKT'XGO7(_!OP9=75U<>,]>_>ZIJ&6M_
M,_@0_P 6.V1P!V7ZX'KU/R ****0!1110 5#%,'9D/RR+U7^H]JFJ">'S,,O
MWUZ-0!/15:VN1-D-\L@^\O\ G_/UZU9H **** "BBB@ HHHH **** "BBB@
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M(HW-&@4@GS NS'(R5."56OFS]B/Q5_9'Q-O]%ENO*M]8L6V6_E[O-GB.]/F
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'Q)1117\CG]$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?47P7_Y)GHWTF_\ 1SU\NU]1?!?_ ))G
MHWTF_P#1SU^B\"_\C*I_@?\ Z5$^,XK_ -QA_C7Y2.YHHHK]S/RH**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ?I_Q(DLHO[3\,S*;64W01S-]E21CYT?[J20>6\C)&4,FTG%?2] !117Y_\
M[0G_  4LURW^,D'P>^ '@S_A-OB#!K,NDWTFLVK_ &1I(@1)% BRQN=CB3S)
MI#'&BP.PWHWF* ?H!17Y?W7Q7_X**_#>\USQ9K7P^L/$FBMNV>'X[6QODM/,
MF79Y$5C.+N39G:-S280LSY(WCZ?_ &'?VX?#W[7G@YH)UM]#^(NE0AM8T%6.
MR1<A?M=KN)9H&8@%22T3,$8D&-Y #R#_ (+5?\FL^%O^QSM?_2&^KZJ_9/\
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MGTW0-,N=6NHK/QKK33/%!$TKA T(!<JI !8#.,D=:_72O*?VL/\ DUGXR?\
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MH$9A 51F2(9V[O-K])_ /C[P]\5/!VD^*_"FJV^N>'=5A$]I?6S'9(N2"""
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ^)****_D<_H@**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZB^"__),]&^DW_HYZ
M^7:^HO@O_P DST;Z3?\ HYZ_1>!?^1E4_P #_P#2HGQG%?\ N,/\:_*1W-%%
M%?N9^5!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0G+R,/4(H)Q[XQ4+&8:5/VRJ1Y.]U;[]BWA,1&HJ+IOG?2SO]VYU=%<;X/\
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MSY%_X8%_ZGK_ ,H__P!OH_X8%_ZGK_RC_P#V^OKJBC^V<=_S\_!?Y!]2P_\
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M3XF?]PS_ -.EI1_P2X_Y,4^&?_<3_P#3I=T?\%1_^3%/B9_W#/\ TZ6E9/\
MP2B\4Z9X@_8G\(6&GW/GW6AWNH:=J$?ELOD7#7<MR$RP ;,5S"V5)'SXSD$
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M_P!'@GBAC@&Y78/OBACFR=I7SMA4%"3\V?\ .=;_ #_T+% '?_\ !:CXE?\
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MP\W@'5?@[J^O7$?BR'4[C5-%L;^0^3-9O%&9(;4EB Z2)/,\0 R)6D4-B4J
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MXU?"^R^-/PD\7^!=0^SQV^OZ9/8K<7-JMTEK*R'RK@1L0&:*39(O((9%(*D
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M_P#R3/1OI-_Z.>OT7@7_ )&53_ __2HGQG%?^XP_QK\I'<T445^YGY4%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7EO[0G_ ")=M_U^I_Z+DKU*O+_VA/\
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M5.Y1S@YP2 <%1QC)'H/[1/C'P-JWPOU"'1]0T>\U2XFA9%M-C3'$@9B=HR.
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M?&+X?_MJ>+O#FJ:AJ'C7P9I?B;6M(L/!NEZ59K<7KJ]Q!I]LDJP>=_KOLX+
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M3KVD>(_B!?\ Q-UK6-9;5[C7M4A>.Y;-M;VZQN7FE9]JVR@,6Z$# VC/MM%
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M&&?^,ZO^&C?^$U_[EG^RO^H7]@_X^?/_ .VG^J_V?]JOJNB@ KY4_P"&&?\
MC.K_ (:-_P"$U_[EG^RO^H7]@_X^?/\ ^VG^J_V?]JOJNB@ KY4_X89_XSJ_
MX:-_X37_ +EG^RO^H7]@_P"/GS_^VG^J_P!G_:KZKHH YSQ]X!\/?%3P=JWA
M3Q7I5OKGAW583!=V-RIV2+D$$$$,K*P#*ZD,K*K*00#7Y\:O_P $GO&_PO'B
M"Z^ WQ[\0>$OMWV?RM(O)Y[+[1LP#]IO;-UW[=\S)BV.-P3NSU^E5% 'YU>$
M_P#@DK<>,/%6C>)OCO\ &'Q!\3KJWLH8YM-WS<.KB1K?[;-*\KVV6G7")"Y\
MS>#&<@_H/I.DV6@Z79Z9IEG;Z=IEG"EM;6=I$L4,$2*%1$10 J*H       X
M%7J* /E/X^?L-?\ "\/VIOAS\8_^$V_L7_A$/[-_XDO]E>?]K^R7TEU_KO/3
M9O\ ,V?<;;C/.<#ZLHHH ^7OVS_V,;[]K+5?A[J>E_$*X^'NI>#I[JYM;RTT
M]KF9I96MV21'6>)HFC:V!# DY8$8QS\UR_\ !,?X^?$*W\1Z!\0OVG=8O?"<
MLRK96KW-_JJ7\2R%U:ZMIYXXXF4I"X56F&[/S?(&;]-:* /)_P!FW]FWPC^R
MQ\.?^$,\&?VA+827LNH7-YJDXEN+F=PJEW*JJ#")&@"*HP@)!8LQ]8HHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /B2BBBOY'/Z("BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *^HO@O_P DST;Z3?\ HYZ^7:^HO@O_ ,DST;Z3?^CGK]%X%_Y&
M53_ _P#TJ)\9Q7_N,/\ &ORD=S1117[F?E04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6]E<7/B"ZU26?[7JD"P22)96RO;Q2R>:8FC9(4D+M)$CM'&[AP#*_P""&/\
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M (2&]M(;C4M1ANY45$N$E4!WM8(X<RI$6ED8HJ!\@9W* >Z?MN?%[P]\>/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_B+_ *%_5/\ P"D_^)H^IXG_ )]2^YA]9H?\_%]Z,2BMO_A!_$7_ $+^J?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB,J&4L".XHH ^*?^"=O[%NJ? 73]7^(_Q'?4)_C#XH^T0ZBM[>K<_8X&N=[
MR1R.L\DS1QS/*S$C*J I$AD^UJ** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M58ZGJ4,$B_\ +%6WR?\ ?"Y;\<5Y%X@^.FM>*KK^R_!NFS*TF5^T-'OE(Z9
M&0H]^?PIV ]'^(GQ2TOX?V;B1UN=39<Q6:M\W/0M_=7]3V]O%O#/A'7OC?XB
M?6=7DD@TQ6VF;;@8!^Y&#QQ^('4YSSU?@OX SW5U_:GC"Y:ZN&;S/L:R9+'_
M *:/_13^/:O;;6TAL+6*WMHD@MX@%2.-<*H'8 4]@(-)TFTT+3H+&R@6"U@7
M:D:_YY)ZY/>K]%%2 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !5:\L;?4(&@NH([F%NL<BAA^1JS10!RDW
M@*&'YM*U34M&;^&.WN2\/_?M\K^ Q5"3P[XWM<_9_%EO=K_#]IT]4/XE<Y_(
M5W5% 'G4VB_$F7A?$.EQ_P"[!_BAK(NOA=XSUSC5/'$BP_Q1VR, 1]%*#\P:
M]<HI@>5Z/^SSX;L6\R_DNM5DW;OWLFQ/R7!_6O0])T'3] M_(TVQALH>ZPH%
MS[D]2?<UHT4@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCT/B!_W[OO\ Y94?\.X_C?\ ]'H?$#_OW??_ "RK] ** /S_ /\ AW'\;_\
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M_P!'H?$#_OW??_+*OT HH _/_P#X=Q_&_P#Z/0^('_?N^_\ EE1_P[C^-_\
MT>A\0/\ OW??_+*OT HH _/_ /X=Q_&__H]#X@?]^[[_ .65'_#N/XW_ /1Z
M'Q _[]WW_P LJ_0"B@#\_P#_ (=Q_&__ */0^('_ '[OO_EE1_P[C^-__1Z'
MQ _[]WW_ ,LJ_0"B@#\__P#AW'\;_P#H]#X@?]^[[_Y94?\ #N/XW_\ 1Z'Q
M _[]WW_RRK] ** /S_\ ^'<?QO\ ^CT/B!_W[OO_ )94?\.X_C?_ -'H?$#_
M +]WW_RRK] ** /S_P#^'<?QO_Z/0^('_?N^_P#EE1_P[C^-_P#T>A\0/^_=
M]_\ +*OT HH _/\ _P"'<?QO_P"CT/B!_P!^[[_Y94?\.X_C?_T>A\0/^_=]
M_P#+*OT HH _/_\ X=Q_&_\ Z/0^('_?N^_^65'_  [C^-__ $>A\0/^_=]_
M\LJ_0"B@#\__ /AW'\;_ /H]#X@?]^[[_P"65'_#N/XW_P#1Z'Q _P"_=]_\
MLJ_0"B@#\_\ _AW'\;_^CT/B!_W[OO\ Y94?\.X_C?\ ]'H?$#_OW??_ "RK
M] ** /S_ /\ AW'\;_\ H]#X@?\ ?N^_^65'_#N/XW_]'H?$#_OW??\ RRK]
M ** /S__ .'<?QO_ .CT/B!_W[OO_EE1_P .X_C?_P!'H?$#_OW??_+*OT H
MH _/_P#X=Q_&_P#Z/0^('_?N^_\ EE1_P[C^-_\ T>A\0/\ OW??_+*OT HH
M _/_ /X=Q_&__H]#X@?]^[[_ .65'_#N/XW_ /1Z'Q _[]WW_P LJ_0"B@#\
M_P#_ (=Q_&__ */0^('_ '[OO_EE1_P[C^-__1Z'Q _[]WW_ ,LJ_0"B@#\_
M_P#AW'\;_P#H]#X@?]^[[_Y94?\ #N/XW_\ 1Z'Q _[]WW_RRK] ** /S_\
M^'<?QO\ ^CT/B!_W[OO_ )94?\.X_C?_ -'H?$#_ +]WW_RRK] ** /S_P#^
M'<?QO_Z/0^('_?N^_P#EE1_P[C^-_P#T>A\0/^_=]_\ +*OT HH _/\ _P"'
M<?QO_P"CT/B!_P!^[[_Y94?\.X_C?_T>A\0/^_=]_P#+*OT HH _/_\ X=Q_
M&_\ Z/0^('_?N^_^65'_  [C^-__ $>A\0/^_=]_\LJ_0"B@#\__ /AW'\;_
M /H]#X@?]^[[_P"65'_#N/XW_P#1Z'Q _P"_=]_\LJ_0"B@#\_\ _AW'\;_^
MCT/B!_W[OO\ Y94?\.X_C?\ ]'H?$#_OW??_ "RK] ** /S_ /\ AW'\;_\
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M_P!'H?$#_OW??_+*OT HH _/_P#X=Q_&_P#Z/0^('_?N^_\ EE1_P[C^-_\
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M_P#AW'\;_P#H]#X@?]^[[_Y94?\ #N/XW_\ 1Z'Q _[]WW_RRK] ** /S_\
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MCT/B!_W[OO\ Y94?\.X_C?\ ]'H?$#_OW??_ "RK] ** /S_ /\ AW'\;_\
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M_P!'H?$#_OW??_+*OT HH _/_P#X=Q_&_P#Z/0^('_?N^_\ EE1_P[C^-_\
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M_P#AW'\;_P#H]#X@?]^[[_Y94?\ #N/XW_\ 1Z'Q _[]WW_RRK] ** /S_\
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MCT/B!_W[OO\ Y94?\.X_C?\ ]'H?$#_OW??_ "RK] ** /S_ /\ AW'\;_\
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M_P!'H?$#_OW??_+*OT HH _/_P#X=Q_&_P#Z/0^('_?N^_\ EE1_P[C^-_\
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M_P#AW'\;_P#H]#X@?]^[[_Y94?\ #N/XW_\ 1Z'Q _[]WW_RRK] ** /S_\
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MCT/B!_W[OO\ Y94?\.X_C?\ ]'H?$#_OW??_ "RK] ** /S_ /\ AW'\;_\
MH]#X@?\ ?N^_^65'_#N/XW_]'H?$#_OW??\ RRK] ** /S__ .'<?QO_ .CT
M/B!_W[OO_EE1_P .X_C?_P!'H?$#_OW??_+*OT HH _/_P#X=Q_&_P#Z/0^(
M'_?N^_\ EE1_P[C^-_\ T>A\0/\ OW??_+*OT HH _/_ /X=Q_&__H]#X@?]
M^[[_ .65'_#N/XW_ /1Z'Q _[]WW_P LJ_0"B@#\_P#_ (=Q_&__ */0^('_
M '[OO_EE1_P[C^-__1Z'Q _[]WW_ ,LJ_0"B@#\__P#AW'\;_P#H]#X@?]^[
M[_Y94?\ #N/XW_\ 1Z'Q _[]WW_RRK] ** /S_\ ^'<?QO\ ^CT/B!_W[OO_
M )94?\.X_C?_ -'H?$#_ +]WW_RRK] ** /S_P#^'<?QO_Z/0^('_?N^_P#E
ME1_P[C^-_P#T>A\0/^_=]_\ +*OT HH _/\ _P"'<?QO_P"CT/B!_P!^[[_Y
M94?\.X_C?_T>A\0/^_=]_P#+*OT HH _/_\ X=Q_&_\ Z/0^('_?N^_^65'_
M  [C^-__ $>A\0/^_=]_\LJ_0"B@#\__ /AW'\;_ /H]#X@?]^[[_P"65'_#
MN/XW_P#1Z'Q _P"_=]_\LJ_0"B@#\_\ _AW'\;_^CT/B!_W[OO\ Y94?\.X_
MC?\ ]'H?$#_OW??_ "RK] ** /S_ /\ AW'\;_\ H]#X@?\ ?N^_^65'_#N/
MXW_]'H?$#_OW??\ RRK] ** /S__ .'<?QO_ .CT/B!_W[OO_EE1_P .X_C?
M_P!'H?$#_OW??_+*OT HH _/_P#X=Q_&_P#Z/0^('_?N^_\ EE1_P[C^-_\
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M_P#AW'\;_P#H]#X@?]^[[_Y94?\ #N/XW_\ 1Z'Q _[]WW_RRK] ** /S_\
M^'<?QO\ ^CT/B!_W[OO_ )94?\.X_C?_ -'H?$#_ +]WW_RRK] ** /S_P#^
M'<?QO_Z/0^('_?N^_P#EE1_P[C^-_P#T>A\0/^_=]_\ +*OT HH _/\ _P"'
M<?QO_P"CT/B!_P!^[[_Y94?\.X_C?_T>A\0/^_=]_P#+*OT HH _/_\ X=Q_
M&_\ Z/0^('_?N^_^65'_  [C^-__ $>A\0/^_=]_\LJ_0"B@#\__ /AW'\;_
M /H]#X@?]^[[_P"65'_#N/XW_P#1Z'Q _P"_=]_\LJ_0"B@#\_\ _AW'\;_^
MCT/B!_W[OO\ Y94?\.X_C?\ ]'H?$#_OW??_ "RK] ** /S_ /\ AW'\;_\
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M_P!'H?$#_OW??_+*OT HH _/_P#X=Q_&_P#Z/0^('_?N^_\ EE1_P[C^-_\
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M_P#AW'\;_P#H]#X@?]^[[_Y94?\ #N/XW_\ 1Z'Q _[]WW_RRK] ** /S_\
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MCT/B!_W[OO\ Y94?\.X_C?\ ]'H?$#_OW??_ "RK] ** /S_ /\ AW'\;_\
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ML?\ 6S _R3^Y?_)&_P#JGCOYX?>__D3[UHKX*_X:<^)?_0R_^2-K_P#&Z/\
MAISXE_\ 0R_^2-K_ /&Z/];,#_)/[E_\D'^J>._GA][_ /D3[UHKX*_X:<^)
M?_0R_P#DC:__ !NC_AISXE_]#+_Y(VO_ ,;H_P!;,#_)/[E_\D'^J>._GA][
M_P#D3[UHKX*_X:<^)?\ T,O_ )(VO_QNC_AISXE_]#+_ .2-K_\ &Z/];,#_
M "3^Y?\ R0?ZIX[^>'WO_P"1/O6BO@K_ (:<^)?_ $,O_DC:_P#QNC_AISXE
M_P#0R_\ DC:__&Z/];,#_)/[E_\ )!_JGCOYX?>__D3[UHKX*_X:<^)?_0R_
M^2-K_P#&Z/\ AISXE_\ 0R_^2-K_ /&Z/];,#_)/[E_\D'^J>._GA][_ /D3
M[UHKX*_X:<^)?_0R_P#DC:__ !NC_AISXE_]#+_Y(VO_ ,;H_P!;,#_)/[E_
M\D'^J>._GA][_P#D3[UHKX*_X:<^)?\ T,O_ )(VO_QNC_AISXE_]#+_ .2-
MK_\ &Z/];,#_ "3^Y?\ R0?ZIX[^>'WO_P"1/O6BO@K_ (:<^)?_ $,O_DC:
M_P#QNC_AISXE_P#0R_\ DC:__&Z/];,#_)/[E_\ )!_JGCOYX?>__D3[UHKX
M*_X:<^)?_0R_^2-K_P#&Z/\ AISXE_\ 0R_^2-K_ /&Z/];,#_)/[E_\D'^J
M>._GA][_ /D3[UHKX*_X:<^)?_0R_P#DC:__ !NC_AISXE_]#+_Y(VO_ ,;H
M_P!;,#_)/[E_\D'^J>._GA][_P#D3[UHKX*_X:<^)?\ T,O_ )(VO_QNC_AI
MSXE_]#+_ .2-K_\ &Z/];,#_ "3^Y?\ R0?ZIX[^>'WO_P"1/O6BO@K_ (:<
M^)?_ $,O_DC:_P#QNC_AISXE_P#0R_\ DC:__&Z/];,#_)/[E_\ )!_JGCOY
MX?>__D3[UHKX*_X:<^)?_0R_^2-K_P#&Z/\ AISXE_\ 0R_^2-K_ /&Z/];,
M#_)/[E_\D'^J>._GA][_ /D3[UHKX*_X:<^)?_0R_P#DC:__ !NC_AISXE_]
M#+_Y(VO_ ,;H_P!;,#_)/[E_\D'^J>._GA][_P#D3[UHKX*_X:<^)?\ T,O_
M )(VO_QNC_AISXE_]#+_ .2-K_\ &Z/];,#_ "3^Y?\ R0?ZIX[^>'WO_P"1
M/O6BO@K_ (:<^)?_ $,O_DC:_P#QNC_AISXE_P#0R_\ DC:__&Z/];,#_)/[
ME_\ )!_JGCOYX?>__D3[UHKX*_X:<^)?_0R_^2-K_P#&Z/\ AISXE_\ 0R_^
M2-K_ /&Z/];,#_)/[E_\D'^J>._GA][_ /D3[UHKX*_X:<^)?_0R_P#DC:__
M !NC_AISXE_]#+_Y(VO_ ,;H_P!;,#_)/[E_\D'^J>._GA][_P#D3[UHKX*_
MX:<^)?\ T,O_ )(VO_QNC_AISXE_]#+_ .2-K_\ &Z/];,#_ "3^Y?\ R0?Z
MIX[^>'WO_P"1/O6BO@K_ (:<^)?_ $,O_DC:_P#QNC_AISXE_P#0R_\ DC:_
M_&Z/];,#_)/[E_\ )!_JGCOYX?>__D3[UHKX*_X:<^)?_0R_^2-K_P#&Z/\
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M  NCQE_T&O\ R6@_^-T?Z]9;_P ^Y_='_P"2#_53&_SP^]__ ")]245\M_\
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M_KUEO_/N?W1_^2#_ %4QO\\/O?\ \B?4E%?+?_"Z/&7_ $&O_):#_P"-T?\
M"Z/&7_0:_P#):#_XW1_KUEO_ #[G]T?_ )(/]5,;_/#[W_\ (GU)17RW_P +
MH\9?]!K_ ,EH/_C='_"Z/&7_ $&O_):#_P"-T?Z]9;_S[G]T?_D@_P!5,;_/
M#[W_ /(GU)17RW_PNCQE_P!!K_R6@_\ C='_  NCQE_T&O\ R6@_^-T?Z]9;
M_P ^Y_='_P"2#_53&_SP^]__ ")]245\M_\ "Z/&7_0:_P#):#_XW1_PNCQE
M_P!!K_R6@_\ C='^O66_\^Y_='_Y(/\ 53&_SP^]_P#R)]245\M_\+H\9?\
M0:_\EH/_ (W1_P +H\9?]!K_ ,EH/_C='^O66_\ /N?W1_\ D@_U4QO\\/O?
M_P B?4E%?+?_  NCQE_T&O\ R6@_^-T?\+H\9?\ 0:_\EH/_ (W1_KUEO_/N
M?W1_^2#_ %4QO\\/O?\ \B?4E%?+?_"Z/&7_ $&O_):#_P"-U]25]%D^>X;.
MO:?5XR7):_,EUOM9OL>+F64U\KY/;23YKVM?I;NEW"BBBOHSQ0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PS]MK_ )-B\9_]N?\
MZ6P5^5E?JG^VU_R;%XS_ .W/_P!+8*_*ROM\D_W:7^+]$>3B_C7H%%%%?0G$
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=S\"?\
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M &O7T?#O_(SI?/\ ])9\YQ%_R+*O_;O_ *4CZDHHHK]H/Q4*PO'7_(E^(/\
ML'W'_HIJW:PO'7_(E^(/^P?<?^BFKCQG^[5/\+_(Z<-_'AZK\SY!HHHK^4S]
M_"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M[;KXDK[;K]<X!_YBO^W/_;C\[XN_Y<?]O?\ MH4445^N'YV%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 >&?MM?\FQ>,_^W/\ ]+8*
M_*ROU3_;:_Y-B\9_]N?_ *6P5^5E?;Y)_NTO\7Z(\G%_&O0****^A.(****
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M;W2KO^UO/\G^RY9)-OE>7NW;XTQGS%QC/0YKRNON+_@II_S3?_N)?^VM?/\
M\'OV4O'WQJTO^U=(M+73=$.]8]4U:8PQ3,I"LL857=N21N"[/D8;@1BN7"XM
M2PL:]>25[_FS2I3_ 'CA!'CM%>X?$']CWQ]X"\(+XIC_ +)\3^'_ +.;R6^\
M.W9G2*#"E92&1"Z,K;MR!@%5F8JHR?.?AG\,]?\ BWXNM/#OAVT^TWT_S/(V
M5AMX@0&EE8 [47(R<$DE5 +$ ]L<12G!SC)66YDX23LUJ<K17U5_P[C^)/\
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MBR,R,4)4D XR.,@<>E4*]SO/V??%7Q.\;>,]6T[['8Z>NMWD<4VH2.@N")Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*?$VN7BQ7$:7EW;.;73R4V[W58(Y&9E9T7:L@&YBP7"L.<_X79X,_P"&Z?\
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M4**** "BBB@ HHHH **** "OJ+]B+_F=/^W'_P!KU\NU]1?L1?\ ,Z?]N/\
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MC]WS8X4 /.U0 ,A1]*_LS_LSZ1\ ?#K2RM#J7B^^C"ZAJBK\H'!^SP9&5C!
M.2 7(#,!A53"_:N_933X^16.LZ-?0Z;XOL8EMDDO'?[+<6V\MY;[0Q1E+NRL
MJG.65ARK)VTLXP2Q'U!2M0]DZ7/;J_M6WMV7S?ES5,MQ3H_6W&]7VBJ<M^B^
MS?OY_)>?T117QQX-U[]KOPEHD>FW'@_2?$GDX6.\UF\M7N0@55"EX[I-_P!W
M.YPSDL26/;V3]GW2_BU]H\1ZY\5;NU2?4_(73]%M)5*:>J27!==J I\PD3#!
MY'954.V5 'R6*RGZK3G4>(IR2VY9IMZ]$O+5W/H,/F'UB<8*C.-][QLEZO\
M#0]CHHHKP3U@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OMNOB
M2OMNOUS@'_F*_P"W/_;C\[XN_P"7'_;W_MH4445^N'YV%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 >&?MM?\ )L7C/_MS_P#2V"OR
MLK]4_P!MK_DV+QG_ -N?_I;!7Y65]ODG^[2_Q?HCR<7\:] HHHKZ$X@HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5]MU\25]MU^N< _\Q7_;G_MQ^=\7
M?\N/^WO_ &T****_7#\["BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%_\ =-']JX/^?\'_ )!]7J]CX=HK[B_X=F?]5(_\H7_W31_P[,_ZJ1_Y0O\
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MB_ZG3_RE?_;J/^&(O^IT_P#*5_\ ;JXO]7LS_P"?7_DT?\SM_P!8LK_Y^_\
MDLO\CY=HKZB_X8B_ZG3_ ,I7_P!NH_X8B_ZG3_RE?_;J/]7LS_Y]?^31_P P
M_P!8LK_Y^_\ DLO\CY=HKZB_X8B_ZG3_ ,I7_P!NH_X8B_ZG3_RE?_;J/]7L
MS_Y]?^31_P P_P!8LK_Y^_\ DLO\CY=HKZB_X8B_ZG3_ ,I7_P!NH_X8B_ZG
M3_RE?_;J/]7LS_Y]?^31_P P_P!8LK_Y^_\ DLO\CY=HKZB_X8B_ZG3_ ,I7
M_P!NH_X8B_ZG3_RE?_;J/]7LS_Y]?^31_P P_P!8LK_Y^_\ DLO\CY=HKZB_
MX8B_ZG3_ ,I7_P!NH_X8B_ZG3_RE?_;J/]7LS_Y]?^31_P P_P!8LK_Y^_\
MDLO\CY=HKZB_X8B_ZG3_ ,I7_P!NH_X8B_ZG3_RE?_;J/]7LS_Y]?^31_P P
M_P!8LK_Y^_\ DLO\CY=HKZB_X8B_ZG3_ ,I7_P!NH_X8B_ZG3_RE?_;J/]7L
MS_Y]?^31_P P_P!8LK_Y^_\ DLO\CY=HKZB_X8B_ZG3_ ,I7_P!NH_X8B_ZG
M3_RE?_;J/]7LS_Y]?^31_P P_P!8LK_Y^_\ DLO\CY=HKZB_X8B_ZG3_ ,I7
M_P!NH_X8B_ZG3_RE?_;J/]7LS_Y]?^31_P P_P!8LK_Y^_\ DLO\CY=HKZB_
MX8B_ZG3_ ,I7_P!NH_X8B_ZG3_RE?_;J/]7LS_Y]?^31_P P_P!8LK_Y^_\
MDLO\CY=HKZB_X8B_ZG3_ ,I7_P!NH_X8B_ZG3_RE?_;J/]7LS_Y]?^31_P P
M_P!8LK_Y^_\ DLO\CY=HKZB_X8B_ZG3_ ,I7_P!NH_X8B_ZG3_RE?_;J/]7L
MS_Y]?^31_P P_P!8LK_Y^_\ DLO\CY=HKZB_X8B_ZG3_ ,I7_P!NH_X8B_ZG
M3_RE?_;J/]7LS_Y]?^31_P P_P!8LK_Y^_\ DLO\CY=HKZB_X8B_ZG3_ ,I7
M_P!NH_X8B_ZG3_RE?_;J/]7LS_Y]?^31_P P_P!8LK_Y^_\ DLO\CY=HKZB_
MX8B_ZG3_ ,I7_P!NH_X8B_ZG3_RE?_;J/]7LS_Y]?^31_P P_P!8LK_Y^_\
MDLO\CY=HKZB_X8B_ZG3_ ,I7_P!NH_X8B_ZG3_RE?_;J/]7LS_Y]?^31_P P
M_P!8LK_Y^_\ DLO\CY=HKZB_X8B_ZG3_ ,I7_P!NH_X8B_ZG3_RE?_;J/]7L
MS_Y]?^31_P P_P!8LK_Y^_\ DLO\CY=HKZB_X8B_ZG3_ ,I7_P!NH_X8B_ZG
M3_RE?_;J/]7LS_Y]?^31_P P_P!8LK_Y^_\ DLO\CY=HKZB_X8B_ZG3_ ,I7
M_P!NH_X8B_ZG3_RE?_;J/]7LS_Y]?^31_P P_P!8LK_Y^_\ DLO\CY=HKZB_
MX8B_ZG3_ ,I7_P!NH_X8B_ZG3_RE?_;J/]7LS_Y]?^31_P P_P!8LK_Y^_\
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M91_PS7_U,?\ Y(__ &RC_5/.O^?'_DT/_D@_U@RS_G[_ .2R_P CQ.BO;/\
MAFO_ *F/_P D?_ME'_#-?_4Q_P#DC_\ ;*/]4\Z_Y\?^30_^2#_6#+/^?O\
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M_D@_U@RS_G[_ .2R_P CQ.BO;/\ AFO_ *F/_P D?_ME'_#-?_4Q_P#DC_\
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M?_4Q_P#DC_\ ;*/]4\Z_Y\?^30_^2#_6#+/^?O\ Y++_ "/$Z*]L_P"&:_\
MJ8__ "1_^V4?\,U_]3'_ .2/_P!LH_U3SK_GQ_Y-#_Y(/]8,L_Y^_P#DLO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBOE3_AZ/^S%_T4S_ ,H.
MJ?\ R-0!]5T5\J?\/1_V8O\ HIG_ )0=4_\ D:NI^%W[>7P*^-'CO3?!O@[Q
MS_;/B34_,^R6/]D7T'F>7$\K_/+ J#"(YY89Q@<D"@#Z"HKXT_:;_P""A4OP
M)_:$T'X1>&OA];_$/Q#J\-FJK#XDCL7AO+F9HXK216A<(Q7RI,NZC;.I( PQ
M^RZ "BBB@ HHHH **** "BBB@ HHHH **\\^.?QS\(_LZ_#G4/&OC34/L.DV
MOR10QX>XO9V!*6\"$C?(V#@9  #,Q5%9A\1Z3_P4\^+'QFU2S'P:_9RUCQ#H
M7_"0)8R:Q=3330SV^X9A>2.)8;*=D>)C))+*D(8E@X(:@#]'Z*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HKY=_;B_;AL?V,=*\)._A&X\7:EXC
MFN5@MUOELX8HH%C\QFDV2-NW31!5"8(WDLNT!O?_ (?>(K[QAX!\-:_J>BW'
MAS4M4TRVOKK1;O<9K"66)7>W?<JMN1F*'*J<J<J.E '1T444 %%%4=6U:RT'
M2[S4]3O+?3M,LX7N;F\NY5BA@B12SN[L0%15!))(  )/ H O45^=7BS_ (*U
M7'C#Q5K/AGX$?![Q!\3KJWLII(=2V3<.KF-;C[%#$\KVV6@;+O"Y\S81&<$_
M2EK^U)_PK/\ 95T/XJ_'+1_^%?:U-9*UWX?B;?<RW3;O*A@B9@PDF51((7;=
M"&82L!%(X /H&BOS@TG_ (*>?%CXS:I9CX-?LY:QXAT+_A($L9-8NIIIH9[?
M<,PO)'$L-E.R/$QDDEE2$,2P<$-7I.O_ /!3[PCIO[7&F_!73?"VH:O:RZS'
MX;O?$BW A^SZB\Q@,:6SH#)&DI1&D+K_ ,M"JN%4R 'VM1110 4444 %%%%
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MT:#6H)&;3[EUD:"6*5X95#KPZB2)]K84LNTE5)*CTV@ HHHH **** "BBB@
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M;]M!/@!X8^']OXID_M.'3YO$-KXDCC2)1 LUZYA,)&ZV43AH_-W%H&488[0
M?9E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117Q
MI^TW_P %"I?@3^T)H/PB\-?#ZW^(?B'5X;-56'Q)'8O#>7,S1Q6DBM"X1BOE
M29=U&V=20!AB ?9=%%% !17QI^TW_P %"I?@3^T)H/PB\-?#ZW^(?B'5X;-5
M6'Q)'8O#>7,S1Q6DBM"X1BOE29=U&V=20!AC])?&?XN^'O@+\,/$'CWQ3)<1
M:'HL*RS+:1&6:5F=8XXT7@%GD=$!8A06!9E4%@ =S17R[^P[^W#8_MG:5XM=
M/"-QX1U+PY-;+/;M?+>0RQ3K)Y;+)LC;=NAE#*4P!L(9MQ"_45 !117SG^VQ
M^V#9?L<^ =#U^31+?Q5J6K:G]AAT9M56QF:(1.\EPO[N0NJ,(D;"X!G3+#(!
M /HRBO//@'\2M4^,7P;\)^.=7\-_\(C=Z_9#4$TG[<M[Y5O(2T#^:JJ&\R+R
MY,%05\S:1D&O0Z "BBB@ HHHH ***^/OV/?^"@G_  V!\4O%/AW1_AQJ&@^&
M]&LY+Q/$5S?>?OS.D<$4T2PA(9)$,D@42OCR7 + %@ ?8-%%% !17)?%#XH>
M%_@OX$U/QEXRU/\ L;PWIOE?:[[[/+/Y7F2I$GR1*SG+R(.%.,Y. "1X#_P]
M'_9B_P"BF?\ E!U3_P"1J /JNBO$_@[^V=\%OCYKTFB>!_'^GZKK2XV:;<13
M6-S/E7<^3'<)&TVU8W9O+#;0 6QD9[/XS_%WP]\!?AAX@\>^*9+B+0]%A669
M;2(RS2LSK''&B\ L\CH@+$*"P+,J@L #N:*^7?V'?VX;']L[2O%KIX1N/".I
M>')K99[=KY;R&6*=9/+99-D;;MT,H92F -A#-N(7ZBH **** "BBB@ HJCJV
MK66@Z7>:GJ=Y;Z=IEG"]S<WEW*L4,$2*6=W=B J*H)))  !)X%?)G[$?[>VJ
M?MF>*O$MC#\,_P#A%=%T&RCGN=6_M];S]_*^V&#RC!$WSJEPV\$A?)P<%EH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?&G[3?_!0J
M7X$_M":#\(O#7P^M_B'XAU>&S55A\21V+PWES,T<5I(K0N$8KY4F7=1MG4D
M88_9= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^&OPG^.'AJS\"^'?^$8U74M&&H:M8Z?#'!I93S&AMW@B3'ER'R)A( %0@1,
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M'XO'.G_8?[$FT_PY>65XVR:-)?-NG@0RYMS,6\YVW-ACEPIJKXW\?>(O O\
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M7<R01M=Z3?VT(9F"@O+);K'&N3R[L%49)( )KM/#7[97P>\8?&2;X5:1XO\
MM?CZ*]N]/?2?[,O$Q<6PD:=/-:$1?*(9#D/@[>"<C/AG[6W[$OP \$_L?^-O
ML7@_1_"+^&],N=4TS6X7$=]]L4.\$,EW*6DF665Q#Y4C-GS%5-K+&5^2_P#@
MF_K7_"HO ?QZ_:E\:2:AJO\ 95D=*M;BYO-_]K7\\L<\T<S!))A(\QT]?.8;
M1]I=FW88H ?JC\8OC]\/?@!H,6K_ ! \6:?X:M9<^1'<L7N;G#(C>3 @:6;:
M94+>6K;0P9L#FO(=)_X*8_LTZUJMGI]O\3[>.XNYD@C:[TF_MH0S,%!>62W6
M.-<GEW8*HR20 37YF_"?XE?"7]I;XR:_\4_VM_B+ZVNF^#K*QU+RO+P2@$EM
M&WDVT6\[(TD\QY-SR-]XS]5_P4-^)7[*?Q$^%OAP_!&S\/VGC*SUI?/_ +"\
M.7&D9L'@E\WS,P11R8E6WQNW,N6VX#/D _9#Q7XHTOP-X5UGQ'K=S]AT71[*
M;4+ZZ\MI/*@BC,DC[5!9L*I.%!)Q@ \5Y#X=_;A^"'BKP#K/C:R\>6\'A/29
M_LMQJVHV-W8PO<>4\WV> SQ(;B?RT+>3"'?!7Y?F7/Q9^VY\7HO!7_!,7X'>
M"(I;=M2\:>']"B:WFAD9OL=I9V]Q+)&ZX56686:X<G*RMA3@LO:_\$\/V ?"
M"_!#PGXX^)^D_P#"7:KJ_F:WI6@ZPXN-+TNWN(PBR+;!VAEDGA6"1WD4E0L"
MA4>$LP!]$^ /^"A'[/OQ.\9:5X5\._$:WN=<U686UE!<Z;>VB32D';&))X4C
M#L1M4%@68JJY8@'O_C=^TA\-_P!G'2],U#XB^*K?PY;ZG,T%DC02W$T[*NYR
ML4*/(54%=S[=JET!(+J#^,G[<'P,\(Q_MX-\+_A;IW_"-R:Q>Z;8SV=[B/3K
M;4KTHP-N$#-';;9X6*[248RA%"!%'Z._\%3/"OPWF_9IU7QAXWT&WUOQ#HL,
MNG^%UFU::R>*\O6BC+QJC!9VC6,3^6RL"MLP^4%FH ^#;']J;PI\7O\ @H=%
M\0_BCXU\KX4>%]9NM0\/P2C4WMT2!5CL7M;:-7>*21X;6XD#"-&,<FX<B,_K
MUX7^/OP]\8?"BU^)UAXLT^#P#<[MFO:HQT^W&VX-N=YN A3]ZI0;@,G&,Y&?
MSC_X)J_\$_\ X;_&3X#W7CWXI>%;C7+C5]3FBT96U6:"%;.#$;2*MO(C!FG%
MPC"4GB%"JJ"6?@/^"P&K7O@OQ]\-/A-HUY<6/PZT#PG9W.G^'UE9H8I5EN;9
M9&9B6E=88$16D9BHWXP9'+ 'WG_P]'_9B_Z*9_Y0=4_^1J]^^%_Q0\,?&CP)
MIGC+P;J?]L>&]2\W[)>^1+!YOERO$_R2JKC#QLO*C.,C(()^=O@9\%?V/?C3
M\,;C3_AQX1\$>*=#2&6"X8VGF:M;+,\JYEEG'VV%F*R>6[LK!5!C(4*1])^
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M\^!&GZ?!K*?:(=6FT+3)M(LTMUVF(26KVT:R2,SN1*A!"HRN'!C,?Z^?"?\
MXL?^RSX._P"$V/\ 8O\ PB'@RS_MO_EO]D^R6*?:/]5O\S9Y;_<W;L?+G(R
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MLGAF=M:U9=2A@N-(GN$DGO)8[I1Y<?D2S3%).0HC4DM@L?FSP[XL_P"">OP
MLW\&O/X/\2W5IY;7.K:EH<WB1[J0Q1Y<7BV\L1W  E(66-7+@(IW"@#Z>^$/
M[<'P0^.WC&+PIX(\>6^K^(989)X;&:QN[-YE09<1F>)!(P7+;%);:K-C"L1U
M7QN_:0^&_P"SCI>F:A\1?%5OX<M]3F:"R1H);B:=E7<Y6*%'D*J"NY]NU2Z
MD%U!_)G]@SPWX>\2_P#!3/\ M#X5:;<+\.M"FUB^MOM-V9'BTXV\MK%*#*J2
M%6EN(=L;*TB+(H<N4>0_='_!4SPK\-YOV:=5\8>-]!M];\0Z+#+I_A=9M6FL
MGBO+UHHR\:HP6=HUC$_ELK K;,/E!9J /@VQ_:F\*?%[_@H=%\0_BCXU\KX4
M>%]9NM0\/P2C4WMT2!5CL7M;:-7>*21X;6XD#"-&,<FX<B,_K-_PU%\,?^%%
M?\+D_P"$E_XMO_T&O[/NO^?K[+_J?+\[_7?)]SW^[S7Y[_\ !-7_ ()__#?X
MR? >Z\>_%+PK<:Y<:OJ<T6C*VJS00K9P8C:15MY$8,TXN$82D\0H5502SG_!
M8CQIHW@3P#\)/@5X:BM[;3M-A756L66=YK2UMXFL[ +,[%65E-V&!+/F%"2N
M?G /MW]DWP=\ KC0=2\?? _POI]E8:U>W*R:U'I%S:/.69#-% US&KBV#HH$
M<.(%>-@JAE8#TKXH?&GP%\%M+_M'QSXNT?PK;O#-/"NHW:1S7*PJ&D$$6?,F
M90R_)&K,2R@ D@'RO29=&_8'_8CLY-4MK=X_!.@(US;VEQ.\-]JDA&]$D9&=
M5GO9B Q3:@E!*JJX'PO^QS\"[W_@I!\4/&/QK^.\]QKGAZPF&DV&C6D[6UI)
M+L,AMTV2"6&"W26-@HP9'G#-(Q$HD /LG_AZ/^S%_P!%,_\ *#JG_P C5]$>
M ?'WA[XJ>#M)\5^%-5M]<\.ZK")[2^MF.R1<D$$$!E96!5D8!E965@""*^+/
MV\/V,_@3X5_9-\2:W8>%='\"ZEX4TQ!I.M:;9R><TOFP)'#/Y;!KAIV5(/.N
M/,,9F:0G[Q/@/_!-GXO>(?@+^QG^T#X]OY;>/PGHLZ2Z MW$)89-;:#RVC=8
ML3%7=]+0DD( Q(9<2, #]!]$_;*^#WB/XC>(/ MAXO\ ,\2>'OMK:Q#)IEY%
M;Z<EF6%S)/=/"((HT*D&1G"$E0&)90>+U;_@IC^S3HNJWFGW'Q/MY+BTF>"1
MK32;^YA+*Q4E)8[=HY%R.'1BK#!!((-?GO\ \$N?V+=,_:$'B_Q?XW;4)? 5
MKC1#H]E>M;1:S.=D[QW#12++Y<!%K*$P \C1,&_=,K=K_P %A/@K\)_A7I?P
MZU'PGX0M_"?BS59KJ#;H%I#::=/9P*K2&:) !YZR7$6QU7YE,H<G;$  ?K-I
M.K66O:79ZGIEY;ZCIEY"ES;7EI*LL,\3J&1T=20R,I!!!((((X->%_$K]O;X
M!?"+Q5/X<\3_ !(T^#6;;<+BUT^VN=0^SNKM&T<K6T<BQR*R,&C8AUXRHR":
MO_!//P7?> /V,/A5I>H2V\T]QIC:LKVS,4\J\GEO(@2R@[Q'.@88P&# $@ G
MYVTC4/V"?V?+R[L_$'B?P_\ $KQ)K&=0U#Q)XA@?Q;<W;O-,V^2>*"6".4EF
M#! CL C2!B58@'T3X _X*$?L^_$[QEI7A7P[\1K>YUS59A;64%SIM[:)-*0=
ML8DGA2,.Q&U06!9BJKEB ?HROPMT_3?A[\3/^"G'@7_A0.E?\4BWB;3-66.)
MC!;OY#)>7TL$,T<301HL<V(3NYB;R_E>.-?TQ_X*2?%R+X0_L@^-Y1+;KJ7B
M2'_A&;&&YBDD29KL,DX&S&UUMA<R*S$*&C7.[(5@#X7_ &*[>;]L;_@I%XL^
M+NH07%WX>T6:YURV_M+2HW15&+72[:4H?+AGCBV2(V78M9,06(,@_8FO@G_@
MCK\(8?!7[--]XWFBMVU+QIJ<DJW$$LC/]CM&>WBCD1L*K+,+QLH#E95RQP%7
M[VH YSQ]X^\/?"OP=JWBOQ7JMOH?AW2H3/=WURQV1KD    LS,Q"JB@LS,JJ
M"2!7/_!3X]>!?VB/"MUXC^'VN_V_HUK>MI\UU]DN+;;.J1R,FV9$8X65#D#'
MS=>"!\;_ /!9SXO3>$?@/X;\!6DMQ#<>,=3,MTRPQO#+9V>R1XF9OF1C/)9N
MI0<B)P6 ^5OHK]@_X,_\*+_95\":!<6GV/6KJR&KZJLNG_8[C[5<_OFCG0_,
M9(59("S_ #$0+PN J@':?&[]I#X;_LXZ7IFH?$7Q5;^'+?4YF@LD:"6XFG95
MW.5BA1Y"J@KN?;M4N@)!=0>JTGQ_X>UKP#9^-[?5;>/PI=Z8FLQZM=DVT*V;
M1"83N9 IC7RSN.\ J,YQBORC_P""D%]J?[3W[>'@/X'Z5+J$5II/V33)2NGK
M/]EN+TI/=7B*C!Y(TM3;,P=E"_9Y#\HR[>@?\%H/%.J>!/AS\)_ /ARY_L'P
M9J?VY;O1=-C6"WE2S%F+6(J@&(X_-8K&,)D(=I*(5 /I[5O^"F/[-.BZK>:?
M<?$^WDN+29X)&M-)O[F$LK%24ECMVCD7(X=&*L,$$@@UZ]\%/CUX%_:(\*W7
MB/X?:[_;^C6MZVGS77V2XMMLZI'(R;9D1CA94.0,?-UX('R9^P1\/?V4?B3\
M%_#NF:#X9\$>*O&L6F6]SXCL];L5O-12^%O;K=R!+Q6D$ E90&B'D;F(7DM7
MI7QT\8>!?^";7[*NHW7P^\+Z?IFZ]^S:-I,C3R)>:E.2Q>>4[Y)-D4;R$R.-
MR6ZQ*Z93 !ZI\:OVIOA3^SO]F3X@>-=/\/W5UL,-AMDN+QD;S-LOV>%7D$9,
M3KYA79N7&[) /%^ /^"A'[/OQ.\9:5X5\._$:WN=<U686UE!<Z;>VB32D';&
M))X4C#L1M4%@68JJY8@'\SOV7?%'[._BWQ5J_P 6OVI?B/\ \);X^U2]%Q#X
M?O-+U&>"W*.I66Y,,'E2Y$:JENI,"0X4JV0D7/\ _!1KQQ^SKX^U7P+J/P%M
MM'MIXH;RWUQ=%T6?2H=H:%K4F)XHHV;+7/SJI8C:&. @ !^XOBCQ9H?@?0;G
M6_$FM:?X?T6UV_:-2U2ZCMK>+<P1=\CD*NYF51D\E@!UKYL_X>C_ +,7_13/
M_*#JG_R-7Q%_P6K\?>(9?C1X.\$MJMQ_PB<&@0ZRFDJP6$WDES=0M.P R[".
M-57<3M!?;C>^[[2^!GP5_8]^-/PQN-/^''A'P1XIT-(98+AC:>9JULLSRKF6
M6<?;868K)Y;NRL%4&,A0I !]$_"_XH>&/C1X$TSQEX-U/^V/#>I>;]DO?(E@
M\WRY7B?Y)55QAXV7E1G&1D$$];7.> ? /A[X5^#M)\*>%-*M]#\.Z5"(+2QM
ME.R-<DDDDEF9F)9G8EF9F9B22:Y_X_?&+2_V?_@[XL^(&KQ>?:Z'9&=+;<R_
M:IV(C@@W*CE/,E>./>5(7?N/ - %OXH?&GP%\%M+_M'QSXNT?PK;O#-/"NHW
M:1S7*PJ&D$$6?,F90R_)&K,2R@ D@'PS_AZ/^S%_T4S_ ,H.J?\ R-7QM^QS
M\"[W_@I!\4/&/QK^.\]QKGAZPF&DV&C6D[6UI)+L,AMTV2"6&"W26-@HP9'G
M#-(Q$HD]^_;P_8S^!/A7]DWQ)K=AX5T?P+J7A33$&DZUIMG)YS2^; D<,_EL
M&N&G94@\ZX\PQF9I"?O$@'UI_P +^^'O_"F_^%K?\)98?\*]^Q?;O[<W'R_+
MSMV[<;_-W_N_*V^9YG[O;O\ EK\CO^"F'[7'AO\ :B\>^ _"W@7QG;S_  ZL
M(5N;K4)K2_MH8[^:5XWDN(FCW2+#"J,K1Q,P$\P7<6VCU3_@E;X$LOB5^R]\
M:M ^)\%O<?!:;4[6X87=XMG"EU!&)[QWFC=)8T1(M/<LS! %./\ EI7@/[ ?
M[-_A/]K+]J'Q')J?A:XL?A?I4-WJKZ"L]S-#$LLACL[!KU'CD5E$AD5R=T@M
M'RN"Q4 _5S]CCXK?!7Q?\.8/!'P5U_\ MO1?!-E:V<^[39K-QY@DVRR;X(ED
MDE:*:1V1>7+,0-PS] UYY\%/@+X%_9W\*W7ASX?:%_8&C75ZVH36OVNXN=T[
M)'&S[IG=AE8D& <?+TY)/H= 'B?QB_;.^"WP#UZ/1/''C_3]*UIL[]-MXIKZ
MY@PJ./.CMTD:'<LB,OF!=P)*YP<<5I/_  4Q_9IUK5;/3[?XGV\=Q=S)!&UW
MI-_;0AF8*"\LENL<:Y/+NP51DD@ FO*O'2_L5?!GXM>+/%'Q+\5:/X]\=>(M
M3O6O?^$A+>)7TTJ\2M9_9H8I([982BQQB5!*JAXPY52H^ _VU#\'/C5^T)X3
MT[]FW2+=WU^&VL9X=-@;3+&XU&28P0Q16L\40@;:(]\@;RW\Q3A661G /WRK
MQW4_VM?A7I/QM3X13^([A_B*TT, T2VTB^G;=)$LRDR1P&,*(F$C.6VHH8L5
M"MCTGQ7XHTOP-X5UGQ'K=S]AT71[*;4+ZZ\MI/*@BC,DC[5!9L*I.%!)Q@ \
M5^*'["?P+OOVWOVH/''CCQ3/<:1X=BFNM8\0QZ%.UJ+J74'E!T]6\SS8X)D:
MZ#D%B8HWC+*9%< 'Z8^*/^"CW[-_@_7KK2+_ .*.GSW5OMWR:79W>H6YW*'&
MR>WA>)^& .UC@Y4X(('KWPB^,W@OX\^#H_%/@+Q!;^(]">9[8W$"O&T4J'YH
MY(W59(WP5;:Z@E65AE64GY8_:V_8E^ '@G]C_P ;?8O!^C^$7\-Z9<ZIIFMP
MN([[[8H=X(9+N4M),LLKB'RI&;/F*J;66,KX!_P1EU.+P#X!^/?C?7TN-/\
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M>J>"_'O_  3D\$^ 9?"B-H^M6]Q 8KK5-:\-:E=:C,S1+$\@N6M?,A9@NX"
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M]GWWAO1;V#P_<*_VFU^T6MB);O4H78?/YF_[;"K(%4[8\,!^\/UI^UM^Q+\
M/!/['_C;[%X/T?PB_AO3+G5-,UN%Q'??;%#O!#)=REI)EEE<0^5(S9\Q53:R
MQE?FK_@E'ILWA?2_CI^TGXP?5]5M](TRY@DO%N8YYM095^WZB65V$CS@16I5
MW958S/DL<E #]$]-_:X^$FM?&U_A'I_C.WOOB#'--;-I-M:W$B"6*)I94-PL
M9A#(B/N7?E65D.&!6O5-6U:RT'2[S4]3O+?3M,LX7N;F\NY5BA@B12SN[L0%
M15!))(  )/ K\I/^"0?@+5/BI\</B9\</%(_M#4(M\,=]<:6H2?4KV0S74\,
MH 2.1$4JR1KG9>X^52 WUE_P5$^+LWPE_9 \31V<EQ!J7BJ:+PS;S00QR(JS
MAWN!)O\ NJUM#<QAE!8,ZXQ]Y0#V#X&_M1?#']I/^V_^%<>)O^$C_L7R/MW_
M !+[JU\GSO,\K_7Q)NSY4GW<XV\XR,]_XH\6:'X'T&YUOQ)K6G^']%M=OVC4
MM4NH[:WBW,$7?(Y"KN9E49/)8 =:^+/^"8?@/2_V>_V++WXA^*%_LK^V_M?B
M?4KN?2VCN+?38$*Q D R3Q>5%)<1D#!%T=BG.YOD+P+H/Q"_X*[?M'7NK^)M
M2_X1GX;^%]AEL;.</_9=K,S>7;6RL/WES/Y+%[AEVCRRQ&$A@(!]^_\ #T?]
MF+_HIG_E!U3_ .1JR?B=_P %/_@5X>^'.K:CX6^(&GZOXHFT:ZO=#T^32[YT
MFNE$J013A8E,6Z6( K(T;;&5\A75CVMG_P $\_V=;#P;?>%X_A5H[Z;>S">2
M::2>6^5@4.([UY#<1+^[7Y$D53ELCYVS^?'_  5:^#_PI^!FB_#70?#.C^?X
M^NK*WAO=<N=8DDO/[-T^SBL;836H(B'G!5Q*J1@M:. #EMH!4_X)N_M,?#/X
M5^,OB#\2?C;\1+B3QSK$%MI5C>:DFJ:E?-:H TYE=(I(V5C':*A9BZBW8812
M-_ZM_&+X_?#WX :#%J_Q \6:?X:M9<^1'<L7N;G#(C>3 @:6;:94+>6K;0P9
ML#FOG;]FK_@FO\)/ASX.^'&O^(?!=Q)\3])ALM5O-0N=9N'>WU12LS )!*(&
M6*7Y% 4J5C7<7R6;\[O'WC[PG\0/^"D7BF?]H;5;C5?AUI6OZQHTPF-SLM;.
MW^U1V4,:V@$BJLHB/[L?,S,SY+NQ /TR_P"'H_[,7_13/_*#JG_R-7U77S]:
M_LK_ +-7Q<T+1-:T;X=> -:T:*]6_LM1\-V=LEM<20NR%6DML+/&&#*\3EHV
M*X93CCZ!H *_&OXE7]O^UG_P53GM]:E\KP#X%O6BU&36=/A>SLM.TD-+>"Z^
M8(+::Z6=/-F8@+=)N' CK]1_VDOB]%\!O@/XX\>R2V\4^BZ9)+9+=PR2PRWC
M?N[6-UCPQ5YWB0D$ !B2R@%A^4?_  2Y_8MTS]H0>+_%_C=M0E\!6N-$.CV5
MZUM%K,YV3O'<-%(LOEP$6LH3 #R-$P;]TRL ?H1JW_!3']FG1=5O-/N/B?;R
M7%I,\$C6FDW]S"65BI*2QV[1R+D<.C%6&""00:^B/"GBC2_'/A71O$>B7/V[
M1=8LH=0L;KRVC\V"6,21OM8!ERK X8 C."!S7Y2?\%A/@K\)_A7I?PZU'PGX
M0M_"?BS59KJ#;H%I#::=/9P*K2&:) !YZR7$6QU7YE,H<G;$!]T?\$\_!=]X
M _8P^%6EZA+;S3W&F-JRO;,Q3RKR>6\B!+*#O$<Z!AC 8, 2 "0"U\2OV]O@
M%\(O%4_ASQ/\2-/@UFVW"XM=/MKG4/L[J[1M'*UM'(L<BLC!HV(=>,J,@FKX
M _X*$?L^_$[QEI7A7P[\1K>YUS59A;64%SIM[:)-*0=L8DGA2,.Q&U06!9BJ
MKEB ?G;2-0_8)_9\O+NS\0>)_#_Q*\2:QG4-0\2>(8'\6W-V[S3-ODGB@E@C
ME)9@P0([ (T@8E6/R%I^F_#WXF?\%./ O_"@=*_XI%O$VF:LL<3&"W?R&2\O
MI8(9HXF@C18YL0G=S$WE_*\<:@'['_&OX]>!?V=_"MKXC^(.N_V!HUU>KI\-
MU]DN+G=.R22*FV%'896)SDC'R]>0#K?"_P"*'ACXT>!-,\9>#=3_ +8\-ZEY
MOV2]\B6#S?+E>)_DE57&'C9>5&<9&003\;?\%F])OM1_91T6XM+.XN;>P\66
MES=RPQ,Z6\1M;N(22$ A%,DL:;C@;I$7J1GO_P#@FCJUEH'[ '@#4]4O+?3]
M-LX=6N;F\NY5BA@B34;QG=W8@*JJ"22<  D]* /:OC=^TA\-_P!G'2],U#XB
M^*K?PY;ZG,T%DC02W$T[*NYRL4*/(54%=S[=JET!(+J#O^%_BAX8\8?#BV\>
MV&I^1X1N;)M235-4@ET]!:J"QN'%PJ,D>U2X=@%*8<$J03^7/@KPWXA_X*L?
MM92^--?TW6+7]GSPM,;>"QO+L0 *(U(MHS&N#//($EGV$M'$P3S@1;ELK_@H
M5^UNWQV^/%Q\#5\9V_@'X2Z+J8L]>US[+=7)N[J'F<RPQQ^9(L,JM''"HV/*
M@D:3:8VB /NC5O\ @IC^S3HNJWFGW'Q/MY+BTF>"1K32;^YA+*Q4E)8[=HY%
MR.'1BK#!!((->T?"+XS>"_CSX.C\4^ O$%OXCT)YGMC<0*\;12H?FCDC=5DC
M?!5MKJ"596&592?@/P7X]_X)R>"? ,OA1&T?6K>X@,5UJFM>&M2NM1F9HEB>
M07+6OF0LP7<! 8U1B614)K _X(8_\UL_[@G_ +?T ?JI7)?%#XH>%_@OX$U/
MQEXRU/\ L;PWIOE?:[[[/+/Y7F2I$GR1*SG+R(.%.,Y. "1UM?EK_P %M/B[
M$FE_#[X76LMO)<2S/XFU"-H9/-B55>WM"LG$95R]Z&7E@8D/R@_, ?:4G[<'
MP0M_AA;?$*Z\>6^G^$[J:6"RNK^QN[::_:-XXY3:V\D2S7*H\JJ[PHRJ=V2-
MC87X0_MP?!#X[>,8O"G@CQY;ZOXAEADGAL9K&[LWF5!EQ&9XD$C!<ML4EMJL
MV,*Q'E?[)O\ P3K\!?#7X8>%Y_B3X<M_'/CK^S/*NH_$RK?VFDK*XG>QMK=F
MDMT6.5I#YB@L[R3.&"R[!^=O@'X1>'IO^"IFE>"?AG'<:9X=T#QR)8(-;F+/
M$NFN;B\B5UWEEW6LZPER6*^5YC EF !^[M?.?C7_ (*&?LZ^ -4BT_5/BKH]
MU<2P"=6T2.?58=I9E ,MI'+&KY4_(6# 8)&""?DO_@IW^U9XN\0?$:Q_9G^&
M+^5?ZS]DLM;FAE,%S=3WA ATT.X5(XW22%I'#$.)A&655E5_I3X&_P#!-7X'
M?!O0M/2_\(:?XZ\1QV7V:^UKQ)!]J2Z=F#NZVDC/!#@@!2J[U0;2[$LS ':_
M"']N#X(?';QC%X4\$>/+?5_$,L,D\-C-8W=F\RH,N(S/$@D8+EMBDMM5FQA6
M(Y_]J#]N[X8_L[V?BKP]<>+K!/B79Z-->:;H<EG=72-=-"[6L4[0(5CWL$)5
MW1MCJQVJRL?RN_:T^#NE_ K]O'2O"?P(D\C6H+W1Y])TG#M_9>K.8F@@\V[=
MUFW-Y,^]SY8^T;#PAKW/_@LWX5^&WA7Q-X:U'3-"MQ\4/%4QU#5]8759FF2S
MMH$MH4:S+F-5E.-L@5>;-P-Q+D '+?\ !-W]ICX9_"OQE\0?B3\;?B)<2>.=
M8@MM*L;S4DU34KYK5 &G,KI%)&RL8[14+,746[#"*1O_ &>KXS_9J_X)K_"3
MX<^#OAQK_B'P7<2?$_28;+5;S4+G6;AWM]44K,P"02B!EBE^10%*E8UW%\EF
M^S* .<^(/C2Q^&O@'Q+XOU.*XGTW0-,N=5NH;15:9XH(FE<(&8*6*J0 6 SC
M)'6OR/\ ^"9VL:)I_P 1OBG^TG\8/$&GZ5:VGG6T>K:Q91QI>:K>&2ZNFM'
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MG=W$NHHC%!<"-(&;[3.I.PRH$MXV889]PG /T2_X>C_LQ?\ 13/_ "@ZI_\
M(U?1'@'Q]X>^*G@[2?%?A35;?7/#NJPB>TOK9CLD7)!!! 965@59& 965E8
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M$U?1O!_B#XPW7F_VMIOB6U%S<2[9[MX/LL=T#&V+90S_ &4' 53)R!0!]S_
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M+=8XUR>7=@JC)) !-?F;\)_B5\)?VEOC)K_Q3_:W^(OK:Z;X.LK'4O*\O!*
M26T;>3;1;SLC23S'DW/(WWC/U7_!0WXE?LI_$3X6^'#\$;/P_:>,K/6E\_\
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M[$-[^V)JFH_'OX]ZA<>)]'UV:?['8?:VCFU65&:%YI7A93!!$R&..%"I)C&
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MW+(C+Y@7<"2N<''S7_P51_;4UOX":#I?PX\"WO\ 9OB[Q)927=]JT>];G3;
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M.UKP;X6\._9O@]HU[=SW%KI>MFY26PLU$*S)<NQD>.YN?)8B-BRI<D(P"B0
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M*HR>2P ZU\V?\/1_V8O^BF?^4'5/_D:OB+_@M7X^\0R_&CP=X);5;C_A$X-
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M*JA>3#SW:L5+ F$* &5@?'_@CIOB'_@K%^U!J?B3XDO<6/PO\&PK-%X=T^X
MA@663$%D'W+)NF$4CS7"KN80; 8@8?+ /M__ (>C_LQ?]%,_\H.J?_(U>Y?"
M+XS>"_CSX.C\4^ O$%OXCT)YGMC<0*\;12H?FCDC=5DC?!5MKJ"596&592?
MOC)^P7^SKIO[/?B/3)?!6C^$=-T73+W48O$T-M/<7VG,L,S_ &F257^T7:Q;
MV?R'=E;8JA?E4#\^/^"97BCQUX'\*_M*>(_#-S]AT71_A_=:A+=>7;R>5JT2
M2R:<^UP6;"K>G !0X^<$[!0!^J/QB_;.^"WP#UZ/1/''C_3]*UIL[]-MXIKZ
MY@PJ./.CMTD:'<LB,OF!=P)*YP<9/PN_;R^!7QH\=Z;X-\'>.?[9\2:GYGV2
MQ_LB^@\SRXGE?YY8%081'/+#.,#D@5^7/_!-_5?@1KWQ/\7:I^T'>:/J/B>\
MFAN=$O/&<LLEI/*R7;7TER\A-NS-F(AKDDERI3YS7ZX>%?V5_A#X'^(UMX\\
M-_#GP_X?\46MDUC!>:79K;)%&Q)9DA3$2R$,RF4*)"C%"VTE: /BW_@H-_P4
M8\&WGP;U#PG\&/B-]H\9RZU#97U[HRWMM):VL1>226UO$"1MNEBBCW([J\<K
MX!!W#H/^"6OQM^#'A'X1^#OA-I7BRWN?B?KT]WJVHZ?;66H%);HJTA!EEA6)
M6CM8(D8(P0M"VTOG<WQO\9OV=_AYXX_X*':-\$_A3X=_LCPO;WMII>JMI>MF
M[>78IN-1N$DN6<120Q&2,Q$MA[4_*68I7ZR_!;]C7X/?L[^*;KQ'\/O"'_"/
M:U=63:?-=?VG>7.Z!GCD9-LTSJ,M$AR #\O!P3D ]MKDOBA\4/"_P7\":GXR
M\9:G_8WAO3?*^UWWV>6?RO,E2)/DB5G.7D0<*<9R< $CK:_+7_@MI\78DTOX
M??"ZUEMY+B69_$VH1M#)YL2JKV]H5DXC*N7O0R\L#$A^4'Y@#[)U+]O+X%:1
M\.=(\=W_ (Y^P^%]8O)K'3;RXTB^C>]DB ,K0PF 2R1H2%:55,:N0A8-\M>D
M^ _C/X*^)'PP@^(N@>(+>?P3-#<7(UJ\5[.%(H'=)G?SU1HU1HGR7 &%)Z<U
M\6?LO_\ !*GPE8_"_3)?CS9W'C'Q6\*K;Z3_ &O<QVGA^W+R2_9(F@E0.YDF
MDDD()3>QV _-)+\V?MN_M(:=X\^)VG_LTZ'XIM_AG\#/!D\&AZAJ9@O+LRM9
MHJ,)8U0S2K \9BCBY5Y8Q*\A!1X@#[]U;_@IC^S3HNJWFGW'Q/MY+BTF>"1K
M32;^YA+*Q4E)8[=HY%R.'1BK#!!((->T?"+XS>"_CSX.C\4^ O$%OXCT)YGM
MC<0*\;12H?FCDC=5DC?!5MKJ"596&592?@/P7X]_X)R>"? ,OA1&T?6K>X@,
M5UJFM>&M2NM1F9HEB>07+6OF0LP7<! 8U1B614)KR#_@EE\8M+_9_P#@W^TM
M\0=7C\^UT.RT:=+7<R?:9V-]'!!N5'*>9*\<>\J0N_<> 30!^LWQ*^*OA'X-
M^%KCQ'XV\1Z?X:T6'<OVJ_F">:ZHTGEQ+]Z60JCE8T#.VT[5/2O O^'H_P"S
M%_T4S_R@ZI_\C5\+?LN?L_\ B_\ X*8?&36/C)\8M5\_P1IMX+*2QLY3']H=
M LJ:;;(&+6]LBRJSOG>WF':S2/)*GW[XB_X)S_L]>(/ARG@U/AS8:1:Q>8UM
MJNFLZ:I#(PDPYO&+2R[3(2J3-)'E4!0A%  /=-)\?^'M:\ V?C>WU6WC\*7>
MF)K,>K79-M"MFT0F$[F0*8U\L[CO *C.<8KP'5O^"F/[-.BZK>:?<?$^WDN+
M29X)&M-)O[F$LK%24ECMVCD7(X=&*L,$$@@U\+_\%"OVMV^.WQXN/@:OC.W\
M _"71=3%GKVN?9;JY-W=0\SF6&./S)%AE5HXX5&QY4$C2;3&T7JG@OQ[_P $
MY/!/@&7PHC:/K5O<0&*ZU36O#6I76HS,T2Q/(+EK7S(68+N @,:HQ+(J$T ?
M?GPB^,W@OX\^#H_%/@+Q!;^(]">9[8W$"O&T4J'YHY(W59(WP5;:Z@E65AE6
M4GEM3_:U^%>D_&U/A%/XCN'^(K30P#1+;2+Z=MTD2S*3)' 8PHB82,Y;:BAB
MQ4*V/SX_X(P^*=+\#^%OVA/$FMW/V'1='LM*U"^NO+:3RK>)-1DD?:@+-A5)
MP 2<8 )XKR#]A/X%WW[;W[4'CCQQXIGN-(\.Q376L>(8]"G:U%U+J#R@Z>K>
M9YL<$R-=!R"Q,4;QEE,BN #],?%'_!1[]F_P?KUUI%_\4=/GNK?;ODTNSN]0
MMSN4.-D]O"\3\, =K'!RIP00/:O"_P 5/"'C3X<VOC_1_$>GW?@RXLFU!=::
M81VZ0("9'D9\>5LVL'#[2A1@P4J0/SW_ ."I'[-?P4^$/[+NB:IH'@>W\,>(
M;+4[72-&O-"@CB,Y9&:1;]S\UPIAMY&$CEI1*$^8!Y=W?_\ !*GX117W["^K
MZ?XFBM]0\/>/-3U25K.&:1':S>)+"6.1EVE&9K6;E&.%92&!)  / ?\ @I7_
M ,% O#7Q:\ ^&O"/P:\=7%YIM]-=R>(Y;&"_TZ9HA$(HK9S(L:RP2K-<%XRK
M F*/.,8;Z^_8"^-OP8OOAAX1^$'PZ\66^N>(?#F@+=ZG;VEEJ$<+2[T^V7"2
M74*95KFX9@O! D "J!@?G'\&?V=_A[^TC_P4.UKP;X6\._9O@]HU[=SW%KI>
MMFY26PLU$*S)<NQD>.YN?)8B-BRI<D(P"B0?;G[67PZ^%?[!W[(/Q1D^''AV
MW\.:EX]A@\,F&YN;Z^2\:43(P'F2OY;);27LBL2J[E4-N.U2 ?-G[%=O-^V-
M_P %(O%GQ=U""XN_#VBS7.N6W]I:5&Z*HQ:Z7;2E#Y<,\<6R1&R[%K)B"Q!D
M'Z.>&OVRO@]XP^,DWPJTCQ?]K\?17MWI[Z3_ &9>)BXMA(TZ>:T(B^40R'(?
M!V\$Y&?G;_@CK\(8?!7[--]XWFBMVU+QIJ<DJW$$LC/]CM&>WBCD1L*K+,+Q
MLH#E95RQP%7YW^&G@7_A7?\ P6RO-*^W?VA]HUG5M7\[RO*V_;=)N+WR\;CG
M9]HV;L_-LW87.T 'Z_5XE\-_VRO@]\8/B-/X%\%>+_\ A)?$EOY[2PZ;IEY)
M;(D)P\ANA#Y'EYP%DW[&+H%+%USXM_P4N_:MU3X-^!--^''@)]0D^*?CG%MI
M[:+*IO+" RHA=8U#2^9.2T$.Q0=WFLKJ\0#=5_P3Q_9$_P"&4_@W_P 3JV\G
MXA>)/+NO$&R\\^.'89/L]LFT!!Y:2'<5W9D>3#N@CP ?5E%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^*W_)\W_!53_H+^
M#-+UG_L,:<=*TP?A&MM=RQ>Z!K[_ ):$_/\ LWJUG+J&EWEI;WUQI5Q/"\45
M]:+&TUNS*0)4$B/&74G< ZLN0,J1D5\[?LM_L!_#7]DOQ5J_B/PG=^(-5UG4
MK(:>;K7;R.7R("ZR.D:Q11+\[)&26#$>6-I4%@P!]+U^2W_!7SQ[JGQ4^.'P
MS^!_A8_VAJ$6R:2QM]44)/J5[((;6":(D)'(B*&5Y&SLO<_*I);]::^:?^&"
M? %Y^T]_PO75]7U_Q!XN6]^W)9:DUD^G(ZP^3 %B6V5OW"B,QL7WAHD<LS D
M@'N?P^\%V/PU\ ^&O"&F2W$^FZ!IEMI5K-=LK3/%!$L2%RJA2Q5020H&<X Z
M5^3/@NXE_;1_X*TRZY!<7%YX4\):F;ZWN+'58[B&*STLJEM+ [#:8)[P0R&.
M('B[<@_>DK]>]6LY=0TN\M+>^N-*N)X7BBOK18VFMV92!*@D1XRZD[@'5ER!
ME2,BO ?V5_V%?AU^R+JGB#4_"-QK&K:EK$$-M)>:^]M--;Q1LS%(7C@C**[%
M2ZDD,8HC_"* /SC_ ."H'C#2[O\ ;]\.+XX\,:A_PAF@66DVU['&SJ^M:;Y[
MW-P\!_=XSY\]N"KXWP-\ZG(7[<TW_@G[^QUK7@UO%VG^&-'OO":0RW+:[;>+
M;Z2Q6*(L)9#.MV8PJ%'#-NPNULXP:]*_:C_8A^&O[6W]CW'C"'4-,UG2\QPZ
MUH4L4%XT!W$V\C/&ZO'N;> RDJV[:5#R!O ?^'*WP0_Z&GX@?^#"Q_\ D.@#
MU[]GG]DO]FGP[XFL?B-\)O#EO+>Z5/-!9>(+'6+^[M'9H#'*8'DF>&X4),\9
M=-ZJX=,AXV"_45<E\+_A?X8^"_@33/!O@W3/['\-Z;YOV2R\^6?RO,E>5_GE
M9G.7D9N6.,X&  !UM 'F5SJOPO\ VF/#/C/P/+>:1XTTVWFFTCQ#H9ES-:2Q
MSR1%98\B2%A+;NT<F%),8DC;A6K\;_\ @HQ^S1\-_@S\>-!\)_!^YN+W5M6A
M1+OP1:>=?3:;<-Y:VZI(Q>1VN VX0,6=2 WW)HE'W/JW_!&[X/Z_JEYJFI^-
M?B1J.HWDSW%U>7>JV<LT\KL6>1W:T)9F8DEB2222:]?_ &;/^"?/PA_9@U[_
M (2'PYI^H:WXH7S5M]<\0W*SW%K'(JJR1*B)&G"L-X3S,2R*7*L5H _/?]LK
MXY>-?&?B3X2_LR>*O%%QX.TW3],\.6/CO5=4E24R:I-!;O-<7-QYY$\$"R)(
M=SHK2K([,VV)U^R?B'\&?V5OV&?@?>W>M>"/"&LW\%E+<Z?:^+HX+W5->NXX
MXX]D;2QR.-[F'>(8Q%$92Y1%+&NJ_:2_X)P_"W]J#XC?\)MXCO?$&AZTUE%9
MW'_"/2VL"77EEMLLN^W=GEVLL>XM]R*-0,+7*Z/_ ,$C_@+H_@37O#WE>(+Z
M_P!5VK_PDE[>Q2:C9QK+#+Y=O^Y$$>3#@OY1D*RRKOVM@ 'S#_P1N^%LGC3X
MN?$#XN:O8VZIIL/]GV++I$<-K]LNW,D[VK(%CA:*)/+,<2C"7@'R*0K?7O\
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M-YX8TG6?^*S_ +9O-2U;1[VZ@\_[MO&MQ;PJ?,^S>5]F4NX_UWFC.-M>5?\
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M?X7L-2\,W6GVU]JDP@MC/]HMI@CRMA(\I#(07*@D!02S*#^Z=?%/Q*_X)(?
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MX726\FMZU-J$WB>2_B$4,2KJ$]Y!$)VR0J1H;B0QH6(6)49F,D1_7O\ 9V^
MWAW]F_X1Z%X'\/6UNJ64*M?WT$!B?4KPJHFNY 6<[W9<X+-L4*BG:B@> _\
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MHNBWLE]J>N;E_LZ6=1Y1NO-"%EMK=9)5\T-B9I\(DA$+2>U?\.5O@A_T-/Q
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M :38ISMBD97>X"LN^$8^Q])_X(R_ O3M4L[JXUKQOJEO!,DLEC=ZE:K#<*K
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M2=)LM!TNSTS3+.WT[3+.%+:VL[2)8H8(D4*B(B@!450      !P*^=_^&"?
M%Y^T]_PO75]7U_Q!XN6]^W)9:DUD^G(ZP^3 %B6V5OW"B,QL7WAHD<LS D@'
MR#_P5\_XM/\  /X$?"/2/])\-VOF;+J]^:\/]G6L-K!EEVI\R7<A?"<L%QM
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M?@7IVJ6=U<:UXWU2W@F262QN]2M5AN%5@3$YCMDD"L!M.QE;!.&!Y'VGX!\
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M- >VAFN(I&5@DSR02%U1@Q100%,LI_B- 'FOP]_93_97_91^!]CXC\8)X/\
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M?V"? /P7^.&L_%FVU?Q!XH\9ZK]KDFNO$364B1W%S())KB)8;:+RI&^=<H0
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M5#>1ZE#XJ^QR1>;<RB66YA$%M$8)]P8+)&RE [;<<$>;?\.5O@A_T-/Q _\
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M44)/J5[((;6":(D)'(B*&5Y&SLO<_*I);JO^"N6G?\*K_99^#'PRTC2M0O\
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M"?P=\>:9XNMY_%'B/4=+FBN]/AUK4D\FVNHI4EBN +>*$LRLF-KLR$,V5/!
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M-;\4+YJV^N>(;E9[BUCD559(E1$C3A6&\)YF)9%+E6*T >&?"/X8:S_P3?\
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MQGI>B_%+PA^R%X)U/_A6/P>T>]L8-9EN9&DB6>]G6Z:>::6<M+;0K<I+L=D
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M^%O^".'P%\/Z];7]_>>+_$MK%NWZ7JFJ1);SY4J-YMX(I1M)##;(O*C.1D$
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M<:QJVI:Q!#;27FOO;336\4;,Q2%XX(RBNQ4NI)#&*(_PBNJ_:>_9A\*_M8^
M=/\ "/B[4-8T[3;/4X]5CFT6:*.9I4BEB )DCD&S;.QP!G(7GJ" ?&__  17
M^#/]B?#GQG\3;^TVW6O7JZ1ITEQI^QUM;<;Y9(9VY>.660(RJ N^R&2Q&$Y_
M_@MI\78DTOX??"ZUEMY+B69_$VH1M#)YL2JKV]H5DXC*N7O0R\L#$A^4'YOT
M1^#'PB\/? 7X8>'_  %X6CN(M#T6%HH6NY3+-*S.TDDCMP"SR.[D* H+$*JJ
M H\A^(G[!O@CXH?M':/\9];\2^,)?$FD7FGWECIRZA =.M_LC(\<21O SK&S
MH790XRTLC @L: /#/VROAG>_L\_\$KK;X>Z9HEO?)8PZ59ZY=6E^WDVDK7<<
M]S=IYPWS+)>X01@*5%R& 58RHJ?\$5_%FA_\*#\5>&?[9T\^)/\ A)KK4O['
M^U)]L^R_9;&/[1Y.=_E[_EWXV[N,YXK[R\?> ?#WQ4\':MX4\5Z5;ZYX=U6$
MP7=C<J=DBY!!!!#*RL RNI#*RJRD$ U\6:M_P1E^!>HZI>75OK7C?2[>>9Y8
M[&TU*U:&W5F)$2&2V>0JH.T;V9L 98GD@%7_ (*0?MJ:'I/@/5?@K\.;[_A+
M/B1XMW:%<V^A;+S^SHWE\B>VD55?=<RXD@$"@2+O9R4(C#]5_P $\?A/H?[)
M/A7_ (5EXPU[P_:?&;Q1Y?B.YT-&1+P6KI)'#;)*3_I?D_9+MV\LLL322?PL
MLDG?_LV?\$^?A#^S!KW_  D/AS3]0UOQ0OFK;ZYXAN5GN+6.155DB5$2-.%8
M;PGF8ED4N58K7/\ [0W_  37^'7[3'Q0O?'7B[Q9XX74KB&&VCL['4K86EI%
M&@41P));NR*6W2%0V"\CM_$: /E?_@J)^Q_\"?@Y\,(O&/A?[/X"\;7FILUK
MH-I))+#K0=U,Z) S$6ZPJWF!HPL2@B(KF2+;[3_P31O?$/P-_8)\0>+/'MCJ
M\6A:?-J/B72K25@\SZ2EI%-FWB=P$221+ET4E YD\P?+(';H/AK_ ,$D/@-\
M//%4&M7<7B#QJ+;:T.F^)KV&2S6175U=HX88O-QM*E)"T;*[!D;C'U[XK\+Z
M7XY\*ZSX<UNV^W:+K%E-I]]:^8T?FP2QF.1-RD,N58C*D$9R".* /R/_ ."3
M,VD^-/VA/BO\7?'OB/1U\1:;ID^J2MJD=O"^Z[G:2]U)&)58$B5&C=D4*%O,
M%D!VM^Q-?!.D_P#!&7X%Z=JEG=7&M>-]4MX)DEDL;O4K58;A58$Q.8[9) K
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MU.(-J"S_ &6XO2\%K9NSJ'DC2U-RJE%4+]GC'RC", ?K_1110 4444 %%%%
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M1!(KK&9UD*C<MPH&0%8@'T91110 4444 %%%% !1110 4444 %%%% !1110
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M\->$-,EN)]-T#3+;2K6:[96F>*")8D+E5"EBJ@DA0,YP!TH Z.BBB@ HHHH
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M;[#HNCV4.GV-KYC2>5!%&(XTW,2S850,L23C))YK9HH **** "BBB@ HHHH
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M 7X8>'_ 7A:.XBT/186BA:[E,LTK,[222.W +/([N0H"@L0JJH"@ [FBBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7P1+I\5_)>W>KV^J>)]/MYAHNFHHM;2Y-J&V2W-LCVOE*"V9TB9V*AW':?\
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M.^&%G#//K&M^8T$VI68Q#/<2QAED> B81QVO&\R!IMO_ "P/C#_P26L?@?\
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M'_!530_ @_L^^\-Z+>P>'[A7^TVOVBUL1+=ZE"[#Y_,W_;859 JG;'A@/WA
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M9GT/7;CP+X4GU/3=%U"^TV1FFU%M1BA#-.%9"T"1W97[/N"N0S.QR@C^I_\
M@EW\(IOA+^R!X9DO([B#4O%4TOB:XAGFCD15G");F/9]U6MH;:0JQ+!G;./N
MKQ?[:W_!,'3/VG/'E]\0?#/BG_A$_%UU9>7>VM[;-<VFI3Q1+';,6#AK?Y46
M-V59 556$>X,9 #BM4_X(E_#J;P:EKI_Q!\46WBSR8E;5+F&VFL3*"OFL+14
M20*P#[5\\E=RY9]I#>T_M1_M+>'O^">O[/7A'P]I-M<>(?$*Z8FA^%[/4,LD
MJVD,41N;N1%1=J*T194VM(SA5"@L\?Q;_P $X?VBOC'X(_:FT;X!>*]>N-0\
M/13:EI%YHNK2+>/I<UG:2$);3ABR*C68C$:NT(5G*KDAQRO[5%G8_MD?\%-+
MOP!<^.K?0=#BF7PM8:O<V2[+.6WMG>2U",T1E=[\SQ*2V6:50I9=@(![3\(O
M^"9_C7]IRWB^)7[3/COQ1'KFK0NUMH,+(M]91-)YL7F/*KQVZY><_8XX@(_,
M7E&#Q#BOV5?!^I_LF?\ !4Z\^#7AGQ/J%YX1O?.AO8;E5'VVW_LJ2^MA,HRI
MDA9E'FJ%)P^ BR,E=7_PXQ_ZK9_Y:G_W;7M/[(O_  2YTO\ 9?\ C);?$&_\
M=?\ ":W5C93P:?:_V0UA]EN)0(S/N6Y</^Z::/8RD?O=W!44 ?==?-/[<W[9
MFF?L?_#FVO$L?[9\9Z]YT&@:;*K"W+QA/,GG=<8CC\R,E 0[EU5=H+21_2U?
MB%^UIXITO]HC_@J%I7AS5+G_ (2#PC:^)M&\'?9?+:VVP+<11WMMN4)(<7,M
MX/,R2=WRMM"$ 'M'P=_X)[_$+]L3PKX8^)GQ_P#BYK]U8:OYVK6/AVVE$\L5
MK=(LD<D,KLT%GYA\MS#'"RB-44[&^6/YL_:T_9M\3_\ !.GXX>$?$/@?Q9J#
M6MYY^H:#KC1Q0W-O)'(5DM9%5V$NV*2 .S(D<HG9=F RC]Z*_&']IR2R_P""
M@W_!1#0?"_@:VN/$'A/28+/1-2US0IU=&L(KAI;Z]21T$<:QFYDC1CO61HXR
MA?S44@'H'_!3OP7#\8_@+\.?VB=4\8W'AZWO?#^EP:1X":VDNX7O+W-U,5N0
MZK&WD$[G,(WBS0$Y**/'_P!D7_@ESJG[4'P;MOB#?^.O^$*M;Z]G@T^U_LA;
M_P"U6\1$9GW+<H4_>K-'L90?W6[D,*]5_P""OGCW5/BI\</AG\#_  L?[0U"
M+9-)8V^J*$GU*]D$-K!-$2$CD1%#*\C9V7N?E4DM^F/P5^&%E\%?A'X1\"Z<
M;>2#0-,@L6N+:T6U2YE11YMP8U)"M+)OD;DDL[$DDDD W_"GA?2_ WA71O#F
MB6WV'1='LH=/L;7S&D\J"*,1QIN8EFPJ@98DG&23S7FW[5'[2WA[]E'X27GC
M;Q!;7&H2-.MCINEVV0U]>.CO'$9-I$2[8W9I&!VJC8#-M1O8J_&'_@J]X_F^
M,'[7WACX71:K;Z-IWAR&UTYKK76CMK&UO+XQRRW3SJ"P@$+68=G^Z89"%ZLP
M!U/PC_9+^*'_  4JMX_C%\7OB+<:+X3O-3D;1]#T^/[0GV59/*NEM(VD\NR7
M,"Q*S+([M&TDBM@-+Y9^W!^SG>_L&-J'AKPAXEN-9^'7Q1TP6DMCJSL;NWEL
M;JTN"[B,)$[!]HCE*Y"3SIL!Q(_[7^%/"^E^!O"NC>'-$MOL.BZ/90Z?8VOF
M-)Y4$48CC3<Q+-A5 RQ).,DGFOQZ_:L\867[?/\ P4$\$_#SPMJ-QK7@FPF@
MT3[5I>I+Y,T2LUQJ=[;>:HC5EB#H&42"46<;*9 R+0![3X ^-VC_ /!-_P#X
M)]?#ZX&FV^K_ !%^($,^OZ?9QR3O:3RSK&ZW%PS8V)#;/9(\4>TNXPIP7F7*
M^$7_  3/\:_M.6\7Q*_:9\=^*(]<U:%VMM!A9%OK*)I/-B\QY5>.W7+SG[''
M$!'YB\HP>(>+?M46=C^V1_P4TN_ %SXZM]!T.*9?"UAJ]S9+LLY;>V=Y+4(S
M1&5WOS/$I+99I5"EEV ^O_\ #C'_ *K9_P"6I_\ =M '*?LJ^#]3_9,_X*G7
MGP:\,^)]0O/"-[YT-[#<JH^VV_\ 94E];"91E3)"S*/-4*3A\!%D9*Y7]FK_
M )3(ZO\ ]CGXL_\ 1.HU]??LB_\ !+G2_P!E_P",EM\0;_QU_P )K=6-E/!I
M]K_9#6'V6XE C,^Y;EP_[IIH]C*1^]W<%17@#?V'X'_X+;:A=R?V?X?T:U^T
MZE>W#;+:WBW>&WGN+B1N%7<S22.YZEF8GDF@#[I_;6_:MTO]DOX.WOB'?I]Y
MXNOO]&\/Z+>RL/ML^5#N50;C'"K>8_*@X6/>C2(:^-_V#_A?HW[-_P $_$_[
M6_QH-QJ6K:G";W39KFUFN-3MXII6B:<&0@//>R2H%D(QY;JQF"3R!:?PC\-Z
MG_P5%_:JU#XH^(VU#3_@IX#O;>/1O#>J0+,EXXVN;<@H8#YAC66Y!,CA)88<
MLI21%_X+=?%'_DFOPXM=2_Y^/$&IZ;Y'T@LIO-*_]?Z[5;W9?N&@#*\#?"?X
MO?\ !5GQ5?>._'^O:A\/O@I;WJ#2-!LV:2*Y\IV1EMD8JCR*CSJ]\ZM^\<HJ
M,JM'%Y5^VW^S+;_\$[?B-\+_ !?\)?&?B"#4+[[7-;S:DT+W-K<6YB#$.B(D
MD<B7(1HFC((5PQ=9-J^OZ3_P1+LM>TNSU33/CQ;ZCIMY EQ;7EIX966&:)U#
M)(CK?$,K*00P)!!!'6M_PG_P1%TO1_%6C7^M_%/_ (2#1;6]AGOM)_X1UK;[
M; KAI(/-6]+1[U!7>H)7=D=* /HG_@J)\79OA+^R!XFCLY+B#4O%4T7AFWF@
MACD15G#O<"3?]U6MH;F,,H+!G7&/O+@?\$E_@S_PK/\ 95L_$%Y:>1K7C2\E
MU>5I]/\ L]PEJO[FUC+GYI8RJ-<1L<+B[)48.YOE;_@JUXJN/CQ^UO\ #;X*
M:!=:>+O3?L^G>=<I-']GU'4Y8ALF?!#1B);*3,:L1YC@EB-J_7W_  4+\4:7
M^SO^P?KGAWP[<_\ "/QW5E9^#M$M?+:YW6[A8Y;;<X?&;**Y'F.0?EX;>5R
M?-?CG]I_XE?\%"OVC;'X6_ 7Q5J'P]\!:/OO[[Q1:W,EE>74",L<EVP1DE,8
M,JK%; @NTBO+M_Y86_''_!%/2M-^$MU-X9\>:QK7Q%LH;BX59[2WCL=395E:
M*UCB9P;=W;R4\UYY%&&8KA@%[7_@B?X6TRT^ ?CKQ'#:[=:U#Q,=/N;KS&.^
MWM[6"2%-I.T;6NK@Y !._DD!0/<_^"B_QX\/?!7]EWQE9:G<V\NN>+-,NM!T
MG26G*37+3Q^5-*H"L=L$<ID8D!20B%E:1<@'R%_P1<^/'B&^\0>*_A%J%S<:
MAX>MM,;7]*6><%--9;B..>*-2I.V5KE),;@JM&Q"EI7:O#/@S?>.OVRO^"AV
ML^-?!$NGQ7\E[=ZO;ZIXGT^WF&BZ:BBUM+DVH;9+<VR/:^4H+9G2)G8J'<=I
M\&])OOV6?^":/Q:\=:U9W&D^(?BM-;^'=&L]4B9H;RP>%U$\:( T;M#/J,BO
M*P5A#"P4AE\WZ>_X(T?#?3/#G[.6N>+HKC3[O6?$VLO'=-9W3226]O;*$AM[
MB,_+%(&>>4 #+1W,1).5"@'E7[4'_!*O^Q_@?XJ^(MQ\5O$'C7XF:+93:OJN
MJ>)&S;ZE:V\3LT:@^9-'(L"($9Y9%)BVX17!C7_@D;\=-4\)? _XXOXBU#4-
M3\&> ;*#7+32XPLCVR-'>S72P;R,;_LRL(RP3>68;2[L?:?^"L_[1VE_#/\
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M?2_@'^Q7X3O]3GT_3/[6LI/%^KZDUVPME2=!+'+(\N%BV6BVZO@! 8F.3RS
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MQ#^)_A?X$>&(+C4WTF:&^U"SM(&DFN=4N$VVENB>5N9DAER/+9E<W@4KNC%
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M_P"%%_LJ^.]?M[O['K5U9'2-*:+4/L=Q]JN?W*R0./F,D*L\X5/F(@;E<%E
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MM8-&\%>$HHH]&T2ZCBE4W%S&2RWMS(TIDFE4QL7DG5960HR^ ?LZ_8_VT/\
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M]NS2;'3O^"J?P"N+2SM[6XOY_#=S=S0Q*CW$HU>6(22$#+L(XHTW-D[8T7H
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M[#9@QK^V'[-OPAB^ WP'\#^ HXK>*?1=,CBO6M)I)89;QOWEU(C288J\[RN
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M?!7[--]XWFBMVU+QIJ<DJW$$LC/]CM&>WBCD1L*K+,+QLH#E95RQP%4 ZO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_:Z_X0W2/!NL^']&\-Z+]HN[N/6=5NHOM=U)M1"8(K9T_=(K!9"Q;_2)%"J
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M\<_#]]X,M?)MKF&WO;IGE@5HB7F1;6+[;(OE*ZFXD)+@G>I9F/U]^P?\&?\
MA1?[*O@30+BT^QZU=60U?55ET_['<?:KG]\T<Z'YC)"K) 6?YB(%X7 5?H&@
M#Q/]G_\ 9=\(_LE_#K5=#^&VE_;M5N]]S-J&NW86XU*=0WD)<7$<)V1KG8H2
M(A 68(SLY?P#]@/]@OQO^S;\4O&_Q!^)'B73_$7B36K+['!<:7J$]UY_G3B>
M[EN6G@1VD9XH"K!CG=+N!)4C[KHH \2_;$^%_C?XU?L_^(O G@&^T_2M:U[R
MK2;4-2U">S2&U$BO, 88I&D\Q4\DQD*K),Y+$#:W ?LH_L5_\*7_ &2/$7PB
M\6:I]JO_ !9_:7]NW6C7&^*+[5%]E_T5I(5(Q;QQ']XC8D+GE<"OJRB@#\H?
M@C_P3G_:V_9RU34M1^'7Q1\$>')]3A6"\1;NXN(9U5MR%HIK!T+J2VU]NY0[
M@$!V!U?CM_P2?^+'Q>^)6C:UJ'QDM_%Z3PA-9UWQ-YR74+-=SR.MC9(CQQP)
M%(A2#SE4OYF#&K +^I-% 'S[^UO\%?&_Q*_9_@^'WP?NM \'W2WNG[+B[DGL
M4TZUM)%GA^QM;(QBD26"V"_+M5 V,$*1\V?\,[?M_P#_  BW_"/?\+[\'_V?
M]B^P>;YC?;/+V;-WVK^S?/\ ,QSYN_S-WS;MW-?HK10!\T?L9_L,^$?V/M"O
MGL[G_A*/&>IYCO\ Q-<VH@<P;MR6\,>]_*C&%+ ,Q=P&8D+&L?SO^U__ ,$O
M?%/Q.^/!^*/P?\3Z/X5U+4)DU"^M[^66Q-I?Q[-MU:R6T+MN=E\QRP#"4,^]
MO,Q'^C]% 'YU)^S!^W7KF@Z?X4UK]H;P_8>'/]'MKG4-+EE_M2.WC9,NEPME
M%/)( N26G4R<AWPS$_<_PK\#?\*T^'/AWPP][_:MUIUDD5YJC1>6^HW1&ZXN
MY!N8^9/*9)G8LS,\C$LQ))ZZB@ K\]?VSO\ @F?XI^-/QLF^+GPS\=V^@^++
MN:SEFM-6::V6UEMXA&ES;74"M(C 0V^$*9W;W$@^5!^A5% 'YJ^(/V-OVU_B
M3X5TWP1XR^/GA_\ X0S]W:WS:?<W'VR6UV&&02NEG%)=YB9MT<\VV5L%VS\P
M^O?V4_V5/"/[)?PY3PYX<3[=JUWLEUG7YH@EQJ4Z@@,0"=D:Y81Q D("22SL
M[O[;10!\$^#?V!?'U_\ M]:K\=_B%KWAC6O#T>IW6H:9I\,+SW3*L9@TY)$:
M&..-H(O)?S%:1A);KC+,9!][444 %?G5^WI_P3+\2?M(?&2+X@?#_6?#^D76
MHV4<&MVNNSW,?FSP@1Q3QLB2@[H@D90*@7R WS&1B/T5HH _/_X7?L8_M*:]
M_9GA'XX?''^W/A1:^9+>Z/H&IW+ZCJ^_>#:75Z\$4[6SB60.K2OE0J*J_*\9
M^PI_P3O\7_L\_'#Q!\2OB+J?@_5=0GLIH--M/#UH=EO//(&EGC#00I;;45HE
M2%,%)W4;%&UOT HH _.#]K__ ()>^*?B=\>#\4?@_P")]'\*ZEJ$R:A?6]_+
M+8FTOX]FVZM9+:%VW.R^8Y8!A*&?>WF8CM)^S!^W7KF@Z?X4UK]H;P_8>'/]
M'MKG4-+EE_M2.WC9,NEPME%/)( N26G4R<AWPS$_HK10!R/PK\#?\*T^'/AW
MPP][_:MUIUDD5YJC1>6^HW1&ZXNY!N8^9/*9)G8LS,\C$LQ))_/C]K7_ ()>
M_$7]H[]J;Q'X]T_Q/X7T;PIK4]@&-S+<R7T$45I;P2L(5A\MV!B=E7S5#< L
MN3C]-:* .&^#'PB\/? 7X8>'_ 7A:.XBT/186BA:[E,LTK,[222.W +/([N0
MH"@L0JJH"CYW_P""@O["/_#7F@Z)JGAS4-/T/Q[H8:"WN-0CVVU]:NREH)Y4
MC:1?+.YXR R@O*I7]Z73[!HH _-7X:?LG?MU_"/PK!X<\,?''P?;Z-;[1;VN
MH3RZA]G146-8HFN=/D:.-510L:D(O.%!))^L_P!D?X">*?@3X!O+;Q[XYN/B
M/XVU.>.>\UV^,LTT,2Q*$L4GF=I)8(I3<NA.P9N)"(T+MGW>B@#X*^ W["/Q
M&T']MS7/CU\2->T>Y2>?4;_3=/TC5[F]F@EN 88K>5Y[6/?!#;2R1KM*D&.+
M "@K7U1^TA\$;+]H[X)^*?AUJ&I7&C0:U!&JZA;(LC02Q2I-$Q1N'421)N7*
MEEW ,I(8>FT4 ?EK\*O^"?/[6O[..JZO!\*OC-X8TO0YYIO+ANY[AH9U9D G
M>RDM)X8YV2*,%E+,H!0.1G/?_"+_ ()G^*O%7Q<B^)7[3/CR#XG:M:S2-;:#
M"TMS8N-WF1>8\JQA8%DDG/V..)8ON\E"\1_0NB@#\EO^"OGCW5/BI\</AG\#
M_"Q_M#4(MDTEC;ZHH2?4KV00VL$T1(2.1$4,KR-G9>Y^522WI5G_ ,$^?C_^
MSKXROE_9L^,UOHW@F\A#MIOB^<RNEPP02L85M);=V/DQD3B-'"GRSD*6?@/V
M8_@_X]^._P#P4BU[XN_$+P/XH\/>'K.:\US3/^$N\+-:K.L>VUTZW)91&D\,
M3PRAE+MNM,Y))D'ZO4 ?G3^SY_P2KN$\=3^/_P!HGQ5_PLWQ1#>Q36]C'?37
MMI=)'$%4WTMS&)9\$(%B^5 L(#&17*+T/[:G["/Q%_:Z_:$\)ZS/K^D:5\,-
M'@MK&6Q_M>Y^W-$TQDO;B&$VK0Q3LC",99@WV>(LV/E7[UHH *^"?V*_V!?'
MOP9_:$\6?%SXKZ_X7\2^(M3AN6MSI,+3.+RZF$EQ=[GAB6!MH>,"-3N6XD&4
M VO][44 ?/W[<?P6\;?M#_L_ZE\/_ ]UX?LKK6+VU_M"?Q#)/&BVL4@G_=-$
MCD2&6* ?,I789.AVFD_8;_9MN/V6/V?]-\&:I]@E\227MUJ&KW>ESS36]Q.\
MA6-T,JJ1BWCMT("J,H3@DEC]!44 ?EK\8?\ @D_\1=/^/6I^./@5XXT?P=IU
MW-)?6D<EY<Z7=Z5+-O$UO;M:0$" *Q5,%"$?RR#MWOW][^RW^V[\2KBQTKQM
M^T;H^@>'EF,\U]X05X+Y&$;A !!:VC2*68 HTP7!W88HHK]"Z* /E/\ ;K_9
ME\;_ +0'P/\ #_PR^&$_A_PKHUM>PS7D=W?3V-O]EMXRD%HD%O;NKQ[F1]I*
MJAMXL*V04]4_9;^"O_#._P"S_P""OA^]S]NNM'LC]LN%D\Q&NI9'GN/+;8A,
M8EED"94-L"YR<D^L44 ?!7[:G["/Q%_:Z_:$\)ZS/K^D:5\,-'@MK&6Q_M>Y
M^W-$TQDO;B&$VK0Q3LC",99@WV>(LV/E7[(^+'@7_A:'PM\8^#1??V:/$6C7
MFD?;O*\[[/\ :('B\S9N7?MWYV[AG&,C.:ZVB@#\H/@C_P $T/VH_@EJFI1^
M%?B[X7\&:;K\*Z?K-QH]W=SS?92W,D4;VJ#ST5G,;AXW4LP61-[&O=/^"AW[
M&OQF_:V\4^';?PGXP\/Z;X"TNR5SHNL7=Q!NU$O*'N"L5NX?]TT:*68[?WFT
M+O8M]UT4 8_A/P__ ,(GX5T;1/[2U#6?[,LX;/\ M'5I_/N[KRXPGFSR8&^5
M\;F; RQ)QS6Q110!^>NF_P#!/;XB^(OV^G^-WCW6?#&N>$X_$$NJVUG;7=S'
M?)% C+I8*);I&6A,=IN!<AO*;<9,G=^A5%% 'P3_ ,%$O^">_BG]K#Q]X5\7
M^"=:T?3M2L],?2=1AU^[EBA:))3+;F$16\AW;I[@.6(&!%@?>)]T_8;_ &;;
MC]EC]G_3?!FJ?8)?$DE[=:AJ]WI<\TUO<3O(5C=#*JD8MX[=" JC*$X))8_0
M5% 'YP?M?_\ !+WQ3\3OCP?BC\'_ !/H_A74M0F34+ZWOY9;$VE_'LVW5K);
M0NVYV7S'+ ,)0S[V\S$=I/V8/VZ]<T'3_"FM?M#>'[#PY_H]M<ZAI<LO]J1V
M\;)ETN%LHIY) %R2TZF3D.^&8G]%:* /FGXX?L[^-O$'['+?![P'KFGGQ)>6
M5MI^I^)-2NY].^U?.LM_=2>3',\DEVXE\U6;Y_M4K.['(>S^P?\ LPWO[)WP
M%C\(ZQJ%OJ/B&\U.YU74YK&9I+02OLB00%HHVV^3# 2&!.\O@XP!]&T4 ?&G
M_!1K]B?Q3^V!I?@63PAKFCZ5J7AV:\62WUOS8X9HKA8<L)(T=@RM;J I0AA(
MQW+M :U^Q'^S?\>_@?>0V?Q3^)VG^)?".AZ*^D>'_#VDRRSI%YDT4ADEEDBB
M9O*6 1Q*WF;4E=4,2C:_V#10!\%? ;]A'XC:#^VYKGQZ^)&O:/<I//J-_ING
MZ1J]S>S02W ,,5O*\]K'O@AMI9(UVE2#'%@!05KZ]^-6B^*O$WPE\7:-X)N;
M>Q\5ZGID]CIU]<WTMDEG+*AC%P)HHY)$:,,9%VKDLBC<N=R]Q10!\??\$Z?V
M+-<_8_\ "OC/_A*]5T_4_$GB&]M]_P#8]P\MFEK C>3CS(8W$A>>XW=5VB/&
M#NSY#^U__P $O?%/Q.^/!^*/P?\ $^C^%=2U"9-0OK>_EEL3:7\>S;=6LEM"
M[;G9?,<L PE#/O;S,1_H_10!^=2?LP?MUZYH.G^%-:_:&\/V'AS_ $>VN=0T
MN67^U([>-DRZ7"V44\D@"Y):=3)R'?#,3[_\</V=_&WB#]CEO@]X#US3SXDO
M+*VT_4_$FI7<^G?:OG66_NI/)CF>22[<2^:K-\_VJ5G=CD/]+44 ?.7[!_[,
M-[^R=\!8_".L:A;ZCXAO-3N=5U.:QF:2T$K[(D$!:*-MODPP$A@3O+X., ?1
MM%% !7YP?M?_ /!+WQ3\3OCP?BC\'_$^C^%=2U"9-0OK>_EEL3:7\>S;=6LE
MM"[;G9?,<L PE#/O;S,1_H_10!^=2?LP?MUZYH.G^%-:_:&\/V'AS_1[:YU#
M2Y9?[4CMXV3+I<+913R2 +DEIU,G(=\,Q/O_ ,</V=_&WB#]CEO@]X#US3SX
MDO+*VT_4_$FI7<^G?:OG66_NI/)CF>22[<2^:K-\_P!JE9W8Y#_2U% 'SE^P
M?^S#>_LG? 6/PCK&H6^H^(;S4[G5=3FL9FDM!*^R)! 6BC;;Y,,!(8$[R^#C
M 'FW_!1;]D;XI_M=?\(;I'@W6?#^C>&]%^T7=W'K.JW47VNZDVHA,$5LZ?ND
M5@LA8M_I$BA5 )?[6HH \]_X4MH?_"@_^%1_:M0_X1O_ (1G_A%/M7F)]L^R
M_9?LN_=LV>9LYW;-N[G;CBOSM\"_\$R_VE?V=?'5]J7P;^,OA_3K"39_I%Y)
M<VOVW$3+_I-CY%Q ^PRRA-[28R'&UC@?JI10!^;^D_\ !-GXL?'+XGV7B?\
M:>^*UOXQTG3IDEAT'0I9C#<*4"R1K^[@CLE8Q6^\P1EI1ORT;X>O=/VZ_P!F
M7QO^T!\#_#_PR^&$_A_PKHUM>PS7D=W?3V-O]EMXRD%HD%O;NKQ[F1]I*JAM
MXL*V04^K** /S*T#_@FC\;/V?[CPQK?P%^+EOX=UV?385\4V>L7;M8S7ZQLK
M-"BVKQSP S3"-;B+='@,&+/\EKP+_P $L_&_Q3^*5]XR_:>^(O\ PF_E[&M+
M'0M0G?S\SM*\$CRPQ_9[8;G AMPO^N8JT6P!OTKHH ^4_P!NO]F7QO\ M ?
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MGE8AB[*]3X#?\$F?$GPG_:JT/QGJFJ^']8^'&@ZS/J%A:-J%S_:A2/S&T]Y
MEO'&9$E%N[@,$)1AAE.T_I_10!^97[87[ '[1_[5OQ<U'7]1\:>!U\,6<TT'
MAS2)+Z]B2RLRWREHUMG'GNJHTK[FW,  =B1JO*Z3_P $\?VS]!TNSTS3/C_;
MZ=IMG"EM:V=IXSUJ*&")%"HB(MN JJH"@     =*_5^B@#YS_8G^!_Q-^"/@
M'7+3XM>-[CQYXKO]3\V*^;7K[4H8K-8D$<:BZ"B-O,,Y8HHW!DW,VU0OQ%\-
M_P#@EW^TI\ /B-<>)OA?\4?!^D747GVMMJ$L]RCW-JYP!/;-:2Q'< C&,F15
M=5(8E%:OUIHH _*OXY_\$H_C-\6O[$\1ZG\7-/\ &OCZY\]M;NO$D]Q!9VB-
MY<D5K8JD,I\M)7O#TB3:\>V*/# _:?A?X#^)/A9^Q;:_"GP++8:9XSA\,MID
M6H+JES;V\&HSH?M5Y'<"-YEQ-+-.@"#D*H\H8*_0-% 'Q]_P3I_8LUS]C_PK
MXS_X2O5=/U/Q)XAO;??_ &/</+9I:P(WDX\R&-Q(7GN-W5=HCQ@[LG_!1;]E
M7XE_M:>%?!GASP1KWA_2M&TV]N-0U.UUR26/SYPBQVKQM'!*WR*]T",J#YBY
M#$#;]@T4 </\%?AA9?!7X1^$? NG&WD@T#3(+%KBVM%M4N944>;<&-20K2R;
MY&Y)+.Q))))^-_\ A@/Q_P"+_P#@H%_PO3QO=^#[OPC%K/\ :%OINFWEZEXJ
MVUOY6FNR&(+YBM#:R2#S=A97 !4[3^@%% 'P3_P42_X)[^*?VL/'WA7Q?X)U
MK1].U*STQ])U&'7[N6*%HDE,MN81%;R'=NGN Y8@8$6!]XG*_P"&,_VK?B1\
M-M7\(?$W]H2W?28-,DMM,TW02RMJ4IM)H8X]0OOLT4S0;VB,H=9S,I?.'"O7
MZ%T4 ?%/_!.G]A'7/V1/^$SU?QEJ'A_6?$FM?9[2TDT:-Y?LEK'N=P)Y8T?]
MZ[(6C"A?]'C8LQ("'_!1;]D;XI_M=?\ "&Z1X-UGP_HWAO1?M%W=QZSJMU%]
MKNI-J(3!%;.G[I%8+(6+?Z1(H50"7^UJ* /S@L_^"?/Q_P#V=?&5\O[-GQFM
M]&\$WD(=M-\7SF5TN&""5C"MI+;NQ\F,B<1HX4^6<A2SV?V?/^"5=PGCJ?Q_
M^T3XJ_X6;XHAO8IK>QCOIKVTNDCB"J;Z6YC$L^"$"Q?*@6$!C(KE%_1:B@ K
MA_C5HOBKQ-\)?%VC>";FWL?%>IZ9/8Z=?7-]+9)9RRH8Q<":*.21&C#&1=JY
M+(HW+G<O<44 ?'W_  3I_8LUS]C_ ,*^,_\ A*]5T_4_$GB&]M]_]CW#RV:6
ML"-Y./,AC<2%Y[C=U7:(\8.[/0?\% /V>_B+^T_\)=,\"^ ]2T?1H)-32^U:
MXU?4KFV2:*)6\NW\N&"02JTCK(=Y4*T$9"L3E/J&B@#R?]EOX*_\,[_L_P#@
MKX?O<_;KK1[(_;+A9/,1KJ61Y[CRVV(3&)99 F5#; N<G)/P'_PZC^,WP3^*
M7_"1_ CXN:?I5JOS0W6K7%Q8WBH)_,6UG6&&6*ZB CA+;PJ2,#F(  ']5**
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MG<ZKJ<UC,TEH)7V1(("T4;;?)A@)# G>7P<8 ^C:* /BG_@HM^R-\4_VNO\
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M]\<W'Q'\;:G/'/>:[?&6::&)8E"6*3S.TDL$4IN70G8,W$A$:%VS\;?M&?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>mgnx-20221231_g2.jpg
<TEXT>
begin 644 mgnx-20221231_g2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X )D%D
M;V)E &3      0, %00#!@H-   U%@  TOL  0WC  %*(O_; (0  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @("
M @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\( $0@!.@*\ P$1
M  (1 0,1 ?_$ 3\  0 # 0 # 0$!           '" D&! 4* P(! 0$  @,!
M 0$!            !@<$!0@) P(!$   !@$" @D"!@$$ P$    " P0%!@<!
M  A -1 @,!(3%#0V-Q$54#$S%A<X(6" H#)P(B,8$0 !! $"! ,#" 8$"08(
M#P$" 0,$!081$@ A$P<Q(A1!(Q40,%$R0K46=B! 83,D=5*RM AQ@6)R0S1T
M)1>14W.&ML9@L8+31#4FEE!P@*'ADJ)C@Y.S5-4G-Q@2  $! P8'"PD' P4!
M 0    $" !$#$"$Q01($0%%A<;$R$S"!D:'!T7*R,W,44/#A(D)28B-T(/&"
M)#0%%<+2)8"@DD-CHE03 0 ! P(#" ,!  ,! 0    $1 "$Q05$087$@,$#P
M@9&AL5#!T>%@@/&@</_:  P# 0 "$0,1   !W\
M
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M?(=[^:;HTD_/Z   \(^5*:QKU/2--<WI]CIWR[>'"_G]1!M\'3F/[31G^?T
M>D/7G2E#2^)_A^AQ!V! )_A8H  X$[4B4X M">*?V<2?F0@263,  5B*.4U.
M;^1?;8TVW#+MR_256X&Z2M954QSG[!H_Z%>D*K[\  &#4;VL[>=?4/0:_)I'
MZ$\RV(FL?ME1U@31KLK,>_*YW!V&,  (7,.Y?HKV[C SFBNZTOT6QP-Z,I^3
M9Y%8^I>R/JVI^PY9  !@_L,3//J2C?<['#[7FBZ=$HION?G,<FS+^%4H')=[
M<3[@"A92,T0,_2/SJ"!CMS2\K"2X:7@ &3)4<UJ,_B.R*COBP9YIPQIT3^
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M>L=:41I3Q;?5YZ LJ@?2E4[9]>TC84_@^<FN)3>_S\Z7X_;X4/\ HIR]'O\
M&P]*SSA\GY9^7E7VZ&?C@   "M)C!*=-?;?:RANFV%WHCO,.+RK"3+6@<7UE
M-OIVH2U;4 ^9N0Z>"NH*1\?X_2W7+EX^/B9-V)Q'/7?G]5A@TC^@;%^P
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M?\X^II"C^R\GT\Y'H)QO>FCW.UH55]$N8/UV^!J[34YI))-7(5SP71W]?P
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MS2-"R7@         #. @KS8ZLZS59GJ/3SD>G7%E]Z$4#9-9?1?ES=:=1X
M        4@/G7ZBH[L9!J=4>/>A\4KPK&9+8@5DN8[L^CR)[\
M5))X(>)P.O           !G 05YL=6=9JLSU'IYR/3KBR^]"*!LFM?HYRSNA
M-="          *0'SK]14=U^_P!5JSQ]T-B9>%8S);$"LES'=GT>1/?@
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M"$"%M@           0X<V6'..*ZEN3^@          1R>B)+(9)F/\/[/;
M                                      &?1PI48\LC8YPF(WW
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ME3IC] >.>0         97%.C0D_4Y [$C(S)-6B/3PR="S1G>>W-6#V
M !E<58+NGNB,B6B'C.\T*/0GYEA"Q1GD>V-03I0     97%2"^IYYP!(Q%!F
MX:7'+GH3V!,9[,G0IV=D:3@      RH/'*R$T$7DVDV$&'KSNSVI2P^@<Q^(
MR-L3I0     #*@Z0H\6:*W%J21CCR&"63WQ30WW,JR"S9 D@     &5!YQ4(
ML 0<6,)8(N(_)3/:D?'"G\FM)DD2*:\       CLD0CLD0   $9DF
M $=DB$=DB    C,DP       $=DB$=DB               RC.I)X../<GJ"
M*"_ACL2Z20:4@        S3.8+.'$GDGX$7&AIB*6)(\-FSR      0J92EX
MS^STYV1"Q*A9 SI.J)&)P.#.+.G(L/2'/'.DQ&BX      ,\R'RH9/1Z8J,7
M^+K&<Q_)WQL2        "EY4,@,DLYXJF:!FAYCL>Q)@-:#J      #%HJX:
M*&1Q:HZ$[HN*9NFAA7<D@H03^>$6&*W'7'4'L#5L        @$CTN   5^+
M@         $(D.ET  "OQ8$       'XF<QH,>Y      /6$2$W
M
M                      __V@ ( 0$  04"_P!AN<X#A9=U2(%C:Z-KRB[1
MYLZNH\M:7EH?D7:N-U5.TK&AZ9Y A[1\L> 1E6RR!BDB+\*W.RU_?)0@HRN$
M:%E<W3;3.T2Q*XH^RW(V\YL>H_0,,2-Z@MUVXRL@XI23V>[>Q7EM FAK$03
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M"4:Y$=^CLJ^+(IZC6U7YSXAXJ^N9 N4;<:V.DR>G*H2G8Q@..(W8?"4"]C2
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M8:HXHH!)8QX!C"G_ #^#(A8$1I8G\,6,YQEF<L."?4B:_"'UT20U<H3)RTI
MQ@+ Z. W%2  C!$E!)!H[.!&]=1C/?T09]>AT1>5-TSKOKV!YP$Y2@\:DW&,
MBRW(\)"<YQC!@\C%HO&< _!2#LDC"+ PB#@83BLDC1+#$*A.H+5$F%@- YH!
MMZGJXQG.69LPWI]2)T\06DB?P0Z6J/IV(P8&'.,ASC/TT6/OA/) H*4$#3&X
MSD.6]9A83UG1=YHW3.AZ#S.]G1!?U_"$:CP\Z4$X/!G&0Y87/R9VG1O XIC
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M!G>P,(1A6I!)#M-2WS)6AB" *Y6)8=IJ0^7+SG <#'D8M$E]S' 1]$4L69
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M1K0H:TFAK*J"UDT,+Q"JI&,8F3'@SH4&,*('H4'%C"/9F=)QCT5_:<*6>O\
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M&B<-V5':5]Q7O:HU.K)D>=$-4TW"+\9QQI2'7FFNJ?/.5\[/\:;ELKM=;;L
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MKANO(W&:0?Z;\A41/V(O&,XZIHXM#C]-2JX.JBXM771H.]%71="Z&OZ)HV2
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MWD2>847>R>[<TZ.K3C2HJ+IIK\.I.K9VD_2)%:ALNO%U9"]($;$0W/ODI:
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MN%-RB-71IA&=$#.,NU[]:L>JG(Z\V!R3E.,@8DO2Y[N.X62779<<PKK*XO\
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MZJ3;&N06E@@"(NY#+=RUTV\^(.=8)T;M^ZE^EJEL:NR=K8SL27&:M8]X,:1
M?KI333JHV)N#O/3;N'QI+Y^+DJR;^R<IJC'X^.6!9#;V<9F,[+"KJ21'9$9O
MU8:.:[54D1%W<N!MX,2WKQZ[T5^!>UDFGM84J.J(['EP90H;9CN3FFX51>2\
M7U(W'R8L:QS ;)V5!C8D[*5S+PM#&+:.R/1E-#'0K0Y24<2*2Z\E\>,;O,;@
M,W&93UD1;J]RF,U05U8T+,F:=^S718L4;B&#2M-,>E;V.'YE0MI(L;(,KLOB
MMNY<6T4Y?HX$'5B,Z LAT*V+#C)L1?'9JOMXJPN0MYEA>%,&GIZ*HF7%I8_#
MQCE-5AB,'3$8R2VM5,P^NFFO/C)\M8>M(T3#2)O):V?6/1;RJ=35!;D5RJ2[
MG%%4':2IN$D7115$IL<@SK;J9 \U$J+613RH])-LGB;;"L9FN:$<SU#B-+H'
M2ZJ[=_"8M<2;21;-QVIEF%352;)JCA.B#@2[8V/,RUT#1Q4!'#%M451\PZVE
ME<W-E>/_ (TOV(\VSG2;!](0M5SD=AMZ6XZX,9OJKL#7:.O+BGQA&,H7'JJA
MMIV3P:W$WK)ZTD/M1OA4R([Z-R:=7!)Q=[\<P:ZNH'KIQ2SJ#)(]#E+^0V;&
M0Y'=8VT@-4XOSW8:8S$"O;JK10CG%:5U1Y$CB*6]->.Y':'.LB#*HM%4RB#)
MX##-5-C/$_ A+&8?KVHRM.NLV9EYMSK#T=4$]$XO\8R*=(LKW ,MN<8DSI;K
MLB5+BM/J[&>D/O$;CC@O$\TFJJJ T/S^0QH,23-D%.Q\A8B,.R7E$;J$I*C3
M(F:H*>/+CM%6!:W>%X18TB,Y?E])CY7=K726*F*L.LV>AGO5WJ'P1-1;ZI>9
M4W=(A7^]6:Q\NLOC%?B3]389)42(=Y?1R2]?;FG%2)'4W'HKS;FT6Q(6S'<(
MKRX[>P3B?#W2A]LP<$1;CS8%@<.-.GR8]6Z<9;.T)\'=\?5#)3-PM-A+QEZY
M#E&1%W8R[M[:8EC4.^P=W!8HU0179INQ6 F6*2)'J8?74E)K:@.;4+[+';+/
M+KO/66\6SDQW^WE)C<>77O/?%WID657$[5D/3)UU#(G)")U-RBO3TXI<FMZK
M()E#9=MF<8KYU96NV1/VJ6AJD8R:V!ZC1H=Z:HJ=02TVKKQF14$XX,\::9JC
M=4EP[/C.,FQ(JV8R\VG; '>FCR(2LZ[M.7':*NFY63L+$.VC&0-$6&QXS-56
MSY4*JLL->E)8D$FPF1@4/5$9/-:;T9]O':X(--E4A.V_<%NQR1YO&[,F/2Q+
M.C?=<KGA:4+!.G7N;=O(N6GCQ@K%2W,%[-LWH&:F+.B/0IZ([$M6]ST)\1<
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MA'VZ7#SM+1?3@ 3C)%%!B"@BY&@B4N+@BE[E>8-Z\0_JH$;2"VOL8(R-%0*
M JK !=5<!0P+. C:"O6^9GBE1B(%AP&%B[0AR+7IBY(N6""^)'N)=I&]QLB4
ME>W=^;@(BP6QW)WTC1)/9>U"7X]KZ#E$@U5"5-9QL;.&A2O!EEL."/(S"F5<
MLTK+9CZ4HWN#5.TLP>;"#$!7< K02K_\<9AEBB#ENXE#-3S+M\=N6@"()/72
M(.7%&J9V)F 4&05@" RT$5@I,RVE=+T$AU;$0 *B%NB!CH!P$V+%5 ';'260
M7'/A#<KUJI?U)?*( 5?23",S&9(A@CVW-5#*?FQ-2HO293\S,6L<,0 FO B#
M,G8B(+1$T6W2)" E6*=%('6R+W9V=)=&(!4YC3,#37.(25&J%6%I#HH!NT14
MW:@WV\&NVDNNJE%G_- (]B9]@@6"@M6D;(B!Y5P5#)/S4$VRC%);>E,SFQ P
MW20%-@IP!84 ELXLT!0%6 NK@-VI-V4N4\0B57 R[-F30KAG<_%3"S5MP-;@
M:PJ:)OL\0.GOUGF*;X]@8.<OB&2DT,KJ_EPADD;)* B2?K4$(J8/H: ESZ<S
M33SIQ.D=6ABI!'6N'E<-N=VM5,[5PDL1 :Q"I&O<4S5-=7'9VF8Z!&39ERBB
ML@W>$<8NSI90J8*KP=X\*$C8H]5[\Q+9UNNRA&LK-3?2=DN&=/;1R'FF2;E7
M4BT91"_>2$2*U^ TW@IT3Q:&*M!RO.RXT=!<<"^]A<ZB!%7.+L"(_=S<(I=I
MC83V#-ID2VH9#1$ND(P0&!8@;*T GH#F*U : D=W8*(?388L7MN!8@]W2T%)
MT'[%W,W+BR;I>B_[TL#$BMP$)0@UA5P,(_D+]H/U8#K,P)Y]I0DI?&("6*8%
M!, @TB08!+6RB>1.&T>R5QEC#[304GK; )!^LLZ.UAP'RA.3V<%!'#*N**8T
M&KEMXV;$G;*?DJ&UIGTFYHUMJ5!$E'=!*5#CQ=$NR38$0$1!JVW8Q_UH<P:"
ME1,MO81K0@B@EJ3Y[P1LR&+7F0EDHR\2$YE9.&B-2+V..9D1D@0'_ (B\KI$
MLG9A[BMLMK:8E<?(K3T271*$J\W-<N)JB@*3!B&@/S(-"^@,0@94CGZF1+.(
MS@@@X ?8):K ;BG2J#EJ>;8Q&IL1V7=!7EN-DX Y:20P$H.,[[U$9%7OE9FI
M[S2Z1@!>3*F]TVC6O3V  [LT?1FU$Q<]BC"XU]VNOMN]@1PP7AL5)BWCQ)PD
M6I]X(_,+HQ!@U28\[ZC90@^5. ==N-'0PEX@0J$OC.A!E^[[6)3L*.B%G"WQ
M@1I=#0F=2. -IID3@3P6:PR??[DUA*I51>!//PR9GUY/4VE@:@F51SP (+0V
M%\T35S*I8G%*:)#^3S3SW/"R8E;4@G<&NA!I8[T0B,)2B1%%, @ 0E%Q$LB5
M><X,,Y,0N1$&H![+>-1C6P@I=RK8V"'&KS.0(!  @R(W$2R)6NZJ2"Q1=D3U
M;6&M1B/T43=$(.P#4?H%]#IH6![TN^"7.%!Z[@]W"!WZQRF@5QL,T$3%M&>S
MFJC;PCV,L(4;V)@]C('3IT7) \)V2+0$-D2&&/$I! 8Q> \W6:($H"A%BAUJ
MLIG:>FJX-$++'MH0JK'A",HW_2CR2^7(D:'9ODP0:8":70*1/CD5:N*X5%)>
MI5(O%A3)"6)$R>"!\8)\N/#&$]6B!J\2+ 0B(;DP;XE0#,TX^.1/4H6-610!
M3BQT$+&6MI.*,FRC.%'9P5_$L"ZAH=CF,4;MNN03R%T13(0H!_P"*O Z5;!2
M ).\J3S:TH $\!>(@AT"P%2VM-;\F# >!,1 =3/7)9[!@(59=B=F;/"L4NE!
MQ'OTK'@A:P*E=TIJ\8LJ8"R@)U#0N[E]("M4!?(C9XFPL[9"#2V8C+B-D;T*
MI.#'^X]LBXA@B(2WF57XIL8#K%&WE;(R/1:Z!DM1+<G.)ROW Q8'B%0%I"!+
M>-ADI8(+I='R,(?KS!$!D$JP76ZW;T+!+TQKD&J04C>3+GJ"<1Z^*,_;RT67
M685>5N$[8H"46$2A<HJM0S,T6"E*'W92[2ZT@19>/,0IX \WU1K!L]YGW^<S
M\"=?_8:BU('&U!_S]O"5QZ)I4_P^S;*8D48TO1JLQ4J]@6)&$,BH0 $-I B
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MPAR@@(0(%C,:4!F&^E'JYCF'XEVWX(\I0%97'([T(I-8X?Y-GCVNDX=;_/\
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M;_>FA-<X"$=+%Z\&WK("%>@(D0PP)0)!-HTJ7J/'BPR\&E 8!T# 8DF;SE=
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MAA\1Q-"Q5NX1QQF' A1+:3<L'R"D5X(CL<0QZYV91616CXCK",M6%<I6&(X
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MVW6+8X0IWX'0Z3OMIF:D5DNA!\W])K2+G7GZY_\ E3__V@ , P$  A$#$0
M$
M
M                (      (      !      !
MJ@    !E@     .L     %2    (!(  () ( (     !LZ    (?P     .L
M@   !,?     )   (( !  )    H+QP   "T:2   &9B>    FC^@     !(
M   )  !(  (OJ.(   !ASD  !)@X=    ;,O@ !! (!   ()!!)(  !I^R@
M +ONNH   #*JXP !P4!C    !(      )      -RYP0!#\EVP   !&DA6
M2.\B    !  ! !         !/9?H K)E"    !!I 1 /6I=     ! !/)!(
M       !?3*4'FD8@     ),#<P202\     ! !$PD4         )8,<!VYU
M      !.F]Y"A<(     !  /CVR          _I/+X^\       !X 829N
M !  ! !+?&M          "1/+XK    (   )] 92:8   !( !!)#+L+
M      !/+X    !)    ! 8B0     ! !( !R!D((         !/+X
M    !(8B0        ! N8#KP          !/'X           *8B0
M  "_0!-H          !/-X           *8C          #\7+W<
M  !/-X           *8C0        !$1ABE6           ?-X
M *8C0         ( P_)(          !O-^           *XC0
M)(            !O-V           +HC0           ((            !C
M-V           +HC0          ( )(           )M-           !*PI
M@          ! (!           !(!            )             )!
M                                        !
M                         !        !  !  ((!( (  !(  ( !! ) !
M    !   ! ())    !!)))!)) !)(   ! )) ))!!!)(    !!!  )))
M !( !  )!! !!(    !! ((((( )        (!
M                                (  !!()(      ! !!()!)
M!    !(!(       !)!!((!       ! ( !  ((     !(((! ())
M((   !        !!    (       !!               (( !)
M)   )      !( (  !(!!(        )!)!(         )))(!        ! (
M) )))!        !   (          (  !                !
M
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M7=4/QV.[YRXNU:>$2%,F\\6_<(Z;@&HQM0B$ H%M^C9*;-J84:@)@   @ @
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MU>'P,C2V19-8,UJW^-Z,C(E$+A!TR)-B[0@T.(50OCKTD2CB5R+%'= S#%K
M&8I&0QD,L,'J<U"6%[P3_P!%W WP7KB2HZ4(B"U=LE[KXW[!X8DPSX[Z (!S
M!I$$ ! 4$B$B(V:1_J@I-$F\K%**$T^%+*:2 !VC\+0I]26MOL4MS(BP'"MV
M) D46FX!BFD)+"068( ITM61 'I-C$6$CN)5&::I2.&>,B;0HZZR-[J,"]I2
M=!SPY0  2K8*-F:)@S-T&@,R3*"@>0L<E8.3*T$F&&D+FV<800W9 /\ X8B\
MHE!I;([S@3*.I%*X"MO(6HI.SM20+5L,FC4A1.?U%VBT*!W:6L^:)M!#[ (
M#+B?[4\+DK4)X-FWZ*K\!30U]J9O.64AM9BT@*4AS/,(6GQA45">X$KM$0
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M,5&'WC5@  2_\\&VH(G!\<,T@-AY)U$[)G7_  T2,H;E>6+Z?V/](AP&H=&
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M)!31*VJHZ]"+-$!5F8X3QCA$\$>@MW.H!J;*"%F 4?Q2(14)0F IFY%U0GZ
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MIS$%D:1(@X /@ML2&@4!P+6@4A1"C6IJX+;LHE[B_L-ZG4"8/%X$"B5R$-:
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MF1HH6C)9QGOA',1M *RZ0&PD <R1\BP.W92J+,*[28,IF" 5!U" 0%:?5]!
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MU$N-%A'Q("@Q()V1A"*)G* Z=B-)HHM9E([9!(V4&BJ314\'=216WAUTV]H
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M:40%< R<H][S!NI4Y$]: ^$GPP!8()(-)0(;P+JK>AT7(HG+?*[^P<//=O9
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&_P"5/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>mgnx-20221231_g3.jpg
<TEXT>
begin 644 mgnx-20221231_g3.jpg
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M 0$              0(#!00&!P@)$   !@(! @0% @0% P(' 0 ! @,$!08
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MFX)BDT0*T;8EFG6DGCG\= 0<F"EFWYJ4;D%E@TI.V8
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M^4V\)2Q+S,I,R9(3:1M-/LR#Q,VTVEYV9>!G2 GZ6W*ZIV.[.-R
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MS,I,R9(3:1M-/LI\J7::9-J3::39=&*>MW3-K6:2-@-)MMA='MP
M     !@G<:O7#?Z86UGPZF]BT7G+Y4(+((GS/*7E-O"4L2\S*3,F2$VD;33[
M*?*EVFF3:DVFDV43)7;'3<OHSUGG"NX,N\_3^T?0     #$AEL  &"3(Q>
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MDM3/2HX\EO9*VUEBF3:DVFDV43)6C7OM1I^5T[ZKS,MZO8;5=<WH
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M62>QY)O':9I;3C[C^8L'^W^94NTTR;4FT_$].NI[','"R[1==WF8]5L0
M   !3,?+TDZQ]#ZYZ?TW!?#['XX.=TT[A\Q8\X'8N;/1/JG'5-CY1>.)B3$F
M):.)I_TE^?M!]=^:IR]9O)6V^+FD\=KEY.&M<C'/9:YKZ]QY_ \SRE?GQO\
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MI:;O6<R5K&NY?2KXS]X]]3L,B^S>;95[/H_3A<NU>-GH$K+F-KL=LQUL
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MF?C)LOP-ML3N_,.QWJWP,   *!,:QWK0BS[18$Q-%YQ-TQ-<AL%2V0XD
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M!$11,1'$_4_4Q)C3%$Q)BB8TQ1,4(DW?AV6=.!VJ]LNN[!>G_!&PN[\N
M  UTO7&LQ5R>*F6Z6\65:,N5G;G'<        #FQTGZ[YH='^O\ &W+ZCA_G
M]$^(B3$11,43&?4_5HDQIBA$FHTSY;X?9LD\3>YAV?0>O7IGPEEK9='
M &BV7'+IN*%5AZRDRW965,9FK.V6.X        'G$\L>B?://GIWU5;^358G
MYW1[.SZ 1$28HF(CB?J8UKIP[7(?%WV0>/O:[?B= .X_+?1/NWRG5<G$
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M34ZW      MR8UDO6@2LR8L.8W\PY-%,V.?AFJMMNL=Y@     $!SY,U&SX
M                 (36J]<;3%E6BZ8;V8LE.1;4KSB8P
M           "4,8VBFHR_6TX
M
M         #B 9U.I0  .(QVO)H &&C*14S5HY%'4PW.  !S/,UFOAU(.1QT?
M,I PD9B)L            %HGYH3%ITU,:%;-9CO4<&S"YT5-YC!1HX;9''<[
MVG10_)X?J',0'"\S,9B-7CK&<F33(_0 4XYDFIA^A(Y.&X!R6.\9H 7>3)DH
MR.= 3,          -!SB0=O#BV?I[/S!F5RXS?4YL%BFXA7#')WJ/R\'ZC2P
MC\WI^G8X:&W1S:,3'0DQD3!J@;&%TF3S04HAU@+'.<9U1.3ATX+",=G=DF@
M        #GN9Q-ESC,=F3@<9"-XCE.=%#4$L0[6G"$ZM')T[Z&3SA"40Z,'+
MLZ4&L9?!NT<4C;,I1T2.+QN04DU3.S)P].T9QY.H!SS-PS7H[<@
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M!S; Y4%B%YDF4@V7,@%<.')U/+,,0';(UU(S8<X=&9BP24-HS#A(E*.Q8
M               !JD;6@         'D:N&U           (3X1GD>I">)[G
MB>I$>)]/4@(P>9Z                      '.XYS'Z$3\>1^L4X4&;#K0?
MFQ-E3K\<8"=.SY^>0_5:8(/S_GZ=S!99!LB:[@ES-1:1FT M<Y;FV1JB;MF/
MS%1L>;+@           '. Y1G2LYI&_9NT<X#I(<Q#LB<,C)AZ'8DXA'?<XC
MF/3] !QX+I*28#,I$D7L=.3 AH4=ISBP==3 IC(T<.LYQP-U#>,RF
M    #G 8[.8AL^=0#E:7$;X')(V -]CF >!^C8X#G;,Y('.L_3^<QRZ#>TYB
MDZ;5G-H_0R:E&MIU .0QL,3AJ08G.MAQK.C1L";%            LTJ)8I$9
M9,*F-39PUF,PF4#$IYF7C$YE@&)S+!H$;/F4RP@9",9&4P 0&IYFPPX;'F*#
MQ-73HL>@
M
M
M
M
M
M                               /_]H " $!  $% O\ TK:;;7:5%?\
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M_EE_B\L/2/0]]Q\DE@Y;>7./2/;_ &Z'D1\F_)ZVF%'DOE#&XZ1K7WU?DI@
MQ3E$ATA\H(\8(\X@@=PHBD1!/R7'E)1'T+@/ _KY(1 ,$1'"$,J=FT*U3^)S
MX \ ^3=H?<(" @*9^/(F,!<$><33.J=FS(U+\4/@#Y229]"*<?&$0##*<]&S
M15R9LU3;%\L/E7L<)>A3"7 4 ?A"<H8*H]"E,<6T5A2E('QP^ /EG4<FOBS9
M9 < 1#/=-GO9[I,]TN>Z7/=SW#9R(]$T%5A1B!Q)!) /,CY<0 <5C6RF*1*P
M8=FY)@@(> J"Q\)&NC82'Q./:IX  'E0\8^;X <%%$<]A#/24/-AXA^?C_\
M-Z/_ *Y'Y[SG/_UN'__:  @! P !!0+_ -M@1 ,]Y,,^X3S[E//N4\]]/ .0
M?FQCE)AG."JH;X &,7"N#AA5R&^8F.4F'<&-\8JAB81<IOERCCC!$1\BFL8F
M%.4X?*1$ Q583^4*82BFJ"GR@1XQ57W!\(B 8*Q0P5C9[A\Y'J!C9[I\!; .
M4?$ B I*^X'R997U#X!,!<,L."(C\,#F#"J /A 1**9P.7Y(X4X\)UN,$1$?
MC%.(8 \^!,_H, \_(SF]!1'D>JBO/D@$0PIO5X&Y_D;@_)NJJGJ\H \"4WJ#
MH \"4WJ+\@,;TE_7JL?RQ1](A]>K8WR%R;Z=#F]!?+ICU(;TF^0+#RIT5-ZC
M>7# 'D.B0^I/SX_4<.;TE\P&$'JV'_#YIHP>OC,Z'*+Y8Z\R@&N*?0G1<?,A
M@?3JV_B\RF?VU(=VS?1A5.,N$D,E.(HJN%'\1*-&G14>3^8#H7],;_S/,))*
M+'0J#HC2FSP13V1<C'M1$1$IC$-*V$)BG]#?Q=$VHB7ULT\^\XS[E(V$CU'@
MA49@0>Q,A'>0#H3],0_F^7A:6^?Y%P#&.)=CD:PF!9@=U7HN(^UX$DR(D55.
ML/2)CC2;QLW0:)!AR$4)88D(MW\8.B?Z8A_,\I#P;R95<,"#+P508PX (8!\
MV*MPP\"O\OJV2!11=45E.M/3 $0P,#)^/_(QWQ@Z)_IC;^/R=;JR\T8Z+.&B
MCG,H>FV+\NW$1*(&S8RO+GK!UM>:3FZBI',NAOH(?Y;, $195*1<E4I*X%>Q
M,A'C4G8$7P,#I8X_["2Q)(ZP_:)X1#U+?:DY51.B*;<HD4;>DGA#H3],:AY.
MJU4\J9($TBW1Y]M 8V<+-%X:80L<<4>1OZWN6&*8#)O[)64XEOD,Q_'1AB@<
MLS' SEN$"8==L0R@MA3J\2@ ]! !!>OQZB_MF# P,#++'_?1V)?Y;+&7\];^
M=_,8I)>[BA10;^$.A?TQ .$_(P:,8O)*(@5 #YL-W_BZ0TPZ@WT8X9S25F<?
M<V"C(^Y+N&Z3I!O"*MK*1@CQ999R:0M5?-")XN&*"!VT98HMLT0<H.4^? )0
M'/1UG6'XZ1:F*=+[)?EJ42.CLUCJ+F(DB#582E**#;PAU .1 . \E6[:]@3I
M&:RC>U/0?3W2-A'4HU@9]]7WASF4/K5L"BKU$,1CT',A:IG\'#U&N@QB+-$'
MF(;#]8^07C7#=<CA'G.?%:8[[QAGN'X 1#/4;H!C!@B(^(,('UQN7D_DZE5S
M2(NG;BD28B(CTH[;V8:XP/VBV:V1],6( 8&R(I*6L/RMJQ-($S72$&$G1\%4
M>^M#G.<YSGPOH&-?X^J+U#%$E4#_  0PH<!B1/03R57KYYITU33;)[%:>MIU
M@F?VC)\S253GH56%>4A#V*]T#_'LK.<O<!^<AAP>K=RNT496XP8TD6;T.<YS
MG.<Y\#EHV>$?4Y(V/8]Y'G\:8<]$">HWDHN-<2SYBR;1+4#Y8VGY"&Q[$NV3
M>%:??2S4/J8H'+*Q;>2;Q;<&;#I-F_%WKH59$QMAUD8A^/@' ,8HLK-(-L96
M*.>8 _3G.<YSGP/&:#]N\:G9.O" <B <  <B0GH+Y*IUX8*+]8\@?$S\FG&
MQDM4O9DZY"U<T3.(!P3%4P4!,/23I;8,9V+C;ZT;14]<)N>5]U4!:W&5*R^@
M^ ?!%2SA@X W.<YSG.<YSUM@ $MX/UPI?2&()>GR;==1JNRV9+HXAL>"< 6T
MTY7!L%63"\/X:4=:Y>>EPHG@?0/%M!=$\[U+@^ ?!6WWW3'I]<YSG.<$X%+*
M//OW_4 YPI?3T11\NTK4N_9.&3QH;*Z__&S ? V4V.E9?@#X(5]]@_P,#/2
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MQ+V_MEM/_(0Q(?73_,FG&)<;53/<LL#U8:E?B('Z;Q4<+$."E3IGO.3H;ZJ
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M:(2Y!\[M$BV";I:R:@MNI;5+="3<;K M4+F;4XS46%?M]WN#S[L>6V"M9Q1
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MRFA;KE!XK!"ZC<=Z0Y;;G'= VGVQ4.RA>:>82D%?++<W,JJW#LUG<N$E]4]
M5"&,5HE_A7&Q\>-:.1V^$PY:+4XRT@B'#:.\6HP'('8&@KN39B%^L%]_GVL=
MZ?\ 6'>7_;!G]A"LVI;7&N]K-YJ04.4A*TKS"JK3G8(%S JX_P"@%C_(D?\
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MD,>SX^VA<2<O+JH+\YIDB/\ %PI$M$%%)5ZD1*KAUXM[ID?DJN[X$^Y=[O\
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MOR"OP"X!%_>I[F.Y'%?:$&,T+76\T()G9(>DNE*;:X5MX";,5H0&E%3_ 'O
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M-R6QR4WU1'&@3X:^[7%[*FQ5MR(OC3GJ_?\ >SDZV*%FNQ;5)L/L,D]NV0R
MU EKYP=6[!-W6WO-M(JY);8J[$=1*+F!X*AN)*]2^#U[#;GC4>U^4E"QZLGF
M/(J.#\"%3'JI3:_7$D7Y*IC9P#_E4'[^/,93^7#':=8;^%2_:ICUTM?Y)O\
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MHE$2J)A N5WMD UW!,G1HQKLKL%YP"W81Z,\U(:+S76' =;+R&"D*X[NE_\
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M4+]]T+JR1:XC$9Q]'VVO;[I1;=*%MLR8BSX-W[#A!1'6*J255,O=W_6&H_\
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MBNW"1$?>>AR8GKTE<I&8X7,YJ@T2K2F-,QK?>H5G6PR+F^Z4QA]Y'TGMP@%
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M91K=)@?I)9+FV"Q3;FRVH@JP!NNFY'YV2(+P^"ZB&B[D7!:KAMJRQ?6])S^
MI9EC.NWB"DF*IT3.L62)-UZ<N'/^S"[?S,S$+]8+[_/M8[T=#L9F;1J>&5]B
MQA2C/.D$*_Q^$E*"U&CW:8TE.JG1]UF?Q!I\>S\/N:>X>:557A.HH]2(XE:)
M^,*K]QT#.EJ@,733_P!G/<BG)L&J;&RW5=BF4T$3\9,0Y\,7'&;!JBWW&X@%
M5$(3\.XVQ)1(G[S+G-#XD<7%@U%!UKK"LVV1"G16-2L ENN(L EPMY-+$S-<
MG*0@1%]%*ILQJ8]'W:;=?:\BW1[P<RX1)_+2K2U+D-,YHK#/">5J]9C0JK11
MQ<6M,:AM=[<M+HLW$+?*!\HIN<1&^(@_N;BM$@EYI**T79CO7M_<KJNT:2ML
M";PK[;]:9.2EWANX7%B4W9X;0.2'8-NEB]PG.SD T1:H0*M[[P]3ZO8UKKR^
M1RCR9<3A-P8#!\ 71C-B9.'ZF,RT"J@(VT.1$VX@Z2G:AM<74ER 7(-F>E ,
MZ0+F=&LC76]PRR(NTJ;,0;9>;]:K9<+HHC;H4V:S'DS2-Y(X)&9<)#>4WR04
MIZ7@T5KRUMF::5N,J+/( S\L,]R#)MTQRFT6&ID!6R7=F>#$&]6N\0&GW8S1
M7&U2);+4ZU3%%.8B267#$_5.U03\UP:$FQ4QJ"19+C;[U)T_">DS(D"6U))I
MU(TB1&8?X!.<(I/+$@^3&J=4]Y'>#J).3N PF=.66\K98K#+S*24?Y<<[3<#
M*:LMH@9BX:YC54Q9+/H^?(N5DMOMB*W+DW [H92PT#>5N#233_.C'FD8=2**
MICN:_P PT=\FL-2JGQ+CO"_J!W^?8Q>8, '7)*-7JX(#/YPV;/J]+O*$43:5
M8L$ZITILQ8[.$Z$Q<]-NW2#<X1O-,NMK(NTZXQ9/#(T(FI4:8*Y]RN(:=&-=
ML:<ELW1RW<G*DA;WPDC_ ,AW.W76Y1G%94TXD> VKN7?44Q;+JYJ[5,.]QUD
M1+Y:8.H&8S4"6U)>X7#BG%4FV9<7(Z.].W2M47%VOFF;Y=+K>W+.MLN34^ZP
M[@K,2Y38TQMYX&([;S;SSUEH"DNU!+'?)LW0-8*GB7]+]-I5/@7P:KTTT2 _
M?-/W:VQC+S0E2H3S<4S^@$A15?%B]]UNKY3>G[Y OTN7;F[J20P?5X6(T^U9
MWE$&YT*9%4\BJBF+JY:Y"Q#AOWZT-2[C(:BP8Q7"+QY<EX^&TRPTCF=QQP]B
M(F]<:+N.K)<ZW:/U';;7"D7F(_RIV[E9,N%,X4I0=1E(*R&9#BY?,=7"N2-:
M:M=@. AD;VIX)Q#;\]#4CB*T0;*X>T[I^2],LMO=L"VZ4^\W(<D1YNHV)XNJ
M\T#;;@FLJHJB4RTPY_V87;^9F8A?K!??Y]K%X>B+Q L>G,TPD[0C_P#"EN@D
ME4W<.1<P!>HJI]UE_41/C,4_#X5\#;3Z;'66I##J>8ZTZ*%4?JKL7W#CR_N[
MO9\8-IEK^77[CI;O0TLP3VH.[:Z-7%UID%-Y^U)+BRT=X8(IO#;9L8344_<7
M757=B!=4BC(M.I+5]JMTYG-E1]M69]MFLN#0CCO9V7$I2HKB1*MTC55A9E&I
M/6^T7OA0LM?S;:/Q9#X@B*J)F,\/::TTS*&W29DBX2RFRBE294R5'C1'GW7:
M-HBE'B-C0!%.SCO%U;I%NYW:X^P;E<F8EQD"Z*,V6',N$.VM<!ELB0W_ #SV
MF24HG7<.\?O#U/(E:KO=VF>T+?9I-LLC=J&*XL:,R]&Y1XG2?BM@X)[%4"2J
MD68L=V<#N<U+=9][NEXC-7NR^TFI^2,5PMX,M37(34=I8EPCN/HZVXG8!O/L
MWI9^\^:Y<AO5I=MLE(K3X# E3+,HE:Y+PJVKHE')L*H)93R)XZZ>O5QLLYK1
MF@K!"EQ[G(C&-MN5WC..W**W#D%V'9#-RNC1$B=$,D\$FWW"*Q-@S&3CRHDE
ML7F)##HY7&G6S11,"1<.2XPW^SBZ1%R5ON;:PVZ[A9&9$E/ *?77%QA:6:G9
M;LZP]/?N,OFWWRBB\#"*J-,M"#8OEL04WXEW2*6I+($XS.3;;+=QB0%1Q<QL
MM 41YUJ.1>AGRIT4QI75MDMK]JN.D+5(M%L8AOB$%]B4Q=6'G[DT3)O39I#>
M7EXJN(2KEKL%$QIWO$N9W9+_ *8:MS-M&+,::@*-LN$RYQN9CE%<<=7F9QYJ
M&-1HF+MIB[K)2VWF*L.8L1T69/"(A->"Z3;H@50^:N(ND[#SAVJ&Y,=:]HO!
M*D*LZ2Y*?1QP&6 (>(ZM.SNQ(ND=F\Z?.41&]$L=P;8M^8US.*U&D1I/ 0SV
MY1)&TZ!1,?HQIMJ2EM65(FO+/?YN1(DRA;;><>/(V"YFV1&B"B43#]V@#?=,
M2)2J3S&G+IR4)5-<SF2.['D*RAGMR@2 G0.+LWI@;D;M\<B.7.9=9O.RI*P>
M:Y5%(6F&A1GG7=P(JYMM<:B[Q+8=V6_ZG:N+-R&5,:=@(-SN$.YR>6CC%;<:
M7F8(9:F5!JGA*ZWJV/PKR:(CUVLTA(,N5E'*WS@DT_&DJ">DH9Z;*[L6W4<,
MK_.N5HF-3H'M"XM%':DL$)L.JS'AQU<)IP:I4J86R:KM;5RA9^,PJJ34F)(R
MJ*2(DEM1=8=HO1L+I14P+3MSUI(MX$A!;7;ZURB4+,@Y!@#V=^ZB[=^!T!<0
MF1M/-L6J,RW;Y*,R66+,4<H+0/O-2.R'+"BU155,+W: 5P_1Q;*_8<RR06X\
MC(1P7%YG@</CT=6B\.GBQ<FH!W(K!8QN%Z<26Z,V>ZZ]0EC,\)AA''9+R"VT
M&7:9(F-9]\.J8I1+SWA7&4=MC.H8NQK04YV7))!<1#"/+F9 :%41>%%$MQ)]
MUEH._A9O@ D-?D'PKX&(A+PY45D.5?7T'$;$2!Q.EMS+MZL&Q+8<9-LE%<PE
ME6BTJ)4H0KT+TIMPF$+(K<9"1''CV)UJB)O(J+N\?PX!IM,H-B@"G4@I1/NJ
MB2(0DBH0JE45%V*BHNQ45,.W#V',M#KYN./-V2YR($8S=+.:I']:VT.;<(90
M3H3'.:8T['C7)6R:6ZR7'9MPX9U0A;?D&?+YA)47AH&8=B_L.J+N5*+Y%PNS
MU!U)DJU[-?-7IJ-4^/PMR705($,Q>=-46CS@*B@P*I3>6_Q>!!E1V9 C7+QF
MP<R*0Y54,R*H$HKO3;@B"W,=KSD<SO M4HJ<-TC;HJ+U80 1!$401$4H(BFQ
M$1$V(B)^S"M/ A@5=B^-%2HDE" J+O3;BK#Q,5555"#C)Y!07&,J)\.,TIXY
M-%14$ X ^-#JX_F1?@P#$=L6FFQ00 =R(GRJJ]*KM7_\5=0Z=AZ(2ZM62\W*
MT-SAO:M\[[-E.Q"D@T-N>00<)E53M+LQ#TS<;9+TQ>[B7!@<R\U*MLR73L0F
MY8HTXW)=HJ CC8H94%%S*B>[@:+T.ML7-:K5S038/-O'>+I*D\)ELD?;RARA
M1Z)3>2X9%]Q'7A:;%YT1X8N.H*(XX(5+(AEMI79[F/==774+5#ERTA1B5I^0
MX](5MQ[(VQ&;=>)!;;526E!Z=^(D^,I%&FQF)<<C VB)B2T+S2DVX@N-DH&F
MQ414\#,W43[KTV:I);+)!0'+G<.'3BN !D#;,9FO:=<40KLVDJ)@G87=Y#Y
M3_=;O+-TFT-=I/-V[A-&0>(D%>O%PNX:>FV);7+:M\A7GFI4"3,-GF'6K?*%
M&G75BM$VKF=L*<4?=Z:+3!0PO%\NTH5*='YIKV;;H=9:"SG;]8LJ;'[5=B(O
M7B'K:[0V[QJN3IF\:AC6R#'**%Q<$9\NQP&&A5XT*;%;8&J5J1UQJ7].[$Q
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M4MDF!<;GL;M]MBW6VJG+R''W<Y<0B1&VZ42M<0](ZNBQPU'"GL62U::MI,)
M@S+QRA"V#R27VS>DH;/%=-VB9=N5$IB^GWN/\."S"@1[#"$;%D-YQU]93R+9
MQS!RC,=L40EHO%V;L&ZX0MMM@3CAFN40 $S$1$NQ!$4P\[=79"621)E7"0 F
MJ';]'V<LD*WQ\WYDY/$::(A3\]()VE:X;LMLL%HAVIMH64@,P(R1R;%*>N%6
MUY@R](CS$2[555Q>[]%M,*V6V(Z]+8M%L9;AA<;W<W4%F,RVT&1LI4A4S*@Y
M6F15:90IB\:IT6]+]EV=PW#M]MCVIFUM<-I'O9D5NX K]VF*Q15;0G'ES)1$
MJ*8TO9AF,VG3QPT>OEKBQ(ILN^RK*X_<G^,^RY,9"XW4* *.>K Q2NQ5QI*P
M:/O/L9V1:YEUO#B0X<TG8\F8$.W=B6P]EX)0)*]FF;-@>\VVM3=%]W4B6PW9
M&V$M2REC2#+V?-N34@9$]U)J4]9E2,JD*)78JLZGU*4=F?:Y5RMMWG"@QXSZ
M6P&I/M$@KD8K"D#Q?1SB2I1-B.Z;[GEE6VV-')6WM0FHC<R9!CF(>UKQ.N#>
M2 RXN54"K8M\1!)2+%AT=W@PR36.D#E61W8P!W!V[OPY$5\@BHD-79#7#HXU
MZIUO(28@MZ:EC!NL/]&=)V26C++B-<JT!/$+#[;K)9[7:GAVILS5WXNO>%WD
MWOFV6)][G!,*)&CI&L5FC,-.(+4-AE'G.=CR*;%(EH*8FQ>Z_F+1;X E)CVZ
M%[,9;C0Q<)&'[S=+F*L'+D;LF86R78(K2N-(V'6,18FIX\BS=WUV 0X59#.H
M)C4F4; IDC.(D]>+1<F8%)*"J(D$+7'C2=37M78UBAO"O*1(\,&^9N,IMM04
MH\7BM@#:*/$,NH2I%[V[J<V\:$66PY.CSFK2U&E6YU\6.(U"8::N,2(XI96I
M(CPT-45<R;^\J\W.4-S@66VY[#I_@08C/M:YO3I5N@MS189=(&6;=P<SAK1'
M$4NO$73>I8T8]50)WL.V:<@+&2W6^2Z8.N1VR60_',W%$5><-PJY=JH@T36F
MHN_>Y#$M-I@19-N0DLJ@#+ SG[O*-;.&=2;!MD0%5[2DM$KBX6SNJ$=+V*W^
MM)U.3%QB&19(SMXNDMI\4ERB!5%F.B*G:3MH*EC_ *J>\6X!?^-.N%G<?(8A
MRK;<H,61*:<CS(3;(R8C_ RF+B$29D6J95%5[K.[AX;2\U+M5FYP6XO/72\7
MAJ(X#02+@*QH$-I9P-YJ(N82/.@TQIVVZOF#<M*W"497>=*&V76'%@QF#DR1
MYFV\"9"F2A;X+"N+P^,:+E5*XTO%[M8]X"!.YU;M<;);O:$I9@'&2% <7EY*
MPVR!2-*(BNKLK051=,.:S3+JD[/$*]ID;;+G5;[?&;9]4$C+3B(-!1RM$3=[
MUU:HDHR+P$*P1Z+3-[4F,MS!7II[,!_RX=U3(U.5@8&\R;8Q'2U)/*0S$8AN
M.RQ-9T5!]=(-M!IO;Q[6B+)OFI%9)A+W<Q:18@.9A>2V0VZMPE?;7*99G',M
M40D$B16M,>L=@I?--:1/(7;;@QDC'?"&E<G+O2)9?!7'"@Q0;CVZ%PX<*.*-
MM@S$8RQXK  E&P$&T$41-B8F76ZDC\^%IR_7V.X[13<NDJ=;H#[J57:ZL6[/
METXT9IJ,Z#TNP6VZSIPMKF5AR_O6\&([E%7*]P;/GR[\K@KTX[E]$OHXT81X
M"W5O=]OLFGHS#K)^:N495T<5!^CMVIBRZBF/,QX#=KNNIKQ)100I$IR7*)6^
MCBR^&RW%;'SB4!'?C6&KY HOL^S/(O92@7'4=R%T314013[- D#2B>=B/9W_
M .AM:LTM9% U1/L%K9M[EQ%%+8JO&#Y#UJ:)C3N@X[X%<+E<DOUR9;<13CVV
MWLOQX8R&T6HC/F2E)O\ S9<7&5&%6I]XTS=+B^XVE#4-57)833Z;E$@LLMKM
M=&6J8U]>?5'=>/9K8-<O&C6]0F2CR>F+4V2@YNA5CCU8-$,%5O\ .(A(JALK
MV_F[,3=4N>NCL7+5>L21>T@1R<>B6H15?1BR+G&R^(/!J.-"VS)%AN[$1,N:
MLEVWR&V.RE%+UI)LQ>HDM]EB5<])RH]O1U1 I#[%SMDMZ*RI;2=6,R3F5-XM
M*O1A%==;:151$5PQ"JJM$1,RI555<=W]E$BY6X72^W-X4\Q7[1%MT6,I>- O
M;M,6#43[C#4*+IE_4DYW, E,N5Q-Z9RN9/SLMV2Z$5M-I;!'HQK353W;6V66
M-;$,AWRK_/66;H+2F<6K*2+3H<\>&M,5-R"E\TUI$E!:FU"C)&.]D-%[/+O2
M)9?!C3^FXJ!'2\:@C",=M$;;2V6.$\Z3;;8T1&VI3T:B;DQ=YK.=J9?[?)E2
M,NQ>7U3J2+817ZKMC>;5?$N-<:@7AK<'KK M)$67/'@0X:S=B^<VW)>F+FZ"
MX*?-Q$E6UP)5I;U7 >8>"AL2(6A[6R\Z\)BE'(T]VQDH%Z0N)XL:$TLV7G'=
M;_+"NSL"Q;K<67IKQ)6-*V!D38<N<?2L:X@*9%;=NAN:HN+1]*5GMJ!?.KMW
MKB[Z@==CL.7#4-Q>NLUTP;2/#M,2,TPU(=*B S&!77>UNXRKBXZKCHIVQBZ:
MJU4SG;RDL $>M]G(QH/#<%V?&):[:IU[<1+'*>)F)"M^F;,V:JB RS<3Y^1(
M'HV'<UJJ_-\6+AIU@FHKUZ:M>FK#;VLJ*D6,_%=DY&MXQ8MKAD.:E$(@'TDQ
M-OTC*W^D%_N<_CDF5$MUK:9M@(1+O%J5#DE7Z6+EJ^2*EROZ5ZQ=XFY'KH^<
M!@-U,S3E\S FRG#V;L7!F,IB-UOEDMTM0V?9>,Y/5"5-P&]  5ZZTZ<2Y'=A
M>;;9=/7BYR6[A)*1:PF<[$8;9)'%>C29[*"TJ9,E//S)OKAS7&L+^WJ35X\X
M;'+D^[$A2;B+HR[D_+F9)D^XR6'S3,8"@YR7M*J*,S7^AI@!J%]IAVY6:0XK
M(7-Z%&!AB3;)E<D:<3+#8Y#RMDJ9LZ+OD]W>K9;UX%FU29UHN<S,Y=(SEO=8
M;D0)TE>W+9-IU2%QWU@F%%4LR9>#QFN,FU6N(/%IOKPZYMWO:QZ?TU-M,-F'
M>2NUQ]J/264=)F&]$A"URT:3FISCJE6G1C3VD9;D9Z?;FYCEP?B9E8>F3KA*
MG.DV1@V9B',("*J(N44\#_>=JNXV"2RY<=37E(]ND3'G_:-^&:V%0?@L-\-D
M;B:^=L5$\$K4_='J)BSQY4AZ2Q!*X3;3<;04M263$A3H@*+UM[2H*$0FC:Y%
M0Z9E9UIWHWMC4ESC2AN$>V-/2I[<BY 0.,S;U<9R [-*.X.;A4('"IF)110(
M+,U-;MMXMLQ+G99KZ&45)*,NL.19J-H;B1)33NTA%2 A$D1:**SK)J76;4:P
M1(UQD6?3D.[W*1;I=]5AP[:Y(CJUR<*![0)#>- -ZF;*-2S8U!%OTFW2[M>[
MNR^KEL<>=CI;H4,&X8$;[$=SC))D2%5*4HJ;=^).NM!7F#$.Z28EQ>;DS)5O
MG6F[QP; ID*4PVXJMD<<7A)"%P'"5$2B(N+;)_2N%?M:S)DJ5JB]7R=<R9X
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M&-F*7V$7-E5>GP0)&L+R%I;NCKS,&L>5)<D'& #?RM1&7W$!I'1J2I1,R=>
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M9'=!.E86-)]VUG7B7CO U)#C\N)_G8<&1&1AEP4VHDB]3(JBJ[/5%U;+%IJ
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M\#<7932IMW4IA;8$2.W;ECG$Y)IH&HJ13!6R8%EM! &E J43'_V_T[_P4O\
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MD**+1A"C- LE9GI^18"A<ALWT.RH&TD9?UF6XJ@TUXN9#E#?I3[IP%E*1OT
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M)J"+46ZKCH9XK.[7SPP'I??ZGBW?6=K9IX=\WS1P[_."QN&-1N12.S""E M
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MA*.TV77[DKP>[A1VY.]0?9I4(@ZK&H[T.P-7!"UZW"M_ 8EYZ^\]>YC_ "X
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M -\WS1P[_.;^&P[.*FM+FM4Y%-N&O3RHY->J/?9"+0'6[JH<P9*B@BRYK^-
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M7$20QL4XQ>8Y89FI;DHP&;%O3@[YOFCAN6U  K95+TL:AEFE%T+.C!?GYM&
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M*#DJD]9HS2CEH<'D&+MW+Q60KM6/+RF#3<T9MS*K3J+YL%:*PJ<D.Z3N ;S
MYA=^= )?G%VY@X9HF&_77>YIX=\PAU0UJ%)-$PYM),+:=5K2F[8:8<%C\C4U
M&CVG9Y9P= #PZ@* &#[;(O=V6$VID9V!-C+A17,!Q!@8,1$:UQVH3A7E-"(M
M@V=H;%;1\EM[_DE(EG/64J1JZO=3+A!PKEPBDN6$:6\@5UV8F8H(TXQCF=3Z
M/Q1H-OD'J*>\TN+/5.-L/R0%*#I1[];I._2.3@#=*RKHYB!X7<9>FC-.9PVF
MK0>@W6)7 *;6TYDX=)K9I\H[?U04-"_))>=1THJO7-8L("[Q8.@P+I&I?16;
MPQA"H6#5E>2R<"HH-WK977W"U6W9Q2CAA#G YN4-+J&'OX=D3PN95GFWN1
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M*UI7KY442B=@0EH -IRS6)F4?-"95JV\#@)V2Q4A=9P"+%?*[D!C6GHJ$8"
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M9&C+J4E N>.'Q8&QO.%Y2:?!W4#^0.\29BW](,''[A8,38.U^(G4PA00++4
MY,]@$6,!9=7HOX]@948LP'3'B"X*6'K'TVN_=0#[) K;-5F?N7A1^*\E<@H-
MZJ,X)*)77>%XL_/B6MM>UC!6VP:CE>J9AP#W<Q9ZI$HK=H>%$*TH7N\*[>6=
M=OQ_^:F%/#IBR:375NFVK<Z\%L8:!(&?W^"BA ))Q7;/(P$4+7AL-!X(L+/
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M^Z&L/H&F:\%_N#BJ.-O]VM_]N'__V@ ( 0,# 3\A_P#6QJX([)$N?I.AZ/\
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MW52O_MP__]H # ,!  (1 Q$  !
M           20       0                     0222"22 200
M            " 000"0"""                      2020"0"  2 "0
M               "  "022"" 0"2"                   0      0  "
M                   "00    0  2                     20     0
M"2                    " 000  "  20                    2  00
M    0                         "_JJ@
M"B4  0&<                       10     !6
M !*        +                     @  #7O\H  )@
M   "P !%W ]I2@ 9                   < #)83$/268 &@
M         ?/"8AZ!CD /@                3 :&YX3$/0.(T <
M        !@#:W/"8AZ!Q88#                 (!#6YX3$/0.+*@
M           8 4:W/"8AZ!Q9# =          "    "@,#6YX3$/0.+($@,
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M_K%H:D:"N+(#C         !E@("( *<!=2B-@OZ!Q9#4         !:@ /\
M%MH5*^OKF56T#BR"!         &; \P$!M/C#M !W#5,<63&X        MJ8
M3F].0.H5,N!P'8?CBQ          #VDOO:SC-=';ASP)D45<3P0
M $@O>D_<YZ/XF>\U<0#APT          "J> 3D/A]\ C.PV)IB"&@
M    0Y((A_P*$G>K9ARZQTDP           ,MED:="8C]/Q]1*%$!C
M      %-D(3AMLJFM6J8Q7T HA           &N!'3II8=)E%3!4=7-Q>(
M         $A7%*%N -U%I7CYCC_HA           $J#,NH\?SR6;.+R8TC)"
M8           +;4LBUD <' QB3 ![-X7           DF*F4Y!T!#%C/>@
M?K&@          $E"W):1,:HNTB)V  FEXX           'O4;]QWG #AHX(
M8  [+3@          !(DO27X+6(C5%PO   )[JX          %0U[W+.G'5Q
MAUUP  $K]$@          N)$$,Z2_!:9$8    %_*J          IBS^(J7
M;^RSYN   &/X??         'B4O0,EEG16XI;8   =;"#$         #5I<V
M;=%RXB?EH   !O,-#         'P94R-Z5TL(WI@    J9E;<         *[
M,;=K&S;A&UT    !($X:0        %8>;."&S/>*#N0    BZ02H
M 'ZJ:^'K,P"]!8     W$/H&         L$BJWYTP7X<X      #M->@
M     #6\,S>P]]?@      #S=L%         "+\6H566:CX        G)&X
M         /Z,$,GXV        'AA83           9?2](&          !-/
M"             $1Q    @       !9X\        @@@  $  @@D$@
M $OS            DD$D$@ @D        Q[NX         $ $@D@$DD$@
M    $KY$         D@D$$D$ $D$        5[NM            @
M       &K<_M    $@    @      $ $       _]C'D    D$   D D$  D
M $D @     !JL '0     @   D $ D$ DD@       J]#I       @D@ $$D
MD$@ DD$@     %H(4]      $$                   %>(<
M                 @*
M
M     @   @  @$$   D@$ @             D @  $$$$DD@  D@  $D @
M        @D D@D  DD D@ @D @$D           $ $$$ D@   @@$D @D$@
M                                             $D@  $
M              @ D  D @@DDD$ $ @@@@@          D@@   $ @D @D@$
M @$$DD@          @DD@@$@DD  @@D$  @$$@                   $
M        $              $@@@  @                      @DD$@ @
M$$$D @ D@D$             D@@ $   D$ @$@ D $@            $$D@
M   D@DD $$   $            $$@D$@@    $@   D @
M
M
M
M
M
M
M          __V@ ( 0$# 3\0_P#%4.\-;4& "JP<*C2O@&M.$*4#X$+6E' !
MJAF:KSC_ /@X<(@I!(?(;X,MZG@LH[,R"-RV9M'C_,)#K'U*Q(S)K-5YHP-
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M"BP 9_U5S;=BO 3G)D3*[H()%B.J>2)FA4!/]42H2R*;M591:' \R$R( ,
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M2W4-2E_RU6<RIT@GJ@M;;<;J6UW,YF(_@E( !\Q$I*X1%$?ZQ^P,SC"&U50
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M1(M"$1;=.I? @4<.FN1 4+!;C.NU!YP1V!%N*:>%8>*U6-1L7P%Q+3VN2&J
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ML_EA*2Y:#<$4;8#2ES4I)4$&I5E6C:P/;[2IULKY<M\Y31@1_P#<^X H446
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M< E![U+"H(!  @B(EB)A$^U4C#0FX8"PB8+\R()1J!II$QLE/,A S_9S?'G
ML((*SFP#!ZPK"3SP$'OGV_$ZE]'7UYP';O\ N$#R8A.;[07> @.DXZT* W2T
M0:84=IRSE#S(AB0;U>7J3Q0;_P %.)&URX8PD>?KZ?\ 8_5\$^9C=ZSZ,NIS
MN_S"(::^A3C&PU(""N_6_/=AN'R10;3V!XR5OM30VK:??YQ!_P#?W ]N^D(*
M:13_ ""^,P#O""D4@NL Z,().N$"-'RA3F=LGI/,[?)"^C^_2$"-(IKGO-\5
M@H83O<^DG-$=RR19/"P@,H>EW]85Y>O5%-MJ%W/<'\7%CN5X[LP>?VNH"CK[
MVP1K2J<T]KV82"UH*ULUIO<(L!8:6LPV!L!4B(LIQ])6":*%LAJ%OL]8U?GU
M^*YD(#:^(2U[0Y7'J0YO;2<E]/DAX$+]?:$#-_6<V!=X00,WG-@&'(P1"23R
M,'W_ #ZSJ^'6 WQXYPB^ I)D(;KE(Z6#V;Z:Z^\(>^@[+"LD'5ZK^ 50-=%O
M%%LLYNC M"\SIX_$5!U9[U^ICZ+\V6,VT=<ZP!:8XQD%^=OO#'0--ET3I*2H
M[AQ=YQKAJ8>Y0'#+=+LP6!%\-Y+FT>1&OL[1ZZ;6;I1L&38CH'*56J".Q+Z0
MW#Z06^>VL"[Y]&#[_F!Y^O[@_P#O[@>WXAX$.3VB$%@'>$%(AX\$YL [P@DD
MDIHP5FH$7(_%-$#;PPW3*FJ%FZ6&BJB-AL\?[D_ABB-J)C)E\UO*.E?+YBQX
M\Z_$Q7Z_[[2ZO57S+#4KE=* #G<K9^^-=^BDT!,&+\LH2+9V&Z\MI>#!4R&N
MY(ZV: *4'V5P.LZT <)JW&C5A4"EK0*>M1 [)9 5*, :#R1AYO:!=_6#-_6
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MN^[PK4,#%44M%8A]G*[*"Y3&K5S*4H6"M66A%FCB()BE4E=+;&[#L0PSCP(
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MEAK,?T$P8,VQPP]VQ!RH$KT>> 6VUTV^"TTB ?A.<ZD$!2QGR@:B93#-<J)
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MP_"*$9MHM06L%0J!#IR"(*<&@&B-%5)D+>"N#_<@98+<&9YG.I%.0!](H%
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MB3L@-9#FP2P48QT6F-HN ^/7S8ZB>SX$?@(<S11N5E-Q4U:--!A;H<TS1#H
M1:D!CY=A12=NFY@T4DTK= (AM6N_";CH9>HCC[DP#;&!7C7.>HMWK6",1N.7
MG+"XD5,2,9R%::\$4%X+.=^_$SUT$BYJS%'<Z6M;IIKC9;:P@(0S\PZH;[W'
M@T$/L&UX?R_I3RA94+]RSN&1I@6FIXYIR(&=YB+-GFX1S/;RBZC<OA/C<?I;
ML9(I+#=70,DD2%+MG0\[J4AG17 49\C28A8OM*R3B65P"P/-DMD$BN@@":4&
MU]Z;WB:B34D.QE2Z4YO<DG\%/Q)_#-4@)>,:GH0A2H95X=,%#('^YM="@)A
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M!5ZY$'OEHEID/4>J:(X5MM=L&*DP)$JK1]/2_P"N.[>8[05S%0.NRTZDTCA
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MR#[TZKE*GE.\HZ11*X(/26)?.5<8IE<+YQ#&42*&$5@1LI!U--(-%#P 4^J
M&S*35EAPG%%N.9^_W] +E+E9'<ZUE$@/,B)>@!65:9C@PF!.1.Q945W#F2O$
M#2!H**-M*0JYGYN'X?*5>970 _;YK-' UEC&C]PH+<!&?K?"=I?6YW=F289F
M(,>65P:=83@IJ<J<*SLOI'/7H@@8!OA1BK&BIJ*O?V+F=KP9'QGD#)#2JBG-
ME>6]:GF,W#B\K<]@M>A&O#),##TI*>L,S#K'EC]18U&%U /E*3P@."\);5[\
M8<OAS?+?VSY06'"<V&KMFY\_6J\JX)N3 S JD-.!-!W^XL=74]Y4ZH$%K1F
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MX5$\@:.D-%W5?CXX41Y(DR2^<IM$368E2DI.*&\>6(G#O$.DI)8I^^58T >
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MU(YW1@!&T'*>: J+_5@4A".8LZL&7#V32-?E@Y LKB'/K"5"@MK8,J\@W7!
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M."LNP2Z:"PCST+:ML@V+*HH6AH<@&BJ%#+F$D0!I,(5M#<QG(8V&"'+4%7-
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M=_0"7YQ=':L$<"*-VFK5Z$/F'CUAIYQJS',_'.4H\]W@M1YUWZ]'3??&'[;
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ML-31-*YJ.KF70:[C,/+("PHN'-5:5(_BJGC8]. 6LI<N&=/VEL!8*M@AUW4
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MT?VSI-^#P1/HT?VSIP8\*%;Q*:=>%G;^X2GC<]."#AG0/[JDKO #!_\ ;?\
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>mgnx-20221231_g4.jpg
<TEXT>
begin 644 mgnx-20221231_g4.jpg
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M+P                        !&<DP 1H(UD_R/)J$G(:[,7),
M
M                   %ERXL"W=7#MK6QW/BM&7'27KZ1-QQVOF'+E>MGSC3
MVLTU=GTB0                      !:LF/3O5YVI.GH89M:R0    N..^T
M>=O;CY71S_2V_P"@                    %GRX] =KDZ:ZW-IK0/X:\V<>
MJ-W%@^QCL.7'X36MB;]CME^"V?:V;9.GFN]+ 9GJ;,A>'U]F\_=
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MQ6IB?<]HK['N>D/17TAZ0^C[/J8^ZAM?G[TA>/U;_@RSD\?Z?Z2
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M>AX>F>MS@.+_ +CGX%LZ]RK&RN9N;^\UU(Y>PX50K7JUT1E?%Z,EOA?T^/\
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M*U)40]D>\1['K#U1Z1'H?43]H^T?1]0']DD!D>#++CSG>$U/)>DS'5V0
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M^S?,\[^.?2O?G;N$_5OGVB?VQ^8,EU=K"/2\$93KYI9>=[HW)R>C*'SW<
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MYQ.1[&&];&.YYJ2H\[T>Q?R3U^:ZV:/!(<QPTX2&(=F*D[C7I!XZ$EZ
M         !36KIKI:$.-+<SZLY7$W8IRRF,3&'Y*1U^D>3@3Z'!34FFK/PG(
M=C#?MC%=LU+_ "[^_#O=[3YFT.$!W?.3Y'<Z*D92>9OHUD<UB0I/$
M        '-#-BS")SB)KH6J6.2P^8I.MS,G[?)UALUP'-.28,O+SV7.R'8PW
MG8QW'+7I9\_]#TZ^<^E X0'=\_.(8\3A-Y')HZSDD"&Q[G3D
M   '.7-COL-C1- 6&6)3%$B>96(N%+U]+ZMW<'YM/M7B;[GQ73-3;&EG[]_#
M?=WG%<#E47TWH20-'D1B@.MA%XA>=*39                .?N7'F:;A"RF
M+S&%VB9^*^YJV  Y%?1O-0+]UP9#<G<[ _*_5[BY.X
M    !$_)2FA:98W+#YC8U4W<>0                           6U$9KUL
M<K!+$IBQHZ'X<F0)                           &A;UUS,64Q:8PNT;T
MI:8>.X                           P:8C]:MHEC<L.F/%$E:7DO2P
M                       %*1FO7&IC'Y8E,8?,;CK;.ZI3TN
M                !I2U=56BQF+3&%6BZ1.T:S?H2UI?Z
M           +:B+-ZV66-RPV8QB8V!$YI6;_  E;2]>
M         8=,1GO7'Y8C,8;,4YG43FT3D4)0X[7Y(
M      %J(>9*8A:,*F)&4M&*]<MB<YB<EA*G':\I
M      HR.-ZZ^M&\Z3NBMH/9<>MYC.XMLFLRDI;^@
M      _A#?)2V%_-[5ML:LZZF(H9*;-K:15)OR0
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MH/BR93$@                          "'62E068QB8PR8D[2\DZ6
M                      &'S$=[5M4L=EA\Q>H= <63T
M            / C3>N+S%AEBDQALQ+K'>0U+
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MQ.[JSOBE@                            +&B/%ZY1$[SK:H
M
M
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MSO.>QT;.E9L(      UH<$S:)TH)?         @T3E            (-$Y0
M     ##CW,J
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M>#6#<!N!/\9MH"$A)"%#DSY6&8Q&Q''^FM/[P!RVRJ3!PG%*9.@N0G(+-YV
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MTMPNC<I20E:5DO\ !]A$/_Q^_4S! @72RF_2-..N.G\*(S()E*[>,B[G%>)
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M"4)3\#4VA8)AE/5<<C"D*0$?B^P67\?V$9CWE(0E!?"C(C"HZ>_C,^Q*+O\
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M3[-H8B\+D9@%$?"H$GJ?@7>2,\Y/4"\]E%B\(2M&A0!':PE7>[R4WR<8$)$
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M&E;2FUF_84DPH4IZ!7T;L-QT1$U*.Y(U%%>)O _G-BOFV_\  -?_ /RO3O\
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M@*HFP=X<W3O.U@W,KYX6_O:];PEU4>-$@.]@:LPJUY$>&V.')REEQ)%55_\
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M2-I^.^T:$!BJB0KBG@BT]OJ?3M5;SD96%565U6P;&8DEXHT98L&3):DR$D2
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MU1J>*.H"G7D=N>%9 FXR("0PG";33SL,D?=D8<TB=5,V1$VK[ENCT<%U6O\
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M/,F*]&P@*((BB"(HF""*)@B(G0B)]V#=<7*#8J1+Y$38WRW(O5;'Z#:>J/\
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MQ*^SH+.";B&R\4BQ X$<,[8N#S^4ZTNXL.LBZ;F:O@3K]J=>4-OJW48J+U>
MG)8EV47M:F//6-##DXBV+8N=0$R"A+2:=T?0V%V<C4(6%IV 0+DQ:^%*!EM[
M.0IE?E31)/.UM65MU >K+N=8V]O;07T3GL/O2EAQD- 4NL59 87X=FM=:QTG
M;4];[UU)J9^38BR(K.GA.*&RJB\XJNC,G">[Z&U#J'247WE;Z=";%F5(N $F
M=6S"8>!V%S2!MR1!>9+%O',X+G5Q(4$I&BK1FXJ=%Z>J'CC5=C#AP;&W*M9-
MZFT]'!&VK>Q;*6V @CI)':%$5550;#;5\[55-*I+6YM*^(S%FB(OK7U41UYM
M\$$S1&GI%JX/G5OS)L6J;G2-LQI8M?,S2LY -)%<HM/OMA7D:\S.C4V!5M#P
MQZ^RUE%RBOJ>S9O*N.\Z+ 3S9C2HLBNYSBHRRY(CRU5LCP'F@*$0BJDDONSJ
MX]MI#2E@_(2SF7$6)"CP6)2Y+!85D;)VAMRD'>W#(LZJJI@A&6U_J'5>GK&F
MCQJ%VNISLFFVBD/SY\8S>;%MYW!QJ'"423@G.VJ]<:/KG;IZ/5!3W-3%)%GH
MW%D2I,.PAQS)%EBJ2R;<;;]HF4%02Q-16'JEFW2BTM'A^Z=/RHD")<7LQMZ/
M7QQ*''&--F%!BO*X3\Q<! "(<[BKC,8U'6/U5W<:AFV$B)*1$DM1&H\.##;<
M02(4%>S..#_.[6.N](T%E<L2KN!J.BM*:,%DY"GPTBR ;EP<'G&G(4V-NYC:
MLN#EWKO%+R=WNLR(TYZQCI21Y$2J@&W "-@_^AUH-FTA2%_/IG7HW;.:K[K(
M,RUK6YLJ122ZAN/-E1(<WF(=/:4[RN.O@TPZK2DC9M."B'B![ATL>H(<K3>E
M(.H::??BL2LTYVNK@VD>1.C."7^_)*2HK)M\D/9.H6!]5<=J"Y[IX4FTJ0K)
M3%[7MQZ^R9<E))1Z.IUD@TL%-6,4YD9$7YJKP3:HK=2:1*H@UCSIL+*KTTY4
MQ79(@#TZ2Y.>>GRE%L$3!OFJB8Y0Q5=J[1G=@Y:S;NI[)'L95$#J7+L67)EV
M-[)IPCJDX''K.1U49S/BR2X=*[6B]Y#EZA2;47:&'J9V4[<QH:1A243HSC.=
M%C/2,.6R[E42$RRHA;_^"+C[[C;+++9NO/.F+;3338J;CCCAJ@@V IBJKN1-
MI!Z:U'0ZA"&38RSH[>OMABD\AJT,@H$A]&2=1LLN;#'!?L3^GH6I].S+^*3X
MR:.+=5LBXCE%W21?K&I)36BCKZ^8$R].S/;)<6)VAX8\?M+[3'/?/U&&>:0\
MUX^@4WK]@DSITF/"A0H[TN9,EO-QXL2+';)Z1)DR'B!IB.PT"D9DJ"(IBNSL
MK3E]2Z@BL/=G?DTEI!M6&7\@N<AUZ"^^VV]RS0LJKC@OW%>OM,]YLK2U6Y A
M1AJ6IUZP /1@(7G^77RFH^+RKY,=H'=0[WH:A?L)\ZDA!;-WVH1AME=LQWFC
M)DIW.464D=;RX;4%]<][<R[JZN>,F;4G8ZC="<R@&*L$W*F'')%4OG(J;.3[
M>Q@U4%G\M-L9;$&(U_.29+C3(?"NR5U%K72]K8%^3@PKNO>F.X<>1&%_G/HG
M2H(N&VI?[/W/ZND;=Y=C:SX597QIVFRD3K"4Q"AQQ5FV%">DR3;9:%27#>J;
M]B@Z<U?IR[F@)&4.MMX,J7RP]9U(S3RO$T/22)E3P)$U)J_3E)+)!)(=E<08
MLS(:*HN=D<>21RE1/6RY=NWZ=NZF]A9LBRJBPBV+ GQY9N1'71;=3I%<"3:_
MU,X]$&?%@/!2193@IVZY>1&*]@&.8V[) 9+HFZ(=9&1)=V&.VG;S5VIM(UNI
MK%;09]<-I K2:*/>64&$B5\N>Y*:5Z%':+>O6S8IN5-B,R$  5(S)4$1$4Q(
MB)=R"B;>[5[PM&I-YG*Y"ZCJ4]MPY.?M7*YV;=EQS9MW'83 A,#%" Q5"$A)
M,1(23<HJFVN?ZPUS_3;:3?N.\:KT.=4DYL8]NY#Y<Z+)=B'(D06I5I6Y9<=6
MA153,A(0XX8)BC]E8L0X$%F.R]8VTQEAL4Q;C-'+F2"::YK[I"F*JF8R\J[1
M[JTU/I^OJ):8P[*7;P&84S#HAR3?1J67F;4EV=?TSJ*EOVF%09!5%E$G]G(O
M5&2,9UPXY$B;D-$Q38JFQUWI*%9 YRG8<G4%8T\P[CEY4D2DIV9W'YIY5V;?
MCNMOL/ +C+S)BXTZV:9@<;<!5 P,5Q14W+L,G45]34,<_4>N+.%6MN+]%LIC
MS*.%YDQ7;L6G]9::N)JXX0H%S D321$S*01 ?[08(G2@X;=Y?]@-9?W=L=M8
M65W9U]/7LZP]K.M)D>!#;4J:K04.3*<:9%27AOW[.LZ9U507K[ YWHU7:PY<
MEIO=[5R,TZ3XLJJX9\N7'I\#CSS@-,M 3CKKA"#;;8"I&XX9*@@ "F*JNY$V
MOM0:?.QD4FGGI;$FS>KWHT:84)DY,E:Q7<IRQ;802X#ZX]/#_INH/_D3_P#[
MW9^1H^_C6JQ,O;(F1^'81$-50"D5\UJ/+!HR14%S+RR5-Q+LYIK4LFV;LVHL
M:60Q*MR6SR98J37M1,4S8)O39N".IG*E]XT!HKRNF5T4B7##//)LX,8=_%UQ
MM-@=:,'6G0%QMQLD-MQLTS 8&.(D!"N**G'P2[W45E%J:J$&9^7*/*"?1:;%
M,7'Y#J[@;!",UW(B[3;?2CLUV'7S_=TA9L,H;B2>SLR<! R+,'*?'?XL*WU6
M[-:AV$_W='6%#*8XLGL[TG @ ARARF"W[1)\?,L>=%8EL*2925F2T+S68?FE
MD/AX(_=Y9V4IO44B75P<H0G'(,>5<HP4%J5-1>6PIA);4E7<"&BKX$MM77<2
MFAF1-L<_F.R9;HIF)J%"C@],F."B[T; LJ;UP3;D<S4W*S9>V^Y$[-AACGR]
ML[9E7A^2Q\VT+4FFIOO&FL.=V67V:5%YBQWW(SX\F8S'?%69#) N(^L*^!RO
M2YFW[[)JV^6G8"SHC1ICBB3WW8<*4B8<6''1W\>.$@=*6ZO3H;0O3*F;'=@V
M<=DB0.=V=Y,DAA#5$(V2< 55$5454VNN[YMZ9#U31L]I>K[&&<3MD3J+VNL>
M)5;FL<IX#ZJXY#QPW%E^PZ<_K_07^PUO@?TAK'5<;3/=WI"RL:TNW6D2HBB=
M*!,6BMOSW&XBVMM:M$R+BXD#&&"+EWS+SNSUAIJ#JNB2++B0JS7\:Y>ND&4P
M$@$C2;F?*&<TR1/-+&R=<,,N_=,MKI\I=S I]34=E,/UYCM?">[/*=W;Y#L!
M]GF%\]S,73MJ&)J.=9#I'3WNRPF4\"6L0;2ZG]NCUI22%%+E18<:3O'!P<^
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M?=D2.PQ'B$X"X*:HX]@JHAY55-K*@NXH3:JVB.PIT8U(>8RZF_*8*)M.@N!
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M;E5-JR>L>);5LH:^\JSF0T<#$@"973VF)C*.1Y ":$"J(N OD7;_ ,O_ /\
M2/!:TNK(T630R8KA3EEF+(109%7>WA*)1[$]"R\P7D5.7ACLUW8+W@WR=P_[
M7E1-ZU]T.@I58CS#J5G8"KD$6G<W((E!&\'>5RT1K:KH=,QF8M) B@,$63YJ
M.@Y[591R,262]+,U<-Q57.18[=X+L3-S2HBC%DQQ[+-E1H<WU=^7L3[F/1AM
MIUZ*@H]86&H9EBHIO*8%W-@ I^4O=\%A/0B>#O"_J!W^G8VTY_6&HOUW-V[E
M?]?E?KG3_@L*^.[R[/6+PZ=BY5ZXP715ZY>_FUKVU87SR$VTMIREUKI>5K'2
M)5VHACPK:(=C(M;1TBU%#84'E=/DE8J28;R2&&'!$VJ.\B]G)$AQZ83U)*1B
M1([+8UQ^[[4NRPV7Y2B<YI3 1 EY9BO#:!IS3VK/>%S9N.-08?N'4T7GFTP[
M)-.T3::-%;P99)>N8\/+LFF8CCA=T/=K/"3J*4T1)&U?J9M3!NN8>%,'H;.!
M!B*_D>::%[5A=N\-IH :::TZ\VVVV* VVV%?I,0  ' 1 13!$3AL[.,1YU'J
M&FGL'\].TF]4N *X8Y3"QQ5."Y47BB;:-NY)$4BXTKIZT?(O6)ZPJ(DMTBWE
MUE-U>E?&TJ,9AZ00ZN0E%EHW20?<UFF*H"$J)BNVFM-?^DUA._9W3]-1=M_:
M*1&[9[IKH\#M79_V3D=G[1V?-DSGEQPS+QVOZ>?H1_3#%?6-OFY)MG+-N<$M
MY8KD;EN4=2@)DX]8L?)M?S&M-3M4=W5\/+&7&YJ,G!9?-ZL<?GM,2 @754DA
MQH@?% >0C4=RB8P= ]WNA;2-6NV$:7:S'GNTHX;&/9PG2FV&J^JK8SI\PB<<
M)7#$<,,,"U+HR,?:W:KNSU@R^\R!?IEG,I+:78/,AAS,C]A)/EBO60<$VU4,
MEAZ.1:N4D%YHVB4?<U8F*(:"JIBFVMA%%(BTCJ01$4Q(B6FF(B(B;U55VULD
MF._'4KZO44?:-I23W>6]$,1Q3;4^H7:6K[ZJX(+L"LJ6Y*V$6F8)N*T;+"-U
M]M%BRJQUIYHTY#@%SC+\H6*,LR>XN3H^IDNX.'6SFHF8DQ)59AN:5I8TIT4)
M5P5T>.SPZ=G"L>_BM6FGYSX*'9;:MDJHQYC?65DADL.1)&&;(A'EQP3;_P!/
M.\_0EZL*IDR_<]C&R@X+,A]V0<9DY66NMH*RG3)IYF0B"*Y<"PW4]#I_N\OH
MNG)*6#MMJBQ4S9@-1JN;)BHK<.*["967/:::0CD[^9@@XJFW=N4>+(?$(#F<
MF67'1'_?+2]90%43=X.[<H\60^(0',Y,LN.B/^^6EZR@*HF[;6[3+;CSA?LU
ME;: G#+#5] 2X **2X"F.VG6WVG&7$GZ@Q;= FS3&[FJF(FB+O3;O(*1%D,"
M<!O(3S+C0E_OEU>JIBB+NVH0CL/2#37M62@RV;I(*:>U2F91!%7+BNW=VVX!
M-F&D:03 Q43$DA-XH0K@J*FU])*+(2.L_4V#ZLN(RN.GGD3!W+DWKY]M+][;
M-"[>:<@?L[-=,&G"B,3=/3>:[7V+S8/=A[0T &T\8Y54EPS*!)M9Z%[K= 70
M/ZAKY-7=:ANS9;J*>MELDQ9)SHO.9-U^,9-AF,#ZW5;)=VVJVY4=^,Y^UY=2
M0RXR>ZGK!7JN"*\4VUMJ;0=&_:VND[6;J3LA-NB-C7,MPJ^?"85,BRG9D>Q5
MOEMES#%5R8ENVL]!:9[O;VIU-?QG:>>V^;L^=$C2QY$V- KX\!F8_*DLN$TA
M$+:MYL4%5PP(;YGLVH=1SO>]C$Q13KV$8;8KZYY1ZO/9:$G'/HF\H_-VU?IY
ME,9%UIJ[K8N]4_2Y==(9B%N4?5DD*^1=FJ52RS-*WMQ62(QX"\T$V25TT9-^
MN(&Y8N"F/SFR3HVU?)6.^D<H$W*^K+B,K_\ MVG3<[ER+O3R^#2HQF'I!#JY
M"466C=)!]S6:8J@(2HF*[1J[3/=;K>ZNFXC+#,5V.C3)N-MMLH?^[V[268<S
MH1M%7ABF.UOWU]ZK'8=1V0/#24Q91?A!+C)"*0_'0G2KVHM4G98[!&KR I<S
M!<,TF=.[OM$39LV0]+F3)>E*&1*ERI#A/2),F0] -U^0^Z:D9DJD1+BNS$6*
MPS&BQF6X\:-';!EB.PR"-LL,,MH+;3+38H(B*(B(FW:>SO\ 9O<&':.4?)Q_
M8G+AS<N3'-NX\?!/TI9S[6MA6!QB>D5$KLTE1CO@]R3S"XR_&>RX&VX)"O'B
MB*G_ *>'00_V3&(D4*T45%;5%SI-"3CVA+-'UYO:,W-5WK*N.U7I2OG6=C#J
M@=;CR;:2LJ7RW'W'@:S8"VTQ'$\C8 (@("F";7>F['-V&\JYM7)4,.8VW,8-
MCG-8[D>94\P+T$B;6VB>\+2=Q:Z..R<G5-]3M"XT)/96G7H#[YMU\F/.99%Q
M8QOL/1W,<V\UVJ=-Z8T;J[L4[MRS[^TCQ8T*I")6S)K9/)7OVS1=JDQACCG>
M:Z[B<5ZJ]X#;0&XX="Z@@V*F9+SV-PB.*JNVG6WVG&7$GZ@Q;= FS3&[FJF(
MFB+O3;NGL@ARYC-8=G,?&(R;IY(UE1OJ"8)E0S%M<,53;_\ @.O_ /X&N_\
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M'J>\ZR%/R?>]J9=R\=E"GIZJI DP(:ROB0!),RE@J16FD5,RX^G_ (8__]H
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MU&!=A,:DP>0K[A%@KJ-$%VCR ."IB-QP879T&=$1RJ)BZHIJX$MM6O\ QL
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M<X8(((($$(0AQ(1$PRE(6@R(Q )H+% ,= N$V#AK3W!?((&=3[G7^P#OHW(
MXW.+E0X8LN<+SV,RK<NE=UFG]9(&G]3MGA@N.@2RU$6*#;.+5.8.=GEE+< D
M9;*-):D;"-O&KPK4YF8<JQYFNF8$5H,OW%JJ8K:Z6XI"R7U^$D.1W8!!2@$$
M$"!!"$(<"' X:H3%T$5.6NYO","E4.?ITVM+K$3!@-@+$=Q/N*;H?0LJ=Q"[
M\<3_ .T-'_BK4 :,ZV.=J"T.>4P\.PPE>1.'F3Q$WR^S/>;3=88>Z@^EM=-C
M:]08J^D$9YK.:9> ?<+G0X)"\9AU1'!!!! @A"$.!"''U^JVQ=FGI&TZE2CS
MX&Z$@MPW-52=7[>A.JAT\@_#SCV%&U58ZJ\3>EC9I&=;7&B>6G_PK@"9V)4.
M5@[-P<+/JP'/N<\M4(!)"!@UX-113$6ZB#>UR=O<@,,'<+^I+NNT*'6""! @
MA"$.!#@?1WK!] ?8'RX.8YR_:AU'V\9U2KO2R[#/1^BH&S5)L0I@M[JQKZJD
M,(6 J=@RRL23*=-<E*J*D%%(4B8I'(G$C##!#!!!! EE,4G\8U-;(ZN9;GKV
M#FNH%[WT3)M)WYF$ V"A,/C 5( (PA>D#,;9[*6K*3UJP7 %1JBI=]#57WU<
MI/2-\OYEV#F9JGTTK<#N5V\_8X-F4FUH4?;BL;H?.+3R;]OZ.]=-O5V_&^@6
M?-M3(U?.E,Z 7$(^ZPVU*Z@0JG1I"DJ*N?+6E5G6CKY+0?2NR^L#IO%DZD?6
M+2TFK[G&LKK(2J&8M0M:3F;&R%ADQ###!!!# @@A.?7Z?+5K*TC:M1JOA6K$
M=+;<-C5C%>TKF)J7TR9'1(F>'=PAB[5P$U_44;4%6 BZ*HA/IR]7F]%>#*M9
MWER&OM]4Z.=+TJM;GG]8_6":(Z%,"A0EPL= %""HL&YZ&IIYA4(\^,C:U>U7
MZ G4"FE"N^^5UA.CQ@CEC/FIM2PQ5*4MR?A%VKHX0A@@@@@01-&)JFO5395Z
M7%EAU.)U.\?P?S>B"Q0#>/&O%*@PM^KEQ25'2UK?FB-?AJOF:?1L]&+$3:'U
MP<YU;UUM?GAQS5>8$;R5F&_MF4+P_4J'O\^)OD<Y^CJT2GKFB0KQ6P-^H3D[
M8!Y'0\Z'1*:WC 1JQ*H5^A)Z9,CD((-M,C9P4U!E*E3?0V5RE-7RPY$LZVGS
M<N>L&:$"Z<!O@A;6'0U'8FSYDSY6+/&CU"=\P.@45GHCD=1R0F(VY$EH!6MS
MUW@A@A@0((0LAJ]2P)I,# A#.' !4?G 7,^8RM]5D..VY>%VV(HF ;?\4&:"
MEX[%C?#]P%K+:X!MO;B]RP3+&N"?,,OJXZ2@J 2JK#FAEX6E@06WZ!"@XFL;
M4+BC 4;+@  ,&QRZ<# 81  % <(FL-0+=)!NHP!S1!+;0EAC]Y-'9$WS?YS=
M*P^P#U ],,$$$$""$(0X$(?64 7F\@3R'W*14JPO0,KK<&T?9A#>UT0 BP'E
M;^ MX.3W*7H W9BD!: #D5NKRU[0Z@&,=UW6J2L9EV*M+5TP76VQKET32S-#
M@6>-8>E>0NM[*V"QH(W^.4WS?/>3F""!!!"$($:]%)V"U@E*'3Q/M.:564:U
MSJNP=9T#BFEY=(Z2HN\%'TNE@75$M0<Z /4/KJU88Z4#Z7'*UWZ&@\C[;C/%
MB4M6+L#Y5!K2\Y;7SGBP/%&PK;=!S.!OP;I:<8MFP:#51')B=4. P@80PSK<
M"R610UMWAM-\W\#(@@@@00A-G'QW3D-Y'R^8ZNN_$TH 'J04'FOP//6+B>W5
M1'4$0$0R)2=DR1Q(=; /.#WITFH.J4AL= QUCHX\A] U$^FQ3(#R.O/BXXIY
M :;LR'K]MAG#?%E)TO,#:M"7L/RXKJN.7J33=P>_$WS0$/3HIL<P?)PTLRRN
M*"!'(X3F3>7<Y^;IRF[A[$,"""$(*=,!JI0>;*V*%#>\1TFE-#@8A$I_]*2P
MX6,SHY=V!>+F-2QU82FF]8?T?37[-[YAO0@[\'LKUCWF8W3?& : &A]L5=F\
MH[66IH"84#NX$E'Y8ENW6+TY%NJ)%(.7&U(N+-T4,J-KNX$#J7O@W3=-!S/O
M@:]H3J<#0PNY.]T0T\S0SP+(AV"I-$E-6A\)P]R$;"]6>BGHP000((0E>]7K
M(]R]7IP]":$THZ8,PWZ-%WEF(@%.@+7L$#LWF)ZIPP[4\X37C5ZE)U)G:&7=
M*GK]&&AUN*\T6]APPO8!<[@>EWV]M*!9+2LV(I-J\?T,Q:-Z$<-A::UHHN#@
MW3?-#T??_4ND*!!I$;$3(C.AOOBWE\SRYYS2EM9EO!/02A^3D'26Z.*L#L!N
M>L,"!! A HLWF:KT#+#^P"]UJG7)PM#@:#!2"H(0M=;U6)EU=#4&[-2^:'E,
M8_K(?)*ZL!$<CA'(CLG)E"@J8W=P=7'7-K_%QS0U!'DS?4+=F>]/'O2$VC4?
M<G'F$:G($\_MVPMVZ.:_EG 8,KXGYQTX-$W3#MW@M;X3?0/+K I1F$&'>0"9
M#8U[QC!IS1S-'@H449V.I6,FISLBSGFT*X&H5#57,11""$)I#6[?0=W'DS2E
M2W[#]',\IJN^7_H?:!47A[QEX'J\"M8T$IEH(ZG,6EY6(@!/88E8:+U+S"OD
M>9-F)3J<A:N99,&&9F3@FYD>J..)9NT='3M7,^W43HLS_FJ[)H(1Z#CU!2%*
M#)MQ.H=3X._%&L==M]C]P\)522TM:)@V5WQ*7, FYU)I9FC+^'8T&P##KGAN
M:## M\Z5D<\C)JL,$"$4L5A"=&:&UTQY #04T3OT(<6)O/D,N\9>!ZO"Z\ZD
MZDU6;,1R@5O&$@W15ANW3OAC0HTQ=L:K<T8E/1N:G(*P#G?D P)S:O*17,X=
M-% ,X:[ E4[D6C;U?N+I"=[2C]EZ#K'4\875Y_(N#?-T75%7:9AX1 &AV!]1
M&B:),A&KSO9AKSUFGF6UGBYH%LXPV33"K;<D$V>0LG.^$%H]+Q-[*.,\DQ>A
M2I .]G,!VPP\#U('.=>=:=2=2$G4"9 A@ 0"QGA;@%&F9IM8'6Q4M2JKE5<J
MLPN>6%LBN0K1C=S"25$Y4%HYV,-PZ@*IL'1+!SUFDL%W;O3*K[IZN&?G--!%
MY-73^Z$Y;9"E(" ]"X(%HWHO?3VX^^/*5EN5)?EPC#!"_>L +I-A$N35L?J&
MY-+,TY@!E@HSK&&$\ )UYUIU)U)U)<>$O43SC(%X,.='AS8G,)PZK6D6!;-4
M33XSD5->04'+.KU(* WWIH>=_..V0S#*?<:'FS&1D]_,#N#/[K.B2;D4\E]=
M,SI'7@:S66&8&0-YP.LVGU+VXVZ.U\P^C<)KR']0P1B&G8S]#-\>=_<V("_8
MT=ALDT\S-K=\@U?-XIUYUYUIU9U)U)[A:WV-J!DZK^PM'I-'G^(=0[WPYV71
MI<9W5TCG9H31XLR8]@&FFAH#.2J> ,:(NR4Q++54O<UJ+?:1^Q+S49U C"%F
M## K$ ; "+,B(CP0^+DV%(K?MP3@I?+CPPKV #66L%K6QS(@XY]DOJJU?&2M
MNAPTO*R!LMW6#G*V\R*01SY.XQ&Q-X9H4-:&(Z>F6D[A&T[6L!EI'!W3?#AE
MJ7J_J(-$SHWPP02_?P@&]3*Y/\B;P1V747O^HDZ\Z\ZLZDZD.@;-3O6A%17[
M'QH'JE%H$M&P%^'*R#+E;7=R\:A'5%.!NNFT"[1.J7<P4:!= 8#!-/C%6!4"
MPH^-%F^.PH89QX$H"@!@X9(6>BZ8O)U6@%R[(7=O:'&BQ]F-RU H "JM &55
MT"*NZ5UAP1/6Z6L4M/Q!E&5XH*JJ$U%^VNOC0YRY$TE5JGMX^K6(%VD6";V5
MFMHD<+]2' 7;BHF$A-4K%(S_ %L-1)V#EIK>"C2"<R*HKGJZMNUR-D=1-/ =
M9I9D[_\ 'PRIG#"O."Y6S"\$LBHT#T)+0V3=P[HY(09P*E%,TU",G6[Y EW6
M>4/_ $DFDSJ1W!EZ3H7KE]"8S9ZOT/>X" #8 >AB6W,&Z#%VN(-UB]9M;L]%
MB#H?1DJVU=K,4/5&(T.-B5\,<R:GN[:I6PQ%-_ZZ&B;$'1,NP^+3336@;RM=
MFNYWO?-6AJK*-Y>84OD?V<W+K0-0G>TRZ%+15Q'CYM2$ND4O ].*:ZJCMU*M
M, !M[!3#@+75&6O:-5]3"O:.$5,7OP8I)-46L>C.MW2(2U*PG5D##=7OO%A6
M\MH5"7.?8X0N:P@@;J#PH^1<AN.C@WPZSR4O0'ZX^P7#8[(\G%-.M2=TWS=#
M6Q57@E1 G_JJ&&,6@\49>&MR:KVXUH32FR#&;LM>L.O)#CLK&.F*.R@:4T<<
M0(5N_$ZLZD'C'\X@ ZQ,C#P-"FC$:@K4?LM>4EAF3(UV2MT@S>!=??$)S(N9
M83&$P YA?ED(TT7E0D*@  )@*^L@>UZ9HU3#]?W%13KR-4@5H"+O_&9B-W0E
M*KHYI9NJ-X/"6SYEQ;&VQ$+&64$C5Z?K7AIZ'"V&61=X?PM@QF:)NF^;Y25Z
M%>CQ]4"K4!4Y,DKWISZY, 7=&_!NAW,R0,!8MI;6D$"%6Y8YX1]HTIH<#?1&
M_B;N'8S.JM>F*C87@V.-@(J0!;LASJ+SN 5R,TA[)H$TYI<-4X@6Q&YM#D;$
MZLZLZL15'+2 .OW-%-_OUHT:JERVF_,V>#?-TJ5R7Y^C^CM/+I2[0<SGCE-1
M3HB\TY8EEM)'O"5YB# T!590:1.D5RQ(3R$W80-B-G4Y79^F)FQMOQ#XPV,C
M-":$TH2UUS%Q)"K*ALFMW81=]PJ 1G9B^>K@?-*DUZOCY: ZQF@E#:_J(ST.
MLT)H<6$1]G=U\C7@]3@DX[CO,PH911 >M[80-==+H@5]^Q6=T";>5O.;P[X7
M2!)\!C@ &L:_:\-&G"AR*1E 43\!$) ZD<CPV0%  +4X #*K'G4T.>5CS:?:
M8#RC@#6SCTY";9U]>?#3Z[/5O=@/S2X5E.Y<]S%+IIAW( C$3@E  %J7 !#E
MQPBJY^!WOJL)"[ !;[4;/!ZLT!#8;Z =5-0[)^CH,'2:?&*9K^ 'EJ]"7)$4
MYK*SJ2QL['-!D6@%LV:#QK.7"/,$LE6VU"I8XEL*#?\  $-RD$8K VP)J,0=
M<X>FA @FB"6)!#:3UZJZ"046:,E=ZH:W]B%O;9#7/38ZP"",#1-)5Y+&6A40
M$=6]\B'\5 P+2!5EVJ%WI*[K<Q$>DU@B]A4OHYAIV5.[GH;]M6@ !0  .0&"
M5W&0'P$P]AF7 M49JT8#7W#I2=3@]7@H&HYY;GZ=YH8FAPS!PY;M +0^!2QW
MEG6)-N.K-B]=ZS+K&HP=>7V+XV7C-:T.5)I4&MO^#4B*OVF18LA+G4(]F0#O
MKZQP8.^.#AG'@2D+ .29\Z0+78!*\O).LR[I 43D)KDV;U+XM<'?@30BP0TB
MU-2:N93>9_96FV7+Z.6.#U>"BB\1?E-*:/$&$V[#"U+5Y@1(5L!JU]*UJO(5
MH."A8X Z54PK0T>!4<W1X-E*  4$<@K%:!2E74-N%8L7=:@LTM!'%N,&Z)<E
M%"RT%X:N9R!R'0U 8,LPB*KK*V-7OE#,'LJ]^Y:-1Z:_?E[ZN[T5A'-*%SFJ
MS;X0'!:4>G>&#AU7-?,T&B]U4/HUM^ G2288SMA1L2Q'4342=2=2%M=CQUFE
M-+AFS_\ N]MH*N5 ,N)H%(!EI4@!Y(6E_2JN&KS)O &MLU(0)2T,*B:E(5M5
MH0;R.'9[(K0;,4,%6*3"GFC&R\83DET4U?*NE!$=(^8O35^M934>MLJ:%B:=
MJ$2D"\%^LZD=!OP&#NB5C>CLVF FI^&[*"4W-3,ULP&M2SL=DX[O3A>V:GM=
MYB>OM(.S(HAEHM1TUN,8,*.R>#M[Y:FE-'BVHAX58MNSHR.Y3ZE02?QDA+'%
M'5R5A4HG>?GL0TWTXV^*I'*78(FH5+)$GN!6G!)%PSQGC_&PE*U3;E:/S9;V
M1%JK0@A)CJ+BAFHN[=I"]E+G@:"S5X/K8EW1D1<XW^!E$4+D50/>1!N:)AV#
MJ]W0E P H.036FK-7,NC62J8TL5A#5EF8,1KB!9E!:92X*%M #LEB;?VF)SZ
MH7PP4]EX)]M,#KHZ33FEP#>Z<7_FEO83[3)SARQBY)*BJ_0?WR"UWL0+*=)1
MFRY.W\E@)B*T>:1U+K.0H(EUK8XN57)S)%D>  #4)GO;,+FUB&>0555J"R46
M==M4V&D<*45 [PK6ZS$H%EA:5591BML!;L"&*B?W9U5Y (*K12/P#U[99=FN
MJN?HE=&(YN'LG/6^%K37S-7,V]*?)Z\UT,-[:?JWJ2;684[46*C/" A?)E%5
M<O.+58F%+NFE!V,O;_A"BIEB$K^02Z%89#DIU"UW'*4$IOWFIF:V8SHU-K$'
M!4?>*7YE0^?=F_\ *3.A+2.+L;";H@&P37E=S4S,I\G>_0M1/##VC1H -VK8
MT,!^9U<E%?*7R::\'6E=YFKF8N!FUX5\W=N[\SHW8UV#R>HVQ22D9J9FMF*=
MA;6BM]69Z'I*"PIU1NI^8W5^&]&@;XPW6)AS!9@=)ZS;OP]?,ULP[DLFZJ)4
M\Z+M#KUL="?)%=*WT_,<Q_3!B9CD7/?R<#6\8FOF:F971MW;L<=[0=.\>#M%
M9ZD<K5GO #( #T2S\MH59UT<PZ*$1<LV4K1W591<U,S6S#&+5GM_L5"8  .0
M;1:31,A7FKRS'-K^68]%'2_Y.'7<ULR@*  5*T &56.C-":$<ULQD=/T_EN<
M1'-!Y8"S135GN! 37S-0O,#JNB'T5 *$S?5;VD'KW!!^ >".((I,NHBNWY8*
M;ET!R&[8!:=(>Q9@&*343!:O6Z"(5&XTT*<_*PZ1>7\LT UC(=.2DOA?!)XU
M[358<SD)P1:2U=?+T11VT/5Z?EE MP&5= CL+FG+3?4-@UR6DT17PK=WA*Y0
M"]5')9IEP&K WP&J673C=F0+QM"JX)SK7Y($W*@&W7TSD.L%H:*:L:I@NP8'
M55_*Z4#[%"WDQG*KFA%@\HY8!9Q0SR<4ASRC=I794/?/6ZY8*Y1?C,4/<XK4
M9J,=W<O\L(=.X6/SP\)B(M.%1P];,MY +%WT#+1KS_+X*NG '?<\N":$RJ:3
M4E-S5S!UN%M4^_Y=,7V\T.DU+2G7@M*4O4/3D2N57*KS-7,T7:BM&CG'W4I?
MY==54]8;D<!T9FE$=>G7K!U!EE1*[E5YFMF-B]"ZQJ\*TLZC2_F; ES)&B'P
M1JI-EU7OJ+UR34FK-7,47F\J[.=G-$"RF_0NAS=C89JV/S*W:? KR 5Z!IF5
MRJY7>9JYB80H!:U(YKCQA>GYE95QK.B]N^8<F4WSFO-::V9C^#[# XE;YNF@
M ;RA(=0!0?F" J/L[>[R-V7KHM[MYV<WS)FI*;S*;S,YPXEP!S5C V 3JY6"
MQ[#N_F:[-$'6\*4WXNKO,YJ7.@7#5S[MU+Z3P9C\P(P5<JFT=P.7D;QMK K7
M4'5$IFIF:V8:%+4=]EN6T.K!-:< %!Z3H&YX#0?EP3/*4!:' ! XI>6*#I;+
MEY&TUI3?C,HO,:IO"M30?P8OZL>)U&]![?R]5-()K5Y%9P6M-?,U<RBRVL/9
MZ< \':;-=.,]Y&OY=!LZ[EERZU<IOWFIF:V8F--,B$1@1+=T(JC2CTB4,*'N
M&S7M"-T(7K0O/Y:UIMS+8=-NK%=A"((@PB.1&47F5_$T*M;+CT(!H+I5*738
M':K"1T9H30\I;.UWR!&F# :'Y>]>6M/WG%ENL+1$]=F,_P"L4@=0YP!B9-'.
M7"QTJV:'Q@D;M[\(\$M;+D&,@V*2]7YP_5PY;GNR\)J*-I%BMZAR:EV_"\B.
MU/-Z.8O.I*;FL!=,RF^5<KJN7_\ Q7M+0R"%,CVPU @RJ*IMHIF3 Q*:D.D
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M>SE B'X4Z[C8:FE(!M*ZN5YVJIZRWL(+'<$-+BYI'11K#HNQ J^N415K6Y^
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M#(E;8+"<'X;_ 'S,J0 6QS40WX%6CB"<DX,A4N:&TLB0;A4EK!CT''J?!B+
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MF1SDQ9 ,H$%BG>TE/= JKDW?$ 03<;_*O@*U1B%8]0=791:7+R5*C T\[OT
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MN$(H@DL4E0=[$!0<*75583UH195QQ_V6_K J%CFOI,?]DGZ0*A09J%&\?DH
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M5BD.[A@92I&2MLLLTDDQY9+6,]S:[M18XA:C4Y**V+.(H6@)=>H>*U,-Q6C
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M#['Q7#3)/6%W_P!E^;GOWQ]!](7GA?!<N<F&""!"'/I]#?\ 0_R7N+\6C:D
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M ,R'_]H # ,!  (1 Q$  !
M        2 "0""                         2002220
M           0" 202                         " 2  20
M              0 0" 2
M                                                #SK"/MD
M                  !V<     #0                     3$ .0];C "
M                   #"@9G8+*4_0 3@                 "(#([1/KJ8
M8C@(                  $!6*)#/PD :" <@               "<1R1J;_
M /80P%FL 8               R %,26.9AN$0&4[@               ' I7
M&Q;?/@" D0>O#@               D-4VQ00MUB ROBY%P            !@
MDO>VP=:L$=%B#US@%             ( EN&"8C'*L0N5\3<X,
M P 96B6RZEDC@D0>N=O88             ;HP27\AX=*$0GB;CL%8
M    ("JPVSIST:T@"'TWKM,#           ' IB.VY#<JITB)\3<=P88
M        #ZPR&/!$', #[6 =K""           H PQM"1X=Q"E5FE*3N @0
M         # %VF7)TLTY@&:=8YM0& @          @!*-2_K8.,$JG\+8UP
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M  !! .<#=F%>6\P![/G+!P0        ) ! ) VK9\TAQ @=[:73_ $!@
M          -^6_)==@6D7>7Q0Y(              !?]&_RO6225[E@:VX
M             ;P%[D5C.Z.=KK:W                 =AM_P YO@[^P<-
M@$$                 !1?M[H#<]] $$ D$@                _\ VD0Z
M4ZL ( ( )                !&>(2R%!H@ )!)!)                .+^
M:  -%0                      !6TN                           !
M_P"1\                            U\H
M   #/[.                           !#R2<
M      4_Q-P                          -]:7?
M         \0*2\                          ;VF8%@
M           !(47S0                         ";63=<
M              +"R7P                          "Z&OA@
M                 +AFP\                          "U^]O@
M                    2O\ FL                           #/!=
M                         Q?<                            OZR@
M                            \,@                           %K
M]/                           %?V/P
M ' !\                           -_L_8
M   ">0 3                           ,% PT
M       T@V%                             #_@
M
M
M           $       @$$    D$@ @            @DD@@  @@D@@DD$$@
M@@D$          @ $D$DD @ $D @$DDD$  $         $@@D$D D @$D@ D
M@$ @ D$@                                         @    @
M                  @$ @@@$  $@$D@$$@ $  @$$D D    $$ D D@   D
M@@D@D$D @ $ D$ @@    @@@D@     DD $@DD $ @@@@ DD     $D$$ DD
M D @$@ $ @ @ $@$D@ @                                  $
M   D                      D$D@$D $$@$D$@@$ @$   $@   D@  $@
MDD @   D@$@@@ @@    $$ D$D@  @$@DD $   D D@$D$D@ D@ @$ $DD
M    $ @
M                                 '__V@ ( 0$# 3\0_P#FF\ZK"1#$
MIXV"EBP0WL/F;CG!:)<+Y2!\1\BUNY&4C2X(^S,G$*31B,X7U=E;IEXEE>8"
M(7#R[:7,"<$/7MX'GK3F.*_'SZ.VC_)ZT?1"]:NXPX!:"-F>Z5JVQD=/ ?T
M[C#;.J '@UQ! H0P&J$2:FB9&YG&L"%3J#NT+P!( %%(G=;LPT6U;4D/*J2]
M9$@UAV$%"@?S1B,"][2+7[\M J2]@%PQU8U08 '8HE5@9K69\)>T"JHA$80;
M1+HR-?1/D88!<VLL>H.9.2*=*'%4WM""C2$! _,6OWX.1-X3LQNJ;O.4">I
M5'XA+<6(YJ\\"5K*4K "?S2VQRG21UU2HD^S!6>2#,"M0YRPV(,D6@J$ )(4
M@"Q;K^:M?@924WX%T Y(E7)3^BEF+2[/JJEEM>+*6G%YEI-'J[!BFIP829'K
MAQ\^$048";&^"!D<[S$A1;BEV\5I#7P3F-@WZ#IW>G+_ /&8,I*;\"Z <FF0
MT22B':SDB9G50@O.+C77F*R89D%Q*T'QU"[F1<[?#R@H8" :(&;.!BB^+6SK
MJL(=(LKK-X,\@($)%I%O"KJRCG-5>\>1QD%9=3Z]"56B5(X!$8&4X*N4P%9I
MTP6R46%F<TFC N(Y0&+)FAJ*7]K-R#"H7\B2/SL@!K3FVH[1,Y403H"+DO*-
M&.M2:T+5U=8NHB9R"@M"U2Y?^;H4$;4HP_EH#4BM10C2PL+;&A34QX%<-#EK
M%0L#@M01!$1+$R(Z(\OQF,(3H(4H"Q:9H!1$A4[XDHCL[/&#%AO1?-+T# 70
M8,<43.0 %H4 "U=(G1VTE1;+0$7:AF4B-T4C8#C-P(TM@UDJFX# 6(8BI&6T
M("EHPMDL(-#3.J5^KASB1A):<ZT*-&<D>!PS4U[7WH#..28>4;L,\,N@J[U*
MSA]1'J:R*.1R9;!6U@>IS54FQ.7T,F8NNG40>J%\O02L\^5  (@ M&%M^(/_
M !2/J\!+5P$T\*LIN4:_  !1C3.B#*N)OL9< <;S&"+S6$)AF(C%B!)$*LL0
M7Y(ZH%,R='(!=5%XF QK\2ZO0_;-#'*OUTFEXQ_LTO%^&:!X\+-WR)H^/%RL
M/5C2HG:6D.T1$FH&/'X#!P C;!5[FH<",#GQ0,P/"I::P!PC";"#Q59;*AJU
M +4X4)2&.)K!86E1$5%$7^&+8N4KA<I N"EJA0]A9H$7ZB*:3P''2SA7QN>.
M6\N-&"B"8'LR#!R.OOW:_;9V5AJR@,<O\Z2]/&/DN65UP?W]R@,=":'CO-#Q
MVFGX\43IZZ=IE.GA9I\O%3^W\)S]I<^/&"7IZ?[+0=OZBUF5=H=HU6!8)!;M
M5H=::#U$JA9AE1'-B(Y.%G=E:.B4&E&'48/5"5W4F+2M9++^$$%%+90"P)*;
M+6V!T^2P:L J@6"ZXV 2G'5VB3[*VA.T%DJV%,2+L9 ='K\?&9=6.W;_ %F(
MF,QK\;^LTO3^^\T,=IH>.\T,31/'?SE>?(\:31\>+E8>K-/QE_DK#QVZ9E1[
M'[9C[^&6,, 40@HJK_0 !@I8@S=JQ[5'&6@F-2@!OF(E('"(V,(M2141@#PO
M(X*_@E2#8L6#8E#&K*VP9U-0)VO.;;V]17@H% "JH !:JX )RB'T:B 6$W;@
MB*Y^XB6E?:N5FCU\,T^N/[*@Q+ZFA1R#QIUFACH30\9_R:'CMUFGX\43?K7!
MVFB<OG>7IT^)_1_1-._'.7/CQ@EZ=,?[/Y':>Y-(]>T][XA(8\H@D4(@C$%<
M-L;HC0@6,)7Q+YS"D"QK0!ZW7X!EWIL9='N2AE(L+2S$5UZ?!52QR?&QVUV^
MZL50O-8-C25U=/\ QJ:97)?UUP31QK7CE+4QX^<S2F(QK\;^L_E_?>:'3Q[L
MT/?]S2Q-,\=7UF_6F#O,)*0]7^31\>*E8>.W3,_D=]Y6=\?V7/"N\_C_ &'>
M'%\X-#UC,:U]H:NF@9;R-(B)9D<B:)!1$41L3")HCSC6PM;NZV5L>;1:'WJ)
MG( "T* !EC%"CP9@8O!LH-)."45!UM,/&C1,<J@4Z^-\RNEWS_/5FCC+X9IO
ME-#$O3T_LT*.0>.AF5!Z?V:'C/Q@FAXQMUFGX_S!-/'0\:S3.7SO+TZ>#KF?
MV_A-/QWGBZS.'+PL_@<"ZCQ4]SX@T(/0@\=(,=XH(T.!1OJ<AEUMTX:Y=&%2
M!3.;'1$CM=%,NJ"A?5JN5+]X!S,B!EK+$UM0XK>\EU 8GXY@3P"=O[<,+?I4
MP  TGF^+FCCKVY>A-'':7IXQ*PQX^,$Q&-<':9CT.^_O-#IX.N6:'CO-+$T3
MQU]Y7FM,'>:/CO*0.>6:/C/^2L#G\;>LJ\OF5'5Q_9F.G"]SX_V'>'?G!H0>
M.D(P,H$$0L0I$=$ER83E.'MM3S3W/ 6]\NRRZA@BE&+45DX=:I<-*TY-\_=H
M +R!E^X4Q7>(KQUVJ:+2[7HG  H 4  "U5P 3%L8_M>/#"B!!52]_&Y,9C7+
MVY<LLT<9?'<FCUP>-)H8\?.67UZ?V:'D']_<J#T_LT/&?C!-#QXS-+Q_F#,W
M_(\=IHG+Y_R7IX[3Q?!/]_&LN;\=)F#E\RCX.!=1XJ8._P 0:$'M![_$&.\#
M:!1'6O-M0(1&^ *E(TS%MA160#1 V "P6.CM;E4RUUH73"^[R#;>%\:G.9:-
MQ&55/K-&LM0*:ID"NK^NDTGFS3\K_1-'QW:F<]/[*PQX^,$Q'IY;]9F,=#OO
MTFATFAX_Q_R:&/&QSFB;N/[XZ2NNFD\/S*0ZZ]II^.Q*@.?CW95GQ;/'\S(=
M.%[GQ##OS@V@\=(0[P6\$V1-0+)H06H:0>%CTNNH- ;C0,6&7AT@&7; ,P(?
M<I+0Z&=M#&6YDKY?N-EX=58 #!Q%8O:E)"B(U<LFDO=FG9U>TT>?CS,33QR#
MQI-#'+QSEU>G]FA70/&O6*G*;;K!F!2 %N(.];.E% K2C,/6[I<I$$J3:+EI
MXTIC"K&4%U$R.:R'3- )AFB<OG_)>Q>Y('H2(IEV@7X?'2>+XZ3,'+YE'P3
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MB@*S#EZ>TKK$JK$4LOSI7KLF$*C9' *1-WE+E,U:K<$J!AD2"H+5/&6!$AD
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MZHI2P1#&TUO:,8M4P%E6[T,QLR.F6T.E-GS2-1X33 [,$O4AHF\*^P@@P+:
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MW-]7)<H-+7E_[-1*"M8<@MM6@,NDHZ0'5N0T4!<A&LRQ3A016(L+E</YBGO
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M'#D6CV_+4 ( L8+G!E2H*U#+M5RPN)&405 !K=WV*N*5H=P64E-_Y[%EZK,
M>&+= <H!Z3(V&E.8\N7B]Y>9F:,=2&*C>H@O5T.N714      % &  P ?E4"
M %  %JK@ E23KU7(TX5@7,$HP]]5WSZXCPZ_K/S*/055L@M N56H4"@!40 "
MU5P 2Y;=B.@6!76-F82%6(]'=$$'DIPO?)I- E0 3'2V1V.WNN T%1G1U_+
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M5MZ1K@N' E:OO$P 1*P@7EUE=FM%9"$!IT%DG+;*I@#J5)*ABJ^ 50(?*!,
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M%PS&I0D:<)L@50"5G$ &"CP!!.@@"CP3GXPUDXL3WRX"3:A.;.B^4*FH)7D
M4LY >C*MD-*RJU&O\*#,7 .\8:1NX"='YLN@W-A-7"<&R7@QA?M8+YH !#2D
MX3$CAE"2B]93V6,2Q%<8=$-**UNS15@T6! #-4XKIIHAU1P6@HEVE?! SPLB
MTG FW&3*U[48"O*)%X 91VDA?S=;>#@1+BK6N8\OF4L]HM!\.&N 3AIIP1/K
M-T+Q!@'06"H@I='($@T1,P&&-<;M5"XR2 @U6EBF=!0-W7B+;GD5@AA!W58
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MPO=(0!F*)A)HND:9RHRA?ELQS4\)VV6UE2YG]4<#8+)@,*!4J253%5]0(HS
M6VEL6!<P@6%@N%W%%JDO9 4&H<%/6HJ$R(SEW$04V)"03,S>MYB!?DA(^A2%
MB21ML^F<$D?1T<#-&*#)IB MNFL!9!!R:7!"D7V8Y(3-"^VED)^8.ZE H0H'
MAHR;7*\G1C#D)M&-6:LU#D&KG7269'8\B#-HAGT22#Y00TEVFES2!FZP[#7
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MQUE\HX=ES3P',6K@7M0!]#% B"(HQR(-"@LWS-*VU=3BCHE$>0'%D6;PMZA
M;  B=G!>6K1>(@&V0'0AEO@YASF[";41A.=:L5\,X)@,N0S_ )[S3]$2VKA
MX1;P3\ 0J!)(!JM ;U$ O$&8P1$&]A%4^4((%TT\[$ZGL&T$(.YL\DU'F()R
ME=U[N_A[KQPK1GFY>R'E]O0<"S8%'R0MV5(""-C+^!>SPR33Q]?!A,W+L6D.
MIHB(Y$08?!*92Q7.4"".(UJ)1&^C"3DB9J.IF&X(DI;$@PG,%@@M*T(1>#+@
MAQEDF@&HLEH"_K5BJ(# MH&@  !%LJ<M#TTA H<0]"6\ B(6(;52LH5&'?7
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MU(T^FWGI,O#*^?&Z#D<%HBMOA54WG2=9E[%6)?*P2 ]5!/<)BKF@5C7 +!*
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6G :.%3TAP&_YQ!*9<TAS_P#\R'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>mgnx-20221231_g5.jpg
<TEXT>
begin 644 mgnx-20221231_g5.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IO:&XN4V-A
M;&QO;@    60 P "    %   $*:0!  "    %   $+J2D0 "     S(V  "2
MD@ "     S(V  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_P"%U>(O^?+2_P#OU)_\<KSRDS1[6?</['R__GTCT3_A=7B+_GRTO_OU)_\
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M$2[41>BBNVE1Y'S7N?GN<9S];I>P47%IZ_(GHHHKI/E@HHHH **** "C%%%
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MQ'Q9\27GACP3]JT^\ALI9[J&W:XEB\WRD=L.P3^(@9.#[T >>Z=8^"];\9:
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M=!Y([B*,\.KQG!_$9%=W8Z[I>HQJUG?029[!QD?A04:%%&110 4444 %%%%
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MVE)#M=I=8U+:5LEXR%7J6/Y<5Z+5/5=)L-;T]['5[2*\M7(+0S+N5L'(X^M
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MO"R7>HWNI6D[PW-W:K;2IG"2A6R">^<9'T-8&G>"CILS7,]M:Q1D%72-5_>
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@!&&88_E6I110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>mgnx-20221231_g6.jpg
<TEXT>
begin 644 mgnx-20221231_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN=^*_P 7
M?A9\"? .H?%3XT_$71/"GAK28O,U+7?$.IQ6EI;+G WRRL%!)( &<DD 9) K
MY\\$_P#!:3_@FQ\0=*;Q3X;_ &@;T>&TE,<GC;4OA_KUCX=0AMI)UBYL8[ *
M#P6,^T>M 'U+17)_!OXZ_!W]H;PG-X\^!GQ(TGQ9H<.IW&GG6M"NUN+22X@;
M9*D<R924*V5+(67((SD&NLH **** "BBB@ HHHH **** "BO&_A1_P %!/V-
MOCC^TYXS_8V^%'QYTG6OB9\/H&F\7>%;:&=9;%%D2.0B1XQ%,8Y)(TD$3N8W
M<*X4G%>R4 %%%% !1110 4444 %%<!^T?^U-^SY^R+X!C^)O[1WQ2T[PKH]Q
MJ$6GV,U[ODFOKR4D1VMM!$KS7,[8)$42.Y"D@8!(P?V5_P!N_P#91_;5NO%V
ME_LV?%A->U'P#K;:/XUT6[T:]TW4-$O0\B&&YM+Z&&>([X9E!9 "T4@!)1@
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M:%Y8;9I0))(T*!W5>I53)&"1P"ZYZBIJ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH45_I/AW7=/,>J3:;9ZM:W)NY;49DMB]M;O/Y$@$T:$"1$<-&OXK_MB_M:?
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M'DFII_P@S^-I[DS/96L=R8IIUL5:*29)%$2I%+N9E'4D#LOVM_\ @JUXN_9
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MS+XSTSXI^'[K2/!MIX'A\5ZG;:O#);Z1)!XKO[F9+B16*PM'#(DC!B"JL"<
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MX&\4'4?'.A:>XFO_  TMS:['-[#&2T36TT0C<]-LPE4F,[Z^IO\ @G%\<?\
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M'!!J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^'M#U;Q#?7KS6^AQ.^J1Z=:R7<\&V)92GDP*\K/Y;*PC52Y#K@'(SYE^R/\
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M +07,<<J9QD;E&001D$$@&C;V]O9VZ6EI D442!8XXU"JB@8  '  ]*?110
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MOC'-^SSKW[0L>M>.K4L+[PCX"\,:IXGU&R92 RSP:/:W3V[*2,K(%(R,@9H
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M_9(^&T_QA_:&\92>'?"UG(J7^NOI-W<VUEN(56G>WBD$"%B%#R;5+,JYRP!
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M%\._M&>(_P#@H?\ L\^$_B)I=KJ_Q5\.RV/A68WRAKB.X.OP?:X@#NDCC-W
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M@\[<X"H@GE^3A2GZA:SK6C^'-)N=?\0ZM;6%A90-->7M[.L4,$2C+.[L0JJ
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M(.IZOHW_  DLSZ!X1LH;>>:ZNY;L6R37:_Z+=+#&L,32^22QARH;>_X)Q?\
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MB+,/,7=<VZY7/,\8ZNN0#];O^"=?_!;'X+?MH?\ !,?Q#_P4B^*'A=O &E>
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M)EV^]?\ !-3X]_\ !&/_ (*":O\ "+XJ?!+X#2>*/CMHMK9WNIV-S!JMS<^
MKB-=UU=37=T[00P+*K"(JY,[21*JY+[ #O?C-_P6X^)GBGQ9^TII'[!/[/\
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MVIZS;ZU ]I:+-KFI3Q-),K%$#0SPR@D@&.:-_NL"?1?'?PFUG]BK_@[BT_\
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M^_N[9;L6;6;6B)"\5M)!+(?.;BZ@V[MS;)?^"C0#?\$]OCNK $'X,^*,@_\
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ML=366WB60S)?6J^=$5$<C.I0JOF5^:OA3X&>/OVNO^#.K0OAS\!;"ZUSQ/\
M#3QS>>(/$/AC3H'>\>T76-0E8+$!E\6UVMR,9W+$VW+#%?0W_!(_X]?\$9?V
MYOV=O@5X$UKX"2>-/VA?!UGI=A)X-N[?5;NXTO4+/R(I]:261FM;2TQ"MVTH
M=0H"PA6EV1, >_\ [6'_  7@^,7[$G_!3KP7^P'^TC^R3X7\/^%O'^IV@\.?
M%V;XCS_V?)87$IA6>2(Z</*D24>5)&TFV,E7+^6PD/V#^Q3\?OCU^TKX'OOB
MM\4/@_X;\+>&;_4KD> ;S1O%5QJ$VO:4D[I;ZH\<MG;BVAN8E2>)-SL8Y4+;
M2<5^:W_!S%HW[.O_  4D^$/B+X!_ _XD>!-1^)'[.GAJ]^(/B/5Y_$< ?3;+
M'D2:&F'^:YNMGFLA_P!4;*W5PK7,6?H[_@W+_P""IOA?_@HO^P9X>\,^,/&-
MG)\5OAQI\>A^-M*DN%%U=Q0*L=MJ@CSN:.:+R][@;1.LJ\#;D _06BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ,R_\%^#M4U^V\5ZGX3TRYU2R7;9ZE/81
MO<0#GA)"-RCD]".IK3HHH *^ O\ @K]_P3D^(W[<_P"T%\'?%GC7X"^'?C%\
M%O!,.IMXL^%W]N1Z)KLNHW$>R&\M=0/EL\*A4WVGVFV1VC1G,F%"??M% 'Y)
M>&_^#>S]GG6/VJO@O\;_ -FK]A&__9NMOAA\1;'Q3XFUS6/B:VK:AKL-FWG1
M:9;V<%]?0(LDZQ&2X:>)TC5U"2;QM_6VBB@ HHHH *BAL+&WNIKZ"RB2:XV^
M?,D8#2;1A=Q')P.!GI4M% $5G8V6G0_9]/LXH(R[,8X8PJ[F.2<#N222>Y-4
M]/\ "'A/2-:N_$FE>&-.M=1O\?;K^WLHTGN<=/,< ,_0=2:T:* "BBB@#,TW
MP7X.T;7+OQ/H_A/3+34K_P#X_M0MK"..>YYS^\D4!GY'<FM.BB@#FM;^#/P?
M\2Z^/%?B/X4>&M0U0'(U*]T*WEN!T_Y:,A;L._85TD<:1((HD"JH 55& !Z4
MM% &;>>#O".H^(+?Q9J'A;39]5LT*6FIS6,;7$"G/RI(1N4<G@'N:TJ** "B
MBB@"AXB\*^&/&%@-*\6^'+#5+42K(+;4;-)XPXZ-M<$9&>#5IK"Q>**%[.(I
M P,*&,8C(& 5'; Z8J6B@#/T#PKX8\)6TUIX4\-:?ID4\[331:?9I LDIZNP
M0 %C@9)YXKRS]GC]EJ7X:_%WQU^TU\1M2TZ_\??$*&PL]0_L>U,5CH^E67G-
M:Z;:[_GD"RW-S-+.^UIYIV;9$HCBC]CHH **** "BBB@#.MO"'A.R\0S^+;/
MPQIT6JW48CNM3BLHUN)D&,*T@&YAP.">PJP^BZ/+JT>OR:3;-?Q0-#%>M IF
M2)B"R!\;@I(!(S@D"K-% 'C?A?\ 9;FO?VN;W]L3XI:CIUSK6G^'KKPWX%TC
M2K8K!I&F7%Q%+<W$LC_-<7MT;6TWOM1(HX$A0-^\FE]DHHH AM-.T^P:5[&Q
MAA,\IDG,407S'/5FQU)]3S4U%% !6;IG@[PCHNLWGB+1O"NFVFH:@0;^_M;&
M..:Y/7]XZ@,_XDUI44 %%%% $5[8V6I6DFGZC9Q7$$R%)H)XPZ.IZ@@\$>QH
MN["QO_+%]913>3*)8O-C#;''1AGH1V(YJ6B@")K&R>\747LXC<)&42<QC>JD
M@E0W4 D#CVJC=>"_!U]J-IK%[X3TR:[L)7EL+J6PC:2VD=BSO&Q&49B221@D
MDDUIT4 5]6TC2M>TV;1M<TRWO;.YC*7%K=PK)'*IZJRL"&'L:ATSPSX;T1HG
MT;P_8VA@M%M8#:VB1F.!3E8EV@80$DA1P,]*O44 1/86,MY'J,ME$UQ$C)%.
MT8+HK8W -U .!D=\"B&QLK>YFO+>SB2:X*F>5(P&DP,#<1R<#@9Z5+10!Y'^
MV=\.]4\5?LY?$2V^&'P<3Q-XV\1>!-3T'25LC8VUU(]S:RPQJ]S=21*D(=U+
M?.2!DJK'@_&O_!LI^P?^UW_P3;_9"\:?LV_M=?!P^']4U+XD7/B73-3L_$&G
MW]I<6\VGZ?:^3FWG>1)5:S=CN0+M=<,3D#])J* "L7Q?\-OAU\01"OCWP#HN
MMBW;=;C5]*AN?*.0<KYBG;R >.XK:HH BL;&RTRSBT[3;.*WMX(PD,$$81(U
M P%51P /051U[P7X.\57-K>>*/">F:E-82>98RW]A',UN_!W(7!*'@<C'05I
MT4 %%%% !7Y9?\'/O_!.G]M/_@IE\)_AE\'OV0/@JNOR^&O$5UK.LZO?^)-.
ML+:)7@,"0*+B=97DR2Q(38%Q\Q)('ZFT4 <3\#_#T8\#Z-XO\2_"1?"WBF?1
M+>UUBWO4LY+Z,QHJ>7)<6LDJ2+\@*XD8;=N0#E1UNL:-I'B'3)M%U_2K:^L[
ME-EQ:7D"RQ2KZ,K AA[$59HH JZ-HFB^'-,AT3P]I%K865NNVWM+*W6**(9S
MA44 *,GL*K0>"_!UKK,/B.V\)Z9'J%M:BUM[^.PC$T4 &!$K@;E3_9!Q[5IT
M4 %0W6G:??20S7MC#,]O+YENTL08Q/@C<I/W3@D9'K4U% %37- T+Q/I<NA^
M)=%M-0LIP!/9WULLT4@!R-R."#R >1VJ33=-T[1K"'2M(L(+6UMXQ';VUM$$
MCB0<!550 H'H*GHH **** "BBB@#)_X0+P,+F^O1X+TGSM4DCDU.7^SHMUV\
M9W(TIVYD*D @MG!&16M110!FZ!X.\(^%)+J7PMX5TW36OIO-O6T^QCA-Q)S\
M[[ -[<GDY/-:5%% !45Y96>HVKV.H6D4\,J[9(9HPRN/0@\$5+10!#-I]A<M
M"]Q8PR&V??;EX@3$V",KG[IP2,CL:FHHH *H:QX6\,>(;JSOM?\ #EA?3Z=/
MYVGS7EFDKVTG'SQE@2C<#D8/%7Z* (+#3--TJ.2'2].@MDEG>:5;>%4#R.Q9
MW( Y9B22>I)R:GHHH AMM.T^SFFN;.QABDN7#W$D<05I6  #,1]XX &3V%34
M44 %9MEX.\(Z;K]SXKT[PMIL&J7B!+O4H;&-+B=>.'D W,.!P3V%:5% !111
M0!%?6-EJ=E-INI6<5Q;W$317%O/&'25&&&5E/# @D$'@@T7EA8ZC$(-0LHIT
M6175)HPP#*<JV#W! (/8U+10!%)8V4MW'?RV<33PJRPS-&"Z!L;@#U .!G'7
M%4=0\%^#M6NK6^U7PGIES/8W+7%E-<6$;O;S,<F1"1E')Y+#!)K3HH AU#3[
M#5K&;2]5L8;FVN(VCN+>XB#QRH1@JRGA@1P0:JZ3X2\*Z"MNNA^&=/LA9VYM
M[06EDD?D1$Y,:;0-JYYVCC-:%% $4UA8W%U#?3V43SVX;R)GC!>/<,-M)Y7(
M SCK1'8V45W)J$5G$L\RJLLZQ@.X7.T$]2!DXSTR:EHH X7X\^',_#[Q!XK\
M(_",>*/%G_"/W-EI,%@ME%?3&5&01)<74D21IERS;I ,;L!CA3^>/_!L+_P3
MN_;0_P""9_P;^)7P7_:^^"HT&?Q'XF@UK1]7L/$FG7]K*BVZ0- PM[AI4DRN
MX9385S\P. ?U(HH **** "BBB@#,'@OP</$W_":CPGIG]LF+RCJ_V"/[5LQC
M;YN-^,<8SBK]U:6M];265];1S0RH4EBE0,KJ1@@@\$'TJ2B@!L4$,$*VT$*I
M&BA4C10%50,  =A5#PYX/\)>#X9K;PCX6T[2H[B8RW$>G6,<"RR'J[! -S>Y
MYK1HH SM;\(^$_$MU:7WB/PQIVH3Z?+YMA->V4<KVS\?-&6!*'@<C!X%:-%%
M !1110 52U_PYX>\5Z7)HGBG0;+4K*4@RV>H6J31.0<C*."#@\]*NT4 0Z=I
MVGZ18PZ7I-A#:VUO&(X+:WB"1QH!@*JK@ #T%3444 9DG@OP=+XF7QI+X3TQ
MM92+RTU9K",W*IC&T2XW@8)&,XYKXO\ ^"S_ .P-\7/V\9O@[I%C\+/#/Q)^
M%OA#Q?=:K\4?A;J6J+I.IZ^C6XBM'L-3*;K5H7:5GC66W\]7"-*%SC[CHH _
M'CQ[_P &Y?[,GQC\7^ I?V:_^"=6J?LXW7ASQUIVLZ_X^USXJG4+PZ?;2B62
MTLK*UU&_CEFE*HJRRM!Y."X+X\M_I?P+\(O^"N'Q@_:D^+?P0_;3B\&ZK^SU
MJ_Q'L-:\ Z]IMU:17%OX=L[J2Z71#:Q1":=[AX[".>2Y.%C6\",_F1!?O"B@
M HHHH **** "LI_ G@>2^OM3D\&Z4USJ:HNI7#:=$9+L(04$K;<R!2!C=G&.
M*U:* $5550J@  8 ':L[1/!WA'PU>WFH^'/"NFZ?<:A+YE_/96,<3W+Y)W2,
MH!<Y)Y.>IK2HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KXH_P""KO\ P55;]A;XN? W]ESP9?>&M(\5
M_'/Q8VF1>-/&\<DFC>%M/CD@CFO9XHY83/(6N$2*,RQ)NW-(ZJN&^UZ^/?\
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M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -B
MBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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M/);&Y^%6O:'8K,WAB>SB$,"K"S+YT'E 1O"67< IW*ZJPQ_A3_P2W\1^(_\
M@HK9_P#!47]M'XE>'O%GQ&\->"8O"W@+1O"'AZ;3])T*W'VCSKL_:+B>6>YD
M-W= 9*I$D[##MM=?LFB@ HHHH *\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-
M'\>_]@%__0UH [KX7?\ ),_#O_8"M/\ T2E;M87PN_Y)GX=_[ 5I_P"B4K=H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KRC]N?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#N
MOA=_R3/P[_V K3_T2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T2E;M87PN_P"29^'?^P%:?^B4K=H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7,TK)RMJTM;)O97T"BBBJ-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\ 8!?_ -#6@#NOA=_R3/P[
M_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3SX;>W.W6%C26[AEW@2JB,VU0R$$9)&Y<XSBOS]^!W_!%3]JGXGO%J_Q4O\
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M5'ZQPOQCD/%V%]ME]6\E\4'I./K'MYJ\7T9HT445V'U(4444 %%%% !1110
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M_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5
M&E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\
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M_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5
M&E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\
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M+\^&/ FKKX4M;Q_+M],\'6K?:Y<]!YYW3%_>,IGTJ'X1_P#!*S]N']HO4_\
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M&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\
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MLX]>C_KR_ ]?@7.N,,;.M@,_PGLZE&W[U64:E]K):-Z7;B^7HU%Z/M:*S?\
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M_GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\
MOT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM
M/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J
M:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\
MY\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT
M*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_
M .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B
M@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA
M_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/
M[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\
M8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"
M'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?
M^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.
MT_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&
M'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^
MSM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_
M0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T_
M_GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\
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M6]O$L<<:A41%P% X  '05[7]E8W%N^+K:=E_5OP9^N+PUXPXG:GQ1F<G!_\
M+JEI'\E!-?X)>I^;7P+_ ."#6J7/DZM^T=\7X[93@R:+X2BWOCT-S,NU3V($
M3#T:OLOX'?L)_LI?L\K#<?#?X.:6FH0X(UG4X_ME[N_O"6;<8\^B;1[5ZY17
MIX;+<%A=805^[U?]>A^AY#P!PEPY:6#PL>=?;E[\_5.5[?\ ;MD0_P!G:?\
M\^,/_?H4?V=I_P#SXP_]^A4U%=Q]D0_V=I__ #XP_P#?H4?V=I__ #XP_P#?
MH5-10!#_ &=I_P#SXP_]^A1_9VG_ //C#_WZ%344 0_V=I__ #XP_P#?H4?V
M=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]^A1_9VG_ //C#_WZ%344 0_V=I__
M #XP_P#?H4?V=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]^A1_9VG_ //C#_WZ
M%344 0_V=I__ #XP_P#?H4?V=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]^A1_
M9VG_ //C#_WZ%344 0_V=I__ #XP_P#?H4?V=I__ #XP_P#?H5-10!#_ &=I
M_P#SXP_]^A1_9VG_ //C#_WZ%344 0_V=I__ #XP_P#?H4?V=I__ #XP_P#?
MH5-10!#_ &=I_P#SXP_]^A1_9VG_ //C#_WZ%344 0_V=I__ #XP_P#?H4?V
M=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]^A1_9VG_ //C#_WZ%344 0_V=I__
M #XP_P#?H4?V=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]^A1_9VG_ //C#_WZ
M%344 0_V=I__ #XP_P#?H4?V=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]^A1_
M9VG_ //C#_WZ%344 8?COQ/X'^&G@S5/B!XUN+6QTG1[&2[U"[EC&(XD4L3C
M&2>, #DD@#DU\W_LE_\ !5']FO\ :8UMO!&OV">#/$,MTZ:98ZS+&8;]"Q$?
MESX"^:1C,38.XX0O7TE\1/AUX(^+/@R_^'GQ'\-6VKZ+JD(COM/NU)2500P/
M&"K!@&# @J0""" :_,O]M'_@C#XY^'7VOXA?LLR77B31%W2S^&)VW:C:+U/D
MG@7*#LO$G08D.37EYA5S"A*-2A%2BMUU_KT^:/SCCK,^.<EK4<=D]&-;#P3]
MK3WG*_5:7LDM'&[NVY1:1^I']G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%?D9^Q
MS_P5I^-?[-5W#\-?CA:WWBSPO:2?9VAO'(U32PIVE8Y),>8%Y'E2], *R 8K
M]1/@7^T-\'_VDO!D?CKX.>-;75[(X%S%&VV>TD(SY<T3?-$W7@CG&02,&M,%
MF6&QR]QVEV>__!/0X1X_X?XQI6PT^2LOBIRTDN]OYEYKYI/0Z_\ L[3_ /GQ
MA_[]"C^SM/\ ^?&'_OT*FHKT#[<A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH
M A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&
M'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH B2QLHV#QV<2L.A6,
MBI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\H_;G_ .31
M_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6
M[6%\+O\ DF?AW_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BFS30V
MT+W%Q*L<<:EG=VP% Y))/05\F_M2?\%@/V;/@1]I\-_#JY_X3WQ%%E/L^CW
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MBBO2/T$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8*XS@C)P016I7T*::NC]TISC5@IQV:NOF%%%%,L**** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!/ZN?!<(>)>2<4S^JU$Z&*6CI3T=UORMVYO2RDOY;:GM=%%%>H?HP4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>4?MS_\FC^/
M?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=
MK"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/_;7_;\\4_\ "N=';4IK.^8BW\%>#K61873/64*2\P'!+2L4'7"BO>_V7/\
M@AMXFUG[-XJ_:L\6_P!DVYP__"+:!,LERW^S-<<I'[K&'R#PZFO#EFN+QLN3
M!0T_F?\ 5OS]#\?Q'B/Q1Q=6EA.$,&^79UZB2BO-)^ZNZYG)M?8N9_[*G_!4
M?]J_XW_MI^'8O$NG37_AG4Y7L+SPIX9TEGBLH)2 +LX#2,8F".TCDX02 !0V
M*_4.N0^#?P$^#O[/WAE?"/P<^'VG:#98'G"SA_>W!'1I96R\K?[3L377UZF
MP^(P])JM/F;=_0_1N#,CSW(LNG3S7&/$U9RYFW>T6TDXQ;U:TTTBET2"BBBN
MX^P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH \X_:0_90^!W[5GA,^%?C!X
M/CNWB1AI^K6V(KVP8_Q0R@$CG!*G*-@;E.*_+7]K3_@FA^T5^QCK)^*7PVU*
M^U[PUI\_VBT\3:&'BO=*VG*M.B'=$5_YZH2G&24)"U^R-(RJZE'4$$8((X(K
MS<=E>&QJN])=UO\ /N?!<8>'>0\7Q]K5C[+$+X:L-):;<W\R7GJNC1^:7[%W
M_!:S4](^R?#O]KV&2]M1MBM_&MA;YFB'0?:H4'[P>LD8W<<HY):OT;\'>-/"
M7Q"\-6GC'P+XDLM7TJ^B$EGJ&GW*RQ2KZAE)'7@CJ""#S7R%^VC_ ,$>?A5\
M;_M?C[X!-:>#O%,FZ26P6,KI>H/WW(H)MW/]^,%?5"26KX4\"?%C]L[_ ()B
M_%B;PU<6E]HDC2B2_P##FKH9=-U6,''F+M.UP<8$T3!AC&[J*\V.-QV5R4,6
MN:'22_K\]?4_/L/Q9QEX<5XX/B:F\1A+VC7CJTNG,WOZ2M+>TI)(_;NBOG']
MC7_@IA\"/VMH+?PTUVOAGQBR 2^&M3N!_I#8Y-K*<"<?[.!(,'*X&X_1U>_1
MKT<134Z<KH_;,ISC+,]P4<7@*JJ4WU7Y-;I]TTFNP4445J>D%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<
M_P#R:/X]_P"P"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/
M_1*5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45F_\
M"8^&/^@U!_WU1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_
M 'U0!I45F_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4
M?\)CX8_Z#4'_ 'U0!I45F_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?5 &E16;_P
MF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45F_\ "8^&/^@U!_WU1_PF/AC_ *#4
M'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45F_\ "8^&/^@U!_WU
M1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45F_\
M"8^&/^@U!_WU1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_
M 'U0!I45F_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4
M?\)CX8_Z#4'_ 'U0!I45F_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?5 &E16;_P
MF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45F_\ "8^&/^@U!_WU1_PF/AC_ *#4
M'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45F_\ "8^&/^@U!_WU
M1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45F_\
M"8^&/^@U!_WU1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_
M 'U0!I45F_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4
M?\)CX8_Z#4'_ 'U0!I45F_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?5 &E16;_P
MF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45F_\ "8^&/^@U!_WU1_PF/AC_ *#4
M'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45F_\ "8^&/^@U!_WU
M1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45F_\
M"8^&/^@U!_WU1_PF/AC_ *#4'_?5 &E7BG_!1/X1_$+XZ_L<^,/A5\*O#_\
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M:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\
MY\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT
M*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_
M .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B
M@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA
M_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/
M[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\
M8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"
M'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?
M^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.
MT_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&
M'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^
MSM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_
M0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T_
M_GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\
MOT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM
M/_Y\8?\ OT*/[.T__GQA_P"_0J8D 9)KYS^/?_!4O]D?X"^)K?P7>^-F\0:H
M]]'!?P>'%6YCTY"X5Y)I00@V#<3&I9\K@J,YK*M7HX>/-4DDO,\W-,XRK)</
M[?'UHTH;7DTKOLN[\D?0W]G:?_SXP_\ ?H52\1Q7.G^'K^_\.^&K;4-0@LI9
M+"PED6%;F94)2(R;6V!F 7=@XSG!QBK]I=VM_:Q7UC<QS0S1K)#-$X974C(8
M$<$$<@U)6FZ/0DN>#2=K]5^?8_%CX^?MJ_MH?MH>-)OA-INE7]A#/</;KX%\
M(6$BLY4E62?:#+,1CY@YV C.U:]G_9;_ ."'?CKQ1]F\5?M2^*?^$>LFP_\
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MMT^NFF[\SP./.&O"C*,EC7X;S6>*Q#FDX25DH-2O+^'#5-16_78]@_L[3_\
MGQA_[]"N)^-'Q^_9^_9VL[#4/C;X]T?PW!JDKQZ?)J(VB=T +!<*>@8?G7>5
M\N_\%./V _%_[>7AGPEH7A+X@:;H#^'+ZZGGDU&UDE$PE2-0%V=,;#U]:];,
M*N+HX.4\-#FFK63ZZKS70^!X2P609CQ#0P^=XAT,+)OGJ)7<4HMJVDMY)+9[
MG3_\/)?^"?'_ $<KX1_[[;_XBC_AY+_P3X_Z.5\(_P#?;?\ Q%?#/_$.W\9O
M^CB_#'_@JN/\:/\ B';^,W_1Q?AC_P %5Q_C7R_]J<7_ /0''[__ +8_<_\
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M,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\
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M#B_/7F=/%^Q<HQ4E[/GNXZ<U^>-O=Y5:W2]]=/Q2_P""2'_*0CX?_P#<6_\
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MYX6^(?C/4#*=O]C_  _TQ[?:I_A/V)!(R_[[-QUK]KOBA\#/@Y\;%TV/XO\
MPST7Q-'I%RUQIT&MV"7,4,C+M+;'!4Y'8@CBM[P_X<\/>$]+CT/PMH-EIEE"
M,0V>GVJ0Q(/9$  _ 5\_F.1YEF.,E)XIPI.UHKT5^J6_>Y^M\'>*'!?!W#M&
ME'(J>(QT>;FK5&K?$W%J\9O2-DTN35'XG_#7_@C7_P % _C3??V[XL\'VOAM
M+MM\NI>,]: E?/4M'%YLV?\ >05^E/\ P33_ &$O%O["'P[U[P;XG^+%OXD_
MM[4H;X6MGIC00V,RQF.3:[2,9=X$?)5,>6.#GCZ4HKHRSAG+<KK*M3YI375O
MOOHK+[[GD\;^-G&7'>6RRW%JG3PTFFX4X?RM./O2<I*S2^%QOML[!1117T)^
M0A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]W[0K1X^G%?MK\&'\3R?![PG)XWU&6\UIO#5@=7NYD"O/=?9T\UV"@ $ON)
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M?"[_ ))GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M--:I]M-U9I,^8?A)_P $>OV"/A-Y5R?A ?$UY%C_ $SQ=?/>;_\ >A^6 _\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\ 8!?_ -#6@#NOA=_R3/P[
M_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY<TYR<I/O*3NWIW;"BBBK.<**** "BBB@ HHHH **** "BBB@ HHHH ****
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M=_#_ /:'L?AWID?CB\^+5KI-UXI$&;V6P;2=0D-J9#SY6^WB8)]T,I( +,2
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M]B'_ (*'?M=:O'XJ\1^#?%%X)N?[>\>:C) H0_Q*;IO,=?\ KFK"OI/X._\
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MKZL_!1D%M;VRLMM D89V=@B@98G))QW)Y)I]%% VVW=A1110(**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD=TC0R2.%51EF8X
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M&'N#5JO@91<6TU9HZ0HHHI %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDO\ 47_!ZO\ %;X977[#OPZ^#MK\0-&E\5P_&"VU"?PW%J437T-JFD:@K3/
M&WHF;B ;B /WJ^HK]@/@U\#/A)^SUX1F\!_!?P+9>'M(N-:U#5IK&QW;&O+Z
M[FO+J7YB2-\\\K!<[4#!$"HJJ.LH ^'M/^&'@C_@I)_P02M_V>/@U\0-#UJY
M\5?L\Z;I&GW-AJD4T5KK":3 \$4[(Q\IDN4B#HV&7!! (K\C;F]O9_\ @V#@
M_P"":W]G3#X]0_'X^&/^%0A<^(3?_P!KM?\ E_8<^=M\EMWF;=F!]ZOZ4ZH?
M\(KX7_X2+_A+_P#A&[#^UO(\C^U/L:?:/*_N>9C=M]LXH _!_P#X+6?\$G_B
MA^SC_P $U/V-_B9X9\-W&LS_ +,-O:V?Q4CT>)KAH+>Y:TNKN^"IDM;PWEO*
M"PR0MR'/RJS+Z+^T_P#!'2O^"GW_  =!_ [XN_L[^(M/\8?#SX*?#70-<\<>
M,_#U['>:;I]W:ZEJFI65H;B(F-IY9)K,B,-NV.[XPC8_:EE5U*.H((P01UJE
MX>\+^&?"-@=*\*>';'3+4RM(;;3K1((R[?>;:@ R>YZF@"]1110!QGQF^!GA
M#XYZ99:3XOU36K6.QG::%M%U:2T9F*[2&*?>&.QK^<SQ!J'V_4&V-F./Y4]_
M4U_3-7E'[<__ ":/X]_[ +_^AK7S^?9'+.Z<(*KR*-^E[WMYKL?<^&W%.3\!
M<8T^),3@/K5>E3J4Z5ZG(J?M7#VDU^[G>3C!03TM&4UKS:?ST6*6TMVD5XS+
M&QPS*<$>_-?9GQ^_X(!_MW^ ?.U/X ^/? /Q#LX\E+&]\_0[^3T55D>: ^F6
MF7Z>G["_"[_DF?AW_L!6G_HE*W:.'>',OR6<WBZ5/%*5M*D&DK7ZQFI*]^DE
M\]+?H/&/T@.+L]S>..R:I4P*Y%"5-5(U8-QE)J:4J4>634N66Z:C':SO_,#\
M?/AQ^W!^RDTS_M%_L1^+?#UI 2)=8*--IX(ZXNX8Y(&_"0U[5^SO^U-_P1O^
M)\-II/QH\?\ QD^&>H&)5N;G4;*SU33A)C!VRVD!FQG^] ,#OZ?T)LJNI1U!
M!&""."*^=?VA_P#@DM_P3H_:B\^Z^+7[)_A5]0N,F36="M#I5ZSG^-I[,Q/(
M1_MEAZ@CBOU7*X>#-6FZ>/R.="4MZF'KU)?=3KSG%?\ @3/Q+Q(SG/?%BAAJ
M/%56.+CAG-TU.$(<KGRJ6M*,&[\L=[VMINSY0^"/_!,G_@GE^T]IRZA^SG^W
MK'XL^3?+!H^H6%S<1+_TT@7$D1]G4'VKRO\ :6_X(@_M6Z!\2[VW_9^\.KXN
M\-I#%]BU"\UFRL[B5O+!=3')*H&'+*#GG&:W?CK_ ,&H7PDGU ^*OV1OVJ?$
MWA#4()/.L['Q/:)?QI(.@CN+<P2P@=F*RL/>O.O^%)?\'//_  3P^;X>?$6[
M^+OAFR'-O!JL?B-'C'W4$%^J7ZC'\, &,8SC&>C&^$/ASQ11Y,CSF$)-W4,0
MG1EZ<[4H2;\EOU//\+,7A/!KB:6?9#E]..(=.5)N7/./))QD]%.+3O!:WVN<
MVW_!-S_@I]\/N--^"OBRT\O@?V-K\$F,<<?9[AOTIC_#_P#X*[_#\_Z+H/Q^
MM$3J=/;5Y(Q]?*)7''?VKTCX:_\ !TG\6_A)XA3X??M_?L*:GH6JPX^W3^'?
M/T^ZB['_ (EVHC=GKUN%Z8^GVG^SQ_P7B_X)??M&>19:5^TE8^$]3FQG2O'U
MNVDNA/13/+_HS'/&%F;^5?%YQ]'OC#(8>U=&LZ>ZG3:JQMWO3O9>MC^D:?TH
MLSQNF.RS"U'UO&2_]*E,^9O@Q_P2S_:,_;1^$NC_ !X^,OQNU'2?$EY'/:W-
MCXPT6XEO0L-S*B&1I)%< H!M!7ICL:W;C_@@5\5%?%I^T'X?=<=9-(G4Y_!C
M7Z9:#X@T#Q5I$'B#POKEGJ5A=)OMKZPN4FAF7^\KH2K#W!JY7SD.'L%2IJG4
M3<DK-MN[:W;UW/Y#XP\/^!^,N*,;GE?!>SGB:DZCC"<U&+G)NT4FDDKV5DO0
M_#+]O?\ 81^(7[!^E>&=2\6>/M$UD^);BZBMXM.AF!C\A8BQ;>!Q^]7I7S>O
MC"^'W[6(_3(_K7]'WCOX5?"_XI006OQ-^&^@>(XK4L;6/7='@O%A+8W;1*K!
M<[5SCKM'I7GNM?\ !/C]AW7LB^_91\!QYZ_8O#D%M_Z)5<5X&/X5QM7$RGA:
MRC'2R=]--==>I^M\#9!]&W).%:.5Y]PNL56@Y\U;F?/+FG*2N^>$O=BU%7?0
M_ =/&3C[^G@_23']*]G_ &0/V3/C)^VSJ.NZ9\';33%D\/06\NH'5=0,*XF+
MA-I"')_=M7ZQ:W_P2-_X)W:]N-W^S;91%OXK+6]0M\>X$5PH_2NU_9A_8A_9
MU_8]N]>N_@+X3NM+/B,6PU)+C59[H$0&4QA?.9BO^N?///'I6."X8S>GBX_6
M:D94];VWV=OLKK;J<O''AY]$S.^&L13R#(<1A,<^7DG[6KRKWX\VDL34C\',
ME^[W?3=<E_P3W_92\8?LY_LWV?PT^*KQQZS%JMW<3+I>HF2'9(^4(( YP!GB
MO2_B_P")/A;\"?AOJGQ9^)OB&_L-"T6))=1O$>68Q(TBQ@[(P6;YG48 )YKO
M:\W_ &N?V>T_:K_9W\1_ &7Q?)H*>(8[=&U6*R%PT BN8I_]673=N\K:?F'#
M$U]K.G4PV"<,.KRC%\J?5I:)[=?0^>X2RG)<MJX'+L3.4,)"5.$Y;RC232E+
M1.\E&[TB[OH]C\[/^"H_[6G[+/[4W@'P?HG[.OQ?@UFZL-7GGU*#4UGL/)1H
M@JG-ZD2GG(^4FODS1_A_XSG4/I?CSPG (_N^9\2M(@*_3?=KZU]C:W_P;G^)
MH=Q\.?M7V%S_ '5O?![P?@2MT_\ *N1UK_@WG_:>@)_X1WXT^ [H?P_;9+VW
MS_WS;R8K\]Q=+B:O7=6MA=7_ "M=/G(_1>)OHW?17XUSB>9+B?%TJDTE9\JB
MN5)+26%B^FNIXUX3_9[_ &M/%=]%HW@"\_M>YN"3#;:%X^L+II" <X6&Z;)P
M#^5=7_PRA_P4\TS]]%\/?B6A/RY@U&8G'_ 9,XXKW3]@O_@D%^U)^S1^V'X.
M^,?Q,NO"MUH&ARWDEY+I&KR2R!GL;B*/"21(3^\=,^@YK]/*]G*<JJXS#N>)
MC*E).UK[JRUV\_P/P+C_ .C9X>\,YO3P_#^>U\72E34G-.'NR<I+D]U;I)/I
M\2T/Q-/P5_X*G:1Q#X3^,T?D\K]FGU%L?38QS^%(?#G_  5ATS]U%I?[02!N
M2(%ULC\=M?MC-)Y,33%&;:I.U!DG'8#N:_"Z]\<_\%A/!%[-=WE[^T!IZ-*S
MB.]@UAX4!.<*)%*X^G%89Q2IY/R.]2:E?X>EK;^MSTO#OZ)L./WB8X?B&6&=
M'DLJLK<_/S?#9I^[RZZ/='VM_P $EK#]K7Q'X[\8+^U!<?$E;*#2+;^RE\8-
M?1QF4RMN\O[0 "VT#..<&ON7_A!](_Y^;W_P+:OP_P#^'CW_  5#^'G.J?&;
MQ;9^7R?[:\/P28QSS]HMS^M;7AW_ (+7_P#!0^TGBMI_B7I.J.[!%6\\+6:[
MR>!_J8T[U."XPRO"T52G&I==6E_\D?TQP]]$/COAW)(82AF-#$J/,^>4ZG,[
MMO7]VUI>R]X_53]M=/$?PZ_96\:^-/AIJFJP:]8:1OTN:TD:21)3(B@JN#DX
M)[&ORL;]OK_@H)IG[Z?XN^(HP?ES/HT!&?3YH>O%?MU;B98$6X<-($&]E& 3
MCDT^OJ<;@*^+J*4*SA9;*_\ FC^2>,."\VXDQ]/$83-*F%48\O+#FLW=OF=I
MPUUMMT/Q!3_@IS^W;82"";XY7.4/S1SZ%89_',&?UK'^*?[?W[4_QI^'FH_"
M[XE?$./4=&U0Q?;+<Z7;Q,WERI*F&C12,/&I_"OO']KO_@M)H'[*_P"TCXC_
M &>-6_9XFUZ'0?LBR:O!XF6+SS-:0W!'DM;,!M\T+]\YVYXZ5\^?M@_\%B?@
M5^T[^S/XC^#ND_ 76M%UK5Q9BSOY7M98H?*O()WRRE7&5B91@=2,\9KY+%8W
M!T?:4I8YN4;IQ:EJUHUO;R['HXSZ)7T@,5PS+'83&8C$TJM%SA#F3]K&4.:,
M;/$R:YTTK2CI?5=#XKK?^%WPY^(/Q;\=V'PZ^%F@7.J:]JADCL;"T=5>4")W
MD&6(  C5R22!M!S7 :IXG$_E?V>'78^Y]XQG'0<'I7WM_P $COV2/VA6^/\
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M;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
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MP^*I9=;_ &9/V@?%?@6^W>9!8ZW!'J]FC#E50@PSQC_::20CK@]*?)X/9_\
M#+$9=4?=>WI+[K57\[!_MM/M)?<_\C]7:*_$G_AB[_@Y5_X)Z_OOV>_C]/\
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M &C5/@'XV\5_#._DR8;:*Y_M?3D)]8;EA.?PN ,=J^?O^'8W_!P=_P $[/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCQ@YQ1_J=X?9YKDN=*E-[4\7#V=O6K&\/N0>WQ-/^)"_G'7\#]MZ*_%30?\
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M:,_X.%?VL?VRO'TO[-7_  2$_9ZUN2\O-T8\67NDK=ZFT>=IFBM_F@LH@?\
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M%%%%9C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ[_V 7_]#6@#NOA=_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@
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M0 4444 %%%5-=U[0_"^C77B/Q-K-IIVGV,#37M_?W"PPV\:C+.[N0J*!R22
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M & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH ****
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M_P >NH'7[6+[W[[PA=[P.?\ EIB8]^G/Z4?\-W?\'1/PT_Y&G]C<^(/*^_\
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M'SSX9_X.4_\ @D_KVW^U/B]XCT7=C/\ :?@F^?;]?L\<OZ9KT+PS_P %U?\
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M_% >(M-QV_Y;O)CG-'_$'>)JO^[8C#5O\&(@_P [!]=I+=-?(_:>BOQ;M_\
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MKV7"6%YZZT>*KI2GZTJ?PP\FU>VDD]R?85J^M9Z=E^K/E[]@_P#X) ?L2_\
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M?ZXJXKXQ_LY? K]H3^P?^%W?"G1?%'_"+ZU%J^@?VQ9+-]BO(_NRIG]5.5;
MR#@8^_X0\?.*\HQ]\YF\50::M:$91?1QDHJ^NC4KZ:JSWYJ^749Q]S1GY+?\
M$#O^"&-QI;:9^V_^VIX(MW\^V\[P)X US3(Y@$=?DU&\BF4A6P0T,> RG$C8
M.T5^SJ(D:A$4*JC  & !2T5^8\8\8YOQMG,LPQ\O*,5\,(](K]7NWJSKH4(8
M>'+$****^4-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)XD\837>G:2TT$=]XIGFA9@RC#HQPPYZ&OK:O*/VY_\ DT?Q[_V 7_\ 0UH
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MYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P#
MMJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@
M#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'
MTC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?
M2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO
M?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]
M_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:
MMBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ
M/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_
M (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC
M_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/
M^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_
M  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?
M_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV**
M ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^
M$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X
M0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_G
MYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P#
MMJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@
M#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'
MTC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?
M2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO
M?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]
M_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:
MMBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ
M/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_
M (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC
M_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/
M^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_
M  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?
M_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV**
M ,?_ (0?2/\ GYO?_ MJ\C_:=_X)M?L9?MBZ4=/_ &B/@KI_B"X$/EV^L.S0
MZA;#L([J(K*H!YV[MIQR#7NE%=6"QV-R[$QQ&$JRIU([2BW&2]&K,4HQDK25
MS\:OCS_P;,_&_P" WBM_C-_P2[_:UU?2-5M<O:Z)K^IO87J+U,<6HV@59 >@
MCEC1<#YI#DUQ/A+_ (+,?\%._P#@G3XHM?A?_P %1OV5]8UW3O-\F'Q R_V=
M>3 =6ANX ]C?!0.B!23G=)WK]RZR_&?@CP9\1O#5WX+^(7A'3-=T>_C\N^TK
M6;".ZMKA/[KQ2 JX]B#7Z?0\4ZN:48X;BG!T\?36BFU[.O%?W:L$G\FKOJSD
M>$4'>C)Q_%?<?*W[''_!5W_@G-^VX+71_AA\=GT?Q)=;57P?XQNO[.U$R'I'
M&KL8KEO:"23\*^I?^$'TC_GYO?\ P+:OSS_;&_X-D?V'?CZ;KQ/^SY?ZC\)?
M$,V76/25-[I$CGGYK.5PT?8 0RQHO/R&OEK_ (1O_@X?_P""-?S>'[R?XR?#
M+3>D$8F\06,,"]O*.R_L55>3LVPJ2>6Q6O\ J9P3Q3[W#69*E5?_ "XQ5H2O
MVA57N2[);]V+V]>C_%C==U_D?MC_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U?
MG%^QY_P= ?L;_&A[;PG^U!X7U/X4:^Y$<E[/NU#2)).G^OB02PY/:2+8H/,A
MP37Z-_#[XD_#SXM>%+7QW\+/'6C^)-$O5W6>KZ%J45W;3#_9DB9E/X&OA.(.
M$N).%J_LLTPLZ79M7B_\,U>,ODV=%.M2K*\'<=_P@^D?\_-[_P"!;4?\(/I'
M_/S>_P#@6U;%%?.&IEV?A+3;&Z2[AN+HM&V5#W+$?B*U*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *\H_;G_Y-'\>_]@%__0UKU>O*/VY_
M^31_'O\ V 7_ /0UH [KX7?\DS\._P#8"M/_ $2E;M87PN_Y)GX=_P"P%:?^
MB4K=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ^:_P!L3_@D?^P3^W$ESJ7QH^!EC;^(;@$_\)AX:QI^JAS_
M !O-&-MP1V$ZR*/2OSD^(/\ P0(_X*0_L#>++KXO_P#!*O\ :UU#5(E;S'\/
M2Z@NEZC,J\K%(CDV5^!U_>^6"<8C-?M?17WG#_B3Q9P[0^K4ZWM<.]'1K+VE
M-KMRRU2\HN)SU,+1JN[5GW6C/QB^#?\ P<B_M5_LL>,8O@I_P55_9"U>TU"W
MPLVNZ/I3:9J10''G-97&V"Y!Z[X9(DQC:#FOTL_9*_X*0_L5?MO:?'+^SI\>
MM&U?46BWS>'+J4VFJ0 #+;K28+*5'0NH9..&(YKT7XR? CX+_M#^#I?A_P#'
M7X6:#XMT6;).G:_ID=S&C8QO3>"8W'9UPPZ@BORD_P""F?\ P;F?L[_"SX3^
M*?VJOV,?%/C7PKJOA/3I=6B\%Z7;R:PEPT7S!;1C(MS P^\7,DNT*2%&*^GH
M5?##C:O&C5HSRS%3:2E3_>4)2;LKP=I0N]E&T5U9BUBZ"NGSKST9^J7QC_:-
M^!7[/?\ 8/\ PN[XK:+X7_X2C6HM(T#^V+U8?MMY)]V),_JQPJY&2,C/:U_'
M/\9OVCOCY^T5=Z5?_'GXR>)/&-QH>G"QTF?Q)K$MX]K;@EMBM(Q/).2>IP,D
MX%?M/_P;=_\ !53X[?M"^;^Q'\;O#>M>*/\ A%]%-SH'C^.)IOL5G'A5M-0D
M/_?,,I)9L;"#@-7M<:>!.8\*<+_VI1Q"K2IW=56Y4HWTE"^KM]I/5].Q%#,(
MUJO(U:^Q^N-%%%?@1Z(4444 %%%% !1110 4444 %%%% !1110 4444 %>4?
MMS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7PN_Y)GX=_P"P
M%:?^B4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\H_;G_Y-'\>_P#8!?\
M]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH [KX7?\DS\._\ 8"M/_1*5NUA?"[_D
MF?AW_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_'O\
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M/?B@#SCP1X#_ &^Y_!FD3Z%\>/!,%D^EV[6<$WAIV>.(QKL5CW(7 )[UJ?\
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MH \%_P"%??\ !0__ *."\"?^$N]'_"OO^"A__1P7@3_PEWKWJB@#Y<^-4_\
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M@#P7_A7W_!0__HX+P)_X2[T?\*^_X*'_ /1P7@3_ ,)=Z]ZHH \%_P"%??\
M!0__ *."\"?^$N]'_"OO^"A__1P7@3_PEWKWJB@#P7_A7W_!0_\ Z."\"?\
MA+O1_P *^_X*'_\ 1P7@3_PEWKWJB@#P7_A7W_!0_P#Z."\"?^$N]'_"OO\
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MA_\ T<%X$_\ "7>C_A7W_!0__HX+P)_X2[U[U10!X+_PK[_@H?\ ]'!>!/\
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MX5]_P4/_ .C@O G_ (2[U[U10!X+_P *^_X*'_\ 1P7@3_PEWH_X5]_P4/\
M^C@O G_A+O7O5% '@O\ PK[_ (*'_P#1P7@3_P )=Z/^%??\%#_^C@O G_A+
MO7O5% '@O_"OO^"A_P#T<%X$_P#"7>C_ (5]_P %#_\ HX+P)_X2[U[U10!X
M+_PK[_@H?_T<%X$_\)=Z/^%??\%#_P#HX+P)_P"$N]>]44 >"_\ "OO^"A__
M $<%X$_\)=ZXGXHZ_P#M_?#;QEX,\)WOQS\(32>+M;;3[>2V\,@)$PC+[I-P
M)*\?PX-?6%>0?M'^!?%WBSXL?"36_#F@SW=IH?C"2ZU:>$ K:PF!E#MSTSQ0
M!B?\*^_X*'_]'!>!/_"7>C_A7W_!0_\ Z."\"?\ A+O7O5% '@O_  K[_@H?
M_P!'!>!/_"7>C_A7W_!0_P#Z."\"?^$N]>]44 >"_P#"OO\ @H?_ -'!>!/_
M  EWH_X5]_P4/_Z."\"?^$N]>]44 >"_\*^_X*'_ /1P7@3_ ,)=Z/\ A7W_
M  4/_P"C@O G_A+O7O5% '@O_"OO^"A__1P7@3_PEWH_X5]_P4/_ .C@O G_
M (2[U[U10!X+_P *^_X*'_\ 1P7@3_PEWH_X5]_P4/\ ^C@O G_A+O7O5% '
M@O\ PK[_ (*'_P#1P7@3_P )=Z/^%??\%#_^C@O G_A+O7O5% '@O_"OO^"A
M_P#T<%X$_P#"7>C_ (5]_P %#_\ HX+P)_X2[U[U10!X+_PK[_@H?_T<%X$_
M\)=Z/^%??\%#_P#HX+P)_P"$N]>]44 >"_\ "OO^"A__ $<%X$_\)=Z/^%??
M\%#_ /HX+P)_X2[U[U10!X+_ ,*^_P""A_\ T<%X$_\ "7>C_A7W_!0__HX+
MP)_X2[U[U10!X+_PK[_@H?\ ]'!>!/\ PEWH_P"%??\ !0__ *."\"?^$N]>
M]44 >"_\*^_X*'_]'!>!/_"7>C_A7W_!0_\ Z."\"?\ A+O7O5% '@O_  K[
M_@H?_P!'!>!/_"7>C_A7W_!0_P#Z."\"?^$N]>]44 ?,7Q;O?V^/@Q\--;^*
M6O?&SP9?VFB:>]Q+:6OAIE>3 PH!/'WB#] :^B?!&JW>O>"](US4&4W%[I=O
M/.47 +O&K-@=ADFN,_:[\*>(_'/[-/C'PCX1TB6_U*_T=HK.S@ +RON4[1GO
MQ77_  ^L;O2_ .AZ9J%NT4]OH]M%/$_5'6)0RGW!!% &Q1110 4444 %%%%
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M*** "BBB@ HHHH **** "BBH;[4M.TQ(Y-2OX+=99TAB:>4('D=@J(,GEF)
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M'XPT;1?A?>:EYD=E!:7_ )#-JER@VR.D,=Q"?LX*.\DJ(6C^9U /KRBOD/\
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MEJ.GZ&+9/[-T>.-KJ\GN+F*U@@B$CHA=YIXT&Y@,MUKXM_X*)?\ !P]\-/\
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MT8M'\,?A;HNA30Z9:B2]U:XM+9+:VLH0HW3SSW4ACBC&2\UU@#+G/YI^,_\
M@G)#\"/^#='XY?L-Z/XFT74_CCXNT2;XL?$+PGX<O$N7T^:'4M/O9;-%B+86
M*"RCMD!/[Z2.4Q[AG'Z,_P#!2K_@F-\(/^"IGPRT/X+?'_XL?$#0_"6D:P=3
MO-"\#ZM:V<>L7 3;%]K::UF=TB!D*HA0;I-S;BJ%<;_@G#_P1J_8A_X)7WGB
M75OV4_#.O0W_ (NM+:UUV_\ $&O27LDT4#2-&H!"HG,C$[5&>,]!0!^1GQ.T
MWQ'\?OA=_P $7_BK\-5DN=4T_P 1V/AZ:6VRS+'IE[HT<C-CG9$FGW3/Z*&S
M7T;_ ,'-.OZ)\%/^"@__  3\_:;U75[:PMO#OQ?G36[FXF5 MDFHZ),[,21M
M18Q<;F/ WU^E_P )/V _V/?@3X]MOB3\)O@5I>C:GI\NH2:(D$\[VFB/?.'O
M6TZTDD:WTTW# &4VL<7F=&R*[O6_@K\&_$OBG_A.?$?PE\,ZAK>Q4_MB]T&W
MENMJ@ #S60O@   9XQ0!%\0_B[X6\#_!3Q#\<K.]AU;2-!\-WNLF73)A,MS#
M;0/*PC9,ALB,@8SS7A7_  1@^$OB;X.?\$POA!HOCNTDA\1Z]X;;Q3XF6XB*
M3#4=9N)=5N!(#R'62\9"#R-N.U?3T,,-M"MO;Q+'&BA41%P% Z  =!3J "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGXP7GQAL?AYJ<_P%T#P
MYJ7BO[.PTBV\6:I/9V'F[3M:5X(99"H./D51N&1O7K7PM_P;M?\ !1_]IG_@
MI3^Q-\1?CA^T1=:7?^.=%^*^JZ7::596:V%I:6ZV%C/;6J!0S+&KS2)O<R2<
M$LS&OT/K\8?^#6#XC?#_ .&G[07[9'[(-QXXTBWOM(^.,UQX<TN348EEU"(3
MZA;RO;(6S,J+9Q%B@.T,I. 10!S?_!0_X.?\%9_^"</[7/[/7[5/A;_@I[XZ
M^)^O_%OXP6'A?Q-\,9UFMO#S37+AVMK/3A,\*V6P31<H)8_DD$F\EE_1_P#;
MC_XN+^V+^RM^SW]ZWD^(>K^/-7C7DM:Z%H\Z19']T:AJFFMGU05\%_M7_P#!
M6_QAK7_!3FZ\??"K_@EA\</CY8_!.WO-"^$\OA;PQ=QZ2=6N!Y>JZSYR6DYE
M8A%M('"%$B2>52WVD>7]N?LRZ'\?/C%^W1I'[1WQW^%^H^'Y?#/[+?A[2W:Z
MTR6WM3XAUN\>^UJVMO,'/V?^S-.1QDLAD56YH _-3_@Y%_9:_8!_9,U+X+?$
M1O@S\3-*\8W'Q?L==^)?Q_\ #_A^\O+B73R97N3/?2/%:SZC+.L4L,*.IA6%
MMBQQ[(G^I_\ @Y5\#? ;]K7_ ((9>+?VL_ /A[0O$-Q;:+X;\1^!O&(TI&NA
MIMQJ=D2T,SIYL4;VUU(Q3(^\01G->F?&G3_^"DG[=?P8^./["/[2_P#P3S\+
M^&M"\8P:GH7@OXH1?$:PO]'%A*62UU*:R#&^%S;XCN$01*))8T4FW WCT/\
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M+X7?\$7_ (I_#59+G5-/\1V7A^:6VRS+'IE[HT<C-CG9"FGW3/Z*&S7ZZ_\
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MHF..::6Q\\!I[>U,EQ:?:L$3!8L22E&(_5RBB@ HHHH **** "BBB@ HHHH
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M>-/.9W>1V .X2$,C+M*%%*D%0: /A/\ 9%^%WBOPO_P=W_M->*-"M)4T"_\
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MQHF\;_'GXE:3#X\^*WB;PM<Q:-X5\,07"0V]C$8H6 AMK 2?O'DC$EU/+.X
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M&OZMJ)M/ 'B6TGAU'2[&&ZDM[<W*SQQOYDJ1"?.Q05F7:"N&/MU%% !1110
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M?_?,:@5IT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &-XW^'/P]^)NEIH?Q(\!Z-XALHIUFCL]<TN*[B2
M0='"2JP##L<9JSX<\)^%?!U@-+\(^&=/TJU&,6VFV201\?[* "M"B@ HHHH
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M6%JGW+:RMEBC7Z*H %6Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-[58[-A<QL\<BB2(LA,;8/RG !]!T4RWF2Y@2XC5PLB!E$D91@",\JP!!]B
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M1U#*<@@$$4 6**** "BO'_B5^WM^R=\'OVD/"W[(_P 3OBM_8OQ!\;LJ^$=
MO="OP-7+?\\+@0&"3!&&Q)\IX;!XKV"@ HHHH **\_\ VE/VHO@A^R%\,;OX
MS_M#>++K0/"NG[3J6N)H-[>P62EE0/.UI#+Y*%F50[[5RP&<UX]X?_X+0_\
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MGV )- #Z*\D_9=_;K_93_;0OO%NE?LT_%F+Q+=^!-473?&%G_9-Y9S:5>,9
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MOO\ (</X9U,LC+.*^)CB+NZI1IN%KZ6<M=K7\SFJ/%*?N)6\[GRA_P %M/\
M@X*T/QQX9N_V4_\ @GYX\>?3M3M3%XQ^(VGB2(RQ.,-96+,%8 @XDG &0=J'
MDM1_P1+_ .#@K0_ _AFT_93_ ."@?CQX-.TRU$7@[XC:@))3%$@PME?,H9B
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M'A3P%XB\!ZA%<>&O$_F7-\-'3&VYC0E$ENA<C#2-*RL9565C(ZY-/]L+PO\
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M@3]JKXM>%=1\$_LAM-/X:'A>UN1>>,KI)+8V$EY'. EA'"MI!OB1[GS2'&]
MXV@'&ZQ_P46_X*7^/_\ @K)^U)_P3Q^$WQ@\ :'X?^$OPR?Q5X<\2:UX#:]O
M;<M::;=)!Y:7$4<Q#7QBWOP$7<4=L"OG[7/^"^?_  5)_P"'.G@;_@JI9ZU\
M,;1],^**>$/$WA!?"$\O_"3J/.=[MYVN!]ARJ11^1"C'<))?- =8(_MOPO\
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MXO\ VI=/FT76;/P5;2PV7AO1RA6.*UEN/WDTP*V[^8Z* UK'A3\V0#Q/0_\
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MF8+-,MIUV_>>DO5;_P"?H?REXF\(/@?C3%95&+5*+YJ;;NW3EK%WTO;6+?\
M,F@KXB_X*\?\$]OA!_P4Z\2^"?V5/C!)+:1W_@7Q=>^'==MEW3:+JL4NBBWO
M$7(#[=[JR$C?')(F5W;A]NUX_P#$OX6?'SQ!^U=X#^,_@V_\)1^%_">B:OIN
MJ:9J4ES]NU%=0-DQDCD1/+MS$UFN%*R>8'()CZCU3X$_&;_@GE^W_P#'S]DC
M4/\ AP5_P4IBGMO&W@[XK>!X?A#XBNF:6'5=/C\5:5,EBLK#,D/D*9K60_\
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MJ3Z)HUIH2R*EG:(CB6ZN);>2,.Z2)$%+&-]V4X>;_@W:_;0\/?\ !.GXD?\
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M?Q%^$/Q4\,P_!+XJ:HU_%\)H;>Z:3P]<JS&&:VN7^5@ \D;1E%RC1C>?)4L
M??=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,JLI5@"",$'
MO2T4 %%%% !1110 4444 5]6TC2=?TV?1M=TRWO;.YC,=S:7<"R12H>JLK A
MA[$58HHH **** "BBB@ HHHH *KOI&E2:K'KKZ9;M?16[017AA4RI$S*S1A\
M9"DJI*YP2H/858HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\Z^+G[('[)?[0'B?3O&_QX_9=^'7C;6M' &D:OXN\$V&I75B P8"&6
MXB=XOF4-\I'(![5Z+10 V***")888U1$4*B*,!0.@ ["G444 %%%% !1110!
MYSX\_8]_9)^*GQ-LOC7\3_V6_ASXC\9::L0T[Q;KW@BPO-3M1&28Q'=2PM*F
MTDE=K#&3C%>C444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %><:!^QW^R-X5^+\_P"T)X7_
M &6?AQIOCZZ=WNO'%AX'L(=8F9U"N6O$A$S%E !)?D#!KT>B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \T\5?L7_L=^.O%MWX_P#&_P"R?\--9U[4
M)/,O];U7P)I]Q=W+]-TDTD)=S[DFMS7_ -GOX!^*_&GASXD^*?@?X0U+Q%X.
MC,?A'7]0\-6LU[H:$8*V<[QF2V! QB,K77T4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788489242368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-5172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="nump">$ 181.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,838,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of MacroGenics, Inc.'s definitive proxy statement for the 2023 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788489040864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tysons, Virginia<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788483097088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 108,884<span></span>
</td>
<td class="nump">$ 123,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Marketable securities</a></td>
<td class="nump">45,462<span></span>
</td>
<td class="nump">120,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">56,222<span></span>
</td>
<td class="nump">10,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">1,451<span></span>
</td>
<td class="nump">4,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,161<span></span>
</td>
<td class="nump">21,170<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">222,180<span></span>
</td>
<td class="nump">279,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">29,575<span></span>
</td>
<td class="nump">37,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, ROU Assets</a></td>
<td class="nump">27,335<span></span>
</td>
<td class="nump">16,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non current assets</a></td>
<td class="nump">1,378<span></span>
</td>
<td class="nump">1,395<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">280,468<span></span>
</td>
<td class="nump">335,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,899<span></span>
</td>
<td class="nump">15,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">28,998<span></span>
</td>
<td class="nump">33,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">9,988<span></span>
</td>
<td class="nump">20,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">4,726<span></span>
</td>
<td class="nump">4,677<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">48,611<span></span>
</td>
<td class="nump">74,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">59,480<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">30,106<span></span>
</td>
<td class="nump">20,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non current liabilities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">138,455<span></span>
</td>
<td class="nump">95,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, 0.01 par value -- 125,000,000 shares authorized, 61,701,467 and 61,307,428 shares outstanding at December&#160;31, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,235,095<span></span>
</td>
<td class="nump">1,213,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,093,694)<span></span>
</td>
<td class="num">(973,936)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">142,013<span></span>
</td>
<td class="nump">239,618<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 280,468<span></span>
</td>
<td class="nump">$ 335,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788490845392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">61,701,467<span></span>
</td>
<td class="nump">61,307,428<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788483909840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 151,941<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">3,351<span></span>
</td>
<td class="nump">2,651<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">207,026<span></span>
</td>
<td class="nump">214,577<span></span>
</td>
<td class="nump">193,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">58,949<span></span>
</td>
<td class="nump">63,014<span></span>
</td>
<td class="nump">42,742<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">273,359<span></span>
</td>
<td class="nump">280,242<span></span>
</td>
<td class="nump">235,943<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(121,418)<span></span>
</td>
<td class="num">(202,795)<span></span>
</td>
<td class="num">(131,060)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">1,660<span></span>
</td>
<td class="nump">680<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(119,758)<span></span>
</td>
<td class="num">(202,115)<span></span>
</td>
<td class="num">(129,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</a></td>
<td class="nump">56<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (119,702)<span></span>
</td>
<td class="num">$ (202,169)<span></span>
</td>
<td class="num">$ (129,762)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average number of common shares outstanding (in shares)</a></td>
<td class="nump">61,433,124<span></span>
</td>
<td class="nump">59,944,717<span></span>
</td>
<td class="nump">52,442,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average number of common shares outstanding (in shares)</a></td>
<td class="nump">61,433,124<span></span>
</td>
<td class="nump">59,944,717<span></span>
</td>
<td class="nump">52,442,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CostOfManufacturingServices', window );">Cost of manufacturing services</a></td>
<td class="nump">$ 4,033<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share, Basic</a></td>
<td class="num">$ (1.95)<span></span>
</td>
<td class="num">$ (3.37)<span></span>
</td>
<td class="num">$ (2.47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="num">$ (1.95)<span></span>
</td>
<td class="num">$ (3.37)<span></span>
</td>
<td class="num">$ (2.47)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue from collaborative agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 119,303<span></span>
</td>
<td class="nump">$ 63,294<span></span>
</td>
<td class="nump">$ 97,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember', window );">Revenue from government agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,923<span></span>
</td>
<td class="nump">1,804<span></span>
</td>
<td class="nump">7,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">16,727<span></span>
</td>
<td class="nump">12,349<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_ContractManufacturingMember', window );">Contract Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 13,988<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CostOfManufacturingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of manufacturing services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CostOfManufacturingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788486389504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,958,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 230,628<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">$ 872,204<span></span>
</td>
<td class="num">$ (642,082)<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">20,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,612,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">170,456<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">170,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">3,886<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(129,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,244,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">295,884<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">1,067,150<span></span>
</td>
<td class="num">(771,821)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">23,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,580,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">117,818<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">117,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">4,959<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">4,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(202,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(202,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,307,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">239,618<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">1,213,002<span></span>
</td>
<td class="num">(973,936)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">20,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">1,085<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">574<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(119,758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,701,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 142,013<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
<td class="nump">$ 1,235,095<span></span>
</td>
<td class="num">$ (1,093,694)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodSharesStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodValueStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788486176448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (119,758)<span></span>
</td>
<td class="num">$ (202,115)<span></span>
</td>
<td class="num">$ (129,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">11,865<span></span>
</td>
<td class="nump">11,258<span></span>
</td>
<td class="nump">11,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
<td class="num">(260)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">20,438<span></span>
</td>
<td class="nump">23,126<span></span>
</td>
<td class="nump">20,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">2,882<span></span>
</td>
<td class="nump">2,035<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(45,836)<span></span>
</td>
<td class="nump">12,696<span></span>
</td>
<td class="num">(10,337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(6,424)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,009<span></span>
</td>
<td class="num">(4,188)<span></span>
</td>
<td class="num">(5,697)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other non current assets</a></td>
<td class="num">(10,704)<span></span>
</td>
<td class="nump">5,915<span></span>
</td>
<td class="nump">581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(10,860)<span></span>
</td>
<td class="nump">7,125<span></span>
</td>
<td class="nump">3,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(4,638)<span></span>
</td>
<td class="num">(607)<span></span>
</td>
<td class="nump">6,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">9,364<span></span>
</td>
<td class="num">(3,780)<span></span>
</td>
<td class="num">(1,324)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">48,821<span></span>
</td>
<td class="nump">9,264<span></span>
</td>
<td class="num">(8,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInDeferredRent', window );">Other non current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities, Total</a></td>
<td class="num">(86,959)<span></span>
</td>
<td class="num">(143,830)<span></span>
</td>
<td class="num">(111,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(120,602)<span></span>
</td>
<td class="num">(231,208)<span></span>
</td>
<td class="num">(223,745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">194,940<span></span>
</td>
<td class="nump">200,800<span></span>
</td>
<td class="nump">221,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and software</a></td>
<td class="num">(3,623)<span></span>
</td>
<td class="num">(6,201)<span></span>
</td>
<td class="num">(5,906)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided by (Used in) Investing Activities, Total</a></td>
<td class="nump">70,715<span></span>
</td>
<td class="num">(36,609)<span></span>
</td>
<td class="num">(7,785)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">1,085<span></span>
</td>
<td class="nump">117,818<span></span>
</td>
<td class="nump">170,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases', window );">Proceeds from stock option exercises and ESPP purchases</a></td>
<td class="nump">574<span></span>
</td>
<td class="nump">4,959<span></span>
</td>
<td class="nump">3,886<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by (Used in) Financing Activities, Total</a></td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">122,777<span></span>
</td>
<td class="nump">174,342<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(14,585)<span></span>
</td>
<td class="num">(57,662)<span></span>
</td>
<td class="nump">54,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">123,469<span></span>
</td>
<td class="nump">181,131<span></span>
</td>
<td class="nump">126,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">108,884<span></span>
</td>
<td class="nump">123,469<span></span>
</td>
<td class="nump">181,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash operating and investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures Incurred but Not yet Paid</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in deferred rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Stock Options Exercised And ESPP Purchases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788489875680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Nature of Operations</a></td>
<td class="text">Organization and Nature of Operations<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company has a pipeline of product candidates being evaluated in clinical trials sponsored by MacroGenics or its collaborators.  These product candidates include multiple oncology programs, some of which were created primarily using the Company&#8217;s proprietary, antibody-based technology platforms. The Company believes our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.</span></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#8217;s stockholders&#8217; equity and working capital, and accordingly, its ability to execute its future operating plans.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital. The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements, and product sales. The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization. It is considered probable that the Company can successfully implement efforts to manage uncommitted spending and carry out necessary cost saving measures, including from the Company's corporate restructuring plan announced in August 2022. Based on the Company&#8217;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Annual Report on Form 10-K was filed.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic and geopolitical tensions, including the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia, and related global slowdown of economic activity, decades-high inflation, rising interest rates and a potential recession in the United States might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to these uncertainties, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788489796464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of current period financial statements. These reclassifications had no effect on the previously reported net loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#8217;s ability and intent to hold the investment to maturity. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable arise from product sales, amounts due from the Company&#8217;s collaborative partners and contract manufacturing work performed by the Company.  The amount from product sales represents amounts due from specialty distributors. Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2022 or 2021, as the Company has a history of collecting on all outstanding accounts.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.  </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods presented. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.612%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,001&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,437&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at December&#160;31, 2022 includes approximately $46.5 million reported as cash and cash equivalents and $45.5&#160;million reported as marketable securities on the balance sheet.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2021 includes approximately $23.2 million reported as cash and cash equivalents and $120.1&#160;million reported as marketable securities on the balance sheet.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenue relates to agreements with various collaborators, MARGENZA net product sales and&#160;contracts and research grants received from U.S. government agencies.&#160;The following table includes those counterparties </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that represent more than 10% of total revenue earned in the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:68.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte Corporation (Incyte)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen Biotech, Inc. (Janssen)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab Limited (Zai Lab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provention Bio, Inc (Provention)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I-Mab Biopharma (I-Mab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Amount is less than 10% for the period indicated.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provention</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I-Mab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD Healthcare and Oncology Supply</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Balance is less than 10% as of the date indicated.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the U.S. Food and Drug Administration (FDA) in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Equipment and Software</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.754%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2022, and 2021, the Company determined that there were no impaired assets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative and other agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company grants a license to its intellectual property, it </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determines whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone </span></div><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s intellectual property</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability  that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 8, Revenue.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product sales, net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the years ended December 31, 2022 and 2021, the shipping costs incurred were immaterial. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the year ended December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract manufacturing revenue</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with third parties to manufacture their drug substance at its GMP facility. The terms of these arrangements typically include an upfront payment to the Company to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue over time on a straight-line basis as the manufacturing services are performed, as the Company believes that its efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including labor, materials overhead and other related costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expense, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented. The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:44.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,514,013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,395,421</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,467,603</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788483044224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities as of December&#160;31, 2022 and 2021 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,462&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,208&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's available-for-sale securities held at December&#160;31, 2022 and 2021 had contractual maturities of less than one year.  All of the Company&#8217;s available-for-sale marketable debt securities in an unrealized loss position as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2021 were in a loss position for less than twelve months.&#160; Unrealized losses on available-for-sale debt securities as of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded interest income of $1.7 million, $2.0 million and $0.8 million during the years ended December&#160;31, 2022, 2021 and 2020, respectively, which is included in other income on the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788490241792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory, Net</a></td>
<td class="text">Inventory, Net<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's inventory, net of reserves (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.655%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.233%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of December&#160;31, 2022 and December&#160;31, 2021 is net of a reserve of $4.9 million and $2.0&#160;million, respectively, for unsaleable inventory. These reserves are reflected in cost of product sales during the period they are recorded.   </span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory Reserves (in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions Charged to Expenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788490132880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Equipment and Software</a></td>
<td class="text">Property, Equipment and Software<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motor vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,660&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,485&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,085)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,809)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,575&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,676&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2022, 2021 and 2020 was $11.9 million, $11.3 million and $12.0 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788490301856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies&#160;<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has non-cancelable operating leases for manufacturing, laboratory, office and warehouse space in Maryland and a non-cancelable operating lease for laboratory and office space in California. A portion of the space under one of these leases is subleased to a third party. The California facility and the smaller-scale, non-commercial GMP manufacturing site in Maryland will be closed under the Company&#8217;s restructuring plan announced in August 2022, therefore the leases for those sites will not be renewed when they expire.  The Company&#8217;s continuing leases each have one or more five-year options to renew</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2022, the Company amended the existing lease on its headquarters space to extend the lease term through 2035 in exchange for certain concessions from the lessor.  This amendment was accounted for as a lease modification, and the right-of-use asset and lease liability were remeasured at the modification date, resulting in an increase to both balances of approximately $14.0 million.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents supplemental balance sheet information related to operating leases:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2021, t</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company made cash payments for operating leases of $6.9 million and $6.7 million, respectively. As of December&#160;31, 2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2021,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s ROU assets were valued at $27.3 million and $16.6 million, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2021 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,972&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,759&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-licensing arrangement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a non-exclusive license agreement with Synaffix B.V. (Synaffix) to develop, manufacture and commercialize up to three antibody-drug conjugate targets using Synaffix&#8217;s proprietary technology. The Company made an upfront payment to Synaffix upon contract execution. Assuming all three targets are successfully developed and commercialized, the Company would be obligated to pay up to $585.0&#160;million for development, regulatory and sales milestones. Finally, pursuant to the terms of this license agreement, upon commencement of commercial sales of any products developed from these targets, the Company would be required to pay Synaffix tiered royalties in the low&#8209;single digit percentages on net sales of the respective products. The Company may terminate this agreement at any time with 30 days&#8217; notice to Synaffix. Amounts paid to Synaffix under this agreement are recorded as research and development expense in the consolidated statement of operations.  During the year ended December&#160;31, 2022, the Company incurred $1.0&#160;million under this agreement. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Litigation</span></div>On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial. On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint. The amended complaint asserted a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal in the Fourth Circuit. The Company did not accrue any liability associated with this action as of December 31, 2022. The 4th Circuit affirmed the District Court&#8217;s dismissal in a decision published on March 2, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788492655568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's amended and restated certificate of incorporation authorizes 125,000,000 shares of common stock, and 5,000,000 shares of undesignated preferred stock, both with a par value of $0.01 per share.&#160;There were no shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2022 or 2021. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0 million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the year ended December 31, 2021, the Company sold 3,622,186 shares of common stock at a weighted average price per share of $27.60, resulting in net proceeds of approximately $98.2 million, net of underwriting discounts and commissions and other offering expenses. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#8217;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $100.0&#160;million to an aggregate offering price of up to $300.0&#160;million. During the year ended December 31, 2022, the Company sold 160,480 shares of common stock at a weighted average price per share of $6.87, resulting in net proceeds of approximately $1.1 million, net of underwriting discounts and commissions and other offering expenses. </span></div>As part of the consideration for the rights granted to Zai Lab US LLC under the collaboration and license agreement described more fully in Note 8, Revenue, the Company and Zai Lab US LLC entered into a separate stock purchase agreement (Stock Purchase Agreement).  Under this Stock Purchase Agreement in 2021, Zai Lab US LLC paid the Company approximately $30.0 million to purchase 958,467 newly issued shares of the Company's common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788489827856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Collaborative Agreements </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte License Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte, which was amended in March 2018, April 2022 and July 2022, for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab. Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017. MacroGenics will manufacture a portion of Incyte&#8217;s global commercial supply of retifanlimab. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies, including in patients with Merkel cell carcinoma, squamous cell carcinoma of the anal canal, MSI-high endometrial cancer and non-small cell lung cancer.  Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.  In April 2022, the Company and Incyte executed an amendment to the Incyte License Agreement to add a milestone for U.S. approval of retifanlimab in a specific indication and to exclude certain other regulatory and development achievements with retifanlimab in this same indication from the milestone events of the Incyte License Agreement. In July 2022, the Company and Incyte further amended the Incyte License Agreement to reflect changes related to the payment of certain milestones and Incyte paid the Company $30.0 million in milestone payments, which the Company recognized as revenue during the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, as amended, Incyte will lead global development of retifanlimab. Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $435.0 million in development and regulatory milestones, and up to $330.0 million in commercial milestones. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $100.0 million in development milestones under Incyte License Agreement.   If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of ASC 606 at inception and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The standalone selling price for agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2018 through </span></div><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$100.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#8217;s initiation of a Phase 3 clinical trial.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$150.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. The Company recognized revenue of $30.0 million, $15.0 million and $40.0 million under the Incyte License Agreement during the years ended December&#160;31, 2022, 2021 and 2020, respectively.  All of the revenue recognized during the years ended December&#160;31, 2022 and 2021 was related to development milestones.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into an agreement with Incyte under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2021 and 2020, the Company recognized revenue of $0.7 million, $1.5 million and $8.6 million, respectively, for services performed under this agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Commercial Supply Agreement</span></div><div style="text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services. During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, and 2020 the Company recognized revenue of $0.3 million, $7.8&#160;million and $1.4&#160;million, respectively, for services performed under this agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Gilead Sciences, Inc </span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company and Gilead Sciences, Inc. (Gilead) entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024, an investigational, bispecific antibody that binds CD123 and CD3, and create bispecific cancer antibodies using the Company&#8217;s DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under the agreement, the Company will continue the ongoing phase 1 trial for MGD024 accordi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng to a development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license under the Company&#8217;s intellectual property to develop and commercialize MGD024 and other bispecific antibodies of MacroGenics that bind CD123 and CD3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CD123 Option). The agreement also grants Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by the Company and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Gilead Agreement, in October 2022 Gilead paid the Company an upfront payment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60.0&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming Gilead exercises the CD123 Option and Research Program Option and successfully develops and commercializes MGD024, or other CD123 products developed under the agreement, and products result from the two additional research programs, the Company would be eligible to receive up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.7&#160;billion </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in target nomination, option fees, and development, regulatory and commercial milestones. Assuming exercise of the CD123 Option, the Company will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 (or other CD123 products developed under the agreement) and assuming exercise of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a flat royalty on worldwide net sales of any products resulting from the two research programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Gilead Agreement under the provisions of ASC 606 and identified the following material promises under the agreement: (i) a license to perform any activities allocated to Gilead under the MGD024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; (ii) development activities regarding MGD024, including manufacturing, research and early clinical development activities, necessary to deliver an informational package of development and clinical data, information and materials specified in the Gilead Agreement during the period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which Gilead can exercise the CD123 Option; (iii) the CD123 Option and (iv) the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the license under the MGD024 developme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development activities are not distinct from one another, as the license has limited value without the Company&#8217;s performance of the development activities. Therefore, the Company determined that the development term license and development activities should be combined into a single performance obligation (Development Activities). The CD123 Option is considered a material right as the value of the exclusive license exceeds the payment to be made by Gilead if they exercise their option to obtain an exclusive license to develop and commercialize MGD024 or an alternative CD123 product, and is therefore a distinct performance obligation. The Company determined that the Research Program Option does not provide a material right, as there is no discount on its standalone selling price.</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company determined that the initial transaction price under the Gilead Agreement was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, consisting of the upfront, non-refundable payment paid by Gilead. The CD123 Option and Research Program Option payments are excluded from the initial transaction price at contract inception along with any future development, regulatory, and commercial milestone payments (including royalties) following the CD123 Option and Research Program Option exercise.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company will reassess the amount of variable consideration included in the transaction price every reporting period.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upfront payment in the transaction price to the Development Activities and the CD123 Option based on each performance obligation&#8217;s relative standalone selling price. The standalone selling price for the Development Activities was calculated using an expected cost-plus margin approach </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the pre-option development timeline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the standalone selling price of the CD123 Option, the Company utilized an income-based approach which included the following key assumptions:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">post-option development timeline and costs, forecasted revenues, discount rates and probabilities of technical and regulatory success. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is recognizing revenue related to the Development Activities performance obligation over the estimated period to complete the Development Activities using an input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the Development Activities. The Company will defer revenue recognition related to the CD123 Option.  If Gilead exercises the CD123 Option and obtains an exclusive license, the Company will recognize revenue as it fulfills its obligations under the Gilead Agreement. If the CD123 Option is not exercised, the Company will recognize the entirety of the revenue in the period when the CD123 Option expires.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company recorded revenue of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.2&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to the Gilead Agreement. As of December 31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$59.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$58.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab Limited</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Zai Lab Agreement</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. Zai Lab has informed the Company that they have decided to discontinue development of tebotelimab for indications they were enrolling in their territory and is evaluating future development plans in other indications.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of  $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, of which the Company has earned $9.0 million through December&#160;31, 2022.  In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.  From 2020 through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it became probable that a significant reversal of cumulative revenue would not occur for development and regulatory milestones totaling $9.0 million. Therefore, the associated consideration, $8.1&#160;million net of value-added tax withholdings, was added to the estimated transaction price and was recognized as revenue</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uring the year ended December&#160;31, 2022, the Company recognized $4.9&#160;million under the 2018 Zai Lab Agreement and no revenue was recognized during the year ended December&#160;31, 2021 under this agreement. During the year ended December&#160;31, 2020, the Company recognized revenue of $8.6&#160;million under the 2018 Zai Lab Agreement, $3.6&#160;million of which was net milestone revenue and $5.0&#160;million of which was recognition of variable consideration related to certain regulatory achievements during 2020.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zai Lab Clinical Supply Agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements). The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within the contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab. The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing service. During the years ended December&#160;31, 2022, 2021, and 2020, the Company recognized revenue of $0.4&#160;million, $2.8&#160;million, and $2.7&#160;million, respectively, related to the Zai Lab Clinical Supply Agreements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Zai Lab Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#8217;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company. During 2022, the Company and Zai Lab agreed to discontinue research and development of the Lead Program.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Zai Lab Agreement, the Lead Program included joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into the Stock Purchase Agreement whereby Zai Lab paid the Company approximately $30.0 million to purchase shares of the Company&#8217;s common stock at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful development and commercialization of the remaining Programs, the Company could receive up to approximately $680.0&#160;million in development and regulatory milestones and $600.0&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-single digits to low double digit teens on annual net sales of products in Zai Lab&#8217;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#8217;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#8217;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the estimated transaction price is $40.4 million, consisting of the $25.0 million upfront payment, the $10.4 million premium related to the purchase of the Company&#8217;s common stock, and the $5.0 million estimated reimbursement by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $40.4 million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes a market participant is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#8217;s estimate of the probability of success for each Program. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to the Lead Program license and related research and development services performance obligation was  recognized over time as the research and development activities were performed. The Company utilized a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recognized revenue of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20.3 million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, under the 2021 Zai Lab Agreement. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022, there was no revenue deferred under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 Zai Lab Agreement</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2021, $16.1 million in revenue was deferred under this agreement, all of which was current. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Biotech, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a research collaboration and license agreement with Janssen to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#8217;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $20.0&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $312.0&#160;million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales. </span><span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#8217;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $22.2&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration was fully constrained until the Company began its work under the performance obligation.  The potential milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $20.0&#160;million allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Janssen in 2020. The $2.2&#160;million allocated to the research and development activities is being recognized over the Company&#8217;s involvement in the research term, which is estimated to be less than two years.  During the years ended December&#160;31, 2022, and </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recognized revenue of $0.8&#160;million and $1.5&#160;million, respectively, for research and development activities performed under the Janssen Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention Bio, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a license agreement with Provention pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones. As of December&#160;31, 2022, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2018, the Company entered into an asset purchase agreement with Provention pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement). As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share.  Under the Asset Purchase Agreement, Provention is obligated to pay the Company contingent milestone payments totaling $170.0 million upon the achievement of certain regulatory milestones.  In addition, Provention is obligated to make contingent milestone payments to the Company totaling $225.0 million upon the achievement of certain commercial milestones as well as single-digit royalties on net sales of the product. The FDA approved the BLA for teplizumab in November 2022, and the Company recognized $60.0 million in revenue related to this regulatory milestone during the year ended December 31, 2022.  In November 2022, the Company and Provention amended the Asset Purchase Agreement.  Under this amendment, the milestone for first approval was split into four equal payments, the first of which was received in November 2022. The remaining payments are due on March 1, 2023, June 1, 2023 and September 1, 2023.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention assumed pursuant to the Asset Purchase Agreement. Further, Provention is required to </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase a total of 2,432,688 shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such were excluded from the initial transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. The Company recognized revenue of $6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018. In 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. During the year ended December&#160;31, 2022, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for a regulatory milestone of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020, the Company recognized revenue of $60.0 million, $1.3 million and $0.6 million, respectively, under these agreements. As of December 31, 2022, Provention owes the Company $45.0 million related to the achieved milestone, which is included in accounts receivable on the consolidated balance sheet.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab License Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company entered into a collaboration and license agreement with I-Mab to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab License Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. In August 2022, I-Mab notified the Company of its intention to terminate the I-Mab License Agreement effective February 25, 2023.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab License Agreement, I-Mab paid the Company an upfront payment of $15.0 million, and $5.0&#160;million of milestone revenue has been earned from the inception of the I-Mab License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab License Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i) an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million. I-Mab paid the Company for the cost of this study as the costs were incurred and I-Mab received a one-time credit of eighty percent of the total amount of such costs against the milestone achieved during 2021. The Company reassessed the transaction price as it became probable that a significant reversal of cumulative revenue would not occur for a $5.0&#160;million milestone ($4.5&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue during 2021.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue under the I-Mab License Agreement was recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, was the best measure of progress towards satisfying the performance obligations. During the years ended December&#160;31, 2022, 2021 and 2020, the Company recognized revenue of $4.5 million, $11.5 million and $2.2 million, </span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, related to the I-Mab License Agreement. At December&#160;31, 2022, no revenue was deferred under the I-Mab License Agreement. At December&#160;31, 2021, $4.5 million in revenue was deferred under the I-Mab License Agreement, all of which was current.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab Clinical Supply Agreement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into an agreement under which the Company was to perform development and manufacturing services for I-Mab&#8217;s clinical needs of enoblituzumab (I-Mab Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of enoblituzumab. The transaction price was based on the costs incurred to develop and manufacture drug product and drug substance, and was recognized over time as the services were provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price was recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended December&#160;31, 2022, and 2021, the Company recognized revenue of $0.6 million and $1.3 million, respectively, for research and development activities performed under the I-Mab Clinical Supply Agreement.  The Company and I-Mab mutually agreed to terminate this agreement in November 2022. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Boehringer Ingelheim International GmbH</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, the Company entered into a collaboration and license agreement with Boehringer Ingelheim International GmbH (BII) to discover, develop and commercialize multiple DART molecules that were to be evaluated during a five-year period that ended in 2015 (Boehringer Agreement). Under the terms of the agreement, the Company granted BII an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated under the agreement.  During the evaluation period, BII selected two product candidates to develop (BII DARTs). Under the terms of the Boehringer Agreement, BII paid the Company an upfront payment of $15.0&#160;million which was fully recognized prior to December 31, 2015. The variable consideration under this agreement included potential future development and sales milestones and royalties on net sales in the event that the BII DARTs are commercialized.   </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, BII agreed to a payment of $12.0&#160;million in order to retain rights to develop the BII DARTs under the Boehringer Agreement.  As a result, the Company received and recognized as revenue $12.0&#160;million during the year ended December 31, 2020. The remaining potential development milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur and therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Services Agreements</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period at one of the Company&#8217;s manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $10.0&#160;million and is eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $14.4&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services. In July 2022, the Company and Incyte executed an amendment to the Incyte Manufacturing and Clinical Supply Agreement which extended the term for one year and provided for an additional annual fixed payment of $5.1&#160;million (July 2022 Incyte Amendment). </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement and the July 2022 Incyte Amendment under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price consists of the upfront payment received of $10.0&#160;million and the annual fixed payments totaling $19.5&#160;million. The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $8.7&#160;million under the Incyte Manufacturing and Clinical Supply Agreement  during the year ended December&#160;31, 2022. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.6&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8.1&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.5&#160;million </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of which was non-current.  </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention Bio, Inc. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Provention (Provention Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Provention bulk drug substance. Under the terms of the Provention Manufacturing and Clinical Supply Agreement, the Company received an upfront payment and payments in accordance with the manufacturing schedule.  The Company was also reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention Manufacturing and Clinical Supply Agreement under the provisions of ASC 606 and identified one performance obligation to provide manufacturing services to Provention. The Company determined that the transaction price consisted of the upfront and other fixed payments totaling $4.6&#160;million. The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Provention, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Provention will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Provention are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $5.3&#160;million under the Provention Manufacturing and Clinical Supply Agreement during the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with NIAID, effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of December&#160;31, 2022 is $25.1 million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023.  The Company recognized revenue of $1.9 million, $1.8 million and $7.1 million under the NIAID contract during the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788504676272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#8217;s common stock on the last day of the offering period. During the year ended December&#160;31, 2022, employees purchased 105,986 shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $0.4&#160;million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Incentive Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options. In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160;As of December&#160;31, 2022, under the 2003 Plan, there were options to purchase an aggregate of 65,103 shares of common stock outstanding at a weighted average exercise price of $5.90 per share.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was 1,960,168 shares.&#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended December&#160;31, 2022, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 15,816,949.&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2022, under the 2013 Plan, there were options to purchase an aggregate of 10,033,826 shares of common stock outstanding at a weighted average exercise price of $18.66 per share. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,437&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Options</span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation to employees and non-employee directors in accordance with ASC Topic 718, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Stock Compensation</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company estimates the fair value of stock option awards using the Black-Scholes option pricing model on the date of grant using the assumptions in the table below. Stock options granted to employees generally vest over four years and have a term of ten years. Stock-based compensation expense for stock options is recognized as expense over the requisite service period, which is the vesting period. As the Company has not paid dividends since inception, nor does it expect to pay any dividends for the foreseeable future, the expected dividend yield assumption is zero. The expected volatility is based on the historical stock volatility of the Company&#8217;s own common stock over a period equal to the expected term of the options. The risk-free rate of the stock options is based on the U.S. Treasury rate in effect at the time of grant for the expected term of the stock options. The Company used the simplified method to calculate expected term during 2020 and 2021.  Beginning in 2022, the computation of expected term was determined based on the historical experience with similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and expectations of future employee behavior.  In addition, the Company  estimates the expected forfeiture rate and only recognizes expense for those shares expected to vest. The Company estimates the forfeiture rate based on historical experience and its expectations regarding future pre-vesting termination behavior of employees. The Company reviews its estimate of the expected forfeiture rate annually, and stock-based compensation expense is adjusted accordingly.</span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:56.211%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88% -92%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86% - 87%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67% - 109%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 4.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6% - 1.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4% - 1.8%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,373,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,794,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509,569)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,098,929&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2022:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,694,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,456,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 2021 and 2020 the Company issued 120,900, 332,767 and 504,445 net shares of common stock, respectively, in conjunction with stock option exercises.&#160;The Company received cash proceeds from the exercise of stock options of approximately $0.2 million, $5.8 million and $5.3 million during 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during 2022, 2021 and 2020 was $6.84, $15.20 and $10.68 per share, respectively. The total intrinsic value of options exercised during 2022, 2021 and 2020 was approximately $0.6&#160;million, $3.3 million and $4.3 million, respectively.&#160;The total fair value of stock options which vested during 2022, 2021 and 2020 was $19.6 million, $20.2 million and $16.7 million, respectively.&#160;As of December&#160;31, 2022, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was $24.3 million, which the Company expects to recognize over a weighted-average period of approximately 1.3 years.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock options outstanding and exercisable by exercise price at December&#160;31, 2022 are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.134%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options Outstanding </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life in Years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.94 - $5.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,628&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.01 - $15.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,355,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.01 - $25.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,041,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,152,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$25.01 - $40.21</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,343,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,098,929&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,694,068&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company awards RSUs to employees. RSUs are valued based on the closing price of the Company&#8217;s common stock on the date of the grant. The fair value of RSUs is recognized and amortized on a straight-line basis over the requisite service period of the award</span><span style="color:#252525;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for 2022:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476,772&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,445)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,743)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,084&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, there was $2.0 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of one year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788503798176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020 there was no provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal U.S. net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(372,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,576)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,521)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,043)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,524)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax asset/(liability)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $777.0 million. Of these NOLs, $172.0 million will expire in various years beginning in 2025 through 2037. $605.0 million of NOLs were generated post December 31, 2017 and carryforward indefinitely. In addition, the Company has U.S. federal tax credits of $94.0 million which will expire in various years beginning in 2023 through 2041.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of December&#160;31, 2022, $13.5 million of the Company's U.S. Federal NOLs are limited for use over the years 2023 &#8211; 2028 in which a range of such amounts could be utilized on an annual basis of $0.2 million to $1.4 million. The remaining $763.0 million of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,149)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,445)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,245)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,385)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,569)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,691)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense/(benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases/(decreases) for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,376&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, of the total gross unrecognized tax benefits, approximately $7.4 million and $7.2 million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020, the Company has not recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's U.S. Federal and state income tax returns from 2003 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forward remain open to examination due to the carryover of unused income tax credits, and from 2004 forward due to the carryover of unused net operating losses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Revenue Code (IRC) Section 174</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to currently deduct research and development expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the United States and 15 years for research activities performed outside the United States </span></div>pursuant to IRC Section 174. Although Congress is considering legislation that would repeal or defer this capitalization and amortization requirement, it is not certain that this provision will be repealed or otherwise modified. If the requirement is not repealed or replaced, it could increase our U.S. federal and state cash taxes and reduce cash flows in 2023 and future years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788490877568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit PlanIn 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least 21 years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to 100% of their salary, subject to government maximums.Employees are 100% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. For the years ended December&#160;31, 2022, 2021 and 2020, the Company's contributions to the Plan totaled $2.3 million, $1.6 million and $1.4 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788504672752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">Subsequent EventIn March 2023, the Company entered into a Purchase and Sale Agreement (Royalty Purchase Agreement) with DRI Healthcare Acquisitions LP (DRI), a wholly-owned subsidiary of DRI Healthcare Trust.  Under the Royalty Purchase Agreement, the Company sold its single-digit royalty interest on global net sales of TZIELD (teplizumab-mzwv) under the Provention Asset Purchase Agreement to DRI.  The Company retains its other economic interests related to TZIELD, including future potential regulatory and commercial milestones.Under the terms of the Royalty Purchase Agreement, at the closing of the transaction, DRI paid the Company $100.0 million for its single-digit royalty interest on global net sales of TZIELD. The Company will have the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, the Company may also receive up to $50.0 million from DRI upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed type 1 diabetes and transactions regarding TZIELD and Provention. The Company may also receive an additional $50.0 million milestone from DRI if TZIELD achieves a certain level of sales.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788483065184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making </span></div>group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of current period financial statements. These reclassifications had no effect on the previously reported net loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#8217;s ability and intent to hold the investment to maturity. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable arise from product sales, amounts due from the Company&#8217;s collaborative partners and contract manufacturing work performed by the Company.  The amount from product sales represents amounts due from specialty distributors. Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2022 or 2021, as the Company has a history of collecting on all outstanding accounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div>The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.  There were no transfers between levels during the periods presented.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the U.S. Food and Drug Administration (FDA) in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Equipment and Software</a></td>
<td class="text">Property, Equipment and SoftwareProperty, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2022, and 2021, the Company determined that there were no impaired assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative and other agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company grants a license to its intellectual property, it </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determines whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone </span></div><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s intellectual property</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability  that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 8, Revenue.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product sales, net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the years ended December 31, 2022 and 2021, the shipping costs incurred were immaterial. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the year ended December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract manufacturing revenue</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with third parties to manufacture their drug substance at its GMP facility. The terms of these arrangements typically include an upfront payment to the Company to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue over time on a straight-line basis as the manufacturing services are performed, as the Company believes that its efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Product Sales and Cost of Manufacturing Services</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including labor, materials overhead and other related costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses, Including Clinical Trial Accruals/Expenses</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expense, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in </span></div>determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">Leases<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span>. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareBasic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788486378896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurement Financial Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.612%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,001&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,437&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at December&#160;31, 2022 includes approximately $46.5 million reported as cash and cash equivalents and $45.5&#160;million reported as marketable securities on the balance sheet.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2021 includes approximately $23.2 million reported as cash and cash equivalents and $120.1&#160;million reported as marketable securities on the balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Percentage of Customer Concentration</a></td>
<td class="text">The following table includes those counterparties <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that represent more than 10% of total revenue earned in the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:68.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte Corporation (Incyte)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen Biotech, Inc. (Janssen)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab Limited (Zai Lab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provention Bio, Inc (Provention)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I-Mab Biopharma (I-Mab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Amount is less than 10% for the period indicated.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provention</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I-Mab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD Healthcare and Oncology Supply</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Balance is less than 10% as of the date indicated.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock', window );">Estimated Useful Lives</a></td>
<td class="text">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.754%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share</a></td>
<td class="text">The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:44.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,514,013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,395,421</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,467,603</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788506221744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale</a></td>
<td class="text"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities as of December&#160;31, 2022 and 2021 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,462&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,208&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788489877904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text">The following table sets forth the Company's inventory, net of reserves (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.655%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.233%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ScheduleOfInventoryReservesTableTextBlock', window );">Schedule of Inventory Reserves</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory Reserves (in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions Charged to Expenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfInventoryReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Inventory Reserves</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ScheduleOfInventoryReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788486649936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motor vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,660&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,485&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,085)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,809)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,575&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,676&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788490621840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock', window );">Schedule Of Supplemental Balance Sheet Information, Operating Leases</a></td>
<td class="text">The table below presents supplemental balance sheet information related to operating leases:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2021 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,972&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,759&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Supplemental Balance Sheet Information, Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788490817072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,437&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Employee Stock Options Award Valuation Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:56.211%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88% -92%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86% - 87%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67% - 109%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 4.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6% - 1.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4% - 1.8%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,373,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,794,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509,569)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,098,929&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2022:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,694,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,456,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Share-Based Payment Arrangement, Option, Exercise Price Range</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock options outstanding and exercisable by exercise price at December&#160;31, 2022 are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.134%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options Outstanding </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life in Years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.94 - $5.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,628&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.01 - $15.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,355,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.01 - $25.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,041,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,152,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$25.01 - $40.21</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,343,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,098,929&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,694,068&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for 2022:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476,772&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,445)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,743)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415,084&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788489025792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Company's Deferred Income Tax Assets (Liabilities)</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal U.S. net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(372,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,576)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,521)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,043)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,524)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax asset/(liability)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Reported Estimated Income Tax Benefit</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,149)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,445)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,245)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,385)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,806)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,569)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,691)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense/(benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases/(decreases) for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,376&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788490301856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788488057232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 46,500<span></span>
</td>
<td class="nump">$ 23,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">45,462<span></span>
</td>
<td class="nump">120,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">45,462<span></span>
</td>
<td class="nump">120,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">92,001<span></span>
</td>
<td class="nump">143,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">41,564<span></span>
</td>
<td class="nump">17,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">32,811<span></span>
</td>
<td class="nump">7,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">17,626<span></span>
</td>
<td class="nump">37,280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">41,564<span></span>
</td>
<td class="nump">98,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">41,564<span></span>
</td>
<td class="nump">17,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">50,437<span></span>
</td>
<td class="nump">45,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">32,811<span></span>
</td>
<td class="nump">7,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 17,626<span></span>
</td>
<td class="nump">$ 37,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788487888720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Janssen Biotech Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Zai Lab Limited (Zai Lab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Les Laboratoires Servier And Institut De Recherches Servier (Servier)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | I-Mab Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">84.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Imab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | ASD Healthcare and Oncology Supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ZaiLabLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ZaiLabLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_IMabBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_IMabBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ProventionBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ProventionBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ImabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ImabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ASDHealthcareAndOncologySupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ASDHealthcareAndOncologySupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788486198592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember', window );">Laboratory and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788490616464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock options</a></td>
<td class="nump">10,514,013<span></span>
</td>
<td class="nump">8,395,421<span></span>
</td>
<td class="nump">7,467,603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788487867552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 45,467<span></span>
</td>
<td class="nump">$ 120,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">45,462<span></span>
</td>
<td class="nump">120,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">32,812<span></span>
</td>
<td class="nump">7,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">32,810<span></span>
</td>
<td class="nump">7,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">12,655<span></span>
</td>
<td class="nump">31,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 12,652<span></span>
</td>
<td class="nump">$ 31,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788486194656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Available-For-Sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Debt Securities, Available-for-sale, Allowance for Credit Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest Income, Other</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788483072528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory, Net - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Inventory, Work in Process, Gross</a></td>
<td class="nump">$ 409<span></span>
</td>
<td class="nump">$ 3,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Inventory, Finished Goods, Gross</a></td>
<td class="nump">1,042<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">1,451<span></span>
</td>
<td class="nump">4,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory valuation reserves</a></td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788488044736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net (Details) - SEC Schedule, 12-09, Reserve, Inventory - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Year</a></td>
<td class="nump">$ 4,917<span></span>
</td>
<td class="nump">$ 2,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions Charged to Expenses</a></td>
<td class="nump">2,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Year</a></td>
<td class="nump">$ 4,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_InventoryValuationReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_InventoryValuationReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788488078832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">$ 113,660<span></span>
</td>
<td class="nump">$ 110,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(84,085)<span></span>
</td>
<td class="num">(72,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">29,575<span></span>
</td>
<td class="nump">37,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">11,900<span></span>
</td>
<td class="nump">11,300<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">3,489<span></span>
</td>
<td class="nump">2,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">9,604<span></span>
</td>
<td class="nump">9,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">713<span></span>
</td>
<td class="nump">713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Motor vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">46,474<span></span>
</td>
<td class="nump">45,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">$ 52,974<span></span>
</td>
<td class="nump">$ 51,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788487990016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease', window );">Right of Use asset and Lease Liability Increase</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="nump">6,900<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, ROU Assets</a></td>
<td class="nump">27,335<span></span>
</td>
<td class="nump">16,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">5,597<span></span>
</td>
<td class="nump">5,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,451<span></span>
</td>
<td class="nump">960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="num">(1,076)<span></span>
</td>
<td class="num">(814)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, Cost</a></td>
<td class="nump">5,972<span></span>
</td>
<td class="nump">$ 5,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">4,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">4,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">5,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">4,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">4,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">52,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, Operating Lease, Liability, Payments, Due</a></td>
<td class="nump">75,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</a></td>
<td class="num">(40,444)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 34,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average lease term (in years)</a></td>
<td class="text">11 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 207,026<span></span>
</td>
<td class="nump">$ 214,577<span></span>
</td>
<td class="nump">$ 193,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_SynaffixBVMember', window );">Synaffix B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Use asset and Lease Liability Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RightOfUseAssetAndLeaseLiabilityIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_SynaffixBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_SynaffixBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788487704352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,085<span></span>
</td>
<td class="nump">$ 117,818<span></span>
</td>
<td class="nump">$ 170,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember', window );">Zai Lab | 2021 Zai Lab Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Undesignated preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Undesignated preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Undesignated preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuance', window );">Common stock maximum amount available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,480<span></span>
</td>
<td class="nump">3,622,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.87<span></span>
</td>
<td class="nump">$ 27.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 98,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease', window );">Common Stock, Maximum Amount Available For Issuance, Increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance, Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788484329632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Incyte Corporation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation (Incyte) | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeArrangementTerm', window );">Collaborative arrangement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeArrangementExtensionTerm', window );">Collaborative arrangement, extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember', window );">Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Amounts recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Clinical trial activities selling price amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="nump">$ 435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="nump">$ 330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Clinical Services | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Supply Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember', window );">RevenuesFromCMOAgreementsMember | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_TotalAnnualFixedPayments', window );">Total Annual Fixed Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAmendmentAgreementMember', window );">RevenuesFromCMOAmendmentAgreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_TotalAnnualFixedPayments', window );">Total Annual Fixed Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_AdditionalAnnualFixedPayments', window );">Additional Annual Fixed Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalAnnualFixedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Annual Fixed Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalAnnualFixedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeArrangementExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Extension Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeArrangementExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Commercial Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalAnnualFixedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Annual Fixed Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalAnnualFixedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteCommercialSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteCommercialSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteClinicalSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteClinicalSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788486343168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Gilead Sciences Inc (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 14, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_GileadMember', window );">Gilead | 2022 Gilead Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments', window );">Target nomination, option fees and milestone</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential target, nomination, option fees and milestone payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_GileadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_GileadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2022GileadCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2022GileadCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788485056992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Zai Lab (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMember', window );">Zai Lab Agreement | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonrefundablePaymentTaxWithholding', window );">Tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember', window );">Zai Lab Agreement, Margetuximab | Zai Lab | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember', window );">Zai Lab Agreement, TRIDENT molecule | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember', window );">Zai Lab Clinical Supply Agreements | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabCollaborationAndLicenseAgreementMember', window );">Zai Lab Collaboration And License Agreement | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding', window );">Non-refundable upfront payment, net of tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember', window );">2018 Zai Lab Collaboration And License Agreement | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_MilestonesValueAddedTax', window );">Milestones Value Added Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Amounts recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_RevenueFromVariableConsiderationRecognize', window );">Revenue from variable consideration recognize</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 680,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,800<span></span>
</td>
<td class="nump">20,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 16,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_EstimatedReimbursementForResearchAndDevelopmentT', window );">Estimated Reimbursement for Research and Development t</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Lab | Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PremiumReceivedOnStockPurchase', window );">Premium received on stock purchase</a></td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EstimatedReimbursementForResearchAndDevelopmentT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated Reimbursement for Research and Development t</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EstimatedReimbursementForResearchAndDevelopmentT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_MilestonesValueAddedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestones Value Added Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_MilestonesValueAddedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundablePaymentTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable Payment, Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundablePaymentTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Upfront Fees, Net Of Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Commercial Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PremiumReceivedOnStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which purchase price exceeds fair value for common stock purchased by collaborator.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PremiumReceivedOnStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueFromVariableConsiderationRecognize">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from variable consideration recognize</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueFromVariableConsiderationRecognize</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788488339632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Janssen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc. | Janssen Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales', window );">Potential milestone payments and royalties on product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Clinical trial activities selling price amount</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc. | Janssen Collaboration And License Agreement | Revenues From License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech Inc. | Janssen Collaboration And License Agreement | Revenue From Performance Of The Research And Development Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments and Royalties On Product Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788487975376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - I-Mab Biopharma (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember', window );">I-Mab Biopharma Collaboration And License Agreement | I-Mab Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Amounts recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount', window );">Estimated variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborationArrangementOneTimeCreditPaidPercent', window );">Collaboration Arrangement, One-time Credit Paid, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_OneTimeMillstoneCredit', window );">One Time Millstone Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember', window );">I-Mab Biopharma Collaboration And License Agreement Clinical Supply | I-Mab Biopharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationArrangementOneTimeCreditPaidPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, One-time Credit Paid, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationArrangementOneTimeCreditPaidPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OneTimeMillstoneCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>One Time Millstone Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OneTimeMillstoneCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Assess Variable Consideration, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788414347472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Provention (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
<td class="nump">$ 77,447<span></span>
</td>
<td class="nump">$ 104,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares', window );">Stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,432,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember', window );">Provention License Agreement | Provention PRV3279 | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Consideration received common stock warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement | Provention PRV031 | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Consideration received common stock warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement', window );">Potential milestone payment to third parties for intellectual property under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ReceivableFromCollaborationPartner', window );">Provention Bio Milestone Revenue in A/R</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Amounts recognized</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_ProventionBioCMOAgreeemntMember', window );">Provention Bio CMO Agreeemnt | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_UpfrontAndFixedPayments', window );">upfront and fixed payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Commercial Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ReceivableFromCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivable from collaboration partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ReceivableFromCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontAndFixedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>upfront and fixed payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontAndFixedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ProventionBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_ProventionBioCMOAgreeemntMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_ProventionBioCMOAgreeemntMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788506243376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Boehringer Ingelheim International GmbH (Details) - Boehringer Collaboration and License Agreement - Boehringer Ingelheim International GmbH<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">61 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($) </div>
<div>productCandidate</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementTerm', window );">Term of agreement (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NumberOfProductCandidates', window );">Number of product candidates to develop | productCandidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DevelopmentMilestonesAmount', window );">Development milestones</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration And License Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentMilestonesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Milestones, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentMilestonesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_BoehringerIngelheimInternationalGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_BoehringerIngelheimInternationalGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788486641632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - NIAID Contract (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>productCandidate</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 151,941,000<span></span>
</td>
<td class="nump">$ 77,447,000<span></span>
</td>
<td class="nump">$ 104,883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_TotalPotentialValueUnderAgreement', window );">Total potential value</a></td>
<td class="nump">25,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_BoehringerIngelheimInternationalGmbHMember', window );">Boehringer Ingelheim International GmbH | Boehringer Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NumberOfProductCandidates', window );">Number of product candidates to develop | productCandidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember', window );">RevenuesFromGrantsMember | NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NumberOfProductCandidates', window );">Number of product candidates to develop</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalPotentialValueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to total potential value under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalPotentialValueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_BoehringerIngelheimInternationalGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_BoehringerIngelheimInternationalGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788484037408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Employee Stock Purchase Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 18, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,085<span></span>
</td>
<td class="nump">$ 117,818<span></span>
</td>
<td class="nump">$ 170,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum employee contribution percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair market value to purchase shares</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock purchased by employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788414328256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">10,098,929<span></span>
</td>
<td class="nump">8,373,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 18.58<span></span>
</td>
<td class="nump">$ 21.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 20,437<span></span>
</td>
<td class="nump">$ 23,126<span></span>
</td>
<td class="nump">$ 20,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member', window );">Equity Incentive Plan 2003</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">65,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 5.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease', window );">Increased number of shares authorized (in shares)</a></td>
<td class="nump">15,816,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">10,033,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Percentage of common stock share outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 10,094<span></span>
</td>
<td class="nump">11,337<span></span>
</td>
<td class="nump">10,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 10,343<span></span>
</td>
<td class="nump">$ 11,789<span></span>
</td>
<td class="nump">$ 9,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares authorized after increase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788483008992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Option Pricing Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 11 months 12 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">109.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788488174768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Option, Exercise Price Range Table (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">10,098,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life in Years</a></td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 18.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Stock Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">6,694,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 21.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mgnx_ExercisePriceRangeFromDollars094To500MemberMember', window );">Exercise Price Range From Dollars 0.94 to 5.00 Member</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, lower limit</a></td>
<td class="nump">0.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, upper limit</a></td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">357,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life in Years</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 3.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Stock Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">143,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 3.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mgnx_ExercisePriceRangeFromDollars501To1500MemberMember', window );">Exercise Price Range From Dollars 5.01 to 15.00 Member</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, lower limit</a></td>
<td class="nump">5.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, upper limit</a></td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">3,355,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life in Years</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 10.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Stock Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">1,211,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 10.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember', window );">Exercise Price Range From Dollars 15.01 to 25.00 Member</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, lower limit</a></td>
<td class="nump">15.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, upper limit</a></td>
<td class="nump">$ 25.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">4,041,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life in Years</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 20.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Stock Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">3,152,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 20.39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember', window );">Exercise Price Range From Dollars 25.01 to 40.21 Member</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, lower limit</a></td>
<td class="nump">25.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, upper limit</a></td>
<td class="nump">$ 40.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">2,343,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life in Years</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 29.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Stock Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">2,187,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 29.64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mgnx_ExercisePriceRangeFromDollars094To500MemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mgnx_ExercisePriceRangeFromDollars094To500MemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mgnx_ExercisePriceRangeFromDollars501To1500MemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mgnx_ExercisePriceRangeFromDollars501To1500MemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788483915328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">8,373,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2,794,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(120,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(509,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</a></td>
<td class="num">(439,520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 22.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">10,098,929<span></span>
</td>
<td class="nump">8,373,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">6,694,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">9,456,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 21.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">9.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">1.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in dollars per share)</a></td>
<td class="nump">15.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">18.58<span></span>
</td>
<td class="nump">$ 21.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">21.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 18.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term, Outstanding</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Exercisable</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Vested and expected to vest</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 1,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="nump">424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and expected to vest</a></td>
<td class="nump">$ 1,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">120,900<span></span>
</td>
<td class="nump">332,767<span></span>
</td>
<td class="nump">504,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 6.84<span></span>
</td>
<td class="nump">$ 15.20<span></span>
</td>
<td class="nump">$ 10.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">19,600<span></span>
</td>
<td class="nump">$ 20,200<span></span>
</td>
<td class="nump">$ 16,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</a></td>
<td class="nump">$ 24,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">10,033,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">476,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(10,445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(72,743)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">415,084<span></span>
</td>
<td class="nump">21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 25.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">8.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share)</a></td>
<td class="nump">25.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited or expired (in dollars per share)</a></td>
<td class="nump">8.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">$ 8.83<span></span>
</td>
<td class="nump">$ 25.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted in period (in shares)</a></td>
<td class="nump">476,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized compensation cost</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788488382784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Provision for federal or state income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation', window );">Remaining portion of net operating losses</a></td>
<td class="nump">763,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Gross unrecognized tax benefits</a></td>
<td class="nump">7,400,000<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember', window );">U.S. Federal and State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">777,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember', window );">U.S. Federal and State | Tax Year 2025 To 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">172,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember', window );">U.S. Federal and State | Indefinite</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">605,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">US Federal tax credits carry forward</a></td>
<td class="nump">94,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount', window );">Net operating loss for limited use</a></td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Net operating losses limited for use utilized on an annual basis</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Net operating losses limited for use utilized on an annual basis</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss which are limited for use, utilized on a annual basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsAnnualLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss carryforward, which are limited for use over the range of years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards not subject to limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsNotSubjectToLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mgnx_TaxYear2025To2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mgnx_TaxYear2025To2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mgnx_IndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mgnx_IndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788488162640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal U.S. net operating loss carryforward</a></td>
<td class="nump">$ 163,071<span></span>
</td>
<td class="nump">$ 175,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforward</a></td>
<td class="nump">44,784<span></span>
</td>
<td class="nump">49,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit, net</a></td>
<td class="nump">65,084<span></span>
</td>
<td class="nump">60,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Orphan drug credit, net</a></td>
<td class="nump">35,703<span></span>
</td>
<td class="nump">24,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">9,585<span></span>
</td>
<td class="nump">7,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_Section174DeferredTaxAsset', window );">Section 174 deferred tax asset</a></td>
<td class="nump">43,192<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">19,733<span></span>
</td>
<td class="nump">16,727<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred income tax assets</a></td>
<td class="nump">381,310<span></span>
</td>
<td class="nump">336,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(372,267)<span></span>
</td>
<td class="num">(327,595)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">9,043<span></span>
</td>
<td class="nump">8,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,688)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Operating lease ROU assets</a></td>
<td class="num">(7,522)<span></span>
</td>
<td class="num">(4,576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenditures</a></td>
<td class="num">(1,521)<span></span>
</td>
<td class="num">(2,260)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred income tax liabilities</a></td>
<td class="num">(9,043)<span></span>
</td>
<td class="num">(8,524)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset/(liability)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_Section174DeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Section 174 deferred tax asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_Section174DeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788484212240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">United States federal tax at statutory rate</a></td>
<td class="num">$ (25,149)<span></span>
</td>
<td class="num">$ (42,445)<span></span>
</td>
<td class="num">$ (27,245)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes (net of federal benefit)</a></td>
<td class="num">(7,385)<span></span>
</td>
<td class="num">(12,806)<span></span>
</td>
<td class="num">(8,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount', window );">Deferred income tax adjustments</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">473<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credit, net</a></td>
<td class="num">(4,569)<span></span>
</td>
<td class="num">(10,243)<span></span>
</td>
<td class="num">(14,691)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther', window );">Orphan drug credit, net</a></td>
<td class="num">(10,846)<span></span>
</td>
<td class="num">(1,449)<span></span>
</td>
<td class="num">(528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other permanent items</a></td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">1,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Equity-based compensation</a></td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">44,675<span></span>
</td>
<td class="nump">64,192<span></span>
</td>
<td class="nump">48,510<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense/(benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788488053984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 7,197<span></span>
</td>
<td class="nump">$ 6,126<span></span>
</td>
<td class="nump">$ 4,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases for current year tax positions</a></td>
<td class="nump">548<span></span>
</td>
<td class="nump">965<span></span>
</td>
<td class="nump">839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions', window );">Increases/(decreases) for prior year tax positions</a></td>
<td class="num">(369)<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 7,376<span></span>
</td>
<td class="nump">$ 7,197<span></span>
</td>
<td class="nump">$ 6,126<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788490419760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan', window );">Eligible age to participate in plan</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of employee contribution to salary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage', window );">Percentage of employee vested contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contribution amount</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage vested of employee's contributions to defined contribution plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to minimum eligible age of employee to participate in benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788484039888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Subsequent EventIn March 2023, the Company entered into a Purchase and Sale Agreement (Royalty Purchase Agreement) with DRI Healthcare Acquisitions LP (DRI), a wholly-owned subsidiary of DRI Healthcare Trust.  Under the Royalty Purchase Agreement, the Company sold its single-digit royalty interest on global net sales of TZIELD (teplizumab-mzwv) under the Provention Asset Purchase Agreement to DRI.  The Company retains its other economic interests related to TZIELD, including future potential regulatory and commercial milestones.Under the terms of the Royalty Purchase Agreement, at the closing of the transaction, DRI paid the Company $100.0 million for its single-digit royalty interest on global net sales of TZIELD. The Company will have the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, the Company may also receive up to $50.0 million from DRI upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed type 1 diabetes and transactions regarding TZIELD and Provention. The Company may also receive an additional $50.0 million milestone from DRI if TZIELD achieves a certain level of sales.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation (Incyte) | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_DRIHealthcareAcquisitionsLPDRIMember', window );">DRI Healthcare Acquisitions LP (DRI) | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_UpfrontPayment', window );">Upfront Payment from DRI Health Trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_FutureMilestone', window );">Milestone from DRI</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_FutureRevenue', window );">Future Revenue from DRI</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FutureMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FutureMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FutureRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FutureRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_DRIHealthcareAcquisitionsLPDRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_DRIHealthcareAcquisitionsLPDRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139788490094992">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
<td class="nump">958,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>mgnx-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mgnx="http://macrogenics.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20221231.xsd" xlink:type="simple"/>
    <context id="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia8eb7d177b724915967268594839281d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i31e765beb79e48d59898de0cccf072fe_I20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="ie9c3771622be4a8cabd1a5821e850e19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4aa22d39a8624176a6fa8407907a9309_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia9cd9cf7c6804d5db20f82023e1a54a3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if4f2d1a2d1e94bbdad3b332217f7cdc1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifa4a44fb906e46059cf27ad3f371c8f4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i80cfdb689d6442978f9b166889e5847e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id6f8af80ca2f4b52802a161c595e5052_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6db8545d9a764d70adfa1bdc46929964_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5e3d5dee46f14e89ab361baca8c84d19_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icb12fb8ba4294ec0b24b921f652da5b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie4583fefc635419baaecffdc14a3347d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0a8c07e35eb0448186c12e229bd209be_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3313b69530a74ec6b2e2460d390f798d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i61e770fa73c645568d90bb0126331399_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i20f8f2550477493380452b0726f39b25_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id38bfa0cc8324178bc6a9c6bcdcbaa4d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i168b736ecb73412f845967d23572788f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib844aa7657c647948f34d81afd439366_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia3204ec3dcb94da6895af490452b85e8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i60ca2d1b9b3648e78bc6323a0e727305_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6042637bb9814b299266c07d6f819e1a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7e5cc6d01e4e4d18ab3182fee2be3b14_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9caefd6e32774b6fa3be813c566241b1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i583ba990216e462fa437b644733fd007_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic8feb38eaa7f4d0284d3e12e8c61f985_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4cb9f5c3fbbf4386b0b1c7457c63b569_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if007d64ddb0940ae9820885f23536cbe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibca9a275183b461588ccd2c99d84a7b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d09ee83f16a43899a8e2f0580a10ce5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3fbdab93b76148c68de348ba99c602c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i28ca167332fb4ffca8f0aeb269e494e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3fb4710bb5ad4ea39e2ce055f9920e7a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i97989f78335d4f06a53493f09437b7a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4886a2c10d494c22822a89f90bb4c4e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie94494340ac149908fbf8ece8b640537_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25b8b9bc70774790a5df2d37523b9735_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7612f92852c41f58ba57ed9d4a891f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a3e10cae8b7460cb0b3c709f1dd7806_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i99fe8fd853b04bf9a915b7facf36738b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2fd1adc97945441f91da73361323fa86_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ide2999adda92451a8ff2e717b50f9e49_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7177857c4ed5490d949b3547941967c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic40f80873ab547fc9bfb939c4cde42e6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13f15ef91e7144c5b9b9a3240d6df07e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i66087c2443374414a3213b8856e0c032_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0f73f14816ca46229e3f5a04cf8f8524_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iecec8ea079224e8494dc049a32f87d5f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ica167215fb9048c3b86ad884a91a3ad7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0424cfbed6734206b9a86432dd4a627b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief2cfe25e2144cfb983dd1db2b3cb8f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i564748a61ef54aef8920e9ee95f57d20_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5df1bd36e7134fb283ddef9208f2d1d6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia2e823de84ae4499891e90615ba17bd2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e6cb699e8f846b9a29724cef42aa3dc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief715af7397b4bbc946fd81d6ef9642c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ea080f686ed4c7985dd2ed9b933233d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i75573cbeb0d94490a290b059cc9eb61f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i427d51006aa64de0a7a8d0cd8c18a011_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6501227d18c4697ad97204a2bb6636d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62ba5b88f01a40738c1cbf6ae8e4c17d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc13d1fb533048d9a7687c94b7811d70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d03481f525f4af8b46765578d2c616a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f32cea665ba4844b458f7cca002f6d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95312e9fdb7544afa0e46c69a02b159e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6c03a9650c248c7bc7c0dcc9ee0ef29_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7eed347f0fb4bc6a341449db8f7771b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib2f906f81cab4560ae73910713996b25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52c92a0b8bdf4ac491affce8a16e718a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53d9dd52b0a848c7af77775ff7df34b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6e62bf001444be7b3fc5d2bac8294e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9fc76d0cb27246d89175301dc8968ddf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7b3c6dbfbcc454e915c319790c99bb2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc945f6be73546b2afbc3f7e91a7829e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie59d44df2b334c9cb26d2a7a0c7871f7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib18dc8cc7b9a48b8903b573ec4c92a4e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b8796d99b14454ea1069baedf468150_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i70e62fd23da147a7bbfb414455b3e79d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic8682e59ba6945349b855aa4242ac643_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i604d5c2d6f54497d9519656986424b6a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1eb0cdf897b34e7299f5aed8a57a554c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4946c226bb1048199aac012daace167d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i12dd7404d2a7431e85b17656e3f960c6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia4eede0cc1bb4da3aaf51c9487514340_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic100551ff962425281acea19be14d51e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ImabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3d1bb961749c4c69a5d4f00e2387e986_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie282942c434e49a58118206bfeb797af_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ASDHealthcareAndOncologySupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9aa7f28c164743c18f02c60499ebf31f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ief36ee226752463cbcd31a9ee80c5cfe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2f68116386e241a1b517c6290a020dfd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i43aae3612f484fc782f7958caa1ea5f0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0d86aae1ee24443584fb111e79fb643d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i83f6d05daae94102afa6b769661625fd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3d7a17d898bc403992983ad4d53cdb20_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ief133d06a929409ea24e246bbecdca4d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia2861d07b8b44b3bb7d2dabf91c6d1e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iede6b8c452354940bfab31e913316625_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f73d3bc964445778f3435766499d956_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia479f3cd68cd4df3b2165aefbe470f19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i269e66b57b7b42519a681c1a8cc89766_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62bfa97ca0b441f598ddfc23f1117719_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iadceb1c7c1874b8ba0b62e7c4d2ff42d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0ecc54ff86bd462dbcf7438abf4ac388_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iddda6f6be78f4602886e324038e7f82c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c41356f213a40cd81fe3fb1a47a4c2b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibc75a33630b8494aa7a9d885440fb55b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6131b1918c0e4fdb853bcc6ad763b7ca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i20d7b43945214a0f9748176a7c4e3c92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd0a8a099634446f9fb626545b035d04_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41a609eef7164eeca03b96057a76706d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ca3bfc3b74349b0824017e2224f2eed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1fb1258352cf41e99f6e755e10b66dd5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1420654e5aac46a18c1f6b2e6ca46fe7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied072b573720413181b76aa300c73290_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1f326cd30a042929083a704f1d6c9b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2fd4290024fb4044a496f5b0095aec3a_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="i7b9d38ff906a423c980d0021ca83eefd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6a3cb7b2a9c84dd89c8cfd99ca5abf7c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a5e971264d548579cbdbbcb85309080_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica4884a38171464fb3771d584bde78ae_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i24a49a71f1f04f838393fe224709a584_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idcbca4caa7f44c80ab53213c339fb544_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icec55a17872746d2856769218fef60aa_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i8b2c42e5029948ed9d33d72c422ec15b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i867d5919542f4494a26a231e8b7346e0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i32e8c25671ba4f6fb24dee37c0820f11_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i66fe51ad0d964f1896d0f96af0e1e372_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ife8f008f05574ef1870bdae6c66d666b_I20210615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-15</instant>
        </period>
    </context>
    <context id="i7335e9f1b9ca42eca438a74f5c67ab3a_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3bf402b9dbdd4d87ae5d49d80d3bfbd1_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5669556108fb4b49ab6793e93d991f6f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia6f88ee6c6234a019d97d24e5e39ceff_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="ibea2d6a312194bd6a0ecf5f54c65238a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i988a06040edf4aa0b8a3f3cd042479bd_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i9110adb267ef45a6aa425a647075f177_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i38eeebe054f049c9bc2b9a0534ffdab3_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="i01a768287b9d4dba83bffa872d2e72c8_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="iee9e9e7ce67a49de83726523a441d2ff_D20170101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7f61d57a20cd4679bf6ecc932ade4702_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i633fd2fb64ad42c4b92eebba0535d397_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60225cd201b84577ac14ccd93f6b150d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2135354a19f64808a2cc5c96c8be75a2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i287b95f9f02e4ed1a66f479666758d0a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1793ad9c6b4f4244b4ee579221db1b13_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i75eb5df4d251413fba2adbdc9e57ccb9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc0cec4a5a73427eb832e2674227c093_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b71d094740b4c1e9c5b2ff8f8b13f29_D20221014-20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="iaf251b9dfa1d4ed89dfd50e9d5821e5e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8b7bc40165fd46a193e3cccf1f049cfa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i96872571cd0a4110aadf271b65708d4f_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i69bfd0f8331b41bba3c4e5efaa36efc4_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i54460e4405804e6d8632d256ca806b3a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ideaa024a11c34bdb89c49cd5c437abdb_D20200701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3160099d486f4eb0ac91ae68ee1818a5_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="idda174e868e34f569bb5414b16d63aaf_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="ia6508d36a64142029325de20e5324de6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4d66046a5ee64f7788d581007532e524_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1d938aac5ed04e51bcb036c13e6fa016_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2018ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1715d94674d945de83bbfd371f7c13c4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i767daa988e954076be39c9747efd7d0d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5e1ac66792744af791f7f6abfa4dcef6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i54dc0d7d758841359d25ada6f2a3f6bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8e5adc3d5e2442fbbb01084952f712f4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i05c59e94ee554f07bf1f21a28ba5d901_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib60793823f51401f91c4fe5a62120d5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b1d84cceaa14d2b82272120f3d141a5_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4cc71ed45f8424fb7ad7a930e7af919_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b4b8204955c40b9a81053a2ea6a7a34_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i11525e01950f45fa820c699ad1b87012_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i823ffcf87c174dfd869db3d5bf2f4876_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1ce4656c88644281a81473a1a311bcbb_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i13845f28c8184f82b5a85649094c84bc_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i7dfb8c7e4fd04324883491a98fdd5523_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="id5332bdbc1ac4d42acfb85ff18b8d769_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i8fdd00452e734cd1a063f90a315bd38e_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="i42483221131f4b7481cd3ebfbdd95b45_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="if91ec42029d64d03b3bab9599a9791b5_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i687253dc3b1a4370bafa13817794d0a3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0f896d007a6a40c48c8fb6cc5e26ea95_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5c37a5c38e654c99b1697de56b18cac8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i58e91935654b49eab232a7ec7b32496c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia1ecd07929384da0be9ffd4764df7764_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i35eba6ff61e44d84bf6a3d50767ad056_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i641ea39eabec428e8868e07727550f9b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i221ddea90685424e9202290d98e954b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d9b291f44c14b62a56b45b107bce2be_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i74eb3a9ad62848108dd74bde2d588232_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8d15a5f2354a420f9695a7e6099f117f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if52c5ab82dd044a69f0166c3ff58ca62_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8e86a555e3f24015bead72636200ae9a_D20101001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="i57cad70ea273424dabf7a187420e4724_I20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="i15b810928e3242aaa7f2093120fe452e_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if20ab34aae324e0ba9bf43107ec6f001_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa77d46ed2c54978a8e628b9c800991f_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="if00f09390f0345d98c06a7e6e9cc8a8b_D20220101-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i1445c3a2eddd4bfeb9296be4f2aca5ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia8717043cd074e1297a517f4c6e6cc88_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i623d0a5a27c445f8a4c07b43115440e9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6d1179302351453e86c2c3157b6019e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ProventionBioCMOAgreeemntMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib46875612ebc4591ae7244a0f9125f6e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ProventionBioCMOAgreeemntMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9c73c17081c04144891915096cd9ed39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5ee02f7ab344826b0c16f694bb46f66_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i691134ba3b13405da417f0241eb6ca6d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9e0c41dd27764d34aa9ab34ec3e0805a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf4d116422ce486bb630e9f82b58aeb1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i169fc1b09cca4f95bc19d111a9403716_I20170518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-18</instant>
        </period>
    </context>
    <context id="i9360fd694d5e424f8c7bd8fd3eb717bc_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i452d203362b14c6ca8da438846c11955_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i957cb602cb054b3ea23a8226a9ddbb3a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia0502d2128aa4313a80c03495c0ed1ea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i544f43f987bd419e8c458062ac60ce6f_I20131031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-10-31</instant>
        </period>
    </context>
    <context id="i07711b76935c4009a2ace4be4f684dd6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i255a59bd218f42e2af9732b94035f04c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iffd00d99f798466d860442a9d6fe22f2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if50f063c6cd94e9a8db88782218b51c9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6968adfd4fe340119028718b06cfb436_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie6322f1cbd714b298d2485ddc0fc3322_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i529ec6ae784044b38dc167bc1dfef832_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26acb212525e4cc19f85aeb7f96576bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e619dc3a61b43d087d92cd2fee49ef4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic0e3bcdcfbcf4c97b49dae77737eb857_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i03b32c2299d94db490057c88800e534c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id868fe5312d548fda66c272fedcbd81c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic345c52c1f4b4493a8a2205795297694_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4a9eb4001cb48e29e15fb1edeea83c2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i458932626a4e44acacb64a6525da2b9a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mgnx:ExercisePriceRangeFromDollars094To500MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i781cf98fff854dee996c091defcba9ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mgnx:ExercisePriceRangeFromDollars094To500MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia4f6bf1229f9423d9d74a89cbee04492_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mgnx:ExercisePriceRangeFromDollars501To1500MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3bd6e8fd9d6e41759ae8ce19e1f15dc0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mgnx:ExercisePriceRangeFromDollars501To1500MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb9b7e3cc6654c6ab1c1abd54c49d1b0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mgnx:ExercisePriceRangeFromDollars1501To2500MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i65f1a38a652c4027a979e5802d9bf79f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mgnx:ExercisePriceRangeFromDollars1501To2500MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d2cf19a216341f7b8ee2b4013afc61e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mgnx:ExercisePriceRangeFromDollars2501To4021MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i734a212745e14c3da7f13584d8590872_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">mgnx:ExercisePriceRangeFromDollars2501To4021MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3bd6e5ab104947eb9423512ebd965f85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if31e41373baa4fea9e84a7408c5073dd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2847395a9c0e4cb490b51246d0a78963_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie1a3ce377fe84955853c621ebe3898e1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic8563ce4345344189c9f265ecff1081e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:TaxYear2025To2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i305df6411bc540c288af86c6048f32a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iabb762e6d67f44868d3a4659e39f91a1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i16521e389da946b0bfcbbb417dd1be5e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic22e2b51dfee4a8e88cd23892f992f68_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6170cef51c304b009b2a8259c24dafdc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia220f44f166a475abc1053b676542ca5_I20230315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-15</instant>
        </period>
    </context>
    <context id="i3ec282a2b1564332bd9e83d00ada0da7_D20230301-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>mgnx:Segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="productcandidate">
        <measure>mgnx:productCandidate</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-32">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-33">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-35">0001125345</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-3">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-6">001-36112</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-7">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-9">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-10">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-11">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-12">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-13">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-14">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-15">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-16">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-17">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-27">false</dei:EntityShellCompany>
    <dei:DocumentFiscalYearFocus
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-28">2022</dei:DocumentFiscalYearFocus>
    <dei:EntityPublicFloat
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-5"
      id="f-29"
      unitRef="usd">181300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i31e765beb79e48d59898de0cccf072fe_I20230228"
      decimals="INF"
      id="f-30"
      unitRef="shares">61838565</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-31">Portions of MacroGenics, Inc.'s definitive proxy statement for the 2023 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-36">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-37">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-38">Tysons, Virginia</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-39"
      unitRef="usd">108884000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-40"
      unitRef="usd">123469000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Investments
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-41"
      unitRef="usd">45462000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-42"
      unitRef="usd">120147000</us-gaap:Investments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-43"
      unitRef="usd">56222000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-44"
      unitRef="usd">10386000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-45"
      unitRef="usd">1451000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-46"
      unitRef="usd">4388000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-47"
      unitRef="usd">10161000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-48"
      unitRef="usd">21170000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-49"
      unitRef="usd">222180000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-50"
      unitRef="usd">279560000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-51"
      unitRef="usd">29575000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-52"
      unitRef="usd">37676000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-53"
      unitRef="usd">27335000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-54"
      unitRef="usd">16614000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-55"
      unitRef="usd">1378000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-56"
      unitRef="usd">1395000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-57"
      unitRef="usd">280468000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-58"
      unitRef="usd">335245000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-59"
      unitRef="usd">4899000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-60"
      unitRef="usd">15500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-61"
      unitRef="usd">28998000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-62"
      unitRef="usd">33755000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-63"
      unitRef="usd">9988000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-64"
      unitRef="usd">20646000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-65"
      unitRef="usd">4726000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-66"
      unitRef="usd">4677000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-67"
      unitRef="usd">48611000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-68"
      unitRef="usd">74578000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-69"
      unitRef="usd">59480000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-70"
      unitRef="usd">0</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-71"
      unitRef="usd">30106000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-72"
      unitRef="usd">20791000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-73"
      unitRef="usd">258000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-74"
      unitRef="usd">258000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-75"
      unitRef="usd">138455000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-76"
      unitRef="usd">95627000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="INF"
      id="f-77"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="INF"
      id="f-78"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="INF"
      id="f-79"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="INF"
      id="f-80"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="INF"
      id="f-81"
      unitRef="shares">61701467</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="INF"
      id="f-82"
      unitRef="shares">61307428</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-83"
      unitRef="usd">617000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-84"
      unitRef="usd">613000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-85"
      unitRef="usd">1235095000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-86"
      unitRef="usd">1213002000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-87"
      unitRef="usd">-5000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-88"
      unitRef="usd">-61000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-89"
      unitRef="usd">-1093694000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-90"
      unitRef="usd">-973936000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-91"
      unitRef="usd">142013000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-92"
      unitRef="usd">239618000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-93"
      unitRef="usd">280468000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-94"
      unitRef="usd">335245000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i4aa22d39a8624176a6fa8407907a9309_D20220101-20221231"
      decimals="-3"
      id="f-95"
      unitRef="usd">119303000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia9cd9cf7c6804d5db20f82023e1a54a3_D20210101-20211231"
      decimals="-3"
      id="f-96"
      unitRef="usd">63294000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4f2d1a2d1e94bbdad3b332217f7cdc1_D20200101-20201231"
      decimals="-3"
      id="f-97"
      unitRef="usd">97764000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa4a44fb906e46059cf27ad3f371c8f4_D20220101-20221231"
      decimals="-3"
      id="f-98"
      unitRef="usd">16727000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80cfdb689d6442978f9b166889e5847e_D20210101-20211231"
      decimals="-3"
      id="f-99"
      unitRef="usd">12349000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id6f8af80ca2f4b52802a161c595e5052_D20200101-20201231"
      decimals="-3"
      id="f-100"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6db8545d9a764d70adfa1bdc46929964_D20220101-20221231"
      decimals="-3"
      id="f-101"
      unitRef="usd">13988000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5e3d5dee46f14e89ab361baca8c84d19_D20210101-20211231"
      decimals="-3"
      id="f-102"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb12fb8ba4294ec0b24b921f652da5b9_D20200101-20201231"
      decimals="-3"
      id="f-103"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4583fefc635419baaecffdc14a3347d_D20220101-20221231"
      decimals="-3"
      id="f-104"
      unitRef="usd">1923000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0a8c07e35eb0448186c12e229bd209be_D20210101-20211231"
      decimals="-3"
      id="f-105"
      unitRef="usd">1804000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3313b69530a74ec6b2e2460d390f798d_D20200101-20201231"
      decimals="-3"
      id="f-106"
      unitRef="usd">7119000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-107"
      unitRef="usd">151941000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-108"
      unitRef="usd">77447000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-109"
      unitRef="usd">104883000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-110"
      unitRef="usd">3351000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-111"
      unitRef="usd">2651000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-112"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <mgnx:CostOfManufacturingServices
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-113"
      unitRef="usd">4033000</mgnx:CostOfManufacturingServices>
    <mgnx:CostOfManufacturingServices
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-114"
      unitRef="usd">0</mgnx:CostOfManufacturingServices>
    <mgnx:CostOfManufacturingServices
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-115"
      unitRef="usd">0</mgnx:CostOfManufacturingServices>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-116"
      unitRef="usd">207026000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-117"
      unitRef="usd">214577000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-118"
      unitRef="usd">193201000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-119"
      unitRef="usd">58949000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-120"
      unitRef="usd">63014000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-121"
      unitRef="usd">42742000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-122"
      unitRef="usd">273359000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-123"
      unitRef="usd">280242000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-124"
      unitRef="usd">235943000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-125"
      unitRef="usd">-121418000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-126"
      unitRef="usd">-202795000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-127"
      unitRef="usd">-131060000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-128"
      unitRef="usd">1660000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-129"
      unitRef="usd">680000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-130"
      unitRef="usd">1321000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-131"
      unitRef="usd">-119758000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-132"
      unitRef="usd">-202115000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-133"
      unitRef="usd">-129739000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-134"
      unitRef="usd">56000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-135"
      unitRef="usd">-54000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-136"
      unitRef="usd">-23000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-137"
      unitRef="usd">-119702000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-138"
      unitRef="usd">-202169000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-139"
      unitRef="usd">-129762000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="2"
      id="f-140"
      unitRef="usdPerShare">-1.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="2"
      id="f-141"
      unitRef="usdPerShare">-1.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="2"
      id="f-142"
      unitRef="usdPerShare">-3.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="2"
      id="f-143"
      unitRef="usdPerShare">-3.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="2"
      id="f-144"
      unitRef="usdPerShare">-2.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="2"
      id="f-145"
      unitRef="usdPerShare">-2.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="0"
      id="f-146"
      unitRef="shares">61433124</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="0"
      id="f-147"
      unitRef="shares">61433124</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="0"
      id="f-148"
      unitRef="shares">59944717</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="0"
      id="f-149"
      unitRef="shares">59944717</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="0"
      id="f-150"
      unitRef="shares">52442389</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="0"
      id="f-151"
      unitRef="shares">52442389</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesIssued
      contextRef="id38bfa0cc8324178bc6a9c6bcdcbaa4d_I20191231"
      decimals="INF"
      id="f-152"
      unitRef="shares">48958763</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="id38bfa0cc8324178bc6a9c6bcdcbaa4d_I20191231"
      decimals="-3"
      id="f-153"
      unitRef="usd">490000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i168b736ecb73412f845967d23572788f_I20191231"
      decimals="-3"
      id="f-154"
      unitRef="usd">872204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib844aa7657c647948f34d81afd439366_I20191231"
      decimals="-3"
      id="f-155"
      unitRef="usd">-642082000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia3204ec3dcb94da6895af490452b85e8_I20191231"
      decimals="-3"
      id="f-156"
      unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i60ca2d1b9b3648e78bc6323a0e727305_I20191231"
      decimals="-3"
      id="f-157"
      unitRef="usd">230628000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6042637bb9814b299266c07d6f819e1a_D20200101-20201231"
      decimals="-3"
      id="f-158"
      unitRef="usd">20676000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-159"
      unitRef="usd">20676000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7e5cc6d01e4e4d18ab3182fee2be3b14_D20200101-20201231"
      decimals="INF"
      id="f-160"
      unitRef="shares">6612815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7e5cc6d01e4e4d18ab3182fee2be3b14_D20200101-20201231"
      decimals="-3"
      id="f-161"
      unitRef="usd">66000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6042637bb9814b299266c07d6f819e1a_D20200101-20201231"
      decimals="-3"
      id="f-162"
      unitRef="usd">170390000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-163"
      unitRef="usd">170456000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="i7e5cc6d01e4e4d18ab3182fee2be3b14_D20200101-20201231"
      decimals="INF"
      id="f-164"
      unitRef="shares">673193</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i7e5cc6d01e4e4d18ab3182fee2be3b14_D20200101-20201231"
      decimals="-3"
      id="f-165"
      unitRef="usd">6000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i6042637bb9814b299266c07d6f819e1a_D20200101-20201231"
      decimals="-3"
      id="f-166"
      unitRef="usd">3880000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-167"
      unitRef="usd">3886000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i9caefd6e32774b6fa3be813c566241b1_D20200101-20201231"
      decimals="-3"
      id="f-168"
      unitRef="usd">-23000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-169"
      unitRef="usd">-23000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i583ba990216e462fa437b644733fd007_D20200101-20201231"
      decimals="-3"
      id="f-170"
      unitRef="usd">-129739000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-171"
      unitRef="usd">-129739000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ic8feb38eaa7f4d0284d3e12e8c61f985_I20201231"
      decimals="INF"
      id="f-172"
      unitRef="shares">56244771</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ic8feb38eaa7f4d0284d3e12e8c61f985_I20201231"
      decimals="-3"
      id="f-173"
      unitRef="usd">562000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4cb9f5c3fbbf4386b0b1c7457c63b569_I20201231"
      decimals="-3"
      id="f-174"
      unitRef="usd">1067150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if007d64ddb0940ae9820885f23536cbe_I20201231"
      decimals="-3"
      id="f-175"
      unitRef="usd">-771821000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibca9a275183b461588ccd2c99d84a7b5_I20201231"
      decimals="-3"
      id="f-176"
      unitRef="usd">-7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d09ee83f16a43899a8e2f0580a10ce5_I20201231"
      decimals="-3"
      id="f-177"
      unitRef="usd">295884000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3fbdab93b76148c68de348ba99c602c7_D20210101-20211231"
      decimals="-3"
      id="f-178"
      unitRef="usd">23126000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-179"
      unitRef="usd">23126000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i28ca167332fb4ffca8f0aeb269e494e4_D20210101-20211231"
      decimals="INF"
      id="f-180"
      unitRef="shares">4580653</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i28ca167332fb4ffca8f0aeb269e494e4_D20210101-20211231"
      decimals="-3"
      id="f-181"
      unitRef="usd">46000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3fbdab93b76148c68de348ba99c602c7_D20210101-20211231"
      decimals="-3"
      id="f-182"
      unitRef="usd">117772000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-183"
      unitRef="usd">117818000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="i28ca167332fb4ffca8f0aeb269e494e4_D20210101-20211231"
      decimals="INF"
      id="f-184"
      unitRef="shares">482004</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i28ca167332fb4ffca8f0aeb269e494e4_D20210101-20211231"
      decimals="-3"
      id="f-185"
      unitRef="usd">5000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i3fbdab93b76148c68de348ba99c602c7_D20210101-20211231"
      decimals="-3"
      id="f-186"
      unitRef="usd">4954000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-187"
      unitRef="usd">4959000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i3fb4710bb5ad4ea39e2ce055f9920e7a_D20210101-20211231"
      decimals="-3"
      id="f-188"
      unitRef="usd">-54000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-189"
      unitRef="usd">-54000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i97989f78335d4f06a53493f09437b7a1_D20210101-20211231"
      decimals="-3"
      id="f-190"
      unitRef="usd">-202115000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-191"
      unitRef="usd">-202115000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i4886a2c10d494c22822a89f90bb4c4e0_I20211231"
      decimals="INF"
      id="f-192"
      unitRef="shares">61307428</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i4886a2c10d494c22822a89f90bb4c4e0_I20211231"
      decimals="-3"
      id="f-193"
      unitRef="usd">613000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie94494340ac149908fbf8ece8b640537_I20211231"
      decimals="-3"
      id="f-194"
      unitRef="usd">1213002000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i25b8b9bc70774790a5df2d37523b9735_I20211231"
      decimals="-3"
      id="f-195"
      unitRef="usd">-973936000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie7612f92852c41f58ba57ed9d4a891f0_I20211231"
      decimals="-3"
      id="f-196"
      unitRef="usd">-61000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-197"
      unitRef="usd">239618000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1a3e10cae8b7460cb0b3c709f1dd7806_D20220101-20221231"
      decimals="-3"
      id="f-198"
      unitRef="usd">20438000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-199"
      unitRef="usd">20438000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i99fe8fd853b04bf9a915b7facf36738b_D20220101-20221231"
      decimals="INF"
      id="f-200"
      unitRef="shares">160480</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i99fe8fd853b04bf9a915b7facf36738b_D20220101-20221231"
      decimals="-3"
      id="f-201"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1a3e10cae8b7460cb0b3c709f1dd7806_D20220101-20221231"
      decimals="-3"
      id="f-202"
      unitRef="usd">1083000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-203"
      unitRef="usd">1085000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="i99fe8fd853b04bf9a915b7facf36738b_D20220101-20221231"
      decimals="INF"
      id="f-204"
      unitRef="shares">233559</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i99fe8fd853b04bf9a915b7facf36738b_D20220101-20221231"
      decimals="-3"
      id="f-205"
      unitRef="usd">2000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="i1a3e10cae8b7460cb0b3c709f1dd7806_D20220101-20221231"
      decimals="-3"
      id="f-206"
      unitRef="usd">572000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-207"
      unitRef="usd">574000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i2fd1adc97945441f91da73361323fa86_D20220101-20221231"
      decimals="-3"
      id="f-208"
      unitRef="usd">56000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-209"
      unitRef="usd">56000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="ide2999adda92451a8ff2e717b50f9e49_D20220101-20221231"
      decimals="-3"
      id="f-210"
      unitRef="usd">-119758000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-211"
      unitRef="usd">-119758000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i7177857c4ed5490d949b3547941967c1_I20221231"
      decimals="INF"
      id="f-212"
      unitRef="shares">61701467</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i7177857c4ed5490d949b3547941967c1_I20221231"
      decimals="-3"
      id="f-213"
      unitRef="usd">617000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic40f80873ab547fc9bfb939c4cde42e6_I20221231"
      decimals="-3"
      id="f-214"
      unitRef="usd">1235095000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i13f15ef91e7144c5b9b9a3240d6df07e_I20221231"
      decimals="-3"
      id="f-215"
      unitRef="usd">-1093694000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i66087c2443374414a3213b8856e0c032_I20221231"
      decimals="-3"
      id="f-216"
      unitRef="usd">-5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-217"
      unitRef="usd">142013000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-218"
      unitRef="usd">-119758000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-219"
      unitRef="usd">-202115000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-220"
      unitRef="usd">-129739000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-221"
      unitRef="usd">11865000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-222"
      unitRef="usd">11258000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-223"
      unitRef="usd">11957000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-224"
      unitRef="usd">-403000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-225"
      unitRef="usd">-1607000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-226"
      unitRef="usd">260000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-227"
      unitRef="usd">20438000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-228"
      unitRef="usd">23126000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-229"
      unitRef="usd">20676000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-230"
      unitRef="usd">-2882000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-231"
      unitRef="usd">-2035000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-232"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-233"
      unitRef="usd">45836000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-234"
      unitRef="usd">-12696000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-235"
      unitRef="usd">10337000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-236"
      unitRef="usd">-55000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-237"
      unitRef="usd">6424000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-238"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-239"
      unitRef="usd">-11009000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-240"
      unitRef="usd">4188000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-241"
      unitRef="usd">5697000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-242"
      unitRef="usd">10704000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-243"
      unitRef="usd">-5915000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-244"
      unitRef="usd">-581000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-245"
      unitRef="usd">-10860000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-246"
      unitRef="usd">7125000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-247"
      unitRef="usd">3723000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-248"
      unitRef="usd">-4638000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-249"
      unitRef="usd">-607000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-250"
      unitRef="usd">6994000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-251"
      unitRef="usd">9364000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-252"
      unitRef="usd">-3780000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-253"
      unitRef="usd">-1324000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-254"
      unitRef="usd">48821000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-255"
      unitRef="usd">9264000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-256"
      unitRef="usd">-8472000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <mgnx:IncreaseDecreaseInDeferredRent
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-257"
      unitRef="usd">0</mgnx:IncreaseDecreaseInDeferredRent>
    <mgnx:IncreaseDecreaseInDeferredRent
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-258"
      unitRef="usd">258000</mgnx:IncreaseDecreaseInDeferredRent>
    <mgnx:IncreaseDecreaseInDeferredRent
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-259"
      unitRef="usd">0</mgnx:IncreaseDecreaseInDeferredRent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-260"
      unitRef="usd">-86959000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-261"
      unitRef="usd">-143830000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-262"
      unitRef="usd">-111898000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-263"
      unitRef="usd">120602000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-264"
      unitRef="usd">231208000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-265"
      unitRef="usd">223745000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-266"
      unitRef="usd">194940000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-267"
      unitRef="usd">200800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-268"
      unitRef="usd">221866000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-269"
      unitRef="usd">3623000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-270"
      unitRef="usd">6201000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-271"
      unitRef="usd">5906000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-272"
      unitRef="usd">70715000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-273"
      unitRef="usd">-36609000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-274"
      unitRef="usd">-7785000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-275"
      unitRef="usd">1085000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-276"
      unitRef="usd">117818000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-277"
      unitRef="usd">170456000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-278"
      unitRef="usd">574000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-279"
      unitRef="usd">4959000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-280"
      unitRef="usd">3886000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-281"
      unitRef="usd">1659000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-282"
      unitRef="usd">122777000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-283"
      unitRef="usd">174342000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-284"
      unitRef="usd">-14585000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-285"
      unitRef="usd">-57662000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-286"
      unitRef="usd">54659000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-287"
      unitRef="usd">123469000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0d09ee83f16a43899a8e2f0580a10ce5_I20201231"
      decimals="-3"
      id="f-288"
      unitRef="usd">181131000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i60ca2d1b9b3648e78bc6323a0e727305_I20191231"
      decimals="-3"
      id="f-289"
      unitRef="usd">126472000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-290"
      unitRef="usd">108884000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-291"
      unitRef="usd">123469000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0d09ee83f16a43899a8e2f0580a10ce5_I20201231"
      decimals="-3"
      id="f-292"
      unitRef="usd">181131000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-293"
      unitRef="usd">118000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-294"
      unitRef="usd">508000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-295"
      unitRef="usd">66000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-296">Organization and Nature of Operations&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company has a pipeline of product candidates being evaluated in clinical trials sponsored by MacroGenics or its collaborators.  These product candidates include multiple oncology programs, some of which were created primarily using the Company&#x2019;s proprietary, antibody-based technology platforms. The Company believes our product candidates have the potential, if approved for marketing by regulatory authorities, to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.  In March 2021, the Company and its commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#x2019;s stockholders&#x2019; equity and working capital, and accordingly, its ability to execute its future operating plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings, revenue from its multiple collaboration agreements, and contracts and grants from the National Institute of Allergy and Infectious Diseases (NIAID).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management regularly reviews the Company&#x2019;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#x2019;s working capital. The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements, and product sales. The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities.  If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization. It is considered probable that the Company can successfully implement efforts to manage uncommitted spending and carry out necessary cost saving measures, including from the Company's corporate restructuring plan announced in August 2022. Based on the Company&#x2019;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Annual Report on Form 10-K was filed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Similar to the other risk factors pertinent to the Company's business, the COVID-19 pandemic and geopolitical tensions, including the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia, and related global slowdown of economic activity, decades-high inflation, rising interest rates and a potential recession in the United States might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to these uncertainties, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-297">Summary of Significant Accounting Policies&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of current period financial statements. These reclassifications had no effect on the previously reported net loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#x2019;s ability and intent to hold the investment to maturity. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable arise from product sales, amounts due from the Company&#x2019;s collaborative partners and contract manufacturing work performed by the Company.  The amount from product sales represents amounts due from specialty distributors. Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2022 or 2021, as the Company has a history of collecting on all outstanding accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#x2013; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.  &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between levels during the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.612%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at December&#160;31, 2022 includes approximately $46.5 million reported as cash and cash equivalents and $45.5&#160;million reported as marketable securities on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2021 includes approximately $23.2 million reported as cash and cash equivalents and $120.1&#160;million reported as marketable securities on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The counterparties are various corporations, financial institutions and government agencies of high credit standing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenue relates to agreements with various collaborators, MARGENZA net product sales and&#160;contracts and research grants received from U.S. government agencies.&#160;The following table includes those counterparties &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that represent more than 10% of total revenue earned in the periods indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incyte Corporation (Incyte)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen Biotech, Inc. (Janssen)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab Limited (Zai Lab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provention Bio, Inc (Provention)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I-Mab Biopharma (I-Mab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Amount is less than 10% for the period indicated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provention&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I-Mab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Plasma &amp;amp; Biologics and McKesson Specialty Care Distribution LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASD Healthcare and Oncology Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Balance is less than 10% as of the date indicated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the U.S. Food and Drug Administration (FDA) in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Equipment and Software&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2022, and 2021, the Company determined that there were no impaired assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative and other agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#x2019;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company grants a license to its intellectual property, it &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determines whether the &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#x2019;s intellectual property&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research, Development and/or Manufacturing Services. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promises under the Company&#x2019;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability  that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 8, Revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product sales, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#x2019;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the years ended December 31, 2022 and 2021, the shipping costs incurred were immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Variable Consideration.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Discounts and Service Fees.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provider Chargebacks and Discounts.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#x2019;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with third parties to manufacture their drug substance at its GMP facility. The terms of these arrangements typically include an upfront payment to the Company to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue over time on a straight-line basis as the manufacturing services are performed, as the Company believes that its efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cost of Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Manufacturing Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including labor, materials overhead and other related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense, Including Clinical Trial Accruals/Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expenses are a significant component of research and development expense, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented. The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,514,013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,395,421&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,467,603&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-298">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making &lt;/span&gt;&lt;/div&gt;group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="INF"
      id="f-299"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="INF"
      id="f-300"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-301">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-302">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of current period financial statements. These reclassifications had no effect on the previously reported net loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-303">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#x2019;s ability and intent to hold the investment to maturity. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-304">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable arise from product sales, amounts due from the Company&#x2019;s collaborative partners and contract manufacturing work performed by the Company.  The amount from product sales represents amounts due from specialty distributors. Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2022 or 2021, as the Company has a history of collecting on all outstanding accounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-305">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#x2013; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.  There were no transfers between levels during the periods presented.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-306">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.612%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at December&#160;31, 2022 includes approximately $46.5 million reported as cash and cash equivalents and $45.5&#160;million reported as marketable securities on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2021 includes approximately $23.2 million reported as cash and cash equivalents and $120.1&#160;million reported as marketable securities on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0f73f14816ca46229e3f5a04cf8f8524_I20221231"
      decimals="-3"
      id="f-307"
      unitRef="usd">41564000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iecec8ea079224e8494dc049a32f87d5f_I20221231"
      decimals="-3"
      id="f-308"
      unitRef="usd">41564000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ica167215fb9048c3b86ad884a91a3ad7_I20221231"
      decimals="-3"
      id="f-309"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0424cfbed6734206b9a86432dd4a627b_I20221231"
      decimals="-3"
      id="f-310"
      unitRef="usd">32811000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ief2cfe25e2144cfb983dd1db2b3cb8f7_I20221231"
      decimals="-3"
      id="f-311"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i564748a61ef54aef8920e9ee95f57d20_I20221231"
      decimals="-3"
      id="f-312"
      unitRef="usd">32811000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5df1bd36e7134fb283ddef9208f2d1d6_I20221231"
      decimals="-3"
      id="f-313"
      unitRef="usd">17626000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia2e823de84ae4499891e90615ba17bd2_I20221231"
      decimals="-3"
      id="f-314"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1e6cb699e8f846b9a29724cef42aa3dc_I20221231"
      decimals="-3"
      id="f-315"
      unitRef="usd">17626000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ief715af7397b4bbc946fd81d6ef9642c_I20221231"
      decimals="-3"
      id="f-316"
      unitRef="usd">92001000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6ea080f686ed4c7985dd2ed9b933233d_I20221231"
      decimals="-3"
      id="f-317"
      unitRef="usd">41564000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i75573cbeb0d94490a290b059cc9eb61f_I20221231"
      decimals="-3"
      id="f-318"
      unitRef="usd">50437000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i427d51006aa64de0a7a8d0cd8c18a011_I20211231"
      decimals="-3"
      id="f-319"
      unitRef="usd">17202000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if6501227d18c4697ad97204a2bb6636d_I20211231"
      decimals="-3"
      id="f-320"
      unitRef="usd">17202000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i62ba5b88f01a40738c1cbf6ae8e4c17d_I20211231"
      decimals="-3"
      id="f-321"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icc13d1fb533048d9a7687c94b7811d70_I20211231"
      decimals="-3"
      id="f-322"
      unitRef="usd">81132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0d03481f525f4af8b46765578d2c616a_I20211231"
      decimals="-3"
      id="f-323"
      unitRef="usd">81132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2f32cea665ba4844b458f7cca002f6d7_I20211231"
      decimals="-3"
      id="f-324"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i95312e9fdb7544afa0e46c69a02b159e_I20211231"
      decimals="-3"
      id="f-325"
      unitRef="usd">7734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia6c03a9650c248c7bc7c0dcc9ee0ef29_I20211231"
      decimals="-3"
      id="f-326"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if7eed347f0fb4bc6a341449db8f7771b_I20211231"
      decimals="-3"
      id="f-327"
      unitRef="usd">7734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib2f906f81cab4560ae73910713996b25_I20211231"
      decimals="-3"
      id="f-328"
      unitRef="usd">37280000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i52c92a0b8bdf4ac491affce8a16e718a_I20211231"
      decimals="-3"
      id="f-329"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i53d9dd52b0a848c7af77775ff7df34b5_I20211231"
      decimals="-3"
      id="f-330"
      unitRef="usd">37280000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia6e62bf001444be7b3fc5d2bac8294e7_I20211231"
      decimals="-3"
      id="f-331"
      unitRef="usd">143348000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9fc76d0cb27246d89175301dc8968ddf_I20211231"
      decimals="-3"
      id="f-332"
      unitRef="usd">98334000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib7b3c6dbfbcc454e915c319790c99bb2_I20211231"
      decimals="-3"
      id="f-333"
      unitRef="usd">45014000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-5"
      id="f-334"
      unitRef="usd">46500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-5"
      id="f-335"
      unitRef="usd">45500000</us-gaap:Investments>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-5"
      id="f-336"
      unitRef="usd">23200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-5"
      id="f-337"
      unitRef="usd">120100000</us-gaap:Investments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-338">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The counterparties are various corporations, financial institutions and government agencies of high credit standing.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-339">The following table includes those counterparties &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that represent more than 10% of total revenue earned in the periods indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incyte Corporation (Incyte)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen Biotech, Inc. (Janssen)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab Limited (Zai Lab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provention Bio, Inc (Provention)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I-Mab Biopharma (I-Mab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Amount is less than 10% for the period indicated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provention&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I-Mab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Plasma &amp;amp; Biologics and McKesson Specialty Care Distribution LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASD Healthcare and Oncology Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Balance is less than 10% as of the date indicated.&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifc945f6be73546b2afbc3f7e91a7829e_D20220101-20221231"
      decimals="2"
      id="f-340"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie59d44df2b334c9cb26d2a7a0c7871f7_D20210101-20211231"
      decimals="2"
      id="f-341"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib18dc8cc7b9a48b8903b573ec4c92a4e_D20200101-20201231"
      decimals="2"
      id="f-342"
      unitRef="number">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6b8796d99b14454ea1069baedf468150_D20200101-20201231"
      decimals="2"
      id="f-343"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i70e62fd23da147a7bbfb414455b3e79d_D20220101-20221231"
      decimals="2"
      id="f-344"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic8682e59ba6945349b855aa4242ac643_D20210101-20211231"
      decimals="2"
      id="f-345"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i604d5c2d6f54497d9519656986424b6a_D20200101-20201231"
      decimals="2"
      id="f-346"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1eb0cdf897b34e7299f5aed8a57a554c_D20220101-20221231"
      decimals="2"
      id="f-347"
      unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4946c226bb1048199aac012daace167d_D20210101-20211231"
      decimals="2"
      id="f-348"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i12dd7404d2a7431e85b17656e3f960c6_D20220101-20221231"
      decimals="2"
      id="f-349"
      unitRef="number">0.84</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia4eede0cc1bb4da3aaf51c9487514340_D20210101-20211231"
      decimals="2"
      id="f-350"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic100551ff962425281acea19be14d51e_D20210101-20211231"
      decimals="2"
      id="f-351"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3d1bb961749c4c69a5d4f00e2387e986_D20210101-20211231"
      decimals="2"
      id="f-352"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie282942c434e49a58118206bfeb797af_D20210101-20211231"
      decimals="2"
      id="f-353"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-354">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory.  Prior to receiving its first approval from the U.S. Food and Drug Administration (FDA) in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.  Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-355">Property, Equipment and SoftwareProperty, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-356">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i9aa7f28c164743c18f02c60499ebf31f_D20220101-20221231"
      id="f-357">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ief36ee226752463cbcd31a9ee80c5cfe_D20220101-20221231"
      id="f-358">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2f68116386e241a1b517c6290a020dfd_D20220101-20221231"
      id="f-359">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i43aae3612f484fc782f7958caa1ea5f0_D20220101-20221231"
      id="f-360">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-361">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2022, and 2021, the Company determined that there were no impaired assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-362">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative and other agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, the Company&#x2019;s assumptions may include (i)  the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company grants a license to its intellectual property, it &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determines whether the &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;functionality.  Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#x2019;s intellectual property&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research, Development and/or Manufacturing Services. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promises under the Company&#x2019;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability  that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160; Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 8, Revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product sales, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product.  The specialty distributors subsequently resell the Company&#x2019;s product to healthcare providers.  Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. For the years ended December 31, 2022 and 2021, the shipping costs incurred were immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Variable Consideration.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Estimates of the variable consideration were not deemed constrained during the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Discounts and Service Fees.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provider Chargebacks and Discounts.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#x2019;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with third parties to manufacture their drug substance at its GMP facility. The terms of these arrangements typically include an upfront payment to the Company to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue over time on a straight-line basis as the manufacturing services are performed, as the Company believes that its efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.&lt;/span&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-363">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cost of Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product sales relates to sales of MARGENZA.  These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves.  All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense.  The Company expects cost of product sales to continue to be positively impacted as the Company sells through inventory that was expensed prior to FDA approval of MARGENZA. The Company is currently unable to estimate how long it will be until it begins selling product manufactured post FDA approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Manufacturing Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including labor, materials overhead and other related costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-364">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense, Including Clinical Trial Accruals/Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expenses are a significant component of research and development expense, and the Company outsources  a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; When evaluating the adequacy of the accrued expenses, management  analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in &lt;/span&gt;&lt;/div&gt;determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-365">Leases&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-366">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-367">Net Loss Per ShareBasic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-368">The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,514,013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,395,421&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,467,603&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0d86aae1ee24443584fb111e79fb643d_D20220101-20221231"
      decimals="0"
      id="f-369"
      unitRef="shares">10514013</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i83f6d05daae94102afa6b769661625fd_D20210101-20211231"
      decimals="0"
      id="f-370"
      unitRef="shares">8395421</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3d7a17d898bc403992983ad4d53cdb20_D20200101-20201231"
      decimals="0"
      id="f-371"
      unitRef="shares">7467603</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-372">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-373">Marketable Securities&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities as of December&#160;31, 2022 and 2021 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's available-for-sale securities held at December&#160;31, 2022 and 2021 had contractual maturities of less than one year.  All of the Company&#x2019;s available-for-sale marketable debt securities in an unrealized loss position as of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2021 were in a loss position for less than twelve months.&#160; Unrealized losses on available-for-sale debt securities as of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021 &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded interest income of $1.7 million, $2.0 million and $0.8 million during the years ended December&#160;31, 2022, 2021 and 2020, respectively, which is included in other income on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-374">&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities as of December&#160;31, 2022 and 2021 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ief133d06a929409ea24e246bbecdca4d_I20221231"
      decimals="-3"
      id="f-375"
      unitRef="usd">32812000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ief133d06a929409ea24e246bbecdca4d_I20221231"
      decimals="-3"
      id="f-376"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ief133d06a929409ea24e246bbecdca4d_I20221231"
      decimals="-3"
      id="f-377"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ief133d06a929409ea24e246bbecdca4d_I20221231"
      decimals="-3"
      id="f-378"
      unitRef="usd">32810000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia2861d07b8b44b3bb7d2dabf91c6d1e7_I20221231"
      decimals="-3"
      id="f-379"
      unitRef="usd">12655000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia2861d07b8b44b3bb7d2dabf91c6d1e7_I20221231"
      decimals="-3"
      id="f-380"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia2861d07b8b44b3bb7d2dabf91c6d1e7_I20221231"
      decimals="-3"
      id="f-381"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia2861d07b8b44b3bb7d2dabf91c6d1e7_I20221231"
      decimals="-3"
      id="f-382"
      unitRef="usd">12652000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-383"
      unitRef="usd">45467000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-384"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-385"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-386"
      unitRef="usd">45462000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iede6b8c452354940bfab31e913316625_I20211231"
      decimals="-3"
      id="f-387"
      unitRef="usd">81184000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iede6b8c452354940bfab31e913316625_I20211231"
      decimals="-3"
      id="f-388"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iede6b8c452354940bfab31e913316625_I20211231"
      decimals="-3"
      id="f-389"
      unitRef="usd">52000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iede6b8c452354940bfab31e913316625_I20211231"
      decimals="-3"
      id="f-390"
      unitRef="usd">81132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4f73d3bc964445778f3435766499d956_I20211231"
      decimals="-3"
      id="f-391"
      unitRef="usd">7739000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4f73d3bc964445778f3435766499d956_I20211231"
      decimals="-3"
      id="f-392"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4f73d3bc964445778f3435766499d956_I20211231"
      decimals="-3"
      id="f-393"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4f73d3bc964445778f3435766499d956_I20211231"
      decimals="-3"
      id="f-394"
      unitRef="usd">7734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia479f3cd68cd4df3b2165aefbe470f19_I20211231"
      decimals="-3"
      id="f-395"
      unitRef="usd">31285000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia479f3cd68cd4df3b2165aefbe470f19_I20211231"
      decimals="-3"
      id="f-396"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia479f3cd68cd4df3b2165aefbe470f19_I20211231"
      decimals="-3"
      id="f-397"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia479f3cd68cd4df3b2165aefbe470f19_I20211231"
      decimals="-3"
      id="f-398"
      unitRef="usd">31281000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-399"
      unitRef="usd">120208000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-400"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-401"
      unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-402"
      unitRef="usd">120147000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="INF"
      id="f-403"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="INF"
      id="f-404"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InterestIncomeOther
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-5"
      id="f-405"
      unitRef="usd">1700000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-5"
      id="f-406"
      unitRef="usd">2000000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-5"
      id="f-407"
      unitRef="usd">800000</us-gaap:InterestIncomeOther>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-408">Inventory, Net&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's inventory relates to the manufacturing of MARGENZA.  The following table sets forth the Company's inventory, net of reserves (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of December&#160;31, 2022 and December&#160;31, 2021 is net of a reserve of $4.9 million and $2.0&#160;million, respectively, for unsaleable inventory. These reserves are reflected in cost of product sales during the period they are recorded.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inventory Reserves (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at Beginning of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions Charged to Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at End of Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-409">The following table sets forth the Company's inventory, net of reserves (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryWorkInProcess
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-410"
      unitRef="usd">409000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-411"
      unitRef="usd">3929000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-412"
      unitRef="usd">1042000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-413"
      unitRef="usd">459000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-414"
      unitRef="usd">1451000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-415"
      unitRef="usd">4388000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-5"
      id="f-416"
      unitRef="usd">4900000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-5"
      id="f-417"
      unitRef="usd">2000000</us-gaap:InventoryValuationReserves>
    <mgnx:ScheduleOfInventoryReservesTableTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-418">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inventory Reserves (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at Beginning of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions Charged to Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at End of Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</mgnx:ScheduleOfInventoryReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i269e66b57b7b42519a681c1a8cc89766_I20211231"
      decimals="-3"
      id="f-419"
      unitRef="usd">2035000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i62bfa97ca0b441f598ddfc23f1117719_D20220101-20221231"
      decimals="-3"
      id="f-420"
      unitRef="usd">2882000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i62bfa97ca0b441f598ddfc23f1117719_D20220101-20221231"
      decimals="-3"
      id="f-421"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iadceb1c7c1874b8ba0b62e7c4d2ff42d_I20221231"
      decimals="-3"
      id="f-422"
      unitRef="usd">4917000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-423">Property, Equipment and Software&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and software consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Motor vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2022, 2021 and 2020 was $11.9 million, $11.3 million and $12.0 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-424">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and software consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Motor vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0ecc54ff86bd462dbcf7438abf4ac388_I20221231"
      decimals="-3"
      id="f-425"
      unitRef="usd">3489000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iddda6f6be78f4602886e324038e7f82c_I20211231"
      decimals="-3"
      id="f-426"
      unitRef="usd">2890000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9c41356f213a40cd81fe3fb1a47a4c2b_I20221231"
      decimals="-3"
      id="f-427"
      unitRef="usd">9604000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibc75a33630b8494aa7a9d885440fb55b_I20211231"
      decimals="-3"
      id="f-428"
      unitRef="usd">9453000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6131b1918c0e4fdb853bcc6ad763b7ca_I20221231"
      decimals="-3"
      id="f-429"
      unitRef="usd">713000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i20d7b43945214a0f9748176a7c4e3c92_I20211231"
      decimals="-3"
      id="f-430"
      unitRef="usd">713000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icd0a8a099634446f9fb626545b035d04_I20221231"
      decimals="-3"
      id="f-431"
      unitRef="usd">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i41a609eef7164eeca03b96057a76706d_I20211231"
      decimals="-3"
      id="f-432"
      unitRef="usd">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4ca3bfc3b74349b0824017e2224f2eed_I20221231"
      decimals="-3"
      id="f-433"
      unitRef="usd">46474000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1fb1258352cf41e99f6e755e10b66dd5_I20211231"
      decimals="-3"
      id="f-434"
      unitRef="usd">45693000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1420654e5aac46a18c1f6b2e6ca46fe7_I20221231"
      decimals="-3"
      id="f-435"
      unitRef="usd">52974000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ied072b573720413181b76aa300c73290_I20211231"
      decimals="-3"
      id="f-436"
      unitRef="usd">51056000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-437"
      unitRef="usd">356000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-438"
      unitRef="usd">630000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-439"
      unitRef="usd">113660000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-440"
      unitRef="usd">110485000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-441"
      unitRef="usd">84085000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-442"
      unitRef="usd">72809000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-443"
      unitRef="usd">29575000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-444"
      unitRef="usd">37676000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-5"
      id="f-445"
      unitRef="usd">11900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-5"
      id="f-446"
      unitRef="usd">11300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-5"
      id="f-447"
      unitRef="usd">12000000</us-gaap:Depreciation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-448">Commitments and Contingencies&#160;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has non-cancelable operating leases for manufacturing, laboratory, office and warehouse space in Maryland and a non-cancelable operating lease for laboratory and office space in California. A portion of the space under one of these leases is subleased to a third party. The California facility and the smaller-scale, non-commercial GMP manufacturing site in Maryland will be closed under the Company&#x2019;s restructuring plan announced in August 2022, therefore the leases for those sites will not be renewed when they expire.  The Company&#x2019;s continuing leases each have one or more five-year options to renew&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In December 2022, the Company amended the existing lease on its headquarters space to extend the lease term through 2035 in exchange for certain concessions from the lessor.  This amendment was accounted for as a lease modification, and the right-of-use asset and lease liability were remeasured at the modification date, resulting in an increase to both balances of approximately $14.0 million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents supplemental balance sheet information related to operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022 and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2021, t&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company made cash payments for operating leases of $6.9 million and $6.7 million, respectively. As of December&#160;31, 2022 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2021,&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company&#x2019;s ROU assets were valued at $27.3 million and $16.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2021 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;In-licensing arrangement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company entered into a non-exclusive license agreement with Synaffix B.V. (Synaffix) to develop, manufacture and commercialize up to three antibody-drug conjugate targets using Synaffix&#x2019;s proprietary technology. The Company made an upfront payment to Synaffix upon contract execution. Assuming all three targets are successfully developed and commercialized, the Company would be obligated to pay up to $585.0&#160;million for development, regulatory and sales milestones. Finally, pursuant to the terms of this license agreement, upon commencement of commercial sales of any products developed from these targets, the Company would be required to pay Synaffix tiered royalties in the low&#x2011;single digit percentages on net sales of the respective products. The Company may terminate this agreement at any time with 30 days&#x2019; notice to Synaffix. Amounts paid to Synaffix under this agreement are recorded as research and development expense in the consolidated statement of operations.  During the year ended December&#160;31, 2022, the Company incurred $1.0&#160;million under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland (District Court) by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#x2019;s SOPHIA trial. On August 17, 2020, the Employees&#x2019; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint. The amended complaint asserted a putative class period stemming from February 6, 2019 to June 4, 2019. The Company filed a Motion to Dismiss on November 30, 2020. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice. On October 28, 2021 the Lead Plaintiff filed a Notice of Appeal in the Fourth Circuit. The Company did not accrue any liability associated with this action as of December 31, 2022. The 4th Circuit affirmed the District Court&#x2019;s dismissal in a decision published on March 2, 2023.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ia1f326cd30a042929083a704f1d6c9b3_I20221231"
      id="f-449">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mgnx:RightOfUseAssetAndLeaseLiabilityIncrease
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-5"
      id="f-450"
      unitRef="usd">14000000</mgnx:RightOfUseAssetAndLeaseLiabilityIncrease>
    <mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-451">The table below presents supplemental balance sheet information related to operating leases:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      id="f-452">P11Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      id="f-453">P5Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="3"
      id="f-454"
      unitRef="number">0.120</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="3"
      id="f-455"
      unitRef="number">0.097</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeasePayments
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-5"
      id="f-456"
      unitRef="usd">6900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-5"
      id="f-457"
      unitRef="usd">6700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-5"
      id="f-458"
      unitRef="usd">27300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-5"
      id="f-459"
      unitRef="usd">16600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-460">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2021 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-461"
      unitRef="usd">5597000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-462"
      unitRef="usd">5613000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-463"
      unitRef="usd">1451000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-464"
      unitRef="usd">960000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-465"
      unitRef="usd">1076000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-466"
      unitRef="usd">814000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-467"
      unitRef="usd">5972000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-468"
      unitRef="usd">5759000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-469">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-470"
      unitRef="usd">4999000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-471"
      unitRef="usd">4004000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-472"
      unitRef="usd">5084000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-473"
      unitRef="usd">4209000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-474"
      unitRef="usd">4927000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-475"
      unitRef="usd">52053000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-476"
      unitRef="usd">75276000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-477"
      unitRef="usd">40444000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-478"
      unitRef="usd">34832000</us-gaap:OperatingLeaseLiability>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i2fd4290024fb4044a496f5b0095aec3a_I20220131"
      decimals="-5"
      id="f-479"
      unitRef="usd">585000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7b9d38ff906a423c980d0021ca83eefd_D20220101-20221231"
      decimals="-5"
      id="f-480"
      unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-481">Stockholders' Equity&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's amended and restated certificate of incorporation authorizes 125,000,000 shares of common stock, and 5,000,000 shares of undesignated preferred stock, both with a par value of $0.01 per share.&#160;There were no shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2022 or 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the Company entered into a sales agreement (Sales Agreement) with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0 million through an &#x201c;at the market offering&#x201d; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. The shares that were sold under the Sales Agreement were issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 4, 2020.  During the year ended December 31, 2021, the Company sold 3,622,186 shares of common stock at a weighted average price per share of $27.60, resulting in net proceeds of approximately $98.2 million, net of underwriting discounts and commissions and other offering expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company entered into Amendment No. 1 to the Sales Agreement which increases the amount of the Company&#x2019;s common stock that can be sold by the Company through its agent under the ATM Offering, from an aggregate offering price of up to $100.0&#160;million to an aggregate offering price of up to $300.0&#160;million. During the year ended December 31, 2022, the Company sold 160,480 shares of common stock at a weighted average price per share of $6.87, resulting in net proceeds of approximately $1.1 million, net of underwriting discounts and commissions and other offering expenses. &lt;/span&gt;&lt;/div&gt;As part of the consideration for the rights granted to Zai Lab US LLC under the collaboration and license agreement described more fully in Note 8, Revenue, the Company and Zai Lab US LLC entered into a separate stock purchase agreement (Stock Purchase Agreement).  Under this Stock Purchase Agreement in 2021, Zai Lab US LLC paid the Company approximately $30.0 million to purchase 958,467 newly issued shares of the Company's common stock, par value $0.01, at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="INF"
      id="f-482"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6a3cb7b2a9c84dd89c8cfd99ca5abf7c_I20221231"
      decimals="INF"
      id="f-483"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i3a5e971264d548579cbdbbcb85309080_I20211231"
      decimals="INF"
      id="f-484"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6a3cb7b2a9c84dd89c8cfd99ca5abf7c_I20221231"
      decimals="INF"
      id="f-485"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6a3cb7b2a9c84dd89c8cfd99ca5abf7c_I20221231"
      decimals="INF"
      id="f-486"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i3a5e971264d548579cbdbbcb85309080_I20211231"
      decimals="INF"
      id="f-487"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i3a5e971264d548579cbdbbcb85309080_I20211231"
      decimals="INF"
      id="f-488"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6a3cb7b2a9c84dd89c8cfd99ca5abf7c_I20221231"
      decimals="INF"
      id="f-489"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="ica4884a38171464fb3771d584bde78ae_D20201101-20201130"
      decimals="-5"
      id="f-490"
      unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i24a49a71f1f04f838393fe224709a584_D20210101-20211231"
      decimals="INF"
      id="f-491"
      unitRef="shares">3622186</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="idcbca4caa7f44c80ab53213c339fb544_I20211231"
      decimals="2"
      id="f-492"
      unitRef="usdPerShare">27.60</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i24a49a71f1f04f838393fe224709a584_D20210101-20211231"
      decimals="-5"
      id="f-493"
      unitRef="usd">98200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="ica4884a38171464fb3771d584bde78ae_D20201101-20201130"
      decimals="-5"
      id="f-494"
      unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease
      contextRef="icec55a17872746d2856769218fef60aa_D20210401-20210430"
      decimals="-5"
      id="f-495"
      unitRef="usd">300000000</mgnx:CommonStockMaximumAmountAvailableForIssuanceIncrease>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8b2c42e5029948ed9d33d72c422ec15b_D20220101-20221231"
      decimals="INF"
      id="f-496"
      unitRef="shares">160480</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i867d5919542f4494a26a231e8b7346e0_I20221231"
      decimals="2"
      id="f-497"
      unitRef="usdPerShare">6.87</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8b2c42e5029948ed9d33d72c422ec15b_D20220101-20221231"
      decimals="-5"
      id="f-498"
      unitRef="usd">1100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i32e8c25671ba4f6fb24dee37c0820f11_D20210601-20210630"
      decimals="-5"
      id="f-499"
      unitRef="usd">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i66fe51ad0d964f1896d0f96af0e1e372_D20210601-20210630"
      decimals="INF"
      id="f-500"
      unitRef="shares">958467</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="INF"
      id="f-501"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ife8f008f05574ef1870bdae6c66d666b_I20210615"
      decimals="2"
      id="f-502"
      unitRef="usdPerShare">31.30</us-gaap:SaleOfStockPricePerShare>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="i7335e9f1b9ca42eca438a74f5c67ab3a_D20210601-20210630"
      decimals="-5"
      id="f-503"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-504">Revenue&lt;div style="margin-bottom:9pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Collaborative Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte, which was amended in March 2018, April 2022 and July 2022, for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab. Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017. MacroGenics will manufacture a portion of Incyte&#x2019;s global commercial supply of retifanlimab. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies, including in patients with Merkel cell carcinoma, squamous cell carcinoma of the anal canal, MSI-high endometrial cancer and non-small cell lung cancer.  Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.  In April 2022, the Company and Incyte executed an amendment to the Incyte License Agreement to add a milestone for U.S. approval of retifanlimab in a specific indication and to exclude certain other regulatory and development achievements with retifanlimab in this same indication from the milestone events of the Incyte License Agreement. In July 2022, the Company and Incyte further amended the Incyte License Agreement to reflect changes related to the payment of certain milestones and Incyte paid the Company $30.0 million in milestone payments, which the Company recognized as revenue during the year ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Incyte License Agreement, as amended, Incyte will lead global development of retifanlimab. Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $435.0 million in development and regulatory milestones, and up to $330.0 million in commercial milestones. From the inception of the Incyte License Agreement through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company has recognized $100.0 million in development milestones under Incyte License Agreement.   If retifanlimab is approved and commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Incyte License Agreement under the provisions of ASC 606 at inception and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The standalone selling price for agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From 2018 through &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$100.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to clinical and regulatory activities related to the further advancement of retifanlimab, including Incyte&#x2019;s initiation of a Phase 3 clinical trial.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Therefore&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the associated consideration was added to the estimated transaction price and was recognized as revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:42pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$150.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; allocated to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. The Company recognized revenue of $30.0 million, $15.0 million and $40.0 million under the Incyte License Agreement during the years ended December&#160;31, 2022, 2021 and 2020, respectively.  All of the revenue recognized during the years ended December&#160;31, 2022 and 2021 was related to development milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte Clinical Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into an agreement with Incyte under which the Company is to perform development and manufacturing services for Incyte&#x2019;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 2021 and 2020, the Company recognized revenue of $0.7 million, $1.5 million and $8.6 million, respectively, for services performed under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte Commercial Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#x2019;s obligation to pay royalties under the Incyte License Agreement.  The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services. During the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021, and 2020 the Company recognized revenue of $0.3 million, $7.8&#160;million and $1.4&#160;million, respectively, for services performed under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Gilead Sciences, Inc &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, the Company and Gilead Sciences, Inc. (Gilead) entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024, an investigational, bispecific antibody that binds CD123 and CD3, and create bispecific cancer antibodies using the Company&#x2019;s DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under the agreement, the Company will continue the ongoing phase 1 trial for MGD024 accordi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ng to a development plan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license under the Company&#x2019;s intellectual property to develop and commercialize MGD024 and other bispecific antibodies of MacroGenics that bind CD123 and CD3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (CD123 Option). The agreement also grants Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by the Company and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Gilead Agreement, in October 2022 Gilead paid the Company an upfront payment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$60.0&#160;million. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assuming Gilead exercises the CD123 Option and Research Program Option and successfully develops and commercializes MGD024, or other CD123 products developed under the agreement, and products result from the two additional research programs, the Company would be eligible to receive up to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.7&#160;billion &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in target nomination, option fees, and development, regulatory and commercial milestones. Assuming exercise of the CD123 Option, the Company will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 (or other CD123 products developed under the agreement) and assuming exercise of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research Program Option,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a flat royalty on worldwide net sales of any products resulting from the two research programs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Gilead Agreement under the provisions of ASC 606 and identified the following material promises under the agreement: (i) a license to perform any activities allocated to Gilead under the MGD024 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;development plan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; (ii) development activities regarding MGD024, including manufacturing, research and early clinical development activities, necessary to deliver an informational package of development and clinical data, information and materials specified in the Gilead Agreement during the period &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which Gilead can exercise the CD123 Option; (iii) the CD123 Option and (iv) the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research Program Option&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the license under the MGD024 developme&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nt plan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and development activities are not distinct from one another, as the license has limited value without the Company&#x2019;s performance of the development activities. Therefore, the Company determined that the development term license and development activities should be combined into a single performance obligation (Development Activities). The CD123 Option is considered a material right as the value of the exclusive license exceeds the payment to be made by Gilead if they exercise their option to obtain an exclusive license to develop and commercialize MGD024 or an alternative CD123 product, and is therefore a distinct performance obligation. The Company determined that the Research Program Option does not provide a material right, as there is no discount on its standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, the Company determined that the initial transaction price under the Gilead Agreement was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$60.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, consisting of the upfront, non-refundable payment paid by Gilead. The CD123 Option and Research Program Option payments are excluded from the initial transaction price at contract inception along with any future development, regulatory, and commercial milestone payments (including royalties) following the CD123 Option and Research Program Option exercise.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company will reassess the amount of variable consideration included in the transaction price every reporting period.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$60.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; upfront payment in the transaction price to the Development Activities and the CD123 Option based on each performance obligation&#x2019;s relative standalone selling price. The standalone selling price for the Development Activities was calculated using an expected cost-plus margin approach &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the pre-option development timeline.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the standalone selling price of the CD123 Option, the Company utilized an income-based approach which included the following key assumptions:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;post-option development timeline and costs, forecasted revenues, discount rates and probabilities of technical and regulatory success. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is recognizing revenue related to the Development Activities performance obligation over the estimated period to complete the Development Activities using an input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the Development Activities. The Company will defer revenue recognition related to the CD123 Option.  If Gilead exercises the CD123 Option and obtains an exclusive license, the Company will recognize revenue as it fulfills its obligations under the Gilead Agreement. If the CD123 Option is not exercised, the Company will recognize the entirety of the revenue in the period when the CD123 Option expires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, the Company recorded revenue of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.2&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to the Gilead Agreement. As of December 31, 2022, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$59.8&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in revenue was deferred under this agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.8&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was current and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$58.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Zai Lab Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2018 Zai Lab Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#x2019;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (2018 Zai Lab Agreement). Zai Lab will lead clinical development of these molecules in its territory. Zai Lab has informed the Company that they have decided to discontinue development of tebotelimab for indications they were enrolling in their territory and is evaluating future development plans in other indications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2018 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of  $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, of which the Company has earned $9.0 million through December&#160;31, 2022.  In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#x2019;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#x2019;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#x2019;s territory, which may be subject to adjustment in specified circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the 2018 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#x2019;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.  From 2020 through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, it became probable that a significant reversal of cumulative revenue would not occur for development and regulatory milestones totaling $9.0 million. Therefore, the associated consideration, $8.1&#160;million net of value-added tax withholdings, was added to the estimated transaction price and was recognized as revenue&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;uring the year ended December&#160;31, 2022, the Company recognized $4.9&#160;million under the 2018 Zai Lab Agreement and no revenue was recognized during the year ended December&#160;31, 2021 under this agreement. During the year ended December&#160;31, 2020, the Company recognized revenue of $8.6&#160;million under the 2018 Zai Lab Agreement, $3.6&#160;million of which was net milestone revenue and $5.0&#160;million of which was recognition of variable consideration related to certain regulatory achievements during 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zai Lab Clinical Supply Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#x2019;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements). The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within the contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab. The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing service. During the years ended December&#160;31, 2022, 2021, and 2020, the Company recognized revenue of $0.4&#160;million, $2.8&#160;million, and $2.7&#160;million, respectively, related to the Zai Lab Clinical Supply Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Zai Lab Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (collectively with Zai Lab Limited referred herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). The first program covers a lead research molecule that incorporates the Company&#x2019;s DART platform and binds CD3 and an undisclosed target that is expressed in multiple solid tumors (Lead Program). The second program covers a target to be designated by the Company. For these programs, Zai Lab receives commercial rights in Greater China, Japan, and Korea while the Company receives commercial rights in all other territories.&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Zai Lab also obtained exclusive, global licenses from the Company to develop, manufacture and commercialize two additional molecules. Zai Lab granted the Company a worldwide, royalty-free, co-exclusive license to conduct the development activities allocated to the Company. During 2022, the Company and Zai Lab agreed to discontinue research and development of the Lead Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2021 Zai Lab Agreement, the Lead Program included joint research and development services by both the Company and Zai Lab. For the other programs, Zai Lab can separately negotiate and agree with the Company to perform research and development services in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the 2021 Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0&#160;million. Additionally, as part of the consideration for the rights granted to Zai Lab under the 2021 Zai Lab Agreement, the Company and Zai Lab entered into the Stock Purchase Agreement whereby Zai Lab paid the Company approximately $30.0 million to purchase shares of the Company&#x2019;s common stock at a fixed price of $31.30 which represented a $10.4 million premium over the share price on the Stock Purchase Agreement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assuming successful development and commercialization of the remaining Programs, the Company could receive up to approximately $680.0&#160;million in development and regulatory milestones and $600.0&#160;million in commercial milestones. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-single digits to low double digit teens on annual net sales of products in Zai Lab&#x2019;s territory, which may be subject to specified royalty reduction pursuant to the 2021 Zai Lab Agreement. Per the terms of the 2021 Zai Lab Agreement, the Company may also receive reimbursements from Zai Lab for certain research and development costs incurred by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the 2021 Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises: (i) exclusive licenses to develop, manufacture and commercialize the products in Zai Lab&#x2019;s territory for each Program and (ii) certain research and development activities for the Lead Program. The Company determined that for the Lead Program, the license is not distinct from the related research and development activities, considering the early stage of development of the molecule and the Company&#x2019;s significant expertise in this area and as such, the research and development services are expected to significantly modify and customize the license. Therefore, for the Lead Program, the license and the services were combined into a single performance obligation. Since the other programs each represent distinct intellectual property and there are no other services included in the 2021 Zai Lab Agreement related to these licenses, each license is considered to be a distinct performance obligation. As such, there are four performance obligations included in the 2021 Zai Lab Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the estimated transaction price is $40.4 million, consisting of the $25.0 million upfront payment, the $10.4 million premium related to the purchase of the Company&#x2019;s common stock, and the $5.0 million estimated reimbursement by Zai Lab for research and development activities for the Lead Program. The potential milestone payments were deemed to be fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company will re-assess the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price of $40.4 million was then allocated to the four performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was not directly observable; therefore, the Company estimated the standalone selling price using an adjusted market assessment approach, representing the amount that the Company believes a market participant is willing to pay for the product or service. The estimate was based on consideration of observable inputs, such as, values of other preclinical collaboration arrangements adjusted for the Company&#x2019;s estimate of the probability of success for each Program. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue related to the Lead Program license and related research and development services performance obligation was  recognized over time as the research and development activities were performed. The Company utilized a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligations. The Company recognized revenue allocated to the other programs at a point in time upon transfer of the licenses to Zai Lab in June 2021. During the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company recognized revenue of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$16.8 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$20.3 million, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively, under the 2021 Zai Lab Agreement. As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022, there was no revenue deferred under the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021 Zai Lab Agreement&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; December&#160;31, 2021, $16.1 million in revenue was deferred under this agreement, all of which was current. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Biotech, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company entered into a research collaboration and license agreement with Janssen to develop a novel DART molecule (Janssen Agreement).  The research collaboration will incorporate the Company&#x2019;s proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. Under the terms of the Janssen Agreement, Janssen paid the Company an upfront payment of $20.0&#160;million and will be responsible for funding all research and development expenses. The Company will also be eligible to receive up to $312.0&#160;million in potential milestone payments and tiered royalties of up to 10% on worldwide product sales. &lt;/span&gt;&lt;span style="color:#58585a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Janssen an exclusive, royalty-bearing license to develop, manufacture and commercialize the preclinical bispecific molecule and the Company will perform certain research and development activities during a specified research term. The Company evaluated the Janssen Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i)  a license to develop the preclinical bispecific molecule and (ii) performing certain research and development activities during the research term. The Company determined that the license and research and development activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as Janssen could benefit from the license on its own without the Company&#x2019;s involvement during the research term.  The Company determined that the transaction price of the Janssen Agreement at inception was $22.2&#160;million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for research and development activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements as well as current market conditions. The standalone selling price for agreed-upon research and development activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. This variable consideration was fully constrained until the Company began its work under the performance obligation.  The potential milestone payments are &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Janssen and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:42pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the $20.0&#160;million allocated to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license when it satisfied its performance obligation and transferred the license to Janssen in 2020. The $2.2&#160;million allocated to the research and development activities is being recognized over the Company&#x2019;s involvement in the research term, which is estimated to be less than two years.  During the years ended December&#160;31, 2022, and &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company recognized revenue of $0.8&#160;million and $1.5&#160;million, respectively, for research and development activities performed under the Janssen Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Provention Bio, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into a license agreement with Provention pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones. As of December&#160;31, 2022, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, in 2018, the Company entered into an asset purchase agreement with Provention pursuant to which Provention acquired the Company&#x2019;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement). As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share.  Under the Asset Purchase Agreement, Provention is obligated to pay the Company contingent milestone payments totaling $170.0 million upon the achievement of certain regulatory milestones.  In addition, Provention is obligated to make contingent milestone payments to the Company totaling $225.0 million upon the achievement of certain commercial milestones as well as single-digit royalties on net sales of the product. The FDA approved the BLA for teplizumab in November 2022, and the Company recognized $60.0 million in revenue related to this regulatory milestone during the year ended December 31, 2022.  In November 2022, the Company and Provention amended the Asset Purchase Agreement.  Under this amendment, the milestone for first approval was split into four equal payments, the first of which was received in November 2022. The remaining payments are due on March 1, 2023, June 1, 2023 and September 1, 2023.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention assumed pursuant to the Asset Purchase Agreement. Further, Provention is required to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Provention License Agreement and Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase a total of 2,432,688 shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such were excluded from the initial transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. The Company recognized revenue of $6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018. In 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. During the year ended December&#160;31, 2022, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;it became probable that a significant reversal of cumulative revenue would not occur for a regulatory milestone of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$60.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;herefore&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the associated consideration was added to the estimated transaction price and was recognized as revenue. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020, the Company recognized revenue of $60.0 million, $1.3 million and $0.6 million, respectively, under these agreements. As of December 31, 2022, Provention owes the Company $45.0 million related to the achieved milestone, which is included in accounts receivable on the consolidated balance sheet.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;I-Mab Biopharma &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;I-Mab License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company entered into a collaboration and license agreement with I-Mab to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab License Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. In August 2022, I-Mab notified the Company of its intention to terminate the I-Mab License Agreement effective February 25, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the I-Mab License Agreement, I-Mab paid the Company an upfront payment of $15.0 million, and $5.0&#160;million of milestone revenue has been earned from the inception of the I-Mab License Agreement through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the I-Mab License Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement: (i) an exclusive license to develop and commercialize enoblituzumab in I-Mab&#x2019;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million. I-Mab paid the Company for the cost of this study as the costs were incurred and I-Mab received a one-time credit of eighty percent of the total amount of such costs against the milestone achieved during 2021. The Company reassessed the transaction price as it became probable that a significant reversal of cumulative revenue would not occur for a $5.0&#160;million milestone ($4.5&#160;million after netting a one-time credit as described above) related to development progress of enoblituzumab, therefore the associated consideration was added to the estimated transaction price and was recognized as revenue during 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Revenue under the I-Mab License Agreement was recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, was the best measure of progress towards satisfying the performance obligations. During the years ended December&#160;31, 2022, 2021 and 2020, the Company recognized revenue of $4.5 million, $11.5 million and $2.2 million, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively, related to the I-Mab License Agreement. At December&#160;31, 2022, no revenue was deferred under the I-Mab License Agreement. At December&#160;31, 2021, $4.5 million in revenue was deferred under the I-Mab License Agreement, all of which was current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;I-Mab Clinical Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the Company entered into an agreement under which the Company was to perform development and manufacturing services for I-Mab&#x2019;s clinical needs of enoblituzumab (I-Mab Clinical Supply Agreement). The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of enoblituzumab. The transaction price was based on the costs incurred to develop and manufacture drug product and drug substance, and was recognized over time as the services were provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price was recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended December&#160;31, 2022, and 2021, the Company recognized revenue of $0.6 million and $1.3 million, respectively, for research and development activities performed under the I-Mab Clinical Supply Agreement.  The Company and I-Mab mutually agreed to terminate this agreement in November 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Boehringer Ingelheim International GmbH&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2010, the Company entered into a collaboration and license agreement with Boehringer Ingelheim International GmbH (BII) to discover, develop and commercialize multiple DART molecules that were to be evaluated during a five-year period that ended in 2015 (Boehringer Agreement). Under the terms of the agreement, the Company granted BII an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated under the agreement.  During the evaluation period, BII selected two product candidates to develop (BII DARTs). Under the terms of the Boehringer Agreement, BII paid the Company an upfront payment of $15.0&#160;million which was fully recognized prior to December 31, 2015. The variable consideration under this agreement included potential future development and sales milestones and royalties on net sales in the event that the BII DARTs are commercialized.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, BII agreed to a payment of $12.0&#160;million in order to retain rights to develop the BII DARTs under the Boehringer Agreement.  As a result, the Company received and recognized as revenue $12.0&#160;million during the year ended December 31, 2020. The remaining potential development milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur and therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Manufacturing Services Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period at one of the Company&#x2019;s manufacturing facilities. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $10.0&#160;million and is eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $14.4&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services. In July 2022, the Company and Incyte executed an amendment to the Incyte Manufacturing and Clinical Supply Agreement which extended the term for one year and provided for an additional annual fixed payment of $5.1&#160;million (July 2022 Incyte Amendment). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement and the July 2022 Incyte Amendment under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price consists of the upfront payment received of $10.0&#160;million and the annual fixed payments totaling $19.5&#160;million. The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized revenue of $8.7&#160;million under the Incyte Manufacturing and Clinical Supply Agreement  during the year ended December&#160;31, 2022. As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$9.6&#160;million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in revenue was deferred under this agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$8.1&#160;million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was current and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.5&#160;million &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of which was non-current.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Provention Bio, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Provention (Provention Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Provention bulk drug substance. Under the terms of the Provention Manufacturing and Clinical Supply Agreement, the Company received an upfront payment and payments in accordance with the manufacturing schedule.  The Company was also reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Provention Manufacturing and Clinical Supply Agreement under the provisions of ASC 606 and identified one performance obligation to provide manufacturing services to Provention. The Company determined that the transaction price consisted of the upfront and other fixed payments totaling $4.6&#160;million. The Company will recognize revenue over time on a straight-line basis as the manufacturing services are provided to Provention, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Provention will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur.  Materials purchased by the Company to manufacture the product for Provention are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized revenue of $5.3&#160;million under the Provention Manufacturing and Clinical Supply Agreement during the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NIAID Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a contract with NIAID, effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of December&#160;31, 2022 is $25.1 million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in July 2023.  The Company recognized revenue of $1.9 million, $1.8 million and $7.1 million under the NIAID contract during the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i3bf402b9dbdd4d87ae5d49d80d3bfbd1_D20190101-20190331"
      decimals="-5"
      id="f-505"
      unitRef="usd">150000000</mgnx:NonRefundableUpfrontFees>
    <us-gaap:Revenues
      contextRef="i5669556108fb4b49ab6793e93d991f6f_D20220101-20221231"
      decimals="-5"
      id="f-506"
      unitRef="usd">30000000</us-gaap:Revenues>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="ia6f88ee6c6234a019d97d24e5e39ceff_I20171031"
      decimals="-5"
      id="f-507"
      unitRef="usd">435000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="ia6f88ee6c6234a019d97d24e5e39ceff_I20171031"
      decimals="-5"
      id="f-508"
      unitRef="usd">330000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ibea2d6a312194bd6a0ecf5f54c65238a_D20220101-20221231"
      decimals="-5"
      id="f-509"
      unitRef="usd">100000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i988a06040edf4aa0b8a3f3cd042479bd_D20171001-20171031"
      decimals="2"
      id="f-510"
      unitRef="number">0.15</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i9110adb267ef45a6aa425a647075f177_D20171001-20171031"
      decimals="2"
      id="f-511"
      unitRef="number">0.24</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i38eeebe054f049c9bc2b9a0534ffdab3_I20171031"
      decimals="-5"
      id="f-512"
      unitRef="usd">154000000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ibea2d6a312194bd6a0ecf5f54c65238a_D20220101-20221231"
      decimals="-5"
      id="f-513"
      unitRef="usd">100000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="i01a768287b9d4dba83bffa872d2e72c8_D20171001-20171031"
      decimals="-5"
      id="f-514"
      unitRef="usd">150000000</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="iee9e9e7ce67a49de83726523a441d2ff_D20170101-20181231"
      decimals="-5"
      id="f-515"
      unitRef="usd">4000000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues
      contextRef="i5669556108fb4b49ab6793e93d991f6f_D20220101-20221231"
      decimals="-5"
      id="f-516"
      unitRef="usd">30000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7f61d57a20cd4679bf6ecc932ade4702_D20210101-20211231"
      decimals="-5"
      id="f-517"
      unitRef="usd">15000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i633fd2fb64ad42c4b92eebba0535d397_D20200101-20201231"
      decimals="-5"
      id="f-518"
      unitRef="usd">40000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i60225cd201b84577ac14ccd93f6b150d_D20220101-20221231"
      decimals="-5"
      id="f-519"
      unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2135354a19f64808a2cc5c96c8be75a2_D20210101-20211231"
      decimals="-5"
      id="f-520"
      unitRef="usd">1500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i287b95f9f02e4ed1a66f479666758d0a_D20200101-20201231"
      decimals="-5"
      id="f-521"
      unitRef="usd">8600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1793ad9c6b4f4244b4ee579221db1b13_D20220101-20221231"
      decimals="-5"
      id="f-522"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i75eb5df4d251413fba2adbdc9e57ccb9_D20210101-20211231"
      decimals="-5"
      id="f-523"
      unitRef="usd">7800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc0cec4a5a73427eb832e2674227c093_D20200101-20201231"
      decimals="-5"
      id="f-524"
      unitRef="usd">1400000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i1b71d094740b4c1e9c5b2ff8f8b13f29_D20221014-20221014"
      decimals="-5"
      id="f-525"
      unitRef="usd">60000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialTargetNominationOptionFeesAndMilestonePayments
      contextRef="i1b71d094740b4c1e9c5b2ff8f8b13f29_D20221014-20221014"
      decimals="-5"
      id="f-526"
      unitRef="usd">1700000000</mgnx:PotentialTargetNominationOptionFeesAndMilestonePayments>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i1b71d094740b4c1e9c5b2ff8f8b13f29_D20221014-20221014"
      decimals="-5"
      id="f-527"
      unitRef="usd">60000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i1b71d094740b4c1e9c5b2ff8f8b13f29_D20221014-20221014"
      decimals="-5"
      id="f-528"
      unitRef="usd">60000000</mgnx:NonRefundableUpfrontFees>
    <us-gaap:Revenues
      contextRef="iaf251b9dfa1d4ed89dfd50e9d5821e5e_D20220101-20221231"
      decimals="-5"
      id="f-529"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8b7bc40165fd46a193e3cccf1f049cfa_I20221231"
      decimals="-5"
      id="f-530"
      unitRef="usd">59800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8b7bc40165fd46a193e3cccf1f049cfa_I20221231"
      decimals="-5"
      id="f-531"
      unitRef="usd">1800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8b7bc40165fd46a193e3cccf1f049cfa_I20221231"
      decimals="-5"
      id="f-532"
      unitRef="usd">58000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i96872571cd0a4110aadf271b65708d4f_D20181101-20181130"
      decimals="-5"
      id="f-533"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="i69bfd0f8331b41bba3c4e5efaa36efc4_D20181101-20181130"
      decimals="-5"
      id="f-534"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:NonrefundablePaymentTaxWithholding
      contextRef="i96872571cd0a4110aadf271b65708d4f_D20181101-20181130"
      decimals="-5"
      id="f-535"
      unitRef="usd">2500000</mgnx:NonrefundablePaymentTaxWithholding>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i54460e4405804e6d8632d256ca806b3a_I20221231"
      decimals="-5"
      id="f-536"
      unitRef="usd">140000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ideaa024a11c34bdb89c49cd5c437abdb_D20200701-20221231"
      decimals="-5"
      id="f-537"
      unitRef="usd">9000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i3160099d486f4eb0ac91ae68ee1818a5_D20181101-20181130"
      decimals="2"
      id="f-538"
      unitRef="number">0.20</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="idda174e868e34f569bb5414b16d63aaf_D20181101-20181130"
      decimals="2"
      id="f-539"
      unitRef="number">0.10</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="i69bfd0f8331b41bba3c4e5efaa36efc4_D20181101-20181130"
      decimals="-5"
      id="f-540"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ideaa024a11c34bdb89c49cd5c437abdb_D20200701-20221231"
      decimals="-5"
      id="f-541"
      unitRef="usd">9000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:MilestonesValueAddedTax
      contextRef="ideaa024a11c34bdb89c49cd5c437abdb_D20200701-20221231"
      decimals="-5"
      id="f-542"
      unitRef="usd">8100000</mgnx:MilestonesValueAddedTax>
    <us-gaap:Revenues
      contextRef="ia6508d36a64142029325de20e5324de6_D20220101-20221231"
      decimals="-5"
      id="f-543"
      unitRef="usd">4900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d66046a5ee64f7788d581007532e524_D20210101-20211231"
      decimals="-5"
      id="f-544"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1d938aac5ed04e51bcb036c13e6fa016_D20200101-20201231"
      decimals="-5"
      id="f-545"
      unitRef="usd">8600000</us-gaap:Revenues>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i1d938aac5ed04e51bcb036c13e6fa016_D20200101-20201231"
      decimals="-5"
      id="f-546"
      unitRef="usd">3600000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:RevenueFromVariableConsiderationRecognize
      contextRef="i1d938aac5ed04e51bcb036c13e6fa016_D20200101-20201231"
      decimals="-5"
      id="f-547"
      unitRef="usd">5000000</mgnx:RevenueFromVariableConsiderationRecognize>
    <us-gaap:Revenues
      contextRef="i1715d94674d945de83bbfd371f7c13c4_D20220101-20221231"
      decimals="-5"
      id="f-548"
      unitRef="usd">400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i767daa988e954076be39c9747efd7d0d_D20210101-20211231"
      decimals="-5"
      id="f-549"
      unitRef="usd">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5e1ac66792744af791f7f6abfa4dcef6_D20200101-20201231"
      decimals="-5"
      id="f-550"
      unitRef="usd">2700000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i32e8c25671ba4f6fb24dee37c0820f11_D20210601-20210630"
      decimals="-5"
      id="f-551"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i32e8c25671ba4f6fb24dee37c0820f11_D20210601-20210630"
      decimals="-5"
      id="f-552"
      unitRef="usd">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ife8f008f05574ef1870bdae6c66d666b_I20210615"
      decimals="2"
      id="f-553"
      unitRef="usdPerShare">31.30</us-gaap:SaleOfStockPricePerShare>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="i7335e9f1b9ca42eca438a74f5c67ab3a_D20210601-20210630"
      decimals="-5"
      id="f-554"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="ife8f008f05574ef1870bdae6c66d666b_I20210615"
      decimals="-5"
      id="f-555"
      unitRef="usd">680000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="ife8f008f05574ef1870bdae6c66d666b_I20210615"
      decimals="-5"
      id="f-556"
      unitRef="usd">600000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="ife8f008f05574ef1870bdae6c66d666b_I20210615"
      decimals="-5"
      id="f-557"
      unitRef="usd">40400000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i32e8c25671ba4f6fb24dee37c0820f11_D20210601-20210630"
      decimals="-5"
      id="f-558"
      unitRef="usd">25000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PremiumReceivedOnStockPurchase
      contextRef="i7335e9f1b9ca42eca438a74f5c67ab3a_D20210601-20210630"
      decimals="-5"
      id="f-559"
      unitRef="usd">10400000</mgnx:PremiumReceivedOnStockPurchase>
    <mgnx:EstimatedReimbursementForResearchAndDevelopmentT
      contextRef="i54dc0d7d758841359d25ada6f2a3f6bd_I20221231"
      decimals="-5"
      id="f-560"
      unitRef="usd">5000000</mgnx:EstimatedReimbursementForResearchAndDevelopmentT>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="ife8f008f05574ef1870bdae6c66d666b_I20210615"
      decimals="-5"
      id="f-561"
      unitRef="usd">40400000</mgnx:CollaborativeAgreementTransactionPrice>
    <us-gaap:Revenues
      contextRef="i8e5adc3d5e2442fbbb01084952f712f4_D20220101-20221231"
      decimals="-5"
      id="f-562"
      unitRef="usd">16800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i05c59e94ee554f07bf1f21a28ba5d901_D20210101-20211231"
      decimals="-5"
      id="f-563"
      unitRef="usd">20300000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i54dc0d7d758841359d25ada6f2a3f6bd_I20221231"
      decimals="-5"
      id="f-564"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ib60793823f51401f91c4fe5a62120d5b_I20211231"
      decimals="-5"
      id="f-565"
      unitRef="usd">16100000</us-gaap:ContractWithCustomerLiability>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i0b1d84cceaa14d2b82272120f3d141a5_D20201201-20201231"
      decimals="-5"
      id="f-566"
      unitRef="usd">20000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales
      contextRef="if4cc71ed45f8424fb7ad7a930e7af919_I20221231"
      decimals="-5"
      id="f-567"
      unitRef="usd">312000000</mgnx:PotentialMilestonePaymentsAndRoyaltiesOnProductSales>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i0b1d84cceaa14d2b82272120f3d141a5_D20201201-20201231"
      decimals="2"
      id="f-568"
      unitRef="number">0.10</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="if4cc71ed45f8424fb7ad7a930e7af919_I20221231"
      decimals="-5"
      id="f-569"
      unitRef="usd">22200000</mgnx:CollaborativeAgreementTransactionPrice>
    <us-gaap:Revenues
      contextRef="i6b4b8204955c40b9a81053a2ea6a7a34_D20201201-20201231"
      decimals="-5"
      id="f-570"
      unitRef="usd">20000000</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="i0b1d84cceaa14d2b82272120f3d141a5_D20201201-20201231"
      decimals="-5"
      id="f-571"
      unitRef="usd">2200000</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues
      contextRef="i11525e01950f45fa820c699ad1b87012_D20220101-20221231"
      decimals="-5"
      id="f-572"
      unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i823ffcf87c174dfd869db3d5bf2f4876_D20210101-20211231"
      decimals="-5"
      id="f-573"
      unitRef="usd">1500000</us-gaap:Revenues>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="i1ce4656c88644281a81473a1a311bcbb_D20180501-20180531"
      decimals="INF"
      id="f-574"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i13845f28c8184f82b5a85649094c84bc_I20180531"
      decimals="-5"
      id="f-575"
      unitRef="usd">65000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i13845f28c8184f82b5a85649094c84bc_I20180531"
      decimals="-5"
      id="f-576"
      unitRef="usd">225000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="i7dfb8c7e4fd04324883491a98fdd5523_D20180501-20180531"
      decimals="INF"
      id="f-577"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="id5332bdbc1ac4d42acfb85ff18b8d769_I20180531"
      decimals="-5"
      id="f-578"
      unitRef="usd">170000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="id5332bdbc1ac4d42acfb85ff18b8d769_I20180531"
      decimals="-5"
      id="f-579"
      unitRef="usd">225000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i8fdd00452e734cd1a063f90a315bd38e_D20221101-20221130"
      decimals="-5"
      id="f-580"
      unitRef="usd">60000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement
      contextRef="id5332bdbc1ac4d42acfb85ff18b8d769_I20180531"
      decimals="-5"
      id="f-581"
      unitRef="usd">1300000</mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i42483221131f4b7481cd3ebfbdd95b45_I20180531"
      decimals="-5"
      id="f-582"
      unitRef="usd">6100000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares
      contextRef="i42483221131f4b7481cd3ebfbdd95b45_I20180531"
      decimals="INF"
      id="f-583"
      unitRef="shares">2432688</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares>
    <us-gaap:Revenues
      contextRef="if91ec42029d64d03b3bab9599a9791b5_D20180501-20180531"
      decimals="-5"
      id="f-584"
      unitRef="usd">6100000</us-gaap:Revenues>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i8fdd00452e734cd1a063f90a315bd38e_D20221101-20221130"
      decimals="-5"
      id="f-585"
      unitRef="usd">60000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="i687253dc3b1a4370bafa13817794d0a3_D20220101-20221231"
      decimals="-5"
      id="f-586"
      unitRef="usd">60000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f896d007a6a40c48c8fb6cc5e26ea95_D20210101-20211231"
      decimals="-5"
      id="f-587"
      unitRef="usd">1300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c37a5c38e654c99b1697de56b18cac8_D20200101-20201231"
      decimals="-5"
      id="f-588"
      unitRef="usd">600000</us-gaap:Revenues>
    <mgnx:ReceivableFromCollaborationPartner
      contextRef="i58e91935654b49eab232a7ec7b32496c_I20221231"
      decimals="-5"
      id="f-589"
      unitRef="usd">45000000</mgnx:ReceivableFromCollaborationPartner>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ia1ecd07929384da0be9ffd4764df7764_D20190701-20190731"
      decimals="-5"
      id="f-590"
      unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i35eba6ff61e44d84bf6a3d50767ad056_D20220101-20221231"
      decimals="-5"
      id="f-591"
      unitRef="usd">5000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ia1ecd07929384da0be9ffd4764df7764_D20190701-20190731"
      decimals="-5"
      id="f-592"
      unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount
      contextRef="i35eba6ff61e44d84bf6a3d50767ad056_D20220101-20221231"
      decimals="-5"
      id="f-593"
      unitRef="usd">1000000</mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount>
    <mgnx:CollaborationArrangementOneTimeCreditPaidPercent
      contextRef="i35eba6ff61e44d84bf6a3d50767ad056_D20220101-20221231"
      decimals="2"
      id="f-594"
      unitRef="number">0.80</mgnx:CollaborationArrangementOneTimeCreditPaidPercent>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i641ea39eabec428e8868e07727550f9b_D20220101-20220331"
      decimals="-5"
      id="f-595"
      unitRef="usd">5000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:OneTimeMillstoneCredit
      contextRef="i221ddea90685424e9202290d98e954b3_I20211231"
      decimals="-5"
      id="f-596"
      unitRef="usd">4500000</mgnx:OneTimeMillstoneCredit>
    <us-gaap:Revenues
      contextRef="i35eba6ff61e44d84bf6a3d50767ad056_D20220101-20221231"
      decimals="-5"
      id="f-597"
      unitRef="usd">4500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d9b291f44c14b62a56b45b107bce2be_D20210101-20211231"
      decimals="-5"
      id="f-598"
      unitRef="usd">11500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74eb3a9ad62848108dd74bde2d588232_D20200101-20201231"
      decimals="-5"
      id="f-599"
      unitRef="usd">2200000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i221ddea90685424e9202290d98e954b3_I20211231"
      decimals="-5"
      id="f-600"
      unitRef="usd">4500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues
      contextRef="i8d15a5f2354a420f9695a7e6099f117f_D20220101-20221231"
      decimals="-5"
      id="f-601"
      unitRef="usd">600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if52c5ab82dd044a69f0166c3ff58ca62_D20210101-20211231"
      decimals="-5"
      id="f-602"
      unitRef="usd">1300000</us-gaap:Revenues>
    <mgnx:CollaborationAndLicenseAgreementTerm
      contextRef="i8e86a555e3f24015bead72636200ae9a_D20101001-20151031"
      id="f-603">P5Y</mgnx:CollaborationAndLicenseAgreementTerm>
    <mgnx:NumberOfProductCandidates
      contextRef="i57cad70ea273424dabf7a187420e4724_I20151031"
      decimals="INF"
      id="f-604"
      unitRef="productcandidate">2</mgnx:NumberOfProductCandidates>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i8e86a555e3f24015bead72636200ae9a_D20101001-20151031"
      decimals="-5"
      id="f-605"
      unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:DevelopmentMilestonesAmount
      contextRef="i15b810928e3242aaa7f2093120fe452e_D20200601-20200630"
      decimals="-5"
      id="f-606"
      unitRef="usd">12000000</mgnx:DevelopmentMilestonesAmount>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="if20ab34aae324e0ba9bf43107ec6f001_D20220101-20221231"
      decimals="-5"
      id="f-607"
      unitRef="usd">12000000</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:CollaborativeArrangementTerm
      contextRef="ifa77d46ed2c54978a8e628b9c800991f_I20220131"
      id="f-608">P3Y</mgnx:CollaborativeArrangementTerm>
    <mgnx:NonRefundableUpfrontFees
      contextRef="if00f09390f0345d98c06a7e6e9cc8a8b_D20220101-20220731"
      decimals="-5"
      id="f-609"
      unitRef="usd">10000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:TotalAnnualFixedPayments
      contextRef="i1445c3a2eddd4bfeb9296be4f2aca5ee_I20221231"
      decimals="-5"
      id="f-610"
      unitRef="usd">14400000</mgnx:TotalAnnualFixedPayments>
    <mgnx:CollaborativeArrangementExtensionTerm
      contextRef="ifa77d46ed2c54978a8e628b9c800991f_I20220131"
      id="f-611">P1Y</mgnx:CollaborativeArrangementExtensionTerm>
    <mgnx:AdditionalAnnualFixedPayments
      contextRef="ia8717043cd074e1297a517f4c6e6cc88_I20221231"
      decimals="-5"
      id="f-612"
      unitRef="usd">5100000</mgnx:AdditionalAnnualFixedPayments>
    <mgnx:NonRefundableUpfrontFees
      contextRef="if00f09390f0345d98c06a7e6e9cc8a8b_D20220101-20220731"
      decimals="-5"
      id="f-613"
      unitRef="usd">10000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:TotalAnnualFixedPayments
      contextRef="ia8717043cd074e1297a517f4c6e6cc88_I20221231"
      decimals="-5"
      id="f-614"
      unitRef="usd">19500000</mgnx:TotalAnnualFixedPayments>
    <us-gaap:Revenues
      contextRef="i623d0a5a27c445f8a4c07b43115440e9_D20220101-20221231"
      decimals="-5"
      id="f-615"
      unitRef="usd">8700000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i1445c3a2eddd4bfeb9296be4f2aca5ee_I20221231"
      decimals="-5"
      id="f-616"
      unitRef="usd">9600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i1445c3a2eddd4bfeb9296be4f2aca5ee_I20221231"
      decimals="-5"
      id="f-617"
      unitRef="usd">8100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i1445c3a2eddd4bfeb9296be4f2aca5ee_I20221231"
      decimals="-5"
      id="f-618"
      unitRef="usd">1500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:UpfrontAndFixedPayments
      contextRef="i6d1179302351453e86c2c3157b6019e8_I20221231"
      decimals="-5"
      id="f-619"
      unitRef="usd">4600000</mgnx:UpfrontAndFixedPayments>
    <us-gaap:Revenues
      contextRef="ib46875612ebc4591ae7244a0f9125f6e_D20220101-20221231"
      decimals="-5"
      id="f-620"
      unitRef="usd">5300000</us-gaap:Revenues>
    <mgnx:NumberOfProductCandidates
      contextRef="i9c73c17081c04144891915096cd9ed39_I20211231"
      decimals="INF"
      id="f-621"
      unitRef="usd">2</mgnx:NumberOfProductCandidates>
    <mgnx:TotalPotentialValueUnderAgreement
      contextRef="if5ee02f7ab344826b0c16f694bb46f66_D20220101-20221231"
      decimals="-5"
      id="f-622"
      unitRef="usd">25100000</mgnx:TotalPotentialValueUnderAgreement>
    <us-gaap:Revenues
      contextRef="i691134ba3b13405da417f0241eb6ca6d_D20220101-20221231"
      decimals="-5"
      id="f-623"
      unitRef="usd">1900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e0c41dd27764d34aa9ab34ec3e0805a_D20210101-20211231"
      decimals="-5"
      id="f-624"
      unitRef="usd">1800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf4d116422ce486bb630e9f82b58aeb1_D20200101-20201231"
      decimals="-5"
      id="f-625"
      unitRef="usd">7100000</us-gaap:Revenues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-626">Stock-based Compensation&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company&#x2019;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#x2019;s common stock on the last day of the offering period. During the year ended December&#160;31, 2022, employees purchased 105,986 shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $0.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options. In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160;As of December&#160;31, 2022, under the 2003 Plan, there were options to purchase an aggregate of 65,103 shares of common stock outstanding at a weighted average exercise price of $5.90 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2013, the Company implemented the 2013 Plan.&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was 1,960,168 shares.&#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended December&#160;31, 2022, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 15,816,949.&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2022, under the 2013 Plan, there were options to purchase an aggregate of 10,033,826 shares of common stock outstanding at a weighted average exercise price of $18.66 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation amounts were recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation to employees and non-employee directors in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation &#x2013; Stock Compensation&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company estimates the fair value of stock option awards using the Black-Scholes option pricing model on the date of grant using the assumptions in the table below. Stock options granted to employees generally vest over four years and have a term of ten years. Stock-based compensation expense for stock options is recognized as expense over the requisite service period, which is the vesting period. As the Company has not paid dividends since inception, nor does it expect to pay any dividends for the foreseeable future, the expected dividend yield assumption is zero. The expected volatility is based on the historical stock volatility of the Company&#x2019;s own common stock over a period equal to the expected term of the options. The risk-free rate of the stock options is based on the U.S. Treasury rate in effect at the time of grant for the expected term of the stock options. The Company used the simplified method to calculate expected term during 2020 and 2021.  Beginning in 2022, the computation of expected term was determined based on the historical experience with similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and expectations of future employee behavior.  In addition, the Company  estimates the expected forfeiture rate and only recognizes expense for those shares expected to vest. The Company estimates the forfeiture rate based on historical experience and its expectations regarding future pre-vesting termination behavior of employees. The Company reviews its estimate of the expected forfeiture rate annually, and stock-based compensation expense is adjusted accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88% -92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86% - 87%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67% - 109%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4% - 4.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6% - 1.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4% - 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,373,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,794,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(509,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,098,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,694,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,456,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, 2021 and 2020 the Company issued 120,900, 332,767 and 504,445 net shares of common stock, respectively, in conjunction with stock option exercises.&#160;The Company received cash proceeds from the exercise of stock options of approximately $0.2 million, $5.8 million and $5.3 million during 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of options granted during 2022, 2021 and 2020 was $6.84, $15.20 and $10.68 per share, respectively. The total intrinsic value of options exercised during 2022, 2021 and 2020 was approximately $0.6&#160;million, $3.3 million and $4.3 million, respectively.&#160;The total fair value of stock options which vested during 2022, 2021 and 2020 was $19.6 million, $20.2 million and $16.7 million, respectively.&#160;As of December&#160;31, 2022, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was $24.3 million, which the Company expects to recognize over a weighted-average period of approximately 1.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The stock options outstanding and exercisable by exercise price at December&#160;31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.134%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options Outstanding &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.94 - $5.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.01 - $15.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,355,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.01 - $25.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,041,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,152,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$25.01 - $40.21&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,343,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,187,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,098,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,694,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company awards RSUs to employees. RSUs are valued based on the closing price of the Company&#x2019;s common stock on the date of the grant. The fair value of RSUs is recognized and amortized on a straight-line basis over the requisite service period of the award&lt;/span&gt;&lt;span style="color:#252525;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity for 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, there was $2.0 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i169fc1b09cca4f95bc19d111a9403716_I20170518"
      decimals="INF"
      id="f-627"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i9360fd694d5e424f8c7bd8fd3eb717bc_D20170501-20170531"
      decimals="INF"
      id="f-628"
      unitRef="number">0.10</mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
    <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="i452d203362b14c6ca8da438846c11955_D20170501-20170531"
      id="f-629">P6M</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i9360fd694d5e424f8c7bd8fd3eb717bc_D20170501-20170531"
      decimals="INF"
      id="f-630"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i957cb602cb054b3ea23a8226a9ddbb3a_D20220101-20221231"
      decimals="0"
      id="f-631"
      unitRef="shares">105986</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i957cb602cb054b3ea23a8226a9ddbb3a_D20220101-20221231"
      decimals="-5"
      id="f-632"
      unitRef="usd">400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia0502d2128aa4313a80c03495c0ed1ea_I20221231"
      decimals="INF"
      id="f-633"
      unitRef="shares">65103</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia0502d2128aa4313a80c03495c0ed1ea_I20221231"
      decimals="2"
      id="f-634"
      unitRef="usdPerShare">5.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i544f43f987bd419e8c458062ac60ce6f_I20131031"
      decimals="INF"
      id="f-635"
      unitRef="shares">1960168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i544f43f987bd419e8c458062ac60ce6f_I20131031"
      decimals="INF"
      id="f-636"
      unitRef="shares">1960168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan
      contextRef="i07711b76935c4009a2ace4be4f684dd6_D20220101-20221231"
      decimals="3"
      id="f-637"
      unitRef="number">0.040</mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
    <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease
      contextRef="i07711b76935c4009a2ace4be4f684dd6_D20220101-20221231"
      decimals="INF"
      id="f-638"
      unitRef="shares">15816949</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i255a59bd218f42e2af9732b94035f04c_I20221231"
      decimals="INF"
      id="f-639"
      unitRef="shares">10033826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i255a59bd218f42e2af9732b94035f04c_I20221231"
      decimals="2"
      id="f-640"
      unitRef="usdPerShare">18.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-641">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation amounts were recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iffd00d99f798466d860442a9d6fe22f2_D20220101-20221231"
      decimals="-3"
      id="f-642"
      unitRef="usd">10094000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if50f063c6cd94e9a8db88782218b51c9_D20210101-20211231"
      decimals="-3"
      id="f-643"
      unitRef="usd">11337000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6968adfd4fe340119028718b06cfb436_D20200101-20201231"
      decimals="-3"
      id="f-644"
      unitRef="usd">10833000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie6322f1cbd714b298d2485ddc0fc3322_D20220101-20221231"
      decimals="-3"
      id="f-645"
      unitRef="usd">10343000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i529ec6ae784044b38dc167bc1dfef832_D20210101-20211231"
      decimals="-3"
      id="f-646"
      unitRef="usd">11789000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i26acb212525e4cc19f85aeb7f96576bb_D20200101-20201231"
      decimals="-3"
      id="f-647"
      unitRef="usd">9843000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-648"
      unitRef="usd">20437000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-649"
      unitRef="usd">23126000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-650"
      unitRef="usd">20676000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-651">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88% -92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86% - 87%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67% - 109%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4% - 4.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6% - 1.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4% - 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="INF"
      id="f-652"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="INF"
      id="f-653"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="INF"
      id="f-654"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9e619dc3a61b43d087d92cd2fee49ef4_D20220101-20221231"
      decimals="3"
      id="f-655"
      unitRef="number">0.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic0e3bcdcfbcf4c97b49dae77737eb857_D20220101-20221231"
      decimals="3"
      id="f-656"
      unitRef="number">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i03b32c2299d94db490057c88800e534c_D20210101-20211231"
      decimals="3"
      id="f-657"
      unitRef="number">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id868fe5312d548fda66c272fedcbd81c_D20210101-20211231"
      decimals="2"
      id="f-658"
      unitRef="number">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic345c52c1f4b4493a8a2205795297694_D20200101-20201231"
      decimals="2"
      id="f-659"
      unitRef="number">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if4a9eb4001cb48e29e15fb1edeea83c2_D20200101-20201231"
      decimals="2"
      id="f-660"
      unitRef="number">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9e619dc3a61b43d087d92cd2fee49ef4_D20220101-20221231"
      decimals="4"
      id="f-661"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic0e3bcdcfbcf4c97b49dae77737eb857_D20220101-20221231"
      decimals="4"
      id="f-662"
      unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i03b32c2299d94db490057c88800e534c_D20210101-20211231"
      decimals="4"
      id="f-663"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id868fe5312d548fda66c272fedcbd81c_D20210101-20211231"
      decimals="4"
      id="f-664"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic345c52c1f4b4493a8a2205795297694_D20200101-20201231"
      decimals="4"
      id="f-665"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if4a9eb4001cb48e29e15fb1edeea83c2_D20200101-20201231"
      decimals="4"
      id="f-666"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-667">P5Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      id="f-668">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      id="f-669">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-670">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,373,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,794,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(509,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,098,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,694,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,456,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="INF"
      id="f-671"
      unitRef="shares">8373921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="2"
      id="f-672"
      unitRef="usdPerShare">21.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      id="f-673">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="INF"
      id="f-674"
      unitRef="shares">2794997</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="2"
      id="f-675"
      unitRef="usdPerShare">9.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="INF"
      id="f-676"
      unitRef="shares">120900</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="2"
      id="f-677"
      unitRef="usdPerShare">1.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="INF"
      id="f-678"
      unitRef="shares">509569</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="2"
      id="f-679"
      unitRef="usdPerShare">15.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="INF"
      id="f-680"
      unitRef="shares">439520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="2"
      id="f-681"
      unitRef="usdPerShare">22.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="INF"
      id="f-682"
      unitRef="shares">10098929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="2"
      id="f-683"
      unitRef="usdPerShare">18.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-684">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-685"
      unitRef="usd">1094000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="INF"
      id="f-686"
      unitRef="shares">6694068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="2"
      id="f-687"
      unitRef="usdPerShare">21.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-688">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-689"
      unitRef="usd">424000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="INF"
      id="f-690"
      unitRef="shares">9456075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="2"
      id="f-691"
      unitRef="usdPerShare">18.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-692">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-693"
      unitRef="usd">1009000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="INF"
      id="f-694"
      unitRef="shares">120900</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="INF"
      id="f-695"
      unitRef="shares">332767</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="INF"
      id="f-696"
      unitRef="shares">504445</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-5"
      id="f-697"
      unitRef="usd">200000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-5"
      id="f-698"
      unitRef="usd">5800000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-5"
      id="f-699"
      unitRef="usd">5300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="2"
      id="f-700"
      unitRef="usdPerShare">6.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="2"
      id="f-701"
      unitRef="usdPerShare">15.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="2"
      id="f-702"
      unitRef="usdPerShare">10.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-5"
      id="f-703"
      unitRef="usd">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-5"
      id="f-704"
      unitRef="usd">3300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-5"
      id="f-705"
      unitRef="usd">4300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-5"
      id="f-706"
      unitRef="usd">19600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-5"
      id="f-707"
      unitRef="usd">20200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-5"
      id="f-708"
      unitRef="usd">16700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-5"
      id="f-709"
      unitRef="usd">24300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-710">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-711">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The stock options outstanding and exercisable by exercise price at December&#160;31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.134%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options Outstanding &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.94 - $5.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.01 - $15.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,355,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.01 - $25.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,041,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,152,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$25.01 - $40.21&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,343,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,187,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,098,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,694,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i458932626a4e44acacb64a6525da2b9a_D20220101-20221231"
      decimals="2"
      id="f-712"
      unitRef="usdPerShare">0.94</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i458932626a4e44acacb64a6525da2b9a_D20220101-20221231"
      decimals="2"
      id="f-713"
      unitRef="usdPerShare">5.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i781cf98fff854dee996c091defcba9ec_I20221231"
      decimals="INF"
      id="f-714"
      unitRef="shares">357628</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i458932626a4e44acacb64a6525da2b9a_D20220101-20221231"
      id="f-715">P8Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i781cf98fff854dee996c091defcba9ec_I20221231"
      decimals="2"
      id="f-716"
      unitRef="usdPerShare">3.70</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i781cf98fff854dee996c091defcba9ec_I20221231"
      decimals="INF"
      id="f-717"
      unitRef="shares">143268</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i781cf98fff854dee996c091defcba9ec_I20221231"
      decimals="2"
      id="f-718"
      unitRef="usdPerShare">3.76</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ia4f6bf1229f9423d9d74a89cbee04492_D20220101-20221231"
      decimals="2"
      id="f-719"
      unitRef="usdPerShare">5.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ia4f6bf1229f9423d9d74a89cbee04492_D20220101-20221231"
      decimals="2"
      id="f-720"
      unitRef="usdPerShare">15.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i3bd6e8fd9d6e41759ae8ce19e1f15dc0_I20221231"
      decimals="INF"
      id="f-721"
      unitRef="shares">3355424</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ia4f6bf1229f9423d9d74a89cbee04492_D20220101-20221231"
      id="f-722">P8Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i3bd6e8fd9d6e41759ae8ce19e1f15dc0_I20221231"
      decimals="2"
      id="f-723"
      unitRef="usdPerShare">10.51</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i3bd6e8fd9d6e41759ae8ce19e1f15dc0_I20221231"
      decimals="INF"
      id="f-724"
      unitRef="shares">1211129</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i3bd6e8fd9d6e41759ae8ce19e1f15dc0_I20221231"
      decimals="2"
      id="f-725"
      unitRef="usdPerShare">10.96</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ibb9b7e3cc6654c6ab1c1abd54c49d1b0_D20220101-20221231"
      decimals="2"
      id="f-726"
      unitRef="usdPerShare">15.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ibb9b7e3cc6654c6ab1c1abd54c49d1b0_D20220101-20221231"
      decimals="2"
      id="f-727"
      unitRef="usdPerShare">25.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i65f1a38a652c4027a979e5802d9bf79f_I20221231"
      decimals="INF"
      id="f-728"
      unitRef="shares">4041994</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ibb9b7e3cc6654c6ab1c1abd54c49d1b0_D20220101-20221231"
      id="f-729">P6Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i65f1a38a652c4027a979e5802d9bf79f_I20221231"
      decimals="2"
      id="f-730"
      unitRef="usdPerShare">20.21</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i65f1a38a652c4027a979e5802d9bf79f_I20221231"
      decimals="INF"
      id="f-731"
      unitRef="shares">3152550</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i65f1a38a652c4027a979e5802d9bf79f_I20221231"
      decimals="2"
      id="f-732"
      unitRef="usdPerShare">20.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i2d2cf19a216341f7b8ee2b4013afc61e_D20220101-20221231"
      decimals="2"
      id="f-733"
      unitRef="usdPerShare">25.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i2d2cf19a216341f7b8ee2b4013afc61e_D20220101-20221231"
      decimals="2"
      id="f-734"
      unitRef="usdPerShare">40.21</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i734a212745e14c3da7f13584d8590872_I20221231"
      decimals="INF"
      id="f-735"
      unitRef="shares">2343883</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i2d2cf19a216341f7b8ee2b4013afc61e_D20220101-20221231"
      id="f-736">P4Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i734a212745e14c3da7f13584d8590872_I20221231"
      decimals="2"
      id="f-737"
      unitRef="usdPerShare">29.59</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i734a212745e14c3da7f13584d8590872_I20221231"
      decimals="INF"
      id="f-738"
      unitRef="shares">2187121</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i734a212745e14c3da7f13584d8590872_I20221231"
      decimals="2"
      id="f-739"
      unitRef="usdPerShare">29.64</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="INF"
      id="f-740"
      unitRef="shares">10098929</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-741">P6Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="2"
      id="f-742"
      unitRef="usdPerShare">18.58</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="INF"
      id="f-743"
      unitRef="shares">6694068</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="2"
      id="f-744"
      unitRef="usdPerShare">21.35</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-745">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity for 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3bd6e5ab104947eb9423512ebd965f85_I20211231"
      decimals="INF"
      id="f-746"
      unitRef="shares">21500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3bd6e5ab104947eb9423512ebd965f85_I20211231"
      decimals="2"
      id="f-747"
      unitRef="usdPerShare">25.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if31e41373baa4fea9e84a7408c5073dd_D20220101-20221231"
      decimals="INF"
      id="f-748"
      unitRef="shares">476772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if31e41373baa4fea9e84a7408c5073dd_D20220101-20221231"
      decimals="2"
      id="f-749"
      unitRef="usdPerShare">8.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="if31e41373baa4fea9e84a7408c5073dd_D20220101-20221231"
      decimals="INF"
      id="f-750"
      unitRef="shares">10445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="if31e41373baa4fea9e84a7408c5073dd_D20220101-20221231"
      decimals="2"
      id="f-751"
      unitRef="usdPerShare">25.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="if31e41373baa4fea9e84a7408c5073dd_D20220101-20221231"
      decimals="INF"
      id="f-752"
      unitRef="shares">72743</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="if31e41373baa4fea9e84a7408c5073dd_D20220101-20221231"
      decimals="2"
      id="f-753"
      unitRef="usdPerShare">8.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2847395a9c0e4cb490b51246d0a78963_I20221231"
      decimals="INF"
      id="f-754"
      unitRef="shares">415084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2847395a9c0e4cb490b51246d0a78963_I20221231"
      decimals="2"
      id="f-755"
      unitRef="usdPerShare">8.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i2847395a9c0e4cb490b51246d0a78963_I20221231"
      decimals="-5"
      id="f-756"
      unitRef="usd">2000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if31e41373baa4fea9e84a7408c5073dd_D20220101-20221231"
      id="f-757">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-758">Income Taxes &lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021 and 2020 there was no provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal U.S. net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(372,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(327,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax asset/(liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $777.0 million. Of these NOLs, $172.0 million will expire in various years beginning in 2025 through 2037. $605.0 million of NOLs were generated post December 31, 2017 and carryforward indefinitely. In addition, the Company has U.S. federal tax credits of $94.0 million which will expire in various years beginning in 2023 through 2041.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of December&#160;31, 2022, $13.5 million of the Company's U.S. Federal NOLs are limited for use over the years 2023 &#x2013; 2028 in which a range of such amounts could be utilized on an annual basis of $0.2 million to $1.4 million. The remaining $763.0 million of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense/(benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases for current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases/(decreases) for prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, of the total gross unrecognized tax benefits, approximately $7.4 million and $7.2 million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021 and 2020, the Company has not recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's U.S. Federal and state income tax returns from 2003 &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forward remain open to examination due to the carryover of unused income tax credits, and from 2004 forward due to the carryover of unused net operating losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Internal Revenue Code (IRC) Section 174&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to currently deduct research and development expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the United States and 15 years for research activities performed outside the United States &lt;/span&gt;&lt;/div&gt;pursuant to IRC Section 174. Although Congress is considering legislation that would repeal or defer this capitalization and amortization requirement, it is not certain that this provision will be repealed or otherwise modified. If the requirement is not repealed or replaced, it could increase our U.S. federal and state cash taxes and reduce cash flows in 2023 and future years.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-5"
      id="f-759"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-760">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal U.S. net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(372,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(327,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax asset/(liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-761"
      unitRef="usd">163071000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-762"
      unitRef="usd">175802000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-763"
      unitRef="usd">44784000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-764"
      unitRef="usd">49965000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-765"
      unitRef="usd">65084000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-766"
      unitRef="usd">60514000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-767"
      unitRef="usd">35703000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-768"
      unitRef="usd">24858000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <mgnx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-769"
      unitRef="usd">9585000</mgnx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <mgnx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-770"
      unitRef="usd">7008000</mgnx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-771"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-772"
      unitRef="usd">1245000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <mgnx:Section174DeferredTaxAsset
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-773"
      unitRef="usd">43192000</mgnx:Section174DeferredTaxAsset>
    <mgnx:Section174DeferredTaxAsset
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-774"
      unitRef="usd">0</mgnx:Section174DeferredTaxAsset>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-775"
      unitRef="usd">158000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-776"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-777"
      unitRef="usd">19733000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-778"
      unitRef="usd">16727000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-779"
      unitRef="usd">381310000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-780"
      unitRef="usd">336119000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-781"
      unitRef="usd">372267000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-782"
      unitRef="usd">327595000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-783"
      unitRef="usd">9043000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-784"
      unitRef="usd">8524000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-785"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-786"
      unitRef="usd">1688000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-787"
      unitRef="usd">7522000</mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-788"
      unitRef="usd">4576000</mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-789"
      unitRef="usd">1521000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-790"
      unitRef="usd">2260000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-791"
      unitRef="usd">9043000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-792"
      unitRef="usd">8524000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-793"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-794"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="ie1a3ce377fe84955853c621ebe3898e1_I20221231"
      decimals="-5"
      id="f-795"
      unitRef="usd">777000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="ic8563ce4345344189c9f265ecff1081e_I20221231"
      decimals="-5"
      id="f-796"
      unitRef="usd">172000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="i305df6411bc540c288af86c6048f32a6_I20221231"
      decimals="-5"
      id="f-797"
      unitRef="usd">605000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="iabb762e6d67f44868d3a4659e39f91a1_I20221231"
      decimals="-5"
      id="f-798"
      unitRef="usd">94000000</us-gaap:TaxCreditCarryforwardAmount>
    <mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount
      contextRef="i16521e389da946b0bfcbbb417dd1be5e_D20220101-20221231"
      decimals="-5"
      id="f-799"
      unitRef="usd">13500000</mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount>
    <mgnx:OperatingLossCarryforwardsAnnualLimitationAmount
      contextRef="ic22e2b51dfee4a8e88cd23892f992f68_I20221231"
      decimals="-5"
      id="f-800"
      unitRef="usd">200000</mgnx:OperatingLossCarryforwardsAnnualLimitationAmount>
    <mgnx:OperatingLossCarryforwardsAnnualLimitationAmount
      contextRef="i6170cef51c304b009b2a8259c24dafdc_I20221231"
      decimals="-5"
      id="f-801"
      unitRef="usd">1400000</mgnx:OperatingLossCarryforwardsAnnualLimitationAmount>
    <mgnx:OperatingLossCarryforwardsNotSubjectToLimitation
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-5"
      id="f-802"
      unitRef="usd">763000000</mgnx:OperatingLossCarryforwardsNotSubjectToLimitation>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-803">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense/(benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-804"
      unitRef="usd">-25149000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-805"
      unitRef="usd">-42445000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-806"
      unitRef="usd">-27245000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-807"
      unitRef="usd">-7385000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-808"
      unitRef="usd">-12806000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-809"
      unitRef="usd">-8100000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-810"
      unitRef="usd">308000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-811"
      unitRef="usd">473000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-812"
      unitRef="usd">344000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-813"
      unitRef="usd">4569000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-814"
      unitRef="usd">10243000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-815"
      unitRef="usd">14691000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-816"
      unitRef="usd">10846000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-817"
      unitRef="usd">1449000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationTaxCreditsOther
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-818"
      unitRef="usd">528000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-819"
      unitRef="usd">1362000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-820"
      unitRef="usd">1199000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-821"
      unitRef="usd">1156000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-822"
      unitRef="usd">1604000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-823"
      unitRef="usd">1079000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-824"
      unitRef="usd">554000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-825"
      unitRef="usd">44675000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-826"
      unitRef="usd">64192000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-827"
      unitRef="usd">48510000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-828"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-829"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-830"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-831">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases for current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases/(decreases) for prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-832"
      unitRef="usd">7197000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0d09ee83f16a43899a8e2f0580a10ce5_I20201231"
      decimals="-3"
      id="f-833"
      unitRef="usd">6126000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i60ca2d1b9b3648e78bc6323a0e727305_I20191231"
      decimals="-3"
      id="f-834"
      unitRef="usd">4950000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-835"
      unitRef="usd">548000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-836"
      unitRef="usd">965000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-837"
      unitRef="usd">839000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-3"
      id="f-838"
      unitRef="usd">-369000</mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-3"
      id="f-839"
      unitRef="usd">106000</mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-3"
      id="f-840"
      unitRef="usd">337000</mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-3"
      id="f-841"
      unitRef="usd">7376000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-3"
      id="f-842"
      unitRef="usd">7197000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0d09ee83f16a43899a8e2f0580a10ce5_I20201231"
      decimals="-3"
      id="f-843"
      unitRef="usd">6126000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ia8eb7d177b724915967268594839281d_I20221231"
      decimals="-5"
      id="f-844"
      unitRef="usd">7400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ie9c3771622be4a8cabd1a5821e850e19_I20211231"
      decimals="-5"
      id="f-845"
      unitRef="usd">7200000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="INF"
      id="f-846"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="INF"
      id="f-847"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="INF"
      id="f-848"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-849">Employee Benefit PlanIn 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least 21 years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to 100% of their salary, subject to government maximums.Employees are 100% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. For the years ended December&#160;31, 2022, 2021 and 2020, the Company's contributions to the Plan totaled $2.3 million, $1.6 million and $1.4 million, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-850">P21Y</mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="INF"
      id="f-851"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="INF"
      id="f-852"
      unitRef="number">1</mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      decimals="-5"
      id="f-853"
      unitRef="usd">2300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i61e770fa73c645568d90bb0126331399_D20210101-20211231"
      decimals="-5"
      id="f-854"
      unitRef="usd">1600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i20f8f2550477493380452b0726f39b25_D20200101-20201231"
      decimals="-5"
      id="f-855"
      unitRef="usd">1400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231"
      id="f-856">Subsequent EventIn March 2023, the Company entered into a Purchase and Sale Agreement (Royalty Purchase Agreement) with DRI Healthcare Acquisitions LP (DRI), a wholly-owned subsidiary of DRI Healthcare Trust.  Under the Royalty Purchase Agreement, the Company sold its single-digit royalty interest on global net sales of TZIELD (teplizumab-mzwv) under the Provention Asset Purchase Agreement to DRI.  The Company retains its other economic interests related to TZIELD, including future potential regulatory and commercial milestones.Under the terms of the Royalty Purchase Agreement, at the closing of the transaction, DRI paid the Company $100.0 million for its single-digit royalty interest on global net sales of TZIELD. The Company will have the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, the Company may also receive up to $50.0 million from DRI upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed type 1 diabetes and transactions regarding TZIELD and Provention. The Company may also receive an additional $50.0 million milestone from DRI if TZIELD achieves a certain level of sales.</us-gaap:SubsequentEventsTextBlock>
    <mgnx:UpfrontPayment
      contextRef="ia220f44f166a475abc1053b676542ca5_I20230315"
      decimals="-5"
      id="f-857"
      unitRef="usd">100000000</mgnx:UpfrontPayment>
    <mgnx:FutureRevenue
      contextRef="i3ec282a2b1564332bd9e83d00ada0da7_D20230301-20230331"
      decimals="-5"
      id="f-858"
      unitRef="usd">50000000</mgnx:FutureRevenue>
    <mgnx:FutureMilestone
      contextRef="i3ec282a2b1564332bd9e83d00ada0da7_D20230301-20230331"
      decimals="-5"
      id="f-859"
      unitRef="usd">50000000</mgnx:FutureMilestone>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MFX_0K$D"&*1FFW;%'\P4Y=FCJOK,N8>4XIZAYM#-%+.>4: [XT:?=L4BGZ?
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M!C GY.XR>/>BQ;JZ3WT46HNL>EQQ!MBE ?R^%$*_OI17M/65_.1_4$L#!!0
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M=\8ZT*)RS64NM&E5;EB8CPE*6V#F%T+HQ\#VJ^;SE/P!4$L#!!0    ( /:
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M4T'3/-E/3%6&DI+7,O]?<P%*XSZ<?U *&(>^43 +"$7,\HLA5.0%<%$%':/
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MTUL\8K=XACQJDHAOFDTX]H/5:?YFTV^6#P]H\R8J(..A>?,"T]$"('=@-F(
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M+D;7\<]6 3>>%N![[0")_$ *INOJJ_\"4$L#!!0    ( /: ;U;U)#\5#B@
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M&DPN3FG;9#L8Q8&=D(0/*N$/*@SI"F+\@XO(D6%_;G?@#;TX>Y&'=4A-W(2
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M&I;&X6:G@<HAJ3J S)F0K]",W&'XGDS?2'Z@=8LN-#?T.(+@+L3-@BP,?EK
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M$\QJ!('//W-3T6:GJD0,O$Q&M[4&"$=3QZ9ZT5Z=C[05*D#,J%.IJ"!A47*
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M)# <Q0ZC-QB/X4YSI9W)-ZL%L)*NV#%Q;*V[N.-%=**>MR]5QMM"M0$U9\(
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MSTNY#\S9R\SN!EV;CI6P#/"*&-"/$*S>OHD+^L>9N+,Q[NP<^_^JU>\QDB,
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MOA8!1+VGO,>;MX0%15VDD$@G#*-V5Y!9-:M!(H.-OHL//#J8^Q0?!Q\6A(P
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MG.[ J-F OJ=*V>V %]C=JF?_ E!+ P04    " #V@&]6[ 59-SP>   GA0
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MAL15 DAZB]1#8Q4M@,&W'0Y@U:+0U<%+[]',%C2BV@$U O?D;=;@!+G* :M
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M?:X*MD:^C-C/#&7(+A@G4*F=[265""S:P+X2T53@> $[PO[LWWD:2W!T!@Q
M)KM)5HI8!;U%\!@NO2Y(<7Y-V[H.ME$#0QE7%'B];T?@0,AQ3<%^)]AW9.$X
M#RTD471W80+4L,-3X$N#/%.ANG X9O3T44 ^,#!\9DTK*5"N#M(]Q:-RU"<
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M$1@?_4)'GW+[G^98+'RWYV_FRQR'T$WS^Y<Z#BG*1J*]P8\(!LVS9AI,1JO
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M2%>3@ 0FO7#KA)<-KA3=\$4E&)QM\'0E:J&Y%67 EDU5/3&U7!K S>*)<?;
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M1F[]]X##</]5Y2>N$3L#BKO$U'"<9P.F_9<*?V/5UGT=6"AKU<9=K@5'UM,
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M]*<XZQODHWG_F[D6=B=9M,(MNZ;QSY\BL'WK[B=DVM N"T/<?,.PYK\=6F_
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M<0#-SRT=O_6 %^B_HB9_ U!+ P04    " #V@&]66, 3[A0J   3DP  &0
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M#S !!#A(,63%=@N"BP:$=70]P; /!Z+PW@U Z4U=;.JF'HCL>_?@VE$F<K^
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M:>!(GY[D)Q]@:P 9I T1.I98TJ\<(KN=T38A#[@)[ 7N2[<B%*/(Z<.@3'I
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MK>K@_SD41]XKLCB.K(*B"Q,(+B?+ZX',:C29T&&;K-LGUHD>_<01 WRW[?;
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M_K8@Y=)8QD;]SD.T7G@L=7AF]Z!,'D"(;^/<S'W9CF.B\.,>04FFC5.F*L:
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M)=NDDA(XM_)R0JR!.>B:J;]_B\#[P1W\Y]E9?:Z:V5'10%MQ!@:I^!,5X5_
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M-\V^".K^%/*%LQN*"RU_)$!YF>EW4^,HZ0ZPMD-+OGR#Z$DUHA# &H&8+,F
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M)S<5/$4V2WVO)RT9@I+Q@07$)4L]@ZG ' ^X.=,,<!ANJZ4%*_I0*H(T8'4
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M=@IT7BEE]QOG8/Q:+?\!4$L#!!0    ( /: ;U9*:7O]T@,  #<)   9
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;)U666_;.!#^*P/U0 RHUF%)ME/;
M0(Y=;(&F"9IL^[#8!UH:VT0I4B6IN/[W.Z0<U6T=%]@7\=#,-]]<)&=;I;^8
M#:*%;[609AYLK&W.H\B4&ZR9&:H&)?U9*5TS2TN]CDRCD55>J191&L=%5#,N
M@\7,[]WIQ4RU5G")=QI,6]=,[RY1J.T\2(*GC8]\O;%N(UK,&K;&>[1_-W>:
M5E&/4O$:I>%*@L;5/+A(SB\+)^\%/G'<FH,Y.$^62GUQBW?5/(@=(1186H?
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MX=.+U;I7 J&YS*V)@9<!=!C4Q81"<]?$UL8@KVDXH,,RV9V>^ZB_H\.&,#Q
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MT&F56BDJZO8P[<&%2[!J;&:;I/OWLPVAM$VB/.0%_''/X=YS[7N9;+AXDB6
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MZ0"-FV[6!3-O@PGV!.,'Z(XS56HOF';A-8&KE>GE";;RS(.#C EDYRCTOZ#
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M%]HWT7:X=J)X;6O^(U>Z@]AAJ7\*0!@#O5]PKK83\X'^-R/^#U!+ P04
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MG^>. T&S_ O7B@I!D_QR2_"&,&4@GS]2*EX&ZJ-9^9%T_A]02P,$%     @
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M\:</X7GPI:E^[TF6O!/97FT[=6T[Q]AC5\[G&I[NO._82EL:WW>T<6R*5*1
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ML4"8 #V_Y%R]=$Q1[-[ ] ]02P,$%     @ ]H!O5FL1OI7D @  0@@  !D
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M%$_RS26C(1-9 _WYG'/ULI-U4+UQ./D74$L#!!0    ( /: ;U9XKL'2UPD
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M4!I'T705-Z:>;3;U&A7/LR11Z7/Y]DC5MOTXQVE;"M?F->BM6JB[!Z7Y4%H
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M9.OJ2:EW65%D2?5V)<*%D&4!]?U]EA4O'\H*=H\DOOP+4$L#!!0    ( /:
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M2N3]S<!?7GWE\EZ5:(-M1B]#=02E>5":#Z51*"V TAB*IBIS*PQLO_=<H/6
M4B62YD%I/I1&H;0 2F,HFJI*IU.E<V#7N\JSA1!A0>2T("%Y]L+C,A(%68E\
M\<;\P,P>K,<U[7BK@[$^.3M#.ZA+'TJC4%H I3$43959EP"PC2%=7;=\>_/9
M\[_=DB2+Q:*2$U)C3,[,'RPU: 8 2O.A- JE!5 :0]%4379Y 'OR[ATR-&$
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M2@N@-.;V@_13RS">Z0+KKCFP?IOSM.#K$TA7>;30]U?0N#J4YD%I/I1&H;0
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MQO["(UFM17[!G$TRO((G$%^R!R;/S)H2D0123FB*&"RGQHU]'=B#7%"4^(/
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M^GWYL S0@A2<"O70FP X3C/V\\3F8AYI;4<U<UXQO0M,UT./ I,P%!8QQ&V
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MHCN#';_K==R)";4V+NF&<+T\%CJ/0+B4*>/9/RKGA?H8KU,_&C_%!\L\-PY
M:0$H+02E10W-[ZSF9X[^:U?S?9<[&S'NH,MW^"FC)47D.,+':K+EV::LNK^:
MLV/5QXU.UMRK3HV<2[?_<;$:+OQL@R!I(2@M@J+U;?1>;/2&/VMKHW2?W.*,
M(XKY@_J"?<1Y29!D:'^<L>N^:334,QAZ^O&Y&J['V8Y"TD)06@1%ZSOZLG/E
M#FZ#+%>=[8C6OD1/PL>N*MX<;$$WIQI:=PARG<G5[&1#(0 M-02E15"TOJ<O
M>T_N_[SY-%S>V0[_=\MHW)EA&GLABPQ!:1$4K;;7[IQO4,)WU4F44&:4A:PW
M\]O4]K3KICKC.4E?N==A?6;U@JF/T.XPWV6%0#G9*J1S.9U8B->G4O6-9/OJ
M%&7#I&2TNDP)3@C7&=3S+6/R>*,+:,\&E_\"4$L#!!0    ( /: ;U8X,&#/
MX 4  /XG   9    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;,V:;6_;-A#'
MOPKA%4,+I)8HR;*4.0822]L*K%B0K.N+82\8B;&%2J)'TG&R3S]24O1D18FS
M0]LWC23S?B+O+QYY5R[VC'\1&THENL_27)Q--E)N3PU#1!N:$3%E6YJK7VX9
MSXA4MWQMB"VG)"Z,LM2P3-,U,I+DD^6B>';)EPNVDVF2TTN.Q"[+"'^XH"G;
MGTWPY/'!5;+>2/W 6"ZV9$VOJ?RTO>3JSJ@I<9+17"0L1YS>GDW.\6EH.=J@
M:/%G0O>B=8WT4&X8^Z)O/L1G$U/WB*8TDAI!U)\[NJ)IJDFJ'_]4T$G]3FW8
MOGZD_UP,7@WFA@BZ8NGG)):;LXDW03&]);M47K']K[0:T$SS(I:*XE^TK]J:
M$Q3MA&199:QZD"5Y^9?<5XYH&6#W"0.K,K#Z!LX3!G9E8+_4P*D,G)<:S"J#
M8NA&.?;"<0&19+G@;(^X;JUH^J+P?F&M_)7D^D.YEES]FB@[N;R6+/KR7KLZ
M1BN6J>]/D$+!]ZC\Z>+PI_!>7U/T-J"2)*EXIQI_N@[0VS?OT!MD(+$AG J4
MY.A3GDAQHAZJZS\V;"=('HN%(57']>N-J.KD1=E)ZXE.8@M]9+G<"!3F,8V[
M $.-N!ZV]3CL"VN4&-!HBFQ\@BS3L@8ZM'JY.1XP#UYN;@Z8A^/FOT?RT1S;
M(\ZPZV_ +GCV4]^ UFOH&SCGG.1KJN*"1#</J-WNDCP4C\_WA,?HK]\4$GV0
M-!-_#\E;OM\9?K^.A:=B2R)Z-E'!3E!^1R?+'W_ KOG3D#20L  2%@+!.B(Z
MM8C.&+TC8M06D71%%*UVVTI$HD4\06RK#=1\50N*D&JJ)OGZ!.6[[(9R]%9-
MX7)BOQM2N.R<6W1.+TYW2VR:ON=;_L*X:ZMWV-"SY[:OIU&[73 ZVF.% 8)U
MA)G5PLQ&A?E<K%7*V^2.<K7V(GI/>92H^+GE240+Q\8L30D7:*L<73AYT,?E
M>[RVC[WIS.LY^+"5A:?.O.?>T3X?ZUX@6,>];NU>=S1XA=DV90^4HFL%UOY\
M*IJ=H/,T95$Y*=@MNJ(16^?)OSJ849XPW5I(\6PL<R%C&20L@(2%0+".IO-:
MT_EX+&MM2CJQC)8[CR%92N*\_=F;CMW[[%<#K6QLN;W),<1RY[U6X>@87NDA
MK_:0-^JA\)]=(A_0ASQ2\5OMM-%E2G*U'S#M(=^,LH[]9"%A 20L!()U!/%K
M0?QOO(?R(46$A 60L! (UA$1FTTV9'[/NZBJ=^W=D3O#>E)WHMCX((Z5#Y06
M0M&Z K;26?R5=EO5B]H;J=FTOYL=[\W12D#20BA:5PFK4<)Z?A$_7*'Z&6OE
M[%'6L=$-E!: TD(H6E>5)M7'WSK7QZ#)/B@M *6%4+2NE$W"CU^7\=>+C4IR
MJE(<V<D-XT6N\]P*!)EWKT!I 2@MQ ,E"]\UL=LDU%UAFH0?CV?\*N9Q6LCR
M?X28'79OYF'7=P[6(,A</@"EA5"TKA)-;0"/IJG??#OG#E7%;-OK9YRK\7$<
MK2%H)0"*UM6PJ07@\6( X(YN/E1 <P^T $KL*RT@:2$4K:M%4W7 XV6'2^5Y
M-3>T"BJFJ1F5J;DDBHU>X?;V)!E4H,3[+07,J>GT!0 M,8#20BA:5X"FRH!'
M\]_EE6(2'FV0\C&*Z1U-V59'JT%G@U8,0&D!*"V$HG7_*[$I&ECF]U6"MB S
M]A4H+0"EA5"TKK)--<$:KR:\IA!=(>?=1=_O![FJ66=O@.U^P3H8:F9Z=J\B
M%(Z/X[5^:G)]:SS7_X7F:FU.BZA$XBS)$R$YT6G_H(= DWU06@!*"Z%H75F:
M9-\:3_:_?F "S?U!:0$H+82B=95M<G_KF=S_-8')&0A,MM,O+@\UPW//[P>F
MPV:^UX>%X\,XUDU&ZYQ31OFZ.& FE -VN2S/_M1/ZT-LY\71K=[S"WP:E$?1
M&DQY,NXCX>LD%RBEMPII3N<J@>7E8;/R1K)M<9KJADG)LN)R0TE,N6Z@?K]E
M3#[>Z!?41_Z6_P%02P,$%     @ ]H!O5BW_FRJ8 P  91   !D   !X;"]W
M;W)K<VAE971S+W-H965T-3 N>&ULQ5AM:]LP$/XKPH.QP1J_Y+U+#$F]L<+*
M0LNV#V,?5/N2B-B6)RE)\^\GR:X;NXJ7,D._Q))\SZ.[1[Y#E\F>L@U? PCT
MD,0IGUIK(;)+V^;A&A+,.S2#5+Y94I9@(:=L9?., 8XT*(EMSW$&=H)):OD3
MO;9@_H1N14Q26##$MTF"V6$.,=U/+==Z7+@EJ[50"[8_R? *[D!\SQ9,SNR2
M)2()I)S0%#%83JV9>QFX7070%C\([/G1&*E0[BG=J,EU-+4<Y1'$$ I%@>5C
M!U<0QXI)^O&G(+7*/17P>/S(_ED'+X.YQQRN:/R31&(]M486BF")M[&XI?LO
M4 345WPAC;G^1?O<=CBV4+CE@B8%6'J0D#1_XH="B". -S@!\ J 5P.XPQ.
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M;5)^4SS\0E6'/&EO7J1E]1\\U-=.O!&8;TI>9*JQ4) E>?T9?56!:#7 R-
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M^;@B>$$JGH#]_ER6]>X++V#_'I2[_P-02P,$%     @ ]H!O5L[$0DXK!0
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M!*M3AC90GV\8DT\W^J3;_[*Q_A]02P,$%     @ ]H!O5@6T J (!   3PT
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M FD,\/M2"/T\,3_H6K+D+U!+ P04    " #V@&]6.S&1=0<#  !$"@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6RM5LENVS 0_15"#8H42*W%6YO:
M N(H17L(8"1(>RAZH*6Q380B59*VD[_OD))5VY75I/!%XC+OS<SC-J.-5(]Z
M"6#(4\Z%'GM+8XI+W]?I$G*J.[( @3-SJ7)JL*L6OBX4T,R!<NY'03#P<\J$
M%X_<V%3%([DRG F8*J)7>4[5\P2XW(R]T-L.W+'%TM@!/QX5= 'W8!Z*J<*>
M7[-D+ >AF11$P7SL7867R=#:.X-O##9ZITUL)C,I'VWG:S;V AL0<$B-9:#X
M6\,U<&Z),(Q?%:=7N[3 W?:6_;/+'7.940W7DG]GF5F.O0\>R6!.5]S<R<T7
MJ/+I6[Y4<NV^9%/:#@./I"MM9%Z!,8*<B?)/GRH==@#AX @@J@#1(:!W!-"M
M -V7 GH5H.>4*5-Q.B34T'BDY(8H:XULMN'$=&A,GPF[[/=&X2Q#G(EO\H++
M9P R 0%S9LB44T'.$S"4<?V.O"</]PDY/WM'S@@3Y)9QCLNE1[Y!YY;"3RM'
MD])1=,11&)%;*<Q2DQN10;9/X&/4=>C1-O1)U,J80-HAW?""1$$4-01T_7)X
MV !/7@X/6K+IU@O1=7S=(WQW8)@"/%!FNQ2:_+B:::/P:/QLTKODZS7SV>OB
M4A<TA;&']X$&M08O?OLF' 2?FK0Z)5ER(K(]'7NUCKTV]OB&LP6;<2!X:1$C
M24&582DKJ &[@0O<WDUBMI-&(7D&JIJV_74K\K7*G8AL3[E^K5R_-<DIJ!2W
MG]5-S@EL+X843ZUBLY6[IE%033F^#TT:EO0?';U];M8QGJOUKE:M ;Q6JQ.1
M[6DUJ+4:_(]6:] &LCW)FH0:_%.H5N^O%>I$9'M"#6NAAJU")7B3B0-)W"&\
MV*JF2,9TJL#.X,;:MZ2Y7 G3I&'IMK^C8=3I'JCXMTW8&>S;)$TVO=JFS-G?
M>5]S4 M7IVB,%&,KWZMZM"Z%KEP%<# ^P1*IK&C^T)3UU2U5"R8TX3!'RJ S
MQ(A46;.4'2,+]XK/I,&:P#676.:!L@8X/Y?2;#O605TXQK\!4$L#!!0    (
M /: ;U8$>H3HM 4  $D9   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM
M;*U9;6_;-A#^*X27#0F06"^.\](Y!M)(70TT@Y$T&[!A'VB)MHA2HD)2=EWL
MQ^](R;*5*(J-\8LMB7?/W3UW/%+4:,7%-YD0HM#WE&7RII<HE7]P'!DE),6R
MSW.2P<B<BQ0KN!4+1^:"X-@HI<SQ7??"23'->N.1>385XQ$O%*,9F0HDBS3%
M8OV1,+ZZZ7F]S8,'NDB4?N",1SE>D$>BGO*I@#NG1HEI2C))>88$F=_T;KT/
MH>=K!2/Q!R4KN7.-="@SSK_IFTE\TW.U1X212&D(#']+<D<8TTC@QW,%VJMM
M:L7=ZPWZ)Q,\!#/#DMQQ]B>-57+3N^JAF,QQP=0#7WTF54!#C1=Q)LTO6I6R
MPXL>B@JI>%HI@P<IS<I__+TB8D<!<-H5_$K!WU=A4"D,7BA<N6\HG%<*YR\M
MG+^A,*P43.A.&;LA+L *CT>"KY#0TH"F+PS[1AOXHIDNE$<E8)2"GAH_%C-)
MG@N2*10NX5>BXX H3)D\06?HZ3% QT<GZ C1#-U3QB"W<N0H,*S5G:@R\K$T
MXK]AQ$/W/%.)1&$6D[A%_ZY;?_">?O".?;\#P '&:MK\#6T?_4[$>RSZ:."=
M(M_U!VT![:WN7;?%TZT>D*BV[K>HAWM8]X9MSC?(&-0U-#!X@SUK"/W]!230
M1)%4_M-6+27<>3N<;HT?9(XC<M.#WB>)6)+>^)>?O OWUS:F;8(%-L%"2V"-
MG)S7.3GO0G^5D[8T="(<F@:;8,%AL4V@-V$1)::>3Y%*"+KC:8ZS-8)1(D@,
M[4MQA-&T #%85A#.8O2(&4&W"T%(JJ&.'_@:,[7>"M5C)]"458*"APGZ3$ F
MB;" X>BYH)+J]4ZB+U-HG ^3DU.PLDHX8^LSOLK L@1G:4QA$49\_A+BJX .
MWT?H"=J2,(Z_[40S,,D91 7M6M)LP<A93!=4(5%I4Q.V5 B6X@7C,\Q0!IL.
M"1%+[<;7OR;A%VCMBN2,_BA2/#M+?ZR6)ZBH'9D*KKG5B_FME*#\VB,$G$)
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M)E%86YDDTHV3HH*5(;91BIO?=R!U&],Q/2P\B:)T?H$E4<T+6(/[6J\,SMC
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M>I$ARAFB',?R(9/ZB^7Q<Q+[\<\T2:(HCK$5G4R\#B;8NL4Q_/C5,&_ P/)
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MZAU_J?=8/O=YO/1\K_$[]U]274[WYLOCS\OODXCSXHQS@A]E[K\ 4$L#!!0
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M?\KZ9.WZKW^RZ.]Y:^KN/9\-?[)<O0)02P$"% ,4    " #V@&]6!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( /: ;U;]VI!![P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( /: ;U:97)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M]H!O5IG"7Y#@!@  Z",  !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( /: ;U;%\(3+.0(  +H%   8
M          " @20/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " #V@&]6M-W4Q;\%  ">%P  &               @(&3$0  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ ]H!O5ID[E9*4 @  J@8
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M965T."YX;6Q02P$"% ,4    " #V@&]6]20_%0XH  !:A0  &
M    @($:.@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M]H!O5O'*W6GE!   &@P  !D              ("!7F(  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " #V@&]6133LS- #  "C"   &0
M            @(%Z9P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( /: ;U8UHSA#10,  (('   9              " @8%K  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ ]H!O5@7]7=2 !P
M@!$  !D              ("!_6X  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " #V@&]6-@K6OHX$  !A"P  &0              @(&T
M=@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( /: ;U;L
M!5DW/!X  ">%   9              " @7E[  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ ]H!O5ED16.\H#@  (2@  !D
M     ("![)D  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /: ;U92B3UP.P8  #T0   9              "
M@:_D  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ ]H!O
M5M*K-8HC P  2 <  !D              ("!(>L  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " #V@&]6V6;8DO("  #I!@  &0
M        @(%[[@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( /: ;U9] MKC$0,  +D&   9              " @:3Q  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ ]H!O5DII>_W2 P  -PD
M !D              ("![/0  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " #V@&]6&"U74\\%   V#P  &0              @('U^
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( /: ;U;# 9Q,
ML@4  #D.   9              " @?O^  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ ]H!O5JK-!A@I @  M00  !D
M ("!Y 0! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #V
M@&]6OP"PSV(&  !J+P  &0              @(%$!P$ >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( /: ;U9B:U^.U@4  # K   9
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M970S-"YX;6Q02P$"% ,4    " #V@&]6#8/_?Y$"   /!P  &0
M    @(%O(0$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M /: ;U9K$;Z5Y (  $((   9              " @3<D 0!X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ ]H!O5D;/E'7U!   *B   !D
M             ("!4B<! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " #V@&]6_S>_=6P&  #P*@  &0              @(%^+ $ >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( /: ;U8LY%'8A08
M 'TX   9              " @2$S 0!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ ]H!O5GBNP=+7"0  GG@  !D              ("!
MW3D! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #V@&]6
M^]N7 >(#  ""$P  &0              @('K0P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( /: ;U;?&'=S" D  /-?   9
M      " @01( 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ ]H!O5KJ_+?*T!   9!P  !D              ("!0U$! 'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #V@&]6G4TV],0$  !E'@
M&0              @($N5@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( /: ;U;VU^)^LP8  )LW   9              " @2E; 0!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ ]H!O5E9V )UD
M P  D0P  !D              ("!$V(! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    " #V@&]6^*W?A L$   <%P  &0
M@(&N90$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( /:
M;U9?J($ H@0  "<<   9              " @?!I 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ ]H!O5C@P8,_@!0  _B<  !D
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M=#4S+GAM;%!+ 0(4 Q0    ( /: ;U;H:4 ;:00  .40   9
M  " @2N. 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
M]H!O5@6T J (!   3PT  !D              ("!RY(! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    " #V@&]6I$.64D(#  ">"0  &0
M            @($*EP$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( /: ;U8[,9%U!P,  $0*   9              " @8.: 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ ]H!O5@1ZA.BT!0
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M96QS+RYR96QS4$L! A0#%     @ ]H!O5N;;ASL1!0  /"<   \
M     ( !-JH! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( /: ;U99=@'X
M]0$  #@C   :              "  72O 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( /: ;U87R,P;VP$  -$B   3
M  "  :&Q 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !# $, 3!(  *VS
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>247</ContextCount>
  <ElementCount>341</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>98</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/OrganizationandNatureofOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Property, Equipment and Software</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftware</Role>
      <ShortName>Property, Equipment and Software</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecurities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Inventory, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetTables</Role>
      <ShortName>Inventory, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Property, Equipment and Software (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftwareTables</Role>
      <ShortName>Property, Equipment and Software (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/PropertyEquipmentandSoftware</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CommitmentsandContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockbasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Available-For-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Inventory, Net - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails</Role>
      <ShortName>Inventory, Net - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Inventory, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetDetails</Role>
      <ShortName>Inventory, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/InventoryNetTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Property, Equipment and Software (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails</Role>
      <ShortName>Property, Equipment and Software (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/PropertyEquipmentandSoftwareTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockholdersEquity</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Revenue - Incyte Corporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueIncyteCorporationDetails</Role>
      <ShortName>Revenue - Incyte Corporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Revenue - Gilead Sciences Inc (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueGileadSciencesIncDetails</Role>
      <ShortName>Revenue - Gilead Sciences Inc (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Revenue - Zai Lab (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueZaiLabDetails</Role>
      <ShortName>Revenue - Zai Lab (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Revenue - Janssen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueJanssenDetails</Role>
      <ShortName>Revenue - Janssen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Revenue - I-Mab Biopharma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueIMabBiopharmaDetails</Role>
      <ShortName>Revenue - I-Mab Biopharma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Revenue - Provention (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueProventionDetails</Role>
      <ShortName>Revenue - Provention (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Revenue - Boehringer Ingelheim International GmbH (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails</Role>
      <ShortName>Revenue - Boehringer Ingelheim International GmbH (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Revenue - NIAID Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueNIAIDContractDetails</Role>
      <ShortName>Revenue - NIAID Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock-based Compensation - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails</Role>
      <ShortName>Stock-based Compensation - Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Share-based Compensation - Option, Exercise Price Range Table (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails</Role>
      <ShortName>Share-based Compensation - Option, Exercise Price Range Table (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SubsequentEvents</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="mgnx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - mgnx-20221231.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - mgnx-20221231.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="mgnx-20221231.htm">mgnx-20221231.htm</File>
    <File>a1022_gileadcollab.htm</File>
    <File>a1023_proventionapa.htm</File>
    <File>a1024_proventionapaamendme.htm</File>
    <File>a1025_hqlease.htm</File>
    <File>a1026_firstamendmenttohqle.htm</File>
    <File>a1027_secondamendmenttohql.htm</File>
    <File>a1028_thirdamendmenttohqle.htm</File>
    <File>a1029_fourthamendmenttolea.htm</File>
    <File>a1030_fifthamendmenttohqle.htm</File>
    <File>mgnx-20221231.xsd</File>
    <File>mgnx-20221231_cal.xml</File>
    <File>mgnx-20221231_def.xml</File>
    <File>mgnx-20221231_lab.xml</File>
    <File>mgnx-20221231_pre.xml</File>
    <File>mgnxexhibit23-1202210xk.htm</File>
    <File>mgnxexhibit31-1202210xk.htm</File>
    <File>mgnxexhibit31-2202210xk.htm</File>
    <File>mgnxexhibit32-1202210xk.htm</File>
    <File>mgnxexhibit32-2202210xk.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mgnx-20221231_g1.jpg</File>
    <File>mgnx-20221231_g2.jpg</File>
    <File>mgnx-20221231_g3.jpg</File>
    <File>mgnx-20221231_g4.jpg</File>
    <File>mgnx-20221231_g5.jpg</File>
    <File>mgnx-20221231_g6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="689">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>94
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 689,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 247,
   "dts": {
    "calculationLink": {
     "local": [
      "mgnx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgnx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mgnx-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 555,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 4
   },
   "keyCustom": 61,
   "keyStandard": 280,
   "memberCustom": 59,
   "memberStandard": 31,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://macrogenics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Marketable Securities",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://macrogenics.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Inventory",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://macrogenics.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Property, Equipment and Software",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftware",
     "shortName": "Property, Equipment and Software",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://macrogenics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://macrogenics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Revenue",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://macrogenics.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Stock-based Compensation",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://macrogenics.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://macrogenics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Employee Benefit Plan",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://macrogenics.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://macrogenics.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://macrogenics.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "20",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://macrogenics.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Inventory, Net (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://macrogenics.com/role/InventoryNetTables",
     "shortName": "Inventory, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Property, Equipment and Software (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftwareTables",
     "shortName": "Property, Equipment and Software (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://macrogenics.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Stock-based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://macrogenics.com/role/StockbasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://macrogenics.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ifc945f6be73546b2afbc3f7e91a7829e_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ifc945f6be73546b2afbc3f7e91a7829e_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "i9aa7f28c164743c18f02c60499ebf31f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails",
     "shortName": "Summary of Significant Accounting Policies - Estimated Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "i9aa7f28c164743c18f02c60499ebf31f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "i0d86aae1ee24443584fb111e79fb643d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "i0d86aae1ee24443584fb111e79fb643d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://macrogenics.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails",
     "shortName": "Marketable Securities - Available-For-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWorkInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Inventory, Net - Schedule of Inventory (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails",
     "shortName": "Inventory, Net - Schedule of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWorkInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "mgnx:ScheduleOfInventoryReservesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "iadceb1c7c1874b8ba0b62e7c4d2ff42d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Inventory, Net (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://macrogenics.com/role/InventoryNetDetails",
     "shortName": "Inventory, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "mgnx:ScheduleOfInventoryReservesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "i269e66b57b7b42519a681c1a8cc89766_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Property, Equipment and Software (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
     "shortName": "Property, Equipment and Software (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mgnx:RightOfUseAssetAndLeaseLiabilityIncrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mgnx:RightOfUseAssetAndLeaseLiabilityIncrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://macrogenics.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ife8f008f05574ef1870bdae6c66d666b_I20210615",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Revenue - Incyte Corporation (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
     "shortName": "Revenue - Incyte Corporation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ifa77d46ed2c54978a8e628b9c800991f_I20220131",
      "decimals": null,
      "lang": "en-US",
      "name": "mgnx:CollaborativeArrangementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Revenue - Gilead Sciences Inc (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
     "shortName": "Revenue - Gilead Sciences Inc (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "i1b71d094740b4c1e9c5b2ff8f8b13f29_D20221014-20221014",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:PotentialTargetNominationOptionFeesAndMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Revenue - Zai Lab (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://macrogenics.com/role/RevenueZaiLabDetails",
     "shortName": "Revenue - Zai Lab (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "i96872571cd0a4110aadf271b65708d4f_D20181101-20181130",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Revenue - Janssen (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://macrogenics.com/role/RevenueJanssenDetails",
     "shortName": "Revenue - Janssen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "i0b1d84cceaa14d2b82272120f3d141a5_D20201201-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Revenue - I-Mab Biopharma (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
     "shortName": "Revenue - I-Mab Biopharma (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia1ecd07929384da0be9ffd4764df7764_D20190701-20190731",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Revenue - Provention (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://macrogenics.com/role/RevenueProventionDetails",
     "shortName": "Revenue - Provention (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "i42483221131f4b7481cd3ebfbdd95b45_I20180531",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:CollaborativeAgreementTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "i8e86a555e3f24015bead72636200ae9a_D20101001-20151031",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndLicenseAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Revenue - Boehringer Ingelheim International GmbH (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails",
     "shortName": "Revenue - Boehringer Ingelheim International GmbH (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "i8e86a555e3f24015bead72636200ae9a_D20101001-20151031",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndLicenseAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Revenue - NIAID Contract (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://macrogenics.com/role/RevenueNIAIDContractDetails",
     "shortName": "Revenue - NIAID Contract (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "if5ee02f7ab344826b0c16f694bb46f66_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:TotalPotentialValueUnderAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
     "shortName": "Stock-based Compensation - Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "i452d203362b14c6ca8da438846c11955_D20170501-20170531",
      "decimals": null,
      "lang": "en-US",
      "name": "mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
     "shortName": "Stock-based Compensation - Option Pricing Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Share-based Compensation - Option, Exercise Price Range Table (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails",
     "shortName": "Share-based Compensation - Option, Exercise Price Range Table (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ie9c3771622be4a8cabd1a5821e850e19_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails",
     "shortName": "Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails",
     "shortName": "Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia8eb7d177b724915967268594839281d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails",
     "shortName": "Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ie9c3771622be4a8cabd1a5821e850e19_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "i60ca2d1b9b3648e78bc6323a0e727305_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Employee Benefit Plan (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://macrogenics.com/role/EmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://macrogenics.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ia220f44f166a475abc1053b676542ca5_I20230315",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:UpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "id38bfa0cc8324178bc6a9c6bcdcbaa4d_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "id38bfa0cc8324178bc6a9c6bcdcbaa4d_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization and Nature of Operations",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://macrogenics.com/role/OrganizationandNatureofOperations",
     "shortName": "Organization and Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "ic626cdb476d04abdad6aca37d44c00eb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20221231.htm",
      "contextRef": "i66fe51ad0d964f1896d0f96af0e1e372_D20210601-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - mgnx-20221231.htm",
     "menuCat": "Cover",
     "order": "59",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - mgnx-20221231.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 98,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mgnx_A2018ZaiLabCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Zai Lab Collaboration And License Agreement",
        "label": "2018 Zai Lab Collaboration And License Agreement [Member]",
        "terseLabel": "2018 Zai Lab Collaboration And License Agreement"
       }
      }
     },
     "localname": "A2018ZaiLabCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_A2021ZaiLabAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Zai Lab Agreements",
        "label": "2021 Zai Lab Agreements [Member]",
        "terseLabel": "2021 Zai Lab Agreements"
       }
      }
     },
     "localname": "A2021ZaiLabAgreementsMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_A2022GileadCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Gilead Collaboration And License Agreement",
        "label": "2022 Gilead Collaboration And License Agreement [Member]",
        "terseLabel": "2022 Gilead Collaboration And License Agreement"
       }
      }
     },
     "localname": "A2022GileadCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ASDHealthcareAndOncologySupplyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASD Healthcare and Oncology Supply",
        "label": "ASD Healthcare and Oncology Supply [Member]",
        "terseLabel": "ASD Healthcare and Oncology Supply"
       }
      }
     },
     "localname": "ASDHealthcareAndOncologySupplyMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AdditionalAnnualFixedPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Annual Fixed Payments",
        "label": "Additional Annual Fixed Payments",
        "terseLabel": "Additional Annual Fixed Payments"
       }
      }
     },
     "localname": "AdditionalAnnualFixedPayments",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Agreement",
        "label": "Asset Purchase Agreement [Member]",
        "terseLabel": "Asset Purchase Agreement"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering [Member]",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At The Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://macrogenics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boehringer Ingelheim International GmbH Collaboration And License Agreement",
        "label": "Boehringer Ingelheim International GmbH Collaboration And License Agreement [Member]",
        "terseLabel": "Boehringer Collaboration and License Agreement"
       }
      }
     },
     "localname": "BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_BoehringerIngelheimInternationalGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boehringer Ingelheim International GmbH",
        "label": "Boehringer Ingelheim International GmbH [Member]",
        "terseLabel": "Boehringer Ingelheim International GmbH"
       }
      }
     },
     "localname": "BoehringerIngelheimInternationalGmbHMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And License Agreement, Term",
        "label": "Collaboration And License Agreement, Term",
        "terseLabel": "Term of agreement (in years)"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementTerm",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://macrogenics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaboration and license agreements.",
        "label": "Collaboration And License Agreements Disclosure [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsDisclosureTextBlock",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_CollaborationArrangementOneTimeCreditPaidPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, One-time Credit Paid, Percent",
        "label": "Collaboration Arrangement, One-time Credit Paid, Percent",
        "terseLabel": "Collaboration Arrangement, One-time Credit Paid, Percent"
       }
      }
     },
     "localname": "CollaborationArrangementOneTimeCreditPaidPercent",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share",
        "label": "Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share",
        "terseLabel": "Consideration received common stock warrant exercise price (in usd per share)"
       }
      }
     },
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares",
        "label": "Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares",
        "terseLabel": "Stock warrants (in shares)"
       }
      }
     },
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CollaborativeAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Transaction Price",
        "label": "Collaborative Agreement Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "CollaborativeAgreementTransactionPrice",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueJanssenDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CollaborativeArrangementExtensionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Extension Term",
        "label": "Collaborative Arrangement, Extension Term",
        "terseLabel": "Collaborative arrangement, extension term"
       }
      }
     },
     "localname": "CollaborativeArrangementExtensionTerm",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Collaborative arrangement, term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Maximum Amount Available For Issuance",
        "label": "Common Stock, Maximum Amount Available For Issuance",
        "terseLabel": "Common stock maximum amount available for issuance"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuance",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuanceIncrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Maximum Amount Available For Issuance, Increase",
        "label": "Common Stock, Maximum Amount Available For Issuance, Increase",
        "terseLabel": "Common Stock, Maximum Amount Available For Issuance, Increase"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuanceIncrease",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ContractManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Manufacturing",
        "label": "Contract Manufacturing [Member]",
        "terseLabel": "Contract Manufacturing"
       }
      }
     },
     "localname": "ContractManufacturingMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_CostOfManufacturingServices": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of manufacturing services",
        "label": "Cost of manufacturing services",
        "terseLabel": "Cost of manufacturing services"
       }
      }
     },
     "localname": "CostOfManufacturingServices",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DRIHealthcareAcquisitionsLPDRIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DRI Healthcare Acquisitions LP (DRI)",
        "label": "DRI Healthcare Acquisitions LP (DRI) [Member]",
        "terseLabel": "DRI Healthcare Acquisitions LP (DRI)"
       }
      }
     },
     "localname": "DRIHealthcareAcquisitionsLPDRIMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities",
        "label": "Deferred Tax Assets, Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Lease Right Of Use Assets",
        "label": "Deferred Tax Liabilities, Operating Lease Right Of Use Assets",
        "negatedLabel": "Operating lease ROU assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage vested of employee's contributions to defined contribution plan",
        "label": "Defined Contribution Plan, Employees Contribution, Vested Percentage",
        "terseLabel": "Percentage of employee vested contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployeesContributionVestedPercentage",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "label": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "terseLabel": "Amounts recognized",
        "verboseLabel": "Development milestones recognized"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DevelopmentMilestonesAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Milestones, Amount",
        "label": "Development Milestones, Amount",
        "terseLabel": "Development milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesAmount",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]",
        "label": "Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]",
        "terseLabel": "U.S. Federal and State"
       }
      }
     },
     "localname": "DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount",
        "terseLabel": "Deferred income tax adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent",
        "label": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum employee contribution percent"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to minimum eligible age of employee to participate in benefit plan.",
        "label": "Employees Eligible Age To Participate In Benefit Plan",
        "terseLabel": "Eligible age to participate in plan"
       }
      }
     },
     "localname": "EmployeesEligibleAgeToParticipateInBenefitPlan",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_EquityIncentivePlan2003Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2003",
        "label": "Equity Incentive Plan 2003 [Member]",
        "terseLabel": "Equity Incentive Plan 2003"
       }
      }
     },
     "localname": "EquityIncentivePlan2003Member",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_EstimatedReimbursementForResearchAndDevelopmentT": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Reimbursement for Research and Development t",
        "label": "Estimated Reimbursement for Research and Development t",
        "terseLabel": "Estimated Reimbursement for Research and Development t"
       }
      }
     },
     "localname": "EstimatedReimbursementForResearchAndDevelopmentT",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ExercisePriceRangeFromDollars094To500MemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range From Dollars 0.94 to 5.00 Member",
        "label": "Exercise Price Range From Dollars 0.94 to 5.00 Member [Member]",
        "terseLabel": "Exercise Price Range From Dollars 0.94 to 5.00 Member"
       }
      }
     },
     "localname": "ExercisePriceRangeFromDollars094To500MemberMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ExercisePriceRangeFromDollars1501To2500MemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range From Dollars 15.01 to 25.00 Member",
        "label": "Exercise Price Range From Dollars 15.01 to 25.00 Member [Member]",
        "terseLabel": "Exercise Price Range From Dollars 15.01 to 25.00 Member"
       }
      }
     },
     "localname": "ExercisePriceRangeFromDollars1501To2500MemberMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ExercisePriceRangeFromDollars2501To4021MemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range From Dollars 25.01 to 40.21 Member",
        "label": "Exercise Price Range From Dollars 25.01 to 40.21 Member [Member]",
        "terseLabel": "Exercise Price Range From Dollars 25.01 to 40.21 Member"
       }
      }
     },
     "localname": "ExercisePriceRangeFromDollars2501To4021MemberMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ExercisePriceRangeFromDollars501To1500MemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range From Dollars 5.01 to 15.00 Member",
        "label": "Exercise Price Range From Dollars 5.01 to 15.00 Member [Member]",
        "terseLabel": "Exercise Price Range From Dollars 5.01 to 15.00 Member"
       }
      }
     },
     "localname": "ExercisePriceRangeFromDollars501To1500MemberMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation.",
        "label": "Furniture And Office Equipment [Member]",
        "terseLabel": "Furniture and office equipment"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_FutureMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Milestone",
        "label": "Future Milestone",
        "terseLabel": "Milestone from DRI"
       }
      }
     },
     "localname": "FutureMilestone",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_FutureRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Revenue",
        "label": "Future Revenue",
        "terseLabel": "Future Revenue from DRI"
       }
      }
     },
     "localname": "FutureRevenue",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_GileadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead",
        "label": "Gilead [Member]",
        "terseLabel": "Gilead"
       }
      }
     },
     "localname": "GileadMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma Collaboration And License Agreement Clinical Supply",
        "label": "I-Mab Biopharma Collaboration And License Agreement Clinical Supply [Member]",
        "terseLabel": "I-Mab Biopharma Collaboration And License Agreement Clinical Supply"
       }
      }
     },
     "localname": "IMabBiopharmaCollaborationAndLicenseAgreementClinicalSupplyMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma Collaboration And License Agreement",
        "label": "I-Mab Biopharma Collaboration And License Agreement [Member]",
        "terseLabel": "I-Mab Biopharma Collaboration And License Agreement"
       }
      }
     },
     "localname": "IMabBiopharmaCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I-Mab Biopharma",
        "label": "I-Mab Biopharma [Member]",
        "terseLabel": "I-Mab Biopharma"
       }
      }
     },
     "localname": "IMabBiopharmaMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ImabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Imab",
        "label": "Imab [Member]",
        "terseLabel": "Imab"
       }
      }
     },
     "localname": "ImabMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncreaseDecreaseInDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in deferred rent.",
        "label": "Increase (Decrease) in Deferred Rent",
        "terseLabel": "Other non current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRent",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in lease liabilities",
        "label": "Increase (decrease) in lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_IncyteClinicalSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte Clinical Supply Agreement",
        "label": "Incyte Clinical Supply Agreement [Member]",
        "terseLabel": "Incyte MGA012 Supply Agreement"
       }
      }
     },
     "localname": "IncyteClinicalSupplyAgreementMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteCommercialSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte Commercial Supply Agreement",
        "label": "Incyte Commercial Supply Agreement [Member]",
        "terseLabel": "Incyte MGA012 Clinical Services"
       }
      }
     },
     "localname": "IncyteCommercialSupplyAgreementMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte Corporation [Member]",
        "label": "Incyte Corporation [Member]",
        "terseLabel": "Incyte Corporation (Incyte)"
       }
      }
     },
     "localname": "IncyteCorporationMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte MGA012 Agreement",
        "label": "Incyte MGA012 Agreement [Member]",
        "terseLabel": "Incyte MGA012 Agreement"
       }
      }
     },
     "localname": "IncyteMGA012AgreementMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IndefiniteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite",
        "label": "Indefinite [Member]",
        "terseLabel": "Indefinite"
       }
      }
     },
     "localname": "IndefiniteMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenBiotechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Counterparty in collaboration agreement",
        "label": "Janssen Biotech Inc [Member]",
        "terseLabel": "Janssen Biotech Inc."
       }
      }
     },
     "localname": "JanssenBiotechIncMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueJanssenDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_JanssenCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Collaboration And License Agreement",
        "label": "Janssen Collaboration And License Agreement [Member]",
        "terseLabel": "Janssen Collaboration And License Agreement"
       }
      }
     },
     "localname": "JanssenCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_LaboratoryAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Laboratory and Office Equipment [Member]",
        "terseLabel": "Laboratory and office equipment"
       }
      }
     },
     "localname": "LaboratoryAndOfficeEquipmentMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Les Laboratoires Servier And Institut De Recherches Servier (Servier)",
        "label": "Les Laboratoires Servier And Institut De Recherches Servier (Servier) [Member]",
        "terseLabel": "Les Laboratoires Servier And Institut De Recherches Servier (Servier)"
       }
      }
     },
     "localname": "LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC",
        "label": "McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC [Member]",
        "terseLabel": "McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC"
       }
      }
     },
     "localname": "McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_MilestonesValueAddedTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones Value Added Tax",
        "label": "Milestones Value Added Tax",
        "terseLabel": "Milestones Value Added Tax"
       }
      }
     },
     "localname": "MilestonesValueAddedTax",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies.",
        "label": "National Institute of Allergy and Infectious Diseases [Member]",
        "terseLabel": "NIAID"
       }
      }
     },
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NonRefundableUpfrontFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial fee received from collaboration or license agreement.",
        "label": "Non-refundable upfront payment",
        "terseLabel": "Non-refundable upfront payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontFees",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueJanssenDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundablePaymentTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable Payment, Tax Withholding",
        "label": "Non-refundable Payment, Tax Withholding",
        "terseLabel": "Tax withholding"
       }
      }
     },
     "localname": "NonrefundablePaymentTaxWithholding",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "label": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "terseLabel": "Non-refundable upfront payment, net of tax withholding"
       }
      }
     },
     "localname": "NonrefundableUpfrontFeesNetOfTaxWithholding",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NumberOfProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Product Candidates",
        "label": "Number Of Product Candidates",
        "terseLabel": "Number of product candidates to develop"
       }
      }
     },
     "localname": "NumberOfProductCandidates",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_OneTimeMillstoneCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Time Millstone Credit",
        "label": "One Time Millstone Credit",
        "terseLabel": "One Time Millstone Credit"
       }
      }
     },
     "localname": "OneTimeMillstoneCredit",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OperatingLossCarryforwardsAnnualLimitationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net operating loss which are limited for use, utilized on a annual basis.",
        "label": "Operating Loss Carryforwards Annual Limitation Amount",
        "terseLabel": "Net operating losses limited for use utilized on an annual basis"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAnnualLimitationAmount",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net operating loss carryforward, which are limited for use over the range of years.",
        "label": "Operating Loss Carryforwards Limitations On Use Amount",
        "terseLabel": "Net operating loss for limited use"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUseAmount",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_OperatingLossCarryforwardsNotSubjectToLimitation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards not subject to limitation.",
        "label": "Operating Loss Carryforwards Not Subject To Limitation",
        "terseLabel": "Remaining portion of net operating losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotSubjectToLimitation",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.",
        "label": "Percentage Of Shares Of Companys Common Stock Outstanding For Increase In Shares Reserved For Issuance Under Stock Plan",
        "terseLabel": "Percentage of common stock share outstanding"
       }
      }
     },
     "localname": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_PotentialCommercialMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Commercial Milestone Payments Under Agreement",
        "label": "Potential Commercial Milestone Payments Under Agreement",
        "terseLabel": "Potential commercial milestone payments"
       }
      }
     },
     "localname": "PotentialCommercialMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Development and Regulatory Milestone Payments Under Agreement",
        "label": "Potential Development and Regulatory Milestone Payments Under Agreement",
        "terseLabel": "Potential development and regulatory milestone payments"
       }
      }
     },
     "localname": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement",
        "label": "Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement",
        "terseLabel": "Potential milestone payment to third parties for intellectual property under agreement"
       }
      }
     },
     "localname": "PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentsAndRoyaltiesOnProductSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Milestone Payments and Royalties On Product Sales",
        "label": "Potential Milestone Payments and Royalties On Product Sales",
        "terseLabel": "Potential milestone payments and royalties on product sales"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsAndRoyaltiesOnProductSales",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueJanssenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential target, nomination, option fees and milestone payments",
        "label": "Potential target nomination, option fees and milestone payments",
        "terseLabel": "Target nomination, option fees and milestone"
       }
      }
     },
     "localname": "PotentialTargetNominationOptionFeesAndMilestonePayments",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PremiumReceivedOnStockPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which purchase price exceeds fair value for common stock purchased by collaborator.",
        "label": "Premium received on stock purchase",
        "terseLabel": "Premium received on stock purchase"
       }
      }
     },
     "localname": "PremiumReceivedOnStockPurchase",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProceedsfromRoyaltiesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Royalties, Percent",
        "label": "Proceeds from Royalties, Percent",
        "terseLabel": "Potential proceeds from royalties percent"
       }
      }
     },
     "localname": "ProceedsfromRoyaltiesPercent",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueJanssenDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Stock Options Exercised And ESPP Purchases",
        "label": "Proceeds from Stock Options Exercised And ESPP Purchases",
        "terseLabel": "Proceeds from stock option exercises and ESPP purchases"
       }
      }
     },
     "localname": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment estimated useful life.",
        "label": "Property Plant And Equipment Estimated Useful Life Table [Table Text Block]",
        "terseLabel": "Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_ProventionBioCMOAgreeemntMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention Bio CMO Agreeemnt",
        "label": "Provention Bio CMO Agreeemnt [Member]",
        "terseLabel": "Provention Bio CMO Agreeemnt"
       }
      }
     },
     "localname": "ProventionBioCMOAgreeemntMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention Bio",
        "label": "Provention Bio [Member]",
        "terseLabel": "Provention Bio, Inc. (Provention)"
       }
      }
     },
     "localname": "ProventionBioMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention License Agreement",
        "label": "Provention License Agreement [Member]",
        "terseLabel": "Provention License Agreement"
       }
      }
     },
     "localname": "ProventionLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionPRV031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention PRV031",
        "label": "Provention PRV031 [Member]",
        "terseLabel": "Provention PRV031"
       }
      }
     },
     "localname": "ProventionPRV031Member",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionPRV3279Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provention PRV3279",
        "label": "Provention PRV3279 [Member]",
        "terseLabel": "Provention PRV3279"
       }
      }
     },
     "localname": "ProventionPRV3279Member",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ReceivableFromCollaborationPartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable from collaboration partner",
        "label": "Receivable from collaboration partner",
        "terseLabel": "Provention Bio Milestone Revenue in A/R"
       }
      }
     },
     "localname": "ReceivableFromCollaborationPartner",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueFromCollaborativeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Agreements",
        "label": "Revenue From Collaborative Agreements [Member]",
        "terseLabel": "Revenue from collaborative agreements"
       }
      }
     },
     "localname": "RevenueFromCollaborativeAgreementsMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromGovernmentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Government Agreements",
        "label": "Revenue From Government Agreements [Member]",
        "terseLabel": "Revenue from government agreements"
       }
      }
     },
     "localname": "RevenueFromGovernmentAgreementsMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Performance Of The Research And Development Activities",
        "label": "Revenue From Performance Of The Research And Development Activities [Member]",
        "terseLabel": "Revenue From Performance Of The Research And Development Activities"
       }
      }
     },
     "localname": "RevenueFromPerformanceOfTheResearchAndDevelopmentActivitiesMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueJanssenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromVariableConsiderationRecognize": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from variable consideration recognize",
        "label": "Revenue from variable consideration recognize",
        "terseLabel": "Revenue from variable consideration recognize"
       }
      }
     },
     "localname": "RevenueFromVariableConsiderationRecognize",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "label": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "terseLabel": "Estimated variable consideration"
       }
      }
     },
     "localname": "RevenueInformationUsedToAssessVariableConsiderationAmount",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "label": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "terseLabel": "Clinical trial activities selling price amount"
       }
      }
     },
     "localname": "RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueJanssenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenuesFromCMOAgreementsMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RevenuesFromCMOAgreementsMember",
        "label": "RevenuesFromCMOAgreementsMember [Member]",
        "terseLabel": "RevenuesFromCMOAgreementsMember"
       }
      }
     },
     "localname": "RevenuesFromCMOAgreementsMemberMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromCMOAmendmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RevenuesFromCMOAmendmentAgreement",
        "label": "RevenuesFromCMOAmendmentAgreement [Member]",
        "terseLabel": "RevenuesFromCMOAmendmentAgreement"
       }
      }
     },
     "localname": "RevenuesFromCMOAmendmentAgreementMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevenuesFromGrantsMember",
        "terseLabel": "RevenuesFromGrantsMember"
       }
      }
     },
     "localname": "RevenuesFromGrantsMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues From License Agreements",
        "label": "Revenues From License Agreements [Member]",
        "terseLabel": "Revenues From License Agreements"
       }
      }
     },
     "localname": "RevenuesFromLicenseAgreementsMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueJanssenDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RightOfUseAssetAndLeaseLiabilityIncrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Use asset and Lease Liability Increase",
        "label": "Right of Use asset and Lease Liability Increase",
        "terseLabel": "Right of Use asset and Lease Liability Increase"
       }
      }
     },
     "localname": "RightOfUseAssetAndLeaseLiabilityIncrease",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ScheduleOfInventoryReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Inventory Reserves",
        "label": "Schedule of Inventory Reserves [Table Text Block]",
        "terseLabel": "Schedule of Inventory Reserves"
       }
      }
     },
     "localname": "ScheduleOfInventoryReservesTableTextBlock",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Supplemental Balance Sheet Information, Operating Leases",
        "label": "Schedule Of Supplemental Balance Sheet Information, Operating Leases [Table Text Block]",
        "terseLabel": "Schedule Of Supplemental Balance Sheet Information, Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_Section174DeferredTaxAsset": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Section 174 deferred tax asset",
        "label": "Section 174 deferred tax asset",
        "terseLabel": "Section 174 deferred tax asset"
       }
      }
     },
     "localname": "Section174DeferredTaxAsset",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares authorized after increase.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase",
        "terseLabel": "Increased number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_StockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan 2013 [Member]",
        "label": "Stock Incentive Plan 2013 [Member]",
        "terseLabel": "Stock Incentive Plan 2013"
       }
      }
     },
     "localname": "StockIncentivePlan2013Member",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_StockIssuedDuringPeriodSharesStockPlanActivity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued due to stock plan related activity.",
        "label": "Stock Issued During Period Shares Stock Plan Activity",
        "terseLabel": "Stock plan related activity (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockPlanActivity",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_StockIssuedDuringPeriodValueStockPlanActivity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued due to stock plan related activity.",
        "label": "Stock Issued During Period Value Stock Plan Activity",
        "terseLabel": "Stock plan related activity"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockPlanActivity",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options And Restricted Stock Units",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock options and RSUs"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_SynaffixBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Synaffix B.V.",
        "label": "Synaffix B.V. [Member]",
        "terseLabel": "Synaffix B.V."
       }
      }
     },
     "localname": "SynaffixBVMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_TaxYear2025To2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Year 2025 To 2037",
        "label": "Tax Year 2025 To 2037 [Member]",
        "terseLabel": "Tax Year 2025 To 2037"
       }
      }
     },
     "localname": "TaxYear2025To2037Member",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_TotalAnnualFixedPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Annual Fixed Payments",
        "label": "Total Annual Fixed Payments",
        "terseLabel": "Total Annual Fixed Payments"
       }
      }
     },
     "localname": "TotalAnnualFixedPayments",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TotalPotentialValueUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to total potential value under agreement.",
        "label": "Total potential value of agreement",
        "terseLabel": "Total potential value"
       }
      }
     },
     "localname": "TotalPotentialValueUnderAgreement",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Sixteen Employee Stock Purchase Plan [Member]",
        "label": "Two Thousand Sixteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2016 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_UndesignatedPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undesignated Preferred Stock [Member]",
        "label": "Undesignated Preferred Stock [Member]",
        "terseLabel": "Undesignated Preferred Stock"
       }
      }
     },
     "localname": "UndesignatedPreferredStockMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions",
        "terseLabel": "Increases/(decreases) for prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_UpfrontAndFixedPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "upfront and fixed payments",
        "label": "upfront and fixed payments",
        "terseLabel": "upfront and fixed payments"
       }
      }
     },
     "localname": "UpfrontAndFixedPayments",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment",
        "label": "Upfront Payment",
        "terseLabel": "Upfront Payment from DRI Health Trust"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ZaiLabClinicalSupplyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab Clinical Supply Agreements",
        "label": "Zai Lab Clinical Supply Agreements [Member]",
        "terseLabel": "Zai Lab Clinical Supply Agreements"
       }
      }
     },
     "localname": "ZaiLabClinicalSupplyAgreementsMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab Collaboration And License Agreement",
        "label": "Zai Lab Collaboration And License Agreement [Member]",
        "terseLabel": "Zai Lab Collaboration And License Agreement"
       }
      }
     },
     "localname": "ZaiLabCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab Limited",
        "label": "Zai Lab Limited [Member]",
        "terseLabel": "Zai Lab Limited (Zai Lab)"
       }
      }
     },
     "localname": "ZaiLabLimitedMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab",
        "label": "Zai Lab [Member]",
        "terseLabel": "Zai Lab"
       }
      }
     },
     "localname": "ZaiLabMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, Margetuximab",
        "label": "Zai Labs Collaboration And License Agreement, Margetuximab [Member]",
        "terseLabel": "Zai Lab Agreement, Margetuximab"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement",
        "label": "Zai Labs Collaboration And License Agreement [Member]",
        "terseLabel": "Zai Lab Agreement"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, TRIDENT molecule",
        "label": "Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]",
        "terseLabel": "Zai Lab Agreement, TRIDENT molecule"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Labs",
        "label": "Zai Labs [Member]",
        "terseLabel": "Zai Lab"
       }
      }
     },
     "localname": "ZaiLabsMember",
     "nsuri": "http://macrogenics.com/20221231",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r179",
      "r180",
      "r280",
      "r285",
      "r486",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueJanssenDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r234",
      "r501",
      "r562",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r320",
      "r455",
      "r467",
      "r479",
      "r480",
      "r499",
      "r505",
      "r513",
      "r561",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r320",
      "r455",
      "r467",
      "r479",
      "r480",
      "r499",
      "r505",
      "r513",
      "r561",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r234",
      "r501",
      "r562",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r232",
      "r458",
      "r500",
      "r512",
      "r556",
      "r557",
      "r562",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueJanssenDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r232",
      "r458",
      "r500",
      "r512",
      "r556",
      "r557",
      "r562",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueJanssenDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r303",
      "r320",
      "r348",
      "r349",
      "r350",
      "r431",
      "r455",
      "r467",
      "r479",
      "r480",
      "r499",
      "r505",
      "r513",
      "r555",
      "r561",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r303",
      "r320",
      "r348",
      "r349",
      "r350",
      "r431",
      "r455",
      "r467",
      "r479",
      "r480",
      "r499",
      "r505",
      "r513",
      "r555",
      "r561",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r179",
      "r180",
      "r280",
      "r285",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueJanssenDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r185",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r511"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r235",
      "r236"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premiums and discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r64",
      "r148"
     ],
     "calculation": {
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r531"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r20",
      "r21",
      "r108",
      "r421",
      "r468",
      "r469",
      "r532",
      "r533",
      "r534",
      "r544",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r544",
      "r545",
      "r546",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r96",
      "r97",
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive stock options"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r123",
      "r130",
      "r150",
      "r176",
      "r223",
      "r226",
      "r230",
      "r245",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r385",
      "r387",
      "r401",
      "r511",
      "r559",
      "r560",
      "r602"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r143",
      "r157",
      "r176",
      "r245",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r385",
      "r387",
      "r401",
      "r511",
      "r559",
      "r560",
      "r602"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets [Abstract]"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r241",
      "r252"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r56",
      "r240",
      "r252",
      "r459"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital Expenditures Incurred but Not yet Paid"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r37",
      "r146",
      "r483"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r32",
      "r37",
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r32",
      "r121"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r176",
      "r202",
      "r203",
      "r205",
      "r207",
      "r212",
      "r213",
      "r245",
      "r271",
      "r273",
      "r274",
      "r275",
      "r278",
      "r279",
      "r283",
      "r284",
      "r287",
      "r291",
      "r298",
      "r401",
      "r481",
      "r524",
      "r536",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaboration and Other Agreements [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueJanssenDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r265",
      "r266",
      "r475",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r544",
      "r545",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r511"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, 0.01 par value -- 125,000,000 shares authorized, 61,701,467 and 61,307,428 shares outstanding at December\u00a031, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred income tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r22",
      "r162",
      "r164",
      "r169",
      "r460",
      "r464"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r48",
      "r49",
      "r118",
      "r119",
      "r234",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r48",
      "r49",
      "r118",
      "r119",
      "r234",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r48",
      "r49",
      "r118",
      "r119",
      "r234",
      "r474",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r128",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r48",
      "r49",
      "r118",
      "r119",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "verboseLabel": "Percentage of significant accounts receivable"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r46",
      "r48",
      "r49",
      "r50",
      "r118",
      "r120",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r48",
      "r49",
      "r118",
      "r119",
      "r234",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r300",
      "r301",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r300",
      "r301",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r300",
      "r301",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r502",
      "r504",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r26",
      "r458"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Product Sales and Cost of Manufacturing Services"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r107",
      "r374",
      "r379",
      "r538"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Provision for federal or state income taxes"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r47",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r242",
      "r252",
      "r255",
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "terseLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r2",
      "r3",
      "r124",
      "r129",
      "r370"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r527"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "verboseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r106",
      "r595"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r371"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r594"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred income tax asset/(liability)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r594"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r106",
      "r595"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal U.S. net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r106",
      "r595"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r106",
      "r595"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": {
     "auth_ref": [
      "r104",
      "r106",
      "r595"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Other",
        "terseLabel": "Orphan drug credit, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r104",
      "r106",
      "r595"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenditures"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r106",
      "r595"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer discretionary contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Percentage of employee contribution to salary"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r35",
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r35",
      "r221"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r325",
      "r353",
      "r354",
      "r356",
      "r360",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "U.S. Federal Government"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r170",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r200",
      "r202",
      "r205",
      "r206",
      "r207",
      "r209",
      "r392",
      "r393",
      "r461",
      "r465",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings Per Share, Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r170",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r202",
      "r205",
      "r206",
      "r207",
      "r209",
      "r392",
      "r393",
      "r461",
      "r465",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings Per Share, Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to non-vested stock-based compensation arrangements"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r591"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r72",
      "r141",
      "r165",
      "r166",
      "r167",
      "r187",
      "r188",
      "r189",
      "r191",
      "r197",
      "r199",
      "r211",
      "r246",
      "r299",
      "r357",
      "r358",
      "r359",
      "r375",
      "r376",
      "r391",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r421",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r394",
      "r395",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Fair Value Measurement Financial Assets"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r110",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r281",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r395",
      "r428",
      "r429",
      "r430",
      "r497",
      "r498",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r394",
      "r395",
      "r396",
      "r397",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r281",
      "r305",
      "r310",
      "r395",
      "r428",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r281",
      "r305",
      "r310",
      "r395",
      "r429",
      "r497",
      "r498",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r281",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r428",
      "r429",
      "r430",
      "r497",
      "r498",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r398",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r116",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r243",
      "r244",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r257",
      "r282",
      "r296",
      "r389",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r496",
      "r551",
      "r552",
      "r553",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r177",
      "r364",
      "r369",
      "r373",
      "r377",
      "r380",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r178",
      "r198",
      "r199",
      "r222",
      "r362",
      "r378",
      "r381",
      "r466"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax expense/(benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "United States federal tax at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "terseLabel": "Other permanent items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes (net of federal benefit)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsOther": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount",
        "negatedLabel": "Orphan drug credit, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research credit, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r456",
      "r535"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other non current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest Income, Other"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory, Net"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r528"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Inventory, Finished Goods, Gross"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r155",
      "r484",
      "r511"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r145",
      "r154",
      "r210",
      "r258",
      "r259",
      "r260",
      "r457",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryValuationReserveMember": {
     "auth_ref": [
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve to reduce inventory to lower of cost or net realizable value.",
        "label": "SEC Schedule, 12-09, Reserve, Inventory [Member]",
        "terseLabel": "SEC Schedule, 12-09, Reserve, Inventory"
       }
      }
     },
     "localname": "InventoryValuationReserveMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r60",
      "r530"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory valuation reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Inventory, Work in Process, Gross"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r59",
      "r122",
      "r127",
      "r136",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r419",
      "r510"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r15",
      "r176",
      "r245",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r386",
      "r387",
      "r388",
      "r401",
      "r494",
      "r559",
      "r602",
      "r603"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r125",
      "r132",
      "r511",
      "r537",
      "r554",
      "r598"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r144",
      "r176",
      "r245",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r386",
      "r387",
      "r388",
      "r401",
      "r511",
      "r559",
      "r602",
      "r603"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Provided by (Used in) Financing Activities, Total"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Provided by (Used in) Investing Activities, Total"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r32",
      "r33",
      "r36"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Provided by (Used in) Operating Activities, Total"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r23",
      "r36",
      "r126",
      "r135",
      "r142",
      "r161",
      "r163",
      "r167",
      "r176",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r204",
      "r223",
      "r225",
      "r229",
      "r231",
      "r245",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r393",
      "r401",
      "r495",
      "r559"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash operating and investing activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r223",
      "r225",
      "r229",
      "r231",
      "r495"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r414",
      "r510"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r410"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r411",
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease, ROU Assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r418",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Nature of Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/OrganizationandNatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r158",
      "r159",
      "r160"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other non-cash items"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r29",
      "r55",
      "r171"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and software"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r303",
      "r304",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Undesignated preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Undesignated preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Undesignated preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Undesignated preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r156",
      "r261",
      "r262",
      "r485"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r55",
      "r171",
      "r172"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Equipment and Software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftware"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r63",
      "r147"
     ],
     "calculation": {
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, equipment and software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r65",
      "r133",
      "r463",
      "r511"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and software, net",
        "totalLabel": "Property, equipment and software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r65",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Equipment and Software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueJanssenDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueJanssenDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockholdersEquityDetails",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r98",
      "r137",
      "r610"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses, Including Clinical Trial Accruals/Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r79",
      "r131",
      "r471",
      "r472",
      "r511"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r141",
      "r187",
      "r188",
      "r189",
      "r191",
      "r197",
      "r199",
      "r246",
      "r357",
      "r358",
      "r359",
      "r375",
      "r376",
      "r391",
      "r468",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r168",
      "r176",
      "r219",
      "r220",
      "r224",
      "r227",
      "r228",
      "r232",
      "r233",
      "r234",
      "r245",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r401",
      "r462",
      "r559"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueJanssenDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds of stock sale"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of common stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of common stock (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r234",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales revenue, net"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIMabBiopharmaDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueJanssenDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of the Company's Deferred Income Tax Assets (Liabilities)"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Reported Estimated Income Tax Benefit"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r92",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r11",
      "r12",
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r322",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r81",
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Employee Stock Options Award Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r151",
      "r152",
      "r153",
      "r212",
      "r283",
      "r284",
      "r285",
      "r287",
      "r291",
      "r296",
      "r298",
      "r499",
      "r524",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r508",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r46",
      "r48",
      "r49",
      "r50",
      "r118",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Summary of Percentage of Customer Concentration"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Awards granted in period (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based compensation, number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Stock Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock purchased by employees (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract]",
        "terseLabel": "Stock Options Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Range of Exercise Price, lower limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Number of Shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Number of Shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Range of Exercise Price, upper limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual term, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percent of fair market value to purchase shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life in Years"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SharebasedCompensationOptionExercisePriceRangeTableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r43",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r176",
      "r202",
      "r203",
      "r205",
      "r207",
      "r212",
      "r213",
      "r245",
      "r271",
      "r273",
      "r274",
      "r275",
      "r278",
      "r279",
      "r283",
      "r284",
      "r287",
      "r291",
      "r298",
      "r401",
      "r481",
      "r524",
      "r536",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r19",
      "r72",
      "r141",
      "r165",
      "r166",
      "r167",
      "r187",
      "r188",
      "r189",
      "r191",
      "r197",
      "r199",
      "r211",
      "r246",
      "r299",
      "r357",
      "r358",
      "r359",
      "r375",
      "r376",
      "r391",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r421",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r211",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r72",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs (in shares)",
        "verboseLabel": "Number of shares issued or sold (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r72",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r72",
      "r79",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r72",
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r54",
      "r511",
      "r537",
      "r554",
      "r598"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r80",
      "r175",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r299",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r416",
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Sublease Income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r408",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r408",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r408",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r408",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r422",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SubsequentEvents",
      "http://macrogenics.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "US Federal tax credits carry forward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]",
        "terseLabel": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r243",
      "r244",
      "r282",
      "r296",
      "r389",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r551",
      "r552",
      "r553",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r564",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Government-sponsored enterprises",
        "verboseLabel": "Government-sponsored enterprises"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r492",
      "r502",
      "r504",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities",
        "verboseLabel": "U.S Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized Gain (Loss) on Investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r361",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized interest or penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases for current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Gross unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r214",
      "r215",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r181",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at End of Year",
        "terseLabel": "Balance at Beginning of Year"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Additions Charged to Expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "terseLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r185",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r185",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r415",
      "r510"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Motor vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r201",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted average number of common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r200",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted average number of common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r515": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r516": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r517": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r518": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r519": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r521": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r522": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r523": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>95
<FILENAME>0001125345-23-000059-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-23-000059-xbrl.zip
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M9AF9E!Y&\KTD#S+.<I*]1O!X1>ROK)B*4BP(IA'\'*>9?+*#:73\WBWU^Y"
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MBJE,R.Y!N?#0CWN2@HJE6BF;+7)L\+:G'2T?9K-PY)7-PWO)EZ4(O_E:C)/
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M\F8.\&AQ W39)DEA$S@3]XD\4,FI32ANPL:A[,)_EX,"L\RLL+E 4;K-?2H
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M\R(,@1TTSFK3V(ROO(A\*7+V[!WTT*J\ 2FR5CI9/HF35)*/HX@FLCZ7;.@
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M8Y2J 4;[A$M%/DW9,BF@OI-HK4A<]-AF:,^G?M\B^4*4*MS8K^ K"D2G EF
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MT?ODNRW"_IX52\";=-RZ!$I!ZCCX2.Z%QC!9 =1_!(\0'!JX:(3^2!XI%4\
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M'U%<+.<XRB=#UM@X9:\=*9>WO7OAFES1\:.?L)5NUTJ7FT3G^ZX;W:%AI#2
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MYY%B5R&S#H$,--=QG""[=X>$/1+R#X)?"[_Y0W #I:%0^EH1\E'15OU:)MO
MVL0\A>$BN6J2I["__L!FO%C7YWTI+I+?Y9%!].=K7G9Z!/\.TT[4.Z9*5"&8
M.@@_-]@S2IQ^)G< [J<8ZQS1:@>5H=0$GO?XFNHBI%?PGM@'*'X^Y_&XOZC.
M+LVXU-KAN.3>D]VNS>1]UV-TKKK.0/EJ=PEX;Q9M6F><PRT+7S)+ EDU(!.#
MXH',3(FM46@[=5DC 9H,OG P1?*]5$_<N7I%?QA<<PA3%F>$3XK:IB!B@S,Q
M16QPQ@_'05(!";U7VC)"#A?!R>9SN$AG4L%?'@DJZ!&9.X2]FC*5L^30B+_
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M U/(!X!M@3VV7K%LJ)$2QB# 3S$IP\K?HR\S@]_$X0T1 JV)WDOP&N#!LU(
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M:08-B;$\'$6Y&T"R'X64ZK2IQ=%U><Q<\#D3/4_?*?:_3FV;<?#>X$C45=(
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M;0YI3V=\8SR26^[6_'<NVIXEZ]PB^Y$KY^^,K5CZ(A!:W4OJ*5)]!0,]\7O
MF+\?HHSE5^W%V!_">\^F=]NT_B::^C<GX_-5SU+?L]1OE+&CH^U9ZGO">:>@
M]H3S!Z:5>\+YYYW9GG!^]\99<'$#D>6KNU6:W%.4^3_CY.'5;\E#[RX_;UQH
M@C'0VF6YNN[<?][3F=]2_@4NL!?_7OP/8N8;Q;_:[4(WLWA!.Z#S#? D_1M[
MN:^5^ZMXSNZXF<[8P)ER.51![U[2)Z?CHV#PZ]H$Y7<NXGOA_UQ=7AY 2L!#
MB3P#1IGW/U9L'D%B_"*=1GE*)&*+).6Z8A;-N38.EY)A)G@79:LB[_L][5C
M89:C1:2*<WK%_!S;8';+YL62 ;.2P"9@$<F*(;W2Y\4B8SD64XE#<Q$15F'/
MA=\SNNN*\ =?X-L#M<)]([M^H7O ]P.@@H8]S-W0GPC];G#L!C,H^:*:?'B"
M21;L[X,)%_X+KIA>729I6E 95@].WKFXU[M9+T?R_7"'CP";C/@>0:3]_@>;
M%5ATR)4_/XG37O9W+/OB'$7+IR=W>O:0Y'$P*-DRP'4[XV:0![CE/9WT9E%?
M]T1FO:P?S*37R7J4@\?D3NSU<M\G6/>8RZ)9Y#\7><;->:_)^_9SWIOE_(T@
M'#;G?\\%W#NE?I\L[WM#O9NB0FZ\*-Z$-Z>#>!@D"R3)^36,OT-P9K8.+I-Y
M+_.[E?GKX"++6);U%#C/7IUXBL$8T?7 A\9[>SK/M9)]F11QQI9]E/%Y26_.
M=7?5;[=1*LY33>-*Z6\9 ^ZE?I=2_\\DX@_MP;^>;(;#=4Z]E/NO.6/8VQ:Z
MR$4Y_RN0L]R%%"3I,SV^9DZ^7KZ@S=[Y7I>-)#ZQNRE+L]MHU6_QG6_QY3KX
M_!!S'[TO9NRJFHMQ&;?78N]+N/R*M-J3>]!5BWZ&6@]5S'U3Z%\ON:'VZO(V
MC-(5/S$/M0.GI\J\MU>>5KQ5/YH7UW+63^3GJ4"_T5I<I\E-&G8?<_6L0-$]
MA7__V]O)+__G__P?_O_'O_A7JKCG<]C+6R]OO;QU68#]>P(Y4/\$[0 [OT].
M(23^ZSH@OH;^_&TCGP:C@G]"*F?0CPE\68U2U6>TF$=ONW1XS&:<+R\#Z6<H
MZW 3D'[%;$W9-XJ=#[K2WTN!!_B)Z"'\1\)?A@&,L'%U]GP?>!;ULJ;ZA7)Q
M=;X)=F9D/UO;@X/= W^P&ZZ&1#$6OUTRWW8C^-,\84\7J1U>T3HP&G"+M9NI
MTINAEL-^PW=R)OJ>#OJ[OJ=#"Y$^.M[SG@[-.Z;OZM!W=>B[.NS-S!YH5P=O
M0V[*3NE[/G3M?LE:W8W+<["0,F]WB1'^Z2D(^SC="UB'NCT1%XMPEA=8+_.-
MS6YC_N2;=? MY7==&$U*#WXW= ]->SL^@<-BPXKT&^ )-P#,,;H!P:_%_(:]
MI%KX7OQ[\=?BWQ-8]=+OFON]B#E\"G-^8;CT$"9UD+)[/'X+LBLFW1]AW=/)
MKA'JC^]>'YVHR0VN4^XN]2KZ657T1'.:7/+?P0L%7XO5:KD.+FY2AM&<SJ7>
M,Q7=8_L/'-N_IYUBW%H6;B,"@7I+'Z:6]:U'CS(FCC%J_K5([Z-[KF"3A0 P
M<54[7=+:]*W9=BSV2?Q*,BSVQ)?/GRHZ!QI 8/\3%<'8F%!37O;"OG-A3UDX
MN^TYZCN2]B/B'! N8T"KT4OYCJ4\>J%4QMVG<O:)R7C/?1TO9'C/Y_ ERYM;
M>W[FGL9-:#)N>2-KNVC)70+F3%Z/CSVP"XZ!F^4RN6<QS/PH^,)6*<N@9QQ\
MGV%+RK_"-.7?1OSQ'[B-?)G<K991&,]8\!#EMW[T[=L/"?]P<0C]YOTPP5IT
MFYP/L0E]D@+U4YRGR=(/8=W3&:\1:FY@I<'[Q8+//-<.1+7U<@Q?'V1]?#+A
M@FZO0"_D.Q7R@^^]Y*EL'V#S)<_2+U1K^8+9VF$"/"9'\<RR?5DT/YWM2:">
M#BYOP^62Q3?]D?/,L?(WU<Q0>4GV_!#R4^!ATH/W/_B_,X@^]&+_O+5S9\'
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M6+LHYE'>4W0_D6Q'*>9Y;XIEF"=P#*HNJB^/I[A[R^1$9#Z:5Z;S7; G]HD
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M"%M&>)4,G0=IZ4O'C8BL@T')IARZ84!;!ER/;1N_SNWW+^]6:_:__S%CJUQ
M*)),+T;6BRF)*?<;+9_4%C1B3"\+&YY%F6 7Y+JA<HWKHI'-)<:]5?']'7YO
MF'HNU,S>7]NR &FRTQ!*N0;)5Y35'Y;)I/'7A,.MGW7 X^$QI'1L;P$(!(C(
M%O"-2GX^]ND+A(O%=SN[23 ^O0P+B"CU\U9&SO"I0MP:[F8(DV!^EQ0=^*+S
M9$6Y6P$'Q.(5!+GS@__5K$A3<':?^&WPCO^(\G 9S5J\7Y:'.;?=_ETD?M5B
M[D[CG?MEF#3IO"2'0R,#0F_8B>5#M.[<;7- MS]KJV8\(J%'O4+ AU^H8CND
MZQ5)6\R-DWE.QX\.;J$= !^9%!4(WV _HBS';(" T]D%IF8J";XU@!VE),]5
M_$K4ZF5#& #W#C#E\!!Q^Y:/@:7H64 JJ::8M;ZRS\Q%P'51O(!GBL\ ;IPS
MC'X6_%R&/ 6#]\/=I^IDS#?OI0@>+L%>Y@RWM ?;IM1Z5'>/ZMX.U7VV/:K;
M=X#VR;@]7NS,I[SEW,N\)>1P/HERSV[32W\D 92P@PX-X_Y0*45Y74P5L';D
M1R?+.60$1/&J5614SK;!<1Y2/:HJ/R(?TJXZA)N5+,P0\J0"/.@Z[M"@2%3&
MP,C\\2_@Q. G#J4O4LU4 $_<:*JHY.,LS)BJU6US[Y%=KJS"L[>,3YD(9O>R
M!@\W:N!Q&KGQIZ=Q'+R_6RV3-2-(DRRSC\DBM"([: A#7H'RPDX*!NE_)RH;
M3!0/4/M/I &R!)VD895&_*FB#AUDM1R*0Q]=#VHDKJ!41CZ2SS6(! CVY)?K
M+FI8Y]U&B_V:D]OD@7$3K-LI<4=Y7YR*N#"W)NY8J4F%!N#*5)*II(!/"[FO
MFXP"$.H$W5CP7&-^L.20T4YBKF>8E143&U;Q10C.#VFAN(KC2XM3Y8>9&E5P
M2V;6S;ZX!7Q4MN)QG(SM:H6\0A8R+RWT=T5*I=\8&)QQ^PUV 9(8P0?%-.,V
M&>P9JPLL58_[!$/D6YOO88+#8)S,WK@C;E(N65;B?2H@"+44P3=0+T 0)&Q<
M;O5-3;N5A>DR G0*ELB :8%(69J0"IJV+B\/%U'5?K(8!Q?* .=/PYB)NAD]
MM/0.'Z,E"^?BC:M,$TB((X@J)$+<MK$=HQ+!X"QX ^5:9J'6%[9*TIR"P6?P
MY1<&_#T9_Q-:IMH_-L*:4/*C6JCRR5XC.IVN.@X&0!S'4J2NJ?L5%)DDZW I
MK;@_N$[_&BYE@=ED@N4+^(NUOE2Y&:JPP:8G,^L=:NG)#F<ZVG*;/BVE2V<:
MET8QYW8 *;A_H$\)O_)6%_\>W45$+N8!<Y!6K9*#RDCYB'H"J$*EQ$1]<8*1
M; H&=1R20^(F1$JK!81#E^M1[=,%EQ@6OBBSCP\@KU0T\"\E 5BU3(=<OB ,
MI@1,J^KP6\BTS# /.V^YFQY#,;U5D>I)V:3IE&?ZR,=M=,&G#$2.:U1NOR@B
M53H$_DI2S%]^3)-BY<DV0X"O"JG1YLJLD7-9?1 #O\&!0[0L9FQ.T:BV%3XZ
M/P@1C0IY1Y@!TYX=/'-%XOK@1A_<V +$&N8EKQK4[IQA_Q=B]-015F4$*W5/
MVT1(-3\4T$41EJ[DMQ(A6XS%FANGLF^TSV[;_G/3^!>5;XJ=4;H+>.VH#^NV
M2R$HA8:XX@#:_X3!C-\!CG=[E3"J#Y6U5F&T4;+*EU$B2TI,Q+7T$J:R:R#1
M&'A0?T)#NY138YY9/I2D$//I%)8OE1[4+I;/6<=>7C9-55WB/O!AX2I%^+XM
MW3B0L%B]!9QR-K+]9M?[<*U-2*6J?5*G9M%TATMJP6-M>RKLUD>M(/PZM:&/
MO;2ARYS6GC17T&E$YYE33]YNG.]<>Y1?#ROK6 KB*ADYHCN@P42F<; O(+[(
M59JBTI1&@5&*:M.JP@7L;D7JS@G?HEQ"92C"S CO$N#G%+L7TA/Z(#7X1&$3
M%K"A5010,3\8L<1Z9G]GIITP7Q0'S>OY_JVO9%!-\&[S\\*@H%#Y5DEQ>D==
M.^Q,C$(1U)-&Y2R\JT;S]%<&5_=LB!E?+C<F; #20OQ$R=W,JH_@)QR7,T0?
M$,4-]/-P4Z0K9S:9/=>=61[EA;!^*Q)0H;#?S%O_=,D65W3B[1O?",&/O6QY
M)4&V?D'E?XK09_]:7!W[V>)*R@;L9LKK[(&4'!UHLL#;[E;JM/G&TCMYV'9K
MBWW559LZHTF&1TR!5V?LD2E;C;*GIK_QC<L8RR$=,)6&BWA5*C8@YHX;?G'L
M\!C-.@?(K$[7W L)!8$F;:U1,*?*!_NQ,*<+V2&H>N,0O)KE_"&:\S,\I?S:
MJT4*[E+,G9E<<%RA=SI@5"=<GU(,)DB9=8%!5AU&O514\)=\\M-D.1R.H'<0
MO]^RR&"^!G@7XRV'P5+,CN: -2?!>$%%R 4+9/Q&6H*X%;GW%^5+BJIA,H5E
MN:SSPXP--[P_/T!@^.IZI'/9>"W,,<XV6#5+J=/LK// 4>A[/#Y&OLBO\BH1
M>:/U@CG@]AK0XP@QXUH"S#%-4)^DNK//&J@F%L729)RFFDYMR/'?VT4PAA',
M#>YD)N,2(LFNI]8./$@'P(A,*!NX2: Q#AIEDE0!YT,R*E1LRD>5M_4%''T!
MQW8%'.<'4L#1!@KFD:GA9_.B]S]6RT3@#P)EG8*Z:XNGV4.[Q*R9U$?3*8![
M\A!Y$$5W]F&S!2/#!)]7^:NKN%PL^=/V"[(T28- VR)3ACB\)S9']LW:$-2F
MCS Y^(_%+FB/(2N'D9P'NGR_#Q' F<4?W/Q,H3_3>AQ\@&J"90@A<0K%RRG'
MEW7:)0:TAGNX^&(_OX.'1H:6-@8S)A_N)$8A<P'4"O-BL8B6$>(-\Z2YG5@;
MAO_3E6>="QML2@W?B_Y7Q&"-X&KFJL7F9F2.7*\2G@0\:5AR)!:':F#N5DF!
M05:R&XG2E6NE%&UBB[6_M : B>*?@-D]%(+$/QT8J*VP*A%#:G"I#595AU[Y
M:6!*E! =J+"SV0CXI1BWE@H9 N(IC+[,(/)TFM6UDYYE_V0%%"JP.6DY+LK\
M-0M9+^<>D3F8<&BP<YN>_Q.#.MW\W#Z!Z'VEY]4Z8>\#-=N&4ZHY$YB"_8V>
MT/OX8<R\6%S1LX:,)/=Z^7C7)_FH/G:$IX.KHTIS4*D&CR2C2_2U?=K09_*H
MV?5)\*AF3&5VN)X!H8U7C:N\>87W\/3X27>:WI];>G!=&=RQ(S<YZ,I/]NE<
MV9&3O%F&MW9\-:^@G,T=>:3!4SIRAF>5&>WC-ZG[T3.[@/)&5/=BKUY;-JE'
M>19>P@*\+%XQ80'& N\!-F#'A81>N9T].&!?P0'B=*@8#);RW'MP@#B='1:(
M>'^5HB[9'_2U;E33)1P@=)@=IM].MH<\PHD7WZZX;I?@-X_P35G^UFD Q4OT
M=/G]/>RFY6>FTQ2;@W?)ME>!O@7T>H7G]%FV4V_/%6]J[1_T:*4>K;0=6NGM
M(:*5O/2,O2Q)4YJ2'51!Q>-ZT_?.<*UX5 _2;JTV\SPVZF(W6!"B<$_];0"!
MHMSLLG0,Y$\U4:.A64YMWAWH<[ ,C>7R28*!7ST'S$4T'\K\E%2VJ.^F+K$G
MW5U92!. %+! S3@"*@9@98RRW.A]8+6&JK0IML/FZI9W(9\5DXI1IP6DE0,1
M55%K)PL/T3\S5$N9JFV3>5T*88.1MF#L%7\B2,P],LJ66CL$URI C 76 (N9
MY5!#'8E ]Y15)F ;NU%PV/*;13&?5SX!4VC$> _DF+A,^F8G>"<]AM:T8;L$
MF'BDV_QT6-W)F&[5FL5%V$:CV3[1%OIM8NLWX?H]MVH3[XNW-_N3/*6:L^;8
MK>%,3?B$:LZ<;5?A-+19BY'$,.'/N!&];>"NE!LS/YT7K*8@WGI?R609TOLP
M+'9?K>U7,M:JLC(#HW49EW(^-J2,0W9$PH) ,RM&?^?$R3ET++ESA4M3WY,"
M&0\G4B!&_6"3V&>ZL(Y[Q87Y)CV:LCG03LQ4=AI)%F,(?=S;[*_(A*C_+.(2
M55*%J8'ZS>$VXAL+XDB#A]MH=CM"1:),FFK^W7R,YK_ P+<D$*[@7*%AM$S[
M8R<'2*_4;.5A%T95 ^CA.>RI'=7?M^[CV8-XJT86EZQ[.,$6<E/J [-C'_+/
MS833"P& (83C2"=2)7D(-%>!P+8@RS.- ?W&#[>)!(CDT'V:GVF:'A40)<:!
M&Y9;O9$I41V:42HK"V2,I]O(+KQI)@BXD4B,#\%H(H^[O6+-(&5/D@DN2[(1
M() /^YCZV/';I;#UY>!1]UD9D/Z <AY0H[H !H!M<9%2IKB'ZKM$AKBFDGL7
MZ-]@?6AQ<#FK4D48M3#P@.D-;B,SA4JN_6!X^Q.M4T5_Z1RIHEVR=AKZ'_P2
M.,RA ,7<D@Y_0?:Z$"V: #<=EG%H9 1P,QOHJXJ8\'_H^,R9Z#.@(!5B0Y*C
M&&:V.9T4RSF)F6Y,R7_.(NAYCWM7**Q5D69%&#M<*&Q,.IO!,%0BWG@CE0*T
M$+K"=*G:2K?@^]GW)Z.":<7,YG(YZI=B5'(;M'$R1:P?M#6)19861B-\UVF:
MA'.!,1QI>T1<:BV* 6;77I=-V0UM[,6-T44SG#/D.4.D;A2/*HI<.%2&0M>-
M.RTU4:$!OS#L-9(D84TB*K1^OK;@W78P$36;0J[RPM;6US$AU!X)RNB0<9 ;
MJ7Z:7Z;9W*VY56GR4_7+6'P3WC KWF ,O[P1L7,$J1<PHLP-EZ"GS%T[+O4S
MEN88XU&;"C=&0Z )=%S%-YJ&&?^1 <4W1_DNRO(TFA8PS)$:LZ9V3=*;,!80
M:!47HM_<6? JZX=#A2B7[+!R+D9^G. U[J$/9_@H(+!,WPA,DH]*8Z;.I^>[
M:\K$%J0C4PBWBNR:;29AW_Z[X,I^(6@R^?9<KZC+A#XZIVMSL\E0JMC$,I8*
M++=!%O%W#K$=F68CIQCE#S!U1;S%V 7\]@*MLQX'&]^NQ7N5SGQ7_R+3HB#'
M3(=J() ,BD:&;8 4,X)S":H?R'TR:PW,>(_1?S' ADJ@3>(;#(EJX\*T(EQ&
MA!Y*\A"S-+N-5O6]P=4CRQ'TC<_BDUUB%BVHP6?-U&=&L"MERXA!B$UYS [E
M76]]TCK3ZN&"HCO4)-&6X59]5%D$1#J +U(\BU9"EG5JP+#KV+Q.G%$,-8[L
M25-_;3D .[6,3GVTC$JU<UWW4;98'C0G<27B:^3?S6UB\AS,&TD7-F,2A[8W
M!39,>B^NYON'+1>$Z;1JHVC(UE$K.(LC[!5D6GD:4(X566@&&I_-@T\?W[T^
M.B%, OU31]=U;9H)KM7TZ]R)6E.9P<8.Q8INN7RY_8M!=%]Z 0D>=9<HBY"@
ME>W2,]]#-WOHYFZ@F\>O#Q&ZV72D=72"2>4S@H":[ HU9]F,>WQD($GU>R8X
M;W0+2C?L?V@PJD\?I^5W1*WS&%V_"V58&4F;R3TR"'PVO=@X>$_%$ORV[ =$
MUJ+<V4K/""*"]2V6@0^1@GOTGA&&%)2;,./[!MZ)?V8@&ZR6ZL[  O]1=(=1
M/G@C;.>3K%9L.5+/@YBL(U22HK6"84(1Q@!K6D=Q#:!/F<3>SOK&)3ZI.KC0
MX&*X00)K\$-\#FG*^%/E9$99'9S11>)A?N\J.$'.64>]^+<TG'/S/?U>I8\K
M%X&O2$J"2T@W&V[J#AYMA81KFSQ40^$#NXW<9[S-)12KQZ*Y=FA5:XH+34WR
MZ] :G7O=&G&MFQ=/ [;<%3$-A4*/792&6S[W9#]I.7_+;MN=NG)O?'3E=/ZI
M1HO8%:Q7\2LO6D@$%PJ07F9ED2'K3?HH@E3@JZ7\Q@Z<M)R#L<MKZ]/V;EP9
M^.1;M;@967UG=&,_E\>JBDJQ=2E$[$9UG6HLC 7_&RR7)+[!W+^F<]DD/AIV
M(L]?:)/-53%W@V[;24\YQ^SDXP%C-;'X,<7LO)JN7U4X*3'18LU;K?Y\9,*Q
M=[5[5WL[5WMR(*[V$V7H]X!QV(@6[INN#>J4K8LDG(A;JOW4/H/^-=1N2=LB
M^@>1*.J(F@,/#(!E "&T4@D;M,G%[*B#67D&(VHDSR__SSAY>/5;0OU+K\,<
M"P+4%)0<B++E8F!AVAU# K@C5X;[Z'/PN><;U\71>40=W4@B9D')HSM^3PB"
M\"-[QD(JD) T8YL>M8*&KDF1+5W24/$_&XY<#$K#V-RI[<V@GFTW_<EX"U2.
M3_[*F8_^ROL?488)Y3]76<Z/A;LJ0"L++E15C2=-0NN;4E>P=[ A#'0Q6T#$
M#<,-=KF:V.Q@5-M?2*/1^K2$Y(  'J)C9F'&1$=T4R$;A5<OK8"HQDV>W;(Y
MQ%KXMNC4DWIIRU%3L.$!?JN%)O)$$6EH=D7;@,$ARQIEP065@@;)"C""10SP
M&UMY;/7F\L3E7NP4XS(EOJ-5&B&S*+\<$/98YX%8(2@74]38,*A;MIP/7YP^
M<C]\.^&#-1C9M6;,9&L"2/PR+, ^ H%0*Y93S01WLF=L]&+GVA9^"%TA;H_P
M359!H_W+:9&;<^[B^:H<Z^/@RL:M]^*^M;@/LB%9-! H(F-KN5;F#7@B(G)L
M+U=O7L#!NJ5]W>MC>G@I\F'6 XDL/@50N%36[F[,XLNZ*)!/R$%CJP=U,IO
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MPJ!H@XF2#;O^%L(D9E'-BYVHYZK\;5_N?U8F*IJ\/NL4*11Y&G9HD8#I-L@
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MQB@(#/V=^.]&9B&[ZT6ERZ(#2M*2E[00NA91(Z\%X-IV'U4W+ZQ ;(VR%A9
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M']@<L*V0N9Y3]W>R?>F&^C'O(AE.6CCN\@XV1"Z[]/P3M)V@I= Q52,B]Q$
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MN7QY"3$7YFA>H$#H&6I[..X6"U1)TG9:OWWDXQ&Y&?G2[9%Y41,\M"RT4L]
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MYBA&,\P!=X*3'G0S#.SA-N*R(^*P=4WAE-5*-+!P74TK]$L^I9"!XX?8"GC
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M#9+930JFP! LB.M\0KBJ>E'=9F#YT0]24Z?8_=Q2)GZAU-K(LRO:V#I@VMM
M*1<?1CAUDA$]5-+LZ4SN!S'D#OE(_N7/1V_^>GR*<0>$S\>0,PR8ZHLZLU%L
MF6&C5=QV2T):9.(_[)2:0D6W4?0*8CJ[KS07MLC  BRO 6!FH%;AIIR,0JY5
MZ]P>0$W\,- H0@E);\E?:OX<WDYP,P=T5X)'K:W <!,^VI3<L"* 'D7@)OF8
M#Z'G#=+<=E-B'U>P+$I^L/,,NW'$0 3>S@AFUXBCMW8E!$VFE;/^=A->$U*0
M: -6//$!2(3J>X:5I/6,VWS1E9'?XL4:@9.,,>7XM% $FZ?TCHXK-5G"M%!0
MLF#5?K/8$>5DE3JOWOR'0O?)\:"UW& >#2( .FY6\&LHV4G=#D=$(_6_$37L
MP5;]7D[VX^$AF%%45A8\;Y0-\UIUP-'D!ZC =;$!J;&AI-OP.PU"/2LS)A #
M>YAYF ;:MT>=27!D+M-,!ZJG[HVR0Z@./;O)57-<U3#:%,;S:NF@*-;QU$@[
MJW''QQC!@'W<?Y7TSF"RTP+97[G&E@-_V!E7S8*3=YG4)/AY6C_TJ_^ D0(8
MGOB6-G\\,]]1I%*7."8JLMI6 TGI+QH!'Z/U!G%=E37V';S6//:<&QXO)@GX
MQU()+SV.S8.U>Y#J\F3<=VW3R<JH:&'8%Z>/(,9D6%*R&9WOX81RTK#$WK:'
M!"T1C6,*UGWMNGB*+273P@QV#>.@8XAVE"QV)V4QGN3#>>?]Y>=6'T_.]3-$
M(= B4,F&-W8JMT\=R' JQEI>\3S_3G@-(DR[C_P_(KE,S5=(0,@=739&!GV(
M;I+@5>AJ"J4,3^A1F>W?O8ZMF.%ME'QWC=/P#(H7#AX;K1 12^C;.)GQSIUP
M!7GY[U7'FFYE[NF&X(.'1D B :#&S/[;U#0.BXR?Q+> 3D6X7M^J"J;FL+<>
M*Y*38O:Y)0('8SO=FW[LZ 3TL:S2)NV8EBSAFBV^O!:'V^A,%9Q9R)E;NW]A
M\A9)%)8)GW41;P_$/#\+C1$EB<)EE8*[FU;?GR5-@HYX(^FD$^=6'$0^(=*"
MG%:/KY*_8I8"/Z5Q2\'KTK@J \U]=)_<(B 6?=MR 4.]9Q<;[@O&J>1W3#69
M_:[@NSY7TU<8-76*-H.RT;ZT-E3<0=0&G"T;8+RG1E0W_=*B,4#*_#'YZY0/
M0&3.4$&6B*=QU[%FA\3I%HGSZN4.B:.1.$V?*#Z_^5V4?K.A:6)9QT'39^ \
M_S2<\>_B](PM;(&;;7@.M! /.QNOW\9V-B(E@?!2+,_@0&R7-MA/7>R_?-O=
M$<FC/")?;6*C)8&K;ITH<E4**N*04$J@4R?Z3WFQP ^!*Y)/-N,86;\%@469
M"'_*<@HE@%<$[EJ&!3,85Z!P&(R5TI#3$I3VY4U>C70JA7V<)DQW":'C(99X
M7"RNR$V$MY<5%@%A>8XK]BEJ0PPI81:\EAZA2_NPVED@E;() 3N)T*IGE9S@
M6(:3%'',7+;X]09!<?LF^WM)]/J-:?3]?K-M*%*+9(O@>?#+NJ5F-E49)@D?
MH7]MMN4^.?GTI6[D9MF!-<978Z2ZZ@N1&+#CQOFDDEA9/?_HL5-MC2BM,BL.
M!:O?*6YS>).-L'0-C![0;4A/WZ4 Z)W^GG/)-FR12136?1]L% EE3LMP8P @
M!9!?#PG8JCOP'F&A:QB<?^"LA+-N.Q[&I3R,$BQM4[<*G5R3.2O!3UU^*NG^
M?V-C"]9I35F-U#&_8PFBDLO6I]VWZMQ'\'GVN=]+/I=S5"CU/"UT%!.^GUV7
MAB_5[WT@9H;$8K-;O\Z2:IVI.8+PT:[1UH!L#PLBMK2)@IM/DE$&M*:AY;"0
M[PY!IM>@"7<BL$P\.\RE:38>BD9;I-<&_S3:@$WF)W89XO09[-H>#\37?:>1
MBR;IJA@QMV N?$CS"5IQ^%<:<8-X-1;:O=A6-FQ ;)3R=<SHBI-AUN]&@X +
MA3;Z5Q1I5&7MNC^;>TL$M%0+RUJD1:B3_!>Y9'=+<GR,I3#6)"-B'2+806*B
M^5V6%;8GM;,%EM@"OE()TJU/[MVB_?5W5Q?>F6W62.(6!UE!KM>A+Z5/MA,M
M_V'YXYZL7\46+84@*MJO6.[83(C33F@5C=U:",]#WT>Q6+ILB40RRUT=HS*J
M4**OHWRN.T@$' G2+35!.$;++4@*:[J27-POJZC&]2VT'VA%/]T8HVHPX@0Z
MY4N+FMH\NH'4O>1RJ7ZGY5!%/!Z<[9L)DK:7N30-*=6J]"J=#V]:'<Y(3[",
M5+/5(^U2IWD#4^R]QD;" 2G;=O/2"G^'<*+,H4%_&"\JR@> PJ@PS(!7@XG^
MDKRN%\T.>?]>I!.F_5MVN#$OP=>@D3+PK=/V><9R4/0(_U?F'I6L:VGM@^%E
M3&983*-J1RPRNK8]#+;J(L8S)11KS>EE20@JM<'/*U+3@9.*X2-'%:#W^I%Y
MI7"Q:(W:F%D8Y>J9_.#XEYT_Q7_0OO_=@&E]#N%NC;G;*&TY.=X.%!J.8+>6
MW <[N[C2IEB'%L.I=^:K-OR>7JO \\?T*F-$ZH/2OH-E4C[@B;;8,2M("*T(
M6+,XW'6?+K/A30';=6TH7"TNG.P6U8HM#=GE_5M1WKWXK;Q;%G]YA_&7E2_K
M#SS2$RM"WB).FJ'K]3?SQQ/WP82[JL3FH@*OV 2W]2$I=YGA\KWN(D(>E;2,
M4U@VHLQ=EP4/DMY^7]$K,)V-UVYL++ES[Y<A045X=+>%(3&-$WEYLPZ7\CE(
MHU6.D"8!DS^:E9W*^6OK9[IQ5):SC:'@#T1-$"SK<A4!BPVTH26!EK6*'XD!
M&N90Q6"O&!Q*EWI/<EJ[FH)=3<&6:@KV?Y*:@K4U3D?Z96P$.7M.GLU9E,4+
MI!<H461<!T64(E<:H8<S(O$'3R.Q0SEP(_L6Q41%#!B_Z,2'5!#,>EV5P5V5
M>J>U< D@_;%:2]>,<7(,!"7BU?)B("987L\SZ1&;JCR*6@DWVF!52BY-LHJA
M!I,G1Y(-+NJ"4<_S.;7UL%AD/+X8+][12R?S&[32 NA"B[*9W5LE>[U9" -W
M^TNC:63P)J96A[%VMU&9YRBLK>?EFBQE9WDJ!V7+?(:^A])A<?2[.(NC?^H.
M\P'$MLXE"2.ODA<&)+#NBH2[*BO^XJ)>L/\R=\$(H==*1FOMIO8($+?1,J'H
M"[YT18.1;F(&$3&,OHNSR?.7*_CB+8M@[<Y&S3?*7C!R" ;).)K%(8K'I F>
M41!7C9T)<NT%*%&6L:HLI]H-0(I4]M7&%.$+2B)87!1D9A),UHO36K31&BWK
M9PC]T"N\#''(<MWIIQ%<ZP"SIBL8FEPF5D+1X=WL97O7>X,$.U["B4CK&IR\
M :>6J<M0-:H'P@4-LZFSUB$9UE*K/T^&\[7:IE 5C%-.HZ!W8&UKJ07G)88$
MY*<O,60:I3M?ZF 1^CY2DO9T[<-@^V<;QN*)/]"^% MP0F%:V-8/"UE:JJ$<
M@AV'3SO )4+,?@^I0+%)0@A8B?\@9&6*IG&6O4AFZM2-<]0Q.><64RO-#_?9
M:E9%"PL3H_1MQF\SO9<T[)XY3;5P3E6'<)N[T*ST8=(+2O(P=:A7VF L[XV%
MP%7&[:\M@UW-KQ.-?Q23PH^R_][*"QFU\O<@2-LP IH(VFU8 >M2[P?L@;NR
M^NY(#9Q5L_U#3SB)5:_5/IGA]M/T==69TV:MT=SMH&;FYG!.8_C0ZF&M1E.Q
M^E=HMB"IJI&?(!M,[F)8SG(6UW6*R>*:&_1)\M?I?HK42[I#JVE\FTVORE'.
M5:RB#VB%EZX /^ *N\)])]FG&W'C4A(H:HQ@ISG>"_*A9EE58SGSA)#8MLU%
M1Y+3W05UG[7W+)B.TOO0TRDBO>!I#!"IJ(6#04J=IK3/JR %R^KYOCI&IVU;
M>#?"UWE>=Q^K#CS5";D98L='+'ZD(W1*I(VL(6TLE8JOX>_^Y^($O>OKLAQA
MR!@.4)#<?>6\8P'<>2/%X5&^D+#U\9XD=YS>*0)Q0'T8)5%!A\783QZCHW.0
MEK^EA](@3BE@1OK+8G2=18*6;()CURP'RU'=<*74>F+$ZKCD:MPV<.*ZF[ZW
M*\]93^MH2T4;"*(V>W6#L,-6_ZR;N8]&D_Q]U97T.XK R[P=;W^SBZLW  TE
MYA4F%?_M]189Y?5P4=>>)I#L#39FKI*[FXR)9.W3C 90"O\:L4D4UA;+9-NV
MB>JM;QWM;9!ZC,F%B[(KHWW0W/V]X*8LW;IPMF2FNT9  +:"T"_PL)>K;S]&
M]#(XYRIBM6& "62VRKP7&1I]J6"T%'8+>[X@D0'=&?DO]@''X&6.@]<]%;EC
M$+5]QB]Y%$JAEF]>U"H0FS(.4L/G-#)+S [VM^ ;E8J<XD/PA2Y=A!/#,85%
M&S0?5*)+NU5+UF)%1W&OJF6'1]OAT;:$1SO8'(^&T\I'_^=/>?KVX.7+=/_H
M('L[/GIS]>[MZ&TV/$RS_</]='__3?9_#X_^M 40V[N]_8/' ;$].X;;_9=1
M4MQ^3>\[I\G:=D>89\?F#V<C2IK;;S-0].AO\"'IUK#Z!Y/>NUZ'(898VO)E
M!@:0!Q"_R'^?WR>?P Y )?[M(GF/ZJ^JD]ZWB__G]<L!3 ?_OZ]8 W7,B^"G
M53;*69FB.8"_ N4_!GN/?W>=YD4]MT!@,[EFR6B1!4/%:]Z!_9^%V!F.?)0@
M+:=JJ' ZS\!9 >,.H8#/2&ANE]OW=4S V$CIGQVX9S2T7*V\$8$"Z%6BD^ Y
MZ!C : >>/.2?+5DXU;=&R\!&G)@EZ15<O+M&,R 4%)CI[+D+V[=$_SBO4-@.
M;W*XO-P!<>R'(LTPB/6O1@_-ZQXUT)$E=OFLY^5U.QAWX/9&3828%M9^PCYH
M9@%W*=#-0X@DW-W,%ALY=WH;!ST -YK!E9,S] S6+@*;R:0+G/H94WP1P@HT
MM9PQ?6#UZ3*5!>)WJ150E5VGU6ABD7L6B^D55S3/:3)<\U(QQ3-%>E8>.;QO
M<OU&;I>R93VH->.G)PEHOJO?B6>,WY'>;SAH62G5E\G'&:AX'[6SF\TY7P^"
M[K;$N'@CEJ8C[VN\DN!C;GY&2R+"%UAB2*]I(BVW5QV 4Y:4O=5[3,,5P5H.
MAXM*]9LV'_3*( BN/0?#XEK)6_IZ7_>A7?-LJB-IT0HU$6*M.H3VF_E>AUGF
M!^L>DQ?C%=&9_>FI0W)OC_;>'#PL)K?WZN7^6B&Y39ZZ_T;%"+?ZV(/#O8/7
MC_#8_;U7!Z^W_]B#O</]=P\/=^Z_TO'.JW3X_;HJX0Z\4,G3X>AU-OJKG"P5
M+<:,%%9QY*-$Z2'Y!)W.)7]G7V#)!S2PT?OSAJ%8>,R?EGBTK_?=J!\/2__:
M>OB0D*N/[J0T+(3]P^460MT6OIWK>*MZ%#MQ7H2[*N_XWP=K[_Y3[6V"_WU-
MDG&];>[&.@J@#]0%?.2%?I([\GKOW4'CAL@O&_?#C0V!R.G"KS\\:-T7<T?L
MW7D7Y]%_<[#W3(_^)@+(M5FV=.1I_0[>F'#E\UJ_IUNB@S_D$FWUFAX<&4KA
MY[6&*[+>CW#>?AIM_BA+M+&B=CS(-XWT]2L':,"'_MW>8V -5J_NZPUU\B,?
MP]>[8[A;HL?W7=X\TS7<:8:XKN2/N7 1Z8']5SL]\%P.W1]YB79Z8 ,]\./A
MX)VF>+I%W+XN.=JW $+/2ID\]<G]*67I;A&C6,2=RFJK7:#_69U9?Y2&8X<O
M?:SC?I> V4AY0"-C+WP@XI'(+7QR$B1@:1"<"!/+YA#)Y+$QDE?]I*>&NZLR
MVU69;:G*[/!1J\S>;*/*[/&HTITJL[?K5W%[::5_+6I$*W:D.6RXV](2F@?C
MJ(L&<RJ!&$.L40IB_;/"J1L+L4-6/^(R/@^0]6:368:W-LU5FC?K(4CL34ZK
M#<IN9W3[84#R)D.J6\3,EB#+33KH%M1R^W+8>.9-C\'ZT&;;]+/0S2V+LR'H
M^0&^E/*3GAS;_/;U_L.PS4=OC[8/ZSW:>_UJ/?MRH\>^W'NSIMD:P6/WP<A^
MO1YD>H=MUMCF$+ Y(E2SH<_?@9ECCZK])&#FH]<AO+_Z[=-?C&9*XR?!+A^^
M?*[ TDBPR_O/=?V><HG6E@<_T1)M]9KN/_,\SPZB%LV=_%%8P9N&6GZ+$+4H
M*HJ6+.\.M1;9.53IZS_@"NT0 #O-L+N1SW>%=F)]=XAV8GTGUI_'C?RQ:L6#
M0+5BS"[ _M'.!7@N)W.G*W:Z8E>W\D0G,MZZE0;E\1]+W^S*,I[3Z?Z)=58\
MB(J?0:LU2EM:S>NMU*_$1M<]C+)^Y>)[/L,NE4TD2Q>+Q.VC&ACKO%B##KL8
MK04*3"OLW#?/X$!0.R7JXCG$QE#8.\%OPD18TV834,(Z$A@R'R<I-0'/AXM)
M6OEC;ZMC2:_*VTP BO[C$6B*\$0--IU5>5FIDIX /+V $[[YB]T6[_K=!?_A
MK!B!3*'5[-$OL&1'C\A[622@Z<99C@$7+0!86L/&  W4>82E6'0@;]);K'/*
M"G, VIB=>6-"NP_/(5#O0/<:;-18F4.P;%@+[O#1Q.)Z!5^("\9#1@W4@J_+
MZ\;3] A"<_!;.S[&F'  [EL"HVQ!'2>]C7IE]->E4W[<AA7==ODYC%$%FJZQ
ML;4X^5D:6!R"NEZVR"LKLS+L^RZ$[>D$?@)-^[\+T+KP]\WJM^H4N\W[XC*^
M.JK@>NVJIAY^DR-8-K=&ZB]_?O7VKPG:LG2LE]V/A]TIK3!1*5!G,,=LG2XF
M\WPV:7FUU!>AM:S-$+GL=3JUKN$_P<"VFQ8LG0<9O# H;N^PY+V-$C#?,.<G
MV(. ]7P'ZPEFO]/@8^EX+,$@(M9KT["D%.U!G3]:IVQ7E_%,\(Z!T_C@V32K
MMQY25Y?T'OGBT!/_&W0/#'V-JY3O=6K5[PW8&%^N9)9L\]5]8&/@8M'BATOH
M?KS'R9*+]I!*P?[:]WV=$K[U^X[_=57(YU"BY3&4GN^_%9-W#=OGQYNP;&=Y
MEGL<.^Z,'7?&9MP91YMS9T1)@^%>K#==U/8>[+WE6MI-3RHLRUOJ*['E<MEW
M>^]>O]W&!6A6?[T;#O>SHZZ3L&X_[7V[]>Q3^C6OUW(&5Z=6?W"5XR@-?F5W
M&WOJ76AU*9LUOY'BV )KZ1>4-J >W1E0J)@Q'91>7Z.1.L_@H?/D@@(XV$(0
MK";/6Q,']3*KP,'&,&R.O&:.EY@\*A)N5W/]/&]!1^[![G3O3O=/>;II!7>G
M>W>Z_] 6S#JWH!D,;&&MVMV/W?W8SOWPX:Y16_B[^_%3WH]XL?=KW:!(+M#S
M4C#1H:F?]15[3#3U_J'57565DQR^ZI+^?__EWE&,X+'S\CZ=S'.\;X6Y?)VF
MJ-?+&!ZN>3 V3S-B:J !O.^V=T0:)?:>S\Y]<@Z"^_G@#"T,TE'2"Y___DH,
M8J#G!&HGO^<$8=)Y((MB7MV_2. #\F_N1='06PAY#BNJP-I>O7KYYF#TB&N;
M=+FQE1PP>VO"4!_!_K=*@1UD8 <9>!+(P*N?!#+PP OST(8;[V+R2%PW8K2H
M$/KH0>24[H//3</T\:H<*56ROR'I]Y+C$6LGT#'W6)7UU%J,E9@3R48-YOS"
M45]K:*]*CR5%E/UD4M[A^LVR"JE]X833)%QYWHBG-[VY-;<A;3ZG?0,(PKR^
MY?B NI9.L#:'>V_>OGN(B <K]^WK1Z"F!\_K:"N:XUE@;0Y>/HVO$$9Y'!?%
M(ITDQ^&(RHJDU=;@./'$2GYL+P\/]KK;RI!_M9J?_[#!E_UZR;8-Q\/1\.F8
MRE\FS.GQ#%(1*P('G0(O/E"O&]"OL[(B,P"#I?K&IRP"5F6L"3,/3RD0@Y_]
M&[\"UL$NQQ!+CB$*919[#HY6>BO7 3Z><B5F6_QE=PMVF;8HD4J1G?]XC+^?
MX8:LERBST/T_3#MD6)KBR'[$V3G[]/=97J7JNE&#0"L8T6T^Y!O6>&9+!RC1
MDNO\-BN"-#KJ;RIXTLO[25$FXT5%#6!-F(?J_ZRJ7/BN*G1&CA<E<I;S]:BW
M8+#)>HL16OX'Z:WI<%@ML%KX+JU&;?1"R\I'=6$G$\WT\IS+V:4>%:5B6LR9
MV,:I %7QM\.]?6)J@M,P*?,Y+_=']6U<8]-LK9QDPP7.A<E67/R"1P&%SQVU
M/)<>R]+;?:;/*>47G>/,G >NO2V\V@L0ZRD)S<D][/BPG,)8%OC#+,U'+Q:S
M 8;Y9MD<],T@R:LJNRTY3H>C4]F<<95E7K=5*N1.DQK$$'Q8?= _6"G,$J>S
MF-#>XC;"0Z9EE25_3U$+G$S2?%KC8_,I!@L#W%16&-&^#1N4J3X CO#Z;6QP
MA$C9W'3$(\/-LHJK8P8B;%'SOO5.R?[+-YV>DCS*4_(Q'7Y' 6!?^F[U[9<B
M(&LP6=*0/\N2*0.D-6'2C:E*'.,\0>:B88ZR+IO?E$0EM*BICWH;^UXR*0OL
M<7Q2@ID+?\0N[_9Z*<(B6P[^ OH(9>-7< .$M,6S 2S>!*/^ES*<K%0LLT55
M+U)F?+-S6L21: = ^UH=;*'?L76!C]P QX9T9/LOWW9X.^.\GK_D<';AN6FE
M=_U36GT'2^YT/(8M[O:JGKF&0W.P=>,D!RX9\@H)I^&4Y^8D&A5IX6TY64RS
MIAD<>JM_,X9E4<_S^6*>[=! ]'*U96+6S\LY6/2USB&W+BQNAK^!S>5VT<)"
MSB8"3RS_:7H/QP*^GEDB\-[0RB'Q(H[$S6UO70Z"+/<X'PN/3DI3RQ4CS<W3
M^"/Z5QF3S[48Q?C=NYM<$?O(0:^4;08.9E[/ZT?EA5R/%KEC*=PNAMU]"NO-
M5OI/7PPY ;SPJ=K@%&DR+3[1(P$TKF7$B+7B'\0_KF02!JTI7N::G&%K6U=S
M7KG'9*4-Y7R<R=;B(CF;5>5MCOS476X*!<0-C@KVJ'D;]=*:. KL34-9@-50
M" MA6;3@M/SG:^P5F:U$BDSW'T>(WVPHDA^7"0$[97V!\(#[_U"BKTV1A$=[
MZUOHKQJQZPXI\T=1VN=JVS],RK**!K??*?'Z\ 9N(]P[NAK#/OX?JO5.Y5?O
M BXY!JV_C,=(6(S&W!F<Z6F1CX7:'BXMF&C@[0ME/JETVS35MAI8P;<IF,7"
MK1D,9<OD+;F@O@WO090B?NXV0\I-T&@%W-5\M&#DZE)AYHDP.^_0-$I+"Y;B
MRFM'R28EFJ]W>9UY-.=KX6*;'EYA@TI]>;?W($EWL!5!]^YU;*'C_?V]&*6:
MXJ-D>^@\PU2X_F%85B/YX7@!:CS2 K==N<FNW&2S<I/7/TFYB;/ 1S]+S>_^
MWGZ,HM+N^W%2UG,PY;].0 72O\G.^)06BW$ZG'-<B'X?I\1TS\TV,W$Q^1'M
MY;__"/6=:%A55GP/XWH#QQYCJQ%\VFF.1B98=K=E/K3-Q%$V!]M1/>'#Y:EU
M4KXLYB_*\8NOY1!C@_S[O!@N*LDZV6^2881CE? Z+'-"]Y)Z8>C"H12MSIP+
MBN"%C8HFOS$( A+0& 0%MD#DAC(8QQ9'N9KCDK8=&+*ILF&6S^8;E D]S+M]
M:%5ZMW'/UD/9H.:PME!B)C )E#Y>Q"2M-?!GE-7#*K_BK@VX[U;01=GXK\C$
MUR_3(JQ/EMZ#$H/K[$(<FT#D0\M2@)Y,6 D76G<SU.J_$>33L>Y?P\^SM0M*
MFY;=V&:5W7H2O..-6G>GUL"+/7"_#JS;LN+A?_1-$Q%WNT%FQ[69+BMX,2,X
M?EF,KK/Y(+88_611=QK?2HO[Y!B5//FC7\ +JQ:%'U7>6">\0YW@;44VO"E@
M4M?WO"OCK.KK%C5;MBP?QC83TYE?]\@WA3TI8-P6"ULDQM<570'3@NG']OAH
M[[7JG^J\7ZP-M@$>!@QZ$#=0AYY!.S1^0^WP#K1YVB?\<^^]<1=.X)T8&TDN
M%K/9A&$!JGV.FY<"HUM9U6*B:_##IU_?OSPX2MY7BVL#H&$S7_ZD[B7\&1]@
MV?GTX,<P\^&#EHG_M#"R9H%%E'V=+YI7[Q"OGLE=ZW9(F;,_KOP]*UYH1'S?
MD^_K9F '!J\@F]KP+EE8P*Y;AT(^VTC)+_'[Y$ P/*8<;^-@^.<BSE#508RA
M*I6*BJ*=Z:-&H58RXT0@*MKC4._]")-FZ6H$>DQDAZ))U//4*M'!#%T;LKG!
M->,$@T"_%7E]X^4;P\&;1[/EG@^"/TW^S3L":OT.%G2>8=T6ILUH\X*]:NL;
MVCG!BK1RVI&!D%Q795T;X"MN41.&:9EW#3QE74YLH4UH1OCU.:;#\!G8M3X+
M,.];X4Z>D/ /Y266>25@SF"O>X6N-Q :F1U]<60RYQK--*:\M_QY#(:1>H2T
MCM5/LMO,-MX73I);?05U(^1-G91'E3NQ(MT?]1CSR</MW'_SUSJ,;;B\R2MS
M&!VJPFDZRI9'O>F$@".LSGXZ0B8%/O[S]#O,Q9S_5BQ7&V:#4 [T7H[@HQ/
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M"A%#B-Z7T*QF?**\S'N5BJW:)B>>/,2R5CF8L-2^Q_$@%)KQ>UYPX?AM.EG
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MN:Y)M<P0*6^RU$_<YL@3=W=N98B,"I_=>MPN T7.H8IH54HG6C*9EB,B+]5
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M='__3?9_CU[^:0LXE'=[^P>/@T-Q "7-.$&<>/,HNX.P"^)"4),/.7SP>H
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M)9YO3PE:0+3Y*VUFI\IKPU)'-G3NQ2W(IK-)><]UI""3"A&"[-DHVU9]7VI
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M"=,*9M8?BO6\:.6AN/<:RPVE^2-*[)9^<[N*$74G99FW>'VZQS;J;AS"=CN
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MP./^7>#J4#6Z11(CG;Z,Y:7TY'QF2;/V%(I<\A0%A,46I>SF9;DZ[=7%.DB
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M:_1%JV*B-L U[XYG5?#V-\'=.E5SHA0*VMAB4FD-E#PV><D_?\_U_FS@21G
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M)<J'8)?Y29@6FY!VZZ\76VA3.PM0-C:ND(]XS( G^&=89"UW*/]JY"8X_CK
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MO"/#95Q6DX74NK8>@=S2../LXJT[.KDPF2E*5>;TW:M!H52".DH$=.N1.2Y
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M3CN&?@D6'71:!^'T">,C=.X]I15D<"7;R]M*4-97V/F9_@[9W[N>)!/1AYO
M]\9P566D.- X<*2XBW,,-Y(9T3'..<4>/1Y'4\49AK_X'B5\TJ*2D+>1+/]Z
M#KO.T& P8*S"8/*JE W-9UBM"KKU0ZS7LW&3?TV-)AZ_R78*V;-W0PCY=K?[
MY0]L&80!U'++U_O<:4=8O0*"JPT$UI9@K8%B=V" ()F3_.4]]\$S>_7@WXK3
M!<OXN'1@IS1XJ[\8:&+DJ^NMJ9@KIHD+W]<)T13FOUY-4;H7'/OB>HEU0_I7
M:M^NT[/:<<3V;=Q]W[CJDL*?X%^459\M[[J25ZFA3-]@]RNKUAM(_JA^13'/
MUBZ=QV6K\.J))A9C9+S:O?O")\]5](.9F!*MMFT0W!UT!U$%NP OH5(90RKF
MKMR4FTX:C!-S*_@;=KUD-I%#9Z<4@V_P.?F^YH@U_JF1[+JPRHO)@F;AIOK:
M(W7B6!DLT%-0Z,,+6LFR=Y1D^"U_K.P%&J4:#[<'RO*IND?]I_6W;:?+@AV^
M G'DH"*SK<\"#>P/']'F;=('L2O\1./ ]6LP]HE=PNI+BW )PHJ1'\6%UAM*
M^V6IZP2!6KE#:J9QZ17H6TH,26Y4^D%E(+(5I?I>/ 0YA\30Y([4QR:ZF35V
ML92<;MCV8;5<[JKGOB7[11W\5G*#GA?C@G-]W@VNDZCM(_\KUFG!0+" 8Q1F
M@EBGL:18-Z:)= *LX#Q"6EZ,'W'5G?0DA^5[$K5%@IB(J"RB4QMBD6?K:]KS
M'V%G4(:3MU#L/[UJ*,GN2*DZ'6PKJ==.!]13-T4L>6ZXD2&LA'9/#=VB!#?S
MP1>FS@3)=HJDK%'%-IF>*%$@<-0L>L\L?(S"IXX79/Y(14BUYL<-,5#OC& 0
M<'$L>/HS(:BA)BC!\(,>XG@0W7.7R-HN*?>><FSUQ@MJ5'JM*D6%)V#"OF*E
MX\(HKZ9]U>X18F6%.$+TIF&&,4<+<A"UY)Y*RN$*?4H5@\50&W:'3PODU#0#
MD-)XPAA'! L(*0TH.<'.HT#EI/=L__#/M$@L,F9(GR7WQZ&6,>QZNMSD8,O*
MR\?(9T+[+$VBH:A:+ ,]9T$Z",$Q.3CI_^I] PU!)]"%J,Y&^J\Q;-&=;Q<?
M=V564[L;5S<7) 5T&(U>?H1\^A@&E#RYO+WZ])4ZH\+K]F$"V0GS*56IQN_E
MJ3;TBC/'I[.47_EL9)025Q(FBFXL([Z*QE1$NNFQ@F^_+"D5+(M*WD$AY[M9
MO3F^* >?:A<^=>#XHE8!4%EV#EL)U?U89-R4(\^+#(-W]@1O^6#4,3*D[(4B
MIX &1S3YK##!--J5",.AZ,-(O&MYGG*0-^"TBG$S/(2-'_G#J<RU,MC)! QA
MC(\17$RWI#@R\1!2J*F.HD(19(GE2#J>KPYT,,K#/!=-N07\OAJ]U+@39=^7
M1HN^ZH.B.^!G>&NP2,BF"8EC"B05/U?#OT35(.B79/IU$!)BR\^)>%00YQ,%
M3I&8!00"[6\V-,A$P.!GX$);3>C4LQ)H:8'+:R95GXC35-(UP^QIT17!\43L
MHR&2Y6;(>1:P;XJTYP7&&B5!&FYCOM,D!AW(O0;$OXU?\!>H)$2X\SXT*:,T
ME+T ^_,5)6#Q"2PQV<4NS61'6=@".#Y)PTI#RHET"-&-Q)A"Y1)IMMOU_G@(
M$WJERMZFZ%/.73.20G;)#N"H5QQTI814'S#)),,_*.\!EA(,':2$-Z@ M1I;
M]M;P5MA7%V_'?R ,4L30DI2(\[B';@=IDX99A.U\81+#A H2F#:89#],)R%G
MFZ<*GE'3:9*0:BIGIBGO7 LVB* [3$E>-OZEU2 FIE/Y.._(&3,^A^6A>@,G
M:GK%.2"_::;58F:8$I\Y><C\7/4YE-DG$H>@WZ>[E2,O+XUC^2CI(!G8 )4%
M)9=R'/J)#.ZP_I?GC'Y3&K-ZY%GRK,VH"( R90^W@Y]&,N5:?;BQR>@7999/
M_E)]4G:C*?NHY USQ3B"ZI0()''#A*B$A9I=RHS2+?'<%BF("/'.TT[SB]#[
M,U*QFA7%<XY1W8)JDL)2*")T1H>D<M2RK$\@%[K)8>/\Y*K(KJR7VU%9$V**
M,OG,"%85[)8)7REVP1/5D2 G-#:PF2-XT.PCBP.[Q$(95&0&3*/QV$9DMK09
M*,PG>='UQK =TS47 08&>TW#4$LH"9&0W52=7_$*U8_Y?<JKA5:(H^^"^-H8
M$>_-$G<C;TJ#$I*AIAA"O%)U*?HM.0T:M;]VNYA,)"EDI(^*DF(J7KI4PCN4
M<?@AS<CP Y%:2;L0T=EC- /![KD'O7\CMY[>J%P@4[6W-K]0ZH>I#_4[H'A8
M[6/EUTR$JSH\- @3K3,M0T=U! $&%?"H@R<99<7>!7_3A8\5%>J\0YMB1)G.
M82JT1YB!K-.,J$Y-<1"J4$Y6[#_11#)U?Z=L-2\[18&%R(?#5-8=-&AG76?!
M_R<?AD66T6&GJDOD&A:TJ6-1]L>W17!^"0 KWW-!*-@3-@<A@X*'HZ@PU"FA
M%*'H.Y$^X<[-IP*X,D';H;9-M!85"UX[\S+\3"I-.:+2C#'4(WA8J*W@Q;5S
M( 7-+GDT<5,*!"DZ-S =F:)<S%G0XO&B+,;7$6O+I8C?B#3DN!Y"ZIV>O#*C
M%]UQ\69X.S=$?!RPK8B1(F%'2=X\'+8WB/WD^VP>*!?/=/',Y>*9AZ]:#GJR
MAG+0P^[QT1M4@YXN&,L\:4:$KT1*)&[V1K^DMSKNSWJEEL(L.D\Z.484^PL:
M:(3U7"#[:%'&H<8YM7J^JLB_E+$U[V)1!.!;KPHU0[^\M98]V>L>'O=64;,'
MAY++[$4UN\QW_>[QZ>%*OYPWV/Y>=__H8/VW/>X>]MLX:IAP:]9*ZC<QF?;?
MAJ>U.7392)'4< +-%\Z>QQW':Y<>O1<Y&LR^,V2XW$KS\'_WN\?'BPJKC;/"
M:+:G7ODU%LQ&B..W9Y,YT,WZ>YCUK_XX=//^_N;]+IK&;N)7FOCU7=K@&K?C
M.BR!;CL&4Z6_+>&@_E'WH+>W9?&@.GW^^BW+DQ7CDK09;Q7>]!L&)L$9/\>)
MA=EF(+I&^J1OV3> R*T_.K0T#*ZVT9>MW3C#=JPO3=O<24+<,,Z1=YD\AC&F
MZ:\NF(>U]_'PX/+R_/3#^?E>_\/!^?GQA]\.#D\^](].+L\/]H_.#D]/; S9
MKQE9])*2??=1KW<2Y#K87RF7<'"X\-FQ7)#K9,6[SAUL6P?=ID517CD:]6[D
MZ*)1K^6F;(<XW-R[N7\7+^OFOC[W,X,EKV]QNOB'BW]L1OQC<4C-46\-D)HC
MI#%[ TQ-G>SET(3B\387'VI/'5(#TE;,61Y&$ [%W/X7X:#QJE_^=CM\" /D
M4^B!1EDOA=0+_31!1(?'38([/+9&<K_\[;^3]"D.@WL5VWC-"-%IT_(ZZO8;
MQ"0^?7LQ+7-BKBB&QNZK)S49]$Z< +97 -OU_HV*M+[9EWW)]RO0]1Q !XT'
MT('3K!LC@.8\B]M7/RM/^9-]INMX)4=SK@F^M!]QX/P(&_R(D[T%.Z2NARC-
M?KD9Z03O,W<5"D2KO.4<BHI(Y&;CY53MI[M"JKG?;26+>=0]VCM8)0+4.^T>
M'>R_!JB^MW>\_MOVNJ='ZR\!Z!UU]T_[KW/;Q63[0G1-+"!:8A0_P!+1*/#D
MQA/?X\+MU;YL"B ?L1VS@0'DN0)2VWFFB-8J0B?!GY3@@1/ASXIPWXFPZ7NV
M8M8EX\T4<>.ATCLLA>T/O]]G*1BA'\1@@Q/\O[7*N.GK[3J1UG=V;[^LWE)$
M3D(OG;Y.0C4)+0#(:$D[;N9D.>5HR<+>BM6T(5O?*1FG9&R5E5,R3LDX)>.4
MS.9NH:U836\HH:V,$#KM:-=D.>UHR<)V(EI6/3H).>WHM*,ULG*VHT42VLH$
MO=..=DV6TXZ6+.RM6$W.LW;:<9O6L]..EBSLK5A-#E[BE.,6+>?%E.-Z$+GO
M7'V^N1"=#)V!VHX0%]?2;P14W_I=,Y\6:A-K:8_74TM[<O ZM;2N:M%5+;JJ
MQ357*;^B4[%A-8G6RL>6A(:U K+%9'Q3 6UCM>"R G1Q1DMB1*:(CIR$-D2E
M6R4B^P*-2S/<USI_F+0U)Z6B%33 '_K8XOKMYYF:DLYAA7+JU::=8:6];+&$
M7!IG*[7K KKTL 5EVG^)8L\I4YLV@E.FSE9UVM1IT[=R QI8/TU&7MGZJ@UI
M]XX/%I"V.[*V1=MLGE[;['/:67V6;*&M6$T;LO4W3\DXX\DI):>4+)204TJK
MNATN^>"4E%-23DG9IJ2<Y>24DE-*FZ0JWH%2<K@-IZ6<EFI=0K8 >:T2T1:H
M5V?S.6WJM*G3IA:(: NTZ0O&ZJ$1^N-1'G?[K: +UFBN.D*$C:A#WWXE_=8R
MW$8PL^-#V+Y-T\R'L$@[X@WD2CC><UP)CBO!<24LJ*D=5\*Z!.3D,]]8<@+:
MC*" XTK82JZ$MS2[W5CL'\M:7:-3BF+9L/E<6_-WK./LE)55478KC5:+)62+
M56:5B+8M5?->,C5.OSK]VKJ$WC/\<;.7A5,REFRAK5A-&[+U-U3)G-H2#7-*
M9D.WD%,R3LDX)>.4C%,R%DG(A:,V0CO^)'+8A:.<?G4B:D?!.@EM@'[=;'O!
M:4=+%O96K*8-V?J;IV1<^9?34W;L0J>GG)?L%&RE=L8B=;I.N@)73;L158S;
MKY)=->TFR' 3(>/.L'Y7!;G[KB#7%>2Z@MPUEPO:8K=96T_IY/."O>4$M!E1
M!%>0ZXK5-M/]<4[VY@3UWD'X<"O=2*>GVM^%IHB.G(0VQ/2T2D1;H&!M5:>.
M3GJC=H(S^USFQ&E3ITV=-G7:U!FG5HC(/G6ZV>OY3;7CSP5*>DV!DOIAU.^V
M$B@Y/EC@+')'D%4*UDEH _2K,U>=KFA?5S@)N9R/X_ES:LJZ3>C4E%-3SGAR
M6LFN/>>TDM-*#C#C])3MN]#I*<=*X_3KN[#Z7#WS1M21;K]&?FL9VE(^LF%"
M= 7-5AT%KJ"Y7M!\Y J:74&S*VAV!<VNH-DF^=@"W+-60+98I*Z@V14T._=G
M@U3^1LMP&^&&S@UOFG#GAKMFUNXXW2 UY@Y+QXO<NHCLRR-N]GIVVG%CC+RM
M6&_OR%!VJLP"5=;KK\V>WDPEMZ;P7=N^B+%9W*%EB36V%7K#F?3.I-^F]>RT
MHR4+>RM6TX9L?:=DG)*Q559.R3@EXY2,4S*;NX6V8C5MR-9W2L8I&5MEY92,
M11)RP:1-08"^J82<5G=:W=H-Z43D=):S>5N?+*<=+5G86[&:'-V[32)ZC^>'
MT^I.JUN[(9V$7"3#:76GU9U6MWNYO8O5M"%NN@L(V*AD'#O@1A2Y;,6*M$J&
MCI7@)V3X,X7^/?8-*H7^1[5"_P.*#+W]!!SO_VQ#,WL(&39;7[PO4L-31VKH
M2 T=J>&"A]2BA&&VV)O6<M(Y^6Q&>LI: =D2Z76DAEO)PK2) 2A[GF0NM",[
M%MIF91P<38&-<6DKC1B+)63+*6VSB-ZAA%R@R6EU:S>DDY#3ZBZ1W/ID.>UH
MR<)VSIQ#ECL1.;7NU/I&+;=WL9HVQ*)SMJ-3,K;*RBD9BR3T+@TC%R]U6MUI
M=8N6FQ.10WT["3FM[K2Z9;)RMKI%$GJ/*FLY"?7?H82<4G=*W=H-Z23DH TN
M ..TNM/J=B^W=[&:G,K:DNRF4XY..5JTL+=B-3F3URH1O4,).:WNZ*RVDT9H
MLU>D53+<RK/CS87H9.C.'T=&%?[O2=^143DR*D=&M> )X\BHUB4@)Y^Y\K$%
ME6RM@&PQ@QT9U5:24=FISBWS%]Z%.V"5#+<1 .<"*%8(T3G_,T^7WF$I;G_X
M_3Y+BR3X( 8;G.#_M25E2\3L#G%+4TKO8M.ZS*W#M6S3>G;:T9*%O16K:4.V
MOE,R3LG8*BNG9"R2D#/!-B6TZ\!S3JM;+"NGU2V2D-/J3JL[K>ZT^B9M2">A
M38&Q6"PBI]7?ZSYT6MW*#>DD]!Y1*.N5T'MLV>"4NE/JUFY()R&GU%W.L>W)
M<LK1DH6]%:O)1:>M$M$[E)#3ZDZK6[LAG82<5G<V;^N3Y;2C)0O;1>A<[LZ)
MR*EUI]8W:KF]B]6T(1:=TXY..SKM:--R>Q>KR67!MN3\<,K1$1QO&"W*NUB1
M5LEP*\U&1W!L@PS=^?/^"(X/'<&Q(SAV!,<+GC"]#;,6K>6G=?+9#"O/6@'9
M DYP!,>.&]%:4];%3BV2D"TJW6(16:*27$;,TJ"OT^I.JULF(:?5G59W6MUI
M]4W:D$Y"3JL[K>ZTNM/J=B^W=[&:-@2;Y4KGG'9TVM&FY?8N5I/365:)Z!U*
MR&EUI]6MW9!.0DZK.ZWNM+K3ZIN./7\7Z\TJ&6[ER?#Z0EP\I.0*,ES3Z4T7
MLSL,V[9.G83>Y4%F3^;#'4)..UJTL+=B-6W(UG=*QBD96V7EE(Q3,D[)."6S
MN5MH*U;3AFQ]IV2<DK%55D[)6"0A%TQR(G)JW:GUC=J13D1.1.]6)SFU[M3Z
MIBRW=[&:'!_YE@1-G')T?.1;AM[;BA5IE0RW406_F0P7DYS.NLSTQ7C['A4N
M& 3)A]2W3W[$ZKMWT#TYG$S??@*.#V9. ',].P"M8S1_!4;S$\=H[AC-':/Y
M@H=4;\/L36L)J9U\7K 3G8 V(ZWF&,T=H[FUIJR+OEHD(5LTEL4B.GJ'$G).
MM]/JUFY()R&GU9U6=UK=:76[E]N[6$U.JSNHQ#:M9Z<=+5G8VY^B7[-V=!)R
M$G)*W2GUS=F03D*;DG%T(K)+1$ZM.[5N[8YT$G+>C MDM#U93CE:LK"W8C4Y
MY>@DY"S>UD7HE+J5&]))R.7NG,G;^F0Y[6C)PG;FBI/0>B74?X<2<DK=*75K
M-Z136:]ISSG+T2D96V7E_&J+)/0NL]].1$ZM.[5NTW)[%ZO)054MDI +"+S7
M;>B4NI4;TDG(Y<"<B)Q:=QS%-DC3+B$Z&3K-Z(1HK1#= ?3N*(9/>XYBV%$,
M.XKA!8^8WH:9B]8RQ#KY;$:RREH!V6+".8IA1S%LK2GK<& 62<@6C66SB-ZA
MA)S3[;2ZM1O2:76GU1TLN?7)<MK1FACYNUAO5LEP*S6L$Z(50G3'R\SCI7=8
MBML??K_/TB()/HC!!B?X?VU)V1(QN\C5AIJG6[%IG1?H7)PM6LY..5JRL-W6
M=^7=3LDX)>.4C%,R3LDX);.Y6\@I&:=DG))Q2L;%DBR2T%8F(IR(G%IW:GV3
MEMN[6$W.NMX2Z]HI1Z<<+5K86[&:G')T$G(6;^LB=$K=R@WI).2\])\6T=$[
ME)#3ZDZK6[LAWZ.9Y2I0G82<4G?,C+9)TRXA.AG^_.'JA.B$Z.K4'#/CFI@9
M#QPSHV-F=,R,"QXQB[*>V6(N6DNLY^2S&1:*M0*R)3#NF!E=?;NUIJQ+Y5DD
M(1<6=^ U.X*G3CDZY6B9A)QR=!)R2MTI]0W:D$Y"3F7]K(1<7^'WN@V=4K=R
M0SJ5Y23DE+I3ZDZI6[W<WL5J<F4F-HG(EHRL4^M.K5LL*Z?6+9*04^M.1$ZM
M.[6^43O226A#D%L62\B%8-[K-G1*W<H-Z23D#%$G(J?6G5JW?+F]B]7D=)83
MD5/K%HC0J74K=Z3#>#B=Y:)43JL[K6[W<G-:W6EU5Z.Y89/E".[>;.D[@KM-
MD.'B"F:[QN+4X?NC6SM>#]U:K_\Z=&N"'0T7WGYW#U>40<!V>$QLZ_(S7L#B
M0^VIPS"!UVB%.8:'$83#-/-I9HL$=A)>]<O?;H</85#$H=?KGAS-7%6:"&CO
MS99>\X\.NALHME_^]L4?9NFG,(F&N?<-]L\HS<:UUUU2%'L$FEY(@";/7Z\F
MK?YI]\24UI]%/HU&S_Q1!+.<3/]K_T@]KE4%UUU,.GN+2F<#-1W<V*DZ*U3=
MR6*+<7\]NJ[?V\- @T5:S+O+_""$47_/%Y3$2H*H2>*H9ZLR6EJ-;[>BVM]H
M1=4[,38A*RKQ84U1&:=E[U1;ZF^X4X\/%M5=O=Z!%,[;C_&7OWF+[(Z-G).:
MVJ#W;732VA#\@O;3P?**>H^@P<9DG1[7IFI_K]'6M%.;;[3N/7*ZUUK=>^)T
MK].]3O=NK>X]W6C="[[X87WUR$\WRD7O'?86V3]'W?X&ABE^^=OECPBV<'+O
M_3[)I["TQM[G" :4A][9?1:&8QA;W3-?/M2X2J3Q6!6*619!W"I-T^MONJ8Y
MJIL4\E,[=ME"FF:_>_P3>N:@WR2#@[XU,EA,TWAG\#_!NI3.2OF-7J^^G/8Y
MRF:IY?/7OQR>S-9)J\4*9X=/5<KG].UOM9'Z]7 =^O68W_BU]>O)]EIR!]W>
MCK^[V#;I_?PV48=3HV(^LDDQGU_T^OO>1?@8QND$=2]F9Y*E].^JW\U,=IER
MW#]"%?'ZMF"? A$O2VR+K<&3C==6C1ONT)X-M["V&KR]MK)>>*"MX"-$S7G?
MLG2:PE.]V^<DG>31<A;CTEKI<#6T3$M=,8^[)[W>*ETQ#V$]G:Z_?>4!J(2]
MMVX(Z0#6EH%@-U3*C2ORR(G;B=N)VXG;B7OSQ?U6PEQ,@LTFZ"&!K$V+O2F>
M=M)M)4W2.YGO&#O;[BWK1M>\^S>T.MDMMPU;;C^C'WL4(S1S.?O=>NRZ?X**
MU"KY.P6YL2O6*<@W,GYJF[O1^#G8KV()+4K4-NQW>]9P[Z![[!:QTYENO6T8
M1\A/^I3U-%"37MWK'A]::S1M4A1\PY=]C0MBDY/=_=YZH(\G!^M-=KMLH:79
MPK>P8/M[3L^^\2Q5)N5XHSR(3<LG_.0>6LQ<:2L&?NPFK+:=[)F>Q??33#/'
MI-/HOH9-O+?@:_2.]GZM_W>KT(C] SL-M.V >IV>=$_W9G^]?BMKPXZ00WL]
M7KOF8\-C8G8)\U6.6[>4WT"U'#65)S;-QU'7$O:IE:?#'NMT&W3/>R%8[?77
MQ+#J[+FMLN>V80\[E>E4YFNHS/VU,+6V69"W'?0,A]W^V]<.-PK.&KG]\K>;
M, _];/C07#"\T=MN+;RC;6Z[@\9M=[!AV^Z4JO9WHA9*81LK8:V1GL:G<O[E
M>JUD38O*\"6RN -+P_P_41GLOG/?N>_<=YOT7:..7ZVAP%'MH'P-'OV3A11\
MKW]\LG]\='3RO_W3[3(]UT*[["A8UF5Z1F]M?/;W]C5&M+<V*Q6_RFTQF<3/
MI67I_7?X[-V%V7C!3AVKT>\=[]41<;/:"[V>A.B._Q5-X7'#!731W4.4>["8
MQU[^$(93+RVF>%'N#<-LZD>)]QU$A]_#50_^U'N*XM@;A%Z4#.,B" /X!WP1
M>K-EO_/7OYST^R6\XZW?>\FU\LK#?,'R!TGU?MWUVI)5\["F*<XXZ3R:</A[
M4F1YX</@X-^WX1 UD:YUO'3$JP)3# .AJCP_">K$F7#KZ5,8\BKZYF?3"%YE
M!_^P<MV\U3I9<HKDRNEZY_Z$?O4?F"K>MT4._QP44R])IUX0CN#'8MN:6Y^V
M]H/_&-)4C$,_01?=GTZS"'Z-MTOQF['<\DH4ZVY+9FA5H8O?.)/5[^X='*V2
MR>KWND>]_MIAY<='W=[)R1; RDUS8;\)8]#;8Z)@G3/Q0^]$7S]OK9A[W==6
MR7.5SK<B V,^) 5Z.TPGH:WEF*^  *H5';6+:?^F'7QS[9Z.IS>-(]WZQ4^*
MD3^<%AE/9<X_"7^ *96#2P?_AKM^BN+0#[POGR[V^@?>15;<(U]@4 RGN3=*
M,U3GJ('5@^^RR(]SCP_I89K@E:CPG^6=R$.8J[$W36\<MH0*ZV%A3[_KM:4,
MZ/ER,;PK';!O56%+;6>+G8Q[K&'?>D9$OX.[UQ^" Q_XR3"$&TP?Z)<^W /D
M1';.)!Q&(_@#[6;>]GDQ?&B\>0ZF&UP -\'[)J!.'J)!M(B"\G.Z(O?'8.[Y
MSZ@_BDG@H_889>G8FX+,Z#;XOZ!/?&6S"_.^!7-][CEY:XC-!D^NZ_V>Q&&>
M>RF(*'N*\!!'*9)^UD38D<I:^M=9F$_@'2)<#3C]QA)J/!R<3E]=I^^WK-,Q
M-O6N]'D5P651H6('#*;*EAT7T\*/X^?FO8MZ]RF+**$-.Q4]ZB@A+1KZ61R!
M[=6@\*-I+MSS-XJ/S5><?#;HR[!5K>E4V4JJ[!!D>-":JTJ/!_]H^.#GX6+!
M'1$ :"E?<(U+XIW9T=:JW:4=7K!>GT(PEGSR?<U[6:%4Y5;PS'76KCEZZ2/F
MT1B9<&'(=N:#[=\8X8CH;!.6ON:;-,[3(.33+Z 4@3D9E/75HR$XFM[QKV#C
M#L-H0MZ$7QE30_1DF":C*!M[[&N\L'+44#CX0<Y3Y:W->U2^G&3I8Q3H892_
M_N7P]%?+$C-JE&VN+4H+PJ3,&</@<.^X'[SB&%H50',OUW<GAH_5D('ITP91
M/BS JN;%XOWC]IQLX"S\=Q%EHH4>*(*9IT!5_:\UJFDOX]DB^9)#PF\TG.LV
MI5 .VTVA" _G6Q8-0U;E5\EC&@TIQ9D$WD481S 7S^^7.V@#_/19<==&I5&F
M4D#E^/+2"2X #Y0.:)*:V;@#MJ21(->4RRY"7HHL8YM 'PG<QLCL> -_"N9&
MLS(C73:4NDP.BO-[]@12Q<#O,KC'"-0L;1LK#-B?H[U9#=CUXJ^VMH)O3:W<
MWZ3H^;CG@"(6 D7V/)Z7+0^LS#@H30MLKTT#S#SJX- BJ)>?>#BZ24A#A)-H
M *XG1:N+A"+:Y'/[11!-FUSX09I^S\F RA"2'-!I^(@#Y$@"W*C(_.&SC".8
MOI)WEL W<#FXWMD]O&K^X,OT5S0>%%G.J#,^QQ>"F1UWC2;8&Q,+JYDV$9FG
MH;1A9N8 S3-ZI@LEXR$Z<+,:=*D\8%[6V1Y311KNWH4_M<-$,=S>B?_LX9H&
M=Q6.'()1BID%NW2,FRRGA!"8FTU1,Q0R9N3E_A&_77 K]!?<"4<V[80S1$HU
MK3B9&@]XQG75X-64&UUG6/(S@1";EVVJP6I_721,8!^L\JC=F,!9&=3^[#_Q
M,783WA>QB1_9^,30"\MEED5CDU*X@PV<T+3X<<<;A2 N_$<6WHN/\BEJ29Q!
M"HHGPPAV>HRS*C3G[TF$RO<6K\L[WN7O=+&/!@CF^;T_BRS*@VC(B"L]O8_0
M*$K\>VG2$84O:!D-/WWYUO$^G7^C.WWZ[=LM/HM.3.-FFZ=?[,AF(S#FV ZP
MI>79;,J\_^%G8 I.EXY@6JNV7E92^]J)9H.6THUX=F4P=WV>CL?@XD2$(+H)
M_1PT%IXYER.$;=;CAZ!,A(GS AR\Z]W- )SN^+NE+P7V#^9.TVP<39\;X:8F
M;I+#XSL#>0OR$P=8HJ4-,]!N6Z*:M'NB=J1W>>&4[9AAULX+U83X:^.*_RE@
MYJ?:)6+XPY>'#_^.8DYS4Q+3SX2PQC#B\J5>> &9T:+4ESP ] G=*8\,33Y1
M@AEWJHNKYL#P;A\OSCJ4((.#BGSQ,)OXN%KPZ7QBB3&DX/N<%=.'-.-7$1@U
MM($-F-JN$$P@!8/E8+ \_*"(X>X$6"N3:A\_7IPWCZ##M0L1[!]?),ISDH,8
MN3QTFX[566/CH>%]=T)CWGQO#/,\+JA&+1YY<30*$?$A;E1,0'P5-![>!22>
M9I.47XH*%E^H4<7 (,X&%F%T/$M<6[F;JYJ]7>^VKN0:X,IC'Z0._T^+'B[)
MRK4*>P#6#"%XDD#?;&+]E%L'?_R1]ZC06Z14C.U"1ERYJV#Q+5B-V%LE$S#C
M%++%?^X=T*J)4CHY\H=H(M'Z:.<V'13J@&D&W- U.'__<TZ2_I\SS\==PIHF
M"8=AGOL9E2V%28[*CA3IS%J%<1A.A7%=6=NZ88T/U!Y3%CB4ZFFV^F?U1"^0
MA?!F< #/'$Z#LF\:&]UQ]A.W'G;0J@=P8KD'4%4JC:&8E@"N5Z6-\=>_'!S_
M"B;#)/:'JH;GHP][/_!^PWQUN'2\8\NA#W:5G.DQ9;*,FJ+%@8R%@SX6]N4L
MS<\G9\"'+"G(2A&$>" &/[+P3[P3F)B@3.-T*LSE("43$G4ZJ4W3B^AZ5R-Y
MDPB#C? 566?-!]',D=2?93S'HR3%( >; )X!1IW^+# 'IKC4@W"$+R -C*9S
M$!\R] L$8<P\+J:S!I$WG)X+>GX9[TAZZ$_8(/:$Z_H:?L20'ECM>8HL( CZ
M$Z) / Z>]&2\O8Z6?[$G$0VXTQ9TDI[N-^960>5A07?.3F_X8X+$*1U<\-'(
M6&\1HB%I8546E%C%"V-FMA7'<M!W.!:'8WGW.);5\D"VT&_T<#7H)PK%:3!Z
M-BHP_U+B)"BZ*7+K$S\*2B0#6S*A"J>*.RT4,C@R>:GGB:Q*5=VNZ7AE%NN#
MRN!L%A=./3V$%*C#_X1XE%2L)B%E$I^ ,.A%ZFG\R(A8W\O25-A0<&#Y\7,.
M-S/X2"I8(\$,AC&A'?*]Z1F3+,6H@LCACXJ,1B<($1;(YKOBT9]PMD];=K9O
MBP&LF"G9A,G].\IDV8RT1Q<P36"/Y>7L>"-4 6B7CF ?Y@]4_3?;O3(].LX,
M--Q!>T":S<X6=+TSD!V# 3!<7QVL/DX.ZH5,-P\:A_W>'.X/YI^6 =H\K;$@
M"*@"]VF/0FVO7;#/]5,29A@2QW5ZE4Q#2OA@&0@LT@G(>GL2YUN ]S%F"_,!
MC3,&)LIC&,._FR@Y\,]ABAABJ9G@-RI=+0E*9Z8$I8USC_CDI'S"!L,&[;$S
M>NT1*M+SKT ?CA,5OWM?.[]%"%]DRMU+!_ >$D8!YW(<C:.I^!N^CB-_P-E?
M@^3L#(40AU[O4&[CRK;%A/#SJX?TEBS6'Q?X9CF2"?D(!F\SF^]TUT_HKGZ[
MNDODGS<!DE@CR]YX!;MYGMP5P?3^+!+. RN0PQQ>2-V0(GU*U.^,H_*](;P.
M#"M[+LN8_RT@$25!)%M-Z'-%>5Z$F/*)_9)#7/UBML\H(T!4(AW5JZX;L"!U
M6)<E0*X:9,0*)->:R^GL"GK6\K$-(#6BN2^!FID"#!$A$6'-5"G_S,1QR3)
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M-2SI281MMLB5EW&=KBONZIB59K9;H:121#*Q?Q5N"3ON/Q2%#EQ*\_%[@>T
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MI?OO5=W>O>%H?)6O<+Z"_KJN5\MO_@%02P,$%     @ ]H!O5G7KC_*^$@$
M)/X( !<   !A,3 R,U]P<F]V96YT:6]N87!A+FAT;>R]>W?;.)8O^O_]%#S5
MTWWL<V65G[&=]-1:+MNISDQ>$[NF[OEK%D1"$LH4J29(.^I/?_<# $&*LF4G
M,269O7I5+(D$06!CO_=O__U_77PZO_Z_GR^#<3Z)@\^___K^W7GPT\[//_]Q
M</[SSQ?7%\$_KC^\#P[[NWO!=282K7*5)B+^^>?+CS\%/XWS?/KZYY_O[N[Z
M=P?]-!O]?/WE9QSJ\.<X3;7L1WGTTR]_QV_@OU)$O_P_?_]?.SO!11H6$YGD
M09A)D<LH*+1*1L$?D=0WP<Z.N>H\G<XR-1KGP?[N_D'P1YK=J%O!O^<JC^4O
M=IR__\R?__XS/>3O@S2:_?+W2-T&*OKWGU2T>R*/CD^/AD>#O<,#N7L:'@^.
M=L-P&!X<#Z)H]W_V8)(_P^5\C\YGL?SWGR8JV1E+?/[KH[W^WOXT?W.GHGS\
M>F]W]Z\_T:6__'V8)CD\+X/[^4\WS%-_LX^?BBB"1=F)Y3!_?7B C\_EUWQ'
M)1&\\>N#5]/\)Q['WA&F<9J]_LLN_>\-_K(S%!,5SU[_[VLUD3KX*.^"+^E$
M)/^[IV$O=[3,U) OU.I?\O7>'CR$/M[Q>Q_".+%*I%T'?O/+KV,U4'FPM]N'
M;2G_5WV5N1>BV8M8C9+7(;R!S'[ZUB5ZW(@/W?7=EO'TH57</X55//_T\>V[
MB\N/U^_.W@?77R[/KC_ A^#+Y7_]?GEU?7GQM[\<G;P)SF66"Y4$TS3#DZ>#
M=!CD8Z6#R!ZAL;B5P4#*)$@G*L?#-"TR70CX*4\#$63RGX74>3!,LR!,DZ%"
M\E$B#G(\>S2$2*)><#>6F0S$=!JK4 QBV?-&GHCL!@:^4_D8+@Z$AE53<%2W
M_O:7D_W]W3=_^\OIWIO_@_^#OP[>T+=[;[9Q O"T-)=F=)BAUO0:_MB1[ ?7
M8UF=W43@,^"/L=!\X5#%, <MIR*#W^(93R>'&Z]D6&3 F6!OX%6"RZ_A6"0C
M"0QD8A[8WV3Z.FX\I6=75Y?7P-*_G/_C[.HR./OMR^4E4M@3&-7SG0R:^372
M]YG6,@\^%QGLI9;!V2B3DHAUB\C?SK2%A34T[V9DJ/U99M2\8-L!K B>(R)_
MHCDX*2K!\V\XA@R.?\P$^\='2\SQS31EU>%U)F.1JUOY)D^GKW>.^OMX^RUP
M.> ZL3DV ]AQ'.&G7_)QB\L:1&*&J_<!_MG?W3M!TI,K0'GG<4KJT@6PP14@
MOEXPF!'A#61^!XQZE1A,\SI^_O+IOU'P?OH8_/KN4R]X]_&\W^(*]D!*7\"Q
MN!,9"L$,9+W L]*C<SO-5!*J*4C":2Q"B00Y0'59:CK:=V,5CO'\BSSX/5$H
M_Z]R( SZ\6P"$PI%L-4^T?Y:S&2V"M2Z2N39/$<X2ZLTR;EM/3B!27XX.__R
MZ;?+C^_.K]H\0#27[W: 3H]W#X,/,D)9!*IW BIR<)&!M.K!+,.;6Q6C7OSA
M L3!R=%NSQRX=@X7O?GS2*/F55\9-D.S,6SF2L(6M<MG:#K;8+Z=OOFN5L<S
M\^TOE^?OKL_>7ZT^*_KC'Y=@/@,;:G&_2;P1%PE"^)48B,X%&*$#E4['(IL
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MXV*T1 Y!<6#T#'LP>IRG.3^*?R,F%0$;P  B/#A3^H:;A<"KIX7&&"0V2L4
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MZKD>W]7@-R<M>0B@##3*3ARQ,.&K,UN?+I%:]I4O^X[O$JQA\V!$7[2$@+/
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MSO'49O@(77#S3/B8*0,_SX,8H)$9J&Z)'*K<S,)DC910NB0M,ID.,<V3>]#
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MM+1S1VLQ2PCAL*1YE9NQ'Z;QC,X/5-(9#%4?IZY;#:1_:+^!:78 !AV P9(
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M@R=+0G4BJWVT?7E[@<]+YNB9R:]7)Z9,PAE6D?=19HX=+3B;:*>;\XBIZ\.
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MW;O.<J(37RL2]O"2KW(.[PZ#LPD\(!2!<)6A 8<%J7!5YZ[[T?S=YVE$XM
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M,;)P/RB/*N'D:E/'1-1+A;K(K6(YXBHH$4T4-DS.R)_)"@+B9J@<6W9/!+O
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MNR.HNX-1C3T:R@ %@;<FVO6*01!1P2BPM5&L!65B$Q0&:%R;^]?6@\P*WI6
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M*$*B#HQ$8RI*S5*J,\<J#KSWLA2(F<8B+%U"J?%>C,"0P,",Q%0:9$:Q&*
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M' ;A$1(6_<E?MYW=XQ17T%9!QD0JILRZM,B=0FU&-!O-FXFM0=BU8[>2=GJ
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M$P^<K;6YEBBBI;O9(?[:()3#W'I4MB&,MN!M+39U#5@KF:WDEK7E@\;-6;2
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M!@,H.2PALS AGN&FL:X^PH0V2F'E3:<E,5O.]..-.Y^9R)P&.8K]!IWGE4.
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MBPJ2\9YA@7@X=#K(>43N: 0@@B?V&*-_UIF?<^8GY?-X0*Z>.\  +-H-L)V
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M(_,VNA,@)) 6R8).*>QLH!!()P'"?N+Y!4XB\S=A;B.T%OP\']88H@K1*9@
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MIM71UI7S';+XCKMB:^6U"JXI;P:CLUR6(M7GV<HJI7]I%?HKSJZ?FTTK1\<
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M+6J,>G!ASB:EO![46?X!;U]2_M%'#S\WSN)8@2^W'K2P>:@R@E O)66( ##
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M@Y;@+W6Q!5GHQ7/9<JY%) /K^DI\8_%"%EBJ/SD9_:51<?1=L7$>(KE&"*;
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MBC"F9[5$1G\EPI):U3#8YV:>XX)7T#*IN(4"T0*EW5O5_X4V@H@F/ ^SO)[
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M0QMY)3V!#4%]F]'5<.6%]+<N"J8>X-S#=T*(2"D% #8IU?_D1U1,T@-_!8X
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MS#@_,EZ195B;!C>@,@\SA7&EM$JT!O(U[R17M-J5>=*J+TMTE>CI:3+$/;G
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M:I.6/F(T3ZJY=),:^CZJ#37L^:SV%N.+!AKCH_ICOV[.\/:B&+;(0](.V*K
M3A?+/%B?>YC,#SL-=KHJ&YAG$0<+LQ!.GV#IX"X'KC>ZQ4+*FFXK8].0I72%
M%$P#@2<$(1(W)7I2%BB?R[:A-4TO.7VU 5 N:GT$L#KT6@RV4/,IQ^AQ#G.K
M746+_" 4W9.CFP"UIJ.)=Y8:*E)G.8^R?(D] ;5^EJ.+I"B<]JPW<_0YFEC@
M2;2847M4.4K.B6AI9GU86G_X^A+G^[1^2>T,!%O<L[L6;W/F'F+_H,1235<1
MNV5=R4C$&J0\-Y)SRC97C-7Q( N\#"(.7<* L/B-[O$=0#"'#K>EG N>SJP
M Q_'OC6WW,'RH88PI8HSVKX=[>J]B--Y^RFJ@3UR2CBM@)'2/F?_(=H"?<-
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MUT>+_3) FJ5ED&]X..;/&TJZ^B/)]E320ARM38(,@ZJ(! T*&S+7O1F^"23
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M5O\VU)>0TBF M[P.RJ!W>%/%)8%$,*L6L>766/9=I6C%PRCG<1%61=$:S%&
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ML!I$E?IC#)F#O8TN!K(BU5^-BC8J/V.%A!,!9F(6ZB0+N"")E6L9PP,S6IJ
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MW'O9_#_PSZZO<*^ZOD/VT?6=9DSM7UO[W77)K/,;'4KN''1VTYG39G<N"]/
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M#F.3[ $/8IMJL(S,D[&^*7>Z5=9[ON(),1NK/P:FDV_T]IUB+JWW427+&IF
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MIM/V* (?Y0A112R@D\GS><=.6'E,G5BPYH8S&S-'%U3\ 3YV^L\Y:5:HZ&$
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MA='0S 5<>MF"S\ $*@[8"S;$=D+-?I14VT3T1R6B^5H):7Y9/I%9G;/ [GB
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M/+?UF^?<D91ASXSIY$#3W(F67AX<X''WF\&L7YJ] IY6D"=K9@BLG6FG<4W
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ME%='T?F&;1EBLTKY!2QO!Y>0,P -;^\%.Z;F$%]Q.4E+1>]$+:+W<T]Y(+C
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M4?6$F*$ET \Q/7Y0<%E<#YZ.UDK,!ENN (+VV+2LFJRN/#-C1M@\*ULQWC)
M#BZ7=M60&O\<O(NY1U0-0Y'"A[.^RD!P*?!F%)>L5 K'?0 .)!8EH]D\ZC:X
M6'JX7<,%L15\+OAVV08^%S[)*#YXY!!\FZ@<[!RYMC-CWWHVYIJ.;_7LZ_2
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MO9M))/NF "J*)C"S?2- EAZ/<Y10;!V@0@LF8&W1#XY[ :J)VK&C :<"<SG
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M.],0,\XV4'3N$!PW#R;E>>9>+SCKNU*CGAFXM/<D[;:@(;$Q&&/\GGP9''O
M;A7'LL7'@M)B!OT)&=\PP,;\_E@9A\%F'2O[^@I'YWU2O;H.I'HXC/^CT<7H
M(.;8M#KCB.G75]<S RM".WGC&Y+ 40:W6E=PG12P]5B#<0_YAM9*<.0;\EI
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M\0?(0L_@3_1]7KA6NY.!],&FEF,,HEP^1^R((*WW"$76_]=O^YR<Z()[2C]
M3E3%+V0IZA_E:.!)M#*VEF!MN6P4NTF+Q%7 =F_KE'[O?;7%P')@2<\6@EL4
MTS$L;!':WBS<$DTXEV%O#>';_D-H[^&!0B^N5Y*KL[=X_GU+KUB3Z4.:;>.Y
MN5/%>4G"H?%V5TVJH'$_^1!3^0<.\BKY6\GYCIMPF[MKYS=7+G/6=CJP(NW(
M$\3K0V<Z[>[U_:''FS*K]YG@?;G9\!46]?\=/?:LPPZOYA5VZ+AR@):I.UXF
M*XDO Y^2(67NS#-Q_]X1*Z7.DJ:C=]/R HB6K4;F)#=1@UE\V9(]*09T\+8[
MN?F/6E^%=S)ZW[U1[[^-3'=:HV@!QS,I'2Q_RCT'E@Z9_D0"K2[EBK"DXS>$
M6,JT?^SLZGP7[CFMAW[8E,30I3<"W7*X\8/C\(,8P57RKAY>65Z39^^!X\'?
MTV4JMX-;Q*M\6(/=,SR']%F$1Z@;R_X*/2DDCX<?**5-SOV7=CO)L+GEWI44
MB_K>O:0]Y23%$\/WR+> % .[V56/4-2'HH)UH/:T+AOWF=C^XFPX,,; H;H9
MVKM!6->]VJU["_D! AU:!R);'UCAP9HN^ =FIU<O@>C2WQ@D3GZD<T'&.X1@
MUV\OKY)_,)/=T]2>XQ;[QLM#3*K(F:VXG7_VX$W@C7KKL>-8X4%5%-QUCO[A
M1XI-XVVMQYBY"/J>GMM?F&,^?ZE9(PJO%D2_J=BDOU2=:3M)@\:V;GUT_):9
M,BTK0X?E-[0J66SPG<G*M.4=U<D%ZW2RG3PJ=Z6MKZKP\F_6'/U=V,8<6#AQ
M;G&O:]9\+.)SB'_.[9(S4Y-++.Q&-O7&U+6W[1]VC:8E*\\ (_NO+=2=,KEH
M$N7"X&(C2TA9@A!%X^U1+\@=_-JI7+(#VV58#!_]HS$#%UOW4M1;M4&^NA^M
M9FNQ[KF0-LSV4ZK=WSTIY.]$>OI6-E/E= +N%0Z++4S;!=3K!R+JWM+G-]XC
M/<?8Z))TKA/O*'QRHXK;VNL7_SI1!%.^7G*Q[U4<?L;^\[W!6^125]B[>^ZB
M=3=V3=?LANYQYYVQ=@KN23#P62V79)@$_R/\OGL*VS^]:U#T_IMH1!]Z8>9+
MR5>CY5[V#@FO,LW+FG%KCI;>NG?S,'I!<1A4"F]^D%&,CSS>I_MOHGBP^L("
MPTFZ-B.#QQ[(1@^R"4M>).MRJ^_$V>H]CHYZ73SNH.]3)UV<AVD*Y]GTW4EY
M.6+I6:,;5AQN$%HXIN[]"^?29_[!FUKG=YSVH4.5A)U[NH0A2?Z*W>%OX8.Q
M=2N>WIVCLG"^D]@/O/@QM1HX[%"]!CMPSR65<!S;\;2FWG7F5W88-\\MC<_Z
M',2I6081CX1@#)^*BS:S&9MVM"1_6[L46)FS'E3[.4KO4_ZC,#+$N,O#O2\S
M%Y?(RLH'5(1G)%AMDTU;F-14Y-<UNPNBV"4_:-C)RJ?OZD360@^8OR7WCS^_
MGX/&NPSXQH?N;+B?#RNW!_*VAQZ9#TT_YFVU<H".3]O&Y+3^^B$6.EB><57?
M=?V #TBO27Y2C4I^7BO;95N&"5]6P,2L[_C)"V&Z3B?)CWOISGGR3I?I1$84
MN-9G1.0L)H*0A?=)I^4:_8<.Q]1K;W 8)VJ?\QU=9.F+YWQ'--0@R0.NX6ED
M>H[JU:)OGICFBFQN&4[HE18)=I$J1= _?_6R5O+HE2K2G7M4D+*MOP[CTE:P
M*ASG%ZGI=+4/=2N1IGOQ?+IC4L6P#I=P* T?D+"'<C+,]1NH5C9SZ)XKEWE5
MQ;]4\IYUV/?UO,*^[WH<A[3!<AZDI&/8]9)?[_FM)+.-W4MAL2>[.$R=2+9"
M/%/C(Q^< FHYUE<Y"UL*T'1]W[I\!"\@L<P-MW23"RC<_%C )809Y5*IYB#U
MQCZ:P%ADR%$K.^VA7 ><_%N@:_L).?+A^-]!]L>A"$((TFW>[/UDR7SB8.EC
MFY/LV6&D\A"I%D;DUN=]D][,ZR;]L'*>KTMR"]!&Y/)!&(%^8@GX&.<&GZ5+
MVWG5PI>"_LQWP44<R+=/'WB==^:Y@>_N(,CJ,Q=[QKPL:M';4</+:=G<S-C9
MI2O@7$,7#'+9VY(^GM1*O>AS(^S6:S]"K*?$P6>)-F'=Q6@<P:NXT W_KI ;
M$^BFJZ$B$V",#UF$[H'Z7L;EG!G^\WDQ_(&@]+E@">X-NCN&_*#C03)$[HS7
M#$--8A.MR)^1D(,]Q$@X499\YQ!?PMZ2/I:_LZ8JM,[VD!?#+'L/#[OWZ" F
MG7IB+F^\TO)@+*<,]^[A(&+UP!T^N')]89@29*%@'1OO)_'5:)>_=I-PM(MD
MU2$\.D]W,YSGJR^AL%H!N)_U;?]B7K?]7>W ]"Z]M.@NU+P#:_>OZ SB;,E&
M<UR>Y<BZ6Y]8V!],RC*A;MR\X@XX0'_<JCI8O49>O:0-;R1@?-.ZD/$H.O2L
M[PI0%HUB:9P6\&;+04S]((X95)!/Z@VUZ:!SB"@*-K(^ECJ,3EU JS#.N*;Q
MU4=3T_C?&3O,;/9\_V%-AC\4I](YZULC-]2!O9(R\T[]JN4/N]BNM5Q:^@V'
MO J2T"2L+Q?.,M2<\&ZZ HG]VK(>&=HG*X?@U7V@G:LEZ2/G>V;D_6!* ,>5
MA?A1&T:A7/2X@&9-3^+2BLI[;J0);G3![^']'1;LN#_EN6"4:U,W71J07Y+Q
M-J6(J>(\=1!G/I/:?>:>1#I,_7 ^I]EUD1/W\._I4XLR)9>0<2T"TW%Y/ [0
M+#5Y@WV"O@?%2*:)^<XU^3^24&*P#TA0NO0LJTY2I8HV+2%8<83YB2E9XZVM
MRCJ<33-(HC?"B?>W.0CU]+GY,U:\KV9=.RN)2,%]RUV6?+U<[_M>W85C<'+Z
M]/ UAZ% )[88&*K5YM)A#4EEFT<!H"[:0=S<7?H!F-S?(XX;KK6+YTB0Q2%M
MBI6Y:?M JP1P@CF8KE5QX^"=O W>J,E#!VRWQLI4+(3RLF40G-N\\"Y_:"6?
MT[FH R_T7@(NH($6'I(>D/*"!I:XS7V O,ZS18_X=_41F<[53F=G?1EFAN@>
M7@9)P!ZP\X.YV$YOR3U(-%?=%$YD]CR4Z3M!=%TXGN T?4ZLR>QNK*MNDY](
M!+;+9>"_+>DUUH/W&)'13N9!K&@G3G]M?3.;I=X/"0X#EO=2%Y>NFF4CE49A
M*P%$Y1O@N4A4X\H>.(?F;J\(>Y8$"R\^^GAN\,\>T@#[(D)4^>+!O3TGK+N+
M\^5SPCH6;1^X00MOM>H'55S0B%<)CY^5XE,O1LB.8IC67FPW0$^<)AF,6WK'
MXL!YKV<M\6>6S#TN(C_S0 $4Q=2S,KEUG!E>"W0_X%C96Q+_XZ'J[U!,TZ<A
M2+UL.-,UN ZD+>LR-1*OZSRLH0%7[\C]VAPB)A:/6V9=/GGX*3ULMK)::MA[
M$U3NO3,^)9_B72EZTH;$!:?T!#32J<L]-=@; ?NM !Z"WQTHPXNA'<PZ/],U
MW6NI\2H&^($AKOFLI<?,$M@'44O.S*9<GV")77/Q5SIEHE<K*0H0\^HYN(F5
M66<<W'S]T00W?V",G>JJ8D:6_>HU?T'X]7^45)C--K?\<[NTI1,,'^>%FKW2
M>3T:L;N6_\,HG;&VJ%_Q5T2R3'81CGXP]X#LIS\=;L_J9=C4^*OHY&C&QUU&
MIT0'5$9/.40286C @;L&JTW9LEE)MJ9K)8"DB[0P1HHKJ_MD 724",>.+_0'
M\B]K!O5US2(]RAE)(UJ5NE,N10@=(<$0V.#Z,[R^+#EA7(^N*CIUT.VO0\_K
MOCX6*NBP(R<SGE'+(2&I=A 4]'C;_.@$.<8HBTX6*0B4YC9E>2OY%RB/J ^^
M+UI]"26+-'>8F  2FQC< A4\CX8[$KN^$Z/!H:=Q53B8BB3"    ':J02U>=
MH^9WQ3>>U:AQ%M^GG1 2I[NA3]NS]ZU+T.(:[,ZKN79/F,\0X4I;:;YY\4RH
M44+]'^15 MM^6)\:KE*F(B\G,'1F%'E!>T3C,=KXX5&)"4)) $VD'3$)\G0)
M@SD,^>MP)S]J-TD$2AHL:ZABA]U_ +?O=3D.6:X ,D9G6&@5C4=Q#>>X<'5Y
M/BB*\5- LB.FOYY$ZH8V0[[3'KRB]>7;OS ""$D6=$#[>T:0,XN\]U[O/(WX
M!9Q7KD>Q,2<(]=^X@CYT]B/I=6<0/75E37&;CR\N.H7<Z"<H?2[&E6=\8=(5
M<5UBDX=W)-94;NJ-;W9(J^+R4RAQ-J9.UT:OKF9A\RVZXK4GG$#TK<)=B2TR
M0- -K(-Z16[6CYO&@W>/-)8:8%$ZB_08MV#""DV##1<-BB0729\Y]78'%$N5
MEV6&O2&ZN#.V#/UR7$,>K.\LHSW!&(,5J13?H7\9P)!=Q>["S1?-W1!2WTT"
M[15# PE=/SIP=%H9"V<=+ F67<4<U,4K[2W=E"XDR55.NJ@G S9/)&0K2$C#
M$X]X;&U99*[[2M=K-WR7H;&^ONH9FW;35MHM8#VNOY4-QRVX]<%4W/84?@88
MU-M-GQT6M&*MAF4+!AS- FH#/8&NVRN2"EV39&Q$I&\D@V3*>:B[,#D+JO@W
M?!Z^:QNVG"<,#(/>U:Y)PQ.VEN$@505.&T*'.M'V?>N-D34H^;^(:YAQX/SL
M[4@QIM5X=/3I* 8WREM9>C*'[PM3K_%*HD\TH3/&)=B^)Y=G@E6CDX'$Q4%#
MWB<-AV7MN5$\+!,;(U$6;$6MPG@<M5J9#W#7)T'KE="^X*P;F<RLV^I>4^J#
M5EJILG8G,6"KU[J08OFJ7>8FQ>:9S!&@@5/X@]Y%%UP4MYUS[0/0X9SGLJF/
MH!HH^:[,<S6>](K.*1?__G&?4G0"73*F&FLCN'F/H;E1IA7W(;3)LLS,>-GR
M"8(0O[86*X.)$&Z(W[@N> K@4U%"/.MB E08/SB!!14.NC^=M1DYRQ;.^$0>
M-MXQ'I8^ 5P/#*+9%FXP [JDIAL* :[22MOQ1,'9-\R:27](;OQ,"F&1+#7)
M_4)&N1?P<(?,L.)Y\FS>26WV=V',AV_DCL<G=FWDT3H=208YJ OT76)7H%)%
MND.W67.Z'ML)< YURFY",_1^#B9#@R/94^WNH]-")F)C^YSL1TJAN0T7I>TC
MI?, %(F3B@T=;^!&\G.$^!PBQ.EK_HH9(49R2(A.7_S[1WY,T5G9A8@/PK30
M6*2$B)\P.G Z-'X"^.Y4:/PD81 T=O@Y-C\3LR?D!>:-6XQ.AFYN,I(9+EQ;
M)@[M?!3*%2M%T V:<GW#]<*S0)Q<:#6.W(M^@;EN^O*<AQN^'AUN&)G;'LRK
M@6/41\4-3J"_?&V8&]U>M39=JQI<L(:><Q1R*T2&\8#P"1(9;M1R:^O6SX^5
M<*"$Y/ Y86QQI]I@[\X\*@'^;,K_(D;]2:N\ 1<<_WCU]ZM%XA>$I(DC!C:5
M8TD#+Y(?BA1;I<^RE+P#8P.$R<WE6IE4V_&94_']1U(\:5-.+",ZA;H>$XN$
MW-FBH7]]IU=X$44Q=4;Q809ZLY1%U.VR-IE1U@BAB(%R[AZ%S4RA0S&NKW2=
M7/BNM_-T.H]IN1;; !]9WM^)T8FID'SD&]%B<YRJ[NI%P*+'M2G,P/UE?E8F
M&V17G<&Y]$4A2--7!M07!BS[UNJ.(UTJX1O%L"N7_9Q]!C*^XBQSD^[694X2
M)A 'G)9^EVQ,T;IYGTC2K RYDZD9%R_QP1QD-]R4=C?@7,6,J\#XUO?<11]*
MF?_[PP\_)/\O";W$&Q1_UG73M8Q#RKP?9H%R^8_69#-MI'^%I$MHI._"12,K
M@38/>0(QJ7(IF&PT4F$63997ML2V240G1>>!#.RM56+*5+7@N#&Z-* _E'F8
M\>"B/M]6)TDU.>$R0$A+J?TL9K6"6[T&*3KJ!D<GPM_*R?'>T;G$N53SUNWQ
MT6]@.<Y"*^<9-!-S'D_0YFA6 U;N827\"P42496U1-2^L40[SGV\W9JL6?NG
M#-_EH14O^[>H95WF;?/X6P9X"Q[4JRT*7/'5/BV&_UW;L)J*Q/F+I=7J]H74
MUWRC\JW:U?M;VICBQ9!^1VS=\JO]SK_]T])^^]!B_CB4!41;=^UR5PFD/Z2Z
M:J;+DX!^Z&S@VV!HZJ[V<1-PI;(A8;VUIFDT-BI:E(T9]T3.O7]%YQ1/.:;Q
ME=>X#W2:'MC@ DO@4/M_^];+<7#I/-H5UG<34\NC$T%R5L6+2NW@ ]3!DWHJ
M!M"WFT4";D"]71OR-=,)=.%'8-]$/[%D+C;&LW7Q'"#@C[\A[[:XO$K>C9/A
M_+L@2[2*X[H]9,1?$54G9)&3 [I+PHL6@IK@KC#6+%O)1PO !)VJGZAD/T&<
M7+S=6J+!,F/^B(CP"2QGU22SR&YMU,YU\1U+_$)+V:.3P&6;CX$GG CS V>(
M<0T0OR<9E  >LK+,57&KL7Z%8X> B@"CX<"]&RN=2F(O'Z_</T$H3(9_U<D4
M2=#AE^B44)NRI4\%>YQ'H1.>@-7.AA97/EK]:YN1$X,U*Y:[I)1Q)EP0K&MG
M=>&'WF!%*)9%G3(9!0%$/X(93*;S38#!LGL2)?P<F@)[!1P6 X=2S3A (K[$
MPN*6T/:-_E 9BQ]L/FY?Q9>7' ;KHTP!:-<%+_Q8@4)O55Y/0'I>KO@KIHHW
M4LB(5+/88C.O8-6-U4>X*-'/PR!/8C6'0;A9.0[,C7X$Z !LHV['Q7AL J![
MDW,$ONMR/YE4B'XC@[N\F$_\^6()G@ ZIC"BG\@:&FI%[CS/$Q^UZ-HW8<W=
M\<+YV.0X8AQ(?&N/B]7AF"YXL1&9_ =9H:5>JWPEZ51P)'S,IHK.H^A)VCP[
M: )_&=W'P+)FQ3=TN0NVK:J3=WVWC9]T<=Y#S3X'ALP>'VJFZKK=@.U\=+3$
MFOJ6<T&^FS)=4E7LDI7YT)!.XUY499G5C MDM&9I=XMDH[E)8Y$9GL/%!D E
MZ,D)Q$K\%J;<DY#;;F!Q*QM.-,K0ISHIM[Z'8QBLPS0ZQGP_<\L9728_Y5MC
M55'\FP)U9*6$$%IS# YVSF"\+M@4V[/1H6(0*P9:Z-[I-Q/]AJ*'^+"%Q&SH
M,,X!7?AABK3<:$:Y6LW%88LD5 MC+5/L3 FHB<+A7F<1(TD GGE,5AJYJ9O2
MZH2[P9JTS97-=TFM&VXQ!&Z#R E,<+72U&C$Z&PJ?=B??-84#B"<\VSR$QAS
M2/KO!7OK$IH603?:JET0IIN1+O4ADZG+\PY\SR(M05K4BZI,U\;2@R=\T.AG
M,GIIXQ_*\-)6=NS6QN\*P3,)P%.6X2VE[6C_\_@95#_"KH*J$EM/=3X_12IY
M<J[B*3Q2+ZW0J, 6B@B<CH]$3R9P4R_;5BR@SCH]^,6\TH,_%(E,Y#-%W8CQ
ML.70S& 8 +E]X!#JU/2IZ*=V% HM-A7\[ ZT<3>8FQ%F5XR[A*<)L,^A7@<:
MQ*O(KG-\"K4KD#3(CJF/CV_@^@88C!?4/)=,Y74ISM!-H1HM;NN#K8 UU^P6
MZ<0,#7Q/D>B!OCE@?H.T/7I2T"E0AU !PY(>G<B]4)<"V7'#P";*NI\&HS(*
M""TRL,TP:IVV=FJL=7R@ [DO).X3>*O!/[=&.&(A*_E[\++)O_4_<T/I17*Q
MO)Q::GQP#ET@:!0;:RMA!8=44XLTQ282L/T/N0TC75Q'C%GX>=!Z1+)VDH8=
M*B@8 QT2G!+AT5W].81&C:-#I]B>C2VBR53U^'DCA>!@YJ7VZ#$E_#AN=T87
M4R[PY%0'-"J7W-BRG9C/'%V1(V\%W(BP2CI)R4#6J8X&;Y;\%5>#/5UO<*6U
MU*+8J2*=Z#<"VG8_':T3/@G<&%NR7Z@;J4SRL^=VB=7<W<#5*'7&!#BSY989
M''/D@?VJ4Z@N/>N4[Y<XTCZ4\IV%*8TNH<2CPOY_]MZVR6T;VQK]*ZS)G51W
M2NYRN^W$+RE7.9-,/;Z5DR?E9.YWB(1:B"F2 4C).K_^8@,@176W <YDP 5+
M/7U.XK1;:FIC8[^NO3:6.(R!NSQ4=0&S7>X8C9V@*V"A,"7Z1=0YG=DK9^CG
M)3<TJ/N,W3*"A!C?9&E2T1-,MU B&",,*'@3W%>H5RN1<PE&>Q1":VA;8_GS
ML#,0?-.4]9X388$.'JN6B NX3GA8:4:7*G-&&[Y9A@[KM(M5W?)L/[HH!).&
M"A/J6+3!*(6!MJ!3<8L74*$:=G0$P\&75AG+\PG<]/%[L/"A8-GSL=1YSI2H
M78Y^MK<7O=.)PN( HB3^<  TTD2WWM"D':V95,*W(!UFY7%*967=!G8 .]CH
M>C3+<YAEBO'W4Y#.T8_#;/+#CB%C\QLP)8.IX07WQ\Y G8(N3?!/;6BG<7QJ
MPP U0704+'KT/:%$0JA^-FDH8R;M.&=HMA#-I>2.,Z&E=+@XK!D]#/M-6.XX
MPTV"EEFQEDR8\L#9 ^W &=#OW > G0$]@=5"6GBP9GY*ME,/KE:UU/80S*/>
M8CNT62O D]<Z\X7/(R84V.@_^5G89F!/^1,:2ID-'#KE #/<$]V4T$\2#NWB
MATL!7K[8HC"\?%?9;W1-#:)"JLRNFJ7Z@*@ZGBDLRJZL ]7LZ.$WK3GC0F:2
MTXYH.-NI38X"Y<3H"2MQ(,F-:*^R=WX(S@R\6/HYL' P."\7N T9]/+1[Z@S
M7N=;X$Y@N@=+P05&(SK>D*IN!7A3/!@5CRXGU_ :C.GQG"_"C0)')BKJ=F%'
M_ HH2:/*)30J:5((2L@8Y$+FW<;RTV%[X(1:%Q5;M>""_H&67E1>7O(98,G@
M_/,W2VI[=1CJHB9'OX7*\*+5R]Z<P.$D=DDYU*J@;_2D]9ES%++"ZUQCJT.@
MS1'[,&S^W4ZI8YV^'3%UK#/&R\/3OULJB[GL)X$,)(TMO[;0;(:OW!^5)1B@
M1]01 +^MT5C=3==V 2[Q.;!Q03[ &6I8T/*%K&^9KV$8OV.K0RVP$7>9(]BM
MI["J*>S.YD &HJ=M$D &#H$F>*8%C26  FJ:1N==\&VL=W%V5]E[M,<"8RN@
M<SXV%^^[U4C%2'M)<_RB@*G/F.L)7P\$;T3VL2RX$QF\$UB=C"\ ;/ RNA)U
M5>X)B,BR1O*-Z#89X;9M%IBOF;SEP\VIN];BY:P2@<._-:],FMK !RH5YQ\I
M33:R"6/<S^!V5=A%=&(%7@I_F,1// *;(6.VZRV(3J0JIEW84[>^5(5<$;X3
M?U'7T+PI %2,>PZ6PJ_@>2T-/NZUZ5+03_WM[==?O;I^\\TWW^A_W[Q!B@BJ
MIP7;&VBIY+8EW=:9FR"B32F-K/-.@L,HM'T[Y-PFM;!LH($]:C,T'QDMX%R6
MX+!(7RNU8L2G!:Y-X=L]>,"9];HZ[Z/5+.Q6<M,&:YA;:SU:0]7G 1>B<D"'
M@0\@AU=]_<7ODR]S$F%(+0UR*NE)UE._4TS;V,SAQWZE^Z+T>R\Y\T\]/%JZ
M&;PQC>7KT[GT M>BB\)?>I\E VW<DL$"O%\W4'V.?E5SBLI*6H@YBEZM(S1;
MS,B4@N<>'<H0&Z[ADU&H0X,FHW1-H!K(5RNM@]ATLY-#%=6,AC/LI=0/ KT-
M6=.W$/%FX;&%./1+$F --*D<& :T6]=^:K#H]W/%ME!Z.#!A?1)M9'![ WG\
M'4$BH1H 3?42AX*>^.Q><+8DM@&0?-51S</5$,DEWB\AIH] BRVF*2'<:9M)
M./J-L"UH!A!HQ1Q,LJ5#]ZXZ!-"+;-EA:<^4M\X0GR^H#-!+G;8] "]. 1.,
M\:H%=V7'-_%L;2(5?:'%O@286!/ 3<(KSB-#?&\SJ/M!LP"TJ94);5]+7C(B
M6'NS$T6[=N\R?I5;)/KT\!*V5'79M9]_R6B[:*[M Y>H5:*OCF4Q_N=:]D_3
ML%O^9"DY^_C$H()>LW+']NKX(VU$]60LOPD?W2P)=)_\[?=+^?:AA_GKBUM!
MLE7=4KN>">8_>O0AX'-*JUIF+%LQ41)\3">0UB79PO\!4-55K2CU#PYH)O B
M G0<;3%X%CN:AQG]9NCU2PZ%>6,[[ $^MU.'6HQ 9:;*0\^CG2.-!5-5.('X
MY@M@FH]^10Q\#ZJFX"61X,(;QW;4>PZOL[94*R&5_J4465-884![:<!]%@G,
M!ILM6VS+*YZ]FS;&'MUN0WMJ._!:VV&LT?,0U]_25^0D092"\.+8_@U:$ /2
M0J=N*A1R/WM)7\AZ271Y^ O7T050<+[Q]SVC2X" 4"[.+4*=C+-7B!D"+!HP
M9?[YHNA"<#L*1RG1,##C=B%<?;;*^!^6L>RW1%7HL.;UDYMOFQ95-+RY>@F<
MX3R2U?4+$L.0]]&>*4>/-(UN+_I]38 ;H!0;6L",A8XXRBHS<.MYDN6*OB(^
M22(\:N&-0]$U4S*AP(BBE:PWV& 37>$E/Z+?;T%3?EM1\,*;BD37":*  3/6
MHN%;HLJI_8#&;\&K!!3U\D\Y]YL(=#HX0['$K;1EF[JKM!L=LR^6+NZ@H,_%
M@O\@.@!I*BH_=**D2$6=="CX*JU0D#9_Y;7RQSLSK!K-.XG&ZVH%'0+CII.J
MHRVP)G'QUT*C>YEWLA6YO^2(-[#1I:#36'V9VZ[E1,3F)ORAC:M5]G\;3LPX
MU6WVTZ>&5]H+_N>VB\Q2TK;K^54JINO9=2^JA[F)?K3+6G':ZGLXZ,H)K]2X
M:F5G=[F<K@=^?G6=BAI;#_S>-C/XEGBRP<T$[,2<86-@958<%!'J<?R'$5T<
MQ,%P1)[BF(ETR+P!2^8=I7Q8X9!TB"X1*08Z#6BR5]]RRJ+@_=B,JOG/GOIX
M (&.[9TA;O!G%\" P%PFI!J;P[M^X]5E,%@PN@Q6PL_3. <,SG7'].M+;,)I
MBCCX;!PI K.WI- R& I:V/I("JNP @PG,YP)E5=#V[9P?F8J)6YT09$-H3F9
M[.)14%Y!_?W2)Z!K^HIY3&><W)CM>5U9.MA! %$971I;5G;@E>]F6&0%!H/K
MA*KOK,(;J]C\\I--O@M;2C2GT]8!2I73[_8.FR\3R*E2*$,0@ J-2^$-HP8K
MUG)(;OHS5+8#*P5XI;/DJJTI>2*V>U%EWI)J?#B=?ED-GN]:9>V.EUN>75P_
M\]88HDMCHW]BK3(#HT(#)0K6\D"Y?P8OBY7!FC4-KP()W1R1,-ROYDQUK&SW
MB^QB?YE-F<O$(^?G\"F<5I*/MG;*FDH Z"!LM2+&L@H;H?J)[.>I$:(S)C#4
M384:MO$O*=IPV>A3>2M-LQ0&FS8SK!G5/M/)*W6/T20>%@%YR*='^+)A^,6.
M.RRRW5KH@QP]N'WQ(A.K3 OXZ,5@P#'<+8R 8$BE8UCTV3WHV:5='WCQO]@8
M&VZ1^E JVS%E2-D%C;5;UM5RG^6L4_8RVL5-A*H(C/O$MU^;IJSWG/L'J^=P
MJ%A8R92X%V_@9@BM-AL>:/;%AX+YL37QP6 VU,\*48I;2PIF]@<&HK[HA[.K
MY4=T/05?;DRFV(C&"**OB2TW6JXSMVP-6I&?T!:(;KJ";8&3UXK1X.RYNU(=
M^57^UF[TTQ"5;75#\6VUU $%6B_M"JV3GBYXEMQT0<(UNOB953]5$=AO,$.[
MQ^((:LHW'P<<!N48#S>@E24\6!%=)/C0I0ZRDLZ ,0''](IN:"[%$HR!]M-2
M D<6\,M8?4^'G?'[V]M%&@U<PB;Q$KVR5'N\OF0P2MM-).J@,G"[/_@@\/S'
M.0=JSO<:_[<(K+6-W[D;:%X7Q%1BFW-Y()N> :T#1I_:@D)"2?V$Q#JZKDQ*
MK./G.3:QADKB_2H-OV=\'M: 4-MQ<'S&O_7D1GV>\ZNL_]"/B:4OTV9V;.K
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MH#G2@@3*K,B#L/LJL2&@J++I_/NGWK(86LNV>T./\]_H8D27&W4QX"7XNGN
MQ\<B3'J4QX"TH#9&^ +&CR"";>O8)V?;UN#6L6O?,OVK.YTD2U.+GA)=1;<'
M-;QR1#==F4!NM"K1;R;C9P!)8$D7VC82HSQ8%(%9D5,/YDP^6J(7]3W:<3#6
MXL\NL$AV!E.=9N/RZZ]>7;_YYIMO]+]OWB EA$5U<IG3+;WXP@\IMIS^?MG'
M\P9E8Y N 8K.1[%IW7[4KW]'O]X5-I+4-OM#B.0QMED"S_(YUHJBD^B.'%WZ
MDD%I"2:K,%10!=N#]^V>=Y7*8E:AZ*> 1XQ?[_H"2D>QU>" <AK-B6<K-ZT3
M.*+X*@*63L$V[-8_)#1#@Y*J:0&$:?3,-!%^-AK(!G=;5%=BBT7:<061#+'%
M0!.&M7_Z]_FW]!7Q&;#L,@< &!G*L@Z$?/'U$NS*P-2?IBGT9Z>E(%BYR%3#
M<_T'-Y-3"&G2 VO-3QHQX5N)"4!,O#/K8H/#/>?BOK3IML6@?Z\SC.V-X/.4
M,X_1 YR@T27@8AYPC8=5^K*TO"*(R2+3_H[OF*$5(!2<:EG+>X:>P\3"YTV]
M>VMCT9M:F4+::\F),GK+W^Q$T:[=[QV_RGF&IX>7L*6JRZ[]_$M&[H)JFUR"
M?,/-S;$LQO]<R_YI&NT@GRPE9Q^?&!OUFI4[ME?''TF;IB=C^4WXZ))^VGWR
MM]\OY=N''N:T/+%W_TGD"N!G]I\,F+VLD?56J DPA!GJ8& 80C^3R,!C/6CS
MZKH)V& #NRL*79$L:CC_MUVN<1^"9PPXV0K)M6V5H3U:,Q2/P8N4#%+?2 5N
M0NFPD(68LH;BAK E:IK"P _I4KU>C8:7C7\OSKMH_&X@$]7F;#>:/SL]ZLB7
M7PQUY'O]QTTE5OI@P-&&[RDI$/CI4]Z5C?DKI'TYX6KE2R_'):!:F0 +A1GT
M4UD@$(X/Y[&W=(]%""BVY=@N3\%7G,AB OCP.2*\<B*!>_Q8PRX6(!MIJ(;R
MNJL4]Y9(9RA1,E57VM=C0PYFVQUWX!271E9F8PY5TR<M&XNM4<X/MV1LUDQN
M2J[ +!*RWN#Q)K<T2@GV  YW0UV'?Y1,T."0%(JJ=D9&HOJCL_EWP9DEJ@PE
MP]%I2+A4_EANC@3(MG?/NWX%UH,)VX?B:T*>=]+@@,D["=-794N:*T5/6;D-
M'U@5<:;$0B+*4!UOCDBS?Q*HTG2FN'F'QN@^L1'?-&6]UT[3?6>1:9-3M8?_
M)'H.R?*VEOWW\!+>&C??/PY2S)WB9@VOOJ*-H9])8.P]A5M))BJCMFN^MHY]
MQ4(HPQ,OWB5 K)' ?BKM35>UW!C\%.U1J/;H7H, D\W5RU+<,CM #P7 ]F5_
M;'TB/#Q_ZM?$\)NSP":/TQY<MK;"@*-:+0OM9,^Z[W.O6*8]ZKWO!0(Y>LT#
MH1Q2JA6_U::/HWGRB8A'E.6JPQ;\-D(1E4J7MUY>R=F4+7.%^S.N/CPV#8Z;
M!DAC<<&0@!!L0'(G9?_"6B4S3 JEUBJ!JBK69EI=O=,@^OW ^WI'E]EJ)4K!
M6EH]/T0PX"EN$S:!-[U;8K4^6L,FADDUT_J&%GS3"93]QF:)#S73L(FS:>2A
MNV:FB7C&N;/92FH;F(<FHFNJ#@VMQZ;2O]540@J$#@4\GA^Q G$KZX!O.;\Z
MQ*$6,(5-]'P*HH[X]K$P^'!B.*6[BX^L4VC;/FR*1H;@P<MXTLAEWV:*R+]_
MRF8*%[S8&<]0SS#RXWIP]K_I<($>,  %CWZ@YUR"(!=A;[?<+P[@5#P;,HU"
M@I<#':C1\'Z+IK<7HZ(0UC<IU6T"/=<Y AV=>'S4YFWQ"/YT(%PP@7<:"%#L
M:++*!=%0K42.9JKC3.;KB;LJX]O24.(Z0V*./0_:T(T5P4=T;IQ$!MC7\+"T
M)ZDLJ4)S7@0=-]A?1)= :3:G8=D3;6TH<#NCKQ04DO8!E3HIE"(/1#*Q1;)A
MY:JK3'JZR&Z9(J8^?5*.J&_'B,#/Z2[8L:"I4-I]@VV!7$Q;QAU;#DM9?^25
M4PVH0='?48MLI,%HT=#-QL;DC135QQ+,TJ+VJN4;?32R]MN,9R_I*Z:*</;1
MZW*N7](7+DG[EKYB'D5;-TV(VSV^$%:9N:R7BZRK0JB1Z$K!)NQ(CRX2DR8*
ME17=T0S]T*-9,5%V?FL275#ZN71VW=0Z=/87?:)+J]^)6M6M\#=DHPO%'SQ&
MEX1+[?2-JKB_S1E=$F9[!E08DC=,$,$T.U#YT:6R6JM$ '4YQP7R^>$;^HH:
MVW_$?G[2$+JV2!VYN'YZB348G2+?A_7 M(;*.T$270P3NCFQ@Z%5)PV=)=23
M,;$UY:A]EA-0$WX_D<)PT%!M)N\@5(8[HQ_01$K@/$)GWH'-XS/X.B)MUPEN
MF @GNCC@T7-?D?*J;W0Q%%RULLLGK*^(+I"A*SJE,QD_PP([.ZYR*9:<=N)D
M(>+UZ,)PX)^3AHGYUO$ 8&)3J.?B&TF#+$(3G?N11?$+<!99U"]:A(ZKNB6'
M/8H?&HD&AG)FJ8%AQR+;159OA.H[382RI?F.GO[%!.JMS1F,%>?9#YTH3?>C
MMCNEW$B(%[T<79#@?7#]Q7+R6@NPT6N8CCU.VM6EMN\&GU:S_&-5[TI>!-H,
M,T!\_?S%\5T^SSLIP+# @F]%[C^)&=Q+D>F7F@<![R\U_L0_X1+[@NS6PE^(
MCB^%2KO2P)Z,Z&(  X<+3H %G1AN.($&]J'0/+H\_-"\Z'?T5FS]I?D9M%*9
MG:DJ:R3?!C;[QF_6K+5710/T;!Q'2BH"&/?X-CQO_2V#Z/)(*(U'BB%@I^(W
ML/R^*W87TY40T%F6Z54(/K0DP!'6A#'GZ*4E;)%YBI&<HXZAW"Y>;:<H^Q6!
MB'>6V#N!X8-^=(XJ-69\S61G(8*>Z'BX=#*TT&K)^**06Z1=%U#C@74HE'X@
M/_X(,QWB[8\>] [+''6<D0N9=QM*!<#8-K]OBU]2PX[).,^*!0R]7TV8 )_!
M5BLAP;%>(^O6,4CT1'<A!,9L.I)1!(0MKVD#@JUCA-5TGBQUD07V]\TCB"F4
MM/$%4H-SQKSV+UA#YP'1KR7_U/!*@3FJZV7+P'56UA F2Q*=+;K:VDFS8B6O
MMURR6W[2?=H7B?5IU_S 5 6>QO+\\N=+^HI92@-WB(7*WLE6Y'[O$#_Y-E5E
M?2&W8HO%%:,9&K2;$#*X)'V..4W.9"G\XP'Q8UDN*:S&B\-[3V<(Z?V@W>C%
MJ9\Y4W_!/Y+K2]H_OKI*Q3T^N^Y%]3!WXCNEM 0WU!V&3JMX^1V[9<E;FLY
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MI^+U-)G>!3I]10?%?>*TF+;. EYGBBZ0);:D015H_R![= D0/D8G28("X56
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MJ_R[8N> 66G#W#!19,L]',Y1YWG7L*H]L#I@/;A^ W:K3RH)=8'FKD-7'IW
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M6F<1\%[1Y73QO_X1NM@R^A(<970AD*-\V%DAY1+$$L06"SEIYR@#G$&Q11&
M/\TA"*1?T6]0@94Q-$\X0S!)(RDY([YHHYC:RY&#"3#!Q#Z:4,<RNFJZ$3L=
M(?$@.#VV,);^K>*S!=)(&4RIOD>71( ()KZQ"(Q?1]<$P],0;N+'CVWL-KD
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M_W 84 .8Y[QI697S?LCTK@FXL(/D)A=]'!,'8\-J2[%OB;,<,PB-/QHKZ&T
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M]4GJX$#%V-+Z]_?!Y$WVTV!-!2#,\41+6M:D%DD\?LJHT)J>#NT"<<F/F+L
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M:!\[!WC0\%9=D8,(K4_(D Y)F HN>K0PE4.P3\ 2/TQ@<@TC5)90M#G21GP
MW <-5<\E8Z-IWAKN[H,N3)DE<U5N-7#=R-KX=]CD3%T99?T +7E>[K5\N5)9
ML_0?-WR73_(\WKQ%S$V5M\W=;QED?KAF5&I0FN?YY;8LAG\N=7<UM;B2YW,M
MQ:=S:_Z_$_F*_)#M6Z(H_7PHOSUN7?.K_9V_^NM<O[KM8OY\4@TD6SOV8J^A
M.(?8^T@MX "EH)F*K@O?X$OH=1,LHC\!<S#21A#](*@&ZR=7*RR(F59M:21V
M#RPD.(&/UH;<^EE:V$B%BQ7C"V)-UX#M "7OL)1I*'B+'CX%!T='UPA8A; :
M&5!VD%*N6E>IS%J-#1 R:5*MYN%>W^@V>J1;-3ZV%D:2(M]_"(/]P!0QT.,2
MNKJ1>KGH"X<M6OTX;.8[<1^7>]9Z@N3:S5 -5JC%ETE;U[F;R(O<HN%L8?1U
M*:I,+=:6>0HJ!>S@(F]OKY6QA7FV$3?D $7WOK"QP#LI3"AW\?P;?D2\@"^_
M>/YMGU$\QBKR%T!OXI8J\I_ 6JAN=5V-C78Z@ Y*19ZVC&N/L,L=HJ[IH:#&
M%=38;K1DPW)=:VG:HL:74..=*IYDO[:Z$KY;IU!QQ/G^Q=B<JV/'T=)<"JS>
M(#V*/AC,H"9'^SWB'PS.\*0CK5G1A7&F.-5L4[Q3]FJCR^$=<BO0AH2BZX^0
MZXYM+MF:-A<&\N);AVNA<C'/Y5B9\$&D@CP0DW#Y:VZC:-!,EG-L GP,W8ZO
MF-E:)Y[/TU)/:/+[19Y0H(\4S"?H1'%H]@^ML46SJ1%BGN:E -<*@?E'A*E*
M:S:@BH(^C%%[Q_Y[PNO1^)D-T(X#<,LLM+)\I'D]^O;;8X))?*O9Z<?RQ!O.
M:AT:G1D_J(7>NTRQ%@%<O][@"5G!$:6MMK#YV[0JZC8?'107W3@&T_K1Y:%M
MR@"-PC;B$SJ'I$KP2HB4"VL;.!BL92ZOQQCK8PMC(=*FTN:HJ=$N'P.KT+:$
M]>(AJ3V5PAJP>;38$C92\T-.'O+Y+I_O&U+]7Q8'WT+H3SNE/\?ZTW,Z+1F/
M%4 "+/>#*1FY3#PP+2$AR7+,W8^/ TE=G#1W'#3^M_HJK#/BI[9_;\&CABG0
M81-2T N7^3IA)=:ED#0CU6=HEC2L'XIN/J#] >YB6E15@V7_=\#$6 HG_DY$
M3R>DLZD,EO#2CDX"PT-89&:^3E8JSQFA,E5-(5JC\/,\'92+;X+N) -5F5NK
MDOM,#[9*0Y5)-Y@6BOAK>K-(7?GW&;J*:7R *; W](>JJ(6V-N?C0&IP>5V^
M?(0EAQ2VQ4NXP0G<\ $NQ8.F":#=AZ$*JR,O<@+WM M=F/-<EE?-,MG2J>C"
MU+(*S12,?A[.33L'MRY /0]HE?KI:@/:]>>R3-MB+K7,9DD)ABSD[ZUJUO8Z
MSN7G6EB@T?U(@:Q<A1&?^-NT%F$6R0.01O7.55B3'X#H]5_@\1VV(-3N#_>T
M+;]@5%"!N=W <3:Z,FXZ5.SD;-.!*4C#C3)N1)=*ABY>9BX4J-==A>'80PR?
M0M:H/>07QW=(V2RQ<%.M564Y@M#3X[;T5N8GK?!%[95_/0!LJ@ML?0LM4YBR
M\0!51A*<8!I)<!T@?(#>_@!I1$IAB'*.<7C&K[RS'2(+I4USGN;"&/: YO0R
MGD.^4*G\\HMGW[S,Q9RM4*77R4*DBCQFI@M(Z=.%*D>P]L/X]7CJ1[0;_6N5
M?KI6>7["\,3/0J\Y#95P GD*X<1F<F4B,JZ%9O-LT)R"7<D[<JE&\-OH,LC4
M8D'FF#PF,Z*"X]>FH8>P]#LS^<G5_V.)8,+3&@_ );RPY@];7YM7JT=C_4'Q
M_<5PF7%\GWVL??50#3%)W]N^3O9IU#GVTAQL==:">Q2*T3Z!@S3Q83'"X81=
M["2QMUA\@3M+L^TYS-CY#+:/9B*]+*<;$ P=<"PZ5QJ523TZ"OL O4-5FV.]
MBG C0/0]<:6N)78-PL;[(+H2J1(&OM1#P[7U+['Q%A1^U,DF$I]PH=M!V(E-
M._]-IN# 8@-.)V"(9C^X/OH6'<+U26O R #C9E-IV7?%18J4>;A2^@#H>T<=
MC(9\J[9)<E6HQE<:;9/"+Z8 KZ'AQDDW(PRPT&E6?GB$%KF#NNX(1^E_)H)]
M<M&W4]=."VX7Q-HHWT:,7 =N80;7XDB=3*)]U;<2<SLOG9$7P;$7\?7]'-S'
M.J>-817J9G15X'I>2'Y$O!YPS+G(>10BM'?D:G3\R 'D (Z[R8N60H/-1I6F
M;2W*=)UDK48W\XZXA=%1(3L,!5L'+W4Q 7V=/AHK)3JA7@UXGSUR&19Y!<8&
M?:,,&&< %^WR+#='^C:7K*6MILJ<ICC+1D_K(9)+F;*'!<TG.YZ3CWYFKD7>
M8I=C AM6?F9:#C0%QBCI=72? LL:4$/#\>H:VB--$1_4FP5W$X9;30XP=F.=
MG"UT%>0\/$"5V)4LI78CDL@PH!L%:JE-S>$W>!R XV]RR0)L%'XE=.:[U\"T
MO]9NSY+6B+FR#=E@SW?1EBX)2M+Y.&K)#H%7T(6,5&[$]RV<(-"<,"2%Z;5R
MG?#H2G29.KKSRKK;8P4L:+0B_BXH;%,14Y;1 1WW_N/[8 5G'%SN@?3G@ I%
M<$)>E-S<"(?[D!*2P=30D0]GPY[6O70&>CQ??)U5P!L1P7T"K"M=FU,JS!(;
M'HEU.&J/KQ#0/K9;"685HWB$[49:<8>H8Q6;1(4;OJMYM\0-BK%5U^B\:>]+
M@!$GES]MQ"=)/H_>N#@F.:.-O;+<(\+E+A)A3%O4-KQ5AKO4<Y6R8X3=X^@\
MRFCJX!#8O9;5 LT[S 0*?E+C!&+L\4CB -HW:QVUT@0"A@4^X[B7\WKLGMM"
M7%?N=/3,HYR M7PYU7#N455[JI\)8S0GHMR]@IW *;X"5V6&D>0#,./*5('G
M,9%QL^-O-3]'Q]-5,%NDJ'/ZS>A.B;Y29\M'[+W9P(0/D??S!FU:)]PU]WLK
M#;Q,[$J/382)[R,Y DKO*O'AKG75R-']$=](CN2@#[!!4^XWEF,L3P=HT4"K
M.UW54J.IKL5G<-_BP$6#.J^U98, UVB1YTI.Z@AT<1#?%%PP8RJL"%A[BP(I
M@0IY^VV0I.;Y-_R(^/4S+'>2BTVLXVD:!N>J5,$936VHQ'@OW@5&9[;/%+XE
M@[R83/&WDC#05L,SBT\ %"2?;I\0X!!YU#V<BH,4PFS*,*#].[)II+8#[-S.
MG;G\II%IJ[F\+Y-U912'W0/9^42HV^JR7 I/:,_\B[^WBI[G*KBY3 J1T9U>
M"Y5; &Z^'H8_@TUQT<G@_V;J^M5?Z8].$(705ZH\GU=-4Q7NKFJ1\=$ZS^6B
M^>[IU_2,[<,7N;HJOV-: +58NZ=4F=%5?7?.+_H+1L#/GE[@UG=;5$\N.U'=
M3EG@RB>9->#RFY<F^5FHTJY4:F<4?-^JG#_+F9F/K2YM_NI-[J)7Y":^2+K2
M3V,GF"_%M840'6+$8Z82.Z3$#@IAS*CKX^37?.2)\U93*I.\XQ!TQIM7\GW9
MDMON3G?$4\UIOPG'-E.WVK3\_5#&L-#:?O 8 VW'RS,1JH&,OEHD:5VU5\OD
M+'W$M/IIWAIU[:3^SL^F=:-8QQE(@!+M3@!2E)OYIW/6U#F)4:]Y,Z](=]/9
MI9W?*-KN \FRF*\<2FFIS].JYA$!7 U()^>#U-?\AA_HJ[5(6>VOA&;<C%_4
M)1R=^L^JM&6E[_H_M<RM*^P1KF);>?!3G0+A'TI6_G*QX#-FHTI'RT^FQCA
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MP^%>A<#N*)N\A8:0R#5HTZ7W@$XWBN9YD#Y-8%@>PWSD'B3#T=<H5Y;1%[E
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MOD]^X['D1U28(-A[%GNMPI%:[)MW-2-8)"KH)<06/W1RP7C_6^S;'Z.YCRZ
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M0_^BS?9*E2KK:QX:::4*>5 N-SM;;&MD;71<+D\FD])DMZ3T=;G?+6-7>^5
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M1 'WX.9$VA%UXT* T,_]0<!D"$>U4A5Q*U+NJ,:Q%@''%5UY?"%%Y-DC? #
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M*@5Q#:*TU-=P5.B'KU"HGJ.(G14E?6(.$CSH4ZU):6NX1;FPSPK$&#UA421
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M]Y\INPU'F]V&P#9"TZEH7-S8@ETLR[1P-; Q0QV: BSYTZOUFV+Q$U<7JJF
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M8GJ8]+3.T?/)T49SD;Z)ZXX\'+Q2B=&IHD1A4=Y452!J9E0I3^7<JT#,@2@
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MOP;/P;3H6'DO6E^>GA28%N"L]KUTODDK]E"F\I_S2$3Y?[9,E'><Q.,XUM7
MI+F=ZCW\(O&GDZ>;E>QEKQ%_3X&?ZY1^: ]_7O T6K"W\;QB7@]D3;'2NJ(P
M!#7@LGQH%5FY '>39\!15'J. CQE8QQG!X/[7G$+X;5VZ:YQ*PMA8SD?X:$L
MN]J_]9)8_4(,Q?BL*?'EVK=/<2SO%'Z]/T,Y-=<J QF*8I)SZB"J2GC[>,6T
M!6<$A\"BH9Y6'W'5B5J@.])3(>I/SV4G@CL=Z4O;ZYAK/'$I2L4*[ZZ3%$=2
MPR/*53==8%])=MHMC[.2E;:5H;$VKTI)WEK%-=/>WF-/3ZXFG(*8H1^2:$P"
MV.1NG69@NMN;@/K /<<DZ0U0#BOS(AHX3 /9Z2T4+]FQA5LXE2^91&'OR_4U
M*/ 8>;@W5VADJL$+G4=%Q29IC251BA:33GG@/7"=NIDUV3HZ*NQ5!57F(JO^
MSL$^@YL1FRY6$\=T8Z#]2U>&^3DQ"]?#QS+T6:J#03U/F9B^RD-_T54T4GC6
M[>?8#TU*;KH_'8TQMIF-%,K;.+X UFI8'2NL)./_>B=FB>D>,04X%FT?/ 5A
MA]))W:C2147MK1^)SBZW3&?_4NG-ZN=?)9><I8NTMJW>1@<>39[WZYL@+(_L
M'!RE6\H+QV"\3I$01<F%J=?IM2K39H%WJ3R!3NQ)$H('@N=)$TM31%NPH !I
M9W=-.07VL/-?5H-68=34*^OC]@L5?\R+FTPGF+4F47=5HI(,HRWX!:G3V0RD
M 0E\>69:FH(*U&=.R=+11T&G*M@N;X#Z9Y$J%)>#KJ.X456]438WGB2PY: )
ME3=IA6P]!%IQ^L4>DTV<S%W%PE95++S8_HJ%X1HVU989-B=%CCX8M1NDFX;/
M&2:)C)'UY,7>[Z,!QI!-[0#U>I,H1]<Z(M<:1+:U<)9-&<_A!V7E^5<FV "F
M3MU30+H]8: G+P:X-:;7] :+9R2K>WL6=TI1B+3.=%C=B,U'65$UKJ%-XDDN
M7#,VK4M719%@ 1 H]M^:Y(ISNU.=I>#T5A@XL(D_L*)#M8\K1M.:2DF+^*,-
MRV,*@*M6J#G*Q;@IYH(]/+"LMIT-B\V 'OJQ1)KK+1/N/ZG?59D4365[MC8<
M9;Z<4WX$"_DQDJBEEVF8U+/.]>'DV0!EB\,A4 ON F3< <KU$.0'(PY4A#=@
M'*JSF2DII" :5FISFA_K%'*M@VY"/-S.D78UDY^6J:NTUJJD<LP6"AVHC<K%
MO"E?IFM3B;B@EHV>V-[,Q2M[F->+SZ782D-!/%@PW<CUXJ$<Q)YD>#OLJZ(R
M">S-DK3:VKH3%T^E>U4IX[)0)0XY69A:PW!M*XS"Y1.<_N2FP'91(=5-8HLR
M=I-@N8<E;Q''S9*$-[S97__R]/D/6"4_'9D?=[ &[G,KZG]MJY5$ZP7R183]
M)IC#-3^5]FE34,CA7]_3LP?A^>0H[%EHM8N3!N)XY;66A40+8/!YMG*/+5VM
MOW]GW#&[6--LR+0#)<2VC1?WE4/1?W?.,E1H#!6QR4S@K[G?"?X__:/3GA[M
MI<2!([Z#-%E0(!_>K,N1^+[7:9'U<+VIL_R"FL]#(/VS9="S+=-\IR"45I)8
MQ;TWQV>SZN_"G3(LA//Z@<)J K2CPI0^,O*-.=*:7D[9EPODPS:4XPX"L?.X
MPJI&2KP=8^"8S>2P$/KS>A6IP,\6]/=O$PI=K&8$:AQ32_ #BAXMS!AX=$LQ
MO5T'.#IK0?&F%&3B%[.FS%.L^W0%H+223N>HUW$ZZV+%@C?1U"0:^U>2R#I:
M53;3IH+=J/SL0:"D:'75/,@B:[P.#T8%W%3-J$MJU2Z6,6WQ ED"7A+]&:-"
M4)@=L Z/<WQ=W#14=L,\.<>(K0U<=C3$(C8TB& 7M/0)VN9V3@-;G>[9&/A)
M&%NV[:]A;-DOLJ6]4BO#E:_PZW/AV1:G7<PE>=J!O*N^I"NZ087\W98IY,NS
MZ!AU&!Y,MB%//,P*[UR>>;)KA[[ZAU]#;3&?;-98.^NOC%DOLL#RO^#8QC$Z
MY&Q/M"P(CN?Y]5*FPA>;J(U'YC<O*T.-EFFR-W@0#Q+00]E/BSZWS)J*RXO!
MU6.#Q@&E!,$/L&FJ1IG^<=C=89+9&-7?3=1FD>-4[O<)FN#"&O8=//<>NU<9
M&@^WO10TPM$U,1,AC#%.#:HA.E@7VH5PSARTF>E-Q7HA22G!SBZP)8%,L59K
M6,>O&;Y8&IB=8043^(")AFU(I]IV /R*8<NWNL;(JZIK%<\Y($;BR&H9_.DP
M:7WZ:9Y.TSHZV:C7,GR>]/9Y&+R84P+!Y2ZMPTZ,N=.%]TET=>R?,1S=*T8;
M9FBL?A5#0>B=9?+%=@/TI8U!E'JF2\G(2#Y>5<,W1GSVV.@ "E-UV')KP'Z8
M D]R7JS#]YZ;$QHN"%I!O=@E+&G&;0&V&R-H+)D!,3CWQ5Y9@Z_.K<[^R0"O
MS082*(&G*0?4[ADP$>#^\]>7/Y-L7-C@TA[MY3K]UMY9]#JF);=:H;_>K*NA
M/^FX$9F('.%05HK9+(V9DXQG[3I7ATG3=6K@G+EJ ,=]1$'==A=77F#V5=>2
M,+?XO BV:K]X+0! ",6+"6H2OE237_$QP^1JFC=41W^;5'%Z$+R1QC7=K*/>
M]!;1,NI(ED N60PX"Y2X@%=(E^@HE50:?:4PJ7+K\V&):<;2@&HK1,WPD(BU
MOT(R31'VU[Q[8C(R0CRIF,%/X(>OM4IPUX#)T7N8I0A*/-5PMY$X<M0Q1K^M
M>,!,\'+-6I&]AWNT7HSM#)0O::#<[9:CQ@C\\(C*,@G(A9J\X?.YDG:7JIC5
MA!9L<RD]/N_8U(/>+R\XZR99D'EZH%R #4NU,G4K!K1X45PSYC]G82R@,78@
MBE1P[&,"&?RFN_:"K6HO>/D8VPLV-4.1<Z!NDAM!LX;'PT3[V-X-C.%^."2Y
M'1N>5L?>WSZVW>5Y(EJN]1Q"I2!(Y6M3G&>*(?*U-Q5KA_(N8%EP?R[?KV=I
MP4_QO1ZFCCS!;\JM/=0_%8'4A55:/4]9YJ5:D<%@"@=LH=?C2!1.MR]1:*P?
MSB?#!Y=EH_=_63(RV$9#CK> *QIGT9P\4\_P@ /(#*^OTZ*ILI6S%<=2I,LA
M?(2^Z2)2AG5E:/T*N"@I8UXP%?AJ&6?]^>L<>S4:_DQ"K'=BZ6.:5AABXEYV
M/3D-SCKVH15ZL0QL%3+<'A9-/N*U5/X$959M%V"NS8HP3$$4O?5U^A#:V[1K
MO=C9I?=B7J$NEU+#/<D*O_6I_,)@6F4K2B'(0VCO#7B OPJ9#F($(QMJ>XRC
M$.5PW/ GL6;LAT2MV-5S2T@1DK8K!+<@QMZ2#T-PJWG&%*W1*VRB !$#IT0J
M036A?2:P)7=<NS_5H&-H7(ALXAVU@V36<W.7_&"=X-QN?19OF3X[X0X)E*JG
M4O,X(!76%__D0*8,M=RZ$3,]]!Z"2(BXJ6:*LT9T-\Q#H:2IIM,KH#,X+"S6
M(^[RX3(B!X17Z9JJ'WG@,]4O%34-UW*SA'J# VY,#.*MH^:D)M#K@N8<[RU5
MFC"B$D%"H1'2L&P1,WG4%S$@&X.M-:K H="\->B]T2E^.*N;"A_Q+00G$.[C
MC5(R;3,ZG(M$.+2V1S$C'.  D<<,:^J?H>+M0:M?,RYX&H[8&SV396R%># /
MJHW=U<..TA]% +)%$$2L%'$! @6Y2.:D36V$@,=^4?3RS/%=\Z1;F<Z\J =C
M8J*ZV]!L\.1PT_AP_< \% 0/Q[G3>2 VQHDH"3%Q+[9:!_0#Y\:I&W-/#-MA
ME;Y,F2/XXP *OIA20Y, [O?R0[MVGR&<\0$!__OINE*G"PXF!.#Q'+VWQX =
M#0/;!1SM&<1HX#P2^R/9,OOCS+9-G$C;Q&8K*'XV_3 $;(?GIED680-G2Q1_
M7OO(KF=D$^+OJ_2,6&=TT$TC&Y1)>LMDTM!;1$+Y4U&]+7&<'7LZMG-1F<>[
MPVVMBHQ;+[O6-/?.Q"V#9@WB-$]'Q(@A-Z4_<*KM6D"8%HP)>AKB9?@S*UHB
MNB\#$0R;42$98(M %G,"4FM3QE.EL)FJ;%$,Q]7AYM"5[6#<&F)*B!,\#WQ!
M&KGLF4/HA7"1&(=5Q2,9W;H[=[K-[*+)X-U8XG32NQ^O+#O8E&H%MAQ7*IAO
M[#B+7RKMT-)5=!+><\U;^25()B2YT#B8/(_.K(T/WQS;H<Q14L0-[<*/SP^>
MAN4WH@V)(]VT7P,>U^5WCJS6''$=<'S HUZV,O0;0HA@\.B(_7PW!,HMM#*3
MS=:<7[)+JF#K+73)&JCD8Y*Q<!A^QHG;=X4N\/#$>LEAW&63@Y!&B*0HQ6F:
MCZ0W]?GVF1EU663L9G>-OX$"\]]7 0O<3SLU<$_-C/K69)OPQG?0ZA:=F=/@
MYGP?-$G#)3K15%4IS9)?<-R)*C7]7*E >=L)?S0VPZ;O7,+PKE7QK#KZ=E=-
MM%751(<'NW*B+X=?9^OPC2WIA^\\S'__O(V]%",IO;L.FX7U"H^M_R@OQ]QS
MH4$:O$<VDRM;M\6F'+"B,2:2M*EKK*J'?_1LKV>_U.H3S76HX/-J8<:5I LC
M"^&[$[5,,>%$/T]2F3G(,> 9S6Q8JK3D> Z..:*V8:P_9LPO'@=(Q6"L,KQK
MP)8RXS)8OJ-OK&]P0H;&?V=IC"L>FP X39]B-%0LJ$6H=UJJ&8[R(RH6 @2"
M]1YS2P%&T5UPT,P^':-CFC#@NP27#/#2R<E?__+DQ0_GKMZFE+:5X@9<H4H^
M1YH5<:JXY=:1H\J+&X./9SXWE[H:$R899MP06D]5C<IPH=>X*+ F%^ON:/%(
M375P4U>($@L:]+;$5<QLB[\VP7L?8=^+)]C2%3:D@P$ELHW<)DZSY27Z9^H0
MW&QY&6+_14L1-F@/O]@R>]C,S\%^) )YW:P%W+();X/+-?T,&8H#Y-N9YI8)
M11A;5/OR"=&[*DU8B[.TSJF4E;Y&K,":!V"^?'[X-'H'&BI&)Y9GZ[PN40 9
MX[I 07.B%LO&0>4O5?F1&'BI,$M.$X',\&Y^Q/#+I :QZ:X1F=J,/%@)EO2D
M'E +$7!:JS59$K^CGE$(O8D%W)*F<N5RE@(TP)93"<1SWJ M&3"%/@UUU6"4
M@)HG\-^X[ZA4T+M![1C=:*QBKLB7 3]_69##)GC.E1>%D^?N]<\X&K6K'8'!
M<U%G/,8A7_D*<BRJ M;@C7]E#1T@./",7(P(8LCW];T<QM;\6/05:<!B6<BJ
MT3RK3$J%.IBL+<%:Q-20^ T@M[V==P^N5_#MA<[FC<W6 JNCVL%@,4[4@N?T
M&#4A'.G+UN29M11I%;Y++QNI95,68@T;)9+#;3-ZMVA)X$"L=LP)%EO1NBT@
MI)U)R;.C=)@)Z&&K68M$# ],MD.'(^SD9W\T6@\^N,C0:RVGX0W-(GNG?M./
M1UV_W#)U?6)2-[@A)FVPV=K!=B.G2X.81A!@\>4*%ZP5G%IL8D,? :STBP:$
M)WJ(4TER  _2U/"PB:,?OS/:&[1NI??PWG(0*I;**GK,_UBG2RD7Q\%C/-/7
MC8!D$7RC2@0[76%8&[\SZB5+L1O!%1$:O% :7R: V+?>$+ZZ4J6-$"CT\Q4/
MA#0!>;+<1%"W*<L1 >&[E=4.[<O"X*<@9+-"5/=?W'*^JLA01#3T_#HM"^-%
MQO[1]+-ZD^C#?:JUNRW1<I+ ;46?N^?.WB$#_3(MBV(!*@']>;L8F[<.)JB1
M4X<@W,ZTDCW-5KU&5H!T9]J4PZROF<@&)Q;;J(-URK *1R(YN@I'5)APA.MH
M8-,*.Q)ZAM++T.CIJ+<5K3,@F92?L8["(1V] .^]I:RLZI.>U&VPIS*$5*UL
MV]YM^%GC+T#]3B$HT%X*AF]AF_MU#Q!5_44ZRM%>2U</(6/0N?=S^[9VD,H-
M0#145"P>X<@"V!\LW9JW&HK'060@_"NJ5A5FS:S[9<QR\,RH,]DUW\.*<"@*
M6$P*;"\E<_J"FC#'A\Y.ZB\&QB+9JX*6HU@NTC.\/ OS:GT#9%OMSXJFC/:.
MGHX8J[[JX]\M\ M_-;+O9^H[&8+J(AP"'E6#D2]@L9_^?7P"MCS*E3U4.0(1
M$Y-1[2**]!O\"NQ/; CS?@:&<(B8Q\X[BD=LLN6+B$T1/\%W@MC<]N9"CFP
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M?U;ZNH[O.Y+]KA+P\Z9'M60P$J([0ZH(9DC9"5*/1+ZN;YQS/H[A[*K#$\X
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M[(<RH'QC4^VRT*!%<?J2@N]%=AD'LPQ*V7B:F7(S(]TX-I=XPU:,8HE9\T3
M\?'&+@Z/(54')*06X&Y58P\=B O5$KW(T3<*(,&(C-A?K]E1\BN=9?B;13##
MJ C\.S)0@0X^HZ]_01XX [&3Z)G.N2N!:GCFJER$/9P&*0-.=36FJ6=C>1$F
MV&]-*>5(+KO0S+B($+\'?JUH/+=,;;*M+YE:@<](-OMTU5WVK5EO65 M485P
MB*>,,I#^;PIJ^]L8N+ESE5_1-S(PP$MB<"T4(J 0S!%G74VA5V91GN1IO8^8
M1&\X8[&@%.@NZ?EP 4C%L-*YCYS>.[Z)<CL"=B&0%HE-!Q5W(@7T V^T1SIU
MT#>(96^_\Q\#AI*,%2%JZ*P_&?MGP6MLT!"]6N_SYZM[9FZX-!W.ZT*9D9+>
MEM=F=J.;J>E?S&-0?0'0CGT:3/(UN&X[]^FST'&(Z6&;L$(.[%65>1!\N$]X
MXI';,ZM^\Q4''R,./HH(4!Z 'MSAV.GQM^I&U%1O.0S<?(E':JKK&^VG#[TN
M/L<<NYV]4YC+7"S9M*;T,;/L 58@E,I<KTR3H@LF$QAI5OL38/T6Q?"'_L6H
M18(9X<(-N!C91[1E<;@KQD/H;KX$H&(F/]#M'WFT?>[Q?*I&O;L$"B?Y7I5J
M.6=DQ\Y2O%Q4W90YL[1[![_*@NAS;6=%[>HP_Y#';J-EMV8P>&+4(]&\\ULU
MKTC'*A"!.POWL]4=2,,BN^8#K<II6HN[W@;'(2+S<$HWOHS!&A=8Y"G"1_"G
M!!JVB_ HCV,)(WOIQEY['YJTK%V?K4%*42CO/3D8^;,6_/Z2]GB"%DQ/T7J0
M2$6JL1WWO*>TI^ 7OZH*&ZMK#'&]/L'$@]P0O_SG\;L+>G?PS%,&"S($)<^[
M"*&[X%RGBX9C%S16"EYHI55I9W_B5/ R)3^<+(7% F,A5+KFZH#M<4 2NF<8
MMP06F/&D<)(8[0')CECDBRLF^4T!7BFK*?D!*T(T65"MF)M2D3)9/QB%$Z!?
MA^4W0^RDO6?R5I/H%5"XUYAIXQLL,9??4&R"HPSDEVA4?+E8U>#>5#@ZKT<W
M.YIS\L%G:LOUZ'$WIL:N3ZXB\9/4HK RX?U;E0VU+WI;G^95,5,EX812C(FN
MZ,4JV!5L;5?!UHM=P=87([)?P-A6V3)ZT&*#QP9;9.VU M.&2,?YB \\1@O-
MP?1/[!XX9EE3H53"CF\TJDFN6=L45D8=2>2-&ZO:2..9QA@J+\N*D:5*O3@B
MWFSDOISB#2(P^JE\56"81;6$HJDH[1K :."$EBN63C$(A6N:IISYDLH9<ZO'
M8?6EMU>!M=T((*O&H+#3)PA?4TG578QZW8-!\B'\P%Q9@%T&\G_1TR<6Q''(
M^T(GR,SKQN1C'#AUH#O V>]4)'O:;<M@L:)WECP#*$08M5U>![<46[/'&GK^
M#E #9A"6J>(26P@14OQA.TBMB%5=-H2.I.*/>7&3Z>3*F#O&29,LU]?FJ+',
M*3;16?-B.<YC1DL&)S88""8PO;*4#P!E\?PTG+=F3Z(*Q/P#7NI^U747&HVN
MH#3$)'Y7/?#1TFU!(;:QO%A/9X+C5H]3VB,2_7L!-ZP(1035!/,/VGIY12YE
MQHUN%)K%YWJCL='.59^0Y0B.G7K.J &MHCD>XE3P0C$+\TA0II^OE<O#%&:O
MRN+C9D>?3GR?RDVR4\0=XLV(OZ;*DET7JE"NK0>6@(=7NXCPE-Z)1!I)+].P
MKJ_ H^4CBLZ:G%R>AF#1^'J.7M!E??+J_%226L,&L-W\SCJE1":BM3A*G2ZF
M34GMCR[+72GLA))<]YX4K)CO4YVTK$\994]\@1N/B>M*9^M50^_MQE'K00:E
MVGL29>_(2O:DWZ@G'=_[!&2U<30KBX50 4LH. Y ?XMHI7RU!1:9477W I_$
M_$H5"Q)U,@'G%IL'7,J;/XZPD*=8Z81KN[&0G.Z1TO-L?849_D:SC];^9")W
MQ5 3U8EGIIXBDTEHZ/NG/'JC)UF#Y%FHCQ[NY;$;FV#A%,=!.UYT(FE6R3+T
M'<Y ;DBL30F-O!7!2F7]0<%+5&F,YJ,!;!$=>U-)\N/^0$Q>M/H=<07F%QNE
MSV-1K"^V3+%R3GNCU<E6LU)ZUC2*CE%EWC(*S)NS%58_<CRX,OY#D$AO8Z":
M:$/1@( $DY)X]"[DQZ5*<#W[F9X)'L5PPC"=DI:M?(N7SP^>@@^0I+'*HA/"
MMHU>E[";6_DVYT7\\3K-<)+4.^!0 N,X.GCQ[. A(F_(+WA<U](D YRG2]PS
MMG(>RPL*0E1<+"EWL6=*J^!/Y]UB(H!@H[2(H-'VBI$3<+DI(1;]]2]/8%]?
M-:@NKJ*W;W_>RO?YD.OH!"Q6EB5;^0H@+U"+ 2->U&!C@7Y\_^M6OD@KVWH$
M3SM\+(+BN!:<4!:'/VE%OLZ/D^@G-063ZY$8N2^WS,@]I:IK=%>LO[%9@_?4
M%A,NBH2]<-/"TG:,'+I^CY<5.I4GIO07+S\UL,0R552<>+:5K\D<1O!><R=$
M-6%P$R\IUX+BJ;D@270>MUE0Y+OA+F')XO,H7WYBJ:F*"5X.=X5>E#Z?H:&O
M$P(/<Z5ET@J*?D"6QL[!=6%G-/,5#JBP70UKZ1428-RJJV+'5N[%+U0U6!RN
M$VW>FT!/.?9F?&:FB8F I*Y6X,ZTW:X&8) U "\?8PW 4!3%T<&6*8J+)D;L
M^*+D<\XB=\/!D5-,,8B4\22W)Y=MV)H$^7UDI.G=0OP."84P[+S(8",2'01^
M3O$14ZM@$Y&FIHXS:T;VIJ4!8L.R#/P;%IQI3-9AN46B0<'0OSCA6Q",?(*E
M<Q473E1FRN8":_PPI1KL"_?E5";;BE%MC=47[XMP5GPE<4OSNJ1=;BA3Z#"
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MQ8P':KN:5HC-@A<8S8:XP%<%C0HQ\550OC<,-)2@%B<50#*]*ZF,@/<!U0E
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ML8RYMA(67,;83<&-6&]+#[;2NZ>[[;>[(-LH>-@DQ3?,9:Z*H!ML>]X&-\#
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MGTIX!M_QSML=;Z6RE'#K88N-!"&X<Y'4+L>)32 Z@,&ZF N#T((!,SHUH$G
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M+79GFL5M<?WY)BUH]#'NPW1EUE+ +1:54K9-"M8S=LD;3#B$[]"NK*C,RAM
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MYN[U[..>^_MKZ&_2>?-_4$L#!!0    ( /: ;U9GI_"F!B0  /T6 0 >
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MU]9J\_I26%3JFR_KRRVZ=)CZ-==>M%ZV-U]NMSJ;']V]]KN]]I#PQK@#\DC
M3/C;D^,G%0HB;=%N 4T(X$KE"\-6^GH:+6HO:VWSZFCQ173J$K-5$F/J:ERZ
M%LUOZS(8F.[ M=%Q_U>&!NJ9!$4#:@TU&HFE+@C '10?7)-DK0$P2X2!:13M
M8/KM,+W01MB:9?O'0<<M(OZ#8=MEH[8>M W3,_"B1S(72QY# QEW!YD=9/[C
M(?/OD^5-!-U.5N_X;@>9'62V S([6;V3U3N^VT%F!YGF0V8GJW>R>L=W.\CL
M(--\R.QD]4Y6[_AN!YD=9)H/F9VLWLGJ'=_M(+.#3/,ALY/5.UF]X[L=9':0
M:3YD=K)Z)ZMW?+>#S XRS8?,3E;O9/6.[W:0V4&F^9#9R>K[9;4Y$KT92#OZ
MV\%N![L=[':PVVD5K54.Z5!PJ2,$W[+6,V)+FN4\W9IF.5<+ZD >WF!_0AD^
M>H^QN[OF4"N7P$U2X05NAMWYIX7F.;]M;)[C%)OCV!YC2^ O._%[& J$FV[&
MKOOB86N:M-5J%1M@JM +,M^TM>$F-'EO&C<M=B\MKLW)N]GX,I"I'K1C_PBW
MAY%M> AO\R3VCI($D.WL&?5L:]B@V//L41G@QYBL\*S5:0SF.PB%JEBIZS*+
M70PW=+DS7%GN=C?EN0KY9)'ZATC!\VR'6],^3DL:-RAUV[/-]JCW*CY&[0ZI
M<W=4_'K"0DS/(\&U))DWV_A:*V/"#/Y+4R@BQ>)'2YV*M!'=C5"R$ ().U4X
M*0!;0'*3\KTO^]CN<08P#J-4^"J99'$BN9>L?M^F-<(>3'])!,)JGSN.PLJ*
M'S6O!B$<8T<O#?^[ #^]K[\P?MJ\SRET,\L644@K-_O@#H]3^MNF;13[TQKI
M_^R.MFX/ZG]<>E']7AF#U.:-4.CD:HX;'A9::?IV*@5K6&[D.Q1]Z?K(3+;%
M/P\=R9NPU<R'HS$ZZPV$N1<C/&:'3CRX%=N6";JC9@DZ-&,\T' ^4:.E@=I)
M435S0"KR;XZ]2MU;5P74M:?(H]9: @Y(^8^%OIN(>\T1NEN?.X\R9I\*I?2Q
MO5N<B+W_*5W8WX8^[7>U3FU @^]]T]MQL0A4/FS7BY+4R *-SUUC1-LAND&-
M$;?!QA\6F^UB/T\SZ(<:<^YC%S <1L+]/36U:9%@VX2BF-)_*PL'W=E4@>_F
M*U WU)17<<??&D7.%R:R]J.;U6NMSM[8A]4,0?@4Q9]!EZ7XUNHXZ_6'$OCJ
M3$W .NIM@6 K[*T)8LRI&PVP>7Q058L9^^W^=M<%#1>%=12V9WM"4^-S.U&0
M6FHGU,K;SX)5/JW<0ZTG8QSNO*YOT8 #24ID"1JU<T1F=+LM%G/QP?745'D\
M8+=V,4ZAN_;WV'%Y,5$(N^WLBTF6 %Z2A)J.;^*A?<3"DJ8JQH#O*;I*TQ+;
MYD8$>DW4EMME4P6M G1C>*BPY==6V:E"%;9ZV'9 _-"/,U>/\DNB:4I*+ZEH
MO:+L<@J!'7LO1HT4M:RGSLEL^L^E!P#"N*HC)(X@BVFD+'YI$63S"=Z:K))4
M:HN+.Y^SU\BF\ZT"_M!O(UTJ_<JGX)$H!GMLHB>\HD2;*S-YDBS^U/V"[<RG
M$O_%,-0--\<7 ;X_T7\BB+Z#3<;4K1S6V<W2610KFC6.5KIY,\TJC+&[\X)E
MX-W08ELRT4N2.GA(;P$\1[$#? K$H@A*_\K4P@K/J?J29N _W#^5SLX86?O^
MAI$CW!Y_&D3X_82%,/VF/SP%PN'?8QE&M]J7WJPS*HJ*Y%"237#L0*IHN*(O
MS3P\?:\?>1DK0_A'I0%<T=NX<+TX>B>!<A(]C+C7!R%[*P/1@7N.P8$^0L]3
MKXL:R*=QQOKH6J9FSSS6ZP+8L?/"$4?MSC/37)^6WAN=BF[LS52*HTH/!B&8
M#A*%TX=6KV5<@$3/,P"@/X?'74,[P&8(8WJ1E2G8<ARHBC1=>:QR+CQX467M
M3=Z'F6Q;G%"K/4>>*,*D])U@!/Y[%L!2X8,_=<H JU@6?P!BG>,V@\Q9@]FW
MP,GY*D!AQW0<6Z!YLZ@1[61VH._0C>-H62+FFGGM>OH$F.82=8872XY_3[+T
MSAD2O&40)O ESXRX* 7-63\^Y$&>ZP@2 K&11PD*)L@/$RLX;E:LH*1@M?C;
M)/"15*J!A6^RE6MM.4NY-<;<)_A4!/08*%!3)NUR(T,9 Y93&U?$0.%-!->_
MPUS;$L6@[_9(%+/G[C>&8HY:S]=H1MN]11%!N.A%\T5 HD0,T%I&BC&S(>IH
M"P.1,= !XI!ORH.1X"VAR)I(+7Q)Q"0)OG/?L8/*IF!=9CS4VX] GND%HH@!
M)0R6.$CFOIRZ66"&0C33\3(L==QI-6)\&,=J:\>HFV$D-%::I'T-VLMVFE:C
M.<NBV8YXG=YI".KD@MH')))*)-F2@#C1SYH@9X3V;4UT:Y.=GV0+-+/Q1Q7>
M1@KGW.TM7$4:%*< P0-HXV4<65^X*_1@]NO'%MWG7I =@049TQ5+,9TJOMN?
M6;I)-7SW0.F\!L.7G+_>4PA(P(99[%!<9Q.0K0"\Y*&HSI,&^;/?$]?I/F?L
M8X_-;$S.1"'YC])(E 2X)YFZ7AK%JXH(PIED>I=UT*+DR41*-+:(9'52@U _
M)2>(!I.)/?11C668XYJP"$Y?*K63:,C>Z#NMGO2\,5QA;@&AMX0&'-A7&RX;
MQXGH$P?SV:OHV@8@P*R-"+\M78X]L&L9(,,27.'!$,==X;>0/'@F,%")7*0F
MFE]"-NUC92LDNOAMC^X\=Y?&UA6]\N:O<V^HR/_:&:)/FL0?8!,>"\70RF2X
MDMO=UG,2[\#P=_(0RH3]?L ?V:,6'W= &XW1&TEN,NV%Y49&E!)&J?+HVP5/
MKHA$MI-KWULLX9#H*EIB+-,!^O8;:,\LFLP?G(U 1*<)3FLT9M%03UV"%Q$N
M;:C@#CE E"T5[9P('*UZ'0B 1<6H=##%O$)AQD[V),(L-I6:T;HQ9,7!*MR0
M)&/^MRQ6B:]8-Q7'NNWC;T2!.9[<& =0JX E+% ?KI[ESUZV7^0>HE,5)EE,
M8LMZ ?I-=G3?A/*JL(]$,^H<'"4]YL_Z-_H+M_L46)I.E>_>*NWU5(1U3D)5
M@8S 7J*QFD<#T/'B7;L3M$-+D6NU0?1*9!_V"C\$H(?UXI;[5N(4!OUAD"?W
M[F.7Q.0B5JSD@/,,Z>LPF:?C%ISYCA;F&2U<*"05@0LM>MU^'S$AR<1"4A![
M\,#26-&U](EO$1@P"G#*(//QJ0E#;5CT O=8#8Y:X;)++MDA>KODTE?!2Q-4
MLH$(#VJ(,*=!$W/9-^+8R/%"C Z5?87?6?BHN*)HI(T* <,SC7(5T$:#KZJ"
M3+RC(+&J\BBI?*HN]J++'DFR\I9)#I1$ SG9L9ZTMZ=XVFHY/D//%T(P-R"#
M4QHJ: RURB)1.LLDM64Y=TO6RDX<BQ>GE#DQ92R!<B>*W/G"EG',*ZHQA#CR
M T:]8LPO%MRX7$^LS=D$2W]ZQ_JPVLD"&OU'_+0!R/< /"AS*B%BH-OAW_C=
M>^8M4V".OL,V6U+-[UAS>&649L&^_[)/Q+:>3B@%/5V N8<Q>P#SOS)@=HJ_
ME!\#080X,CJY4)]5&R<V-3\A9C=BU,$ :+CG:Q(F>UQSI!=L7XUQ(ES'5RP;
MA\)*K *C= L;5LL9>!U%9P(-(BP,]K5*7?/JUM];#I?IBN (_)F8IAV'F-FR
MO,?[V/^>$<S'C$=-FA2/:A,@AE,J"%P@Q*,,Q_8F1&,/(EFGG&3D)[E<R0@*
MQTH))J$:I\"$MKQB,N*N4,!#0NL."P ;,,=-LBF<A07V1]TRDX'OY'D#3@#X
MH*)6TB\X],:+9S@D%;>\K.VF] :<<7S'1MA7OSM[\L"O;X#J R&:+X1L!-(W
MY^>]'X7KO"9Q72$*;&E6IY1_!\H;21TW(QL^R8-!--1;4_!X!LM*Q/5"I;^'
M(%59%_1FX&2*]U$ B_]14.<W"74L,/]HUH<2/5CLE 4<%BU[NGE,'I7^C;03
MV,NWY<[^78D!&V[1QJ=V_Y6)(/EU"^SBH3=8VY&1&']2*O$QZ4HVB:Y()'Q$
M4W=#-%"7NFPB,+A$8?A<QN?QE5 7H9N"#"[_][(XYM@\W!!Y7K8 ]*]L?3,J
M#% JIG3)R8L&Z5X*]^B(ISD4QK8_/IE7/!DC?-/B]C!-OBRF)ZTI7_6=Z"1"
MX1MZAKK+Z79MR'IYC1!H?.7;M^7U,_<M"4-8 $Y*F9'!JU>'-XT,QUU9@'6U
M=9'L5RRANLP>\;0-WMD(E+%0UL^D;.)J?2)C0UW2R@J028057+#%*5K^Y.\M
MX0:T+3 4"P /7/ /(W]EA0CZ:%0B9;=8@5"U3*$8<ZQ$O,%QMIDBMQKTSS]@
MA]Y3'17*I(_DP6E/<>-SQ;*'M8_OBSU@YH#/+ 4K1S2^9/0NZFI"#2D[R.4H
MA',O7Q2.3H'8F;"-#R_ VVO3G?@1?2:G&O.HL)A^H3[4Q0&K6&)UI*#ZM 76
M6^;GINY.$TY,BJQ&^!1SXYJMB3+OW'>1\4G.Z;6C(XXK9T'*93PD1.4F$4K>
M5$[<FR17!EK#9DQL0>U]^'%L/J5FE_#C W"+NY%?O R9EC(9@+<H21=8 &M<
M$%U"@&?!Y!2C#WETT8*Y>#JO$ILJYISQC^5CA(AH/'#VPT0)ILTQ3DY:[6,$
M1/VIQ?L9$G&3*\"R/PHK!=^%>'$JB5:00(Q:*KNN2,Q\&E'*A^K)[3SS_7QK
MSGQ?7_:[C]OL(*<LK*Q(6 -PE-W%(!%<,N%A%'-A%![X*DFS>,*GA?$IHK\]
M.H#98.O@L6%M#\21[8DUK]J%$!>@CVZ CV52*EJP)WHP;H4AW:2A%6/F6-&C
M@M>$[55BZGX0M#9<8,I D HJ9Z7<U!8^GT= Q5U+TUPI7=,%Q"DB8Y=3?KK+
M*7\5O$KGQ@KD=T9G1W+[&BW@,D6B#+ZBC"Y=Z-LL\D92K7IQFX^Q.?F)^D+'
M!_ " M?#(-EZ[7[C/<(R])H@_1U*?&)T81Z!*9YG@0 O<]8#5#N&N9QU]6 *
M.)%8^ @6ECHISF60DFC^P4[K#YT51'(34+//VH)#)CIPG =];2;/R<\**RPS
MVSMN[^/)Q&3CT<1:*RLK9X'E%(N(T9FD4Y!405RJ0\#(X8003]%O5&/E8V [
MT^&;30<2;83WG-<*2%LJ[9I%$_:GJGYW*&\BP$*A+0YBHL"WL;QQ8W]S10O6
M#^2I"EH)8M@>0'6]SV&T#*1/=U @!ZR=0!9#(L9LK^0\:MDM+S!=%S(;A8\I
ME#$)THS/4+$<*L<33/@#O5'ZGCXO.M.')&L790,IL>0@N^D2(UGMZ)/X?A93
M@3 WABDCC:I9;4B3?)ED$7'A$9]T91CI@Z;%E6X 5"&,4M(EA<5R?R!^_31+
M&"HUL2"3$4=.U7_C+("&47Y"+P\&E$Z/F+(C6)NES6I/F[4#K5[@8D3;$1@/
MLX5KZY+'E+"5Y<P]U%. ?+YF#?_2T4,W =Y,3?C*[*+P>+&B5Z34\P7NE2$U
M%6+3QUL+;)5M(QW]8%(+\%I>9,>%0";X92)^?+)+53L'%83Y6FT$1O]3+&J6
M\R(!5$OM"O MG/ PZ]$YEQ*V8ZGF?&">#A/)\O'I"K YWJ]@FR!8 CKAG\B@
MU$6B!D FJ6&84<6^+I6.LO0@FAXL(N^S-.?454@RH%Q?Q8=#0WU$R(JZ E\Y
M6 H\Y7.J<5$R<@K.VI6: U8F,T>$5:-N+;[+=74L40,,\,(+EC.I]U1O-O&I
MD8A(A 17WA^!H%(*2I/DW<K UXOM"7P!["G1UI?D[C8E"%;5L[6-64[VO#O:
M?&[N[J<H>9PGCF=1H#-[57#<U[%J4\.J[23;EUM#MJ.KLZO')56J<:@W(ITZ
M-Z-.RI5[J-5UU/N@C[H(W+"XD."9PO5L7FCI1P?VV=;DDBI=P@#JT%8P2LL
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MDW9IVT\L5ELM)'K1+2PMC4+="/8TBZG'T/GYA^UDL*M0BAYXS2PJMG(+* U
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M 3]C*\3!H*\))T]N#5O56\/F*%.ZDE^1GNW6JR?&9_WD.6)Y@AZVFZTVSKD
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M22@"!K,U MQ)RK15G!O#""/&"49WMO(.QWVPDP5BGCOB1>2,:>DUQUIPH94
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MUV:'7C$6;T]4??EYG-)'MY'E(D<1">K2TA,+&LQ_JY0$\Q$KR['3/8@7]H;
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M]@/RK\W1=')>U>4_@_]CY$.=@^1OQ[FP_,",FE\O7WX.M2N;\*XN75@B?[N
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M^*_-/ 7J(J7F5I\OBUQ+,,O<V=Z$S/@F=\ JAB'D&$&2*HD/SZL!2%10UG4
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MWC;XFX;2/7N_^-#Z%?M%62^OR\_6ZJ_5N&G'MNR0M,[-$_K3W.FX\;+[:=1
MP?PQKR4OC: 8AE2 OFQF,PDO6UU>?;7#HF7N].>6);SK<>)N *%#7XH*SHO=
MF1P?3LO=8(2.)O,HS++WE-;MAOD]8=X^)D"!%$]1C**Y'/DZ+5(^.7Y_VBY*
MS!35(+E],1Q,SG-(()?JSW/>6M#G95X42H9S,ZNB,#0PG9,4K\QU%"9E&TV<
M[</H#.("',4TK>=F$ _2(_+.XU22?=+NQX(/N6J7K]*=OV='ULZS^U.>W2M7
MO&W7P;K80"<*9IY=F?;&@2>1BNYUD>OA=%9((Y=Y2]2'N_@J[;%K]VZE^&!.
M+_=M4C<X&--!6[RH<X<RL=O&EBTTOKC$T9DP^3$S-ING7;2GW4M [OKF@S4&
MY-+Z7?9.RSP#-G%ZWH!ZD*;MK,Y1.G!-EY;A9CDO@[9OP\S'2TT 4MC_<G_9
M-+RV.>Y&2LQ\V=$NI_A="_3-7.,OI,5<C>!V*Y,_3HHOD'0]>T02G=XMI5R\
MG>7(',_L\7>=%WY\U0O_>V8MT.7OVS6AXT5IPO=Y->C/ 7I#X/LAAT)RHP-
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ME7HK!Z1S!^5PUBDJ(6KVL61R7!GUT[B>@XUI3XF7H WF@9^)RI3=4BHX2SH
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M[P+?OH[!BU]S1C9G-+G[.://M'3+G!B@D)NQ+8L[_:7=.5VF5R71KK&4S@3
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MXC:S"RCR,(/&(092'F^@AN!.(-L-JY68/#4FSJ0=ZC%1#X\3TXS'&LKD33Z
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M<<.AH>8^W3#6@"Z_>VK@Y[@6)/1'5BH9PE9RP0H,%,2T"RX:ZEM_RB$1U[S
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MW[W[/R7QYQGN.BPC-MLM=9TT6U(H$.8=JTO*G?LLU*I]/)^SVV4EK282M,J
M$I@=@AB/Y-O^BD?MP\(%TL<+<8Q<I)%G:++])"E[Z2YG6Z!O7UO,,ZMK(N*)
M!<<N0FB1HL^%+%<<X##1R%!VVPLD8LT.DA,)W(F?'C](N%IXW&2PV1;7?-()
M=^71301'CW 8 KA@;&K4*MW(>G8.+7PTRAM)@JJJLGD(J1-%7FX;H<@Q$'H'
M,AH4!DV1E'+>DO+DBVZ5<KL1S]Y6 K+D"1Q9\5'R.5X/-2;2OCEUI"L9"!4U
MS8Y_KD>8H<C211O"S=TH0J)EO@ :&0AUB(%UZ- NX%N4GFRV"@&)NMX/;_S=
M$P^GGF&0A;,WHJBK\PU!",\8U 5#BYJ2YJV^66Q7&T67A/!]"N8/\0O+RI87
M$269,=2L(C 1<S/4#@$*6="V]K[LTL\'.B7"1X=HYH"+23GE#D:*BW)@O[O?
MX_\+1N:(FI][/*.M=16:R0#/"[=ZVGF*8.;Q%A,7&DHA1&7=OG55J?E!#AQ5
M^051A42K:BM[2._3O736%R_/ DPF?*5%L!(#N 8(X_$2AVK>.&F1];]W%^_-
MZU@#=JF/.J[)#A\J@,=\M,)K+RU\"5&P_B%S:X<N#%"C@>&#[?@KA"; TU<P
M#-8'V;C<5*]!U!4I*E.AX"&ZM' =$\4[W-\E/2<U,>#O+@>I!_P-&B6[2PQ,
MC+!78Z _<</HX'<MK@&&!M<IN0$Z2;\I<WI 3-R/Y6!I) JY)XVD52-=* F6
M1>0)^!%R %%W]) U&, ?)WT&>F,WF/=0^(@YX6H?^(KB-[:]1(B_L96<<LQ)
MO.,1@SOF0M9N,Y^*+0J41I(5N(.7[PU \['^-3O0*]":<]\(9< U&6]9A7#'
MJ *03G96__ )"[/!82@NQJMLV?QP_.C@N+-8X\FCS[9:Z.Q^^.#)YPMIQ:LS
MN8_5^>;_G-G#'/7PR[6!;-0^)SK.HY OZQ]JK^)AOH;'&@2.4G,]^;K%?^86
M_QHSH^U>[7]+R,*C+P"R\/52?/*E^ FL@1!X<:"^8RM\E4Q_LO)A]D?1& +C
M&"*"3*(406V^MA PMB8%A;V1()2E9NH#[YNT$PUI]*];_*=N\6E,NDE$FAGE
MI*DY06490*78@K#PS&%*[/Z>FEF")$_<QU\W[<_<M)>!W%11H+%CQ$RG=XC>
M]-,Z8\=^7R<CMXLAG*O--/A !3OV9Q2Q#QEOXBX^??9ZNB]Q[S@SV!V!M"G0
MY@Q$^*NL(X&HBMMH43@#;70)1M"N#?)'(XE1E[8XVZ5O"T- XD"B];54"C[5
MK!!F8*B6*7O&7==_YSJ&J=E0MW$CJ14#02\0\FP+CV-!IU?SOMMY#C\1,3$U
M@:;0-N4SXR*04ITB&:@XNL60]K8-6*[R%#5O*-;DI@&S647YC6RAM3<#[3D
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M,ON!KU"P QK\@BX*#D#JU[>KY[R5]YJWV)V_Z07%?O>><R:= HFA,-LW<=$
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MW!4XM:/(0Y)%D;NS8C8WME"X4;@^%4"U"?<%1ES319I>#O%VE*!!N*^R&$Q
M!F>TGO5%_4]E@8J/H>SF&\&<-VW:RMJ")2=G9=6BA8YG55XUS5J4Q[F;_02K
M\K"JSQY<P\;)\OS1EN=@=CBZ.1*['D@3F[\E!YK 6GC+.^?$LG7"\R/U2W+E
M"#U_%6*!X&=1QDZ(2%&*FFIHZ"%H!ZE*85A+B AH$#YAK#HB=N!TLMUI[BZE
M_I3N]E(2)RYZ]+Z^(YSUDN<L_V!R1J)M#%*3OJB1CZA4-X7S%RJ.J  ZU^S=
M3< 5Y8;!*%,=)XXDXX/X%=T[0?&3WW3'?A,0='[E&,&<N!^E8QD,'S?"2*]1
MH9HM+G:E,O(&1DS%\#+6R$.BCE9-K/%!B=V[\NJBS5:;TYR&547,7*5M<.()
MU<4E/!+FO 49^2DE\6?GU!Q1]M&2JAZ:1^==,LE=42F=PAR<HI-4V:^91Q"@
M)Y-\1F!8R0GO)::4.PES$#QBDGFD%=.0EN#0YO5JE!UQ6 1;W-4^>5O+L/TW
MM7P(C<O!<'4D &3:23>2UM&XPE64J>F3NBW.&(.4'MC)R9%%!8,_YM7B?=*7
M2UR?426ZF9]3*@O1+$%_5J+OTTEPE\ ,;=W[1-Q5DA!! 9G62[/Y-)8+<[.A
M8D$533_*)F>4'[;/NGY8@ZX\P2.-6,V/01K\D7 @TR,ZK0RUU=_%VGG7YYM-
MY@'U)_C/ATE/'[)CE ^.X@I:06:.Y6"T:^#"9 %%:=P#^ 8M4<? RDK2Z(,E
M/<95ON,\K]!K(9] -VLB4;A1 "MOE#35:R!&%R.HL(?(F<2I03[RMJ7:#E]P
M#CEQ*\8M8EYU^?,[_);*X&DA__ZP3!Q.Q8XROK138ZCBFWTC)/^0 #;E'./D
M$9F 3+^%I=_T+ 8E5<!"2>SJX@/6SR[(JA\:RB</<C8_.\<(7!@57ZR#K8WC
M7&"!57ZC)!TQC.4P6[E%'.7VHMMW?;&]Y=2$."EB<E/ \@JI<,N.R#.&$\[?
M,IC4;:ID>K()=V@3$D%C1Y< 2?9WE-C5/\9E4\^T+J8:1*-TX&G.[Q;HY$$Z
M5:EFGZS%4/::HW,(_27: WH37A@ZRQ#/-@:(7R X9N<%Z,V4%4$2')XAE6%O
MM[K4)TCPAS$82OOK &$F,K27[MMU69D4!GB'G?!$9OKRHYX&UK;QT+.6*ICA
M@^XJ64,MVAQ/LWZW,1 D3L@%H, BL\V;9'_&7TK##X7?K$F'7<52#H;/D[3:
MH9:%\\4/>5AOK?2\QD-+'Z9AX=W$H GUH:!KFV4E%+;=J'PD#Y0E#^UR1":_
MKEW\+3%M]]Z3/@S)G,TKG=;U'8=$XUC(U16XV6X4&;'%8JIUFNJRWE B2/WI
MZS#/M.9[#IHMP\.:K 48\=B"V7K5'7*:^KOU@B;9%^TT!-NQL@[WTO_:2]_X
M"!3>'<G[2_@CG5J&V#G4<3+I(SQ&'W=:$7_"(3<J3JO$,%$"%"3 ];1IVV'7
M+UXR25AXG@LM^'$:-W@H9RO^$JT5\J@UT7>@PMQQE Z?V5:"AU>7UR7"_%4;
M'&/RMX*9RBN6T51H(.$AR ,K<J+%$PPW4_%SH;*PPCG?8]S<]/N894Z+] ,N
MTBYRKE%@=6ET^J(L$"O5$2*Q)AV2/N&O[D'XK-!J6QZ:]W'+XP2I2R%UGY\@
M=?_TVU)#D'&<X9$F:2# =/80CB_SR[KI>M)Y&55MTB"&&P:*2.8\XW$D<4C[
M;G'(*?CX@![HNHET2N(5(&NO&7L)*YP#:KJ(QDHK6DM&6<SBS]QB^![MS0^.
M)>P56)->12J$A!1,^RB>C0@(GLZE&^B7+[U'+_]8/(U[ZQX.ST$*P_D!.U'*
M/%1*F3_'>+U;!?2#J7+.+^+[3*YS'^D$79'?;7+J-$KVQ+NTE,]58@[O@W?;
MR[']D]CME#QIVL@)\: \V4[0R(@/I"8FC5-C/]/[=.&]Z]._2<WF.XR+GP^P
M=1I?;+SC<NBQMA5SU#=_.7EF=^>9N2U2U*1K+6Q/B<XG+[QLBB!T-(S)5^>@
MA=^>IO4.IY4Y-[@_\;IA\ABEVS!(BQ LRI=!>F "JF/N@9CYT_D\3>>=32<?
M9G+0KPR*,&?Y,;>NA#-Q_X2&,]8HW]OCO:/AF7>)3G6".UQWCNQF+FHXF?0[
MM@%>QG"YCS::2#[ T"&$ZE+%^.3IJQ?=I[&$GX(4)+ 08"L'PF4;G#]%4 _P
M(XD(IZ[QZUR2-_BUR\RQ5)%V+U8B*6.(3/Q0LCHLR4MP\<NV[)783JHP9);H
M%#JMJSM<5WQ"1+PB=WVR0E6/<*EO<R)P*U9MX2N -(D5J;P,C'D/BU.4JR1[
MY]"X9#:*7UF_/DS[:8+O<((A($;S&5.P N0@SNRR@SG?!2^/Z2TB*]]UV; 2
MQ@CK,5H19E[F%\0!!,AI"7R0**_:NSZ>]\D'4#=PT@PZUQ-XFM0[G%1OJ@\U
ME28=5-FB*+%1@^O S$BZ"+1/^R"5 ?@ WDX:I6(-3X"(K@&U/6WQNUT-?NK(
M)MNY[E+$I+9;39N<#R;P/$E1RCM"U5GBR9[A$2W"83'<@F1_MWSK:05]$$<P
MIHS2AB8DAV98:QR1Y,&<P;V)VX_VR3WH"?34(!R>)<W]I\UTAW-!(JUGL:69
M59=-A-0G4RZ+>L4] RIT-9-J^9:VU6GZ[G K<3UN+D\.GKZJ.#YAOYV$Z]X@
M*$YB(/=*#.3AE^J%OAN9RC!&1<<C.F+!J?(E-<,1'XY)$Q"!@WS7DT0D[55$
MM$T+-0YD"AX.8R"K,W:(<_-OY)^]A3%;H<:^Q5S$-N$:@;RH%0@B_A,+7.DD
MPLH*AX"L7FD,/LXT]!\U:N*O^T@@*LN%KT_G1OC_LJ+<CH@U1$@#4=0OOBO!
M>+OJ%G\K5P2/7UQPBA;O_\EW?[OX5/TZ(PZ?JD/P5UQR]P!';]C7D*B8/#S3
M3A]0%PAO17PV1.7>]?DEAR?C_3/3L,!2@L3K+IC4$UK;H[6_^.C0VA]H),N:
M6)98BW)\&*)C)AB7G&P_I<X6_S:$@^')HR=/ -RKZX:./9$'J)I.VC=IX[^\
M(B'")ZBH[RUL%A@LPX"DR8%A>^&=8.>*FMHX^^$?0SC<Y(!:EG4>/7])]+1A
M%V_R&H?@ GC$(HQMP?_6?E:B@C\#@7)/],)ZEBI/J<JG.BZ_;='GI)I<KA:O
MGS[]\>^,#5)*!98@[B*DB8K7>,.;O!.M!%0'C#5(Y5")RSAB$?BJ(VOVMPLE
M1S/?(QOU?40O0]R0\S_'N[P?B,*C-T\T)S81N.\AV,?.OD1<8DM2FII!+$A9
M ,P(9#0F,A*9F6HEIP2#0CO%P8)D9QWL"YWE3, 2OO;+L":^W(K;<AI(/^?U
M2D2O+#]]@HK=*1B R0R8P6#2+$Q-<CC;QR QIP8T5.CO0PF(7'K]*A$F\#7K
MRT;RERJ"PI<Y)2\^X$Q+5X90IR4Y_C%'X+AFX/\FYO@TE7<XE:*W%L[*$'B<
M2C)WFT1"/S-B_TE#\VDB[G BROJ709R'T[C?*>R@@V-.!WL+;W/=YC?LRY_P
MA!^Z0J$LI47Y#V926!?2&,^I)HC4AGCMM&GN=%ZNFVJHP9W##M2:-TD4F@P.
MLX M=\.R"F%2GP9JI]FZ2U1NT^=)3.-MGNE1A7^=9N4N#_RMIFOYJ!D%KM;_
MZ(-3$5>IPU.E84NZMVC?G6;R#D/1S=#EK+:D$G\%-[!\][>+CG4A=[NJL-JZ
MJ0/JWTF*M;FDXL*TKG&T8O%1%-PTO;<17J<#A1M(TZ,YU?-/4AJWY:8^[2BE
M]+?E9#7!BDQM/6R7)!LSV_W'8= (+,:2%M(';L2HFZ:=[="E$I'UE"))E&0F
M8E$I4^[%(N]$<D/XF_B.LS\B_B#26;^LN3X7%F.+$K9R*R0Z3;$01E\EBMDH
M&H@ALNN>+U[-@#THAXWZ<B8DL T1X=?[4;I[^I0;=@I,3ON4#/TP=FEN;ER;
M_IJT"=:H9H C035:3E[ '7=,*;V;SDTP!9N2V5 7["-<QR^AR%WD;546[:P1
M:R9]L:<)O5-G8&I)=6(WI=CIV,;\KL>0PT>CN)E3QG0S5*>Y_=!S2[])Y)UI
M?O"ATF<[%8AFHL4H[@EOW%B9^);^>9K:#[YM>>ZD[33ZE WE-'C.\G6SZQ&2
M.>_K/I-WS<_+1;UG;P_X+8/98U%:35XZ]<T-CB$*$YDYGJ192E-7BC5R(&$$
MB@"O8]K6BFZ#N/1^<3-2&/6P3)#NR9:+) 06<Q_DU00[/O0QHGP>B4]F"W9I
MITZ_$W*R)Y9^% <&@P^=)_5*D=H. SETPLC.KR=MSW)5%PL@BNF*Y&+T37;0
M@6(!+]9&G <D2]%PA2O1'6:\0FZ44\V\>[ARWQ,5_'PSV_-SJ,N'=<VK)FST
M=<:;@. _6 J['7VV$7D-#FA,4&,YPU;]+KQ-A_@> 3E:]&%P"+:;=Z6A.76A
M>ST&1B)/T,< G6(CTTT<.X)7&?DM@E_W)&'P<Y'-@G0R3*1@?P0(5NV%,4A:
MQ1DL-M,2EN@VA2^$(<T9^2L0,<55<_BM_Z*T#I%>46IN9L%MFZH(ADQ[U#@*
M+@XCP#T4CL#'(8 '?"Y;//_IKT^_^>Q+3.Y/?WWVZ,GGQ&>T;6H@;?-=:=#;
M"<SNB%"#!P6J/B@AY-8"_VW6Y8;!QW@I>7G;2V\N?KIX=?'TWP4Y!Z7?GG(4
M0WC1$**$M4MOS::UORJ%3P^W$>4JPHPO$@38\WJUYTS'^\XAYV3\"$8>@!3.
M=3"?AB4DP,G#S<<,F/;+)17=\+?"&\MZTCP/0PXG2W 3!H6]1\#6W*U/D&$/
M&?[RX4.&/]#0^25,V5!9BT)1CNTNH/O,5(#KE0G%F1!E^!OYN^,5[/GR'9NI
M.U!W.'=HORWWBZX@5;IJAG#OE"6\P\C'-$[+;C5TK#>G:@C:;*'"!M,8*7R6
MMVO%@W>K9E?$8])(94_YJ ^:8%3>2JM^1.9$[<4-AR?AH4OI(BS[HO. V5EM
MYJTHSK&+2@YQ7@6+NX9C7-2789&L73=0\G,ZVR[;?)N4-[MF6R3M_,K_UN5;
MBY80O'4'CN;3TKK+^H*E#%R6@%H:V$FCV*,=2FG6:%/N3NXJG''CZ5T??_6M
M=^I\Y!472TZMG1+Z$XH!.!,3,VW+[K0:[G0U+&:7P_' F"97-;)-%('Z6O.Q
MN8 .E%&QQ<["&^IZ2I96IZC\T^S?*7QU2NCI:A9$Z-FEY?/Q%)^FZRYAW^.N
MEFS6S6N0O81+V#<9!*AO\$5I@3G-X >;P3E+Z[I>#A$JS>-*-*-S<M3OUX0&
MKR=XUO&()-<W<GV,CLB^:+<SY7]'?HJP+ORSVS'20_S\\!,B8>5$'U]$G7KI
M8YVE**B+RP9I4JFFD,]^39C@5+(SWS9$F0H* JQ&?\_3"OO *TR.ZN>OODOJ
M61KW3?RP7(I<R1(ZS>)=-JRX&J>/X".2>T*.A\((&&PXL4^*-I1C-L@7+0JD
MY7/^0R172_F$3A1/=QQA.Z1E+.;&DL]R;TL@A,Z_O7)[7VI[;]@[N6RAW]*.
M!#N"AS)?^ON7B>P'K^9E4:BD.516"3_\SNGI V(PI]ST':[_@62?BXZF40Q1
MV75#2O^+,@(LV%";D2-\\YGR< G,0\Q=Y_BS,-%:4TR22TP0C0:FINM*,H7K
M(N^OCGDL)PK(=W=#4,&UZ2(GPJKN%(S.I1!9!UP3/6-0QLD'N<N:D3B0GH+'
MD<NE<H6GW,!=3T^5K]ZB8*MB2FLAVCZ%]Q^N#D?$>G5"JCCV69;[! $RBKP0
M-Y^F[(/DM.%<$)0G?*<6;4$S?#[C$@G1A#:*"5AGICNF9>[-G'Z\+D>Q:NIF
M6Z[$H2.(/<]6B -DB@&=2ZM*-&EN[R&,KAH =KVO&'9VV[0ER6'V?;"\P9%D
M5I6A;B&2"24[^),H9Q.!74$=?%"21;=/5:[ZDU;=!ZI6;9N:PN>XH?-U\=\#
M<^>N3:J .>0B^R#I4W39*!8EXT[P]3K$&S3O_RK1*J<Z3VW9=XY\J0O.>+7%
M+DP<LTOR.3P%8(X !6&#4V_6T$E^K"XN\Z03#X>"Q:<L.K823#Y!0ID[^"-H
MT7XJ_4MI$3_A7:2E?3F4:ZB^,1*H:Q;-"@AU)Q MTS&N$!23CC=7M<#T;2K4
M']#\H/U43-SME*'F^\;/%Q=T R.(','HVT(+&5K]P'51$0&BN!N6U%QQ[/F>
MO_I.\<=GA*@61R]ST"B#01<,?,X(YR^VQ0G<IAFO<?J=&8K'"]=Z38C58\VI
M+%OF:Z3L0YA,;06.2SJ; ?5Y%FGZ&E4%&N1."D7X3<L!R,ADBLZ8<73X\!2&
MUFYGW,@YUX*8KIRH?5A:.G=-^J?TV[T(\UU!:&8-E"A*-BUO?IGG>3,Q+C._
MBP_\3XEQ_^KA8]Q/N^]/2GXO).])5&@QI\"%ONDI%2Y .V^H'7! 0)*@IK\W
MT><_PY1J8DXC#!.Z9@L;N<A'TRA'8^)N=F)/F>LZN*E(3"C!^2G<N//MND/W
MYI(Q.Q1/#FTWY+4I01BTAC9OQ/30@0D?2.L9ZI=152,X;-G"L=K/]IAAZZ/@
M2?Y5F/M2@EN%S]MJ&DG1.)]MKLOMX0<N,RUVAWN '<A)B?(PXM6$!)Q;U<F?
MIJDM22-H<9%^295.UMH=N"W7'09=/"E4&65[DP//X)P^*8!/ X","1?',8QT
M:C9M(FH0PHHKC1LN4,R6JDVJ7V1=_U%"Z'W:I[DU^;9V_UNZHX6!7_5!%6 D
M>MTSK &C1F9CZ%J7H.F_*M;WDH+A/1O9WSAV(.![BFLHT,Q%@,+J%+ZS+@74
MLU%[(=?@MA\H6I1;1(G-;D%W94*:*6>!L%^$;X;CJG+=@::0<;B)C]:NU@.)
MWF[?E:R9$VZ52;,RC!,(T#;V6/K=3&)E%3ESL./@RK0#HV)8A"/I(.[30?/:
ML4C_"F?_H3'LPBMVTO:<!B\;WQ)WBPR3UYN,@FL?D4E58T((4<GS<)X!ZD@P
M=#.GSOEB;)-IV'F<BIABP^IPZ;=D_=X4Z@'/S.[L <GVE?K:LX4G[ANG@[($
M^NB(%?29FY1RRU)\KSF! TQ#W@8C.%Y<ZR9, :TN8F[B UN>M K3S&D8$1=I
MIIWM:MQ<GFA9K'*2MYW7Y2+<2WO&,S&WSFGR((%3;(.[T,.B>L XAQL 7&@)
M69P8WAWY2C-4[Z%,1DVA.P)Z!%=%F(]PSD%WJ&V&RRN!@%3C9P['ETL*L5)+
M69@"V8ZH7O)5,6A59SV$=]HG-9JKII/<Q"7J+TCLA<6S$KXMIZD79J?&8A"J
M20"7U\F1V17]DBH]R'VLKW- B2;]D70T2=T@$NJ$M]X&#QV<K6RC9-&4DQ[)
MC\$%^YD3O]R=1P65X)]4-!=V]&"OL^F/M&C>N=(L:NF%F>B<JR!80(O,'2]A
M0=1G^758X AU^;2)_)@\Y/1O18<1*5N8#E5[9IL# LUV[BR,BIJ"E:7EV!97
MIMNG*E'&\S:2@W3T1LR;T6B5T;%#K!,O,*I3Z7>Y?W]N#/45F;>4'@@4Z3"!
M3@8P=0SL)M1G*S1T3'=BL'T_,OR@1*'1.@XB=A'V['::Q6[0SA=M*88DHC/-
M36;C38!,T1@C#^Z-OJ#W6W %U!?"R<Q]9C9)>7AT/@BN:;UJOS!(UM;$(!_;
MBR-K%"N,V<,MD>QV5%9Q$")'E5M]^-%-8=Y9)<N=G="):Q*BPS)8!HW!"/&Q
M"Z]%5RKJ]2XX.,K3)+&_'AV70]X&XU-(BW1"_',VO@2S#E/=>YU^K&>)/,;:
MUR@8 EZ/ ),S.DKBS3/A2E[6_F%F^SP-F]XMFJ-BDG1\> W)7X:V[-9"C/TQ
MN/0_%Y"EES"._K-N@GL4?(G550T9S#@:HW#]B$J]/X:/U75XBAU;X3I.#%95
M.$-!4,65-O]0'\%AY.0],<:)?&>PAG:\ /FA[[ZGD*$/6S(E*_AAM7BQHQK>
M/R0F>G;QZ@TFX,VKY\^^__N;T>C]M21W $5IFO!>FYE'PPPF)C)U-4Z,FZ9]
M"TG&0K7PWGFJ*8]1M/3<,98!T+:#ET?644Y.]8%$W#$BU+9%N-RZNR6 /YP<
M.%]\SR\-[^ZGBU=__?[O_W5A!WIP\=L=.>EX !I1XL\6'QAN&C'C*1'3:,!M
M5C)H-MIZ]B7.'CB>DNSG(N^ZH<W%P>MM&&$/E;I33L693<:/P1D56QA\"H<A
MH"_9.1/.[#Y_2Q- 3@R[&N)J9DG 01L"%=L:]%CM^HQ\@[U-2F9M=1+;<PH_
M><=;EP'3?(%9X[ )L2XAVP&CA9GL <<TGJR#74[U^'J]&$LRZO,S*QA104";
MFRG,VD*/75+;#A-IOANG+ZFA?_+$NH2DL6.]GLEH1;GOXGSQC$'G[\Y,8-G1
MV8[9Z%^)#3F6!M/D_$=R?+D)=0&I4'H$ER&XF[ 8=+;)'&B*;VX]H2%M*&GP
M%KMR5[!#.]?,!MXU%4"7*RJU38SFR.Q1YIV:V8Y1B;*;$2EER/^4L'B5[S @
M_P!/W1Q/H_^I\RFUL0[M<EQKD\0^+U>S1[F%H6 R+:^:9@UI61[0C^"LO5B\
M+<),587W7CC5<$F5S/=<(;$Z]JZK147J.8K2/*6=N;-;FK,0L^42K:4D^L,Y
M"S[P61[#A'Z_XVY[T7>@!$8EAR"3<K+ O'!UQINXW8,EJD6=$*AP)>'6EUX'
MN[L2U(_JE:_HU -!9G#_"SKN.CHAFG*['6J(4#3M6A"+X2;H":7?Z=,;WZD>
M0\)XJJ;OV($"=0%))'&OJ?@$Y0;2T^W8B$2^S3C5.+7DO;,1L^T1TURNX>;L
M4XLE^W*#/5SVD\![;O:/\ YQM-A=-3<0E<:,43Z*7@<DD]IU9K7:5?ASOJ+H
MLNM)\UZX09D*V)R3/<9FJ(7IF+MV4U\=KLL)-^-Q,U]_=+B9#S22DI>9D2,2
M/#NR!\9[S=B2FBBSGV-CKQN5LC"S'?<YNF[9=M#%EL5E61O]DW$DSWI]4NG;
MY*L"!I=.]W[$63ZJ#2+44\\^C$8(:%+W\0_@#W?>7L(?_N"/\>^DSJ#TP.IO
MQ1'A&*4.>PKI*A?KW)"570V@M;8C3WG_]'B^U7B3H:9B,.)5YW6%,S5:8CNB
M""!SV3 %987$<TLF'PX(N)J'FJ/CH]S(ZK7QWR>N'LHK"PX9U>:K/^>KV'I(
M,6Q71V:15^@BH55D<!T6&\!0<TE_WA>]+IGY)2F5^[R:NIVR,9-WYL?HG#35
M3.7LH&]RV\0=FB<[??=E06Y;O7>/'[:.O)*^Q\B Y%1:Y%X,S0M+77@ZS,B.
M4SFM'_'='Q<4*"0H#XN?,B17"]R'GJFEC= 96GD:0IC'Z#M 2"YK1>4 !G=+
M<-[L<S)4>=M2&6%K)-;D8-%_2$JDET R9L@14*#(1.4\\LLV $PS=IV)UIHJ
M31:.">=YL?'K? 3\_O]YB$ ]9I@2+-7<Q*71NR^*ZMF&%&U98X0GYQR( Z[V
M71D&F!3.(HF S^3L\GTC?C6>Q#*[6P)I('-//CAEU>N"#D?*U6^:Q(IH2/C@
MCY)_REE+2?;-(T$A2=\;GCZ,G7'*(_=;L+:$;O6<3T]8>%1BWF=)W),U\/PP
M29&;5[/]/*6H2 E@MJ*O(/2V24W"4P.(>5=NXA#ZEB3$A91Z=,<G)W;7!8$T
MZ6;3A332TSB6&"1_E1.]7+D^UMX2 EX6DU(_JV].'2]WW#-HD!=N%E;GPH[@
MCA$HK6AP5L'KJQFV9+FA$ZK^KB>-BN]YQ=S!8=J0[BLY+P=0FLO$?,N?,,8)
MA$\N@\OB)"LXQFO)1]7,@1K+;Z.Z[&R%X+0"[G %C.$)P+DTOMJ+Z"0L$,J+
M&FO>=<%Q^FF[WO5V#;LJ;+S2]FLA(.!\#?BV 2%/AO:^S=R8!<6\:13>VJ);
MM>6R2&RB!<'$'FWDA2+/).93^+YVS4XD%!%UM_OQA:0NK1<Y3?\=3W_8FD5]
M2:FS3<P-9S"M,J-KVKYE\&-I$D4@[31-=SQ- J(0]J)-$MZNJ*6?D.&<PI;
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M<Q6"5V&EF_FQAPD-M6;2=;K,FE6D;)3\7$0NO7I;%X-O>N(Y-[2E)NXVU?5
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MF@$;F3(=CQ0_A.2/YCQU^9J3QK<'=)-N?FB_9'-^Z9$OCTX#\>DA23>@(YE
MT*H?X,W0?(20>E88DKJI\;M2DA!IQ.AWT,KR!HG49,=MV,/'<'C\$$82_5H'
M!Q-:U7-L9HE=1[.,&!KNAA\1SX:)53YP=E/!Y1D>?6(K3J#:NX0\A7-63\\?
MJ.6:IOOSKS^CM"V:5,.\_9RSV-K?BKXOVL[Y8K$^,'/PG(K6=SF/6PVZ:"8W
MH*&.NY:9CXWP^#0S=S@SJQ8Z$,BN=Z "!2S@- -W"DVW8Z8;.I1LX$B!7J%1
M[!,"B&E^_#17=XHWU.DQ(76)?T:]2:=9N4M03=/GIL %R$<R38D[?YJ8.^V)
M4J:-28[W- ]W. ]ML1DZTOZ+KC&%0))1@KX%I1LXJNKU\$%$*P%4_/HZ_1[3
MH0LD9CC9O0\PK<SN!A4+I6MMA%A#ZTR,A2]^E0\L2Y*0WIWF[D[G+DV91;R7
MSP!*]T(J?C:NW9Y O!^^::$KRG\P9?.#S[F]N7+</9)G/9AEBS4*1R^49B0=
M5[ KPQA'EZBC.7S,KF6D FE3D0,Q%_: J#X"(HXBA)MV! $0E*D]H>\PH0QO
MT;9EN)MF?%6C0[<L!V9XI&*$^:&<[+6T\D\5'OI$$#M;U#G78EJK0FXLYS\[
M:CQ*-')Y2Q)0L..20_=B<I1BGQ/6\I+?,ZIZ1*+2-OE:"0\H[0_&UC%$T$U(
MS%4?J7P:21GS+8K#, _LNK46,5)#7-Q@T1!6L6C/%Q\!6HXKIO\Z&4KPP6KY
MF8&G!%05[%S<&>T,FB:"FX>>V--T8X]8;P6C@A%U\)V(TVD+OB8S4Q 'ALZA
MX3D^ A/XO%8)85NB"2_\+8/H<&>NN.T!+_-32F7>R*C/ )I8]*@)+:_"'-=Y
MNQ^579."!]6G!)\^U#W L9$NR34L%(3PS5?[\\73-(&A)(#"OE(7<J5]@IJ&
M] +[_O,*"?AQ^B"J*3FUZ:,;&6/TMLB-7W_Z*T4 >.9?9&;<;</[7>CW=Z*'
M'2Y^C791: 7&<5)V(F5/=@<%U>9TF)0 L9GPTK#YM1^-++$4H[GB/()3S6/J
M.(K.P#=-^&7C4(HJ4,.XTHXF@U@\.XROU='RL\NG;K@LL\9I&XHV5Z@@ES!-
M;YKVX&RF,T_Z"2)4=^/F"\[%/%@O]@P\>?3D$;;6NL&:$*F5_=R!/U7TD)>$
M9!%3'>25+Q'?%+-%VT.["YKQTTNQ]V"CS0O)CDPANK+$+4]23R2KO5J9B&8A
MG8CU'*NNL\#S]G?2SZ(7I2Z=H\(O_Y30NB]/T+H_C6\NBFUL!LXQ*=]>&E!X
M.1$-**1AI*RCYKW;!5=EJ[R8V%YOBWWP@'-B_2*AXWCI8&<[0M%6F<45J1@$
ME&Y%:Q?^]+* S)YQ9([]*3Y@P)X*^8AP\=8JS3<E9#WY1@P5L3?B5K2B)1)?
MND5-=/M5=&0W6@8B"VM=[C$SH!O;?L"G5+6_C?G[-XN'WT_OC )470HN/H5M
M-*"7)C>3R19 G!=A2L2-*;\"&L.8@7%+<SFL+PL5Q^/ES&I'V6TKTQ8A/QJ\
M)CY#134)#:4D'5FH?P2F73IY4M0<_$B(6W"P36>JM"FIZ#>&6IB%1<P$A^6F
M"F,PY.+1B8HYY&B96YJ=CY$?X5Y?W]E<R[E=:RL7$;GEM-Q2C4/+VP-^'5W[
M(->[BZI!!QK!A[VD*I0='PZ) 3P[HU$D78YJ*/D\'6J)QRFL_0BVP[.R:P=I
M3)9I3ZUKDJ,!@K:K1+&4%HOCSE:I')]%YF7%O@C%I![S''\YLQ;2:/)H1]RH
MAP/]E]S0$"(BH!Q5.=D)J+M;7H4%W%T-/404[ >R$\A1%HVNF<25TQQ3 #=V
MRU6.!,5F:"LXK*M65AF^,GMT%>'IFWVA6F6Y=!EW/?%2Z\]]AHCX6&G55B$
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M@T/YE>N;Q5O[V$B$%?H5UL09TK^_FS/D-'._=>8FNA5I#^^\IW":F[N9&ZJ
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MI)"CTA'AI4Z3UT0G<:1&ZCU:\]T>>_#ZZ/U#I25#?HH.BSJ?5O5,#7H-BB@
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MJONJ[%M(/3A@UT?6Q;M^#C0(?I1VDL/)3RVL-(,VXMJ,-3@QWZ3Z?+IOBA@
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MXN2V,;4R58?"-F!?HF;P*7NM4]\/OLN'7B$?.LN)6 1]%&R\A]MWNC2D16,
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M//X]HQ[[Q.VMH5#DT2Y*[77AL!K9:V2&F@&B2R@05L2W([V7A*&;BE,HP>K
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MMH[R+DA<"R:7+ *O38BVE"TG(%%_R.9S->1RKJ;V-*7/AXRXVV'TGL4<-;M
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M(V!7D@JY&]<9^G!QOO_I8/_ 61)L@ #+$)0T;^<SR0>5[I5]Q,%'.BB%]6I
M6K@0HN:>"9J4\$_MB_"+S\T>H3>PNVB*K)XX,ZJ64K;SN3N9)\#5S]AL,'6
M/%/GH-B_/3G12]!1T[KR4@M'@6[]ML?CE+H5P\:/[_R$*9T8K3*/LV*U3PGI
MIQQ^X2S8:FL1:OVT0EPT0]5/J]HIU-WHLXHSG?9;YU6]G)T['X0A\A&5A9RZ
M*B,#=8J4<XL9(TF.WOWW\8N]@Q_=J>$&ULV$G*%YM:ZHE$SK:K-V%SBCP%-_
M^8'28)D(:3=,PHV\&(JWOWZN,QA'.I=H-;LEOF77?&S2'RJGQ>BJ&!T\#L/1
M.T=46Z>$>'(!0KU9>S4'&A<HC]N/,4<=%GE_8XZY[%#VONK[,Y):U%S*.?=Z
MI EY5D@?%-/<NQ\$-"$GIR0Z G+#CRTW0CH\'<D#P7Y0EPL.84JK5_.'& <)
MZ,M\P2F=PCE"H5NCYT':\Z!T_F_/_336*.UT['632;ZKQ>8MK,=A(O#0OY)!
MKCV0I/I^$KC?TNEB&D>.R7-9H5H0>6@4VS2-,#3 5Z/1H_S-"FBZC<6RZ:3J
MZ,PO7(JV<L"$^V2'YV.[!=B),T,-ZK\C,]8H*H'ERTMA@F:2F8']B74A/,RY
M.BD#-SX7/]R%$SEGOS(\ Z5$5N[PD>.FY>0Q97_RY9IFI]6V&%["><Q^ W],
MXQW_#<](C;*%,SF?P9Y+ ,O]A&+4906VU%"@V?(A12\B\)1=H=P6RG^X,X7R
M;S- H]N3&[V8)V?.#%-ABS?+ZGQ6G9?<RD5?X8VV*<5.(-C0@Q+-O!WA!FE\
MBQO(@IT:;1P;*&M='RO[E>66'V]SN>4HBNCO7LSQ*>=(&)68;,FY#Z09:15-
M\O8\AQWNG7X*J9/#-4%_Z_),SD6N_G:_XYW_J ZRG_SJ^^*#B'LG5=)J1ET/
M"!_66Z^1.O1!84MN@\;1FB=1UXI_CJY6'+JF%UQ^L5FCH$^J+K[+58BB-,Q)
M5=9.,\N0FI1ALN&/E],2? &R"47D/@1YK;5T'UBIO$[*BI,%VOO9&26M^;06
MA_%?UUB57TS0^/@9_?\[3]!X+;S+,&7C<3G=MGG(/WRC72V1!>%AE\[.G_GH
M+DZKT2H4@L&02^>-RB\2L:@]X,\>HG11N\TQSTKD;]#,S%AS45%"(;.LIDO\
MIY8-%0(#:K5&*Y$K,$D2$#TGMQ3>G-MK!\F#]\X]?*BW3=[(@Q[J@SY4VX'<
MA7_^&#XK/R;MJ&K"=!-F5$*@*29!ZT9V$X^&"78,4$!!UH1!\(C'W"&\!/.=
M=*W0E7$C+M%XVQGJ@"AP-(,%+GLW.-2V?(Q083VO*\K(B:HJ<D+/'NV'M"AB
M3:_PYRT/NBS(]%$.U7S=6UFDT&4DV\OS5%3:=Z^S*$1 V:O=E-;>_NG)DV?F
M9D79&W13]NT84O?;1_%OC=$,WTVY%P(X(Q8=I0+Q]>=VLDUT8Q]WI[T)=;GN
MQ7+I6U(@V]"8N-. JF/A9" 0^+-_IZ\\?OKO8$AVD7(OZ0Q^F=SJY.A*F%9[
M[G$HCHD?U.QJ%#Q^[R691G:CB]&('@6PMZ;W'4#,Z&8/FH?:BR+DFJ8LX!^!
M25YT\/%.D$A2VS=LT!@4IY '7(+B0.YJZ"V-#L,/@6NF0K_#U_MS$U(2C";H
MKATU7T?ZM1/.Z@0SQDT[I603_%,//*FE[0V/!M!*5>O*Y?OY1)8W_$9_%P\P
M^J#AF[U'O4Y_SK\ZW?/OX$V\=I8LFWU+7P('S;MI6P4X@H!%^-F2DRF2O(U6
M\?GCATQIC+H;5^[#F2NFBHUEY(WXI2]7L7O$6*>>F4W>OG[QZ/'30:=KDDT_
M+]R)5<[V9,SF^'\_W=0(XFDYGSLIM&5(BV7B&9'=#Y"K%]2EK[5XP0ASC1VV
MOD#GZW(;&2NE15MEOQ6KS0K)O7-"E:VS>OC6+8 ZH7*CN##O5'W+9><.I>X2
MP,*[E3.,:EF(,8&YX?+6&E7/ ZFZTJDA*S6;4LMV\2V'F&4!LV@54;7V5@YQ
M2NEO,"/C.)2U@8'W+I#W8O+?R#( ?Z[&!J )/C?EMT0QA7@@-DX:#5W%W(08
MWNPNLZ.Y("#)$N>US)*C%P>/GS!?T8LGWW+RDP?\*.\P/%RI,O87?I0 372\
M=(39SW/C1B'<O*BIA])9&E21@<@4I1!&]XY8'6E2<"$+@I?SJF^'%#?D4;3(
M+)G9];;-\!->-*4#H5TZX/L+5<"R*EH?# 10K@?(PD8BV=I]\N3!!_WDO7SB
MA_FP0<E!:R]]&R>?@&V!WAE)K3JGW!1C2@9BO.]=*,11F(WSE#!A).[@D?_3
MP?X/_--)"*5DCH+B2ZK;:)XKVB8:1 O/C=D]!T,Q>4>=2"G:FO6H;09#@YB&
M0"X<@4U_DS:Z2SW3!=_!@[_DIWXN6[L#TMMYTIA:9*.E<P]OHUUDPNO>AOJV
M;N2M',]#79+>J&A1U*Q&9_"^Y=#)-H9)OC"'D"8D!CFK-I,.>@UG46ER71%V
M[3;[S@^^:/,^_*;95ZN1=*L&,QM;[-]RM,:L/+$EN"/%XB]'UB\EB3HVT;=8
MJ%GL!SFC>8Q=UN*KLQ;_FQ7)FVSRS=,6W$%PGG=R$5>O@<B+)&^DR?:!?/ P
MRLWIMWQY@;H_< 1?GFB6J@/A7]UOP1I^Y'SK+$U^=C%D\K>*$#MOLVFVP04^
M9L6Y&TQ]#I_C<Z]7%^1_<6WF04%0JM"'P_69U6KCAHD\N15T@D.[RD"I)G47
M<5=I\PD!8N0BUI]'DD+]8LC#+$H.L%B9EE+ S'],V8=E-?V<S6!QJ*B#EWES
M^'KOB??*0XHW;ME):A6H0?]VTFY6E72@G.8KYW0NJP72JBL@8#(A@*6_NS<H
M*+E*LU4TPL*.AK@]_QH?/QR_>/F+>9/QKKOD 2TH/]VV#*6?X:2&<SMX 0F:
M_&R%'U)YBOEGT'S'(2.XVQ'>SG*B1IZQ1FOC4PWVVF3+PV1A6$TIBJ^%%K^\
MK-WZ%]9_3B?Y!\*P%8UV-\*.,NJ]FR7 FE7B:'^;*YI58T2OW8;3L\_?R!K_
MZOT.-WHK+[@\O$12_Y$/[,K!4.ZQK8A!HXJ8\=RZAD$B!BZ0@&6_\;?WG^F7
M*;3\PDI7;"GL(E+RA.XF@5%E:%$WG'SZZ M*>JGM0N453]Q^;L'_Z4=SN8LK
MCU%)- PX%]_<&&-;=8MM;I>MW8 0Z[@S,@"]8DB*V5Z;YYQ3<-.-[11Y'7;0
MZ#U'+7**B^UP@A8G^/S.X 1OOQWB9=I;GW8;7[0\L2D/AE;XT,:_9*5'THR&
MQ"V;_7TC-(346,UG+Z$^BGJZ65$;D3-87U5:_'8Z#\[@_]AW,I&+";*8%Q>=
M+R@R=P>[7VN.#!$,MIEY=13'B\_4I7"=9JE;-?+2NOZU[OVO)\F;-T=Q:\=P
M  !6%;H5\P 1T,B'!,SLT^MD#?EL\R1[:%GU?QEH*I%PN*%"*GI!&Y0'Y]Q3
M*HEON/35GJ=V"&GJ!Z!1&7)50=*$K+VFJZ?4%M:PI-(LA,I^SPMHRW,;-B-%
M2JIP-%38$#Q#Y'9+3IFOU5""W=VHX;Y,SU$1>?@/WM#CR#C(@S<$BI[UGURO
M7C$#)<4BF2\<$#4"/+4F-^07.C;BP%@TBHG*7B/=7VM0]M?,+74.+O[F_++,
M KS8#QJ\"N'"A"Y"C"6HGO01D-KK@]-2A6YX"6!MH0_%J32&@?0J59V<L%D@
M@RO1A#):,4,1PJ=>4DW([,W=DJ+RR=Y@[4QJ-WTH7>CW<X-23;5I=<,M(I'P
ME> ,_"C1(NZ%0*.-AW*"V45T-RW=:* QM,'3WDL'%K._5T79C@^8/W?<IG'#
M<*HE-[F'WT4*6^[MI"F-C9@FMZ;*?%&U!>J 9 [H";VNK3G\+G\> :D)+?A=
MG,+C?A,LT].ZS:A1V$5S^@7!HXL'_;:G,R6+"X_4ND=<+'Q$:0Y&+)8IENN=
M0Y9][!D[N[5S)OLCBUF[^P0>R8,3_.6]_L5 ?T"]YU9E;Q@B3OP_18A06F%Z
MJ1^?/4^??O^#6Y'GQ%+MXF1J'/#<^WW";O>L"65 \N1/[IH'8'$A]M[?0,93
M<+?;GYX<[#]Y)$Y=G=-YEF/80!6^_]1P$>2K@B YVGV-6^N%>'&/O3S:'N[D
MFO_B= 06(OHCZ=?J!UUM!0[G)/:?))/!C,35*M>_=V*!^2425.A@"GME.X[I
MX+R"3"^*RRQ[B7N6/T<1F FZ0IBE-13WA!LV05WZB^$AW4_>7^?D<>-/H1^\
M&9T"YR6O)M0;)&I;Y,#H3\GJ=!MK>J? M&I::<:N@T.W0Z'>9#WGK^X.SK9]
MVZ86#O@>#05\?O'T([_8@S;'C<5W10E_4^+P$1!.;!D%E5U0O*M\+ '*R*,H
MGX:&4%UFO4XT12@GII!I"@J.LC(G,4B.<H1QC3S[?H#%X4;,2D=Q"DG*4$U&
M0\70.=/9W 8!HR]\F=?1;3!1U)'T>P.L,*\"ZQ!%0^ /06/XIRO@&\20/SEX
M'">70\UHH*F%Y1?[S15\,4IY135E[=Z#G?T#RL.[%CDU)X'G[=M6B"\H$8\3
MS24/#M\?/F2+8&CL[('*'J'YHZ? HUU?X$:@,TP"<9_=C^X&Z'XQ5QC$O*62
M,V@B+T8H'FG'I4.HN'#/]*H0P1\Z-9V1&@Z ZOR3QX^?7:$[ZQI<A]<G.3QX
M\7M1&J8*IR2=K46)VCDPE_8%@P$25C(%+(\0'B>A;-4;!8VE[!):">4%KP^[
M7/1/6#;T0?QLX<&@N".Y/[],B**Q<2/;\LI'?O%/!\]"\"+FU"8.06NJ9A8U
M9<NR%K\*O8?A7=.*(H-RU,D/-ILJS6[L_KIQS\L#Q+\YR=<M7U4^Y7:O6EJ^
MAE;O (V; .$&J-OV[6!3,1Z7#2FG-=994<_V*(K>NIVWE$[7B&B$//GA^Z9Q
MCY9(M35"LL32YPO:S/99W5TS>:L-76'AGF=![L/ <>=/MDY43-&//9V%4LW&
M_VGDBMO7'-:$EEZ34-ZP"Q7:4[->A(%%^XJI+5+[@R)67I=X*NL'12:<,AWY
M<2(CUOUA%D2[-KM9F(QS'6B%X]Q'S$X*]Q(#@NR)<YLNABO<EN#;TONR\F#C
M;!O.'PT&[3DD-A9O>W[J/-?M7G5.N6@73KK1+<!(/$]>?#A.?@:MSY1VWL>:
M<K4/W*</;4-IX.T+)$5RKXBG4#D3#1V52(%YKZX3G>^*Z+:(_N.=*Z+?EMTQ
MXHQ\,N=8UFV%[T8^R&30AM#<Z5481,>I0T<[LGWK?/+,12R<.=0DV047=J$G
M?J1F4A))[:G;AH0BZN2T+NC9%X\NHA'P+^\I2ZHI<Y),A:TDWPOI)V8FHEC,
M\Y-FLS.J^6L,*?9GD+.;D[;.!BU*Q+GDV"EE7I1JZI +1 ]<^'L(;TMCQF9)
M_C3?ZGKAW^\*8[O).'(TB!MF.;HSD>7QWMML0@D:)E/>_Y;Q93**#;D&0J'S
M0LD#?'!),W1>DG?:;B3(&X#^LI##WE]^V/OYR44\+9V2OTU8O9H"J;_2Q/T
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MT!"67\&G4:DN>RF<6$:\U**$6=TL $V#V&E7GRI>R_G</93\QJ ;YL42HJ&
M:"V'=5;#>B7"C9H.%/.TV!@5-_@ YG&5=_Y$HHUK9#AVV JS^KY_=.>P%3>O
MB#,\=)<Y1.AJT>;!O<EV3WMY)YG;S]@ (Z+QO&4DS2?MO'X#9,)P0QZ-6@&!
M+&H:E__6YBM5L\3^OJCW1*Z^R__^@1&TJK'MZ2&L4QJ$&9V;G-6JF3/)RWQ>
MM+M<U(U.BG>:^K/CSC:2\XPUC4)O-S;<;K+^P,E"S^J>,Y_P8%<T/UP.4(M+
M 9W7/,S+!6#O%]F]X"+L)NX/G+@9]0Q/"]_XZBLRVX'L"$&D V7UVGE1TK.P
MI*0;0?HH5T#(93BENXG[ R>.6+ 9%L.YFP8M>BV,XD3SMU5MHP&_UZIZD96"
M96J2!T<?WC4/C>$T6//D+"]G1(1"/A'4226DB2J -BB) F6./ZSPZV1#A= V
M60J935NE1K3+W803T:E=B+@OT[EDRZWST%+J2,_(VM "=::$UR0$XIM6'D._
M:D*6W3'P!R]*K2[HNM35@^B4DB9%+FO)3*_\83<S?^3,H/NAE/UI-SCGSDPU
MI9,0C[9R2&'9]-99 >$VHJR8?LX6FBYK:5.7B]VT_H'3ZF4E\LCU[5OP@-^(
M"F=[<H%1=?$ J479=C>7?V3QO;,3(?]:("4M%5*?JY-N->Z*O'N9U6,TQ47"
M\[.<@9WRKD'M'.Q=5G;>J.+RD"E]C@C2HLN?F[B,7Q(QX'4=%+G"4,:3*(SG
MQ"J90_L:K=59J]U]VKR\R,L<G I2=F\"GGA8W$4[=8@X?O3N7%,3%-A ?S47
M./WHI#(>3#JP$HZ&[KL.<)2-W!UOY@*$G.P*9<P(NY.W>."Y>I?A&(#ZIY>I
M%Z(#F8FAA["SXU/7\06H6S(^@)@X&@]>>R-E]9<QO:=9B6/(X!5D^,!*%;4=
M@?>[KB;9A%((>#GI=(>C G6=WN!TQZ;<N#DF ,+ N" >;N5NG=,U6^MM.\P_
M[DSE/P1R"K-#@.GP*YIIIB"@383DU7FRHKP(=5)O2$<H,[) ''(3)4:N?5 -
MB>>UHAL55;EX%*BX,3@(49U<Z J:QK<M#/[FSQ''H>^RO(L%KQ,N.J?):VQ^
M=JT.9VZ&"H <"3YZ9VM?_N46YN6R^.6&RF!1GE3/,LF7BGG"KO*Y(&G6%1HZ
M(IR< YCN_F.9+^3&@RW@%$PV[L&;)J;3.MVXMZ=5[JX[Y4(L1:R]%J'@+FG9
MRFV7*5/()\EU!@ M@!X.W$%X&&V8&C("H;-*2=_BXX'<MI(:U%\2L:@+9),W
MQ3Q7C4M?Y$^)+]:&MV&XW C-W;"(HGP.#,H=W&#O\%K'1#U[06TP?OXGMV<+
MO9,Z*1[?[I$Z9UWF!%P+G$"KFH9Y(=SK?,Z9BZ%Q6Z(.66W3+(]+"H2OX@TT
MS9K3%/^+-)WS#GQ=>/"25[6X!X_'1_0KNV6>W:%NF2,:-3H5#Z< )]/I_5(0
M2M?!V]R6M;FI3>KLSP!.3C<P&5&F#2Z<;Q0B'$(AJM<P[Y1T9.\YM!"Y'W$=
M0!>F^Y HE7$2A&M1LH[C%Z5LA^0"6O*<9^B,(!<(6*0T!$%9&/^U\Z&FQ-G<
MJ)$F4,Z4VO?XMX"=EL@SGK3*?GCHS*V;R>3!Z\/#]\*8QC>T[(]RK%WXX!J%
M-<(FNR)M7(6MN=?Z^V:V".@,D))H;P?Y]1DZ)(5JDLX?0MA) HTB U8\YWX*
M=@;5$@CAVH;;\!FXMT#19.0W'BD%WU7^>^*.:AK6YC37'PT\2V##9#PQ?<U7
MO#WHW_ ,\>\Q/VZ@*]9$1ZX6Y[P.#RV/4V<1J]I@67# 9>Q24[!!'K44\[JC
M!^S?DMKH!;#HK&I3 3TH/ ;4Q\:/RT(ROEYO'X'46<L]%LI%]5]!./:&N(C_
M%;/C80 5+>!FGBY@)GQ2;7AJI^[4WR)+1ERNE\VLSC]>,6P(/\Y9$R),.Q/[
MSB[!.=(]J7_D,6W 5$#QMAM*C4SM4&#(G(>.W#S6,06FFNWC@(H!=&UO="[F
MF(J[8D6WL\)]!)$Z>"?9O25=D,(>#5;@32TQH.89B+]JCF \Y_94%GO BC-?
M2V6!>K,5W9I63(,W8E95K"G YH,UN=PF.-\+.':&SOHL@-UX_(YT21W_?0)R
MBC'VC3$<4P5SYP&QO-ZG>B(5\W%PR+\D<.K@C@.GGNRRIU]0X&C#<9Q%&2%/
MK2(;"$PZ/LVTO:0=:9?8_OK$=FS3O1W+:G-J;]U9^)E,IK-N./BR8)F92T(=
MR@%_E#*S@][H'<R-?X*:AUO"F]5*.,^B_*;Q?]U)-$6:E#(@C3L0)G0J@9\3
M'(@MD4<65W?#C4LETG\6N3AP8Y!!N&^M"*_O#R0Z?QN*=I-MM4G0P+Q<"F,?
M0>Q]=[%1^(LGUGHQ6#*R .;1 N*_!Z?+/?]&U%S8H=<+7_KN]Z CY%@;<2Y[
ME5O6ZO&)"BMFY0W1R!:-9.B7(?Z8MEI;\ Q_FF;T3E>0YQW(X/NH8<EL1.?
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MZ7:3MHRD626RD:&0/5R%3:O L\25U 9GNBRJBTYV7.2=WM,&EV^WJ>2!;F[
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M;M>MBE K0BT).E:$6DBH5KU9$>KVW95SN)1G'GJ5/,WR866WM6<X^7ZIE-L
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M8E NBQ6^Z;.6DO48C:WC*&PA'T<]7^+H<] +;<T=!\LPH7FEQ:YH>[L!,M6
M [7,!JO5/T%U;1#@X[.+<Q#TSRR*O4=J90W0PGU=A&/@.P!*SP6FLY"@J."W
M3OA-4!+SPV P$/59$U)AH,ST7!?SWYX; E@_\'H;_AN#21'&M@?V!?I@HB@
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M1IX/Y*O!_^,Q\^7C7$?J;N ,^7#[!].>[&>FV9C\PSB\;,#-(>SE%;'3456
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MKG;O>*@="O?QKK:!*KRV@J8V+ *&/U+%&U=]%NCOLK:61UMBCF<1";(Q^8I
M;F/6@=99P,:![]PX<8#9;]R5IEKPQ/9I851T?+!0P#B@.$&0XJ>3P4][#OSD
MX0WANQ>?2/ Z==6C$C/Y5'B'^6&Y)\8)P/202/!+HVZ N3<8B'^'8 [X8\:5
M2&6GSURC"\B^2_:<30\LR@ZD;_[2[-8[ZIM<&9V0K\QZ+)-O\W,E-\Q-(!$T
MFCHM1?%5;^M]8M"?!RX97'3R5J-5T^[4LY*?TW;@2 2'<Y XP1 #BL?BWL_N
MS_%K\KJY<QU%'7<TQB^!-&[)Z@]Z0 C"]X(KBNNWPQ#]+;C93QHHQC:J=3U
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M"?R?EH+_Q+&7@M![K[$F$M;H;[/L0,5^"$EC#DQY>+8'F<XI6<UBKM,WM%W
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MV_K1J=FHZ8TR.4 KGWM)N?C:L<\@]WN[6Z;NNH>@CD]7-%<>^$V7-2N6KDI
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MFFEU*VS;7VQS6_V.W0><LXV^U6L:G89AZRW=:7:;K-EH&FO2"&;-TX ][_%
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ML9\#-&>?]LD:0,XG=64/!^0$]LE98(Z"K755OO>U/ST$;?UZM@1!>Q9T?M"
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M'-(U9DLRI*IEDO"*!B8NVB9 RC$N09)A1I*/Q?D$J!8/)<>?PX;T>Z'/K-*
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M,)_[=IR9)GBL;LR#V,D2+[7A $,[<OG] ^/;JE2"%YU9KC-RW'!+[NJ6[OS
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MQ/LW(ZOW>5=24B[\4#*2_W7%9ZUN4S&?Y/PG=5RZ7$ZPA<Z-:'OX$SL25=A
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M9SDV9KQ8P@=I>;0Z6%-U52PG)$E@UPF(S!&1%9Y'F4I))E^H+KC=&D[^LEK
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ML7PW<)W$"C/33GS3C2(>9XZ5/<8F:,19JWD_;"-Y [;I#?BOC5 #=G6Z,L+
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MRLV5Z2,R&QN$]T@*KIKU6'M^L13OPN:CKC)UZT0F@4U:XFMEO'1M?<NP@;A
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M&;:&P=7JM2@OV4QV5ZZ,5^^^?:E>CTC;@3JZE#W$<A5XPN4N)PM6]ZJ '\C
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M+RC%+]\0PO_J%O\UF=5\, 3-&6,/J=@\*;#=%%@CE;JC1#L5>#W&N1RQ(#J
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M]VKH+S!8@6OF!=H3*CQZG9,>S+[R7(!- 6=:)/<EHXZ(EO;Y#-1@]\1B)^Y
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M'<-P&-*M/UKMU&4SWF7C/N,NFXU=,YTN&S.($\L$LG5#DSF)S4/']EPN$\E
M"-G>IFD$;=5XH%MK)],[J>$1G7AA7"U'Y?LB6S\X:X>G3IPX]E"3\3$FCGFF
MN5XA;!PXMB8+,SI]["@#P3NEK5^5:<2/J[N[^?TS3U^_BY>9[ERV-L"T= +>
MPV#XRZH%JI?FK:=^$)![.:P;G=1V5+I*U"YPIE _1?MBPT6\'!_:T01&TOL8
M"=-3*\=PV&J@;/RGYL:KK75DV/H#*0.,Y:X*M:ON[M<US[1Z8@8L_D::H#F"
M1>2KZVK8$D48\0=8[TU-!;,A=ZPW.[W:M!J0CID00>4(1<]F[X MB4PJ>*L8
MT71D#0FD>B(1O!8H<:%"':M&9J 5[%S ,<$;8DFQ$RH@T'WQK>AJ<QWH_,SE
MLG:'UIUMS_%2^<&&OP5>,/9?E[_KG/^+N@D?VSE6>:PJ!E0/-I6%8 3,N,G0
MJZ(9:G!^+[LT-,Q$DUT?[?58^_9Z F&YW$ULQV6<V682>J'+?>F989A8EI\\
ME=?CF=;ZVKW)WD'BVK'+H\ 6PF2,>V%B6IX7.TGB!C'86$_E^'BFO;[><I]@
ML1L$;6< 31UHOETA# %\M :H:-:PM*1P'S_C^0/2_IS)&^1'V-(;^',.O[PU
M$$4B5\#?<):_W49_?Y86 W+O?@K>MCPEX\7/;]Z\)!F=%C$JGMF:C/>MQE]O
M0\SJWDK232KK5%L%U0@P+0W^ (D,8K\CV&3@<==U)7A7S+3<2'+AVY[CV:;)
M9<@IU0G_4ZE.US*1_4<S' NA;>>ZYQG8HY_5@*5568V2_9VSRP18^QS%?"D$
M])(OR_ ;;59I -66Y<(AUJ?=M)1&ZJPVS'Z#&^G,?:O&-O9&P,VJ^U>"I2QO
MZZ.5$.ZDDE35%<^TN4)C>SIW>BT7&%YNB:P&[F53*<JZKUN=T8SV4,BYFL S
MJ@FT713#*JBHN%MZ[<= "*;DMN^ AR=XE/C<"GQ0?I+Y-J-^;DT.X_W<94>V
M'C+ZJGQ9L56BRZR)@YU=+K\.#%HOK;MJ&T73($0&H[,MQ@EBB'S4&3Y"S=U.
MW/;8A06>Z8X4%K33+K7SJ[J_&U:5PB&%D^\T \!329..I-&'8%WKJH.Z/UUW
M97?]#-7X/-H[W0):ZR.?TN67]*$F[+7 9('/GF&9%R@R0MU2H7\29Y6IPG<E
M6R#4P#)#.Y".S6S.N9_89NC@2!&)K90Z@NSI"++I;=LT625,BYTJ#L"]!<K=
M:OXPB!:9*T&LZK\J )KFC,F:'FK!.R0@@#:N"C7$'-1RS]G0Q0A4Z#*4Z)MD
MG]LFCQS&.9Z]-",>1@ES+-.7L9> H#CNZE7/]+>ZH>U0]LP>!MT@A,738U:4
M\(O'!UHQ<539>LB*G7$IRM#&0X:''3,NQ3'T7ZUUW-ZVPBL?RYA6Q>#%\_=-
MWRSB^Z7<5F5[QZ6RX7JHKZ4'&]KQ0=OW2/U#8T$,W7RE3N6%_N^$[Y-GJN.=
M8S%N]0FPP&556*U?%*WFGSOQ5A5;7>^.)MSW!?.DL&.7A7[  ^G9013&@6F&
MH96HCD_3&O="OS3'DFWO?0;@8-S SM>ZGWQI:+B+QA55X?WV&<'?,(M%%:QC
M/3^3[V34TGBH8P*61 (670A_.LP581";'L8W91C'< F]^K@GJ7CVS!",ARTF
M F*&HQ@<\\ 7"_3$D_0;.A2E-4">W7^ X^ Z,!7QI7$[W6'9N\%@6XRY,0Y1
M%$*P*)%1:(=>)%EB\YB[4F[5N?P)WWQ%._@5-U#:9E./T<*>*G;!UA]C.[E$
M"EYK:#C-]#9:Y87&#"Q[.PK,6FAP\3KK4B5<:B3L$O"UF[A9+UVHO? ?J_F0
M6*20K&(?^4W&5-;.%S5&<I5>G\QBVLTE;,L2H)GH G?^A*+K%UP ]MQL+<,L
MZ^P2Q=.@!,,]E\DK53];X\93&VV?3R8W% :^Y9O,P=8))BT[]+EK^0F+/>F!
M% FVHOFK:DW[('P;RV;[L%IM\?&BHK&27*Y*,GJY==#^B.R)-9U>T[FAS$F.
MG]'4/K$U">A1D9"O%F1LJ'=3\K4RXQ&E61:Z.[G\P :13KWB:E0)C;=!F9,J
MI+#K#'PH%5ZJY-"FWJ*^]T$N5+&L5'U7/5>J^[O0TY:SM9ZF4/:@4MY)S^Y%
MYNQ-SS(XAG!3^?J GJV\Z#H]794A$'0>12R P\^1VQ5^7EF ,&*9\T:Q0H=S
MUK7N80Y#)K!MA5*@GE!&9D9>5<8"*LV.>\"9XJIW>*CEL.&*UV7V[4W6@9,Z
MGA+/P56?WS<[JW33(T9_J*2$UEY518P9%O\<CD>KVE%56*XB&97=4]L\-8)]
MX]=]VV;()**2("4^RT,;&&"LHB?MI7>Z4@?"+Z?2V<VEL]XS+IU]2"GLX6R1
M1M";) ^&VAJTK%%=P2(IN:M$+>Z-KNNPE#8WNFRETCB*IRNVQ DHJWE"'DT;
MY+SDHYC?49SI_W38GLJ4"A6T5W*DXOY<5EY/::NLDS3/+X/4#K,^&*;.=H3)
M76[[,;C$2<!9;/H1<RS+9<R4X9,53EGNV65PX6\P41HE0M-MY0U9C':M6@F?
M=GS(&FL!&X\*S/6A499'*4.W0!2' Q5Z+4([*$;IICKX9CK^1 PM8GBEROXG
MTX2/PF=#(.*@-#'4W'!PW-2CNWYPF.,=*0#;^C9V-A^2!%H4 $L\+UM<)I7!
M'&ERL(%(^G.:S5"[/Z >]UA,M4:QSY[3AHWS>M'X^^.G#QLO&T@ACJ;2=EOC
M]NDT"I^7D2H-U)H+BF70>0VX /&-%*MYMW#A:PE@<Z"<RH1P]G'2_'AT>S<:
M>(KP=9/@ZU4^(*ZL L?-P'(=E=I'6-43EN6'CFD[KL5<1P9>;,>.Y?J19UJA
MW"ZLJ@/*5POQL*@JHBUOLJ</$U2M[_(46#UX8+7!_GL/KCY9&*LYP^X4RCJN
M4%;$O,!W/<N64<S<T.+2MQGC9A):MIMX\LE"6;:):>U^I]Q8*&M'Q3@IFK6]
M73%,"WMT;X8]@-]0^B]H8SMTMA^-(_/'FZLWKXW227W>+-GKK]/BC"QJVNBL
M ?ZML"8;$\1=U6$R4Y38Z%,O!6JW7P3?(KZ0GE2#NB<P?QC[3FSY9F#%)K,8
M"T(KM%PS]&(12N&$PX@7C]4/95LC_5#M1K*9&O#&:/?X5]LT7K0IJ-48U?Y5
MVSLB_=+HE2CD4/,5Z3":.FG]EUWW_"^UQB$5E/,[N5JFL<&O)4VBIXG!"/:J
M$=7P^E%/+^)[7?U.<@B[Z,O9]=BV03WNX#C.YV@@)*K?C;Y\L[HM1PAD0B9I
MG-*SOJ3YJC!>_/W-/U_J+Y#EJ'9==>N7I8.J$ 3V4R,ZE-7IY9DT J9Q\] :
MN'%], "MTO5K-52H$>M0D^[\+'N@6L_&DA7$62T5=1%G=[+AJAPG&,E:<? 1
MD<@UY$ 'DKQ+C.K?!-':&C*(TXDS^J8Z*7E[IXP\W?*5Y2GLG7#?&N92535X
MFPGJM% /H)Z)VO\BO#@LD%&P?^KK"DV9MX;?M+4A7M2T'GPI33OQL=&'!;87
MF;'E)5[((K Y$F\BWBN5L[PO.V/^B:MM=_-,MC?LLTM[J(ZN >Q:5Q,JL7&+
M4*[(2MB/TSABW4DA2L\%O16$QFOX,*L1>418?@NZU[(:S>FUA3PX7QE:EL,B
M[D3P'],5G%E^8MK,DI$7<T\\G9%'8+KAGN#M0FG&S!+"1OAJ@>UD(1*;C!UI
M!J;+GPSEP<8:J8N!^<J[XE?$"1.6Y3';CB4+O"CR'%.&26!';L!E9#T5NIUG
MNV>7_KH9KEVZK@1*Q]">"._81,6XV*8*B,I)0A/H(+(]TPPD.#$B#$$&.5RP
M0":>;UO_:[G^64.3C->L;!LW=P[6_!1>K"W<CCT;K+B(^9XP&8\$%QZ/N>,+
MQF+3E-V:2D5!;9IYG1880@&/_EV"L@@\;CVLG%31*_3=:2KYSQ@3*"-AGV )
M/\^S^'--0UX7 4^X+FPJ3!S)0Q!% 5R9%7A^X@0,N-B$E4B@Q#LL,\I7$A0J
MSJS5J*G-E70+PMMW.%AQM/G5[:4&8>#P, :5%0K&09FYB72$$_B!"TZR)S:
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M?]&'F.;UF<<-\IHUF0JY@/B6)LZ4L-7M"]0AYF)C(Q5S;8$(_)X=62P&JSL
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M$YIU5!;S-45[CHIRJ21DAHFW6,[Q;Z :$DFS'@D5M[8CRJ&/-_P+6B0$MZ2
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M\WWBAH[)A6>'KF7:EN>UQ2"QKV[<CM,J8+R$P*%LM+/XP++HO+BA-5B<,1I
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M_8RX8_:,V&=&G,,P(ZY61+Y11IQ"[0M![9V@=7V"]0[A>EQU)(N.F@Z]=DQ
M;S"LZBV2CH?>EU%V="L'=<YW>UZN77.W3J+MS.3Q=KN^ZAZ7>S1=F)K8=./"
M#J=/U+&O;-B&CKT%-EG'<EE'M\[0@5!VX+G8@>WVWBMRV-1[MV4-G&&>G_ I
M[_U(WOMB;ESDO:_1 \[!U"7EO2O4;HOWOAL!F?;>R3P/W;VZ8?0,_?.3<$G^
M+E)L',P'@2;&781C[0=\?&&)/R?JHN0;>#L(QCU'8_QHZR-)5[^Z<3O,M#JZ
MO;7QU+Y4BJT9N'62W+BOQYGHP'9[+JO%LZ%#XQ)Y'.GNJC]/BV1R1[%PY= T
MM=<:,^D6?HY+\922':)OA\+X<\'XEIY2KI:;<?/$[4XQ74.>8LZ9\'<\T*_U
MH)^2YHT[T!^0[63W];R>6YY*YKT0I2^$4P*T[$%HR!A\\*1%LOA[\4R=5A2B
MSV7GQH8_6UR)WFE(@(V:3QV= .;5C6'0CCUGPJADCF8TV,,X^P/0P,)"2M9A
MK.[[:0.1:?FKX@F_'_?[,8HM+*JCP8<(A=$/T7OJ:-$ :?'/T2 GU&.4/6A3
M\PQ$67O>S8'L6T7D$N$+N _8 CQ]T(9)#-@5I%J8Q'TIFN5O<1'5F\I5\2'\
MX">\708+T?[80+EL*;37YNQV?2E6_AX6OD6O"&NR.38._:J7"6H CSWXH]/H
M?;>4T4.\KPR-UX]/R_>50MGDE;<4R4.\LHNO7&^I,'[E8*':FI;![G:S7(ZA
MD1$#'LLV[3QW.+1[;.-T'6 ;ZI!'B?8#S2@4]%+F[_/N<DL(HSWR=#F;M*5(
M:IN65O++MT"G\5RB.KS;NHY.F%,/NJ^ C@4$VA)"VD@@(FNQY]0_K@:;!43:
M$G3:2"19M=*=D]BB#462FP@S:*2A<&=QQGLXF;OH)E^3Y5*SKY3F%FGY':4X
M3+H'?$,J;>(V6I,-6C")-[>UVF$MM))NX (9R[3OT0V.5E+-Q*'BBZDV P43
M@S_'@VFU/FW0/SY$_H,\E-Q2PQ\$!;:.Q):;,@9?TG@OL)V<.T?T6^(CM(9.
MF!ZVS)=JB:BW@53@A1&K.R<FLDR^EU4!=*0;GTO_: #N?GP_ #\!@_^3%Y5I
M"0/P\A/1XT5V CS]N@"#*9SHR- $/*^\-APWY='@<FDGP$5-46+#<'-M)]_U
MA[WX28@[D?R(?#$?PS_%@_S5Y!ZF$I>KW[^)T^Q3G/U#P.)*@C7>2O NZ7*H
MSA&W&@'-TT-2I/]XJ[08S$6-U]VUH62V>B!FSP=A>Z-P(3QQ4GR$UZT^[+*)
MCJT1C=GP>#[7=<8U/_+85!G/NQUE#S&.'0U^'03@QDQ"&5]ZX-&_?IHZG?Z*
M"%0;JVH34ANK>BIAAYDPXN0<ITB0&J>U:=[3)/XX1&)H/%L <QI05@/(R6>\
MIB_7C\@ )4YFK"MXRXQN-L]S^7>&PW8_)91U'6,?(TWWLEBS2ZBC%JO8@!CK
MW7;;FKJ]MMXCYNF6*RP8J"NU1F%N:Y73?VT?V?OC>[CG3<=%Q9)[Z!W50EI(
MVPKMY^GIONN,;=ZK>)_>R*SY],V3HI' N>6[E:@V'/ITH22?';VLC;,(M>KH
MX(]1*#!Q0 [G5;MR\%V9!AP-/-]<1!3R[ =Y%(NWD\4WK0+;B&JKAH(?*]VX
M^3$W,QW7H!:U.!.,<9_[GL6X95(SX-1S^6Z2)=8*5]6#51_C1Y'D?T7]*)MS
MIDTH'IG.:1>D76]TZM]J<OPZ'*XBAX%Y2',R0;=OX+.+)LT7W/S4=H@?N@[@
MM&.R0 C7M7S=)8$(?8^[PM^R '%#CLJ5V^>PX@07_ES##%2;X!F\:7<LNG7?
M%#6^N"WZN7EUU$;XN<X!ZH8,7F?LG35PM(EY=>-,\ER/61JE!MY?X,#[S53*
M?!/E8/(V]9/7XCX:H/"]YG [O])OHJ)8+$SNLNLFS25H%653G:Y-50F(;VI3
MX:1&9G3H]KWH3HG[E;)3RNXDE%U=PI<IN[G*S9'*;5'*=[O$^T!38$XSCL99
M:'DAH=0-74:-P ULQAW7]X30&7-IV^-HLH!-KW<IV3".UFIRK(ZC45W6$^TV
MD+;NX8IJ*7P5&5Y@"2<$OK$$([;I<N$ A+J"A,0,?/W4PV64 /!W#-/LM*N7
MGNIUND7P:R/0.]'@%Z48_-I-7R %C VUZV;H>&J1'VK(>E5SZ]9I+<;'"V/I
M$]3UVX=Q*';HZ5!".F1GPP(5+Q^=ET\+GK>/55!3PK&[=;"B?:V?SS,DX7FN
M9PO#]RW+9+[%/>(3[@7P-W,#XNDM#TE0*_?!=Q:3:#4]UHA)8.USBY-[S@G;
MYW?',T/"#0>S&7RF4YN[MBM,1Z>!ZX6V&YY\3,*YNF$=G9&.N_W\/=6NN!TQ
MB8U [U1C$BZVR2*'2,BY5&!<TE1L(W0\M9B$H><-2,ZYG?N%L?0)ZOKM8Q*&
M/'\@)NV8YJY2JQ0O'YV73PN>MX])&%3"L=&Z1NLJ36)!5\V ^B%Q.266P4AH
M>XX0U&,Z,7CH6T2T/"9A&+D/OK.81*OIL3HF83!P&>>:0RI/XC IL 8#WJ$V
M,P5AOA%P.R2&Z;# ,5W=L>FIQR0,$P2N8S"CXSCU_F?G<W9R47D2&X'>B<8D
M#&NJRZK*DSAHTO!&Z'AR,0D\&'"[ICI;/AN6/D%=OX.8A(.ZGCAVAVP?7U.\
MW!9>/BUXWD%,PI5P;+4IK7?;/(E=G*7MH,BQZ(UJ !6">(2=5F5QRP670.YY
MKO71_3^&A1AZ1W>=CKM]\MP.N:DM >Z+.LS>V^S=%CJ.C.!AMMF&[A(74%9[
MWL6SNQRNWEX_F%$Y:MW<5;%\&^%>V4KG:BMM[S\S S1&QW)91]]UPXA3-I64
M=E/:[03#"(Q=W5#2->H#G=LR0SX_V9TU3^'?N#O18,3S@^"%$U,FLV-N_M-+
M7LP<&6__LX*O&.W:.$UE&*=R#M!+.6TJ^B$F0U3^=#7UP^)!^N0GW -L&V6+
M?U+SJ0XO/G*:RWOM6D,_>>KPO?*?#TFYHB$PX;67"/[]FH>PX)>\]\B?TJL7
MTZ0'NL_0<2D)ZG.!YFW2>()2E5,DXT=AX(8&%DRY9L "87#/"0BQJ>,$%N8N
M7:W%&7L@N[SCRRB#3?:7-S&6&_%5I!D(!$XUR^<D_ I EJ[)XBT;LU2.%.-R
M )?V]>Y7.59,%-.[TF[^$<Y-D@,A TW"J 9[BA/)_!Z(T>"^F+L4A]4Q9?_V
M!X<2^U4Z-9:^_*$<'UU<+^=%Y_-HIR=/RD='J5:91X?#GW@_!B#[/5\%A_LF
M'-_J&M\0EP>_D,/0\-Z)^-<H DD76IH/(JO,0\/OY7N76S=G$ZB)_SN]"6^
M3[PDVH[XW24/W?O.:]/,>M!Y9S4U/!$G*4VW@V#F$RE>MSC,,,J>OJ&&JD\Z
M8^;)3CK+AY&A%!43QD9]6"_<1(JCQHL71X]!#C%K,+6L:@/\<Y1F4?@$+WHR
M@\Q,UB66L?/Q36!Z@1&Y\UE3I$O(9A.LELZ:<KNNN9-94PWBS6T-*R\85K3N
M\(;=4&!5QN[Q[,;U9BXLA(^V+%A.O-=PY+V&,W(U.21W3M+IH2O$C^$S5T*I
MG?%02ZV89TD6\KQJ+KNR*XG)/:(SE]G"PXY.)J'""US+#!U31A5JH[/7CA:N
M,?O]'5BEV=.' =@Y(_PP_0S&:/+M@0^*D,)X,FX>0VP<+[0PPM QYU24M[']
MI.HNJ[K+[K5C2V-A7[/Z8J>B/A-&E&H0M>!X4/P\0<\[1[CU6?!ME/,U+=3J
M(^R6RZ'<)1&LH8G/7JV&!A&,&+;A<<Y"P5WA,&XSW?%-W3:"8$7!TT'UJ]RV
M],,@GR;?6+UB.PW;ZM@V;29W^U.6#8Z7SXD1%^/^EMQX0 4PS8L;:0%7=NP\
M C/NR <[":C_N]32V_A<)RAYSTY6!X!=E0M830#+ ]K&N&_F*:N,U4]NGU](
M"M()LO!9*X\<E+91'B:1+H35NFR$\W(4WL=)*"(\-(X33?P<1LFY>@VGJS)6
M2MMX$S?U'$QZ=6/3CLWJ%>^+-(CR&13L+V+$$8C31IAOH,-@-ZQC:Y'#T&JH
M7WIH0W=P:#,_9W=IVNY%'.Q0A]F&:W+7UP7S/>;JGDDHLP*=VXYK&5NF@;?@
M8,?$KCS$[.C.KMJX[HZE6G[Z<P%G/.=]DK.9=)_*28Z9CYS>NA/287/"5R<)
M'SJE[C8;J]R<<J7>[6#"9R*T1YXN[^>V$[:[-F?Y[EV14WN7)Z+.9\,Q"TF.
M2[_%&>]5OW\3I]FG./N'@,652;&3.^4_FF7+]72,->%$3![HUC,'--BM'A(+
M<V=Q84"U2FJN7UDF_"/--)F-#]]D,5R9OY;,Z>UHCP^1_U!-%D:/6/B93#X>
MWS-/X^7P05%JJSV6N4P\EZQ*-N^R+-:-[/H#[5[N1X(]7WR$UY&Y-<2/H(A3
M,9CLDWUU$P^$AK7%LX+9G<F76E:ZT2"['W\E<_E=W6*!1RU==P1C/'!=4PB#
M!\P1H653\AM(WM5:*:K%)VA>& < C?DI_43OYF!1@.U^,Z(_#$!6Q#?^\VV4
M8@8]>''UC&;3R7$(M@SX"3E!-RW3H3XS34$9LZCK!-RD8>"8AL6PQ?],!G3^
M& V> X1:6&R^N%YC]?.FUV=2EWH<KC,]@PD0ML /C< RN<_@5O;2^HX6Y62#
M*$ID0K%*-0'K"19J%$P=D34)\(=>T2\-U,M&_+1,S[P9)0F0<,QD[WXB_HC7
M8B!"[/19509A]!/ ]'>1Q/,L$O?J9A#7U< PB7]$*;X6IJ1'.9=EDLN"D4 $
MAW_(''/@[10^O8=')Z@).EHXZO6> *[#5&2:]P3@CM4>.=-QS(/'"O#N=K4T
MARIG>"M" :0.@,:W\)Y9>CL(/D;<BWH XB)=4*D N#A;J7"LRH,43+XH!/-O
MD$GM#<H$K-J9,IY_AUTM7K2RUQJ7;ZP]ZTU>^#FH9^!_8/^\I &^C;#:)Q[!
M0H/T^;APX; %"*[;M75[D_H#F\$OK=VG].M=RUC\]:;U!WK7-'9?+"$7N]Z"
MMJT_<$^T_J :X9MRTW97D+%V6E[+2;4T_MGD=2^+9J0)6YU%"/WM0I7S<AW^
MV3R]=:_M\':_PAU-)#B-$W0!E.$][=?N75<;@/T8#]&LQ+@ &IJ:SY/D"4S2
M:DGO)IT8SRTX/.\53S<XO),.(=?&K%E?,^8_E\SU$7CK386UTK< 2"G0:KVX
MFC&Q_,G5#;&,CFZ?80M<)6!G*F#"]0W;)A:EGF#<\<%K)MQT*!&.J0OBSJ^?
M.8Z 89<XV^PX>L-,Z%8WZ#TE%7V78=5N0]U\P>FGQU=F<L<P<!7[*%,-!<ZX
MNF&L8^\L&:%%Z02**X^H ;;C2LR1<3ON*64TGY6C]E6D@B?^@SP9"<0/T8N'
MF#"A^;#[4=9!!;&1$CC/$0J'4@+PQQNY 5.B5FY68RDSKVZLG22BM<^94<RX
M=^S?,3-:P(QZQR1M8L9+,OP_)\,'>&J0C.ZW1OF+,*H.C/(R)ZRQ5-E7-X;9
ML?4V)24J\_ZT(7XS3L3Y8:SCM&H P"69])\GX1S!4Z%5TCZ4);\OC._?#WXN
M\YIQ)RH)1XV%RKVZ<3NFL[6;K SX]O+@MNB^9QZT]:L;NZ/K6^.ZLMNWR[-(
MQ \QJ+395&;2H0SV\H,\87=E?FY%=LC5C6RR3E^UR"I2]GG+$'PCQEL#N?&P
MM4/GM,)1%OE!CEI%SCG$9I,$[7&:G#+*]VJ4%\0'VL]*56,QPB-4HT/<-J4L
M*"N\91C>B.F6&PUL9T:#,KDW-+F'"6RQK'E2YO;!S>TO":8F94\XW2V['<BJ
M?GDZ/4]83+!Q6A5S5-9URY!Y$SY;'ZRM-GIXEV1ER],*94P?/F%QDU,BVP:X
M=CNVL?5YI;*EV\MS^TM'W(CG'"SJZ-ATZPD,RIS><  #YI<O+E%7,Y):!.MR
MLQJ+F'MU8SBD8Y"+FF:D&/6(NF C1G5T8%3#ZA#BG@2C7I(A__=ZFYD+,^L7
MM^4^H (8;\-MN0N-A8R D-FT0ZVZQ;7^$ 9EX+>8^_:&ZCO@/@K<1^V.Z6XS
M J1]IGZKL?N3R)2!?QH&_J?F)Z".@6F(^IR)"&VTF91Q?_K&_29,RJYNG(Y)
M=]QU?;^&?;F*<@/R_JJ[ME=._1Z7H$'GM=.JI/!OU5.K+9VS+KX_UM:)!:?K
M71S7]*GDO^_BU-<QVYBBH]S<$W!SFW/B&J:/A8F^EE-/@SEEA_<D$'VVZN[K
MYU]WX/2>N5CMNNJN(E/394]?<8&?PU]3D;L5C07+QMHGD]8S?]4PV;/@Q%W7
MWNV/$W&>?<>TK79PXB49[5\2,>3@^^/\FT&03W2\,./]R =34S:3W(QB8D9S
M,7+14C)IO;VK.I@Z"^[;M\6^%?>Y^M4-'HO6DV24G7ZT'+1M^V2<XQ' ,?%^
M/!5IBYX%+EET8-786E)G5>?"J+M6#3MA5+KHT*IEC+HC@[_5.F)I$L.+\1RM
MI\;*>N4 YPMHO=^,!NU&G3:D<51 IW98OO3LPC5V?7;1:&M;/@1#B>K%BNK>
MDEDV%]6==P(XB*BNL!7*J9'P-F*Y=!_JRNDIZK-3>#>:<'I@7A\/#"V'=8\G
M=*?SQK<60[R#D2_F=*:1W^)\4=X'%LK@3YYI4:KUXP3;2GX7O2?\;* -X@PO
M]03<"QCA=Q%TM0\#>9,TQ3,QO(G\0?00YS/ \POE<CH:O#&_%WG?^7B01L":
M.)'TN1:.,,HJ.YXE*8@9_E+\C%)YT%:.KLU$?Q@G/'G2@BB$=Q#X8J_@]Y,;
ME)<6QISXZ?=&:?1#Y"O!F\L;SKF1;(Q?'8F2WQEN/7//:* -DRA.\HM1\(JQ
MQ%%8^0BH-Q1)/\IPP#J()0Y-'PY[($+R33 ,P1]?R8<^BW[(AVC I@,Y4CW-
M<#3O/<!'5_LV-?85Q[@T&"->< NC71OGL@[C5,XR?RFGP -97I4#125R5GY8
M\+H^^0GWP,$898M_4IO8>"2A>*]=:X8^0Z3*?SZ,<_"&P(O7'C#H]VL>PH)?
M\MXC?TJO7DQ+/XC^#!V7DF"]J>U+9GROG-D],^.;P;>ZXWD^#05C(769[E/#
M]XGK.8'%[:OE8':D;5KH=Z'H(,XL 9]1%DGP&<^V1M1!J0,I3T=A&/D10DP:
MCQ*$/OAT/CQ(D1_U1[DP:%X<?R_G8S\^1/Z#]L!_("BEHQZ*<0SX,1E#WIT1
MQ%-0&+>2&(LFIU<F3,.;I_E0Q["8\(BT2A>-DGKVZ?/'Y]/HB0\"Q$OBGV W
M9;B)?VQBFA%N^ *LLU XS#5-QS1\"PPS3QB.ZPBRP(NJ#5YO,M]FY/U3^-FW
M^-W/891(>5PON&--S#?SZL:V[6X]W*_!9O;@CZ[V64[R3H4&)$L[C8CB.Z8%
M5&$&,PW&B./Z;D@M4_AA2'2'B)82!7.5;+J$*-HC_#>>MD:)5*\_..C745JH
M50\48:X6X2MX01/H!Y;N_0/\P["[C2AHZ&806HP0SS<1)1V'AX[E6SIS0H-R
MJZ44M'&2AKF,@B!LR$_YM/=[,<#5 &*!]L[&XJ[EDD[LFJFC(3*%$= -Y#2W
MZ, IR$VVI:" H)V/EI#RWF0KN.?9%A568-DA8X[E! 9GEND*PPU=PM>6\+D=
M[6^E'=N8SL[5C<N6,JK4"HW8U:BP*R/=T],9:(".4FE!9U.VZ!0G /=)MIIP
MQ(PZ &H42CBG$Y?F/EBZD9]--+D/BOY>R*NG'Q8_ D^G#]%P_!2>P6\]L$CA
M7OZ_1I'T: I23_]6?IV;L:"UE^O )BQ,+!-4$BBD@+O,\G0O]#W/8\0. N()
M4_SV%N^I$YU<+^=EF52T&$(^1N!'2.1(/P\PH6@S[L9,"*-;KY&L@LB<'7X_
MV>%\UWJX'" V/#YGC"FS*.=Y&<0@K_ ?#FYF+CA<2W![<S,-_RU?) 6JCGK!
ME&&'OBO^'QC&/<WC:=087WQ*!?5,$H0"@SO"<?R PE[1T(7_MYQ5^+)B3V[E
MTB8[L]&>.+I^=:-WZ\F&XRT!D6CRTA:Q=5^$)O$-G7FZ[GJ4.]1T?<H"'@9^
M.UX:9RYWZP=@$QL)(2<1?1Y)'&VD53:+OJ]+@$]Q-M;G$S(T)@ %,]$RUM'G
MA2]4BERNN <H*G$8HK/$[X%*H.3G.C@=$#.Y6@FM(LG@VOQ>.9I($1Z(1S#.
MQ8!+'):1"5!A:4]>LJV3,Q5:FQ%0BUI^X#';"G3&O8"#K^ISPPX8\W5=>'/1
M<UKWW_D/(ACUQ.?P71AB)]8?8GQ&^Q4,H*\"GN@#I,AW^8:4^0;/?]V+_>^3
MW3"N- %[-$0'/AF)(ZK99&J])1XG8A@GN#<X@+DO[;J*S^R!L1=&V;P(WJ.$
MU=Q]U;PG&8!Z*J-T4]H;';M1%B=/\I9H.Y;W0V>O#'P!_"/+8$P1HW:HHL'N
M 9Y,GX^KU61,=1)%DL%G(&&/#U/QLOSC51F3C0:2$/)'KZ89"N,L,T%GR5_Y
MUT4(QG6[MFYC%*:(/A</+@(T71F@F0F5Y]]9M$N9L?!KO4L6?K?LMD3O6L;B
MKY?==OEWIJ$6:QGK+6C%<<3*G!IBUJZ=<^R7!SF/=/9ESSW[^@<88-H[ .!@
MRNF;.C/:ECB5H]AU\T]:3C74+NL4VZY\W<NB&5$T:TPSO8DHGD65^Z\#:;C*
MX>'I5-P(#)2)V8$FQW[RW\XM9:/9R[<[5Z-),N=&[L)TUD8*+PQ_S7H1$Y=A
MROP>?UPD_[_.#>W;K B(W)7,.^5R-,P'=70&P&!V"*NW)VQ90NB.,I>55"NI
MK@:LA&WK(;<-WV*F:3F!JWN>3JAE&,1P72G5I)3JN;E8K91J\^J&T0Z;,XE+
M2;62ZG.7:JJ'3DA-4V>VS5S# "UG4D^WJ14:KD=-*=5Z*=7ZR4BU!;K:GCM?
MKV52?0G%&]*E0$\";OE,YJ2$8_^B"(K6=D75S1[/GI;[=3L(/L9 K?$UC2NH
M'%VVZ##FC,A6%=UGP9D'MPEWQIDX=X1V0$\HUCQ/UCRX8;,SUG2Q[!1>N!V<
M>0F1SWG]/7GPSU&:8?W#I74+.ZQE4DGF6"<SH)K..=FA,KNE)DP$9XKH:@3E
M&?/@#FR0/?,@N;IA]J[ZLRL>;"$/[L#8V#,/XN -MJOVZQ=9B+JWXE9%A/./
M@'T5J>")_U DW'<P64]%O/9O5Z[PV<85*6FY04V]-6+(WI_6-F?"*H[08E;<
MF7FY?U9D5S=$[]"M.JLI7FPQ+^[,S-P_+YK BZQCN2UIYGH)4:S/R1!K[X-D
M=+^UF7&Z7EN[S8Q-AJ0[Q)+ [K"6-!A7X8/3-S(V8T0;.W2S721 *CYL(Q\>
MWL H^+#.:L[5C4FW&9K3OHD*[;8><"-D(RP^P(X\42;ZES9*H86F@]R6\4>#
M^P^X+8UQ6TY6,*QZ];H:B'8V''DH&V(G'$EUY$CBUBT)Q9%GPY&'LB9VPY%$
M<J19][&.QY&7$+7 P8K9T[7'4X$OV<>D\,UGL)ZNF=Y"V^-3C/7I(UB/UQ-%
MNO[= T_$:]RL-Y6]>A.G30=C.I3*P9AZFPZEE4=YHD;)GEG50%;5[:VM%<6J
M[6750UDK35FUSHWLZL8TVP2;EQ ?>2/;'>9-)&L]VU6<Y-BV2KX]'P:U=J]_
M+W?KMMRLQNB/%<*L8]GU,B;EK)X-HQ[*4MDGHUI7-Q;K$%?%^<Z840]EI^R3
M46U 5*=CDGJ-DPJV[)/-/DSJFT1N>;YXMJ@ >\VR^/GCBE07B:U)<S: M3\3
M<+J%Q/K#NQSJ[&QXUPZW_#0:PRB!5P)_+%-Z<X%WE< K@5<"?VHNR<8";^CG
M)/![&()YJ';_OP[&XR[1A2QV,OT:]WKO\U$-"YK]XTU;T.S_=D&K_\GP()ST
M( :!_#-OZ0^7  NE*<C,Y.6K(P!2U:'_+)O>G]1B58=^U:%?=>AO!\U4A_[F
M-+N\#OVOQS:'QWOSSIW7M&$OVF>[&*],N+YAV\2BU,.Q>CY8\H2;X!()Q]0%
M<>6 M36B+PLL^*:'/@:.4NL0U]ZM/W86(18ED)<@D'J@NT(X1D@LS@S'=;DC
M:*B;CLZ)[@M3"N0:T9%=":1Q=6-U"-TZXUT)I!+(]KQUDX,*W><T()[K&19S
MA.UXOF50@^O"IK:A2X$D[N$$DF$O(=?<.BOBE!K7RV?;+9>D#P,_$3P5^1A6
M?Y0D6"*+0Y1E5&\8%R.K51[HP9( %LC<>*>^REFJ0-#W2=Q_D^_8%WC-&*_^
M4F[8/"DTKVY,MG7+6)5"UUYFW/D!]?Z8T;JZ<2V5>'S&S+CSP]/],:-]=>,8
M;2K9WE'0[[1LD!?/8/?S/Y]+>V0(>Y?LRAHYW5JOXX[4D9V;5XC>VV+?IB3P
M"^[>>O+G7-T86W4:5?6'[=4#N^UCOV=.Q(8R<V;GJ'+8LV''W;:TWR\[,ISR
M8>SJ8*%%P9%6&R3O\IRGID>1Q9NJY-+]DN9L@(@[PK,#8MN>39E+3-<"#'),
MEX$6H@X)Y*G)Y@&CID%:1N1,0WM7?8).(8]\A2^O1%V)^CEF++!=92PH45>B
MKD2]S;D0;%>Y$"T0]3T4BQRE\"+%.HHR]3K?!H-T-+3V9,T%ZH).68Z1Q1GO
MK:JZZ&A\.$SBG\ $F>@]:7_<OQEJKLFPWQYX]G_B42_XT!_"8L8CX(KA;^OQ
MLS7A9P:JJUOO$:7!1O5DZR(@8)/7WU U'^OU37S]>AN4\>L_XK.TD/^($Y"3
M)RV2CY6<A!VX^.#IWU--E*NHSH5-8#D=+1'I,/^N]]35;GM8O'/_T-&"$;+B
MS'T"D8FD'PWR^J$,7E5>$,R;.HL=-HK5#>),Z\>)T'K1=^36#*=[X(>>@.>#
MY ,)@:/G]:,J[B O]!%LX$)LDBJ C+!ZK)G#T2#E:^=7)S+XHCU&V8,L1UJ+
M%%WMV]2%(WAZDG&X0>7"\D0"WH1[42_*GK0'GL+RQ&"\0"3;'(H GL 7<1@B
M7:2@(Y6R+(F\428TGR?)4YC7D1755VEW#-8G@W7OXT2^')[AI%A,5BDZF48^
M^9^DQ#^]4]TG2=3#A?@^?'J__M%C7L[Y10QX+XM$>CL(/F!-@4BSHL1S96VG
M/I%NZY"!]>.]IGW(#)OCO:9S=0.H5L/JU1]H%36/[!\5:]#P3+1<&US4 YP*
M2EA>"E!I%<!#A,9TY#],\"N:OMU"*$JUQX<(?OC  3$1LI]$EL/=*(LD<$_A
M)AB'L%"\#KOR^#A\8<:*F0>FL (\@XQ"L 0'&2B(\EBX"N$#X \M>Q0]6$@?
MV.5A"3RV! RG%<JOW;NN]EZ O0SV'<)>F@']I]20R$8);%V8Q'T 1=W0RC><
MLWIJXO_N<?6E,DI$'YDL!D;$G1(_^=@"J/"89)H8S'FT8T>#43J]U_D8+[1;
MX<7+]V-:^8P5-T(-#\\'-8UQ^AZ8QJ+Y[M_\IY>\N*G]ZN!57S3/@0 )!\'6
MOHH?8C!"/@F$]NS#US?/M3N10R2QV8+5+GB5EK&_M 5@[W-;8%)FCJ7GB<9#
MH(#V-SX8\>1)&QL%R * R-J;$2 ',LO?8B_5;GU9BPZ@;VNB%TD&1(,*+HZ'
M)884V:P2/[ M+=J!^:Q:O$\ A.[%0YPN7;8,RQ^0B'^-H@3OQG\.^9-(I*'F
M\V&42=-47@06&3BJ\ ]X9%^3[!FB$9F_&^:N3!Z&YF4D$1M8%K6'% 6YV%]!
MZ\&_[C*Y?+PQ,=>^1PPDB0(QYT;3G(#:!15J-,BMZ2G>*':(T:Z-M?0E!K^4
MV@#>Z%595RW#()4?%K:F/OD)]\#?!X6Q\">UPLMC,:)VK1EDADB5_WQ()G7.
M]^+: ]WS_5KRYTO>>^1/Z=6+:>L;3.\9.BXEP7I8=#!$FD^D_YSA&FG51"PT
M MWQ/)^&@K&0NDSWJ>'[Q/4<,,O L!N.DG0$:AN%!N"KBEX3?Q+@;7 /W"W;
M1<!3D(\3B>6 "FFOXD^6'MP0_$*$">E)P5?XNU(D"Q]Q(I;Y!X4@HX1WP/#
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M:;!'N!5AA"3 V%R6")[)_*_[!*Z>#)R_>_>F.QVM6TKZ5M*:F$#K/ZQ-Y:!
MU!DRR\W27_W?/__YS_]/_DU>S:&W)WP^ E@&VL'.)$(;Q)D&\@"+!C*C"."'
M2-GL:8A_\$S[A?M)_!<QB/RT*#J3VY&B  V3Z ?\NA2>\8Z--V6WM*1KT5*K
M_,^I,X<4Q/]8Q!P?"@Y(80]Q2J'D"P0QQ#Q-2E%_* 8IS^+D21OV^.#DI442
MY,^+"/)^"J?/Y&47O^TH&43IPUIOW)YY*"^\.'B"_WK(^KV;_P]02P,$%
M  @ ]X!O5EVGF:-F%0  1^<  !$   !M9VYX+3(P,C(Q,C,Q+GAS9.U=;7/C
MMK7^GE^!ZYE.TIEH+<EV-M[);D>VY5VUMJ5*VDU[OW0@$I+0D(0"@%XKO[X
M^"Z*!"C9"5HZ,_':),Z#E^< .#@X '_ZRY/O@4=$&2;!^Y/>F^X)0(%#7!RL
MWI]\GM]V?CSYRX=OOOGI_SJ=?UQ-[\ -<4(?!1Q<4P0Y<L%7S-?@9Q>Q7\"2
M$A_\3.@O^!%V.A^4T#79;"E>K3GH=_MGNV_IN_-+]PS^>'[6@>CM6>?\$OW0
MN83+1>="_.?TNS]<])9OOU^]6_[XPQE"<-DY>[MT.N>+Y5EG<=%U.Q>7YV=]
MU[GH(G2I0)_8.^:LD0^!J%C WCVQ]R=KSC?O3D^_?OWZYNO9&T)7I_UNMW?Z
MC_N[F4IZ$J?U</!+(?73@GI)^K-3^7H!&4J2^ZO@*4WN0X>2%0JPP]XXQ!<2
M_7ZO?]9+$DLH7 .. \9AX*3@+J<=OMT@ME]&O#Z5KV4^W4ZWU^F+G"#G%"]"
MCFX)]6_0$H8>?W\2!K^&T,-+C%S!K8<D>X4$N=<<TA7B#]!'; ,=I*_=AV\
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M$N6-#Q'?!B* ./SK?_]Z>O+3%YQ,A^/1WW[F?V$__X2C-,[#T<>__?S[A]_
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MPC6N&*=7(XHG^)]G.$K?YF8J&A\PT3*L57&@8BT8J03M[%YPP7W2B*TSESK
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M^[H<V1^O^M?7?;GH^&TX"J.:%UR+J4S.ZB//XX6=#=Y[ URFFEZ>54T+)>.
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M-"_8OA70ITFN[76U@F$['^9V13TH*B69"JLY2Q%4EJG>328HG#9OZQTCW_9
MI'J:/-I((RNHTR#(Z1:@OX_R<#HOH(;YY==$O_KLM'XW$%)J1*4A,DV$%Z*
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MCPU/$"--KF89L-RZ0>,]IO!>2AH=GL&;*'V?)8TL\]QYY4%HFVK= ;*3<HR
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M.[ZLD/2Y_EEK+A.D&[4!!]PP>NFE V,5R:QD#SX4!5)9S<G!5C%T\RVW!/#
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MR0Q420&BPPB2,\V=2D+J3CERA^R.-]8?/\%@4 3<W16/U40/;ZI7M%SUDNE
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MIUN*1PD;Y]*BF1J[P>,$'0P.%)V,<!X1?+3;+N>U3"@C%(%<96ET:=[\;@2
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MZ3AY^]B8:G[XD"!MY\XU <M@[\-'[E*[]AU=6!IT_/-)[(S3CFMTJ/49R9R
MDV=B D5)A0D9<%$GK47R#ND_!,Y"3%$[(=R$CH!AH?]$H[&7@/Q#X-&\R_L]
MHGXB'?RP/#L+JS7SZOV2I'&9)'Y59",S>B<3Z$JC,N1\!F4#,&+":^%B*G?:
M5NWK_'[HTL\\V#U&V\O!5-6ZS?RCU&K&WR_Y77(3.EWG\X$14H 2Y(<%S31%
M-,FQXNGGG$]'UH-KOT*K3V4-NFGQ+;WB+KT,BY&H,Q3K-2@O CA%II'H[]M0
MLI-W<ZB. =?#B[^BJU=U-;Q&>YI>L:57,<%OT:N+ML9$HM>Q"$JK $$F <)8
M6^C_+HIN@S..6/P57KVJ:^\#8_\='V\(+RSR.UQOB,<ZTJ!^_0]:]$W:S/^<
M;[XT;P%Y\,I]]80\301W:N*L#PPYB\*A5[K8P!)JFQE3S'IE\YXFD0?3,'K7
MR&*"CXHQL 4+&9,+$)UGH*VT1D3!DIS,<."?1^\:>3\YJ28@_725@!0L:N==
M;7U#X:*I$WZ"421:99EDVF0W&5D^RLE4SHG>D-QC1<*Q@)A24\B]$],+(T^>
MAPBQ!'*VK*QMGEP"9E,H)C)I9?,YLZV9>$;@;HBN_@!_!#0F6+#V-_J+F_7;
MQ65VP2QB0%8" T9;"BB*(2"*+"%DQYDS*()LWORK*0>O*!\7%'UD;&QG"J[7
M%YA_N%B1F"[)N@RF;GB>UY%3GDDO>."Y'H*6@\*0P&>.$ *729-@6?L:_(.I
M?(5J_\H=+/>UNQ!):@7GFPOB[]K"F!3$5%)URJ:J62H<?)2QSE=023GE,T[-
M@WZ C5= 3P >]Q&OQD;\CY\_S5?;?_.5)321NV0XD/=$+#%6P-?)[KYPH:+T
MP:9>^NBV9>,5\1. QWW$Z]X1O[?5YGZ>'LN*G<GL1"HE@<D"0?$DP7$A:X\Q
M+$5R[_W@32 :\_AJ*U,'UGU#,F,?'??C;=16"N<$Z$('HK+U697Q *D(Z[,U
MP73K&3J=JY@Q#N3KE/V=5)7FA JG@419;S&*@V@\@USAK+B26@Y3:'4"$Z\;
MS.C0N+^#N+&Q_@]<U[UQD:_;]2_KE^YO+)%B2B,% \X5\6DT@ZAI8Q'*>Y<<
M9N[UQ$R@*V^OEC%5(-TW&#^VP=P(0"^9/<3?N"Y/LXF<BQ0,V"Q"[7;M(1A!
M?T25D=.VX<K4K*D)X\_(U*;QA#@\W";X"M.QZ\<,HZ?(. N(-?-+&<? .\LA
M6#JCG4O"Y:FY:1U9>T9V,QYPQ^DG>!#JQC"NIV+FV\]9C[*J9%$"I:IY;JY.
M:D!PTED*-E5DT@<>_. /_>W8>S6R'HQL)/0-UJWSH,NI2VZZ<2M8H?@Q)N Q
MDC//0H'@D@&T-D;.;$E\F**OOCA\-;<1S*T_#([QEOP4MP^\%C[*;P[<L3J\
MA-.. BH;0X<Z1=$8930RU[ESS=M3#,SCJ]6-8'5]XG""+]I=/6<G$MHD'; 8
M-2A%; ;F X24E/(Q:S2]-%L:.EX;]0GC<0VDA(&@#]9DL@HM!/B<'$2A3"G!
M83!32VCLR-KK/C=\Q-P'ZB;XZOKT5?>CW$>?I73(P<9$FWL(#D+MPFP2;7D8
M221V:K=4IW'\:HK#F^* &+UOH79L"WV3\Q9AX>R'^;HV -MJ\DHOSF,(EL(8
MBF*0F",.77 ,LD.T$E5TV&DZYX &^"A#S\B^IO&HT@X>@S7(O\]</-A#W3\3
M $WVTF5ROUT=W^ET;?0A,\2$3(>8DA2]#(@9ELUG9"?M@=JIQ^ET4#987^'N
M+._W;O>QS&=)66Z4+A"5-13A9DF[7*X:\P%#B;JP7@;\#<OFJV$]'Y1-\,0Z
MV%?=+PG!2]9,>#"&5Z\")7B1!11I!+,Z!Z^'F;\T!O>O9OCL,3G!@KP;++\E
MSN:+]3S](YQ=X,P9.KF30?"U0;E*F@'IR(#DLAA,N0:[$XNC]C+S:CM30TQ?
M[QIMSN;;C/&9#(*.7!X F:N^;2H0HI%@O'%::RXM[Z5"J1=N7HUA<I@9HXKO
MY"O&-Q\^K/!#V-SA?):,DM9F#ZFP#$K07A 5H[/1<=1!6^W#U-[]CF;VU9:>
M&^*F].+TXS\OYILO;Q<D_(MMHL&OFX^X>O\Q+'8B^66Y^',KE9MU(%$GI:3/
MP+(7=,P2W][H!!:SD)@EXW$R%]Q'<?B,C&KD&^_^ 32ED*4[MU?%2(PGV@,D
MQ%HLI2S6VBGGP#/T01GE,4WF+?90YIZ1D0R TN$-Z@B(3:GVYDE&[[3!,KYH
M%)9VML1<;8-%+&*@4"\X3*D8H?J9G#< ;Z^6-(HEG0"P,=+_]_%)$K]DZ![#
M-YIVA8"EWA'6\80U%"2VDDB@>#0:HR>'=3+UH!WX>368/@RF-9">E>>V2\G"
M_+4)$D]2&;8=4QM!Y:J#S"V@)P<[:AV<&CQ9OQU[KR8TRIES&LRFE(M_L*-*
MWFCQ7"E@KN;\<4N.:K8(H=ALE0\Z^L$+SOJ)A2:IA3OOB5OGYX>PP9_"?+6]
MQ+II/,B,X.00 ?)(VSSG!F)A'G3)SAHR*Q&>8=QZB B>T?[X;*Z >H/@\]P7
MGQ3'3$7RJY@KX"TSH(1W$+G48+)!7PQR*9_AEODDW\_(]J8 _@D:\D'(?<:W
M4D\+0DK)I2<W-.9<9QSR0K^+!5)M'2P<\J G$WFW9O[5CJ=IQWUB>$HW8T\*
MXO+!M[L@@HHY>"-!;,>R26TIA$D*#+H@5'8Y3R<CK37SK\8\36/N$\//\0:O
M9I,\+07NO13H%<AMI*0Q@3/! -?>:1-U,,_H8?80SE_->)IFW!MZO]78F.D<
M/2H&02N2@;$D@Y0XI"R*,]GSG.6SL>!C8^,C=/?HQ)\'&9QI.B]28 IT;6"O
M!!E+]$P3W)(*AC,G3?-I(8>3^8QVMD8W=CVKLH><X-]6RX28UW4"\L/CI93@
MK*!T]5G1D$!JU1E*#9F7%!0*Y*IUA=631+TX9+55TY027H^,@',2Q6>4P'E-
MLDJYLIL29)LP,31,B\$'Q+1E\<5A?,H0FF#+DWN-'=\O-^'L3AJ\R#E('B-8
M(TD?2C+P2#Z9X25CTID)G,QEYP%\O=K&V&#I:[+)"857M^]=KNV<S[CA40;R
MKGR](U79"8C21T"?,S>2R^1[N5KH@9>7"?RQ0='#5)(?SS^=+;\@_HZK/^<)
M'Y;R=1"ZY6B]M=F;W_]^N=[\LMS\!V[>85I^6,S_FQQ!9WGT*1JP0C ZUA*Y
MA%Z3%2NODO!9"M4Z#.^-F1<']VG XH'W7S99P.\L>[G:?:G^/3Z3&*)R$ND8
MXW5$+ 8(/)"'Y[4K6FOCL?7#T+ <OIK&= #T@+T\FX2)F<P%8PZT$TA;WY*=
M!V>% NY<\4+[F,7SN;9]K(QG0GO6UT^Z_$=WV9@IK*U$G0&-QA,$:^E+#@*X
M+,49%PO3S^80?XK9UYULDK!Z8%,[^:UYX#T\<*.=I@V-A<QI#S<6HM 69(YH
MBM!:-K\D'-,)..*021\Q7YSAK^5)D]@[\>!][70R,](EK*V#75:6[,%38%43
ME)S6213-C.7-^QZV(K[A!A3.SB:[[8RC[(=R2?^ERB]O_E?M-8+Y7_]"ISE^
M_>)RL<'/FQ_/MI3\ZU_6^*'^YE2H7Y)/?_G-Y_EZIIE7S&4/-B628Y#$@2(Y
M2AG16AZX;-XPXQ8!#2'WD3YRE2XB GV5=%D?7O=#<!P,+%OI8E+C]+ZRL<B_
MG87%+^$<?]AZ()UXFI':P\799FCG^@A^6KIH5R"%.^S?!^L),&DVSZ>QCI\+
M?GDF%F3R4&3UG"3/$"5Z,"G(K)W1=-B\6-Q>?O1SA>TAJNT!KN_(\5W-:R^O
M;1[#'Z20];O?__C[-F2;21&3%X5#,20RQ:*%4%*"A"[KH+F6I;7'_BA!$XQ-
M>]?YLB^%W4?3R;?*5WQN3<TG;NB_4%,O)2C-')!;HB%QF4+ 3(YSZTN3F^N_
M;)_N:$WT4)]R!_U=J.G)&9N"&W6\9O:H^ 2Q]G"@W*$JHL<@? 0>5*PS@R-$
M19#.@?O(N,W1M)YL,@&?HR\='R+-AKH]_[#XO,NF723:H^9_8B5,,"YWYX[3
MN607': 4M2LIJMJD(X(L"347IAY"M]5</W.K.RXDW^KOR56&/_U/$?^R#]GM
M/;/_]U_O".5G^N/V&]NO5Z;?8?F7^NL?[]Y>"^@\D#P^X&*>UO\S+<__NA4.
M$;H\Q_?A,][H1?MV49:K\^T)]@-NPOQL?9NF]?S\TQD^I>.N'_W7KZ3?9FGW
M^;>TW(X)_+S!149RD>;Y7_\RCR($Y8/%&%&%XKSD#A$#B]YI6]*LZR*G;:G7
MJ_SX.9S/%V$GB]T=)(N8>$H!T)KM,,=:?)HX<">*%"[:G%J[68\2=.H!\OW%
M:D5V<F.-ZCKA=[@@(&QFR=IHI0T0ZANPTLD J<E 248%1PYNC*WSWQ^G:/A=
MJ1T>[AXW#67?0W3Q Q8D^L@[_OQFO<;-^E=RRXG[Q8>?E^OU]V&U^E(N:]C6
MOU_$_X=I\W[Y=7;D#)6CO5LH2+:>PTS3B:P#(^EXKA53.8O6R#F-XF\)60/J
MK@>GEJC^GHB?;VX2^N9\>;$@HW J))0>4-=ANJF:AT@2ZF2!9"@"MZSU'<DC
MY'Q+F&DE]88A[=:;VP_=G^?G\\U6 NM?%W^L<4=L"8EE9Q4PILG#2XKH=#F"
MCY%YS5GA_$G/Z:B5OP4T]"_RAE7\3Q#[9K&X"&=?2;XB%C4C]CGX$BTH(8C.
MK#)$JX/,(6MI_8GX>'CE%X"/!B)O6"'^!+&_+#?7I]]7DF<*T3B4"K3(1*PI
M=/!QVO$T*SDX6TM3^8GX>'CE%X"/!B+OH0[XC\7J.M6(A+%SP-?O/X;-OR\O
MSO+;\T\A;7XLA>B>_UGE]2YL<&854F"*$@(+_'+,2D@^0+8L\J),<*GU;=MQ
ME'X+P!I05SU4".^A^EI,O^$BG&WF2!MH?KO8X K7FUTX.)/,!>]T@:(5KW&@
MA1BD(&G)HCFFPK#UE<,)Y+X K#776@\%MONWX,O7KF2%\"$8,H#M$-V2P47-
M0$;A4V;&!>D;@^H)DH9*1.P/+BUE/I7,P6MIO;G8?%RNYILOVU<6@]9F0C)8
M)C0=V,R"4^30<4,'.'W3R-*Z!\O#E(SU[MQ4U\OF,N_A5N8^5;MWFBYT]?3"
MO(^F<=Z:6^CM22B<(/0A01$\^NA< &ERK;CD=/Q99$2D#2I86RQ3SQH,3[Q)
M#XF%0V3=^IV:2""G9YYNDA46^7<*[)!^_9G^]=G_O5C-UWF>JM O7V%W;[%1
MH><U?\H;2V&?I-C/%U\@6:T+2TD;>>>-8$^D?0H5(SJL)RER.886^GAGVM'^
M?;TI6GW9$164T:BSA\PEB:*(!([' EF$&$1"PD#K<3</$O+,T=%.R/V\\UP6
M=FVW1BMTP>!H+]2N]H(S$:),!I@S016GHFE>]7F+@&_1DSQ>PCTD)EX3L\-S
M%W)Z\AOOD#*.NWB"<O:I^03)]FG?5SYK"$ZZHB#2+Z"8=>"5SE![MM?NMX++
MUD'C((I^PA7L3\^'"+2UXT>T_ >&%4E<OU\*)NWN3.%>%F93)G(*>1-\^PKH
M& C:IH)S+$0C._ET>Q88_D ^2>K+QB)KZ(!M:7J[V(D0=\04U)$<#0/<H;F<
MKA!*\L"+R[64!R-GG?1W]Y.?L>).$E)#PUNO-K-WM9SA,I;, ITK K0BIU!Q
M\@YB0 2F4<9 NPOOYB+3I][82NE/7[?16PM^2P[2\9)LF+YP3<0.55W(.,0A
MZJ+8]K;YM -T@O#OJN\$R?5AEU=QE98EU8[61D5>Q](6<"E8P,0$USQG+3L5
MD(ZMP#V.37O]'2*PQGK[.TGJ_.)\1X@MICA>$)RHM8(8-01+&[N++$;I7#2E
M4\O8)S1W:]'A#L:3Q+YL(;.&[LN6D/#Y!B'>92540M"BEG9@S5*TE@$=^\()
MY855G?I:/*6\FXL^0^4=+;.]EM>R'.;WB[C&?U[@8O/CG[5H\X3REWT?=7JY
M2R<B[Y2WH+6I,"V*E5Y);Z,*-C.=D*&W1NG9O@\]L4/"[4_]^?JE6Z VBD@"
M9+90(!H%.)8#>.=$R((7XUMG+^VCY:0(YI?E@L!UL<C5&?SC$QG,8O,3XGJ6
M'$H2K("2JU]8:WF]"@E0&IZB98:;;J\+^U88H3Z^A3)OA39-I-<Z*-W1L:O1
MG@FEDP])D8=AJX?A([@Z;BCDI S#Z!EV*W>\_;G?@OI.D%3K"Z&?+NJXJ+_/
MSW"]62YPID6]W%*QCA00M>V"!P)1A!!M'8?D@[I[V[=':W<^^%M0VRFR:EU?
M<4G+.R36+BB8UD@G4N!DYS'665X>R(>CB)IK(M$7CZ);\<2MC_UV=':,G/J8
M6WB;O<N+D"BE,5$4*$%K4,J01XB%00HF,Y0E>]M\,-8#= S64;"EBIL)=NS$
MO>KB;U]Y<?4IK#9?KALC<)U]4MY!<2F!"HPB-%\2Z""C-,PS:UM<2CRT]FC-
M84Y6YK*A4%M?..&GBU7Z&-;XYL,*M^"Y2^)5 Z0.1+:\5^Q*V/"WCJ?K<#F4
M D9#B^;9"&6(NHR*?)%Z(V"B)7-1)C!K@O&=,L.GC9)'KC9' LDA<F_MN[]=
MI"\;_'ZY^K2\+ &_NE>7M"4FG<!P7F^'#*]/*PZL93$@_1!!=?(&]RPP\.U9
M/[I8-A9DZVCZAW=O_PW#V>9C"BM\D_YY,5]OA;S^^3?ZUH[ S)7.DBC*D4"N
ME$@0M0SU3E>)4*(.RG9+Q>RPVC>G]N8B;KS[_[9:YHNT^76UZ\R^W=*24.0!
M%0'&!.*6 LV:3RCI!!4FH?=2BA8;_4-K?Q,.X<E";1C)WZ"G%J/M*%KO<-V%
MJ(8.X%Y"AG?X3M?1?84W$G _)OX <3H8IXU6P+&&PYD+\/05L-';C-QQY)TF
M $Y+ZX\X< ,I_1"YMG;8=M=0VY'(/Q--BQN'VWIWWJ0@6-;" F?<D\^!FLX;
MK&UP67 A<J9BMTR\#HL->Z(WTLFR1X'V4"CQ#M=('_B1N/Z!J#U;?MIVL/W:
MX/;[Y6*S"K6UPF^XJEWQ?EJNME-PUM]]N6[)';F-3J(!06XG^3C%04 324RY
M<)^--+KU\(<FA#][EV$\-?9P_WP"$Y6%JPZ?'9CHJ0*@"0/CU V, *!V$#Y1
M^_WTY&_ 3'*I,*ORMFJ.#AXD]T(470>.JF1\E,KUT+M_JA!^HB+B6T'P(4KO
MY\KN[W][P[BX]E1VC@K3GI@7!K+B%A2=2.!2=5F<R)D[E:QP!US;/;C(\$^Z
M(^CL_M7>Z0+OP3.\ZZ-<64CQGC/A E@4'!1G9!S(/.0H?5"ZN.2:3S=]F)1O
MQGMK(>J&'>X>(6N']RZ$]36,:Q]1X_A-353W-!Q.D'L/WLU^ I$9[9U'0%^K
MH;BH61)$9=!"LLART,V[UPT,B">\D&'Q<(BX^\?!5?9WB2'5;E>!.5U?->DP
M3$&!=<QZ=%)B:-VD^T%"1L\/.U91CZO_""D?.G)B]^7Z4PQK_#__X_\#4$L#
M!!0    ( /> ;U9X6_5T J,' &^\"P 4    ;6=N>"TR,#(R,3(S,5]G,2YJ
M<&?LO DX5>W;-[QD"IDRA[9"RIA9DMUD2D)ECEUF"4E"V%L*F:<0E1U"YLQC
M=F89DB&RC9N,&?9&VV9/[]+]/._WO^_NXWC^__?[OO=YWO=ILP['L:R]UN^\
MKO,ZS]_ONLYK4;]2IP&.2]IZV@ -#0UP$_P!J&/ !8!VW[Z]7_!#!_[2[Z>G
MIZ.C9V9D9-A_@/G  19F%A96MH,<K&R<;"PL'+P<G%S</#P\!]CY^'FY^0]R
M\W#OW82&%OP.'3T3/3T3-RL+*_>__*%^ #CW,WQGBZ.E.0KLXZ2AY:2AM@(0
M *"AI_GY ?[M0[,/Q,C N)^)F06\H)(#V$=#2[N/CG8/-?C?0/#_ !TG_<$C
M\N<8N(QO,1[UY%9X%)^Q7_1\:1//U7ZLF*+MO6 F9EX^?H%#XL<DCI^05%)6
M454[I7[AHI:VCJ[>I6O734S-S"TL[>P=')V<76Y[W?=^X./K]_#QDY#0L*?A
M$0F)SY*24YZGIF5FO<G.R7V;EU]67E%955U36]?<TMK6WM'YL6M@<.C+\,C7
M431F9O;;W/S"XM(R;F-SZP=^F["SNV<7#4!+\^^?O[6+$[1K'QT=+1WCGETT
M^WSV+N"DHS\BSW#PG#'C+4^NHPJ/]G.?C\\H;6(25;R*Y;&]U\_,*Z:$$<?M
MF?;3LG_.L.#_)<O^IV'_CUUHX  M#=AYM)P %"!?RVQ(P<>1WV@H$N4(ASK:
M-$^4?JEDU=PTCKT<(W/X^)M4!]^YN(-B\0SCYUM$%L1]VW5WNBD0&JPK)00I
MC)BF1U(!\>'/6::9\T_<0^X']FD%R%,!]B"",A4XWQ>#PN[KHP()BU0@[$/
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M(ID1QX',.@]ZDAPNI36V"M$LCCGCU0:S&\67K!BH^*-$'ZR^(%6<]G&[XR2
M_OJ)3=V# #I\%&)+3P-4$T\F%JB 8)Y7Q$34IKJ45_MA6IQJR\15&6B;)N1+
M@_);@_VOI']$"L@<\PUW8#NH=>!ZDL,!!B93@>EAX:LNRT_^/N7 SE/Z$.^0
M;3"TS@7*))8<'1.-:=_D%7:U?O4Z>.:B@ZEN$L\WN#XK1L51]2KQ6='%A4.N
M:>Z=_L@SQC 3RE?(N\/EQ.,$U\LX59+XL*8DECPW_M!]O>Q,-MI:W>"81M'
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M3:@A)@28=JXP6$4YUMPEY$J67:VO'^S,/=RQP,IM;-/_W&P*@MU&'D8T9U/
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MQFI(D6L+QGQC_/F+H17%JU7-5<-EDJNAUT%I^DE7XJ430+.!7*W%CK0@]R-
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MQL3$Y"Q 0ZS'^6N5D=]"[0,]E5Y)SI #K#">^<Z[@3V9D]?N?B[JC7M@L:^
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M'NG\AYF.6+]9%;1<]HJC.8W5:YY]#A*B.X3!64C;.OI\U_>KN(5(Y3XF7_C
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MOLUB6G9.1N[$N,MNR,N/9RKG*G).923IVM_W%BDX 03O%PDZQU]R@0J$OB:
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MSX+)R+'AOTH/_U^:8:"$*UK\[W!%OO8.RMBD3]9[#] L.0X= YQ)71'<BJ%
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M!W<S>7[_ &S3-/Q?4PS5H$M*J$#,LT5(W,6D102?G7NVBJ-+P97[W]I9!W;
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MP>T!922!/AH$1]1 *1,)>?Z^:Z$(RD3"YQQXJ/ODU=D>.?_^@U=X:6]7A\;
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MFFS[9?)I]5H =MA#:?)L\@V6E"_6PHG<SYJ>\L7?]MBFSKTL3(T@UX_NNR]
M=9J92W@[X%;#K]49ODG#&3O)7,51[]SK/(IL8A=,%!??S?!*33LH1H[@3N)-
M<9U8;W1!0@!%W#D?:8D1GGERWL-))W]$W%_9.5'T9OP75Z;&IXSE4X8#W"H@
M\+N #8+2,4 PH/' ]9]YT!NL,V>P9W 5>"4WZ.PW@>KJ"?#55LO!*C>C.K35
MY^V^=V)-Q3&?#5K>#GR.!?K3E2-82#*045N9<?6%11@'01_C-'/[ZY#<YF'P
MKV)969&B,QJ9FJ:7%B1B32(^",3'$CW1]Y)@D-&"ZA8>Z:XP'N@I7%'7-8Y?
M+D7\\%(:B;,O;#D^>;IH=U2G7&FZ3164TFP5/MYI6.^EFIJ;JF&AEO09,9V$
M!6$R*?R_D]($0<O\Z-)C@'U8#@HTZS]$X8H.3M?VQ]Y=^>RU<:YO1?DJD>Q=
MD:#*8T"G(/EM5N'UD@C"(/0S:(<\%B9+ZL7"/H050% Y+9\(&RXH1&>^.$9H
M$8$2P0"QH:1)2DVR#-H&HJ"B*,1WQ4EUWW1$_S' AA<UNPZZZQJLW(9$B1(D
M8.S03G+ZZV@C#1\#8IM)G)/876QT,I  A;J$DGPSX>3_8['O/0MOD.W65#9>
M3RR?_"KDN/<$^Y+X7!6*E\;Q([O5+X\3E,K<#[/C'SMH%<W-Z<BDKV3<UTZA
MY?5CHK[Q17MQ]27DG\6)(<> >& ]HCLIR9:[X=]T3QJ+9FVJ?IH> Z8;,O N
MQB'C\%OL9R*3>TX*Y:Z$:WT_!OS)X0--WUDF\+LK#/J)*T+NX?[QX/$ +81]
MA-E 75AV#_"E=:,H#4EG3,Y$#D3PZC+,=]!G:!X#GLK<9MXN6S-HR+4@%M8U
MS_MBRW %I>Y_K(M843-D\E1QBZ_5$[>[4_8BEDG^MX!E<OPZXL%ZPQ_A0+>Y
M9?2G+\K*]Y3E+9&%J?LW+L+*[@Q?]Q%V=;V\?N>SCLB 7WCY.<&2:[@8H^?&
M@6E/A5:@].0HS O6"RWY3!+#I9>X-86_*K?Z/N/5]%R2ZRRS4_+BA9@Y1I00
MU;V5%/HH@A<Y8_H1''# I<L$O5#O8ER11FV4S@%3TJFYEB%G=L[^7K[JGNV/
M#KJ:E9P&TWU/4P=".K$[N+455K[NY5!U@2VR0]P5:1@-"-5[7\!>F2"HZ9VV
MG67<,.+"+G_)),A>_&<1Z20";Q*2A$W&09>MI'GTB6^68:=LNM<]#&:0U-:6
M<_1NP0R?^1WJC"YW"*+8PM8E/'E2N[[:CN@I3#V6QSQJ)9MWM"]!EVRN9)3%
MI(_W[8"BR7;2H4QQDFG(9" 644/,0?$J$@M\LVH3FAMV5H*4W[MBL3A)^C8R
M//?L^F6:0_8C5QS49+IR\SXLY?0M==U*]W/45T<"/R:<+KO@:-O(#+5N9=FR
M/)6$/X<C.UJWKJ]H) I,Y:A>#I?A?9$]'+#J_JR+,SYN+:HO4B1*\Y2?I8.L
MW/,+U\(T..<(W<1<Z&+6,8!-707GJ8VQ+7EGC@-V-.5O7DCY=5D$D7$^*W%9
MQ9[SKL\4HZVQR*-%N30IR/ "9>/JBP)J584*'$QOK!+LMV0C[Y6JX\B1;-=]
M:J#73Z2:N?"*5]1E\9<?'W'>2EN'2$#;;T'D"5JXI_R(M[AR?'NV3<)TX^@5
M-7[OES=?OQW+C01Z'@-,2YZWIV4\9#/I8QVSF]+%1HXAW%G#%:^1FO=#,N\V
M9VJ/^W#11:G$%!DGNVB8"JW'FL?97UI8]S:Y7UA3971&<US$,XB$D"W.CU[B
MA'1".M5/9&+MB"\"=U\T167Z/JGRL/2>C.>?YKKJDC$B;HC-0#TLZ1?7C#(1
M_O_(>^^@IKNN;30J19KT7H)4Z=)%D(A(EZ+2J]*+ 1M-(5&4WD% 08T*2.^$
MT"0@O4N'4!,0!2D): B0A!.\GW?FNV^?\[WO\YT_SIPY?S##9#*0_/;:>UUK
MKW5=EP?3V,DG4<-?#;I M#-AEPB?EJ$,/CMSY@7?'VWBL\#B_:>4.ZG;.R+[
M"F]TG!.+!+Q>.I-QT$Y!YXSD+H+"(77GD@D4X8CJ)Z6CWRCYJ&D> 7*KKU5H
M,N6^+'W-5M*O1'S'IO\2L<EYT6\3U'I]=(,8@3.(#53@#<FQF?J5 ZOSXRN;
MFYI""-D7Y*B4NZ?6O:-O\)0$ )2? #"?<O'!I!CR.<AHY=QBR&-SQ$@MS_M=
MURE*_KN(ZEM#O"36"[H]D#E94?\AX\9S92EI_C:9O4\J@@;MH"I2$NQ02S4!
M444(FB<JWBNZ4L60'VBD_:7O.O<F6Z[6DY[BCUXTESG@/G&EW_45HUT:J*R&
M8U69":(!L1^PV7.VE)SD'W9]I:/;M&',(ZK'V'B_6#YCOJ]0#MZ<XL"0<2T-
MR49)Y#JE1&K"^[(0Y@YN-?5'71DKH6,^U9K_,O89H?O<\^ZK@?#3MW0_?@%1
MHOBG!#],)WP2(DR\/!*XJ>1=$*[N-*&@GGO;74>N=L,JXZGUK$B&Q^T4G6]1
M!#CNIC-A8KEIFX?PP2'TU^85?F__542,?EHM%ZY5[-P%QL_" QS4<X-PR]OZ
M+]SL3/;23.EFW^]!B:S+F*%\8&RS%[;+MGE>Q$$78^*C?NY0JP<[.W">76%5
M-N6^ \/*W;PFUEW0YB;6GOGI$:!V*O9GF;HY>1A++JFQ&WWO(B8<%99E.WJ>
MZE[>CWM\9RVN='VZSS-.>A9VVV/)!;6+?IL+Y>RH'"ZLRRSQ?P\;;(HPL8V=
M:P6SF95V:]#S U).'"23&>30G]2F.I ,S3J<=?.N!V,65?7UN_S?HF@C#&U\
M-/4G&U^O ,R(;'?KOY&%E/I]SOX$'?.V?_;\_\0(B_;?<*TLH6VW0"M?FU6/
M?2$0Y,S?QH;_(&D90!: _TJY\2B#N&:9$D* ^=C&SW.UB&3;AOHDSPQY>7&Q
MTTOW$.SG>N^LJ N<#(L=4L&]'@VR5EF0_+:W88!CMR,$'-X(TV@<*9@E%94X
M>&=5UEQ(\G,HXN+EG.#QGZTW?/=5MYN?)0B#-$,N%0DQ5^/4-^++?=5O# LL
M"(V7!IKH13XQR/C(E:=MF=;B-!X->%:O<*%'V^I0BI+&9+\17'"TQKB*#ACK
M]/H42FZZ::PVG#I_A['G^M);NWDW-W@[\)PP53';!L/9Y6-B+ @.>88QE8.<
M";$^>/RC_Y*1?)ANN-==ZPD^8?0=6P5VI9Y^T8B@+NR''?3ST*'K':ZWUOS
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M(EX?UY*,!\)#$]T*'0PE:I&) N]#\EP(#!QWRXN_VW'?'1X#_4F8_U5!Y'1
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M03?)]+F'-M^UQ4:GEKY%!A2T-->,IWWK4)\,I@9?_W"&JS,"IRR;4'U!\DX
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M9SR,[@?3[-1EG.T%^D#;]$'@85;R<'"VP5,M!B >&@?75)GPFBJ(DTJ;'!_
M%>OR1UFGHB09A_*M'M%X,0D%_K#$QR4*=J7!9W9LNH<)XI0*&_:LD0N.,>6W
M&FWV0B=*<S769W,?<FX$C;2.#FJE&!I37TFH3[(3K,Y3$),.V273N>'<T-^>
M$G4Q;PPZM)E@YE]^_GACMJ[I-ULCT\D(EGG.=.>$*\<3!H"9DH$]FDQ'7H3Q
MM+"$U#'I[W9F(Q(?^D@DPIFX.VR&@[)8S]VRUO!8P*H)5+H+<UG.54MO@JI
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ML)-*"]WHV6!L9U<^?8=\QH38H:[459=:XX2=4R+%KU[S FY,C-G#C<\G.#7
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MK[YX,8W7ED6'EHI%_X%+%>B_B#_'$=!+RFR^OK2(TL6KCF@!_4J.  .YP*C
M)DV_EZ!:6=#(PN";%.Z=O?T;6GI3JTZE-H7<B8XIS[Z_O$I4J_@.[09RNXY
M3JTCV9L5?0(P3MJ+5[1%:J/6OV[<V/ER15),(W:&ISVM>&1GUJINI9)81:I!
MWC(%XFT(GEH.'IC#;1;*9@U)$E3K&EH=.7LH5](6*,56[_;-Z+ PZI?M5/3^
MF27N=06")&BS" WC";OP!<(3@K1!C#1[O&OGROG8"Y6U:"^>W69U,* [83-T
MV2V^3R.8OIPA76( !W:5ZBKE'#W]?2-TCZC]Y @P(G0$Z(=1POS[$2#Z"_!
M=''_P1%@3_ ADA6TE$3FF-(R5=U^1GP<CKXD AXF985_3#3H]0S2=,L:BGWN
MFV]EU8[H,PJ23 )A"C8XL>IX)X(HQLFKVUFY?JK93SX:RA7+]*NG.@YS!'@:
M( [/N]JWD8"5H4DS; T*MKJAUG?PHC27'S%V?3TL"XOL@F&K0?[,=(1:N]\<
MHP"B7NU$2_?J_EL#6%%>D_HF?]W6[)O<"]^5GQYP4V+VR3%9#SM%2IQ</#!X
M[/(*^3_H(S[JF\XVHKLSW,-WO,M?4V#9O CE,%:%\!U+G2Z;D]>XR>BBY9;N
MP@]_O?2')]5NB0/A%'Z%]-9?Y8>3?ZB6(H8'++19F]/TX+&;="WWE07'T"*!
MOJNWEX53TS2?F0CL>YD%N!\!>NZM0T[]*:>:C:PKV/#R.!3Q@=!>Q9EVQP4R
MLY@6UDXQ><J)Q)VCKL@L$=K3K)&-?-ER&G4R@6TQGY(=DO>5D/_*#AD3^A?S
M?"T2<BD(<$ T%R0,\H0]HVRREI:+!,W6@ =X32?K#5*Y1WA2796H*2AS5H".
M\7K]M2*G3IW67F )D$];YC=J\ U1,!@CBF.G K=CFK>KVPL:N_')-3T)1P"_
MYI3FP5JGJF09>0V=2A:_G1]X/4+51R(S*4^+>=G4\Q+J4N)LYV.)5=* <J=X
M<SJ:=:89_J*W5DJNQKOK/LCQ". #G:EH R(,VL//_###637?]-DUDH_'A M9
MC<L%U10[=ET7HY.N>LX8Q5C!LU\IR-,%6NBT)( J""<$:[4IOU!6^C*A"@==
M1D2&B;LM#3-U?OB1O<(U2 W/GQ_<_!1_36M*B2ZBQN#,JH]69:Z;HL6)4Q-'
M@#]6/HMP&^N"ICS_18S-\S)5L!N9RZ!SF-<7GZV?@/1T,-\HD8D=I?-O_K03
M"GVDL\IF?RW4D#-LKSSWG\Z<E<[#/SCFQ3WV,\K@6L-_&^MT43J>K492,OQ?
MH]6F=7!*X?*_&*"U>!SK $![U\/^D@'( ?N5PPY72*">Y.KD5]^/#<VT_YQS
MR?TG5ROYC_F8/X=O*>']<C&U8.:W], _G#('%O_N/>_RT>7W8*\:['BP=YYR
M N0%6>WG_%,&W;O]"- \SCX#O';LJ?9WNMGU?VW(3,J&C%-;/+![;/!'1Q?X
M#ZQ3"QT(Z(&ZDSA(;U:S.I%5V^W?M10P#.$@BYRVS""U[(E2GY Z=3_/RBS%
M]#K]*(^SN6Y[N1YW;L41:2K&@ 3QX<UGN6L7Q6%M+MS.4*]YU;E$=,D:7HQM
MO^Q3:2P]?8^'CR!#YH*'8D2>?L4:K):6R%;Q&<;=(NP+D<=N)R@T \-+G0;#
MBU!S=HGZM-E72@=/*^F/^$,5I[GNO=*VB'MOQN$K*V[W^6/L1MMAO^XJ](^G
M_G.1($=+'%D\3(!N)H;S'\H1S)>\6A5BLKL_0Z,>O3CXEE PEC<./UQMX4Z*
M]PM<R;.1S=,3Z-LS^W!AV9J!5^G6"X7=+"+7,[+W-JD+A._ZR'FI7$G)N)]\
MBG]4\N.?S:16\CF<6L[2(N&<6D7%#VZ0V\C/BCAV%^>YT#MD2T7?+B-^WXC!
MR!MW3TCR 'Y6M/RE*0C6/J90-WZC[(*-DG_3.IK\::,F4DQ950I,NL%$>P-'
MNQ&\G#=FOY\'/Q1?F:P[7PKSCM(LS-81/D=!W0,#/9;)8FRSZB40OJD?VQN@
MP[LA-LL%[8<N43"VK5)PLQ-UWB,;HMDW-AV,H:.LS.ZU[H'Z\#;WV%@E+OEW
M$6M"W!T!!-'%B,#-:TXA,ETHQ//;:3X>V?T6<%,S#FOA;@'),+.X9W<'$F7.
MSV92L<W<7B\57[,>NPX?+ 9)_O@UC-<E99'YPZA).0^'$YWEL5^1L6$V7)&2
M\>+- 3]K_.ZP.+7651E5J[QR2U);T,>)&E(UG>[N=<%:*,Q T8L;-4> TT*Q
M2YOZA]<G54&(A773$A<#5=1G[8',UFX^D;S'D4.3,YD!Y[G 3Q06@57!G<,G
MR".PZH5G2S)-);RJFN9G8&=^0+@/[W%#/:+$X3Z5:D9?^_GU%US#BL?NG+&C
M*U.T<C)6?*W0M_ AKD;;B4!9 .IXW*6AHII6[5.C#TG:4A]=:D.2?.2_-L:+
M]@;(<\=<F::JWGKA\81I)VTQ#-(/9-<RQ:4O 9^'^6 VY1?UI^ QGO69HZ@%
MV[,[+2,BK=_3E-6F(MU2V#K.WVU=BB,@+"G;VX:H3M M6@A9[D9R^/.C/R8K
M+RRL(>RAJ<JS)\,*A=;$90<Z/@"EQ4/I9'CT V7PBQNS.%U]0B_6IOVM#'8K
M^EA*(GH+,N97X//XNO:P'_B!7*VN*Z#H1:1Y9H/ET)<!FN7V&+Q6_'0%[/L-
MY,W]]8HYY'X7C#2J0&JW0>=#5LC]SN>P 9MG#_F^OV6&4X[?U>O)[1?GW\ '
M@"@NX/=MSZ$>AOW'Q"(AD1^[\I,RX\P&P _/&R6NFK?[_CLGWQ?(.]O3[ :D
M##)O,M=,2,MA!P@E)!IM6E734&L(Z??%.AE?+>?9'X6LG_UDK8HFZ]93'R#^
M* D*N*U5[Q*_H)8I*T&+,XBM7:2AG%LZ\'#HL5-%<GZ81?8!?KG?:^=]O+62
MX:PEUQWI]"=T%UII\R&O*6^\)ONUGI1 #!!QGK//8_?9Z6>4X77(5_\BF26Q
M(G9.MN*%]&RNR\LBCX">X7^>IJ#*(\!F&]HE"<:\">$+,VFLJL,]Y$I=<\%I
MOC:BC3U[M[)B4!FHA-ZC3I,0Z[%MC&#(\V.E$S>KM=J_P[J>W"--HISW$1<)
MVOA=S%ZREI5 YH^"M6R!1XXC-4"-_(9Z(S=IM:5"KOL1)B<9)$[TBDZTB$#;
M!(E2Y2'9?HNT!/SAYT=79V&'\H>F?,EI QM!W0IOV$]/&!>71 >\2-LP%RHI
M#JE9VB.R*RPE+CPM<)GS;:RMT<X'OYM;IY,H*G8<?&$D(/V44?@R2Y_H:2K)
M$RN:CF5QD;Z0H<RRB,3D>.12>79^YOM#,Q\6^P6'N4$W]&-;^>4HB^T J8;&
M%V)/!')Y5A(_OV8K+WC/N1?]7Z"J!.>'\>HP]<),=3 ][N(CDB%594Z?YF;M
M_BKI%P8^JS@5QMEN6EK1/G6I1?X7&B_LT)T9RZ<=>1[80/ YKN3^S%.G_NW+
M8\EDYD%Z3=BK?[!VD-=!2V7:_..!PS/^HP==L\/PD3 #K_!PB5\N$EQQC^].
MNS)X.L1DT=/M[R:<-/BZ^(=;T 28QA!T9YL@J>EC'_@+#\?0$2]DLI=FI897
M.WEVB!8/BS9%[A9$J$OH,XZ8E1IS]?2S[%]*-(LG Z9NXH):D*27%'22+Z1%
MH/T@&:WZ T2PU>:LK74 *W5M;=@/WX;'6F2=5/=*]I$6O3M[I8LUU:(D[*E+
M*8B"Q]-!3"VBCK8_C@!,6C[WT()<!YQOP).@S7@I5^_EG;<H7:4+UB=>UQB=
M<Q.>K04P6TL\='WA)\>KB-1%:0.)3H03A^'?:]:JU[@NX@O<?)2-/A#2S2W'
M2\]F-"/2N*DVY^N4W!$I+^3.8$HM;;X:;"8?JL)F_)95R!R("5#=P_C^JQ,/
M^V.YV<M*>L5\TY\ =CD_!,XA90"E)S//(?-^MX\WKJ-AT\'...X.!;8P$T1+
MA)/&PYK00@>#?#M[/3%<#:^0T6MEE5CZHKEW;.V,CF#B3](G2K&3R(!_0=A
M[47)E;/KC-9.__0SZ7^=NUAZ?U"JGC6%3]5-@[YL%VPERU&EA_[L8U=L6L\I
M!]=@GCX"M-MGQ1T!?,TC,^V=*E#^'W"";W:[5Z5=^4.M,4']+-JV'X):-33O
MGA [A8?]+XFV.9=,IXPM=^&!?)F"*&7*1(X1SW[L/9?-FWIS,UCZBYY S(RG
M]?/Y2FD:/M5^QDC?1:PU<TQT)ZQV'/)_L?<=4$UUV[I!4)$B@G2$@(#201"P
M $&1+B)(1XS2BQ 4:5)"45"0JG0%Z1VD5PF](])[%Y">@(1 0O)V_G/N?>>H
M]_R>.^Y[[[YS'</M&"2PU]YSS37G-]><ZYOL 1Y;Q1A]U8K2Z&&7P_KJ!&D:
M'@'FL'C^_*'8YZ:F#>V*DK5)<N+\7F]$BSV-%>GU,_[3#1[^_^FT^Q/06DBL
MWPKW)F;\C^ </^,@LYH,\ =?]^38_?#&Q(Q_R(!D3[^$0_SY!U$AQTC:.)9J
M _^<)GG;@KF7Q4;PJPU:DP$5N+&(PK:QWM5C#6ON,1IG7CJ=:]W7D*%1>>PN
MBWVDM$43^$W1W0T>.A*.$XH,*ZVT 1%ZG#]L_W<CD-JP?5G-%S-[)XG[;?E>
MDG_6,WPGFP"JTQS !6'Y-N&SD7C>@2?@\<C-3O1R>_5P[657LP?@Z+9/<19^
MLP4ZIRJ#IBT!1;SIS FN03SLG=#>0RL.XH3/)![W;S'R1E W*3A6CY5&\W->
MV _J.XP;<3CW*O=XQU5?+1]CU/(LK"5$?1;:DD3EMJ8>W%O=Y]!<"*M2'N>Z
M;Y9(W1UZNOOE.^FCO*Z;9WR4US\5P9 >> I)I-IXH_#C^35-P_Q=J4#-FE#J
M.\I5'*9\\=P?M5[L+#3EIA[I?OZA0*RE0:G45N.>K%IH&Q K( ](": ;'@20
M"!R_4'CA, TQFP%\^AEQU%,9">!X!@2:!HT80\P_.*Q!)PEV5@7!=^&6&A.U
M'Q%N9B[NK32Y-G"DDOHE9W7E03GANR8V:^*2W8QUX%/J0O(AJY&27<],Q4D9
M[I\@"VBE^02N<&V$^(-)-VM9YF@"6!'HY1="!% I4W.%MBW8[JU8%"/Y,A_9
MA?;G#J>[%/5(=-K3HLS2^>9XM01LMY8/7NZ D^'(FQ"ZE>KE==<Y8T&V,+DU
MQ9I!(=&%T::.N(*T2LI(L;&@><;.2#E/*T[??4'L+>LK,0$0:\3+>)><D7ZH
M\OS59;L0-=X CW3W:95-%BU:^--7Q4>"<A3\WA\YZJ&).PVLH>Y@M!G*'ATX
M_[PRJ5Z.,UZJ)E[*U4O$^:AB_XT3>GID0LGZ'@)*^J[10)@C[RWCW0(G!^97
ML"W>L@IM;[KTR=C:4WG.(U9$6'1,X@S,$621U&G.IR9^X?9M1'L"=\)J[$LU
M.%4@BAMU[B='&PK544FXTS1SR_4(7[P,*B98QLYK7A:JT@_;?,@2+2NJN1-2
MPILCX_%N6K.408 LA_V5]>UM<,^/+.*Y&?G6>LG2)Y^E6WX??I4!AN![6E3/
MGA_B..B_17M_&XD(0_?X< %UW#\K10/\T[\[_6W2?_A]#@I*+1JNG/W/N?8Z
M" 9RD6_S1\YFXH' O]G3D??^A]\_",+8> 9R9-8CD*IP0)EH-E1=+3R<OIC8
MW3M34_0AK,ML^69Q@Z.^ /E=19B$Q0OPN2OA-!_@#1:EU*J(.7T[M9&!%4!^
MUH;5^^IH=<.$=F>Y^_*-JKK012O._')=?3I&W#>,%9$J3QU%>@T5X N)R+.N
ML'$]N>2LZI(4?UE*O"ADY/&5 +:H,=4O(^N]_G@>3\# ^(5XTL4T5<=6:%R?
M/RV\'&A>=2W'>N3"!K2T7F52]V8.G6,-LVK1H$,D)^I$7R$KNGJ5DK@56R%S
M?!8[\^+>96"U/B_=MY\=E.Q1FE OBUP,:HSL/=O\O#.;Z]I]50H5EGI9P6\[
M^#,S0!RI(0=@=<K3P-P_4\;[PDW]-PB@U2("" Q?)8"&/6=06WO>]Q"RGH:H
ME*[&I!*:C;?9LUF(<D_(K!=4M4K%"*.R=\=8V9ZW4U6,3"CD2F?!D3GF#^1'
MGK,[-C>6/,K\6* >$M8?QFR((YZ!M\)QA357@WT+)*FO;S]*4_;BZ)"DG(BN
ML $E+BG$)CM9LPSSCN:Y"LE$0/E7P4A]2# '+\K4$'.UGH,ME&TEU5^SO\"T
M9A!V3X_"E[1%Z+J>S8EQ1D['SLO<YS>A08FD&'NLAR?Y:\U^G"8LV^;QS9AJ
ME[*TKB6Y),\B"ZHB<_;&RTBD"H-?NW([UM!;C0 *L,#H Z9^G@ *3D:1-B.0
MQ;7J3%USHB</GS^LF"X\9Y^AZOJP$RSYX<.RH_Z;QN-1BOV1WD.7==8WC1$*
M*X48?@@N#OJ78N'.X3J6']=P%>)[=D>,U0\NKB 0"T0;!?5XSA_[DN=N0K]W
M@!C;CS>)-#TW_KO2])C+2;C9::.@.+J86\7]&]X#SC2^I6Q[8=TZS5)K-H^N
M NM(2$ME]/AY!Q"/#YQM#:V )D$IA6"O>S=70$XZR]X[\-B0Z\<V72E?>R/]
MR&C2O4ZAI;+*H)F./%4D6<&X^KG V_W*M9;K7G&/UKVE1[Z#/9=DM.;RU1OJ
MS@U]H[:<6'_:&N4J&;)1MTO,L+:=W;RN^Z%3Z1KG F=$CS=@*?^.F?&F61V'
MACN1K6<)8M\[ 5O0;Z09A[=ZTR%C7@'@]B]M2,OA8WIW'NX(O8_"NW-9 JZ^
MZXP5J0]HWVE>>>,=JG"^->;PW;SFBZ>E!QX*%^G&5O#WDJB;M7V*>3H<(EZ^
M\:UXZ.MSU(?4R>K##_N 2T]SZ+.QE^1T/41\)GZU\9:^G!F.=PUO%K ,1.'?
MD8_N2!$WP/_VS'JY-(9N_Z=T1(6?$62>U!A=8( ]#"."MFR+"F[OEJM<6HH?
M'1$:@CGT#'X2GEFW=&)MX5C+T Q7ZCG%MO=A>6?@^_L,;IUTJYBKV-C RDRN
MB$,G)L?6GCK7V%V1>Y<%S_BZ=[0B!]')8GCN>9!$1H=G?H/A21I&KC*E*#R;
M(/ZHLHNGY (-1D@_;,M99:9QFA2Y%)R9QW5OQC!^X79<>I?%LXA:"OJ0]_S:
MU\@V+X.\IE *=X<]-; TF!)#%$?28=0\M<+<U-1T:N8^#<U80=)-UVB(<(?Y
M^&*,'5T3\_FS=?($4*"WI\!A.'S^JR<4M84[Y\W2+V<' W"?F7 %^CEJB=DE
M(7!GIRPL:CM[HEJ)EL?GT!>E\$=>X@&1):1B'3Y& $T00"<+=J%%^W56$<LK
M8:(Q".NI"A=I>Y96QROZLC#32=F@?NR;PD&<'$8?Y=$*)JLU!+^LI2VX:WVE
M7QXIV4P1R=V\L*3*[6P>\9C4WH)3/!=$X0>YZ4T!;S#Q!,_;;'S;>IG(48DT
MG[YI.SX<W^MEOOW,3%!&+?&A@*'.V:S8I9L2H/2P[AFD)G@L=PZQ<1F&$I1'
ME=R]EF_4E-F;-FFS-ZVX?L']M5?Z0D@%3W#$$0D9!WJ5RG$#5C0"\Y@ .M03
MQ95#L,4U171-MVY)/K$[P!>H(10J#RN);QF8*(>1=D*)SJ47!,X9S]"LT*TB
M4#P5H;+2^@/]Y^+J#/1A<27"9W+D'*]+Z:2V+ &H+XG.IKR.%Y,ZM^_@LL8T
M'.^U^Q$1/2,C)H/JGO 9ERH;)"7S<_U"&M!6B1\%EQYOZAV+0=O68""9JW!D
MA%LD]"2\D=<F+7T2YFISHL1 L6=.L=G@95]CU!U!,8IDURO>#[W;H:4W$"7@
MU@V)EBW[1UXI790K!RTAY;U7/%3%;C7.^G2=5>8$%2R<TEYE#[%0DQ1\D,GD
M.NK0D90!*4O"T7/LH74QZ4S/1.HXC#&A;/E7V+7[\=2>$S4W-GC,56G+[K_B
M";KFTTVQ<9DL"LK\]XDP+U%4ZFQ2(P+#I]EDPJW=CS-$IV:X]Z3;Q;,W=J!5
MK7Q9DJM\$1M3T^=I.Z5(JF5[DA)KI8%E9-V7[YQKXTP !4F/)X;7U*Z92"NJ
M7YY9Y'+IWKF9'3!^R^RACWP#5Z"L: Z?4<Y>3-:NG/OA!\CL^R3DT S5M]X3
M\,;C!!!YX>BN]2ZT'/[PL-"[_5RP96])VZO]_:G*!9C"V[!PNVD"R)[F!.X<
M4K1%6/ :YFKVQ)H1=6B@'6-ZEC%4<O4N=#.\-N!A[%B\!,F#D]QZ0D>RJ5(;
M!">2F94H(PQ9Q(A=RL%5<*0V?%\<\=< *"K_YXFOQ<691F]$BHA'DB>\@<-3
M.MO$TQ&5].)L^53J*,9Q].Y=]^!MC4=.E(TUJI.NPGG+G*>D[D=$]8;]D!%!
MS^#H1.?NUC%@>.=IV*:4']%/"P[>T,L94$)V6-G478S0?=S>:B,RY)]XP_:Z
MS^.96 2[W%EXXSBF9P'*S+,W,+YF5-8SE8E^;>F6;Z3P16E&@J18^ 7]!5UR
M^C,DMX*76VZIF^?1F#L.:BD^-?^'#"S Q1'W8XWK 6OA<@P:^@=L527"UM<
M;(W0_R9Y[Z09JNWS\%5PK^B//:0+;QYF0;XL>@L3<6HN?,6\;,EY8P##E)P
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M@\J ^\#!M=SSR5EPJQ5*E^BG7=+QJ/(D0;)*T3,W+B;0[P=5/JCCF["[3WH
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MP=P540)PC E;FU7]]&T:-'K4C!BK&;AFN[:VNVT:=^["7=GM[4Z&N\;Z$F&
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M^ 6_C<S\8<1.L/^%\EAWZB[6,&SA?.\L,5,YW!_H3Y\R=+-\F($R-^MWL%H
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MVZ5\O^+O$HB8HE[,PA7I>V']_?=RU^( DCM6H5,A%H;50R=D_F+&.6?2&$Q
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MF"9X\8-HEY7'(Y9W6P=-Y^#G]6]513-=2&?E>7>*_IJ]1C9 J*8P_L%&B3)
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MZ-0)YA E?U39(=R%/2O%0'J)YG@G_(>_NDH3+<\HZK4EY')NB%T)71!Z2F!
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M$7X4O'G,N/L"OEN:JV$.'UE^S3VP=(XK7 )@K9>PN\G7MLK2XQ0B>X]4JF;
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M@TR%(V.[3H^GM2U_GII-\F.O]2BU0/M$RPWK>4'U:&Y64?(&'TX?W"GF6HQ
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M;PV/X9H8EYK2Q1+.*.:O>2)L.+%.%?O0<HZ^(4'P*'/7)2'!3!T2O1))I[F
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M_+43%_]C1]OER: '&$UR)#0&A)>KI0"K0X2 SQH:F,->(WI7#6G,AW)H56"
MZ0LCUY G_8_C4QA$PH:&/I>+ 4/4#S8M$#)P\>BX>ZL!GB8L2P&859? QZ?Q
M5*\XZ4$!\+T@3'<H#05XAXA!8,XO4H $\S38+0H0W@(#X3U6=CGP.@\P4XD;
MWQM8[F[HMV:-]WW-#[)+>^]_:^I&FDQAN F'PLMK9O1$C>*E:!+3(AL88^-
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M#V8-GJ3HUUW3K27E+JP)F90(O C[-5>D/9?ZSRI%(E!11'H*<!/.#E\R1%
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MC$_=FA2?Z)A].OI(D%%,)J:811)HZ=I53TBUI2)%6@2IH!&,I,=YZZH;EE$
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MJ8565V?/0?3</5^*Z1+:YVXV?HE2V=?<9<_I!-LAHEI!U-0U(X;*R8V%KE$
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MR0A[AJMQP0@V*4M6XPP60E,WJW8=:GW3KDFP)R[61SD/<HG,G'FA[U-BTMR
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M6_%Q]MRS @*,**+EB5B.H&BK&QEP%EN+PUWI:$;B*$PK1<0$]'^%.ZS-">S
M5&Q)\;^(Z1O;I+?RXGEX%X'M)86^ ".)RN3_V!?";E$L4A8QL_X61A#[8E!9
MH.&'N^=B\6E5&9.DF]&O>[!VJ-[Z-RRM]<SM&)6@./',7",#9K?R/1?S;I6A
M;=E;VCM([6%QE%]J:G>-\>7'$6QE=75,[.PJ0@D \+:Q.(0D F\2@=W*A>E0
MMG =!6J]93W?7B@TK"-DKE::P&L7?X+9?JF;)JE+)=7#S?NB59Z@VEDH@PCI
MC ,F;"$IV=X>@\"&C\FFR4T;:"4-;%[;EH4^$M:ECY"="2_I,UJ^/:<50@-*
M==>E"L)SIN,<^W%7CD;.QI0&X%L^\>Z2@3*) K [V_3B3?^P5/K)=P=)[C/W
M)N@BF.P?7V#,@_^E:XG).():^114 ^N%\\S!B36]A$]XI4(^F7UIF7FDW4A;
MG=;(^\N9_B, &.E^R\L*(E: ;<$X9\:06I-7<-1ER@)U-F[VW$1,(\I(TP@;
MUK:EC5WK=AAA:R9@2[+O-JW)/YPP. W)WC+O5JO2BKFS,]<^IYE1:>9J:SJ8
MG:06*70R_.2<QEVCM9ZN4YK /$P$+4&@9),A#>?0#@VD(0'^P8(_<56^CW2F
ME/M/J"T[STS+._?-=G"W:TM;%F^JH25(/#KS)A$-?' 7BHU0)%9@(;@4_[>;
MCW3>>K.1@;6JKYMSQLAZR3JE19H3XVW;DV4H>,<WV[B.!MI!@MIS=(>S[)E"
M0MWO3$VEMEC%+],R3O6ES3=HI*G?]# NNVWDSQ-UL \HIC?G$8P'W1^Q1]=_
M>NY@8*[%(T]YVHV8*+Q7DJ)NV$DG%2=[YVU8HUI\P@_C<=*9*KP:U._1H,PM
M6FPNYF1.8*'SV*GJ2#*@5UG]?:*@M.5DI"77!UDZEE<K'8&](0> FS\QF@S,
MIRLS$>.V)2K6K=QT,2;1>W2".3-KR9>O%B90R[_7Y[6UFZRSX8VJ#Y,\D4TM
M]88Q_]G1%;^C:#98]&C'<3FD#L5BXH72XH&S!$IB&.SX&X3^#'^&G)*8M]K*
M_G9^V,VEXB&=5D-Z/_(QCQK>3#).V ;J*C.$.]N;>%(CZ4Y Y  5A)(T<H.7
MI" GX!L/*)YT\&9O0*")@A]ZOWDJ+KH 9N6#*A18:7L)NS0U_.A#LTA#57C8
M2<&/N?%L$4*\*M3[,6L>5(/CG6"T83&H;1XRT=)^/<9\47/$^Z!0QHFC4DIL
M1KKONPZ5#4CT1[G)A2JF@KHW*\\-]BJ@VYMZ>!F<'[8(I^D[G\YD.>.P([[N
M_W4M:?*J-31\E>_KK<;[=3;>SR9BNC:#"RM&J*FQ)]'R!#'$Q")*.1&+W&0L
M?]:9?S!GDERU633>\$B>;P.OWCMY4.G:O/(,%X9E'2WPVL:)IG=,^]5U^UE$
M'1 T71SHA_)NM6:91!KP/?Y8=WHA'END/3%;>T)C'/D=O.&WD#Z98U17/4Z2
MPV4MJ'^H?>I@_BC$?[DIQV%0[$K7[7U6AJ[2S L/@]A^7I\.G6&<ZB:=&<X@
M#8&8RY'AM8S1%8RAI%ME>*G*W!RS+[D2;ZRR/KY^ELTI^N!^F6^.X^U(SL#;
MM,,-RIC]L 9VG*(Q!A*Y9^'/V%)K>,FO;CU)4= R$  X[.PN&+%QV-E2PJN_
MY8!(@5R\9L 4G!O\S&D3O*G,"U'4&=S:<V*/7>!,7+2P"<]\W_IFHOGBN_SM
M$R@IR_L]WD>*3U.#R\%(]4V-+Y*!#C+ !(U3J_KAT!'VYX?VNJY&J_#3E&L2
MYR:^T&^=QBL24JB"/*O^@!J5J2A,1] Z*+.AOR:Z9>!\[K]6<;!VSK%Q2J!D
M@CT]K66*+#V4/PD/@0"?@&$#-4P.Z>PHVJ")(T"P.I+QC*K#-ROS<@\EN?$W
MW'OR:NJB=5^#Q60=F#Z>2)FQG@ _%%M"AB)*G1L8B<7UUICU5F7I*DQ =J&J
M^\G05+E7_'6K]]LOHR3[A)WK7PSZIT/5[$T\.I8?(_5T:9<AF[(R$![X?"'D
MI!*S_8)B^&?T.[D/(:/Y&H(M+KY4Z09>AD_S:Y]=+#../]-X):W]UJO?Z3A1
M,.%]3FL_/A2^.C1$$>TI"PJ_&-O38Y*0[ 1FC)@ISF#1+JQK1)9![HJ(7ZBI
M\>FEB*2%2T'U;YX^+S :D>C*\87[HT6:;I1+!*)ADAAX>$5<>.7N:C*/:VF!
M4Y4'[P]-5_D#_)=S-FH7U>]2=5^DL?I5M$#U"X+6BCN0U F%[[,>]168A253
M'.@7XF?Q"KJX,P2>8?.YM46=%)A:P8,ZJ\(ER4[V J @15VR4R8V-G S83:Q
MI%5@K(-T!H+10C7\X$A&([!O,+2O"=2^?MX^OFXTR<95<BE&3,SL]:OL(]'L
M+)IG7E%1GW1E\JV*4V:#^K4@T;INDXOS$BUG-C?+P4"O0P%2PY]9,UV/@9CA
MI[0;_NJATMB+)&B[M3XS9Y=NTVUE NX5N@'?1 9*D!$-_ ZABZTODY+1:RLM
MV$*'9W/>A%*'F!/.(5IR*[9<MTV7 FG&5Q $EA7L+=Q5O!I,'/.B:I$H06*!
MLYBN7^ST0FXZ%)+:G'X)=D@DNUT$;UOE6/69Z4RB/[/#2(CQE9QV.$ZXH=!^
M<9L)NHN%XN+<T:G&(RA#EU-#6E%B#_M%R]>2C;>75:E/FM&<$-']#8B&W'T,
MN@^3((:2:&#\H_!R@@1Z6..5OMGGFLA=?2E' PLM.HZ8>;^<^ Q;Z[3!1*$0
M$443'D3%?EP&SAHO =/#L'TH; ]S/Q7D<S(IXYF-64;])^F3N>K1KNK2W4SG
M),O?M :> 2G"*#XLV LWAVQ[= X#:NN?8J1DC' 4Z$?9>"%!$9LRU\=@3*O)
M7C^=8KMK#9GKB&?3[CKH\LA!(IR*)W<-B=^4&68(RB68.,(%XZKQI-TU3LBD
M$QS[[:+U^5=.]T+ +TLZ?YB"9EU^M^K21L&;+L+HR,#IN WWKVL(5SR$(,S3
MBRW^=6"AW%TZUMW=MX@ 6R/KZ$AEKLI6'>M(=ES6T6T)[W3F=1_PT6V)*Q5T
MZ\57CVY+2 O%5:C8->?>T-5L!Y2,:9L@H1R0DP',.(W&6O>J! ;J!\%M15<+
M.4:OV:H)N#3%:)X=ZFQ0_Y70UYJ@*0)O"^ <(GBBK.Q;/LQ639=;/>UR43X<
M[WE&F!".[KCHJL_M4:!N&"S]1H.-Z@!#L2I6Z*4],A#8($I0&]E+C3'1QX#"
M+Y;66OP8>F!;%=ZWSR@M*253&. 9_\9:* D9="3WMDF@R'1*L&G?'XQM$*P>
MOB9;J.--K.T0>M-<Y7/=W-RJW-=TR4;L)9OK3!:T*T+*7V0>0F %6^+H,)S:
M(UZ@.-+U5XUR+_NQ==";;4+E6KU?N!9KXJ\IY7JP""76!RU?9*>2.KM/!BHY
M-WB_!HQ\$D571?\IYEH#,<+\4&3@&I?L.M>'Q>OJV^*WU2F+$O>H\4KD8JX)
M8MAA PYUVHX.>!@H&]#Z<K9_PLM*H,OESN%ZMX/2MXO1G8*;NF8E>=IL+.Z!
MC.S_F?7_T4[$B^#J=(B)2F;HS-U%DW EM04=EH-.GT4PTW2:RD*P2WRW&WO]
ML.2]J5D>)6Y-DR1-MMP+)A7$=W![/XE)M_E/\?.\6NO^=@M#3JFI/Y[RWW+^
M1#*SLV>Y%S23;-KC[BK>X7S_!@!0M<&;U)6%X<W%Q%AE0:LVY71^4K&-#*^3
MWW['E/+8PIDD8?KL)0N?3VK4-W:BF(Q,^8IQE\"4^-L85(H(;AC\"K=SG+NP
M6Z_B1XI?\<_:9"3%R--WI1:R#"]QM2O;,M;6(J8-L :4E*$19Y$-E2>QQ.'N
MDEH*6O*)=7CP9AU61>G1HWXY)?O^OLV.K46^7R_W6[9/3A!DT8RA]1>^:KDK
MIWYV2)HR*AAW+I1NH]%BX13-T&+7U3Q[RC/PIBYM(QQMH<-KYD &3BF#H.KW
MBGCU1V$JE_+IN_)_%1@G];,%Q6Z$7O5CUF4+9M]1!Y3?XE] .4GL< (KG3GZ
M60-IF!*C^JFC2?%8I%@77F-R6_SIKIRK2VJEO>MB]*((=Q$E\0DAOMG3B4L'
M!; 1;B=37.(DCWP+?MK_SG0+?*(;G'[32F@7/'7W6_=R@1QF/O_D3A55TF-_
M_'] 07;=""R+I <&J'0B)53_L^H#$:8D/0[@9W17[RPVPT^5CU755@\O0YB=
M6*^-._D^\%!S L0NZ45[/!3,^JQH4V7K+$E;44JQ0B8$?9Q;L5HV08+X14D%
M!0;F'LU:S5DT"8\6]GXUNDNCYG93S5OPY-V$.X\;;S=9O!9XNZB#$X8$$E10
MQ:\?L0W+=F[ KLS':&/)@'Y%PW>S(L*=*H/I3E$==^K;>O5U[J??B%U_& C/
MYP8.#31C.[!VQ-2-Q9$M5]E">8K"O!YT+;IZWO##EABOY(\A.?^\GE(6M@:J
M\QS;$ YX$R=,P1\^+Q&)8/:^9;=H-%*OL7"ZP#5IV^LMM\N"](^6GIX',6*0
MC[]LN#J%J^;]5S &J#U$6UR8LB#:=CGWV[.I@!_VE])]?+(/+LZKG)\6O?!!
M@<GMSD]-_=L>AOE RR[2F+(!YK G%"F;,R,P$3-E8W@?UHS,+7DIUM7U7F2+
M>!<DV.L@6# <<D^W*B$H4&1IBBW0WP'O'##\ ;31A@9;CKK*%F\@.1V33.0"
MN*N"A3XM6.PR,W==A+_KH)-2BEY\QF4I?5,02@8(+/98WQ\X6?RM_H48C_:Y
M<4O,R(!CJ29#]_W>['##R3-LK#P*4I9:(=TN::IO6IX:X7PI%J!\J*/5 L1-
ML,>E+S#&RA_:OQ,7WYN8=<%>B*_/#Q(?KA\,>[YP_6<*/;^-B6UQ#N)9>IPR
M/S&5Q+S>< /#T%N;_4Z\DD.Z[ZG_?70^EXO@!<OM%Y8V8LZZ?2V.D@"(LL.:
M%:MP!\:8]+-P6P3=0]?#Q.6O'\:J8)D*D(=Z]!G7Z5=WL\NL+)6NL:<];&@_
M^ G.--=^:_MY]<5+NQ3[O[7/S*ZH2/NB==0^DYV9^?;9R,]_JP^8-VD[*E4/
M"A!--L28;((PHGZ^!!>,%$W=\*9+3I)>SJKG]12#JX(,1?G.@M%;SYX&"\_1
MW928D?F/=F&BP@BSZ4%^KORY_<]N!_7_D:C^UJY^G':W^E\ S/^T1;(-?!G\
M?B__HKS1D_@#XY,K+0AZI+1,+7_L\MI@,U-ZF[N5,!L5Q5PV9Z/CR<![&?@^
M5H<DFE.!LT9IR9L\/-6;HKWD(+@+_B,^;J &J#@Y,7P,,*IG;N(B<8U<)H3H
M_/.7^ ]+[H-&H;9#ZJWS?D]]1:#20!8C7F:DX>Q'CL:2E@^?7/OE@E;,E93[
M/;!T6D'M5NC-F_\/%54U_<RP6Y2 P]N*UW"<()VU_C(V"CSEE=][OUTLHD!X
M)J:!UOO2I5D>O@S:RSDE'1K_ZWK1_7<*8/0HYJOZ;^_8DP%W,/&FU?BHU_^0
MRHC_VXJ)U] RK#+:)X(,..@PPCQ>Z8_),/(Z,'5068EL1+@$Y'U7;U]Z-#NE
M#K6]GGR.2_T;6Z[:DZT_?VD]^7\2+ =O#VW!OD?+_4!9><Z[A?PA ZPXMX=E
M#37C!2+/<ORJ)AK,>5_LK"@"]G$;W\M^_LH_?S93)__R9\;> [ S:%ILH3W9
MY3.4$^M1C8:')S]XB]<RQ["7#]RQ%>,Y4T":_*7&*E9VLT70DN7TS\>Q%N.(
M)Y )XT6L;3V&-E;)?8$1IZ4LA@OK"\7K!R\[N&0&+;-4,YXW^:!IQ:(I'*_R
M\^SG)Q\@)=_^G;5X ;A2/#M.<#&G_19U!TF9$N\LA'OQP>UQZMAEQHW+U=R]
MM<W\^]5F(%A,?6;65LQ=Z]\\E_^O)J#_?J)>N'\Y$Q'?_SOP/_'A?R6BWJRE
M+*2(<>7YOP"88SJF_QE$W44&4&D$!3( GLHA$J/(0,P@&:#?1O4?D$;!VQL0
M@NL/_<B#_CV?*V3@,_13/[;O">5_4Y;@Z#X2'QE(WS0@D=K(0/MO2K+F@UXA
MD '']'VL!$G^4:X::&V+DL/=QC!N?FPAP:7_75\%'IW)(04M@*85P@@D^T0R
MT**(\R3!*W3P>$XRP)M%XD:VI.\2\^#("01N]F4V&SR_1H=(W0JN]&0\(/2+
M_16&!D$:$09>P1N2 40I'%.[=_\R&3#Q2#^D#8<[+X-V#SZ9_ 5$',X>?@[>
MCZ5X-/A3,K#HO?9.CU2T!/[#R$2:[ &O["H5_ST(T%^V8GWT<A;1J@O^6^ "
ML>P]O'_9%_(7$."_[,-XGI[&8=T[,C"@I(JWOTYY5L\.XB\PO.!_OQ/%AIEQ
M_P=7PHZ9<LR48Z8<,^68*<=,.6;*__9,>:^GQO['/OJ?W7_^F([IF([I7XI,
M8H^.YT["C##3C3<#@E"@B-J.YK3[2(/80RM[-9:4KQ%/DZ1=834H1;I[Q=W,
M[SMH@Y4I-C7,G>!&!K(&<$%D(& ;<6![&_29S62%#! 4XQ;A1(&P5D;\OC\9
MZ!8%HV;@O&3@]Q_E\W!DW3;)3)?V]TGV@Z,RJ7.+."09T,C 4).(2/A.5QS.
M!]1.!@YO,8:#]K?P9"#)D.J02NUHT%=+-4F># S^AMVF> H?).%[%HF_ X,@
MQ:DNT!+Q#61@*1$("-0[JI9";X%CR,"?ER F\/;L/AD0_W8,]QCN,=QCN,=P
MC^$>PSV&>PSW&.XQW&.XQW"/X1[#/89[#/<8[C'<8[C'<(_A'L,]AGL,]QCN
M,=QCN,=PC^$>PSV&>PSW&.XQW&.XQW"/X?Y+PK5<:=D^AX2"&Y5Y!F1O.?ZM
M0=!7"]-9)Q._U^,[;2Q9,\K+=C,;V7UFL:9+<>:_?_^SK]$=TS']B]%\P&78
M?3+PFF-L:J[K\K9L_E<!M;I<0>XFN[,J*Y^I<_NS 9\1XQ<ALH3#6^]J/^HU
M?5.Z/\[<EA;^R^.4YNH>>*S\V;_ *OY*+9BP<#"*#?VIJI"8O@F9K)1^Y,N+
M]?UDZ8SW>;QXH_VY^Z?0CP9O]2Q*Y6U?N.H]8D5+8U/!/$H6/IEDH%F6&//+
MM&)[2GEV96M:R*'*+:FZC[!RJ];ST:;%>,MHB\[DJ#%\_.F5D1C37979DVQZ
MELM!_[6_@#4NV:!Z$'8K;TVN4M_1QSCI>S][M +R^>^0)-E&$?';CZC6!\9[
MP&5QF]R+;N$0-IM!V>K%D?+U7TGP/W[N7,-W3CU6T7O++6Q]T*E@<U#V9K;\
MN;<[6XXY1[G\]5QSF14NK1?^+FIL)LS_V  $(D+J2N>M=\"(+ AD?(7&F9$&
M2L.T$I8NX,69GZJ(BY[3H_K=<UU;8;6#OV/3#./9FDX'D_X";U9DC+^6K2A4
M6W97B*/N1,GM@FR?&U>[[<_&!1&TUG2N%=+K-UMY@JM_Q5YB^;+N=6LA<B=]
MLF/A6AD&C,JN+"Z:\I4??(!%.)IV"?^^C4 8-5(+)2IZU,67QM4V%%JRY]Z/
MT33XM*Z:R6)T\4OE$S4V8[60_[:! OL./) D!QTW)WYSA0GZ%AR0!.*,1@J3
M^C=*BK<6S'JLH;>15]167F@K]/D>-M=)FIJAA+EZ"_5?^K[7+^3IK/[SXNSE
MS.K>YG_V'*-C.J;_-(DJ")D.IDV(?NNT^WT2L,7EMXX%L QL>2N.3=,++D$6
M7FQDS9"!B%MBW0WL4-?]]D_GTSMN'FXY\!%#9QO6%@,;0:A'KV98)UC3_67(
M '\]M/*YM ;*ZDJ54A09N*KMGI[_..@WE?)G?$Q%N?$+C J-$YODY;LQ)E2&
M] #MYZ\G(R]GOODWC31Z^-T"W+U[!QY6K3PWATP$+#(_%-;%#Z7]]]N?_*\F
M=S+ !?Z5@!LG-28C#[7W)DQ F%<D38D8^,892@3Z9=M"CR1^RV39WF#>_B>R
MI)^06&A!:GP+7U7[X3\,H0MH >\85[CA3SPD ]D<>_L/_<RV\8M_-#BH<>#K
M1=3MZ7Q*#&@L45QVF]EB:J[*XMG@2H(R6\PZ3^F#4'UYJC?0/@95S/@"-4$:
M9U7H9#S4(9!58F%ZD'!9&1;F^#V41N'V@U3WG]$KU$*P*/P- G/RHD]$<44_
M4[_[I3#[ZPE;ZA++CJREX@:]X/V1U_R--X-B4,E\'*<2S:7:GMJ,WL#.?E\?
M?V>7:V#R5CEB .Q<''K8D8ZM*]12W<%ND@:^2RRO*$S_2I&,IE_A5Y?NNY5Z
M?TQ<226G#9X]-[W&H;_275.>:!N#OO]1ZB,?DP;M-]F%1S+$.*4S^= 76XR,
MJ]^?355K^#F%-*0,=)<&BP>KBFQULU\M/]4X?XASVWB+H=9'R[>!<'>]KPB5
M#WN;)$Q9*';LA/Q8B$NL+/GYXLH2^TD?#LM?F9%SIDK71*/7'T]K\Y1O5B4B
MYE/R1AVTKQ<[*7_#Z[1]$A^",:#P:4[F-7B.%*>RONJ=J8=U[R\2\LXHV%$'
MS964IT=_8AA7XLV%YO5;Q)0SW%2/7,::VH0+!A96.7VS$WD) (I1@!2TR E;
M2@82J!?2\=YD8*C::0DYB42-CK?_%$&W9_BXVZ(8!!QD%9-*GPLEK=G<R]3G
M2T0]?<%0,N\;2,1$HZO/RI8DM(Z^M?P^/M2-\?E^K?+B\X)<M4?KAP<@>RCM
M0D>(\F7_.A)SF@%>9T,9,@4>_!IF1YR&CUU<4>3]^M(OL@GG@!%#%4?5J^5:
M0*4LY,:NZ2(ALI4?L/U284T)&L_&?6=%/'3Z=#P-8!=PO)\)W#>+L<++6=[$
M[%\'2+=XD, C8MV+S$7%/L]/K[B6&QX30^&_"AV16)I4,G#_ZN]03D;C3Q>S
MN95-A=V4]X=K![0+[W5]M$N<W28# /YKO58;J**C)8[A(.)<CGN1I89D$&IH
M,VJ1NSO,/[[6QEJT0X'&QB96"SN"2_%!(1A6&SB&KQ&B8JQ[_)9#=84LC*A>
M2,V_29 &O6>.9Y4X7^&97I:\4?<9FMST8DX(DQC3]JL*/S74VB_$7,"MFW!=
MM_!'9 V-I'YL3H*' (@V+)3[*29F\@?+.A'VXT[VRX3\C6=;5?;U#F1 0.E,
M'M3$"".<$RZ8KC$T=V/[DNDE)-6+LRGA7PF2CZE/GD?5'&C+PQ@QM"UD@$4F
MI4+G'(0,.)BV25;ZPG(OM@89A;=\N\6M[1X;4+$SOBF,O[&*. <3\UF TVKZ
M6C_NYZ_,^5K1CC/FL)EH+)UKZ3/M-)9(\GY2+OR2\VA2D5"J"1DHF4$>ZKBI
M.7-PKKFQWWFX[N*2\W:7>()]#>]FJR><L?VRJ/0)BJAL0=3'(G6^1PG8]L[D
MLSDDL-F^G[=YHW#K7C'_"!EPU@G]X+_T[KJC2>U''Q;G!#\+$<,*;FJOX-O1
M&D*$H+@NZ&HZ+3&OWB6/< ]70QLL$T$:MK:6D3/&/I_)C5W80W._1U/GPL7H
M6Z^H+_E<+X:BMS=>H1?O#SIO>E\5?6A'NHR1RQ >P<ALCJ1%G#?B#^0^3Y70
M(334A'I>_L2$:]IS]/*TFR(9:"2T;>:-?LQ2$[M6\ =Q$J:*1K8^O+6MI)@_
MO?8FY[ M(CQ!/(D:YDQ]Z7XEQ0A)28DBHY3,ON!X6_9OCE5X8J]*C=NGN2^5
MI_I<5SLP9/'HH:7^ 1-S'B3UII>7E%>,?'$1:%_CNF:78I&J,,C?&L7-VR46
M?/WZ(UF7'VS^>GA3,M!)A=$AUI*!54O9-%@#&X;-^HR\=G;!X60%"8X^FQ/^
M+K>WPD%]1>L+P0;M6C,_J]5F_'+&Y;/#D(R)_/<6(16^DRYU5JJ2B@, U8PI
MU=LVG7E0E  ;+@.[C5/WUMD$EQP<3:I7_\"?NN]"!DRC/FZXIJQNB2V"_OT*
M'5?8P$1@& B@3S/!L^SJU9*&=F#;53_CXB0"9NOTW--6%/I5HCUU>%\USQ^L
M[E8I1WW?'?9SVC\;XEA18VO;372&->'I*2LU'T5LG)$GO;,8'T.R$HQ0H+,X
M^UY,F049>&KUH+)=,5^]-E;SNHVNM:$SL=E#G4H/R;ZC<R1WPD[&%+D30A[J
MN3WZ@?>$=UX: F_(,Y+>SIADO-<WVC4=?NN@Z%+3'Y::\]K#ZIJ?3A!!)0.7
MU5P;D(7*%7Q[QTO2W/>ZS.E\7BYLGE3P9W;14[3:-]J>K%%"=O8LZ*22H&^A
MK_(%7U2E!?C[ [CO90.N.:;B"^-I$]PK7++]I$[DSNVC)MIND$,365@I7FW6
MT1A4<2K?/4L\KD#-.Z?3IJ1MN2;%95YR\P%_QPME2[Y/"GUBK^B2AUN?KJ&6
M+KWS+=QY,:[ZLCK"(.MLA)O;ST-$!Z(\/;!!H-?3WB\?_LSQ.6.ZSM!P_UO%
M+JFDGS'\]X3R:TNH<\[S(\/ 7$IB&/U>VP%9T^7:,PU6RFZSLZK-6[/<OP*M
M5+R[[ /;Z[<INEZZ'725P.M@7>"08+E>Z/1]13_X4/=NC[)=M,TE]KCN&H6S
M=4$*_1T#1<7HX870[)S?^IW^^1,S<PX<P[=CA5^X"U?B1BU$R8"<X2DAN;GJ
MIM66)9RXL\A9EF2EEW5F%#V1S@TO5+]OQ%*VX5^WN#T5U0AAW"[R.M@N\K;2
M'W.[N-"O]:I'DH_%8\-8NISPY90XUR(?G_?<*5P9"A0AX(CSM*P:L0L3WD0/
M]GUVZ?9UI7;NOCQS:N:C_?G(70@CJ:.!I@KMDAU;^E73LZBBJ#OM/MVJ"NOU
M@P^2;]X;@Z_]^B6Z1;,"EH:)UR)P!GB-B55CS@#?,(N;_*W1!1'N= ]_2=H8
M']Z@><-M^''Q?4Y0T]/<AT^6KD&O59:1@:#I$8]B\W>+FRQEFP-$CF(0QGY3
M#XUL1CCH;"(V4ZOER$#6JB0WH7<"GX!A;E0 @[D$O[7YS-T:6,& @^K5LLS+
MW6<=;WJW?7DH*1KT)2)>B^D,M9 ]0!3K@DG@^6%*@U[O-_<LQ.*8D,^''EG.
M=#(JWK[ (J*;_^8>K2=#*\<-KAWT8+-9-QORB\MAFK>5TU3B#[.Z>?B4&XH,
MQ!;+X.FLS+7XS0]Z]"8<.39YMSK/9C=*+I7(!:XHOO-?C-RK)9 !XK=ZNGDP
MS=J4S*,SGV;MW,I5ODU,.X(<\$KQWT_.<:=D/35KHEG<MP:>E.T5;^PN4$)/
M;A@/NB$_MWL%J<1(\]8V(KDK<>%<6X3P>W4Z%E^A3]*1&QV/'?0SZ(WH=KJU
MM+P1!URH]2Z#1-&DV@U8&[J%I/-TE]3RH8,4Y E1Q>&QF6C.%OQZFK+?>IJ)
M847JS^JRH?E=>@V:CW7LT9O@*U11IVYTT((N.NKB@G>Q[S G<T**A,K&7?<V
M[PS-+<@JO-84+_UY8"1\6]W#DO[;R2 N&G\C%'*2%M6>F#DYM69N^*&7H+?@
M<D<K=\%A.E>1Y7:>(B!UFUHX5G//D^N)]4TCR:L(;Z$L1/X.0?N!3%YUETQA
MW6A:?R!)"JJX8+O46QRZ5[W'F_^L]?OM@6ZZ31'>X)]YIM2!]_JD:MK5_3X0
M%G$1*'\MK#-ND-K!1.I>I9M 1H[E@PGI.ZTQWT]/L$@)Q81U5Y^Z0158/.#&
ML#XV=QF]E5@P]25^VE&NU*JU#. 3"N<[!;PY=[J/T1Q31L]VO8O]F=8'5G/^
MZI=;^>\N%0HYZ:FQ+Z9E_$]LGOC_9Z)%];+I00I -_[IU\__-R"_N TM,B"B
M,-^/AU&"\ROK>\8(4<13R(%"_RGX] HI7@>25X$^0.);X2V'96/-,,;Q/RIJ
M;";]_\/$D\;@_IL[.W4N=T^F_ B[5*HDLF@EUI[D,;/J(^#82K)H;W'*V(S_
M[0<J?G[[MU@+S!V5IHK2"4>@KJ&GMH:%%=V<X4$>+Q_#J3:)P]'>C8_]$MEC
M4&ZL9M ZM5?Z)6]A^G$I?ED^QON@>8U3E0Z 21SL,29D.=^?$@8RSJUQ1G.L
M)C8L?'K!.BV8="NL2/OF=@22Z0*:,6SJN='>F5W^@JNS=:6@V4<-A'/2'YIQ
M"O/<7A8.2JKY6V\?C:C$?]#YP2+9=PX>49O>Z-X'><\/#R* '.;AC$U?IP@;
M")EAGR35T;@=ZI(3M3R7O_S753]\S/W\)8\W&]7',O_8E:[X!@U\]!P96 '%
MKXCPR&H8E>&M4JE(I0$VAX<!MT2OLNKAO8M[297@Q!]$QD5"TV>&FY<S \_^
MLVF1=!W>*8PI)@9)(/ZDK9<4:2UDI[5GH%O:L)4#G9[><G&^;+K-(7,:S_A$
M\V(UA8*"1L;*K?+:&GY'IM,IJ_Y]&K6^]8$PA[X6AG%"519>RT'UTT.C=!J2
M6)UWX4_J4[/$"]0%I&[F?0SZ='/'<X8,- \0OX!7^ELAN <Y9$!P?,+.#%;Z
M/LPX[5ZV;1T9"(3B+.]DZ23HP=W7R4 EL;"MHUF,^T*PIG75V(4DNY@SS+F1
M-O2M_H,U[VSV'RN.ZDP\W:'%61>9%V J>LQ;NH7.+KX4:SIM+#9RZO(\:Y-H
MHU=1U/QF501)#'81<RX9<W,*XUKL^K6<SN]QTO>"2Y<C;UZ(OF;4S>Z1L_P(
MM[@R0>(BF!#38-!Q$O?P-=EO$"_F.0<LV#%V"QC\:7QO1%JM.H0V48&A(E9>
MP/QZS(.K#VH-[KO[6*7W#'FXY_/=CRJ#R/BO0M($V,A Y"+V2V7=('RX<*M>
M?^K=55*QUQD/._N6^6CU[!+?&XW<C45UIC@R@($OK+PN+I I9G =VH)U:]45
MTMW[Y+_VTPAE9WW>,C_X.35C,@UU?TE #QDHB^EH/G"E)..L&O;@<!$UCOBV
M%(9@=N+\[+Y/Y>:7;S?./O^EP/9[F-299>S]I>9700)131]B^9&-(\HB#;)I
M34G>:-O 6,K69C\?9\73FS6FTWMW9P?+UB2;0K^DZ;IYW[L@FEW[)GLF$'HR
ME=\)0?PJXT?TFP^+<):IXXVY<^A6YONBLE0F0?G:4^L07<U&&O0-8%P"SPOU
M,48C6OBUA\V&MF6BJD9_I3SY40GERP@&N,0"[_T45/X<.]JB[4[J^NA6#/X=
M&R&R5UWG10:DD4ZHHR'(]\<*R<!C3<2?S+F&U>)HA#7\!"ZYF;+,"L5"ZY;:
MHGCG0Z5X\?$QJ=LA/6BFC!1U;:H;ZX'^EQOO2S8M&+PL1^BVBFSF@B$#G<2:
MC2U!7$:FY7L;CN^_,:UOI?ACNY7:WLG?,;S)0GO^>K\>Q(C 7E_5@%.=SW59
MB?7B42M0RWR.,KMHZ/USJR#[WMKI\W^*5+$I. EWC&<3=D5KAPQ4_<GE\5-+
MC"SXW1UQOF\^S\*1J97Y';4H5\E!:A,98"9=A5%5OVIQ^6(I6[^K>3(I.=^T
M/KZ^;41^,N6TQ"YS8+3NP>M K1-^U@_M3,]ZY6I>:=K <RDHR5TT2-BW'3DT
MP/X8+:3L1M#+WA^M#9;CN],6%M>&?'Y>,KOWDX8Q05[A!NC:S7A34$D_(<$%
M0FKQA*_>^N$KW\9X%KJ^(-(RZ[F@T0J25B?UW7L\Y'4:]>R.:W6$<'R6AQE5
MYYI/:=//N[?GROZ6>ET:)0,;\O*DM]-#N>HR4C4J][=3+5S\KBJ1@1Y!>0.V
M+Z/ERE:XB,_$.FP@YE1B;C\QC&$E?%E30H+UQ&G;:J$'JDQRSH\/A$Y4*W#W
M^J43KDL0=2 '&F1@<Z\"KQ_0)R]P/6&E/8 [4G.O30W_XF.-IU=DAFHK>"4S
M+]  U\AU$ KJ+8=/018HBMX6%R9K)8A7-4CMYHA?KW5>P!HYJT=FF-&GV)Z7
MI.]I78I362U0%^2\\[%$EL7!7'.ZN_8EWUQ?&D^"T:(7UAY"!NCIR(#!.$F/
M#.#]7Z[\1;AIT<7M8.Z&"S#=H6OU:ADS4'CS&._4SJP+3Y>\-<TZ+[,TM_!!
MBHJ1L(KA4RI@/),TS'.+] .MVEK)8Q73GN$O/UE?9V'Z01/$*2G9_$UH_@24
M#W!JRS=AWNMB;C/4=\C)+J^SF![8?.V YXE]9UX+CV\,:.%X+M+"[['Z.,;5
M=DS@BH@A[ZS^Z?NYKE^N^)P7H++K,#_4KZ?#RJ&W"E'PT)MI7\NRYQPXW?([
MI5K\G-$*JC3 =1,@_HVZOPI_/M*IK^=+=O2WX88<;7;S:)T0Q)/T S'S*F+0
M)8JSCWJYMSV=2M*4BR<#3ZKA?SXMU.]CY=$2$3 )C*)![9B28MXJ1W]6)TNO
MO[70:<M^JK/<[VSF66.K:8=^J&([*0 6XD)OVGZ-R9YSW'?([Y!6M77>K5:A
MF2\UI E*..5_CW]]KG7D52]*;#5C95AGS<-8G@S8;!^<5^:@*$,Q4>Q#@S<N
MG1)]E-I3 /2"R,#MRN(O9,#.7X ,J. NH/(9]-L7=1K"-I5M"T<>\D6DIIC:
MFIZ0.JT4J\(^3U&8>KH%BVU*%&!6A=ZB)-!%I=GWIUZ_D)*ATG/9KWK/Z<KI
MT-EWZIS[*]/Y%?;8ULH_CO 4[TQ2L:9%U2__5 @=08<,O)V@9'4ERW%DX+.%
MR2P[)KG5[00N"8^M*Q]S(2CFS3Q;+W#0K\S@CXX!#"W\-Y=/3H=,>7@&O?KX
M>%Q YW)[H;:]FSLI%#<R8^WZ&R^'N E?WD!L0<G ]"$E.PPF RA+7!6)QPUO
M06+V=\)+D%C(0#FQ"J_L)MB)=]V6#IAQF>[;6.0;FQ3/ KGT;&[%QSS<,?-6
M_D3,:A"Q(ES!.7CFKB*N%?I(F4[V#$:P7.&2YGQ\C^^B A]SG:L*=_''!K:
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MWKW+\KT>JZ_/RN[_5--3?/1T,JZ:2GA1&C:7,X++/%(6V[7E84DMA>_/VQ1
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M,;"VZ@[QYF52K^J\]R7XCX.$$H-&@;[YY7E,F=*#5]X![/AA[]]B!P4?[?\
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M,"'\^#(?!KXVZ,EI7CGA6?ZBT>K7C*$FM)GG.UESO&3TH\9UU!Y1'W6NTW<
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MW4,/5"GM+%J6]G9WW59__[*AOLXY\OTKD[F-)C4*LZ3OX(5?2LEHX5G0+P+
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ME %#1HVT'E)]O]:5=.V=UIUKZB&^L1TE.N[U,#4(AI7;_4I'%"WE?D@__X<
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MR..S15M%V^ =!UJ-A1_[+PL2HU%JCP#0*7,A11?^2U@@0W70XQB;'_B)4B)
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M$IT64N@6&'B9F!Y"O6 ]M]15U:FD5T!L$4/?@.:=< K>V[2V/]Z!!)3%P_I
MG*!7]'%&8#5<.@%0)W-T;5&7>W,E\H W:0<A='6]8/@[1.J21@]O'<MA/M7
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M:9F5*.ZTRX9G&(WF8]>P9=9#0Q-8CYC?PL'=@_2??WF]?UAD9O<BOAF*7:A
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MR?RPOW$QR967,/H>=IL,.)*!(\6<<!CVLNOL\:US+VJ $!BE&]R1BZ-!TF3
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M!L2,YG/PK#+(_89.I+O'/_\8"G)WS8T%CHRQ.&(\001_EZ#:- J7K:9T@_]
MVZC)@,-\Z0JS3=?I,\ESS; C++ZO:;'54&V1F\6X'_0*6<V9!/.$6*#&-LD
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M]S*FI\LB38I5GKG<XPMO'PZ6OB[P &])&9,$Q[]5LJW(P!!WZ9P@3BB),#J
M#X-M$4/RW">,TIH+9MPRLK,1>9_M;F+'E/R\I+X.L!9;Z.I07[N60LE&Z6C#
MP9$L;B VV-P;,E!S#E%X*16!S)NY)5VMG,"9[C;/+YV?D*\=)%>7;64O]3$M
MH95UN7VA#R!.YR*TT$@">R 6BCD3X0$+GB?>:K-XX#E;L)YQ:7*J+4I".=-_
M*7H;N#HI\K1-194*B9/$>Q$DB)](5VS]!5&D@B+_L/4Q'8@[Y %>R]!#6_N#
MBK7@+/7;'XQ%4[I5'D^/:%RI5B4(YA3;DR #W</^A:3V7CA1I@(^D?%_^/7O
MPG>*4RB +5U3TR4FAK"2@4$UGY#?8_.<6R__UG,G VAS<XQ C<_?ZO(8Y4@?
MA@VX=/[NQ]B)5GU!]["^").G']\DGIJ[1[NU=?]??/D"84\&HO)(/\'[#T"[
MX26P7<6 0@(;$_8'>A]9P6<]T%;V;-:L#I>L,'$N89B*NK/O3L5L3^U>U[+:
M2UZ;BHE&HQZ51[Z> &X6:X0K1B&3<M#WM@P7:#O S*L"+,-;B&&X]20NT<.Q
MSD7;T(-7.\WXBL8/YH5DT8F'F49_I@SA)13G]4AQ)X(R*4O.@;C]E;M(%S""
M,0J]X\_C&OGICT=WMP.M7O>DZ&'T'NHRM/:P%=N..8;EOQX'?]TAL#*T"%;K
M;A(_$VY@^IOG&7C+['<W\%I,3'8M/-)?3+A +RHG55FX[;,(7RP>)WV:DISX
M6\V=V@)'^3Q;7D7Y&(AM>DRQ5K$_GTD_2:._I4.ZL&51W7N$1DV2';&QEC#I
MG4C18=(?IH5V4#739C/JG+-A9ERVMU[$<WZW\I64@ ^[T\QWX))%UQ0&WQ6*
M<@ _3:NN593++HP1V/ HZ"8& WZ("Y[7I.KD;.A/6@S.73"LJDD9;_HCDNTK
M/Y7')U5RWO094P7H,JR%ER0VZ\\[O]+.%$X2PNND>Q7=PFX$@TP;/?SJD-4.
M_!T-UM^H^S&(E4XNZ:2?^3(/#H9"M>R([V#_TR5ZR J"<;=:U61C%;8,>N^\
M,4N!N(].J-S1E[K_FM&/A7^RT.04\$C 'R"$XZV#/#%,6P?XFZ[(JI66/N=Y
M/.HWJ\Z,T*A"[R/TG6[EG>T98[G;HVGK]S[V2%4%#PLI;8%+#XXL*.>1(P,E
MXV0@K9 ,^/ZBI4PK- ]P'I\(O,17)&Z<6-OK !ZEJ'D/7O7@'[&[6U\1TU*9
M[&;YR75ZFVR>?LZ=1H%D@,"R0+KS )5#I$R.^VM^X PR4%M(8 W_6V8 Y9FZ
M((BSA*'3B(W6<7IX)JS8GUIH6$!0'QEP?:.RJ[0UH87U[F1"4D:-#.QQSM%E
M<#64<!FY3[&56!>\) FQ"5I8&: <,6<=2<%T#]6*IMA9-4ZBJP-< 8OV4:_W
M%/F&'BTL7*^-HQ*W2"WD<-2C3['H;7P]=\%/(FONP@LD[K)G67!92-LLHXPB
M;V_<VD+8\;AS?6J^4ZPD_EUN/(=HA-X@LT5N21$70+\'QDDIMR-QMT%.>DWR
M-)T?/ DV9396AAY/R<#:F5'&:8VO18]"K![7F-MS7W]W^I2/R 3R$9@*UMI(
M3-1B70-#2+_P.O$9R.RE@,"0B:W I06O_H'J)],YF<Z;,KZA3!]=_PNL*?ZO
MV BJN;&2!^$K_]F+P/\CV_DDU%C4IH;90AF#W@CTT_#SS-(?0\>[@45EMY4F
M7Z:VI[R.;:%BSEJ< _0!(AAE:S@'VXS*MA]N%T17!P5>:I1NRH"FC6)13;_H
MKZ7I^0$5];*B'_E*(GQIYR<D8Q&\&^>'WMQ?3P=;U'^1>/:D1K');+[,II-T
M$3&FV+OVCW*$2O/KL*:5CP CS3W@'G#J.@  5)=C)2LNL3NZ++<BBHCA0?IS
M.Z<\/BABC&.#=#T^35FM#4[:M/D]B\%&YSNG0)*3$18/H!?HWX-4>?4EDU)7
MRX.T!;^8/,^LZ2W4TO?F/.AS/VQOF/E4NOZ 6'@?^2UE>QGR2;EGTW;2/31/
M2O\[</Z[&;UX^:L4\]N4%.+.C7]K"SZ[$;0+-MXX''0^Z/''M1G^#*/ =CD-
M,/KUC>+FIK2V;L=77^RO*>OLB$2:FQCNZM#XE[&G6M\K$S"(7?W6W3%-\W<G
MP7]K]Z'_M_9?8!="NV!,+TF?.$#TC2,#M]A7%5=F^9"+.5-D8,P5N2\'!K4+
M[HIWP,;J86M2!\_@A\>"\TG+SP69D(NZOV ;/;)$:HM;#P_;=HZ8]P6/=RG'
MN,'^:ZR DBH]+R!QD?06*%Y:H+"4T!HK7K[P[G\WP]PTLY=6TZD.]U/ZO@,^
MHK]H%3&\'=US.70S[NIC6UR[92/(6/.U@R[II.L>/V N@@S=11Y^,Z(-C+UG
M[&,RLX?J9E0/&%H.9BUAS!I&?IC +J4)K==ETO'&2S;PZV1@YO7Q>?E-VG+M
M8'84Z/RDOW$;]H49_+CQ^41?/-2A5^XX*V>HU/',"-M]D_^0GOQW-MK%NDTB
MM 36(@^":%JT""CFX.51G$D:/Q0&6, ]GZ=3Q)PK/UBUB[#H+G-=-IX6YLU1
M1/J*.!,OX\;0G-^1U;H1D"!5#.U-TNQ@&=3B7N38EA_'I(MIBF+PKP:YUIX%
MZH7EM>\B-EU@.@(S!K0)0K_W5V\C2>//DX%*F.?:4SMB3L@T"9R14.7;WB^7
M7?HAK&$"Z/S7=R5Z,J@-!*QT(D,1-,1<#4D/U$"T&B>6E.#QHN&5$M+C6^VD
M6GYRZ7;$8"*'!9>8H/+=4P*RE(#@&_$=<O4]&5@*-"4#BQG'Y;' GNPK4)5+
M*QD(_=HA&-K$E(?S10FE_%F_,'F4/M2^&Y# EV[<X,;I_R#J&6!&=<J4R>C_
M>GNE'<$0THFD1;K V*;]DU"'KT H@='R+YG&&1OXN[LKSQDQ/[IKW;)UK$55
M <'T\##OK>K_70\/D]KA$7;,N&Z41])Y_\FV#%C,<ZLZY7$HBFE)741W^?;L
MBRNG&R.2Z1NVU2U]RALHR=L#$K\77@XV*$\&>K#%E(A<<1U& W/*B0!5(2?
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M*_Y*D^T"RDW?W&3%=A6((D8)CHCF1Q8_Y70V2VO8P]6K),I-7;QSZRK&ELE
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MVK!*[M$[R^3I.S@7=+D*I$HWM3:9C#VE5W0T!IQ0 &0FA24$RE 7?T.H!HM
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M>0E7<'ZEY=*E.W\4,&#B?"II%$B @3V()O@$6TQIN]+"9:1AK?_MN(4Q!^.
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M-O&>A-%#\Q&)$#6"+H0+DYGBZ2Q$UUK57&LHPU_TI\5036L^_+C >C59E,/
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M(#61]&>".[TN;28\\0M8.?Z.8.I\V>S4.=>75P-3Y(^\-6=1&/O>G75#M?N
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MRHM+QR&B#76APK$5?YBMTM),[H4<],6*Q@8/MERT3]0532\FJ)'[X&PP!U)
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M_'7GE*RURYU5L)WN4UW-SWIO&B^F1$IW2')[Y^1\>U@#&.7EC%#O2V_+/GZ
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MV)MSX'MCUD*? ,'"A$\+.=SF,^YQAHA"8YT?>[ *=.!1[0E$$;JW,,?M*47
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MTW=+?19P)W6R0.H$)B$Z6)H8K1*SS>XW8Y0A(A]X8%N7$7@3OI]$KY1B88D
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M1WA=C^W ^0C$Q$HL/0*I>:'(-! <XAOL.=-;-+.ZE)\ZJ2-8.N/FJ^<?9QR
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M]N]S;#A7LD):%^I0P!.VD'.83.717D)36.I0.(,@?=+]2/AL'VJ1WUYM#2A
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MYJ.IN2;(8*PJ4R)0MW%$7D4E2/M!8SBV[-76HOG3;&'#LOC8,\_M!)EOG[K
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M!$BT4:A[BE$\K;=%3;(=PL$WXT6!O6OA6MJ[INK^K%E=<=GV=>.AH1#&V"^
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MSF??QL2TV-051FLF3/=="$K\;VUH]?D<? @)/N/9#YK=W#)W6S@[M1&EMAL
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MU* )4BU<$J%?XK32%@='5-Y_I^)+"_[&>3'J(P(,PPE%-YU^18C6AQPX]I&
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M6X\#S3Q@:9-[*_+#;=G]M%<;O;M'8L*1?>J!ATZ[O;U#I&CI0S03JZI14CH
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MFC>(\DC+B=Z157J5#=979JZ:>1<?G67H=DF\=?2RSJ$>P'&3 -IL(I-('\X
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M5+R3E!Y6YQG$00.SN8;B/U/5FR<?!!(9<>%S$5"E*ERPY?=N#_U1.SKOZ:1
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M]?=",-1-.%>BG?-,4ZQLTX;U&7U5H\AAK.\U#*QQ*Y!XN7I$VC'$W4/.@*W
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MJL'C)ZZ7VYYKOF]P5P,)_J4DW7@JSQ[QP)VB!%5LL\YN1:\A@Y36M\PE7].
M*AG$/K? P*N>,DYQ98%4AYS\S@PQ@PX%FP)Y$6L?.A!^KA+RIO5N\^SW@:?W
MTEY;U*>OI&O&:>FT@<O1T6<'UZ3<E:]5@ @;BZ ST^+1*-#JR;F8^:2,A\QQ
MTTM$>1=WOS'_DH;?**6]RM![X#OS\<7<@^5TX-&O&?'C!)8LFG;:#D/#H2]\
M@ S7._NOSG&WTH$C:KDOO+"K&NZ"'"&1/F=+[,LKA^<->_T7J_]@ORNRG@QV
M%C;[:%0Y,I6X[?9KM^#1Q9(V(Z:43I6LVQU2CK[4>[5:1E@[Q*PB0\\<VY@E
M!#7;3;KVJ908E.YUCZZ\C+FX].T)<\B1*][B'IC*RI1"AL!A&VEG_#5AZ+N(
M8A06U>)N-.O7".99V2\T)]A*6CR%9YUG_WE=Z"1OP%X)R:(7Q-R@X$H'V&$[
M';#MRA'!/8?[9HZB:H)2W[3\@I,G8KJS0^-X,P6KRK*E4<^-/HQ9HREQFN(V
M)V^5^%Q4,;M9DKC[:,]LFDCIR]<^1G&K(/VLR:L<.C<4&IY<V_W. !1,>\,4
MHA;\I?H2_$DL5\6;BO0;-2&_NQ;2X[4L\Y=$H^8(;7"1;<P;%(]<@Y2_QY)Y
MR5"Z<9Q&6.7%!NU'^449+R\QGE*$5-4<?%A; 8^.V<"-I)%UCT_)( DWK%H0
M;YN#^/='/\0YQ#7W-P>9YZ>GI<.2%1Y73.2$605#7K58M,@92QUF94E5]H49
M[Z\$U1,D9@^CFE&')TF1N(D[81(BA9X&)X*)[,?6Q"_WW>P>H,E/0$%'<PB=
MRYOZ+'=Z9*WV7E:M_\YC*HGSS)AM@"?-LE+.04IS<G,G#6OO##A55 9-W=)S
MW$S' T@*L]9J!=Z$\F'T,QVPLT#LJZZ6"K?>NGVZ1FE7[(1*87DRCN3N'F>U
MP(\G>1?H8\S>B=:.JJ'FZG>U)&8VVMB"%9?W0[NO/$F#_5ZP'+,V/8?[^?;:
MN):6+-]L*NXLE@Z$[2>YFEX[5U8@M?_[X=-(GFWGQKWZE]HDI!8U457BJS]W
M6Q76+]VV+)1&_#W_)#BYE=8=+%I!6&HUUC=%G[&]5F3_HJ=,0:?;]JH3Z^O=
M:"^,>'+K28RH#<>;[)M&XZ/U\X,#4A,PDD.QU>UC*;("YE\AI5DP'_4":,-2
M$46#6N!-!X3]$_OT&_H7!W/JDA^%.6;<3$\/Y4J^J_1421E-*()$0<I3XO%+
MUD&"XVWNSN:W DK:3\5=Z@!"Y4.,GEUB1CT@V'W(\S?1'4'*%2-5)J#1Z<(W
M1K=4' *?7&;AZ6NX\E2K8#X^,L6:#C0BXNZ1:LE@W.BSJ0X?=Q5":FCSZQ_/
MM%<59EF?7M6ZF%G8SO/!\?W]%;.[=8E>IA8Q+ZIQ5!O?9PNDP"KE5M7;2;%?
MQE^G)*:^JYJ@$+6JL! <'XP@V@+YK6XMUA:;I_*$$);4K5/^^'7RW6-*SX][
MCM:GU<&Q?HP\PQYH/G(*4J* F+4TK?NV;F;U2V*)QS F(2XKYJ7_*1$B^_[)
M_,("^[TI1PM(I&Q@FJWIS*)W\DG],U^67?%5\+2@D"AIY,/-Z__20>?_.T89
MZ0^6\\<0_U#K5!6Y_2%MVJ?Z:8?]6;O)CZ<%1J2&4LW&;\"U1@J^I^).L-^"
M7W$:/2^BE0B37P;C+10C[&1(4+(Z"7H/GQKI$\^^<I=4.CYNU"-(L[F<*>'L
MWZ9$^'[62.;CUSD9;ONKH*<#D 0X-]P!,Z$Q:_(R4'46IT@,KWYMC-[N<K<>
ME>T36352TM4TDF'E.,K4])WEB,3E1BVH+#&(FJ<-9I#/"F(Z7F<6%N&AZ>/Z
M CGA@A[=K_P$^RB"__G=SL;NDE(HVX#!F6?\!37OXO3D7H)*5"Q:(96I:QUD
MW4!G4G;V*IR-)DL'FCBPM4$BLAJQZC1>+?W;6QXI 5,YF[BLQY?U(_WXJM<:
MA9BUF>@ )P?9@T$ V^$+A&(X(0J@WO^".@ZW1P@&>I"P9!M_OV9/BBLAK!9;
M?VA[]4K%$D7RQ)#5U&_K[ESJK<V6#?YU^VCHN06K715_<VMJ R/0LM@-DFQJ
MBZ) H"HUG:*:1S)JJ6D/]3D?:.7N?G8Q&BZ?T<=35N<@[/^;-SOY]J!G,NOW
M3]S5+L@T\$Q&IAQ:TY,L3-$<I>@7KHB?'BU&E0</Y+FEFGAY*DSI+9P(C#-2
M&S$S3?IYYPJ373+YU@IZG'L-0["Y/Z2HH$+5ZVIZ7M%3M/"UB+__9LJSTBM7
MWG9V_CS^,X2-1038'I?=LJ"Q31 <&,67(1MA\";'.=!Q_[(U\!CH,6UJ1*J>
MK$T'*C<V*6CWVLISGFBWI4]("+44_ @5@:KP:_G&VS?;VAZB+:0>CBVO';!_
MD?ZU#A6W;JC3\5@R2M V5GB+(X6+/?8]TTO6,6^+V1,X'K(XY29#VC+B:T^Y
MC3=IA6B/SA*Y9'%I@4K+NV'8NHEX&9N@P5;52OGCI;5O>T)=?@F#\T&ENZU=
M\>/I1'M\7\Q./9C,N]IB[F?.* 3&\_UK_DLIX_HA]QU3Q-J45LRJVJN!^>)-
M)ERYQ1+KVA*AH!U59H+[,6LRMC6;&ET!Y_._!_F0B\^LFHVNJJF>G-'Z1'ZP
MJ+0JZ=:O=*:4FG=([\AC^7WP_WLZ\AF8*UB&I#\G%5I$T9]!\"S3S@XXC:/<
MOK\'OUN+EDJ5H?[YRO['6IU]M=K#=+!FA=(Y@IJ)W9WF)*@N16KS4J"CFK)Y
MUM>7]&QJ]8RJLR_P.[X@!SA(%[<V/@Z7B=-#-TXR[9L4N(U:'TL-R%OQ2]GW
M_>#,,3DY;=M9HL-BD/UQZO?+;_E')=\"+)F'@^_"&R_<,T(S1!L\EB:!=P^G
MW)%WS(^]LM+96K2&#0DR/RHWRU%QP^9+;*?>]8\E%S@VCVL82]&.NA+"9U-2
MG9T)*&+$J.I'M8E[1BG].(4-57^[LW<X(U4G([[WFBU>G38*90&E>YH2-]9V
MR1<I6M3W@;)JD3/RHFL@Z&;ZG>%B1^5I-UZ]5\P]$O"?[\\<CK76EXFNGF?>
MJJ6Q*W)3E.-Q>_BLN1MJS\/2L]Q C^J'-\IK"R<A'<Z7HHB2.J<FTL]51.2-
MB8:?2OK %9SES]H^+4[*F\%)M0;SC[CO]!U;^1Z)4RQZOY;P[!K+<6$K2X''
M#X6MK"P/L17#YQ _^]AH _!C/MR'_8=,R+Y)/ENM*OY&T9>'CZ<>O\SZ.#KI
M=0B;7*&P\#N*: &\45[[ D5^<$..QA8\(-(6FS.Y GM6(S8UM9C ?J/S:L)B
M><*H:]-7:9N.JS_Y-G'L5[49HBXD.=!K2)N+UMF@^#U(WR2Z)5BV-$EGL'SB
M9^^ND=KOXC$>-HFNJD2]K:-LQ8]8SXY8YU)X-[#\F*/PQ]R<'0%B+2*I43FI
M+>CC?2K/SA1B>2?;R]8+;'3<3YN??:WA#/+QYPX#XPTQW*XHAMS$7B']('!;
MDOH*]%64VP613QS"%K*NO[0+2.P[V_GR]'CZP-5HZ%&>J/CZ;\R;2.)A.O N
M)W@ LWN1#BQO3C?D,1XWBPYT1 7>H@/5SK2/\N>UF6C-$#SCHALL B/$N(/:
MW^'7-RBR$4T2-6:G/Z:-#A)#[V]H[:YM$H-:IS((,2 SZK<&QD\W&U+8">K-
M\3@421]>V<"@D7R*I4$%'9L>7Q!4\^VIVLZ)W3!UYXR'+P,@%-XYVJU[6 2U
MA0YL+_M!!(.;<3"R."-SZ]7YX9-LAE6YU'5': -?EDVG,-<=/G8G3"XG/4AV
MC/V:."&=?K\Z<4V/Q^@[Z"L=*-WXB2(Y];VR$R9Y4JOHP-$31,5QU*PCT:1T
M;]IGN(P.Y$^3??=J@PF]DX0,[O/4,O ,0OLX];NBG,]J$>P.'AFS33Z=.^&6
M\DO!/9-)_3TOU,D14Q5(OJGIK)38VI3_DKL NLE*_$E*_AQX@Q&PHL S90,*
MVK\#%0M)\&L-U?KZD<5)]Y5_?>MLU]#NEWCH6]IQ,DJ_*VE96XR!?D0)K!G<
M0;#_W2]M'9E#DI&&EV[7@XU_H&K#5IJAK0LF;ENM)SD6V-"=>LE/NW\TA4PG
M>](!EEQ\6#3A!58_NDY@%D;2W48>H@/.A@JIY]XI%*M&XI!VR^M2-;RY&V<G
MCR/DWK!]OJI[_PYWS=]IZ[*;2!K'1SJ@8D*;@Y/M(?G)F[FX?UOET>P";V(4
M&@$DY30&'TNMI=F#/<@FX]I]=,!X=JSJUV[O^N]YYI4:2@I!,<H;Q<KX&D^Q
MJ)'UX ZH*BXG,S'@R5[FTK6X<9:FD&!7I]AG>D?6$@')X')T)Z32F<*WU 2J
M/+P05^]3M"(N0,A$/%8AN]\=.]Q3]O/<UB'C)]VUQ V$JW[,XEW+:K,[3#ON
MP5<I%TD?/E,>,,(TJ#\+.V9"[!&!3DS(OLCV]JXFJX6K%AB)2BC5>?0K2S!O
M29S_V<&,IJ@S8C-#VIV5M[ >I)VA#6M+U^#OEP6]MUJN*?[LHU;TL'M5Z792
MIT25<[3+1'1H=\RQ&10XWY^5=K0*NQ&*J&A+)D0WI5$;PK$X&:;#N2&X\M<E
M)\@7?B=ZQ,R7*?,I:^A9?4CWE$P]);Y*MH1W%%(>TX$292LZ,"A<L  AG4%2
MTOJBX&M>#-DY*"I"-IEM?P7'N@3*$^)?Z^X270B"L0%?@VH[MQKZB!'BBLI.
M"YBJ8-]UX38EY;1-U&\D\1Z#B(-)-ODD!ON()QEI3Q7V%% 93'7-1KV1Q<ZN
M3^W6W*]>7/.&P\G'+WW@%>&,V[69D/E4$=33:0UFC$C),.IK(2F7UJZ!I)XN
M09;3Y/Q/T 3#FS!")!4(W"F>QP6=IC]1A]18HP,NKV:WU#QLR7Y+'M@,!XG+
M2%EJ%!UP!),8\BZT!OD:CI5FU.TRW'CW.&H"549K+0L\KKNPMO6X5S-F?5*;
M>+'-@-7B'P]#\ M:5\,E_.Z:*ATXS$/*FD$(3CWPEVVTSD!?L4-XH,.@HCZ)
MLQJQ2M!<I9/2E8^^6,@-4#_MA3(EIQ+/-3RC%H/M-YB"T6FV7VM6'[C8R0Y]
M3A0#MUB[Y7TP2XYJOG*A!2\7(SF6_-#OB?]NP\;[(OA,.KS<(KP"QZ?3#W=#
M'+?V9Q_M>0B-0.Z(0J/EH[I.7K#,;HS,NE,BK1WHS_D;\O8(T,GX, V!#$X3
M&EM,42:Q8H6WJ5ZM)\:'_:IJGL"BTU_D\5_+;1DL8\O:TAV>+_CXD^W!FCFC
MR=37!ODKM&.1#"Z,Y5*RB=R>8KY5.5CD5.OHFBE]QO+M#S-VR_P0@SO*&4R#
M#5#J6_A,1@,S]9T/A&38^]ESSD0L0/X0U(*XS*GFUHV-+01*(M/4[OLY^YZV
M/*^;T$^%704EP_$ZH+TBQ"X+'9C8I]Y')H/M$;^=:4(H&A^,5 3',E+!FZ0U
M\-91,O<8XVO%[\,4J-/P2K7=/I!9/^OE E=M05(VMJ!'^5[9 ,46NYSS EJ@
M4?VEOCS14DKFSY_&=^5>-Z[=54(*LQZ&;C)2>"@91)(E>@_6722\QOJ-:_+D
MF<RRE*4;#\Y[ARI\<*Z)6Q^K<AI+^"PC$<_&FOI=__L&D3L"@V<DH"C?!C52
MPAPL% +:X69?M5,8=1[!Z%<9%<E,428^G.7I\8$]7:/=[3DW>B$C(T;ZV75_
M$]I16<\Y;@&7Z7.D#4)X"XBON&CM<YR[>N#DE>J$(MJ$"E)VPC'WP9GK2]W3
MG,ZG7@9ED[7]<^\3VG^"PS(E1M>#IXJ@XL)#JARK2'F'+>>4T<N20=\.%2\^
M>OJ)*1,X:?%YX)]?T?"O6/"# 5T!RA^XWC\ZT_T_@8EGD1D%N^,I'DVM8W =
MN8K=HD"!_^E2<%$3?%V9#HA2O@2;M"(V^NG (<K\WTU#\@C7_A,,N?PWL[,G
M7^<DG>/>IT"H3*M#JVF$WH(<EP;QM"V+<IO52V/P9P/ADRTS3R?]5G>0W)J?
M3]ZVL7NW^"G#=F),82D[9<3;\UV^GF:/:J[7!WQP6(,DZ>*1]XU>GBSYM;47
MDJ,0/U_9G<#&'EFU(YQ#?*E.<(#&%HDZSY^$75J[7@R?4=TQ?^WI'/!E[('E
M]4KBLY9279%/MOG-EW[.^.!N5_5OK]JTUX0TC<KF]#K%"1SS0DMR;D%.QV$O
M.7GC3<9E[\8XR&M?*@B:T'B>N7Y",X7=,KFC< )*+L+L[XF[DG7T^)IJ[KMD
MR$\#=C\ES"VBZJZ.6S0:"[:=HP,&PZRI%<_WW%JJ5LN#S]6G,&A*V<@9'COK
MYH#CES<78R[U%7/I>&*I2IML]HC;%9E"\!%]2?8N$/E3')A]HQU/D^"):GWD
M,F)*'!Y1S1J"TM@QRJE<:8/9UT-%WL+&>KK0+X*E(OWUL: (#Q59Z(1Q0/FO
M];?&\RWK'Y_S53$GO+94\]V%LP>?LY&?;'!K6UV\52\N!;JXU,^'KD;F.,3:
MQYH*F-U_*(,'Q$)-&_I5>FXZINS>KJA)UAL)F-$_]?QQ7/*2^4P^_[)IRA$/
M@;SJ!J<):UCV6O%._UINB\_9*]%\XFY>QE:2F0V^PWAPQ+CVYQEPA!%RO'71
MNL^3^&V^O=/R8W>N^-Y<-3C57@K'E5.1^7!P/8T4O_.D:^$U#2\Y1V/>LRBP
MM6[V\>COX?1J:3YRF?\"^-5LF1Q%^-,R&N12,5#HOG2OVE"L)NS>FF<[UM84
MN];.'%FDB>3_?+M@T<UTL>Q%!1U@[=R]$%#)QZ>7X5G^(/OPXZ$*](=Y<#E+
MV,IJ\]WWQ/*W93S+B;D"L%F+$+FO)+\<MU&UIXU>[IQ<LCI"AT?><6;XG(Z8
MWT_;H>KH?A\)+'MA#_-U(&<&WB0'?SAYO\>5I;+( ]^&5UJ[4!KRYKE#CE;!
M38I"B1EA!&H,A@EEYY1XFJ,PSMFU?$97O,]C/]^6?W%NHWBY=F)=$]&(YJ48
MD$R^N6PVK)(]%W+?!V@8^&_A$JJTHQ_$-X,C0/BB=<7M'KLV>XZN'W79HK-O
MGSX3BLL2(_OU!#'E_JD4N<W@+9838WOO,?,W\FK%E%_UZ.:1G&^._AA6Z3)J
MHVWW%X"Z8T:5L75NE@_,3EZWC+JXL.A:(;T*+=IP7O(R6"3YX;X-?YT2B4]#
MEYG\PL,BIC539WT6$5]=1M6YV!MFBK->_/+_<Q1@RJ1V7&KUF58RUFC29AZH
MDRKH_M)W-\K(YH? LWM/.Q+@4[ZL>*3Q( 6<X^+6?'L(5UCELWGFOM3*560F
M3</-9#8^4O#*V0)9U>]&CG2@N/@9/"W^&])"YE?^G9;1=B<! >L*"]G2\OLO
MSN["+6#QPA^:LF7\ R4OGV;U*9H(ZKN(CX^L,R0KDP;7.7K N!KW&=$1H8CU
M+-;S<K>96$.>!I!;CFOX@(11KL9\L_HO/;S%-&X.GZJI]I_L\"HQ5;L$PSZZ
M[1D7TI";WOS<?3'^2/H+!UB0,S]4*&SQ;(*VZ:OF0[)GAK FK^6<MXKJ9+-:
MI793.L'X8MB:IH_(O29[3X[?G?N&ME]WR[0@N#H!M_[6V:<;XVWCN8_'QU=I
M)S=!8]/3EF!G.&]J[%L#=$QZZ@9WV;=?.\(L0=>0IZD(FHP+A@-6L>Q3I+V"
M@[% 3XQ]L1B_\^/R=#/(WQM9W<(3T7)&U;(2MTEHT[HX)!!.!]BWFE#;<G\P
M)"9NALRT&?ZUVKXRV#QR\_X]ZX)IFL7%W(]W4D<=(KY.0E6V?2OJUKP0'-H7
M_D#XX[(%8UU]'C^YKEPT?/,#=_4AM1)0TW.R171P>^6R5['_^'DSQS 7>W/S
M/]=<F4#799>+I)IK[%XOT@&GY<KG?NFQ#/K\R@$3]V'\B&?2WI W@LOURLFA
MCIQE\^<O^F@519\LN^9R?..>9S94_-%LJ+>N=AM9S,CSLNM$+YJ;;VONO+^3
M;<2G]T8D]K:-[?1D\3HMMQ'%'ZC\ H]LLY/ SW-)$=UG"\ZMS5H:%28@GF7[
M)JV(U*\V!@:W^]&!G84 .I!E5S]W']\;7_0KT<W:+.[S&4X)6QO);/U/<L=D
M? ;63AC3>@7-5W/7+E)3NTP%AT9\'82(K0'O;XO[W])U>YNW?ELIRGSB P:O
M)6=Q7,Z6767!9#HFZ]Q&[4U,Y!9BS<LI=9J78%O81<Z;CQ4+^O! 9(N;V\T:
MM=9'>+2$(RK9VKC[@_(Y(H1?'0L76N&/#\QKOT2&&.!IJ=@_F5J*QA5##F_7
M?<I?/>(,8I!6O0KLE&*+>8->7J[UBNFQ&WY/"U\&J1\[7Q?RI0F+O5V4/U"?
M[:[J5_&F[(^F6<!P[G,S=W^,K0#2JZT</EY@1+"(+-<2U1U0_)ITIR;NZ./:
M\9"S#F&GSKNW<&8^O7 ^%5'!'?9YQ*>(M57D[##(L29M I92UJZ4)7 XN23D
M:N\%_?KGB^$S<&Y_.[U4@P$YE>7W[DHV-F<NBG]@OI1EC5<,US2\D&[67T[5
M,UL^VU.J$?S8J996D/Y"RY/G&6J37%DY1>D%%2[8#=WD-:VD3.]LH-S+M35)
MT)S6.? X^X0I/B5=#?&YT;\J&.)B?Y?#F>6E4 C \JJ:*<.I8:ZP!W1U*! ,
M);HKFU0,%>WOF7\OA"(>2)\<_0A[YQ@OGWVIT^(=1KFT=-NH),[] ]SU?DR6
MJ)Y,Y_K&2 -6E]^BSM_^_Q-B<9;L\K<O-E27+$.Y35 R@3O[",:J?DP>32$K
MN*\7>T)A,FH+YTNMYA[]7+_S]9LD$%39</]_ZC:29NY$S<30 0X4EI^:L=,G
M;.N*<$01G$IINKOCZM3\II$;IH&O(HRKCNP%F#ED9!0WZU,$"VC&SDT8XN5Q
M!AOCVGEN0>%%F9<.H^PQ3#9CTS:3DZY;;N;HIXTRM1.=L/6S1T^Q2K==EGB:
MR_HDZOEQ: ]\I@*R"=469+3OO6@&5X!]8WY),F4H1#^2%;YY!O2Z[CP=8$/$
MJ()Y_?V:U9X[I\Y;-[MZ^L#<$AQZR3I7]'H1\$XY_B5["?< Y%KZS!@<UC?A
M94%:F-6RT,<G-T3GC:_>\7<V&99(O5L-O>B1TGGFT8.KK^0IJR%1Q3VEJG>[
M[<E91"?JAV#N54P9O.GCO7ND>S.Q.J9U^,PD+Y\ /^S$9:=,B[+(CU/C2MW=
M+8DMB8:2Z$48A=\+FQ-.EJ+]MA8OP#=QD_2^IG7VM::,$LYHU8?N3_6R)O"=
M-XM1+;T4$W;'ZAV0;GH5[+TZ9T*2R6V/##X6W(7>5_C@!1/_,>?:^S)JJ.V<
MD;H>M,-<REQ)*H6%\ZHHU^"%AXW7]G<-ZU+O#*ZMK\MYJ!1$8@T=2VI=QJ&^
MCBPMB^K^77D:AGJ.ORX]N@#=Y",.5Z<3VQB?-,'?!"N.T&K%A'M;%95K(-:F
MS-5U3=.+[BZ>FNL*\Y_%B!:+15M)GX[@><E=2 =FWJ'*\DB*Y,O79C_>E,^4
M)&PD%?1L.7=]9\?8QR\DO%T06YH\])U\NTTXQ@'GEO5U6<WZ6*ISCFN*[]_>
M:78;&ZOQ&W][IS^;\O #W_+_;<;XL<.!8V036@<=X&G0\-]OAN#C<<RS\:%7
MW"L_B,6DJ454G1/.MG+T>AI86VWA)1>5D7<I-D 38-KA^GN<8J,;:GXT4)X.
M.'Q$TMYB+.#X$T194BX^=;8M?!;%0QL*OD *_[),@X]KJN?+]U?58F"21JB@
M[8)-Y<+7T@'7AD(N<9/D+2AI?:&H-:^*OUT;*P !]AM-8P_"5_V=[AUX&D]N
M><X=H^CS$81#N%0/KA4]KH2I;0:@';0Z+S9U?EK0/[4SDSDT!Z,(=,W0@19D
M" V,C_N 18HVYOF_;MX/2W97G8I-:TKL<Y<TZ#7_\_;5>][KB4>><M_<1I*D
M0&N[^+)V4 FBN0?6 N?2/#TKYK1*UL&)I.1]&I^<[*HR_:&+D?CLU)3_K6-&
M6BSTN05.F:Q$ ?7#G1CR>3SG SZW420XRQFK9;TXNCG47.EIS)+G+"N156B?
MG/SR]"N6XVR?N)/ ,V'@+1OP^M&_F['MIN*TR";^%L3;^&.(V8T3KOMM63G3
M;I[+ILU?FOF3Y)#\I2$W$MO4W%^%7>N]21B.?PW_]^[[#G,FX0V"I.3LUAQ_
M5/,5<%3Y[YP3%\=6?2_:74\,=3S&JRLC)'N!\\C3%C\5ICT.LDWP6"2CDK)4
M#P0+D31N#5!XL$9<M^7M(#S^6[850[81\;\F&^<WYRQ[NA>R8G-3=,T<S<8[
MX??!C#<,48.4Q3>".0*O#.W(QCIQ"1X5J.!X9SD>X)B\F!RBR)9C"'%;B"KN
MMXJ0"[[&@&<$=X"/;IN,.3\@5(4'"F21]%NTA=-&;6SBCUDV/TKET)H4W-1_
MFO")MWA,74%OX;&HY1&?X +:4=:Y#1[_5:)I]>L6D8JV(E XY9IV;(YJ!R>1
MZ J%2CX]TF9EFOWTAY0;[EJHV1TF+!QO'<\QZ0]KA;!I2_[QK0E#%.D0B[1A
MQ\<,E8(^SOCGEEP[\['$0'A#\KI:K;M#HH0H_%8#R'^P?=;B[R H54DV0F4*
M?JMRQ-V^ULPJ\?RLU9U+YHRP 5<?*6?PC38(,=YE9&7T#JV'=FQ(LJ[*]N92
MZ]O)9J?!;VF6664U5I+W>Q?ONS[BO/I3Z92DA_#^$-&$#B19D=3IP",G!F/Y
M>J&?M>"?GG'W7]P.=MCX_^<.&P&[[8I[4KO@G7%%*J?%)S0B\!D=2(1[T0';
M+W2@OS60#AR'_\H2H -V"XQ7*QOI1&'^P*/ '_H#M?\>X<1H9Y#2J&T>6RXO
M##=J7K\?OMJI2&6QT+%+8:8.II(<]B3B^2C/,Y%;[-)?:N,>?HF2!OZ=,<NV
MI.%08=ZBN+NK5.-R)V/4M): _H]+H'L0[4">P6)-5\*9+4@]=79"\(<OC4\V
MJ3SXQ?OG[@4H4)W_.#&/-72[TM4ARI08+_MQRYO](AIVRT]R]U"],Q86<N_G
M-%]EF2/(/76W2AZ]^\:[[TN,XHS)\Z*W8LG\IG?_\3ZM!ZFM\8?H0%,_R68.
M="1Z8VU@5EYDRX#LE[P4A, =U[1SZNE">5!PD\HQCYU51P>N@CY \'J0R 27
M&D@+)&2\#>'YU;_LUO \NJ=^W"!)*3EL<%$JYA./BI(NV^ET+^%?[)J5JNL(
M_#W,RX8KU,\TIC_B)TE!GQEWU"FR)J5A[J1-X)[:"+QR]YASGE+^DJ'R[<*Q
M8(_W+#'<\9CO55'Z.'DL) X"* 0J8DV$KZFV]OZ S0J?M1$=L[TN+"CTZ9F(
MRWRU8<1C*9G52(Y?P3.?N#L@1TD0&KOA#(S]S_3) ?>&YBP7XE-7HEJ#<]C\
MYJ=(%L^<Q;/I;M^$'QFV2^X4P5ZC\$;@"(AP@X0109:82A!?K5UM#/CF(C@4
MN0$CID)DH!'O=6'BO&(%'A">B[H7!&Q1^>_N,$'>@[Z#UZ"$\$8Z4-%60;"8
M@[S1;O>1S_S\S68%,YX"^VB]>-\*U%GQ/C[M?'$;^YIH-1#:ODS]?R8^MV/^
MY8C$?W?YQ(V /^P+;9!B$#XIDFCCM-(0N*3.,(=:B_.U"[RW%^RXTY*WU;(6
M?OZ,.J=GQLF341MTP 7,X99YB<1*4&Q..ULU45'DT'PE$^$ 790+?K(YWG'2
M]<<OL\GN(Y8OE3N8T[:O2#,S&@_:46.R N4V-8T.8%T83]:.1U,D$!.0,?A#
M.A 96H3^.$]%]M !4PG<Q&+[;LG'26=6$93X9VHYA8ML"$U#-XEJ@=O@G#O<
M9X@8G1&%M9[RNT%Q&@&/X-H&'A(M"<(AS:=B4CD-%6704]YW6!=86S&OX56Y
M.'<OQ5!-]UP7&CO^=I:*'Y]E\S<KW9RK_>WO>(4D,]=UG>],"/WZHF?>].8N
MXA,=*&-0M2_!W> CVS FEZ0@U%KZ4L.(R-0IAE)]NY[HQZ8=\2G%,>Y2?YE[
MS_-6!U(9V8O&8^M,XT&LT0&2H7:K.M&96$D'2H,*[#<938SBTN8N;JIJ<2+#
MZRHHF?&%9%<1XP[$08:4D=))]1S23(=V%1AKNZX_D4+YSU?[V38ZQHD:%.5V
M/I166@\^UC>:1AHBRE)#D0WL_EVM"+X&V0<N-#D2JLC-3YT'*@(M3ZDLN<W<
M(VG0?^-,II7XPP6+0UKYZ3H&HFLU__P!QO_%C=1%$^IK0VT+],,W*'2 XA1/
M<@"+,'*'!2,WH!A%FI!&5HO:,]EQ5ERC;:V"1P/;:\CQ,2AL# 5*!Z[9LM+H
M0!\=:&.4]C!E I)ZV!M$I@-@.B",+'/)HEIUD<%U!TX'3@=.!TX'3@=.!TX'
M3@=.!TX'3@=._^<ZO:=QTWK$I4AP I\!>H<#=^Z%!EC]N8WQ^;<;H?T/51[Z
MV&-RH,N=TD@8\ZNLU"'O;T^FZ,#9?7%Q#3&;"]_RT<^S83VTS[K\%I\"L/]T
M3]A_&) -(G31#*E]5-]H.J C\$=U"7,2-8^8I -H%]3V10BX!;0IW0I'_X O
MR^T\0^[N@V;C%[U!_Z'K\<%N\\8>SS9H?Y/Q&]<$^M'9+^F =S9-B&8PUT('
MQ',+*$U1TL5S[_^[C/V2:!8J/)5LIF>D#G#?N\J+?D=Q(I5G\I0%R=Y,AEAG
MN,O543/$Z<!&9G/5O8G+8%Z:IBYTT55;"%9A!^Y$=W6>@_^@SFT,#6GI<H>B
M#CLWU-C"6]T&.R0"2L;ZNGYHKB=I;J%=YW?7N0*^2Y)X\#7W$P)-"MNFH8&C
M;[O0B#T7.!'2UX^N'3+SQ5^YE_>WJ^KE/RWL#^S _D\V68Y6.^%*@F^T6KKO
MICYGJ(VW_R3;9?&*6ET'ZUA-W<NF^4CA<VGKF8OO5FZ^&S'04,U7WOZH)@^Z
M55[RVB_)G;<E/>[V",!)'@WE-VNZF"O 5B!YX^O\9.::K/+=$83QPSX'3ZV&
MRRE3@3TH,Y":UD_57%W+&%MPFXC"MVG;AFRW(7B?X%O)URNQ8:#D)\RU"5;C
M5>'>/3Z^*R)!]3-T(&?@B/VVEC[V03>"55-U*RB3HT ,LX7S7@$#ALQX?J9)
MIY(=$T&7&I%%.F!65D$'G S?J<_\Z* <?N85>*S? SPZM9(83RR^1H,:0O$G
MF@2["XFI)S1NXTI[?U-2^7]V$D X@<_+*QU?KZDA/7?-*M_/]0W'T!"QGENN
M*)[@"S=13\P'57QA-3^;Q<%3"XB59\K]4;MB$HW[H'":N\;-B@KXWI\$+CJP
M.["T4Y2O!<P$LN+]=/':$R]1XR*I%.IME#<=^%X7NK\9M-KP)>KJ/SVP]V]F
M$4<;PI1QA\*A(&"9QD/P_5SH.NZ>F2M><')<;D!?^6:"T7&6CI.OG<9^SW#.
M*VI=VPNGG2S"Z]#"$!$@TH42.C!_!: "7U",K(WMQ+" _[B27M&!UQP@FD[6
M ?( >8 \0!X@#Y 'R /D ?( >8 \0!X@#Y 'R /D ?( >8 \0!X@#Y 'R /D
M ?( >8 \0!X@#Y 'R /D ?( >8 \0!X@_Y,@?_2%3W.4D* S("Y_G5LILT'J
M5X?DRPNLBL>LG:/84B05S*ZGR'Q*Y.=< KR+XUZR2W\YL ,[L/]F2# ICR!!
M._Y"2+XPP4.UH(T#=DS=7;AMEE5SF_G'/L]5\5>Z3G]X,5U?+#OR=4]:1U\O
M\CP)]WG<?LJ'YI/]O['MB0E%-;R1>U\.P4T'\-\8%7JN@@!IJ46*P1OUZ( K
M0IAR9J"B7J<1=:CN\ N!^&@!N\D';NI/']S^$7-8(; ]-D2V[$;(F)/CEMJ-
MH"%#.A!B0>NYXIOJ[.PY(QMK/LO&*PPKWIG82<,F7U6Z%.=]=4W/0->LX]*=
M"]+,*[%2YJ7H\EHMDUMU5</>7;_N+HYO#IJE",_Z<,;%?0W3N\MVZNTUEJ=N
M.\$/(2[C2Q1>A[D38:";Z INWN#>Z4OU1K9WQ>S%#;UMLME*'WPX'>W\H4Q)
M6I=+Y6F'\'7[./M]D]EX09=@UGX/'Q0OU!H>OFUCBW(9KC#ZABN:G6P\$1AW
MO7C1T32IXR&K-?#[2S6<-]"#Y#-#5=0=4:4#('^(SI#/M^"A[&DWZYZ*.G6"
MN][6*;^G9VU+3T^^B;F2L2F#>=4@YR\Q&]! !]YHM&F#"+#?OD%(,L?]D-TU
M\NZ3+<U<]_1*->48W!-O%:;1 0@WO/$6"EJO/V/2;*L]A$6TB($,2+$G(N0_
M#7M7B_=N[HNJEU>_^R"?;?'X+L;9?8%U^L%)=?!]DM2<7S,RTOIK&N1-(!P+
M%W"[T^3QN&Q -1W:D7BJ,^=Z0NWQ5Q_T#-JL] +XF2RPZNV8<)08N J%/41P
M0LS"UT2''+X%A<:O?UWB5&=J.-?\)%E=CRSJH#84?QW)2TVA"5&X2#Y86UO:
M$?U/)EEVTZ'#JEP<9K3A+:D;#W3/-AO)!D;-1'39!PXV7GMFDNT_-'LBM$%D
MV=,M6)&@%H^U5;,*+?=+F]HV?UJ7;17"FA"2(E-X_77&>:U8P-O;(M/?AOB&
M9#,7ZXN^@5]J0;'YO[:JF2(&J1NABSP\',>S)QZ[GG9J*KCX<^:\U$MHQ4@%
M5)[5J&YX1Z,K2.-66>BZ!TQAP?)SB.3=WO6UJ_?-6!(-@$,FAUXJFC[06FK;
M"+?V>_U$T]9O;H-CG'3OSOL):^@05*W#P5-:@=.S%]+E>^3\$6:^]Q/]L__B
MU]+E9](W'RDL%U/8NC>\(;^-4^H]\>-'76WRHS"V!".-VA(FT_N\AJ> HYKL
M!?_KA\:3HFGL!7/+@3I81#@&"-3(GYCP1\[J1\C-I F/JX7*M:PDI,>)6"87
MIQVQN*$16MZL*>"&P-^"\$\&RA$L6I%C62TGKKS91X?LI'_4,:@>EDA3K'#M
M7A;5O'-!ED4W1IV=)1P^T25]2OD[ZY_#_(S@Y_X-_DR0[^H- NAO\.%6%1/$
M6/7[Z"+WXD>3G]&!L%..G:7??\U?D B19N[_4RRN&(LYEO.ZV8_'GPXT\]J0
M$ITJ!\[9.OW.*9 Q.../,PB\M2HA(W#K;3?3_"OK!A52*!865O/ &A%-,<XB
M61BGV+N++58%"60HGC=_^&K^8794P?%/2^PF#E?%Q 1^K6($-7FP)@*N#<*C
M=0Z?7*8EARFH[W_VPW)93J3:.;R?V_SL=XR<(6#[:>$5L^2CBCK3V1[NG_M<
MO56SQE 3/"T:6O5W%SP?L8HZF_=G-A+^;AR3KQ0@!ZQ>%>7_5\M:_Q_@2UV7
M.36G@?N/2/9B:GZ@.5[OX[>Q7B+:W"]8HBS.Y:R>#*%&Y55R\JO#!BS'KQ73
M@?_%P^B!>MUGYF !"G<>O,F$"!8B!6_0>(+HP,3T[3QF.O#X"0:%L_2:=]_,
M[OM0)6[CO)YQ'V_"*,T0W@I#%10;B0XTT62&/[^9['#^ E5#)TE>2[X5*N%[
MFEDI)B&F-&93FKGZ2]U6*[A<J@G#O%IE+15!.TO2:=[O*<:4N];DU$/=O007
MCM7.!3 KF"6'Z9]^=9+'MCBIP HZ;IN9FV-GLW+%<?Z\EWN JTP7)^%*F+[^
M71V)\RS'#4Z%7%)A>AZUI.E*X&C"<'E75X!/D-+U\<7I<DWC&CT>^[*7[.X6
M-C+_:C02,#]]K9<_LZVTCH]0BT6W%-TU5FS2!N-14172]NI*5G_2>BKF.XX[
MWCMM,!5QM3M+TD$N2S,*6)<N]FI#'*^3QZ.-HN\1X)'E</;ETF[YK+K1C2]E
MH0LRW<<U8_A+S![QG\0:KD%EVS"B#6*!JB,2@Q3;.3K 0;*XF\;C)99953AA
MU4T0=.1E21A^)U>H=$2I4+GQT['9J'8\*EH%?-)%;1P3ME,$;A&1']TH6[&V
M'?93V\0]BBV]<=8&*GN^<2:/-3M09VYC(FVTG;A/@F*#3LRB0S$S%8NO5/8G
M^S&NF[^+9N+O2$O67[ZH]@>G?>W,DLS%K4VFW0J!7G_%OTW@6==G*\''&4W@
M;)':^=CRU+2SVQ9OOWXVBSH1&Q7&WGDS*>."5JNW][_;/<X+Q+,#_<B*W8C<
MT3@:&+VJI; R.VW[N=(@05GV8<@Q-E86'C.A'QVZ/GR!^6O+?Y"]2!(4%(7:
M5H4O: _1@5@+C#@/P2P\-E Y9W7\<:9C*$56,S#O\:\%4==32AD%P&WVA/%Z
M30\;FT-9,BFN1#H0IB_/>>LBU[=M=9<O#5!JH;8&%,4%4Q$3;19YYRN2W*0U
M,J%:^FM6;BWBT,H]SJ8',X+BUMNLB_--V/Q'*_DJNTXC;GHQ)Q=*MK,%-N%K
M>83:-@1O\.D5$>>('02.0\C[A\)=4&FCH"1OTZ>%X^(QS2QSF1F>.Z'FBAR:
M8A!'TQQ*J%XY5#_SM&Y@ @%*'#&03#?&<_),%NB!9_U\8P"Y(H2,(+!@>%>8
MU/G]MYX0 4-(!/'&4[K-G?JH/2 -.K"!3H]%X=S[W"?W^3>C>MFS V1<Z8!R
MV>7LF-"]AQF(A%U= ;PM&B=&0/[T&_43E[")^)P*3W8N<NF"B;4=.<;^]8EO
MRKW-JIQGQ[BGDSMB?@XW;OXH'T9"-=;<]7E$T O&-M6FD,PT$YPB(=ZN(:K9
M"*V@*KKLM6 ]OFP^^(MT.([_NN%/EHQC+<3B>)I@..XT'= ./L.HGH[@/?'Z
M\X]]9G R"1!UFKY2^U!*ON+^'L+;%"(<"*96^\A>EJ@B9":(?W[RK81::P11
M",S/*-/K*>E2P]0X<&P]% ?V,<V99X8";3^/N^WK3OJ-^PP&O)W4'PC7:9P_
M?NW?6AS@M9V=+#/D",[\BG;]L?Q+43X-1Z"F=GZ$]%G:1SRL"36>:B2V_EDV
M8FU[%-'Y(NN'WTSHD\-W#24=-"Q.?>_K4@N6IG[25OO=%Y#5E:?_=8\6:));
M;OTD,-4VH?NFRK>O%R1>.#![]G)!0[M6'IW&.9YE\_/ > IX\N0JW$@/2M@U
M$R"D-D'&AUKVX3&G\'2@!:0P._HBR5UKH>6HJU;,FWSN"UP1/)9B/[_95W]L
M]Q@BNCM$-XXT&NHA;=/&TDR+V#L)[+*S_L$7*##27, W>).PP[GTK+7$0Y47
MVR)>:W$-_Z;BK?C6E3*9#]L9V[N):Y-P>,6UKN+)E>N=ABGNXY^,2&>EP#7J
MPL]JWSCO0L]\%WYXY%F0]/P(I'I%UV0/EM=)*,$D3]3'U[L@-4ABA.O@: 3W
MVDYEE(;[-;$B9!%VJO1R$@M.[HI2Z27A2YCRQ&O(&\ACV9=-TW-5G>)(';=E
M3,="!4)G-P0L_66;KZ34YW4L_+:\/M31&19XC,?O.,?%IF^2C[^+K<YB#M&&
M,#QUI@2-YDJ+YY.>RS5Q2'?.RJ>_?_(\2O3A$BFY/N,N><BR\G*'ZE1HUZK#
M:9FWI:8;^R[V-CSL\GJV)K5_OD1MW7[[/^S[=V ']E_<X@P%59Q]V?.5K&J8
MK@H'RQ!4$6_*-3[>WJEL9MNS('VLE=X%SYK<W-P(M1.M)^1&2!%Z&VK3],'V
M5;":ZID+K"2+3[LL1)8EC#&X'28NG\$Y0+*XZ=[':&.[[F4XK_P^]1PP^:8]
MY^XN\+'NSC615LZ;/!)F/\V8 :8_YU\]BI+^^G^OF1>X]R2E;Y/2C\"N<U=5
M52U<%?R34^ Q[YW[+ZV[9UU"4GCN&9:&$V&$N%RQCS4K%MIR:>/0UL@;@ZUB
M'POT1;65.F/ELJ]=.J)_BJL=_-EL[Q6^O4WP+T<?1[;;'2%DK8B ?R)$8",4
MY?R@M,65Z=''X]/6AQ/-]P1ZRHLJ<KP$LKX;_!:ALI:1IO"KIGAW.A!=I!F$
M?8%D=]WB@-8_%W,:6W-?. O$&3;ON;1T"34^]#JS'_,R$$T'#KL.!6H%D4^0
M0H)<BX;NE@UO[VWKILVW]#QWYJF.U>%6I?6<'?NM WQ&@,YA6VF#F,VP*0E:
M2]]1.O '=Z4.3422?IR@\#O,P<+@SJ#09Q-]V"#%>^X0*T)?TMD6MGX=.0]\
M!,F%Q_&QE5!HFNO_Q=Y[ #49;?^B'XBB5!%0J0&I4A5$4"#!0A,5E Y"1$":
M=*1(2!"E@P@(*"TJ($J+=*6%WI$F($624$4()( AD/;BN??=-_]S[LS]WSOO
MS9W[YC"S$_)-\JV]UU[MM_;^UCYC&7336&X,0;B+EQW0HT7J(#YX! <?P'/<
M>-*]O=T\3G1Q\<D6//P8EP!86@+ $0#@><7RE"),[P4?)X):&4!LOC:YM)#I
ML$_HN'T*??A-Q*-VXM2D77#ZLL&C1_ARERM<X9(V ^>2OF::/%LY%V :31]O
MX2=D4?G72?UD=:)FZX O=HLCM,2K4?7$+]):P&2BCUPB/G#?0U(&UE@3BE_4
M2VW.O?EQ3OZ@@'YLE+C8@1%&NV*.3'MD721ZY?./*P>)V1O;#@P]&C%<OJ;(
M6A(\+'I57T*0K>'(P^3*'30^!?4+46N(;R.HXF*?!6'(MS\0Q&ME5I.<;4YX
M7YZ?J'@T-&BN+99<J3SM<I=C,^/,X4+ETT ? XCJ@1TFJ,;2Q6=@EI]'J"D@
MKWS9ZO$_W/;X0#22]<<]>=.SN9U?3HXDE3S;?KRTBH=$82I1;5O3F"Y-1RER
M!(Z7;%A;6BH[OM) 'V_Z^O.03H":=[;;G<QX'CWV92PVESK-G.N2O[6;"?6T
M%\'H@VL1T""/%J61/RD;J,]>EYE @E2>^KV& 50[2",?U4)5-8_CY0:3PD:6
MIQ0IWU=7A  RE'ZTE '(5B\@*:*;Z-V8[B^\/U X\!L* F9(?D;1HSI7,X%P
MCFG]I/4-PG#,EJ^=282&I&+@4I_P>^G*[G2]!-Z^L^&9F1?=N,(9P#^?]+:,
MP+Y&'*]!3T\YDC,HEV'76L:IZHNZD$Z,Q_A2RU=W?INP3!'OS':;\> MA7FC
MI]HK)D6N-Z5.L/Q&UO5LF!+&=K#PKXO0P^Y/$!V\0N03_:N=#8[5.)'3-7MN
M=4G?'KR\RA^\)?\H77O!KZQ89,S$D9?<O !ZP0 ()A"!4$P74W07Q Q;YR43
M-A=F)#ENCL@L?WGY%F<[>7Q0X/#<4*V%DZ'7W_+BY#4<Z!FB6C7YD8[AQWT[
M5.(%+QJGP?A]EDV?XNR?[Y6.I\85[ @6OLR5E^!J?%_/0L#@\K\24NC'(.5D
MMTZ_B!3;V%;A/_BN4JF"6=H'Q<:B!/W'5L9\;I:/I98?WU>/-&+/9@!MY]&N
M4,[0'2Q/+)%SP2J^@+RRL"!2#NK(O%Q;:&W5X),EMKM]>5_UN+GVO.[LF].]
M;5R>99$-N:@7((X@WQ\]I#]DE@5D=' F770<+ND9\,NN)Q9/_5/CKSQW?EAV
M5&6DR-?9'6MI4Q!N]/HLI> 7BBS30WU=W &AQ#. M;'-IE(ZQR4&('>+<HH!
M_%C!'#@4F?T#_L?3IT%BR@S #3'=TPU7H8_0AR<SAS:"#* R2]XW7,_ZW+UD
M9'OQ_(ZM'Z8QP6"FS>@M[VN(FYC= *GT[SD ,%/R)^\PW_)04USWFU.Q,%W-
M[)(UI187@]";;(6$2PYWGO4.WICKO$I@>XSPX5Q/F0XAC9,UB-O=T(UA[O77
MA*G$#XFF.1OTJU]X9<9;I_,-ZE_5^%>E\>0(L>H]M4Z@Y2"PJ6B>%FGJ$0(D
ML<EM 2IP94$9<3/%,E/LR,&T]XFS#"#<1\#$TT8K^CT/)Q\Z^-AIC5)B*?WH
M*F&] W),!UI&EH,2FQE PNZ06CC^8O=R.<IJT^9EKW+G>?ONS>W#YRLF>]W,
M8[HG 8H<Z1NYZQ/U$.UU$V(Q^:3NS"32Y:5-WU?#5-W.T5E#L)@8M-_C>8Z0
MD7?.;?74'0:P<9["1=5E -&:. 80QP#XJ+K%5'UR]**)5#G&T_&,G$7B0).B
MCI[^Y8V=X+!'VVHU^<Z#;-%'!0?<Y^6)<OA*!L#V9JI,205=WQ1>;*N"_&BX
M/->G.]&=%\C=>_-S2/Z*EPWNT:?[.Z9)*,F(X?]I^_699?L4WH%R@1Q.@M/^
M5C6@76N;TA1&1%-M%W/"EPG9JQN7'18<U];]E4M6'WFIU5Q*4AU8BN09B@>A
M_O6(!!:*/RR0D-*9,EM-\B!8QVKPXAWLV^#J=2FVV5P:3>K#B >'O_C!/<PW
M\"O N:*HU=#'MQD G=/RKXG!^5)$\8C=F(-(700.LL%+F.WP<V^1(^8_\UU
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MJIM^J'Z"JJ_ZM$9>MB7F8'-HQ:(R3O+E%85CIU4$M%EG+:VU+ ]AZ$?I0PR
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M:]FS%U3QS6&^@<0GW?)N+XR5:T+/O''VNWG3]4W[9U 0WO61J%]_>,(!!<L
MJ&G0PX@?)WH8@/%8BS,!M7&VM"^LL7->JKJNSE@*[)B6HMW_5;M[39#-[32
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MKQGPES1^D)IW)_J+C!Z'JYGIMUK2%O62/3:6Q@TY#B$X,?U%;Q#+$H1@#!*
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M/VQ++U9NIL[@LWXM#R&<G\H'932])-==UNX4B>N/9[ZLFN*@JF&V=&P3>0.
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M"3>('TAR=",^=Q!CV';("SN;_FC\72F;6>.XFUC:C@C,G= Q>G&N9+C=[+/
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M!5'Z.3ZYXV:YI;'J_:A#J5"\7O,"EXY$.%8R>E6+@]0C$GN+<PSTWZ4YBM,
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M!E"9I % ?R5--_*@$M!QL! =E--!B\4+UXEQE(A_6RZ?@6$M"<B*HP6?D O
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MR7:4.F_>!DK3<@MLW%GBI)E,ZJ8G#F[?]#3._<CU\/ ;B6>9]!E"*()AH[;
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M:+*6L#OLWLD*4NFF2PPOB2@NO-J<N]C<\NQ#&U*JTK",EAU/RAGZ*L@J4GG
M^=QX9S4>C.Q."),)R@Q17'9J&#^J&[</?AG\4M;][1]]_E;P%W[?N"MQNPJ[
M^QACO5A4K=T=5K#DX'KWC\=Q!E_LOP [8M#IH2)[!K11:=I"7H[?3L&^FW::
MU^C$G&[(_CE>?X7(J56#?6L:7^&K0,:" 8OZJS_6X!.R6_GF*0^X<]E,/<D
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M2!+Y1_I9O&K$RQ&]\;;I6?&.'GP7F_5M]O><FL6%)6E]F5L</ISQE?=XG%^
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M>.FK@_]Z=9@':Y=@//8G8[T9+2,55RMU%J&#^!:R+@RM#B0.0,Y"X%^8FVK
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MMZ(*7!YN+V-^I-155+1MQ;N8(U\HII@R_/B-W:/ ZFEAP,#3J]?5[6WM,Q9
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M/E]_OL^VEUZDO.]4'K<2#=._25>=/N5M<+^LK-3,;-2Z_5HWHS;KW>EO;Z0
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MY50W"3L62P-@@QG46M )53ZR.S$+*\31@&*%G4A?ZFFK[ X"EVSJN!Y3Y[3
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M#&'7OB9,3.(@WJ(*VBM?VGF>?PQ4/))Q*?HWH5<.J3I7/> 1]_K!ADX<Z^,
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M^1*,SI*WGO5R'SB[D8HNESYQY\#)N!/QDA<@/_^QS]#^)PDQ)G0+1+1%<-*
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MN,P@*'R(!@[2C@\-:!L![P/>![P/>!_P/N!]P/N ]P'O ]X'O ]X'_ ^X'W
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M>P_18/I]-Q_1#R$$7>SHFE^^@!Y_Z%S!2);L\5GW/N#S,15='MHU<>54Q)/
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MM[&F<'K.[ZY$[URZG5C2@'<IM5L2%%]A6-Y77N13&)/(KG.,87O^/_.X")0
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M2<@9F!EQX%J3/W^'AK+'$F7@3TW.N.3.U5\;[-'V8E.2]5'5'.IGU<Z'W@:
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M_K6CP#22*J37>5@:#WJ8J$?A]#>8,2)JYA=^-%M3"#^E82O40>@6&FR\4"7
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M+5_/PL!M7FU;JD>'+^,NIQ\#H$7[MH8E8 KJU_%R*TCR[2<F63@FS>1KM#(
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M";XY'B1->FZ1(S/4WP_HB"S$N8/& @,2FS;?#:RBH&@G+@"2C14%+66B+LV
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ME.J4P[/73?*WE;.[SY\NX(_9Z= )P(/Y(%+1[;WY3_9+]-N8'OE;;%^GJ:H
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MMRK^;PSV9?0%Y$(6K;>,.2)WKUF'6@?A>BB:Y'ZR3S05N,.^0[I%ZQ@Q)N3
M5$IBOXDH%8!]HHA0'&YAB92[0?24QFPJ\%/-6ZX?HDH%$D"T@^$BR%U6*^8
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MN:N5A7"L;WNK&!8[EC*P_T7K?*("ZIOTHNF%J\<<CIUVV3E+>5Y*@:V8TL;
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M!KB;UYO-BIS*M,3+@H:E?CS0ONC0PG1K]LXC@$7R4/0B>P/8C08DOH!L;>+
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MM5Q4\NCOE__9AR"+VUCID5+^>]M;^.\U9+K'ADPX#=B]MP_-1Q^I;.[;,=&
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M-!JQB-JGAJ1<JD("3?1[R3![(ISD'MC2E5&84QPXW9$!B:FKN-S5T6R7ZMS
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MX^4A5_%WGB@GXN"Z,NS%LRLA4RY'E0ARGU?B8+ACW%%E=UF3+GOA[#EB(XH
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M?_EUP-%+KVZU9%"I@^I%E;6UE<&=G1-7$AW#WO&X*6<*=30?T ?4>)X#K:A
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M%Z:P!OV;@DJT 8C_+SF$_V!_=X <N$ =O&*3\)PB'83?->\/=JP3^!'5'CC
MQP9^-B8W+!+V_25K^07C [NPV![P'5JA8_:Y87!,C[[P_&\]@0U,2>&;*@>8
MDQ<J,F..9X2G<[E[TWHE8X##ZM:]39,;W[[]5X9#FH0_[MY!NSI9]EUQBQ%
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MN/-Y&Y_9>&P.[N1P%B(PD[2/JOXYASRZ-@LY$GX'76(S.\ZCL!'GK8%T8NW
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M PN-_)&H.E91D\<'(BE%A[X',FG5RKD_VZ_JR?>=@, QX@ &9]38_X-3P)L
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M#+T;]0R8)4@LQ>94M7?UHDIZ=2O7]HVU8+VF-)ZW@V2VL:_O!:0675=_*H#
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M$PV\[(BM=L0*S3,%?&/X-32TID\X[$,S^ZPI$IUK \J!\!L)$^'1CX;<?'-
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M/,L-E7A3!$ZH*6GKG(Q9R8[:K5.C?J'M@FJ*%UF%-<=W$N__W77NTAF!?A@
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M7^,[.H/OY[4SL7%JKZHS.+_2K2?%@="Y2S7PB-^;Y2*' &QBSHVIMH4]CX#
MYY%-\Y]Z^K<Q03E1@&VGB-2K%\,VETXDH4P#>?E^3T?3A<.=#@'\(?'M?T$O
MP9W/74:*"[P>-R:2MN,$T5&&388&BH/2,=!BWII5J8)IJP$B'9DU_4'\5\U3
MQ(/ED! YY4, @P=N?7_><Q@BVED_+3U;<2O5U#XW82R#A>OT[>55N] 04C%U
M&LGP*R>A&!<'9YT'=5ED\IR-A>2![\WEQ;J:.B?2\-QGI^<=A.@P6159]'*>
MQ((!Y@;K@)_>14)V41&]0E?Q=P_X]*(?96Y:X9F><VQ[RN5/"ID\^^VK-)Q(
MGUP1\=KJ76[0X.5DNY"Q_TY&N0%_">9MY<:OM8\1"[\Z7&S "[W<OU'5&.:@
M&F<&4GZBNU&M2Y2:L]>2&NB4&C#F_@R;!=.UZN'YNX3.5.+A&5ACYI"ZNACG
M"7F1AHF4H<JFE!>%+[4XW,TB1*_>NA/:51WQI^:H!1PB)CTE@:@C\-JE;L9X
M> UJ??JYIT=Z^O0; S?_8JF%,M4?!8RNMEDZCWDXK:?>%0F7QAT!%1]8E]I2
M;7UQ"3&WRR:AYP.N>L2Q8"--U1+"@?I5]&T^)+9#P27,RK9O*UA,5[3353\4
M9$%E//Z&2/<DCH6@IYB#^$, 1GBZW#O+)'.&I+@WY\V [QEM=K]_C\^,AS8G
M*RS4[]O))"Y!S-USH$@XSO 0$+JH@"_L!)^;6\]<1:H49'DX!8:$^)_?QOXI
M$%Q9O!4K 'EZ^53N(DO!;U=3S0!*).C1MCRA\1M4"[^T3-H04D7BC;;&UJ=K
M'.J:[R0K).P,VO95*.!;63M)M0G"5W4MDA[238'^98KM0"PFZ4/5B-)H0=&>
M13F\T9>DE[^#,1'&4^47T_[R%Z1)9HI$+8C)E MXMW]%W1384\+UDCG="+9$
M-;1\*"YH\R:.D(0&<;87HSP(AI_7MVFOIS2\'_5^]++L2EO'?O!.9$R]U0%T
M@&X8)C$.]2J"MXM )?U*K$?]/QT=+JP.:W<R>9+'EPP5[+K&]9UX==3V["36
M*^?R3#0M7K$PSR*/8#Z'QA5\[M=,MU>M_$=GH'>0K^D^K/_%#T.ZK)4!/*A?
MJO25AG=KT8BBXCG)'.+"\=-0WC_[HF1"C,>6PB_8;CQ5YM+_9NBGO%7:--#-
MH!%IQCE/"BA^1AN^P7RT*-J5_;UD:0@ W-G"$@?;];^0]]?K_K=G5V;"LGI+
MU2ES,S:#JP"VYY9]#@RXI1@XNA18][9->>;7PJ,9 A17V[/(R#]8!6 0-97-
MO5+!M-_'9DU@&^MJUT#K-#UDGO1E/!:&O=(4L TB=#[8TQ!]ZHQ*\<S,8UO_
M*6O&I79!CI-7%)7?6<GPX *]*3UN^"0X%X<D<T@3&GP3EX3D-,\B7FV3:7#I
M.I/=V5\J0M(V?BPL: ^M6CDE#24[IMI<Q=RO6M$2-:CM&7M>&$Y^<;2-?N",
M0UUPGU63RFWG;SYJGE)!G/>TM'DU-"9C?+')"ZS(]; E-+2GJ*M:BOTF$ 8]
MR4#.D_R(2,$=H,]&<"'P--V9\*ARE]%DP4'NIJ9.$;4WI\^F00K,9%=*(4R\
ME=<0 [M$\?3_ 5)J)$.HUM3R_O8S=5F^9W7S_82,[TMZM/RI H49TKU">WER
ME-Y0HV? JM&O+4O$RW3=S#QD+^+NC9XFS"9]U!O'7)M[T],IAI5]D GG<*N'
M#09.#W//ZKU7TN^Z(P8@Y7X%XDR29@^P@:]J$0S$0*S*EY&FDB'9LH]-$[X0
M-@]]=2<V8P9=P1C4QTJ9;O,G731_=DG7*4F$;T?UH\0K6QTT>[#(/^;KAC_3
M(HF"P,:\'HG43KCJ@$ 9R*T'BDWFZLX#8:2:W2/$?3]G-@G#W(Z<C9KH<3@_
M]NP0$.V@A(O<CB,^-?V6;\L_6/QJ3#C1@&Y7SMDJN?""08;-V<=HWD";HP^Z
M0A;.Z@"=(ALLSS56"#?B$PM$ZBPRU:)LU6_@\TI*]T5Y?[3J7@AF%6:@&_H*
M_.2_EL-'/6YW G'EB!CJQ4WD=SZ5J8UUW,)1N[/V;"M%O[B>(X#7ZOV/5] O
MP8"_@C!U>+LMV2,$GT7XA./N8&;J]2W>L%&^8J/C4_)MR-_( -O=8B!Z;H G
MK3\UBO,NHBGQG GSF#S7L;Q)@QF]Q'Q40(4T&L:5%YYS-$\(-U>UV&[&NRF>
MV]%)3R5$AI$+YY1T6=M,>7;M<L[!?9C#@8*M3MR1&JS+@R'@+L5.,=SW8:=
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M7'4/5CU-DN*#PPO0FDOQK@#^2F("MU=PTLMZB;^6SA+5>T%SFF*3Y-%JJT.
M,UAK-=A/ [$_>/ICAVBVE1N/P&OICQ-PKZ27F3,],T2]0N+((@G+]-3(&V54
M5]X5(QXGD6:FQLC[4E%$<V4IU<7YZD.+IC^: +(PY9W*+@_Y*>[@Y1'JYF^>
M@"J%4$J=,"M6VQ7E3E9NOG*3R1Q/PEQ/_W%5<1)-G]=W(3J=E#6H0+>Q6%YJ
M[7[=?K6P>-%V'>7R7O[IT^! J6XF5I&TP,!'IS\7B:7<!+ %<:XNT< ]Y:-
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M26<==A4?V(5@MO/*%JS,/"]])]*?NR%RI_Y/@_A+N92=VUX/\RIO2<)XDM[
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MZ*("B:E8(Z?K49^PQBQ?J;)-+8&9KDMB>"T9U@%#A8=A@J&ZKZ](=='\S '
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MH/_]^>XWR+_90_Z+MJ\&U'KZM REC39)<+434 CVAN!)J!?_H.:$A>KN>\4
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MIES&KWXD/W3P,_<X>'BA>Z5#2*[)EMH5_^D>.,0G??C<<1.6 1#!;HS4< @
MT!AA,A.@"9B._]J]UH]_:KCW ZNTWWOF^,$&@Z5@"BK"8I<DJ4>-VU=),81U
MX RZZXP/7+XY%=O]Q*/90#+.&MW$_^-6PV^^>=,'@K6<7-+S^N;R;#'6!5=%
M?^U@S/8AA+0M"\(W&L^8R"' Q_"N^*9C3.-:SOE$/.8Q9^'GNKI310/1%]YW
M9P#N5!G<_1=^"3"@$[_((O@7,&'<58D0UX6-:\J+;<2UA4T&<_UJ;,X%QM<,
M?RPVZF9U]5D.>,0^*":8;?R,Z:ZH7G@I$;ML&T?_4!AJAK[XZQ]!&'@SWLE?
ML>&BZ(B,V?D:M0S5:>&]2S7H86RNQXQ#GNFX67G.)T'X65H_Z#A-B')M"N0+
MY1^ILB^-OM/X1?KSO?O5D,<MF#Z,XKW"YFA9[Z#ODKR]WYA\M:68G.X2T+,<
MN/L?R$'P<0QR"T34,4>/4W2*%^<07>)%LML0CXR%U)&,<W%GYUI9((FUPP$J
M<1$9/9<NTE5L-1F(A4D0%J9[$<!#P#U0+U+DZCFP897)8F!6569"T! 'W]ZG
MP5,3FN@+&64V(A[J:/HT<YEJ- /.('L_^QX8[V=5KVXCF0L#][.2R ;'@@4B
MPZO.J7F:W)U!I8$0U[3VN1[]P_ZH#\,2EB2-3M($D2SA2H2Q_=$"F"F]Y&M]
M+:&F[1>3O6?AP^Y C/[+G=W?E#9B<[#(F"!=SS!)4ALU+RIT/*GI!,?I8 G9
M,!/B_2WV->R5V5#J*['A%0N(=$7[1FZ ['&FXX:+H]=Y3X8Y_LN9:@UM!$FP
M0$:#ZIGIPIR-.TZ3>M6)>.5/)?1=2.RJ=TMCJJ&-1X(5GR;.'LJVYN8@\,%6
M^1*0$V9%"JB =X((-UW,NBXL]"%9>M")3S[YPEHAF,Y@3X_:HL'[$_*.VYKV
MGVXQ2<M!#*>$;N?"^^F3SH4B_3<3%)>K+O,W$W2"E(<763O*!)5V>K$?_L7?
M!U*LU//>^][R=HT-V1K>33M!K=&RX%X@3?; %6N;/[_.4U86YPLS*;3->CXL
MI>%D*J/'BG<6QC#ZQS#60A$3C_-56<SJ)S6']?Z&$JA65VU)'X426);%)P*L
M;?ZN?);C$>I6AE9?JE:G--N&S<(V4I3P(:Z*-=5"VGD+N29\K],E--9O+HD[
M/&2V3DX$4*+__73E*^*?$7@"_8^'+*?IQ6X&T8EM7"O'D=&B(6F]0MH' OR&
MGNYO+'P%E";J<CWDS7QEO>^>,HLD7TIY\#I;Y=B1:T*-QFM^Y!DE?,I)GS_R
MC/K"S ,X]XREE49Y53^%&:PW-FA/"+K9GVL*^&VW@CW*(@RT2$2>,A"A<!-J
M:9^GI&<UL[4/WD0C;WU\=M6?<9R/3Y=70 .5\BKGPQ_K#&SEDYN9GG1L>.*5
MZPTM]<U^4-+8^*K83.#,M41!7MY+[(FO_[Z%);M1>K'M- "@J*5HW)/U@W8T
MGEM8=6<N8_B6O\)D^E>@/*!6M:YY6\#(W8W<?2W5X07?I8MC__O&,<KT#WF5
M^@Z->T[CHOC3>C[LPJ5",LG2T]WD*@JI<.8^;?PA.?[R:G&4#V0V?7GH MM9
M,AD,I'#2)ZHS183$2Q2[22Q)+I D&E2_A>_V ?F<Y\:@_@:7S6),EM(TY$]T
M]49FM@#6JUX+(98*L+60G,UZ0CN7!7BB>A+_]@,;Q&]OS"G3ES=\?+9G"5!1
MP3/ \S[TLM["+57T*ZRH%I8I9)+&7HAG)@WC*E/T.NTD)%WX+6O;VL*L5N7>
MS&)<47.%9SL^-?TVC )(NUU^YAZ\;0C[^'_ RGJ9T(Q+V_Q /GT(\(*9$E".
MB*?5,/.U[]IPZ:E&)VSM0B'60,BL_(:;+E-ZAB[)U%HJ9>9Z/F6:CFB1&A2.
MR48SO<H4_[Z#$A2_;)W]PKIM)5=7Y7&W1^)U)H(1F""-)K9NAH']FC3D^[$(
MM(\Z@"36*?JV%I]V(N1V)R%><T'A\I255*!]4:S,F0+=&RD"/C:G7G68R9LN
M^C!D49O0'MQ/@7PHL67N>"0/$SI2:T"SUP'VB#-#V>G% $]#]OI17/,]I^NY
M+M>-DD\:V=$EO30B!N5J<#KD6T^ DQ\OB:G!O71^(31&96WJ&L&4'2++)FN2
M_$V27W1X$*P5',[[3]NLX:5+0  I# >.:D"RA]R^WOR9HE=R1;*AMNEVG=:@
M;(:IEY>;PZL$+_HO4_D(D)2!4DBF*;4<O51]P2@.?_'ZXEC7$X5X*0)%^V"K
MY$.LS>0P*OM&?N10LUV"OH]S/>_C*-^.5+2=@0K,:]S@)$6,F-8#;/QQ4(#$
M;2@/PM!;C+'*264<O?L6>FML,LX*Z<E"?.)M9ERE:^A$),$4&042,I )2>L+
MSJM)^NE/?;)O?F5[TFQ*E3:J)JM7\IC?:6 Y+/LA!P_'LT)K)HGR&EHOG/4K
MPDM<9TGK;3F>B[OC:[O=2TSX)^[0T#KW!XOW,J]*BFVSYJ(:;YQA;[NM>,G@
M*,SR#.7\%,407Y. %=&:_<4Q5YE&2N\N<UZHPD(*'(36_[SERG6\9#N"ZI,$
MZM*(HU@N^C,%I(F_'3OZ<I9/OOO;L6/B<67LYZRCCAUR*ZN<54<=.^Y$1Z!5
M[J2>1$[7S&[L(PC-FV.$]OZ.=AZSN$G(6MZ:T_".XL+"L$RVNEZ_*-M)M9E.
MY6?I;PX!K#7*U"+T763T(:"IH!Q7(^9_H;U6O,?1K=.W,@1\*VZPO3[HW)6'
MQ&$Q10T]Y;YC=T\/WA'V8:FA*_0(DC\.'*>\3#7K+P F==:%)C$W"A4*?)V^
M&7EEO&.@?RSS]ZUCI\)>/K\C\,P0;AR"Z+N-Z#0YRN8X^45NXITTP3R::":$
M+/,E+A:+FJ?^H+0U6@I#/O5F)>6P3C_5,1&\&E;:!YY5W_<[.N0CV>[A3U0<
MQ*6B;"YF?4'&4)27M9NF[NVHSYZI^U@5<'7-6&C)Y573&S3#R)FO-11>Y'[@
M(2 :VI'WK>_B+14P*>G3A"8T?WO&4)%\#:D2#=3 G\EW85"?U6!S\&$8 /ER
M)_+1YH'-7[,(>CT22BV$X*Z/8F"D4>(I8XZ1T/L9LA/BHS;?\CS"0D3J!#UO
M7'-9<3"(I]8T<,_6[&M2D;]2SAD26"+$^NL<3L(NEJQG:V-2R]><3:6KY_)?
M?,LVP4G[,IB_F!ODB16Q<JGI@Y+DO#L/ 2E8?LKEY5>W;Q&-$LK]'W'D5UYD
M#M,+L]!QJQPH^_HN6.]T^DRMRO;FDR].:2191(>#P:E.G,E=(E/UQ&)_: #>
M9\<M_-;RG9<J*CL<AJ="6E;=$B_2K.6:!1@C0L$47O#2V+Y"-U*$8HYNF NL
M<7V77FH:4+H9V-@LMIHA,I>3ZN#!.O1:C2R5T7/W?,V_*/@):!20%761((R+
MBZ,PX7RVI3__M'=4=-R^K3)1KV<JFSI_?$RF[=EK194K%67L^G'[Q7\]SU\+
ME";TC?'#:!Y?Q]%\C\?$P$)78V$D("B=SS#[M-V*][/(0M.]$_@.14ONZ]0"
MB@X.&@=BI8@L@3DV+AC50]]\%U)3TT0J::(2;2#--.?['7*?TL<D8>^#]EB]
MI%+@=TEJ>/"<,8U]4NT#4V_OMQA]N?+\C; D<5N]>+?ZB:&2AO=Z7&_9=A@U
M3N)9DIHEJ3^4?\KL0ZA)^OQDI1"[WCR+IUH6/(8(O#G:=UI]^T[!KGC\!O?S
MM[R W4\9%[83ZD:#=RPKE.!T:O"^IKMF5MB:R%R*$TMQMYUJC)=JRM@#A_F^
M;4[4]CK-T<_H*3A3'B@;>_8:(MJ2911+<.*Z>CMI"?CTGO2$/E4(RL^V'0AM
MJ*#F/6Y\=3=J2.;1GTK9+=0IA5D"_&"Z M&I!+,K7#\$U"(C&\RXO+I^.X[3
MYJ@E;^=<C.5Z<_++%E"NC_W,C#]>]IQG7F(3V0!?@[F0SOV]?)O9M7B10/U[
M^5;-$+7Y]_*M1^HUSPR=3L_Y9#9;3UW;._#S_]-8'*%_"*"QRY%MG6CCH%E0
M?5K';_H*(CL0N;90>27["2HZ0H^DX0=Z)JN=MICA4[LWWI7S=3>^7+L+S*+-
MY[%0-'0VH82B_9 XJ\EMBFG%HG-(4L_O/,U#@#?9J-]=U(+UV+>4 AN3U9S[
MB'J!:*8K_0=Z9$U:[R& @\[\],)R]05+G"W>N5[=]T?S^$W^^3W-&YHBF29E
M>WY:[K)].D-H0,[\D.B'0\!_8?(&;"$\0-$:%#9J7CLP1'Z;+J95]6XX!'*$
MY;KGXE"O\O!K9XB4JG+-.J5G%D.5>SJ+H'Q@4TD/MDF'(I#4A6#]^6=;C:+W
M9@12.$\O]>NUK4K)"WXY9UDDG,_U"Y$6'FPZ#E[FO)0,[YD> 3$C[B !%&$2
MKHKBT/2%KI331-;1_AG^-;Q:SQ/$>S]%FKZ3MH>\^7^X>Z^H)MNN6S@(TA'I
M54":2E6J"B8B742*= 24WD)$I0DD2N]5@L #2"]2I'="E2Z]AAJ*TA,0B"2$
M'?SVR;^_]^#S&>,?8X]]Y)DWN>_K6FO.M>::ZR 7DOXZ")#06]^I2]&=B7X6
M.\=D@$W#J3G"JG*A0L17+]JFN[@9YQVKWZ"JD>$;$J.G^-WNDI8C/_R6W)TH
MGXB=V5DFR3'850(MH7_IZW ;#MGBTLYS=0JR7 G_H5.#>?O*<BOU:-Z]AZ=W
MSF3-O650H>M.6+94\LT(DVE#G":L_2Z4E3#!RX!8D<-<VP^3>>!4DEU53WSN
M.W,3QNT!\5I3+V238I.IS;SYGBKGA^ R8W5B(%;'7Q[%4Y5[^_9C+A\1OM3
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M,U['][&;R]>DNQ<9T*JM6?F6RDQ]M%#A5KC++4O!C\CGE/O<ZO?%(GBDNHJ
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M)JF I'Z*& /.R7E+/DQA[=S(9JMP2XB6;+R%A45."'OS/%A$_]%H91.YVBJ
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M*[H.S]"Y+!EZM.V"PPVS8>%3XLA?+<\,PL5_]"=Q#34S/)9+8 ?'^^C]$Q5
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MA$IOZ%[L?_/CV(HEXKR+K7:WL49@IC8S^1G@]+I<5M'S?H?F"<'H2Q2I:N>
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MDS,AL07%%4C:D(ORUG(HC"HURXO'I7\91+C)%E%ZNH*4.,/>Z!A<?;*M27?
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M#;,8^5U=G^:H'^]86Z^L7\X!\[FO+8X+^HZQH\V JW]OKKTF\)GPN^Z%-'_
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M4<>]*Z?5(O"XVSOW-8X=.B+Q,,F?'?/HW^,NBD=N,KY!> "_YV"3LVVUS1)
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M/=>]C\1O\7-&.SO>*M>S3))\\5XD(<!> %UBT94M@)E[\>80L$Z^Y@[FU;+
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M1LR Z_1JEW$41<WX^E\L+Q87$F_/GG&61B%_A92TV[!NWN\/CSA2O6,,WXQ
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M]:CWA7 -D^V'RB&.IS ![P#4(KHF69"%B?N $=.!WGQIXAC=T&/0IP)GM0]
MY!N@-?8!6&E7Y+#93IL;@PM-]&,UQAXS%''8H)9IM)/EQ)NF"3*K,;8UR$=@
M-<;8?>S$HS(&/4^^W ?0Q";PZU;%-&.*!U2]+4=HA*$X*7?+>]O3P:FQ3E5)
M,.O.3F%.]B%YL#)8'X>I#>F6Z&"#<Q+!T47)BR=^>V@;H%W'_17BW?KIJY.)
MXS>3VS95H\\!3AZX!BA@[7OD225::#Y"U2E,58>O4-/%*2G]3Q=^3?@WZ@F=
MWW-X<>GJQ^.&EK^TXZQD[?36W7QVS_FP_<+-HIGT3;P;E"S-2<(EPZ-"\*JI
M/+ _)WY+V:A8WJ1Z*GXG>T05G%*S7\\0%EB4.Y!Q2 ;6&+.A0*]#+E5J_\IP
M=[\.L^]VS>UH;*K^XM44KWI6K<S-FNT]]D8^T>QXF@RL]0YP\4G'O];SSFS+
MR)FJQ9 Y*0:/.7XLI>61N#A"^K-O\[0ZIJ[N[8*HA?J]5O^+((TC*RG>B;/W
MU;U[Q60^G*7^FQU2 !/N_LE>< 1<YS2S#P@"4E1*$I9,Z*BHY78Q,A XKTHO
MF2:(-<BZM5\4O[F]^X(QQU/#8=]@=!+4)B-=3CV!Z$0H40:I)RFF WAPZA\@
M)\UX4FUU4ATNMX12P=HX$80'[AXJ+',_F:DAKUQ==OXS2L.@\OT'O#E8E<9%
M3$]AXA.$HCR=T,:VA!-!=IN$^>&A4<)7.H@_<SW;)_(M%[=.O]Z-V0T-T2Y<
M^&K%)C";:$#_2((DZ["*&!>2=./=OT7,"[N.EBTLJXC1MJ1>$PM4>1K'_O(&
M6Q_B$FLG)UPUE+1";J0\):$A]1-]BR_(J1<&&R**J,9%[X9/X'B\XQ^?;ZS&
M6W@:]<IH23UCVT#]X]3&2D@LB'@9),F8QCHE,#3A#RA%%;:*&.[VQO%*/=MP
M,G=62<.)VR.?7<N-2DR",VK*3D(R<[/!JI3=<A?$-(1X;1C$\\LIFPBSM25Q
M8.(ZQJHN-JA,-00CI@-J3,/%\D/OOW\R-ULEZUYZ .D?%N0Z;#*^J7OV\M;?
MW1:1+UX,-SNR=EO4MK8*B(J:R#\! )YV%@"[@'/VRWJ-5&;ZQ73^BHID" $/
M0)VR$;KC>3_>4,T;OK35.82QGZ\1^%BCK;G)+K:N=Z,?TP#ZE^>S:.O;<G[]
M/H#_"ZM/$MMW7^BGN#$?D?#SY]03A6][+_@-E.NSA.XY6GYKW?*^Y:"OB?WZ
MW<P2[/T=@.X+2<!.,\]_J6(?4/?Q70%EK%\R(=:(MV06&>P&\[,>(9-,.'KM
M$C^=4HDJ?K)Q::'E-'N&@.+,-+D$([L/@&I2%*(VNZ)870<Q!)!2M28%!H[2
MFSD3BA<X%G.@/+G>V8O4T9%47HW?C@Y1*3UMR4:=0 0121,27Y[N0:?DLY%0
M"6W^^$>-Q,62O,I^5%E47GA;MKB5>O?%S'Y9ATSMI3=QDP3[([OER\S\K-\E
MT2&$^)3CVH=+WS""X#4E;</1-B7S,U;"/QR#M*P-'A'D*H9$Y9/.S54'Y:P>
M> 9L1+)TRG7?>L'I^6*DM:25!2A#"$PQ1]:*VTX&>QXD#NC<+;1ZXQ[11%5Y
M'W[(=/RT7V JYM_7,"NS89&^&(K\40@70AD&&D"<(/W!)%;IG%B9+/T4I//N
M> (A\471;!@Y>J3:MN;<)3/8XT/G)![B%WF;<LA,FA-3-UQE$AH:L6S+'>"[
MMX@?<$C#2U3\KGD7I':XQS\FLHLOWN AGO !_. B78F.-M:T_FOZ%[L"M=+X
M:_KW>F)#_?5?TS^W2'\>*Y;I7_\(%UBE<0AWC^;R5PQ^TX?)A1/!@NYS8^\@
M :$4A,!4RC?7/G8KHQ>^@X:^T.>-,@#?66[U_D] #$(7;EM#426F]RV>F31O
MR]X[E'MV:VY^H;+,?2@17AXJ=U"T^*DWM$OAU3GV#. W<9I@PG)_*5Y3%'Z9
M,E@U]O;Z@CNR-^V8Z1K!EQJX]:'1:?1DX-#XP8:@-2W [MA.VOT_2*)+.E:5
M(8@Y^!W)J?,..4$S7_VY-S:\$RC[C)X/SM,&YH8>B?JPG+/^7*:BWAY?W(:I
M1M&$W*R(6+=Y_WQ5TIN3,XL?6J[=WU;H?RV-_ZG:]%4AMCC/VG]-P/N0 5&8
M[0:G*LF0G$3:I(F4KG123A&]KC<1PWMX#?Q0SE.T_IB@BR.>1S84'FM_( J>
M3#.\KI_+9M/(< 9),$-F"LS&8 M &!/3>RL];1,[@/$0 2ND/-3'7\UQ;@WL
M9]EC'7+F=;E<KKMXNL2YY:(_^X!_MD'@95%M/WI1'28>6?OG6T\KOY/?8YK/
M:A?9T+ A?@UW62@X/YRK5&MP]474XVN6"CE2C^ZH ^#3_R[1<<7\N\_K_3P@
MS1-,$^*\VMRZ#[ @@7HW3PW63H+'99$$44'-9S<[T\]X'PK;EEI]>KQ95N7O
M#4!W2["ZKCC8XJW*OUU7^?)0]AI6US5_4?FK!>OM.*DF>M7'O;K3 ?"3B3H%
MH ;"YCHAI 1^EH(L=8>"Q6E7>)"^%XX576[0LI8S.SHL/:[TZJNC9>&!^%6U
MI>AWFBGP_\:(<@@+["D'490;"5](*HO()+$]_HYWN@1R0KEMB6I'(31$_C;6
M;2!XC"U8[ 88;#PC4?.T.>$S^'\QZ *P^*?#,!X4AZR?[@?'#.,-4ZV[\]3.
M/#W;:B$7'SEL38TT;W4>]!(V"NR*:1S1.Z2^6G@4/6";+&U,9Y8M0<-CLZ0V
MIU#B/J"S(2^_M+#X571D8G!>KXVJ^\)YZ>.&1MD!5YSC'@5A>3DCC#_0$S%+
M^6?\UL/Q*"%*&D0,V>U7&=!PY0>Y$3);Z44VC&)X#]:Y6]9$/,XXFL&S:P1Z
M5=Z'"4RGR(_1U-"BL&$\N$=3("KG^N3.SY#E8Z9G/U_'M<5]T_*HBQW<UG:Y
M\N69I27N:*#1>WZ/2 87BECSC:I/%1\P/CE!:YU9I%)-*H/;J%=0VLH-9N)9
M<J$-]FLJ2VMZ8Z#7]:PBA#V+7H%0AE^C9%71SI#021M&+H4SWX5^-N2<:=S<
M+,C26#8U'K?-E7W?$IADG;6UPG7%Q'XOZW^K@_K___6_T9T>B.PZ!UYZU8BI
M1R?JC!VA>/7I[6DF_U[0TBDL_4G2JFY)"I8T-PZ\,<C[-N_.Y4$VQKJGT2F0
M*E%_W9KJ#X-T-70<3%]AI!?!3I0T6KG93J*5.JH;S80(=5F$J\Y?A!1X#]H(
M'14U-*L&E]39<<92MLE.-90XJJ(-T?X:B;_[[,?<$([I))F&*[I?:'<4>G#6
M4EJ+$^Z%>7:0N[GR(P]?1,'=B.4,[FVJ*^/CF2HT9S?Z\:+$^._3:R^&XS<B
MX^/#?,\I19Y05XH_/2O[6.SJ2('(88N[>UGF ,0#.)/$Q/A1ROL@XK*4+.HE
MRA8P"5M?,:[;$,MK?==S)3Q7_/E6Q<T;+O(LN[]LS=9!4Y+T-(-'G2H'MZ=7
M89;YQXVD*BA("^)B"CFEM>G/*\>?FO4+5O4"SV4;[M''53DRJD-^)XFH1%O3
M*\T!=__%G5L,ID_F(#&!E?"GC!9.B4/#O%R)OQ^\FBHL\2=V;R]H5_CRGY:W
MB#=8N26[!1EQS'R4_>MQ[1'.Q4D[SG_>;=$#O@&>/?.-K$!Q68E,/_;S.L@#
M:M=.#6/4WT1JU:;8-$9+/*H\8U&]&[@3/"("K]+N!8BO2^X6,7B.5\$PMO0L
MN-,;F'@/0X8$2C*R6OU^Q6R9H/P3*"+LO:#S5C2Y?^J'CEOW$[0:#&OI Z!]
MI+]@'!C^^^ZRT/@4K+9WNJ4_MF28?>^Q^*?%@?M[4:N],Q,$;Z'HB:ZC6B.M
M=A>VYLKB4U2 GZ7EZ,G((";9A)^&'/P%.D8#1RUC%M7>#U<LTE__D!?B3(XL
M]%;*UQ-JTOJP_ARKMRP"#&.>L!.-O8.B1-6A-T(^;^B$B,%>V#=U=-1/UC74
M=-0G*^H1W88Q.VD%Y[<5EPJBWKUORPZI^<ZVECY[ERQ+3%B/7/;P_-;U"=GM
ML#)'/7YT;[%5N7%[X8IE8^H3?;V&495-&;4J[=;'':X'5I'O0>OB*\C91GQ.
M*D.&9DG20.$UA:".$*^8%>M)I99MVH_>G3OS=42YNL>D<PZQ1S=R;LN_ X5]
M/@<ZC9@'UYS-(402,^\9H-5_IXO^."5%$+Z6+WK/Y6)69(3SB<P;SX(6WG_5
M"3T-7'T4\A1QF-&+:<!TGCUD(]RY#Y T A7?JDS-"QI=Z/M3)Q%^]^M Z$W9
MGN8W]T/4-/ F@4M>OQG)@-TBLCG]%4.!IM). B4CM."6^X"XS)6ST-4X9(1Z
M1V*\OS2LXNO3X _?F$G?+\V@\%S0BD>%(!<IA*+L1Q,>[M\'U"?T:1ZF#'1U
MR!+I";/W?,8UUL.F\_DB[@ZK6$GU'6W=B2I\>+6\<?@J;\AQY#GE N#+?8 7
M[A%2RECBQX,Y&I3R-&1E].*MP#JZQN+@UR=2AFX^.3OI<@/"5D:5QL=F>=_'
M:X^##QB;4'J8J09%22FE/9BDA1)5!R3!L76_FM]TU*59#[_2V+R8'82'1MZO
MBWX(<%1YKFP*SC:9:]\'7'U; !RSQLV&D!<H6:%>Q; Y<NKGWT"@6G\$NDT&
MS;%U,K4;(%-?YR]2"[A2PAO;RG?%/$J8ZH$8>N!'.$8UF*<9C O;$O],O2!'
MH@[K/_L\.V-[\%FJ45,B[Y&D-[$'G&4'F^1$KD!,F,B8A>1 +J$P#4KKF^1G
ME"A29!<#5-^RZ#O!P(7=O?61<?T'8DPWI5=>5AYR4H->WGB?6[2<M,+@UE]!
M)DFK$&^/(V3\]UX]TK-#)\$=\,U^3=.Z4N2H''&YKW?E_4..U=V>:^^\)BB8
M,29?PUK1+O(_W*A8Y;3BU$O]^R[+8Z7RO-M@2('_4YQZ^RB699Z2,-0H=/*X
MJXN>19N0RR3 "K C2MRAB2:'2%-2EHPSES0/P"[T22NA>A_D#9?I/2PR+N1Q
MF?.TU? U]TW*N]]P3X:_F]ODQ@%' ,6+K$1/;C.C>L#T\1=Z[Y-\JPLH<Y<F
MEY#\L%QTK$)_!:^[>_T$()B-?VI$Z2I/7=] GEUQE/!*R R8W$N9*/B.$*0D
MD,9Z=A;YZK>"JFXVMK?X97/<2HK(#/*D!J:LJKYKRGBR].JGRW-Z%)63=N3_
M'* 2/M=4]W> 2C?*P6>"\7> "L<LXU@#5/(<J#59CN7;HHB'!4!A.FH?X(/C
M8@PB#]=[ )<;<L@$Q\VH$6Q\ZWVQE:NOS"*X0T./*GE#7R4+R0J(W7B\ODIC
M([/18V@A5#W:51*F%Y3$$B29XVT"AM=ON_L_>+1S'?G*('_#+3N?_7YFOC+/
M>Z]7XQOL67(;+<ILO9A VSB&/N4+%4Q)Z<P_T#'QNQ)Z?:M2<5)7W312)W[2
M$GWRD,0;?Z,^6_E^TW+YC]8">HT'J,J,/B2Q>!_@G2X(ER7YOB,SZP(QI#\R
M>.'6M!0^A7 E*H<N^B;.LJ\M%+0HYVGZ+:L37<Y\K(9 ,6#B921VCGSGBZ[Z
MA>7I/A [[$[49=$8DM@&'G_DB]L=L60HI^E/ZZ"HUF>&T>?N<SJM--*$D/B!
MOLTD5[WZMW#O1M(#6RX;/P^2_LL<NUJ/,;G*U"=R T>Y11*O D]?P^3&2K[G
MW7MJ#H!3J6XT4>8-0<\R@ DXSHTZ(.>"^@:J!K]AM6Y_N;XNTR]A/2CPL6>F
M0LR,YG"]G=Y)T\QM/]JI1L(^8!_ U4B3PQ$[:" ZBJSY/J+#*ZIV>+8V'(NI
MA>\#3AW=;:6-XO0(\]/?*T4.;%]8]Z/R42Z0C3^A\S]^8PBE'_D9D;8/Z)W6
M>\UY,I@U6-E.>]LO\IZO;_Z0IVE_-6V3"MD'=&G"[4F&*UV4(B*R=P\<%Z9N
MZCVI6;FYFMV+A0S4!GVIR/[4&GP?HC4,Z+8;:V\;N; '9C* ,*7U+FK8K[S#
MJ&4;*#F>B6@)X,^$JC!^#1=DO5QCZE.-'%X?D2W+@U^S7UUZF0 _);P#[L:P
M(;OK*'>7<7QG-\F54Z^\,Z\'I(IG[Z5^EJK2^"KU?/?ID'?N3.TIH\?66O+Y
M+:RMA-/DCW^91NF*;?]@AP;\%&FA(Q8_W%RQFC?AZ%^9/>4&>^1_-RCL8%UB
MIUG(HQ.OYN8MC:^!"J_9<:ZA$\%>(7,0O&W</1P[;'CE6\(^8)F/OE"Y[;^C
M#PK,GKX9;Z):_/*JQYIBT.<QO5DWCCGPR;T=LCT]RTB.JD [;7L8%FJ\4.ZQ
MGN,RO9:HT%]\)H9-@'M6<O51Z$'3@U9JZQN,.>89"R_A9L0'F/5EXU0Y"8<7
M:U].A?9\_AGN&I];VL,[=F^H^KG.UTQ)B974@I1!I):KA9!;E?:(-RB2M3IJ
M]POU ;)+FV9%M81[I^ Y>^A^/7OF4T4^1R47JEK/CB "B0^/VO=_>!+;(I/Y
MC.<A/!JGE9E(%WT=#08SQ!']X+J2=GKN,B@-=!39:"SBNOMD\?O>H=([>VEH
M#$POQPG-;E]?F^1]N%)UU?1U&0U]A,J#[#*D0:A&M-LDSEYT8@LJ]H^':>2)
M@HD@H[.W[KN-&3TLSC_YR31[[HJK@J4]AU*8E$A0R"<>9;;M6#*&>1C7*:7X
M\(%8TH6E?4#2;R3/3]='@V\A;KAA]:0Z3+KO7+F+>N']^?4.K^P#CPI1D1'/
MT\81(Z#&Z\T%/Q@B4YA;(< 9V%VZ-/:;W?AJ#O6J(6Q6^\?MABNV\M$:5OZ3
M@Q_">[3 KYF$5HZ([L01*XV/4L)[@)'T\K!2%WFGO"+SU8ZB>Q:_4IH/K1E[
M;^4JWE<;&9,3&K%2VEXAU[/^/)HYO0@3$")(V;$E@>-^A_! [6<.Z6O/#T:Q
M7W%UZU+E<@2ISTB\RH)_X>]4:S:@Z[Z.-@B)!7&UG26*+R<DT#B6;VW(?OKM
M[*KLNF&O-EYK:"6?-G]P3*XUHT!9S;3L+8]Q.&O@B=$-)D[G'4XJ@]VUF_@-
MEOY^LZ"Q:5)N+B@J8+VX(/]:ZAN(V@;L U]!6YG33O'$NB3S!CHMEZZ_HH;1
MY(@5TD>) P,@SKGO4U3S]JI"HY:$V<]7O)Q?0U\96Z3I7K.K?L?5MFPBCZI@
M APR.O\$17A):IB9:M96\.#4^M,K^=L>'=JC.EIJ%X7ZE'*Q5C>2[>]\O]SU
M(HDKE;<A:C$90%%=TE^7(TF9T!MUQ](A0KH$Z54EU!7,Q#VZG%-S>QYW\(%X
MU8CKD<X[7?QU-1:M%S.\4@#*JI!KB'$0>R#FUF8,X@0E[&V DZ2.Y*1@V4^Q
M#S4Z0GTJ-L(BP<?.9RJN#F5[=&H_D7@0)')@%_KO=02.]E^4$*!/S'2QY<;@
MV5U9^*MMB4>RT=20=;I<#38*J1UO_VI;!+!=.N<?I9TWYT/+^?EL(!SD&XM=
MF$!GC  S/G9H=T!F:U=T.U*77GPP:WB!WQVIRN$3N-@O6I>],+.KE6F0>O3$
MUD?3; 0;V8L"7L$Q$91X53T2O]FKR48IZEF4KLW;=I\ +VL0:UTK?DG/>9R9
MS[XB:<MGRU?XK#6X[J.5HLE>^SG0*W#M-YI0U;)1&#A]'W +)8KL'B6=UZ^V
M"?$Z]GNZ(<?JJ,DUG/5=B6RXP$//73LU&:U,]]>_P0VES",3)[?0"XV4*L;0
M/R2=>OBE>:%' I'U&XCYSSK]UG.)-_4J^>QK3C[V>:X_BU>;V77:=%4&H&.0
MGA@F"F$.(6_9BL'=*6@T!=+;(3NYW R]^Z9[PJ"MY;E5:'CS<M*-H,*5@[J&
MV7B39VQ0.H&)7W1J*$V,U$@ 4L$_(4 :,&R9JEKI29ZFFB(%!HUN-51;*M$G
MSJ>=CW<N &EGS7A_OY]G.Q-"#FJB9X/]Z/I=>:4S"B3YG$;7>'1X\9C.U(YP
M6YS7/>VRS!08X5-TF?:CI2?.= YFTG"EW62>N2W-?()Q-@!A0!%=205U8</F
MQR&N%Q16/^:$%UOKD73;6UW/G8M6%;TD<APT+$-8I-,WUQNIP;2+3=7C;4%4
MB^][G G97D;3BP).,;L2%LL  5>L3K)+M/($1]="O/)KC.GW N"S?4 P9C:'
M2;OK.)DD'TC3IMP$)]!4B]RN]^A^#0^?F)FC9R]J9[C*BY$WT-)K%[ 7RZ1@
M[RLS[+^ ?3 Q&"(S[=2RS,E![6-S5761<N3AN*<C%BW9%_)7AH,2+WFZ>'-G
M\;_7N'/'MH)):#D06-3[]%X(]A?Y$3&_UACSQA_"IP-3K_"I9DPW4^^>GSBB
M&7S\$;9.Z_*';JWL&SB_Q%JO54B-L1I,G"&6T(V3H.A D+[I@K>F\R[,M:$-
MUYE!\Q"_K1?L00W_%KS\TDON=%5#,H!60)%CLOM/]+<,[H"\9PA12NLR\I!_
M"TVU])>^Y-F%^>VH9XW:YE+8@NW/+B/!TOI71\3.+_:W3S!XCE$E:;[TRC;[
MY3DD-Z6G9R\DNJY5X>[K7^+A L&3UD/22Q6.&Z =&\D3OH;_1WM?_@[U]_\]
MHJPE6]::"B%KPI1DRI*M&DOV9<J^3V4;&:84LF4K0DRDA%#6+!F[LF9L&<L8
M0I9A)AJ367Q?WI_[#[B_[^N^KON7SP_GQ[E>9\[R6,YY/L\3'5ZC0E7><19F
M2R%"^?= [7)$9TD#%FY4$[/>=\$?&-00'P:]J5)%+=__]VW$"TI#+KN228_F
M)T, #-;>[=<*:3E-2Z3NHI-G+X^CSE4@;T*/FI5.V4\Y3_>@TJXD-=K)9ZZ(
M>U\/S7UT7[(WH/MZ'J'@%C".',!/#;!S^2P%Y@>=2")<E";G,+Q-,AVZ'BEG
M$0=ORI1WD'G>%WA'P/%K6&#^W$770QQV8"0FF!F[!_*<2IETHZ)'4.*ED=%P
M09,( +QV'CAMW4#<N_35!J)_MD2L_MD,%\\;^9O<LBG? 86PS$E" Z/YA0+K
MW$SAG$]IVP,)_6*)C-9R9YBWU&,S'85\T"<&ZFVJ'/5(#9.H'B5V;GU=ZM:Y
MXT7,E]# +T%71Q@*Y5'?9\$?R<N[EVL'"][VJ5*+0BE5'CBB?V&^"<@I?:0D
M(W4SUA5MZ/V:/R?J0M0@2XO"N7Z?P-G,6>&SW)F5:8./*IZ_8;H1>8D$U^Y#
MA\AE2 W)9 7*;EGG+M-O?=CH.;7. OI5?7AS/8]\#,JU)A'3\F9><N#FLO7H
MTJ?LHAK!EJ^I5QSDIQ 9?!RQ')NJCY/8M@%,IA0SA/VH<A08Z=%;VC$8EU^.
M[HL29*A?5SK!<<LMUKOBF-3'=(U0OO+ UPIZ8L8]]TELY5&=Z&IT#_;13NHD
MPXJ65TS+:M<^D;!K%,>X7-2GM"*:K6$I+IMI7.CY.Y--RG36<_3%&)^I%O:'
MACEG&YP->P?\%,]/:JA /:"E57KO*.CL)K-RBU<DO@RL?S>[RW?.L7<+W]/"
M%? V71-_Z[&4'=M5A]V=!9O$^4HAE"PE%$#DW BPR.H#=ZIVR)^![3H3+Z7W
M;J('O-^D&WAWB(OZ_JR2GVZ8_M(%_+D=AE Q56EB_Y*3AS;$$OQB"QMEF,Q+
M3D7N@7[L\"OG.+0F_USHCX4(BN8OA%GCI;N/K/_E_W>S#?[%!%;U**::DS11
MX:V-CM&LQ$MV4$]([8&,ZAI&-1H\6*//9K6N-SHI/[?Z=I(WW2%$_?YQ<C\,
MR[C+S&,$S//_6&SA1_([C0S%JRJ5US!AG3DOIG?#\"TAF:Q5V)F+^28JTV9+
M99 A:HG]S#-]IC* R8MT3E8_9+^JMAU#^H/OL?]4U<ZSM<KI]MROJGWZ*IOW
MFX"6ZVJ"8D+-+4?4.(=K+*X<C+H;!<A0LAE!F'&31HZ29X INBE$9S/S;$W>
MM8B_'I^TLBCK4R%^LC4J4WE9_?=;U9Z?WT2<%V"E# .494)7BYIYL/2XF&;E
MP"QHAMXA#FU'^.7IFV7"2<:D!?>^M^V3ACKIH ;98BNY4P2^3OH>J(=_DM ]
M>Y+YS'%NY^&? 1U:^N_>J?VY*'$>*HXL6[9';!3]=LO^F4[J;/'==RV^+_)^
M_(3B1LTY!^$?T>L=$70YU,&4=NWN L1[6NR65<-8R,4/GC[*')55,D>/)6A-
M_>Q@._7H4M_< BB\GB'L2+U&*Z8[H]LEBY 0>S(KF?A%E"0:=F]-NWP4[M>8
MX7M*S=!_A5YDPWO*E; B*&\-RJ([)("V"#1+/)@A#Z7=0ON.0HF2>Z G7BP!
M6&UX/'6HBIFUWK3C/[GDOQPZT-0P]4QQJ[X52[Z.Q=M20RACU+=DQ()JW/8:
MMQ:ZR,4DR(\Z;=#'RG#[Z72%SE?U9!;G=JI[_ *X]#E@.?:? ^&8I'VB],U'
M9L7O@7PV$\99YW#!*^EVP<=Y[),@/.9*:94;<\^^V74AFMO$?:XQ:A!QE<',
MQOU8 DG6=S [ TKN(SYA@<D5R0$1?!-I,P28&X+JB.R]ZIWJ.-78')$-]CG[
M/F"^O>XJ;-_.]I>SL[C?4*JIZ,_D[GJRZ/PB-BYD<ON';9?6@ZZIVJ2)-4E%
M#?FZ2BDRNT:[YN?$8"2?6#4CLYD7Z&DU!=L%3;"=56<6MP!RK!VQN.YG=IS7
M/(_!&,0U"^I\[*%&W&EHC9U6W5TZ.^S/AC7]_T"MJ$/,)U'2WM"ZI0;*VORU
M+V^FB[96(;N!F"+?'4CU5>56M2Z$XI#?"=JINDSC"1]+OGNW#Q[T6T])/'%P
M#Q130*[OUCTL2IA\T^F@N91&W50<I$/Q)Y'- [E943-_ISY[B7T=]"L'[)2\
M+A? /AI07VBTP[NWX)@H%1J\+2<0R[.R.]"=$A:F0_!0[D^[1GVOLVT3)!F7
M/%I], WRJ;(*BAB:1#@QRW4Y\4A81TXWILA/2V*@I3(07_BY'N,>I#?<5%AM
M]'OZ_"&N27E1]M#%71> R/MH^O2#K/%9=K(__/ \[<\;VGGB:+6)3CEQ,E"E
MLEP,<_Y8_SC91**F]&V:BC0\W^948M47V$,"V00CB))CEM9 Q5=S*N/^I,1)
M'*G6+;CCC8\9HA88,[I'9J]D4KK=30R;/O,=?7XGUJJ&A0%V=S:\3G2=C6[$
M&L.*:AY'6U"*'TUT' NZP1FG$:]:Z6JFJ$Y0\!Z?[,E??8]K69IN!87*^#97
M["]G"K-Z^[C*T/417>C4"C[@E4* GY?/PF7?_W-\-O6PM/3 0Q (Q&G*A!<^
MU UBQK,X&3=HTG/'[X_,3R1OZ(3/-S%A PE_:]=(IF(?QF4$N@M_R2<W=UQT
M38 <NM$_=4NU$WYX#S27A:XI;N5_.G'B# U.,6K;-1QUB2RO*U#:D=_1JKC+
M01WP43*ZR]6M[FX=8BGVW*9R/ <P Y4+&(9@R@*DJW(=)K"*%M78 TG0=I>'
M @+7.C.FKWIY)R]^$RE/*%+'*,M&=.!D\!12@HX:U(<&GX/&ZQZ+ZJK#\J!X
ME6.S%RZ@U/'N#M&K65I4LN_Y KKUS[ #D.Q[&M4W'Y[\>39%_G;E=X#H>@CD
MFY@?U4[,%(;B I1F^L<9:D61>XH(V-D#N4WKU/GX'8!DI*B+31N[1"3/V'JG
MB%VJ0K<98CW@\>C:XAB4.'&(PV\6C*L)T*(NF(^20K[)I@R].MWC2ZFY:THX
M_>6[]%G^EPU\5Z:HAX79.A@BM#L>9%LB^ F*MU@R_.1WC:]*#O/XX0#+I5L6
M2]-BHZGE2KD_ TV4UDUDTJ,@>Z!8=LH>:#\PY36<_$4'$39'QW)U 1[2VW&E
M,6!QU>7LE.-?![\JL>B_"=_QWTYNA1ZS!8E<@OTZ*,Q&AC&$S5C<F_,8?$?/
MK @%'1U2#KXY^F&[!Q<B%D)O<(TI-+E>MR0@TAP7NK+!GGGRMN&CG?A>X)OG
MF651,BBM,<8I"H3ZI#[RS&%ULX#S-[Z;*?I:YIH4/+NL1U\?OOX=X9U4,!ZD
MGC4HI3CQ"]"6%-@^BPM,0-UAM.M_T.*^)\#C*)/RR'P<[H8$)&L]\]-&V(%P
M-R/F6M6Q)'GX-O)'M> !,-D",2DYCR&%[(&X M/F9KPZ=B&QV_ :YYF>#ZOU
M%I$5JS?>/VD3J2[>2+-3BDE$%QD7W#H )_D"]CMZ"'"IP/@ J/[B-VL (UZ^
MC>"8U3M>0Q =] C^?#O:1JV\J&ZCYUM2?*<W$99Y7[AZDHF!SKT(XUXH8:#I
M!K0RUC%$PJDO"7X18IOOOM0T&L_SO-MU?-E9/?>$5[3WT1VVI(1%T6V <!3C
M:&.%M+). C?*^0WRS-)L3]>#_.S+S_(B@R*5T^W[SHIUM>;(_TR34.LVQ#<H
M)4!4PE3O ;P?^4]=[D3-_:>LVUO. S15:3WR!RJ(C*42T-3+'7V>F1^EPR]L
MG4KNC%G^/#,6^I3RN.DR)T.8G1I!2Z3#&+(C.KQSE\V,AE]G6)F1'!9L1RL"
MTKT+;7Z3&)]OIYJ62W^("S<OYW!7%'J^&YL ^HV>1,Q5,LYC <,Q5QFW&41=
M*S_QE5E%=-\2J'B;MOSY]Y2KD%BF_0$/?7_>5Z\RR&"&-K#;VJ )<'(:@XO6
M4+QB4[:E'U+FY&0W>Y:;T56;=R?6KJ+PP 4S!$^ZVL6G(#;F+0!<-37WJP(5
MDR3IQLBR&S \_T(4YCW2M*<WBP[MN#24LW**7K<'\JJO?Z8O5?WHOHV14^GS
MD+E(*%T_:E"[HI9^!HX2IRD>2IM;BWAY9\35+Y&>>"' OS/:+"5'_FVZU\M#
MSZ[0MCA^5S=)E3'%_[U^ @1BFSYT+M\%POR@JX , ZB#(AJWKMOW1B4MS*VB
MF>S6EV]O:3PKOTAH(O'QO'!N<4AU#.?=90,^.4Q78!RA88E@'EIAQ\)."H!$
M\5A\:&BCYKO,T@F;-#N]#,6_W78+6S\QI(/N7LG9XS($F6PVW0O[9'B+$4Q3
MI032.^$<+6>]=\_D"7?0M;?,L8VU+1&1W^2C-RZ4YRL\UY;WN/@,KG3.<+"+
MZ0)@+0\9N_Z&;HNZ0MF)J]#58 0/;S*$WEZ7:_J.NLP;KCUZS2YI')(J^^7#
M_38-TU_76[S-.[F^AI8#4R%?OYY,@5$!V?$$8DP.K"8R)3L>J.)5-A;&0QS?
MMTR$G!G5NYTP.;)C_.&87A<6)V->RJ9*K06$<)L7L$3_TO9 =&U:[U^TYU#2
M^"XD&G'J"!Z1N*S>Z*1V55',!N<8YO:SVV!>XVYQWT4>^W76$(9LVO2$,LJ"
M,@M1UGL@7DC7T=DNS2])82,N>&>9>P>M(I7[7>W)>@<3%Z]\?-AM>#]Q%]#!
M2"@IC:[X@S6!X2*2/0A/573.W_,IZ2B=7#WJJ-RK]#[]FD':,<M5MYRK#U?U
M _Q3>>I[P)QH5_@4?.[$XS/Q<^CD$_RX&ION :VEC?E=/-^EAM]NGS^FW9G&
M78)DBMX[67?WW"X:F#L%NL)^8I:*[G'4-7@"5@)E#W01.F\0(5,K]$USK/;Y
M+U.CNUZO_F:I*YEP)36>?/KX89=;\!_8U!;5<0+J!WM$S1<B+WT"S,Y ;#6B
M;*KN?87R\J34]YK 7Q^&&?5\;=%:I@=;9QJBLH!9XV8FH-TJ\6#J PH@*X=$
M45;#2S3[PH&P]X;$2,'PC<-=H]^_<275I!I8@D8T%MG5P]]+]LUV&T+W<UMO
M3&WBX[H=O)XU'RS]M2N:J//\TUCYGQ#O@$K7*[/./=E\L%-Y5^T&R6UO[%H5
M%N^PJ,#FNZ"Q_^['7QQ*@B7V>&$SAG##V_/A0%"XSLZ4NY)=XJ3&UEVQP$M.
MQN)J3:8DI\C+!0Q."K8#,VG;J7O@.^K.'H@;UCEPK9=ZC-)2'J2;=^]>R+W&
M"QM+>;K#D&P$6\S1Q9>)=JD:OFRPUX#+3<'.Y4$_>3;0P33;;C3YQ6HC8'!A
M1V>G-ED]G\/]<>,<"+D3[N<^IS;O2#96#)]0"_-*9-9" ?.(K9T@<1,O>T:B
MC7$M8MYD1[L^-V9E$'4I_IVZR[0^=ZVW:U[:$S>EMI8A <^>7NR#X2M2T.YR
MT2Z7,S2S>9)D&T2+JJLXNOUM/7AM+7?%/WW0WKQ;A6/82.;I<*RZRM@W=XN&
MH(:H4&"[!;.Z<I;7T42X. "SMJ4KNYAX'?T(!)9^@KA8;68GT/PJ/+5[7F]K
M.G"UR0#9-H/Y^)]_5DBHJNS$XD?:6_C(R]&:F_PK#EJY$??>^X8V_DSO61X4
M<*M%XB_((M)<?@F\X.QWBCT9L"OWOPJ0GP8D+P;P<*U14 J:(<S+$BU.WF"
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M7N1"+"O%E/9 $197I%*>,([O@7BPQ,!D(HROF/J2O)%\)/N=49G37[@W7>?
M!8,M(R'_F4]AVIWWTO7 3?!34:WHC_!D0-D0$EP@M,<4Z<Y&]--FDW+[R&>\
MR:KF^6M#6\5",WWW1UJ?X<YWL=GP!34ZMZ8714X 7BZ+%$_&=N^!)+" A11
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M9<G3H,:-B4.U=:.R^8LGEL8&0?F3Y;)/-]C$NJ\G5)3J"R:,[8[L1T90"-2
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M,4B7[[VY;F?<>K1/F)UV(Q)A"!*V^&_[;_MO^V_[;_M_V=![D_\#4$L#!!0
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MRTJ!1M5F!8!HA7/+*]CO&-I&<:RRG([<).A^:9695U?%WS_!%3S0S*?I? &
M!"IWE)_N&RK=X+ZD2AXHLBR&E?LM*<^#3U4.CWI?M:P2A# !H/5Z6_S"[\Z8
M6%-I6Z=?,7^ >;%DQ5O$:3TEU0I4E#PC:K][_JT7C>\)&'7/BR^PD,J0@1IN
MW_(XZF0S\J#^ 3_)VU%@ Q93A54,_I7LNIC8I(FMO9R\V<H#@,.BYJP3^496
M2\.[U9UIU8OKHK@!@ ?,FA\5D B^9(VVMEO_ M#J)AGQG1P1.8;>%QJ$.!--
M@1_Q '!6'MZF_: .\?351NORJJCI\0YE<MF+"N^?J)N'=6'9RSGT-'S?^0H^
M]+!X..N\\O:=+1>)++8SBP=D]IM]XT1_G&?BT5-D^/GW:A#Q]8GT\8AB\J43
M%?["<MO](CH='(:IM;7QSI"#1ETRC#6=W[F2A8E^_B<QPJ6:ZS?>__$= QTJ
M[@9GKW%KVKKR%VP@LZ;=(/L<?@&$A5@7=UH.-)F/[C0'H?.[HHV:V"3C[<)#
M[7M(QB_VN=W R!9*AS5E377&6P\"K"3/'P  )!&?S=,+ET_&.<$U I?PN)*)
M=5IS 0=/SM^F3FZ]D^P1T@>>O_00436F8U5U?#HX(R&I:Y]R\1Z;_RY1X*5S
M'!C/U4/.4_-.CW>;L]E]  Z%GS*H"X.Y2-'$8UQ TB'6R7]#!U&6P5,=K<_%
MZ!@.6_7ZH:.,J]K?-+>?35<*-9V@L'1[2F:LN/$X5$G!^7UB/&G[[D'I%R W
MO8/P%P /26:"RR<KT<] _>[ 8ON]:,!.FX 7R?LV+0_C%2[J'T1?(S+2],@U
M9#OZFG$\N>70ZRHAI;0@9L(>P4K^>'BE7V P$!"@E%],E^1WW[_5,IH6S+8Q
MK'['A"/TZ0$<TF?_Y;NAU"^ X42K@(]\(M\,^D1^[PH8%URGU!^GFPK^N&>9
MNGXF*!D;\';#8+=O>%L9/\M*RM4M/SMG<'H2:3+F^@6H'+K]Z>X*WHNR9J'I
M[ER1V+"9I!)=37$"G_ZIA7A=&.BK6/];V?#WA2OHM!\VYFX<3N*<;B.J*=\R
M!*7N@/22P1,<^_,(O@S#$TTCN%Y>P-/\5'OM";>]),VK"0YG_)3:3NXAI'5?
M_$^LK4S_N!IL'S<YTZ"2\(#'?KU]@4'!9)).U]Z+BOE%K"Y'8'JK\H8JA6'L
M>-X\<H/AD?A/$-Z(!'5L3C_F6_RLNG\9+1OX'I&#"G>^?R\K[N0K-G)(1;-7
M1:W7*CWB]@IQ2%.Z['I+\JQ:%W&)L;)S&X:S $=)S_.[9H-<GR9<UCLGKZ>\
MJEKRA7.N'.<P9.:WX]LWMEX)"IFH-P'.&);'F<KWVOB%E^<R#7/;\")A47*6
M3L%UG<U^*X!4PNT$N5Z0TN(T"?5"HFT=2)XM20Q8/^ 0I,=:<]ZX.:6EG_C8
MQ!M?]3T;0:++ L1]Z$\D0'JQ5:'63_35F492"L.[=)D6/X\+%,;F/3-2S8Q+
M9J?;>UG>\^I@:$XQ&+VZ/>"VR2M8D<=KDNA=Z!.\?OY-=.\- !2;SZX=$]LG
MP]S\U/3C&L1UXR0%%2?T.N&"%_LI3PA7C5K7#D,%OAD76<>UL=ZT'];FD/*A
M08,-C-?O!"<+;.'; /D&696U.9&<AKFJZ.=T2T%Y^M-W>7%@@8]BV0ZLX,BF
M9>W(:R2D;9E!]KM+]L%_? ^ X&-Y0NN\>U[S/5G=F+/G>DH5B3EISU+D)@QP
M[#C,6SVUU" 2:PD84"";^PA#DKRW3  <?4]/L#WP)[]WSK=^S-PWG-[RO76'
MHMH[+Z+FAM7.GG[C/&AW;[/F-E_Q5TR?<;$\$1!-7WDU"Y^QX40C.GJ?E6I*
M?2/F*?3.]$?5\?R"/4/GJ(*V1T.D]8?'B0.="<L3CP+=A5T3C5\ V3LDM0GJ
M[B)(!RR?V+_[,(@0;,D^D:J4\FM2_.$^V:0"9P>;=T8%;.]!$I/=[!O;NXB
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M_^4FD8",'<WYZ^JQ7T*QK"Y@/\X =-G_&(IW9<4U\-L_0OAQ(G!TXCL&CA1
M+A8+>JY_S1"!^JHH"2T4W/AO!P@B_I+Q.%=E0<M_; 5W\B*5)0&:"_8^\U<#
M_G<-)$L25LUDA,PDG9+,M^M_*PH 8-37"OV9M(W_Y8'@ 8 21@6 [HN/1C_[
M@AV@ %7,?=T$ 'OD(G;? $B0IP/(4!6X5%O!/\)P$7TA KX; ()..'NL^ E
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M7T-SJ\O_GW2#CCUT 0"J^K_\?7Q(&;5D/ON35+=!4O+_;PGX?]*0?BT#H$%
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M  WJXN8%%"4;"0!DFD1X2J9WP)I\G^9-N3ZBQ0';O\)O9->EUX F]Y+Q&:?
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MP T6Y/F:;?H'SG"5B;^L?RB'?&I5YJG.O^NJDCZ"G>(/<_Q!Z387SQ'>,E@
M)6_&8K'C:'EC+&5D75CG+2T^\,Q90_DMXFA%A%%Q4#JC= U,83-_M*'T\'1$
MIT)=H*EHAF:\%ZC1X"+C39JPZAL<" 1K:48#2A"TC-)+DSNHEA'V&ZEB-!0Q
M:Y?@)250?G),T[XNX[<N^P6X;@?ASP92BA?1OQ9!RW*)S2ZA18[<J^H7VI>Y
M@WHG.DALKJ9,U'X8@-XYZ_ZZP,3NG4P.C(]?E,8->2:(/9T2O64[E'JH8$@@
M?PUQHV^"X?<YUZ=U:NH67;RL1Y7O2%7E[9<63*SOG)TI3(,P7T$B4*2O3!BB
M"VR\9:,@\^7;"%=W7+!S\_'R;;0$#V#%K2!<H0=7D\D6P9C!1 \!(RFV"3@)
M<!N/8$>SE3:2,MO.H:I02&3W6T%:_KF:*T.:8*&L36A&DN:B5!KEG-UG:_2L
MJI!J@Y%FP^?*U]BJ25X+7V!C.9(VOC+"@$!1?)*RRJ&O-@I7\_WEHMTUO[1<
ME]A!7TQ.Z 88ZRQ?%@)_;=)CCF=>8?#1D297:$)05.H#&$VJ1*]ON=D<W:U\
M\DSCE;-.02&=-!ZP5<9M@0.H07]!7W4*),]EU[A#;<WT\2U56,?$ $W2U- -
M\NNN7.C5(ZF/GS?<O$6H@Y/[!5!2U+41<W7NUK!QRG0P_=IZ^OI\-XM0:CX[
M0UQT4JTC=OJX1&XZ5J<A$MR@#%3!8)F+V$Y"0S!OR-TY36CAY(RI")UG9GA_
ML;JC!$IOG"1Q<[('EE,-*''Y&S$1A!6@>P@R]%O'.]M+A7_X>/A\3+4*2AS)
M#V#+8^T>CAJM<F$5IPM=<X(S6G[48WB@GT1HNCZ?NMJ+RV"3.HO4K&=6.=%X
M;%#I);F^/^\HL:RUC7<'_>&79P@?(T-(CO&*]&E"+PVB!8>;3AJ#2B^IH7YL
M-/6M89[#_,*S7F4NRL&[0[3>/ZJ_W;A4TT&@*(/P(DS_$%7KH0"/O7(.NL*V
M!/#3&+%1OC;>H9RSEA-22ZUBP!"\@.Z8_DC#?(?\!W,=+\EGRU.JO3WE%EX<
M5>$D[]M2W-EF\?TD]8,FZ/M=\B3\4#3_=E*!FY R5P[RD 5QA"#MB74O"U4+
M/>JJX4YG[*A@X$7L[AQP#RAK-O^\$\ZMVVU7=$=CUGCU+3ON;D)\C[L-3L@=
MOP5MUDM7=U&.G>W*J?![\:JNVD=^6_5Y'W,"-IJ[2/6ZPM/OWS4QQ7R6U/SF
MJL<<8Q:G(MX.OE2H^WQ3-L6 J+*1F(44/<<*KTFI3M3PFQ]@I,-+K--<J5R,
M%S5+2#1Q;;_[S!HZ/3Y&G9GG%NSM1/I5,6FM!O:GZ0*HMOI2W)TL1,ABO;&J
MQVMDOX?A9"A:95"8:HXL4O BG>JW.+BQVO+0'Q%AXKS289XQ=JGCJ@Y2\=_[
MS1KR [@U)ZB T.P\!PO!<2,:#8U+QM=YC-!19AS61?BTO"RL87U^<[7:^<K/
MN)R^.+(CAGC6/!VZWNWC[9DR^]=NZBQ26M:R//9B53$K'"]9C=YA/TP_U==2
M$3K$N1'5Y1FV>N"@*_#2T2I,<5T?5QG9\+#Y%/E_#OMA!C83J<!W\OC##J)G
M,Y"C=BP_H<Z;?PW"*SQGU55G \CM+68*=+I'T\/=.&X&+C-0VT2Q27"CK\*7
M>+KQASDPZ6!MK^03G =T*C3FGJ+ ]#5BX4>M*96PBBILERYDL-B!XMZ3<#JJ
M=UOOI86 BRR[>\F-#L\U+XD4TA8]#O.L\V7)PA>'L]4-GU+9HG$6>BTK.@_.
MUMC!0CZ]7#?S;$:+/38?W8:ISJTC6HPE-&L,T/QXW,-5LZ/^(,IHE61PC$VO
MU?XT"9Q^=DH9HDK(/QJ*UERT:,NN4M:(^J'!Z$2=<6[8G>]M%,L[9'W8,.]C
MMU&UBSE6IC(S P<SW+>BE[ V3;%B%X?:?S.619TX\-78TA-?9YZ\,:JL"W]:
M>B_.K3 O1Q7*1E,WLJWS_D47ZLOBU_*1,X?@\9[5XU:K*/5N.P*:A/K15DFV
M, T4MWUV!2>U9HNE*)^KX+O/.-;VTG!U&"%-K3:J&=?Z/1N8S$B:X"?.M*C/
M"76#C4>#D0-[!O,5?:V\!+#W0_%K M->W@D-NWB!;!O=]?I5%_79*^1/FKJ*
M.;-@JX=OW].KM24$8T]3@7G+HI?2.0M]C>I$?G_P.@RVL<<2A:H8XJG9.=I4
M6D2Z\40PZP%=94]_ >P4D1M'3[.Y]6Z[%EU',+[-X!3IXE#P:].[S= F7C2"
M@X0,1]=,CPV:9FAGN,WPN&S TT$F(C3\&+2ULY>87E^N(/X4MQ!+J3-/^PL0
M]?W/EVG0OU^F;2JC(=BS!>Q)V1[RDY"&GMEI8*1$@VX/;IEQI-:9EZF(/RE2
M\BUJV[\71'LL<P!T-UE4+EW1@!()TJ;B:8N;)5L=#'-#MZC._ _TL^(VZM&(
M\:S2T^)SO'J1HF':#UWX.@%P*C([YL2J2Y*XSU]F,XP 61?!9T:2WV*$N<84
MR3J)79%B7U/L6&]/S%48Z\EGP*@GHF%F@+'!$3(2H(9")&^^7V!JW2)%UQ#S
M*C-A4CUM>P-LMDDFC :7[B&P!YB#CV6%DJ]'51S%H3=A(/U2?LQ<6#@-0+1:
M&>X!B(.$$R7[!MJ4I+%2:"M/]C(R8&^'\1-1I4L1HIF_]?UTS"9ND)$H/J4
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MU$8=.:_Y]5_JS.JA522M[45]GX\O,LW3C,+82.X$/@WIP?M.\\W]E3'15Q;
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M<*@T1M4-F716TN529"A>P]_GCH,,N\]3U!(W4I4]!14&O\7,:\[@R1FQ/?=
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MM9GH>5$#L\:);/:H^_I=A+79/F14*T5-M!LKBV*A4.VD+QFCW@#-E+6#?B"
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M^"8K1KT_@31:+L'"= .Y#C@T_ZCK^6NI58.$=V[8#O+@[AZ/2,$PL+RJI=O
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M(K6L''(AL4O7%<(K1;J(FR\[P#Y:M7>K??=X$DT?E= UGG23V#8#Q)4*L.]
M=LO3A7ER!C+7[TBU>8@(D=B,6GHZF@NS67)_GG]_\%TH$2I[+-BI(.^E,1,8
M:;\VGN!).OS%4&'^-H45(CMFH\;5BK7T8E1Y3^^IB80B\U7+02@,#OE\M;H_
M^&N^]V=@>O+XX,+*9.<YK]*M9DE?4[-U.3WW.T.2J>_$NA4,4J5QGVOELV\7
MJ*1_^[(0&>0&Q/V!!$ASQUK41Z9_$ZCMGDA4%U*LDMC]&4\U[W,P5DBB;!,9
MWYE$VU;[T+]W\^/[C1Z.N8#")XL6NS$(Q &>R;,:$[S]D*/U'RRSSYEJ:HG:
M$@'R95*)_G(#L2;D94N8MGD&"H^NER%OX964=9X\J7$30X@:>O,V&16L'RF@
MO*CMCH^&Q,E4:4_V9K,PPSPG*(SI\QX[ER[@WA#J=]F[$F!,1)2,<4@-L^'1
M '.RYP<&+.HM@YF:J0$L,/_*I=VG8FM-RW8BX-I?UE%E;D31>GEB0CMC<9?\
M3%@0N@0A4!V("_1#C#+^0ZJ>65!M3<Z%UH1B""?=2'AQ!#Q&]>[!P964%9=>
MXS%3JS8=/O+Y?:#4+.^CA17I=CSRJ0%BA2L[L_#KYTULI[NK?T@?OBCX[:'2
MFW\P84M<9Z1CTXJU.%(H6(:6M5 RK!%)@*D*ZEU,:X9](1RVFFW)/O^0Z M!
M^_B[O:9J@4H?ZZB4<'+?V@&6"5/MJJZ1PIJ%G&2 NU!?W0S*GC%.4B<S#8>F
M4R/!>$&<[%Q%1H/3J>5;R[PC=0E#W4B<>SR(WQ58YOQFU0 1*]H8M8Y0&J+(
M&/0V4*MT7\&UX(L VQ(L+CNISTB@]-&K&ODR^!ACP$,\U_*R.?&8BI1U5O44
MLVY(9DV=ZW/0!D,HPMS)CTL36X6<-'?;,_U?IOA3+/4GZX)EZHR]A725A\I6
M^3AXCZQY#QOE$U.8JR^V9M7W.RAV.Q8>D/,LVDG.2V<_6^L:][L/7^N?TQW-
ME:;]D P Y"[,"MFL-B/EBZZU 7:;%\\I.'Y 5T 2$ED!,8B"V%/V?0*%.J7-
MN)$V$BO!BKR%1+$ERKYABSS>7C>'Q\<YSL3::E+IJ?@DQMJ-6P +WBK?2]SR
MBSBWXXFP[S\D_% W-+NLK;*Z[-:E.7OKYIEVR^B*1\0,?Y)6)N6V-6U?JJM&
M:MZX,BT-Q,>(U6Q_9;XOVI"=,NMC+;7!']%U:/=6U"\@^\SNC M$V#+!2@]+
M)2]AY$H\$2C7JH?&NMOHF+)H_C66Q-#1]&_&%LH"LO^=02I9TP 7N<NO-K!4
MN@.;@,!Y1 9@'H5W0E??1VFBU]SI12NQM7)QI5%79A=&(NZUMV!2P!:E_)/:
M>%92\2;%V)@P&US,ZHZDHI"YY)!,\Z99 38=Z5<U56FS[#2?Z\.Z>E= 2)NX
MO*A.4)FE[V2*OT^_1FU=)AIY<<,#7#IA, _W.=C]- CYC9:L,[2X6K-S[7Q>
M 8WZ E<E6I[&G?Q5\6Z>"IQ1WBG#J8@.A'F2*D^-"UHR_\WYIG-#D96/B/N]
MM"+>/&I'EC6<#IZ.+6'S!U]M&<:-GXF<5C<K;YJ8ZGLF/JMSD::G3TVT$+W9
MUWF+?!?Z5=\;3<M73)@\ZM>5>XY()>SV^I./V3PO51)5?80+RT^=V<'C?CFC
MU>TBN^*+=+X3NU( 0Z"]DJ_=8.HNZFH&>=NN6+%>G/MF8YC)"5OR&./WR#K#
MXQAV..1JXT%0AM+YC(_3R44*]VRG_3/4*@@?V[9^5B!^SK=LFV'OL.1JG8(J
M\4]LF&ADE,F+)=@TA2S,2+O6?7@ZGW\==2;;Y;0^H@ZVRES?N\A_GXX^R2 =
MO)G"4QT<Y)W]@)/,HA^G :^F3A;EE/JMYG70Z4.U*D-0.P66TL4/03'4G+RI
M6=84(SA5'JP"ETR&BJ!&?#=JW460TMMPOTV"WN&8[W(%?C-;1_)VSO)I-H4T
M#97F3@##/RZ-Z QJO*'P2^G2_NCJ[9XMD/CNX46'0XH9FKVZ/&R**G6;E9LD
M2L85K5))Z6$8!XF=5 DI( /UFXU_X/O0/&[Q?4V%CPD+NHP=AH24 V ,"YI\
MH76)QS;27 6^.V V&UV6"*&&6PA]QG2X@.29O\ -1UCW2(+Z,C&>YN1ORD_H
M53VL0L!D8EA"$[W&_@T:*7?N*P8!@4R-)7>5-*7P],4$*]U/6#ZLV0-+"M+Z
MZ99LJ>[ ($3>+O.DL%:&^ARVQQIF\OQ>>M($:#(<+="9)2\!Y/WI1&@W#!LT
MSZ]FW%=%FVB!X\&WT1:^'O"Z8Z6;6@+K(<Z;4$BA:Z&,VN G48V?+'+A6I!0
M\"]D5>LPMR:%^5WP6\O?FG/MC(+/MF**Q-9&C*F=1+_Q:"^-#QE'_O)?P+)U
MY29-W0KA+9?.)FY-.=<CR<!E7C<#"U>YA9*MRVZE>5-&5[NOF3[XIJ"*IMYU
M?L*(9V'JAK!537K3JSVD.M-X*4KO>&^QN* FP3"8X^($XFQ(VX#EYQ\]'#W]
M.62K!+QG3GX-))(R,:_:?_WIF(!?=1K&+'WED-=F^/KKKH&II#(E4RJ)'% Y
MZEBF]+W9D@^)2#TOMF.JNZ[XC&:&@I\8B+><D45+RJVVETVD/J2?;-52W#&3
M;185=^HL8SWH#I46JR^#YZ1X;)3XK G8C/'8P<2'NXR(2=VV\J_LPBD+57^!
M^;:44R<1*\-N5W&=N3@?3(7:VCJ%'3\$:$\L9./["$TJJ-S2XK+ S]%@E_F3
M!).-;WFESZ"2[5\F"Q:WY>)502D%<FRF1LXG=)DX[<[F]:4;*A^!,SP[+<3Q
M+H,J!GN$4%)BC?9UGR$(1G9Z("4^,AY_S'^<$SJ<X\[>@U-6.>#!WLI_VD!B
MH_CH8:%E\^02(]Z9&\)WM3^AHMZ5)[@>'PCCWLI>RUF7#+*[*G0>=M[M4@,X
M9Y%F#,0\+524"+FH_$-J 9WOX'.40NX_,4%'S%62<#=8\ ROK/L<M%0%XA[;
M 0!O/HB#&.80?:RUOH\X@PU-]JXO<-9L<03M.&DW'8]YM8%WA73IS$2??*&/
M4C3/)G_DAR<\CG1%1-'NG;ZUNI9%GA[/M*.I?A).=Z*\C8J?*$5HR94&N\$I
M2_L<USM?0&YRO<V=.FZL-!<HL^(]JF#7DH#$>QWB371(ME ,LZ%?_W7(F?6\
MK[(9@T?38Z='VT,HUWR7(%9;R[5&P\Z;Y43!IL:UCM:U)GX:6V^8KQNUAIEQ
M;R97<%O@ E7] >XR9C\7H6-$/NIJ<'MZ ?2*TU:-.=E%'P92L1J(=G?XE8(Z
MQ<T V-_9I(@;VFT^OI3..+M4=( ?K448>.RDG?G6+:KO)<#WEV(2[ZV-SWR8
MNU4#!X.9U\PIE@JU?(_&$B);YN7\$U<=VR$KJ.>"CA47U'?UP#U"1'6'SW7]
M7UBS*)U]I>WGVWOA(<G8Q2GO],.1<9_X2DK8^2VP5<!E.UN%7</:[$Q7 :&@
M8=C&8I+,5_*+H#JCK,X5N+I<U$#\TGMNHB&C1LL>3<4GHP9>DL]\8S7DA,1:
M+(COF1]L*+4L52+@P@ZA;V+[(LME4SC*Q5J<T$(]:BOE6<K5BT6XN!HW'K?K
M%!-LK.#-"_A/J#^'NDVFV<VX?4L*@+%S;?<([\R@"HOE]](Y=V<SYOJV)&S4
MKQRT\I)T?^/3?B(A]O:P4BM.%:5 =]'H(M?)$VT \\^OM"+C>M-L#;V3B[9R
M5$OW.9AY&C.*LY+VKL[P+./E&[4>?BL6[CH9U\L_NH>Z+#NB0J@;63')#=%?
MDLG0V.)2MU^/5]-_6QRKW/&6*:P-(#6'K:9AY*95R('%$P@7;1XYKFZHJUXK
M'W'T$."B7]#G^C'D',OD=AO<'EK%RI ;I*_&%R?9U3^T;W5U:/,R :OO'/'0
M+28'OD)0;AR3XZG(9>;EZ\[]4?S]"QY+F,+R\[,F6_5VUUB8YFS"4S8 K:@D
M-8Y6QN6ER$JF=VV/6RV@@T0&N5A^T+VB2AK"OIWD.?<#M,P9U;:ZMBH9;!B5
M@KF(;^'"7"-1C$0#JEE.7&I4>L4-,MT1DOGV<GE%U[!VU/FZ6Z;><7FU,5 K
MF7/ ^VG@\*NAH >I_VNYD6Z75E,.$5;S"8*^HE/7(0RG(8E(&W8@K)5DW$68
M7-M-M"?TK,"Y:3WC?AE<4TIMH+-Q5Y7SY%<TY7*-QN>Z<#>&C2E FDC]*=\<
M^RO9ZBTE6Q4>F:NF&E5)0POH3DNERUP*_A=K8YY_5\;36V!%G$'99B\<A*'(
M0.7G>ZZQ'CZJ90(40%7)LOQ9(.R;T",#(+0*M1#%%D1Y8.M/1M#V !SK8&+6
M*OBV<:<-1)13O9X&M2&39P&4^%]8'4!!^@E0B9/2Y8S*N02K.9=0)-+21$8V
MP:ML"W\QJ2N12B'8LX)KZG!\B1S">B\=+0MDM3H*FD_W-EXJ4RV+QN7S]^I[
M#R<M)QSB7_N;4KFPI+&HD,1U;87L1"/?G<)B:6'Q ?LU!P^GNI*>[=DFDX3(
M_SW%T%,*[<(^)]U"P*F>AXG@>\Y'34ZFU_*Y7.K000:H=T<Q$[H[>'L%V.H?
MJX(]M2A:IG?!]XG(8Z]RAF?<I:,+6_G>(,'H[RU01*"^L6E35S"OFM0[]2>N
M(,U\ZW+ZV&E]8+\NBX']PE+OL-(=Y'F@X&";U$1<A5E5E"K4<EU[M&DF^;CF
MM(BD_1(]>29("[0_JS VN\9]D0#+(%ZAR-F+-@'3K+#%LW$:DBZA0[]N!>80
MBU72$$A3?;Y2]@7TK0^3]9TT.09T5E(*(SU$D%Q*IR0#NY>%#JM".*'4<_!P
MQ<6] Z7A>Y/S5U%P%]%J<XC'^H>L;;Y+Q5GE''*+M+9ZH5UKS$5YFB/<3-@U
MI(&TVWB#-0I;[5OV;K/[>[**.+>:7Y9_2%Q$H+NWWWF"[TB1*,E4<VB84^.V
M[=\1UDVZ97)BK.R=.:+[9=:,#76,#K(=R7/Q+YWL"-A%V.RT(\;@ ("I[4;M
MQ GG[@2MK"5=;6?-YZO!HU]SWW!"B\38NR%;&DC3?#"Y W71TAA?U'Y:F_FK
MB[6AOMKT9:N!TUR=_+RSW+:O;KM#Z/4J6CI_STT,&BAWAC8ZHIXV)EHF#OK
MN 5$I^2C-92A%-9OB Y!G(*PNVOMW[MMD8G6;A#/S<4A@=_.&Q&["WR)8CM"
M9_ZL#1H'.6^7',[<T2@X:?X $LI^<LG[LYVM,3)ZUSC.PN'---*1I) L-@_^
M+.N1BDOU >78_05!APY7CR^L)_&4GI]#=8U.B0@*\?VKIIE/:$C^(>&L7;53
MY)2Y$[[O]=J%T3\LC'?O^Y*]X]4ES6^E!_43,MQ8-=9%HM+6"XWC%?'4-G2N
M5F$=(=&TAPV'4]5@_D/J+\2D*"W[AU3[,*;[Z-6I<4NQKC^ZJ/[[28S"1Q%8
MKV;(NSF76&9/MZY@!W6C#.Z):"+V#TP/1TFV]O68QM5*B(>E+<[0[O[UUN/^
M!JKUA=<;0A.K5F3=T$FD=%=.F,',IS27QX"K/%_!<?D&R?'/S)#=A7#VA"K0
MUV@Y@@W_6_:4T#I)B%VAZUW0L^SASTBTPU$T=4FC"EJ*%=#K!9V$7Z_5J.?R
MFVJ.XY$:\IR2EIC9'O8.5@#K42W#ADD*+M5I\ZRK&B<&(\\V&A!- 2<BTAN/
M\" N+B^=4,S>,+ABT]EKH?VK$<J,MXKTC!;X>4UU12W2:.Z:+*8_M9P3ARKC
MKHNDCOQ@N8-FHZ85?\+ XX6WDB6N"4JDHP!,CY!N(CFBE DV9^DN)Y5]7H,>
M5XJA#$T8O9.F_D)'36.*@J>BH1%B;^ /W71J75\K8G]C5Z50A<=4'Y%S51(T
M8=U4B/&^-FV>) 2JA1NLO73O93YTFN6]+]KF Q5*L1\5TYE8<YHL!]J-(,>V
MT4VG-VO/$Z0>O;R'A' "K_3.6#-/Q6CP=S[(XN)__BAU\ABU_)7.>$S8RP3Y
M1\2/0;0/0#1Y!5X\/%5%YL+/\2Y\5C/.7E\'TINO5NWBJX@*U4ZR4 7NNVI^
M7!E2-.X2Y8IQ"M?V<T \M)C&DI5%M.5U[ZZR='T7[WF'6:@\F.Y6APJ<JGAP
M:B*-5MBPA;F\4B8; JA5(D#MIJH&/D_(9:6M%]Y14K$\7CY-];N/:W^!$W*@
M@6P/HX1G2X?!J"FC[+&[H5"T.[![8=_45?OOH'CH[[RVGIK;.L/P-I5FM=H8
MCN8UIM/1?<I8F-$)]*MUCT2_:[/+)I'H]\/%JV,[CX\#&I5J<<^O#7U[A@MT
M3"]H4$"O8%7'Q0HA!S_;TH.MBW# A2?C1QOA%>4EU^UI6=!9Q"9O(Y&V+UBY
M3Z4O!^*_QO.5CG+=FHB0!+B>=RLL3/87IN41LS!3@9N/PYV ,'EQ&(;D@3J7
M*5+3=JDME&8/$:!MJTSC3(H^^-C./Z0K$Y_L?6/Z>1_C=""7L3K4K6)-:-V^
M%KJ3*ED'E^TVK6NP;<IC_)CIGV+ST$;[,,2D*[FLLQA$15<N++S"F5F%2^ZN
M]4T>9Z:4_KC$?<46$;_V!&&-#:S# %.@91NYQ:+:CU4?;2)7+:22=]7X5F&P
MQ0WQ:'PY>8#L9XU9<#E]MI2ILZK"9"NSX$7Y/%EOS:VS(; UU,%'WEUL%G8[
M7->DJ[';X4\_)**M\]*4+P;?I6"QRE)3LO0D_$$DCA4[HZ3$-\7ET.M$O30Y
M\*$WS['<TQ[$=A[""IUT>+H<$/0&EKL#*&3U6-[HI!B[IQ !I^SW=_F:INSW
MQ.,U3*U36?\(ZF,9CB<^,\"[+;.*-#DI&-5L,!55Z2J6*KI4< 7=R6&:"!51
MT*)2$XEY\BOM=U\)G(-:I%:?",MJ3!=YPC<H[DAY,[CG:/*E*C%'/416/M:R
M?MZK-_Y8\;5PH1+V)7(ZTX*S"N3[G.9:5N[C,_9\QC))EQ\0(R^E^WQT EFT
MV+.@MOW!/*I; QN>9?*%9+DWV5( (P?Y2R] 0+6'**VK@(>DA@B()!3VOCW
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M8CYR4@V%BH*"N;""F*X_]HPY?XE!KS896=K/#(LY%R+KFWC[M!FL3]&?X&Z
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M CO8="3V073R4XBI8*DA^B3+=-8,&AV4[YM>PZ[]+/]PO)O+).J@@/TI'X:
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M1C':736!U@+ (  B4=LG\LBJ0&DH.0R.X8KIG10RN<[''H$Z) \2M)7G"2
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M\-G-M!Z-R#(N?9AHE1Q>7 9U<(VZHU\$Q&']?]3_#WU!_2]]M06%\>,9!=E
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MAOI? '^Y3D#_PXN0)JD=_X=!X%\ 4/,O +B'8_'Y#T#YOP!"_TK?G>ZL_;>
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MOL_/L;U!?!\=DBR(K2MDH?*):<H1\75GQJ;Z!7^/%I618'=(\ ^QO2KOF3&
M56.\%$(&A!VAO-$V@(*6BJ>R>$#-.20WJOH1@^J',S).U3'6^*LF'G&T '5'
MT5I4K']<0:"R@*?H\V$'RJ#@LMQ+KKDT (>?7R_"$0TXB$^KZ3O*YAL\)]YN
M**K*)RNLU+B.9E\WF)J84S'CNEX*I1$O2ZX:C&P5I:;H7&'J;K-_)7C?]<)-
M!QO!>EE$C,],:/SEM 1_*!E++M/:D;?H\F]L4/"B#C+AQ>E[*%1KO?")HC'/
M':JGPD*LZB@A95(2<=&%6[WD+L3'XA ==@M)G_NQ?E99WC<EN^+%>5&_@%.^
MM%8-47T[C8\>]D*5VF(%=SX>"74*C>##[T^ZY5.$^&,9O8R$1#U/;V0K41[P
M4HF1,(UV>X,NL!=T<EA9>E&5Q[S:)SBH+V@C*2W+R\'3/L97V.U</KF^_,XO
MH&WRV"XIP[<-!P5 XK( AY_G[N#\PW,[U4S+D ?P!+> !S@&X731MT=T#E)3
MV<U>;N$/-[?2:;['K(+Z1&"MQB>KTSGD:9AU32K7A;?+^87 ;>_WC3,2HAI(
M6K/3),$,31K:PY9T!?"C6F[2;(&47'0EU?N;7EET\W5M_.-/_$8^SWAR.W,%
M$OO?A5/X?,^BJBK=6.8K7*@"=T=L>>,D#00SX^K?ZMV&VKV7C$LLC)87.36X
MM&$/89G9M2M"JQ]9P53]ZT*5Q3F'B#8MX<8W>H)O9JW?WI(.(V[:C2.T*QF,
MV]GEJ="T@@O->T$/XDMCI+53R$!5AR_K,I OGCH7QQ$R-[07:)M=?NH4?ULR
M""4Z</"4N:N"E$2#&>IY6V_<VCFD=%,T0;-PGF(0XBEBM-R7G8ABB&$=G\NX
MZ:2;H69!75S1I&P@BK"=?X?-/"8\XJ8U8JYATC/DRL)SG(059VSV;''<LP#(
M?K6%-*?#E:_EYJ(D@Y0N-TD0IQ/P.O5N.E[YM3,-%K'R(,Z?P?'6:3N+"F_1
M"Z2!@A)=3!>:PI!5]J-M/T&H&:,=#=KLX9Z&L,(>>+&^%:*V:JT?;E"LX%=[
M<R3HH(%>NB'F9D"9B]$\SRZ?+">N>S>[5EOH*O'6)0M&^6%6?E.OQ=K^I/$P
MT#C*=MW]JKOR9OP$0CB 8^@7\$YO>93J#B4[U_B\(6."=E)(GGF-L3;VC?K6
MAE TA<12=@<7L-E3:#B%\*:[3WR:[4#5'J^'62VQNNR6S9V30V0Y@WK_&=TJ
M(CS)V-N];0'.C+=4$@VM>Q7P$EI%(YXT%B=QS'%Q6TIEK)@&%/B(-'T,KV?V
ML?L%2((O)XTX;.8[69<J):H$;UV:>X:GC]X$5>A]OHT]VR%"<\&]QG:(MGZ4
M1UJ0BC';(;0BUX+N$,0<X8RV%Q>C4QJ0\SW\!;QYB'+3\M<-.%]X,;J32,H7
MN_ .<CTY!8Y\J,N=#!- 0-[&X;*Y6D+>7\J-;2MK(60;:/7;W+?B37KTY9,9
M]KCBDN'%--I\P>%0!PQO@[&"7!)8Q:-KI?34UM ^AV9Q0X!WNRY69&?T(EGC
MM *RWE9;?@C)[-U81GE'B!9V5*IHB?7=M.5*W34$S\FI?"XU0^FUD-W&7MYZ
M'8N/H2=%/W)MTV49";'69P-/:M-$>VV<):3?WH1:T$9'V"??(]:A>K&E3/J
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M89^5#*2VVO4B-66QJ,9[!7V)S^ VEPF'/=HZQ*Y=3)-UIJ!!209/P3D=PM6
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MRO**!UFR>DJ/;N[OVJQN 88CR\75M=[<DZ[Y'7.[3S]T4WD/,7C\1XR]WOG
M1).9*,N4XOJ0,2 _24BXG/)LUYB@D#'^J[_I4ZI8'4E='K^R17ZR<_*3R;[H
M7/'_HC!KVL4HM<9EH-@LD@=9"N$@^=\=)*1W+)Q$OXG7T=K?MC<:\>A;?XWV
M+.#H9?8ZSWYT.2LG R?=6[DL6ZY+AL/L&<LH*[F<*%,<6F"77-_FD!;T\>Z3
MAB'(I>3PG2IVRMCO $*:[HXEQ O+24M8[2T@I9UXH EBO&"/ZYTG:H(E;![=
MF+. '4N[84IGTO,(')*39BJLVB#'82L%'K7),"GFF-R)>SN]ULS<N77"TN/A
MZ/$,H0OI_(>(9&=\4KAEQ'[KA@+/DY%*4[DZ ,!#UD+$93OR-,B7AUE\)Y'"
M[W^!A5B/-O=>3;V\@51]UPN;4H-Y<W2)_COO1?CH-W^N][@G'['533H_(I)=
M-UPX,D&R=*R^6)Z\MLOVH1L'VA-6G1-R!=6<1'P&)NZ054^\/TQ_$"YVGJI\
MF.0NK1F7$)T014,WRI,(BCY7AG/U5-%!I"H"(L'6"YYU7NG02PH5;BL>'=[)
MLW>_HOHJR&AS<"XF(B;>[^,CGTRBK@-]$3;*SR![17@H,@QW6#HCO[P(^\$/
M<X02<K*T&7C5)(?H+6[9V!D08L9XB_'$_V]B?=-T*3IR?N[[.8H>5C=K.^%V
MEQVD;/%D6X_S,Q&9SJ]Q[ D];=)R_1R?^8G')YNLY*?Y/H[<E%_S> Y!%:(-
MDCPI7.NN#=8C<H622D<K%'4O](HF*7A[P@+\/_:=;8(*IO=2Y.=VR;Q:E=L;
M^[/Z$RAY(L"0G=S>.,L<N7R>1+EHV9A,_6/!Q7PRA83J"YMSS/?]<RRE4[](
MC4[&P5_Y#O#:JD;KM,3J6*30J52P (@\+HPS.EBWJY,[=<5EK.^&HR2HH$<L
M-^.YQM%XL7NX,&MMF5SR/.]X<"C9!^.B=VL87A AT'/FWXN/4GA,]-\E.I8D
M1]=+)SU2ZDFV-S)8V;<@A$)-"SMO<)T0_%,%R'@PP11)>H)X8=^3A0"+:ZNP
ML+@Q^=FC-,4FM+5G#Q)Z5RWM;6'&4@T*NJ56IQSGCB.GI*PQ:$/K0Y[=:7R7
M<AWM0P8KA\R+8EOU*1=HA[C@[/\G@A.?I2]<$\->-JT/.W'<E!J"YYT]_[2P
MBI,]G77[Y.N8!1'3J\6UR110>A^(OOABDM7.*ZXOZ6"NV189V5*(L?-'34=S
M^5%8CV6-&6SR89"SN?UQ'4J[D'SY^%DL"M@CK#3>K3_@,&R8%X5$J*U]3?WG
M=)7S7ECDP5[!,=.>?]\4.@_DR4ZM%OW[_LFFEGL7*TZFD#S01RW9)&5;KJ3G
M"4P239MN+8KUN9SV+G6G!)(U4^AT4W^Z&87VZ2#E^=ZT%ZCF2'[>T[_5)5AW
M ?7<?['>O'/>)\!KJ'MZT7&CEE=F\U)NNM$@7%_N+"2D=<>+8,\W5<G9<X-J
M&G;U4[=^\N-%B=1YYNQU(7NL6_:QIXCTS@U/T,>@U&4$BJQJFP+Y9VD]ER-C
M#>3O3V^:*@2$2HBF#H"3);O<)&7;U2VE\/.D>8&3?X(:LT5Z-?ZCIR;%H,PD
M%87K=UY)]@7MH4&]+6_8JFW-K1K,!ZYI=@VX@EU_P-/2AC@O+YM\(O9]^,9/
M!SV.*0H\C3=O 10'N;W"MX !/<A&<L-B(S+-61K1CUD].ZK@DZ'$ZR[.J_/M
MDR:)5JO8L^PF(U.XM+RW$EUY5U]^6KH(!9P.]CZ,/]FC0+O!GW>J^L',?K67
M.'@]S0/F\N]>L#C*X:8S=*K&J./M:6Z95/S[''L(WKRV_W3C>^KO"Z)8MEFM
M.AH)<FWJE9^N*!7,L4!Y>^&<ED*Q_<2_'\972>?5D@:IH*#7 :>]\O'8JCX+
MR]-+\]=>,VZ\R#ER\^6]J2ZQ\CB*W^.5D55>& >+H7:13VX(U)Q1]%7-$<%U
MIZZ9(L>&I$-?QIY*SVH9)?!DS5CR*'&HAWC!)=)B(,V%_7V>35_&70<V?R>=
M&#1VO3+>4;^0NGSDHH*<H.]\BN^UX!$[#RQ]O+:7!,K/(!/9G&W@*;C:%1$Q
M](DXAFN[-TP?2V[8LUT;=-'P\#%=!:N]')LJ#6N"\GF/[."1:C$2E@J%T2P(
M]H^"8/9OD]X,7P!Q+G@[RZ#U'K;4"5\D( H5:8QZ.?]R+<SZ%"5[IQ(3C6[]
M1+X+Y'#^^TA$-N#2SVP;8KI<3)]O@;(D>Q)T^SG NEK$F4-Y9BO("_?M&;QA
M.\4ZPQ=G8QLE6T=V1%L&TF+5.O ;IL_->5?#78)V0ET];9I#,F$J?=,4\4+J
ML'U[[6+7E'49?.E0TJBI0WGCQG'F/:W3XOQ9$,)%M.X3V)8"4>6E<.S?_=,P
MY=8M27+5]Y&?/ (N%@%_XX9D>B"(";WL;;YIU05M(.K<W%/(_FB1PL%+@/Z3
MC] %JZ'1#%QB<M#!'ZUF]8;UW7' (-GL1C#MJ$]"("N^OM#Y,0ITH^R2?F!2
MDOZ!<U1H9FR"E^2'E:4!\^YK;-@^A5Y=8TO36-E:WG*?2. 1N(<W%(); Y9C
M<BN"0C?WNGB:C[3^U?VRR5RWDG2ZPJ)</>-,ZAS,?WOX:24W ;37GTIAFM:5
M1N5XOIC5HGYU/LP2= Q7H<=,$9+9[--.G@V=TWH^1*E["U!O.4LU4-DA!_D+
M?STGF*T]C['.N0@EWA&VU%LSK.7GLYK> CJ6KX>0$U)YKRL=[2Y&WA!=Y*3[
M,_]",^:)%GWY6E*79:*.O/#J>1#*I6_"GT/R0$A@VXOT1VL?6,_-(_Y$Y^EO
M_&2[^D;ERX^%Z[:N>1_L7U*$8KC)"?KW:QZ]GZJK'!'.[U*=.A=?#0A@IZ/-
M#,B]ICV_%#U93,QEU6J,J?Y9EW4PL[ZV7.S$/F1:8@V;\[C"Y.S5@';> J3F
M%D0VQY]H406<%1>X.ZFRFR0'C+2,^(;9A"Y.;B$.S]F%ZLTAC:D-87S=H^R9
M';,@A[^."70K+_C)T/:D/DB??L+-8/ LPB?HC8XX?H!%%"EU0 "//20M59D\
MX6AG'<9K=2$]OK)1=\YG/8>@_TES+6$%71I%PCK#S>?9"H/61=5QMHW2@TKY
ME:::*6Z>&A>89NFF DU[\^3&&.+RP(\3D :J7V@]_>%]@/!!/<B1\(\3^ 0H
ME8[.W2VB<('#"@768G5Z_$('KZJ,-7$<4NH@A"_L8A#!FO I7\4;I\LC[J@$
M)GZKT7*3@O7LCIXVC2'IS_E>, 9WZ_PMS<,D$X4 GY3:EVU-&FQFM>X)T+I&
M$/DUS<_.H+)5E9U:MK49,EY>(V[O_ L=4S!)45?!U%^7;M*>H](RL'FAU\3C
M:GNQ@=Q>EH!0^FTC627V">,@L9K0H5(=X9;#JA;8(HOG#M@GBKR20(0>W3XB
M-#TQ\CA-NM0'_V5^?I-,WV4Q]$ !HD;J83UG,TF $U&ZZ'Y5R+]))LGJP,^O
M\3EMN.=B%]B]R<M+]^3['],/(MIV="4.]D;TO*N]K&RQ1UKYXJ-PM?G #@'L
MS+BR#J',N-KD\LUS)V$)MD,FYZ_)H(IU=7QV&!*,)9Z@^&^.3H/ZC+PEWRWK
M"&X!;10R:HVSM>H.9G7GFAP:\R),7D<_:^CBK)F[AJ+8UJ:;__U^!3D-1+(M
M['A<FLM]"Q R#@C%$KO6YHM?QC;2?@YV9&^E;<[ABU\Q+DY@UR$?.10K;?(V
M=CQTF/ @A#JI3RQOQ&7G[&GUQQ19UX$8?PXM")T(/@G:6;"-\1(.@WSNJW*?
MWL2NV.!I(*LD^]=;VS<X;7MDU\3C@R)&94[*--?:SSW%.C +Q9)#>F&7US/>
M..I<^OFNYA,KMF[VE7RS35T[POP90CH+-\6D5,UHU#N^O=8??<>9&H/57HSG
M&%?%E:X-+%3&%BU(GZCT7IH9P;P8ZU09E7C '8U:ZL%-6K/>;G]99BO)'*YM
M66OYE@CIF^R3V=%^'C]Q$1]%*NMPB3-\,WET)B20-ISR=C>-;;C<&=XH^+)E
M:/MER6:+NH<&C0Q(#GFV6=BKI8L DQI/1Y@_.2+P^&I1H']#>FX\M>+GF4,3
M7\(NH>HRC(%C/B:*/0$F:!JZ],?P0[_CL-SSB%'AS.^Z)4],' )$U /IGH.E
M BS26\B26D_B9+:\Y.J/T&8C<F-*;-Z4PD]/R5++MH0DGM=DO3Q-L9NYI#[,
M684Z6'L'JYQ;-UVCE>G,W,@+;RQMV2O/SM2'ZGVVJ#>R'L['-JUAHC(6' 4F
MQOT5,S_2>HO;YD(:I-S,!U=)1#V /:+]6E;)(L-(RCUJ"S7#9\(XX1+_Y&L(
M._,I\YL+SJ6Z6X#6>7U+=X?J@'R5>VGAWD:8[H-\]F_GCI,9=BYS95',=9I'
M).A2T_6Z?TR@M'W09[JP+N)G-C==[93$P568BH_]&HJ5NSTBUH&H6V8L4EE7
MD,ZV<<#Q)T'F)Z7#OD]U]7*'#M-BKQ^-+V2WSY7,+CU[@NZY;;OE)K9&F* \
M'1/$7C%6W:W\5VV\:*9_MS09=!,/4^\J@3"_S?#)H4$8PC/?'J'CX ,A\I@Q
M0O>+J<NX"N.9 <'-UK(C^B)*0M2K<L4[-W2 GY82TL;6$B9%/;']15(E$.7+
M1S)_(?1=VT!^93'*Y\/V(*0 ]$D&).O(?E?SCNQM.PBG91U"?F4K/C9 1&4+
M!T^).0*FVR +<CYA_0Q$\5I?0I*4%#HR[H\!!UA+MR?"Y5C+P&5_5*-+P837
MNS&Y+S]J58,4MG]55SM8Z9=ZRU L=9_B$^%/CB(JN(B$1&$OJI#*ZW;VJ);:
M-/D>-5#;"'P#/%&R6IX5?U&5\X))0B>[AH2L0.HOU13;(A*'YD,W[9/,84HA
M(D8^_1TX6SBXLE*(1MF>5B@6OTSZ.P]TG+_SP#_[4.;&?7[CM*5_*\@(@+1A
M92:MC"9OU HVN9CEF  ^CKWXHYL+,P<DTIL:<A+;:./I+16*A6",#$@ABRH@
MD(XV(P"! S8"EL#*$XLH(E*%L2Z<RI?Z^CYS'D,F0L9+;(![JN.DT9GXR1T?
M+7K4JJ!/EF5,-L/_4$7H0F-LKFR+0AW6V9<MB7/"C@!VQ5BX^(2]O0L'ERI)
M_"Z"B_C8.YMW)R T1^[3RI';4</5C^'4D\-N )(<MSGM\\^9[.]F6&<&UG'T
MOO2,3M[[?6\"0'.E+])BYNFWX>[3+@B*RXHIL3-C&W_ZA;@V'X*:LC)BXOB(
MFB<V^N3('Q0RT,/G059ZLC=$6@7>7 (\(")NB@2_'HXO8R80DX/BZ'_>PJG@
MJLG[ PM![K5@+T; R6G-SM4%%4W7G:^!=#3M\1G&GZ0"[/,#Z4?IGHOS7.*0
M(F)(^-E3<85>W;Y[U5:^4+S/!@ \QR'N\AP.$AYY)RM'D"P'P=']\D-Y&H/F
MMW9+<_4+G ARYS/RXEWOUN=B\1EWQTY[^]T3;9H.U!4CA;%VL$,HW?.T_ #^
MN !PCR;__-<3A0] 5M Z8G^U&7?.B&A\I2W^D_8?2I]7<9S%=N1LHZV?_;E2
M'M^DMZ4]OZ:8F"]-&'%RR)"5NB,CXHA!$!V1A"AL(P0[Z>[:<?R*7;]N\<<E
M^^JN2O<P;1#O\C  @&9DK&VOXZ-NTO&9O8&O-)O?TND-@_IL0.C)']*HY/=>
M[?WLVFY^LG:RH].W;:"";70'#U<'#D)U(!T'#>*)3_'=?8+;RGPJQ=>LIS&U
M:=97[PK6X*&-@ <31Y-5!]NH#ZSPYMM4A?%6B'F3U8,SG/)H\)_LKE$D@Q8S
M4ZP73@IMUWTX0_GBPPI!LE(A[*\1J?AE@PN1"I^<4GF)5EB#VIX/@>FURM$M
M@'?WY1IB^V.IS\RZK.X],<D#6I5F[&H9[YDXC$W99X75?[<99#1K(92/S7(7
MQB%U9&Z/;03N(]B#H"$"]G@([I]0<*GD%OU-4_C("D[[2G8(<J^PRAI:6'X5
MI$N38U&';BJC:;U.1XQ%7TQ*7=>?"Q9_^:A/PX:_Y,4M@,3I(I0">JSP-8 =
M2ZP#A^CDKB/G/!=+#.%<;Z8PZWDIMVLX?4S>Y&G>JF5M.O++,XMJ7:>MVG0U
M_Z*L/J"Z:J=9$3Q6\/>-!0F*TT<><!HF[.DVKGXCITX/=?$2%/83NR,-=<!%
M_$2] ]R)@@ 4[GXY _^9 M@583Y6:/#.5>MI_[6?&X6672X#%E#:FB<5.U<4
M$+PG-6/U5U_GN@647'8QUU/,$-:\GS>Q;0<?;=I>U1?8_G1@$-(]:?2>C<(?
MW&JK3"G168R9Y#4'7VTUS[=MO/S8#_N=,5P3BX=6"@2R<B./7L_$A+&7':<D
M9O_5TZ4G6?(VFW*5!*"-L-BD\8.2EH8>%9%QNO&&.I Y+_PEU)"77*N29.C9
ME.U0K+P.ZN]=R#@S]4JQ<2[RXD6]B%9N&1*;72W\[X]Q<1.AU;67+1&QN6DR
M+B;+( 1O'?*Q/__. S<]+1NH,-':DF,Z)H![QLK D.'=KPEGTM61%JBMC%A3
MKZ$,XX-&W76V?.)C%;G\%ZM'2R;&U>OO2I-?\/Z<P"E=^@4ZH_,1S\MTK4AF
M2\THO;3LT[\<N%I*RUR5Q; @*7/<AS$,*;<)'#N+92;A*H4>)N=S\ \?*<BK
MX'YD)+FR1IK\_34(/DTG4I.E:3&[H39'"G.M)ES_[:_Q7Y_:71T03,</&(B\
M@4*?3N.8#VJ0).K3@7@_01F",2J3D[B?S#H__)LN<K,<D^QGX W$42%77-%D
M;KQE_SL-&TB0HXBN + $O0"&CV-?XU9";O:.B^[:C_F/[2L!EF3!_!AFJXQ)
MI$;&KK\W2"=F1D8;01!=D(BJNHDRKI _L/H/P&@V*QX& AEFK_X%.> !UWAP
M=$9L<,=[B^9"WF0YDZE>[=T Q,1$%'T"*6(^T$EQ#L?C5_MG"2*$[7,#P'WN
M P]'[T8><W![GJ3W#H,U<0AH6/FJ?J#ET)LQ6")(0BHM@.U<-$N=WO6DW\7G
MTRL^5:!)L[P#\;9*G_O"D:C<+8!+=@HB%YI!9+)1-QT5*U&?D)<7A_11_M=E
M_O']SO(%,-4@6).3/!N*XRHV:9AF:1.'??>5"I%B6\Y5PN;RR+"S?>_[\$':
M% H.]C:.+L[TD:/$G"F"'X/&61+!9$OL[%TJX*[[Z/6TTEL.A(3P7\S]U69?
MW;59W XC<H[&%3OWE,CL"E,3A,=9 O<M#FHEP,DW[#U3'W5"2W$S$^AFB+O-
M.:K-J.:YNN>054*^T YD/8PA[)_C%$,?I6;FE).O^86KD[$6J_;]HIX@#&-?
MMK41V2GH<F*A;7V7QUTT2$A#4=PDPH!_R*>)PDD262WUH!R2Z2!:?ORQ4K[X
M[X#_EGN*G3R!5AS7MGS_P^3_%^'S,U?)?X4 E*R4SN\A,4>$"K?%FM)8F[,?
M@'2(4ZO47QE#DHR"(YPM(CZ@[%^[M.DW/G7DRLE:J ^8"8XYV+1"Q>4VV)0R
MOTR3N@G.N"A>I5+D.3\E9>5DCP_1%^AT,H%0'P-40DT2XWT^A<J3^#EI[A%]
M>[ @F_"\&_I*]J^ N4A71&?;@LRW=JY^).C6#ISPEVGFK."UD:9LB["B;'.5
MA0UL70#Y+&Q'!C)QR!ZQ1[!9O2__/&IR)"I-.7&OB[_356QM&?*AE7UZ/M+B
MCTX,KX3V:>?@+C-Y%"+4!>IHJ#BZZ(LW5;FH\L6D*8*;)D>?:)]N_NBKS'Y8
M'O>C01(WI))!4BR4E21<64Y%D,/A&$[4%96'\G*@C7OS/[^E^R^!K#K($NI^
M'K5DJ-@0> %QEK$9A7PS2R5Z-TB'P1'@\)_+D7[VBVCGWI,/3-X1?&P2];5+
M:= JCK]^_8/IFT3)3=FK HILG'<8WO@>@?UYQFTNZ-R\[1!LL =N5(%XO3<+
M9\SG:GUQ/_N$K"^*3/2O_F"( @WN_D+-.S;"F2.1&!]^C4F1O (7M')RF#MZ
MD#BF*:D\4,T?;FA<AT*(,93,Q_NLI1_LO#]=F09U#J4D"MX>:3.NHT=,D?+S
M?&\50S'\2RN^G++ L/;#;*SP^+R>3@\A=&7>JY6>X2-?>7,R%)[OZZ)&! ET
MRNAQ'$BZ?$ZN+RN?O )V3RIS&@Z2$<672;VQZ.=[&YU9_NZ?X1=(3/C]>;IF
MM5SUUSBJPB?SB.W7[JG0@&TQ]S0%Y7ML'JE^_PF><RV4_0)+A%P2AKLLFH0!
MIDC",95O(7U'+S^4EOKF1/O=QZ,;GY1^?*V'W8F[CYRY\2.27C$[QVY,$V?8
M38?UJ]IX5"S]I0N%#T,IA8D_RWZZ09(/(Y*T79#*H;O'/WTJZJLD:) Z_O@:
M0.K.$AGYCI,!6WS'9>W[E\]DN7QEKF/?<SBX'&#\7<BNZ*L<\7^IPW @W-F@
MK(0J8JC'836CT(3X\4YM("WYA(0BIU3R/W,NNA9)[F+YZ"5O%)4SGCPC\H8N
MFWC&%;#&7M:^G/^07F#*L6ASI(RNXU^Q5DH'&$40F;3F</,X3!BS);QJSTV(
M"Y8W]3-R?D%\W^8\N@^5"+530@7PE#C5K V#A-SH8_LX)*/KV_^%K_]_%\S;
M&0 J$A( Z<&]6\!H=9(M, ;O%D!]G*H*'&QLEK)EKE(?*SO&V-9<@"<9UQ&'
M%L="&GJJYUP/;-0#X=)\7KDC2QOE#H7SA,<M<R2*C,0U1A4S:M+ TX#:G:&(
M,X]+WG07NKQZ*T_YA(F978U:>+G6#._C7%?/"2VP^E0)[V)]B[7&:8C9CP6Z
MEM"(\=G>D&J.2=O244JRLW(QN=G=E<U^U^:87>84#.T$8%"]BDW3FO57MXN6
M6D8,B'/Y7GG]1*[EKK^^.M/,S/&L"229)4CU&>' F4Y-6_4\(]8%3'O"U46X
M>U?_?4FVA= H[+)HR(FB0B_]9F#S%K#;L@9:\!G83M1PXA@C8]*>&\;P:@/<
M EQ^/IE\1W%$W5"(/,7\)NORXYAG2;AMD&;T+F^C)<'HY3UDO5%8. X6>SC8
MI_,5BF!CFA=*7H-ACNADE8;+ ;IK<_]N@H-SAI?:6!7MIDU\18AMY?7>Z61Y
MB_E.!8RC"ICT#5B%K"-]AEG+/3'YQKB_KAR8/D.QLQ!V [N1G(?N+ 3LHJB/
M<JL1N,*:(I@7*'93K5OVZ.L*N$+VU$XO&TZ"I%^:K4,X3E,/"PYWH,^\<B&'
M#N'5><79K^&<AJHG:[%G =;U7&EVES>?VO1WF;#U.N"IVY%4Q+Q50U-%3O,$
M(=N'$% !O-6-.TM^D'Q(>WZ,[)'[9PB^1\K)-T,=-U03U>'K?R$$E&Y\T,IY
M(V)95&BU_8#N]4!QWB3#$]/BO)$);[!%L9PC2!GBV1L,A^$KVQ+ D][R.:,@
MHVL%5UKHR=C'E$P:6CE,@##S[;#QT#VDO]64JR_!(Q3Q?EJ!)67PU&OLC/2G
M7!SQ2]6_,3K6D)F+M<32UP@Q/]ZP>DC5@:-3^%UEE<IUG!&CX]#<;I;-6JII
MD@=7X7NSW6/\*K=; .-QK.+9 S13P;[JH0QK\(I@)@1[MT4_SEK&4TXY'9Q9
M?#&K9;N9$B>?K;]]^9AB76A^9J%#<7M8B7@E&.(%O_ZZ)V\7/K7+L=C +,_S
MHN1H$0_6*)4UA#<*C%, ,UT3*-P"XLI4ZT%Z6AXTE!E>H S*AJ*]XXVB")[5
M.2R!4 P9H/V,"G.E87#5Z7E62Y5\;XOU<Y%; -NN[[H0Q/.C\=Y0TRW [%C-
MRZ<;5FR8S:/G;+T>#='.K#,[;@JHJ<'\> LXG=!=&4_./542AEQ8"V9+NX+F
MWTV0C6@;FEH<SJQ6@6BO"X!JEUJ536_FH;U>5;E-J9,N233J_=^JX9?FUG7H
MI@K3PTYX<DIEAFY62M5-L"K60:_@4:59<P,#7ASY#5J;75J=9^K%E==I,;<
M7T\;X>DP)JM/D,OK]LYER'Z2)WIS[>[G"GQBW,:)K&]6TXQ?4H;KJR65("=?
M22S/* ]C(J1:U:Q =M%M!4V-FC#.=?BH&>3Y:RP.!A+RRL4O!QG8Z$S<VB<\
MG!O6@E:S>!6M-/1U8C@B)=1L-1;IK3J4Z%_[.UC32@<,9"2[C/OJRL>.*QO7
MO"V$@&/:NB8CG3S=->XJN.OGWL$-A!4]LP8-;81=%%\[M:X<,XH'])904;V+
MQ !T\&_A!06%:=UBFJD=P=Y14EP^RA4]O-+ WL;P*TQY3TDAZF3OAV&D[-KX
M'HWUOO1:)DG9(L)%%<UX<:+E9#K&BET$1,@KD",THS"R/"IC\\9RMBCE;B,"
MK37VG X%0LUTDZ.PQTR,\YI$8^N1YZQ;L9:+W<5++@>%N&O,A13X>N8HI+^%
MAP0]PNU1;?#GQC=]8>\K8Q)*,1FC*Q4B=7)\YD7N5\70U2ZW[D9O\OT6&\3R
M+[WPP]>$QK2$_=PPS.=9*F,Q<B[-XC3G?!LR)9DQ]:CO7]NUF@MC_?@E;89E
M4XA-5/0F[\@F=G9>% M 3)LE'2,O_4'F&S?["_]<AAE144IIH/XB>.=@_JF6
M!(S-/>G4]UFXN_J3:,7M_-$!UDW,ITN_9/G7>G3_MG6G]MU*)O+KHDR6Z+A;
M@$&X7JKGTRVF9YH3YOS1O%\=?LNOQ5_:EO?/"Y@-C"ZSC%O*?2^N3.RCH?BL
M^#^F3D"FZ$B"1.:??_*X&;ARCG;> O8HW+M0?@EBWYUWPA28J<NCRIG",B]0
MI"]+&[[^K"K=L^:1.,ZUJOM &ABIX*V<R</2N5B_I]E4XF9=L(,M]*-A0M8R
MVKS*+UW.#92?D0JSG16?"7(/?4>)IZBN04MV'83I]W=@VPSW?WH+6^;_L&4>
M#6W)S^TH]O72FL\FN"C4.KTNUY;=8IF@G%^LCAG:K2)P.*Z#(U>M>8U?%QDC
M,5O"C<5LMO$K)?6[8#B9H_) <L+(I,!'.4IVD8BVEJ@Q';!E[WS\$_GC+_D=
M$ \%IG_;VLN(Y1Q4ISS9+*:V6T @_EMI?W>*0YFW:R;9GB<Z,7$)D$_PE:AK
MM((4&ULA"Q6WUR/;.@1-%,[7>9,\;P-#OX)KX3!S<6#F7OE<;;W^!<D#AIG^
MFL6\_"H3E"6&DA1>DP6[:8/PL"UCG878_\'\2H*H[SDC4!5]*_%G-<;"B5"&
M^0V+Y<LOAJK?1&>P@Q;G!VX2+.$URK/9EMJ8&L,F+&.,S>V!Q'+O3O"\9$:W
M66735:NNK'-M$ZA@9ASZ,C8C/38?"MKR:9T!]S[DT]4[NU3!>';#PG:;-C]9
M#BH :9M]--'2(FURF(@U'C!;R7X_9#_Z=QW<^87 GP)W@ VZF+>N*D;O(SPU
MP@VOO=3>EK8K,%S& J#)0P+]2?#@5VTATN*FS'RK6C00B^/J</1'PY)C?-/W
M$ZG61P?#1C(=G2J5<P)P>!Z]S:?/N 40;_Z3A3^]5;@LN_;/E3',KK)3YXDT
M1(/KW^LTVII#Q#UX*LL9I[_-7"S\?,%P6=9TGX]PX_NR6\GGF6LC'[^$<DXC
MLYY.$5_R_V0-0R)7SI6$<M2)]+G0^W+-,1V.J,B::14IKH@Y@<V( H9=7M6"
MC<^6\#;7ZH7$\;G)TT<O2KJV1I:%<DUO ;E?+T*YBYMT<PN8VO(FBRKX#:0@
M/'0VLE-*T!<OA#M?.=5IQE2)")?ZR1Z,1;W5C1TO\UN9E4O,;?@X.5*:7G31
M;;04\E=<A?9FN=$F/JDRIC;551*CSJ&F*1;=(U'5JZ?,)@EP.9_=<KKW31TN
M$ .C&*/X%_>Y\7]6?3[;B@UP3$JE\G^[)?T!?FT_T2.NP^&^=-!ICT,\0@N8
M'@2AD/Y@T^V5J)-$??G8K'T@ED[$BY1?2W58('I1:<Q 9[[O%C ;F \]!FGG
MZ2@51>P^)Q[[5;+^'9QZ983;9FHDH$;>B&J!%/,'-H_B,*2K@5"LG=9C\(0Q
MW!&_X.5G_:'7YJ>X ]6PZ>)RSQ7^V3YMS#RK 0$<L6@\\_M;O!)]7O8';_LD
MZ2DHG+]0,1OPN,=3 *:W!QW%E#4>A,>A;=,]]>B9H @+G^1@CSQ9!Y\,E[B"
M/4<$.>R5=+*+:A+>:E<Q"ZDY@$@[N0=;QC=^ITQ2,I^9+E+J6R0#F6NX6,C(
MH4:Q+9Z=Q*)<Y(>8B?U;P,=LEY2JLM)N789R#;ZU2*I']@G(-=9/CF59-A8D
M6T6[;N1?JSLH,)#015O/30/3+'J24/GQGF\P]&D$U+\J>,?@YXULSG],>OQ%
MF_H&[O\2=5#.B\9A^8%:=)1JSK6.3!\;2NA\D^)OF :$4%EMB.2-S["%%8QW
M<-.E2(B'K%\!D-[D3(/.U$.,':Z2;!9#KX'W2-NY@D8;7M_WZ41+UIJ>I%77
MI,UX@1'M:O1V2K1U_;5D[+K.XQ(\W0=LF'XV4/ZN8?9((DIY[R\L@7FD_Z;_
M.RQB9J\+NX:8J;TNB7/FCZX2V22T'$5)33C,MP"MB0.FL\.GG$SAQY<JUK)V
M*QYG;J%I;3);"DE78MDWSP_PLT("0G$=/U96N@3'K[! 5!Y7X]DPUCY^1P'X
M^7#0$<(3)D4M+G9.BW_!K/*G<R?6%Y][V!1VH)TM2/\0Z*W#\:QI3(NF.L^'
MON;IBE!_NR49FT_1/DD_OE0\1U91E<14ZP;,1^X9.DI>TP2=:.3R"_MN2Q?0
MM7>A\A'AMS1.'K>GE:12T@3&JY45&JJUYOOE(.VC)R,HGI78PZ',O_S+*F4Z
M^13-\HJV:.>W#R6Q@:'2S&D16 #TAC*U,A&\(1CC.>!R*CQ?]OZ)LZG7OH:7
MW-4+-:(84-<TZ55_#+#L!30;J'.@L..P&$KA+N?G;;,#'^,7\G]$@D/*(EZZ
M4[\]/_J5M  #3Y=Q2LVA8.DNVZ:;:.>5B(B]K7K&@@I<Y:JTOJA]NQE@I3G)
M8)V1WG1'(:)/?V%*(*#?&S$\!N2@4.K4HJ0^6]-HPB)@[F;\5E#*/Z3O^3+<
MR<3O)\IW82F<[8!R]M;0AUP&NR3'I.]J:@-0D(2=KUH-U5N+/VL(K417VM\"
M:&D0627L;(IU5<[C*N+M;?*=\&6F]2YNEV%/]H_<<O]\=:V[CCLTI.^<6BHF
M78M($4K;?H$EJE\6G^CW;M-K1A=2BYJ*YKMFPQRN04%PD$_\@SA>=BK6YXUA
MV;1!GK2F @H2B8%MS,6/,#^ XF&UY1A3>,E\R?FH<[&R5DBJ5KD:>)J 9H8J
M:@?*/^AY%#I\^:EK+.%7!,PW>,H\='Q*K:0]"8T3= 76@*55O*:UQR^-$"TD
MZ%O21(F2H.G E^Y-(LN/KZV[3U\K1V>+U@]&?RS,&>JWA5&LF:ZG7F?J.]Q_
M([SLC1,_/?0Q&5H0D)/'1$SYY0'V4V%2D+C85/PR"C+NA9%U"KLM&]]X9"2M
MS?P1/>'O1IUX#/[4IN=^+AJ6_8/M.^ Y #583^MH)"S(DC MKKR?'@FUHI=/
M6VMQOF'0.0V%_TY_>J#*A_(.4@&K;PQA]R+*/GYNBQM3%$8ZH!V,6.'!S7PI
M(2_\=IV<G=/85_G+<T]IY8!/10 D,9PGQ4V?I10XZZ$B'<]A<"US80SGU$;H
MW6.:*(H<#J72'0Z;:T)5K^Z X0$6FJ9O57 .]ZB1Q:A28MEISO31?XH*-B6L
M.]!UC*YSEI+T<'P* /<_.?GR'3H!1:@2\N@M4Q_B?"0!44=M"!1HXAO0$/M:
MM7Y8=4UI]2%0W]/<POHM<3^OO(,[&^"Q-)W-LR7CL6N+]_N8"%YNU"3H1M,,
M?2:UJP^)B73!)$W#[R(J$?.Y!?3M\-NWC=W_KEQ25E(C[TT*%>)FA4/YZ37+
MVK>NV[ HZ96&PXVRLHDQ)@4Q"JR>E0KIXVQ'($@9)OG@E !YB8*:Z&6L3R^M
MP(PEPR=A7$\*_"[^XK:;PKX]!F'L!(/IL$'G7ZX/Z-"2CWZ6"#+EM)X6M&K'
MG^%NMU>+4Z>R;M)0FSV=F&!N;.4NGN0?='Q]^>FM.^Y=E>?GJ_6!F:.JIV.W
MNT[/0 [-#>-L8 X]S>>=IGB.M&Q?-KUU2#>J,$OC9K%%?%TJF)>@_/O.$+^A
M263ACWX ,F2_06^TN-$"B58, JY[Y/T46O'1=)H%D3MD5"5T.00_%8*,DR>^
M"W?%)7IS../T7D;R#SK_4C&9#/TQZ/P%P(;[A85;2FUPD'J6[(7B%<4'.-(9
M/%P#6P7G1CN^F7_ QN#X%L!L[/'SXD989<YKZ6[7KP>$@F?(<=.YRJ?;/B31
M@/9&45V%<VFCGU#N.M^1QNIAYU.P(6]6<XEDQ[\M%CN(# WH^Y=+[;<8+8@7
M17ON5]S_;<:EPN#KX6RVKUG\_D(LB'_0V_NGQSYB']/G6P 3(WKS:.E*]7=\
M6W]2/%D#TG7#UF)BL).DA8?>3BG>]!M'BCM&=_VQ,XJ:^O4TCVPV.HJ1P3WX
M):XC8L<:_:@PL>1.W&'#ECQU#LHU;ZXPN7,:!?]=NT@/B3HE@<7O]>AZ6U]C
MD:H0=/%CO^1@J+@G,T<?O9AV&D7Q<_%WS?RR0*5TZ7^>1>4A$@*]3B_7=0QU
MXIOCH3QX$!JQJA]S9$_?T@*G$RZO&T*P[*<'(@ZH$%-Q$^HZ.<X^GB_IU_WO
M4R5\77P#\CA2LI05S.?QM92!3N?,%P;''L].)*$BR+_2LFH3,%<2:2HN9*U'
M@IZV)(V)U=GAV,EWK5/8255"D_-T6D=7S72MIM 7^"U?:*PRM?$8FHNHP;O2
M_M#<-:O G6)PX=2T3X?R%;)2NTIP0V]+*EDK:B.N*WNN)BN:&SGS0H12K(<&
MY#\])._IO PM_14>E2;:>IL?NIHBT;GO1XY[%FV(O?@W3$(FM$;!XCJ,'^HP
M.MHSX#H1F;XT\ H%[>X*;8[7W8OO]YV33Z"Y0@CDDX_-1C0*N6VBN*S#,8M&
MAQWZ80>^#U[C*4MQJ 7"C(.+V\C-C.DR*%-HLF0-<:EKGO3@V7-(^[W_V&-W
ML=^IE<)+7;V=XZ)ZE\1DJ! _#.%<I47#N!:G>"![>:GIPDA^",.!+_HL#07=
M19[3\NICYTY!PHPNV9R]%R5/S%$0$"EF8\#C(EO49.R+"R)#QI."+R-=H6T(
MLJ;==Y'Q;YVN0,<)" A/]A7[5I['];.Z1X5HU+PU"=69SKSD\PJTH[S3NO3*
M/VINYAC*R\_T:._=^Z]V=]W-TWFDP76>[-,]J7>@>_DRB37\^1 CQB<W7"LY
M5]O2AIB?R?T[R@>M'6X!!8=F#/)Z<7D31O9Y:%,;I>_G2#I_OHQ&<'F,GZW&
M/]PQQ+H8T@Z1HZHP.13M$)3.<S3IR7*V#_,,5BH*?+PB;8C^_N)7=WGE<5AC
M*XIF2H+'T:&A@V\U/<BD9^0M9*I+?/S5_/@J%;OVV%&@QY'P^=H!S5-)_N[$
MX[F9F %\^)M7XTLP"P^"'9T>+I^.=L%CM?:PSS<X*U-0[C+,\O5840(&3:X!
M:7-:L%!,7K<2\T@\L"1R6S6&KZQD2"J15U%O[1[KJS0J;B&69]V\=N,B#+9^
MCV(9GM/BJK7? F)S6$.==0BN10;XC#H6?&4FCB[T:T*6EK4QM_9IZ*B,D"1M
ME6Q:Y074*,(\2H-<%76P;Y3OJMO.X-B>LL8U=+%&NR2SX?G95!/EW!LM6G6I
M>Y2F)74&V)X#II%)7_1@/0_9>S+-2OB8S&W)(Z[:9?6YW4<.=9S?41<_3RPU
MHG9-7_\ Y"E'#5ET.Z,V=9YMOBFE5[;FZ2R[ &*_Z.83[04=^*[L+<X.F1I4
MI9&9*#M%'[\NPQ;[[0-PZUG(H5";K[-6#?C(MB)U$IYDH/;\NF#.C$6@6(/
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MR^$"D.>ZQ1*J78WIV]DMLW7][,>Q?JZOZ=1$<=#K>3<9V^)%A^I-%+#5^BW
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MUNR>6JS[WV88'22?%=OOACYA8_N*D_3RK1VLR78VF/7*:=B$RRMM%4D1_)\
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M ^6=1R:^+-ED!P!$,]TV>]GNDSW2Y[I<]W/<-G(CT3056%&('$D$D \R/EQ
M!Q6-;*8I$K!AV;DF" AX"H+'PD:Z-A(?$X]JG@  >5#QCYO@!P441SV$,])0
M\V'B'Y^/_P WH_\ KD?GO.<__6X?_]H " $#  $% O\ VV!$ SWDPS[A//N4
M\^Y3SWT\ Y!^;&.4F&<X*JAO@ 8Q<*X.&%7(;YB8Y28=P8WQBJ&)A%RF^7*.
M.,$1'R*:QB84Y3A\I$0#%5A/Y0IA**:H*?*!'C%5?<'PB(!@K%#!6-GN'SD>
MH&-GNGP%L Y1\0"("DK[@?)EE?4/@$P%PRPX(B/PP.8,*H ^$!$HIG Y?DCA
M3CPG6XP1$1^,4XA@#SX$S^@P#S\C.;T%$>1ZJ*\^2 1#"F]7@;G^1N#\FZJJ
M>KR@#P)3>H.@#P)3>HOR QO27]>JQ_+%'TB'UZMC?(7)OIT.;T%\NF/4AO2;
MY L/*G14WJ-Y<, >0Z)#ZD_/C]1PYO27S 80>K8?\/FFC!Z^,SH<HOECKS*
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M1!R@Y3Y\ E <]'6=8?CI%J8ITOLE^6I1(Z.S6.HN8B2(-5A*4HH-O"'4 Y$
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M:?D(;'L2[9-X5I]]+-0^IB@<LK%MY)O%MP9L.DV;\7>NA5D3&V'61B'X^ <
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M5F"QK>#^5OZ@)/NQ!^ES5_JH4F4GH$K0K7Y9%XD6K57LJ$VZ=H#&>AH]A/B
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MX<\$*_MO?S!3 O*SC\U5@WA^"O-W^9PY\^_K_D1J;2!6XQ"RS,BKYHE;5]8
M!HS=[*H]SL$!Q?D&)R*"7?8^>@_S%\LNZT][.O=+G9)628M$AD'1VP]4F?Q"
M9P'DR[GDY;DKG]HZC$.DNLX,+QCLLHP1I=N97NUU1?2Q^]!>N$C<P=,M?:\Z
M+RACMR!A!J%/26>.S9Z=]N_:]C9WE@8%U9(1<I.Z5K[E\^(X2V*P!E@S"!@.
MY)P,SR+A>U,QCUF#$FOF@()28 A61>NM]H&L U8F8.!WG[J]NJ8DF[3^7&$&
M/U&S6/<HJP5@5C9&0JHUIKE:.>V T\2EC-YSJGXZ3_(O%H6T\?,>[7-NZ6L9
MR9.MM!MG32#K;Z72F\<-^2?X0RV249$5QN%? BM3.J#&#*N&0ZMG19.W4H,\
M@D\XRO6Y^;ZR@F1:GWI,].;OF4G53K-_P9Y "(19^$*7!F'JE'9 *5(%_)RO
MI6PE.<I0"%W(L>5;/-PD0C*EN,1PH<)VVXAY6/D.UUBPWL3':"G&3JYCK6[;
M9)* 5TP_W#//[==5X)=&(91)4Y%%Q!!BB.A+Q,OB!-+P=# 8!M,'LDW!#/LC
M9OYSOMS*/T3;Q\9/1Z4() (+ :9'Z!YPF7.BH%5D2<9/&R2I;NV\9J&KGX$$
MV0J ICKYGL5%)^2+6Z*;C:#QH+1I+DM7%3VK:)[;LMN,-V:/,X,W.L+)ADLG
M\TK5'2JY_F!Z)WV2W(,KD>8 &C WSC207S7<B_L(RI5:;R-JT+YM;B5QSF=;
MI"A))XU@3]!RP"D-8AV5L$.B%15RV3T9-DRZ M>W+FX)V70S1YJU?<#*%EJ=
MC&]G-L_N^()R([5>_H.$Q?324MA=?B79VEYO]YW3HC=)2 ,/CYK%.*G=9(A<
M5&X&='""9W)$-6M*ZL)N8@2099 ]"=F#'W[ 05RR$Z< ?CCM(7[]G!*=2?^M
MM1^CNZRMC7+GH=A.XC$6TQH9&B_)(;^19CYB7[OS;Y<>V'2N1?&N4!Q0=-,<
MM=Q:$[HYF!T1EC@)(+$#G3N>$FD<F(-:WW H)-&"*2-50"U9^V4X_'+9\*'F
M$5#IF9MI\WDI,JTZA:.%54>CIUL)1E8_9CAKG]X)5Z/W?)7:ZM&-I;J;@L.-
M*IU?46+'L-&S<HJ<RT6')X?/290^1S79SD$?C/W^=XI5+:5G^D"_GDWO_/X:
M8AD-46U*2[.SW6B75Q?^#_GE]?9*/.?9GUZQ_:[4I:0PYG0QD#5S1(>T,2]1
M+<0GY<STQJNNK20[I#B?O"FA :1LN<!$#R[4Z=!$\^+QFX2,:?(2+GEOCYUA
MR/9_5M]YPV'T[)^CAIU:\=:O7"9CV^C[;!P$:76,.>:*A]P%?J]!#BM^72?=
M0GO&^VDAD4-!?YJ7X-V;N(QQ\LC#=3(%N(!1$DY/U0AULVWR[!EV E>7O"I)
M7]HNWY*JGV+X30[?87%&C)O+A#=@,QF-O_GR1^KDE:3H,T[WTJ_'% "70D#_
M/S0=,XZ1 *RI.Q7DNOJ7?QV_DQII75R(C72M9Q8N(PO61!$\O>O/UF;5=[]]
MOYT:BF],^H=4+0'N/#%NC2KDE'T'9D',C-\ P.A1O13M79B\3M2I[@H@XJF>
M47Q?]<;1=V=V7AX4_D6F>?A?+  >N.8]A-6H (Q:FXGR+9+?1!W?DAT;'O_%
MTE#\BP5=;J;D%C6I'LURF=3,:EIID)MX2T"-/6:]GV2S\#V5RWB 4LBC*@]W
MU],#*/AY\E4SN1>M$-"^CP04]&O4?K'IBR>MD;M90G;\<EY]XR);%C7F3Z\!
M#^<KGT/V4!IS\D<Z_F7*[*EI[^G+R8*K8]J,F/ *0,0+77*KSVJTJ1OIQ5JV
M81^]<.LSG.;=JY3('$24GF/G8+,D&SOQ%$_RGNHN9OF_K&4H:=+J(IUS--\<
MR;YWSJ^BT5YT*LG3UO+F65,MK7YF:G<;87?/_U;).9<"%G\E1>Y]!2R&^,^O
M'VO/1W<K75F*3FFM#9U$T:4K_Q0]=HQ3+Z77 =T!(F]ZPAJ7\IEO'SWOA(P;
M;I#TVK.5!2J5_0[,1*T3:@/"U49/G@0*R+HECY!&C&.J.AH48BCGJWHA'7..
M(EVTV6 ]7@$UL1*.*@B:U.LGX&6CT6]GN^M+2S(NHF![1>]O(R Y"S+9^P_!
M+Y&58#+J/H4#Y<4 &VUH@DV.JW?X>FA)^.S.F_^NJ0X%]MFNAC&5\Y=_IH$V
MOHO=><XNKT)99/##.=GDR4*+&"]47WD-&?[YH;?4LF*N7.-:)NILLND8-BBS
M3^?N$L1MAI\-/HME5ZD9#A,@V'VZ'X+W0?,)4AV)O1VC#QQ<&[3**=;*7?U:
M)FT4<GOV/^GV11L.W7LOA8]5W]\HQJ!J140%)IJUK<_F@^ EAPL309[*2\R+
MS"0>P$4*X*"]A,U?K&U:L.%"&A:95)JCB4[HG8HBK=!<?=#X9^X_K_44C,9;
M)5<(%I(ZU%Z"V$G"58]6ZR#-S>>JMYQ67$-P8D,RA(5\MP:] W*B6G3#M[;G
M$%E5MPDY=QU$GA>WL@=Q&]0+4BZOG-L[+]T6] MU6THW%>01O[@U=EV,4IU=
MJ.^H)?'#S(;G@D_MP.JN6?]XK?W$V7W47*+&,D:>EQX<VT 2 +OU[ZI8?B^K
M/=PU*,Q&K\[?L=AJ5-/U:[-(-Q]3E@F< N4 6X"*M9*<FZ=HGKY?Y;WD#SI+
ML#]MK3SU>#,Y&)7D/-@>H1CGYGLX=< E0?VY,V!+QA?J:5;&%R,D'N,CJ=@2
M\(HY,057RT9(VCX@\??'Q@;50O>!K+*GM.[@!R/VH6/_8G*891?A+):E'DF"
M3?Z<ROX&#.55ND94(N/;B<'DC68SJZ/:>6\#;EI&(-\AM7 &'-4'N?5&U8G>
M8G7L_ /_>7]MUO=W9"MX;<)A@/M5AM-F(H:3FPB'!^A:9?6#>N-UL(;QYV'I
M<2#2Y5S7&F_&YEE37Y_V_JGHP\?'*;Y6G.[./8/\_#M^4U# RO+->KGU-**7
M@4%00I M;WW J: IA"* &P,S/*A?(27:KF&^^VQ\*DF98GB2O#-S5JQ ?#Y5
MH>YV*:Z:']T, D7FVOQFPV]6 =CPT <^3MG;+$0T;"M?.'BA<NCP W]_O4GJ
MQ 1(0>EW<MWE"[HS/[FR&PIH+=]Q_0$=X<3F-,BJ9+(;7_HI\6;1;=UF\?H-
MN.Z(/;E[6OH7*_G4^IJ"XX-UD%R.FF2[Y'J 0=3QA7"5FY H$,7JE94\RYVQ
MN\XVZ/,1O ]6QULKGH>1RALN[1':$)=!-:,"_1M__:9,@:CN-F@G+4^'N@:X
M7,9N':QVI H_&,D,17SI3O3SE3K'O]_#[ PE2+_K]BI[=%$^XEN9\>JIO%,F
MJ,)]9_6D0NW[D_?DMTE+B5? \H%CP*O;J:F_6"#K6_[XF4G)DA M;<JASS^*
MQLK(_ES>U.78Y/K-]1FA:5[%2-/SL/J_?W22.JM^57V_\(EKZ_U\&][ZX'RL
MY8:T[@N?$,8Z31K-LS>!V+<!J^=70CM'NHL\K]7+SS&VJYO+_*/S[,\LR+NV
MIVN ZBTS)X;"C\ZNCPZ4K/[0?T.>MO]F;#8[%ZV5%D1X\8IVJ09QSV^D15<-
MIFTB\&48%EF_9+4\S/FF:NT^4IP^*TN,"BR15?R%O.7C*=0(JUCG,98B ;7D
MAMQ*YEY.R.P 9+;73'4G&1+:C?W$.9)LA^)EHG#FVZ*_^';8!IJERE:/J,RF
M;!?^OGF'W.&B2FB\>K'(]A<KLS6/QCPOK+/U^<1N<0CM\IR'X:ON<.0OP\PC
MO"L>[ Z-X+&7BB((Q!%$W7N6B#?+)9ZJL;H'K?^'AV$@(N+A6<@=9]:I[U+=
MLU&G>+^(/=+;8(]5:H+ V6]$"3)XZT QJF\+Y Z"-CF)<JKB'@!3Q-FF)G+\
MI;%SQL/[XK[JT_MD=2=[T$S@T8ON%POJ)Z4G8HY%M_7]!6T]3:2N7(\:883U
M]QN6#,D@F;#E _[NH\8,/<BE_A[O%F#S_)9:G.#;XG$#VXB^Q\)3AJINV..3
M0E3QAU!CY[0K$FE!\AM)7*QOWN^[]T66R$6& >.D%#=$C24U[OM$T09T>[?=
MK1>3! B/C3X'KS(N-=D/ CG:YQ5C[%VKB2OR%"H!I;D5 2R\/M=)AT=0(Z/6
MHHE>8]^7$94D'.%9"60N)CQ)-"/6-1*$I)1[6DGU=)$^[\815+<E.3(NJ5_;
M&,O;>9X ;I#'9@VTNO/$9D+<[LV_@CZ;AQ4T:F;9AMBOLOW/0[1D[;]8ONUO
M*I+ICB5:;3_E.KNG2"05.DUZC!'KD]-%*)47&+Y5]-]AH]G+R'!>CCZ]JKDW
MGX@XC3!U;Y2%WI)N@MU%??J/DR!MW[6=AFM4H_;AYX6*M;>:;8 6G-2DWL^[
M=5(L'Y]3J_6?&"7Q)/%2KPNC7EXO@QK/@*<;?'DY\4=2E'WYA1ZFK$4O+4RY
MO%VAQ+GN'HWW.0X2MK#[!!'K]%?:BA)CFE%!UMUS+=7+H73D^FR3>Z<5>#(6
MG\;NS)%S.@O:/( 80WVBR-87+(O,S]T8?L99#**AD,5OG]^!(5#6HN[]SF2/
M7.)=>:/10G6%$B '9#RB4H*_*WI-@,:7^]I:>Q#%)N2$JU4  [SL&8'I\?2W
MM!CHXQ&:PGXF64ZQLB(=P2I Q!0%*#(K!>!2W+S07(4_:)PA3^!/C $36[YS
M9R?)I;H=4";LXUUZ'MXF5/]? .>G>6>!+'.$XH9Z>^NY7 8#VG9;1$8L[>6$
MP0UF_6X4H/^(O=M%>>_[ JB=],Z^XDXAS2FP:,HHFIDYY2"[X 6/%F?-(GBV
M2[G9C-]HT V]TNA4@%>"V%8"11YKWT*A/GY-8P \^X%/KXF![C/#7:S/6U(3
MTD#"!RXE.5[:NA<XGH$HRX>RV7=1Z?IS.05;&G#H'CLEE2+LP7\?([<$?5%O
M!R'A%<E)U%I#4H^1\1<=U;*H"%.WA':%(^MMP[3GLYJ 69*MZ^ 7B@I'F[2L
M^N5SRR/)(%1;)I_V+D)KV94[*"C)H*#)+ 0\()[\)JB@U4H!1V<(B=?RVCFL
M/=,[C:#80.A[W88YXI/B+UG%6.O@JY&X'^3+!]93EUU;ZE[?N?7CQO?8<];M
MI5CO^&+XJ.2+=T@?UHU2NB@7S%V3>-YK8'GB^:A)!-C:BV0II)E^,GQ3Y<A;
MK^@J\4R8/+]/'?)=>Z4EX#!U>C"&+]!QRUAJ',Q'.M=0N=#B41[5R8:?'&(3
M]7BT%RONW4WP'<J1$6Q5H])3O0C_BS6B_^B[''N +ZB7&G&$B8E=[D>P]M20
MWR'E6Y\>G)*G6X4?WU MQGIUE3P8BD%9H$SZ'(E0J-\7]_XN\_7;>O;H*!<V
MDH'(./&VX+Q,AA^M><N=0#OP[#]!3-:=\WK-8': HE;-TG?J]3 0A?"HST##
M9H4-T[>.5M$*SF29N?OL_$Q: W=U![O%2\<9!]KIZ_9WR KI5\GW(8O(AO0(
MXQ^.A[<N][\"NU5>::O@$@<')P:S<%5"M$C+?YND^+RPODMMGS\4FE=KHA)M
M>.V)\N[,50%Q0[5,$8?:1H4J/F.#)XA3.Z'S2VIOIX)Y5^Z'[8=+]8+E/^D(
M!.(*! U@O0_!(4\KT2P]-RWY^5+:=RGXELQG#4\K\LZOXU#X+U:T8G0,5AWN
M;A!49J7+^5.OCW:8PONZCSA._3$:$(X<<XR-1ZDTC?]7?*T7!X2(4D6UQRW(
MT)P2^E+?I,3)K)92$,BX\";R920>8W%T9$2MKLU]NT-,Q!OO\*=G;J*LE0.J
M5V#G;^JAK4?.OB [6#V0-T9\_\\_!!*7F/UNV40YQ=9U**#N,/<J<!+7=N>%
MSB&9IX'O2$UD VL=Z% >RM'PWVJ) TNYYJV4+T'#!O0H0%.C<G]@6S(REJ@]
M1,4'J5H^0PJY Z7/M<ML:00\2O9JW3GU64_3W&JWV:1?C<_<_8LVN%HT!J)I
MMUHP]0$E+7IDZL+OP/"VE!TODE+#*GBMOD>F^20)A76&6H9+L=+E)X;)"5E!
MA9)2/-S\\AS\FN?_*&D6*5VW>%I/L.78D_2#-,Y^!&VQ!QXIYO=UDS<)C/2K
M49RW%*$&4\TIRGX99Q>#OYO.L]7UB\6>+:W">KMQ_-&^>W\T#Q BF4O1,_N;
MXK;KCKNQ]/Z+;Y( E?4U?-9><K9QK-!6UFX,7%=$,/OI*!5J"3^3,O?;5%+Z
M3-4),2S%J&BF VN50UP=I;#([W3/_7;$[JC+PV%.?DNAZXS+-Z%O0P</RRTF
M5<).S:;E_-O0$U]O^CQ$;CD(Q&PG&<%M0#/6U@EI/9T,_5@+R+YA%@#+PN$U
M=P(0-.+UVHELA^QYR1'90/1,U"H!A13\N6(W"WI=]!:$ES^ESX/374^^$P(.
M&?J*NM8$%[73T]AP32HH!EL*ONJS%A7J^C1A;7CY_!=$ZJ#;@E/Z=4:?-O69
MO'<?=T::!/OG/3-.8 1>27QJCZQJ9&0.7M3J_\%0[^_A8E5MH\PU-Q>!']7O
MGH[^.U;/%XBA(JACR@11M,PU0?ZC8\Q?K*P>TWENYQ011-]_)"GHD=:R[_OW
M41#WAO:ZJ'V%P='4;FUWV8RQ6K\NB5CS,HE3+</X+HT.]*<ML5UL9S.> 'Y)
MI9A\/8_M,LZ@!+L\PO5VL1])OPJJ.;][@5]ELE,)DCL_Z=!W1!0W4][@MFGN
M^3>_<"08-QH.5@MT=78'I+6OG)G<:Y^BV0!*2W0,@:;=VG_JFV4/OM?>6I=R
MS)N"N9S5,;VPS*'QF#M:L<HEQ^EGWU+*?,6J;KXXG_!LL>WX7HOR\K!.?V%9
MJ4,3&N2?I4PON(LYU&M^.^YI5!F]S@Q@\1YC2.ZK=63MC9TXPESH*5'C.M-0
MJ#;QH5L/[.JD76/3ZYYM"6J3=_;$!52WL5) /]IL$?2A6!.T0GDY8;C6JQZ"
M AMOF2+/TJVO8[:M&G0C?R5FN7%G:>';6Q[8>ZQFI'RJ%^$?4HE(?QSEX6I)
MF&\281.;V.X.FEXQX/D 73@\,IKHQJW&LS,^1$?RP-B.XR,$H90I\O5C3NBN
M%'H#4Z7Y!JKM%6PA,"N.2'@(+G:"]48G]^B.8_WVA?=<POKV[^;/3S'R:TIQ
M_"&+E[I9_H5[LQO@#U'+)?>"]2^'ZT80Y&$"%_54ZK44@7*_$OH,3(S6&])N
M^.#6+?+>&9^_>C;S,VYV6)HQQH@M=<)U JF]EP4XZ_K+ (5^ ,,/7O[,!F].
M\_+XC_:C*_"4N&-OZ-U]&3EK8J!D 3Q.ET([-0%Q]1CQ19OWG9;DGOAOC*T7
MS;XK9[GYXZ@']W8K'2(LM1NLT5?&C7"][RP"+4;,7*$Y!"D#?=_RSC.<32*0
M[/?J&H(VH:(9=P;8"2ZKD<-,E,$T_7$H!)2T)/U=@^%1/($G]L!8/O4ANL.[
MG7M6/E]R,C1JQ#WLR?10_Z<"KMCCM+]8QI-YN]=?CLTTOLQY?RFAZ?F+=?6X
M]R=GO/74.6P!H.>F36LWCI!M&M/"H=(5\I2RDY=V!;5:^XO,F*Y*?_OS3RO2
MAVL#* W*<3R<0:^"QFQKDD!V-VF>*X=$U[FZ0=W#9?*>E9!:&<[/E8X".CP5
MFW7SI\:Q:M$!@KQ\&;1,;Q"?9Z)&"\8!"P6VUSD11R8.]O,LR>F3FJ3Q6 2U
M5+LG^!QR<SB^'U2>I0VHJV44GU1?KJHEVAQF0)D_U,%-D\.4:PZBA=U6MXW&
MHZSUT8N>.85"V-_KEX5'+J#6]6@*MND%!ZXF3]N8GOI,B/-74];:X5YAR5 ]
M7V]=8O>$_8R;H6:OZGGO!F(]&W$9Y]@?TO<.9TL)V:ZYXZA$RD6;;>&1P75]
M5U6"==7& 6K9BEGP?YZ6$_9!SV"44O!8EC"((,9:-:/.VK8U!9=_=7DYC]2]
M"ESH_V3W/<ET;OA&.#I<<J*;+4J;%&R4;>@NG5@G14HV/=N8^08_NMBB\>A"
MXT/-PBIV,0&-,#VH#T"LX<M8J@*_[SWY#%MD%7=I4(ZS#YT:EY3O_PA5)!TP
M FB^T8Y'3:C4/8WH@BVI6/>ZC>8GN?_RB3%[*SU[^2V>&>>N]/EJU^K@*9[;
MD\%[7L:@Q#& I4WE,JY:D[C'=5E1]R2 [7-U7_BAWK'$II?2"C)^KY>V.V2^
M-VI&ETITK5EIQ,4=<V$6S".)WUPT![;ZGG$Z:4J@)1H(K%)B\IORL-5&^4 7
M8ER;OY5'I=>(QO#=8W$"KZ^63YR</%M8CJO6A" 3.M]D+=JZ3PW=7]$SU+&\
MI?YIOEYDV;LE(\7 ='DG9M=X3KBNL]O$1WW?P@USR_&:1/<G400V]YE^('GZ
MX<?7"_I$4KBHQ6N2**L@@KK\#7#=C2>^1IO_K\8J")J9)-N?P;[<L1%J/QY2
M-YP>)4VP4K&&0S(-*DC1'EI:N0K-_XLE7V.F\1=K[K\O)<_^WQ+D^^X-@,5I
M::4APH,!K ^<N1%<_-_JV8#UV8ML1I8SP& Z0+-$<<X9P*TQ)G+7\N5%TK+4
MRI<*F7EO(^QCCPFDI;6J%/VZQV"'>R_!RF=]PR;#SX,ZM-9SZNE\NQ73SHZ?
M@$<PN(V]YM&%UDCS O?:@&+#,LW6IIK/!_Z-JLH&"W:QT98*P<O_7X6[;4Q$
MU1K:>MT(5*B%M&K%;PY80W-DYFSSB'*K$JZ^J38-?4B.$3EP7)?X8A_^D/9D
M'!N\)FW%O.UA-V/TVQTG4SBQO["S8J\;A"&4&!NT+U2JI?L<]91' DV% %JH
MV*1RG^V+G)BJ;,T1C73\YU5?NC^+IV$015G4\G*61ZJ:%[J\OFP"MWS7N+#:
M\MH@NL3/2@W?$GN'$"R/X\K3(\2RV\G5F*;E2 (1-7'\GRLY-L\$GI_TS+>U
M_IFMO)6&-QOOH=" #B?5+(_"\SWM\^*@8Z=Y]LV]N>L_"MQ/+04L =0L%PP7
MONX=,[J[06LQM)NA6:W6G((96Z_&&%)L\@0@HV^F0SS2A3:+7X.\FUG*L]-1
MA^!Y5%,"/YZVQGJE[32E;W(UX:]ZD@7[_5G"*5 &I>' ]_+QGC2MQZ253M?U
M!]\:L;B>=_\Y1S'UYL1UZ?0OR-I!.M"G0D;9^KRJ^]S@S2S8*$XOGX('F[SQ
M?ZP-,4)&2%QP1$[-@HJGYQ^3DK]88T>O)V6N/QGO8_U_J'?&N@\Q3EKDH3HK
M;1M-#'C%=&)WSQ-K"BY^[V%;PS6)(<.1)04SL<Q'1M52 ):I'9O%9FZ)33_^
M\SNOU)N-?I</C]V-3<ZNS#&_*S?P,S2;TMKIUJT(E)8S)]%O*<$=B54TGW-"
M^^4=UIZK\#E/T[NGAM#B4#S3AI5;:Q'Q^OW95)SBSPCC+E7-G457.IKZI8]6
M](Q:O XDDG(4%:R3%$8Z@K25-HIVEH!+RUDE6\N]*G(Y%A4.JE5C3UY#?6N*
M6.UAZ'U*WC][3?Y?V2C6U;[Y-QDXKU"I%&Y>B+#M^12N7DX$\,PL_$?\KFKA
MLV'QZUB7UZF[Z.%$6<X=XJK!P][\$RW%!D"3%9>3LJ,  '='VNT:*-SK)4YB
M->=M(M;'8"-29)@]E 4P-&-H:9AY,E%)VZ@0+9KS;JB[VZYHOW*X=?.S:MV^
M'F$&$HPJXULLTR> 6V)G%64V21RHGI;SSUN4&[+^![:I8E*56U+2Z%>T2BEB
M,?+-FSFQ+C)'F_XGOA=#PYSATK=M\G7DI\F/P?Q>!Z1QB-OCMY,7+9[H^$-
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MB/43&XLU4JHG#V=."T?W+-/PX/&>:A28L:.5UNK+%1?N4N1/$XUJMI><.P"
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M+G&R^(/!J.-"VS)%AN[$1,N:LEVWR&V.RE%+UI)LQ>HDM]EB5<])RH]O1U1
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MF0+3A)D=-&]I)GHNV\:JN$ZVRK,,&[P-.,,/OOW!H9L^/RKL]7(D9GBA:FC
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M%%**9Y! ,Q[UHB)CNN[NXT@XL/5FH'#GFGFDXW*M=KMV:BU<;8*ZNN$*[,R
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MDT!05^@+:VH7RJ9^*=(BJ*<P_)M@&@C3QL+22&<:VT;[FZ?ZF9GE:7N-(I9
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MD?U+\&8G:PUUJ8&OOHJ,.+%[6 *BO_:'A)1; 0NBT: I<7MP.@ZHZH ")3D
MR&@92#3$M5G#*[MKQ#7.HF$=@TDM2;C*@.OHJ&2$_3N:^@F03DML\%^ V;<6
M6T^;\?*)\A AI!FT;"CI';-=NAIT*V-P:"5[Z4[/PCTD$:5*#3;_2K8;":IN
MN^'=,2UF.MDF%?@PB(37BO8M.O42M(NY@:RU*?H7P".OQ&E$*]LEY7DD.&^$
M*[7S;P_Q:M+B\^M,V(,FP3VP\HB*+02@&;A?@NOB0$6_%6D UD,6A?!? -X
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M.WCBB"&,(/:/7M])^K>S<7"+"8E0$,3EW'8C3/>N)"N[?^@-HS&OL*HB)C@
M.6'5G%)*2)?YC,[ZJ83BB%&*L%!0<B!QTKO$CA^9(-?*I:)04D'SV@N]Z8[7
MQRJ4#B 7P0J;DWE\^&56!%I^HOEQ(=(?;3_MV[H:O(4Q8LW)=K3C!WJVSPFH
MY$C\E2I,U5E(W:TD42;!IMQOQ,Y:@HK?8/ (?Y2$&W"C U^>X.F#".,>_VC\
M@4L\.L1+J/=%+@XP9[R>2T49EVXG&_ YM/]P-L$"=D/YQ$UL7GS*N '3L(EV
M_&^VK, 'AYLNG.EU(X9>C3H GP'&Q8JM>R$J)_F#@&^9TA2(8"+,:[A/" -L
M8*!-L+=%4#LJ1'%NSJ AQXU9K'D8YTMB',<7E/U0<4B5;R/>9-U?0.79G<A9
M&=GH@6N* 63%4#2JW^L<*Z;%Z);/7-@V&UT$V3DFMGSYG;>EM&[LD9PW1O<+
M!2V'!*$(Y:U5[04^.E<%EB93^'?VD"KOX^CI7;ZFPRTN@TTCJ&\+;+HRU ;>
M?A(Z=$Q.%!-*Q?H^3AF-Z+!C!L$BR9/:9VX7VMLA_98G=;I;X>,TNM28YE9O
M6<U+VNG22?MJD)FI]*MS1@H?"X2"(B[83PKU4"IO'V\Q= S%ID2_,2>P)BGD
ME6X!48+X_N@!+=M1%%/&Z%Z>K??E@A-:Z6*AJ<) )/AR3980ML+;G'A9LV*%
M8$(/.* &+476T8IX.PIF24RHBH\W6Q&'V\0>RDM/.]TK*#O.8WZHH'JL.W-(
M0Z:^_KY-$R":L]0]&-'P8[E717D;:=YPX64JV'3X%-,2'^(,AO1CJ=^:F)BH
MQ8/F%#[.$Y;EM]26:V^AFPP"%0=+"T)%$!1451[SHP92!A08MFM+^"0L@RMI
M-)4T)#$8>K^T(A()RRGUYK@+TB@6YZ8$):%XJ7#+RULPX&K:3:OXNK<XC!+4
MJ(7"9F9B(S30:"R.,4X/NTH[Y!I4,\5M?QM "T>0(&C(MT;'P6 'J\"1)DWO
M"70?X8PK1156<#G^@.N?@ !S#\$, %%Y18(@0SUWU%<F)GB30FM#7JT!IWR=
M*NSZ0R .9T&@L!M:T' $H"C,D3\IAI.>T#!,JXJS=19K2$I"3$[]^6L(FMAB
M;KM$(<ZPFK=&N#&2TR=XUX(J: H4!T8>!:1H(MFA<, OWPHL\&#!4&$VVK>=
M ]#SMW<ZZ- E9]@!6LY->LPY8(N)JH4SB<::3S?VZF<C9+6:9JC:)(V+W8'+
M*14FX?"*J8RS!_Z-*WL>$^A1NM[1Q+XNW:8M$4S1T%<UMB067:VZ-#Q%!F-)
M70!?;I-V5JK_7!:TIAL#QE,)G\HC%X95:_):W$S7EQD[*(BGGPRA<@#]NKU=
MS)LK>8VU'NN<'[,0\Q'?&@YA+>T,CCH,T#I0C1S;7,VX*.304(PB?H1>::R+
MK0N5XVNUC%Y:03_Z.CME; #C99U,!.8J939K<HF9U61#J39HYB#<YLNN7^0C
MDI!<Y)".9:ZR-2G\5?07P 7D1EABD7.?1C2@:"T*QD\=4<MG>ID"AK_LQ+#(
M!Z%^\2R5*-+P B!ZA)NE-6Z8_'YVU]8@:(Q S$.BD; >Y15/W;89^2H3&A-!
M:HRG?NZZ^W:G8"6Y+P-3&"XCPVV2W;QXE3+8>$2"S!G<X;+-+-O]^<Q>#H$H
MA+T(VQ!R JM;\%'S"C.^T(/.,R7&+1J1D^G4V;0IGP48PN"G485H_0D5K5*A
M!;N+6E<';E;UB3\BU*4U<8D./RX\6J$J3U*XD+&V"F<B1!<1XJ TC?'TM1"4
MODQ$Q(Y[V5Z#-),\5Y@Z*5 LU\Y0QXXXV.G5+FEG@(2O;"5M1PU?!!0(!R:Y
M[G#ZI8;1IBF"<*VIF='#FO==PB&<$>GUP]@>1#%W=30_&J/PT,F3<!J8?#KG
M-7(_\=87A5N@% ,6S:<K8R(]F4T S05?E"R0B:?M@EWJRPCPQ04C0,L2:I8;
M+Q.9=['P6T1O-DZ-8E7F+"D:-^&\)?JYA;L^:"ABTS3Z16[ 9-=?6/817M;^
MF*>3MMVF0W+/A]#4'_ 2*\CP?'V/$5&&Y;DJ!:T,\N&$6;D^\]PA:*PJ%>O6
M!NES]O([J+))3(_Y4G\!^"0CS_C6SB29+#3!2-_-*>((B-B'^6@HB,)LCZJ:
M*6X]BIM,P0;5'H0MLL]].)=IF2F1<T&7R7G!R7'U51G12BJ63@32\%/0KUGR
M_*$'05N!=:8IQ/69B]2<Y.%LTF+UHU( TN9G.2SZ2;LSI7Z$+UQUJ!'<#OUY
M$S::DN7,SL3!#7OH&MLDW#VQ1[B[C^5Y7ZHU$3^L,O/!QA5Y<U-F8T6*PW8*
M]YH50)PS'&QYUWB=QQ??96")_@*\F:?/)6K+N!LLN;@^",] 3]T.CTY1-MHM
MNR6E3 D+.U4U7/)_'[#Z_ 8';!RC-A;( )F?@</FNO/1M(^^+&Y=0X/(XZH4
M+G_47R H3Q<4MBN'$ZW-UDIQ1,3NZ%3A@X9\S&$C[85L0 GD<)(PH:T=-4;^
ML!;*]JX6&!X#6^UF&V.9:I6$3&PB:<E-?I&P26"#!&_%=#9!X;S.9(0KVGF&
M3*FL^Y8<3$V$];0;-_]OE[N1!TY0O_2E(YYWKYG+@=EI8R,LKN8,LTE=_[PY
M-W+!^V\?5C[$#/7!\%("OL;@RSW&G.KKW#SZTZI$AH]_L ^?AW!BLM5#*^DQ
M9BJ*BB[J1E7WOPN[[OX%O$<**[G"8@R%3CAD8N7G*?H:E..)L>*MO1)C%3(/
MZ(4H\,3+_J(+ 6O#21"5+GO<_%(77QSMCQ_F/U0ILJ)X4A?0^H7"8QE+V*Q&
MWL9WQ4U64CFLQZ/5PT[''/*V.B/^YC>=[GXX@D7=9N8@0%<!6EJ<ICT)Q]8T
M=GTB4+8LA]I#0QC&?S?PXRR#/=+PWF,V)H3^T<I9NR&\A9:&#@,0"\NY7R.W
MK!IU9*6CK.9O$J@;=<H/YQXCV*A(KQA3@:B*<1HW3A/9K%;(]@Q W81TS0!8
M>)&7M=4KSCCFNZG*\F"9>>062+C -J0N?5@AKVT$WTP/\:DHV@"[XS^-T9-@
MD<!KFQPGA?K7!L/X=;1T0[^!>8 8=>IHK9]>+C1UMV V9X'N491@H'67U#*V
M 9?G#P\XZ89!(09Z]VU]K3\(X,-18?9P"1PA%A22G&P_'G-H#J]\/<R:EJ(>
MFD&P1=I3HJWP!CY*-8UT[>#LWE1.?"9P9Q8+W[L=+.$I>2(EZ4Y*=Q$6)OF]
MP=*2>[,TU8!4&Q-)S]_X*DU";SVN=21;[D%]WGJ)G.X9'N%&%W4<56'&*"0-
MA3Z7VW8H.&0'M#>*JI[WP@"3Q< DC\!]%8ZB/5%KE(%]S-?]8(JMO>:9%M[#
M6*J,T4XW+K[/3N,;EI8:SU651)A/9$H?#;LK68F/&B6G5N A-/4H'+R7Y25C
MDA=T/UDN"?=.?;"9K0%2L1P@25IMN713A'^%+'4-)FZD*Z@,+Q4K/#RV?)NN
M(##I5C):B5.4LR[6AVB7PTJ4?KP9;OH$$X67T+:R&/+. <=6S+&-(5_H6VYV
M6O#N$MO?,0B+D<81P(KP'J%),2T_8WX*OU<L."_I6"73L$3"_-.;EH>>//H3
MZN=?/[Y=QB'%^ ZE>IU0.*LJTJ6XV>"RA=!4.\H/7?4_A>YX;HD2*;C "MO
MJ[>[22A+:+SY+[*/8J:&8C&_E].Y%C(B\USC$MCQ6'".)L(@/[UW!)\G86KA
M'&#6:-XH#93G$:"Z5O4"%G3S,?FQQ6)83N,6.="#%@0+1%5)>9Q<B%1:ZCI1
MG*5%\V'7]"_&_JA36$[_!>B'#PMBE4NIRI(S5$C!3UIPA4P65R )+L]EC\MC
M<4;L,[=(I"8OD+8^8F=%:Y9<$;X6$::<9+D Z0S$):S8)\=L30&2RU"N485,
M+)>-^F4W"RO:CQ%5MV4D56C+D0#D$K%37EHRW!0ARMX3$Q<_>D%]@(SZ0< -
M+"^=+=PES!)\7JLI.O.= '"N&X%9(229LFCEJ&U75[VRNJ)F+R)T3"&J7H:B
M =%M*"9>_+1%W"F)A\!$><S_CJV_0:4>'N'U4"_8-,>8F5W8>O,D0[U8O&_Z
M3K[5 M*2P6SE,B=<KS(=]M.X)LQ9<'0\;HYNJ+=YG$Z9_]0"V7OP@#F:&!B$
MKID#?8 5YF9<Q57*)#?)(:-C%Y#VW46\D(H&&_EE@+W GN DROXAU@RCB&;P
M^QK_8"Y.)AWA'^@R=@G819=I1IS.D@1!N#%+4> TA.21':6=4TF($TY:5\O<
M:-[]!W9G6P#ECL1RLY5K2'>JM5'V8KCK<B'05(-5E&8SM0",;Y!J:EF$HXNM
M!6V*)8"6MUCSH4=L0<_*KS]00-<].4/2D)Q?UW+D[7"BQ%$3'NZ*W5K 1+0#
M&D! )4 3I1_7@"Y@(,NQBA-+^S8^YG=8=D=2Z^'8G\.+9OW5PILA&422%PSJ
MB5";&7SF5%F+C=QV62I-$AYK_ =R'S*+^ PG01&X-#WQ[&D5]Q5J\Y)YM"SW
M>*1T7JY^HDS_\#%D3ILM):+):/^&[0Z=RFJ=(FXE<D)"" ?&""H8?M R15TF
MW9-P[JJ\AT&M$!%?<6-(#%\;*EFYC072T>S(' ,\9^/-G6A8?'-'>Y.ZRI;\
M!7J.\K]"55+:;[H>A(^H5-$-EI&_,O?-@.N43"^C!:^)"_TZXW=7M(2#*PO$
M:EL<ZK.E*GW&6\9)/B=(4*A,^ZS1@4KIJE'=;,SP%V" 3=F 7%'RY@%TXPDF
M-$]2AS##\#)R??W *9L_GDB04\M-R!)]]J<=^Q+0"\]T]T$>4IQ*0*?)=ZI(
M.>!N1KKJ#[,X*-JOW;F\G)O00/#>+V%]?CN?+GU;NM_K8P(//U1P,6Y+ Q;
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M0>:J?.S"7?4HX4G&5I1?%J0=VO:A/,YP^=*W6B6&5-"UG(0E'K\H,,[G'4X
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MU=Y=M6L6S:COU2V>_<0KMB60-Q,=>'JM](7N$NJBMWO9XYIOEEM[P@?.*$(
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M_#30]E4G%^DDH2K@^R.;GT)S>.[&4L6K3_Y:2 8&@OU;U7ZLR@<\F/T>,DN
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M.;+0M,1R'*LFRT$6<=-FW7E+[B%/$WD$DZ@\UH^=Y59X_&F4 O- B46X6KA
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MF]GU;>^)MIR,Y/%GILAGW'*RVJQM"XBY/N:F?=+IF@/L966U!(/OIBA&S-D
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MQ#R<\*+N80\VK2:B8ER:=48YSVS6F*O!+U>/#(00+E2PBOB<&P,/EU4D$)B
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M'W#W15 \$R\FZPM]4>7IM0_?1Z3,E& 7J0/FY";#H_=*%[,1J=^KVYZS1YR
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M6U&Z#\/3!H%3D=30TW"M3G=MG,.D_6D,$,6$<41-J,D>PA_CYP*[7#@='_1
M>N!%%YX:M5UJMDKN85S0M4_[PC+K9_35*CW?\H]LC7&*;9.D6FUUR*&7D,M)
MB"/-/=*C6[ M3\_UE5>@_A=V:3T..[C0 AT!P+*@96/N#BB?15GY:EUZ;6]M
M(E@E!P,;T;FP0K2J[SW+SCP"66;(YBK%B^8DQ$?UA,X(4,4P/FGJUVCE.&W/
MCL.:U2JD1WL6+5CMRG.'9 )=0Z'"*H_&_(BV.S%B%%KY(+U9]6Q82;>AKV>
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MU(YW1@!&T'*>: J+_5@4A".8LZL&7#V32-?E@Y LKB'/K"5"@MK8,J\@W7!
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M."LNP2Z:"PCST+:ML@V+*HH6AH<@&BJ%#+F$D0!I,(5M#<QG(8V&"'+4%7-
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M=_0"7YQ=':L$<"*-VFK5Z$/F'CUAIYQJS',_'.4H\]W@M1YUWZ]'3??&'[;
M#4KUCP@[(LFS-$*)!7/- M<KE;85_.: >JR93?=H9SG!S8-3 @M$1$O%$$=<
M0*#&GRV]L0BQ@NT.>'&P4.' 4C('R8TN!A;%^92KJ=$.RC#+"N[4@AS$@'#I
M,<E&9RAI- K7N S[M8EJ$J:XF=]NU6I/*%6P,K( -KJKF*6.XCP/F/YDYZ'K
M/22V_P!@ 4:0NA-B5M>V;?L]=#;G]QTAP&3"Q0KI2F%DT)DG5#G'I%7 $KE+
M2' N"(&$,J&;!?5 JL+61D($$(AQO:8W1H,059CX*@91G%>/.4%6&D8!L-((
M8(S/$%*<D!<-0/1TCGT:^9@36\;#,Z%XEI!IWEG ?6$NU/>UU]R_6YHT.F6;
M)U']0 *-."IWU,O8^7WF"YW75W?C3[BEH UP4%B66.$;D&D2E"#C0 !L$0=X
M*4=97*6D'#F@C,D((L8+M#GA*WP4-NM4NW-#UE[U%N4W-Y8!1U46-@"=N>;9
MJ58060P1(M32,,4C9AF'^5Z_N.IE>TM(&PI)JI6+=/"-"ROHCN^#FVX%E4E3
M&@LTZ"= (%-4H(<$<PH//5B2JNRB%W'J/ER\ONM48M39FVMM3HV<B8KWEK64
MFC,-8<D.>8=)DA H%UG:6FL((L@B$KFT-!$;-T*75EX8\O&C?.7EO[R("'@8
MN^8C#Z8P=\(-'F&@[$PC+%SE?=&E#!,J)UZ8*I[B3NMEB<..LU:U3 W(";\=
ME?F_Q+!,:M;?T>0<&,=GW!\%  %JN  RJX"&^PM]NK>XZQB@P$IZ?S"T.2'/
M,M,,PZD!YP1*.NL++J2ML-0UF];P/]4U.$T:%NRNT*9G956&KF;M3HEA8$MP
MP24OM&;PJ\%X** M6&SV,J)O0M75+31G<#>4I^Y.C Z,M6+YPBQ@\IH7VT1'
MHH[RNL$J:E/L<TN:B<(1)C'1Q^H\T8>:,L7FWVO;SOCI%M^C4_<$FZ8C1J6[
M-E9-NHH%NA$*W8![P@D$$2S64[I8UAR16S!*=-9>V)FRK0DM[+DN(!(2#VE*
M>L6:$=V)M'-')9E:5Z,2:0E*!;MS45C4XX5CE-Q!'<9::P@@4;LP[8//WE[0
MPYC-&"6_YB6,$4K '7QY&\T6Z+YKE?-5G5^IF[[@OP^P/<L\+O'=QZ_Y<N89
MDTASPY(*$')#GF6D :EOBA$5@@I.@P3WNE4 U'(@E\H2 RT D5AXH;I#:F,I
M"N\$6!7A2VWQL\W# 35A;T EM67;?+162&I%/A TPQ%N\YC.IS05,[2M(GKQ
MJ>MT<UQT6:]%= CU4NI#!&#P3+1 C3Y,:-9(6W*-Q/,$?0CU=RMZ /Y)A&8I
M1IT&U[Y7K6(:MM"?B?GZ&;ON!K;)C?>S6@;EUM/=WX/F6(<\.26;RN4$0+""
M005$@ZYUB#8H],1M;O,0M(\QCKQ#FP9$5I7JW,D(% NL>.-JB#K @;YBO#!M
M*!G25@H*V'BDRT $#3Z!2IHTRS?3Z&,W?;ZX-9E6%TM3&L*"&JK!V0!\_,'E
M+YSM!&L PC#,FD.> V@B$#![S+O,-,D!HP6T ZS#I+364X8NG4FJY(^JL#ES
M\@RM%T"@=M C(C43^;PMJ@LZ1X6K-8"P4!1Y&>):$P!K=5&@@#;2:/TW%FL(
M<6,T?;C57&K+H0V-= Q@=DOZ7B%;2QK ,M\ICM,FD.> VE\Y1M+$"PY(2"")
M1UE&Z4:P#I!P5,[2\%UC!AHZ9M>=UU]D^JILTA";1C/R?;WB+15A87EAGFD(
MST"_2*6W-P8* 8+M#G@[DOG.TL:P+"+&9-(/> =(000.6N\I-)UPY(J!Y\"A
M-ZX;)UV'BCSM^I+*8EJAQ9H^W-JKF*&LHWH:;,VAHLZ O[H0-PZ2^<'E#GF-
MH(U@&#4PS)I#G@\I?.4.DL0#!Y0@1@II .LIM$76)SE@K,ZVO>;OKJ=>+&8%
MP;^VS3;\FFD/,O:W.&^<WOC@*$$62V#!D ]X*:0YX/*7SE<F4:P#!>4RE)I#
MG@-H* 8/*"[.LQ-^/>J4:JWO-2>:O\3&:(-/3[90TJEW<AY8^9!8T:0(IPM(
M01=P>4ZH+:=<.C+&L!!326.L+U,PYX<DZI0Z2QV@76$%0=B"9"!NA1U.WK^!
MX,8ZS1P6WVHN4L<JD+@P@C#,P@DC$MA B 8*:0YX)M.K,QMAFX@6')+'6439
MGTX.S2) =YK>S7;^0TXC?VA6J:%,UK[)P#+@P@BQG:6D((L8=)U0Y(<\$V@C
M6 8*:2QUA>ZX<\SO(['^_B.-96B+8W3Z&E#^ .G!UXD.0<!K[03&Y>U*FF^$
MO;NE3W']'Z0@>4N"2Y<&$$6,S""2,2V @B 87M#G@C,M2O#Y$(X@5*P%IM(:
M$S@QHBU_"=.#'C?IPZQ8^S-KA1C(%YXQ3G;I.1_H!/F9&G6#+2DN=4'E+@\!
M%)VEI"",IVE\X/*'/!'2-_E3GY_CO&!"7\A$+A8A!*#*5_A=)OP>"5B$)^9S
M?9TCE5T(^^5&X&\0Q*BK? V"GE"+EP80)M+99+8,&$$6/"Q"2+&"Q<9,B_ =
M7\2HH81L=!5,O%W)6K6S'^'1P8\+#K-(,%S3[/I4LI Q3@'"2^M5[E:(@!$$
M1$$J5DP7]2U\RGD2V$$#+EP64@\IU0>4N#P$$=I:0@X6=W8<WXYL#C'?==UZ
ML-31-*YJ.KF70:[C,/+("PHN'-5:5(_BJGC8]. 6LI<N&=/VEL!8*M@AUW4
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MT?VSI-^#P1/HT?VSIP8\*%;Q*:=>%G;^X2GC<]."#AG0/[JDKO #!_\ ;?\
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MNAVU_GK>BIU[JTM""0<8A8HM AMM!4T"AMX8-[-#SA=I#QE:$D]Y=8D5USQ
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M%H($E;X U 0.M3CZ,/5D1J- &5\B]-I> )33HBMT!Y[I%86[UL?ENZ>'0R\
MZ%*OV1$OX)C]2 3T ]?P97NX-]UJ6O/7)ZW=!:J;OAV$!#5+F*L6U-C#G7A=
MUR8N*JH<:J];N[\)01,^G8(GKRP&.0W(IFOJNK \+#"H,^G/#EG,M V5Q?G0
M]9_V$N74M?<*1OG.C+G/CMEW1:<4Y*&\'AS;(U^U,-]I_6L[3RK?4:P_0AYI
MMQIDKW.P%DB)Q_]ZK]G&^<U3-8&"F6DJ S'_06B4Y:2>#>%*6^!^:,_:QN<L
MSL>VN:XQ[5];,*I6==[]'J@@MG$G;XJ"Z4&]+,G<JLO*5XLC0_5!H4DELL%B
M.\HW^ 4@=Y01YSGLKR:PJ<?1A2FKE[?1/;8'O26KF+_AF3-9'7='I-7:#O5<
M,>3V1%ND-SJQR7'6:FZK*3L904'M,"7W//XXX0N"CNH2P((W<A>2)::DN]@L
M+"VP#;O&N/K7PQMLB,FH=TNM94W'49EBH2OJV+!.O]5?C^*[&N-B?I@Q[<'2
M*APH?/?1$T1:%.,#''.;';'KB>\Y:IFV?JJ^#]+WBMGCXUOW51UX1"Z]3#RO
M]6)"!^91RDQLY2').?&8VXR$"SX'W<M9/;F>I7V>7<%/T^#[>;3,O^I+?W3Q
M>BRGRZ)I.77ZES+@H;["E]KSUZG#!8Y(YJWEUEV62'56KFJ,6WU9OQY)2R\
M>%!HVJ,*2$WGVOV67\,6U'@"NB]+=(@(B<"3#"B6]YA<B76G$8V.Y3$7CB%(
MF'<O43[V90D4<CRK:S?_V;;;XS(F';=U*7TJ,%EC;NVI61TS>LO&\.^M#("
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M+CSI&+TU1_Z9I0N6\]_M#';/20[+VD_K]'&G4G!X;B>I:G@N-6!K.XE.09;
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M=3=M#$F?#=5?SZ;79"!2J)& $-6#Y1= H:/W^Y)E-\ 6$UZ5EE<R00%; 4O
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MN3OA[B9UYU>6Y$GK4O59@P<>EUCJ6ECAJ?4V/M]4#[\ \&8_XNMU7:30XZ$
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M;P/>@^TC,>XZWTJ^KS1N)!2C63Q'H$.DZ*52O5E(2GLM?FP)=QDUK,3H&<]
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M 08_ O\ @U<:5M*;6;]A23"A2GH%?1NPW'1$34H[DC445XF\#^<V*^;;_P
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M$)C^$X@M_+LA 0D*\"%4)%]"IN^Z/,ER&V!Z,Y=8L/H F)FOH1=E&OC$ZO\
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M_P 4DX$*^1=VPQY&6/.Z!_-/^=K'@7U?N(LB07F::'\H\?T03S=*\$VYL@L
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M;SBA)BF.._9';2CMZUM<,')];,A@JKN3 I#+8[UV2+6P9EA)42-(T&,]+?4
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M X[ Q$?DU[[A(#8\R6*D9+E%,TP9+*J2]&;':1%H&G)4MTU61*3*DE /'.^
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MZQR[N9%@DTD:.7E;<E'G7SLIXD"+,/G>[^T(R\6*NJW(Y'LW"^?R^1N7CO\
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M)@ 8+CGF1TX"N_V@=/%-^./B#Z$_<VRE\"^ /]7?_<3P_N;8+L/FQ_=5?&P
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MF=54%Z^P.=Z-5VL.7):;W>U<C-.D^+*JN&?+EQZ? X\\X#3+0$XZZX0@VVV
MJ1N.&2H(  IBJKN1-K[4&GSL9%)IYZ6Q)LWJ]Z-&F%"9.3)6L5W*<L6V$$N
M^N/3P_Z;J#_Y$_\ ^]V?D:/OXUJL3+VR)D?AV$1#54 I%?-:CRP:,D5!<R\L
ME3<2[.::U+)MF[-J+&ED,2K<EL\F6*DU[43%,V";TV;@CJ9RI?>- :*\KIE=
M%(EPPSSR;.#&'?Q=<;38'6C!UIT!<;<;)#;<;-,P&!CB) 0KBBIQ\$N]U%91
M:FJA!F?ERCR@GT6FQ3%Q^0ZNX&P0C-=R(NTVWTH[-=AU\_W=(6;#*&XDGL[,
MG 0,BS!RGQW^+"M]5NS6H=A/]W1UA0RF.+)[.])P( (<H<I@M^T2?'S+'G16
M);"DF4E9DM"\UF'YI9#X>"/W>6=E*;U%(EU<'*$)QR#'E7*,%!:E347EL*82
M6U)5W AHJ^!+;5UW$IH9D3;'/YCLF6Z*9B:A0HX/3)C@HN]&P+*F]<$VY',U
M-RLV7MON1.S888Y\O;.V95X?DL?-M"U)IJ;[QIK#G=EE]FE1>8L=]R,^/)F,
MQWQ5F0R0+B/K"O@<KTN9M^^R:MOEIV LZ(T:8XHD]]V'"E(F'%AQT=_'CA('
M2ENKTZ&T+TRIFQW8-G'9(D#G=G>3)(80U1"-DG %51%5%5-KKN^;>F0]4T;/
M:7J^QAG$[9$ZB]KK'B56YK'*> ^JN.0\<-Q9?L.G/Z_T%_L-;X'](:QU7&TS
MW=Z0LK&M+MUI$J(HG2@3%HK;\]QN(MK;6K1,BXN) QA@BY=\R\[L]8::@ZKH
MDBRXD*LU_&N7KI!E,!(!(TFYGRAG-,D3S2QLG7##+OW3+:Z?*7<P*?4U'93#
M]>8[7PGNSRG=V^0[ ?9YA?/<S%T[:AB:CG60Z1T][LL)E/ EK$&TNI_;H]:4
MDA12Y46'&D[QP<'/@)"A%FH>\'NZDVE.L2[B0I,;M[\AR%*)I^57VT"8Z7:V
M2;?AJ!BIGB3@*."(6T3O+AY6]17-)6PHYBTG)CZ@FOI5SY@-JA +<-]I]YH2
M1150$5X[?^H7>*Y;W4[4DZR=AQULY$9%CQYCL1ZPFR&B2?)G2YS#JXDX@Y,%
MP7'';2^HM%SK,M+WK9O/ULQ_F]IC0I+35W22"#DA,9;CS&G(YN)G:,Q7%2',
MLCO(/MKE[51:*JK#&6X->D"9=9S-8*ID5]T;$NON7!!^CMI+6=W&MSNYSML\
M^<>U=CQU.MU):P8N6.(*(HD>$&/E7;3/=A5V"5<6^BA:Z@?-_LK,B))L'*VL
MCRY6(HW6MOPWW7T5<JY05=P[)4EWA:56][(@%JM.\:K[9VWEIC(&L]]>YNS\
M[?RE8QR;L^/6VU5W<V<]+*'IYMNQH'1>[2U&C=L<A64>+(3,CE<X^XRZRB+E
M',:IZV[7/]8:Y_IMN[O^K]1_[14;:Y_\L_WPT_LUJCO#EVMO KWI6GM+4K=@
M_$BP*Z(ZLN4\KD<@D>UL9KJ V)"(Y55<V9,C>B^[RZLJL=6-5M74OK)_26H.
ML26F?@2'VNL\TW*)Q -41T40"3V@HYM?RZHK@=1TE!/M6;J58N.)-EUD)R88
M2X2 L,(\Q6%%>6"$&;%%7#??U$Q\WXM#J!!K.81$L6-80VY#L1O'<,<90&X*
M?2=+9K76O9SL,0K8U6[%>NF:6IF%%<?<;?E225J5ST9=R8-/-)E'R[:<O>Z#
M4-2S<,7!1I];0:P]_2(JM-'*C6J*5K8V=>]$E1LF;.@YC3@J;[:\GDASKGN3
MGVTTT1!0Y=CH5V7()$%$1$)YY=KQ[5TRS=TKIVP96'10YIQ(\V[LHN$R7))O
MVH(Q"ALCU%$RS>LB"J%I'7_=O-LJEM;;LO)=E').MMF&2F0W8LEW%YV+-C,O
M"ZT[G3J8;Q-1336I@;1I+^BJ[964QP8<GPF9+K&]5_(..*/%>&TV+!<5J7JR
MQC::Y@*J.-P9#,J;9Y?JR(<$HY?5?V#3##2-'6Z)G]NP3*KUK(JY$JUD%TXO
M6#SB[^"8)T;:L>N:JHG(WJDVU=LX,.2@,>YJU2!3E-'E9ZRXIPVEL=V_8TTK
MV"S&W;HR#W0TW^S*%.98Y&$?L8:H%CJABV+VX=R)AI>+-C1YD9V@>YD>4RW(
M8<R:*U&X&=IT2;+*X**F*;E3:;5S-.4\"<Y'<&NNZZMB0[*LE95Y#[4F,VTZ
MXR#N"FR2JVXFY4VU3H:Z>>>>T/80P@=H-2=CP+#MS)UH9UYG(KIE8>5%]1'D
M%-R(B;%JG5FIK&STC2T_.I]#8(Q7LW+++W/D/N-9.;$=R"X6*%(=,E!7$9 6
MUU7_ &O+]35?@I-;T\2/?]V]='<C:SH(T44N(R/O(JWH2R4B5F*T(H.7(VVN
M;FXB?,:I=(=Q0*C0'66VJ]:7%82P*>MSMOO5W89* INN8*RYO$W30@97#%\=
M_P#A^[MI3^UX_J:TVTU_9^F_5T?:RN;%WDU]3 EV4Y[^2B08[DF0>]4]5IM=
MN]COMF Z%\YJ]F^J<N='&:RH.0Y>)$?11)(D>-;IE7H6MPVTOJK,)2;"M;"S
M0<$Y=O"4H5J&1/4'MT<R!/Y-47IVUG8:M(['2&@GI46MI^:?87F8=BY6U,4D
M;+!(TYR.]-?P+VKG57%M<-O<<^)HJ#%!H4]SRV**-'%DDZJ>[WA!M&B3AU<-
MH\/2Z5+=-"S1XL>D6+[NC=;FFPR$->0U@3N.5/+X)C=BNA]*V]OS[Z6,L(+-
MI."?*DYY2<T3F.1G);+J  >S%15 %-K[O(T'3/5?=M$@R&1L_=SU/674Z34L
MU[R5<4VV4=23/S2B1 1!0,[B X8HO==WRU0JU.IKQ**W)M-]A ,'I[,)S!0Q
M1Z"$]DM^) [Q3+L#K9(;;@"X!)P(#3,))YE1?L.G/Z_T%_L-;X-3Z>[UH(%I
MB]O;Z7$?FS[*KAQUU ZY<T,UVQB3H3_(]LD8W"<5M'"7/AE5162>C60C(WS5
MD%JO5HL(UAFYBNKJ+)R\.G'#;4<'N^9B-:<DUFI)S:P;67<Q7IBP'HDMUJ=,
MG6!G@</(J(YE$@7=CCMK#2]E.CPY5\S3SJ<9#C;(RGJOWDW.C-&XH\V4;4YL
MQ#CE;-4X+M7Z-"7'=O;:[A3W8 . ;\2KKVI#A2I#8DIQT?E.-"UF1.8F?#U5
MVH:[LQE94-95ZM?B9"1\(;LV18RD(,W5<@U=J3CB%P1HMV;:FTZU-BI>Z7<L
M8-A6\T!E\AVQE3X4X(Q&KQ1'8TP0YF&7F@:=&&V@M!:8>CV]M6+.BO#"<[0+
M=MJ:95QF*UPV5<1)#(U@&8HF(([O\B7$)E"-JN+2D;.B&N#4>XK(H&>).***
MN5-ZKO7CMIAD)\17:=[4+%J'/;0J]Y_4MQ/9"7BJ<A78<MMQ,>(EMH?5UC!=
MG:=FU,2KGLB4@4D'2W$N;.A*^V\TL8YM;9B@()MEU2)%Q15VB75#I>+:5<YH
M7HTR'JO5SK1B2(N4LNH<6GF\<#;+ P+<2(NUO([OZ^!$N0B-5]R,745K</QH
MTA[M#+$N+/M[ 89/.P\1Q$#7(O1CMKG^L-<_TVW=W_5^H_\ :*C;7/\ Y9_O
MAI_;3G]8:B_7<W;NL_K#NT_O@]MKC^R&I?U--VUQ_7]=^KBVU4YWG6\V4,%F
MPFP:)N<Y$YH-6;<9NKA;^;&K*V,O7!G(Z2X$I8YU73E+HNJA5>IW[%R5.89L
MK*PF-TH17D19O;[":;(R);P*UFP4T L-P[?_ . ?_P#.MM6:-F3H\6SDV,.Z
MJXTAQMHK '(W8IH1,RH3S\98S2D''*>*)N+#3.AHTMB3<>_?V@G16' ==@1X
M==-KXJ2Q$E)DYIVIJV*IBJ-*ODQT-33P5N=7:5HXTUHDRDQ+"O8[3'5,5WL/
M*H>?#;0-@8DL.'K#"0J)CUG(#K[8X>JI$U$<P]&VHS A,#T[;D!BJ$)"5;(4
M2$DW**IM=7>I+'4D2367WNQEJFF5D:,Y'2!"EXO#-I[!Y75<D*F(F*9>CIV?
M9TG4]GDS!$9UI+>.9:3 !<P-NRG/R; KOY;0MMX[\N._;2?]02/[CZEVFW^H
MK"/&".PX<."KP#.MI2"O)@5\?>Z^^^YNW"HMIB18"BJG>CJR+,*AN-?.E!TW
M<$V:=FD0?>9R;9@4_*1DL[/(BHGKQB3:GL]1]\?OZCAS!>LJ?L\@>WQD$D5C
M,3:"F)*GQ;67]7S/]G<VU7_:\OU-5^"H[MM$PG:;3VI(;[NK-?$0DS"K0<Y,
MRG8!MQ'FI+[)IU>J<I#R HMB^:55WW5L6>LM&7I5=-K#2DB2Q[Q:?4VHC=]'
M<+L\; '7%=5S!!C(1H>#"J;6VE/[7C^IK3;37]GZ;]71]HVDX!$MMKJR:KA9
M:QYY5, V95ARD%<ZJ_)*-'5,,#!XDV:T367'=_'TV,"9 6L>")(S1K,I#D]J
M0\>GW3>.0<MS.N9<5+CMK_N9U(HLV5/.=MX+6=2:5V,;5=<I%-S(KL>2WV20
MQ@*9FU,\-N\G1^IG@J(>JI<LJ69,5&(KQ%9NV="A2)"H@A-K9[@B6=45]$;W
MDN[56O+ABS/4$#2M@]'<8L7&(J'3U<IZ%FC("B2(8=;Z6UM5Z.U%^RM\]K68
M<:ZR&?9VV0HW9(900B_2&!(/AV"UUOWJIJJA:A3&WJHF7FA5]P$Y,E3= 01(
MZHJ[,6^IM-55_*]W-P8U@\KJG[NSOR66V'X[[?LN9,,Q(5QZ^*+M4Z![O+&>
MND[IIKWUI8K"380*]V573YDAH0?<=<!VO;8;EB9*KPB2B1*"JFU:R:IS96LZ
MH6!W9L6ZN[=</#''((#@JITDGEVHHTA%%^/35C#PKQ1UJ$PVXBX[\4,?L,'O
M6D7%TS<0)M--;KF5@^[3<I6F&6!//$*5D=2.F?!ST>!@-3P7@GPP)J#>5CH1
M+>(T1*:L"^;3[,B-G55Y;S;@"JJHHBJJ["S*USK!^M \P0F_=K*B.?%,KCD:
M2PAH*KOY/%<<.C9G0E3VIFFCU<RJ9)U[M$P6IW:%?=)XPRD\KDHB]7+CT8;M
MI&FY+EU+E.6CEI'U,KT)F]A*Y&C1NPM.-0NQNUOZ-FY;K1]<R5%1<,(]M:V%
MSJE8;P/Q:ZP[+%JU<;5#;*:Q%:YTWEF..17!:+@8$F[90414%'*H*B**BJ8*
M*CP4539ZRIIMQI-9+I.O5]<L234 1;R['$E,\^&)'BN07N4/  %$PV&Y@A.O
M-0B!@S<71L.%!1P5!WW9$CL,1XA. N"FJ./8*J(>553:RH+N*$VJMHCL*=&-
M2'F,NIORF"B;3H+@0&*H0$B*F]-E=356JQKE<S=B_P!TK)1O^32>L')\/(VD
MZ>U16,6M7)435EW,#C+X8\J5$D-J#\26UF7*XV0E@JIP545WW7K75]= ?7VL
M)2KWR(<2S-]H;C11(,A8#F;)4Z<=K"#IQ^UEG;.QG[&9;267GGG(@.@RC;<:
M-$CL--\\\$0,V_>2[6_>E%M[E^WN'K=Y^O?6%[M:*X+,^C7+BA)P:^;B:^?:
MDDW=O<UA43,YF.E4L+*Z,\XQN*]VN+)7$%BIAAAQVM]&VDN9!@W'8.?*@<GM
M;7N^SA6C?*[0T\SUWH(BN(KU57:#I&JF39\* ]->;DV'([493I;LQQ#[,TPU
M@!NX)@/#;3O>5-M[F-:Z<>H7HL"*L+W>^6G[,K2,C_-BN2<'GBRGE-.KPPVM
MJ60XXTQ<5D^K>=9R\UMJPBNQ''&LXD', '<4Q14QVMJZDL[6S:N)K,U\[3LG
M,;<88Y BUV2/''(H^7':7J:NMKK2MA8R7)L]FK[,]!<F/*IORH[+P(]$>D.D
MI'E<Y>*[A3:TTVCER]87$F'*EZLE/1)%\)Q)"2.5$4XG8HL9W$Q-$:SFA]<B
M5!5/_3CM<SW7^QG[$]N]CV_L'N/W%VO\EV?MG9^OZF3/T8;MF-.&Y<]NBSI<
M]G5#3L)J[(I8L@423A#6%*@ ,8,H$UF#>H$*F6,6^G3;;5,ZO?;DU[%GV9BL
MCR63%QB2Y#BM(<IYEP<11QQ6O*"^"]T]#$2MVD:MJ/,N"+:UJJZVQCP%9T<G
M8^*[AYN.S5/8NO,7])7O:*U5%<'E6,25&BG7MRG67DSBY+A(AXD*)ST<'YB[
M6-+2V-G9,65G[T==M.R\T'>RQXG+;[)'CAR\D=%WICCX#UA8:BU)4V)PHL+E
MU+D!MH&XC9M"0$]#>?0W -<W6V"PN9FI]5N 8EV:YLV A.9/R:/!70X<MU!\
MBOY%3<HX8XQH%?%CP8,-EN/$AQ&6X\6-':% :888:$6VFFQ3!!%$1$\#\8E4
M1D,NLDH^L@N@H*J8XIBB%M8TM+8V=DQ96?O1UVT[+S0=[+'B<MOLD>.'+R1T
M7>F./BUU+=6-G6L5MG[T:=J^R\TW>RR(G+<[7'D!R\DA5W)CCLB)KW7R(B8(
MB3:Y$1$X(B>[]R)MW?6\_4.H[).[F) C4T"6Y!*)).OL'[-N5/\ T/F.2'I;
MH\Q144(6@'H\$/O;BVEO6WS#+3,N%%6)[MLT""Y5FLP#C%()7J\A;7 ]W+$D
MW[,?M-!?;L8C:M0KRK=");QF552Y'.-J0Q)C9R54;>;<$555'!579(4CO)UT
M]4#F$:U'XH +/606DS@]&3 "P7V."^39-,Z;6><#MC\]QVRDA*EO2I ,MNN&
M;3$9E,0CCN !'9YAS'EOM.,G@N"Y'!4"P7H7!=G6=+]YO>+IRN=(E6MC6HDP
M./S$[,E>A BD7K(2X+QZ5DV]6EE<:AF ZV]?WTAJ7.!M\L[[<466(T>.CY)U
MSRJZ?!35-VVDN[FM3M>E^[EWW[KF4**4/MCCL=PZEUT<S92%8CA&%-Q"Y(?Q
M3V18?\!H%QJ<+,XEC8>[6$JXK4IWM'9GY7M =DQ4%OEQUWXKOVIM05Z/) O:
MFNN822 1M](EG$9FQD?;$W!![DOIF1"7!>GQKF]D,OR&*6JL+9]B*',DOLUT
M1Z8XS';W9WW 9P!.DMKZ6WIZ1IYZAF1([C+D[WFQ(:G-/N1W6IB0:].<G9CY
MC61<G57%<WV#2M)7T5=;-:@C$^\_,D267(ZI.")@V+*923*6._:ZUE(KI%L%
M2,3+ C.<@GWILZ-7L(Y)5IX8K"/2D4W%$L$X(2X(L/5K-2_2J_*FPGJ]Y_M8
MM/PG<A+'F]GB)+8,53K\L,"Q'#$?L%CW2.45<U70I-LP-N$B2LTTKJPYX*3*
MIR$5PQRKYON+I3^UX_J:TV[M/[ :-_N[7>!_0O=II1_76HXK[D.4\WVIZ&,]
MC,DB'"@US3LVS*(:8.FA- *BJ)FXI#KN^#NSFZ6A6"^RL8L6TANLM8H)R @6
M@N^\V&E+VG)>0@\A+U=KW6M;R+>+6:5M-3P4;?RQK-B%4OVL9 D@+F5F8#2=
M=$+!"QPV@SX6E"GZZM;6=71-)P9KTIN.S%&.3=A+D-P^U&,GM/LF0:SN$!;Q
M1,VVL=8ZSTBWI^PTX5R42H6+:5G;XU711K5"<;M.=)$'WGE;YB8CN7=B*[:A
MDP='5&C&:NV996%3$TK$MV5%YQRG!9@0!1[J(BK@JKAQVE]W/=)HK]MM05CD
MIBRF2I)1JZ/)@GR9S8@A1D[-"D+RG)+TAAKF]4<V(DL2@USW25\*[GY#A"Q=
MFU$F Z]R6^RO,I<Q'U1SJEED+@O'#:5J_O'HA[OSKQG2K"!)FI.[+71$S-RB
M<:;$R<D#ZK2#S%+ 4155$VGEW3]TTB[I*YXF3L;$9TLW=V<.:, X<2#),%QY
M'.?/+OZ=I6B]3T+^C-<1.?EJI1O*U8+%0CELLC*8C2H=A$;%2..XBKD12$EP
M)!T1IN33Q9-9JAV.MC<2+%8?N>&=JQ DRN3V9QMX8S#BN]9QM.KQ3CMV'NQ[
MO7[[3;-FS6NZ@F0KF4,C.^C92\E<#;57'4%S!SC(\G6)!]5.[7^KW/UTSMJ3
M5+M-$U"U7-UK3M-.-&XDYJTN:ZH<;?(H\H>6(3U+!0)"RX;4^HHU!!TQ'?>L
MXS-+6D!0H@0;"1&]ARXT0!1U6\ZHC:;UVNX2Z$F3-4M6<6LTQIZFER9[EZ3R
MV RGW7AK5<C#"6*WU ;>==)\4%,$,AAQ>\WNL<H:V<6=M&VK2MLDB(>5V1%]
MZ\R+:%'S)F$>3O\ G#CM8!W-]V=IK6DJG29DZG<K;J3!DO-@)NM1(E<PT8X"
M6(YW>:XBX\I$XS]+7E&FG=4P8KLP&F7G'85@S&=;9F@ 20"3"F17'4Q9)7,1
MQ7-U53:-=5^D['5TF99L5+,&O=Y7*D2FGS8<D*W'FRE;,F<J<MD\35$51Q39
M=1:B[E$@:9;5LI#C[=S#D1VG"$![5)=5_L68UPS.Q11%5$],75-,V]&$GW8%
MC7R%$WZRTC TY(A..!@#P\M\'&S3#.TX*J@KB*:RU7:,2I<>OG:@!J%"#/*F
MS9E*L.%$9QZHJ_)?%%)?5'%=_#9BYU+W+OTVEGWP$2GL7T&1E<P4&2MY,48;
M<IP?5SQAS?1W+M7:KH2<['/$P=C/Y4E0)C!9)4&6($0B^P?D7 A5"3<2>#6$
M^JM>Q=U6CR]S0X+,&L=74MNO-:&:[8R(3EBW'R@<C*RZUE'LZ*BXN9M4]V7=
M_K:KI(\'"17LV]12'#8C,5%?,D LQ=,W-BXX;L@E3-FX\43:A;[WW*'5NE;N
M23!W%1&CLNL@T;7:RB' KJ91EQ&7D<1I^)@^.*"6.8ATY;Z)N1JI=CJ$(;\H
M8-59"_"*KG24 1LX<YA!)QH2S"B+Y\-FK9G7>A]0HK+<D*=N%5,O20-OG"UF
M=T;2M"1)U?\ I0;UX].UKHS6%..F.\*@1Y9M:@NM19[45P&);D5F2;C\67$>
M/VC!&YU%0P(DS9-EO]0+(<YKO9*ROAMJY+M+!6R<"(RJX,L]0%(C-4$11>*X
M"M=IG5H#IRCM*R;:!HY*ZO0X<,Z)ZQJ5D3WHBW?:7 Y;IYG6\27\F">S39VX
MU%:0J>K8-IMV=/>%A@7'W!:9#,7$W'"P1$V[5SV>R\GM':>8'(Y&3F<_G8\O
MD\OK9L<,-FKC3MI"N*M\W6VIT!X7V"<8<)IX,P\#;<'!47:1-EO!'BQ&'94E
M]Q<K;$=ALG7GG"Z ;;%57S;6\+N:]VZ0T;3O)'=U+<1V#DR,^;EJ^<F':*W(
ME-AG!B-'SLCAS'4Q3:HCZLU;IG5>BY!NE;RPBQ.UP6@C/N"+0)745AVB3*$&
MA5"DM@A9E'<J;7^K)?>?HXZ>F9>G'&A556]/[(CR"VVR$GN_89-Y!-/6=3T[
M0M6T?>?I*+73GIC+3-M44[$T2@RG8CJN-P] 3F$$G&ERX.+N\FW=%3T^H&X9
M7V$?4_*K*B8U926IM)%?-L["K=<C-GVEW#E(SN+@F"8;2)DIT&(L5AV3)?<7
M!MEA@"=>=->@&VQ55VH+'4<_)W7:SU;?:<IH3M931^Q\OL:0$[>S!;LC]V.7
M4)'7''2$T)SI'J^"UU-?24BU=1%.3(/=G<5.JS&CBJIS94MXA;:#YQDB;6M-
MJ:3V'3TC3LO4%9IKW=5M]@BR_<\RD+W@$$+23FJK$3S&ZJ.<S'*FY$TJW>6O
MO#NNUX/NMEAZ#6,EIF[$V(YN#.BPF9S\5''6G%[0Z?LWG</R2>/I3^UX_J:T
MV[M/[ :-_N[7;7\^+F65!I+69&0<N;GQH+[S.7.J#FY@)QW;=X=^\@O6C0T5
M<T^?6?:C32M)DWVBJIX37XC2EY59VOILIL"DT=A06%:XJ#G;DR+F%4/9"7K)
MG@V3N.'';4?:U<)8&B.\RN8<<XG%CQ+U8Z"N*XML YRAX8(WAMJW5[L9IVX&
MT9H8DEP!)R%";A-39(QB5,6UG.2QYGE1H?/CKC^R&I?U--VUQ_7]=^KBVUPS
MWBQ)D*JU(-FE;J!N$_* H<BX&RA3VQ81QY^#*93*^C*.N-/B@JG5+#06E.ZQ
MF=>.U:6HOVW8)D*-_OEZJ0WG EL,3(\"J:K>8Z\Z #[3=YP@LNON!8ZBH:J<
M[CB3T=EF;99I*J:+@<RL:5?6Z^'IVT_5:1[F!NJ-&Y4N-=(^^)6QS)DB0[,<
MR.(BEG/EIY !$Z-M&=X]GW83]+(U?:7:NG(O7C) BS&H=A/D.&^CO_@YJ!_4
M#;N_C(63M%/*8S88Y>;:@&;#=CAFVK=/4<1N%5U45N)$CMB(X VG6<<44'F2
M'SQ-PUZSCA*2[UV[M?ZO<_73.VN?_+/]\-/[:<_K#47Z[F[:WM7FVW'ZFHFM
MPU,$)6';&X;;=D-*OY-WL[!-XIOR.$G3MIJ:38K)CZWB16G<$S Q+H;]V0VB
MX8H+AP6E7[U-N[]F&T+0/Z>AV+V"(BN2[/-/ENDJ(F8CD2"^#:_;9;!H/>FK
M7<H(@CS'Z*2^\>"?.<><(E\Z[0ZV5"FWVI+*/VJ'1UYMLY8RNDRU(GS'$<[*
MS(>;,&\C;SA$"]7#?MJX'NXUZCTW.TK>MV4^VL7 EUU8_6S1D6(QIS-6^XY!
MBHKJ#R<<11<-Z;:K_M>7ZFJ]IC4U&C;C:FN[%EIU$+F3*W3DJ;"4,?SL:4R+
MR+T<K;6E98"T465I>[$U>$2!D@KWW696!*B(Y$? 707%,I B[:\KR-5BQKJH
MF,M[\!D3H,IF2?'#%QNN:3\';7EK'51DPM(Z@>BDGS)25<E(SG$=S;RHJ[\<
M$VI9C0BCE]:W]I)5.).LVC](.?=Q1BG#X-M:ZC]Q6FHN6V43W;4#GF%VK3]0
M/-1,CGLVL-^[;3-+"[OK?1FC*>P.3-O;L'P50C1]8W!E;=/U.;%M>V(;,[%M
MVYG8MFW;)[9MVYS8UF0FR3?W]]3[?^_>W>M:UUK=55VUA5NG*\G)9"4==WTC
M@KK;J\F':[&HM-SCXHR:!UI==>0X,T#[B L; 65T/>Y4*WTK=U^ C:TM*0&5
M(*G&<'WUHCT5EA]B5@9TV3TH:SOTG 9@+M=F,E;570RY B&373A[39N5-W.\
MO2*)E VS\>)7[I[*>*33$(*:=FIR5=^J/?YY<UCO0_6)B 0X&B!33Z",BC5.
M(@',4A!$ML^4Z/8%F/H"? $D[[07+\873.<GHG[):YG3ARB:JNWNHD5*- C
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M;M/2JPMH([ML[988VA]#_W"DM@;DL YIS*/M@T7)!)3Q6:WN68WJ2KT'8^V
M_5S"[P!E1!8Q/FUU!R5BB8 YX(\KL!X*&]RF:X#*J*.[K%'BAA81.:ZUJ%DW
M.B5IRENDS94@U*:BKG>V[("<1B56$/TCHL-)Z!Z%</L5E2U/2=&DY-4?<L$7
M4Q&3A^5YH@/;'5QU^;9,NUOLC+M6X\1-37K,5H,1PSL"7%G7OM$SP3OAS>P
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M6I9BA.O&1#C[)CLJSZ!BBA5K\Q)J5?&GX[@BV*;&1$:L_Z_-!/W:4NG'F?J
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MC1*^J@AY\@#Q0.R4J%S-)#AYZ6!+;(ZRNR8*B 8>V^\S[!^]TG@!=C)*( O
M$W6JIO3G+X Q[GJKE72XZ<8U#'K,>K8-M7KH,FPB@1:Q1N?ZPI?>=(8-!;&?
M/'*//J_)&?_L""6$1+P'(S=H%5::D%^A^2152[QEMJK>-1<\RLK3)2ZIZ!:2
M6*8TT%6T!9H7\(Q<6Z-I4@I^[CBYYA<6//['CFTD4D:=L?^W*M[B8]K:K$<]
MOU)]39O0]+[]0*>V8[3Y0,&*J).QJTC (!3*$.\V/&6BB(Y[V)+/7O]X$,P_
M>9++\7&7%_$D9LJXN.Q#EP80E6 0V=SQ/T='7J^(ND((BK)2?C.=()!TK4?F
M%CA?M$:JE/SI@N :%\<?/L^!?MX@&_# ^WAP&.4)++L:]_IHQ1WRT9):? 2W
MGD^O_]M>6Q6G7[+D#MV'[C./\G16-L;LD\/>1%]+32)!'G(B=[Q]>G(^:??K
MZK_+!$.S! 2E$/VLB<+@ZI:0*F7GQ@F1]G\JJ?]EPE:<[@9Y<,)![VI$4_8<
M_N3+\8>KUZ@'AN_.FVY5X,3$90\'*@"/^*?:1G=Q2UI90(8B7SN:TF]CG3;-
M'AZLBTB,X'1\94;Z'0S68INN0/!*[_T=+CEHMMO .DOY<G 1^ Z^'92EZ?DY
ML/%PPTIV*3EM8MBA[9"?3.I>-&<#_TDJI??*)?EVCWZ. &PA>W$9PI!?++:G
M.1E0/J#E"H6/*R.O<@AI^3%D+5:_])NRA:79#JW7!XZE:WL=N\ZZP^ +T+F=
M*-VWI[E BX&.DRS9^OX#8:38"W7(R*K&LFC_7S(SR!)['S(EU"A6J WH9&R%
MO6]MZ=,/ISF+::MFW>CSTL3)"2YI9P?52/UV7D-@$"BD8-%<F: GA/K/?B97
MD.O$X/R^);,R7!!*R^JS9J:K"P?4U7*OI:>LR?NX3U)G/2I!'.IXW,1$"C6M
MB;N#J^,:9]_(&#L'A">;K_!.YJT"T5/()@>QD^,):N4X^MSU%KS;V4E?F@,.
M:^^W4T)N=KDEI)W]EEYT7_"I:CBE#*%P3T F8JSW*+/5#,$,$1R&4FY<J0E5
M.1_9K&<S76"%*H<&"X8PC+ 5HMV>T,Y8,GNIC-_0DS-_656OP3NQ)29V>+?9
MOE<WW"H[6J8E>>6TMKXZ&4#!*%+3LD=FFN[(,]F<DC<GM"K3="#,W'0_.Y.H
MXC#2_)J0D$^#[7I9/IKMT[J+*@CUC/L9DE0:(=N1-UQE_W8$;TRO;?UC:%!-
MBH'!,H-3PT=:MY_J5-G*W'+JS8T='S!4ZV%GR=S?-IN:.$=.586 0HK1H"GL
M8AZV)NL)8,=8X'LB'8GL_HW0-:H/735X.5MR(:?^<]@I4&<4#7%!';]-_LU$
M.);%;;3*69Q2 #\K)Z@>R?T(',S9^B%1=Y:071'A5VU_JOR1-N>SW\$Y[.YB
M_(874L/R?>C*Z0,CXJ.+GI*&58:'*+!PG5@)CRJ2%;5J]L6H3L \SZPEC]$2
M:Y9Y@WVPIHT"W2*AT;D715N "=V;^I _&;M0.@'IQ1FXA<"/K S-LY9KM9PK
M*;4,FT :  $VZJ$3H%1FGJU)^%.UA;8J58.V"3Y/4X>L VXA=GM02HE'49MG
M?<CA JRRWD4&6L \:<#=[FFRKM.KW>*4?5[L:&7I3R&/;4(I"8D ?!!DL1>3
MKT#[G\-)=9U4RM\.,<S"'Y< QF0CM*.5AO>PH\7II0Q@&AQ;M5'('9CKJ;;K
M-V57RK&0'M''F$ /YE.)<,YOS#F\-598D$VJ<M_9$E7TA82F>'LDJ1%?R\)S
M_QZVBC!/^HZ&9[,D)N]-(^W/W305275@/!CHL?%*Z$,U:1EEX()[]E]RYBN_
M'-K%K4U_CQVT&?=7', )RXWY0-@C<G_E)&%:7UC_F:S QMGF$ZPQ<Y#K^0^/
ME5RIY;Q?-KZQ%;B\=5<,1,D2^0>$(CUWIV8+I:/N&I*GYB$+!],9+\"R+#QP
M'MH\P&A$%R4+?8MJSXPUPTOB'[1'I5S!&%)S!&8Z%*A^F"8R,GZ4MPY.C*B]
M-HC]TH?#(;@7 $=:O?;J&"O)8;YI+ZC%Q[2FDX"]NSJP<6<5R:GUD2Q!XKO\
M(6H#5YBEXFH8>7F9MOPO?/G5>EPK L(E'VZS2J^^BF#1V=B[ 8@^?QBH9]:.
M'^/9 X3I2MZ?1?+=E[/5%_(EO% S\L^%F)A_B/&@04J6: OUV+\FQUF/;=V=
M[BLD5%4".\^;X9OE*]V9E0KT@ $#[&\CFIA@@_&Q6/9Q@V&X8X'4< ##7TE8
M7HP9W;GJ ;I=I.[VEHY%8QNQ4XK4 -H:@)G:/%GMN9[1 /KJN0U&\U^A%#./
M A (7<EO\_)0)*<#74H-Y.WQWA*!;84%VY.:M4GAT*=, +D5%1D2LD*'$?,%
MT$$4S0U.R]J%8P]R)JNH]>ILO7;BE%!BOR,T3S.]_0(0(U3F,-=Q,ZI/,T$T
MTK(C"\N(F.X,=?*00CG0*LDN*<;DVOT&TUOU%/D"2%$E\R9NXWK)AUZFSV?,
MY-7-O[;# -:!9\8ZSE!G+&[MP:[1J[9V<V(1O,3BTJTKF].*S^+D(K&1!@C.
M5.5=K94Z"&)<GYUX5,.$Z(Q#!TMR' 7V='I9-^X]C^IAH$FN] SEW\0;,U,U
MX(JYUZQGR@L:J(<GRR&=8DS@2U$VH.(VY1IF@.T5QE! RPJNS2:'@0K<2QRJ
M"G8?% W%"E;#V6R;2X2,<GVN%CCBRFVWIOK#)B:L<[Y)"*,-#(E=P5WQD6[8
M87&P#^\<)9.@7_L?R"&31OX<%?F6;RY[7"(ZF!I!JH+Y[R <$ZS@$5P/&R?K
MGO;5D,5LDE&[*?WZRPDD/CJ<\R@^:CP5"0+!4+N_\M470H?$LR3@U;(Q_(AP
MEL/6<,M^4_K*FN:RL6[2.R0S^WJ^][#3T9E&+"']2$9^6C!+8L?"P@4 ,$.Z
M2Q)O_<QBU:'GCQ$QW@<.2<P"LMN_YL9<+I2TG3REV2"NX$&=[V8C#:W#PJ-:
M0N0:Y9?Z>%X$#&%:V![^\(:CYI&=]MG'E%Z89_?/@E6*F#RLTJ_EWSN8(7?P
M[^S"G5D%^S5;TU83!$-UTGA^$5LN9A$@/HE_4MT0QLR"ULIH.;&#36(#HA(@
MNTAGBQ[;(9W8)+VI ME/TA%5(K"&[6R1Q(<O_M%[6(V@.8#W8P9C[W8U%@^D
MVYK]R.G!-;-8ZF207_S.I\"8TB4T?1JGHB0?T;V41IFV*-%-Z1G!S ZIKFB%
M7J)!+ZE RF4$;LSIRJ.77T;UT[8/Y6W(A)R=*F0QI&6-Q9&"=C)LHF8G1.\5
M+D#<S?CWQ;[/8LE:U>%Q >^H)25BW06Y %*3L*6C$>J+N^L#Q_XS-\5A^RT;
M'*X8"E%;*PK'FDP1I.\?S-QYJEWUQ^RA7FQ)-!\H;@#>:)_-D'@.M1,-KJ#2
M#R!* F_B^-T&4!#0P@U@K2)R9><Y-IDIWS3D+P[@:(J7%[;-]?6\6[IL6NE9
M1YYAQ$RYT7UED2G+<">!&9:'%01HIP-0CL=@0*?[[KU5L/#U0/L6?'ZBZGF4
M=?L"0M5EOF]G9\PN63[&F77[T&EUPKJ)&">-397T/Z^<A1(M(9O,@T>;TF$>
M(1K56I=I-0]TX!"_   1IP1Q.O"?L!7#A,[A92$P5!&4D1"<R6N@3EA(+,L)
MO8NPMA=2>]N$-0%.WGZ2&$1T*8VD46U,%-25G@?2OZH(\)*89IN%[B6UE\ZH
M1,F:9"^83,495ALJ77EA'RV6 $@ @ <8I.&80 QD?L%-!UO!K1('-W XEUK>
M?_:@QHOSM//+/0FC"D<8&$J[!C1_AZ1W3W.-Y#RLXF32NV2]Q(LA]/2-/C0[
MY*A!4LU2Q=OZ1)2,ZK-*-!Z7R146R 3<UE4[&-[&(?U3+QIXP%'F8PF\7H#T
MPX-\$^,Y4/2(JH/37OFM96 OD)UL )%L>3FK(V77XD4]VVSJ[#@.62,HB@G5
M3T7:\AX*W6X(7GGE!$)2O=]Z;;$%](!9L%]H$L"K)DLG(A&H-+.POR$-@(1P
M@ANQQ"C5$['#C,9VK:!?G)? .H0Z2Z?$H&_&#JNU('$B1!0TG&*. %W2F6CT
M*DX33?;\28N5*.OSTW_OZL$,<9;&Y@'-]*(08*5XN8<A$6IP/++C,;DJOG.T
M[7^3HL*975=JH)=0XD#[9XU8:R9C6J7L[>9S7X"N+4O:8T'6 TN, +-22>!1
M:.D';2U>]T0WL*9)&862 8&6JI141ZT0ZH';S9NL&9]%!%*S9##/<G1J%#U)
M#V/EH38%E9#\A$G.H,:,@ZAU,@N+*K="M 1^P*^IDA#J+Q3266KLV=6F(57Y
MKRYJ2BX.-HXF8(T,'V%RW*T\=JNUM][)M[KFX":R"+.B99?50QSFXD8//N_C
MRE)VC]8B(DSCK:9B\@Z%2D6IOZ8A#2.$NJFATM\\?U^)R#T=VD>5.*4;1E:H
M-HKF[:OGH(D-\5O$W]>GU*C8J<?/I+V(:E<)PTC%%1V$63->;PJ_*)\&%C1I
M!%\:ZRTD8G/O[9NA"A^I@>^*XF=1$097[<RG(  *CM"UK6=TIXJU:#,61XP0
MM<P-AVTBL,P@RY3W"VT!?)21;2\9.>^%/LPJ&Q[?MF21.GGE>$K[N3H=_4_2
M7M"O69W#Z8V/DHJJGHCW2%IVA^%I%I6R&>7W)@RIR)H]2UP9FQ(*(EUKXAC5
MG)PIM(@ @&4J[RWFCI8(BP0U-6MX2BS7+=5U*P(:,<%;N-5+%FHL36TU=:6H
M+:!=?QCMMU<+-4] 4)48^1VR_H;91BWH]"QU(>+DUU7.<R]6\]KTRO368OZW
M.H[Y(6^K][9*JE4C^67-BCD8& ,J)36GQVBUR%#&\U)H$R;[-^&H3&.TO@29
M0DU3'IIE!G>"4HBRCY,R\U837@[.!FA(B5T:/S.1TYWL+P -6R$#>71#?781
ML%[.4V]&=KI\8O<#7HF?^246#\!EO3[?[V>A08GYD#Y1UDUHI7=B?6*\;[X6
MZK.SU?7(RV6B%SQQP3E"46+^+[IQ;FA+4=M*YIF7-#R<J_B%GXFK'_Y"@7T,
MEV:&,V0&X;?JK3YD S8=YAL9JHLBU<>B:Z2>GR[?)C 7VY8>"<:>!B(SCG1?
M'QPXNHUM3JS--<1WMAK&O(66NCWXQ"PJ"6JT;@&L &31IG^>:*%',%04(C;%
MJ=SLKI:BNSR].LT2K>[MWZ"8 0!/L,5*%AW7R.IN(MC\U(H7(V3ZS>VZO3I=
M0 W I!.$4C,I_B?@SCHLB4M/GSHYHLY"QP%-8AP6[2CH!FR*W?T7G:1/JF A
M,\\ZFT*7VRA^P/TXDBC9SHC:O30X.SW@N-TZ9+FD-Y8A3LFR+%:=3D&$JAW[
M?/D/.J1$3W_Z>403TJ6DI#<#B#R.:PY-9Q[8 :RDE;6I!0RW^6<O/RW!-F"J
M"\P5H]64W#-BL&Y:LJC&8)M[2*TB_(H$9999OW7_'A"DY7+H9@H_.@_:S[DT
M2(+8KH#:\65+N(0L+,IJ !EV04&K&4R>"_[!8#@:=:K*0C5\B-.$S%&<^X81
MSE_LEKJA^#JG4ZM)EV(0,X+L'+5L7DRX,_6W/ES^E\GCT* QV5*H!+(.ZZX@
MO=X30K/-W,,;[7D_X2M_.U7(9%FRLHJS!K-KNX[JGT\]%M_N^7,.!IJUH,64
M'I&E1+I47= CAS.[7D4-'L_8CK3!\9J:RBI^8K^+N96HZ_E:-:%0FJKTC9IG
MUD9L]'SG:!W<XFRQS.]L,-T)/-([<9!<NMIM18^3G%05AS.&OCWMU:D%NV!C
M]A-C.)>)45;K#]8VJSNZ<4@OJ,S4R5H-SZR.R!!JR!K)D_;[T//?J:F.U6<]
M72<$F7*/68_:-N8F;]^'P"-U3LX+@-V%I,M H=]!8,57US</7&:71;O7IQ9<
MTYF5--V3]FP\0Y$.T!PFX(;H5:E!8_4WG^9=[$*K=Z5<!Q>W;%GIO)!#&M^O
MEWN3!S+^]L=@.E4VNX.G)W;;5L.M*;J*EEF;VYCC8;00ONBDS5\,<)0#,(B2
M"^P\$*&/!]@F%;'" 2C<I<=12&E3Z8G-JRE[,9-,+"![N.5Y?RBFB['(97NA
MZ[\]JHNP-?IB%I U'/_PHV[<'-HX[^<G+)MQ.10XLOGM@L][H^5TJ4'3YUF9
M69.1L20;(6HHVN9"5K$8+YG"7'B#SW$-LP.CW\ST(ZVE;'O*:,FN6L,()HAD
MD#P15^Q$XYZ==G4J7AA8T*E&X[)."!J4$+>40Z;Y>>T^CEJ& !5^?*NOO?2:
MHV57WRSZO/&OGZY6AE8\!1B;+LSJTKM4F8>/PN*W]<'<R>@P"L4$&R<]^SE\
MZ/+8>3?>945Q)AJW53A9Z_7!C\<M/WKQ1,^6E)W48\M.VJ<Z==8:? %&O&5$
M2$)9!>J785@K0+9%F<G@:%D)YP!3.]&^"NB_8+1WO"O]0I82K,SD-0?*>RN6
M>.4;(GK!]:.$[/VR$E@0'/V.P94##LIE[  @*9@FM)!$<OTT[H7'+%J()?J_
M1B.]G=PTUUA[]$:)?E0J@%34$D5I/L3)F=A4526 3S9NX:^%(!RF!6;44IN@
MH&)W+=?3YIDCW]A6(CYNQ05]B4="@.]$6*)#8Z I#@0OLV5#99];:TL9%69'
MP;$CFSG$Z:S2\P4J#M:DG-W6)5TLH\IA\K;8"74XAB'$;K:UJQ,>E%I_QDNY
M%9HOM^($TW7<N&QH=92LE2%= 9_KXJX:6$*+.PH3GZ7R9*SIC(<I-:U1"[$^
M(1&Y\0*T<&(N(O- >*7#]]CR$.ZGH1:PXPGJQ$CZ)TH$>TUJJ#GQ$M8U8"N)
M'&0]H;I-*C/$9'SJNB\4.1/ZB%?L;G=!2.L=>E=FN&Y.^B#'F"H_)GKD(.&.
M[>$O*L!6#-5M^6I(1[O]7KA16D\K D\E/_:_#K[^CT $&CX%"(Y":'[_&&S'
M4YFML89HN!@C22Z4UHDE+(/\):+89VGLIZ;J]S-+C<'BY5"9U%+90H'WO-3(
M00'-=E>:*A@)+QFF#E>VGGTHM0((95"$H&&>LR/!:ZNBC_@AEB%%R466*ME)
MNWA E%]3H7=& 2LNVZ(5.+%A/'3/CN^V2LC K.UG#&_1&9YN8N\""J:]1,N#
M8O)V%VKYB_7"#D$*4/:\0,5988%#RX!L?RDL;-B*7)!&4/FRR&?+;! Q&H9&
M22NBT7-$ %'L@%#KA]![2-8\J*8U9B1BFDU+AXT%'2@5TE@%2$D.9=8KKVZQ
ML1"#JVFIC%J!5=;FUJF7/B\-BJ%00UQ,5\7,"T>\;+!%6&T)Z2O\QDC1OU@?
M.)D,9Q68J'K$NMO!PJ>DH<=I'B82I[JO:E:[P<U0P3&BOD+*<)%D>(SO< R4
MO"*2MT%+R]YQVVVK]<3)=%D]_NO-(QCAAW'9OFYM)0FUV-FA[P;*:]P=A"<<
M0&1DM"+$L$&*;@"KJU7"M-')#PA\$2*1_J;DEOQ+Q6%-A1J[\7#;2F]Q,R+E
M]_XL^#ZF?%=+^P_C LPEB+_A/W W/6C;YQN215?ZXSQNWBHNJG3$%@H@,A;?
M/SE< 6!UW"J,%<&HU M"YCF-ZM4;&_0GDN/-,-@!8+%DZU/0V#P.J&"%EF7^
MU>V6@208G3U!^[AI4_R679F3"KRJN8LB<@FJ8TRWDF9,$AN+S? 5!!NMX'4^
M/@WV(#U0RM#?O"AG-AQKD6EM6?I;P>W&#C/\+M8,7_I22NX3 8'M[TK:U>SK
M010)HW.I\6H6H5T%P+H%9"[K -Z;DI&+10;,GUK2V6T17C7+&E-P%8U'PAWR
MP3IZM^!H9A*J9]2P'P'1IK]*P<XTPLK$9Z.<?2\A@;@IKP,H:O%26(+]X VF
M%\9T@@K ^ELJH7)%'&/3<DJ]0G9]@XH=E**#JXBP979)%NR,BOQ3QFH5C]HP
MXL:"4"U%4JDO0')Y^T5H7NSDQC6*/X,;79'BK$M/A"E#';MLU60=RYW5#P#=
MPH'1=UEH1\,.CU)8;9JY;D"T1E]I&*FD3/?T(URPEK&QJ:3+(4+--0PIP:R^
MH@RK$\I.F)XGDH<(S I2R,\#ED#:@.-$,JR!F@S<TNI6A,0?;9-CUGJHN>R@
M7NT:S-_XT%5UFGK[)=;H2@95(DMQXK$9!7K6!^20HLL%7>-XO)0Y-R)":S/B
MFKS0C7"]VU2T<?VFD%^ H[C2"1B<FWIX1XQ?+-0+X_0<>C\>!$M$;5%5%5_D
MVR>]UUDJ-W_LIT: &T)H)0*TQC])!$"X&M;)=X79N<< $Y">5HK" R8D!3 %
MA&3GP@N?K#FN0R^<=D[=TD2D76:@KE\'WN"5PQU P8[-!2-GF%+%6]US_N>&
MGV!@N\7@;:Q9KW0A8 "]8?AB(81R\!$3\&UEW @8TZZ$B">N'REQ)3O+'':M
M"R%J;RW$KO!,<!:^GIECI+>>(0]+^?+@H5C3!<T9;X<9[PYU@@"A?%+4N2L#
M@8^J8D=TZ!4CDC LZ47S A)<+)ZB@$Y<:R<;A.$4DX!!<33#+%KH%\RJ\&G&
MFQG-^?6+L99S=)R:FTM;CN]3(10A4L>P/H<X[ O@,UT)P!KC0-D+5(\CR4D.
M)E4^"5L<3[##I*S&>2+PRH<BZQ>1Q\?BSW4N#;K#A62F#H*:Q8U,ON]L@"I6
M'3: $4BI]IPRWY-\$[D*-9G5YHKK1-IVV@SU)H*YGX\B"#@X"UVNCQO'(B;8
MB5U$C&F=5@^[=??)C%3E?'+949.%_R6&WQ=7H6*)$(&,1K^OBFGP(CE/&GFI
MMVHXOO0994TE<8R7,*XF^Q@HJ:,9"PY@JP" /;-W,.JAHR6'0B.6VG2CY) #
M0/H[TBF $/5J):!Y'JF2,'YNH05=K]X$/0Z:&%81?:+VK4;30RE<,U)$2:(C
MA2QNMTQWKR3WNUU9JC$J!RPB]((03*?6N4-!1_I\X]$[1=6KA6ZG.,M"(-%0
MY40*5+"C@'K_9^$I C_T-@VD?]Z+"'E5V0[ ,Z*'2G.TJF(CF.AB[U@<'"$9
MI6LHZ'P0 $TC%> /QJNM'80F?]1PSG+QC&;!34(^C+A&-]&SRK%]A8029KDK
M/4,"41G180,CPV0+JSBRT5=V5#]S2J-D!)6I8AXO2)Y)7TWB6E&2294HM:_-
M%^R;I$V?)U<K!<!,AU7W>AI3?7Z-P[Z>MQ$9MN 3@,CC_@*L1-9E \$'&*/A
MQ0J%;X+F'STZ#W2R)QV0(/VJV].DS]"$?[(')0VZVC7!!9T#30Q9DL#18@9A
M1\P!]X8U9NI29292!:(%-)@Y5M67_+@711/H".%N<*DN[YR3TD+4R$7R;M*Z
M(P/"BEEP(2Y/X@J_9QRWL&$R,PF.1A(0"H2,<Z\I!>9I:^7V4"#0'?LF>\%:
MQ$DUGZ$US+#2F2BE8Q#Y;SX 8L!@<OM.&\--7T/(,ZML'AXPFW9"W+=X>-83
M3BUG23-NX:=!!RL,*5KJ"& E.W[W#K5.6&5YB2*%I!5Z,3XL<. + %'U@A1T
MC)&NP2-^ZW;@F=K&GEJ["6]C-/0C5,6\MXIS9' $KDD6IY$;6I1>[EKH0ER>
MP8LQW"N7@^PB-:6/W6]X^@)S)S(D1KCUSIQ:E51]2E3(Y\H'L4B\708OU636
M"HK)H>.NSOB8@<XA#%[<V0?5LXV.:9[QXN4,\8/QF94DR?QL(P#";/2#@/<@
MZH9P0>(NN8/!?C&:M9SAH%)Q%M?>^3N)-T%6YS$Z[/@?:6H1+4+#AI%*#[G]
M.HF:;%8[FP64ZTZ=DBHPC?M3#@RL()@O +&?B,#OBL9X3.M5H5*J@)$U.5W^
MP7ZN_+=%^4@+FR)%VY\.MOG4]_E1UZ=XZQU\$!)>R9(,E)3^4)K$'I!"$$K]
M*0V-]&UNA5DV-8[7XZI,Y$:7O"].8*/)TEGO/UF["^KA5<0*0O@H$*,@06D:
M,.I*Z((ZP!1H2]ALK?5YJQK;:1!/- VQ%("W*9(4'FE=LPADW85@<?/;HBH0
M5]$< UN;NZ7MIH*QZ]3EE#Q*PR/SC8 @VX7$N"RQ6((&@\$NL=!M"/%OB7.=
M]>^8F8U<BQ*:(;#A* =\:5;9&E#/(:LLT-LON6S.: 6<_(ZZL(9<HHYPK:(0
MX2:&I+C6 )R-/0>OG8RP?;- 4M/DHBR/UEJF7K;6606S]^UT/>['5=MSH&+#
MC ,=\]BP;K08'BCE[T-&&C%"NS!UD Q&*K0W"@8!C:N:D8"E6*KCV$?:9STM
M%D]=R=A'DE\"+09NA5*WGS0 P"RT[^O[L\WE!C-E:#OU"[ ,1U:-$DG0^;T&
M^",L.U9YA34;@HU O!3<U?)/2$*+51K0$FK?/<-E6.B!</$7GD?9/GB$ELZ)
M)E(+O5$,T5.$LXO(%R <MV6B]LK21BY09_"MF*X $V,3WJ"*&_X\4_UXL3^E
M:XX1$*<)KVISV8X3+&&EMXGF'U(4WBNRI=4B\K/=LPG*N.$+@ BD+=6M+\MB
M>PM7/AO('"^I<GZC]#R"AIN]#:X%U4 :;AH_R:(QD+Z3Q]! 0.*9UM/72-6Q
MX,W3@2EOI^GRJ"YXB.G:S-@<\H%-D*"QZDZ-87VJ'\&T@%@?XNA<% ^7;=5#
M9.7N;:&DHA2_  5K,ZRT]566%)E;0 2,E>T1SOQG'==?]1*B=@/]Q5EX^!SA
M>B8\VV#?.P>TO@"U@;E- :.I,72_G\XKN)MI@[+.'TPRM#%P7%@5&ADVM>]%
MV&V3TT)/K4FW2]H4$AADL+!"B$V)G#+&Z&(/(9=DSY8')(>5APJ49%HRK4LX
M"DJ]H'K5XU6]J\V.^&"P)2!28S(R&LSMA/-<"M"QY<R0#S3;1]%H,?(?'O/"
M#B@0*MK%/+'%J* U(8V+1+G[ZT)^O%W %=3_CHQZ]OT",#X3#C+M;S]C;.F@
MUKO/:_WJ;_X=N".35Y1M8\Z.]$Y.[^J]:(*\.LAOB9ULF,&GKA*64ZQ3)9ZW
MN=#9YP%#AK4ZE'>>OYOZ\Z1)LV@@75M:;9#G;:/?N0$.5@1NG9*4:D39^6P$
M7I[B'+M'#+L2=2\!'FA6>?)'+R0O%3:'/Q\VKK[OWI6>JQYB+C0K--IZF7QZ
M(W_4]B2PS7I1E?V$!#C/5H(@GG5]IHU54(JU[)B!<"4\G1L<T2'N1/;AR:\,
MOT@[&;#E, ED[A3N2%5V+#B;F)_AC_D@S%2!WX<L);4Y\9B'E2>()B#-I7_2
M9E-+YUKV*\#UN(0K?F*^(JR9$.+?GL-*"4V R$URR8!A6!/#: N*FCW2L1*^
MQ]I0S[&#5^EJG)$]<,N@'A25>P\>_ZZ):@[WQOOC;)GU+>4O:(0'6JA&8;4Q
M@A3%+$J,73D#I:+;WGK5C*$A9;V;7MT((>[QL](,T>';=3%A/#%->(=>T:1T
MK90I,?IF*FP*,J,^Y*A-.&-0T*O.O.@C,I1ON=6OP#2Z*\#'CZ6.</2^=9PO
M0 Q@U;K]L)=_R0F1E-G0 .B]4B HPI!9RW _OH7UJG[OP/D9:-)?=MZM4&DI
M\&I'+1PPHF^BN7TB(!9KYJEW 4--<@5N[LN"!ZC*53*%1.R-[!]'D0^"33EC
MLA%)<M@ ,U0$0**-K(B1\#;&Q8S7S7\!:L@Z.[9WWIMY%ROI(O33^:$#+HW^
MF$^';)PE):F%K'"D\P/G[ C':E:JF J0RJD/Z/<["Y8JCG9">DJ6+Z5+:DF]
M=$4^ 5$/G0&3 YJN#M*%?,GJ-$@W.+C2B4FM4_2+4BS'2:MLVYLWRYH'6,4J
M25'K31&%EK"N%T1T*H@CEOV[+C&_&%PM[* >2RQ@;:KXY"V;@.HUJH:,; I3
M963&6C$)_WO"Q'(E*E.5"*&'@:2H((I,PYIR#+C^= W.DIVQ32I6J#ZK)@+3
MZ$9\WN7>W4)@T,<=*<[*4E8RPC)]I8:I;!@J3[L9QSLT+(K=^KO9L#'0O642
MIA$,&+!).Q64HZLH]JPM1G5 7SGT2T28V2S&FMO2M519 Z6'T?H%7TN4I88R
M&CJK=!6'BI<@*H1)4 =0-!T!ZK^JT#%* ?8#^35U>U#G?UDK8B[I;!]&R6.3
M(IQ@FG(H6=N2@52T17BLP9FCET/X,V"[+>-NR]:)\>L#X+R+WYPG8[CE4.>-
M\RFPQ6%F?C!F1$::LXH1$ZO#VZ]$]R%7]$Z,./T$$TLHK!WF +19X9DI[VR^
M$AJJ5(\:-C;I4BLG_%0)>8QMXEM):/Z9#J4>A'ZQ#,<DS\&S1? !+ZA<6?>1
MT3NNV,P8IS3!QO3V ]42NC)0/V/S*0)U%\VAVDR_4[B 2#??+%:DS.4)!BSU
M56L 1]FR,:W-]07PRPDQ01MQ7SWG9+]!%;)P8<?_(_[_KXB#_6]%_(D&%+-)
M9'^$?"+XW);_&_D#^<7E\U[AY0M@_.=;CGKP0OBB;U^3KM42"SI27Z)T4(-6
M5>'A'_9[K]//,$6V[RL7LJFNR*,KV>9:9[; DN]A16OETWX-MUQ,Y9_][L__
MYJ6.2WXH_QA_,O^<I:J&SQG6?'$/#1Z!A!_Y4>MV<E^ "?6JR.J).7M-A/6'
M'TT2X7MKGPK-&S3GD1DNKU%+"L18 L<HGWYXV;I>^T[7H]E; C#_4C,$BX'P
M/_@@7:1P=B]1GO=0JHJ=>G/__$3O?[!K<\\G?E*[_DCU:R=N@(KS'+;7]^/1
M&_C[%SN8XC[PL$2OK^ZT[L/@K>#7H@]P-'MQ^R,_ !Z4O;ES.EI/B*1GL.S1
M9WK?E=LQ^GFKGW^Z]P4XL5"X)1"+#L[^2_[TX][_\D_\+6 90]^[?/>W@OL7
M@#M2X%82&H<Z?K-/@SUO&[5W]AY=Z-64 PMMP?'QZ0O 7_S?6S>G4C'/<9B]
M*N]^-Z$5^X>[H1\>YSCW?A-?@##$3P*,"Y@I1;]C>"6CN(1#U8XOP)SE!S)1
MTA7T3MR6%_(0[S8'^"["@GNTI[%6.104HI7Q'H/?Z)K=-FMXT_N?['_37?E8
M']Z?@>I^I1*_1K@;Y'L$;<;;+?=3]H+D7;.5J?;0W9YBZ4JSEOW';O[G_>LK
MIM&>XXPE>= / Y,0F[M?,R&O6S=>]W-UOT=?+;H/#PX^D!<L0.4I&IA7]_'D
MLU@9I+_X$]A6VF2WYAF-S<YUS_1G;BT5V\ 5TNWZS([TSA(Q;>4Q9W+>OP!]
M]FM05L'R[#=97L17_K^41TVXHC_O3'^)Y"4,UBMI!(R1OL9S::B]_W@^^ Y
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M,"#W8M7_LSU0__R@_I\X(DP<%#4@#L82![_LZ*5"OQ +:+F_&$R<V%_&0.3
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M<*%(4LXT!#&RRP:.1;(#9@IU5:[(ZLU*J+GE#A"TW5BOHG$?@(H!RI_;$.-
MEN249',H__SKG2>VY*85W:67N*58MY7*)R26UF[+=B-.!)?ANV2*S<IL+HG
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M_KJR5MU)"_HM#*&9Q9S$YU,<,;QUFRP&A"R\P6PYW(7:S^-A 63$5>HHGL]
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M%TYJ.AH-F_*20]M$DV#IQD_H_"JR7Z,Y-)TK$W#G*L0:ZX.@%ZW2!8\&M>L
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MMS^0>?L3[4BDRQ]*R?RE6M"&T*_AH:BZV!Y2V\U^'"XR"FVSHHB*JSM/J)U
MDXELD 51._CW[7/ZN_CS!!;(XL?HS(QTI_/IY"8T::[&5B"'0&M6MBH"4F5@
M0P-S-UOI=Q10A>+O,AJ&"H #];CL\$J(!C0Y'3:@B0C2C[+Y!U*$*>/Q2A3!
M7"!] %9?L?ZN0=:+LF@*HJ"Q&OH&I;6;+3[6;$$"]Q<-$K^5AHCS!W&F=VPL
MKZ6%0%NAGYVR7&.1I.),<6@@][$H=\%)J)!P#$]%1FS_3 @^UF## +;!_PEL
M,9/.$*&H1'3*S5(56T" ++/"% YDS>#C@X IT#LC"9JRHJ%8SNZU\*@\,OV
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MUX+P4TX/#NQG;LZGE!5*<VOD[^==V-P1U'#P7D39^3D]3,L+^=O_  _]5O\
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M0'0AEO@YASF[";41A.=:L5\,X)@,N0S_ )[S3]$2VKA X1;P3\ 0J!)(!JM
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MR/T'AET8 LTB'6KX^H/T-@.L$0OI']]HGQ4:,!0: 11A$(.>0  - % &P%<
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MT9UX/ 2G/$V?;/ ]67::P*UEA&&&L>)>K.3.K",.%F3DYSI9ZD/.*TFW.+#
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MN[\X'H#]^<*AC,["5Y<)S_6#CSN6&8#CS!(,[LZ:TQGP]?P/K8Z+FFQ7_0?
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M^;M3^'CU)J,SG9N_"N/T[IO/5=LUIQ*NW_;[D$T-XK8T"SJH]UVY1V@&?W)
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M^(SQ.4VFF-K+EI4]);(#71.AW8HMS5YZP%NV1 ]-_LGU,G1CKL%\.Z?9=4R
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MS13I8C5UC=KJ%.+!8O+LU3CF\VE5X6\ME95UR#8-DP6XJ" AO7TJ&@+X*P]
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M\7S5NWGRMV?"043X%T=AQ9-J2S8V-U>./#^WA04T2R /0.LP)%(T=O9GL _
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MZG87AF_X2[/+YU?,_:+@T57D%2GYH\6/PL?NVY0?@.WO!ID&^L<^]V)I' _
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MHV+9BWQ&!Z>(/=6PZBG.5*G.1?P@E3$;F^_W,[XUG?;Z%8$_NT;48W0GG1\
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M3K1I^<%T&WZ=;]+]7<]^\L&IJXJ/*3--O&*:L$GI1486=NVN/>/X>,K?'[J
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M_/VUE=Z.6ZHU-H2'-.ZTBT:QSY"%V\]*^K5'!"Y/F9A6^4\W"SYRQ\Q?C\[
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MC\7U.-77:VDZH,+X3O_T>3^O:2=E??_9G03'WNV"'4CX#F3!@373P;Q5Q+;
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M:,Z\EECG1+K5:F1!8*!&(Y^*G<MQ?EGJ#J2YC2.3P=+>SL;$EV.,MRNQU@N
MJ1=35Y X2QHLN*TQW1-]4K7XBK'CI4>\_%?/=GSGO3[^&EP ,\.,X8KR@);^
M#/ S [%\F)#MI^4,0N9JGF8;8["%FN4FNIBO]R!U0-KK>W' Y9,F F+8=?-:
M2@1P*(8C3:;)#SC#[W3HT-VI&7"%KX9IE6CW_O/.ST+DLU?O.5[N<?1SNRHV
M<];9/R&8E_QE-P*K$&<;TKD&AYR_N'T-]O,(*SFKF6>FJSQSN^""YN7<-X;M
M7P^%_&_C]O]#G1M+H%3C%,UW(, A5\Z!?,805SAV9=MOE:/"$,PR6SQF2Q2V
MUNJIO]Z*JOIJ^L_CS,ZACC%O0-+C^93&Y[_"#8S*I.9Z42(EWI1X2XYDT)TX
MO[@NX5GN-13R8BU53M5"J _S!++8EGF5((BCM(*QH4/?M>^?'4CB"%J'*YK+
M\*>Z-:V()Y,9>>M6A/XXG!C);$M1LW7" 7E;TVY-[77SR=&C?^2"HF\4Y^"^
M"=[;@5 :<(Q_Q ]@C!N!1BINL90Z\ E?151:6/^ +I2?J<@=&@WM",E'S^D<
MD:-)'[3A,^/YC)/%JF%'H(P(<8[TRB!<HL[L#Z*W=?G(=(NX &#JF'8YSWO)
M[;OSOS<SPOI?#F9.WO^<2DG+GEU(_NF+XXIF,-U9?M.$H AY+!G?M)G494PQ
M(GGU'>3 Z]'6 Y;R30 L]FE+H5[\>>N,X,+ A5CA6.IEB6<$C23^KE&N6""@
MQ#Z!ZSV)HV3?UAF$)D-Y;=R??5419?Y UY]E&%8C'WE\25/>+EER"E.XEHW0
M1AN6"&RO&MM4J[IG36,JP011ZJ+!%:E@6^%ZX;@ \?FB?E)05A>")KZW8O!)
M)8!E&I*)LX2%O[Y=1?+?)+4GCSP\<V"X#=GZ(/J\+N\O):[(7? :;X%\4.]+
MVYU<&>Y;8^S0?<[Q*:[>:*5VULO@'C.+OWG-6]^"-/6"#.H?_!0,'=S7I_?]
M[!A4,Y*%8R#$21E4 D>&](TK7,QVP/4>HZLRLPG/M,C$:L0>SHF<LY91SN%!
MB4KM=:J)1U;F\_ZTB<"C5GLT_I486H,"1X9H\L3Q?;A>-/RJHWE$JN)5H[N_
MQ_?YH,OB:NT/WWPKF$HI>M^AR5W=7_!L=&5-J2/*B7V)XPUXRG-4/!DY_3\P
M#A\&2RN#"V]'<Q]'>V RXMK-?$](">;?FLDM"[YX\*BVW?YA&9XM'8YT$U?T
M'#.&50QZ5S;G(CA>X<[ FRS2*% HP'L&?[:ADS&>OCJC;Z2>1"?V33KQN;RN
MF#:IN7,\<%G$?H0W$L='H'3A6N;HLJ#&!  P2_!- "[@R&&,?<[!*MF^3(U>
MY^J=+C%M>;0A-TA;7W21(O(*W]EC5FBKX: RXQ;[](\S:Q]0S1@%$_O=_IXC
MJ$*05WC6M#Q2NC!EEO&VY4B)WF)_R]2E6MKU^;SC'_ZQ.*ACW# D\ I.*2$W
M!_5"%TJY8O>W&VS"F#L0VIEBJK( =[2_ \T4ZS[2-D4/BH]QSN4?&Z7I78PP
MR THR%6TSSX<\S;]#;2<P'"" P:W\+M\8@:FQY$ _C BL?LY7H!6E8\W\(UX
MZV\QH:5POW:A<)W!1U7<DHOHD&: A:C])3)6O@\3M ,1U.2<8AIM&-'(P,&Y
MC2FV!>#L!;A27-,BT>[>C!U(FHUW#)+FG+J*EK.N;5QH:6G'M1SO._PSH<8I
M_LUC!AY0A671ZE.AC$N(Q12N")$QU7N[#H1M&D+6"PVC#<X\0)>CL@*C]T].
M:6SEQ5HXW><AA:\(%@Y@8IEXUG(I5P0.:OKI]C,;'%.)Z*?9R!Q,6=FV^$PD
MB&)5T(8_AGJQHA_&Z/DN51_-:YQ1!K]>F7WHFJO7>B^QOT #>3H!2^$N$!@>
MC0Q>KO QZB:@)]\+33R,)A*MWA<_#3$%4'Y,4:3[+=;?S,:3Z2K6<4E(_Y)
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MHIR+^\\7+FC//RZQ;<;GR8>G.ZX0*"2Z/)'0'+1[N/]D!](T?H^KCKS501A
MB(WZ4SVS?B2_SJ9\8\37J8JM:V0NO7DW(K3G%)?Q5O#C\GYP62XG -AD&V%
M-TQ,X8[B7M6GM-3?(?-WG2&Y?&!",\+U6W8@TD21Q='H6)2B5Y=%Q@'+LR.-
M(^_?M_,]Q;2LPUL^<^2A1+@0CO+ ;_=1@F;N.X(0':PX+'W+WEO7BGLQI=?E
M"Z_%W0UF2BMWCS1_^%@]H'Z=H"%[:__XVN<-+:8@$?'*E:-4S [@]A.:815A
M5&A&1T2.N:\A(J5DIL^VVL>ERF/=[=9SI:N8X5FGJ__JV2N<[O>0ZIK=I%]B
M'T-_9JF"IC[^"WIG!]+L7Y_2A:+5*RY\L^B1F;GF4:_JG>7CJ]60EHHS#RNX
MEF<3GME9#;GX07 :#H53/D%)&JP80(LAS7H+%('.36^9Q(ISKG@,#/PB2)R/
MOZHME&-3R%H/EQ\1><\HWF_V3>%C*_L!OHI J<(Q/)9$6>) /0/'<@.<&1U0
M%8P'L%:_L+XL/EG_^U;#5*A:>V?ZI-[H\.Q!J+^+KDCJO8;L\YX66>0,',.3
MD+8#$;-QW8$(_.7V]L@P/F?_RM@^3W:&!T_5_-Z_6F;4-"^D_3%]H"B@<C0T
M6^GN6/S<[@'V#.Z*BS<M9^,"^\0R=T(Q(I%[D%A+"B'OXVKZ7?W9-X&\'44B
M=WY]KM'AB&%*V:Z^RMN2$@S\IP,2]PF4C__A]HMF**#'7\21,AK<@32V)9H;
MR8[R/W]JE/6+D#XUO["$/&^K/# PT/+@;T#VS][PH*CPJ1S3C3J^NZIS7P:P
M7M@^/W'0R+>YDV2&VY@W5P1.,P(.RO?EI)$5?^\396N\P8MS^%\X(%'E7EI%
M"Q5Y^^L,53YQ;]U]_Y%R2+4,D9]T\&]2S3<O>(I9Z2-<OU5+2U+2@WWF:_2-
M;S*'3SW5_[YQ\F6"L.9]B P/9PK7&TL(A"MP]L[^<@7TY3> G.??N K;S[L0
M3]$9YYMS2N,6(Z3\_)"6-8*(8IVD1X3.\.)5D>VTV=U[+0*X7E=" #Z!*PKX
M?;U))MF3E)T'"\\.=ZUS%:;N1:$39VV7O%:&)YYM3;^R"HC=@?2)BV)'X RW
MG'E!UK_;61AE)KZO3"V_GR!K@VYH+:ZVO?$WGHB*\D62[I_2*I']E_0N3_>@
M^@I*8F85ST"E;%2L(.9S6$I,=SH_&X5^C/:ZQ32L?!QLX6<X[=_2RA@L"(S7
MCTFO/WCI+ETQ[Z-9\1%<T_$%F[."(P3&M3QU[!*T^?%%B%$*O2_!2IQ^%%U/
MX&J T'O3)G"%+,.=7I;=SH!)HETOY;.<)R.,ND*QJJBVUAC%K7GL#.M70_+R
MPLQYC2 SE'[>)X>#[!9[,=P1'.5]3CIY[R_X(GEEL* >S79HZ&#:WX$PUEI8
M3P^8A(2:6UA?=E<=F<^%71K^DR([B=FEY_<0W(_X%G<Z@6W*\0 B5L1%VE)Z
MH.C*TP"*44DM2HR0P\FA+&:W"AN_EFFT-V2,M1L?&C)QN$4;DSO#VZ%VG_>W
M)>LD>)V97:[8C.-(#9T#OU4 [.,]#-=DCC$28Q-8[F*U-!H8%S*2%1:A*F2X
MMU937>JDG&GY_<HC#.48KI@ L,48.KU=B@LVRL0U7DIJZX.34-[Y9Q@K0%S_
MG'S'9DI!G7KV)*K9X@7?9J1,7V!;VEU^)\BM ")&"XSB9>#HBO@BBKO/$?C&
M/H@=;YTC$7+,<%!8*Q?:W%!JF<8_^PAC\#2^5+O$L5;[H)3IT<C]ARSKL+4@
MCF (E%;"J\$7;$&.]78J3->.I@"SP,#V4<>LJ=^+J<[5G73DU>*!9ZT#_C^N
M+DKKWVC^<:KAWX!8Q2.,7SQT>!N"(T_L)S3$<&2E>PD,UX@#V&$FD.+,;"V]
M4H54T6%\3@\L/5=HW1X>1FUU.;)P1VOJH_?^/.,C;B:#SG5GEN]2(SAR02MX
MX@YD88MU=_LY@?(<T:"3UK,''4/Y7H$43Z;7U[NL+NM9[M-$AB'5'*GM]_\Q
MF'J?5+(G/.4]7_@, URYE(;H0^,H=/@"WGVN*_:)726 .LF@UW7'1+_H;U@O
M\C\[$^CX^598HZ/-O-+>$RI756@] "A[(2Y@/(/<:LF10@R6"0&2Y;[?8*H,
MUHM*(&^?Z)G,8=B+"*3:3VJ:?/$!.XV1*I/W5T0>-T(28LF[N8< E2<$C2^,
M4U+H:VP$=K1,^4./""=J5FKD/4X474=C>S$>1CUK\O+Q'=*JB?33+&0,Z]5H
M*>QA:!ZYP)SC*"^QD9CSP!/V20P(YXD(CBZSIA FQ?3+?PZD]$<A?^+U/,O^
M<IV]]Z\=PL7N51?XUVCI6O'^U<$D]#B@NYF%@;-#<;W\\"NX^126^_0&!\ET
M/3]GYFP$G&C6>X8_UX)WF:@W8Q.:3U9&OW*P^=:])O+R6:/:"?,-/.,ZF2/I
MS"J;[5'@B&PWX0*5!;X-<DT!)<9/>T9;YB\7[:7G7=VM4\;FK4_#1+*V^+61
M_;E5)C)Y)B]/PB#P$)@@1QZ(9%MAH(RY-_A[,,6V"8XI]9CB/E.[J=JG(HTG
MI/@5WB@]:O#\]\>[=T.:^7X1#&^6+&#*/L*=P\OA4.1DQ?BR-,N!)6D[5WFD
MQ:WJO>)5ZS\035\U$V5L)I95\R&!CTVDO!QTWG6!"9;?"%0/"KN$;ZP=RN:<
M8-NCH8X-TQC8& VQ#R@=/(NTPJ<8G7(8:VWWU$I'(:GY-]($/A:(99YP@Q?!
M&6"$$_$D(]9+1@I==,65)-]/D/A]\S6C(#N7L3+@9S(3;9TA&KNI-EW>F3=3
M&263I\NVH'46RU2MX%2A(0@0D+ V**8H*Q(89N.X[^!-V"P:#B1Y?%U(^93?
M!LYN3)O6DO'T&;]Y/[]UID&G'=\YK56IQ\49_R0UK38LNA$H+\B,ZS[P!LN-
M&0:"U0OHL8^MXZ6[>)F5+O)6YF/D3,U)(P.%VLDU69I<U(OMCZ4>$7NS,Y^I
MM/S9S<]F0 8X_MHN,(O8/<+ZAP#HDXG.XV+HUM'!L<@K%4#BHGL9^9*1C-R/
M]1U(X*N/33 VNB+U3]CGVL%SI2+B%;A>TBV$(.P ]PT"+/UZ<4D$,0H0CT)6
M?[4D&1%1:>>,FK/,Z7-!I0*LX)X@XM[[>7(N_2\>B[=Q/$'5TX#?# >N")*1
MPCJX786[PH[@!]Q7,N5T>KW>8<V<E_S&ZL-59J?)WD/R^4K%,^<=I1Q^W'MR
M[Y7L(309T&VCGV-;<XZ!@7:'$ 2_@U<F4![!))GX[&CTS5M -#.%*]WYNNZ7
MM7.M_7>^GS>9H6IECH9J91[$SGLF*?;VUX9&$0P?7#9<(+H>,)+?D%T)@]+:
M4L*;PU00_"%6K=5A-7VL6;<<FMDCG<+CB_Z91/;2N^,+R5^BO$!5>8UGX$0-
M<)1UUP6HWVL@YXE62HI9O0B1)OIIYLJ/F\-BA!>.4M2ML'M_;O0#-PZ_TKAY
MV5%PW6@(#AQRR/AMM/AW!\(53F-+80Y_P""8UL0R2#LS*-L<(?OM@A?2:U_'
M,^WEJ5!))X.!=V/1R/LBFLCK6>WO5Q$\# ?.@0E*EC]76&%%'#@HG@4/[ YR
M8%K>Q83WB+0#\=K/3\F7+#X[<\=(4>*\Y(&DU7W08H6T*914Y@Y$'7,56*C&
M]<K *5\0<MPY1(M%P4MOCBJP\M0%)9A%K]%J3PHU?-*46WPJ9&"LA?[02=.Y
MF.](M-OR'<))0G@]J9,K7,T&F6VO34N8]TI$DGEW% O#C,EL[M[#IHFL6RKZ
M'!Z+-OK^N]9F3*+D8DO'CYB/L2<UBJ]/":UE)MRNW$AA!W,GH4H]1H![[S(,
M\&=L7F3H9'+E$4 G$2$/DP/>?[XXV2),WS1;C*K<7]F25KMVJ3MWRY3PKP9%
M0[,*?]&=TL:1^$FU'"0 VI\YL@2:_$8.VQ([-<&)W'ZH ?A'KNQ#G6-D38;(
M%?[SU255C[?+.*1N8G_7:_RVNKQ46%]5QB8>T-#AR*.H01PYJ >01#7:QQ&=
M[>*I!42<8TM=9Z(]-MW^]L442%U>/X"]^')"4O.41.<<BC#6S/L13JE) ,%\
MB%6X%ZQ*,GA65 @LOL[Z,0)@4O-5& PD)M!MF,4GY2>><7Z[P##@H-);LU*#
M.PN7TNLB\WA4I1-NNW]QY\BYT^!@.DK!,9RA)'FN-%D):64\"Q-!5[M,VK^H
M<N#I[L([MJ<KH>_F?CK]P^I0^6K>&QY$*9X1&#.0DT02WT P46^L-OO#Q(9\
M,F@7OKY"RI?4&/O4ID[23W3\6+@;>YQHB%!R*-SE0E58D#0P(G/HT6P/HR&0
M''.D=]'NRY:*+B!])2JFVL<'<PFZX"+;M%2SMAJGNV;2V ([Y9@R-KJ)/AG8
MDP/^V1\T-PHKC5W",5QP4N"7DUP]M"=,99YCW3E-AZDMQ#<L]2*ULFHL(PPZ
MZ>X%*J*IGA?"Z1O^2F_WDO/!U4_L0$#?$^+ 5\:!@["V.H[+A]":WQ'"7TG)
M!> .;!7]O-)^W[^6VL2C?HW&TW[#U 2'OO:9(S%'(:3A0L4!BU%6RW8N=V_(
M[!Q.PMQ5:3E$,2CE<M>)F!N-ZW]M&(/21_=0-];:[(^<7U"@4'CIKJD(1F31
M(#X)+-X(?5! UR&=<-7;#=C'Q VYET&GU*8X3C9<G:E:6IG'E>X2K3:V<5Y$
MT\<.+[W\U)E3_:T.7QE'%>K[<8"E$5?T!-N88[2=] L*Z,30-<)HUN(99+'H
MQ6TCXC)?&R.:_NDI34UKH^WL0,2!2$GE=S?>,4S^N2KYY_3&2.<";)ZY ^'(
M$?JPH+<D]NX^LJ(6RS9!OPIS[B?I6X:M7.ITU29YAJYV7O(.M/_Y^&+FLR)1
M7:&O*R@^@^/0Z^Y9N\J&'<$$;)? K^+3",TZ;R($ORA^3K.1IHPY^+2^8L(J
M#%K^39\D.:WE9AIWCHP>"!T56OAT6"@@U3CZ3Q%K]T$S-D9[^S6!\A0J!:)C
M)'>\3(L1WD*);;&;^%U[[;>FXINI[TG=;PL_VM<&Z8QU2S0GE+=^LN?Q7B<
MND6)G M,#:XPFSE%)=_Y99WEZC7'%4/CSTS\6CPR.AH3#2N(DCE;GNU9O'"1
M9SKW.!0/9X1LT178$=@)<I-.&E8/X\?82NZRI9+E.%Y,@6H:+E6>:_+:-^RW
M0ULS[#0RPW\U_N%5<S=YYT;8I4R^L[MZNGN3@-J!D()89MOW=R H?":^*6*C
M/8@) 9PV,$ZT.'I,_WK%^M]KCP(CJIQT??1&HZ]/I"E?L;NT*%V8ZSWJ!/L
M7N,D#HE/[-D'BG\3G4]!I-L$R::D8<R9@CZSF O(.%&B7%*E*,K&=]E5U:/V
MJ7YV1O>=:TZ'A;)/XB5!G0MB#W%,&4-@2<<5.5$.% W]A3V*K<(8=J!$K>GV
M1P+;I=>MNIOMS6[Q;XV;&>_E+2HQ__I52) NN)$+YK1Z@)^YQ14^!E9 _&Y
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M E+PS<1['>R+F "R9KX.LX!Q6/31X:'XX(+QX(UVQ?*9QI:V\9Z/&Q,3$PF
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M.HH2L?Z#*D2[SGRVCI/_.6-&";B3.(&US/'(+7.>F@^XU;]B.ID5D"B<<?#
M/62VO)\GCR%3<1?&>1.+!:]!E,,*S*7K8GZYYIZG]J3W5%D[331H#$A<OXNP
M2;>L3=W4<7ZL57G:U>J%EKR;Y;YEY8X] 0%NK!=HO33$OR?AN8T\A+7^7!FT
MC=[O@?*[O.!?:]Z<]6[UO7="/?Q(A-MLM:/)D/C/U8?PB4U0!<40[2,WK[^
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MV*-!%<>^<6\.1'2'.H? ).NPF/T>E>'<W2.QIY!>Z5,UK -+= L_8@,M[U7
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M)ZE:>;$K]Y=V8<T*;@M_#C64OWH0+>A\W<F0\/!HP1&) OCP7LD@>3%-A2:
M!!RRF6EA*/ B>Q]QRL(*)0X1+NZ+HQW3-)UU][C%M=R.T:V[V1\W642$_DTD
M$)K-$/ZU7!.#)S]EL5.;UWRJO@.,H\R"P*7Z=NJ<4<I Q=O4^>?9"B.\:%5-
M;DT>!^<<VR,11T_K*[TW/9M+^1:#8/$=;F+&:FWO1Z>D4B^"+K:Q2[8,)<0,
M 7AB4/(%[[,+ZX,0>SUYV<?#B.J>#L4_VA%PE6X 65?S8MUD)TH*XT'[9@^&
M4*0XJ9/3GGK:R8?'4W]%ANIZJ5L<70U:\;G!O(?(N\7VUY:JR.*Y2\&#RND,
M(<X!VBOF6]-#&/2YEH;ZD=\$&.CZSM0@U_Y1]R/KZZEHJ<'0:_Y:7@K'\T^*
MVJ>I.L=83ITI(1-!=7P/.@[9'-&%G-*CK8!:2XL\ 42)=@%F&]DFH--4+I\V
M,\/D2#5-QFC+)R0^/'MZ3J5?45>[1ZN/M*?9\2EV[]$^#V29,@Q-"-%XG1W#
M7ENJB9-<R8V@6*<:VA &,C_^D#V_\W#CHD_:C)]BDN-)!UT?CG1E]XYM*&2,
M@3O0WSU1J&C_7=B!#G6L(,BGDF1J[-O4%-&:E_I1LFIPZ%ZUHONDHYW[O/&I
M@[SJKQ,J'AE;";[ZTO&.?V?9D"&Z3/%)PCK3S_DA7MNN[<(*P%4+YN.&4Q%4
M17>J+#$$S:S!5MWT&6V8"B(_K$TR-AX<?4^R[FHPOU(9_Q4%ZCBNMRT10-5%
MAI0S>7$6T9G//H;5"Z+LPA)R(,#JG\FM5/^F.9\UX>5\NCP'J2NFIFJ_$&ME
MKU1.)8*'T>L!2XN@7!E#I(N6R<PBDHL,7>(?M.M1#9U8GX=- B)+YMQ<YO7?
M?OW29.CYP?QV] KO=+U"W+2Z^K'+TF4C!"!L<UT(:%X68PAHG*4B'Q2^':[$
MVE*-SZ.YG##)MD;>"[7>^^96-A8^!=57[C_7^B>C*##L>I(,-ZP;#(=F?@S\
M <W?9V8F_OI=WF7TFL5^(FE(AJ$%;,3Z47Z8W(AW#O$K_0$,EO.J4GPI]Q*S
M?#W]K =%><7%UQ!VD,FAB>1&UI[VKG$ @D^ED9G]>S'!1:?;&5U5^!SSR=UH
MX\/*V&PV2LGY?)W&X0\B\J2Y2IXT;L9#Z!-4A@/H0T&!2GB&4-198#']]]W3
M.Q= 5]\=VFVCE%#KP-<_C,P:2L^:'S88XAB6OA\?9_8SA>LS"HC<Z;&-PZF,
M(KUCEM(3C+3+5OSO3-0B:+?+A.D-?\QS%-ID7:4[Z0@O0CC-8.3V<]C=1Q"^
MV?\)W 8@8#<,[!4+#M*=63T&N/TC.,T?!I/YW./K)OXY:47^S;IN70&T[X7I
M_8Z151YJ"FGF D<XK'3ON8X1_>&@QHF=/=7UHOR]8J"+K \(_M]H888]5?:)
M017%W;/[;WM3*S(V,'/"M>37 P$K_9[N#+.6ZRA-MJ-*Q$^W6<%XDC?.@"$]
MAB1_1T_1^R0C>M#\<[XYCO$,A9G\>G3525I6LD'+2ULA*]W:LWP'@0_<<N(K
MJ:S5?7?%^O#<C82I"A8_9707YC^4_C?%2*6+D+(@\<:6&S/K_/Q4F=:6+[<O
M3="M1:#O6.;GV-2G@O5=*1O";#O0_ :P> 9>X&;Q4C@M7!]!B"5]ADQ(0>W7
MIZ<:]]R12:M$-S OSVC$-;.&:_.*4F<4?K98"3AS#-^:34/JX\E#^$0/+E '
MR*7U@&U4#8]X*^!;;.,)%8?)<#72M)\/FK]&<^0AFY*ZHC3,JD]D!K(+(5-)
M_W]MZJ+@IB _OS+5&!6@$WW3 Y-\:J0](CSL]8\[W9G^$R,-GZ'Q#J"%'0YN
MJF?&#"9\R_D3RN);!MV1ZT%T-MSB8IUC%T+4;V 9+8NY_1ZT.Y?%5,AB9FE=
M+/W<C5 K/G)V,_7E-^TU+PA/G!Y@\1\$ERGP*<=N/." /HCKNZ-)@)D8+G=_
M+AD)9ES3Q*FWCLYL\.JLGST5''0Q.3EA<JVD_QAZ$<:.V*MP@):6=)?%AGN/
MJAN"@E,Z8C]6*(2JX<HL<% &+RT-8X^"&XK>,1_S-ZYGBG/8A'($B3N$*J[]
M.=U6\[4LQE0+8]A)!/SPZ<1K5:$7K7527E(O('D)L9-RI1U_<\&<#^!)3?C?
M4^CZR@?7CA]Y_?- S7EF&Y05$?=0=9,,@5S:81!!1S-.$R&N5-_5H2( BG4/
M20YX+^7FTH?+4:E.5S?J&QV:! _\4LGEN,;?)5\ ;V3IXDD^Q$#;Z3(6CR$9
M"2K#N_%374N;B8P@JM"IQ@GL"8J[&&7\TZ/2 8ZXK[(([6_6S]J_1&F47!Q1
MS0[$3'T2S2<";NFI^7O[9@;\D(#E8AJA#A''4%%NN^-Z%KRW*."3/WNY-LHY
M..AK-'N9\@_OK1PVJ6/[;@YO!NY;B 1X+T ?C&+-06OL4,/!6B1(X\EEB_L9
M453C3E.)9F '0M=Q2#AZHG/8Y\RM79@?,J E,^K'Q^QF[8>%U4./E&V>5?NP
M^.>9&5A_4P'&4>C;REA#/_0)Z:8<8.&@SK:Q^"]=OY'YXJQL+@F5M4F*5L6H
M6.:C=U"2AI#-+JQ!I7>/_C02>^#1DLV=2/YI4&5I:K0@OC?+0RTGJH).;_-N
M$PVZ,9'PL-UAY)1F_*=@[8+9MM# ;!;/40CPG^@PKH"= O4H*="77<W-P4,D
MCD[ABL;[\*ET(R6/3@69RF$6(MN=J9P+AV:#&H-.M?_1'&O^.#QC/NQL;FMJ
M_SSRBX,80P3YKS+4.")P@9 ZD]VM(_7#2%J,P-UNY>.M7%5N$:P=[#6RX7!,
M<<'BF6(MVZ5;'RUA0B<13Y& 5_/,),T47%;.$[8-W87Q<@Z]=W[^2B_5).C@
M2:6#VW+2=R2WA^XA@)N3ZQ'TR]A+X []!$,4FJ8@WYT%/5">OW"RV9;JI/U(
MM;8E?R$BTUG3\Z&H+SY44%&"5V:0I^(84 /J1E$(73:\- Q$#W;<P)C"Z8 Z
M<&3T8KQ%VQ@E:<7:['70:&4@*4=_Z\O<NVNWGV=X7(.2@AHX#43L@>MHR"_.
M8NVKL)<!9NFS"C^<\EA#U>EOCK'R[?7N#LP93-Y3;D5NS: 6*_'P$STP7#Z>
MI$XD-^,/$LD%", 6(<&:1XIB)1!=4RQQ=_]_&*?JTK:KU\EI(Y^,>UON?Z@P
M,M$]*"_552$WOU6/#:)?Q9/L\ %(4"V>(:!'BV:6,E3HDB#^#"A3/NWA*WEB
MOB\MWU9(_4S(OKP+UK9UR3[-@@_3)3\II23R_"%!,#N/2%XDQAI]6X=\F@/.
MK"-Z;3[(::R:3 ^?G<U-5>P:=B]H;86,QKO^]'V]A_56[">EER($N<GC^&EK
MVC>0?8D(ZK<MP]?D*01!&T]J1!>Z^D<S'DZPS:5?L= NS+;! $'S(NVGK02=
M4?Z]GQ]?ERERA-%]6 =BZ;Y8&6B^L-!\U>'XF)4=1NYNJ>R=(YC$P;PD#;>?
M8KJ8M+^J6E<=Y"24G@R;6]ISU!]ZU1VE$@?EE/I%89P4UI+Y; T92)S>Z5H0
M!&K6/:\BWAFEQYM<TE\?BMLL<75LJ!V;<,5DG=%%N=3D"5R23OEY\=6?)W\J
MEFSOYYLRJXGD3U6\2T/O7'FK0KMW87PFH9$4"*Y[7KB_0%T7<QH[?+66+;NG
M<68NQ>=6]^RM+I'?A@Q!Y#(4?;)I*\R\COT8(1>06R45Z8OB<OYQ6Q!CL+%H
MW_9F9)L7J:"V79QE'N!J??YT<Y!J.,^^3I&2:2%8U"YL'3*6_62PARX(\>=V
M,3H;:P199QO+0"ZA$3]OQW01Q&Z Z4@:-DM,\*E#I(+1S:UB*XLG2D'*4_V.
M.E]?/V3&T(49.'";?@Z4I5.:>^ Q+"F(P:.W-3+(4H-2/8Z2#V9HCQ^UNOY,
MEVZZ39F1>OI$)='06/SKZ5FK'EP GO31Q7!M%1J#$GB&HG,/S\Y2P@A= C/H
M1AC_'0H\83N280&[:S @>S9'\AHK(+<J/T!^%W8EL&J\L_&C\U]C%A\$Z:-+
M012+1X?.B8GJ,OV'FOJ<(-(A[4?]CC,8*7YS*3Q"F*=VUC_:9,-W)7E@@1PD
M5%GQ;O8A_+/+?Q-]^C_7]'088N1U.U03U:-LZ83NMRMU[DUW'M,$WG:SYPN>
M-E3]\EOQ9961:L&^CKW=N$0\Z;BI(@X*N@UBI$51S"19)QYW!"L*G#?*Q=0O
M1="^W%%NTRX*D7V/U@IG_UK?^<+N;ME,4,;,41_=:Z?OTLU@."L,FL6WQLP/
M3Y^I(!.A&#I=01,@,G.K.L2Q9K54V\3&04]*@/],7!M?;N2P7Q;M)@IU,EEI
M52!SJ2QQ1#^<6YG:O-WT7Z03RE^\KFUNS?G+JYH9D-J![1?G4QZ.G;-08;^?
M_T1+F$TD+S4K#S[]FWZL(*7MR)ZXRLIQ%?86I<RH1U=^0Z =8VLY4<VP*L%X
M7F@<0U-IJ_0HU9&HYV&_I&%#G\.5&WS_I?QT<-"0A.,?;AP@"GUG"8UJZ6OL
MPD#6F%:E8EI4?BB]7Y@39W$KX$*2*GO.!.L@ T'5[C!QI"!C927']$_>TM>8
MYUEPO3_*<M$573.FB8Q82)Z-5GVH7LYF;PZ3?=QPD3/H6TR[8CD8O=B3$Q_;
M,+WM>E3-[^6@IY3;R3*DNJ7Y5^E\MHV <_^^XGWQ">T:2^GB3GP:/1W2K\>U
MSE;(-8T%CF"ZTE(;21(2Y/'2U[68PM@UBAH[.X]XKZ+<51&9UT;72Z"5_@WG
M 3T['49=,'9=+KAGPK\:1LW*IHMYE<HJ7I]D\[R?&4EIKZ=AF%DE8  UH@_5
M,-D=9'V!2-WI5@W4W(:O1=F)I*67.$<.!I3.;/[YPJLU^''D$]TELNS&M& "
M)7WJ^W\[Z.O@*OH YL) MQ[8--0E&>92-7;=N.J"ANH$Q4N\L^%>\+5WY/S.
M2M/DHH$*BYK^XEE]QL6C1SP:>&Y8/HU^CY"*SF13/*;$4V\&PRS&[L*\6VKP
M ;F+LT*4K*(RMU47?'QUNR'97?%<DP9G1JF;FYG68'<=<C D*BPHR+!CS++H
MOOS)Q?8<E%=A$BQN],+HFJ1C;6V<D$FIU<=+^W]);]_HNWS75E]?^"*;<ZL/
M-/6%JX;Y"L/M&J4S_I+W.5FLB=YC*RTG\)B?[$B*C=^_!>,$/*:F_1TR_?ZF
M/G<\=#Y6.1K35?3RYP$3@37?MM>UQ*V>[<=VD;J)UW]Y\M7VF4M\M[A^?$^_
M)Z>W?U/L4M2QU$[S2RI'4G\61U\QO,C-GNY?%$XF<J'\#7)Z-A_\[J]>.QP9
MJ%WR.K6X*6.JOCW0_-+33"MQI4P;O^&3(MM!BN<F&Z8;@D+/-[^M;TDIZ:F:
MTU"Z]?)G9>6!:VO^,GI=IE+#DBK#[4A/WZL-KDY\587FGO<O.!R>X3PD:'GI
MW="YMV:PLS11W06+\@%O(;>S*1D7AJ._5Z6^,[S(SVF!Y9&OK6MNR=E:^*24
M0WZ9?R6%\Q$[>XCT<W[..U<:+G)EL*87^;=M17"?4 ):D(]*VPIA9KL].,9^
MRQP.3$UM'$L/#= \4C$W;R58+#]OC?UR/_-57PRUAB&E1N=B3>(!&^(T;R^A
M'KT>#MP$\5?&.I3<P.SS8VN,4V6+,VZN@V4_:!T7@KY%"MH'&'JV[%L/[Q)Z
MB+0J+]A7BT4!LTN3W0(\X,X[(^TFK=GP-^._RX.Q10]O=5S/:[^'V=#P3X(E
M]?8.G*]/OC :2&ENCO[G(8GCFJ ^.YN]!0Q^ZDKXYG[0N,?1H#E?%<A_]M+F
MFLHS3RWF@U#]-B!"_N8Y62Y%F?W0)/]+$Q#GC"<-[>&H65L6CS= 6,HF;4ZS
MDU^M;H$!W8XNG^HK%L%'%UXW)7JP[SM92 E_\J5?T]+F?L@O04O$2VBFA !D
MUW Z^_<%':I.IQG0G.0SK+4>GAPU5I_Y5T]2/?*6FTN_NB513B-1/&CV(?^5
M\-;>U&),_/E<L\G?%0&KQH^G0_PB]PT(5WS_\"Y.MML^1W5?=6JA;X?TJ/RP
MR8EBEREGU^K9*&N-\"35N-!8,YAJ_YIZ@RPO$%Y=#T]8;U<IM2AW=4EVC0+7
M%(7,8.("&O=;[)@/0]9=PBZR79SWF[G[^^%@E.?!(;3.L^"1;O%N4/'6HYT+
MW!*RC?K";'9NGX_J"/VX]1UW>#A(GU?MG=#THJOFL"7;^[FT R;W(F5>V1C:
MC#8$' BK4NCD=77%=-^F30QSI"E)[[>_N._^=_4[_^T,2'85UB$==M[<U6'R
M6Y5/XTII-A=0:]^;W=M];ATM"_92/RG7=-/<+."2&>S&=UE^(#U6J36[<T%D
M-&RB(W?P;9!I[S&;[N>,S==\Z_U?OOQRN0(MC5FDMT_YS-NT%W["P(<VKSC?
M+HWTTW .R#XY]/QH8EJ\<TY=\DUW:5\I'-U3BAJ$UIN6[]?\_:%H5!X@*PKT
M)017;C;NPOB=4+9EMM_\?GDX%]<$J2!,O.^KSO&;PT5P2;#HKO.C8>5?XJU'
M"YJL?")+7#'V[._7G.?N';^AE'DG\Y;_'=6" T$-ZZ:?_*H#UZXE66?#0Y1"
M]OLYP=B/(#!DMD=35\:@D=Z8QAAW&@430REOC3MG B5+*!QM8R]J4[55/(Y%
MPN:Z[I-.Q/[7F()RFO:_;>?7^N2YH^B.P%%'T5^],H?-Q;V]3?Z1>WB*'&/V
M-3:MZ%#,Q;JD,&>1<>64?PZ6J4^=(,%BIL:@"[_L-&T=(<-H"CD*5&CJ';W:
MRME+AD,>'3(I8G$10,4T!E2XKCMVWO'^2#/4"O'6[WD03/MUI#^#6\)");.+
M(V>T\)[\V%$ZGTMOD(Y];=S*#,4@C;+P7^2[U);N2Q_RKWZTI,/S72.X%1$7
M1I?W"0Y:WU^2:?'E[(7S?@U\%?FWT_1<A"]RV#DYS;F?N7OBL>V)-V@%GQ2Q
M])M=02I/WK,?6SU[V^"2>W^YF8_@D.ZK :->]C=NZQS;<E[+)W3]75398\%?
M2Q\9IE2N)(8BD((IZB$ Z7/3?O\X:3UV')6X]/!LMMCELU"(KP]^>##XG6<L
M,A\)!.HPA-IHGR$PXL.0 I\ *%H'J'Y4@F%!\=6O0CB^IBKGX0/4M5I/?OZG
M^8W?Y?/52X^G')'_'./:5OCOFC,?(;>Y235D*!=UWO&A]2=_,").*=(=/GJB
M<U/!/O%/ZLSQDJKMABS'B>'!@^67G4I.?OAI?D ../7[I6H!9P_'/Z>;/I]^
M*:EZ)55XOST[C&W*'LZ/079ZP.,"T = UPLC16^>#H3(YGE*\VK&0]G5T+!E
M!4(3!]?1G:9"5*WQDIT$QI$R?Z$?6W^:A#RF+31FD8BCD#%BI%-D]_L._UO>
M4L0:!7R+;W<LZ2_$E)VJ&ZLLD1OP*7<I'C[.I:A*CHD9.M=F!CM3YC>#R_#D
MSRZ>.A,0A!9/XPW 1%M(LMU[57$/]EL$RG*<7OF\0%B',DK2>NG$D<;'R0,V
MSI6*ANI/>X>U#>]'F^NE!5 @0*/Y+U7_4!HUE[R1X0G4=R$%<:+@F9X=EYH>
M1&QK5GGKA;*:(M>$*MDN.[76\1>WG^3K9RT..1X8B?UDNEQX#REK D%RSJ^L
MCP1Q!HJLAK]!!%4<7M*/S6-"^UQNU]> =#?P53AO5]GLN<.9(Q\^3%XBICF7
MJ"?5??@<>4R;=WD 7\+@!9)9/$O4&%HQV R<H8TFDUIKUK8K&!:O)]K9:_R:
M'3+<7,';GWY:EPSS55[B+HN*3^L\_J7EF-,$H(A\=@C5KOK?#QNM([S+Y\K\
M2[=[1&JU<_OIG_S2S2!/('--?C]'5;/N?CG/VR%I&@Y),#-[>YX"&"=,IL+X
M+!#Q *L?%5D.AG:V!A-"RJU74$/>GM*VM_ZHA*44B!U7>91?VE#^/QQH^I_V
M_TCK4(7\O1IBM_:N-%&P!3"DN0'>.W$-Z2*,4*JG7P9FM)?:KYRZ%&1Z7"XM
M8)J2YG1^2_3-V20]3:NV4,N?%7%TCXX3_Y;Q5<+[P$&-9M*\#GFG!R'2'(<-
M+3B\\@+8Z7$X=;AEM'_K\A?]-EUFZ?C36>Z+(O+MA3+\NFPKBW4UZU(0TSL]
MX@-8I)N$+".Y&2Y@*"4]'?</H)+\]5%G4$D 3BQIH+NUXYDW7KBI+C<J^;+F
MB]0BC,-970MZO^ZG=BZ&"'$YFR%]F).P3$S=.Z0'S@]:OT/QX,1*EL^WSJ<V
M3B:9.,MD;38MG@F(0FL>F7Z9ACK,9E66AM3G32R\!! 8 O4L'A5Z!#01"L0
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M_Y_^__3_I_\__?^?[Q^H;Z#ZNRLN^D_4'$(O*+@^M*3IO_R?#R?!_J)?QWW
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MXHN)8JZ/=-1KAHX:B[GW#RJA?3!#*$ KC,EM2K-$S+=+ 7XT:V8G"W1 ?M1
M+8H?VXPE]S[/N5<;;2KO&Q$4H'O@\;RQ?*V?S'H)8=XY?O"L3 69@\G>V(-(
M*,EPXW?86M45) D>OTSY7<.6+H(?/F0/=_!UD)ZL*%S*IAZT_VS%43Z9+<!
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MCD!S5_>))T.$Y;)K68Z/*J6OO;R:,.IZ6$OM?7EHW@!6&TJ7TL;+,?+3J8R
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MD79KU% T"V1PD@7"O;0'_]USWR/,CVQS^-8+IFTJ_JVKY*.X&[RR"F5&N;)
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MW1XB)#.9 -B7K/7?!,Y&[DF7I#DD]NJ>&K5WH!"YJ0%T'9@N,D?U G91T?R
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M=SLM-QIB3-Z.^^9H6JE7?3C1PNRFH\G[*^)/;J:YV[0,R(K\VF#/S._S F<
MCCX#U3$D/A-)ML;%7O%"BB@S(<MW*^\3HR_.W$C<Z($YS/\LTJ_HYBFE\O:T
M-C6FGHP91&Y=D'6]N1D Z(<+ *$-76ZI2$*$_6T6*-#/X1[T&H*#;@66;.<*
M/TW2&H'6<"71CQ?[&EIH&H3-&$SX23%AS^K"5C?._)QMZ@T\G4@O "98(*Z(
M*&7 DQ+? ^>C"])VT<]34I\0U@1=?N0@$S?;[ ].P5(7PAXYGS?X.)UHD3N5
M%EJU YM'<(XP=0$4<]\6 <F'^"#D_8EN.,YF\T-*@QT-#G7+CHZS2T)>G_I$
MNMZ7+%ZXU&DI_.6%E*<&,!Q$.X?L^ @FGX7O 7SM 1:(8*%*%'B'YG&T]X:[
M)DI*&YI7OTV6$SQ'+3,9I7;M.ZBU^#3"<>:<O<# 62@<Z@T%(,6=+- TC<F]
MA1^>BZ<F U<KO7(:4"NUBV1LYYSOTV\3E760[U'?E7FK+AA?8WH[WQ-<=8WS
M>S,6!68/^\NY>>8\B<E=08/1C[P% BANMN0HA"(YI!U%'*OT=CD\-FWQU9AO
M;-;!I,$Z.I\49<$_>OAQ82I(85V3R7^>4:5N-6?ER+B'.$77=FQ![@U?5*!(
MYZ7,2!*;\K?-4DW<^P9&SUH7R-V\V<XOF4]C\D83L0?"3S/YJQG)(2A>BZ/.
M0X7AQWK=! _G^F)$?";'4G7%/#+ -[PXMG/^X8DR*XAC4>Z ,]F_=\H&>$ER
M5#FX0'43*6^H//OD7;_UO8@^#3RN#K<:1E,'OE&]*:B'K?(4E#%V'+,9FOCQ
M(_>U5DR3Y4CF<@\HFO/OSIWQ10'V)"@OM O,K[,<>.".Y"E^*SK%;.&_6YS<
MGZ@_4?_540+)K2?V6C: .$I5X)K,,339#C,328U.C1;JTNF@8!\5#*2HGGT:
M(0@MG)(3M@S>=_;GOD4C-[B@,1^_SUM3&;N O$5Q?A'B;9Z1(O[UR%_RK>@T
M"[3U::52C^L@<;G\S/7M56,6B-.#\93MA)&U0&27 X9^C"D7#V%DOW ZWA#;
MYUW9=.';X8<'M60YC1!WHT(9;=!;J+DD.%2@MB5W.?H,8\ 1T.P@FY2>NGL)
M=LI2+7E-=^\I$=\II/LP('N5!4I #!,QLVBBG [GLRX6J//T*\NTA4;F2@VA
M(/Y[ONOA+1L7N0TGNU-.3\60<\,!ZS0FB4*W2G R[\E<C,'3)7T]'5[5PG*L
MYIVG3OMAJB)4>S%SZ=0Q1FN4!0O$@SOO=^':TGZ[N0Z7_?49<OTLD$6HAVGO
MR6M-TVJ/R^#1;.JB"/40F#6D.@.P<N V*64![>=6MM 770@@)#$&),N,US/)
MJ4W) ;S@]^73BI;GY&"U44* %4T3\3%?4N80H$'PDS6L=]]-=+RCHM_/)L2Y
MI\RB9U)U;[3 _S!7/SK<,Q4G=WKNIMK0H7BF3/PG<G9\^.>R,_:302GYLJ(>
MM0%/CI5/-O>'CJK!!U]Y9(KD_B$TW_@/,;J17$MQ__Q3D+>U/?9O4;Q_"+2]
MO/=/U)^H/U'_.2A8(K+C E.0?AY8IDD!7018)T;@KQJ)BIQ6-I@2E@G(+'%D
MJW2]CX\:4S7]KWF*B<OQ;*'_22J$SCC)(:-TT".']E%J6+4@U[V.K)%[N8S[
M7)UOD6)CB[-&I/Z)'*PA)9TI?83MOO>Q%1N"K=@PIFS%]H:*!10\Z4(UU%Y
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M4NYZO]#Z7L^!X[+K91-4GU4(>BA36-:Z1+?LQ_<(S1[HG"KU+"!/$F>"HV#
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M3(E)%C?6K-I;\M967+U(0>I#AT&:>GM[0A:O?:8))@3U?KH<VV!5F>-/'^9
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MS\*SI#!4U?AB6*JH=''35ZU?^-@%_)89/9@LDT+""@*58UTX/O7Y*QN.[;@
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M<'?^U-!+\9+TCWL=T%3VV!5WV=.5]&E,V4C6R(2A J;I9QF<\_1)8#R$UD+
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M_JHG:!HYSS"A/&:Q\!C$M,T(WCN /$'JN5FB-QYY86YP>/MT+4,LWF"%;YA
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M]K$RZ21:^OW81D_,J_9Y?1%[A@#.97P<X5@:%G^VXDWP?&++R6UYT?1&Z/Q
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M:&NL:@TQ_A/.H__/<YXWQR#<X"&2?NYO=?3OM))CD MZ3A3864R/X#;Y7L=
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MKR/5P<?6*X\E>_?:G6@[+PB?/).!S'*T,W?5\O=L-4LO3X]FB/<:N@<!N'D
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MPU?S;$,;3DE]QOF>/CM?\ZE25M4K^-:1"(5:M;9X#RJWV3$H2><()T[Z=PE
MMX'K4RQ749OX8Q"3/.-F*G E&LH02*[PC\1GE\ARYI$>)CVON2DTY.VR\@:S
M=;^*O2!D@%BTA.A$)RP("LD UTG0[FR9\;.\&.)"W>G-^_<6%>Y\XZ (7(2R
M9+TJNO1J\]!;^MI]>Z_897@2 !VHR<UR-8<SV_YF<//#O5O_1VT>_L_Z5 81
MTGNQX:B3K=P^)/"22D\(>U?&Z403GW(@]G',R*R88]WC 2G)[>?"DJO2#*4,
MRT$/@ %U/BQY#( 0V&>P]'.L%$V M=5Y$?NF_6;S--41[]<0L)73-%QF [7M
M0LE'FVI\:"4JN#N=/W?X[CL3#E<S3>5()_/02JA&XF_A9^'C0CR3P7?3T^LW
M\)\^8:M<D_D-/U84^6]NW_4VY!LZE??MKL2=7P(7[8JVV"F/X".X:FCW.ET2
M/G8,XM-46T2R=R;2\@@RIAH^J1W8]$M5\XJ1M9X1WC_XJ S!$"I+'V,@'1:0
M G=A3EG]YIM"Y01[ F:D[E[$I7T,RX*;>EK6F1*"EIG)"[>59\;UUG7UGQ,?
M.%*J]?F;KS_96T40 Q$=T+ ,YTV_OR=/(JL OT+]I5ALK$6ST73,7=ZVM,[:
MK#LZKDZ:AS9;A']1KV\F@:1[WL#' /8^.C?P:3&$GZ#_]L"XX46[\)C;@8S0
M_AT2+7?*/^U)_LS5LLI?/AI/SO!V@DCVDHC%$LB76T"4-A]X5JQ[2[P718QE
M]:"(42@LE"#WG4W4%DJ$HK'UXQB4#JT-F%EZ[H^^0"N":_N7D9\R@.;U-EW9
M_[)IVI#-&.9YB)B@$'U^<,#9QZ=@SEI7_>+H4L#DQ-%G]$!9!5LG8G&(W^WQ
M;%$VCG/X1[K'\ J#V=PE[F#_U <W[1/>0'+1\1!^^$7Z".*\CT?<,4@0?M5%
MFX-8&>ZQZCJ[W>#_Q6:NY,IC+O?R;^;F9ZP^AA:+O@D OX'4[VP.4(S\:YX
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MV;-.:SY[_7%WV\EX<T-Y7V.958Y^!VQ]:$G 4;DLR4- D<:ZT*G6<4TP3"/
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MPX](T!9:X)AD:;$Y"'0#M&7;U&=DII3)AY;0M5_WH;H!"O/$O9XX\ D'TKD
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M\V66OA .).]*\MI-P_ENKX'#)=2OQ1<%RDMBTA]^^:R:UR ];'E$67--?NM
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MEX3T[:I\XP#D80[$4\\FF2!L7VESUC]?^["^=H5#]%P;KA+&E!D!5;Z.]=J
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M,X::H7NH,9VG-'K,:.B"$OM.%WU+/O?:RI3'G^ >>ZZL[ G47INC.#!$F4I
M&.,D4->1IA1KX*P]F9%3V6\:-OUR-NJ%QN.3QUL%@J4WB?_R'-Z\H1@@86H5
M+;?O3$!(Q.NQB/1J#B23QP%T+O\KJ\3Z7QS.^R^4M/=7Q[\Z_M7QKXY_=?RK
MXW^UCJLP8A";IXHAA?Y::[U5WA3[H!;S2&V'H6/CNZ7^!?'6=XD+!\O?<F?4
M5;_RXP_)%1MYT.GBMW3!5]*\//^ROKEJA\5 T7'SX\\JD_LZ\%@8]4Y?!P<2
M/JF,>4RB6A"(H_!!;8?K#:6Q^ 6D<W#\<*=XMKO8+>[7B78#=PT]!"Q]#<&@
MXL$G3//%K7MW# ]7 2!KV&G"2OZ=$'1Q+?1%Z.D>5L;]8[+V,N^YOI)V<F7M
M5)B[E[&XKE;.="-C=X6:4$=(#]@'4*871N^% ,PZBO(U4&+B%*R6=I[W/7W_
MZ,]?!E>*TJP39>+NWJ/]^A+G'7*2AI@HVH'K*FHL_HXRY@[6\&7"OX66,/9A
MFN$8\BM2-;EJ@"T9&A@&;4MUL F%SLC@ERCG/@:;2M=)ECH0>128R@N(O\V5
M[H.-R[#YG[)BT(;I>!%V7^HFM@4AU)MJ]RM9I_9<XOV-XA]W!^@0(Q7W>F9T
MHSTX_DBV !3\;&WF)+0>-Z/4JJJ3(QQ;?\9E#]]XM[[ZD@T\J>+.4;,?9>!O
M"UZ)M!NN\]\V3X9S(&K';1_BB6+P#VI=R(GX\=%LIMU$$.([^NN_EJV+>(4H
MFV/*;F/(,-U#D#SL83F)8;:HU_(Y/Z>^NDN#"DGYF\ 3"P$KCX-?7Z\=:-;>
MU*$RIJU:^^*=1*MHI)8^67>VPH Z/" 3_\;3VG'\PA\ICK (_,-I@;W3%\7Q
M2Q475'X&>CNI,S7ACQLM,T07+Q?CN7U)?R."Z3\K622V%IWWGR-]^*_VOYI@
M&@=RQPI0P"R),'P5/^?2LLFN"81'/MM@U!<H+VETX3X.1*97<ORNJ?/)C]F#
M!+VMP]/-VV'D'-@[G7BU1G7PKZ,<B)>CT=58AT\808NW:JEO/Q5UMQ_4.P$G
M![!64G@ZY+49"..P.4$@J?V5OM'"\&+(=?V!@>*&W!-U?CU7Z[.F_8=;!@J7
M1W !V3#)QJT-PX^$*L12V8QD(R^FV09S2]5IZ%)-2V_I_.85C[2GIWWGM),[
MOJJ=66R4.GC!Q5T//]@WILSF-6*(H<>)H7[LSSBY2F^$M7M-[U1/@65> 81+
MM7;P1GFR+-_;6S/1\FF_$(]QVPWYV/UL@=0I#J03$94F&'_O6OG%#/S/I]\Z
M$AXC+<DOO@4&M J\CF-NK;&]!$7Z@*L@M/0]9!]A%1)<H*+ :$LM_N&OGP'N
M]1*YXUW%BJW&:SLK70Y^:VI=D="PJ#QRP$3YY[P-M36AJ"/!7K/G^!6/(U=8
M/WC,ZI2;B9?JQDP&'*_%V]7R_ES#GY+:S*5AZ0F &.,4!W(#-.AEH"1KJSAP
M@J>J_&GVUP8[]/A]I8E8S<VREE*3\Q_[O!"=L XD47]FCB(6E(M@W@>ZIJTD
MO[D'WRT;=*,=*E.=(8X_<+A9^=A*X7MF/I<"&4Z!_7&6?N=5@,(XNT$H@W:L
M\"\Z'08!"6&L<Y(;.Q.;QQ![A;*I'%: K7_2>':M[%UD^ C%-S]"#\M[ET#/
MW7>VY&A0@,V'RPF_GJL7U1"MX$-EHIJ[OQ1]',&7;<X8B\+)IEFBUL:0?ZV)
M_6F5=[1H]#GZ&P>RZLX&O_H='P<R[W5:=O1/-ENL_J<31_\Q!;'_FS3H4Q+5
MQ@HXL<*6EIBI3J?5T>7K_J_TQ<K8&=9V8,,VT,GEMN7ED:MA%N.E.L?WO.CA
M9>UF1?ZA=A$PJA4RX@1B!WKW/&D"AQA=SD94>\'3[XZ*O&,F<_=(3YGZA>7%
M,?;-8%%%ISZ^=97\9I3,JZ]6SG8*JO]@^[1Q$GEEM_/\T-LYL:*MM&S=?W-7
MZ3_5Y=#_?VY_^=;_8RU]SF@N#->+.%9*3O_0>6%FL%Z'S>M-&YWA7NK:JHP&
M--! [B0>K@V51%DTU1 3(_GL-Q;W=$%U^.5V/W6^/"1J<.Q19+/VA@CXZR1:
MS5(K"/%^0/Q4@K05T6*Z%$?+&J>C1B0ZG;0XD*CX0B(JNK-='E[A'.)V])N*
MG_W2;13%9=?$S>TZC\2TMC%&C-'*F&8T[ YFG(MNS8HAN!*^\K4CI+1W-RJ&
MVI\(=FLG2;G#.V3JQD,4RFOJSZ6IYAT/./7U]JUFUZA^9FG3)#! &[^P=7H-
MT]R-V(5QQ8_UG*^DIC9S((DP@4HOJ'CHJ0%G\4WKD>7?_!=;1B]%3_CN@QMZ
M5[VX;V-TOD1MM;WG$O?2Q'^=3<+_CHU;B38TPPTJ4CAT=Q4'\I@DAF_LF2((
M_*0$E4R([CE0O8,[<$=$U9D>MW?:@#RH;]/@A&NAY,D(BEX1^PN!>F'Q-P O
M!=2GM-?;59%6_=H\JOM5W0H<FK6(7B:M2Y=W+TLC5&&!DT[#5U77T PF C"E
MSLV06B@AY)KV%=[F4A2B7?HZ,; AYWI=H2.Q.]=)XV-WSY/@@AV!!QO-H-2S
M@F.\<]/B&;!']==H?$Z ;QZ@6*^'I!:U(82KBBCZ'R6JUZW/#O8$WWK6K>GS
MVJZK<>_9O<<BW+E6N=E\7#."6 ZD"KFT=8IQ#I3\*3-H,$>"^'C50TYKN/=U
M](DZ1D!Q2NJ%PNUOZJ('IV=XMU,#$]YSS>, Y750CT5"0SF0R#(.Y)8Z-W!V
MT.S'@,&!*8S0PB[%CP_&+6B[*@HN?#:=D'-LU%ON/OD448:0A=WJ&R/0GP-<
M00Q5IA=P*FL1#:E[%_T)<"ZICP]!O>'=+W1?47HLB]CH<,XZFWCB:=PLQHWT
ME9M^E_7*\/ "!R++/)*]&+R"_=U[B%_I$HV4P+0(*O'LO!@C9_,\2,)/+QIR
M]?AY^LH-J?5WN\)/%8*X(J Y<R*6UN,PI)(%R,Z$21C5F7TE691X)/B5=]9$
M7=I-]/_L-4<B%C63JE/2&?I -6-:HL.*V]->Q?[*B6P7UZFQ@RGNZVHVB*#N
M8'^$_>@K]"A:E 9-Q-S&20*F+2?/U6PFLQ,'KHTU;;N/\,O(/@6\%M2EFH9S
M(,@/3*D<JS>A*.H%<:O<\:I7(BB/L9E''75B6#\)2.;O @Z$E\'F!2-@TYUD
M*Z;B9$/\U.^$R52RK."%857B$<JO$/?\V,WL8G,IJ_?[X[Z^%@0]4%08J&6"
M'$CV ZH2>^^**5-Y!3B,8>V3  E+:O!ZX6&N9LP4 M-L!%)(<CT/R&GK!O[%
M>Q;B(%0$ "=1+X'HH:N^'3.E]@O3TKAU=QP',M", A&4)P@?G!5N(,$66V>*
MPMB)?$TXP*(!2L43R&] /WC7:0=(S1T7)]_^)=4_7*H??0E7P"#K=*-0Z-%1
MPT.>,%FFC.^NA)L^BM%#K;I/F_8[6SSX,/>^A,"/<F#S2DQ#!3PVF3 H4R V
MS%6L12%3PKM;E@OBVW&?XA3)< 2NM*'U6&FA+E/0W3_WDA;@F_K&;FZ0G3_"
MN@,?KT_7<B Q7W2"$>'W3FE>JG'/KQF@9&4J+226'78U)#\XS-7YGW*(_G-.
MW'\GJ7[WA'KBV+P[J9%3MA]HFM; "GG\D9:7B*_*B4RIML1M7+S7Q?I.M8>9
M.OG^/^I8N &CU4D<_,8H(*8U#4T0[.1 N+(0UXSOQBI%C?O%G&[:YYL98K/R
M)PF6$(+%/K\(D/G@VV]\!JR0V>/&!E8CLC<O=8<U[[!MAZ#4__G'PO[TG:,-
MUJ?E^/[\L=@_O67EZB7N!^"(_FD.LO_Y\(>,B&XC$_XT!_/_8OB=?AO_)=8_
M7"RH$M-Z%'2H*]&3&E2WARMH/>"LAX%C234.J5@3??K\"Q/$O?0(111[GS2%
M\*?^7T@4*!DA@:J8[FRQ1+:F[5D/3(,^5J@=R7^XO?K="RFCFE.:[<&L_\K#
M\Y=8_SZQWN/B3G(@%!9UO,-I#S5CI1.VVU(IOJIZB/*]FOJ11V1WSW+2704\
MM#4280=_@AY@[Z0%Q1NJA"I\8>J][@OR> .T6)38HTXK>_%$/-?W'S*XM$OI
MO]'P_"76OU>L3PCQ%0P2&PGEUR;$V:]W].U"$-W30KY9>'A-Y<&3N'BW&81-
M"_9+;RHU2Y=,-I ;Y*\/2UFV+Z<B#7Y(0.HZBK_*1IN5:M+KJ/F/F/X,+:"S
MQ5!X4)$PC/\5&/?Y,X2OF_&<(K72'L"!_!L>\]*N]C\ODXKQS[YQSE=!OG5J
MW=ZC82R<=NG-=Y>H,YG%5I" 0Q\<W>A1P,ZIOCAQV(Y0(UIG,QT,"_L-TZ?X
M2"+V[86.!5+\8D7G%9\(\707_#PM&R76C!Z$5@DNK3/V,U4;@!'&!:;C@('4
M5/RVV"I+GR43A="]!V-W.=UWX+YC7:3O$J4]BG)H(RHEA![/ WI:=5KF+$>*
M#S0,+=N8Q]Y(YNH ]@LGW[AK<O\UWR]X"P=2:<J4T)E:;\&-=;809-&\[(\(
M\4853R?UH=_\3N" [*'2WN,N]E/4%:M.MC/?W>_R\#CRJ%XE2$KTE^.S.^GD
M?*9$-OT2L%4ZJ9S6QQ13:IF4'E6]AXAY\FT<2&_>C$A0?SWB8A=:)'PP)>%A
MK_^=O<ZKTS?LE)6SPL/:C=%AS*T=VG;FZ2$.Q!,YMD(/814R9:>\'/7IKP$K
MC^F5&"<%:M:W,W));WL%B0*Q]VKV]M!Q$Y7FJ8]NDN0+T^\))L_![N" (UA*
M,\,0T^P-<Q/\BK/K9TJ\9BH"Z2&!@]=_7NG!%'@9]=36Q"G'*CW0KAS7JT[M
M"3_>!?G<;7Z)^^<I,2J!*8JG2X""O$(3"94^"?GL'AS5^I0+/11PS@;4A LF
M ;^197Q PDV'.MQQV\/Y$0,W(U0; Y]OO]U2).:GUP?H]$T%=?1M0RG-4/HZ
M",293IS4K7< I0"P.$-#)OXN*BI0*]&ZE4B\]L8B=E9(WNG4-,5T_Z/GWVGA
M@OVU?]<RZEMDE:K^A?/?A_'DFFMNYV]Z_-@M9WKC;:12RLW37 5*V\,/9;V?
M\*(_9F4R=6CF/63DHT9]0*.U@_BLR&-2L(%FG&-?TG_#_ 5%^HSF@VWRGJ\B
MKA(\$$0</8B5R!9W8GJR\@W5YS/YJ+V/VFI3J@)%>D&]BC[^4NEY>&"[=$6U
M[I73LBPQHY;&0P,&7E,).AU.T@T2)WU*G/F7<7ZB;U-X+AD@'VR3LN7>X98&
M)-$?@:/Y Z4_A5F:F,(DXK;#7#!Q'(B$-E+"HS:QPGE*D'O>6ZLV,,;COG8-
MO?&- =])>_M/SNI\0KW[E2+*Z.%A(\:AFE0K-M\80SD4M, 'ML <FS=Y"LOK
M%9AFVOK>Q[O>DCQQ9L;AJ[;[%^C1+M?KV2I;VG7C>&R$JZWMF;[0/Q0KU'00
M5"PLJ%BAK*)ZQ2E=K3YBS)0Q+AXMBTIJN?1M/.]I@24W42 ^L$;$@H[?4JRG
M+X*Z#A;47!I_SO5++H[Y92N=GYQ+JH$N;8!@5L-Z!;M9XF9.=8JD8J==*>-F
M)Y)44C=3*O? ;6GM_JIMPB5Y8[V56;I<^\A2&6;V/V#D]PBJ-?81K$R)*6I!
M#Z3V4;C> GVG6<F_*2<WK>06,[D;&LHS&7!G7]%+WZY_+;^^(=Y$_":#NG7E
MJ)F:K?>#DQ#6U:Q&,"9YP,N\!$S1_)MA,O57BD-OCS Q5"=8@G1)_M+&-';O
MHM^"?<+G2-'2Q!+_N[V^VK6ZQE'+/,^C_)_E*J\4_GUI^GDRZ;YW5??,*]Y2
M*_.1B7NP37?Q\1/-9>575'@'/A*SMXH%;\$)H%51;H@1K2.A#4C+ >W%D**$
M4ZLF8S.Q8UEZ.YR;]':%G_14[C,\C/Z"J7!KQL0Y"0(':+"9$U$YJ,[.S?!R
M*B9JKFX"4]!3E>@2L<U7\FM3=Y.)@.@[!2X=BC[C'$H9Q!,I?&@8$)6[D$IT
M>I#"OHW+.K,O-=6OSU>L4NAL>9>TUC-++?<W&29V?H>Y&K((!N ,O<%1?96:
M"( 2J3V=P+6(*8]I)TD#+JV;E?:(QVQ%E%OKFWO\ZI?N%G\1GOADJYR>8RLS
M+1#A\/V;G2[B$JN$0"Y&\!L*H[CH]X?1.].A>SU)5=#'6MX24V&SN;.FKCMS
M.9 GO8777X_+YQS_=A;]F5>_Z^@!=[;;)4'\8?P3#L39"CA2C6=<8MX!5A@R
MJ+6FD[;I- S9A*"8,9&<^$;!'AE[YY8Z_90)U\$NQ<)&(0N1^QU0#0TY2T#.
M# 3/2G!^T]$@':\R98I)T#-9B3#/7JX6^ST(7N=WV!:V+#7>S'<';ZI(SOJN
M5=1,VGQW.3&C=Y_Y]M*OV8HU$'3\ ").3H=53?!<&3>U!A^6L# IS,H*=24+
M2K*[@V/3R>SD*8R0I8NWEW..18%,36:OI%&!3%E^-?A*A6:#^;:07=M8@EL+
MK>QOADK@OW&89AVT-'LD\]00A1)J5O)S_03Z4.*@ZM-3K(SA+TD7X@?$KPB^
M$KJ;Y=CPEFOA[]L+>ML[43BA&G^]0\G]4SR/;_WK_>)<I=OVNWT+[M_Q'*Y*
M1B;"=AHJ+6[BHPREF3>H-8\"+ 4LTR;3WP /B,LS5M[M@7W[+O8*?Y3?P[T_
MK@7(9EQG]T)W-BJC],GP-@XDX:1XTHP5=&%[7S-;+&TQC)U_:-2[:_NN .SW
M&ZXWRJ);4KH@X<':8DULT-U46D7"7 4C[-<[2="?]AGLEZ]SWX?!C*/UU%8.
M9<XJN^^/<GVFI6&F-?!ZSX+&A-<T2%IBF/N,J4%LGG6:_4HS,74I@A;4*;>7
M2J\ 7XN,9>_K-VC@,A_>M\MK=^ELFP[<71(9'^H,JM@UN\/<\V%BJX(4) @A
MMP D-:D)6M'XAKK_*RK>EE5@X)SM3MBC7F7\5*6D1)T9'79Y5ON(0NR>("&0
M.D4G3)I9\W6N::P1*I288@[3R$Z,&'L 4^X,',^=8*(!GJ)348F1^8A3C<G3
M'_/]Y7!OWSRO3+DD?CS]X>T738F2!G7O((;D+(*\(3][@@.AVJ^,R;/YH-0>
M^E;UHP14_!2^39"'Z?NN_@.5U=?:L&^\/>O%C4S35=DW<8%"E?O/UVR_T+X_
M(.GN?G^,-,8'032EOP5ZMI+<8YIP^Y@(,H,T9M5<'03=M<14FI:)/ZQ:JO6=
M\'YXV8<RXRR0,]1SJVRIULSZIG?<ZV=M7'2GN T\FX>'@?2$4JW5 25X*XS8
MVA983?4BTI\JUL3MK[)\6EK@89"2JA++Y%%X4EGX0?^RC90N/O?OS&7)TJGV
M0M7ZUCVZKF5B'/Y1Y_F.[<W!Y+V[@F_%_6!NHZV3X>T88<])(<"!5M3BI#A2
MR6/0$&31;V#J==\WK]&W&C7U-$TD\QC9_[2LM]@L290#N2,XED3&MQ.X0W<
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M8[6VZYBQ+[4"8Q/+#A"57/F ^6II"(:)A8BAO7I[\I\W##/5IS\\E2Q_U!F
M8?>]S3RQHGP0PE*6"(-"ARZ4RP>, ,K>(FNS5M_*NA&A\&>6K.6"H!4659@<
MK:FM:5N3^J7_R#;#XMSE+QV&'Z1UP^5MU:3%8[F7>Z&#;<%*QEP/OBYL^8$A
MW&<"CVC;Y;?J]NR'J%B&DZ^A4A3MPUU<B<%X^,TG7X:T/WC-JQ?'VC]\=6G'
MAI3(;Q$@C+F]K_EG*/< ') Q6[!71+:P<2]J7YL<:#876Q 17&1-E>)Q+$WZ
MVFE0Y896.-874[1C'*]UT%G]7GOD('0L"[L/>G^&%0=5Y@;!X[J=%.@MJ>4
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MKIA/LIN/9L5[%\Q:(>-1M=)O6'OQ[0XD_U51[.4A;7[\ T*][EN7&VA^,$]
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M]*AD=Y_3(6-"]ZWUSCL/J'3N57]PKY>E!$8P"\%[+ TL#OQ-A4?-+LSF0"$
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M7D$]DT)A9MP$POJ;/Q;GY5&R8V)"M8#,W"\6>JBJ3/8R*WD_;ZG!5 8]^(U
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M6X*%5'71A_*:*UUY)[W^" 5;_RUL9@Q9@U?;6JFUG3P9<*%CE)Y$WOT*E_0
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M($6V7@6Q>+"IWU3F&UN^'#;@&_J @]F")^?=#$PJM!L^\7@A-X\7]"N=<"B
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M@]"E=V::&,FWS6J/>3'"HV'H!N B>R&]H3;ZY6I(A)O=1L<Z!3\F$3HHYF!
MT\-G([X,"R:!)R$QLI89?O;LIJ\G)W<VVFO(7!D@/4/$%X3'8 IT5WCV&[9:
M.LU"6IQ$$!B#W0/>(Q%-:GZ_^11:6.&M_#023ZO&LZ&_(B@SNOL<>5;SQ@KF
M6<60X/*_-(B)!*A=B(52!$0H__Y76ZGEG.LB!_K(3FJ_K9HT)?;^4R7V.'5[
M\WOCC?[:F3_-HS#K'Y,/H \:PMX@D0&,#KDOYU+TH2-X<(B7PV%7DJ8'VL_X
M9V1+L+OJ*\?9/JE;\GZ%!.SGPVDJDE7.TH7'XFY(9^,FGQ/ P[1L- SZ/;]%
M*$\F0Z;\K60Q3G865FX^"B9P# -V]*Y@Y"Y*N@43=\;=]KWH7,$;R65')-S=
M,M[;)3=/'24@XD?X&9/YO#F0BHB%/R5'5M<-Q1(Q!%(UUZN]W)PSUXO+59DU
M*C>R8%@9R&?J8+I^B-URV#C^7)AO+E@E@[RTV*N"M.*JZ?,WA2;DB%KP^V/A
M7Z0Z-N&#)4%^UC0FLGPLH7POR[]SW3/&J8:XNY]U3'RL4P+8K Q$3%/H23Z^
M_ *11BWV(=PI8#2F-5 5XH%3#M&J# *80PJ90M!@<?/P:W]SA^/)GH7R$O$Q
M4OW?>:H=Y(^YFMJ8!,=.6#%84#( !/=>\;5BX*^:D;2GZCN(67RRJ15%#VS_
M4GPW5'R<Y8A+#:IJ.)GGW&V5]SQ'<63Z[5*(=[J5HS F$L6-=X#)0J">V$9@
M);;^,1ZZ!EMS,EK 2*YZ\6!E (GJ7&C@DS1>6WT[W7MM\R/XI7U-]C5-*ZSC
M:KT'=.9;$2.T=T7M'DX,NLA5Y/T5_! ^#5IE )QM8'W6>;STN^B2V=^G/'P[
M)((M;CI&IMX/TG;5>>!][;'F]6-#Y$/+U__7[1)%6([)M9I_+?2A]-.E++$J
MT"JE<=N';^HRX*6>K)Q2AW.Z;W).YKE\_UXB8B3/:G[IGF.B_,^ZGX\%ZNA<
MDBDL]@M",P#I_;Z"0X?^FP;63XTO@4E#B5R047:IM#76VN]H4_2^QWKA&82E
M)M]V%+O(Y!CH^?YYR*7S?J%*K#"(SJ0A<!OZ-G_R)NC9Y%[%MIVP$5%V=L\*
M)HTL]?OW'H?2":MFYXH@1>]SQ^RK,-B8A.+ =V9D=/GK-RT_M*0GXRJ)E]$H
M!O5W.O0J;"K+6WADUNL4V4/CX_R"=D;87S5KC#Y)A!P^E'1YC9WM ( ^]Q):
MD(850GW04<N_ O(V.E$+MFKO.'[8#0&^XV)VPNTE\=+G[F6%.(;LPXHZK\_)
M7?-C:/XWJO5JY-,IB*@D-QLR4.Q@KPU3Z62PI6&[N\VCQK6/JEGA?RH>S$9;
M*)HSLF\Y)',*'3+S$^HU#U%"O,9L5BF2+)<?X4+IJ__9EH72R,= PWZ;R!+D
M U7L_E!TX[[P>WI%,?=(B5W%/L8Y02=RA^FYVG;?0@[$&AM>CF$@[ZE@=".R
M2EEN#SNA_3$X >(_^C;'I6[%*D!>G;X;LXW.A:ND7AW<S60=A'*.C@95:NQT
MBM'*-GK:(#!-9H,N"QGJNY9?460HXR@PSH0-8I^2Q2 ?Z22R#(<F4MN=]R?O
M@7;Q7[$9#17:]E)?BNI\'[A\>>%I;MN]0Z29#1[J944>7"7[A,P1\4QA<$2Q
MJDIWL33TM:<T7-+ L;&I8=#2VM6[*,50N9A4G_/6CG'.<'8!7??JU=T(]N55
M&J.@ :$[E-V&&(,+O/N<.WI--0/D/:_(39L_?;_Y=^Y[ZUU.P99ET9ZCBB[P
MNYV9&K>DQP<?-V=#5BR_ 5M%9 A8CPO'7_?5J^4LC#YF.#$V I*S/QUC.$7[
M3"M,H[O2TOQN9X4_...2K<=>+Z-IT/=O5&5,]N;7M^-'K!F$VE[&@C@! @36
M8%7XA$@U>,M*#Y!CM^;EC'Y3++[P=$0TK[4/3NT6/KI.M3",PJBK3BU QE@>
M:XIZE5U7ST/-I0_(OC*/JMX*1LV/1&Q57S-HL[,^^-@Q>J1?VB^7@,$@PRMW
M<C<F!1-O-XZ=_(J,4L&C &00.D\4&B+OV/7X#(HV%+)*&MP>?MZ#7^IMJWC7
MD"WM^&2^*;.<<Y&9>;W.U$*_._3(W@?TM6=E2:O9]U?SR.3E,E3"Z9EL##!9
M@%L+A./6C9$CZ0,\V(\V=R9<[*S4];FM%7=C@V(2HO)S?79FL\=8#>8U%;GO
ME-/R9XG7"?7Z\ZCIV!"%OLWCG7 7I?\"&9"F&,!!D%D9]+ -V/0E.?)9ZO3
M+^5RH]/STS_R#*[5"\Y:-EH/^DS=V)Z\OA9SB0YB.PGRMGK(![IL[3!%SSN"
MO:DF=*"&+C[B.WMVXR7'<NW7C7<"[N/"KASF#EHT*Z'Q87NZ"<X2F$15?>G
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M3.FWX%2^"3P]2/F<]D]OLAF7Q+N?YQ!&?<?D<Y5#ZDRZ*JL-W<3<G^IZ8!\
M+?+ :5H6'3Q"2U1QX@4]@P]59[36[=E2E\+%250D1>1;J1MGF>L]VLY4E=N0
M_GRPR>&0S8SU""ND3;]^#BM!)V;&".)?@Z7E_-X6-[XT(]_9DA=_H)]FP;-R
MJ-2RR&,=S.@NC+W5H<N*M:EX9U$:D+1% [\6/?M0H$6KR01H,:='X3, &<IF
M^"C8C5O?M#TB$U!L#8O^7HB7]G]FEAP9F;_DC?EQH.^6_\,#5E1=5\REW_^E
M8B;_3<VYZ_DC[[6B+2)OC/]S3@O!L]^B"'"C'A@ZS[S(LK[3';\K_XQ1SL&4
MIU4O-%,JMYSX/[*UGRZ4A!^.J)RCE?K5+GKRUGLE;]E9<JBK1XE\TF![2<69
M@XG#Q_Z+B=^T/5"#4(/R#J@125M<4(5)R_F4K226;U^SR@$:=V']<(27I\:.
MXYIY7'U2TRG)'SEO16HOH-,??I NFJ<4?-3!_4GZ#GFIRU*M1?][DHZMS7(V
M<)*:3I6+:K*$\<MYB!J4W>$;P;!84)B;$'W1^)'G</(.(_YP:W]IOTO <[.;
MU[T>_C_P,?PGMK@9%9'Y>*$VR8L+KV!J])-0;T1-42%F5Q1-S'4JJ(N\2/$N
M*-K?$,FX=JC]%L:%8M="<_J_TTW8#+03*H'Y^"F:PC@: W:L8*J -K?0P(\Z
M/TU_O?%J+KS4/LY<'-?IWQ_0VZ!7;[GZKW42FPZ'<WK3; T@+$?2E1$H=;V3
MLQ5P!S\]'WJE(G.U+J8QQ/6X78>V8<"E_Y84J?]I_]/^?[0U*R/_ 5!+ P04
M    " #W@&]6+9X"61 & 0#Y) L %0   &UG;G@M,C R,C$R,S%?;&%B+GAM
M;-R]Z7+D.)8F^K^? C?';";33,CD FXUW3VFV*K#;BR:"$75=*==<\,JL=-%
MJDBZ(C1/?P$NOCL=H(,4L\O*(B,D$CCG _'A #C+/_^O'P]+\,2+,LVS?_G)
M_=7Y"?",YBS-[O[EIV^W[V#\T__ZUW_ZIW_^?R#\/Z^^? !O<KIZX%D%7A<<
M5YR![VEU#_[.>/D'$$7^ /Z>%W^D3QC"?ZU?>IT_/A?IW7T%/,?S]W];_ 4E
MS,<Q\B'FD0]1PD.88$%@(/]'/2<,7!%=W?U%Q*'/.1;0CP2%B @?DL!A,$B0
M[S$:.)PG=:/+-/OC+^H/@DL.I')96?_S7WZZKZK'O_SVV_?OWW_]08KEKWEQ
M]YOG./YOW=,_M8__.'C^NU\_[29)\EO]V_6C97KL0=FL^]O_^?CA*[WG#QBF
M65GAC*H.RO0O9?W##SG%58WY6;G R2?4OV#W&%0_@JX'???7'R7[Z5__"8 &
MCB)?\B]< /7?;U_>G^PR^4T]\5O&[]3(WO BS=G7"A?5!TSX4DI?MU8]/_)_
M^:E,'QZ7O/O9?<'%\6:71;'3JI(R45*ZH9+ROYWJ[+<+Q+<D;W4HJP7A:G4_
MV9*Q#]-/UL2]E?S QQ=XJYN+16X^J+<9F^K;77=UL>CC2VSKL\@KO)S@L]AT
MLR7R4OW@@_Q;VXUJJ(=,ZWY:ZMX2E?^H>,9XPY8[38.4_<M/\F^+A[OLQ^+=
MJEH5$J(GGJWXPD]<@@/B0"H7*8C"@$#L>@(B%@M$ Q)A'B^J]=>\X!G\]K7K
MN&[]5-,_&6A3G9B5!2_S54$WZ]G#\M@B)=<GM:+%OV7X@9>/N'U!RJ>6_D;D
M?VV$ ZUTS0K_YLO[?_YMHXH1<LL1\5A."<5@!%AK0-6K_TA([/3QXHCD=$>"
MI;)\\F)?Z9SV*-UPB/J]Y C/<[W&QOEO1][X[6 TKHM. %S0,_"U3_Q&<VFO
M/59PYYM27_\Y2:O\W  V*,B.?@)YP7@AK>XC0J\_H54)[S!^7'S@9<GYYT=>
MR%'-[CYP:?)]2#%)EVGU?(.?U7B7;^0'%E+/\WV&81R@&"+L!M*BQ@&,.$>Q
MYR>.&WHZY&3:\=RHJY'["JPE![7H5V M_!7HQ+\";W2GM/%X]%/>F"B/3(@Z
M %<Y(%S"G+++Z6$H5!L#I)1:UC@)7)):T;;-WQ2K_,:75=G]I.:9FF.,NYV$
M@8:"T?'3X/?-V*NFP3=<I!EGK_.L*E*R4HO2C?R2WDHK,7_FO-S^Q=]XV9C4
M5*U?=Y+.?$I0$H:0A)1)"\OU8<(2#ED0"N[Z3LP#I&UK72+)W/AM(QG(!>"M
M"N"I%AO0+4T,;)6+ADK#N)MJ $:FOE8-L"TN4(I<@;4J.[^\ HTV8*/.5*-B
M8'!.-3H3V:=;,Z2=%5L3Y7^4.W.D5$L5:X=U^Q?@4;9IR;:U@6^O*7Q1!]-9
MSC9PV#&TK30X9&7[\O[?.%Y6]Q07_)K^8Y66:?TU?;B1O_K('P@O%IA[(O9#
M+,<KEBN8%P:0)*$+W1@G(B&!"*)$?P73Z'%N*Y44#&R$!MM2@P\WX&?Y^U],
MV% '=)VUR#*48Z\Y&BB"WQNQ_S_;<)HL(I9AG6BQN.@C-5P&#!#JIWN=AB:D
M=0.]=NG;Y$4SFF8\7;S-*KF9N69,?B_E35Y6>/D?Z>/KG/$%]I(H0#Z3>XHH
MA(@'#DQ"%D#/XYA%?NPY2:C#S?W=S(V0&TE!*^H5:(0%4EJ@Q-4CCS/(]A.P
M/;Q&9MVA4&DS@AX21\XP2DY_O<N??I,--,<7\B^;4XLSS4Y""GJJ=4R@^?2P
MT].;(G_D1?6LK,+J.F-O)<<\JE7EFI15@6FE>4QWMIT9?;J=K%?USK0".&-@
M+2_XO9/XM*U@?#*GC8ZE([GS_4UZ%J>M_OXAG/Z+0[]^+GA1</:URND?7^_E
M*EM^7E7**T4Y^BQB1 +7B3&4GY0+$<44RGT)ABSV?!%R!Z/0-;DR.-/?W);#
M;QGC97J7U?Y,CYWLH%3"7X&R%A_D&_G!SVG6_EASWZ([$+HD9 W>T2FH _-K
M V8C+-B2UB;[:,%BC7OZ>YN8>;14/^0=O=>&L<X7KJ1/EVF]<_LLOF6%_,E=
MEOY?SF[QCU<\XR*MRK<_Z'*ENKM^R%=95=Y()L1I)G]PF[_]@1_4P8Y\_ NO
M5D56?LF7RW=Y\1T7;,%$*!CW/1A$.(+(YQAB3AGD7A"2$$<T]!T3VAI;X+GQ
MWJZ^ZG!T6V,@=0"=SE=@K35HU08;O=79::=Y_5JK._A=:0]:]34/)2;[?/3(
M=DX?Q<AL/9OOP9CZIQHD2VO'Z.).NOA,!?[^ZC59OY:WG'\M\K)<$!>'3$AS
M.W&2&"(N/$B0BZ$7(41\U\,XIF8V=U]W<UMZ-GM3OMZ1JOUIF8M*8F_HBW,&
MZ@NW]L8 ON2^_@K4XDZPI]^!9>P-?=/9/';S.XIK;^5WWQIPU_@^HX7RSGG#
MF_^^SW:<=5)>+F*'(R_D(<28>6H?+YH=?8 XB3R?DR#PM6\:S_<W-U*IY0/+
MC8 &MV :Z&I<*=K%;&0>Z80%/[-6W%] FH'EN"@:W"3:17.B>\2+436[2]3'
MJ/<F4:.9Z>X1]77:N44T>&V81?<^>Y+?3UX\_PTO5_5G](67O'CB[25Y[+ D
M<!T/NL0)(')=!+$($RB('Y#$D7]&Q,2D.]/?W.CWZ]O70$4\LM627P'7@TYR
M!5J)K\!:&3/3[ASF>K:=121')F5-$,\[>A@;>IH86;+TSO4VJ:FGJ?J^K:?[
MVE"VH?D#ESO3-VE)EWFY*KCA965/"S/ZXALIZV.BC9RC7$]JX&'MZS[=T\1?
M]EF5#[_J\Z\,^Z+?M+<-LNVM1?GDCFD1$1I%1"0PXK$#48 "F#C4@<QE"8\]
M'F"7+K9#6L_."$,)M&;)V>!=NX[GCP6GS8F7V4)J"KX>Q8P!Z&0N_,W-I"*>
M+=FO0._YBCTV&@B=)88R[7U2UAH(S3Z3#6UFP.',JYS?%VEVQXOW\H_E/4\?
MWF?2Z,[JF8J7?WT@__8Z7\KG\Z+^D>SX0TIY5O+KNX)SU7]KT3IN['F>H##$
M7@@1<WP8^RB!@<N)PV.$ BRT#W'LR36WW<9&,["C0#U=6Q7 6@>#,PR+0ZEQ
M8O0R S0RMVZ-S5HKL*,64'KM#=SUL8$;XM%N<00-3JM>9B0G.M6R.**6#K[L
MP]U[0&:QN^D.TNQCM'/@-D+SPS86Z_WW]7*9?U>IMDK95;L9+]]PMJ)U.,'"
M<ZA/0^I#$7&YMN*8P#A,&'0I<4."'"]F6FNK:<=S6SPWDIEM(K2!UML]C '?
M2YS/K?4 &T5J.Z13Y0JLE;&W@3!%S]+.0;O;2;<,IF#L[Q6,WQ^6!Z';CUR7
M):_*XVD7U"V9XXG(92&'$<8^1!YU(<8BA%R@6*B;A=B+3+(>:/8[-Y[:I!:Y
MY%;2 '<-BWT<-*<\[6C$/DC<LGT*,@ZZ9JD(1D!YJEA26V@;IQ<PQ.Q<,@'=
MYB9-'6"HXWZB -/7!Q#]I]8 ?I^555JM*OY9R&6%%W?/<DUYGPFNUI)5^28M
M5:=E=_##/!$2SJ#C8PX1"F*8".Y#-^)ND#B1[QAX[PP286[T_^G]]?LW!E0T
M#'<-SA\=S9'IOY,?K!50WMVM"K6ENE$"=%H,.7H9-@(&Z\+H(S'1$O%%7>24
M*KD6P("N-\EY4389M;_?I_0>\";Z^!ZK[03 ZT.Q@B_K8+4J;W+58%HU&P[5
MIN2J>W!78-5VP2E/G^23=>;.;[]^_17<Y4]RB]YXW-[QC$JN^]72 G31X/2N
M1<-:GFY9NDCSG17JLI:&G9]\;;VN90_=7]_P)[[,ZWN1UWE9=3,U\3A!GDL@
MY[%0:Y0/XR3$D& A?Q[+52K1RL9FW//<EJ:O@QS5]8'6.T 9!;ZQ3U!:06N^
M6O]C2VQ0RSV"AY,Q6I9.3/3[G?3(Q!B._3,3\P:&T=,[G!;J?$92X;LTPW+)
M:NBQJ!?J\B9?IO1YX7,_HB@4T,4$090D"4Q<+&#LD@"[8>@*S$VH2:O7N=&2
M$KH^CJP-O+7<8$MP,\;2PUZ/K:PC.C)3:8"I$L(HJ<'O[7]O^8\*O)+3[ ^+
MQ&4$G"72TNMS4L(R@F&?K,Q>'D94GWCU&I?W-T7^E#+.7CU_*[FTV92?:*G.
M&*ZE[?94GRZHA(1IMI(_:P\@\JQ<>W<&V//\P EA*&*5P5MP2) TLA(488YC
M(8DN,&$R.V+-C>J42D L\^]EL[E).W4 7NMCQG66AD^/#*<?E+'/&+BTW-28
M="H!\@Q^5EK)H?D%K!4#&\VNP$8WL%%N%.=?NWA;(EE+0DW*PG:!W*=IRZT/
M.;S-,SFXJXQALN3?'B4 6?6.\U)*]EG<XA]_3ZO[^WQ9Y^NA4>31T U@[(6J
M$(SC2',32>)F+H\)I1X-M&Q.TX[GQL52=+B1':P:X<%CDS_^"F22&Z0)5>$?
M]>E6JX7)N:+!H.B<YXX#]=@,NRTU:,4&2NXKH-CWLZ@OG/X^.L(FY[7C(#W1
M*:U%Q U/4LUAZS\_-6AOPE-3<RUWSTH'O#_,LK\M<%8*R:3JK(,73RE5Z\[1
MG<2M[*$\_JLW^0-.LT7(@YA3C&"(_00B%'&((Y[ ), LH8D(8]_("\VF<'-;
M68[NNL'OC;"&&:6L#J*>E?]20S/VR<BP43$VVL> SY+I;E6T20WX,4#=-^-'
MZ<.,NLNB6GR1'VT7*1ZR1+@D]*'@(8<H(1'$ 462?['O>]1#*&$ZK+O7[MP(
MLQ9-CQ?W$>JGM OT'OM&29F!<G=()1]]Y%A%K#:A(];XZ(3N?50B7]FB$?FO
M#87LMS;)[#^A0C=Q3_W:7K%"%4ZL$K!]P15?1-0C;N(QB 2-( HB"N.$)= 1
MGD .C9V8XTN+%&YW.+=9VLD&I+P6"@_N8*MGF=A$;.3Y?;+0X!K%+WTH6BDP
M> R:$0L+[G3WX@4%CRFO4TCPZ'M#<P=L M\7,<68!X3!B/BA9(\D@80'<CUW
MHYB0A"(W--I ;3<^.Z;8D@WP'X\J>LHT\G\+.CUR& K(R$2@E?U@0"#^H;+6
MHNRWFIXXA/Y0J</X^"//#/0@4PG$WY?EBK,W*Q43>,.+-&=-2O'ZEY\?ZQ/Z
MMS]X0=.2LP4B?N"ZH0-)F%"(8A)"[' !182X@WU,&"5FV3W,A=#ZMB=-\+$6
M;7B1@0%CH<<*(^$[T29!20E?X;(NV_F@>+0-V2L*9??6.P;R#+:?:^O?@FN5
M#EC9'[5V*O=UHU^I,OLU(%CT4AN,LBUW-7,!IO5;&PS0@0/;\)8NSH#4A)]L
M!9Q\XM4"T3B($2-R6Q0F$&%)ASAB'O14,3+.62S-GD655WBI:]CT]F=DZZQ[
M'=>%@'6Q4VF3%TS=&6(E^V\_=]%_SX:$> YU79O(&I:CFTE'PL^DB*/D+NK#
MPGZNHJ.]O51NHC[5>W(1];XVP&'A9$*CMV65/BB;Y5O)Q6KY(17\5MV4-7_P
M'U7MI[B@0>A[CAM":>IX$$4^@D1NIZ 3<Y\(RAGG^K'&%PHSM]W76FK0B T^
MI$]&T;&7#DX_-TT-^<C$U6G2)EZ[WBE8=V0HA$H;J6[F?V_^H^-\:W^(#+PA
M)ARJJ6JL=T/VN,Z5MZGHP-=#MFJ&;"GULA5L9@G+7K>)2_N8SI7"$AH[[A6V
MVAQH*Z_3CWX6VQNV+TWL8QU>4EOJ1.W5VJW:EA-U%&$BG$".:A!!Q%$(XPC[
M4'B._*\KW! ;%0>[3)RYK6M;F79SL;L?;A5JHK#:BGV0;.^'M1QTQQA334-]
MLI&:\,AB?12Q=5HQAINT'?!L&?Z7"3/MOL *< ?;!CNM#F/@:\;2)ACY!J?L
M??8:/Z857DHY'O*L/AY9R 4SB GU8. Q!R(_D2SK,KF5H*K>C$LP\K5R5NAW
M.3<FW4@,'J7(,,T ;80VHT8-L/7HSRZ$(U/<%GI*6G6>VLJK8D.4Q$WE6'L$
MIP^/)1+3Z'!2HM('8)^,#-X<:/+E#VK+0%^K2^/BN75+"HC+F./5]AN#R$4Q
MQ''"H/#ECTGLR::,?$6.]C(W6JE3=;SC$CN56G6=LL/0W#J*IZ85=2E*8Q]R
MMO(UAYRKZCXO5*H4^UD#>H&P9>@<[6-:^Z5/S0.SI/?A89/_<W7/BT]26%S>
M-S4HWC;>#@N7>C&F$8=>P)2S6( @D58&9"H+(@]XX/B\NRF^U>>!DQT.N!6^
MG8 2:GE!EF=020S2BC\8!KB>AEB/$RY#;!I>:%!JA01M<9F?6SE/7QP9T\)9
M+"Q1P^E^)J6'L^KN4\3Y%P9<=7RD_R\ORSR[6>+R ;]*\V5^EU+E9-[]YNNC
M\FA95L^O53:25.Z#4K)21LN'#Z_;]8\X49*X(8=QC#%$*L8>"Y^H@FW8(=SE
M =(OL&!#HKG9'IWDH%$*_'?\\/@_P5JW^I!W_<Q:/?"ZSN.SI2"0&AJ<PUL9
M7(W[DJF';&3"LSE:0U+^61DV@SN4J8=OHHN422:=V0V+3:1[KUFL=#3=78M-
M7'8N7*PV/#B%3;-:?U"5TST6LDB("/HJ7!4YE*D@50Q%$KN8B02Y/C'Q1]II
M?8[>1\N^VND:@!&Y'PDX#J#P1 Q1E,20!)$ZL* LB$A$"/$6<C-/<H/D/<,@
MV^YEWJ#I;3X& S'R^JL0Z+892K1?P'753,O:)Z'*P8V<JS8KQQU%PEY&FJVV
MITXL<ZC6D?PP1QZZ)$JMB53A)2W2VMFSOL1>N)&3N(BZ,(RHW"3$*M$IDYL$
MY@HWB,(0^]Z  +6C?<W-_._"K;H@JXVXK9^-X:5O'\QZ4]\2>",3P06X#0Q1
MZT7$:G3:\9Y>(#"M5^7C,6G]KPR\&LVJE*5+:7H]\:^<KHK:D?/M#[I<,<[>
M2>'5;>VJV31\%F]QD:7977G#B_JV]D.:\??J_&X1^M)DH"B!3L1=B,(PA#CA
MOOPC],,P0(+X1CQC2["YD=*V7F"C&.@T:W( ;NFF_%HZ[52,1N/( GY7&H):
M14,:LS;DFM>X+S"08U_V3CF&YA?#E@&W=7UL2ZQI+YDM@WEP%6V[_1=9!JX?
MU/W9PO-])PZ%@(S%#*($Q>JJ.X%QS%WA"T(CO2R"5J6:XP( U^Q1*F\#D#?1
M69/R>#MFDY"X^4C\.1C\"C2:S8:\=X&>!W.W,OV9:'L71LN<O=?XP#CU%2GY
M/U;*A_U)_J%R3UW_2,N%[[&8!S&!B KY!R,($HHQI$$D NXFL4NT8J#.]#,W
M4MV("6HY@1(4_*Y$-;2.3P&KQY,6X!J9^08A91[[W8^#K0#O$[U,&\7=K^I!
MJ/:9QP>F]<0_FI#O-JDC<@D1H8<A$XA"Y!$7QHE#H: )8LR+".&)46;.W?;G
M-OV5ZUPCW]",FGOXZ<WV"U 9>9:; &*>S/*XVK;R4>ZU/FU*R>.J'62%//&8
MO21S753U<Q<*\6;%KX6<2__.<?%.&AX+A**(,H=!-U!7FJXO-UM4;KMX'(2>
MSU",'*/-UB I9D<$][S@6$EX>2ZZ\T-@<N@_(K 370<<9*U;*W&E+@<)KR,?
MKD -/U"* *7)N.GLM($<,<?=>1E>//&=-DPZV?#T&QO@&?EZ74)4-K05)'C+
MBX<%00%S$S^"PHE=R7FAY#S,"10>9B''B9=@K4N&LSW-C==V9 5X(ZR<>E)<
M R^W7GS["<TJ:B.3UBY@U]N W5H$S,#=SQ9P$[GQ#070S#-/!Y1>C[O>!J;S
MI-/18\=#3NN%@4=#])ZSU9)_%O5Q4QUVO1URVV0%:R.-_B]GWS+9]E:2,)4E
MH7SUW*4*NRE2RNN,RIM,(5X2)-AE'!)&8H@2[,"$.@CZGL<IC>7_8Z/MY?@B
MSXW0SX3$=SGZ-BGZ0*T4,,B*/N'WH'DX-JM1'ON<[9(!-LD#9'XV-]DPV#KF
M&U_@:4\,)QN @\/'Z7H>MG:IS#S5LQ(IS^0L:4_C6!S%@6 $DL1A$+&8PD0$
M"%+F"!:&+(Q#HSJB1WN9VPK1" G64@X\V3R.J!YA7XS3R!QK#I$Q6?9"8(G?
MCO<Q*27UJKG/(OT/6[O/;#]52ASD^"Z#) X]=<[I0!P%'I0VJ!]35V[[N=$Y
MY\F>YD8 )V[J!K' :7@'WVO.C@T&XF7C;G,46CC=STO?;_;3P_D7+CL6S+/K
MC'V0ED=6\NN[@O/F#'*=8&HK(2SG#O<"%1N-$TD=7@@3:4C V L"/TB<B"*M
M2EF#)9@;I7SA<D16FOO'X;B;'2..@N9TQXLJ\W[&0*L V&@ MG(3_CXLH^L@
M](>=28XR"A.=5=[><R![2270;(.YR M =\9)A1XOVW'":QUMY7&]!$S=,T[]
MAE_D[--8[U-GHN8-#?1[IO(#7=4I".L\'\JH+?B][#9]XIOXO.LGG"[5B<R[
MO/B*EUM>?]?L/U=EI:3K:O4NJ.^$/$84RBTJ@0C[&":A4#=5'@]<U_$P-BKJ
M-(*,<UN7ME0$>9WWAFXK.2 P=XR!U3.57WBX1E[XKC^_?J]" DFUY39]!=;:
M0,FZ4.DC?[;6H_,)D*I8])0>#V=;?M,C2#BM%_5X$!_X5(_8U;"EH>E4MO.%
M*[C295-?[/6].N]\GQW4P?@;7JZ:E6NYS+]C"? BX0)[24@A9I$#D1=%,&9)
M#%$0$NRZ$7:1T379Y2+-C?@;T56VU*=.5H [8<T8W\)XZ1'\M*,P]A&J$)S6
M5_QMZ@?E.:K*7()=[:[ 9JB.E.4!:R7!6DO[P3'VD+?$\!8$FI30[0&XS]\6
M6QYHR=?-OL-IH9KFFZW"@I.8^]R)H1,P#R+A!A 3ZDBCW$LBXOEA$B*3W#\G
M>S(BUPGR -VJ/IJ:8R5X:.J),X K(*3L->$:4NQIC#5-8QO(C6W@MF7&E)0U
MJ_&M<QR+UNLY*&S9H"?[F=:2/*?N@3UX]H6!]TS#[[T/;[T_K52BLL_B\ZHJ
M*YRQ-+MKZRPNA!<'"7$CR A'$%$DE*>J!P.'>90@CP2.9W1K-8W<<[,/&TE5
M\&VCZ@7%9"<:>,W[M/D-Y]BW<Y?X0UUUP[^EHL4+O6D'P];UX$123WO9..U0
M'%Q=3MS]L#7L6U9((_LN4[)(@_H5S[A(JU*:X(4*SRB_\'*U5-$:=2CZJE!)
M^YIP-16WEI=IPU0)3Q@) A^Z'$F[V L2Y6(10A1AY 04.W&"3)8H.V+-;05:
MB]_<)S5B@V<5W:0J^CYV<INM1I:&4&^QF7Y@1EY+MA6J#R$ZE:Y IQ18*]6F
M\F@'K@V*K>-CSPZ=\4IB%VE+"X4EH29=!^P"N4_SEEN_8"="+*TUAVO,WWEZ
M=U]Q=OW$"WS'=UYYQ>_23.4D>867ZNC%E=N5,"*!0-!5?R#F^#")O0BZ,0_C
M$(>4A<1XNS(3Y>:VHG3"@U;Z?8M7;7&8N@HO2O H-S_U=F?(;F<F^)MLB68B
M\HS6N@OW35M 7($S7Y[E'=7,QM+FMFLNJDV_-YN+YGT;N+G).,#=M774+&L#
MY./GC0M44QNA+3:"* X3)V8PB)T8(B'_(#R0BW@2.<R+.8E$K.W?JM7EW-;2
M,T(;N%KJ(=Z_E(V#X\@+S!EYAU32T</2P$_5.J83.:8._3S-'$^-T.GU--5K
M:3K74B/-=GQ)S=ZT67;APSH_-DFHPQGGT*$QA8@2E0V=<LBH2]3]#R>!44WI
M,_W-C9O[R@A\&)J\_!SF>GL-BTB.S,Z7@FBI(,,!-*,69?CP,KF^-577*\YP
M^-HPDE&VZ2?Y@=1)2%F '!:' @84<XAB2B%VD0_="-.0(<]-0J,B"]N-SXT^
ME&Q "3<HC>L.;'JD,!2,D1E &P?CJ7Y,84OS>J?I22?Q,:7V9^S19X;LTM1N
M\+/X5O+:746%K.SD1^L.E!=>1*C+70<Z;HPAPEPH[[- ;MF2B-$(N]S7#T34
M[75N$[J66[ER?%/A5TKT.B"K%GZ32W!]@V.RW] =!YWMVPCHCKV#>WE@3?9R
M(P \U7;.$M"&VSM#P/IW>+J-3;C),]1O=Y]G^O) [^*3<2<J%&KSKT7,$\GU
M20!C'JG$VP&#"4$)#(3KL1ACG!!A5C=3MVN3^3)-2<V-;(9NQKI@8T&I'S,*
M/<^3RRKR/4@0]6! (AK%Q!,$F=4<&P'J*5;6C:_R2$#K&=!CP#?RTJD1R&C1
MY]L0'ULNX+K=3NL1;@C&@8.XZ?L6<Q&__5&IP,0\JW/ .L(5C 0$BD"52L:(
M0^RH S\Y$LB) A&Y6E%^^EW.C7]ZLA/S3FY;>8IWL=<PZ*TC.C(E]23>78ML
M*X?Q+I@6DAD/!O7ELQIK@FLGO_%1G 8E.MYMZ>4S'A_53"OU\?$W!]#VISS[
MPL4J8VIY^/8H!<^J=UR:,3X3U/40@Q'U7(@<%92#Y!^>*V+F> X)?'VF/M7+
MW,A9R@F+M:!@U4@*'AM?(@,2.0FK!@G; &MDWAT?)P-^M8'71)3Z/I-V%EX"
MP3DH..5R4K?E$W>3+^7%8>XE6ZF7SL'5RZPG7YZ.3,_)O\.?9Q^V&1FYQ<_E
MJ^?-,ZTKXO5W7+#6.4H:XH*GU4I^7.^SQEVZSU]JX04T"0+,( V$W+V["$-,
ML8"!'_E1%%&7,:U#\9=28&Y$WXJO4B@5TNY^3%6TMS5GXBF_#+WCACF/]\AK
MU;93\+;RVQ9M"<@S..H]K"#H_(95I/L&!I7=HP%B:F?A%QC'4>,P1Q1_!@&9
MXP^.7F3F!'(,6TS7L9]=X:RO_*Z6<N%P-_(BYD#&N0=1[#@P#BB"#(7"82P*
M?+V<M&=[FMORM GES]>%Y,I65K/UZ#2X>@N'%<C&WHVLT=J4W?MZ#BUCZCV+
MA"6./-W/I&1V5MU]UCG_PL R%P^/R_R9\Z^\>))D<YS<I)W_Q$O%3XK&RCJ;
MS_;O7^=E]2FO_IU77];1C)N6FI?J7'JW]SCKTE-XQ&5.Z"=0Q'X,421\&#N>
M UTA/!83$@:)62F-E])D;O36)%M:;4<FTVW+C$H=#2MWO-A'HD>C?XJAG] 0
M/QJ=M]:_,[O?_J#+E0HI6@?N*0CD<RJI0 4V*-A/G_?B V:K7LJ+Z3%M39:7
M'JZ#NB\O+M!E+M1MQ1,>NL1S100=%".(_$# !#D>C)4=CK&#0TZ'.%'/LXK,
MEOOPH,HQ>^#I+0W#(1F9KPW0&.Q./4HQF+W&7\2ENK_LRXFGADW9@WRAFPK4
M>5F^QD7Q+/*B)HNO%:ZX\ON3 [1<!![W">*)G,U42/N6$8A]+N>Z8%@:M\K\
M-=I>#Q5D;C10"P<R:6%L=M\JJSZ@6RJ8,</@,=+CD"F0'YEMCB1*OMK:SRL]
MP(XB5Z 9I]JK6"ECCYTNA=,2CPT68U+&NQ2L?6Z\N+V!5WJJ+;4/^2Q>X_+^
MW3+_7EZ3LBHPK70O67J:F-%,6XNI3LR4H*"6%/S>R6JS_IL&)+;N%OJZFO8>
M0$/I@S-[G7?,OFS&T\7;K$JKYVO&Y ?43)?/Q4V1/Z4JA;_O<>2[*(:"<2:-
M>^'(]5_^,Z21Z_$DB+#0BKD^U]'<UO=&5M *VZTC>0$Z@?76]K/X]K.&3=1&
M9HSA@&D3ABX:1\BBY/37N_SI-]E$PQ/R+QMZ.-OP)-2@JUY'"]K/#UOLUKG"
MWV>/JZK\P)_XTFU3C;@H(8$?1C!, @>B)'9A[.,0,L?EH8A]ZCBNR:Z@IZ^Y
M$</_7N7J]+&^U*SO]Z^;<A\?<?&'J@N@LIJ^9ZIZGK0WUD9JK1%PS38$?2.@
M9VU8PG5DZMB$VZA\HTK0-6#GL^48FQL:F%BR-OIZFM38T%!YW];0>>7"NSJ5
M+ZS]FIU . (+"N/032#R?%52)/:@YX<TH![S S\:=(NVZ6-N/-*)"&H9!]YD
M;4%H>,<T#)BQ;8@=3$:8^SWJV[Y+V>KA96XY#E4\>?]PY%&;.7BW+O!:IR)R
MPJEH*T/@GC/1%ZY.0>7/7^=9O>%9X:6*:_ 6W'=4YG57E;(/Y!\T@<1% B:Q
MGWB(^BP*C+CC!728&S=U<D/<NBH6G>2 ;D2O(]"NM$I(S.9CT3RDF?<G,.$=
M_"EG6%U?V/YTN6LTP!8<EL+%9C"6HV;('5>#&23"G62(]/+=3B/*P$P:JO=;
M^6Z3T$PD ?(2#H,8,8B$%TN3.DZ@W+![Q",)2<PVYCNMSVV9JH4#2KI!*<UV
MD=-;&0;C,3)GZT-AGF7AF,JV4BGLM#UMOH1C:ATD13CZT( 0VG<KY2G_,5WR
MLLHSOD@BY@2$<#D[L9 ;7C>$.)!&*R-!$@0,1W&B=:Q^K/&Y3=.U8$T4XYLO
M[PV"/_>!ZY^FE\(Q]D%7+1E8BW8!#@:QKQ?@,5'(JS8N9E&L)Q3O#5[=?V>Z
MF-43TNZ$JIYZYK)<+-+ R=B')I9XG=BYSF 1NXD;>P+#,$+JG#^)8<*Y QEC
M,0J=,'"H/DWI]#@W[E(RJ2OP=81U'0"JJI7IULO4!UN#VFQ#.#+?[8@+KI43
M3ANQOI;XZH+4*Z>A')9YQ0JDTR=>&0CMX,0K9V'2S;MRNJ$72;MR5J]365?.
MOSB GV^*G'+.2B7O5FF5=5D5)OM\^_7FYD9^4?>JR-J"^(E4G_J0AD3:E)SX
MD(0.A;Z(72_$,4.^5O:^8=W/C;D[!1JCLZPO%/(FT3MO=2AKOT"E!7CLU#!@
M(O,1TF#X47$?F>YW(6_N<%KQU\'NK.:J&O.;23 W6 I&Q7ZB=<'Z&)@M$X,A
M[%TSS%N=;@$9K/'.:C*\E8'Q]+Q2+H2UJQ#C[-7S-]G'^VSM1EL[M32Y2J58
M@LGU Q*,7(A"C" .0@)IS)$;)<3WO7!1J; DO2-%_:Z-EI2U ./-+2EYXPO;
MR:YN07Y6XH,T^V7+$7VC@K3!E&"&\?CZ@Z-W:CD.Y".O)@/0MAC(;XR8K<A^
M_8ZG#?4W!N0@]M^\A0%F<YN_2]+EN_3'^HJF7 BLDA7&2"&N_)B#"!+7]6 <
M1")*?!Y2HA6GW]?)W$S@+N6>LG*%$K1+OF=B<9T"5,.6M0#3R!PS*D(&EJ<%
MI":R+P<@9F9!GH&BUTX\]>YTUN 9Z7=LOG//#K/L-I%0.W4;VJKKB\0GF'N!
M P4),$0L2F 2JHI7,7,QB1$*/*-XSO[NYL:(366192NE<2&%,]CJ&6/V$!N9
M'+<"*YMB>6M9KT KK3V#2P\52T;6F<XF-:ST%-\WIC3?&BESZ9G4<&]5KLSZ
MG75JN 4+41PF<MM((M^#"%$!,18!%('G!7[LN0@EBXS?X8JS6XLY2LU%U9J!
M23,##P0>;S;:],K;TGJ3H=)R#M,!WX@>?[[4D/_YG"_-AME^GM'A S%5*M$!
M$LXK6^APB(T3@E[0U<!EB-YSMEKRST(K4=+ULOYDY=\^BTTJI$82E22IO%7Y
MO1<!BC&)4 0CCT00<=>%./ H3(00F"&&B!L;A0N,(>7<[.9.2>4*L0G2:?1L
MJ8@<4-85V"BK7MRHVU)1G:FM!+_7*ALZ;X[S<6BN0"\]Y!.N04>3\,FYKNZZ
M67T*\!H_IA5>;J?8.SNDYFO-F)#;6FU&D7':]69,F ]6G%$[&^02]_"09TTT
M'/Z1/JP>FL]YNS3:^[)<896X 5'LNCQ(((KDK@;%CEQ"0J[.EVG 6>3$(2<&
MKG'Z/<]M;6AD;STL'AKI 6YX '?RUV'Q::N!D;>7P9!H'$F/!?3(C-QB7,M]
M!5K).[)=RZXJ#X#W(X-LY%HW#MB3N=C9 ]W4V<X<N#-.=P8-3NE\9Z[GGA/>
M@ 8NW8T<CQ'[PLNJ2&G%62W.=<;V?O(M2ZNRO>1\KM>J6_ZC>B7!^&,AA"^X
M3V,8"N%")-P8RKU(#!&-XB1&D<<C+3_K*82=V_JSO3?Y\O5;YP[P/'0_,<+P
MFFXK7G;07GIWL=&J]5]3NXR#'RIEK]:#W>XX@%(8U!J/LOD8;V"L[T%&$/6%
MMB+C@7YZ1S)BGT,3^&X78=XOUKS'-S&),(EX# /L<;DWX1S&+/9A&*O$7(ZZ
M;'',DO;J=SZWY6&W 'G95X#\<N#UB'XL.$<F;HW:[J/2\!#8K&79->AZXLRZ
MYJ <9M,=T(89C95%M5#IQ+IHF?^]PLM4/-=N?U19[.6;M*3+O%P5_$.:\?<5
M?R@7?A"%GN=02"B79C%U?!B[B0?=.'02EZ"8(*TSED&]SXW(OKY]#;H%Z@JX
M'G22*[#6JC:2-GJ!3C&PT0S\KG0#M7*:I^W#AJV?!4<?C+'MUVG&09L>+\*S
MCQ]EPUO<*/^UX<5A?4Y"C!?!T3'C98T,.'I^*P2O\XB^SVC^(#GWQQ=<<77,
MG=%TF=9R;"<]9_^Y*JO:7; Y\%C$02(-/B>$)'8B58H]@-@7#'HD% YW?19X
M^L%_ETHS-^I<UPU(:WU A7\ O!':X*CTXG'2.*.>$OV1N7*M"FATJ0LW*&W
MKCI78+>TPT:ELU6[1A@C@R/N*<=JHF/O]H [%Z"ZYX"E4L."2\H%A%??.<]
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MQ!22, H@IRCRW9#)64U,*D!LM6TT92<H\5!7:QB>('@;-3UK:" 6(\_1#QH
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M+XA-F/]\EW/C\^UJ0IWT3=V,3G0SCM8 78]Y[4(Y,I]VPE[5V:^K70#;ZDI
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M6[7G'A]ZI/?PF&=UT(UXTQ:AN<4_MGPLUO[2"9.<[;@QC/Q(59O @:JG[<'
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M(O)5&5 ?XL1S((VPZ]"842<RS/Q[T,?<UM5.1-#(>-54BS)-Z'L(I=Y.Z4*
M1EZK#+$9D)KWI/;6,O$>]C!QXMV3*A[FV3W]Z"5U?Q<H%AX*$P*#F,00\2"
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M6C,E:6;*MB3C39A-(MAE70?LR^=O1D<VPX=#8],X&L03^>B=2-5SD'X7U$J
MST)E+P1GSH\LP6^P"QU[&";:GHXS'&:[UTN@[-W6#FIXNOWN)7KO;(0O:FC
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M\ F1<!3'L8"ND"R*L/Q;'.,(HD0P)R0T"5RA'_]SJ3AS8]WW4&H$UBJ!'9V
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M7CR_DQ9=><_97_.<E0M"Y+3WF( A"EV(D)LH"G EDBR2W$ 1\;2,K?YNYL8
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M-U@JF6VL6):&^I+%:OH!G'"=.IJ)J='K:G_?5BMS!6K%FG^ #[WC;&D9LCL
MHZY ED2=P>)C%W2]=<=RG\.K<>?%8YNZL U9XCYS?>X(2/T80Y1$#DQB2F 0
MQ"3RA$ XBDPK<.]W,C>*[\H;;^0$/S<_TW1/Z454X[[8 DXC,^D1B(87TSZ
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M&/9]2=P:<+]4JS;:@M<Y>]L"E5^$,N7$7D>63B=6;4YH.NW)W<R= \D/9DT
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ML^,VA>L_J\W75\_U9O4HUN\J0JN%LG+>*T"?UVLESYP7$L9E!@&*$YUMD5*
M2B0 YAE,$TH1,<NY:MGOU.R"U]H[<:UF^KK-%#6+EEM9;?W_S8 W/:[W#F?P
M@_HNZ_1?E0[EZF2>15NI&R^F:] Z'-%; >7M<-ZLUY&/Y:V@.#V0MWO]AN):
MU%,1E@_/FWI#EOI$I2MW>53-\J/0"1?4/_?*/9/%9[%^3.=$ZA-_J2\ ,GU>
M@BG .<, <9*765Z*O+"O&/GR>DV-7T]*0F\EC_9$5R0A&W_O_Q!D73N4\'IY
MX&VJ?;V\M!-:-VXL#+:'P9DBT.>_-@V!Y_IATQE2GZ7&)J#5^%7))J#TA15Z
M:N+Y+/73>23/4YJ4F,42R")+ <P3 8C(J/I 42HIDY 41DF1C7J;VFIY4-^%
M[\3U46&G!]ALG?(&6^#5XV)%G$[4T 5NCA )6KBF[VL"!6F.U#8K-'/\DAM]
M]#OV+K7SJVY;#2G")<(YR"76KK\%!"0I&*"0IWG&:2:X4;'$X6ZF1AC'QQ=V
M1'$!2C.&N!V@P-2PQ>9C?[3SRO?APS &GLC@0B>CLL"PHL?3_\K3;O->QRLV
M--(E]2L$$EB[%_$2Q@#&D ,$>0YDEA><0,I*:)0VX$+[4YOIJOE(]"+:3?-C
MY,SF]PUXA'9ZZ"7SF!;QBM:>IO)QZZ/.X0NJ'4_>2X\YN$-\7FW(XFZY5!N'
MM]7?V[N0>DY*EE',,,@+]1]8TA*0,B<@IQ0B+@A-F-'AVV O4YO!C9Q1*VC4
M2-J?=QB>> UC:N FX .IP',[,$@6-^D^P!KI#MP%-+L;ZVM@#-XU7WQYO%OB
M:_(?W.]>??B&FP^7:^,V4\/]LMZLFZ^I;FI7??Y*EMW!35O9YG[Y(-;5BL_S
M B)!9 D2+G7=>"8 IA("G,LR27,B4P'MDKV-);K-W!HG8UPCGXMGV.BC3K(R
M0T7:['VI&O4L [1,<T E29'(8T+M:E]/<<Q'"9[1.M31EV[@==JM1LX?X!.P
MN(*:V,".>,=TT6V0?C^?3T6K/HM:Y:,][=MZVM%&Z=_=4=6SJ(5 ?S4M")ZO
MF48<-I_W2&.(/?Y%T8B#<?8F:,S^G:]Z-NN**1YM[J/^6%:;^N.G/_KZES+/
MRT0@D$%6 DB%=FR/.2 QXQG*U%J66YW@#/8VM65F)VR;.C5JQ+6^Z!F U_BB
MQP]HX2]ZSN 5_:1DK7\.<!!DA(N_ZYZ!OL:^[KFN]IGK'H.71MXUO5]UE'9"
M>?U=.)]S@CF") :2ZL)G@@M >:%LYI@0GA.U5\)ROA1?='K<P%:S@;A&LQ&W
MLW%?Z( GL;UH+V <FXQO8(/8UYC],$:P4ABT&I^QAW<>6E.P>BW&YJ4M71-1
M?PSKU@)T;Q:M39_.(15,:!<HW<O'JO[7K]]_%4OV]9&L_W7W=U7/24(@0HB
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M+>K#*_V^%K$DG,HT 46B78]XS %). :"<I0ADB<%A79U85W$L)EHX]2+W>D
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M <QC B#F18Z27&!L7R#E?%]36YJWHD;5GJP.67<O0#N\7GH&+/#:M\-J7\P
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M(AS$3->=D%D)FMR\*8<(EC$7"3'.AW*YFZDQP?VKMQ^C3M1H3]9("VL>)CV
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MV[3]15KD"8(2L%3]!\88 \)0"B3*(2TI%DEI54_A<E=36W</)(VTJ#?42AA
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MA.E'IE&IU2N,QR3LMW'[\^$WR\W.[?2C>%JMM4&IKS&?ZWF2H8)*I"P]+ 6
M!41J/Z=^8E3FB2QR+A,C!K[6T=1(M95UFYUB*VW4BFM^G#R([O7395^8!>9
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M>OU=F0R-8\^<)H)*S-2,+'D!8)(SM90+K/^C]G5IEO/"RJ73J->IS58M;7.
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M-C#K7( R5$"U%4R^(O7,A(X;@F<%Q%%LG=W=+CU$!-.;S7&!UJ7('LC/MN#
M+$HB2=,DAAFC"*),K>QPP4K(<(:EY BGV*)?R%DYDZ.A3E.@5 5\79YM17YV
M)9!L^E2<AW:8:SP"%II<1L#*IG^'%\Q&.I)SQ,ZR'<=%1(9;;YR_?<0V&Q=M
MV&^I<?ER-V?N79_7T'OMI^.>/RT7SZ)9"7[;;<OI(FJ[_ZY=S4_+U7^(U;U@
M2\7NNAF$S,H2T5@J:LUCB K%M(10";'D6,19HHC8JG9W,$VGQM5_+.J-;CI
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M_CG'XQ&PE='I@?'?V>CJ 9I@HR.+#R=(ZZ-!3'UT0CHM8'*-D09Q<.F3-/Q
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M8\2I8@'U_6<0(>578DEU7^($E3JJCC)A5QS!3+#1JS]J,8162[!8+@#KG'Q
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M":;CLT<\Y;S.^OV3T"N?=6YJVAWHC^JG__V_UK]1?^A(X__]O_X?4$L#!!0
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MPI5EM\*"[!\+N_-R9#"\/%I63KV9KE*8_0>&Y=D>B!\Y%>1D!61#'%$!8L
MG+9C,\N96+;?77;'REM!0O4+B28<[41%?%F&^6I:>7^JYC"R(%F.D%E2H$S.
MX!S]IR@G4+.0O!=M3(5K*V^%"MTO*IIP=&14O)ZOI^OC-],9OC\ZC+B<.,PQ
MLLPA*+*!E GTE4=''E4H)64N4M)[H>'ZBENAP/2+@KTXV(7T/^'7:67"?/T^
M'.*D"&F5TQERYH3>PE@EW8%0+*:@.5J[GP%YVZI;H<#VCH(].-D%$M[.TV))
M*FS#^,_$?WRY.)JOE\<O%QDGFEQY:23M1!D"-IG!$*.W$-$PSYTL!6T#8-Q+
MQ%8X<;WCI!V?NX#-E_#S;2;V3<OT)'!UJ@FUX];(JO\B,G*E>0'BBP0=6:Q!
M.\FU:@"8.Y;?"BJ^=ZBTX&T7(#G(F42P.OWCW72.?$*78S2>+&>4VM)5R<BI
M\E%!T=&:'-$*RQL Y):EMPM9L=[1L2]3>T+&2_KRP_++XH_Y))<2O)6:G&U5
MG6W)R=G6"(P5;9AU-H@6BN/&PMNAHN-(9@N&]H2)S=WX8?EQN?@QG2><,!EM
M1"D@64/8#ADAA*R!NR2%+5%[; B,:ZMOAXZ.HYS-6-L31#XN5NLP^]_3[QO;
M";TQII1(AK:B73A9H_=D15F75>#1FQ):."^WK;T=/#H.?#9BZ]C1S[J')88-
MW44DHYT1X'0JH'01$)VU(*R/S >O>/)[P>'R:ML!H.<PYZZL&UGD];U\]O';
M8GX6@BG1B\1$94#1I,M<(5V&!:)5M'OGN-CS]?/ZBMN)ON-8YEXL'%G\GS$=
M+0FZ1-*7Z7J&D^B\E\44$%(1=#WI+2<E0E287,HF:&WV$O_U%;<3?\=!S+U8
M.++XORQ#S4CZ?'P8%[.)R3Q&R2TDXQRHK!0$&\@%<C)XG3US6NXE^RO+;2?X
MCN.6NS.ODT/_^F?Z%N9?\23@ZH)E*6>(Q1I0Y "3F:),C8RP0MXO&;7[/5[<
MMNIV&.@X)KDW*[MP!_Z.L]F_S\G9_8QA1?=8?KM:'=5 F=5",/20<U2@.$O@
MC)& /#N?G8TFN[TP<>_RVX&C^RAD"^9V@9*_+69')(#EYL%NN9I8LG*=T63;
M6ET?\*T&5\BQ09:XC%*6Y%N\:5Q;=KMTJ>ZCC_LPLPLTG.9UG#S;UVN0A'"T
MFGCZ'UF\!HIS9/M*FVI"L01O(W,V&2]3;@"*VU??#AO=QR ;L+8+B+R=TZ<1
M.Z8_\%58A]-M320+TCNK@"-'8H[F$-$Z*-QGEND<A+)?TLQ]JV\'D>X#D0U8
MVP5$-MKO95CCU\7R>((!D9LB(9A$"$^YD.?$$PA#5Z346:HF-\J51;<#1/>A
MQ]T9V04./A^&V>S%T6HZQ]5JPAGYT#R0RTQH)E:0 1USX%"0<1,)X%RVP,&5
M1;?#0<<1R'T9V04.7A_B\BM=>7]9+OY8?WNY./P>YL>39!W:S!DDI24H6IH<
MJI3!F*24\EK2O=@ #[<NOATN.@Y/MF+LR/AXF\KRX"A/Z3<.UFM<G<C@S2Q\
MG3BIM>(\@G2&;KTD%1#L-21$%5(AKTKL%[JX>^WMT-%Q]+(16[M0'I^_D:M]
M!FV6E%$J"4@Z"%"*D6N5.7G;WA+E+A54^Q6?W5QS.S!T'-'<DXU=@.#C49Q-
MTYO9(JPG.8F@(M,06$TBK74&,9&B\^A*MMDJ[5JD/%Q:<CL(=!S0W(^)72"
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M<*"*)0=:$@HUXT&A]DK%_5XYKRPW3ANAE@*[8@ONS,FQ/8 3PC=98#GR&+)
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M[DN>VB=.?)62;L"TEYSO"!/OP?0^H+,\HE5O\&B2B0D^B ).D#&@9*T9<IC
M.!Z5=)R;<E_IQ8[HN9V8<2^[X0#4@/4=8.C5Z;*?\ ?.C\Y/@A.A<$_XK\-$
M:!<%(6:=@6LM-2_>FM Z1'@[)>/ZZP.AIP'3.X#.U0C$&:O.FG=-F*D9B:0]
MK>$,:HIB'6^G@(=$?/+&A]SZQ>I^BL9UXP>"4D,A= "I6_1I(N4I$[=@=$Q
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M+JW?B8NUHRRO0V-7QNX,BN^XG"XR;6.Y;J0];K12S^CKS2J@&OZ@B"/@LE3
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M,24RY$6TS7N]/H*\O5_>:)V353;#9C[2];D\7^Y4#'=X'=GJ:&MU5+"@O)=
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MEM--A\&)#$;G.HC*R#I?2&"DN]QKB,HHH>E"-[Y]&]+'T3ANS[V!8#:HH#H
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M[W2E;WIQ+E]-5]\7JS#[4-XMYE_?37]@/NFE<'V/)NLD:H:^56AJ#(]#,#8
M1VV,8]9RU_H1>A<ZMPNSLF>&Q,$EU@$J3TL*R(%9?)U/J\2N;RB3\M:.):B3
M.(F#1H C=QF,\C8Y9XJY/C5E;P@^2-1V>'MN<?VVLN@ 7#57]4.I S!O'!-O
M9'U0Y8 Y,U"1!_!26*!M^%@<(QW>.C)[-S7;P>FYQ?H;<;\#''TB@1 !-;[W
MBL[(;+&Q!S:M?U=G$9=8B\DR'0A>F 4E'1T-2QK8UM&5DOFD3>NBORW(V@Y9
MSRV\WUH>'4#L'=)MCN_JP)(;IP4M-]E91K37H#&W=?J#84!L(F?9NNB:&V'W
MD+,=I)Y;^+X5_SN 4LV'7.*WFJWX T_RK6]_H&<H;1#<@I ^@7))0V Q0,P)
M';<L^MP:5]O2MAW(GEOL?A#)=("XUV$Y)U[5 4R;RJ#KVR%]:V/1!IC2$93=
M% SH!"BT9(5+XU3SVO_[2=H.7\\M9M]2#AW ZCW^<8E1R\6<ODQXZ?GA^OZB
MDU8KG4$5;FKGI0+1,0W*V)Q-H-V'UCA[+(W; >^Y!?8'E=2S3FW]4A]E!TQL
M/?W\ITMKO6U#3Y#4JK $Q<B&YW507V)U=(!(X!5'[8LK0K1VUX=+:CU_6CV)
MX&W:$(0XG6V:W/Y&)N@1(?S#_%-M?+L\&6#S?C%?GOUUDWZY$<.EQP]9&&9'
M#K5-I-DQ1/!,%=!625+XF+5N[7VVWT6_R;*/0-^=[^CC"+N#:_QS^H;YB)1&
MK2>_] #\H=2'WQ?'];]OB,V+Y:4H=L)0O/=@7*B5H'0U>);)F8\I6IDX,DRM
M:TX>3V:_*;I[ '9H<74PM_WV][VSM.3\^PK+T>S=M.#)P;MZ^FJ[EV1IF]$@
M^692\\K6!$D)E;,W.E[WFN^>XKX/(?TF[NX OB>73$=Z\4,Y($;FZ>QH/?UQ
M:03%ZY]U<#'F-\3\&CDX.IMP=-W-N_0DS64L"AE8K!5CD2F(=>"2,KHF-HM2
M3.LZF/:[Z#<]N(%6'4G8G?I0MTU>V=UCNN?3AAH3,Z W](@1'(DIA@8-U#:L
M=; D!T?")^=:"AN"+^W+3)YN6$S]^$N?^B-,9Y7I;Q;+^K1X[0IP03EK18!<
M:MXSV</@:E)A3BZ(R VJT#JD_1CZQN[I,@BB;C20&DI@G2JQ\XS$][C>77G=
M\BE-1[?<0=P3S' QP?F<I "6F2%W-5EPMEZ;K#AKG$?M6L<F!ISA<G&1GR_R
MLD[]G:^O(5LG+D)FEKQTK,UMT=4Z?CI"H9"-JB/#T+P+\):TC:^&6F#E;A.K
MH63&]E9OV53-?EC^P.M1H4S,4H&LTRQJVGQV$6*0 4I2SFG#;6;I(27TN"7'
M#7^TAM& [.[TXKIO]L[N%]D6GSKTX* !+[J'Q[\43%QI[4!$]'7TG $78J:O
M$*,0##6VKH8<;WS0Q7D029-S;"*0]VGK\Z&J?K&"8(4I+DLOU9,-#>KDHFN+
ME:WK%':32:<ZZIZ).[NKJ(<_=.!A00,JJ,>-==&\F&*RKH&L>HMA@J XX5$R
MH1.SCG/?^-0^R<B@:Y?YYZ/O!(O-+3%[$>C )/S\#7']=EX6R\.32!L=IE!)
M.<D!O';;6^YCRI8!WXQA]AC &9\@U?Y<7EJ7V'9C!]K1-'K3Q8%@=H<]]J0B
M[.!U8+.'FD)_W>XTFC#E)/AD:O-=078G=QJL=R99[Z-SK8O@[R!E7/-_> "V
ME$07@*H9SE?/R%DJPO%O85WC=<?7MBAEP4)6!-A QT69S"#J$,!S##$D$Y-N
M_9ZT YGCOH0^)1"'E6"G)N#M8T'V2*R[[_.&FV,RH,VWY[2(%"SIK2(A&T=N
M0M5FP='-&$NPMM:3HFC=LF#<:2875L59/_3/N/PQK1;%V5R+*TVE9YN//,F!
M.2F._"\B:M->;$/II428(N@.*'3(&%D:2I9,MP,WM8]89AADL:*U%SS89I[U
M!)3'8/KN0/*8\.C 9+AD?5\?^'+P1UCFC:+[L.F@MZHYCB?L6*V.#D^^=_VM
MS]FHE \@F5%T]TD&02<+4@650M#96#'8X6BQ@W$MWBY.Q),#H=-C<%D EW=_
MD-;3'S?-,!&S"CI($%9MNC+0F4]"@";F>\T2.0O->ZCO3?6X=G5G<!]0X,\!
MXO6[JX.C];?%LMYNOY/5NKS$AAJ$7KTX?OT3EVFZPH]+NBT_!?*#+KG+R5G+
MG(!B-XU)C =7@S \!VZSU+:8UJ'&X7<U;JYBST?D:0'3WQ&ZX?]]0F+[-)%<
M-FS83*JY\IW?Y]/U7>K$!UND+W1%^BQ %;H[O;4:F,HJ*<&,'S"9I/U^QNW,
MVL^Q&0\DG<9Z+HTZW">5[OJ'-)[".&@BW=US]YRTPJ? 2:J\P&:D>>3&@"E9
M:.ZX4;EU/^\!9S%>'(57I_BC96XKDKN&<N4$(NT4BJE]'E..$"VWP#4=0JF=
M]KIUD?>.I(Z=9M<&27>KL.'DUM5U_KH4K H7SSGZB:Z)&NF9)]KJ17#W8J\I
M>N:U9N3;AEB?ANAVR+)N.(7H/=)FAXMT/)[>L1/YA@;JP!+L"JV_U]KATQ@D
M;?1L+N&GQ6SV9K&LP9IK.V5!V:(\@VJW@%)D,/AH"O!2K9S(68[#A28>2^VX
M(8GAD3JH]#JU^6X,P-NC9<:MGS3$G,D!3< [IPR*Y%0VR4)MY K*&%5C2N0:
M>V-C<#H[_[33)L=HJ/(*UV$Z&["CRMD"3]=2Y=8M#=]3)?I$Z*G]-ZTB/S9$
M"\XY!?0M*4L))O#6,87A>JJ\/SJ,N/Q0SK,C/N/7C=L^<2QH6:O"G3*R#A6O
M>5])@Q-<L1J.+:'UD^R=Q'3;X>0Q6+C1_*D)Z[N]G+8YP>>_==[MY;2S2^7#
M^?B4C9,4KOA(@VNSO2E[.C78EHE/H#\S1Z$C ^,SH5NX3-=Q]L"ET\&QDNBZ
M?C;ZLUF;HHDLS!1A(N2LB2U,9'#22> VA^"#L"EVVXJJ7_W\"*P-UH'J4:+M
MP"D^W_B+X_,O_SJE2VJ9OAV_JXVC#WY.5Q,5O?51(1BI$AG3P@/MA@$S]']<
MN)*:F]7;438N&D>"S5W@;2?#GI!YZ89;W=S?J\5AF,[I\*>48\Z 6=5!RCQ!
M8*;&%Y0.FC.A4NN7\T<1V E.&R+D+A V%U=/6'P[_WZT7FTXQG_#:M-/K)&U
MT2#=,U[K.D:2F.8D QF%1^F$$*%U&[Y[R.D$9^U!<!?<]I1(I^ 2IUO)Q0O&
M48'.-45*^P1.YP(^<.*0DLY@ZZY%]Y S[AO(N.#:12(]@>O%\<9&>5D'?6^4
M/<<@(Z_-46OBG9)60BB%&)2LB\79:/U@/LAU8CH!5B]6W!Z2Z@ER)^R\A8$;
MCOT^7\3:-:0R;G/.KKXU7N;"Z9$.BNG O  3E:[/1PX\6@9%E1**4E;HP6[:
MQGOIY)K>#VKW^]#CR+T#_/^VF./Q22/$-T?SO#J]. I+661-QK6KNPBQ9CO[
M4/F;B@]U+%SK?(?;*>D$>Z.B9-%<9!T [_?/7Y8;=E[J5GBZ$Q:=Y(5QT*[V
M096.0:"=T15E@\7:'EVUONSOIJ:KV[X/ #82W<X@_('+N&@&P[\LZ//FU3[_
M_'TQ7RV(BM=SPOGWY72%JZN]+T]W&8P53&8!K YB55IJ<(9;8 K1B:2LE:TS
M%G>A<]S<FDZA.["XNP#UR\7R^V(9UGCK=C EX>LT(,'R)MT]0M R@$4LQH28
MBFW=<.1>@L8MN>D2INT$V 4>+YGPEU^ EYM$I'2\,>;1^(")+@VMB@,5/4)0
M@FP8+[C@/FELWF5O"[*Z4J'C^_I-I->!\7EK0L+9AD[/KU/>.A8XH&%(IRR2
M*>WIT"&+V46OA=6MLP&V(*L3?Z@5%+9XE]E'+IU";75^8D\UNK-&!L\1+#EK
M9&%P!M'1016HM<CDOV&63X"UZW1U K968-CF$7 ?R?2$MCUNC'?3.;Y=X^%J
MPA+QKYHP(HF:[H=D:&S:[$6#S$N77![LG;K%!KJR+,>^O9\<$1T<AY,]G[/@
MEBH/.M%!1TWG.]91X"D;(*/=@],E:<YYYKIUH/-!HCI1NT\/F,60TNL CB_#
MZEMM*4A_U.;./\+LRJOPQ08GP=678"-J(7H!\A@5>";)IDH915(:;?/.2EL3
M-W).95M07'>\!Y%0!]"[/K7G(JAP-<0P44;HDIT"YFRN\WOB:=C"(_%4.A^;
M5V-O2]O(TSD'!=X@\NDB^',GWR:>"QE-=""X"K05SL$7F6L;/<=\9-XT][#O
M)&;DX9O#8JN)!'978HMUF#6!TJ5Y9Y-4>,@RD2?FF /E@X5(-D8==B^42AAT
M\TS&2\MW]2HXHHFVJT0::J91R\->+F:$TQJJ7RQ7ZV]A_0E/"?EML<0OW\*<
MLT7Y4D_ )_R!\R.LXS\QAWD^_=0:<<#IYEWAZ6K'!B%[A,*RX=D_?-494UHP
M8QP@=Q&4#0Y\C P\9PJCY4SJYU.U>V7 >!TL?A+ 0"]<=$B;"KXVWV 1G/0<
MM&;1&.O1V]8EN[=3TFT]V&-0</.U<&^F=^"AW-C%B^,O]$\W;PI)VB!X4J#-
M9AXR6;YDYPK@,BN>=+!<M)]J<R<Y8P]JV5_:#P%H1];WB**ZD=/' A658T&0
MMXZ2UW8;&GQ2"E+@2EM;NW>WK@N\AYS.4+2KR!_41;OQOP<H':W6BT-<WMC2
MZ=.0$,Z[X@2P5(LV.)VXP&. +)+BFK1VXJV[]SU 4F>0VE7TUR'54 X]P.KF
MR7N!\_2-+-I_;(Y?<=['P"6PP@7Y4=&#MT4!,R[I7)#VUGI&ST,TC3T9ZBEN
MO-V%T"6HSG9S>@!U4-[K>O82*79EZ.Q%YW4=3!GH^$0O9>OTJH=HZDQ;[86
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M9,":",IS.J8\DV',@BOTUR14ZY+P^^CI-'PQ\!W\6$%TT+GV\AF:>..TC2&
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M*[<H]E!!60'2U+Z'PM#NJ&T$23A.40=N1>M\[6>F,V\IT@YV?[I_UFXJ[^!
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M_JP%AI]7IWFQ_'22>=(D60)TA31%+@Q4FE2P=!Q%"J!TR</20$<,>D3,'KL
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MI(_;G7CWW@<U9-Y];HH[4N_>X.\C?<Y/](U_W=*>>D1D3C!0OA"2HJ$M)LL
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MQA:9&V ;%G-2X:^+/S'?!&@GWH6HO?>@?62T2"JC47(%.,? )#,H!Q94/C'
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M\3^"#\6 $=:CQAB%'\:X\-0(1U3^L#V&6FA_;@C=N7"Z??>_V'2?#2XR$;(
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MU!<G-6\'^)GQVM9D!Y5"N/[N \W_\F?]$ING$0X:;;I4PO'"]I%.*(K))6$
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MG!6BYLYIO>;U+:6FTD4P#J.MB?",N;VX]3N)T?>S\#Y1.LC)WQ]D#GO5/%3
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MUQ?LY_C>VAX=86FSQB)Z#,)'J%U\*[M\A*A(*SEP'QFW.38G3.[IQ-S>DD]
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MMEZ*?^!Y7,U]*)*-KE7P0$5W:%%#P%+O<&O?XQHRDR*22*!X-!JC)^>\&]*
M ?(<Z*O! 2VWUJ Z;.[0%PVW23#$_(THDB>I#(6[S/,(*E>K96X!/8434>O@
MU-XKH]J)=Z#!W0$MP(DA=^3K\;YC3MYW\5PI8*[FOW)+CGFV"*'8;)4/.OJ]
MUQ7O-0[L[P7BF-;B+G []$JGX<JYEW&P=MA_ILWDU[ X7U\9WS4T,B,X.?&
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MKJO?0TD>>'&9N>PQ<C;(]O<_>=Z3H9G1=U+8C-:^.+\\>5\?1*XCO2S0N2)
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M-!5X]8Z[(E1S#Q&X7(PE]X&- Y=C*4SFQ)U8#HIT-.G>F3")5*9"/4>>6LF
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M(U!+ 0(4 Q0    ( /: ;U8BH(V\].P! .3!%  6              "  0
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M87-E+FAT;5!+ 0(4 Q0    ( /: ;U9(0^+X@!$  %Q]   >
M  "  ;K+! !A,3 R-E]F:7)S=&%M96YD;65N='1O:'%L92YH=&U02P$"% ,4
M    " #V@&]6V%ZMSJIM   &3P, '@              @ %VW00 83$P,C=?
M<V5C;VYD86UE;F1M96YT=&]H<6PN:'1M4$L! A0#%     @ ]H!O5IS/PU:/
M#P  I&<  !X              ( !7$L% &$Q,#(X7W1H:7)D86UE;F1M96YT
M=&]H<6QE+FAT;5!+ 0(4 Q0    ( /: ;U9GI_"F!B0  /T6 0 >
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M &UG;G@M,C R,C$R,S$N>'-D4$L! A0#%     @ ]X!O5LP?!#\(&   R^
M !4              ( !'_0( &UG;G@M,C R,C$R,S%?8V%L+GAM;%!+ 0(4
M Q0    ( /> ;U;HX&W17'8  &1L!0 5              "  5H,"0!M9VYX
M+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    " #W@&]6>%OU= *C!P!OO L
M%               @ 'I@@D ;6=N>"TR,#(R,3(S,5]G,2YJ<&=02P$"% ,4
M    " #W@&]6($3)MH%" 0 D2@$ %               @ $=)A$ ;6=N>"TR
M,#(R,3(S,5]G,BYJ<&=02P$"% ,4    " #W@&]6,E[X<IW6 0 <Y $ %
M            @ '0:!( ;6=N>"TR,#(R,3(S,5]G,RYJ<&=02P$"% ,4
M" #W@&]6G]LR31-V 0"R@ $ %               @ &?/Q0 ;6=N>"TR,#(R
M,3(S,5]G-"YJ<&=02P$"% ,4    " #W@&]6>]8\.G5"  # 7P  %
M        @ 'DM14 ;6=N>"TR,#(R,3(S,5]G-2YJ<&=02P$"% ,4    " #W
M@&]6,;V*C JK 0"9%0( %               @ &+^!4 ;6=N>"TR,#(R,3(S
M,5]G-BYJ<&=02P$"% ,4    " #W@&]6+9X"61 & 0#Y) L %0
M    @ ''HQ< ;6=N>"TR,#(R,3(S,5]L86(N>&UL4$L! A0#%     @ ]X!O
M5A<'QDKSI0  GK4' !4              ( !"JH8 &UG;G@M,C R,C$R,S%?
M<')E+GAM;%!+ 0(4 Q0    ( /> ;U;%%AD!0P0  -$>   ;
M  "  3!0&0!M9VYX97AH:6)I=#(S+3$R,#(R,3!X:RYH=&U02P$"% ,4
M" #W@&]62#OOP?4'  #5)0  &P              @ &L5!D ;6=N>&5X:&EB
M:70S,2TQ,C R,C$P>&LN:'1M4$L! A0#%     @ ]X!O5GI7J4+S!P  4R8
M !L              ( !VEP9 &UG;GAE>&AI8FET,S$M,C(P,C(Q,'AK+FAT
M;5!+ 0(4 Q0    ( /> ;U:[?'25[0,  *L,   ;              "  09E
M&0!M9VYX97AH:6)I=#,R+3$R,#(R,3!X:RYH=&U02P$"% ,4    " #W@&]6
M$MCO ?<#   B#0  &P              @ $L:1D ;6=N>&5X:&EB:70S,BTR
B,C R,C$P>&LN:'1M4$L%!@     : !H $P<  %QM&0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
